{"docstore/data": {"e646e0fd-f57f-41c9-9d7e-50ce6fbc15e3": {"__data__": {"id_": "e646e0fd-f57f-41c9-9d7e-50ce6fbc15e3", "embedding": null, "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 19 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n02-Feb-2022  \nMcKesson Corp.   (MCK ) \nQ3 2022 Earnings Call    ", "original_text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 19 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n02-Feb-2022  \nMcKesson Corp.  ", "page_label": "1", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f1de019c-ee93-431e-83f5-688557649411", "node_type": "4", "metadata": {"page_label": "1", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3bade10fd16483e1e4933a432756d1bf2e99842058381b49ed83ea7c714553db", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6bd3b4dc-856c-46e0-b943-fe828ddb5ede", "node_type": "1", "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 19 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n02-Feb-2022  \nMcKesson Corp.   (MCK ) \nQ3 2022 Earnings Call    ", "original_text": "(MCK ) \nQ3 2022 Earnings Call    "}, "hash": "3d54a0259fa92d3db55a3c52805745907b9747692bcfab3d516f79964c1938b5", "class_name": "RelatedNodeInfo"}}, "text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 19 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n02-Feb-2022  \nMcKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 165, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6bd3b4dc-856c-46e0-b943-fe828ddb5ede": {"__data__": {"id_": "6bd3b4dc-856c-46e0-b943-fe828ddb5ede", "embedding": null, "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 19 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n02-Feb-2022  \nMcKesson Corp.   (MCK ) \nQ3 2022 Earnings Call    ", "original_text": "(MCK ) \nQ3 2022 Earnings Call    ", "page_label": "1", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f1de019c-ee93-431e-83f5-688557649411", "node_type": "4", "metadata": {"page_label": "1", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3bade10fd16483e1e4933a432756d1bf2e99842058381b49ed83ea7c714553db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e646e0fd-f57f-41c9-9d7e-50ce6fbc15e3", "node_type": "1", "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 19 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n02-Feb-2022  \nMcKesson Corp.   (MCK ) \nQ3 2022 Earnings Call    ", "original_text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 19 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n02-Feb-2022  \nMcKesson Corp.  ", "page_label": "1", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0182a3bd37a5d352748d848551889d17471104eaf196d774e4c7ea17df1ac427", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d575b349-ba00-4d24-98a5-00ba5fe86008", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "McKesson Corp.  "}, "hash": "08063e96223da51a04d5ccc6b78f95dc9d5a1af1db08a032af33db4b8936eec2", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2022 Earnings Call    ", "start_char_idx": 165, "end_char_idx": 198, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d575b349-ba00-4d24-98a5-00ba5fe86008": {"__data__": {"id_": "d575b349-ba00-4d24-98a5-00ba5fe86008", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edddd1cd-f6f6-41c2-b7ea-bb7d91760227", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "345378e352831eb1f293851e3a3db986a3b0d1db4c8a7c733b7cd595a129bf0c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6bd3b4dc-856c-46e0-b943-fe828ddb5ede", "node_type": "1", "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 19 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n02-Feb-2022  \nMcKesson Corp.   (MCK ) \nQ3 2022 Earnings Call    ", "original_text": "(MCK ) \nQ3 2022 Earnings Call    ", "page_label": "1", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "882acb76f0adba6eedd17da7776cf167762dc25e9f3829e64c701778a3e5d3c5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "59579895-53da-4bd4-9a79-539b1492c451", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Micha el Cherny  \nAnalyst, BofA Securities, Inc.  \n", "original_text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "653f275480904db4bde071297706f0f34fef5a2dc665c929df6bd783ade9bef8", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "59579895-53da-4bd4-9a79-539b1492c451": {"__data__": {"id_": "59579895-53da-4bd4-9a79-539b1492c451", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Micha el Cherny  \nAnalyst, BofA Securities, Inc.  \n", "original_text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edddd1cd-f6f6-41c2-b7ea-bb7d91760227", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "345378e352831eb1f293851e3a3db986a3b0d1db4c8a7c733b7cd595a129bf0c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d575b349-ba00-4d24-98a5-00ba5fe86008", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc975452186e8b9f4fc78fc8e5c6c5dd23da7f066cffb26dd27b042fe34061b3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a3c5b0fa-b6a9-4bbf-994f-6f0ba66c4093", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Micha el Cherny  \nAnalyst, BofA Securities, Inc.  \n Brian Tanquilut  \nAnalyst, Jefferies LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n "}, "hash": "1071e2574b40276028ec99b1839ed437550e26fac689b1a91c413972d93eb603", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 16, "end_char_idx": 341, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a3c5b0fa-b6a9-4bbf-994f-6f0ba66c4093": {"__data__": {"id_": "a3c5b0fa-b6a9-4bbf-994f-6f0ba66c4093", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Micha el Cherny  \nAnalyst, BofA Securities, Inc.  \n Brian Tanquilut  \nAnalyst, Jefferies LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n ", "page_label": "2", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edddd1cd-f6f6-41c2-b7ea-bb7d91760227", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "345378e352831eb1f293851e3a3db986a3b0d1db4c8a7c733b7cd595a129bf0c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "59579895-53da-4bd4-9a79-539b1492c451", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Micha el Cherny  \nAnalyst, BofA Securities, Inc.  \n", "original_text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db141cd516f7c38df61972b5afb449673f929f1e9df27b2c26c47f18119b6106", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a2f08546-6c81-4801-a2bd-6d76e2511802", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Micha el Cherny  \nAnalyst, BofA Securities, Inc.  \n Brian Tanquilut  \nAnalyst, Jefferies LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co. "}, "hash": "614bd89eb7e65d05ad89a7b6809eb8e769e39e5ad4025ec7b78b23c4fa6ca523", "class_name": "RelatedNodeInfo"}}, "text": "Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n ", "start_char_idx": 341, "end_char_idx": 428, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a2f08546-6c81-4801-a2bd-6d76e2511802": {"__data__": {"id_": "a2f08546-6c81-4801-a2bd-6d76e2511802", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Micha el Cherny  \nAnalyst, BofA Securities, Inc.  \n Brian Tanquilut  \nAnalyst, Jefferies LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "page_label": "2", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edddd1cd-f6f6-41c2-b7ea-bb7d91760227", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "345378e352831eb1f293851e3a3db986a3b0d1db4c8a7c733b7cd595a129bf0c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a3c5b0fa-b6a9-4bbf-994f-6f0ba66c4093", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Micha el Cherny  \nAnalyst, BofA Securities, Inc.  \n Brian Tanquilut  \nAnalyst, Jefferies LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n ", "page_label": "2", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "896ee1e3145de5dfdf4bb968a4a7f2c1d246619e3ae60edbf82eb8fe7e871941", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "18779052-4a57-4cd7-826b-aa88736ccb44", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Micha el Cherny  \nAnalyst, BofA Securities, Inc.  \n Brian Tanquilut  \nAnalyst, Jefferies LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, ladies and gentlemen, and welcome to McKesson's Third Quarter Fiscal 2022 Earnings \nConference Call. ", "original_text": "LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Micha el Cherny  \nAnalyst, BofA Securities, Inc.  \n"}, "hash": "f559bcb556fe24c4cbb9485756884fa3f54626e3e9c663349351269ee239a080", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "start_char_idx": 428, "end_char_idx": 859, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "18779052-4a57-4cd7-826b-aa88736ccb44": {"__data__": {"id_": "18779052-4a57-4cd7-826b-aa88736ccb44", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Micha el Cherny  \nAnalyst, BofA Securities, Inc.  \n Brian Tanquilut  \nAnalyst, Jefferies LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, ladies and gentlemen, and welcome to McKesson's Third Quarter Fiscal 2022 Earnings \nConference Call. ", "original_text": "LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Micha el Cherny  \nAnalyst, BofA Securities, Inc.  \n", "page_label": "2", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edddd1cd-f6f6-41c2-b7ea-bb7d91760227", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "345378e352831eb1f293851e3a3db986a3b0d1db4c8a7c733b7cd595a129bf0c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a2f08546-6c81-4801-a2bd-6d76e2511802", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Micha el Cherny  \nAnalyst, BofA Securities, Inc.  \n Brian Tanquilut  \nAnalyst, Jefferies LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "page_label": "2", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ce2bb349a8f37d81cf2b380aab15d4609034dcb560c1a47e47573cbd0f2c5675", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "84888ded-99fe-43a8-bd52-b48d77c36be1", "node_type": "1", "metadata": {"window": "Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Micha el Cherny  \nAnalyst, BofA Securities, Inc.  \n Brian Tanquilut  \nAnalyst, Jefferies LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, ladies and gentlemen, and welcome to McKesson's Third Quarter Fiscal 2022 Earnings \nConference Call.  Please be advised today's conference is being recorded.  \n \n", "original_text": "Brian Tanquilut  \nAnalyst, Jefferies LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. "}, "hash": "a35be25e27b5ff1ebac5de467dd3b68cf6d3bea72a0b33f5a04ee7030821c7ea", "class_name": "RelatedNodeInfo"}}, "text": "LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Micha el Cherny  \nAnalyst, BofA Securities, Inc.  \n", "start_char_idx": 859, "end_char_idx": 979, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "84888ded-99fe-43a8-bd52-b48d77c36be1": {"__data__": {"id_": "84888ded-99fe-43a8-bd52-b48d77c36be1", "embedding": null, "metadata": {"window": "Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Micha el Cherny  \nAnalyst, BofA Securities, Inc.  \n Brian Tanquilut  \nAnalyst, Jefferies LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, ladies and gentlemen, and welcome to McKesson's Third Quarter Fiscal 2022 Earnings \nConference Call.  Please be advised today's conference is being recorded.  \n \n", "original_text": "Brian Tanquilut  \nAnalyst, Jefferies LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "page_label": "2", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edddd1cd-f6f6-41c2-b7ea-bb7d91760227", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "345378e352831eb1f293851e3a3db986a3b0d1db4c8a7c733b7cd595a129bf0c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "18779052-4a57-4cd7-826b-aa88736ccb44", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Micha el Cherny  \nAnalyst, BofA Securities, Inc.  \n Brian Tanquilut  \nAnalyst, Jefferies LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, ladies and gentlemen, and welcome to McKesson's Third Quarter Fiscal 2022 Earnings \nConference Call. ", "original_text": "LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Micha el Cherny  \nAnalyst, BofA Securities, Inc.  \n", "page_label": "2", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "159cd741fb657066ea782f53cf17372581ca0b2801c8b16fb32d4e4591606f98", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0d8bc9e7-8f3e-4503-b604-ff5b455cb2aa", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Micha el Cherny  \nAnalyst, BofA Securities, Inc.  \n Brian Tanquilut  \nAnalyst, Jefferies LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, ladies and gentlemen, and welcome to McKesson's Third Quarter Fiscal 2022 Earnings \nConference Call.  Please be advised today's conference is being recorded.  \n \n At this time, I'd like to turn the call over to Rachel Rodriguez, VP of Investor Relations. ", "original_text": "LLC  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n "}, "hash": "f083f0e447c7630346ac04575340591be72a786f6485a57d8e56bd1400b7ef12", "class_name": "RelatedNodeInfo"}}, "text": "Brian Tanquilut  \nAnalyst, Jefferies LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "start_char_idx": 979, "end_char_idx": 1074, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0d8bc9e7-8f3e-4503-b604-ff5b455cb2aa": {"__data__": {"id_": "0d8bc9e7-8f3e-4503-b604-ff5b455cb2aa", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Micha el Cherny  \nAnalyst, BofA Securities, Inc.  \n Brian Tanquilut  \nAnalyst, Jefferies LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, ladies and gentlemen, and welcome to McKesson's Third Quarter Fiscal 2022 Earnings \nConference Call.  Please be advised today's conference is being recorded.  \n \n At this time, I'd like to turn the call over to Rachel Rodriguez, VP of Investor Relations. ", "original_text": "LLC  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n ", "page_label": "2", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edddd1cd-f6f6-41c2-b7ea-bb7d91760227", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "345378e352831eb1f293851e3a3db986a3b0d1db4c8a7c733b7cd595a129bf0c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "84888ded-99fe-43a8-bd52-b48d77c36be1", "node_type": "1", "metadata": {"window": "Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Micha el Cherny  \nAnalyst, BofA Securities, Inc.  \n Brian Tanquilut  \nAnalyst, Jefferies LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, ladies and gentlemen, and welcome to McKesson's Third Quarter Fiscal 2022 Earnings \nConference Call.  Please be advised today's conference is being recorded.  \n \n", "original_text": "Brian Tanquilut  \nAnalyst, Jefferies LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "page_label": "2", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1ed43ae2d3951ae06013b6e1d0cf935df50fee7ba87f7b945e1da936026930bf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a3a029d4-2c20-44d2-9ba8-2040631223a2", "node_type": "1", "metadata": {"window": "LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Micha el Cherny  \nAnalyst, BofA Securities, Inc.  \n Brian Tanquilut  \nAnalyst, Jefferies LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, ladies and gentlemen, and welcome to McKesson's Third Quarter Fiscal 2022 Earnings \nConference Call.  Please be advised today's conference is being recorded.  \n \n At this time, I'd like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, ladies and gentlemen, and welcome to McKesson's Third Quarter Fiscal 2022 Earnings \nConference Call. "}, "hash": "3ce38b91dab21a710df17af3be3bfedf2c776af320689dcd6df4129cd5fe9a0a", "class_name": "RelatedNodeInfo"}}, "text": "LLC  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n ", "start_char_idx": 1074, "end_char_idx": 1137, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a3a029d4-2c20-44d2-9ba8-2040631223a2": {"__data__": {"id_": "a3a029d4-2c20-44d2-9ba8-2040631223a2", "embedding": null, "metadata": {"window": "LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Micha el Cherny  \nAnalyst, BofA Securities, Inc.  \n Brian Tanquilut  \nAnalyst, Jefferies LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, ladies and gentlemen, and welcome to McKesson's Third Quarter Fiscal 2022 Earnings \nConference Call.  Please be advised today's conference is being recorded.  \n \n At this time, I'd like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, ladies and gentlemen, and welcome to McKesson's Third Quarter Fiscal 2022 Earnings \nConference Call. ", "page_label": "2", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edddd1cd-f6f6-41c2-b7ea-bb7d91760227", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "345378e352831eb1f293851e3a3db986a3b0d1db4c8a7c733b7cd595a129bf0c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0d8bc9e7-8f3e-4503-b604-ff5b455cb2aa", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Micha el Cherny  \nAnalyst, BofA Securities, Inc.  \n Brian Tanquilut  \nAnalyst, Jefferies LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, ladies and gentlemen, and welcome to McKesson's Third Quarter Fiscal 2022 Earnings \nConference Call.  Please be advised today's conference is being recorded.  \n \n At this time, I'd like to turn the call over to Rachel Rodriguez, VP of Investor Relations. ", "original_text": "LLC  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n ", "page_label": "2", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c051aa1c776245d8d8add588be15759a297e0a6d12441514c3422f4323de20bf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a806af34-c310-4a78-9d3c-09f2237e9538", "node_type": "1", "metadata": {"window": "Brian Tanquilut  \nAnalyst, Jefferies LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, ladies and gentlemen, and welcome to McKesson's Third Quarter Fiscal 2022 Earnings \nConference Call.  Please be advised today's conference is being recorded.  \n \n At this time, I'd like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, Keith. ", "original_text": "Please be advised today's conference is being recorded.  \n \n"}, "hash": "128785806f1a31ca0621949505c98044718181c783c5d8c5fa4b2daf773987aa", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, ladies and gentlemen, and welcome to McKesson's Third Quarter Fiscal 2022 Earnings \nConference Call. ", "start_char_idx": 1137, "end_char_idx": 1568, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a806af34-c310-4a78-9d3c-09f2237e9538": {"__data__": {"id_": "a806af34-c310-4a78-9d3c-09f2237e9538", "embedding": null, "metadata": {"window": "Brian Tanquilut  \nAnalyst, Jefferies LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, ladies and gentlemen, and welcome to McKesson's Third Quarter Fiscal 2022 Earnings \nConference Call.  Please be advised today's conference is being recorded.  \n \n At this time, I'd like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, Keith. ", "original_text": "Please be advised today's conference is being recorded.  \n \n", "page_label": "2", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edddd1cd-f6f6-41c2-b7ea-bb7d91760227", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "345378e352831eb1f293851e3a3db986a3b0d1db4c8a7c733b7cd595a129bf0c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a3a029d4-2c20-44d2-9ba8-2040631223a2", "node_type": "1", "metadata": {"window": "LLC  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Micha el Cherny  \nAnalyst, BofA Securities, Inc.  \n Brian Tanquilut  \nAnalyst, Jefferies LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, ladies and gentlemen, and welcome to McKesson's Third Quarter Fiscal 2022 Earnings \nConference Call.  Please be advised today's conference is being recorded.  \n \n At this time, I'd like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, ladies and gentlemen, and welcome to McKesson's Third Quarter Fiscal 2022 Earnings \nConference Call. ", "page_label": "2", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "240ba9adfbb5daf7990a65c827537a3ccd325ab7957692843ac78ec5e5e631cd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "64de42c9-2a0d-443e-b172-8fa15f4a56f2", "node_type": "1", "metadata": {"window": "LLC  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, ladies and gentlemen, and welcome to McKesson's Third Quarter Fiscal 2022 Earnings \nConference Call.  Please be advised today's conference is being recorded.  \n \n At this time, I'd like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, Keith.  Good afternoon and welcome, everyone, to McKesson's third quarter fiscal 2022 earnings call. \n", "original_text": "At this time, I'd like to turn the call over to Rachel Rodriguez, VP of Investor Relations. "}, "hash": "8205676218e167d3b15ab7c76b4fa6bfcae1e20eeca65a55d203a823f1ea1850", "class_name": "RelatedNodeInfo"}}, "text": "Please be advised today's conference is being recorded.  \n \n", "start_char_idx": 1568, "end_char_idx": 1628, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "64de42c9-2a0d-443e-b172-8fa15f4a56f2": {"__data__": {"id_": "64de42c9-2a0d-443e-b172-8fa15f4a56f2", "embedding": null, "metadata": {"window": "LLC  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, ladies and gentlemen, and welcome to McKesson's Third Quarter Fiscal 2022 Earnings \nConference Call.  Please be advised today's conference is being recorded.  \n \n At this time, I'd like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, Keith.  Good afternoon and welcome, everyone, to McKesson's third quarter fiscal 2022 earnings call. \n", "original_text": "At this time, I'd like to turn the call over to Rachel Rodriguez, VP of Investor Relations. ", "page_label": "2", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edddd1cd-f6f6-41c2-b7ea-bb7d91760227", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "345378e352831eb1f293851e3a3db986a3b0d1db4c8a7c733b7cd595a129bf0c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a806af34-c310-4a78-9d3c-09f2237e9538", "node_type": "1", "metadata": {"window": "Brian Tanquilut  \nAnalyst, Jefferies LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, ladies and gentlemen, and welcome to McKesson's Third Quarter Fiscal 2022 Earnings \nConference Call.  Please be advised today's conference is being recorded.  \n \n At this time, I'd like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, Keith. ", "original_text": "Please be advised today's conference is being recorded.  \n \n", "page_label": "2", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0f43cec37de12da67f067dc35b1a301961e3edfebd70e0f9875be4a829a71fa9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "75622da2-8a77-450f-8120-ce716bb89c21", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, ladies and gentlemen, and welcome to McKesson's Third Quarter Fiscal 2022 Earnings \nConference Call.  Please be advised today's conference is being recorded.  \n \n At this time, I'd like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, Keith.  Good afternoon and welcome, everyone, to McKesson's third quarter fiscal 2022 earnings call. \n Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. ", "original_text": "Please go ahead.  \n "}, "hash": "35737306f5e73a9dfde810e4ee77da6ff81ba4f9c95c8a7ab9c99beb8470ac2f", "class_name": "RelatedNodeInfo"}}, "text": "At this time, I'd like to turn the call over to Rachel Rodriguez, VP of Investor Relations. ", "start_char_idx": 1628, "end_char_idx": 1720, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "75622da2-8a77-450f-8120-ce716bb89c21": {"__data__": {"id_": "75622da2-8a77-450f-8120-ce716bb89c21", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, ladies and gentlemen, and welcome to McKesson's Third Quarter Fiscal 2022 Earnings \nConference Call.  Please be advised today's conference is being recorded.  \n \n At this time, I'd like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, Keith.  Good afternoon and welcome, everyone, to McKesson's third quarter fiscal 2022 earnings call. \n Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. ", "original_text": "Please go ahead.  \n ", "page_label": "2", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edddd1cd-f6f6-41c2-b7ea-bb7d91760227", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "345378e352831eb1f293851e3a3db986a3b0d1db4c8a7c733b7cd595a129bf0c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "64de42c9-2a0d-443e-b172-8fa15f4a56f2", "node_type": "1", "metadata": {"window": "LLC  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, ladies and gentlemen, and welcome to McKesson's Third Quarter Fiscal 2022 Earnings \nConference Call.  Please be advised today's conference is being recorded.  \n \n At this time, I'd like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, Keith.  Good afternoon and welcome, everyone, to McKesson's third quarter fiscal 2022 earnings call. \n", "original_text": "At this time, I'd like to turn the call over to Rachel Rodriguez, VP of Investor Relations. ", "page_label": "2", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b15c5306bb1260f2eb7e6a1483e76f3daecead67f226782fbb8f194d23e67e81", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a01cca2-c589-4a83-b9c8-a35332967b83", "node_type": "1", "metadata": {"window": "Please be advised today's conference is being recorded.  \n \n At this time, I'd like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, Keith.  Good afternoon and welcome, everyone, to McKesson's third quarter fiscal 2022 earnings call. \n Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, Keith. "}, "hash": "a73264bd3593f1287d0200f7a51e194d329126dba80b2df91315b98ce0a8656d", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n ", "start_char_idx": 1720, "end_char_idx": 1740, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a01cca2-c589-4a83-b9c8-a35332967b83": {"__data__": {"id_": "4a01cca2-c589-4a83-b9c8-a35332967b83", "embedding": null, "metadata": {"window": "Please be advised today's conference is being recorded.  \n \n At this time, I'd like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, Keith.  Good afternoon and welcome, everyone, to McKesson's third quarter fiscal 2022 earnings call. \n Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, Keith. ", "page_label": "2", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edddd1cd-f6f6-41c2-b7ea-bb7d91760227", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "345378e352831eb1f293851e3a3db986a3b0d1db4c8a7c733b7cd595a129bf0c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "75622da2-8a77-450f-8120-ce716bb89c21", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, ladies and gentlemen, and welcome to McKesson's Third Quarter Fiscal 2022 Earnings \nConference Call.  Please be advised today's conference is being recorded.  \n \n At this time, I'd like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, Keith.  Good afternoon and welcome, everyone, to McKesson's third quarter fiscal 2022 earnings call. \n Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. ", "original_text": "Please go ahead.  \n ", "page_label": "2", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8b6e242345c89d6727638ef3d92cfa60b76a1e0a9f77816f918a6cbabf9b942", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a0286b72-ede3-4a91-8d03-906d0faffcc4", "node_type": "1", "metadata": {"window": "At this time, I'd like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, Keith.  Good afternoon and welcome, everyone, to McKesson's third quarter fiscal 2022 earnings call. \n Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results. ", "original_text": "Good afternoon and welcome, everyone, to McKesson's third quarter fiscal 2022 earnings call. \n"}, "hash": "306500c0d2785122c53c7cba02cce7afb494eeb93c5ade7aef3bda084d63a21f", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, Keith. ", "start_char_idx": 1740, "end_char_idx": 2093, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a0286b72-ede3-4a91-8d03-906d0faffcc4": {"__data__": {"id_": "a0286b72-ede3-4a91-8d03-906d0faffcc4", "embedding": null, "metadata": {"window": "At this time, I'd like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, Keith.  Good afternoon and welcome, everyone, to McKesson's third quarter fiscal 2022 earnings call. \n Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results. ", "original_text": "Good afternoon and welcome, everyone, to McKesson's third quarter fiscal 2022 earnings call. \n", "page_label": "2", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edddd1cd-f6f6-41c2-b7ea-bb7d91760227", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "345378e352831eb1f293851e3a3db986a3b0d1db4c8a7c733b7cd595a129bf0c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a01cca2-c589-4a83-b9c8-a35332967b83", "node_type": "1", "metadata": {"window": "Please be advised today's conference is being recorded.  \n \n At this time, I'd like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, Keith.  Good afternoon and welcome, everyone, to McKesson's third quarter fiscal 2022 earnings call. \n Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, Keith. ", "page_label": "2", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b03ad93e008e3484cf1ca772c73e227ea9bf54dcc2346c6bbc1dc84f08edab8f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7ff2612b-e637-4733-a4ed-3769022e2965", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, Keith.  Good afternoon and welcome, everyone, to McKesson's third quarter fiscal 2022 earnings call. \n Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and the Risk Factors section of our periodic SEC filings for \nadditional information concerning risk f actors that could cause our actual results to materially differ from those in \nour forward -looking statements.  \n \n", "original_text": "Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. "}, "hash": "d974a43f025df2efe09e0b0464512120199b7b7004abe5c03ad1ff5ccf0fcce0", "class_name": "RelatedNodeInfo"}}, "text": "Good afternoon and welcome, everyone, to McKesson's third quarter fiscal 2022 earnings call. \n", "start_char_idx": 2093, "end_char_idx": 2187, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7ff2612b-e637-4733-a4ed-3769022e2965": {"__data__": {"id_": "7ff2612b-e637-4733-a4ed-3769022e2965", "embedding": null, "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, Keith.  Good afternoon and welcome, everyone, to McKesson's third quarter fiscal 2022 earnings call. \n Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and the Risk Factors section of our periodic SEC filings for \nadditional information concerning risk f actors that could cause our actual results to materially differ from those in \nour forward -looking statements.  \n \n", "original_text": "Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. ", "page_label": "2", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edddd1cd-f6f6-41c2-b7ea-bb7d91760227", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "345378e352831eb1f293851e3a3db986a3b0d1db4c8a7c733b7cd595a129bf0c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a0286b72-ede3-4a91-8d03-906d0faffcc4", "node_type": "1", "metadata": {"window": "At this time, I'd like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, Keith.  Good afternoon and welcome, everyone, to McKesson's third quarter fiscal 2022 earnings call. \n Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results. ", "original_text": "Good afternoon and welcome, everyone, to McKesson's third quarter fiscal 2022 earnings call. \n", "page_label": "2", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cbfd9ba753b4568c2eab4332884c19e9b32412b2c532dca654d81a116c26f7c7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b509d8f0-b69c-40df-90e7-1da97cacc4ad", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, Keith.  Good afternoon and welcome, everyone, to McKesson's third quarter fiscal 2022 earnings call. \n Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and the Risk Factors section of our periodic SEC filings for \nadditional information concerning risk f actors that could cause our actual results to materially differ from those in \nour forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of these measures to GAAP results, can be found in today's earnings release and presentation \nslides. ", "original_text": "Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n"}, "hash": "ce04412361cf13c711adfce7447bac2692fe268e5e35c1227b18604419f0f4b3", "class_name": "RelatedNodeInfo"}}, "text": "Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. ", "start_char_idx": 2187, "end_char_idx": 2298, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b509d8f0-b69c-40df-90e7-1da97cacc4ad": {"__data__": {"id_": "b509d8f0-b69c-40df-90e7-1da97cacc4ad", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, Keith.  Good afternoon and welcome, everyone, to McKesson's third quarter fiscal 2022 earnings call. \n Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and the Risk Factors section of our periodic SEC filings for \nadditional information concerning risk f actors that could cause our actual results to materially differ from those in \nour forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of these measures to GAAP results, can be found in today's earnings release and presentation \nslides. ", "original_text": "Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n", "page_label": "2", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edddd1cd-f6f6-41c2-b7ea-bb7d91760227", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "345378e352831eb1f293851e3a3db986a3b0d1db4c8a7c733b7cd595a129bf0c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7ff2612b-e637-4733-a4ed-3769022e2965", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, Keith.  Good afternoon and welcome, everyone, to McKesson's third quarter fiscal 2022 earnings call. \n Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and the Risk Factors section of our periodic SEC filings for \nadditional information concerning risk f actors that could cause our actual results to materially differ from those in \nour forward -looking statements.  \n \n", "original_text": "Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. ", "page_label": "2", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d23a01e18c267b0b462396fa0ded8ab0898bf0e7615f16563c582589bdb449ff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6a447823-afff-4ef1-a1e6-5f8f84dcf5b6", "node_type": "1", "metadata": {"window": "Good afternoon and welcome, everyone, to McKesson's third quarter fiscal 2022 earnings call. \n Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and the Risk Factors section of our periodic SEC filings for \nadditional information concerning risk f actors that could cause our actual results to materially differ from those in \nour forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of these measures to GAAP results, can be found in today's earnings release and presentation \nslides.  The presentation slides also include a summary of our results for the quarter and updated guidance \nassumptions.  ", "original_text": "Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results. "}, "hash": "adc016bc0e3ff72cd9c6f0808c619aef0395f189e0152911b84f77e4a37ad115", "class_name": "RelatedNodeInfo"}}, "text": "Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n", "start_char_idx": 2298, "end_char_idx": 2400, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6a447823-afff-4ef1-a1e6-5f8f84dcf5b6": {"__data__": {"id_": "6a447823-afff-4ef1-a1e6-5f8f84dcf5b6", "embedding": null, "metadata": {"window": "Good afternoon and welcome, everyone, to McKesson's third quarter fiscal 2022 earnings call. \n Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and the Risk Factors section of our periodic SEC filings for \nadditional information concerning risk f actors that could cause our actual results to materially differ from those in \nour forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of these measures to GAAP results, can be found in today's earnings release and presentation \nslides.  The presentation slides also include a summary of our results for the quarter and updated guidance \nassumptions.  ", "original_text": "Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results. ", "page_label": "2", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edddd1cd-f6f6-41c2-b7ea-bb7d91760227", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "345378e352831eb1f293851e3a3db986a3b0d1db4c8a7c733b7cd595a129bf0c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b509d8f0-b69c-40df-90e7-1da97cacc4ad", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nThank you, Keith.  Good afternoon and welcome, everyone, to McKesson's third quarter fiscal 2022 earnings call. \n Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and the Risk Factors section of our periodic SEC filings for \nadditional information concerning risk f actors that could cause our actual results to materially differ from those in \nour forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of these measures to GAAP results, can be found in today's earnings release and presentation \nslides. ", "original_text": "Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n", "page_label": "2", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a9ccb7959223c0e9f8371e4a6b45b89650bacbcad0541d87633acaf8523be8d1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cd8e8e70-8379-47be-a193-6d61700969bb", "node_type": "1", "metadata": {"window": "Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and the Risk Factors section of our periodic SEC filings for \nadditional information concerning risk f actors that could cause our actual results to materially differ from those in \nour forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of these measures to GAAP results, can be found in today's earnings release and presentation \nslides.  The presentation slides also include a summary of our results for the quarter and updated guidance \nassumptions.  ", "original_text": "Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and the Risk Factors section of our periodic SEC filings for \nadditional information concerning risk f actors that could cause our actual results to materially differ from those in \nour forward -looking statements.  \n \n"}, "hash": "082e29e51d93176a91140df9269bf8914c4d277b495a772f26f8f82d0afb1257", "class_name": "RelatedNodeInfo"}}, "text": "Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results. ", "start_char_idx": 2400, "end_char_idx": 2527, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cd8e8e70-8379-47be-a193-6d61700969bb": {"__data__": {"id_": "cd8e8e70-8379-47be-a193-6d61700969bb", "embedding": null, "metadata": {"window": "Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and the Risk Factors section of our periodic SEC filings for \nadditional information concerning risk f actors that could cause our actual results to materially differ from those in \nour forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of these measures to GAAP results, can be found in today's earnings release and presentation \nslides.  The presentation slides also include a summary of our results for the quarter and updated guidance \nassumptions.  ", "original_text": "Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and the Risk Factors section of our periodic SEC filings for \nadditional information concerning risk f actors that could cause our actual results to materially differ from those in \nour forward -looking statements.  \n \n", "page_label": "2", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edddd1cd-f6f6-41c2-b7ea-bb7d91760227", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "345378e352831eb1f293851e3a3db986a3b0d1db4c8a7c733b7cd595a129bf0c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6a447823-afff-4ef1-a1e6-5f8f84dcf5b6", "node_type": "1", "metadata": {"window": "Good afternoon and welcome, everyone, to McKesson's third quarter fiscal 2022 earnings call. \n Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and the Risk Factors section of our periodic SEC filings for \nadditional information concerning risk f actors that could cause our actual results to materially differ from those in \nour forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of these measures to GAAP results, can be found in today's earnings release and presentation \nslides.  The presentation slides also include a summary of our results for the quarter and updated guidance \nassumptions.  ", "original_text": "Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results. ", "page_label": "2", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "57073a9966dd956167805a4dffb17602d8b41f9b0b0fc751f362a02d8918a215", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "213c25be-6c18-46b9-bc61-98411824b897", "node_type": "1", "metadata": {"window": "Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and the Risk Factors section of our periodic SEC filings for \nadditional information concerning risk f actors that could cause our actual results to materially differ from those in \nour forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of these measures to GAAP results, can be found in today's earnings release and presentation \nslides.  The presentation slides also include a summary of our results for the quarter and updated guidance \nassumptions.  ", "original_text": "Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of these measures to GAAP results, can be found in today's earnings release and presentation \nslides. "}, "hash": "ccb6abbdfd6c9dc73643d60ca4f220ed9b8c8f61934f6f8668a6c456a323b1eb", "class_name": "RelatedNodeInfo"}}, "text": "Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and the Risk Factors section of our periodic SEC filings for \nadditional information concerning risk f actors that could cause our actual results to materially differ from those in \nour forward -looking statements.  \n \n", "start_char_idx": 2527, "end_char_idx": 2891, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "213c25be-6c18-46b9-bc61-98411824b897": {"__data__": {"id_": "213c25be-6c18-46b9-bc61-98411824b897", "embedding": null, "metadata": {"window": "Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and the Risk Factors section of our periodic SEC filings for \nadditional information concerning risk f actors that could cause our actual results to materially differ from those in \nour forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of these measures to GAAP results, can be found in today's earnings release and presentation \nslides.  The presentation slides also include a summary of our results for the quarter and updated guidance \nassumptions.  ", "original_text": "Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of these measures to GAAP results, can be found in today's earnings release and presentation \nslides. ", "page_label": "2", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edddd1cd-f6f6-41c2-b7ea-bb7d91760227", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "345378e352831eb1f293851e3a3db986a3b0d1db4c8a7c733b7cd595a129bf0c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cd8e8e70-8379-47be-a193-6d61700969bb", "node_type": "1", "metadata": {"window": "Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and the Risk Factors section of our periodic SEC filings for \nadditional information concerning risk f actors that could cause our actual results to materially differ from those in \nour forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of these measures to GAAP results, can be found in today's earnings release and presentation \nslides.  The presentation slides also include a summary of our results for the quarter and updated guidance \nassumptions.  ", "original_text": "Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and the Risk Factors section of our periodic SEC filings for \nadditional information concerning risk f actors that could cause our actual results to materially differ from those in \nour forward -looking statements.  \n \n", "page_label": "2", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aa4f48376c51f4b75baeaaf43fd03d488b502f57e96571002829c05363301b44", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "04275573-d7b3-4544-8201-1e9543c15528", "node_type": "1", "metadata": {"window": "Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and the Risk Factors section of our periodic SEC filings for \nadditional information concerning risk f actors that could cause our actual results to materially differ from those in \nour forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of these measures to GAAP results, can be found in today's earnings release and presentation \nslides.  The presentation slides also include a summary of our results for the quarter and updated guidance \nassumptions.  ", "original_text": "The presentation slides also include a summary of our results for the quarter and updated guidance \nassumptions.  "}, "hash": "70bf441677a0f1dfc54f8a215fabbe005fee400bcf67ad5c644d5c54e9c94c7e", "class_name": "RelatedNodeInfo"}}, "text": "Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of these measures to GAAP results, can be found in today's earnings release and presentation \nslides. ", "start_char_idx": 2891, "end_char_idx": 3110, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "04275573-d7b3-4544-8201-1e9543c15528": {"__data__": {"id_": "04275573-d7b3-4544-8201-1e9543c15528", "embedding": null, "metadata": {"window": "Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and the Risk Factors section of our periodic SEC filings for \nadditional information concerning risk f actors that could cause our actual results to materially differ from those in \nour forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of these measures to GAAP results, can be found in today's earnings release and presentation \nslides.  The presentation slides also include a summary of our results for the quarter and updated guidance \nassumptions.  ", "original_text": "The presentation slides also include a summary of our results for the quarter and updated guidance \nassumptions.  ", "page_label": "2", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edddd1cd-f6f6-41c2-b7ea-bb7d91760227", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "345378e352831eb1f293851e3a3db986a3b0d1db4c8a7c733b7cd595a129bf0c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "213c25be-6c18-46b9-bc61-98411824b897", "node_type": "1", "metadata": {"window": "Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and the Risk Factors section of our periodic SEC filings for \nadditional information concerning risk f actors that could cause our actual results to materially differ from those in \nour forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of these measures to GAAP results, can be found in today's earnings release and presentation \nslides.  The presentation slides also include a summary of our results for the quarter and updated guidance \nassumptions.  ", "original_text": "Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of these measures to GAAP results, can be found in today's earnings release and presentation \nslides. ", "page_label": "2", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5997a52bd97788989c0a17284565715dbc67bbaeddbce25d4974d937c2af5d65", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ed98d39-26cb-455a-bc74-83cfe5265996", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nWith that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Exec utive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and thank everyone for joining us on our call today. ", "original_text": "McKesson Corp.  "}, "hash": "72263fa43b6ec65590ef86a37f3116bc532174cb7e4564a545fc792196966dc8", "class_name": "RelatedNodeInfo"}}, "text": "The presentation slides also include a summary of our results for the quarter and updated guidance \nassumptions.  ", "start_char_idx": 3110, "end_char_idx": 3224, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5ed98d39-26cb-455a-bc74-83cfe5265996": {"__data__": {"id_": "5ed98d39-26cb-455a-bc74-83cfe5265996", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nWith that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Exec utive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and thank everyone for joining us on our call today. ", "original_text": "McKesson Corp.  ", "page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a6099167-af59-46fd-99a8-7c7f028b5ea4", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "50237b3cc005e6e5b1d6f16cc6b7aac546814ffb83bee9ce12a76c4e7ab6cfaa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "04275573-d7b3-4544-8201-1e9543c15528", "node_type": "1", "metadata": {"window": "Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's earnings release and presentation slides \navailable on our website at investor.mckesson.com and the Risk Factors section of our periodic SEC filings for \nadditional information concerning risk f actors that could cause our actual results to materially differ from those in \nour forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of these measures to GAAP results, can be found in today's earnings release and presentation \nslides.  The presentation slides also include a summary of our results for the quarter and updated guidance \nassumptions.  ", "original_text": "The presentation slides also include a summary of our results for the quarter and updated guidance \nassumptions.  ", "page_label": "2", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f5a39da4a1f7d3dc3464bfc85a6582edb19c6f6c7f2f9b365161eb589329f82e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f1524133-35b3-42ab-a861-041a1cc185f7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nWith that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Exec utive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and thank everyone for joining us on our call today.  Today, we reported third quarter fiscal \n2022 results, another quarter with double -digit adjusted operating profit growth in all four segments,  reflecting \nstrength in the fundamentals across our businesses. ", "original_text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nWith that, let me turn it over to Brian.  \n "}, "hash": "34bbd841cf9d9500d2a3d70bdbdb947521f5abd381129af9fec2ab3b12f786fb", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f1524133-35b3-42ab-a861-041a1cc185f7": {"__data__": {"id_": "f1524133-35b3-42ab-a861-041a1cc185f7", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nWith that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Exec utive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and thank everyone for joining us on our call today.  Today, we reported third quarter fiscal \n2022 results, another quarter with double -digit adjusted operating profit growth in all four segments,  reflecting \nstrength in the fundamentals across our businesses. ", "original_text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nWith that, let me turn it over to Brian.  \n ", "page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a6099167-af59-46fd-99a8-7c7f028b5ea4", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "50237b3cc005e6e5b1d6f16cc6b7aac546814ffb83bee9ce12a76c4e7ab6cfaa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5ed98d39-26cb-455a-bc74-83cfe5265996", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nWith that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Exec utive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and thank everyone for joining us on our call today. ", "original_text": "McKesson Corp.  ", "page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "72bd405ac2af7312dcbd82ab9acff03c349d7f900f381af3056abdcbab2c3d03", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "42a4a8d1-8e25-44a9-b8aa-f54a4d9c0e22", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nWith that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Exec utive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and thank everyone for joining us on our call today.  Today, we reported third quarter fiscal \n2022 results, another quarter with double -digit adjusted operating profit growth in all four segments,  reflecting \nstrength in the fundamentals across our businesses.  Our focus and execution against our company priorities \npositions us to consistently generate strong financial results despite fluidity we continue to see in the \nmacroeconomic environment.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Exec utive Officer & Director, McKesson Corp.  \n"}, "hash": "d82a30e7329407dcd087522312724e14fad16adf70c8e3abeaa091213692dbbc", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nWith that, let me turn it over to Brian.  \n ", "start_char_idx": 16, "end_char_idx": 226, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "42a4a8d1-8e25-44a9-b8aa-f54a4d9c0e22": {"__data__": {"id_": "42a4a8d1-8e25-44a9-b8aa-f54a4d9c0e22", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nWith that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Exec utive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and thank everyone for joining us on our call today.  Today, we reported third quarter fiscal \n2022 results, another quarter with double -digit adjusted operating profit growth in all four segments,  reflecting \nstrength in the fundamentals across our businesses.  Our focus and execution against our company priorities \npositions us to consistently generate strong financial results despite fluidity we continue to see in the \nmacroeconomic environment.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Exec utive Officer & Director, McKesson Corp.  \n", "page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a6099167-af59-46fd-99a8-7c7f028b5ea4", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "50237b3cc005e6e5b1d6f16cc6b7aac546814ffb83bee9ce12a76c4e7ab6cfaa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f1524133-35b3-42ab-a861-041a1cc185f7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nWith that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Exec utive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and thank everyone for joining us on our call today.  Today, we reported third quarter fiscal \n2022 results, another quarter with double -digit adjusted operating profit growth in all four segments,  reflecting \nstrength in the fundamentals across our businesses. ", "original_text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nWith that, let me turn it over to Brian.  \n ", "page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "96cb01ba4652d9cb1ab5910cc97369fa891e9b6ea53cdbf879cb789aa2b65917", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb76a09c-9c23-4065-9a9e-d3542dd9a8fb", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nWith that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Exec utive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and thank everyone for joining us on our call today.  Today, we reported third quarter fiscal \n2022 results, another quarter with double -digit adjusted operating profit growth in all four segments,  reflecting \nstrength in the fundamentals across our businesses.  Our focus and execution against our company priorities \npositions us to consistently generate strong financial results despite fluidity we continue to see in the \nmacroeconomic environment.  \n \n Before I discuss the business performance, I would like to just quickly remind everyone of our company priorities. \n", "original_text": "Thank you, Rachel, and thank everyone for joining us on our call today. "}, "hash": "ac94edabea0650c17b84a4114ec561c609fd6a564f8ba7866a5cfab2763392f5", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Exec utive Officer & Director, McKesson Corp.  \n", "start_char_idx": 226, "end_char_idx": 569, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb76a09c-9c23-4065-9a9e-d3542dd9a8fb": {"__data__": {"id_": "bb76a09c-9c23-4065-9a9e-d3542dd9a8fb", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nWith that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Exec utive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and thank everyone for joining us on our call today.  Today, we reported third quarter fiscal \n2022 results, another quarter with double -digit adjusted operating profit growth in all four segments,  reflecting \nstrength in the fundamentals across our businesses.  Our focus and execution against our company priorities \npositions us to consistently generate strong financial results despite fluidity we continue to see in the \nmacroeconomic environment.  \n \n Before I discuss the business performance, I would like to just quickly remind everyone of our company priorities. \n", "original_text": "Thank you, Rachel, and thank everyone for joining us on our call today. ", "page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a6099167-af59-46fd-99a8-7c7f028b5ea4", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "50237b3cc005e6e5b1d6f16cc6b7aac546814ffb83bee9ce12a76c4e7ab6cfaa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "42a4a8d1-8e25-44a9-b8aa-f54a4d9c0e22", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nWith that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Exec utive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and thank everyone for joining us on our call today.  Today, we reported third quarter fiscal \n2022 results, another quarter with double -digit adjusted operating profit growth in all four segments,  reflecting \nstrength in the fundamentals across our businesses.  Our focus and execution against our company priorities \npositions us to consistently generate strong financial results despite fluidity we continue to see in the \nmacroeconomic environment.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Exec utive Officer & Director, McKesson Corp.  \n", "page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ed5b7eb35ac34e562f4f05c0ad5d9e06bf8fecb8d83710ce26a3f793c626822d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d2fb990b-8f56-4c8d-95e2-f4451495fa7f", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nWith that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Exec utive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and thank everyone for joining us on our call today.  Today, we reported third quarter fiscal \n2022 results, another quarter with double -digit adjusted operating profit growth in all four segments,  reflecting \nstrength in the fundamentals across our businesses.  Our focus and execution against our company priorities \npositions us to consistently generate strong financial results despite fluidity we continue to see in the \nmacroeconomic environment.  \n \n Before I discuss the business performance, I would like to just quickly remind everyone of our company priorities. \n We have been sharing with you our strategic transformation to a diversified healthcare services company \ncentered around a set of four enterprise  priorities. ", "original_text": "Today, we reported third quarter fiscal \n2022 results, another quarter with double -digit adjusted operating profit growth in all four segments,  reflecting \nstrength in the fundamentals across our businesses. "}, "hash": "fe480fd0c9a914d706c18bd81b2aadc84668557c5316543f0cda40cb28391116", "class_name": "RelatedNodeInfo"}}, "text": "Thank you, Rachel, and thank everyone for joining us on our call today. ", "start_char_idx": 569, "end_char_idx": 641, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d2fb990b-8f56-4c8d-95e2-f4451495fa7f": {"__data__": {"id_": "d2fb990b-8f56-4c8d-95e2-f4451495fa7f", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nWith that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Exec utive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and thank everyone for joining us on our call today.  Today, we reported third quarter fiscal \n2022 results, another quarter with double -digit adjusted operating profit growth in all four segments,  reflecting \nstrength in the fundamentals across our businesses.  Our focus and execution against our company priorities \npositions us to consistently generate strong financial results despite fluidity we continue to see in the \nmacroeconomic environment.  \n \n Before I discuss the business performance, I would like to just quickly remind everyone of our company priorities. \n We have been sharing with you our strategic transformation to a diversified healthcare services company \ncentered around a set of four enterprise  priorities. ", "original_text": "Today, we reported third quarter fiscal \n2022 results, another quarter with double -digit adjusted operating profit growth in all four segments,  reflecting \nstrength in the fundamentals across our businesses. ", "page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a6099167-af59-46fd-99a8-7c7f028b5ea4", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "50237b3cc005e6e5b1d6f16cc6b7aac546814ffb83bee9ce12a76c4e7ab6cfaa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb76a09c-9c23-4065-9a9e-d3542dd9a8fb", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nWith that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Exec utive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and thank everyone for joining us on our call today.  Today, we reported third quarter fiscal \n2022 results, another quarter with double -digit adjusted operating profit growth in all four segments,  reflecting \nstrength in the fundamentals across our businesses.  Our focus and execution against our company priorities \npositions us to consistently generate strong financial results despite fluidity we continue to see in the \nmacroeconomic environment.  \n \n Before I discuss the business performance, I would like to just quickly remind everyone of our company priorities. \n", "original_text": "Thank you, Rachel, and thank everyone for joining us on our call today. ", "page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5763974a006d2136125225c3322de3c6b5eec877eef4591960a9e768c0aa8cfe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1bfa31cd-76de-470f-a02f-2547094afda2", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Exec utive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and thank everyone for joining us on our call today.  Today, we reported third quarter fiscal \n2022 results, another quarter with double -digit adjusted operating profit growth in all four segments,  reflecting \nstrength in the fundamentals across our businesses.  Our focus and execution against our company priorities \npositions us to consistently generate strong financial results despite fluidity we continue to see in the \nmacroeconomic environment.  \n \n Before I discuss the business performance, I would like to just quickly remind everyone of our company priorities. \n We have been sharing with you our strategic transformation to a diversified healthcare services company \ncentered around a set of four enterprise  priorities.  We believe the execution against these priorities is critical to \nour ability to generate long -term sustainable growth, and we want to reiterate our focus and commitment to each \none of them.  \n \n", "original_text": "Our focus and execution against our company priorities \npositions us to consistently generate strong financial results despite fluidity we continue to see in the \nmacroeconomic environment.  \n \n"}, "hash": "be137979334787b31bad3075e89c22562af379872688b73a60e98c89e1eb0c54", "class_name": "RelatedNodeInfo"}}, "text": "Today, we reported third quarter fiscal \n2022 results, another quarter with double -digit adjusted operating profit growth in all four segments,  reflecting \nstrength in the fundamentals across our businesses. ", "start_char_idx": 641, "end_char_idx": 851, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1bfa31cd-76de-470f-a02f-2547094afda2": {"__data__": {"id_": "1bfa31cd-76de-470f-a02f-2547094afda2", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Exec utive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and thank everyone for joining us on our call today.  Today, we reported third quarter fiscal \n2022 results, another quarter with double -digit adjusted operating profit growth in all four segments,  reflecting \nstrength in the fundamentals across our businesses.  Our focus and execution against our company priorities \npositions us to consistently generate strong financial results despite fluidity we continue to see in the \nmacroeconomic environment.  \n \n Before I discuss the business performance, I would like to just quickly remind everyone of our company priorities. \n We have been sharing with you our strategic transformation to a diversified healthcare services company \ncentered around a set of four enterprise  priorities.  We believe the execution against these priorities is critical to \nour ability to generate long -term sustainable growth, and we want to reiterate our focus and commitment to each \none of them.  \n \n", "original_text": "Our focus and execution against our company priorities \npositions us to consistently generate strong financial results despite fluidity we continue to see in the \nmacroeconomic environment.  \n \n", "page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a6099167-af59-46fd-99a8-7c7f028b5ea4", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "50237b3cc005e6e5b1d6f16cc6b7aac546814ffb83bee9ce12a76c4e7ab6cfaa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d2fb990b-8f56-4c8d-95e2-f4451495fa7f", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nWith that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Exec utive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and thank everyone for joining us on our call today.  Today, we reported third quarter fiscal \n2022 results, another quarter with double -digit adjusted operating profit growth in all four segments,  reflecting \nstrength in the fundamentals across our businesses.  Our focus and execution against our company priorities \npositions us to consistently generate strong financial results despite fluidity we continue to see in the \nmacroeconomic environment.  \n \n Before I discuss the business performance, I would like to just quickly remind everyone of our company priorities. \n We have been sharing with you our strategic transformation to a diversified healthcare services company \ncentered around a set of four enterprise  priorities. ", "original_text": "Today, we reported third quarter fiscal \n2022 results, another quarter with double -digit adjusted operating profit growth in all four segments,  reflecting \nstrength in the fundamentals across our businesses. ", "page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c8a07f4b2002a0a2ebeda0d37343e6f6ced38ed0277ba031adc6cf0b57ac90d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "38b029e0-f8a8-49f9-9daa-a5b41daec436", "node_type": "1", "metadata": {"window": "Thank you, Rachel, and thank everyone for joining us on our call today.  Today, we reported third quarter fiscal \n2022 results, another quarter with double -digit adjusted operating profit growth in all four segments,  reflecting \nstrength in the fundamentals across our businesses.  Our focus and execution against our company priorities \npositions us to consistently generate strong financial results despite fluidity we continue to see in the \nmacroeconomic environment.  \n \n Before I discuss the business performance, I would like to just quickly remind everyone of our company priorities. \n We have been sharing with you our strategic transformation to a diversified healthcare services company \ncentered around a set of four enterprise  priorities.  We believe the execution against these priorities is critical to \nour ability to generate long -term sustainable growth, and we want to reiterate our focus and commitment to each \none of them.  \n \n Our first priority is our people, our teams, and our  culture. ", "original_text": "Before I discuss the business performance, I would like to just quickly remind everyone of our company priorities. \n"}, "hash": "a654141d782f0b940d4e03a2a22e9656989ae7172caae624b0eda7abbbcb0879", "class_name": "RelatedNodeInfo"}}, "text": "Our focus and execution against our company priorities \npositions us to consistently generate strong financial results despite fluidity we continue to see in the \nmacroeconomic environment.  \n \n", "start_char_idx": 851, "end_char_idx": 1045, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "38b029e0-f8a8-49f9-9daa-a5b41daec436": {"__data__": {"id_": "38b029e0-f8a8-49f9-9daa-a5b41daec436", "embedding": null, "metadata": {"window": "Thank you, Rachel, and thank everyone for joining us on our call today.  Today, we reported third quarter fiscal \n2022 results, another quarter with double -digit adjusted operating profit growth in all four segments,  reflecting \nstrength in the fundamentals across our businesses.  Our focus and execution against our company priorities \npositions us to consistently generate strong financial results despite fluidity we continue to see in the \nmacroeconomic environment.  \n \n Before I discuss the business performance, I would like to just quickly remind everyone of our company priorities. \n We have been sharing with you our strategic transformation to a diversified healthcare services company \ncentered around a set of four enterprise  priorities.  We believe the execution against these priorities is critical to \nour ability to generate long -term sustainable growth, and we want to reiterate our focus and commitment to each \none of them.  \n \n Our first priority is our people, our teams, and our  culture. ", "original_text": "Before I discuss the business performance, I would like to just quickly remind everyone of our company priorities. \n", "page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a6099167-af59-46fd-99a8-7c7f028b5ea4", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "50237b3cc005e6e5b1d6f16cc6b7aac546814ffb83bee9ce12a76c4e7ab6cfaa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1bfa31cd-76de-470f-a02f-2547094afda2", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Exec utive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and thank everyone for joining us on our call today.  Today, we reported third quarter fiscal \n2022 results, another quarter with double -digit adjusted operating profit growth in all four segments,  reflecting \nstrength in the fundamentals across our businesses.  Our focus and execution against our company priorities \npositions us to consistently generate strong financial results despite fluidity we continue to see in the \nmacroeconomic environment.  \n \n Before I discuss the business performance, I would like to just quickly remind everyone of our company priorities. \n We have been sharing with you our strategic transformation to a diversified healthcare services company \ncentered around a set of four enterprise  priorities.  We believe the execution against these priorities is critical to \nour ability to generate long -term sustainable growth, and we want to reiterate our focus and commitment to each \none of them.  \n \n", "original_text": "Our focus and execution against our company priorities \npositions us to consistently generate strong financial results despite fluidity we continue to see in the \nmacroeconomic environment.  \n \n", "page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b2d10bba2378f962ebc051fdee4efd13c2b97dff39ec597b848628a2abb0a301", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3c942233-1832-4f63-9260-2b94d3225fa2", "node_type": "1", "metadata": {"window": "Today, we reported third quarter fiscal \n2022 results, another quarter with double -digit adjusted operating profit growth in all four segments,  reflecting \nstrength in the fundamentals across our businesses.  Our focus and execution against our company priorities \npositions us to consistently generate strong financial results despite fluidity we continue to see in the \nmacroeconomic environment.  \n \n Before I discuss the business performance, I would like to just quickly remind everyone of our company priorities. \n We have been sharing with you our strategic transformation to a diversified healthcare services company \ncentered around a set of four enterprise  priorities.  We believe the execution against these priorities is critical to \nour ability to generate long -term sustainable growth, and we want to reiterate our focus and commitment to each \none of them.  \n \n Our first priority is our people, our teams, and our  culture.  Through our diversified portfolio of assets and \noperations, we as a company touch and impact many aspects of health and the healthcare system, including \npatients. ", "original_text": "We have been sharing with you our strategic transformation to a diversified healthcare services company \ncentered around a set of four enterprise  priorities. "}, "hash": "89abd2a6ffeecac33f500901eb2ab67ca083481dfd6f30d8feb0f0fc8a5841ed", "class_name": "RelatedNodeInfo"}}, "text": "Before I discuss the business performance, I would like to just quickly remind everyone of our company priorities. \n", "start_char_idx": 1045, "end_char_idx": 1161, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3c942233-1832-4f63-9260-2b94d3225fa2": {"__data__": {"id_": "3c942233-1832-4f63-9260-2b94d3225fa2", "embedding": null, "metadata": {"window": "Today, we reported third quarter fiscal \n2022 results, another quarter with double -digit adjusted operating profit growth in all four segments,  reflecting \nstrength in the fundamentals across our businesses.  Our focus and execution against our company priorities \npositions us to consistently generate strong financial results despite fluidity we continue to see in the \nmacroeconomic environment.  \n \n Before I discuss the business performance, I would like to just quickly remind everyone of our company priorities. \n We have been sharing with you our strategic transformation to a diversified healthcare services company \ncentered around a set of four enterprise  priorities.  We believe the execution against these priorities is critical to \nour ability to generate long -term sustainable growth, and we want to reiterate our focus and commitment to each \none of them.  \n \n Our first priority is our people, our teams, and our  culture.  Through our diversified portfolio of assets and \noperations, we as a company touch and impact many aspects of health and the healthcare system, including \npatients. ", "original_text": "We have been sharing with you our strategic transformation to a diversified healthcare services company \ncentered around a set of four enterprise  priorities. ", "page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a6099167-af59-46fd-99a8-7c7f028b5ea4", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "50237b3cc005e6e5b1d6f16cc6b7aac546814ffb83bee9ce12a76c4e7ab6cfaa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "38b029e0-f8a8-49f9-9daa-a5b41daec436", "node_type": "1", "metadata": {"window": "Thank you, Rachel, and thank everyone for joining us on our call today.  Today, we reported third quarter fiscal \n2022 results, another quarter with double -digit adjusted operating profit growth in all four segments,  reflecting \nstrength in the fundamentals across our businesses.  Our focus and execution against our company priorities \npositions us to consistently generate strong financial results despite fluidity we continue to see in the \nmacroeconomic environment.  \n \n Before I discuss the business performance, I would like to just quickly remind everyone of our company priorities. \n We have been sharing with you our strategic transformation to a diversified healthcare services company \ncentered around a set of four enterprise  priorities.  We believe the execution against these priorities is critical to \nour ability to generate long -term sustainable growth, and we want to reiterate our focus and commitment to each \none of them.  \n \n Our first priority is our people, our teams, and our  culture. ", "original_text": "Before I discuss the business performance, I would like to just quickly remind everyone of our company priorities. \n", "page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "218d7d9a80d63948e02b240e611ab0d6a7c5ca9756ac4a3497285168acc8ee3e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a4b1f1d8-3012-435a-abfd-fa64cc5c9b67", "node_type": "1", "metadata": {"window": "Our focus and execution against our company priorities \npositions us to consistently generate strong financial results despite fluidity we continue to see in the \nmacroeconomic environment.  \n \n Before I discuss the business performance, I would like to just quickly remind everyone of our company priorities. \n We have been sharing with you our strategic transformation to a diversified healthcare services company \ncentered around a set of four enterprise  priorities.  We believe the execution against these priorities is critical to \nour ability to generate long -term sustainable growth, and we want to reiterate our focus and commitment to each \none of them.  \n \n Our first priority is our people, our teams, and our  culture.  Through our diversified portfolio of assets and \noperations, we as a company touch and impact many aspects of health and the healthcare system, including \npatients.  Embedded in our daily operations is our purpose, advancing health outcomes for all,  and our mission of \nbuilding an impact -driven organization. ", "original_text": "We believe the execution against these priorities is critical to \nour ability to generate long -term sustainable growth, and we want to reiterate our focus and commitment to each \none of them.  \n \n"}, "hash": "b2c17b54ae87c9b5ed1401212b725cfa9211cd408ad03c05baeb55b71a11f897", "class_name": "RelatedNodeInfo"}}, "text": "We have been sharing with you our strategic transformation to a diversified healthcare services company \ncentered around a set of four enterprise  priorities. ", "start_char_idx": 1161, "end_char_idx": 1320, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a4b1f1d8-3012-435a-abfd-fa64cc5c9b67": {"__data__": {"id_": "a4b1f1d8-3012-435a-abfd-fa64cc5c9b67", "embedding": null, "metadata": {"window": "Our focus and execution against our company priorities \npositions us to consistently generate strong financial results despite fluidity we continue to see in the \nmacroeconomic environment.  \n \n Before I discuss the business performance, I would like to just quickly remind everyone of our company priorities. \n We have been sharing with you our strategic transformation to a diversified healthcare services company \ncentered around a set of four enterprise  priorities.  We believe the execution against these priorities is critical to \nour ability to generate long -term sustainable growth, and we want to reiterate our focus and commitment to each \none of them.  \n \n Our first priority is our people, our teams, and our  culture.  Through our diversified portfolio of assets and \noperations, we as a company touch and impact many aspects of health and the healthcare system, including \npatients.  Embedded in our daily operations is our purpose, advancing health outcomes for all,  and our mission of \nbuilding an impact -driven organization. ", "original_text": "We believe the execution against these priorities is critical to \nour ability to generate long -term sustainable growth, and we want to reiterate our focus and commitment to each \none of them.  \n \n", "page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a6099167-af59-46fd-99a8-7c7f028b5ea4", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "50237b3cc005e6e5b1d6f16cc6b7aac546814ffb83bee9ce12a76c4e7ab6cfaa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3c942233-1832-4f63-9260-2b94d3225fa2", "node_type": "1", "metadata": {"window": "Today, we reported third quarter fiscal \n2022 results, another quarter with double -digit adjusted operating profit growth in all four segments,  reflecting \nstrength in the fundamentals across our businesses.  Our focus and execution against our company priorities \npositions us to consistently generate strong financial results despite fluidity we continue to see in the \nmacroeconomic environment.  \n \n Before I discuss the business performance, I would like to just quickly remind everyone of our company priorities. \n We have been sharing with you our strategic transformation to a diversified healthcare services company \ncentered around a set of four enterprise  priorities.  We believe the execution against these priorities is critical to \nour ability to generate long -term sustainable growth, and we want to reiterate our focus and commitment to each \none of them.  \n \n Our first priority is our people, our teams, and our  culture.  Through our diversified portfolio of assets and \noperations, we as a company touch and impact many aspects of health and the healthcare system, including \npatients. ", "original_text": "We have been sharing with you our strategic transformation to a diversified healthcare services company \ncentered around a set of four enterprise  priorities. ", "page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c0bba6f5e41397c59c053cdcd96164810ca81a62d7c434c5e5075d9a56a67926", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "83cb1f47-7bdb-4f60-973e-60664b9c1545", "node_type": "1", "metadata": {"window": "Before I discuss the business performance, I would like to just quickly remind everyone of our company priorities. \n We have been sharing with you our strategic transformation to a diversified healthcare services company \ncentered around a set of four enterprise  priorities.  We believe the execution against these priorities is critical to \nour ability to generate long -term sustainable growth, and we want to reiterate our focus and commitment to each \none of them.  \n \n Our first priority is our people, our teams, and our  culture.  Through our diversified portfolio of assets and \noperations, we as a company touch and impact many aspects of health and the healthcare system, including \npatients.  Embedded in our daily operations is our purpose, advancing health outcomes for all,  and our mission of \nbuilding an impact -driven organization.  We have been focused on enabling change in three areas: improving \naccess to healthcare, advancing health equity, and protecting our environment.  \n \n", "original_text": "Our first priority is our people, our teams, and our  culture. "}, "hash": "56f2e91d79f55d277588ef7d3347d7918ece491494e474bc2272121ffc4437ff", "class_name": "RelatedNodeInfo"}}, "text": "We believe the execution against these priorities is critical to \nour ability to generate long -term sustainable growth, and we want to reiterate our focus and commitment to each \none of them.  \n \n", "start_char_idx": 1320, "end_char_idx": 1517, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "83cb1f47-7bdb-4f60-973e-60664b9c1545": {"__data__": {"id_": "83cb1f47-7bdb-4f60-973e-60664b9c1545", "embedding": null, "metadata": {"window": "Before I discuss the business performance, I would like to just quickly remind everyone of our company priorities. \n We have been sharing with you our strategic transformation to a diversified healthcare services company \ncentered around a set of four enterprise  priorities.  We believe the execution against these priorities is critical to \nour ability to generate long -term sustainable growth, and we want to reiterate our focus and commitment to each \none of them.  \n \n Our first priority is our people, our teams, and our  culture.  Through our diversified portfolio of assets and \noperations, we as a company touch and impact many aspects of health and the healthcare system, including \npatients.  Embedded in our daily operations is our purpose, advancing health outcomes for all,  and our mission of \nbuilding an impact -driven organization.  We have been focused on enabling change in three areas: improving \naccess to healthcare, advancing health equity, and protecting our environment.  \n \n", "original_text": "Our first priority is our people, our teams, and our  culture. ", "page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a6099167-af59-46fd-99a8-7c7f028b5ea4", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "50237b3cc005e6e5b1d6f16cc6b7aac546814ffb83bee9ce12a76c4e7ab6cfaa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a4b1f1d8-3012-435a-abfd-fa64cc5c9b67", "node_type": "1", "metadata": {"window": "Our focus and execution against our company priorities \npositions us to consistently generate strong financial results despite fluidity we continue to see in the \nmacroeconomic environment.  \n \n Before I discuss the business performance, I would like to just quickly remind everyone of our company priorities. \n We have been sharing with you our strategic transformation to a diversified healthcare services company \ncentered around a set of four enterprise  priorities.  We believe the execution against these priorities is critical to \nour ability to generate long -term sustainable growth, and we want to reiterate our focus and commitment to each \none of them.  \n \n Our first priority is our people, our teams, and our  culture.  Through our diversified portfolio of assets and \noperations, we as a company touch and impact many aspects of health and the healthcare system, including \npatients.  Embedded in our daily operations is our purpose, advancing health outcomes for all,  and our mission of \nbuilding an impact -driven organization. ", "original_text": "We believe the execution against these priorities is critical to \nour ability to generate long -term sustainable growth, and we want to reiterate our focus and commitment to each \none of them.  \n \n", "page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b19c211ee93b527dd20094ce5d1d33e893cac2e6c67e4a475ba41bf972ae90ae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "33030885-3af4-4088-aee9-4925fefdcd7f", "node_type": "1", "metadata": {"window": "We have been sharing with you our strategic transformation to a diversified healthcare services company \ncentered around a set of four enterprise  priorities.  We believe the execution against these priorities is critical to \nour ability to generate long -term sustainable growth, and we want to reiterate our focus and commitment to each \none of them.  \n \n Our first priority is our people, our teams, and our  culture.  Through our diversified portfolio of assets and \noperations, we as a company touch and impact many aspects of health and the healthcare system, including \npatients.  Embedded in our daily operations is our purpose, advancing health outcomes for all,  and our mission of \nbuilding an impact -driven organization.  We have been focused on enabling change in three areas: improving \naccess to healthcare, advancing health equity, and protecting our environment.  \n \n In the past year, our employees came together and shared countless moments of impact, finding new ways to get \ninvolved and to contribute. ", "original_text": "Through our diversified portfolio of assets and \noperations, we as a company touch and impact many aspects of health and the healthcare system, including \npatients. "}, "hash": "9e057423ff83be9850c22245958ed9b167c89146ae94e1ac6519229682eedb67", "class_name": "RelatedNodeInfo"}}, "text": "Our first priority is our people, our teams, and our  culture. ", "start_char_idx": 1517, "end_char_idx": 1580, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "33030885-3af4-4088-aee9-4925fefdcd7f": {"__data__": {"id_": "33030885-3af4-4088-aee9-4925fefdcd7f", "embedding": null, "metadata": {"window": "We have been sharing with you our strategic transformation to a diversified healthcare services company \ncentered around a set of four enterprise  priorities.  We believe the execution against these priorities is critical to \nour ability to generate long -term sustainable growth, and we want to reiterate our focus and commitment to each \none of them.  \n \n Our first priority is our people, our teams, and our  culture.  Through our diversified portfolio of assets and \noperations, we as a company touch and impact many aspects of health and the healthcare system, including \npatients.  Embedded in our daily operations is our purpose, advancing health outcomes for all,  and our mission of \nbuilding an impact -driven organization.  We have been focused on enabling change in three areas: improving \naccess to healthcare, advancing health equity, and protecting our environment.  \n \n In the past year, our employees came together and shared countless moments of impact, finding new ways to get \ninvolved and to contribute. ", "original_text": "Through our diversified portfolio of assets and \noperations, we as a company touch and impact many aspects of health and the healthcare system, including \npatients. ", "page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a6099167-af59-46fd-99a8-7c7f028b5ea4", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "50237b3cc005e6e5b1d6f16cc6b7aac546814ffb83bee9ce12a76c4e7ab6cfaa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "83cb1f47-7bdb-4f60-973e-60664b9c1545", "node_type": "1", "metadata": {"window": "Before I discuss the business performance, I would like to just quickly remind everyone of our company priorities. \n We have been sharing with you our strategic transformation to a diversified healthcare services company \ncentered around a set of four enterprise  priorities.  We believe the execution against these priorities is critical to \nour ability to generate long -term sustainable growth, and we want to reiterate our focus and commitment to each \none of them.  \n \n Our first priority is our people, our teams, and our  culture.  Through our diversified portfolio of assets and \noperations, we as a company touch and impact many aspects of health and the healthcare system, including \npatients.  Embedded in our daily operations is our purpose, advancing health outcomes for all,  and our mission of \nbuilding an impact -driven organization.  We have been focused on enabling change in three areas: improving \naccess to healthcare, advancing health equity, and protecting our environment.  \n \n", "original_text": "Our first priority is our people, our teams, and our  culture. ", "page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41a614b73c67ab96f79aa8f13aa0f51a90728d930a6e478cac5edc9f028ca1a6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "64d5b098-dc25-4eca-8eb7-ce552eb8de8a", "node_type": "1", "metadata": {"window": "We believe the execution against these priorities is critical to \nour ability to generate long -term sustainable growth, and we want to reiterate our focus and commitment to each \none of them.  \n \n Our first priority is our people, our teams, and our  culture.  Through our diversified portfolio of assets and \noperations, we as a company touch and impact many aspects of health and the healthcare system, including \npatients.  Embedded in our daily operations is our purpose, advancing health outcomes for all,  and our mission of \nbuilding an impact -driven organization.  We have been focused on enabling change in three areas: improving \naccess to healthcare, advancing health equity, and protecting our environment.  \n \n In the past year, our employees came together and shared countless moments of impact, finding new ways to get \ninvolved and to contribute.  In 2021 alone, we completed more than 26,500 volunteer hours and supported nearly \n1,500 charities. ", "original_text": "Embedded in our daily operations is our purpose, advancing health outcomes for all,  and our mission of \nbuilding an impact -driven organization. "}, "hash": "d28ee7136720240ba1fcf612634b08374ba7ce4459ebcd141e020b22b3c10267", "class_name": "RelatedNodeInfo"}}, "text": "Through our diversified portfolio of assets and \noperations, we as a company touch and impact many aspects of health and the healthcare system, including \npatients. ", "start_char_idx": 1580, "end_char_idx": 1745, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "64d5b098-dc25-4eca-8eb7-ce552eb8de8a": {"__data__": {"id_": "64d5b098-dc25-4eca-8eb7-ce552eb8de8a", "embedding": null, "metadata": {"window": "We believe the execution against these priorities is critical to \nour ability to generate long -term sustainable growth, and we want to reiterate our focus and commitment to each \none of them.  \n \n Our first priority is our people, our teams, and our  culture.  Through our diversified portfolio of assets and \noperations, we as a company touch and impact many aspects of health and the healthcare system, including \npatients.  Embedded in our daily operations is our purpose, advancing health outcomes for all,  and our mission of \nbuilding an impact -driven organization.  We have been focused on enabling change in three areas: improving \naccess to healthcare, advancing health equity, and protecting our environment.  \n \n In the past year, our employees came together and shared countless moments of impact, finding new ways to get \ninvolved and to contribute.  In 2021 alone, we completed more than 26,500 volunteer hours and supported nearly \n1,500 charities. ", "original_text": "Embedded in our daily operations is our purpose, advancing health outcomes for all,  and our mission of \nbuilding an impact -driven organization. ", "page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a6099167-af59-46fd-99a8-7c7f028b5ea4", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "50237b3cc005e6e5b1d6f16cc6b7aac546814ffb83bee9ce12a76c4e7ab6cfaa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "33030885-3af4-4088-aee9-4925fefdcd7f", "node_type": "1", "metadata": {"window": "We have been sharing with you our strategic transformation to a diversified healthcare services company \ncentered around a set of four enterprise  priorities.  We believe the execution against these priorities is critical to \nour ability to generate long -term sustainable growth, and we want to reiterate our focus and commitment to each \none of them.  \n \n Our first priority is our people, our teams, and our  culture.  Through our diversified portfolio of assets and \noperations, we as a company touch and impact many aspects of health and the healthcare system, including \npatients.  Embedded in our daily operations is our purpose, advancing health outcomes for all,  and our mission of \nbuilding an impact -driven organization.  We have been focused on enabling change in three areas: improving \naccess to healthcare, advancing health equity, and protecting our environment.  \n \n In the past year, our employees came together and shared countless moments of impact, finding new ways to get \ninvolved and to contribute. ", "original_text": "Through our diversified portfolio of assets and \noperations, we as a company touch and impact many aspects of health and the healthcare system, including \npatients. ", "page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cdae59b2e048b339c63781206453911794a72f55725455bcdcc729f8e74478c5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2ffd2410-d9f9-4e10-9ec0-2629fd764876", "node_type": "1", "metadata": {"window": "Our first priority is our people, our teams, and our  culture.  Through our diversified portfolio of assets and \noperations, we as a company touch and impact many aspects of health and the healthcare system, including \npatients.  Embedded in our daily operations is our purpose, advancing health outcomes for all,  and our mission of \nbuilding an impact -driven organization.  We have been focused on enabling change in three areas: improving \naccess to healthcare, advancing health equity, and protecting our environment.  \n \n In the past year, our employees came together and shared countless moments of impact, finding new ways to get \ninvolved and to contribute.  In 2021 alone, we completed more than 26,500 volunteer hours and supported nearly \n1,500 charities.  I couldn't be more proud of what we've achieved so far, and I'm confi dent in our ability to build a \nbrighter future that in fact offers greater health outcomes for all.  \n \n", "original_text": "We have been focused on enabling change in three areas: improving \naccess to healthcare, advancing health equity, and protecting our environment.  \n \n"}, "hash": "3d5c27d8ed82ea12f9a7d43598ab30aa51aba0689b16c8c45529ec153d217894", "class_name": "RelatedNodeInfo"}}, "text": "Embedded in our daily operations is our purpose, advancing health outcomes for all,  and our mission of \nbuilding an impact -driven organization. ", "start_char_idx": 1745, "end_char_idx": 1891, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2ffd2410-d9f9-4e10-9ec0-2629fd764876": {"__data__": {"id_": "2ffd2410-d9f9-4e10-9ec0-2629fd764876", "embedding": null, "metadata": {"window": "Our first priority is our people, our teams, and our  culture.  Through our diversified portfolio of assets and \noperations, we as a company touch and impact many aspects of health and the healthcare system, including \npatients.  Embedded in our daily operations is our purpose, advancing health outcomes for all,  and our mission of \nbuilding an impact -driven organization.  We have been focused on enabling change in three areas: improving \naccess to healthcare, advancing health equity, and protecting our environment.  \n \n In the past year, our employees came together and shared countless moments of impact, finding new ways to get \ninvolved and to contribute.  In 2021 alone, we completed more than 26,500 volunteer hours and supported nearly \n1,500 charities.  I couldn't be more proud of what we've achieved so far, and I'm confi dent in our ability to build a \nbrighter future that in fact offers greater health outcomes for all.  \n \n", "original_text": "We have been focused on enabling change in three areas: improving \naccess to healthcare, advancing health equity, and protecting our environment.  \n \n", "page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a6099167-af59-46fd-99a8-7c7f028b5ea4", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "50237b3cc005e6e5b1d6f16cc6b7aac546814ffb83bee9ce12a76c4e7ab6cfaa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "64d5b098-dc25-4eca-8eb7-ce552eb8de8a", "node_type": "1", "metadata": {"window": "We believe the execution against these priorities is critical to \nour ability to generate long -term sustainable growth, and we want to reiterate our focus and commitment to each \none of them.  \n \n Our first priority is our people, our teams, and our  culture.  Through our diversified portfolio of assets and \noperations, we as a company touch and impact many aspects of health and the healthcare system, including \npatients.  Embedded in our daily operations is our purpose, advancing health outcomes for all,  and our mission of \nbuilding an impact -driven organization.  We have been focused on enabling change in three areas: improving \naccess to healthcare, advancing health equity, and protecting our environment.  \n \n In the past year, our employees came together and shared countless moments of impact, finding new ways to get \ninvolved and to contribute.  In 2021 alone, we completed more than 26,500 volunteer hours and supported nearly \n1,500 charities. ", "original_text": "Embedded in our daily operations is our purpose, advancing health outcomes for all,  and our mission of \nbuilding an impact -driven organization. ", "page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "75328c1e9ceee7bc6c3fda8520ad0508439429344fe0686f4fabcd9ebc8e7ee4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "456a4aeb-58f2-4fde-8d06-f4d6eda5599a", "node_type": "1", "metadata": {"window": "Through our diversified portfolio of assets and \noperations, we as a company touch and impact many aspects of health and the healthcare system, including \npatients.  Embedded in our daily operations is our purpose, advancing health outcomes for all,  and our mission of \nbuilding an impact -driven organization.  We have been focused on enabling change in three areas: improving \naccess to healthcare, advancing health equity, and protecting our environment.  \n \n In the past year, our employees came together and shared countless moments of impact, finding new ways to get \ninvolved and to contribute.  In 2021 alone, we completed more than 26,500 volunteer hours and supported nearly \n1,500 charities.  I couldn't be more proud of what we've achieved so far, and I'm confi dent in our ability to build a \nbrighter future that in fact offers greater health outcomes for all.  \n \n Part of our focus on culture is our continued improvement in diversity and inclusion. ", "original_text": "In the past year, our employees came together and shared countless moments of impact, finding new ways to get \ninvolved and to contribute. "}, "hash": "fdf819cc322453cb9cef131ed22f5f5c6d28a8063c3f2c0ab185cb0b197c5676", "class_name": "RelatedNodeInfo"}}, "text": "We have been focused on enabling change in three areas: improving \naccess to healthcare, advancing health equity, and protecting our environment.  \n \n", "start_char_idx": 1891, "end_char_idx": 2041, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "456a4aeb-58f2-4fde-8d06-f4d6eda5599a": {"__data__": {"id_": "456a4aeb-58f2-4fde-8d06-f4d6eda5599a", "embedding": null, "metadata": {"window": "Through our diversified portfolio of assets and \noperations, we as a company touch and impact many aspects of health and the healthcare system, including \npatients.  Embedded in our daily operations is our purpose, advancing health outcomes for all,  and our mission of \nbuilding an impact -driven organization.  We have been focused on enabling change in three areas: improving \naccess to healthcare, advancing health equity, and protecting our environment.  \n \n In the past year, our employees came together and shared countless moments of impact, finding new ways to get \ninvolved and to contribute.  In 2021 alone, we completed more than 26,500 volunteer hours and supported nearly \n1,500 charities.  I couldn't be more proud of what we've achieved so far, and I'm confi dent in our ability to build a \nbrighter future that in fact offers greater health outcomes for all.  \n \n Part of our focus on culture is our continued improvement in diversity and inclusion. ", "original_text": "In the past year, our employees came together and shared countless moments of impact, finding new ways to get \ninvolved and to contribute. ", "page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a6099167-af59-46fd-99a8-7c7f028b5ea4", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "50237b3cc005e6e5b1d6f16cc6b7aac546814ffb83bee9ce12a76c4e7ab6cfaa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2ffd2410-d9f9-4e10-9ec0-2629fd764876", "node_type": "1", "metadata": {"window": "Our first priority is our people, our teams, and our  culture.  Through our diversified portfolio of assets and \noperations, we as a company touch and impact many aspects of health and the healthcare system, including \npatients.  Embedded in our daily operations is our purpose, advancing health outcomes for all,  and our mission of \nbuilding an impact -driven organization.  We have been focused on enabling change in three areas: improving \naccess to healthcare, advancing health equity, and protecting our environment.  \n \n In the past year, our employees came together and shared countless moments of impact, finding new ways to get \ninvolved and to contribute.  In 2021 alone, we completed more than 26,500 volunteer hours and supported nearly \n1,500 charities.  I couldn't be more proud of what we've achieved so far, and I'm confi dent in our ability to build a \nbrighter future that in fact offers greater health outcomes for all.  \n \n", "original_text": "We have been focused on enabling change in three areas: improving \naccess to healthcare, advancing health equity, and protecting our environment.  \n \n", "page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "282d54ddd401ae9b0fa51f70c691900630d58879b7cd6458517437d20e0c1d1a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "96026bf6-6411-47a3-aaee-a1f9d6ae4af8", "node_type": "1", "metadata": {"window": "Embedded in our daily operations is our purpose, advancing health outcomes for all,  and our mission of \nbuilding an impact -driven organization.  We have been focused on enabling change in three areas: improving \naccess to healthcare, advancing health equity, and protecting our environment.  \n \n In the past year, our employees came together and shared countless moments of impact, finding new ways to get \ninvolved and to contribute.  In 2021 alone, we completed more than 26,500 volunteer hours and supported nearly \n1,500 charities.  I couldn't be more proud of what we've achieved so far, and I'm confi dent in our ability to build a \nbrighter future that in fact offers greater health outcomes for all.  \n \n Part of our focus on culture is our continued improvement in diversity and inclusion.  We put a particular focus on \nhiring, developing, and promoting what w e call a best talent strategy at McKesson. ", "original_text": "In 2021 alone, we completed more than 26,500 volunteer hours and supported nearly \n1,500 charities. "}, "hash": "fc48bad9c72f4c1997187973291bc580a797441ef948835f9625b99fbf654ef0", "class_name": "RelatedNodeInfo"}}, "text": "In the past year, our employees came together and shared countless moments of impact, finding new ways to get \ninvolved and to contribute. ", "start_char_idx": 2041, "end_char_idx": 2180, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "96026bf6-6411-47a3-aaee-a1f9d6ae4af8": {"__data__": {"id_": "96026bf6-6411-47a3-aaee-a1f9d6ae4af8", "embedding": null, "metadata": {"window": "Embedded in our daily operations is our purpose, advancing health outcomes for all,  and our mission of \nbuilding an impact -driven organization.  We have been focused on enabling change in three areas: improving \naccess to healthcare, advancing health equity, and protecting our environment.  \n \n In the past year, our employees came together and shared countless moments of impact, finding new ways to get \ninvolved and to contribute.  In 2021 alone, we completed more than 26,500 volunteer hours and supported nearly \n1,500 charities.  I couldn't be more proud of what we've achieved so far, and I'm confi dent in our ability to build a \nbrighter future that in fact offers greater health outcomes for all.  \n \n Part of our focus on culture is our continued improvement in diversity and inclusion.  We put a particular focus on \nhiring, developing, and promoting what w e call a best talent strategy at McKesson. ", "original_text": "In 2021 alone, we completed more than 26,500 volunteer hours and supported nearly \n1,500 charities. ", "page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a6099167-af59-46fd-99a8-7c7f028b5ea4", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "50237b3cc005e6e5b1d6f16cc6b7aac546814ffb83bee9ce12a76c4e7ab6cfaa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "456a4aeb-58f2-4fde-8d06-f4d6eda5599a", "node_type": "1", "metadata": {"window": "Through our diversified portfolio of assets and \noperations, we as a company touch and impact many aspects of health and the healthcare system, including \npatients.  Embedded in our daily operations is our purpose, advancing health outcomes for all,  and our mission of \nbuilding an impact -driven organization.  We have been focused on enabling change in three areas: improving \naccess to healthcare, advancing health equity, and protecting our environment.  \n \n In the past year, our employees came together and shared countless moments of impact, finding new ways to get \ninvolved and to contribute.  In 2021 alone, we completed more than 26,500 volunteer hours and supported nearly \n1,500 charities.  I couldn't be more proud of what we've achieved so far, and I'm confi dent in our ability to build a \nbrighter future that in fact offers greater health outcomes for all.  \n \n Part of our focus on culture is our continued improvement in diversity and inclusion. ", "original_text": "In the past year, our employees came together and shared countless moments of impact, finding new ways to get \ninvolved and to contribute. ", "page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "35d07bec1dedd559a38cdb2cb26f2341f7ffc7234c11910647e5667314ab2d4f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "263e5bc3-24ff-4da2-887c-6ecbe33e4cdc", "node_type": "1", "metadata": {"window": "We have been focused on enabling change in three areas: improving \naccess to healthcare, advancing health equity, and protecting our environment.  \n \n In the past year, our employees came together and shared countless moments of impact, finding new ways to get \ninvolved and to contribute.  In 2021 alone, we completed more than 26,500 volunteer hours and supported nearly \n1,500 charities.  I couldn't be more proud of what we've achieved so far, and I'm confi dent in our ability to build a \nbrighter future that in fact offers greater health outcomes for all.  \n \n Part of our focus on culture is our continued improvement in diversity and inclusion.  We put a particular focus on \nhiring, developing, and promoting what w e call a best talent strategy at McKesson.  Recently, we were recognized \nas one of the Best Places to Work for LGBTQ Equality, the ninth year in a row we've received this honor.  \n \n", "original_text": "I couldn't be more proud of what we've achieved so far, and I'm confi dent in our ability to build a \nbrighter future that in fact offers greater health outcomes for all.  \n \n"}, "hash": "8c57432583967ef52aca997bbcc6e12dc58dbde105ccfd6ab245c37de5b01b95", "class_name": "RelatedNodeInfo"}}, "text": "In 2021 alone, we completed more than 26,500 volunteer hours and supported nearly \n1,500 charities. ", "start_char_idx": 2180, "end_char_idx": 2280, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "263e5bc3-24ff-4da2-887c-6ecbe33e4cdc": {"__data__": {"id_": "263e5bc3-24ff-4da2-887c-6ecbe33e4cdc", "embedding": null, "metadata": {"window": "We have been focused on enabling change in three areas: improving \naccess to healthcare, advancing health equity, and protecting our environment.  \n \n In the past year, our employees came together and shared countless moments of impact, finding new ways to get \ninvolved and to contribute.  In 2021 alone, we completed more than 26,500 volunteer hours and supported nearly \n1,500 charities.  I couldn't be more proud of what we've achieved so far, and I'm confi dent in our ability to build a \nbrighter future that in fact offers greater health outcomes for all.  \n \n Part of our focus on culture is our continued improvement in diversity and inclusion.  We put a particular focus on \nhiring, developing, and promoting what w e call a best talent strategy at McKesson.  Recently, we were recognized \nas one of the Best Places to Work for LGBTQ Equality, the ninth year in a row we've received this honor.  \n \n", "original_text": "I couldn't be more proud of what we've achieved so far, and I'm confi dent in our ability to build a \nbrighter future that in fact offers greater health outcomes for all.  \n \n", "page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a6099167-af59-46fd-99a8-7c7f028b5ea4", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "50237b3cc005e6e5b1d6f16cc6b7aac546814ffb83bee9ce12a76c4e7ab6cfaa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "96026bf6-6411-47a3-aaee-a1f9d6ae4af8", "node_type": "1", "metadata": {"window": "Embedded in our daily operations is our purpose, advancing health outcomes for all,  and our mission of \nbuilding an impact -driven organization.  We have been focused on enabling change in three areas: improving \naccess to healthcare, advancing health equity, and protecting our environment.  \n \n In the past year, our employees came together and shared countless moments of impact, finding new ways to get \ninvolved and to contribute.  In 2021 alone, we completed more than 26,500 volunteer hours and supported nearly \n1,500 charities.  I couldn't be more proud of what we've achieved so far, and I'm confi dent in our ability to build a \nbrighter future that in fact offers greater health outcomes for all.  \n \n Part of our focus on culture is our continued improvement in diversity and inclusion.  We put a particular focus on \nhiring, developing, and promoting what w e call a best talent strategy at McKesson. ", "original_text": "In 2021 alone, we completed more than 26,500 volunteer hours and supported nearly \n1,500 charities. ", "page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffe1475a869fc4a7ed565f2a355ad31159daf50fcaa8e9bc9a241f103f79d923", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0aa3fec1-2b8f-42ef-a895-5f76bbd303a5", "node_type": "1", "metadata": {"window": "In the past year, our employees came together and shared countless moments of impact, finding new ways to get \ninvolved and to contribute.  In 2021 alone, we completed more than 26,500 volunteer hours and supported nearly \n1,500 charities.  I couldn't be more proud of what we've achieved so far, and I'm confi dent in our ability to build a \nbrighter future that in fact offers greater health outcomes for all.  \n \n Part of our focus on culture is our continued improvement in diversity and inclusion.  We put a particular focus on \nhiring, developing, and promoting what w e call a best talent strategy at McKesson.  Recently, we were recognized \nas one of the Best Places to Work for LGBTQ Equality, the ninth year in a row we've received this honor.  \n \n Our commitment to diversity and refreshment includes our board of directors. ", "original_text": "Part of our focus on culture is our continued improvement in diversity and inclusion. "}, "hash": "20be4234d497bf0cf0975b9ba96c198e40b4aaad17d730ad30c616b4cc7522d4", "class_name": "RelatedNodeInfo"}}, "text": "I couldn't be more proud of what we've achieved so far, and I'm confi dent in our ability to build a \nbrighter future that in fact offers greater health outcomes for all.  \n \n", "start_char_idx": 2280, "end_char_idx": 2455, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0aa3fec1-2b8f-42ef-a895-5f76bbd303a5": {"__data__": {"id_": "0aa3fec1-2b8f-42ef-a895-5f76bbd303a5", "embedding": null, "metadata": {"window": "In the past year, our employees came together and shared countless moments of impact, finding new ways to get \ninvolved and to contribute.  In 2021 alone, we completed more than 26,500 volunteer hours and supported nearly \n1,500 charities.  I couldn't be more proud of what we've achieved so far, and I'm confi dent in our ability to build a \nbrighter future that in fact offers greater health outcomes for all.  \n \n Part of our focus on culture is our continued improvement in diversity and inclusion.  We put a particular focus on \nhiring, developing, and promoting what w e call a best talent strategy at McKesson.  Recently, we were recognized \nas one of the Best Places to Work for LGBTQ Equality, the ninth year in a row we've received this honor.  \n \n Our commitment to diversity and refreshment includes our board of directors. ", "original_text": "Part of our focus on culture is our continued improvement in diversity and inclusion. ", "page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a6099167-af59-46fd-99a8-7c7f028b5ea4", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "50237b3cc005e6e5b1d6f16cc6b7aac546814ffb83bee9ce12a76c4e7ab6cfaa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "263e5bc3-24ff-4da2-887c-6ecbe33e4cdc", "node_type": "1", "metadata": {"window": "We have been focused on enabling change in three areas: improving \naccess to healthcare, advancing health equity, and protecting our environment.  \n \n In the past year, our employees came together and shared countless moments of impact, finding new ways to get \ninvolved and to contribute.  In 2021 alone, we completed more than 26,500 volunteer hours and supported nearly \n1,500 charities.  I couldn't be more proud of what we've achieved so far, and I'm confi dent in our ability to build a \nbrighter future that in fact offers greater health outcomes for all.  \n \n Part of our focus on culture is our continued improvement in diversity and inclusion.  We put a particular focus on \nhiring, developing, and promoting what w e call a best talent strategy at McKesson.  Recently, we were recognized \nas one of the Best Places to Work for LGBTQ Equality, the ninth year in a row we've received this honor.  \n \n", "original_text": "I couldn't be more proud of what we've achieved so far, and I'm confi dent in our ability to build a \nbrighter future that in fact offers greater health outcomes for all.  \n \n", "page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d410b6e776bfda8d74c940ea66b56cec342992c84884f98f3e1e876daa24e230", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "925e272f-b81e-4828-b250-2a18d7178728", "node_type": "1", "metadata": {"window": "In 2021 alone, we completed more than 26,500 volunteer hours and supported nearly \n1,500 charities.  I couldn't be more proud of what we've achieved so far, and I'm confi dent in our ability to build a \nbrighter future that in fact offers greater health outcomes for all.  \n \n Part of our focus on culture is our continued improvement in diversity and inclusion.  We put a particular focus on \nhiring, developing, and promoting what w e call a best talent strategy at McKesson.  Recently, we were recognized \nas one of the Best Places to Work for LGBTQ Equality, the ninth year in a row we've received this honor.  \n \n Our commitment to diversity and refreshment includes our board of directors.  In January, we welcomed James \nHinton and Kathleen Wilson -Thompson as new Independent Directors to our board of directors. ", "original_text": "We put a particular focus on \nhiring, developing, and promoting what w e call a best talent strategy at McKesson. "}, "hash": "d19af707faa20137549fccf17f5af22d1456f3e2640332b37e350b7cdf341539", "class_name": "RelatedNodeInfo"}}, "text": "Part of our focus on culture is our continued improvement in diversity and inclusion. ", "start_char_idx": 2455, "end_char_idx": 2541, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "925e272f-b81e-4828-b250-2a18d7178728": {"__data__": {"id_": "925e272f-b81e-4828-b250-2a18d7178728", "embedding": null, "metadata": {"window": "In 2021 alone, we completed more than 26,500 volunteer hours and supported nearly \n1,500 charities.  I couldn't be more proud of what we've achieved so far, and I'm confi dent in our ability to build a \nbrighter future that in fact offers greater health outcomes for all.  \n \n Part of our focus on culture is our continued improvement in diversity and inclusion.  We put a particular focus on \nhiring, developing, and promoting what w e call a best talent strategy at McKesson.  Recently, we were recognized \nas one of the Best Places to Work for LGBTQ Equality, the ninth year in a row we've received this honor.  \n \n Our commitment to diversity and refreshment includes our board of directors.  In January, we welcomed James \nHinton and Kathleen Wilson -Thompson as new Independent Directors to our board of directors. ", "original_text": "We put a particular focus on \nhiring, developing, and promoting what w e call a best talent strategy at McKesson. ", "page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a6099167-af59-46fd-99a8-7c7f028b5ea4", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "50237b3cc005e6e5b1d6f16cc6b7aac546814ffb83bee9ce12a76c4e7ab6cfaa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0aa3fec1-2b8f-42ef-a895-5f76bbd303a5", "node_type": "1", "metadata": {"window": "In the past year, our employees came together and shared countless moments of impact, finding new ways to get \ninvolved and to contribute.  In 2021 alone, we completed more than 26,500 volunteer hours and supported nearly \n1,500 charities.  I couldn't be more proud of what we've achieved so far, and I'm confi dent in our ability to build a \nbrighter future that in fact offers greater health outcomes for all.  \n \n Part of our focus on culture is our continued improvement in diversity and inclusion.  We put a particular focus on \nhiring, developing, and promoting what w e call a best talent strategy at McKesson.  Recently, we were recognized \nas one of the Best Places to Work for LGBTQ Equality, the ninth year in a row we've received this honor.  \n \n Our commitment to diversity and refreshment includes our board of directors. ", "original_text": "Part of our focus on culture is our continued improvement in diversity and inclusion. ", "page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3730abb1c296e7e387f4ad0a3effb51c6da7d0706569daade404a2bc4e60c89d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a507df3b-c3ee-44ae-8656-f067ee679fc1", "node_type": "1", "metadata": {"window": "I couldn't be more proud of what we've achieved so far, and I'm confi dent in our ability to build a \nbrighter future that in fact offers greater health outcomes for all.  \n \n Part of our focus on culture is our continued improvement in diversity and inclusion.  We put a particular focus on \nhiring, developing, and promoting what w e call a best talent strategy at McKesson.  Recently, we were recognized \nas one of the Best Places to Work for LGBTQ Equality, the ninth year in a row we've received this honor.  \n \n Our commitment to diversity and refreshment includes our board of directors.  In January, we welcomed James \nHinton and Kathleen Wilson -Thompson as new Independent Directors to our board of directors.  Both James and \nKathleen have served in multiple senior leadership roles within the healthcare industry. ", "original_text": "Recently, we were recognized \nas one of the Best Places to Work for LGBTQ Equality, the ninth year in a row we've received this honor.  \n \n"}, "hash": "121eb7c066ceb70ff26aef18dba9c1f88b347d14605ce76a2e2f09d136f64519", "class_name": "RelatedNodeInfo"}}, "text": "We put a particular focus on \nhiring, developing, and promoting what w e call a best talent strategy at McKesson. ", "start_char_idx": 2541, "end_char_idx": 2655, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a507df3b-c3ee-44ae-8656-f067ee679fc1": {"__data__": {"id_": "a507df3b-c3ee-44ae-8656-f067ee679fc1", "embedding": null, "metadata": {"window": "I couldn't be more proud of what we've achieved so far, and I'm confi dent in our ability to build a \nbrighter future that in fact offers greater health outcomes for all.  \n \n Part of our focus on culture is our continued improvement in diversity and inclusion.  We put a particular focus on \nhiring, developing, and promoting what w e call a best talent strategy at McKesson.  Recently, we were recognized \nas one of the Best Places to Work for LGBTQ Equality, the ninth year in a row we've received this honor.  \n \n Our commitment to diversity and refreshment includes our board of directors.  In January, we welcomed James \nHinton and Kathleen Wilson -Thompson as new Independent Directors to our board of directors.  Both James and \nKathleen have served in multiple senior leadership roles within the healthcare industry. ", "original_text": "Recently, we were recognized \nas one of the Best Places to Work for LGBTQ Equality, the ninth year in a row we've received this honor.  \n \n", "page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a6099167-af59-46fd-99a8-7c7f028b5ea4", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "50237b3cc005e6e5b1d6f16cc6b7aac546814ffb83bee9ce12a76c4e7ab6cfaa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "925e272f-b81e-4828-b250-2a18d7178728", "node_type": "1", "metadata": {"window": "In 2021 alone, we completed more than 26,500 volunteer hours and supported nearly \n1,500 charities.  I couldn't be more proud of what we've achieved so far, and I'm confi dent in our ability to build a \nbrighter future that in fact offers greater health outcomes for all.  \n \n Part of our focus on culture is our continued improvement in diversity and inclusion.  We put a particular focus on \nhiring, developing, and promoting what w e call a best talent strategy at McKesson.  Recently, we were recognized \nas one of the Best Places to Work for LGBTQ Equality, the ninth year in a row we've received this honor.  \n \n Our commitment to diversity and refreshment includes our board of directors.  In January, we welcomed James \nHinton and Kathleen Wilson -Thompson as new Independent Directors to our board of directors. ", "original_text": "We put a particular focus on \nhiring, developing, and promoting what w e call a best talent strategy at McKesson. ", "page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1645078064b8ebb14eb612602e9b2e31ce09a4e43d10d0b2e8ff8cdd78679214", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "50f92404-c7cd-4b9d-a7e0-dda012994e24", "node_type": "1", "metadata": {"window": "Part of our focus on culture is our continued improvement in diversity and inclusion.  We put a particular focus on \nhiring, developing, and promoting what w e call a best talent strategy at McKesson.  Recently, we were recognized \nas one of the Best Places to Work for LGBTQ Equality, the ninth year in a row we've received this honor.  \n \n Our commitment to diversity and refreshment includes our board of directors.  In January, we welcomed James \nHinton and Kathleen Wilson -Thompson as new Independent Directors to our board of directors.  Both James and \nKathleen have served in multiple senior leadership roles within the healthcare industry.  Currently, Jim serves as \nan op erating partner for the private equity firm Welsh, Carson, Anderson & Stowe, and prior to that, he held the \nrole of Chief Executive Officer at Baylor Scott & White Health. ", "original_text": "Our commitment to diversity and refreshment includes our board of directors. "}, "hash": "09a87f9252f57120a03cac87805d004027d9ac4f3c6755039f3a4adda80d1ca8", "class_name": "RelatedNodeInfo"}}, "text": "Recently, we were recognized \nas one of the Best Places to Work for LGBTQ Equality, the ninth year in a row we've received this honor.  \n \n", "start_char_idx": 2655, "end_char_idx": 2794, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "50f92404-c7cd-4b9d-a7e0-dda012994e24": {"__data__": {"id_": "50f92404-c7cd-4b9d-a7e0-dda012994e24", "embedding": null, "metadata": {"window": "Part of our focus on culture is our continued improvement in diversity and inclusion.  We put a particular focus on \nhiring, developing, and promoting what w e call a best talent strategy at McKesson.  Recently, we were recognized \nas one of the Best Places to Work for LGBTQ Equality, the ninth year in a row we've received this honor.  \n \n Our commitment to diversity and refreshment includes our board of directors.  In January, we welcomed James \nHinton and Kathleen Wilson -Thompson as new Independent Directors to our board of directors.  Both James and \nKathleen have served in multiple senior leadership roles within the healthcare industry.  Currently, Jim serves as \nan op erating partner for the private equity firm Welsh, Carson, Anderson & Stowe, and prior to that, he held the \nrole of Chief Executive Officer at Baylor Scott & White Health. ", "original_text": "Our commitment to diversity and refreshment includes our board of directors. ", "page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a6099167-af59-46fd-99a8-7c7f028b5ea4", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "50237b3cc005e6e5b1d6f16cc6b7aac546814ffb83bee9ce12a76c4e7ab6cfaa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a507df3b-c3ee-44ae-8656-f067ee679fc1", "node_type": "1", "metadata": {"window": "I couldn't be more proud of what we've achieved so far, and I'm confi dent in our ability to build a \nbrighter future that in fact offers greater health outcomes for all.  \n \n Part of our focus on culture is our continued improvement in diversity and inclusion.  We put a particular focus on \nhiring, developing, and promoting what w e call a best talent strategy at McKesson.  Recently, we were recognized \nas one of the Best Places to Work for LGBTQ Equality, the ninth year in a row we've received this honor.  \n \n Our commitment to diversity and refreshment includes our board of directors.  In January, we welcomed James \nHinton and Kathleen Wilson -Thompson as new Independent Directors to our board of directors.  Both James and \nKathleen have served in multiple senior leadership roles within the healthcare industry. ", "original_text": "Recently, we were recognized \nas one of the Best Places to Work for LGBTQ Equality, the ninth year in a row we've received this honor.  \n \n", "page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "826bb8f843d74d96e4c93700353621a1b023295790c98b0b4472e20afdfc9602", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fe016eb8-117e-4790-a5c8-0675ead5bb5b", "node_type": "1", "metadata": {"window": "We put a particular focus on \nhiring, developing, and promoting what w e call a best talent strategy at McKesson.  Recently, we were recognized \nas one of the Best Places to Work for LGBTQ Equality, the ninth year in a row we've received this honor.  \n \n Our commitment to diversity and refreshment includes our board of directors.  In January, we welcomed James \nHinton and Kathleen Wilson -Thompson as new Independent Directors to our board of directors.  Both James and \nKathleen have served in multiple senior leadership roles within the healthcare industry.  Currently, Jim serves as \nan op erating partner for the private equity firm Welsh, Carson, Anderson & Stowe, and prior to that, he held the \nrole of Chief Executive Officer at Baylor Scott & White Health.  And Kathleen most recently held the role of \nExecutive Vice President and Global Chie f Human Resource Officer at Walgreens Boots Alliance, where she led \nthe human capital strategy, including merger integration and HR transformation through digitization. ", "original_text": "In January, we welcomed James \nHinton and Kathleen Wilson -Thompson as new Independent Directors to our board of directors. "}, "hash": "d4a4cc60641a15e8efd34ebc33983f8e1149464d0e7f4375913436378640ccd0", "class_name": "RelatedNodeInfo"}}, "text": "Our commitment to diversity and refreshment includes our board of directors. ", "start_char_idx": 2794, "end_char_idx": 2871, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fe016eb8-117e-4790-a5c8-0675ead5bb5b": {"__data__": {"id_": "fe016eb8-117e-4790-a5c8-0675ead5bb5b", "embedding": null, "metadata": {"window": "We put a particular focus on \nhiring, developing, and promoting what w e call a best talent strategy at McKesson.  Recently, we were recognized \nas one of the Best Places to Work for LGBTQ Equality, the ninth year in a row we've received this honor.  \n \n Our commitment to diversity and refreshment includes our board of directors.  In January, we welcomed James \nHinton and Kathleen Wilson -Thompson as new Independent Directors to our board of directors.  Both James and \nKathleen have served in multiple senior leadership roles within the healthcare industry.  Currently, Jim serves as \nan op erating partner for the private equity firm Welsh, Carson, Anderson & Stowe, and prior to that, he held the \nrole of Chief Executive Officer at Baylor Scott & White Health.  And Kathleen most recently held the role of \nExecutive Vice President and Global Chie f Human Resource Officer at Walgreens Boots Alliance, where she led \nthe human capital strategy, including merger integration and HR transformation through digitization. ", "original_text": "In January, we welcomed James \nHinton and Kathleen Wilson -Thompson as new Independent Directors to our board of directors. ", "page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a6099167-af59-46fd-99a8-7c7f028b5ea4", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "50237b3cc005e6e5b1d6f16cc6b7aac546814ffb83bee9ce12a76c4e7ab6cfaa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "50f92404-c7cd-4b9d-a7e0-dda012994e24", "node_type": "1", "metadata": {"window": "Part of our focus on culture is our continued improvement in diversity and inclusion.  We put a particular focus on \nhiring, developing, and promoting what w e call a best talent strategy at McKesson.  Recently, we were recognized \nas one of the Best Places to Work for LGBTQ Equality, the ninth year in a row we've received this honor.  \n \n Our commitment to diversity and refreshment includes our board of directors.  In January, we welcomed James \nHinton and Kathleen Wilson -Thompson as new Independent Directors to our board of directors.  Both James and \nKathleen have served in multiple senior leadership roles within the healthcare industry.  Currently, Jim serves as \nan op erating partner for the private equity firm Welsh, Carson, Anderson & Stowe, and prior to that, he held the \nrole of Chief Executive Officer at Baylor Scott & White Health. ", "original_text": "Our commitment to diversity and refreshment includes our board of directors. ", "page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59885770706dd765a7840e41ae9b4f96246ab1b3c1ee31a192506d5b33f6ff3c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e4af05a4-2ebe-40c9-9347-be0b111e4d05", "node_type": "1", "metadata": {"window": "Recently, we were recognized \nas one of the Best Places to Work for LGBTQ Equality, the ninth year in a row we've received this honor.  \n \n Our commitment to diversity and refreshment includes our board of directors.  In January, we welcomed James \nHinton and Kathleen Wilson -Thompson as new Independent Directors to our board of directors.  Both James and \nKathleen have served in multiple senior leadership roles within the healthcare industry.  Currently, Jim serves as \nan op erating partner for the private equity firm Welsh, Carson, Anderson & Stowe, and prior to that, he held the \nrole of Chief Executive Officer at Baylor Scott & White Health.  And Kathleen most recently held the role of \nExecutive Vice President and Global Chie f Human Resource Officer at Walgreens Boots Alliance, where she led \nthe human capital strategy, including merger integration and HR transformation through digitization.  Their \ndecades of healthcare experience and proven record leading complicated organizati ons and executive leadership \nroles will be instrumental to McKesson, and we are excited to welcome them to our board.  \n \n", "original_text": "Both James and \nKathleen have served in multiple senior leadership roles within the healthcare industry. "}, "hash": "483352bbd2425f1174821576e4cbd49683eaffad51da39e15fddee5ec926492b", "class_name": "RelatedNodeInfo"}}, "text": "In January, we welcomed James \nHinton and Kathleen Wilson -Thompson as new Independent Directors to our board of directors. ", "start_char_idx": 2871, "end_char_idx": 2995, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e4af05a4-2ebe-40c9-9347-be0b111e4d05": {"__data__": {"id_": "e4af05a4-2ebe-40c9-9347-be0b111e4d05", "embedding": null, "metadata": {"window": "Recently, we were recognized \nas one of the Best Places to Work for LGBTQ Equality, the ninth year in a row we've received this honor.  \n \n Our commitment to diversity and refreshment includes our board of directors.  In January, we welcomed James \nHinton and Kathleen Wilson -Thompson as new Independent Directors to our board of directors.  Both James and \nKathleen have served in multiple senior leadership roles within the healthcare industry.  Currently, Jim serves as \nan op erating partner for the private equity firm Welsh, Carson, Anderson & Stowe, and prior to that, he held the \nrole of Chief Executive Officer at Baylor Scott & White Health.  And Kathleen most recently held the role of \nExecutive Vice President and Global Chie f Human Resource Officer at Walgreens Boots Alliance, where she led \nthe human capital strategy, including merger integration and HR transformation through digitization.  Their \ndecades of healthcare experience and proven record leading complicated organizati ons and executive leadership \nroles will be instrumental to McKesson, and we are excited to welcome them to our board.  \n \n", "original_text": "Both James and \nKathleen have served in multiple senior leadership roles within the healthcare industry. ", "page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a6099167-af59-46fd-99a8-7c7f028b5ea4", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "50237b3cc005e6e5b1d6f16cc6b7aac546814ffb83bee9ce12a76c4e7ab6cfaa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fe016eb8-117e-4790-a5c8-0675ead5bb5b", "node_type": "1", "metadata": {"window": "We put a particular focus on \nhiring, developing, and promoting what w e call a best talent strategy at McKesson.  Recently, we were recognized \nas one of the Best Places to Work for LGBTQ Equality, the ninth year in a row we've received this honor.  \n \n Our commitment to diversity and refreshment includes our board of directors.  In January, we welcomed James \nHinton and Kathleen Wilson -Thompson as new Independent Directors to our board of directors.  Both James and \nKathleen have served in multiple senior leadership roles within the healthcare industry.  Currently, Jim serves as \nan op erating partner for the private equity firm Welsh, Carson, Anderson & Stowe, and prior to that, he held the \nrole of Chief Executive Officer at Baylor Scott & White Health.  And Kathleen most recently held the role of \nExecutive Vice President and Global Chie f Human Resource Officer at Walgreens Boots Alliance, where she led \nthe human capital strategy, including merger integration and HR transformation through digitization. ", "original_text": "In January, we welcomed James \nHinton and Kathleen Wilson -Thompson as new Independent Directors to our board of directors. ", "page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "96ccfa5d27b63ab716fb23bddcf4c74b5cdb98b29c4ecad2a90fcf3bad08503c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2f8d3820-b140-4dd1-80ce-887782cf523d", "node_type": "1", "metadata": {"window": "Our commitment to diversity and refreshment includes our board of directors.  In January, we welcomed James \nHinton and Kathleen Wilson -Thompson as new Independent Directors to our board of directors.  Both James and \nKathleen have served in multiple senior leadership roles within the healthcare industry.  Currently, Jim serves as \nan op erating partner for the private equity firm Welsh, Carson, Anderson & Stowe, and prior to that, he held the \nrole of Chief Executive Officer at Baylor Scott & White Health.  And Kathleen most recently held the role of \nExecutive Vice President and Global Chie f Human Resource Officer at Walgreens Boots Alliance, where she led \nthe human capital strategy, including merger integration and HR transformation through digitization.  Their \ndecades of healthcare experience and proven record leading complicated organizati ons and executive leadership \nroles will be instrumental to McKesson, and we are excited to welcome them to our board.  \n \n Additionally, we announced today that Don Knauss has been elected as the next Independent Chairman of our \nBoard, which will go into effec t on April 1, following a planned transition led by our current Independent Chair, \nEdward Mueller. ", "original_text": "Currently, Jim serves as \nan op erating partner for the private equity firm Welsh, Carson, Anderson & Stowe, and prior to that, he held the \nrole of Chief Executive Officer at Baylor Scott & White Health. "}, "hash": "c5a4cf33ccf41f895124d06f73016b7f22b832629e672d828a4f8deddf4f3b68", "class_name": "RelatedNodeInfo"}}, "text": "Both James and \nKathleen have served in multiple senior leadership roles within the healthcare industry. ", "start_char_idx": 2995, "end_char_idx": 3100, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2f8d3820-b140-4dd1-80ce-887782cf523d": {"__data__": {"id_": "2f8d3820-b140-4dd1-80ce-887782cf523d", "embedding": null, "metadata": {"window": "Our commitment to diversity and refreshment includes our board of directors.  In January, we welcomed James \nHinton and Kathleen Wilson -Thompson as new Independent Directors to our board of directors.  Both James and \nKathleen have served in multiple senior leadership roles within the healthcare industry.  Currently, Jim serves as \nan op erating partner for the private equity firm Welsh, Carson, Anderson & Stowe, and prior to that, he held the \nrole of Chief Executive Officer at Baylor Scott & White Health.  And Kathleen most recently held the role of \nExecutive Vice President and Global Chie f Human Resource Officer at Walgreens Boots Alliance, where she led \nthe human capital strategy, including merger integration and HR transformation through digitization.  Their \ndecades of healthcare experience and proven record leading complicated organizati ons and executive leadership \nroles will be instrumental to McKesson, and we are excited to welcome them to our board.  \n \n Additionally, we announced today that Don Knauss has been elected as the next Independent Chairman of our \nBoard, which will go into effec t on April 1, following a planned transition led by our current Independent Chair, \nEdward Mueller. ", "original_text": "Currently, Jim serves as \nan op erating partner for the private equity firm Welsh, Carson, Anderson & Stowe, and prior to that, he held the \nrole of Chief Executive Officer at Baylor Scott & White Health. ", "page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a6099167-af59-46fd-99a8-7c7f028b5ea4", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "50237b3cc005e6e5b1d6f16cc6b7aac546814ffb83bee9ce12a76c4e7ab6cfaa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e4af05a4-2ebe-40c9-9347-be0b111e4d05", "node_type": "1", "metadata": {"window": "Recently, we were recognized \nas one of the Best Places to Work for LGBTQ Equality, the ninth year in a row we've received this honor.  \n \n Our commitment to diversity and refreshment includes our board of directors.  In January, we welcomed James \nHinton and Kathleen Wilson -Thompson as new Independent Directors to our board of directors.  Both James and \nKathleen have served in multiple senior leadership roles within the healthcare industry.  Currently, Jim serves as \nan op erating partner for the private equity firm Welsh, Carson, Anderson & Stowe, and prior to that, he held the \nrole of Chief Executive Officer at Baylor Scott & White Health.  And Kathleen most recently held the role of \nExecutive Vice President and Global Chie f Human Resource Officer at Walgreens Boots Alliance, where she led \nthe human capital strategy, including merger integration and HR transformation through digitization.  Their \ndecades of healthcare experience and proven record leading complicated organizati ons and executive leadership \nroles will be instrumental to McKesson, and we are excited to welcome them to our board.  \n \n", "original_text": "Both James and \nKathleen have served in multiple senior leadership roles within the healthcare industry. ", "page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bd9c2943583a6c7d899bd61b0c07b757c73424f25ec9da94c137dc89a15ab8eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ff268f41-851f-446e-a78b-9a089011dbd6", "node_type": "1", "metadata": {"window": "In January, we welcomed James \nHinton and Kathleen Wilson -Thompson as new Independent Directors to our board of directors.  Both James and \nKathleen have served in multiple senior leadership roles within the healthcare industry.  Currently, Jim serves as \nan op erating partner for the private equity firm Welsh, Carson, Anderson & Stowe, and prior to that, he held the \nrole of Chief Executive Officer at Baylor Scott & White Health.  And Kathleen most recently held the role of \nExecutive Vice President and Global Chie f Human Resource Officer at Walgreens Boots Alliance, where she led \nthe human capital strategy, including merger integration and HR transformation through digitization.  Their \ndecades of healthcare experience and proven record leading complicated organizati ons and executive leadership \nroles will be instrumental to McKesson, and we are excited to welcome them to our board.  \n \n Additionally, we announced today that Don Knauss has been elected as the next Independent Chairman of our \nBoard, which will go into effec t on April 1, following a planned transition led by our current Independent Chair, \nEdward Mueller.  I want to thank Ed for his years of steady leadership and invaluable contributions as the \nIndependent Chair to McKesson's board of directors. ", "original_text": "And Kathleen most recently held the role of \nExecutive Vice President and Global Chie f Human Resource Officer at Walgreens Boots Alliance, where she led \nthe human capital strategy, including merger integration and HR transformation through digitization. "}, "hash": "c075097d7a97aca21ad32c8dab630360cb87df4e300fb721f960338e39eae05b", "class_name": "RelatedNodeInfo"}}, "text": "Currently, Jim serves as \nan op erating partner for the private equity firm Welsh, Carson, Anderson & Stowe, and prior to that, he held the \nrole of Chief Executive Officer at Baylor Scott & White Health. ", "start_char_idx": 3100, "end_char_idx": 3305, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ff268f41-851f-446e-a78b-9a089011dbd6": {"__data__": {"id_": "ff268f41-851f-446e-a78b-9a089011dbd6", "embedding": null, "metadata": {"window": "In January, we welcomed James \nHinton and Kathleen Wilson -Thompson as new Independent Directors to our board of directors.  Both James and \nKathleen have served in multiple senior leadership roles within the healthcare industry.  Currently, Jim serves as \nan op erating partner for the private equity firm Welsh, Carson, Anderson & Stowe, and prior to that, he held the \nrole of Chief Executive Officer at Baylor Scott & White Health.  And Kathleen most recently held the role of \nExecutive Vice President and Global Chie f Human Resource Officer at Walgreens Boots Alliance, where she led \nthe human capital strategy, including merger integration and HR transformation through digitization.  Their \ndecades of healthcare experience and proven record leading complicated organizati ons and executive leadership \nroles will be instrumental to McKesson, and we are excited to welcome them to our board.  \n \n Additionally, we announced today that Don Knauss has been elected as the next Independent Chairman of our \nBoard, which will go into effec t on April 1, following a planned transition led by our current Independent Chair, \nEdward Mueller.  I want to thank Ed for his years of steady leadership and invaluable contributions as the \nIndependent Chair to McKesson's board of directors. ", "original_text": "And Kathleen most recently held the role of \nExecutive Vice President and Global Chie f Human Resource Officer at Walgreens Boots Alliance, where she led \nthe human capital strategy, including merger integration and HR transformation through digitization. ", "page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a6099167-af59-46fd-99a8-7c7f028b5ea4", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "50237b3cc005e6e5b1d6f16cc6b7aac546814ffb83bee9ce12a76c4e7ab6cfaa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2f8d3820-b140-4dd1-80ce-887782cf523d", "node_type": "1", "metadata": {"window": "Our commitment to diversity and refreshment includes our board of directors.  In January, we welcomed James \nHinton and Kathleen Wilson -Thompson as new Independent Directors to our board of directors.  Both James and \nKathleen have served in multiple senior leadership roles within the healthcare industry.  Currently, Jim serves as \nan op erating partner for the private equity firm Welsh, Carson, Anderson & Stowe, and prior to that, he held the \nrole of Chief Executive Officer at Baylor Scott & White Health.  And Kathleen most recently held the role of \nExecutive Vice President and Global Chie f Human Resource Officer at Walgreens Boots Alliance, where she led \nthe human capital strategy, including merger integration and HR transformation through digitization.  Their \ndecades of healthcare experience and proven record leading complicated organizati ons and executive leadership \nroles will be instrumental to McKesson, and we are excited to welcome them to our board.  \n \n Additionally, we announced today that Don Knauss has been elected as the next Independent Chairman of our \nBoard, which will go into effec t on April 1, following a planned transition led by our current Independent Chair, \nEdward Mueller. ", "original_text": "Currently, Jim serves as \nan op erating partner for the private equity firm Welsh, Carson, Anderson & Stowe, and prior to that, he held the \nrole of Chief Executive Officer at Baylor Scott & White Health. ", "page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4bb9e49c3e4140d9dd67f9633ff1dc2e671bdb8b7966cfcc26a33f6db1d7beb4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6d3708eb-fd30-439b-aadc-aad7ffebcc27", "node_type": "1", "metadata": {"window": "Both James and \nKathleen have served in multiple senior leadership roles within the healthcare industry.  Currently, Jim serves as \nan op erating partner for the private equity firm Welsh, Carson, Anderson & Stowe, and prior to that, he held the \nrole of Chief Executive Officer at Baylor Scott & White Health.  And Kathleen most recently held the role of \nExecutive Vice President and Global Chie f Human Resource Officer at Walgreens Boots Alliance, where she led \nthe human capital strategy, including merger integration and HR transformation through digitization.  Their \ndecades of healthcare experience and proven record leading complicated organizati ons and executive leadership \nroles will be instrumental to McKesson, and we are excited to welcome them to our board.  \n \n Additionally, we announced today that Don Knauss has been elected as the next Independent Chairman of our \nBoard, which will go into effec t on April 1, following a planned transition led by our current Independent Chair, \nEdward Mueller.  I want to thank Ed for his years of steady leadership and invaluable contributions as the \nIndependent Chair to McKesson's board of directors.  And I also want  to welcome Don to his new role. ", "original_text": "Their \ndecades of healthcare experience and proven record leading complicated organizati ons and executive leadership \nroles will be instrumental to McKesson, and we are excited to welcome them to our board.  \n \n"}, "hash": "5a37bf1513a949b492b5bd6d296cbdd461e1433c3b3b5f7d97001e8bcbbabdfb", "class_name": "RelatedNodeInfo"}}, "text": "And Kathleen most recently held the role of \nExecutive Vice President and Global Chie f Human Resource Officer at Walgreens Boots Alliance, where she led \nthe human capital strategy, including merger integration and HR transformation through digitization. ", "start_char_idx": 3305, "end_char_idx": 3561, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6d3708eb-fd30-439b-aadc-aad7ffebcc27": {"__data__": {"id_": "6d3708eb-fd30-439b-aadc-aad7ffebcc27", "embedding": null, "metadata": {"window": "Both James and \nKathleen have served in multiple senior leadership roles within the healthcare industry.  Currently, Jim serves as \nan op erating partner for the private equity firm Welsh, Carson, Anderson & Stowe, and prior to that, he held the \nrole of Chief Executive Officer at Baylor Scott & White Health.  And Kathleen most recently held the role of \nExecutive Vice President and Global Chie f Human Resource Officer at Walgreens Boots Alliance, where she led \nthe human capital strategy, including merger integration and HR transformation through digitization.  Their \ndecades of healthcare experience and proven record leading complicated organizati ons and executive leadership \nroles will be instrumental to McKesson, and we are excited to welcome them to our board.  \n \n Additionally, we announced today that Don Knauss has been elected as the next Independent Chairman of our \nBoard, which will go into effec t on April 1, following a planned transition led by our current Independent Chair, \nEdward Mueller.  I want to thank Ed for his years of steady leadership and invaluable contributions as the \nIndependent Chair to McKesson's board of directors.  And I also want  to welcome Don to his new role. ", "original_text": "Their \ndecades of healthcare experience and proven record leading complicated organizati ons and executive leadership \nroles will be instrumental to McKesson, and we are excited to welcome them to our board.  \n \n", "page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a6099167-af59-46fd-99a8-7c7f028b5ea4", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "50237b3cc005e6e5b1d6f16cc6b7aac546814ffb83bee9ce12a76c4e7ab6cfaa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ff268f41-851f-446e-a78b-9a089011dbd6", "node_type": "1", "metadata": {"window": "In January, we welcomed James \nHinton and Kathleen Wilson -Thompson as new Independent Directors to our board of directors.  Both James and \nKathleen have served in multiple senior leadership roles within the healthcare industry.  Currently, Jim serves as \nan op erating partner for the private equity firm Welsh, Carson, Anderson & Stowe, and prior to that, he held the \nrole of Chief Executive Officer at Baylor Scott & White Health.  And Kathleen most recently held the role of \nExecutive Vice President and Global Chie f Human Resource Officer at Walgreens Boots Alliance, where she led \nthe human capital strategy, including merger integration and HR transformation through digitization.  Their \ndecades of healthcare experience and proven record leading complicated organizati ons and executive leadership \nroles will be instrumental to McKesson, and we are excited to welcome them to our board.  \n \n Additionally, we announced today that Don Knauss has been elected as the next Independent Chairman of our \nBoard, which will go into effec t on April 1, following a planned transition led by our current Independent Chair, \nEdward Mueller.  I want to thank Ed for his years of steady leadership and invaluable contributions as the \nIndependent Chair to McKesson's board of directors. ", "original_text": "And Kathleen most recently held the role of \nExecutive Vice President and Global Chie f Human Resource Officer at Walgreens Boots Alliance, where she led \nthe human capital strategy, including merger integration and HR transformation through digitization. ", "page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0a41b5516756c31eda01c837377320f19f769eadfd62e850bfc61d6453ab13c5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b3d7bb83-db8a-4f02-b12d-cadb20610ec5", "node_type": "1", "metadata": {"window": "Currently, Jim serves as \nan op erating partner for the private equity firm Welsh, Carson, Anderson & Stowe, and prior to that, he held the \nrole of Chief Executive Officer at Baylor Scott & White Health.  And Kathleen most recently held the role of \nExecutive Vice President and Global Chie f Human Resource Officer at Walgreens Boots Alliance, where she led \nthe human capital strategy, including merger integration and HR transformation through digitization.  Their \ndecades of healthcare experience and proven record leading complicated organizati ons and executive leadership \nroles will be instrumental to McKesson, and we are excited to welcome them to our board.  \n \n Additionally, we announced today that Don Knauss has been elected as the next Independent Chairman of our \nBoard, which will go into effec t on April 1, following a planned transition led by our current Independent Chair, \nEdward Mueller.  I want to thank Ed for his years of steady leadership and invaluable contributions as the \nIndependent Chair to McKesson's board of directors.  And I also want  to welcome Don to his new role.  He brings \ndeep leadership expertise and shares McKesson's values, culture, strategy and vision, including his commitment \nto board diversity. ", "original_text": "Additionally, we announced today that Don Knauss has been elected as the next Independent Chairman of our \nBoard, which will go into effec t on April 1, following a planned transition led by our current Independent Chair, \nEdward Mueller. "}, "hash": "e5f3dd2455add9d684be0d1cfa8c86f314d9f461ac87657cdfe7ed896b45e2fd", "class_name": "RelatedNodeInfo"}}, "text": "Their \ndecades of healthcare experience and proven record leading complicated organizati ons and executive leadership \nroles will be instrumental to McKesson, and we are excited to welcome them to our board.  \n \n", "start_char_idx": 3561, "end_char_idx": 3773, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b3d7bb83-db8a-4f02-b12d-cadb20610ec5": {"__data__": {"id_": "b3d7bb83-db8a-4f02-b12d-cadb20610ec5", "embedding": null, "metadata": {"window": "Currently, Jim serves as \nan op erating partner for the private equity firm Welsh, Carson, Anderson & Stowe, and prior to that, he held the \nrole of Chief Executive Officer at Baylor Scott & White Health.  And Kathleen most recently held the role of \nExecutive Vice President and Global Chie f Human Resource Officer at Walgreens Boots Alliance, where she led \nthe human capital strategy, including merger integration and HR transformation through digitization.  Their \ndecades of healthcare experience and proven record leading complicated organizati ons and executive leadership \nroles will be instrumental to McKesson, and we are excited to welcome them to our board.  \n \n Additionally, we announced today that Don Knauss has been elected as the next Independent Chairman of our \nBoard, which will go into effec t on April 1, following a planned transition led by our current Independent Chair, \nEdward Mueller.  I want to thank Ed for his years of steady leadership and invaluable contributions as the \nIndependent Chair to McKesson's board of directors.  And I also want  to welcome Don to his new role.  He brings \ndeep leadership expertise and shares McKesson's values, culture, strategy and vision, including his commitment \nto board diversity. ", "original_text": "Additionally, we announced today that Don Knauss has been elected as the next Independent Chairman of our \nBoard, which will go into effec t on April 1, following a planned transition led by our current Independent Chair, \nEdward Mueller. ", "page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a6099167-af59-46fd-99a8-7c7f028b5ea4", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "50237b3cc005e6e5b1d6f16cc6b7aac546814ffb83bee9ce12a76c4e7ab6cfaa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6d3708eb-fd30-439b-aadc-aad7ffebcc27", "node_type": "1", "metadata": {"window": "Both James and \nKathleen have served in multiple senior leadership roles within the healthcare industry.  Currently, Jim serves as \nan op erating partner for the private equity firm Welsh, Carson, Anderson & Stowe, and prior to that, he held the \nrole of Chief Executive Officer at Baylor Scott & White Health.  And Kathleen most recently held the role of \nExecutive Vice President and Global Chie f Human Resource Officer at Walgreens Boots Alliance, where she led \nthe human capital strategy, including merger integration and HR transformation through digitization.  Their \ndecades of healthcare experience and proven record leading complicated organizati ons and executive leadership \nroles will be instrumental to McKesson, and we are excited to welcome them to our board.  \n \n Additionally, we announced today that Don Knauss has been elected as the next Independent Chairman of our \nBoard, which will go into effec t on April 1, following a planned transition led by our current Independent Chair, \nEdward Mueller.  I want to thank Ed for his years of steady leadership and invaluable contributions as the \nIndependent Chair to McKesson's board of directors.  And I also want  to welcome Don to his new role. ", "original_text": "Their \ndecades of healthcare experience and proven record leading complicated organizati ons and executive leadership \nroles will be instrumental to McKesson, and we are excited to welcome them to our board.  \n \n", "page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "69e377ebe649f4af5db0b94a8815299332868a1873c1246119a09a909644d4bb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3db867be-77b5-40e2-acc5-bc752bc7b778", "node_type": "1", "metadata": {"window": "And Kathleen most recently held the role of \nExecutive Vice President and Global Chie f Human Resource Officer at Walgreens Boots Alliance, where she led \nthe human capital strategy, including merger integration and HR transformation through digitization.  Their \ndecades of healthcare experience and proven record leading complicated organizati ons and executive leadership \nroles will be instrumental to McKesson, and we are excited to welcome them to our board.  \n \n Additionally, we announced today that Don Knauss has been elected as the next Independent Chairman of our \nBoard, which will go into effec t on April 1, following a planned transition led by our current Independent Chair, \nEdward Mueller.  I want to thank Ed for his years of steady leadership and invaluable contributions as the \nIndependent Chair to McKesson's board of directors.  And I also want  to welcome Don to his new role.  He brings \ndeep leadership expertise and shares McKesson's values, culture, strategy and vision, including his commitment \nto board diversity.  We look forward to his leadership and stewardship.  ", "original_text": "I want to thank Ed for his years of steady leadership and invaluable contributions as the \nIndependent Chair to McKesson's board of directors. "}, "hash": "f3fe7eb1433361a142371bbe9cf357765753fe2daebab56e96d576912701dc5d", "class_name": "RelatedNodeInfo"}}, "text": "Additionally, we announced today that Don Knauss has been elected as the next Independent Chairman of our \nBoard, which will go into effec t on April 1, following a planned transition led by our current Independent Chair, \nEdward Mueller. ", "start_char_idx": 3773, "end_char_idx": 4012, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3db867be-77b5-40e2-acc5-bc752bc7b778": {"__data__": {"id_": "3db867be-77b5-40e2-acc5-bc752bc7b778", "embedding": null, "metadata": {"window": "And Kathleen most recently held the role of \nExecutive Vice President and Global Chie f Human Resource Officer at Walgreens Boots Alliance, where she led \nthe human capital strategy, including merger integration and HR transformation through digitization.  Their \ndecades of healthcare experience and proven record leading complicated organizati ons and executive leadership \nroles will be instrumental to McKesson, and we are excited to welcome them to our board.  \n \n Additionally, we announced today that Don Knauss has been elected as the next Independent Chairman of our \nBoard, which will go into effec t on April 1, following a planned transition led by our current Independent Chair, \nEdward Mueller.  I want to thank Ed for his years of steady leadership and invaluable contributions as the \nIndependent Chair to McKesson's board of directors.  And I also want  to welcome Don to his new role.  He brings \ndeep leadership expertise and shares McKesson's values, culture, strategy and vision, including his commitment \nto board diversity.  We look forward to his leadership and stewardship.  ", "original_text": "I want to thank Ed for his years of steady leadership and invaluable contributions as the \nIndependent Chair to McKesson's board of directors. ", "page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a6099167-af59-46fd-99a8-7c7f028b5ea4", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "50237b3cc005e6e5b1d6f16cc6b7aac546814ffb83bee9ce12a76c4e7ab6cfaa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b3d7bb83-db8a-4f02-b12d-cadb20610ec5", "node_type": "1", "metadata": {"window": "Currently, Jim serves as \nan op erating partner for the private equity firm Welsh, Carson, Anderson & Stowe, and prior to that, he held the \nrole of Chief Executive Officer at Baylor Scott & White Health.  And Kathleen most recently held the role of \nExecutive Vice President and Global Chie f Human Resource Officer at Walgreens Boots Alliance, where she led \nthe human capital strategy, including merger integration and HR transformation through digitization.  Their \ndecades of healthcare experience and proven record leading complicated organizati ons and executive leadership \nroles will be instrumental to McKesson, and we are excited to welcome them to our board.  \n \n Additionally, we announced today that Don Knauss has been elected as the next Independent Chairman of our \nBoard, which will go into effec t on April 1, following a planned transition led by our current Independent Chair, \nEdward Mueller.  I want to thank Ed for his years of steady leadership and invaluable contributions as the \nIndependent Chair to McKesson's board of directors.  And I also want  to welcome Don to his new role.  He brings \ndeep leadership expertise and shares McKesson's values, culture, strategy and vision, including his commitment \nto board diversity. ", "original_text": "Additionally, we announced today that Don Knauss has been elected as the next Independent Chairman of our \nBoard, which will go into effec t on April 1, following a planned transition led by our current Independent Chair, \nEdward Mueller. ", "page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0390671af07ba18f51d31b95abc5034cce7ac851d2e39dee9a4a16376fda67d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "81452c94-929d-4c31-b60a-339efd74d994", "node_type": "1", "metadata": {"window": "Their \ndecades of healthcare experience and proven record leading complicated organizati ons and executive leadership \nroles will be instrumental to McKesson, and we are excited to welcome them to our board.  \n \n Additionally, we announced today that Don Knauss has been elected as the next Independent Chairman of our \nBoard, which will go into effec t on April 1, following a planned transition led by our current Independent Chair, \nEdward Mueller.  I want to thank Ed for his years of steady leadership and invaluable contributions as the \nIndependent Chair to McKesson's board of directors.  And I also want  to welcome Don to his new role.  He brings \ndeep leadership expertise and shares McKesson's values, culture, strategy and vision, including his commitment \nto board diversity.  We look forward to his leadership and stewardship.  ", "original_text": "And I also want  to welcome Don to his new role. "}, "hash": "ef5bb48a0b4d101b60daa9956349bbb0fdfc89ba7eb795174f2284b42f2f7383", "class_name": "RelatedNodeInfo"}}, "text": "I want to thank Ed for his years of steady leadership and invaluable contributions as the \nIndependent Chair to McKesson's board of directors. ", "start_char_idx": 4012, "end_char_idx": 4155, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "81452c94-929d-4c31-b60a-339efd74d994": {"__data__": {"id_": "81452c94-929d-4c31-b60a-339efd74d994", "embedding": null, "metadata": {"window": "Their \ndecades of healthcare experience and proven record leading complicated organizati ons and executive leadership \nroles will be instrumental to McKesson, and we are excited to welcome them to our board.  \n \n Additionally, we announced today that Don Knauss has been elected as the next Independent Chairman of our \nBoard, which will go into effec t on April 1, following a planned transition led by our current Independent Chair, \nEdward Mueller.  I want to thank Ed for his years of steady leadership and invaluable contributions as the \nIndependent Chair to McKesson's board of directors.  And I also want  to welcome Don to his new role.  He brings \ndeep leadership expertise and shares McKesson's values, culture, strategy and vision, including his commitment \nto board diversity.  We look forward to his leadership and stewardship.  ", "original_text": "And I also want  to welcome Don to his new role. ", "page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a6099167-af59-46fd-99a8-7c7f028b5ea4", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "50237b3cc005e6e5b1d6f16cc6b7aac546814ffb83bee9ce12a76c4e7ab6cfaa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3db867be-77b5-40e2-acc5-bc752bc7b778", "node_type": "1", "metadata": {"window": "And Kathleen most recently held the role of \nExecutive Vice President and Global Chie f Human Resource Officer at Walgreens Boots Alliance, where she led \nthe human capital strategy, including merger integration and HR transformation through digitization.  Their \ndecades of healthcare experience and proven record leading complicated organizati ons and executive leadership \nroles will be instrumental to McKesson, and we are excited to welcome them to our board.  \n \n Additionally, we announced today that Don Knauss has been elected as the next Independent Chairman of our \nBoard, which will go into effec t on April 1, following a planned transition led by our current Independent Chair, \nEdward Mueller.  I want to thank Ed for his years of steady leadership and invaluable contributions as the \nIndependent Chair to McKesson's board of directors.  And I also want  to welcome Don to his new role.  He brings \ndeep leadership expertise and shares McKesson's values, culture, strategy and vision, including his commitment \nto board diversity.  We look forward to his leadership and stewardship.  ", "original_text": "I want to thank Ed for his years of steady leadership and invaluable contributions as the \nIndependent Chair to McKesson's board of directors. ", "page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8dcd9da12ec1ec49f9ae41ec4241e7769c19559d4e413a31acaf9a1a66fb8819", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f37ea09-571e-466b-99ad-a20692bf7bd5", "node_type": "1", "metadata": {"window": "Additionally, we announced today that Don Knauss has been elected as the next Independent Chairman of our \nBoard, which will go into effec t on April 1, following a planned transition led by our current Independent Chair, \nEdward Mueller.  I want to thank Ed for his years of steady leadership and invaluable contributions as the \nIndependent Chair to McKesson's board of directors.  And I also want  to welcome Don to his new role.  He brings \ndeep leadership expertise and shares McKesson's values, culture, strategy and vision, including his commitment \nto board diversity.  We look forward to his leadership and stewardship.  ", "original_text": "He brings \ndeep leadership expertise and shares McKesson's values, culture, strategy and vision, including his commitment \nto board diversity. "}, "hash": "3e219a42ade486c7f2e03ba45a1eee98e49f164c529229a18f6fdb655a0185bc", "class_name": "RelatedNodeInfo"}}, "text": "And I also want  to welcome Don to his new role. ", "start_char_idx": 4155, "end_char_idx": 4204, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f37ea09-571e-466b-99ad-a20692bf7bd5": {"__data__": {"id_": "0f37ea09-571e-466b-99ad-a20692bf7bd5", "embedding": null, "metadata": {"window": "Additionally, we announced today that Don Knauss has been elected as the next Independent Chairman of our \nBoard, which will go into effec t on April 1, following a planned transition led by our current Independent Chair, \nEdward Mueller.  I want to thank Ed for his years of steady leadership and invaluable contributions as the \nIndependent Chair to McKesson's board of directors.  And I also want  to welcome Don to his new role.  He brings \ndeep leadership expertise and shares McKesson's values, culture, strategy and vision, including his commitment \nto board diversity.  We look forward to his leadership and stewardship.  ", "original_text": "He brings \ndeep leadership expertise and shares McKesson's values, culture, strategy and vision, including his commitment \nto board diversity. ", "page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a6099167-af59-46fd-99a8-7c7f028b5ea4", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "50237b3cc005e6e5b1d6f16cc6b7aac546814ffb83bee9ce12a76c4e7ab6cfaa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "81452c94-929d-4c31-b60a-339efd74d994", "node_type": "1", "metadata": {"window": "Their \ndecades of healthcare experience and proven record leading complicated organizati ons and executive leadership \nroles will be instrumental to McKesson, and we are excited to welcome them to our board.  \n \n Additionally, we announced today that Don Knauss has been elected as the next Independent Chairman of our \nBoard, which will go into effec t on April 1, following a planned transition led by our current Independent Chair, \nEdward Mueller.  I want to thank Ed for his years of steady leadership and invaluable contributions as the \nIndependent Chair to McKesson's board of directors.  And I also want  to welcome Don to his new role.  He brings \ndeep leadership expertise and shares McKesson's values, culture, strategy and vision, including his commitment \nto board diversity.  We look forward to his leadership and stewardship.  ", "original_text": "And I also want  to welcome Don to his new role. ", "page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d1434459a4a403f9c042fa31357b918823e7a88644d03a0a685874f08b4b826", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d4de066d-8ee4-46c7-bea0-6b7640867e61", "node_type": "1", "metadata": {"window": "I want to thank Ed for his years of steady leadership and invaluable contributions as the \nIndependent Chair to McKesson's board of directors.  And I also want  to welcome Don to his new role.  He brings \ndeep leadership expertise and shares McKesson's values, culture, strategy and vision, including his commitment \nto board diversity.  We look forward to his leadership and stewardship.  ", "original_text": "We look forward to his leadership and stewardship.  "}, "hash": "f0b7b874f56884013d690203f13f94b7d754e7ef8c4f2d2908e9f9fd066d8ad2", "class_name": "RelatedNodeInfo"}}, "text": "He brings \ndeep leadership expertise and shares McKesson's values, culture, strategy and vision, including his commitment \nto board diversity. ", "start_char_idx": 4204, "end_char_idx": 4347, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d4de066d-8ee4-46c7-bea0-6b7640867e61": {"__data__": {"id_": "d4de066d-8ee4-46c7-bea0-6b7640867e61", "embedding": null, "metadata": {"window": "I want to thank Ed for his years of steady leadership and invaluable contributions as the \nIndependent Chair to McKesson's board of directors.  And I also want  to welcome Don to his new role.  He brings \ndeep leadership expertise and shares McKesson's values, culture, strategy and vision, including his commitment \nto board diversity.  We look forward to his leadership and stewardship.  ", "original_text": "We look forward to his leadership and stewardship.  ", "page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a6099167-af59-46fd-99a8-7c7f028b5ea4", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "50237b3cc005e6e5b1d6f16cc6b7aac546814ffb83bee9ce12a76c4e7ab6cfaa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f37ea09-571e-466b-99ad-a20692bf7bd5", "node_type": "1", "metadata": {"window": "Additionally, we announced today that Don Knauss has been elected as the next Independent Chairman of our \nBoard, which will go into effec t on April 1, following a planned transition led by our current Independent Chair, \nEdward Mueller.  I want to thank Ed for his years of steady leadership and invaluable contributions as the \nIndependent Chair to McKesson's board of directors.  And I also want  to welcome Don to his new role.  He brings \ndeep leadership expertise and shares McKesson's values, culture, strategy and vision, including his commitment \nto board diversity.  We look forward to his leadership and stewardship.  ", "original_text": "He brings \ndeep leadership expertise and shares McKesson's values, culture, strategy and vision, including his commitment \nto board diversity. ", "page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "046acde4b75185575f87c6a9dc53623a653dd97fbed102051dcf9c44747925b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c067af5d-352c-4e48-8fff-bbb9598dfd19", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nOur next priority is to drive sustainable growth in our core pharmaceutical and medical distribution businesses. \n We have a vast skilled distribution network and deep expertise in global supply chain management, which have \nbeen a critical and foundational part of our long history.  We're  proud of our operational excellence and our ability \nto capture efficiency and deliver consistent and high quality service to our customers while optimizing operating \nmargin.  \n \n", "original_text": "McKesson Corp.  "}, "hash": "5fe0beecd3326904368fdade0a804caef870dfbfd51d2707d42c04df96cb588f", "class_name": "RelatedNodeInfo"}}, "text": "We look forward to his leadership and stewardship.  ", "start_char_idx": 4347, "end_char_idx": 4399, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c067af5d-352c-4e48-8fff-bbb9598dfd19": {"__data__": {"id_": "c067af5d-352c-4e48-8fff-bbb9598dfd19", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nOur next priority is to drive sustainable growth in our core pharmaceutical and medical distribution businesses. \n We have a vast skilled distribution network and deep expertise in global supply chain management, which have \nbeen a critical and foundational part of our long history.  We're  proud of our operational excellence and our ability \nto capture efficiency and deliver consistent and high quality service to our customers while optimizing operating \nmargin.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2657d877-6c2d-4cd2-9c56-265576a1cdee", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c29fa0957bcae0733c3a2c21697f2b2b71094219a4937c934c306563a44c36e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d4de066d-8ee4-46c7-bea0-6b7640867e61", "node_type": "1", "metadata": {"window": "I want to thank Ed for his years of steady leadership and invaluable contributions as the \nIndependent Chair to McKesson's board of directors.  And I also want  to welcome Don to his new role.  He brings \ndeep leadership expertise and shares McKesson's values, culture, strategy and vision, including his commitment \nto board diversity.  We look forward to his leadership and stewardship.  ", "original_text": "We look forward to his leadership and stewardship.  ", "page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2533934650478c348ff08c46c373fdf0b0bc8f6ae362153bb1ffc617e8480205", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "55be5aff-45a9-4209-bb0b-fe7e56a5cf31", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nOur next priority is to drive sustainable growth in our core pharmaceutical and medical distribution businesses. \n We have a vast skilled distribution network and deep expertise in global supply chain management, which have \nbeen a critical and foundational part of our long history.  We're  proud of our operational excellence and our ability \nto capture efficiency and deliver consistent and high quality service to our customers while optimizing operating \nmargin.  \n \n Building off of this core capability, we've been very successful in expanding in to new product categories and new \nadjacent markets like our lab solutions and our government partnership strategies. ", "original_text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nOur next priority is to drive sustainable growth in our core pharmaceutical and medical distribution businesses. \n"}, "hash": "3d0c5f67c15c597a26f6cd6f8704610e0c86098219f15e26d82b1505d88ad99d", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "55be5aff-45a9-4209-bb0b-fe7e56a5cf31": {"__data__": {"id_": "55be5aff-45a9-4209-bb0b-fe7e56a5cf31", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nOur next priority is to drive sustainable growth in our core pharmaceutical and medical distribution businesses. \n We have a vast skilled distribution network and deep expertise in global supply chain management, which have \nbeen a critical and foundational part of our long history.  We're  proud of our operational excellence and our ability \nto capture efficiency and deliver consistent and high quality service to our customers while optimizing operating \nmargin.  \n \n Building off of this core capability, we've been very successful in expanding in to new product categories and new \nadjacent markets like our lab solutions and our government partnership strategies. ", "original_text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nOur next priority is to drive sustainable growth in our core pharmaceutical and medical distribution businesses. \n", "page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2657d877-6c2d-4cd2-9c56-265576a1cdee", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c29fa0957bcae0733c3a2c21697f2b2b71094219a4937c934c306563a44c36e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c067af5d-352c-4e48-8fff-bbb9598dfd19", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nOur next priority is to drive sustainable growth in our core pharmaceutical and medical distribution businesses. \n We have a vast skilled distribution network and deep expertise in global supply chain management, which have \nbeen a critical and foundational part of our long history.  We're  proud of our operational excellence and our ability \nto capture efficiency and deliver consistent and high quality service to our customers while optimizing operating \nmargin.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0c9e0b925c88415dde038892f97c51ea180989e6b11e74b1ce2b34bb3effaada", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4f88069d-f7f4-4e5b-a610-fe288c857dd6", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nOur next priority is to drive sustainable growth in our core pharmaceutical and medical distribution businesses. \n We have a vast skilled distribution network and deep expertise in global supply chain management, which have \nbeen a critical and foundational part of our long history.  We're  proud of our operational excellence and our ability \nto capture efficiency and deliver consistent and high quality service to our customers while optimizing operating \nmargin.  \n \n Building off of this core capability, we've been very successful in expanding in to new product categories and new \nadjacent markets like our lab solutions and our government partnership strategies.  Our scaled assets and \ncapabilities also enable us to play an integral role in the response to the COVID -19 pandemic. ", "original_text": "We have a vast skilled distribution network and deep expertise in global supply chain management, which have \nbeen a critical and foundational part of our long history. "}, "hash": "fb2983fd8e706a1b5543f9cfdb3c6e3a8cf94a16e5852a046a7f607bf1c60c2e", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nOur next priority is to drive sustainable growth in our core pharmaceutical and medical distribution businesses. \n", "start_char_idx": 16, "end_char_idx": 296, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4f88069d-f7f4-4e5b-a610-fe288c857dd6": {"__data__": {"id_": "4f88069d-f7f4-4e5b-a610-fe288c857dd6", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nOur next priority is to drive sustainable growth in our core pharmaceutical and medical distribution businesses. \n We have a vast skilled distribution network and deep expertise in global supply chain management, which have \nbeen a critical and foundational part of our long history.  We're  proud of our operational excellence and our ability \nto capture efficiency and deliver consistent and high quality service to our customers while optimizing operating \nmargin.  \n \n Building off of this core capability, we've been very successful in expanding in to new product categories and new \nadjacent markets like our lab solutions and our government partnership strategies.  Our scaled assets and \ncapabilities also enable us to play an integral role in the response to the COVID -19 pandemic. ", "original_text": "We have a vast skilled distribution network and deep expertise in global supply chain management, which have \nbeen a critical and foundational part of our long history. ", "page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2657d877-6c2d-4cd2-9c56-265576a1cdee", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c29fa0957bcae0733c3a2c21697f2b2b71094219a4937c934c306563a44c36e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "55be5aff-45a9-4209-bb0b-fe7e56a5cf31", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nOur next priority is to drive sustainable growth in our core pharmaceutical and medical distribution businesses. \n We have a vast skilled distribution network and deep expertise in global supply chain management, which have \nbeen a critical and foundational part of our long history.  We're  proud of our operational excellence and our ability \nto capture efficiency and deliver consistent and high quality service to our customers while optimizing operating \nmargin.  \n \n Building off of this core capability, we've been very successful in expanding in to new product categories and new \nadjacent markets like our lab solutions and our government partnership strategies. ", "original_text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nOur next priority is to drive sustainable growth in our core pharmaceutical and medical distribution businesses. \n", "page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5c3d27e5a3829b2815b83f12a05c173e5766a5896ae8e8d9bfd1d2e56aba5f25", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1bbe9603-efd6-43c8-9d10-af4e8a038e69", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nOur next priority is to drive sustainable growth in our core pharmaceutical and medical distribution businesses. \n We have a vast skilled distribution network and deep expertise in global supply chain management, which have \nbeen a critical and foundational part of our long history.  We're  proud of our operational excellence and our ability \nto capture efficiency and deliver consistent and high quality service to our customers while optimizing operating \nmargin.  \n \n Building off of this core capability, we've been very successful in expanding in to new product categories and new \nadjacent markets like our lab solutions and our government partnership strategies.  Our scaled assets and \ncapabilities also enable us to play an integral role in the response to the COVID -19 pandemic.  We're proud to \nserve a s the centralized distributor of vaccines and ancillary supplies for the US government.  \n \n", "original_text": "We're  proud of our operational excellence and our ability \nto capture efficiency and deliver consistent and high quality service to our customers while optimizing operating \nmargin.  \n \n"}, "hash": "1558678813171777191ab6b993f9cf5a69b7d1b503ec2815b4fb2b6176d1ceeb", "class_name": "RelatedNodeInfo"}}, "text": "We have a vast skilled distribution network and deep expertise in global supply chain management, which have \nbeen a critical and foundational part of our long history. ", "start_char_idx": 296, "end_char_idx": 465, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1bbe9603-efd6-43c8-9d10-af4e8a038e69": {"__data__": {"id_": "1bbe9603-efd6-43c8-9d10-af4e8a038e69", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nOur next priority is to drive sustainable growth in our core pharmaceutical and medical distribution businesses. \n We have a vast skilled distribution network and deep expertise in global supply chain management, which have \nbeen a critical and foundational part of our long history.  We're  proud of our operational excellence and our ability \nto capture efficiency and deliver consistent and high quality service to our customers while optimizing operating \nmargin.  \n \n Building off of this core capability, we've been very successful in expanding in to new product categories and new \nadjacent markets like our lab solutions and our government partnership strategies.  Our scaled assets and \ncapabilities also enable us to play an integral role in the response to the COVID -19 pandemic.  We're proud to \nserve a s the centralized distributor of vaccines and ancillary supplies for the US government.  \n \n", "original_text": "We're  proud of our operational excellence and our ability \nto capture efficiency and deliver consistent and high quality service to our customers while optimizing operating \nmargin.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2657d877-6c2d-4cd2-9c56-265576a1cdee", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c29fa0957bcae0733c3a2c21697f2b2b71094219a4937c934c306563a44c36e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4f88069d-f7f4-4e5b-a610-fe288c857dd6", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nOur next priority is to drive sustainable growth in our core pharmaceutical and medical distribution businesses. \n We have a vast skilled distribution network and deep expertise in global supply chain management, which have \nbeen a critical and foundational part of our long history.  We're  proud of our operational excellence and our ability \nto capture efficiency and deliver consistent and high quality service to our customers while optimizing operating \nmargin.  \n \n Building off of this core capability, we've been very successful in expanding in to new product categories and new \nadjacent markets like our lab solutions and our government partnership strategies.  Our scaled assets and \ncapabilities also enable us to play an integral role in the response to the COVID -19 pandemic. ", "original_text": "We have a vast skilled distribution network and deep expertise in global supply chain management, which have \nbeen a critical and foundational part of our long history. ", "page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b95c6c77c933542d9b0351bcc1aebde81ac934ac4d08bf97c32121219641c219", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9d4d37a9-a0cc-4e6c-a1d9-0c13d7bf4980", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nOur next priority is to drive sustainable growth in our core pharmaceutical and medical distribution businesses. \n We have a vast skilled distribution network and deep expertise in global supply chain management, which have \nbeen a critical and foundational part of our long history.  We're  proud of our operational excellence and our ability \nto capture efficiency and deliver consistent and high quality service to our customers while optimizing operating \nmargin.  \n \n Building off of this core capability, we've been very successful in expanding in to new product categories and new \nadjacent markets like our lab solutions and our government partnership strategies.  Our scaled assets and \ncapabilities also enable us to play an integral role in the response to the COVID -19 pandemic.  We're proud to \nserve a s the centralized distributor of vaccines and ancillary supplies for the US government.  \n \n We've also been working closely with our partners, suppliers, and manufacturers to navigate the complex supply \nchain system. ", "original_text": "Building off of this core capability, we've been very successful in expanding in to new product categories and new \nadjacent markets like our lab solutions and our government partnership strategies. "}, "hash": "3165099b690f2c61799e1c8ff60db611ed6e549b29b549ad6333195410d88d83", "class_name": "RelatedNodeInfo"}}, "text": "We're  proud of our operational excellence and our ability \nto capture efficiency and deliver consistent and high quality service to our customers while optimizing operating \nmargin.  \n \n", "start_char_idx": 465, "end_char_idx": 652, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9d4d37a9-a0cc-4e6c-a1d9-0c13d7bf4980": {"__data__": {"id_": "9d4d37a9-a0cc-4e6c-a1d9-0c13d7bf4980", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nOur next priority is to drive sustainable growth in our core pharmaceutical and medical distribution businesses. \n We have a vast skilled distribution network and deep expertise in global supply chain management, which have \nbeen a critical and foundational part of our long history.  We're  proud of our operational excellence and our ability \nto capture efficiency and deliver consistent and high quality service to our customers while optimizing operating \nmargin.  \n \n Building off of this core capability, we've been very successful in expanding in to new product categories and new \nadjacent markets like our lab solutions and our government partnership strategies.  Our scaled assets and \ncapabilities also enable us to play an integral role in the response to the COVID -19 pandemic.  We're proud to \nserve a s the centralized distributor of vaccines and ancillary supplies for the US government.  \n \n We've also been working closely with our partners, suppliers, and manufacturers to navigate the complex supply \nchain system. ", "original_text": "Building off of this core capability, we've been very successful in expanding in to new product categories and new \nadjacent markets like our lab solutions and our government partnership strategies. ", "page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2657d877-6c2d-4cd2-9c56-265576a1cdee", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c29fa0957bcae0733c3a2c21697f2b2b71094219a4937c934c306563a44c36e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1bbe9603-efd6-43c8-9d10-af4e8a038e69", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nOur next priority is to drive sustainable growth in our core pharmaceutical and medical distribution businesses. \n We have a vast skilled distribution network and deep expertise in global supply chain management, which have \nbeen a critical and foundational part of our long history.  We're  proud of our operational excellence and our ability \nto capture efficiency and deliver consistent and high quality service to our customers while optimizing operating \nmargin.  \n \n Building off of this core capability, we've been very successful in expanding in to new product categories and new \nadjacent markets like our lab solutions and our government partnership strategies.  Our scaled assets and \ncapabilities also enable us to play an integral role in the response to the COVID -19 pandemic.  We're proud to \nserve a s the centralized distributor of vaccines and ancillary supplies for the US government.  \n \n", "original_text": "We're  proud of our operational excellence and our ability \nto capture efficiency and deliver consistent and high quality service to our customers while optimizing operating \nmargin.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "502766cb037991b7fa3e58f378697336d84bdf187d4fdab61c64450a030fd320", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9753bbb7-b117-4d4d-9a8a-925b2064ec63", "node_type": "1", "metadata": {"window": "We have a vast skilled distribution network and deep expertise in global supply chain management, which have \nbeen a critical and foundational part of our long history.  We're  proud of our operational excellence and our ability \nto capture efficiency and deliver consistent and high quality service to our customers while optimizing operating \nmargin.  \n \n Building off of this core capability, we've been very successful in expanding in to new product categories and new \nadjacent markets like our lab solutions and our government partnership strategies.  Our scaled assets and \ncapabilities also enable us to play an integral role in the response to the COVID -19 pandemic.  We're proud to \nserve a s the centralized distributor of vaccines and ancillary supplies for the US government.  \n \n We've also been working closely with our partners, suppliers, and manufacturers to navigate the complex supply \nchain system.  These relationships have allowed us to con tinue to provide stability of supply and low cost for our \ncustomers, and as a result, we've been able to manage through some of the challenges that the market has been \nseeing.  \n \n", "original_text": "Our scaled assets and \ncapabilities also enable us to play an integral role in the response to the COVID -19 pandemic. "}, "hash": "a543430062c119cac501a6660b8ced264abd35f08da10044aaaff8e34fb317d7", "class_name": "RelatedNodeInfo"}}, "text": "Building off of this core capability, we've been very successful in expanding in to new product categories and new \nadjacent markets like our lab solutions and our government partnership strategies. ", "start_char_idx": 652, "end_char_idx": 851, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9753bbb7-b117-4d4d-9a8a-925b2064ec63": {"__data__": {"id_": "9753bbb7-b117-4d4d-9a8a-925b2064ec63", "embedding": null, "metadata": {"window": "We have a vast skilled distribution network and deep expertise in global supply chain management, which have \nbeen a critical and foundational part of our long history.  We're  proud of our operational excellence and our ability \nto capture efficiency and deliver consistent and high quality service to our customers while optimizing operating \nmargin.  \n \n Building off of this core capability, we've been very successful in expanding in to new product categories and new \nadjacent markets like our lab solutions and our government partnership strategies.  Our scaled assets and \ncapabilities also enable us to play an integral role in the response to the COVID -19 pandemic.  We're proud to \nserve a s the centralized distributor of vaccines and ancillary supplies for the US government.  \n \n We've also been working closely with our partners, suppliers, and manufacturers to navigate the complex supply \nchain system.  These relationships have allowed us to con tinue to provide stability of supply and low cost for our \ncustomers, and as a result, we've been able to manage through some of the challenges that the market has been \nseeing.  \n \n", "original_text": "Our scaled assets and \ncapabilities also enable us to play an integral role in the response to the COVID -19 pandemic. ", "page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2657d877-6c2d-4cd2-9c56-265576a1cdee", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c29fa0957bcae0733c3a2c21697f2b2b71094219a4937c934c306563a44c36e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9d4d37a9-a0cc-4e6c-a1d9-0c13d7bf4980", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nOur next priority is to drive sustainable growth in our core pharmaceutical and medical distribution businesses. \n We have a vast skilled distribution network and deep expertise in global supply chain management, which have \nbeen a critical and foundational part of our long history.  We're  proud of our operational excellence and our ability \nto capture efficiency and deliver consistent and high quality service to our customers while optimizing operating \nmargin.  \n \n Building off of this core capability, we've been very successful in expanding in to new product categories and new \nadjacent markets like our lab solutions and our government partnership strategies.  Our scaled assets and \ncapabilities also enable us to play an integral role in the response to the COVID -19 pandemic.  We're proud to \nserve a s the centralized distributor of vaccines and ancillary supplies for the US government.  \n \n We've also been working closely with our partners, suppliers, and manufacturers to navigate the complex supply \nchain system. ", "original_text": "Building off of this core capability, we've been very successful in expanding in to new product categories and new \nadjacent markets like our lab solutions and our government partnership strategies. ", "page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c4f930881b50311c0f3cafb9009ba50f2171a20cca9c907ec15ebfe19a45dbe7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1cdf88f6-7a6d-4247-8087-bcaa8577025c", "node_type": "1", "metadata": {"window": "We're  proud of our operational excellence and our ability \nto capture efficiency and deliver consistent and high quality service to our customers while optimizing operating \nmargin.  \n \n Building off of this core capability, we've been very successful in expanding in to new product categories and new \nadjacent markets like our lab solutions and our government partnership strategies.  Our scaled assets and \ncapabilities also enable us to play an integral role in the response to the COVID -19 pandemic.  We're proud to \nserve a s the centralized distributor of vaccines and ancillary supplies for the US government.  \n \n We've also been working closely with our partners, suppliers, and manufacturers to navigate the complex supply \nchain system.  These relationships have allowed us to con tinue to provide stability of supply and low cost for our \ncustomers, and as a result, we've been able to manage through some of the challenges that the market has been \nseeing.  \n \n Our third priority is to streamline the business, which includes initiatives li ke the split -off of Change Healthcare \nand our strategic intent to fully exit the European region. ", "original_text": "We're proud to \nserve a s the centralized distributor of vaccines and ancillary supplies for the US government.  \n \n"}, "hash": "19fb45aaff5105d2bda56a36ba02824053170182f45d44527b9e53d92d284b86", "class_name": "RelatedNodeInfo"}}, "text": "Our scaled assets and \ncapabilities also enable us to play an integral role in the response to the COVID -19 pandemic. ", "start_char_idx": 851, "end_char_idx": 970, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1cdf88f6-7a6d-4247-8087-bcaa8577025c": {"__data__": {"id_": "1cdf88f6-7a6d-4247-8087-bcaa8577025c", "embedding": null, "metadata": {"window": "We're  proud of our operational excellence and our ability \nto capture efficiency and deliver consistent and high quality service to our customers while optimizing operating \nmargin.  \n \n Building off of this core capability, we've been very successful in expanding in to new product categories and new \nadjacent markets like our lab solutions and our government partnership strategies.  Our scaled assets and \ncapabilities also enable us to play an integral role in the response to the COVID -19 pandemic.  We're proud to \nserve a s the centralized distributor of vaccines and ancillary supplies for the US government.  \n \n We've also been working closely with our partners, suppliers, and manufacturers to navigate the complex supply \nchain system.  These relationships have allowed us to con tinue to provide stability of supply and low cost for our \ncustomers, and as a result, we've been able to manage through some of the challenges that the market has been \nseeing.  \n \n Our third priority is to streamline the business, which includes initiatives li ke the split -off of Change Healthcare \nand our strategic intent to fully exit the European region. ", "original_text": "We're proud to \nserve a s the centralized distributor of vaccines and ancillary supplies for the US government.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2657d877-6c2d-4cd2-9c56-265576a1cdee", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c29fa0957bcae0733c3a2c21697f2b2b71094219a4937c934c306563a44c36e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9753bbb7-b117-4d4d-9a8a-925b2064ec63", "node_type": "1", "metadata": {"window": "We have a vast skilled distribution network and deep expertise in global supply chain management, which have \nbeen a critical and foundational part of our long history.  We're  proud of our operational excellence and our ability \nto capture efficiency and deliver consistent and high quality service to our customers while optimizing operating \nmargin.  \n \n Building off of this core capability, we've been very successful in expanding in to new product categories and new \nadjacent markets like our lab solutions and our government partnership strategies.  Our scaled assets and \ncapabilities also enable us to play an integral role in the response to the COVID -19 pandemic.  We're proud to \nserve a s the centralized distributor of vaccines and ancillary supplies for the US government.  \n \n We've also been working closely with our partners, suppliers, and manufacturers to navigate the complex supply \nchain system.  These relationships have allowed us to con tinue to provide stability of supply and low cost for our \ncustomers, and as a result, we've been able to manage through some of the challenges that the market has been \nseeing.  \n \n", "original_text": "Our scaled assets and \ncapabilities also enable us to play an integral role in the response to the COVID -19 pandemic. ", "page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "05e6e0ded7580b79e3c6f9e835ca31d23ed6900c15add984d09e1bf30d43f05b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a421e3f3-650e-4ce9-9257-0e8b6b9aed00", "node_type": "1", "metadata": {"window": "Building off of this core capability, we've been very successful in expanding in to new product categories and new \nadjacent markets like our lab solutions and our government partnership strategies.  Our scaled assets and \ncapabilities also enable us to play an integral role in the response to the COVID -19 pandemic.  We're proud to \nserve a s the centralized distributor of vaccines and ancillary supplies for the US government.  \n \n We've also been working closely with our partners, suppliers, and manufacturers to navigate the complex supply \nchain system.  These relationships have allowed us to con tinue to provide stability of supply and low cost for our \ncustomers, and as a result, we've been able to manage through some of the challenges that the market has been \nseeing.  \n \n Our third priority is to streamline the business, which includes initiatives li ke the split -off of Change Healthcare \nand our strategic intent to fully exit the European region.  We recently announced the sale of our Austrian \nbusiness, which was completed on January 31, and we have agreements to sell 10 of the 12 countries where we \noperate. ", "original_text": "We've also been working closely with our partners, suppliers, and manufacturers to navigate the complex supply \nchain system. "}, "hash": "d67564660e50a1cdceafb6f82792fb0de49195342c33fdf9aeaca62a68572eef", "class_name": "RelatedNodeInfo"}}, "text": "We're proud to \nserve a s the centralized distributor of vaccines and ancillary supplies for the US government.  \n \n", "start_char_idx": 970, "end_char_idx": 1086, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a421e3f3-650e-4ce9-9257-0e8b6b9aed00": {"__data__": {"id_": "a421e3f3-650e-4ce9-9257-0e8b6b9aed00", "embedding": null, "metadata": {"window": "Building off of this core capability, we've been very successful in expanding in to new product categories and new \nadjacent markets like our lab solutions and our government partnership strategies.  Our scaled assets and \ncapabilities also enable us to play an integral role in the response to the COVID -19 pandemic.  We're proud to \nserve a s the centralized distributor of vaccines and ancillary supplies for the US government.  \n \n We've also been working closely with our partners, suppliers, and manufacturers to navigate the complex supply \nchain system.  These relationships have allowed us to con tinue to provide stability of supply and low cost for our \ncustomers, and as a result, we've been able to manage through some of the challenges that the market has been \nseeing.  \n \n Our third priority is to streamline the business, which includes initiatives li ke the split -off of Change Healthcare \nand our strategic intent to fully exit the European region.  We recently announced the sale of our Austrian \nbusiness, which was completed on January 31, and we have agreements to sell 10 of the 12 countries where we \noperate. ", "original_text": "We've also been working closely with our partners, suppliers, and manufacturers to navigate the complex supply \nchain system. ", "page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2657d877-6c2d-4cd2-9c56-265576a1cdee", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c29fa0957bcae0733c3a2c21697f2b2b71094219a4937c934c306563a44c36e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1cdf88f6-7a6d-4247-8087-bcaa8577025c", "node_type": "1", "metadata": {"window": "We're  proud of our operational excellence and our ability \nto capture efficiency and deliver consistent and high quality service to our customers while optimizing operating \nmargin.  \n \n Building off of this core capability, we've been very successful in expanding in to new product categories and new \nadjacent markets like our lab solutions and our government partnership strategies.  Our scaled assets and \ncapabilities also enable us to play an integral role in the response to the COVID -19 pandemic.  We're proud to \nserve a s the centralized distributor of vaccines and ancillary supplies for the US government.  \n \n We've also been working closely with our partners, suppliers, and manufacturers to navigate the complex supply \nchain system.  These relationships have allowed us to con tinue to provide stability of supply and low cost for our \ncustomers, and as a result, we've been able to manage through some of the challenges that the market has been \nseeing.  \n \n Our third priority is to streamline the business, which includes initiatives li ke the split -off of Change Healthcare \nand our strategic intent to fully exit the European region. ", "original_text": "We're proud to \nserve a s the centralized distributor of vaccines and ancillary supplies for the US government.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aac3fcef150e641fb2733d4b38cf3c4f1f893eb9e91e67167b776f0511b28077", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5e80ff09-5ba4-48fb-bc96-02e574563eff", "node_type": "1", "metadata": {"window": "Our scaled assets and \ncapabilities also enable us to play an integral role in the response to the COVID -19 pandemic.  We're proud to \nserve a s the centralized distributor of vaccines and ancillary supplies for the US government.  \n \n We've also been working closely with our partners, suppliers, and manufacturers to navigate the complex supply \nchain system.  These relationships have allowed us to con tinue to provide stability of supply and low cost for our \ncustomers, and as a result, we've been able to manage through some of the challenges that the market has been \nseeing.  \n \n Our third priority is to streamline the business, which includes initiatives li ke the split -off of Change Healthcare \nand our strategic intent to fully exit the European region.  We recently announced the sale of our Austrian \nbusiness, which was completed on January 31, and we have agreements to sell 10 of the 12 countries where we \noperate.  As a reminder, Norway and Denmark remain the only countries that we have not entered into an \nagreement to sell.  \n \n", "original_text": "These relationships have allowed us to con tinue to provide stability of supply and low cost for our \ncustomers, and as a result, we've been able to manage through some of the challenges that the market has been \nseeing.  \n \n"}, "hash": "1e0fb1557dfd00f25d29b26dd91e8e6b0544ecea420a05b491eb84f822e18d9c", "class_name": "RelatedNodeInfo"}}, "text": "We've also been working closely with our partners, suppliers, and manufacturers to navigate the complex supply \nchain system. ", "start_char_idx": 1086, "end_char_idx": 1212, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5e80ff09-5ba4-48fb-bc96-02e574563eff": {"__data__": {"id_": "5e80ff09-5ba4-48fb-bc96-02e574563eff", "embedding": null, "metadata": {"window": "Our scaled assets and \ncapabilities also enable us to play an integral role in the response to the COVID -19 pandemic.  We're proud to \nserve a s the centralized distributor of vaccines and ancillary supplies for the US government.  \n \n We've also been working closely with our partners, suppliers, and manufacturers to navigate the complex supply \nchain system.  These relationships have allowed us to con tinue to provide stability of supply and low cost for our \ncustomers, and as a result, we've been able to manage through some of the challenges that the market has been \nseeing.  \n \n Our third priority is to streamline the business, which includes initiatives li ke the split -off of Change Healthcare \nand our strategic intent to fully exit the European region.  We recently announced the sale of our Austrian \nbusiness, which was completed on January 31, and we have agreements to sell 10 of the 12 countries where we \noperate.  As a reminder, Norway and Denmark remain the only countries that we have not entered into an \nagreement to sell.  \n \n", "original_text": "These relationships have allowed us to con tinue to provide stability of supply and low cost for our \ncustomers, and as a result, we've been able to manage through some of the challenges that the market has been \nseeing.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2657d877-6c2d-4cd2-9c56-265576a1cdee", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c29fa0957bcae0733c3a2c21697f2b2b71094219a4937c934c306563a44c36e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a421e3f3-650e-4ce9-9257-0e8b6b9aed00", "node_type": "1", "metadata": {"window": "Building off of this core capability, we've been very successful in expanding in to new product categories and new \nadjacent markets like our lab solutions and our government partnership strategies.  Our scaled assets and \ncapabilities also enable us to play an integral role in the response to the COVID -19 pandemic.  We're proud to \nserve a s the centralized distributor of vaccines and ancillary supplies for the US government.  \n \n We've also been working closely with our partners, suppliers, and manufacturers to navigate the complex supply \nchain system.  These relationships have allowed us to con tinue to provide stability of supply and low cost for our \ncustomers, and as a result, we've been able to manage through some of the challenges that the market has been \nseeing.  \n \n Our third priority is to streamline the business, which includes initiatives li ke the split -off of Change Healthcare \nand our strategic intent to fully exit the European region.  We recently announced the sale of our Austrian \nbusiness, which was completed on January 31, and we have agreements to sell 10 of the 12 countries where we \noperate. ", "original_text": "We've also been working closely with our partners, suppliers, and manufacturers to navigate the complex supply \nchain system. ", "page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c2e446dc8c501dab2167c1ca1d0c3dcbd98a603569883c94b5ad71d8f691d898", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5dc58ca1-5d1a-4f76-aa35-e1f751201544", "node_type": "1", "metadata": {"window": "We're proud to \nserve a s the centralized distributor of vaccines and ancillary supplies for the US government.  \n \n We've also been working closely with our partners, suppliers, and manufacturers to navigate the complex supply \nchain system.  These relationships have allowed us to con tinue to provide stability of supply and low cost for our \ncustomers, and as a result, we've been able to manage through some of the challenges that the market has been \nseeing.  \n \n Our third priority is to streamline the business, which includes initiatives li ke the split -off of Change Healthcare \nand our strategic intent to fully exit the European region.  We recently announced the sale of our Austrian \nbusiness, which was completed on January 31, and we have agreements to sell 10 of the 12 countries where we \noperate.  As a reminder, Norway and Denmark remain the only countries that we have not entered into an \nagreement to sell.  \n \n We continue to work towards the closing of the other pending divestitures. ", "original_text": "Our third priority is to streamline the business, which includes initiatives li ke the split -off of Change Healthcare \nand our strategic intent to fully exit the European region. "}, "hash": "ee1e23e9e2ec961a3e2cf3845c3fb879e0d91f5f4fc011b804611eac21da2c97", "class_name": "RelatedNodeInfo"}}, "text": "These relationships have allowed us to con tinue to provide stability of supply and low cost for our \ncustomers, and as a result, we've been able to manage through some of the challenges that the market has been \nseeing.  \n \n", "start_char_idx": 1212, "end_char_idx": 1437, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5dc58ca1-5d1a-4f76-aa35-e1f751201544": {"__data__": {"id_": "5dc58ca1-5d1a-4f76-aa35-e1f751201544", "embedding": null, "metadata": {"window": "We're proud to \nserve a s the centralized distributor of vaccines and ancillary supplies for the US government.  \n \n We've also been working closely with our partners, suppliers, and manufacturers to navigate the complex supply \nchain system.  These relationships have allowed us to con tinue to provide stability of supply and low cost for our \ncustomers, and as a result, we've been able to manage through some of the challenges that the market has been \nseeing.  \n \n Our third priority is to streamline the business, which includes initiatives li ke the split -off of Change Healthcare \nand our strategic intent to fully exit the European region.  We recently announced the sale of our Austrian \nbusiness, which was completed on January 31, and we have agreements to sell 10 of the 12 countries where we \noperate.  As a reminder, Norway and Denmark remain the only countries that we have not entered into an \nagreement to sell.  \n \n We continue to work towards the closing of the other pending divestitures. ", "original_text": "Our third priority is to streamline the business, which includes initiatives li ke the split -off of Change Healthcare \nand our strategic intent to fully exit the European region. ", "page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2657d877-6c2d-4cd2-9c56-265576a1cdee", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c29fa0957bcae0733c3a2c21697f2b2b71094219a4937c934c306563a44c36e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5e80ff09-5ba4-48fb-bc96-02e574563eff", "node_type": "1", "metadata": {"window": "Our scaled assets and \ncapabilities also enable us to play an integral role in the response to the COVID -19 pandemic.  We're proud to \nserve a s the centralized distributor of vaccines and ancillary supplies for the US government.  \n \n We've also been working closely with our partners, suppliers, and manufacturers to navigate the complex supply \nchain system.  These relationships have allowed us to con tinue to provide stability of supply and low cost for our \ncustomers, and as a result, we've been able to manage through some of the challenges that the market has been \nseeing.  \n \n Our third priority is to streamline the business, which includes initiatives li ke the split -off of Change Healthcare \nand our strategic intent to fully exit the European region.  We recently announced the sale of our Austrian \nbusiness, which was completed on January 31, and we have agreements to sell 10 of the 12 countries where we \noperate.  As a reminder, Norway and Denmark remain the only countries that we have not entered into an \nagreement to sell.  \n \n", "original_text": "These relationships have allowed us to con tinue to provide stability of supply and low cost for our \ncustomers, and as a result, we've been able to manage through some of the challenges that the market has been \nseeing.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6e0de682b56d2a14fa3144890fb6427f65ea6773ef259e5be271c36006f3043e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6a5b58fb-dd17-4721-b56a-3406a2c428a5", "node_type": "1", "metadata": {"window": "We've also been working closely with our partners, suppliers, and manufacturers to navigate the complex supply \nchain system.  These relationships have allowed us to con tinue to provide stability of supply and low cost for our \ncustomers, and as a result, we've been able to manage through some of the challenges that the market has been \nseeing.  \n \n Our third priority is to streamline the business, which includes initiatives li ke the split -off of Change Healthcare \nand our strategic intent to fully exit the European region.  We recently announced the sale of our Austrian \nbusiness, which was completed on January 31, and we have agreements to sell 10 of the 12 countries where we \noperate.  As a reminder, Norway and Denmark remain the only countries that we have not entered into an \nagreement to sell.  \n \n We continue to work towards the closing of the other pending divestitures.  These transactions are the result of our \nintentional effort to  evaluate and assess our portfolio for strategic alignment. ", "original_text": "We recently announced the sale of our Austrian \nbusiness, which was completed on January 31, and we have agreements to sell 10 of the 12 countries where we \noperate. "}, "hash": "74144d6a892ddd95c0cd60730abec8c0b67299e9061efeb279c69b69d1067ba0", "class_name": "RelatedNodeInfo"}}, "text": "Our third priority is to streamline the business, which includes initiatives li ke the split -off of Change Healthcare \nand our strategic intent to fully exit the European region. ", "start_char_idx": 1437, "end_char_idx": 1617, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6a5b58fb-dd17-4721-b56a-3406a2c428a5": {"__data__": {"id_": "6a5b58fb-dd17-4721-b56a-3406a2c428a5", "embedding": null, "metadata": {"window": "We've also been working closely with our partners, suppliers, and manufacturers to navigate the complex supply \nchain system.  These relationships have allowed us to con tinue to provide stability of supply and low cost for our \ncustomers, and as a result, we've been able to manage through some of the challenges that the market has been \nseeing.  \n \n Our third priority is to streamline the business, which includes initiatives li ke the split -off of Change Healthcare \nand our strategic intent to fully exit the European region.  We recently announced the sale of our Austrian \nbusiness, which was completed on January 31, and we have agreements to sell 10 of the 12 countries where we \noperate.  As a reminder, Norway and Denmark remain the only countries that we have not entered into an \nagreement to sell.  \n \n We continue to work towards the closing of the other pending divestitures.  These transactions are the result of our \nintentional effort to  evaluate and assess our portfolio for strategic alignment. ", "original_text": "We recently announced the sale of our Austrian \nbusiness, which was completed on January 31, and we have agreements to sell 10 of the 12 countries where we \noperate. ", "page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2657d877-6c2d-4cd2-9c56-265576a1cdee", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c29fa0957bcae0733c3a2c21697f2b2b71094219a4937c934c306563a44c36e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5dc58ca1-5d1a-4f76-aa35-e1f751201544", "node_type": "1", "metadata": {"window": "We're proud to \nserve a s the centralized distributor of vaccines and ancillary supplies for the US government.  \n \n We've also been working closely with our partners, suppliers, and manufacturers to navigate the complex supply \nchain system.  These relationships have allowed us to con tinue to provide stability of supply and low cost for our \ncustomers, and as a result, we've been able to manage through some of the challenges that the market has been \nseeing.  \n \n Our third priority is to streamline the business, which includes initiatives li ke the split -off of Change Healthcare \nand our strategic intent to fully exit the European region.  We recently announced the sale of our Austrian \nbusiness, which was completed on January 31, and we have agreements to sell 10 of the 12 countries where we \noperate.  As a reminder, Norway and Denmark remain the only countries that we have not entered into an \nagreement to sell.  \n \n We continue to work towards the closing of the other pending divestitures. ", "original_text": "Our third priority is to streamline the business, which includes initiatives li ke the split -off of Change Healthcare \nand our strategic intent to fully exit the European region. ", "page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dd97100b357e0709a09047a242bb46d2f6e9c007fd285380edde2f3873d34249", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "70f232af-594f-47cb-8016-490ffcd7f9c5", "node_type": "1", "metadata": {"window": "These relationships have allowed us to con tinue to provide stability of supply and low cost for our \ncustomers, and as a result, we've been able to manage through some of the challenges that the market has been \nseeing.  \n \n Our third priority is to streamline the business, which includes initiatives li ke the split -off of Change Healthcare \nand our strategic intent to fully exit the European region.  We recently announced the sale of our Austrian \nbusiness, which was completed on January 31, and we have agreements to sell 10 of the 12 countries where we \noperate.  As a reminder, Norway and Denmark remain the only countries that we have not entered into an \nagreement to sell.  \n \n We continue to work towards the closing of the other pending divestitures.  These transactions are the result of our \nintentional effort to  evaluate and assess our portfolio for strategic alignment.  We believe that by fully exiting the \nEurope region, we'll be able to better focus our human and financial capital into higher growth and higher margin \nareas, which leads me naturally to our next c ompany priority.  \n \n", "original_text": "As a reminder, Norway and Denmark remain the only countries that we have not entered into an \nagreement to sell.  \n \n"}, "hash": "a811dc9de6a1460a18a71da7e518323cbe9f3704e947ff6fa84d96569168abcd", "class_name": "RelatedNodeInfo"}}, "text": "We recently announced the sale of our Austrian \nbusiness, which was completed on January 31, and we have agreements to sell 10 of the 12 countries where we \noperate. ", "start_char_idx": 1617, "end_char_idx": 1783, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "70f232af-594f-47cb-8016-490ffcd7f9c5": {"__data__": {"id_": "70f232af-594f-47cb-8016-490ffcd7f9c5", "embedding": null, "metadata": {"window": "These relationships have allowed us to con tinue to provide stability of supply and low cost for our \ncustomers, and as a result, we've been able to manage through some of the challenges that the market has been \nseeing.  \n \n Our third priority is to streamline the business, which includes initiatives li ke the split -off of Change Healthcare \nand our strategic intent to fully exit the European region.  We recently announced the sale of our Austrian \nbusiness, which was completed on January 31, and we have agreements to sell 10 of the 12 countries where we \noperate.  As a reminder, Norway and Denmark remain the only countries that we have not entered into an \nagreement to sell.  \n \n We continue to work towards the closing of the other pending divestitures.  These transactions are the result of our \nintentional effort to  evaluate and assess our portfolio for strategic alignment.  We believe that by fully exiting the \nEurope region, we'll be able to better focus our human and financial capital into higher growth and higher margin \nareas, which leads me naturally to our next c ompany priority.  \n \n", "original_text": "As a reminder, Norway and Denmark remain the only countries that we have not entered into an \nagreement to sell.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2657d877-6c2d-4cd2-9c56-265576a1cdee", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c29fa0957bcae0733c3a2c21697f2b2b71094219a4937c934c306563a44c36e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6a5b58fb-dd17-4721-b56a-3406a2c428a5", "node_type": "1", "metadata": {"window": "We've also been working closely with our partners, suppliers, and manufacturers to navigate the complex supply \nchain system.  These relationships have allowed us to con tinue to provide stability of supply and low cost for our \ncustomers, and as a result, we've been able to manage through some of the challenges that the market has been \nseeing.  \n \n Our third priority is to streamline the business, which includes initiatives li ke the split -off of Change Healthcare \nand our strategic intent to fully exit the European region.  We recently announced the sale of our Austrian \nbusiness, which was completed on January 31, and we have agreements to sell 10 of the 12 countries where we \noperate.  As a reminder, Norway and Denmark remain the only countries that we have not entered into an \nagreement to sell.  \n \n We continue to work towards the closing of the other pending divestitures.  These transactions are the result of our \nintentional effort to  evaluate and assess our portfolio for strategic alignment. ", "original_text": "We recently announced the sale of our Austrian \nbusiness, which was completed on January 31, and we have agreements to sell 10 of the 12 countries where we \noperate. ", "page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b021d5a4f21d6bf32696038278cda0d178680ff5b404adc43ddc58890ddfa878", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a4db77b4-a29b-4551-a651-f3cd1c8d8e45", "node_type": "1", "metadata": {"window": "Our third priority is to streamline the business, which includes initiatives li ke the split -off of Change Healthcare \nand our strategic intent to fully exit the European region.  We recently announced the sale of our Austrian \nbusiness, which was completed on January 31, and we have agreements to sell 10 of the 12 countries where we \noperate.  As a reminder, Norway and Denmark remain the only countries that we have not entered into an \nagreement to sell.  \n \n We continue to work towards the closing of the other pending divestitures.  These transactions are the result of our \nintentional effort to  evaluate and assess our portfolio for strategic alignment.  We believe that by fully exiting the \nEurope region, we'll be able to better focus our human and financial capital into higher growth and higher margin \nareas, which leads me naturally to our next c ompany priority.  \n \n The last company priority is our strategic growth pillars, oncology and biopharma services. ", "original_text": "We continue to work towards the closing of the other pending divestitures. "}, "hash": "6fb6d5819126096c74d4569595d49a0a8ede85b96ce05da9c4fee2d49976cb29", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, Norway and Denmark remain the only countries that we have not entered into an \nagreement to sell.  \n \n", "start_char_idx": 1783, "end_char_idx": 1900, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a4db77b4-a29b-4551-a651-f3cd1c8d8e45": {"__data__": {"id_": "a4db77b4-a29b-4551-a651-f3cd1c8d8e45", "embedding": null, "metadata": {"window": "Our third priority is to streamline the business, which includes initiatives li ke the split -off of Change Healthcare \nand our strategic intent to fully exit the European region.  We recently announced the sale of our Austrian \nbusiness, which was completed on January 31, and we have agreements to sell 10 of the 12 countries where we \noperate.  As a reminder, Norway and Denmark remain the only countries that we have not entered into an \nagreement to sell.  \n \n We continue to work towards the closing of the other pending divestitures.  These transactions are the result of our \nintentional effort to  evaluate and assess our portfolio for strategic alignment.  We believe that by fully exiting the \nEurope region, we'll be able to better focus our human and financial capital into higher growth and higher margin \nareas, which leads me naturally to our next c ompany priority.  \n \n The last company priority is our strategic growth pillars, oncology and biopharma services. ", "original_text": "We continue to work towards the closing of the other pending divestitures. ", "page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2657d877-6c2d-4cd2-9c56-265576a1cdee", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c29fa0957bcae0733c3a2c21697f2b2b71094219a4937c934c306563a44c36e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "70f232af-594f-47cb-8016-490ffcd7f9c5", "node_type": "1", "metadata": {"window": "These relationships have allowed us to con tinue to provide stability of supply and low cost for our \ncustomers, and as a result, we've been able to manage through some of the challenges that the market has been \nseeing.  \n \n Our third priority is to streamline the business, which includes initiatives li ke the split -off of Change Healthcare \nand our strategic intent to fully exit the European region.  We recently announced the sale of our Austrian \nbusiness, which was completed on January 31, and we have agreements to sell 10 of the 12 countries where we \noperate.  As a reminder, Norway and Denmark remain the only countries that we have not entered into an \nagreement to sell.  \n \n We continue to work towards the closing of the other pending divestitures.  These transactions are the result of our \nintentional effort to  evaluate and assess our portfolio for strategic alignment.  We believe that by fully exiting the \nEurope region, we'll be able to better focus our human and financial capital into higher growth and higher margin \nareas, which leads me naturally to our next c ompany priority.  \n \n", "original_text": "As a reminder, Norway and Denmark remain the only countries that we have not entered into an \nagreement to sell.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4783fab77ad85f522e7c1b088ed212a247f9e069780dbc60b0ebd3d9b6c701ca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fada4ae4-119d-40b2-88e3-7ee898b0b6d7", "node_type": "1", "metadata": {"window": "We recently announced the sale of our Austrian \nbusiness, which was completed on January 31, and we have agreements to sell 10 of the 12 countries where we \noperate.  As a reminder, Norway and Denmark remain the only countries that we have not entered into an \nagreement to sell.  \n \n We continue to work towards the closing of the other pending divestitures.  These transactions are the result of our \nintentional effort to  evaluate and assess our portfolio for strategic alignment.  We believe that by fully exiting the \nEurope region, we'll be able to better focus our human and financial capital into higher growth and higher margin \nareas, which leads me naturally to our next c ompany priority.  \n \n The last company priority is our strategic growth pillars, oncology and biopharma services.  Over the past few \nyears, we set out to accelerate the growth in these two areas and build out what we refer to as ecosystems. ", "original_text": "These transactions are the result of our \nintentional effort to  evaluate and assess our portfolio for strategic alignment. "}, "hash": "5bc6f9d6ba6384e885eb1a48724be8a24755f8319e190bf5cea6115be6f45cef", "class_name": "RelatedNodeInfo"}}, "text": "We continue to work towards the closing of the other pending divestitures. ", "start_char_idx": 1900, "end_char_idx": 1975, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fada4ae4-119d-40b2-88e3-7ee898b0b6d7": {"__data__": {"id_": "fada4ae4-119d-40b2-88e3-7ee898b0b6d7", "embedding": null, "metadata": {"window": "We recently announced the sale of our Austrian \nbusiness, which was completed on January 31, and we have agreements to sell 10 of the 12 countries where we \noperate.  As a reminder, Norway and Denmark remain the only countries that we have not entered into an \nagreement to sell.  \n \n We continue to work towards the closing of the other pending divestitures.  These transactions are the result of our \nintentional effort to  evaluate and assess our portfolio for strategic alignment.  We believe that by fully exiting the \nEurope region, we'll be able to better focus our human and financial capital into higher growth and higher margin \nareas, which leads me naturally to our next c ompany priority.  \n \n The last company priority is our strategic growth pillars, oncology and biopharma services.  Over the past few \nyears, we set out to accelerate the growth in these two areas and build out what we refer to as ecosystems. ", "original_text": "These transactions are the result of our \nintentional effort to  evaluate and assess our portfolio for strategic alignment. ", "page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2657d877-6c2d-4cd2-9c56-265576a1cdee", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c29fa0957bcae0733c3a2c21697f2b2b71094219a4937c934c306563a44c36e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a4db77b4-a29b-4551-a651-f3cd1c8d8e45", "node_type": "1", "metadata": {"window": "Our third priority is to streamline the business, which includes initiatives li ke the split -off of Change Healthcare \nand our strategic intent to fully exit the European region.  We recently announced the sale of our Austrian \nbusiness, which was completed on January 31, and we have agreements to sell 10 of the 12 countries where we \noperate.  As a reminder, Norway and Denmark remain the only countries that we have not entered into an \nagreement to sell.  \n \n We continue to work towards the closing of the other pending divestitures.  These transactions are the result of our \nintentional effort to  evaluate and assess our portfolio for strategic alignment.  We believe that by fully exiting the \nEurope region, we'll be able to better focus our human and financial capital into higher growth and higher margin \nareas, which leads me naturally to our next c ompany priority.  \n \n The last company priority is our strategic growth pillars, oncology and biopharma services. ", "original_text": "We continue to work towards the closing of the other pending divestitures. ", "page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "353d8c209c246bde600e09c1f92cfb48af0138230fcfc4b6c7a6188e8ec19833", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "57c21ed2-7d03-465d-82dc-1c3448658b59", "node_type": "1", "metadata": {"window": "As a reminder, Norway and Denmark remain the only countries that we have not entered into an \nagreement to sell.  \n \n We continue to work towards the closing of the other pending divestitures.  These transactions are the result of our \nintentional effort to  evaluate and assess our portfolio for strategic alignment.  We believe that by fully exiting the \nEurope region, we'll be able to better focus our human and financial capital into higher growth and higher margin \nareas, which leads me naturally to our next c ompany priority.  \n \n The last company priority is our strategic growth pillars, oncology and biopharma services.  Over the past few \nyears, we set out to accelerate the growth in these two areas and build out what we refer to as ecosystems.  As \nwe shared at our Investor Day in December, these are both large and growing markets that have significant \nunmet needs and opportunities, and we are tackling some of the most complex problems in the healthcare \nsystem, with the goal to bring efficiency and benefits to all st akeholders across these ecosystems.  \n \n", "original_text": "We believe that by fully exiting the \nEurope region, we'll be able to better focus our human and financial capital into higher growth and higher margin \nareas, which leads me naturally to our next c ompany priority.  \n \n"}, "hash": "be8d0a20a05d374e25e0c706f850de520778b9bdd9c15a87e8ea8fb26e01960a", "class_name": "RelatedNodeInfo"}}, "text": "These transactions are the result of our \nintentional effort to  evaluate and assess our portfolio for strategic alignment. ", "start_char_idx": 1975, "end_char_idx": 2099, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "57c21ed2-7d03-465d-82dc-1c3448658b59": {"__data__": {"id_": "57c21ed2-7d03-465d-82dc-1c3448658b59", "embedding": null, "metadata": {"window": "As a reminder, Norway and Denmark remain the only countries that we have not entered into an \nagreement to sell.  \n \n We continue to work towards the closing of the other pending divestitures.  These transactions are the result of our \nintentional effort to  evaluate and assess our portfolio for strategic alignment.  We believe that by fully exiting the \nEurope region, we'll be able to better focus our human and financial capital into higher growth and higher margin \nareas, which leads me naturally to our next c ompany priority.  \n \n The last company priority is our strategic growth pillars, oncology and biopharma services.  Over the past few \nyears, we set out to accelerate the growth in these two areas and build out what we refer to as ecosystems.  As \nwe shared at our Investor Day in December, these are both large and growing markets that have significant \nunmet needs and opportunities, and we are tackling some of the most complex problems in the healthcare \nsystem, with the goal to bring efficiency and benefits to all st akeholders across these ecosystems.  \n \n", "original_text": "We believe that by fully exiting the \nEurope region, we'll be able to better focus our human and financial capital into higher growth and higher margin \nareas, which leads me naturally to our next c ompany priority.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2657d877-6c2d-4cd2-9c56-265576a1cdee", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c29fa0957bcae0733c3a2c21697f2b2b71094219a4937c934c306563a44c36e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fada4ae4-119d-40b2-88e3-7ee898b0b6d7", "node_type": "1", "metadata": {"window": "We recently announced the sale of our Austrian \nbusiness, which was completed on January 31, and we have agreements to sell 10 of the 12 countries where we \noperate.  As a reminder, Norway and Denmark remain the only countries that we have not entered into an \nagreement to sell.  \n \n We continue to work towards the closing of the other pending divestitures.  These transactions are the result of our \nintentional effort to  evaluate and assess our portfolio for strategic alignment.  We believe that by fully exiting the \nEurope region, we'll be able to better focus our human and financial capital into higher growth and higher margin \nareas, which leads me naturally to our next c ompany priority.  \n \n The last company priority is our strategic growth pillars, oncology and biopharma services.  Over the past few \nyears, we set out to accelerate the growth in these two areas and build out what we refer to as ecosystems. ", "original_text": "These transactions are the result of our \nintentional effort to  evaluate and assess our portfolio for strategic alignment. ", "page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4fcc04a9acc7571e31b64aa94e181c8ab59a29e9df4f3aba98b83aed3b083678", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d1a6f385-a027-4d73-8132-22161d630704", "node_type": "1", "metadata": {"window": "We continue to work towards the closing of the other pending divestitures.  These transactions are the result of our \nintentional effort to  evaluate and assess our portfolio for strategic alignment.  We believe that by fully exiting the \nEurope region, we'll be able to better focus our human and financial capital into higher growth and higher margin \nareas, which leads me naturally to our next c ompany priority.  \n \n The last company priority is our strategic growth pillars, oncology and biopharma services.  Over the past few \nyears, we set out to accelerate the growth in these two areas and build out what we refer to as ecosystems.  As \nwe shared at our Investor Day in December, these are both large and growing markets that have significant \nunmet needs and opportunities, and we are tackling some of the most complex problems in the healthcare \nsystem, with the goal to bring efficiency and benefits to all st akeholders across these ecosystems.  \n \n In the oncology ecosystem, our growth strategy is centered around our support for the large, growing and \ndiversified US Oncology Network. ", "original_text": "The last company priority is our strategic growth pillars, oncology and biopharma services. "}, "hash": "97a121795d3ba5a7ac1e6e0c1ec8a0fddbd3ad9a26ecf87d87f1d20c8d65efd3", "class_name": "RelatedNodeInfo"}}, "text": "We believe that by fully exiting the \nEurope region, we'll be able to better focus our human and financial capital into higher growth and higher margin \nareas, which leads me naturally to our next c ompany priority.  \n \n", "start_char_idx": 2099, "end_char_idx": 2319, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d1a6f385-a027-4d73-8132-22161d630704": {"__data__": {"id_": "d1a6f385-a027-4d73-8132-22161d630704", "embedding": null, "metadata": {"window": "We continue to work towards the closing of the other pending divestitures.  These transactions are the result of our \nintentional effort to  evaluate and assess our portfolio for strategic alignment.  We believe that by fully exiting the \nEurope region, we'll be able to better focus our human and financial capital into higher growth and higher margin \nareas, which leads me naturally to our next c ompany priority.  \n \n The last company priority is our strategic growth pillars, oncology and biopharma services.  Over the past few \nyears, we set out to accelerate the growth in these two areas and build out what we refer to as ecosystems.  As \nwe shared at our Investor Day in December, these are both large and growing markets that have significant \nunmet needs and opportunities, and we are tackling some of the most complex problems in the healthcare \nsystem, with the goal to bring efficiency and benefits to all st akeholders across these ecosystems.  \n \n In the oncology ecosystem, our growth strategy is centered around our support for the large, growing and \ndiversified US Oncology Network. ", "original_text": "The last company priority is our strategic growth pillars, oncology and biopharma services. ", "page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2657d877-6c2d-4cd2-9c56-265576a1cdee", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c29fa0957bcae0733c3a2c21697f2b2b71094219a4937c934c306563a44c36e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "57c21ed2-7d03-465d-82dc-1c3448658b59", "node_type": "1", "metadata": {"window": "As a reminder, Norway and Denmark remain the only countries that we have not entered into an \nagreement to sell.  \n \n We continue to work towards the closing of the other pending divestitures.  These transactions are the result of our \nintentional effort to  evaluate and assess our portfolio for strategic alignment.  We believe that by fully exiting the \nEurope region, we'll be able to better focus our human and financial capital into higher growth and higher margin \nareas, which leads me naturally to our next c ompany priority.  \n \n The last company priority is our strategic growth pillars, oncology and biopharma services.  Over the past few \nyears, we set out to accelerate the growth in these two areas and build out what we refer to as ecosystems.  As \nwe shared at our Investor Day in December, these are both large and growing markets that have significant \nunmet needs and opportunities, and we are tackling some of the most complex problems in the healthcare \nsystem, with the goal to bring efficiency and benefits to all st akeholders across these ecosystems.  \n \n", "original_text": "We believe that by fully exiting the \nEurope region, we'll be able to better focus our human and financial capital into higher growth and higher margin \nareas, which leads me naturally to our next c ompany priority.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "815caedde0b0e65f953a2b22115705e1a7df2676fc711accd916cbae8874068a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "98be5750-3483-46fb-8611-609aefc19ae6", "node_type": "1", "metadata": {"window": "These transactions are the result of our \nintentional effort to  evaluate and assess our portfolio for strategic alignment.  We believe that by fully exiting the \nEurope region, we'll be able to better focus our human and financial capital into higher growth and higher margin \nareas, which leads me naturally to our next c ompany priority.  \n \n The last company priority is our strategic growth pillars, oncology and biopharma services.  Over the past few \nyears, we set out to accelerate the growth in these two areas and build out what we refer to as ecosystems.  As \nwe shared at our Investor Day in December, these are both large and growing markets that have significant \nunmet needs and opportunities, and we are tackling some of the most complex problems in the healthcare \nsystem, with the goal to bring efficiency and benefits to all st akeholders across these ecosystems.  \n \n In the oncology ecosystem, our growth strategy is centered around our support for the large, growing and \ndiversified US Oncology Network.  With the reach of over 1,400 physicians, The US Oncology Network treats 15% \nof all new cancer patients in the US at one of its 500 sites of service.  \n \n", "original_text": "Over the past few \nyears, we set out to accelerate the growth in these two areas and build out what we refer to as ecosystems. "}, "hash": "fcbe85227f4276cbffa41dabeb16268aaa8afb60c603549a49b553527bcd4b87", "class_name": "RelatedNodeInfo"}}, "text": "The last company priority is our strategic growth pillars, oncology and biopharma services. ", "start_char_idx": 2319, "end_char_idx": 2411, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "98be5750-3483-46fb-8611-609aefc19ae6": {"__data__": {"id_": "98be5750-3483-46fb-8611-609aefc19ae6", "embedding": null, "metadata": {"window": "These transactions are the result of our \nintentional effort to  evaluate and assess our portfolio for strategic alignment.  We believe that by fully exiting the \nEurope region, we'll be able to better focus our human and financial capital into higher growth and higher margin \nareas, which leads me naturally to our next c ompany priority.  \n \n The last company priority is our strategic growth pillars, oncology and biopharma services.  Over the past few \nyears, we set out to accelerate the growth in these two areas and build out what we refer to as ecosystems.  As \nwe shared at our Investor Day in December, these are both large and growing markets that have significant \nunmet needs and opportunities, and we are tackling some of the most complex problems in the healthcare \nsystem, with the goal to bring efficiency and benefits to all st akeholders across these ecosystems.  \n \n In the oncology ecosystem, our growth strategy is centered around our support for the large, growing and \ndiversified US Oncology Network.  With the reach of over 1,400 physicians, The US Oncology Network treats 15% \nof all new cancer patients in the US at one of its 500 sites of service.  \n \n", "original_text": "Over the past few \nyears, we set out to accelerate the growth in these two areas and build out what we refer to as ecosystems. ", "page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2657d877-6c2d-4cd2-9c56-265576a1cdee", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c29fa0957bcae0733c3a2c21697f2b2b71094219a4937c934c306563a44c36e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d1a6f385-a027-4d73-8132-22161d630704", "node_type": "1", "metadata": {"window": "We continue to work towards the closing of the other pending divestitures.  These transactions are the result of our \nintentional effort to  evaluate and assess our portfolio for strategic alignment.  We believe that by fully exiting the \nEurope region, we'll be able to better focus our human and financial capital into higher growth and higher margin \nareas, which leads me naturally to our next c ompany priority.  \n \n The last company priority is our strategic growth pillars, oncology and biopharma services.  Over the past few \nyears, we set out to accelerate the growth in these two areas and build out what we refer to as ecosystems.  As \nwe shared at our Investor Day in December, these are both large and growing markets that have significant \nunmet needs and opportunities, and we are tackling some of the most complex problems in the healthcare \nsystem, with the goal to bring efficiency and benefits to all st akeholders across these ecosystems.  \n \n In the oncology ecosystem, our growth strategy is centered around our support for the large, growing and \ndiversified US Oncology Network. ", "original_text": "The last company priority is our strategic growth pillars, oncology and biopharma services. ", "page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "677b325e0b8d38147925d89cf07b684e62fb06efa6393c0df3519c2e0591db99", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1fee1a09-b409-4c54-8724-8710d0797765", "node_type": "1", "metadata": {"window": "We believe that by fully exiting the \nEurope region, we'll be able to better focus our human and financial capital into higher growth and higher margin \nareas, which leads me naturally to our next c ompany priority.  \n \n The last company priority is our strategic growth pillars, oncology and biopharma services.  Over the past few \nyears, we set out to accelerate the growth in these two areas and build out what we refer to as ecosystems.  As \nwe shared at our Investor Day in December, these are both large and growing markets that have significant \nunmet needs and opportunities, and we are tackling some of the most complex problems in the healthcare \nsystem, with the goal to bring efficiency and benefits to all st akeholders across these ecosystems.  \n \n In the oncology ecosystem, our growth strategy is centered around our support for the large, growing and \ndiversified US Oncology Network.  With the reach of over 1,400 physicians, The US Oncology Network treats 15% \nof all new cancer patients in the US at one of its 500 sites of service.  \n \n One of The US Oncology Network's important initiatives is its participation in the oncology care model, which is a \nfive-year experimental payment model with the goal of bringing down the cost of cancer. ", "original_text": "As \nwe shared at our Investor Day in December, these are both large and growing markets that have significant \nunmet needs and opportunities, and we are tackling some of the most complex problems in the healthcare \nsystem, with the goal to bring efficiency and benefits to all st akeholders across these ecosystems.  \n \n"}, "hash": "a688d66d54b325f03031633b13097bc411661feacfe16f4825ff4b2b6798e444", "class_name": "RelatedNodeInfo"}}, "text": "Over the past few \nyears, we set out to accelerate the growth in these two areas and build out what we refer to as ecosystems. ", "start_char_idx": 2411, "end_char_idx": 2538, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1fee1a09-b409-4c54-8724-8710d0797765": {"__data__": {"id_": "1fee1a09-b409-4c54-8724-8710d0797765", "embedding": null, "metadata": {"window": "We believe that by fully exiting the \nEurope region, we'll be able to better focus our human and financial capital into higher growth and higher margin \nareas, which leads me naturally to our next c ompany priority.  \n \n The last company priority is our strategic growth pillars, oncology and biopharma services.  Over the past few \nyears, we set out to accelerate the growth in these two areas and build out what we refer to as ecosystems.  As \nwe shared at our Investor Day in December, these are both large and growing markets that have significant \nunmet needs and opportunities, and we are tackling some of the most complex problems in the healthcare \nsystem, with the goal to bring efficiency and benefits to all st akeholders across these ecosystems.  \n \n In the oncology ecosystem, our growth strategy is centered around our support for the large, growing and \ndiversified US Oncology Network.  With the reach of over 1,400 physicians, The US Oncology Network treats 15% \nof all new cancer patients in the US at one of its 500 sites of service.  \n \n One of The US Oncology Network's important initiatives is its participation in the oncology care model, which is a \nfive-year experimental payment model with the goal of bringing down the cost of cancer. ", "original_text": "As \nwe shared at our Investor Day in December, these are both large and growing markets that have significant \nunmet needs and opportunities, and we are tackling some of the most complex problems in the healthcare \nsystem, with the goal to bring efficiency and benefits to all st akeholders across these ecosystems.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2657d877-6c2d-4cd2-9c56-265576a1cdee", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c29fa0957bcae0733c3a2c21697f2b2b71094219a4937c934c306563a44c36e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "98be5750-3483-46fb-8611-609aefc19ae6", "node_type": "1", "metadata": {"window": "These transactions are the result of our \nintentional effort to  evaluate and assess our portfolio for strategic alignment.  We believe that by fully exiting the \nEurope region, we'll be able to better focus our human and financial capital into higher growth and higher margin \nareas, which leads me naturally to our next c ompany priority.  \n \n The last company priority is our strategic growth pillars, oncology and biopharma services.  Over the past few \nyears, we set out to accelerate the growth in these two areas and build out what we refer to as ecosystems.  As \nwe shared at our Investor Day in December, these are both large and growing markets that have significant \nunmet needs and opportunities, and we are tackling some of the most complex problems in the healthcare \nsystem, with the goal to bring efficiency and benefits to all st akeholders across these ecosystems.  \n \n In the oncology ecosystem, our growth strategy is centered around our support for the large, growing and \ndiversified US Oncology Network.  With the reach of over 1,400 physicians, The US Oncology Network treats 15% \nof all new cancer patients in the US at one of its 500 sites of service.  \n \n", "original_text": "Over the past few \nyears, we set out to accelerate the growth in these two areas and build out what we refer to as ecosystems. ", "page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0ebbea32019480c67a3a64371eca0ae5c77efd27e8e6a1277e749f4653aa2c23", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8e5f57b6-0f02-4a18-9bde-b27e23f99ac3", "node_type": "1", "metadata": {"window": "The last company priority is our strategic growth pillars, oncology and biopharma services.  Over the past few \nyears, we set out to accelerate the growth in these two areas and build out what we refer to as ecosystems.  As \nwe shared at our Investor Day in December, these are both large and growing markets that have significant \nunmet needs and opportunities, and we are tackling some of the most complex problems in the healthcare \nsystem, with the goal to bring efficiency and benefits to all st akeholders across these ecosystems.  \n \n In the oncology ecosystem, our growth strategy is centered around our support for the large, growing and \ndiversified US Oncology Network.  With the reach of over 1,400 physicians, The US Oncology Network treats 15% \nof all new cancer patients in the US at one of its 500 sites of service.  \n \n One of The US Oncology Network's important initiatives is its participation in the oncology care model, which is a \nfive-year experimental payment model with the goal of bringing down the cost of cancer.  Based on the latest \nresults, The US Oncology Network practices participating in the program achieved high marks on quality metrics \nand provided significant cost savings to Medicare. ", "original_text": "In the oncology ecosystem, our growth strategy is centered around our support for the large, growing and \ndiversified US Oncology Network. "}, "hash": "83d44d726ac8225db2f5d8531135065b65a23401893148f35848b741fa57a54f", "class_name": "RelatedNodeInfo"}}, "text": "As \nwe shared at our Investor Day in December, these are both large and growing markets that have significant \nunmet needs and opportunities, and we are tackling some of the most complex problems in the healthcare \nsystem, with the goal to bring efficiency and benefits to all st akeholders across these ecosystems.  \n \n", "start_char_idx": 2538, "end_char_idx": 2858, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8e5f57b6-0f02-4a18-9bde-b27e23f99ac3": {"__data__": {"id_": "8e5f57b6-0f02-4a18-9bde-b27e23f99ac3", "embedding": null, "metadata": {"window": "The last company priority is our strategic growth pillars, oncology and biopharma services.  Over the past few \nyears, we set out to accelerate the growth in these two areas and build out what we refer to as ecosystems.  As \nwe shared at our Investor Day in December, these are both large and growing markets that have significant \nunmet needs and opportunities, and we are tackling some of the most complex problems in the healthcare \nsystem, with the goal to bring efficiency and benefits to all st akeholders across these ecosystems.  \n \n In the oncology ecosystem, our growth strategy is centered around our support for the large, growing and \ndiversified US Oncology Network.  With the reach of over 1,400 physicians, The US Oncology Network treats 15% \nof all new cancer patients in the US at one of its 500 sites of service.  \n \n One of The US Oncology Network's important initiatives is its participation in the oncology care model, which is a \nfive-year experimental payment model with the goal of bringing down the cost of cancer.  Based on the latest \nresults, The US Oncology Network practices participating in the program achieved high marks on quality metrics \nand provided significant cost savings to Medicare. ", "original_text": "In the oncology ecosystem, our growth strategy is centered around our support for the large, growing and \ndiversified US Oncology Network. ", "page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2657d877-6c2d-4cd2-9c56-265576a1cdee", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c29fa0957bcae0733c3a2c21697f2b2b71094219a4937c934c306563a44c36e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1fee1a09-b409-4c54-8724-8710d0797765", "node_type": "1", "metadata": {"window": "We believe that by fully exiting the \nEurope region, we'll be able to better focus our human and financial capital into higher growth and higher margin \nareas, which leads me naturally to our next c ompany priority.  \n \n The last company priority is our strategic growth pillars, oncology and biopharma services.  Over the past few \nyears, we set out to accelerate the growth in these two areas and build out what we refer to as ecosystems.  As \nwe shared at our Investor Day in December, these are both large and growing markets that have significant \nunmet needs and opportunities, and we are tackling some of the most complex problems in the healthcare \nsystem, with the goal to bring efficiency and benefits to all st akeholders across these ecosystems.  \n \n In the oncology ecosystem, our growth strategy is centered around our support for the large, growing and \ndiversified US Oncology Network.  With the reach of over 1,400 physicians, The US Oncology Network treats 15% \nof all new cancer patients in the US at one of its 500 sites of service.  \n \n One of The US Oncology Network's important initiatives is its participation in the oncology care model, which is a \nfive-year experimental payment model with the goal of bringing down the cost of cancer. ", "original_text": "As \nwe shared at our Investor Day in December, these are both large and growing markets that have significant \nunmet needs and opportunities, and we are tackling some of the most complex problems in the healthcare \nsystem, with the goal to bring efficiency and benefits to all st akeholders across these ecosystems.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "04e3a9d98837d6bf17bfe1fa162a87622d970c10fe949536ee299941ce21618b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f15ac60-66e1-4deb-a1f4-8bbf404238d9", "node_type": "1", "metadata": {"window": "Over the past few \nyears, we set out to accelerate the growth in these two areas and build out what we refer to as ecosystems.  As \nwe shared at our Investor Day in December, these are both large and growing markets that have significant \nunmet needs and opportunities, and we are tackling some of the most complex problems in the healthcare \nsystem, with the goal to bring efficiency and benefits to all st akeholders across these ecosystems.  \n \n In the oncology ecosystem, our growth strategy is centered around our support for the large, growing and \ndiversified US Oncology Network.  With the reach of over 1,400 physicians, The US Oncology Network treats 15% \nof all new cancer patients in the US at one of its 500 sites of service.  \n \n One of The US Oncology Network's important initiatives is its participation in the oncology care model, which is a \nfive-year experimental payment model with the goal of bringing down the cost of cancer.  Based on the latest \nresults, The US Oncology Network practices participating in the program achieved high marks on quality metrics \nand provided significant cost savings to Medicare.  By representing approximately one -fourth of all providers \nparticipating in the program, The US Oncology Network demonstrated its leadership role in transitioning \nhealthcare to a more value -based approach.  \n \n", "original_text": "With the reach of over 1,400 physicians, The US Oncology Network treats 15% \nof all new cancer patients in the US at one of its 500 sites of service.  \n \n"}, "hash": "1842831ad61ba06cae7a555445bcad9c2c231416e931b4b8a1232a51e25eb7d4", "class_name": "RelatedNodeInfo"}}, "text": "In the oncology ecosystem, our growth strategy is centered around our support for the large, growing and \ndiversified US Oncology Network. ", "start_char_idx": 2858, "end_char_idx": 2997, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f15ac60-66e1-4deb-a1f4-8bbf404238d9": {"__data__": {"id_": "0f15ac60-66e1-4deb-a1f4-8bbf404238d9", "embedding": null, "metadata": {"window": "Over the past few \nyears, we set out to accelerate the growth in these two areas and build out what we refer to as ecosystems.  As \nwe shared at our Investor Day in December, these are both large and growing markets that have significant \nunmet needs and opportunities, and we are tackling some of the most complex problems in the healthcare \nsystem, with the goal to bring efficiency and benefits to all st akeholders across these ecosystems.  \n \n In the oncology ecosystem, our growth strategy is centered around our support for the large, growing and \ndiversified US Oncology Network.  With the reach of over 1,400 physicians, The US Oncology Network treats 15% \nof all new cancer patients in the US at one of its 500 sites of service.  \n \n One of The US Oncology Network's important initiatives is its participation in the oncology care model, which is a \nfive-year experimental payment model with the goal of bringing down the cost of cancer.  Based on the latest \nresults, The US Oncology Network practices participating in the program achieved high marks on quality metrics \nand provided significant cost savings to Medicare.  By representing approximately one -fourth of all providers \nparticipating in the program, The US Oncology Network demonstrated its leadership role in transitioning \nhealthcare to a more value -based approach.  \n \n", "original_text": "With the reach of over 1,400 physicians, The US Oncology Network treats 15% \nof all new cancer patients in the US at one of its 500 sites of service.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2657d877-6c2d-4cd2-9c56-265576a1cdee", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c29fa0957bcae0733c3a2c21697f2b2b71094219a4937c934c306563a44c36e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8e5f57b6-0f02-4a18-9bde-b27e23f99ac3", "node_type": "1", "metadata": {"window": "The last company priority is our strategic growth pillars, oncology and biopharma services.  Over the past few \nyears, we set out to accelerate the growth in these two areas and build out what we refer to as ecosystems.  As \nwe shared at our Investor Day in December, these are both large and growing markets that have significant \nunmet needs and opportunities, and we are tackling some of the most complex problems in the healthcare \nsystem, with the goal to bring efficiency and benefits to all st akeholders across these ecosystems.  \n \n In the oncology ecosystem, our growth strategy is centered around our support for the large, growing and \ndiversified US Oncology Network.  With the reach of over 1,400 physicians, The US Oncology Network treats 15% \nof all new cancer patients in the US at one of its 500 sites of service.  \n \n One of The US Oncology Network's important initiatives is its participation in the oncology care model, which is a \nfive-year experimental payment model with the goal of bringing down the cost of cancer.  Based on the latest \nresults, The US Oncology Network practices participating in the program achieved high marks on quality metrics \nand provided significant cost savings to Medicare. ", "original_text": "In the oncology ecosystem, our growth strategy is centered around our support for the large, growing and \ndiversified US Oncology Network. ", "page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1ffb65bc70ce5c0574cb95638efad098a7ba426076ce25598764e9be57ad2b2f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e41ca812-34ae-44d9-962d-029742b9d2d8", "node_type": "1", "metadata": {"window": "As \nwe shared at our Investor Day in December, these are both large and growing markets that have significant \nunmet needs and opportunities, and we are tackling some of the most complex problems in the healthcare \nsystem, with the goal to bring efficiency and benefits to all st akeholders across these ecosystems.  \n \n In the oncology ecosystem, our growth strategy is centered around our support for the large, growing and \ndiversified US Oncology Network.  With the reach of over 1,400 physicians, The US Oncology Network treats 15% \nof all new cancer patients in the US at one of its 500 sites of service.  \n \n One of The US Oncology Network's important initiatives is its participation in the oncology care model, which is a \nfive-year experimental payment model with the goal of bringing down the cost of cancer.  Based on the latest \nresults, The US Oncology Network practices participating in the program achieved high marks on quality metrics \nand provided significant cost savings to Medicare.  By representing approximately one -fourth of all providers \nparticipating in the program, The US Oncology Network demonstrated its leadership role in transitioning \nhealthcare to a more value -based approach.  \n \n Building upon our deep reach in the community oncology space, we're creating an oncology ecosystem with mult i-\nfaceted service offerings that are all interconnected. ", "original_text": "One of The US Oncology Network's important initiatives is its participation in the oncology care model, which is a \nfive-year experimental payment model with the goal of bringing down the cost of cancer. "}, "hash": "b2f8128a4466fda6dd54bf525c2f712cdcc42e7d59d7d879807a5febf0559b05", "class_name": "RelatedNodeInfo"}}, "text": "With the reach of over 1,400 physicians, The US Oncology Network treats 15% \nof all new cancer patients in the US at one of its 500 sites of service.  \n \n", "start_char_idx": 2997, "end_char_idx": 3151, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e41ca812-34ae-44d9-962d-029742b9d2d8": {"__data__": {"id_": "e41ca812-34ae-44d9-962d-029742b9d2d8", "embedding": null, "metadata": {"window": "As \nwe shared at our Investor Day in December, these are both large and growing markets that have significant \nunmet needs and opportunities, and we are tackling some of the most complex problems in the healthcare \nsystem, with the goal to bring efficiency and benefits to all st akeholders across these ecosystems.  \n \n In the oncology ecosystem, our growth strategy is centered around our support for the large, growing and \ndiversified US Oncology Network.  With the reach of over 1,400 physicians, The US Oncology Network treats 15% \nof all new cancer patients in the US at one of its 500 sites of service.  \n \n One of The US Oncology Network's important initiatives is its participation in the oncology care model, which is a \nfive-year experimental payment model with the goal of bringing down the cost of cancer.  Based on the latest \nresults, The US Oncology Network practices participating in the program achieved high marks on quality metrics \nand provided significant cost savings to Medicare.  By representing approximately one -fourth of all providers \nparticipating in the program, The US Oncology Network demonstrated its leadership role in transitioning \nhealthcare to a more value -based approach.  \n \n Building upon our deep reach in the community oncology space, we're creating an oncology ecosystem with mult i-\nfaceted service offerings that are all interconnected. ", "original_text": "One of The US Oncology Network's important initiatives is its participation in the oncology care model, which is a \nfive-year experimental payment model with the goal of bringing down the cost of cancer. ", "page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2657d877-6c2d-4cd2-9c56-265576a1cdee", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c29fa0957bcae0733c3a2c21697f2b2b71094219a4937c934c306563a44c36e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f15ac60-66e1-4deb-a1f4-8bbf404238d9", "node_type": "1", "metadata": {"window": "Over the past few \nyears, we set out to accelerate the growth in these two areas and build out what we refer to as ecosystems.  As \nwe shared at our Investor Day in December, these are both large and growing markets that have significant \nunmet needs and opportunities, and we are tackling some of the most complex problems in the healthcare \nsystem, with the goal to bring efficiency and benefits to all st akeholders across these ecosystems.  \n \n In the oncology ecosystem, our growth strategy is centered around our support for the large, growing and \ndiversified US Oncology Network.  With the reach of over 1,400 physicians, The US Oncology Network treats 15% \nof all new cancer patients in the US at one of its 500 sites of service.  \n \n One of The US Oncology Network's important initiatives is its participation in the oncology care model, which is a \nfive-year experimental payment model with the goal of bringing down the cost of cancer.  Based on the latest \nresults, The US Oncology Network practices participating in the program achieved high marks on quality metrics \nand provided significant cost savings to Medicare.  By representing approximately one -fourth of all providers \nparticipating in the program, The US Oncology Network demonstrated its leadership role in transitioning \nhealthcare to a more value -based approach.  \n \n", "original_text": "With the reach of over 1,400 physicians, The US Oncology Network treats 15% \nof all new cancer patients in the US at one of its 500 sites of service.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c52b121cfc67a28d02601cbf706bc443dc6493b1714e7c78cf0dfc25ea3a619f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "50aea7ab-528e-4ff9-984a-f1b1a8a7b4ad", "node_type": "1", "metadata": {"window": "In the oncology ecosystem, our growth strategy is centered around our support for the large, growing and \ndiversified US Oncology Network.  With the reach of over 1,400 physicians, The US Oncology Network treats 15% \nof all new cancer patients in the US at one of its 500 sites of service.  \n \n One of The US Oncology Network's important initiatives is its participation in the oncology care model, which is a \nfive-year experimental payment model with the goal of bringing down the cost of cancer.  Based on the latest \nresults, The US Oncology Network practices participating in the program achieved high marks on quality metrics \nand provided significant cost savings to Medicare.  By representing approximately one -fourth of all providers \nparticipating in the program, The US Oncology Network demonstrated its leadership role in transitioning \nhealthcare to a more value -based approach.  \n \n Building upon our deep reach in the community oncology space, we're creating an oncology ecosystem with mult i-\nfaceted service offerings that are all interconnected.  At the center of this connectivity is Ontada, an oncology, ", "original_text": "Based on the latest \nresults, The US Oncology Network practices participating in the program achieved high marks on quality metrics \nand provided significant cost savings to Medicare. "}, "hash": "5114e07585df921ad34446fce07bb31a05234187471f6866cd5363482be7df65", "class_name": "RelatedNodeInfo"}}, "text": "One of The US Oncology Network's important initiatives is its participation in the oncology care model, which is a \nfive-year experimental payment model with the goal of bringing down the cost of cancer. ", "start_char_idx": 3151, "end_char_idx": 3355, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "50aea7ab-528e-4ff9-984a-f1b1a8a7b4ad": {"__data__": {"id_": "50aea7ab-528e-4ff9-984a-f1b1a8a7b4ad", "embedding": null, "metadata": {"window": "In the oncology ecosystem, our growth strategy is centered around our support for the large, growing and \ndiversified US Oncology Network.  With the reach of over 1,400 physicians, The US Oncology Network treats 15% \nof all new cancer patients in the US at one of its 500 sites of service.  \n \n One of The US Oncology Network's important initiatives is its participation in the oncology care model, which is a \nfive-year experimental payment model with the goal of bringing down the cost of cancer.  Based on the latest \nresults, The US Oncology Network practices participating in the program achieved high marks on quality metrics \nand provided significant cost savings to Medicare.  By representing approximately one -fourth of all providers \nparticipating in the program, The US Oncology Network demonstrated its leadership role in transitioning \nhealthcare to a more value -based approach.  \n \n Building upon our deep reach in the community oncology space, we're creating an oncology ecosystem with mult i-\nfaceted service offerings that are all interconnected.  At the center of this connectivity is Ontada, an oncology, ", "original_text": "Based on the latest \nresults, The US Oncology Network practices participating in the program achieved high marks on quality metrics \nand provided significant cost savings to Medicare. ", "page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2657d877-6c2d-4cd2-9c56-265576a1cdee", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c29fa0957bcae0733c3a2c21697f2b2b71094219a4937c934c306563a44c36e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e41ca812-34ae-44d9-962d-029742b9d2d8", "node_type": "1", "metadata": {"window": "As \nwe shared at our Investor Day in December, these are both large and growing markets that have significant \nunmet needs and opportunities, and we are tackling some of the most complex problems in the healthcare \nsystem, with the goal to bring efficiency and benefits to all st akeholders across these ecosystems.  \n \n In the oncology ecosystem, our growth strategy is centered around our support for the large, growing and \ndiversified US Oncology Network.  With the reach of over 1,400 physicians, The US Oncology Network treats 15% \nof all new cancer patients in the US at one of its 500 sites of service.  \n \n One of The US Oncology Network's important initiatives is its participation in the oncology care model, which is a \nfive-year experimental payment model with the goal of bringing down the cost of cancer.  Based on the latest \nresults, The US Oncology Network practices participating in the program achieved high marks on quality metrics \nand provided significant cost savings to Medicare.  By representing approximately one -fourth of all providers \nparticipating in the program, The US Oncology Network demonstrated its leadership role in transitioning \nhealthcare to a more value -based approach.  \n \n Building upon our deep reach in the community oncology space, we're creating an oncology ecosystem with mult i-\nfaceted service offerings that are all interconnected. ", "original_text": "One of The US Oncology Network's important initiatives is its participation in the oncology care model, which is a \nfive-year experimental payment model with the goal of bringing down the cost of cancer. ", "page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "729aea7039e79a853dbeb63582a3ee31aeac69bd22738120882c4a8c826e28ae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a5171deb-d415-4af1-ac40-7182db334d30", "node_type": "1", "metadata": {"window": "With the reach of over 1,400 physicians, The US Oncology Network treats 15% \nof all new cancer patients in the US at one of its 500 sites of service.  \n \n One of The US Oncology Network's important initiatives is its participation in the oncology care model, which is a \nfive-year experimental payment model with the goal of bringing down the cost of cancer.  Based on the latest \nresults, The US Oncology Network practices participating in the program achieved high marks on quality metrics \nand provided significant cost savings to Medicare.  By representing approximately one -fourth of all providers \nparticipating in the program, The US Oncology Network demonstrated its leadership role in transitioning \nhealthcare to a more value -based approach.  \n \n Building upon our deep reach in the community oncology space, we're creating an oncology ecosystem with mult i-\nfaceted service offerings that are all interconnected.  At the center of this connectivity is Ontada, an oncology, ", "original_text": "By representing approximately one -fourth of all providers \nparticipating in the program, The US Oncology Network demonstrated its leadership role in transitioning \nhealthcare to a more value -based approach.  \n \n"}, "hash": "d7830c8df0bc8eb6894128e2bd0a969ec2e9f90ca15bd222c5f67ffe679fec13", "class_name": "RelatedNodeInfo"}}, "text": "Based on the latest \nresults, The US Oncology Network practices participating in the program achieved high marks on quality metrics \nand provided significant cost savings to Medicare. ", "start_char_idx": 3355, "end_char_idx": 3539, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a5171deb-d415-4af1-ac40-7182db334d30": {"__data__": {"id_": "a5171deb-d415-4af1-ac40-7182db334d30", "embedding": null, "metadata": {"window": "With the reach of over 1,400 physicians, The US Oncology Network treats 15% \nof all new cancer patients in the US at one of its 500 sites of service.  \n \n One of The US Oncology Network's important initiatives is its participation in the oncology care model, which is a \nfive-year experimental payment model with the goal of bringing down the cost of cancer.  Based on the latest \nresults, The US Oncology Network practices participating in the program achieved high marks on quality metrics \nand provided significant cost savings to Medicare.  By representing approximately one -fourth of all providers \nparticipating in the program, The US Oncology Network demonstrated its leadership role in transitioning \nhealthcare to a more value -based approach.  \n \n Building upon our deep reach in the community oncology space, we're creating an oncology ecosystem with mult i-\nfaceted service offerings that are all interconnected.  At the center of this connectivity is Ontada, an oncology, ", "original_text": "By representing approximately one -fourth of all providers \nparticipating in the program, The US Oncology Network demonstrated its leadership role in transitioning \nhealthcare to a more value -based approach.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2657d877-6c2d-4cd2-9c56-265576a1cdee", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c29fa0957bcae0733c3a2c21697f2b2b71094219a4937c934c306563a44c36e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "50aea7ab-528e-4ff9-984a-f1b1a8a7b4ad", "node_type": "1", "metadata": {"window": "In the oncology ecosystem, our growth strategy is centered around our support for the large, growing and \ndiversified US Oncology Network.  With the reach of over 1,400 physicians, The US Oncology Network treats 15% \nof all new cancer patients in the US at one of its 500 sites of service.  \n \n One of The US Oncology Network's important initiatives is its participation in the oncology care model, which is a \nfive-year experimental payment model with the goal of bringing down the cost of cancer.  Based on the latest \nresults, The US Oncology Network practices participating in the program achieved high marks on quality metrics \nand provided significant cost savings to Medicare.  By representing approximately one -fourth of all providers \nparticipating in the program, The US Oncology Network demonstrated its leadership role in transitioning \nhealthcare to a more value -based approach.  \n \n Building upon our deep reach in the community oncology space, we're creating an oncology ecosystem with mult i-\nfaceted service offerings that are all interconnected.  At the center of this connectivity is Ontada, an oncology, ", "original_text": "Based on the latest \nresults, The US Oncology Network practices participating in the program achieved high marks on quality metrics \nand provided significant cost savings to Medicare. ", "page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9651cb562f616a2b56baaf8fd8638ed18c9cff95ccb6a538c181ff9f4ae9276c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d09cce28-58ed-4e87-8b91-7fef607e7c5c", "node_type": "1", "metadata": {"window": "One of The US Oncology Network's important initiatives is its participation in the oncology care model, which is a \nfive-year experimental payment model with the goal of bringing down the cost of cancer.  Based on the latest \nresults, The US Oncology Network practices participating in the program achieved high marks on quality metrics \nand provided significant cost savings to Medicare.  By representing approximately one -fourth of all providers \nparticipating in the program, The US Oncology Network demonstrated its leadership role in transitioning \nhealthcare to a more value -based approach.  \n \n Building upon our deep reach in the community oncology space, we're creating an oncology ecosystem with mult i-\nfaceted service offerings that are all interconnected.  At the center of this connectivity is Ontada, an oncology, ", "original_text": "Building upon our deep reach in the community oncology space, we're creating an oncology ecosystem with mult i-\nfaceted service offerings that are all interconnected. "}, "hash": "b508750c9034114fd3a3fe2f49f32bd8d767989dee69cc412f0bebbdf5ca0ca2", "class_name": "RelatedNodeInfo"}}, "text": "By representing approximately one -fourth of all providers \nparticipating in the program, The US Oncology Network demonstrated its leadership role in transitioning \nhealthcare to a more value -based approach.  \n \n", "start_char_idx": 3539, "end_char_idx": 3752, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d09cce28-58ed-4e87-8b91-7fef607e7c5c": {"__data__": {"id_": "d09cce28-58ed-4e87-8b91-7fef607e7c5c", "embedding": null, "metadata": {"window": "One of The US Oncology Network's important initiatives is its participation in the oncology care model, which is a \nfive-year experimental payment model with the goal of bringing down the cost of cancer.  Based on the latest \nresults, The US Oncology Network practices participating in the program achieved high marks on quality metrics \nand provided significant cost savings to Medicare.  By representing approximately one -fourth of all providers \nparticipating in the program, The US Oncology Network demonstrated its leadership role in transitioning \nhealthcare to a more value -based approach.  \n \n Building upon our deep reach in the community oncology space, we're creating an oncology ecosystem with mult i-\nfaceted service offerings that are all interconnected.  At the center of this connectivity is Ontada, an oncology, ", "original_text": "Building upon our deep reach in the community oncology space, we're creating an oncology ecosystem with mult i-\nfaceted service offerings that are all interconnected. ", "page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2657d877-6c2d-4cd2-9c56-265576a1cdee", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c29fa0957bcae0733c3a2c21697f2b2b71094219a4937c934c306563a44c36e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a5171deb-d415-4af1-ac40-7182db334d30", "node_type": "1", "metadata": {"window": "With the reach of over 1,400 physicians, The US Oncology Network treats 15% \nof all new cancer patients in the US at one of its 500 sites of service.  \n \n One of The US Oncology Network's important initiatives is its participation in the oncology care model, which is a \nfive-year experimental payment model with the goal of bringing down the cost of cancer.  Based on the latest \nresults, The US Oncology Network practices participating in the program achieved high marks on quality metrics \nand provided significant cost savings to Medicare.  By representing approximately one -fourth of all providers \nparticipating in the program, The US Oncology Network demonstrated its leadership role in transitioning \nhealthcare to a more value -based approach.  \n \n Building upon our deep reach in the community oncology space, we're creating an oncology ecosystem with mult i-\nfaceted service offerings that are all interconnected.  At the center of this connectivity is Ontada, an oncology, ", "original_text": "By representing approximately one -fourth of all providers \nparticipating in the program, The US Oncology Network demonstrated its leadership role in transitioning \nhealthcare to a more value -based approach.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e52ab004068d8c48aeec7def4866500310f7900a008e0efb78bce69d226bfbce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e7edafe-4a85-4771-b2e4-9bcc4e8495bc", "node_type": "1", "metadata": {"window": "Based on the latest \nresults, The US Oncology Network practices participating in the program achieved high marks on quality metrics \nand provided significant cost savings to Medicare.  By representing approximately one -fourth of all providers \nparticipating in the program, The US Oncology Network demonstrated its leadership role in transitioning \nhealthcare to a more value -based approach.  \n \n Building upon our deep reach in the community oncology space, we're creating an oncology ecosystem with mult i-\nfaceted service offerings that are all interconnected.  At the center of this connectivity is Ontada, an oncology, ", "original_text": "At the center of this connectivity is Ontada, an oncology, "}, "hash": "763ed95c2fc3c90913064b07bbce420b71466835224a7845110284e60818583f", "class_name": "RelatedNodeInfo"}}, "text": "Building upon our deep reach in the community oncology space, we're creating an oncology ecosystem with mult i-\nfaceted service offerings that are all interconnected. ", "start_char_idx": 3752, "end_char_idx": 3919, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6e7edafe-4a85-4771-b2e4-9bcc4e8495bc": {"__data__": {"id_": "6e7edafe-4a85-4771-b2e4-9bcc4e8495bc", "embedding": null, "metadata": {"window": "Based on the latest \nresults, The US Oncology Network practices participating in the program achieved high marks on quality metrics \nand provided significant cost savings to Medicare.  By representing approximately one -fourth of all providers \nparticipating in the program, The US Oncology Network demonstrated its leadership role in transitioning \nhealthcare to a more value -based approach.  \n \n Building upon our deep reach in the community oncology space, we're creating an oncology ecosystem with mult i-\nfaceted service offerings that are all interconnected.  At the center of this connectivity is Ontada, an oncology, ", "original_text": "At the center of this connectivity is Ontada, an oncology, ", "page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2657d877-6c2d-4cd2-9c56-265576a1cdee", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c29fa0957bcae0733c3a2c21697f2b2b71094219a4937c934c306563a44c36e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d09cce28-58ed-4e87-8b91-7fef607e7c5c", "node_type": "1", "metadata": {"window": "One of The US Oncology Network's important initiatives is its participation in the oncology care model, which is a \nfive-year experimental payment model with the goal of bringing down the cost of cancer.  Based on the latest \nresults, The US Oncology Network practices participating in the program achieved high marks on quality metrics \nand provided significant cost savings to Medicare.  By representing approximately one -fourth of all providers \nparticipating in the program, The US Oncology Network demonstrated its leadership role in transitioning \nhealthcare to a more value -based approach.  \n \n Building upon our deep reach in the community oncology space, we're creating an oncology ecosystem with mult i-\nfaceted service offerings that are all interconnected.  At the center of this connectivity is Ontada, an oncology, ", "original_text": "Building upon our deep reach in the community oncology space, we're creating an oncology ecosystem with mult i-\nfaceted service offerings that are all interconnected. ", "page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a91eb0b8711432cdf788e63640455c9cb63a28177cbd960a4784402f08b09fad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b4b015c5-f548-4f6b-838d-6b538e084fd6", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ntechnology and insights business dedicated to help advance cancer research and advance patient care.  We \nrecently highlighted this business a t our Investor Day.  \n \n Since its launch in December of 2020, the team has made great progress transforming ideas into reality. ", "original_text": "McKesson Corp.  "}, "hash": "51e92dc0d714002becae57bf7639b79b24afecc2692c7223b7d92e4229d1aa32", "class_name": "RelatedNodeInfo"}}, "text": "At the center of this connectivity is Ontada, an oncology, ", "start_char_idx": 3919, "end_char_idx": 3978, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b4b015c5-f548-4f6b-838d-6b538e084fd6": {"__data__": {"id_": "b4b015c5-f548-4f6b-838d-6b538e084fd6", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ntechnology and insights business dedicated to help advance cancer research and advance patient care.  We \nrecently highlighted this business a t our Investor Day.  \n \n Since its launch in December of 2020, the team has made great progress transforming ideas into reality. ", "original_text": "McKesson Corp.  ", "page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70da607e-7d19-47fd-81bf-839e155c79d6", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "710553c2e6f132af3ec5ad89748d4385c3b8e1b3f0458f626a90856dca84f213", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6e7edafe-4a85-4771-b2e4-9bcc4e8495bc", "node_type": "1", "metadata": {"window": "Based on the latest \nresults, The US Oncology Network practices participating in the program achieved high marks on quality metrics \nand provided significant cost savings to Medicare.  By representing approximately one -fourth of all providers \nparticipating in the program, The US Oncology Network demonstrated its leadership role in transitioning \nhealthcare to a more value -based approach.  \n \n Building upon our deep reach in the community oncology space, we're creating an oncology ecosystem with mult i-\nfaceted service offerings that are all interconnected.  At the center of this connectivity is Ontada, an oncology, ", "original_text": "At the center of this connectivity is Ontada, an oncology, ", "page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d94c6591113d29b4ecdb63a30a341fb4efb2d626cd85ff39f1a30dfc3dacb24d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aa1d20a5-df67-4a93-a139-1abc98830009", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ntechnology and insights business dedicated to help advance cancer research and advance patient care.  We \nrecently highlighted this business a t our Investor Day.  \n \n Since its launch in December of 2020, the team has made great progress transforming ideas into reality.  Ontada \nsigned two agreements with strategic partners to improve patient outcome and quality of patient care, and it was \ninstrumenta l in the launch of the MYLUNG Consortium, which through real -world research and study, provides \ncritical information to improve the patient's journey.  \n \n", "original_text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ntechnology and insights business dedicated to help advance cancer research and advance patient care. "}, "hash": "d472f85ae20957f55f4b433412023e3b38f0a9a59201daeff073c3488f3ed436", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aa1d20a5-df67-4a93-a139-1abc98830009": {"__data__": {"id_": "aa1d20a5-df67-4a93-a139-1abc98830009", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ntechnology and insights business dedicated to help advance cancer research and advance patient care.  We \nrecently highlighted this business a t our Investor Day.  \n \n Since its launch in December of 2020, the team has made great progress transforming ideas into reality.  Ontada \nsigned two agreements with strategic partners to improve patient outcome and quality of patient care, and it was \ninstrumenta l in the launch of the MYLUNG Consortium, which through real -world research and study, provides \ncritical information to improve the patient's journey.  \n \n", "original_text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ntechnology and insights business dedicated to help advance cancer research and advance patient care. ", "page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70da607e-7d19-47fd-81bf-839e155c79d6", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "710553c2e6f132af3ec5ad89748d4385c3b8e1b3f0458f626a90856dca84f213", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b4b015c5-f548-4f6b-838d-6b538e084fd6", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ntechnology and insights business dedicated to help advance cancer research and advance patient care.  We \nrecently highlighted this business a t our Investor Day.  \n \n Since its launch in December of 2020, the team has made great progress transforming ideas into reality. ", "original_text": "McKesson Corp.  ", "page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2d73b794024418dfaddc915c5e636a9ba182a062fbf552f09b050063c575be98", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "634ca735-845b-4105-99a8-84c0dd462500", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ntechnology and insights business dedicated to help advance cancer research and advance patient care.  We \nrecently highlighted this business a t our Investor Day.  \n \n Since its launch in December of 2020, the team has made great progress transforming ideas into reality.  Ontada \nsigned two agreements with strategic partners to improve patient outcome and quality of patient care, and it was \ninstrumenta l in the launch of the MYLUNG Consortium, which through real -world research and study, provides \ncritical information to improve the patient's journey.  \n \n Within our biopharma ecosystem, we've built a set of differentiated assets and capabilities, including b usinesses \nlike RelayHealth Pharmacy, CoverMyMeds and RxCrossroads. ", "original_text": "We \nrecently highlighted this business a t our Investor Day.  \n \n"}, "hash": "e34ba50a09284487d4c8f52f7b9695e81d87a902c3a8ecf4da40a39eb8fa1bb0", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ntechnology and insights business dedicated to help advance cancer research and advance patient care. ", "start_char_idx": 16, "end_char_idx": 281, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "634ca735-845b-4105-99a8-84c0dd462500": {"__data__": {"id_": "634ca735-845b-4105-99a8-84c0dd462500", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ntechnology and insights business dedicated to help advance cancer research and advance patient care.  We \nrecently highlighted this business a t our Investor Day.  \n \n Since its launch in December of 2020, the team has made great progress transforming ideas into reality.  Ontada \nsigned two agreements with strategic partners to improve patient outcome and quality of patient care, and it was \ninstrumenta l in the launch of the MYLUNG Consortium, which through real -world research and study, provides \ncritical information to improve the patient's journey.  \n \n Within our biopharma ecosystem, we've built a set of differentiated assets and capabilities, including b usinesses \nlike RelayHealth Pharmacy, CoverMyMeds and RxCrossroads. ", "original_text": "We \nrecently highlighted this business a t our Investor Day.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70da607e-7d19-47fd-81bf-839e155c79d6", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "710553c2e6f132af3ec5ad89748d4385c3b8e1b3f0458f626a90856dca84f213", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aa1d20a5-df67-4a93-a139-1abc98830009", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ntechnology and insights business dedicated to help advance cancer research and advance patient care.  We \nrecently highlighted this business a t our Investor Day.  \n \n Since its launch in December of 2020, the team has made great progress transforming ideas into reality.  Ontada \nsigned two agreements with strategic partners to improve patient outcome and quality of patient care, and it was \ninstrumenta l in the launch of the MYLUNG Consortium, which through real -world research and study, provides \ncritical information to improve the patient's journey.  \n \n", "original_text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ntechnology and insights business dedicated to help advance cancer research and advance patient care. ", "page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3b15e01e75a1159b6f68a6060452f9709a881fdab3c829789307ba51e3a80e0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "725dc139-4e44-4a57-9f90-aa333aa90209", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ntechnology and insights business dedicated to help advance cancer research and advance patient care.  We \nrecently highlighted this business a t our Investor Day.  \n \n Since its launch in December of 2020, the team has made great progress transforming ideas into reality.  Ontada \nsigned two agreements with strategic partners to improve patient outcome and quality of patient care, and it was \ninstrumenta l in the launch of the MYLUNG Consortium, which through real -world research and study, provides \ncritical information to improve the patient's journey.  \n \n Within our biopharma ecosystem, we've built a set of differentiated assets and capabilities, including b usinesses \nlike RelayHealth Pharmacy, CoverMyMeds and RxCrossroads.  They're combined under the Prescription \nSolutions business, with a shared goal to improve access, adherence and affordability of medicines.  \n \n", "original_text": "Since its launch in December of 2020, the team has made great progress transforming ideas into reality. "}, "hash": "62571aaabe3505180d2a6fa6c4c3b69d96f27ccc934951ce2602400b185bb94c", "class_name": "RelatedNodeInfo"}}, "text": "We \nrecently highlighted this business a t our Investor Day.  \n \n", "start_char_idx": 281, "end_char_idx": 346, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "725dc139-4e44-4a57-9f90-aa333aa90209": {"__data__": {"id_": "725dc139-4e44-4a57-9f90-aa333aa90209", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ntechnology and insights business dedicated to help advance cancer research and advance patient care.  We \nrecently highlighted this business a t our Investor Day.  \n \n Since its launch in December of 2020, the team has made great progress transforming ideas into reality.  Ontada \nsigned two agreements with strategic partners to improve patient outcome and quality of patient care, and it was \ninstrumenta l in the launch of the MYLUNG Consortium, which through real -world research and study, provides \ncritical information to improve the patient's journey.  \n \n Within our biopharma ecosystem, we've built a set of differentiated assets and capabilities, including b usinesses \nlike RelayHealth Pharmacy, CoverMyMeds and RxCrossroads.  They're combined under the Prescription \nSolutions business, with a shared goal to improve access, adherence and affordability of medicines.  \n \n", "original_text": "Since its launch in December of 2020, the team has made great progress transforming ideas into reality. ", "page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70da607e-7d19-47fd-81bf-839e155c79d6", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "710553c2e6f132af3ec5ad89748d4385c3b8e1b3f0458f626a90856dca84f213", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "634ca735-845b-4105-99a8-84c0dd462500", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ntechnology and insights business dedicated to help advance cancer research and advance patient care.  We \nrecently highlighted this business a t our Investor Day.  \n \n Since its launch in December of 2020, the team has made great progress transforming ideas into reality.  Ontada \nsigned two agreements with strategic partners to improve patient outcome and quality of patient care, and it was \ninstrumenta l in the launch of the MYLUNG Consortium, which through real -world research and study, provides \ncritical information to improve the patient's journey.  \n \n Within our biopharma ecosystem, we've built a set of differentiated assets and capabilities, including b usinesses \nlike RelayHealth Pharmacy, CoverMyMeds and RxCrossroads. ", "original_text": "We \nrecently highlighted this business a t our Investor Day.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "50a6b817d5b72439ffb6301de4016ff2d80efc1c9a4e8ad93b2b2429e0d29904", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d8fa293-34d2-4b17-b034-976f7ce36055", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ntechnology and insights business dedicated to help advance cancer research and advance patient care.  We \nrecently highlighted this business a t our Investor Day.  \n \n Since its launch in December of 2020, the team has made great progress transforming ideas into reality.  Ontada \nsigned two agreements with strategic partners to improve patient outcome and quality of patient care, and it was \ninstrumenta l in the launch of the MYLUNG Consortium, which through real -world research and study, provides \ncritical information to improve the patient's journey.  \n \n Within our biopharma ecosystem, we've built a set of differentiated assets and capabilities, including b usinesses \nlike RelayHealth Pharmacy, CoverMyMeds and RxCrossroads.  They're combined under the Prescription \nSolutions business, with a shared goal to improve access, adherence and affordability of medicines.  \n \n One of the key customers of our business is biop harma companies. ", "original_text": "Ontada \nsigned two agreements with strategic partners to improve patient outcome and quality of patient care, and it was \ninstrumenta l in the launch of the MYLUNG Consortium, which through real -world research and study, provides \ncritical information to improve the patient's journey.  \n \n"}, "hash": "92a3eef43f7d2bb994fb35cd0f1e52d230b5a2dc365c29e19b8e64073c65e771", "class_name": "RelatedNodeInfo"}}, "text": "Since its launch in December of 2020, the team has made great progress transforming ideas into reality. ", "start_char_idx": 346, "end_char_idx": 450, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8d8fa293-34d2-4b17-b034-976f7ce36055": {"__data__": {"id_": "8d8fa293-34d2-4b17-b034-976f7ce36055", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ntechnology and insights business dedicated to help advance cancer research and advance patient care.  We \nrecently highlighted this business a t our Investor Day.  \n \n Since its launch in December of 2020, the team has made great progress transforming ideas into reality.  Ontada \nsigned two agreements with strategic partners to improve patient outcome and quality of patient care, and it was \ninstrumenta l in the launch of the MYLUNG Consortium, which through real -world research and study, provides \ncritical information to improve the patient's journey.  \n \n Within our biopharma ecosystem, we've built a set of differentiated assets and capabilities, including b usinesses \nlike RelayHealth Pharmacy, CoverMyMeds and RxCrossroads.  They're combined under the Prescription \nSolutions business, with a shared goal to improve access, adherence and affordability of medicines.  \n \n One of the key customers of our business is biop harma companies. ", "original_text": "Ontada \nsigned two agreements with strategic partners to improve patient outcome and quality of patient care, and it was \ninstrumenta l in the launch of the MYLUNG Consortium, which through real -world research and study, provides \ncritical information to improve the patient's journey.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70da607e-7d19-47fd-81bf-839e155c79d6", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "710553c2e6f132af3ec5ad89748d4385c3b8e1b3f0458f626a90856dca84f213", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "725dc139-4e44-4a57-9f90-aa333aa90209", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ntechnology and insights business dedicated to help advance cancer research and advance patient care.  We \nrecently highlighted this business a t our Investor Day.  \n \n Since its launch in December of 2020, the team has made great progress transforming ideas into reality.  Ontada \nsigned two agreements with strategic partners to improve patient outcome and quality of patient care, and it was \ninstrumenta l in the launch of the MYLUNG Consortium, which through real -world research and study, provides \ncritical information to improve the patient's journey.  \n \n Within our biopharma ecosystem, we've built a set of differentiated assets and capabilities, including b usinesses \nlike RelayHealth Pharmacy, CoverMyMeds and RxCrossroads.  They're combined under the Prescription \nSolutions business, with a shared goal to improve access, adherence and affordability of medicines.  \n \n", "original_text": "Since its launch in December of 2020, the team has made great progress transforming ideas into reality. ", "page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e23e93ebd564095435702979920bae0b5c9af894e844f8bf071a83409905f5b3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c6c12c04-6302-498a-a509-b0e845e6aeb1", "node_type": "1", "metadata": {"window": "We \nrecently highlighted this business a t our Investor Day.  \n \n Since its launch in December of 2020, the team has made great progress transforming ideas into reality.  Ontada \nsigned two agreements with strategic partners to improve patient outcome and quality of patient care, and it was \ninstrumenta l in the launch of the MYLUNG Consortium, which through real -world research and study, provides \ncritical information to improve the patient's journey.  \n \n Within our biopharma ecosystem, we've built a set of differentiated assets and capabilities, including b usinesses \nlike RelayHealth Pharmacy, CoverMyMeds and RxCrossroads.  They're combined under the Prescription \nSolutions business, with a shared goal to improve access, adherence and affordability of medicines.  \n \n One of the key customers of our business is biop harma companies.  Through our scaled and interconnected \ntechnology network, we provide biopharma a range of commercialization services. ", "original_text": "Within our biopharma ecosystem, we've built a set of differentiated assets and capabilities, including b usinesses \nlike RelayHealth Pharmacy, CoverMyMeds and RxCrossroads. "}, "hash": "ff2bd0856b7f8d519052422cf156a57d5101c02088e5a24171720048699b6c37", "class_name": "RelatedNodeInfo"}}, "text": "Ontada \nsigned two agreements with strategic partners to improve patient outcome and quality of patient care, and it was \ninstrumenta l in the launch of the MYLUNG Consortium, which through real -world research and study, provides \ncritical information to improve the patient's journey.  \n \n", "start_char_idx": 450, "end_char_idx": 741, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c6c12c04-6302-498a-a509-b0e845e6aeb1": {"__data__": {"id_": "c6c12c04-6302-498a-a509-b0e845e6aeb1", "embedding": null, "metadata": {"window": "We \nrecently highlighted this business a t our Investor Day.  \n \n Since its launch in December of 2020, the team has made great progress transforming ideas into reality.  Ontada \nsigned two agreements with strategic partners to improve patient outcome and quality of patient care, and it was \ninstrumenta l in the launch of the MYLUNG Consortium, which through real -world research and study, provides \ncritical information to improve the patient's journey.  \n \n Within our biopharma ecosystem, we've built a set of differentiated assets and capabilities, including b usinesses \nlike RelayHealth Pharmacy, CoverMyMeds and RxCrossroads.  They're combined under the Prescription \nSolutions business, with a shared goal to improve access, adherence and affordability of medicines.  \n \n One of the key customers of our business is biop harma companies.  Through our scaled and interconnected \ntechnology network, we provide biopharma a range of commercialization services. ", "original_text": "Within our biopharma ecosystem, we've built a set of differentiated assets and capabilities, including b usinesses \nlike RelayHealth Pharmacy, CoverMyMeds and RxCrossroads. ", "page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70da607e-7d19-47fd-81bf-839e155c79d6", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "710553c2e6f132af3ec5ad89748d4385c3b8e1b3f0458f626a90856dca84f213", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d8fa293-34d2-4b17-b034-976f7ce36055", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ntechnology and insights business dedicated to help advance cancer research and advance patient care.  We \nrecently highlighted this business a t our Investor Day.  \n \n Since its launch in December of 2020, the team has made great progress transforming ideas into reality.  Ontada \nsigned two agreements with strategic partners to improve patient outcome and quality of patient care, and it was \ninstrumenta l in the launch of the MYLUNG Consortium, which through real -world research and study, provides \ncritical information to improve the patient's journey.  \n \n Within our biopharma ecosystem, we've built a set of differentiated assets and capabilities, including b usinesses \nlike RelayHealth Pharmacy, CoverMyMeds and RxCrossroads.  They're combined under the Prescription \nSolutions business, with a shared goal to improve access, adherence and affordability of medicines.  \n \n One of the key customers of our business is biop harma companies. ", "original_text": "Ontada \nsigned two agreements with strategic partners to improve patient outcome and quality of patient care, and it was \ninstrumenta l in the launch of the MYLUNG Consortium, which through real -world research and study, provides \ncritical information to improve the patient's journey.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0c2d8da868a1b2a4df2efe83191e8877039f61828b1acac8ee694db925d023c1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8478f3f3-2b33-46e4-b9f3-43d5fb8109af", "node_type": "1", "metadata": {"window": "Since its launch in December of 2020, the team has made great progress transforming ideas into reality.  Ontada \nsigned two agreements with strategic partners to improve patient outcome and quality of patient care, and it was \ninstrumenta l in the launch of the MYLUNG Consortium, which through real -world research and study, provides \ncritical information to improve the patient's journey.  \n \n Within our biopharma ecosystem, we've built a set of differentiated assets and capabilities, including b usinesses \nlike RelayHealth Pharmacy, CoverMyMeds and RxCrossroads.  They're combined under the Prescription \nSolutions business, with a shared goal to improve access, adherence and affordability of medicines.  \n \n One of the key customers of our business is biop harma companies.  Through our scaled and interconnected \ntechnology network, we provide biopharma a range of commercialization services.  And by automating and \nsimplifying the process of prior authorization, we reduce prescription abandonment and provide biop harma \naccess to new patients. ", "original_text": "They're combined under the Prescription \nSolutions business, with a shared goal to improve access, adherence and affordability of medicines.  \n \n"}, "hash": "f0c9d8184b63e42f6e39c83c5d0f2c7c4f940b0e881fc6a3295ee582ebada5ae", "class_name": "RelatedNodeInfo"}}, "text": "Within our biopharma ecosystem, we've built a set of differentiated assets and capabilities, including b usinesses \nlike RelayHealth Pharmacy, CoverMyMeds and RxCrossroads. ", "start_char_idx": 741, "end_char_idx": 914, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8478f3f3-2b33-46e4-b9f3-43d5fb8109af": {"__data__": {"id_": "8478f3f3-2b33-46e4-b9f3-43d5fb8109af", "embedding": null, "metadata": {"window": "Since its launch in December of 2020, the team has made great progress transforming ideas into reality.  Ontada \nsigned two agreements with strategic partners to improve patient outcome and quality of patient care, and it was \ninstrumenta l in the launch of the MYLUNG Consortium, which through real -world research and study, provides \ncritical information to improve the patient's journey.  \n \n Within our biopharma ecosystem, we've built a set of differentiated assets and capabilities, including b usinesses \nlike RelayHealth Pharmacy, CoverMyMeds and RxCrossroads.  They're combined under the Prescription \nSolutions business, with a shared goal to improve access, adherence and affordability of medicines.  \n \n One of the key customers of our business is biop harma companies.  Through our scaled and interconnected \ntechnology network, we provide biopharma a range of commercialization services.  And by automating and \nsimplifying the process of prior authorization, we reduce prescription abandonment and provide biop harma \naccess to new patients. ", "original_text": "They're combined under the Prescription \nSolutions business, with a shared goal to improve access, adherence and affordability of medicines.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70da607e-7d19-47fd-81bf-839e155c79d6", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "710553c2e6f132af3ec5ad89748d4385c3b8e1b3f0458f626a90856dca84f213", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c6c12c04-6302-498a-a509-b0e845e6aeb1", "node_type": "1", "metadata": {"window": "We \nrecently highlighted this business a t our Investor Day.  \n \n Since its launch in December of 2020, the team has made great progress transforming ideas into reality.  Ontada \nsigned two agreements with strategic partners to improve patient outcome and quality of patient care, and it was \ninstrumenta l in the launch of the MYLUNG Consortium, which through real -world research and study, provides \ncritical information to improve the patient's journey.  \n \n Within our biopharma ecosystem, we've built a set of differentiated assets and capabilities, including b usinesses \nlike RelayHealth Pharmacy, CoverMyMeds and RxCrossroads.  They're combined under the Prescription \nSolutions business, with a shared goal to improve access, adherence and affordability of medicines.  \n \n One of the key customers of our business is biop harma companies.  Through our scaled and interconnected \ntechnology network, we provide biopharma a range of commercialization services. ", "original_text": "Within our biopharma ecosystem, we've built a set of differentiated assets and capabilities, including b usinesses \nlike RelayHealth Pharmacy, CoverMyMeds and RxCrossroads. ", "page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c0c7a24f1b8e3c6ca8212b2a3cf3edb78e66f215ede54f43d295276064e5dd8e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "33705a49-f63f-4c73-bd47-06ce4eb1dab0", "node_type": "1", "metadata": {"window": "Ontada \nsigned two agreements with strategic partners to improve patient outcome and quality of patient care, and it was \ninstrumenta l in the launch of the MYLUNG Consortium, which through real -world research and study, provides \ncritical information to improve the patient's journey.  \n \n Within our biopharma ecosystem, we've built a set of differentiated assets and capabilities, including b usinesses \nlike RelayHealth Pharmacy, CoverMyMeds and RxCrossroads.  They're combined under the Prescription \nSolutions business, with a shared goal to improve access, adherence and affordability of medicines.  \n \n One of the key customers of our business is biop harma companies.  Through our scaled and interconnected \ntechnology network, we provide biopharma a range of commercialization services.  And by automating and \nsimplifying the process of prior authorization, we reduce prescription abandonment and provide biop harma \naccess to new patients.  Our unique technology capabilities also generate insights into patients' needs and \nchallenges, enabling greater ability to impact patient actions and get better outcomes.  \n \n", "original_text": "One of the key customers of our business is biop harma companies. "}, "hash": "2fc79c7863b72df739cfd073e0f525c2361a4646bb48d9d475e4c8d91decf68c", "class_name": "RelatedNodeInfo"}}, "text": "They're combined under the Prescription \nSolutions business, with a shared goal to improve access, adherence and affordability of medicines.  \n \n", "start_char_idx": 914, "end_char_idx": 1059, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "33705a49-f63f-4c73-bd47-06ce4eb1dab0": {"__data__": {"id_": "33705a49-f63f-4c73-bd47-06ce4eb1dab0", "embedding": null, "metadata": {"window": "Ontada \nsigned two agreements with strategic partners to improve patient outcome and quality of patient care, and it was \ninstrumenta l in the launch of the MYLUNG Consortium, which through real -world research and study, provides \ncritical information to improve the patient's journey.  \n \n Within our biopharma ecosystem, we've built a set of differentiated assets and capabilities, including b usinesses \nlike RelayHealth Pharmacy, CoverMyMeds and RxCrossroads.  They're combined under the Prescription \nSolutions business, with a shared goal to improve access, adherence and affordability of medicines.  \n \n One of the key customers of our business is biop harma companies.  Through our scaled and interconnected \ntechnology network, we provide biopharma a range of commercialization services.  And by automating and \nsimplifying the process of prior authorization, we reduce prescription abandonment and provide biop harma \naccess to new patients.  Our unique technology capabilities also generate insights into patients' needs and \nchallenges, enabling greater ability to impact patient actions and get better outcomes.  \n \n", "original_text": "One of the key customers of our business is biop harma companies. ", "page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70da607e-7d19-47fd-81bf-839e155c79d6", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "710553c2e6f132af3ec5ad89748d4385c3b8e1b3f0458f626a90856dca84f213", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8478f3f3-2b33-46e4-b9f3-43d5fb8109af", "node_type": "1", "metadata": {"window": "Since its launch in December of 2020, the team has made great progress transforming ideas into reality.  Ontada \nsigned two agreements with strategic partners to improve patient outcome and quality of patient care, and it was \ninstrumenta l in the launch of the MYLUNG Consortium, which through real -world research and study, provides \ncritical information to improve the patient's journey.  \n \n Within our biopharma ecosystem, we've built a set of differentiated assets and capabilities, including b usinesses \nlike RelayHealth Pharmacy, CoverMyMeds and RxCrossroads.  They're combined under the Prescription \nSolutions business, with a shared goal to improve access, adherence and affordability of medicines.  \n \n One of the key customers of our business is biop harma companies.  Through our scaled and interconnected \ntechnology network, we provide biopharma a range of commercialization services.  And by automating and \nsimplifying the process of prior authorization, we reduce prescription abandonment and provide biop harma \naccess to new patients. ", "original_text": "They're combined under the Prescription \nSolutions business, with a shared goal to improve access, adherence and affordability of medicines.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "771a315c6dc7e94345cf90797417aa827e3603a8f69e1698ce11ca24155e9492", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c411ec14-e3fe-45ec-b889-aa785134a5d7", "node_type": "1", "metadata": {"window": "Within our biopharma ecosystem, we've built a set of differentiated assets and capabilities, including b usinesses \nlike RelayHealth Pharmacy, CoverMyMeds and RxCrossroads.  They're combined under the Prescription \nSolutions business, with a shared goal to improve access, adherence and affordability of medicines.  \n \n One of the key customers of our business is biop harma companies.  Through our scaled and interconnected \ntechnology network, we provide biopharma a range of commercialization services.  And by automating and \nsimplifying the process of prior authorization, we reduce prescription abandonment and provide biop harma \naccess to new patients.  Our unique technology capabilities also generate insights into patients' needs and \nchallenges, enabling greater ability to impact patient actions and get better outcomes.  \n \n We support over 650 brands today, covering 94% of the therapeutic areas, and we're connected to all the major \ninsurance companies and most of the regional payers in the United States. ", "original_text": "Through our scaled and interconnected \ntechnology network, we provide biopharma a range of commercialization services. "}, "hash": "afea802874c4c24b34cec126ad1c4e7e6015b3ccd1adb6f5334fac54c6d1ed35", "class_name": "RelatedNodeInfo"}}, "text": "One of the key customers of our business is biop harma companies. ", "start_char_idx": 1059, "end_char_idx": 1125, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c411ec14-e3fe-45ec-b889-aa785134a5d7": {"__data__": {"id_": "c411ec14-e3fe-45ec-b889-aa785134a5d7", "embedding": null, "metadata": {"window": "Within our biopharma ecosystem, we've built a set of differentiated assets and capabilities, including b usinesses \nlike RelayHealth Pharmacy, CoverMyMeds and RxCrossroads.  They're combined under the Prescription \nSolutions business, with a shared goal to improve access, adherence and affordability of medicines.  \n \n One of the key customers of our business is biop harma companies.  Through our scaled and interconnected \ntechnology network, we provide biopharma a range of commercialization services.  And by automating and \nsimplifying the process of prior authorization, we reduce prescription abandonment and provide biop harma \naccess to new patients.  Our unique technology capabilities also generate insights into patients' needs and \nchallenges, enabling greater ability to impact patient actions and get better outcomes.  \n \n We support over 650 brands today, covering 94% of the therapeutic areas, and we're connected to all the major \ninsurance companies and most of the regional payers in the United States. ", "original_text": "Through our scaled and interconnected \ntechnology network, we provide biopharma a range of commercialization services. ", "page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70da607e-7d19-47fd-81bf-839e155c79d6", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "710553c2e6f132af3ec5ad89748d4385c3b8e1b3f0458f626a90856dca84f213", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "33705a49-f63f-4c73-bd47-06ce4eb1dab0", "node_type": "1", "metadata": {"window": "Ontada \nsigned two agreements with strategic partners to improve patient outcome and quality of patient care, and it was \ninstrumenta l in the launch of the MYLUNG Consortium, which through real -world research and study, provides \ncritical information to improve the patient's journey.  \n \n Within our biopharma ecosystem, we've built a set of differentiated assets and capabilities, including b usinesses \nlike RelayHealth Pharmacy, CoverMyMeds and RxCrossroads.  They're combined under the Prescription \nSolutions business, with a shared goal to improve access, adherence and affordability of medicines.  \n \n One of the key customers of our business is biop harma companies.  Through our scaled and interconnected \ntechnology network, we provide biopharma a range of commercialization services.  And by automating and \nsimplifying the process of prior authorization, we reduce prescription abandonment and provide biop harma \naccess to new patients.  Our unique technology capabilities also generate insights into patients' needs and \nchallenges, enabling greater ability to impact patient actions and get better outcomes.  \n \n", "original_text": "One of the key customers of our business is biop harma companies. ", "page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "67ba37d878214936930b7bd8e421d85ed4ed9b7f5a3e491992c705a466d0f110", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ffa573ef-dea8-4e84-899b-5898d6e2cc3f", "node_type": "1", "metadata": {"window": "They're combined under the Prescription \nSolutions business, with a shared goal to improve access, adherence and affordability of medicines.  \n \n One of the key customers of our business is biop harma companies.  Through our scaled and interconnected \ntechnology network, we provide biopharma a range of commercialization services.  And by automating and \nsimplifying the process of prior authorization, we reduce prescription abandonment and provide biop harma \naccess to new patients.  Our unique technology capabilities also generate insights into patients' needs and \nchallenges, enabling greater ability to impact patient actions and get better outcomes.  \n \n We support over 650 brands today, covering 94% of the therapeutic areas, and we're connected to all the major \ninsurance companies and most of the regional payers in the United States.  The reach of our network is deep and \nbroad, which is why it's the foundation of our biopharma ecosystem, and we are incredibly  excited about the \nmarket opportunities it brings.  \n \n", "original_text": "And by automating and \nsimplifying the process of prior authorization, we reduce prescription abandonment and provide biop harma \naccess to new patients. "}, "hash": "887391f4c90678dcf02645d34962a0f9c78b887cfbc066026e6f21308125bfe7", "class_name": "RelatedNodeInfo"}}, "text": "Through our scaled and interconnected \ntechnology network, we provide biopharma a range of commercialization services. ", "start_char_idx": 1125, "end_char_idx": 1244, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ffa573ef-dea8-4e84-899b-5898d6e2cc3f": {"__data__": {"id_": "ffa573ef-dea8-4e84-899b-5898d6e2cc3f", "embedding": null, "metadata": {"window": "They're combined under the Prescription \nSolutions business, with a shared goal to improve access, adherence and affordability of medicines.  \n \n One of the key customers of our business is biop harma companies.  Through our scaled and interconnected \ntechnology network, we provide biopharma a range of commercialization services.  And by automating and \nsimplifying the process of prior authorization, we reduce prescription abandonment and provide biop harma \naccess to new patients.  Our unique technology capabilities also generate insights into patients' needs and \nchallenges, enabling greater ability to impact patient actions and get better outcomes.  \n \n We support over 650 brands today, covering 94% of the therapeutic areas, and we're connected to all the major \ninsurance companies and most of the regional payers in the United States.  The reach of our network is deep and \nbroad, which is why it's the foundation of our biopharma ecosystem, and we are incredibly  excited about the \nmarket opportunities it brings.  \n \n", "original_text": "And by automating and \nsimplifying the process of prior authorization, we reduce prescription abandonment and provide biop harma \naccess to new patients. ", "page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70da607e-7d19-47fd-81bf-839e155c79d6", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "710553c2e6f132af3ec5ad89748d4385c3b8e1b3f0458f626a90856dca84f213", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c411ec14-e3fe-45ec-b889-aa785134a5d7", "node_type": "1", "metadata": {"window": "Within our biopharma ecosystem, we've built a set of differentiated assets and capabilities, including b usinesses \nlike RelayHealth Pharmacy, CoverMyMeds and RxCrossroads.  They're combined under the Prescription \nSolutions business, with a shared goal to improve access, adherence and affordability of medicines.  \n \n One of the key customers of our business is biop harma companies.  Through our scaled and interconnected \ntechnology network, we provide biopharma a range of commercialization services.  And by automating and \nsimplifying the process of prior authorization, we reduce prescription abandonment and provide biop harma \naccess to new patients.  Our unique technology capabilities also generate insights into patients' needs and \nchallenges, enabling greater ability to impact patient actions and get better outcomes.  \n \n We support over 650 brands today, covering 94% of the therapeutic areas, and we're connected to all the major \ninsurance companies and most of the regional payers in the United States. ", "original_text": "Through our scaled and interconnected \ntechnology network, we provide biopharma a range of commercialization services. ", "page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d4742c55eeda2f252a81ab06ed00efea161890cc673beb73d5fb88681cad625", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ddeb0920-b1b8-4b80-88d7-4bba3bea28a7", "node_type": "1", "metadata": {"window": "One of the key customers of our business is biop harma companies.  Through our scaled and interconnected \ntechnology network, we provide biopharma a range of commercialization services.  And by automating and \nsimplifying the process of prior authorization, we reduce prescription abandonment and provide biop harma \naccess to new patients.  Our unique technology capabilities also generate insights into patients' needs and \nchallenges, enabling greater ability to impact patient actions and get better outcomes.  \n \n We support over 650 brands today, covering 94% of the therapeutic areas, and we're connected to all the major \ninsurance companies and most of the regional payers in the United States.  The reach of our network is deep and \nbroad, which is why it's the foundation of our biopharma ecosystem, and we are incredibly  excited about the \nmarket opportunities it brings.  \n \n Our progress with each of the company priorities has been truly outstanding, and we see the strategies working. \n", "original_text": "Our unique technology capabilities also generate insights into patients' needs and \nchallenges, enabling greater ability to impact patient actions and get better outcomes.  \n \n"}, "hash": "750fca49f671566b9d74dd98853d04526b089062e88f113d580db80d9e907192", "class_name": "RelatedNodeInfo"}}, "text": "And by automating and \nsimplifying the process of prior authorization, we reduce prescription abandonment and provide biop harma \naccess to new patients. ", "start_char_idx": 1244, "end_char_idx": 1398, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ddeb0920-b1b8-4b80-88d7-4bba3bea28a7": {"__data__": {"id_": "ddeb0920-b1b8-4b80-88d7-4bba3bea28a7", "embedding": null, "metadata": {"window": "One of the key customers of our business is biop harma companies.  Through our scaled and interconnected \ntechnology network, we provide biopharma a range of commercialization services.  And by automating and \nsimplifying the process of prior authorization, we reduce prescription abandonment and provide biop harma \naccess to new patients.  Our unique technology capabilities also generate insights into patients' needs and \nchallenges, enabling greater ability to impact patient actions and get better outcomes.  \n \n We support over 650 brands today, covering 94% of the therapeutic areas, and we're connected to all the major \ninsurance companies and most of the regional payers in the United States.  The reach of our network is deep and \nbroad, which is why it's the foundation of our biopharma ecosystem, and we are incredibly  excited about the \nmarket opportunities it brings.  \n \n Our progress with each of the company priorities has been truly outstanding, and we see the strategies working. \n", "original_text": "Our unique technology capabilities also generate insights into patients' needs and \nchallenges, enabling greater ability to impact patient actions and get better outcomes.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70da607e-7d19-47fd-81bf-839e155c79d6", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "710553c2e6f132af3ec5ad89748d4385c3b8e1b3f0458f626a90856dca84f213", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ffa573ef-dea8-4e84-899b-5898d6e2cc3f", "node_type": "1", "metadata": {"window": "They're combined under the Prescription \nSolutions business, with a shared goal to improve access, adherence and affordability of medicines.  \n \n One of the key customers of our business is biop harma companies.  Through our scaled and interconnected \ntechnology network, we provide biopharma a range of commercialization services.  And by automating and \nsimplifying the process of prior authorization, we reduce prescription abandonment and provide biop harma \naccess to new patients.  Our unique technology capabilities also generate insights into patients' needs and \nchallenges, enabling greater ability to impact patient actions and get better outcomes.  \n \n We support over 650 brands today, covering 94% of the therapeutic areas, and we're connected to all the major \ninsurance companies and most of the regional payers in the United States.  The reach of our network is deep and \nbroad, which is why it's the foundation of our biopharma ecosystem, and we are incredibly  excited about the \nmarket opportunities it brings.  \n \n", "original_text": "And by automating and \nsimplifying the process of prior authorization, we reduce prescription abandonment and provide biop harma \naccess to new patients. ", "page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f6c7b32d74338c849d1f11f479087ac4a3988b5cb104bd66470ab6a46a092d76", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c57e2082-9ec5-4b25-bf15-9f816b83e910", "node_type": "1", "metadata": {"window": "Through our scaled and interconnected \ntechnology network, we provide biopharma a range of commercialization services.  And by automating and \nsimplifying the process of prior authorization, we reduce prescription abandonment and provide biop harma \naccess to new patients.  Our unique technology capabilities also generate insights into patients' needs and \nchallenges, enabling greater ability to impact patient actions and get better outcomes.  \n \n We support over 650 brands today, covering 94% of the therapeutic areas, and we're connected to all the major \ninsurance companies and most of the regional payers in the United States.  The reach of our network is deep and \nbroad, which is why it's the foundation of our biopharma ecosystem, and we are incredibly  excited about the \nmarket opportunities it brings.  \n \n Our progress with each of the company priorities has been truly outstanding, and we see the strategies working. \n The strong conviction in these priorities will be our North Star as we seek to advance and win in the marketplaces \nas a diversified healthcare service company and to drive long -term sustainable growth for our shareholders.  \n \n", "original_text": "We support over 650 brands today, covering 94% of the therapeutic areas, and we're connected to all the major \ninsurance companies and most of the regional payers in the United States. "}, "hash": "85895b036d076b0577bcef785860a846ee2fb107b5edfe648cb281a160e17754", "class_name": "RelatedNodeInfo"}}, "text": "Our unique technology capabilities also generate insights into patients' needs and \nchallenges, enabling greater ability to impact patient actions and get better outcomes.  \n \n", "start_char_idx": 1398, "end_char_idx": 1574, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c57e2082-9ec5-4b25-bf15-9f816b83e910": {"__data__": {"id_": "c57e2082-9ec5-4b25-bf15-9f816b83e910", "embedding": null, "metadata": {"window": "Through our scaled and interconnected \ntechnology network, we provide biopharma a range of commercialization services.  And by automating and \nsimplifying the process of prior authorization, we reduce prescription abandonment and provide biop harma \naccess to new patients.  Our unique technology capabilities also generate insights into patients' needs and \nchallenges, enabling greater ability to impact patient actions and get better outcomes.  \n \n We support over 650 brands today, covering 94% of the therapeutic areas, and we're connected to all the major \ninsurance companies and most of the regional payers in the United States.  The reach of our network is deep and \nbroad, which is why it's the foundation of our biopharma ecosystem, and we are incredibly  excited about the \nmarket opportunities it brings.  \n \n Our progress with each of the company priorities has been truly outstanding, and we see the strategies working. \n The strong conviction in these priorities will be our North Star as we seek to advance and win in the marketplaces \nas a diversified healthcare service company and to drive long -term sustainable growth for our shareholders.  \n \n", "original_text": "We support over 650 brands today, covering 94% of the therapeutic areas, and we're connected to all the major \ninsurance companies and most of the regional payers in the United States. ", "page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70da607e-7d19-47fd-81bf-839e155c79d6", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "710553c2e6f132af3ec5ad89748d4385c3b8e1b3f0458f626a90856dca84f213", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ddeb0920-b1b8-4b80-88d7-4bba3bea28a7", "node_type": "1", "metadata": {"window": "One of the key customers of our business is biop harma companies.  Through our scaled and interconnected \ntechnology network, we provide biopharma a range of commercialization services.  And by automating and \nsimplifying the process of prior authorization, we reduce prescription abandonment and provide biop harma \naccess to new patients.  Our unique technology capabilities also generate insights into patients' needs and \nchallenges, enabling greater ability to impact patient actions and get better outcomes.  \n \n We support over 650 brands today, covering 94% of the therapeutic areas, and we're connected to all the major \ninsurance companies and most of the regional payers in the United States.  The reach of our network is deep and \nbroad, which is why it's the foundation of our biopharma ecosystem, and we are incredibly  excited about the \nmarket opportunities it brings.  \n \n Our progress with each of the company priorities has been truly outstanding, and we see the strategies working. \n", "original_text": "Our unique technology capabilities also generate insights into patients' needs and \nchallenges, enabling greater ability to impact patient actions and get better outcomes.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5999ddc8ccbe474b9b470d88b3a33a98401fabc58b566bcdd097f16620ff7349", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f270d553-674d-4e9a-af17-2d046271f47a", "node_type": "1", "metadata": {"window": "And by automating and \nsimplifying the process of prior authorization, we reduce prescription abandonment and provide biop harma \naccess to new patients.  Our unique technology capabilities also generate insights into patients' needs and \nchallenges, enabling greater ability to impact patient actions and get better outcomes.  \n \n We support over 650 brands today, covering 94% of the therapeutic areas, and we're connected to all the major \ninsurance companies and most of the regional payers in the United States.  The reach of our network is deep and \nbroad, which is why it's the foundation of our biopharma ecosystem, and we are incredibly  excited about the \nmarket opportunities it brings.  \n \n Our progress with each of the company priorities has been truly outstanding, and we see the strategies working. \n The strong conviction in these priorities will be our North Star as we seek to advance and win in the marketplaces \nas a diversified healthcare service company and to drive long -term sustainable growth for our shareholders.  \n \n Now, before I turn to our third quarter results, I want to provide a brief update on the progress made towards a \nbroad reso lution of governmental opioid -related claims. ", "original_text": "The reach of our network is deep and \nbroad, which is why it's the foundation of our biopharma ecosystem, and we are incredibly  excited about the \nmarket opportunities it brings.  \n \n"}, "hash": "406d822679cd9c90f6c42e7d8a85d496da98623f271c89b294a0540dc4afc6fb", "class_name": "RelatedNodeInfo"}}, "text": "We support over 650 brands today, covering 94% of the therapeutic areas, and we're connected to all the major \ninsurance companies and most of the regional payers in the United States. ", "start_char_idx": 1574, "end_char_idx": 1759, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f270d553-674d-4e9a-af17-2d046271f47a": {"__data__": {"id_": "f270d553-674d-4e9a-af17-2d046271f47a", "embedding": null, "metadata": {"window": "And by automating and \nsimplifying the process of prior authorization, we reduce prescription abandonment and provide biop harma \naccess to new patients.  Our unique technology capabilities also generate insights into patients' needs and \nchallenges, enabling greater ability to impact patient actions and get better outcomes.  \n \n We support over 650 brands today, covering 94% of the therapeutic areas, and we're connected to all the major \ninsurance companies and most of the regional payers in the United States.  The reach of our network is deep and \nbroad, which is why it's the foundation of our biopharma ecosystem, and we are incredibly  excited about the \nmarket opportunities it brings.  \n \n Our progress with each of the company priorities has been truly outstanding, and we see the strategies working. \n The strong conviction in these priorities will be our North Star as we seek to advance and win in the marketplaces \nas a diversified healthcare service company and to drive long -term sustainable growth for our shareholders.  \n \n Now, before I turn to our third quarter results, I want to provide a brief update on the progress made towards a \nbroad reso lution of governmental opioid -related claims. ", "original_text": "The reach of our network is deep and \nbroad, which is why it's the foundation of our biopharma ecosystem, and we are incredibly  excited about the \nmarket opportunities it brings.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70da607e-7d19-47fd-81bf-839e155c79d6", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "710553c2e6f132af3ec5ad89748d4385c3b8e1b3f0458f626a90856dca84f213", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c57e2082-9ec5-4b25-bf15-9f816b83e910", "node_type": "1", "metadata": {"window": "Through our scaled and interconnected \ntechnology network, we provide biopharma a range of commercialization services.  And by automating and \nsimplifying the process of prior authorization, we reduce prescription abandonment and provide biop harma \naccess to new patients.  Our unique technology capabilities also generate insights into patients' needs and \nchallenges, enabling greater ability to impact patient actions and get better outcomes.  \n \n We support over 650 brands today, covering 94% of the therapeutic areas, and we're connected to all the major \ninsurance companies and most of the regional payers in the United States.  The reach of our network is deep and \nbroad, which is why it's the foundation of our biopharma ecosystem, and we are incredibly  excited about the \nmarket opportunities it brings.  \n \n Our progress with each of the company priorities has been truly outstanding, and we see the strategies working. \n The strong conviction in these priorities will be our North Star as we seek to advance and win in the marketplaces \nas a diversified healthcare service company and to drive long -term sustainable growth for our shareholders.  \n \n", "original_text": "We support over 650 brands today, covering 94% of the therapeutic areas, and we're connected to all the major \ninsurance companies and most of the regional payers in the United States. ", "page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7143bf7c66cecfead1abfbf32972515c3f3d65294ffffef76e844913bb2878ae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "73b8efa0-617d-4472-8084-fb0a245826d0", "node_type": "1", "metadata": {"window": "Our unique technology capabilities also generate insights into patients' needs and \nchallenges, enabling greater ability to impact patient actions and get better outcomes.  \n \n We support over 650 brands today, covering 94% of the therapeutic areas, and we're connected to all the major \ninsurance companies and most of the regional payers in the United States.  The reach of our network is deep and \nbroad, which is why it's the foundation of our biopharma ecosystem, and we are incredibly  excited about the \nmarket opportunities it brings.  \n \n Our progress with each of the company priorities has been truly outstanding, and we see the strategies working. \n The strong conviction in these priorities will be our North Star as we seek to advance and win in the marketplaces \nas a diversified healthcare service company and to drive long -term sustainable growth for our shareholders.  \n \n Now, before I turn to our third quarter results, I want to provide a brief update on the progress made towards a \nbroad reso lution of governmental opioid -related claims.  To date, 46 states, all 5 US territories and Washington \nD.C. ", "original_text": "Our progress with each of the company priorities has been truly outstanding, and we see the strategies working. \n"}, "hash": "52202ed5574e1a74fbe5202223eddce9322966b7b02c66a7f5e80838013a891f", "class_name": "RelatedNodeInfo"}}, "text": "The reach of our network is deep and \nbroad, which is why it's the foundation of our biopharma ecosystem, and we are incredibly  excited about the \nmarket opportunities it brings.  \n \n", "start_char_idx": 1759, "end_char_idx": 1943, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "73b8efa0-617d-4472-8084-fb0a245826d0": {"__data__": {"id_": "73b8efa0-617d-4472-8084-fb0a245826d0", "embedding": null, "metadata": {"window": "Our unique technology capabilities also generate insights into patients' needs and \nchallenges, enabling greater ability to impact patient actions and get better outcomes.  \n \n We support over 650 brands today, covering 94% of the therapeutic areas, and we're connected to all the major \ninsurance companies and most of the regional payers in the United States.  The reach of our network is deep and \nbroad, which is why it's the foundation of our biopharma ecosystem, and we are incredibly  excited about the \nmarket opportunities it brings.  \n \n Our progress with each of the company priorities has been truly outstanding, and we see the strategies working. \n The strong conviction in these priorities will be our North Star as we seek to advance and win in the marketplaces \nas a diversified healthcare service company and to drive long -term sustainable growth for our shareholders.  \n \n Now, before I turn to our third quarter results, I want to provide a brief update on the progress made towards a \nbroad reso lution of governmental opioid -related claims.  To date, 46 states, all 5 US territories and Washington \nD.C. ", "original_text": "Our progress with each of the company priorities has been truly outstanding, and we see the strategies working. \n", "page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70da607e-7d19-47fd-81bf-839e155c79d6", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "710553c2e6f132af3ec5ad89748d4385c3b8e1b3f0458f626a90856dca84f213", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f270d553-674d-4e9a-af17-2d046271f47a", "node_type": "1", "metadata": {"window": "And by automating and \nsimplifying the process of prior authorization, we reduce prescription abandonment and provide biop harma \naccess to new patients.  Our unique technology capabilities also generate insights into patients' needs and \nchallenges, enabling greater ability to impact patient actions and get better outcomes.  \n \n We support over 650 brands today, covering 94% of the therapeutic areas, and we're connected to all the major \ninsurance companies and most of the regional payers in the United States.  The reach of our network is deep and \nbroad, which is why it's the foundation of our biopharma ecosystem, and we are incredibly  excited about the \nmarket opportunities it brings.  \n \n Our progress with each of the company priorities has been truly outstanding, and we see the strategies working. \n The strong conviction in these priorities will be our North Star as we seek to advance and win in the marketplaces \nas a diversified healthcare service company and to drive long -term sustainable growth for our shareholders.  \n \n Now, before I turn to our third quarter results, I want to provide a brief update on the progress made towards a \nbroad reso lution of governmental opioid -related claims. ", "original_text": "The reach of our network is deep and \nbroad, which is why it's the foundation of our biopharma ecosystem, and we are incredibly  excited about the \nmarket opportunities it brings.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85eca7811ded35aa9b2fa3ad8d503bf0caf344842ca1b20dedb963acfe95ad38", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "56768881-e6a2-4f6f-85ba-51067d398aec", "node_type": "1", "metadata": {"window": "We support over 650 brands today, covering 94% of the therapeutic areas, and we're connected to all the major \ninsurance companies and most of the regional payers in the United States.  The reach of our network is deep and \nbroad, which is why it's the foundation of our biopharma ecosystem, and we are incredibly  excited about the \nmarket opportunities it brings.  \n \n Our progress with each of the company priorities has been truly outstanding, and we see the strategies working. \n The strong conviction in these priorities will be our North Star as we seek to advance and win in the marketplaces \nas a diversified healthcare service company and to drive long -term sustainable growth for our shareholders.  \n \n Now, before I turn to our third quarter results, I want to provide a brief update on the progress made towards a \nbroad reso lution of governmental opioid -related claims.  To date, 46 states, all 5 US territories and Washington \nD.C.  have joined the proposed settlement. ", "original_text": "The strong conviction in these priorities will be our North Star as we seek to advance and win in the marketplaces \nas a diversified healthcare service company and to drive long -term sustainable growth for our shareholders.  \n \n"}, "hash": "d9afe11cedeec12c01a9ee573a4507d7fff3bbc350dcb91f90f6394bbfdeff13", "class_name": "RelatedNodeInfo"}}, "text": "Our progress with each of the company priorities has been truly outstanding, and we see the strategies working. \n", "start_char_idx": 1943, "end_char_idx": 2056, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "56768881-e6a2-4f6f-85ba-51067d398aec": {"__data__": {"id_": "56768881-e6a2-4f6f-85ba-51067d398aec", "embedding": null, "metadata": {"window": "We support over 650 brands today, covering 94% of the therapeutic areas, and we're connected to all the major \ninsurance companies and most of the regional payers in the United States.  The reach of our network is deep and \nbroad, which is why it's the foundation of our biopharma ecosystem, and we are incredibly  excited about the \nmarket opportunities it brings.  \n \n Our progress with each of the company priorities has been truly outstanding, and we see the strategies working. \n The strong conviction in these priorities will be our North Star as we seek to advance and win in the marketplaces \nas a diversified healthcare service company and to drive long -term sustainable growth for our shareholders.  \n \n Now, before I turn to our third quarter results, I want to provide a brief update on the progress made towards a \nbroad reso lution of governmental opioid -related claims.  To date, 46 states, all 5 US territories and Washington \nD.C.  have joined the proposed settlement. ", "original_text": "The strong conviction in these priorities will be our North Star as we seek to advance and win in the marketplaces \nas a diversified healthcare service company and to drive long -term sustainable growth for our shareholders.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70da607e-7d19-47fd-81bf-839e155c79d6", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "710553c2e6f132af3ec5ad89748d4385c3b8e1b3f0458f626a90856dca84f213", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "73b8efa0-617d-4472-8084-fb0a245826d0", "node_type": "1", "metadata": {"window": "Our unique technology capabilities also generate insights into patients' needs and \nchallenges, enabling greater ability to impact patient actions and get better outcomes.  \n \n We support over 650 brands today, covering 94% of the therapeutic areas, and we're connected to all the major \ninsurance companies and most of the regional payers in the United States.  The reach of our network is deep and \nbroad, which is why it's the foundation of our biopharma ecosystem, and we are incredibly  excited about the \nmarket opportunities it brings.  \n \n Our progress with each of the company priorities has been truly outstanding, and we see the strategies working. \n The strong conviction in these priorities will be our North Star as we seek to advance and win in the marketplaces \nas a diversified healthcare service company and to drive long -term sustainable growth for our shareholders.  \n \n Now, before I turn to our third quarter results, I want to provide a brief update on the progress made towards a \nbroad reso lution of governmental opioid -related claims.  To date, 46 states, all 5 US territories and Washington \nD.C. ", "original_text": "Our progress with each of the company priorities has been truly outstanding, and we see the strategies working. \n", "page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da6625f3218f8993ead43790fd5105d0ecfe166aba29691ba62df871c551f9b0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ccf9017-219a-4422-a744-6116a14463bf", "node_type": "1", "metadata": {"window": "The reach of our network is deep and \nbroad, which is why it's the foundation of our biopharma ecosystem, and we are incredibly  excited about the \nmarket opportunities it brings.  \n \n Our progress with each of the company priorities has been truly outstanding, and we see the strategies working. \n The strong conviction in these priorities will be our North Star as we seek to advance and win in the marketplaces \nas a diversified healthcare service company and to drive long -term sustainable growth for our shareholders.  \n \n Now, before I turn to our third quarter results, I want to provide a brief update on the progress made towards a \nbroad reso lution of governmental opioid -related claims.  To date, 46 states, all 5 US territories and Washington \nD.C.  have joined the proposed settlement.  The sign -on period for political subdivisions in participating states to \njoin the previously announced proposed opioid settlement agreement ended on January 26. ", "original_text": "Now, before I turn to our third quarter results, I want to provide a brief update on the progress made towards a \nbroad reso lution of governmental opioid -related claims. "}, "hash": "910ca807b003af95a5413e1784bc21673a6f30a4ff33463a6888929145e5fc62", "class_name": "RelatedNodeInfo"}}, "text": "The strong conviction in these priorities will be our North Star as we seek to advance and win in the marketplaces \nas a diversified healthcare service company and to drive long -term sustainable growth for our shareholders.  \n \n", "start_char_idx": 2056, "end_char_idx": 2285, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5ccf9017-219a-4422-a744-6116a14463bf": {"__data__": {"id_": "5ccf9017-219a-4422-a744-6116a14463bf", "embedding": null, "metadata": {"window": "The reach of our network is deep and \nbroad, which is why it's the foundation of our biopharma ecosystem, and we are incredibly  excited about the \nmarket opportunities it brings.  \n \n Our progress with each of the company priorities has been truly outstanding, and we see the strategies working. \n The strong conviction in these priorities will be our North Star as we seek to advance and win in the marketplaces \nas a diversified healthcare service company and to drive long -term sustainable growth for our shareholders.  \n \n Now, before I turn to our third quarter results, I want to provide a brief update on the progress made towards a \nbroad reso lution of governmental opioid -related claims.  To date, 46 states, all 5 US territories and Washington \nD.C.  have joined the proposed settlement.  The sign -on period for political subdivisions in participating states to \njoin the previously announced proposed opioid settlement agreement ended on January 26. ", "original_text": "Now, before I turn to our third quarter results, I want to provide a brief update on the progress made towards a \nbroad reso lution of governmental opioid -related claims. ", "page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70da607e-7d19-47fd-81bf-839e155c79d6", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "710553c2e6f132af3ec5ad89748d4385c3b8e1b3f0458f626a90856dca84f213", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "56768881-e6a2-4f6f-85ba-51067d398aec", "node_type": "1", "metadata": {"window": "We support over 650 brands today, covering 94% of the therapeutic areas, and we're connected to all the major \ninsurance companies and most of the regional payers in the United States.  The reach of our network is deep and \nbroad, which is why it's the foundation of our biopharma ecosystem, and we are incredibly  excited about the \nmarket opportunities it brings.  \n \n Our progress with each of the company priorities has been truly outstanding, and we see the strategies working. \n The strong conviction in these priorities will be our North Star as we seek to advance and win in the marketplaces \nas a diversified healthcare service company and to drive long -term sustainable growth for our shareholders.  \n \n Now, before I turn to our third quarter results, I want to provide a brief update on the progress made towards a \nbroad reso lution of governmental opioid -related claims.  To date, 46 states, all 5 US territories and Washington \nD.C.  have joined the proposed settlement. ", "original_text": "The strong conviction in these priorities will be our North Star as we seek to advance and win in the marketplaces \nas a diversified healthcare service company and to drive long -term sustainable growth for our shareholders.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "40d13f6b98c9bf6d5b65aa27897d828d0fcfb2867ae52195628e0462f8222a62", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d410f7fb-5b8f-4b11-9722-04e957e5a9d2", "node_type": "1", "metadata": {"window": "Our progress with each of the company priorities has been truly outstanding, and we see the strategies working. \n The strong conviction in these priorities will be our North Star as we seek to advance and win in the marketplaces \nas a diversified healthcare service company and to drive long -term sustainable growth for our shareholders.  \n \n Now, before I turn to our third quarter results, I want to provide a brief update on the progress made towards a \nbroad reso lution of governmental opioid -related claims.  To date, 46 states, all 5 US territories and Washington \nD.C.  have joined the proposed settlement.  The sign -on period for political subdivisions in participating states to \njoin the previously announced proposed opioid settlement agreement ended on January 26.  We have now \nentered into the evaluation period. ", "original_text": "To date, 46 states, all 5 US territories and Washington \nD.C. "}, "hash": "244c2eded8e1f264fa87d058b50359fba1670bc1c3ca3b277c77dab83d0bc9d9", "class_name": "RelatedNodeInfo"}}, "text": "Now, before I turn to our third quarter results, I want to provide a brief update on the progress made towards a \nbroad reso lution of governmental opioid -related claims. ", "start_char_idx": 2285, "end_char_idx": 2457, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d410f7fb-5b8f-4b11-9722-04e957e5a9d2": {"__data__": {"id_": "d410f7fb-5b8f-4b11-9722-04e957e5a9d2", "embedding": null, "metadata": {"window": "Our progress with each of the company priorities has been truly outstanding, and we see the strategies working. \n The strong conviction in these priorities will be our North Star as we seek to advance and win in the marketplaces \nas a diversified healthcare service company and to drive long -term sustainable growth for our shareholders.  \n \n Now, before I turn to our third quarter results, I want to provide a brief update on the progress made towards a \nbroad reso lution of governmental opioid -related claims.  To date, 46 states, all 5 US territories and Washington \nD.C.  have joined the proposed settlement.  The sign -on period for political subdivisions in participating states to \njoin the previously announced proposed opioid settlement agreement ended on January 26.  We have now \nentered into the evaluation period. ", "original_text": "To date, 46 states, all 5 US territories and Washington \nD.C. ", "page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70da607e-7d19-47fd-81bf-839e155c79d6", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "710553c2e6f132af3ec5ad89748d4385c3b8e1b3f0458f626a90856dca84f213", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5ccf9017-219a-4422-a744-6116a14463bf", "node_type": "1", "metadata": {"window": "The reach of our network is deep and \nbroad, which is why it's the foundation of our biopharma ecosystem, and we are incredibly  excited about the \nmarket opportunities it brings.  \n \n Our progress with each of the company priorities has been truly outstanding, and we see the strategies working. \n The strong conviction in these priorities will be our North Star as we seek to advance and win in the marketplaces \nas a diversified healthcare service company and to drive long -term sustainable growth for our shareholders.  \n \n Now, before I turn to our third quarter results, I want to provide a brief update on the progress made towards a \nbroad reso lution of governmental opioid -related claims.  To date, 46 states, all 5 US territories and Washington \nD.C.  have joined the proposed settlement.  The sign -on period for political subdivisions in participating states to \njoin the previously announced proposed opioid settlement agreement ended on January 26. ", "original_text": "Now, before I turn to our third quarter results, I want to provide a brief update on the progress made towards a \nbroad reso lution of governmental opioid -related claims. ", "page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2369c5e189b3be8efe1e9be48e87fa785775837d44fa44d0b9d6dbef52bb993f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9f64acaa-167c-4083-bb4a-5404cc673a7b", "node_type": "1", "metadata": {"window": "The strong conviction in these priorities will be our North Star as we seek to advance and win in the marketplaces \nas a diversified healthcare service company and to drive long -term sustainable growth for our shareholders.  \n \n Now, before I turn to our third quarter results, I want to provide a brief update on the progress made towards a \nbroad reso lution of governmental opioid -related claims.  To date, 46 states, all 5 US territories and Washington \nD.C.  have joined the proposed settlement.  The sign -on period for political subdivisions in participating states to \njoin the previously announced proposed opioid settlement agreement ended on January 26.  We have now \nentered into the evaluation period.  The deadline for our decision is February 25, 2022. ", "original_text": "have joined the proposed settlement. "}, "hash": "821da1d274c443f6bf6f19431fbfbfeea4166faa6c356334e0adef6f8c6f6b32", "class_name": "RelatedNodeInfo"}}, "text": "To date, 46 states, all 5 US territories and Washington \nD.C. ", "start_char_idx": 2457, "end_char_idx": 2519, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9f64acaa-167c-4083-bb4a-5404cc673a7b": {"__data__": {"id_": "9f64acaa-167c-4083-bb4a-5404cc673a7b", "embedding": null, "metadata": {"window": "The strong conviction in these priorities will be our North Star as we seek to advance and win in the marketplaces \nas a diversified healthcare service company and to drive long -term sustainable growth for our shareholders.  \n \n Now, before I turn to our third quarter results, I want to provide a brief update on the progress made towards a \nbroad reso lution of governmental opioid -related claims.  To date, 46 states, all 5 US territories and Washington \nD.C.  have joined the proposed settlement.  The sign -on period for political subdivisions in participating states to \njoin the previously announced proposed opioid settlement agreement ended on January 26.  We have now \nentered into the evaluation period.  The deadline for our decision is February 25, 2022. ", "original_text": "have joined the proposed settlement. ", "page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70da607e-7d19-47fd-81bf-839e155c79d6", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "710553c2e6f132af3ec5ad89748d4385c3b8e1b3f0458f626a90856dca84f213", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d410f7fb-5b8f-4b11-9722-04e957e5a9d2", "node_type": "1", "metadata": {"window": "Our progress with each of the company priorities has been truly outstanding, and we see the strategies working. \n The strong conviction in these priorities will be our North Star as we seek to advance and win in the marketplaces \nas a diversified healthcare service company and to drive long -term sustainable growth for our shareholders.  \n \n Now, before I turn to our third quarter results, I want to provide a brief update on the progress made towards a \nbroad reso lution of governmental opioid -related claims.  To date, 46 states, all 5 US territories and Washington \nD.C.  have joined the proposed settlement.  The sign -on period for political subdivisions in participating states to \njoin the previously announced proposed opioid settlement agreement ended on January 26.  We have now \nentered into the evaluation period. ", "original_text": "To date, 46 states, all 5 US territories and Washington \nD.C. ", "page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7fbc333d621017a20b3f968dfbdcebfd578b371a540b969e86c3113c597b7770", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0a9cbe31-545e-4ee7-acf7-8b6f3f33abad", "node_type": "1", "metadata": {"window": "Now, before I turn to our third quarter results, I want to provide a brief update on the progress made towards a \nbroad reso lution of governmental opioid -related claims.  To date, 46 states, all 5 US territories and Washington \nD.C.  have joined the proposed settlement.  The sign -on period for political subdivisions in participating states to \njoin the previously announced proposed opioid settlement agreement ended on January 26.  We have now \nentered into the evaluation period.  The deadline for our decision is February 25, 2022.  We continue to work with \nall parties to bring meaningful relief to affected communities and towards resolut ions, which will allow us to further \nfocus on the strategic priorities of our business.  \n \n", "original_text": "The sign -on period for political subdivisions in participating states to \njoin the previously announced proposed opioid settlement agreement ended on January 26. "}, "hash": "3ace7d0fa4c8ecb37133b08bfcc42459ae065e2c44a2eeeff3c86031cfddf6bb", "class_name": "RelatedNodeInfo"}}, "text": "have joined the proposed settlement. ", "start_char_idx": 2519, "end_char_idx": 2556, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0a9cbe31-545e-4ee7-acf7-8b6f3f33abad": {"__data__": {"id_": "0a9cbe31-545e-4ee7-acf7-8b6f3f33abad", "embedding": null, "metadata": {"window": "Now, before I turn to our third quarter results, I want to provide a brief update on the progress made towards a \nbroad reso lution of governmental opioid -related claims.  To date, 46 states, all 5 US territories and Washington \nD.C.  have joined the proposed settlement.  The sign -on period for political subdivisions in participating states to \njoin the previously announced proposed opioid settlement agreement ended on January 26.  We have now \nentered into the evaluation period.  The deadline for our decision is February 25, 2022.  We continue to work with \nall parties to bring meaningful relief to affected communities and towards resolut ions, which will allow us to further \nfocus on the strategic priorities of our business.  \n \n", "original_text": "The sign -on period for political subdivisions in participating states to \njoin the previously announced proposed opioid settlement agreement ended on January 26. ", "page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70da607e-7d19-47fd-81bf-839e155c79d6", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "710553c2e6f132af3ec5ad89748d4385c3b8e1b3f0458f626a90856dca84f213", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9f64acaa-167c-4083-bb4a-5404cc673a7b", "node_type": "1", "metadata": {"window": "The strong conviction in these priorities will be our North Star as we seek to advance and win in the marketplaces \nas a diversified healthcare service company and to drive long -term sustainable growth for our shareholders.  \n \n Now, before I turn to our third quarter results, I want to provide a brief update on the progress made towards a \nbroad reso lution of governmental opioid -related claims.  To date, 46 states, all 5 US territories and Washington \nD.C.  have joined the proposed settlement.  The sign -on period for political subdivisions in participating states to \njoin the previously announced proposed opioid settlement agreement ended on January 26.  We have now \nentered into the evaluation period.  The deadline for our decision is February 25, 2022. ", "original_text": "have joined the proposed settlement. ", "page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e585c09e63b0e5368e0a41edd2c0deffe32608d2e676bb6ad3ecef1e54718bf4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "06c8d1d1-9781-4d51-9c8d-de67a48f2152", "node_type": "1", "metadata": {"window": "To date, 46 states, all 5 US territories and Washington \nD.C.  have joined the proposed settlement.  The sign -on period for political subdivisions in participating states to \njoin the previously announced proposed opioid settlement agreement ended on January 26.  We have now \nentered into the evaluation period.  The deadline for our decision is February 25, 2022.  We continue to work with \nall parties to bring meaningful relief to affected communities and towards resolut ions, which will allow us to further \nfocus on the strategic priorities of our business.  \n \n Now, let me get to the results. ", "original_text": "We have now \nentered into the evaluation period. "}, "hash": "d03ff32076f29290b0ba409c443eaae8bf8c7fa9bdb3f17c234f541d52c05973", "class_name": "RelatedNodeInfo"}}, "text": "The sign -on period for political subdivisions in participating states to \njoin the previously announced proposed opioid settlement agreement ended on January 26. ", "start_char_idx": 2556, "end_char_idx": 2719, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "06c8d1d1-9781-4d51-9c8d-de67a48f2152": {"__data__": {"id_": "06c8d1d1-9781-4d51-9c8d-de67a48f2152", "embedding": null, "metadata": {"window": "To date, 46 states, all 5 US territories and Washington \nD.C.  have joined the proposed settlement.  The sign -on period for political subdivisions in participating states to \njoin the previously announced proposed opioid settlement agreement ended on January 26.  We have now \nentered into the evaluation period.  The deadline for our decision is February 25, 2022.  We continue to work with \nall parties to bring meaningful relief to affected communities and towards resolut ions, which will allow us to further \nfocus on the strategic priorities of our business.  \n \n Now, let me get to the results. ", "original_text": "We have now \nentered into the evaluation period. ", "page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70da607e-7d19-47fd-81bf-839e155c79d6", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "710553c2e6f132af3ec5ad89748d4385c3b8e1b3f0458f626a90856dca84f213", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0a9cbe31-545e-4ee7-acf7-8b6f3f33abad", "node_type": "1", "metadata": {"window": "Now, before I turn to our third quarter results, I want to provide a brief update on the progress made towards a \nbroad reso lution of governmental opioid -related claims.  To date, 46 states, all 5 US territories and Washington \nD.C.  have joined the proposed settlement.  The sign -on period for political subdivisions in participating states to \njoin the previously announced proposed opioid settlement agreement ended on January 26.  We have now \nentered into the evaluation period.  The deadline for our decision is February 25, 2022.  We continue to work with \nall parties to bring meaningful relief to affected communities and towards resolut ions, which will allow us to further \nfocus on the strategic priorities of our business.  \n \n", "original_text": "The sign -on period for political subdivisions in participating states to \njoin the previously announced proposed opioid settlement agreement ended on January 26. ", "page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2ffdddf20045d0e9623dbf7770ecfc8c5806d4b2fea11c4bb34d5663d77f3876", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bbd193fb-35e4-4ff3-a3ab-f36b5701bb62", "node_type": "1", "metadata": {"window": "have joined the proposed settlement.  The sign -on period for political subdivisions in participating states to \njoin the previously announced proposed opioid settlement agreement ended on January 26.  We have now \nentered into the evaluation period.  The deadline for our decision is February 25, 2022.  We continue to work with \nall parties to bring meaningful relief to affected communities and towards resolut ions, which will allow us to further \nfocus on the strategic priorities of our business.  \n \n Now, let me get to the results.  We're pleased to report a strong third quarter with total company revenues of $68.6 \nbillion and an adjusted earnings per diluted share of $6.15, ahead of our expectations. ", "original_text": "The deadline for our decision is February 25, 2022. "}, "hash": "3cf14a60e9ee79c751af69c013a1ed14905442f0e545bbdff46b3f1c429bd717", "class_name": "RelatedNodeInfo"}}, "text": "We have now \nentered into the evaluation period. ", "start_char_idx": 2719, "end_char_idx": 2768, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bbd193fb-35e4-4ff3-a3ab-f36b5701bb62": {"__data__": {"id_": "bbd193fb-35e4-4ff3-a3ab-f36b5701bb62", "embedding": null, "metadata": {"window": "have joined the proposed settlement.  The sign -on period for political subdivisions in participating states to \njoin the previously announced proposed opioid settlement agreement ended on January 26.  We have now \nentered into the evaluation period.  The deadline for our decision is February 25, 2022.  We continue to work with \nall parties to bring meaningful relief to affected communities and towards resolut ions, which will allow us to further \nfocus on the strategic priorities of our business.  \n \n Now, let me get to the results.  We're pleased to report a strong third quarter with total company revenues of $68.6 \nbillion and an adjusted earnings per diluted share of $6.15, ahead of our expectations. ", "original_text": "The deadline for our decision is February 25, 2022. ", "page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70da607e-7d19-47fd-81bf-839e155c79d6", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "710553c2e6f132af3ec5ad89748d4385c3b8e1b3f0458f626a90856dca84f213", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "06c8d1d1-9781-4d51-9c8d-de67a48f2152", "node_type": "1", "metadata": {"window": "To date, 46 states, all 5 US territories and Washington \nD.C.  have joined the proposed settlement.  The sign -on period for political subdivisions in participating states to \njoin the previously announced proposed opioid settlement agreement ended on January 26.  We have now \nentered into the evaluation period.  The deadline for our decision is February 25, 2022.  We continue to work with \nall parties to bring meaningful relief to affected communities and towards resolut ions, which will allow us to further \nfocus on the strategic priorities of our business.  \n \n Now, let me get to the results. ", "original_text": "We have now \nentered into the evaluation period. ", "page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9e234b1794235c7df489a87ffcb6eedc3bb474582777cff47903cd1a4b881a75", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ac67a572-79dc-4953-bb2b-401da20871ec", "node_type": "1", "metadata": {"window": "The sign -on period for political subdivisions in participating states to \njoin the previously announced proposed opioid settlement agreement ended on January 26.  We have now \nentered into the evaluation period.  The deadline for our decision is February 25, 2022.  We continue to work with \nall parties to bring meaningful relief to affected communities and towards resolut ions, which will allow us to further \nfocus on the strategic priorities of our business.  \n \n Now, let me get to the results.  We're pleased to report a strong third quarter with total company revenues of $68.6 \nbillion and an adjusted earnings per diluted share of $6.15, ahead of our expectations.  As a result of our \nperformance in the underlying business and the contribution from COVID -19-related items, we are raising our \nadjusted earnings per diluted share guidance to $23.55 to $23.95. ", "original_text": "We continue to work with \nall parties to bring meaningful relief to affected communities and towards resolut ions, which will allow us to further \nfocus on the strategic priorities of our business.  \n \n"}, "hash": "069a332c65081d36caec3c9c0e3310deddc5ebdd0642176b58e51ca6e397fb8c", "class_name": "RelatedNodeInfo"}}, "text": "The deadline for our decision is February 25, 2022. ", "start_char_idx": 2768, "end_char_idx": 2820, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ac67a572-79dc-4953-bb2b-401da20871ec": {"__data__": {"id_": "ac67a572-79dc-4953-bb2b-401da20871ec", "embedding": null, "metadata": {"window": "The sign -on period for political subdivisions in participating states to \njoin the previously announced proposed opioid settlement agreement ended on January 26.  We have now \nentered into the evaluation period.  The deadline for our decision is February 25, 2022.  We continue to work with \nall parties to bring meaningful relief to affected communities and towards resolut ions, which will allow us to further \nfocus on the strategic priorities of our business.  \n \n Now, let me get to the results.  We're pleased to report a strong third quarter with total company revenues of $68.6 \nbillion and an adjusted earnings per diluted share of $6.15, ahead of our expectations.  As a result of our \nperformance in the underlying business and the contribution from COVID -19-related items, we are raising our \nadjusted earnings per diluted share guidance to $23.55 to $23.95. ", "original_text": "We continue to work with \nall parties to bring meaningful relief to affected communities and towards resolut ions, which will allow us to further \nfocus on the strategic priorities of our business.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70da607e-7d19-47fd-81bf-839e155c79d6", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "710553c2e6f132af3ec5ad89748d4385c3b8e1b3f0458f626a90856dca84f213", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bbd193fb-35e4-4ff3-a3ab-f36b5701bb62", "node_type": "1", "metadata": {"window": "have joined the proposed settlement.  The sign -on period for political subdivisions in participating states to \njoin the previously announced proposed opioid settlement agreement ended on January 26.  We have now \nentered into the evaluation period.  The deadline for our decision is February 25, 2022.  We continue to work with \nall parties to bring meaningful relief to affected communities and towards resolut ions, which will allow us to further \nfocus on the strategic priorities of our business.  \n \n Now, let me get to the results.  We're pleased to report a strong third quarter with total company revenues of $68.6 \nbillion and an adjusted earnings per diluted share of $6.15, ahead of our expectations. ", "original_text": "The deadline for our decision is February 25, 2022. ", "page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c651e2f580f010dbcec00c5dcaeae2c82a2c099e8f93dca7903e3802fbf9f593", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "61853ba4-7eab-41ad-adb2-1f46a9d041e6", "node_type": "1", "metadata": {"window": "We have now \nentered into the evaluation period.  The deadline for our decision is February 25, 2022.  We continue to work with \nall parties to bring meaningful relief to affected communities and towards resolut ions, which will allow us to further \nfocus on the strategic priorities of our business.  \n \n Now, let me get to the results.  We're pleased to report a strong third quarter with total company revenues of $68.6 \nbillion and an adjusted earnings per diluted share of $6.15, ahead of our expectations.  As a result of our \nperformance in the underlying business and the contribution from COVID -19-related items, we are raising our \nadjusted earnings per diluted share guidance to $23.55 to $23.95.  This is from the previous range of $22.35 to \n$22.95.  \n \n", "original_text": "Now, let me get to the results. "}, "hash": "054763db8109bd65126e1a17048caa46e23fe28b3dd7ad8cf3dddbbed4e30503", "class_name": "RelatedNodeInfo"}}, "text": "We continue to work with \nall parties to bring meaningful relief to affected communities and towards resolut ions, which will allow us to further \nfocus on the strategic priorities of our business.  \n \n", "start_char_idx": 2820, "end_char_idx": 3022, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "61853ba4-7eab-41ad-adb2-1f46a9d041e6": {"__data__": {"id_": "61853ba4-7eab-41ad-adb2-1f46a9d041e6", "embedding": null, "metadata": {"window": "We have now \nentered into the evaluation period.  The deadline for our decision is February 25, 2022.  We continue to work with \nall parties to bring meaningful relief to affected communities and towards resolut ions, which will allow us to further \nfocus on the strategic priorities of our business.  \n \n Now, let me get to the results.  We're pleased to report a strong third quarter with total company revenues of $68.6 \nbillion and an adjusted earnings per diluted share of $6.15, ahead of our expectations.  As a result of our \nperformance in the underlying business and the contribution from COVID -19-related items, we are raising our \nadjusted earnings per diluted share guidance to $23.55 to $23.95.  This is from the previous range of $22.35 to \n$22.95.  \n \n", "original_text": "Now, let me get to the results. ", "page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70da607e-7d19-47fd-81bf-839e155c79d6", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "710553c2e6f132af3ec5ad89748d4385c3b8e1b3f0458f626a90856dca84f213", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ac67a572-79dc-4953-bb2b-401da20871ec", "node_type": "1", "metadata": {"window": "The sign -on period for political subdivisions in participating states to \njoin the previously announced proposed opioid settlement agreement ended on January 26.  We have now \nentered into the evaluation period.  The deadline for our decision is February 25, 2022.  We continue to work with \nall parties to bring meaningful relief to affected communities and towards resolut ions, which will allow us to further \nfocus on the strategic priorities of our business.  \n \n Now, let me get to the results.  We're pleased to report a strong third quarter with total company revenues of $68.6 \nbillion and an adjusted earnings per diluted share of $6.15, ahead of our expectations.  As a result of our \nperformance in the underlying business and the contribution from COVID -19-related items, we are raising our \nadjusted earnings per diluted share guidance to $23.55 to $23.95. ", "original_text": "We continue to work with \nall parties to bring meaningful relief to affected communities and towards resolut ions, which will allow us to further \nfocus on the strategic priorities of our business.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "487f78a1fcedceaa3d5aa33ca7447a09261136a7716391eb8a7ce88728cb93c5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8457722b-d6af-4bc8-adcd-a0bb79281f8b", "node_type": "1", "metadata": {"window": "The deadline for our decision is February 25, 2022.  We continue to work with \nall parties to bring meaningful relief to affected communities and towards resolut ions, which will allow us to further \nfocus on the strategic priorities of our business.  \n \n Now, let me get to the results.  We're pleased to report a strong third quarter with total company revenues of $68.6 \nbillion and an adjusted earnings per diluted share of $6.15, ahead of our expectations.  As a result of our \nperformance in the underlying business and the contribution from COVID -19-related items, we are raising our \nadjusted earnings per diluted share guidance to $23.55 to $23.95.  This is from the previous range of $22.35 to \n$22.95.  \n \n The third quarter was another example of the non -linear nature of the recovery from the pandemic. ", "original_text": "We're pleased to report a strong third quarter with total company revenues of $68.6 \nbillion and an adjusted earnings per diluted share of $6.15, ahead of our expectations. "}, "hash": "80ce47eeaa4050c3521a0616fe08938cd19f3cda0a08630535d033bb26bb4138", "class_name": "RelatedNodeInfo"}}, "text": "Now, let me get to the results. ", "start_char_idx": 3022, "end_char_idx": 3054, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8457722b-d6af-4bc8-adcd-a0bb79281f8b": {"__data__": {"id_": "8457722b-d6af-4bc8-adcd-a0bb79281f8b", "embedding": null, "metadata": {"window": "The deadline for our decision is February 25, 2022.  We continue to work with \nall parties to bring meaningful relief to affected communities and towards resolut ions, which will allow us to further \nfocus on the strategic priorities of our business.  \n \n Now, let me get to the results.  We're pleased to report a strong third quarter with total company revenues of $68.6 \nbillion and an adjusted earnings per diluted share of $6.15, ahead of our expectations.  As a result of our \nperformance in the underlying business and the contribution from COVID -19-related items, we are raising our \nadjusted earnings per diluted share guidance to $23.55 to $23.95.  This is from the previous range of $22.35 to \n$22.95.  \n \n The third quarter was another example of the non -linear nature of the recovery from the pandemic. ", "original_text": "We're pleased to report a strong third quarter with total company revenues of $68.6 \nbillion and an adjusted earnings per diluted share of $6.15, ahead of our expectations. ", "page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70da607e-7d19-47fd-81bf-839e155c79d6", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "710553c2e6f132af3ec5ad89748d4385c3b8e1b3f0458f626a90856dca84f213", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "61853ba4-7eab-41ad-adb2-1f46a9d041e6", "node_type": "1", "metadata": {"window": "We have now \nentered into the evaluation period.  The deadline for our decision is February 25, 2022.  We continue to work with \nall parties to bring meaningful relief to affected communities and towards resolut ions, which will allow us to further \nfocus on the strategic priorities of our business.  \n \n Now, let me get to the results.  We're pleased to report a strong third quarter with total company revenues of $68.6 \nbillion and an adjusted earnings per diluted share of $6.15, ahead of our expectations.  As a result of our \nperformance in the underlying business and the contribution from COVID -19-related items, we are raising our \nadjusted earnings per diluted share guidance to $23.55 to $23.95.  This is from the previous range of $22.35 to \n$22.95.  \n \n", "original_text": "Now, let me get to the results. ", "page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8f08404c4fdcf2961edef75a0797f08c2567b7e299cf7680e18626fd757ca5c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d89069f0-cf12-42ff-8d14-f07af910cab2", "node_type": "1", "metadata": {"window": "We continue to work with \nall parties to bring meaningful relief to affected communities and towards resolut ions, which will allow us to further \nfocus on the strategic priorities of our business.  \n \n Now, let me get to the results.  We're pleased to report a strong third quarter with total company revenues of $68.6 \nbillion and an adjusted earnings per diluted share of $6.15, ahead of our expectations.  As a result of our \nperformance in the underlying business and the contribution from COVID -19-related items, we are raising our \nadjusted earnings per diluted share guidance to $23.55 to $23.95.  This is from the previous range of $22.35 to \n$22.95.  \n \n The third quarter was another example of the non -linear nature of the recovery from the pandemic.  At the \nbeginning of the quarter, volume and utilization trends were recovering as COVID -19 cases continue to decline \nacross the co untry. ", "original_text": "As a result of our \nperformance in the underlying business and the contribution from COVID -19-related items, we are raising our \nadjusted earnings per diluted share guidance to $23.55 to $23.95. "}, "hash": "36a3e9781dc0e37af799715d7797097fee5ab7dedb0ed74a11cd6847ee62f27a", "class_name": "RelatedNodeInfo"}}, "text": "We're pleased to report a strong third quarter with total company revenues of $68.6 \nbillion and an adjusted earnings per diluted share of $6.15, ahead of our expectations. ", "start_char_idx": 3054, "end_char_idx": 3227, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d89069f0-cf12-42ff-8d14-f07af910cab2": {"__data__": {"id_": "d89069f0-cf12-42ff-8d14-f07af910cab2", "embedding": null, "metadata": {"window": "We continue to work with \nall parties to bring meaningful relief to affected communities and towards resolut ions, which will allow us to further \nfocus on the strategic priorities of our business.  \n \n Now, let me get to the results.  We're pleased to report a strong third quarter with total company revenues of $68.6 \nbillion and an adjusted earnings per diluted share of $6.15, ahead of our expectations.  As a result of our \nperformance in the underlying business and the contribution from COVID -19-related items, we are raising our \nadjusted earnings per diluted share guidance to $23.55 to $23.95.  This is from the previous range of $22.35 to \n$22.95.  \n \n The third quarter was another example of the non -linear nature of the recovery from the pandemic.  At the \nbeginning of the quarter, volume and utilization trends were recovering as COVID -19 cases continue to decline \nacross the co untry. ", "original_text": "As a result of our \nperformance in the underlying business and the contribution from COVID -19-related items, we are raising our \nadjusted earnings per diluted share guidance to $23.55 to $23.95. ", "page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70da607e-7d19-47fd-81bf-839e155c79d6", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "710553c2e6f132af3ec5ad89748d4385c3b8e1b3f0458f626a90856dca84f213", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8457722b-d6af-4bc8-adcd-a0bb79281f8b", "node_type": "1", "metadata": {"window": "The deadline for our decision is February 25, 2022.  We continue to work with \nall parties to bring meaningful relief to affected communities and towards resolut ions, which will allow us to further \nfocus on the strategic priorities of our business.  \n \n Now, let me get to the results.  We're pleased to report a strong third quarter with total company revenues of $68.6 \nbillion and an adjusted earnings per diluted share of $6.15, ahead of our expectations.  As a result of our \nperformance in the underlying business and the contribution from COVID -19-related items, we are raising our \nadjusted earnings per diluted share guidance to $23.55 to $23.95.  This is from the previous range of $22.35 to \n$22.95.  \n \n The third quarter was another example of the non -linear nature of the recovery from the pandemic. ", "original_text": "We're pleased to report a strong third quarter with total company revenues of $68.6 \nbillion and an adjusted earnings per diluted share of $6.15, ahead of our expectations. ", "page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4ba869c48b15e396928df78ed3341dd1f05ac05cb89055f7c2fd1d4ad3bf3750", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b051128d-89e6-485e-9c12-fd7bc32d4b56", "node_type": "1", "metadata": {"window": "Now, let me get to the results.  We're pleased to report a strong third quarter with total company revenues of $68.6 \nbillion and an adjusted earnings per diluted share of $6.15, ahead of our expectations.  As a result of our \nperformance in the underlying business and the contribution from COVID -19-related items, we are raising our \nadjusted earnings per diluted share guidance to $23.55 to $23.95.  This is from the previous range of $22.35 to \n$22.95.  \n \n The third quarter was another example of the non -linear nature of the recovery from the pandemic.  At the \nbeginning of the quarter, volume and utilization trends were recovering as COVID -19 cases continue to decline \nacross the co untry.  Although we expected a non -linear recovery trend, the emergence and the spread of the \nOmicron variant in December was unexpected. ", "original_text": "This is from the previous range of $22.35 to \n$22.95.  \n \n"}, "hash": "d1525faf5374983f839a9757d5c8a5c2afeae582fe203aa09373ef36272a7ca8", "class_name": "RelatedNodeInfo"}}, "text": "As a result of our \nperformance in the underlying business and the contribution from COVID -19-related items, we are raising our \nadjusted earnings per diluted share guidance to $23.55 to $23.95. ", "start_char_idx": 3227, "end_char_idx": 3423, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b051128d-89e6-485e-9c12-fd7bc32d4b56": {"__data__": {"id_": "b051128d-89e6-485e-9c12-fd7bc32d4b56", "embedding": null, "metadata": {"window": "Now, let me get to the results.  We're pleased to report a strong third quarter with total company revenues of $68.6 \nbillion and an adjusted earnings per diluted share of $6.15, ahead of our expectations.  As a result of our \nperformance in the underlying business and the contribution from COVID -19-related items, we are raising our \nadjusted earnings per diluted share guidance to $23.55 to $23.95.  This is from the previous range of $22.35 to \n$22.95.  \n \n The third quarter was another example of the non -linear nature of the recovery from the pandemic.  At the \nbeginning of the quarter, volume and utilization trends were recovering as COVID -19 cases continue to decline \nacross the co untry.  Although we expected a non -linear recovery trend, the emergence and the spread of the \nOmicron variant in December was unexpected. ", "original_text": "This is from the previous range of $22.35 to \n$22.95.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70da607e-7d19-47fd-81bf-839e155c79d6", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "710553c2e6f132af3ec5ad89748d4385c3b8e1b3f0458f626a90856dca84f213", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d89069f0-cf12-42ff-8d14-f07af910cab2", "node_type": "1", "metadata": {"window": "We continue to work with \nall parties to bring meaningful relief to affected communities and towards resolut ions, which will allow us to further \nfocus on the strategic priorities of our business.  \n \n Now, let me get to the results.  We're pleased to report a strong third quarter with total company revenues of $68.6 \nbillion and an adjusted earnings per diluted share of $6.15, ahead of our expectations.  As a result of our \nperformance in the underlying business and the contribution from COVID -19-related items, we are raising our \nadjusted earnings per diluted share guidance to $23.55 to $23.95.  This is from the previous range of $22.35 to \n$22.95.  \n \n The third quarter was another example of the non -linear nature of the recovery from the pandemic.  At the \nbeginning of the quarter, volume and utilization trends were recovering as COVID -19 cases continue to decline \nacross the co untry. ", "original_text": "As a result of our \nperformance in the underlying business and the contribution from COVID -19-related items, we are raising our \nadjusted earnings per diluted share guidance to $23.55 to $23.95. ", "page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1ce2c658c6379356ed43a3a61469d02d8f729866396733cad8514b1c699ea996", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c0d07f0f-c7b9-4fa3-ae1e-7da456577a31", "node_type": "1", "metadata": {"window": "We're pleased to report a strong third quarter with total company revenues of $68.6 \nbillion and an adjusted earnings per diluted share of $6.15, ahead of our expectations.  As a result of our \nperformance in the underlying business and the contribution from COVID -19-related items, we are raising our \nadjusted earnings per diluted share guidance to $23.55 to $23.95.  This is from the previous range of $22.35 to \n$22.95.  \n \n The third quarter was another example of the non -linear nature of the recovery from the pandemic.  At the \nbeginning of the quarter, volume and utilization trends were recovering as COVID -19 cases continue to decline \nacross the co untry.  Although we expected a non -linear recovery trend, the emergence and the spread of the \nOmicron variant in December was unexpected.  Since then, we've been closely monitoring its impact.  \n ", "original_text": "The third quarter was another example of the non -linear nature of the recovery from the pandemic. "}, "hash": "0349b65e5cb0b835e1802aec83e3d1cac094478078d925189d9756983d744417", "class_name": "RelatedNodeInfo"}}, "text": "This is from the previous range of $22.35 to \n$22.95.  \n \n", "start_char_idx": 3423, "end_char_idx": 3481, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c0d07f0f-c7b9-4fa3-ae1e-7da456577a31": {"__data__": {"id_": "c0d07f0f-c7b9-4fa3-ae1e-7da456577a31", "embedding": null, "metadata": {"window": "We're pleased to report a strong third quarter with total company revenues of $68.6 \nbillion and an adjusted earnings per diluted share of $6.15, ahead of our expectations.  As a result of our \nperformance in the underlying business and the contribution from COVID -19-related items, we are raising our \nadjusted earnings per diluted share guidance to $23.55 to $23.95.  This is from the previous range of $22.35 to \n$22.95.  \n \n The third quarter was another example of the non -linear nature of the recovery from the pandemic.  At the \nbeginning of the quarter, volume and utilization trends were recovering as COVID -19 cases continue to decline \nacross the co untry.  Although we expected a non -linear recovery trend, the emergence and the spread of the \nOmicron variant in December was unexpected.  Since then, we've been closely monitoring its impact.  \n ", "original_text": "The third quarter was another example of the non -linear nature of the recovery from the pandemic. ", "page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70da607e-7d19-47fd-81bf-839e155c79d6", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "710553c2e6f132af3ec5ad89748d4385c3b8e1b3f0458f626a90856dca84f213", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b051128d-89e6-485e-9c12-fd7bc32d4b56", "node_type": "1", "metadata": {"window": "Now, let me get to the results.  We're pleased to report a strong third quarter with total company revenues of $68.6 \nbillion and an adjusted earnings per diluted share of $6.15, ahead of our expectations.  As a result of our \nperformance in the underlying business and the contribution from COVID -19-related items, we are raising our \nadjusted earnings per diluted share guidance to $23.55 to $23.95.  This is from the previous range of $22.35 to \n$22.95.  \n \n The third quarter was another example of the non -linear nature of the recovery from the pandemic.  At the \nbeginning of the quarter, volume and utilization trends were recovering as COVID -19 cases continue to decline \nacross the co untry.  Although we expected a non -linear recovery trend, the emergence and the spread of the \nOmicron variant in December was unexpected. ", "original_text": "This is from the previous range of $22.35 to \n$22.95.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a45c380fdc89f9676cfe9899238050d72b643dc0b10f689f423d9f26bcad2faf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "58f52f9a-d989-45e1-bf79-e1c4abcab881", "node_type": "1", "metadata": {"window": "As a result of our \nperformance in the underlying business and the contribution from COVID -19-related items, we are raising our \nadjusted earnings per diluted share guidance to $23.55 to $23.95.  This is from the previous range of $22.35 to \n$22.95.  \n \n The third quarter was another example of the non -linear nature of the recovery from the pandemic.  At the \nbeginning of the quarter, volume and utilization trends were recovering as COVID -19 cases continue to decline \nacross the co untry.  Although we expected a non -linear recovery trend, the emergence and the spread of the \nOmicron variant in December was unexpected.  Since then, we've been closely monitoring its impact.  \n ", "original_text": "At the \nbeginning of the quarter, volume and utilization trends were recovering as COVID -19 cases continue to decline \nacross the co untry. "}, "hash": "2b181d7ccb0309a6e19a8186673f4750e35a9f379a4c2bdc8b74726cb494be24", "class_name": "RelatedNodeInfo"}}, "text": "The third quarter was another example of the non -linear nature of the recovery from the pandemic. ", "start_char_idx": 3481, "end_char_idx": 3580, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "58f52f9a-d989-45e1-bf79-e1c4abcab881": {"__data__": {"id_": "58f52f9a-d989-45e1-bf79-e1c4abcab881", "embedding": null, "metadata": {"window": "As a result of our \nperformance in the underlying business and the contribution from COVID -19-related items, we are raising our \nadjusted earnings per diluted share guidance to $23.55 to $23.95.  This is from the previous range of $22.35 to \n$22.95.  \n \n The third quarter was another example of the non -linear nature of the recovery from the pandemic.  At the \nbeginning of the quarter, volume and utilization trends were recovering as COVID -19 cases continue to decline \nacross the co untry.  Although we expected a non -linear recovery trend, the emergence and the spread of the \nOmicron variant in December was unexpected.  Since then, we've been closely monitoring its impact.  \n ", "original_text": "At the \nbeginning of the quarter, volume and utilization trends were recovering as COVID -19 cases continue to decline \nacross the co untry. ", "page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70da607e-7d19-47fd-81bf-839e155c79d6", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "710553c2e6f132af3ec5ad89748d4385c3b8e1b3f0458f626a90856dca84f213", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c0d07f0f-c7b9-4fa3-ae1e-7da456577a31", "node_type": "1", "metadata": {"window": "We're pleased to report a strong third quarter with total company revenues of $68.6 \nbillion and an adjusted earnings per diluted share of $6.15, ahead of our expectations.  As a result of our \nperformance in the underlying business and the contribution from COVID -19-related items, we are raising our \nadjusted earnings per diluted share guidance to $23.55 to $23.95.  This is from the previous range of $22.35 to \n$22.95.  \n \n The third quarter was another example of the non -linear nature of the recovery from the pandemic.  At the \nbeginning of the quarter, volume and utilization trends were recovering as COVID -19 cases continue to decline \nacross the co untry.  Although we expected a non -linear recovery trend, the emergence and the spread of the \nOmicron variant in December was unexpected.  Since then, we've been closely monitoring its impact.  \n ", "original_text": "The third quarter was another example of the non -linear nature of the recovery from the pandemic. ", "page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8e803bbcebb8d8541469f35a1d66c8b64df8133a72f64bf79a9bb9a1a1040fcc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "883ce365-fbfb-403d-8b0a-8bee1ae1303b", "node_type": "1", "metadata": {"window": "This is from the previous range of $22.35 to \n$22.95.  \n \n The third quarter was another example of the non -linear nature of the recovery from the pandemic.  At the \nbeginning of the quarter, volume and utilization trends were recovering as COVID -19 cases continue to decline \nacross the co untry.  Although we expected a non -linear recovery trend, the emergence and the spread of the \nOmicron variant in December was unexpected.  Since then, we've been closely monitoring its impact.  \n ", "original_text": "Although we expected a non -linear recovery trend, the emergence and the spread of the \nOmicron variant in December was unexpected. "}, "hash": "861c1bf665672a6a233512c0cc8f8502c789c4c0f8319d4b84a16a028e28e88a", "class_name": "RelatedNodeInfo"}}, "text": "At the \nbeginning of the quarter, volume and utilization trends were recovering as COVID -19 cases continue to decline \nacross the co untry. ", "start_char_idx": 3580, "end_char_idx": 3721, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "883ce365-fbfb-403d-8b0a-8bee1ae1303b": {"__data__": {"id_": "883ce365-fbfb-403d-8b0a-8bee1ae1303b", "embedding": null, "metadata": {"window": "This is from the previous range of $22.35 to \n$22.95.  \n \n The third quarter was another example of the non -linear nature of the recovery from the pandemic.  At the \nbeginning of the quarter, volume and utilization trends were recovering as COVID -19 cases continue to decline \nacross the co untry.  Although we expected a non -linear recovery trend, the emergence and the spread of the \nOmicron variant in December was unexpected.  Since then, we've been closely monitoring its impact.  \n ", "original_text": "Although we expected a non -linear recovery trend, the emergence and the spread of the \nOmicron variant in December was unexpected. ", "page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70da607e-7d19-47fd-81bf-839e155c79d6", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "710553c2e6f132af3ec5ad89748d4385c3b8e1b3f0458f626a90856dca84f213", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "58f52f9a-d989-45e1-bf79-e1c4abcab881", "node_type": "1", "metadata": {"window": "As a result of our \nperformance in the underlying business and the contribution from COVID -19-related items, we are raising our \nadjusted earnings per diluted share guidance to $23.55 to $23.95.  This is from the previous range of $22.35 to \n$22.95.  \n \n The third quarter was another example of the non -linear nature of the recovery from the pandemic.  At the \nbeginning of the quarter, volume and utilization trends were recovering as COVID -19 cases continue to decline \nacross the co untry.  Although we expected a non -linear recovery trend, the emergence and the spread of the \nOmicron variant in December was unexpected.  Since then, we've been closely monitoring its impact.  \n ", "original_text": "At the \nbeginning of the quarter, volume and utilization trends were recovering as COVID -19 cases continue to decline \nacross the co untry. ", "page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "600b8e12492477a39453c5db4dc604956c12356d7eeb2aaa94b589c7dd444aca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bfa9c64d-023f-4dad-9f67-660b907b1e51", "node_type": "1", "metadata": {"window": "The third quarter was another example of the non -linear nature of the recovery from the pandemic.  At the \nbeginning of the quarter, volume and utilization trends were recovering as COVID -19 cases continue to decline \nacross the co untry.  Although we expected a non -linear recovery trend, the emergence and the spread of the \nOmicron variant in December was unexpected.  Since then, we've been closely monitoring its impact.  \n ", "original_text": "Since then, we've been closely monitoring its impact.  \n "}, "hash": "7e09f2898ff52c30a63233a34ed71280454ed0655914915ce79e077755d840e0", "class_name": "RelatedNodeInfo"}}, "text": "Although we expected a non -linear recovery trend, the emergence and the spread of the \nOmicron variant in December was unexpected. ", "start_char_idx": 3721, "end_char_idx": 3853, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bfa9c64d-023f-4dad-9f67-660b907b1e51": {"__data__": {"id_": "bfa9c64d-023f-4dad-9f67-660b907b1e51", "embedding": null, "metadata": {"window": "The third quarter was another example of the non -linear nature of the recovery from the pandemic.  At the \nbeginning of the quarter, volume and utilization trends were recovering as COVID -19 cases continue to decline \nacross the co untry.  Although we expected a non -linear recovery trend, the emergence and the spread of the \nOmicron variant in December was unexpected.  Since then, we've been closely monitoring its impact.  \n ", "original_text": "Since then, we've been closely monitoring its impact.  \n ", "page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "70da607e-7d19-47fd-81bf-839e155c79d6", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "710553c2e6f132af3ec5ad89748d4385c3b8e1b3f0458f626a90856dca84f213", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "883ce365-fbfb-403d-8b0a-8bee1ae1303b", "node_type": "1", "metadata": {"window": "This is from the previous range of $22.35 to \n$22.95.  \n \n The third quarter was another example of the non -linear nature of the recovery from the pandemic.  At the \nbeginning of the quarter, volume and utilization trends were recovering as COVID -19 cases continue to decline \nacross the co untry.  Although we expected a non -linear recovery trend, the emergence and the spread of the \nOmicron variant in December was unexpected.  Since then, we've been closely monitoring its impact.  \n ", "original_text": "Although we expected a non -linear recovery trend, the emergence and the spread of the \nOmicron variant in December was unexpected. ", "page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6782798f8cee69cd128e16b5fcb1e6abd403d3e51ed6f7ebd9b9588f90a515a5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8e4368a9-f037-46be-b4ce-b87fb7f600c1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nOne thing we've learned in the past two years is the resilience of our business and our communities.  Regardless \nof the trajectory of the pandemic, we're confident about our ability to adjust and adapt to support our customers \nand their patients in these challenging times.  \n \n Let's turn to the US Pharmaceutical segment. ", "original_text": "McKesson Corp.  "}, "hash": "88469240b5dab2eaa2d84580f578bbe144e928938a0d9b5072df1bf488f6b545", "class_name": "RelatedNodeInfo"}}, "text": "Since then, we've been closely monitoring its impact.  \n ", "start_char_idx": 3853, "end_char_idx": 3910, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8e4368a9-f037-46be-b4ce-b87fb7f600c1": {"__data__": {"id_": "8e4368a9-f037-46be-b4ce-b87fb7f600c1", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nOne thing we've learned in the past two years is the resilience of our business and our communities.  Regardless \nof the trajectory of the pandemic, we're confident about our ability to adjust and adapt to support our customers \nand their patients in these challenging times.  \n \n Let's turn to the US Pharmaceutical segment. ", "original_text": "McKesson Corp.  ", "page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ea37bd0c-fbe1-40ae-aa75-ffa08508dd21", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aa05efcb14edae5b17785cfe97740e25aa1bdbfb060bf5106d520e4e3113a759", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bfa9c64d-023f-4dad-9f67-660b907b1e51", "node_type": "1", "metadata": {"window": "The third quarter was another example of the non -linear nature of the recovery from the pandemic.  At the \nbeginning of the quarter, volume and utilization trends were recovering as COVID -19 cases continue to decline \nacross the co untry.  Although we expected a non -linear recovery trend, the emergence and the spread of the \nOmicron variant in December was unexpected.  Since then, we've been closely monitoring its impact.  \n ", "original_text": "Since then, we've been closely monitoring its impact.  \n ", "page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e7ed144f88851ebe49cf931a48a9a855a6a06ec60dedc5e098311958b3a58850", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2f187df5-cbf9-4722-8477-3128a20244b6", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nOne thing we've learned in the past two years is the resilience of our business and our communities.  Regardless \nof the trajectory of the pandemic, we're confident about our ability to adjust and adapt to support our customers \nand their patients in these challenging times.  \n \n Let's turn to the US Pharmaceutical segment.  U S Pharmaceutical segment saw 12% adjusted operating profit \ngrowth, which was underpinned by the contribution from COVID -19 vaccine distribution and increased specialty \nvolume. ", "original_text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nOne thing we've learned in the past two years is the resilience of our business and our communities. "}, "hash": "c67ed64cf050f40850d44a1db283ca7a67ef543de63a9df9af23f0fdc5c5e544", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2f187df5-cbf9-4722-8477-3128a20244b6": {"__data__": {"id_": "2f187df5-cbf9-4722-8477-3128a20244b6", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nOne thing we've learned in the past two years is the resilience of our business and our communities.  Regardless \nof the trajectory of the pandemic, we're confident about our ability to adjust and adapt to support our customers \nand their patients in these challenging times.  \n \n Let's turn to the US Pharmaceutical segment.  U S Pharmaceutical segment saw 12% adjusted operating profit \ngrowth, which was underpinned by the contribution from COVID -19 vaccine distribution and increased specialty \nvolume. ", "original_text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nOne thing we've learned in the past two years is the resilience of our business and our communities. ", "page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ea37bd0c-fbe1-40ae-aa75-ffa08508dd21", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aa05efcb14edae5b17785cfe97740e25aa1bdbfb060bf5106d520e4e3113a759", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8e4368a9-f037-46be-b4ce-b87fb7f600c1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nOne thing we've learned in the past two years is the resilience of our business and our communities.  Regardless \nof the trajectory of the pandemic, we're confident about our ability to adjust and adapt to support our customers \nand their patients in these challenging times.  \n \n Let's turn to the US Pharmaceutical segment. ", "original_text": "McKesson Corp.  ", "page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "77c009545a6e7fdbbeb13d69c32e7754f0ae90a6449a9d67023d2904b79174f7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5b2bdd58-f465-49a4-9b90-414522bb4107", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nOne thing we've learned in the past two years is the resilience of our business and our communities.  Regardless \nof the trajectory of the pandemic, we're confident about our ability to adjust and adapt to support our customers \nand their patients in these challenging times.  \n \n Let's turn to the US Pharmaceutical segment.  U S Pharmaceutical segment saw 12% adjusted operating profit \ngrowth, which was underpinned by the contribution from COVID -19 vaccine distribution and increased specialty \nvolume.  Through the third quarter and into January, branded pharmaceutical pricing has t racked in line with our \noriginal expectations and consistent with our experience over the past several years.  \n \n", "original_text": "Regardless \nof the trajectory of the pandemic, we're confident about our ability to adjust and adapt to support our customers \nand their patients in these challenging times.  \n \n"}, "hash": "f995759b31fa4e61476d732fc6693e3b62e81634d6e9d70afe06f260e5370714", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nOne thing we've learned in the past two years is the resilience of our business and our communities. ", "start_char_idx": 16, "end_char_idx": 281, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5b2bdd58-f465-49a4-9b90-414522bb4107": {"__data__": {"id_": "5b2bdd58-f465-49a4-9b90-414522bb4107", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nOne thing we've learned in the past two years is the resilience of our business and our communities.  Regardless \nof the trajectory of the pandemic, we're confident about our ability to adjust and adapt to support our customers \nand their patients in these challenging times.  \n \n Let's turn to the US Pharmaceutical segment.  U S Pharmaceutical segment saw 12% adjusted operating profit \ngrowth, which was underpinned by the contribution from COVID -19 vaccine distribution and increased specialty \nvolume.  Through the third quarter and into January, branded pharmaceutical pricing has t racked in line with our \noriginal expectations and consistent with our experience over the past several years.  \n \n", "original_text": "Regardless \nof the trajectory of the pandemic, we're confident about our ability to adjust and adapt to support our customers \nand their patients in these challenging times.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ea37bd0c-fbe1-40ae-aa75-ffa08508dd21", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aa05efcb14edae5b17785cfe97740e25aa1bdbfb060bf5106d520e4e3113a759", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2f187df5-cbf9-4722-8477-3128a20244b6", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nOne thing we've learned in the past two years is the resilience of our business and our communities.  Regardless \nof the trajectory of the pandemic, we're confident about our ability to adjust and adapt to support our customers \nand their patients in these challenging times.  \n \n Let's turn to the US Pharmaceutical segment.  U S Pharmaceutical segment saw 12% adjusted operating profit \ngrowth, which was underpinned by the contribution from COVID -19 vaccine distribution and increased specialty \nvolume. ", "original_text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nOne thing we've learned in the past two years is the resilience of our business and our communities. ", "page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "eb7099632bb39918263c052001ee1a759b4e23d8dd37dad41d973f54e5ee786c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "38fe2b25-3fa9-4855-9579-c060e0076c50", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nOne thing we've learned in the past two years is the resilience of our business and our communities.  Regardless \nof the trajectory of the pandemic, we're confident about our ability to adjust and adapt to support our customers \nand their patients in these challenging times.  \n \n Let's turn to the US Pharmaceutical segment.  U S Pharmaceutical segment saw 12% adjusted operating profit \ngrowth, which was underpinned by the contribution from COVID -19 vaccine distribution and increased specialty \nvolume.  Through the third quarter and into January, branded pharmaceutical pricing has t racked in line with our \noriginal expectations and consistent with our experience over the past several years.  \n \n For generics, we continue to benefit from the success and strength of our sourcing operation with ClarusONE. ", "original_text": "Let's turn to the US Pharmaceutical segment. "}, "hash": "51ddeca9e7efe8a16a40b7da1dfc03df4bf0581f88a11a951b1507cdc8152833", "class_name": "RelatedNodeInfo"}}, "text": "Regardless \nof the trajectory of the pandemic, we're confident about our ability to adjust and adapt to support our customers \nand their patients in these challenging times.  \n \n", "start_char_idx": 281, "end_char_idx": 459, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "38fe2b25-3fa9-4855-9579-c060e0076c50": {"__data__": {"id_": "38fe2b25-3fa9-4855-9579-c060e0076c50", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nOne thing we've learned in the past two years is the resilience of our business and our communities.  Regardless \nof the trajectory of the pandemic, we're confident about our ability to adjust and adapt to support our customers \nand their patients in these challenging times.  \n \n Let's turn to the US Pharmaceutical segment.  U S Pharmaceutical segment saw 12% adjusted operating profit \ngrowth, which was underpinned by the contribution from COVID -19 vaccine distribution and increased specialty \nvolume.  Through the third quarter and into January, branded pharmaceutical pricing has t racked in line with our \noriginal expectations and consistent with our experience over the past several years.  \n \n For generics, we continue to benefit from the success and strength of our sourcing operation with ClarusONE. ", "original_text": "Let's turn to the US Pharmaceutical segment. ", "page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ea37bd0c-fbe1-40ae-aa75-ffa08508dd21", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aa05efcb14edae5b17785cfe97740e25aa1bdbfb060bf5106d520e4e3113a759", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5b2bdd58-f465-49a4-9b90-414522bb4107", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nOne thing we've learned in the past two years is the resilience of our business and our communities.  Regardless \nof the trajectory of the pandemic, we're confident about our ability to adjust and adapt to support our customers \nand their patients in these challenging times.  \n \n Let's turn to the US Pharmaceutical segment.  U S Pharmaceutical segment saw 12% adjusted operating profit \ngrowth, which was underpinned by the contribution from COVID -19 vaccine distribution and increased specialty \nvolume.  Through the third quarter and into January, branded pharmaceutical pricing has t racked in line with our \noriginal expectations and consistent with our experience over the past several years.  \n \n", "original_text": "Regardless \nof the trajectory of the pandemic, we're confident about our ability to adjust and adapt to support our customers \nand their patients in these challenging times.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a1f2b0f0ec042ef1f25fcad56deddd5cdeb8a003031c6c38b8b0feb8cb9076e8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "086981e8-b73c-4cb8-a3f7-4da221613f18", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nOne thing we've learned in the past two years is the resilience of our business and our communities.  Regardless \nof the trajectory of the pandemic, we're confident about our ability to adjust and adapt to support our customers \nand their patients in these challenging times.  \n \n Let's turn to the US Pharmaceutical segment.  U S Pharmaceutical segment saw 12% adjusted operating profit \ngrowth, which was underpinned by the contribution from COVID -19 vaccine distribution and increased specialty \nvolume.  Through the third quarter and into January, branded pharmaceutical pricing has t racked in line with our \noriginal expectations and consistent with our experience over the past several years.  \n \n For generics, we continue to benefit from the success and strength of our sourcing operation with ClarusONE.  We \nhave not only the scale, but the procurement expertise to consistently source products at low cost, while \nprotecting the integrity and the safety of the supply chain.  \n \n", "original_text": "U S Pharmaceutical segment saw 12% adjusted operating profit \ngrowth, which was underpinned by the contribution from COVID -19 vaccine distribution and increased specialty \nvolume. "}, "hash": "95d7346fd661222bb92aab490b8c14043b06958125cceb506a70250afec16f0e", "class_name": "RelatedNodeInfo"}}, "text": "Let's turn to the US Pharmaceutical segment. ", "start_char_idx": 459, "end_char_idx": 504, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "086981e8-b73c-4cb8-a3f7-4da221613f18": {"__data__": {"id_": "086981e8-b73c-4cb8-a3f7-4da221613f18", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nOne thing we've learned in the past two years is the resilience of our business and our communities.  Regardless \nof the trajectory of the pandemic, we're confident about our ability to adjust and adapt to support our customers \nand their patients in these challenging times.  \n \n Let's turn to the US Pharmaceutical segment.  U S Pharmaceutical segment saw 12% adjusted operating profit \ngrowth, which was underpinned by the contribution from COVID -19 vaccine distribution and increased specialty \nvolume.  Through the third quarter and into January, branded pharmaceutical pricing has t racked in line with our \noriginal expectations and consistent with our experience over the past several years.  \n \n For generics, we continue to benefit from the success and strength of our sourcing operation with ClarusONE.  We \nhave not only the scale, but the procurement expertise to consistently source products at low cost, while \nprotecting the integrity and the safety of the supply chain.  \n \n", "original_text": "U S Pharmaceutical segment saw 12% adjusted operating profit \ngrowth, which was underpinned by the contribution from COVID -19 vaccine distribution and increased specialty \nvolume. ", "page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ea37bd0c-fbe1-40ae-aa75-ffa08508dd21", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aa05efcb14edae5b17785cfe97740e25aa1bdbfb060bf5106d520e4e3113a759", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "38fe2b25-3fa9-4855-9579-c060e0076c50", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nOne thing we've learned in the past two years is the resilience of our business and our communities.  Regardless \nof the trajectory of the pandemic, we're confident about our ability to adjust and adapt to support our customers \nand their patients in these challenging times.  \n \n Let's turn to the US Pharmaceutical segment.  U S Pharmaceutical segment saw 12% adjusted operating profit \ngrowth, which was underpinned by the contribution from COVID -19 vaccine distribution and increased specialty \nvolume.  Through the third quarter and into January, branded pharmaceutical pricing has t racked in line with our \noriginal expectations and consistent with our experience over the past several years.  \n \n For generics, we continue to benefit from the success and strength of our sourcing operation with ClarusONE. ", "original_text": "Let's turn to the US Pharmaceutical segment. ", "page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8201bacdfac370ed025e67d6813ccb7a9463bfd6374727b2f3fd056983d9accd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bda270ba-819a-4481-8c6d-5bedb2af63dd", "node_type": "1", "metadata": {"window": "Regardless \nof the trajectory of the pandemic, we're confident about our ability to adjust and adapt to support our customers \nand their patients in these challenging times.  \n \n Let's turn to the US Pharmaceutical segment.  U S Pharmaceutical segment saw 12% adjusted operating profit \ngrowth, which was underpinned by the contribution from COVID -19 vaccine distribution and increased specialty \nvolume.  Through the third quarter and into January, branded pharmaceutical pricing has t racked in line with our \noriginal expectations and consistent with our experience over the past several years.  \n \n For generics, we continue to benefit from the success and strength of our sourcing operation with ClarusONE.  We \nhave not only the scale, but the procurement expertise to consistently source products at low cost, while \nprotecting the integrity and the safety of the supply chain.  \n \n We are also proud of our role in supporting the US government's pandemic response effort as the vaccine and \nbooster recom mendations for various age groups continues to expand and evolve. ", "original_text": "Through the third quarter and into January, branded pharmaceutical pricing has t racked in line with our \noriginal expectations and consistent with our experience over the past several years.  \n \n"}, "hash": "c2113cb0adaca7db77bbe438be1abe0c2352b73c3a4d2219a883afd59c7acd5c", "class_name": "RelatedNodeInfo"}}, "text": "U S Pharmaceutical segment saw 12% adjusted operating profit \ngrowth, which was underpinned by the contribution from COVID -19 vaccine distribution and increased specialty \nvolume. ", "start_char_idx": 504, "end_char_idx": 685, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bda270ba-819a-4481-8c6d-5bedb2af63dd": {"__data__": {"id_": "bda270ba-819a-4481-8c6d-5bedb2af63dd", "embedding": null, "metadata": {"window": "Regardless \nof the trajectory of the pandemic, we're confident about our ability to adjust and adapt to support our customers \nand their patients in these challenging times.  \n \n Let's turn to the US Pharmaceutical segment.  U S Pharmaceutical segment saw 12% adjusted operating profit \ngrowth, which was underpinned by the contribution from COVID -19 vaccine distribution and increased specialty \nvolume.  Through the third quarter and into January, branded pharmaceutical pricing has t racked in line with our \noriginal expectations and consistent with our experience over the past several years.  \n \n For generics, we continue to benefit from the success and strength of our sourcing operation with ClarusONE.  We \nhave not only the scale, but the procurement expertise to consistently source products at low cost, while \nprotecting the integrity and the safety of the supply chain.  \n \n We are also proud of our role in supporting the US government's pandemic response effort as the vaccine and \nbooster recom mendations for various age groups continues to expand and evolve. ", "original_text": "Through the third quarter and into January, branded pharmaceutical pricing has t racked in line with our \noriginal expectations and consistent with our experience over the past several years.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ea37bd0c-fbe1-40ae-aa75-ffa08508dd21", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aa05efcb14edae5b17785cfe97740e25aa1bdbfb060bf5106d520e4e3113a759", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "086981e8-b73c-4cb8-a3f7-4da221613f18", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nOne thing we've learned in the past two years is the resilience of our business and our communities.  Regardless \nof the trajectory of the pandemic, we're confident about our ability to adjust and adapt to support our customers \nand their patients in these challenging times.  \n \n Let's turn to the US Pharmaceutical segment.  U S Pharmaceutical segment saw 12% adjusted operating profit \ngrowth, which was underpinned by the contribution from COVID -19 vaccine distribution and increased specialty \nvolume.  Through the third quarter and into January, branded pharmaceutical pricing has t racked in line with our \noriginal expectations and consistent with our experience over the past several years.  \n \n For generics, we continue to benefit from the success and strength of our sourcing operation with ClarusONE.  We \nhave not only the scale, but the procurement expertise to consistently source products at low cost, while \nprotecting the integrity and the safety of the supply chain.  \n \n", "original_text": "U S Pharmaceutical segment saw 12% adjusted operating profit \ngrowth, which was underpinned by the contribution from COVID -19 vaccine distribution and increased specialty \nvolume. ", "page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "071ad30e8e5f6b71fc3b1927c4cdb26f927bd02057f2e00185eb4f017aed2043", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8388bdbf-921b-42d0-ac78-03b28c46fe09", "node_type": "1", "metadata": {"window": "Let's turn to the US Pharmaceutical segment.  U S Pharmaceutical segment saw 12% adjusted operating profit \ngrowth, which was underpinned by the contribution from COVID -19 vaccine distribution and increased specialty \nvolume.  Through the third quarter and into January, branded pharmaceutical pricing has t racked in line with our \noriginal expectations and consistent with our experience over the past several years.  \n \n For generics, we continue to benefit from the success and strength of our sourcing operation with ClarusONE.  We \nhave not only the scale, but the procurement expertise to consistently source products at low cost, while \nprotecting the integrity and the safety of the supply chain.  \n \n We are also proud of our role in supporting the US government's pandemic response effort as the vaccine and \nbooster recom mendations for various age groups continues to expand and evolve.  Through January 31, our US \nPharmaceutical business has successfully distributed over 370 million Moderna and Johnson & Johnson COVID -\n19 vaccines to administration sites all across the United  States and in support of the US government's \ninternational donation mission. ", "original_text": "For generics, we continue to benefit from the success and strength of our sourcing operation with ClarusONE. "}, "hash": "5cd5f87c3340f44550f783f9308161f8e3286b74b03b9b0ba394c7d62974046e", "class_name": "RelatedNodeInfo"}}, "text": "Through the third quarter and into January, branded pharmaceutical pricing has t racked in line with our \noriginal expectations and consistent with our experience over the past several years.  \n \n", "start_char_idx": 685, "end_char_idx": 881, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8388bdbf-921b-42d0-ac78-03b28c46fe09": {"__data__": {"id_": "8388bdbf-921b-42d0-ac78-03b28c46fe09", "embedding": null, "metadata": {"window": "Let's turn to the US Pharmaceutical segment.  U S Pharmaceutical segment saw 12% adjusted operating profit \ngrowth, which was underpinned by the contribution from COVID -19 vaccine distribution and increased specialty \nvolume.  Through the third quarter and into January, branded pharmaceutical pricing has t racked in line with our \noriginal expectations and consistent with our experience over the past several years.  \n \n For generics, we continue to benefit from the success and strength of our sourcing operation with ClarusONE.  We \nhave not only the scale, but the procurement expertise to consistently source products at low cost, while \nprotecting the integrity and the safety of the supply chain.  \n \n We are also proud of our role in supporting the US government's pandemic response effort as the vaccine and \nbooster recom mendations for various age groups continues to expand and evolve.  Through January 31, our US \nPharmaceutical business has successfully distributed over 370 million Moderna and Johnson & Johnson COVID -\n19 vaccines to administration sites all across the United  States and in support of the US government's \ninternational donation mission. ", "original_text": "For generics, we continue to benefit from the success and strength of our sourcing operation with ClarusONE. ", "page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ea37bd0c-fbe1-40ae-aa75-ffa08508dd21", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aa05efcb14edae5b17785cfe97740e25aa1bdbfb060bf5106d520e4e3113a759", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bda270ba-819a-4481-8c6d-5bedb2af63dd", "node_type": "1", "metadata": {"window": "Regardless \nof the trajectory of the pandemic, we're confident about our ability to adjust and adapt to support our customers \nand their patients in these challenging times.  \n \n Let's turn to the US Pharmaceutical segment.  U S Pharmaceutical segment saw 12% adjusted operating profit \ngrowth, which was underpinned by the contribution from COVID -19 vaccine distribution and increased specialty \nvolume.  Through the third quarter and into January, branded pharmaceutical pricing has t racked in line with our \noriginal expectations and consistent with our experience over the past several years.  \n \n For generics, we continue to benefit from the success and strength of our sourcing operation with ClarusONE.  We \nhave not only the scale, but the procurement expertise to consistently source products at low cost, while \nprotecting the integrity and the safety of the supply chain.  \n \n We are also proud of our role in supporting the US government's pandemic response effort as the vaccine and \nbooster recom mendations for various age groups continues to expand and evolve. ", "original_text": "Through the third quarter and into January, branded pharmaceutical pricing has t racked in line with our \noriginal expectations and consistent with our experience over the past several years.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "76b62358a4b2beb2480aaeb46d231dbe34d8fe09674b7f726c760e925d6be831", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7940deef-3c3a-4cd1-b396-60b409fe4d76", "node_type": "1", "metadata": {"window": "U S Pharmaceutical segment saw 12% adjusted operating profit \ngrowth, which was underpinned by the contribution from COVID -19 vaccine distribution and increased specialty \nvolume.  Through the third quarter and into January, branded pharmaceutical pricing has t racked in line with our \noriginal expectations and consistent with our experience over the past several years.  \n \n For generics, we continue to benefit from the success and strength of our sourcing operation with ClarusONE.  We \nhave not only the scale, but the procurement expertise to consistently source products at low cost, while \nprotecting the integrity and the safety of the supply chain.  \n \n We are also proud of our role in supporting the US government's pandemic response effort as the vaccine and \nbooster recom mendations for various age groups continues to expand and evolve.  Through January 31, our US \nPharmaceutical business has successfully distributed over 370 million Moderna and Johnson & Johnson COVID -\n19 vaccines to administration sites all across the United  States and in support of the US government's \ninternational donation mission.  In January, the US government extended the existing COVID -19 vaccine \ndistribution contract through July of 2022, which is roughly in line with the first quarter of our fiscal 202 3. \n \n", "original_text": "We \nhave not only the scale, but the procurement expertise to consistently source products at low cost, while \nprotecting the integrity and the safety of the supply chain.  \n \n"}, "hash": "867f30b502669c51d03cb8509e750de13530c4a245a5ba29849ab8fba5e61c87", "class_name": "RelatedNodeInfo"}}, "text": "For generics, we continue to benefit from the success and strength of our sourcing operation with ClarusONE. ", "start_char_idx": 881, "end_char_idx": 990, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7940deef-3c3a-4cd1-b396-60b409fe4d76": {"__data__": {"id_": "7940deef-3c3a-4cd1-b396-60b409fe4d76", "embedding": null, "metadata": {"window": "U S Pharmaceutical segment saw 12% adjusted operating profit \ngrowth, which was underpinned by the contribution from COVID -19 vaccine distribution and increased specialty \nvolume.  Through the third quarter and into January, branded pharmaceutical pricing has t racked in line with our \noriginal expectations and consistent with our experience over the past several years.  \n \n For generics, we continue to benefit from the success and strength of our sourcing operation with ClarusONE.  We \nhave not only the scale, but the procurement expertise to consistently source products at low cost, while \nprotecting the integrity and the safety of the supply chain.  \n \n We are also proud of our role in supporting the US government's pandemic response effort as the vaccine and \nbooster recom mendations for various age groups continues to expand and evolve.  Through January 31, our US \nPharmaceutical business has successfully distributed over 370 million Moderna and Johnson & Johnson COVID -\n19 vaccines to administration sites all across the United  States and in support of the US government's \ninternational donation mission.  In January, the US government extended the existing COVID -19 vaccine \ndistribution contract through July of 2022, which is roughly in line with the first quarter of our fiscal 202 3. \n \n", "original_text": "We \nhave not only the scale, but the procurement expertise to consistently source products at low cost, while \nprotecting the integrity and the safety of the supply chain.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ea37bd0c-fbe1-40ae-aa75-ffa08508dd21", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aa05efcb14edae5b17785cfe97740e25aa1bdbfb060bf5106d520e4e3113a759", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8388bdbf-921b-42d0-ac78-03b28c46fe09", "node_type": "1", "metadata": {"window": "Let's turn to the US Pharmaceutical segment.  U S Pharmaceutical segment saw 12% adjusted operating profit \ngrowth, which was underpinned by the contribution from COVID -19 vaccine distribution and increased specialty \nvolume.  Through the third quarter and into January, branded pharmaceutical pricing has t racked in line with our \noriginal expectations and consistent with our experience over the past several years.  \n \n For generics, we continue to benefit from the success and strength of our sourcing operation with ClarusONE.  We \nhave not only the scale, but the procurement expertise to consistently source products at low cost, while \nprotecting the integrity and the safety of the supply chain.  \n \n We are also proud of our role in supporting the US government's pandemic response effort as the vaccine and \nbooster recom mendations for various age groups continues to expand and evolve.  Through January 31, our US \nPharmaceutical business has successfully distributed over 370 million Moderna and Johnson & Johnson COVID -\n19 vaccines to administration sites all across the United  States and in support of the US government's \ninternational donation mission. ", "original_text": "For generics, we continue to benefit from the success and strength of our sourcing operation with ClarusONE. ", "page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "194d4696f5abaf1131078d4cecea8ca814727813eb19976258a59cc1560446f5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "51c98247-99f5-4e2a-91e2-8cc1fb435bb7", "node_type": "1", "metadata": {"window": "Through the third quarter and into January, branded pharmaceutical pricing has t racked in line with our \noriginal expectations and consistent with our experience over the past several years.  \n \n For generics, we continue to benefit from the success and strength of our sourcing operation with ClarusONE.  We \nhave not only the scale, but the procurement expertise to consistently source products at low cost, while \nprotecting the integrity and the safety of the supply chain.  \n \n We are also proud of our role in supporting the US government's pandemic response effort as the vaccine and \nbooster recom mendations for various age groups continues to expand and evolve.  Through January 31, our US \nPharmaceutical business has successfully distributed over 370 million Moderna and Johnson & Johnson COVID -\n19 vaccines to administration sites all across the United  States and in support of the US government's \ninternational donation mission.  In January, the US government extended the existing COVID -19 vaccine \ndistribution contract through July of 2022, which is roughly in line with the first quarter of our fiscal 202 3. \n \n In Prescription Technology Solutions, the segment had excellent momentum and delivered an 11% increase to \nsegment adjusted operating profit in the third quarter. ", "original_text": "We are also proud of our role in supporting the US government's pandemic response effort as the vaccine and \nbooster recom mendations for various age groups continues to expand and evolve. "}, "hash": "2d52ba942a58788f181dd117b6c665ac24ad3775515440c9d8db4228f51bc817", "class_name": "RelatedNodeInfo"}}, "text": "We \nhave not only the scale, but the procurement expertise to consistently source products at low cost, while \nprotecting the integrity and the safety of the supply chain.  \n \n", "start_char_idx": 990, "end_char_idx": 1166, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "51c98247-99f5-4e2a-91e2-8cc1fb435bb7": {"__data__": {"id_": "51c98247-99f5-4e2a-91e2-8cc1fb435bb7", "embedding": null, "metadata": {"window": "Through the third quarter and into January, branded pharmaceutical pricing has t racked in line with our \noriginal expectations and consistent with our experience over the past several years.  \n \n For generics, we continue to benefit from the success and strength of our sourcing operation with ClarusONE.  We \nhave not only the scale, but the procurement expertise to consistently source products at low cost, while \nprotecting the integrity and the safety of the supply chain.  \n \n We are also proud of our role in supporting the US government's pandemic response effort as the vaccine and \nbooster recom mendations for various age groups continues to expand and evolve.  Through January 31, our US \nPharmaceutical business has successfully distributed over 370 million Moderna and Johnson & Johnson COVID -\n19 vaccines to administration sites all across the United  States and in support of the US government's \ninternational donation mission.  In January, the US government extended the existing COVID -19 vaccine \ndistribution contract through July of 2022, which is roughly in line with the first quarter of our fiscal 202 3. \n \n In Prescription Technology Solutions, the segment had excellent momentum and delivered an 11% increase to \nsegment adjusted operating profit in the third quarter. ", "original_text": "We are also proud of our role in supporting the US government's pandemic response effort as the vaccine and \nbooster recom mendations for various age groups continues to expand and evolve. ", "page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ea37bd0c-fbe1-40ae-aa75-ffa08508dd21", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aa05efcb14edae5b17785cfe97740e25aa1bdbfb060bf5106d520e4e3113a759", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7940deef-3c3a-4cd1-b396-60b409fe4d76", "node_type": "1", "metadata": {"window": "U S Pharmaceutical segment saw 12% adjusted operating profit \ngrowth, which was underpinned by the contribution from COVID -19 vaccine distribution and increased specialty \nvolume.  Through the third quarter and into January, branded pharmaceutical pricing has t racked in line with our \noriginal expectations and consistent with our experience over the past several years.  \n \n For generics, we continue to benefit from the success and strength of our sourcing operation with ClarusONE.  We \nhave not only the scale, but the procurement expertise to consistently source products at low cost, while \nprotecting the integrity and the safety of the supply chain.  \n \n We are also proud of our role in supporting the US government's pandemic response effort as the vaccine and \nbooster recom mendations for various age groups continues to expand and evolve.  Through January 31, our US \nPharmaceutical business has successfully distributed over 370 million Moderna and Johnson & Johnson COVID -\n19 vaccines to administration sites all across the United  States and in support of the US government's \ninternational donation mission.  In January, the US government extended the existing COVID -19 vaccine \ndistribution contract through July of 2022, which is roughly in line with the first quarter of our fiscal 202 3. \n \n", "original_text": "We \nhave not only the scale, but the procurement expertise to consistently source products at low cost, while \nprotecting the integrity and the safety of the supply chain.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46422ab1fdb106cf047b5dbc0ca997ace5ee20dca4070ba9f90809f7af27b64f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a1b03d82-6430-41e5-bd7c-10d023ac5308", "node_type": "1", "metadata": {"window": "For generics, we continue to benefit from the success and strength of our sourcing operation with ClarusONE.  We \nhave not only the scale, but the procurement expertise to consistently source products at low cost, while \nprotecting the integrity and the safety of the supply chain.  \n \n We are also proud of our role in supporting the US government's pandemic response effort as the vaccine and \nbooster recom mendations for various age groups continues to expand and evolve.  Through January 31, our US \nPharmaceutical business has successfully distributed over 370 million Moderna and Johnson & Johnson COVID -\n19 vaccines to administration sites all across the United  States and in support of the US government's \ninternational donation mission.  In January, the US government extended the existing COVID -19 vaccine \ndistribution contract through July of 2022, which is roughly in line with the first quarter of our fiscal 202 3. \n \n In Prescription Technology Solutions, the segment had excellent momentum and delivered an 11% increase to \nsegment adjusted operating profit in the third quarter.  As I mentioned earlier, we offer a range of commercial \nservices primarily to biopharma com panies, and this quarter, the growth was led by third -party logistic services \nand our access, adherence and affordability solutions, including our access for more patients' product.  \n \n", "original_text": "Through January 31, our US \nPharmaceutical business has successfully distributed over 370 million Moderna and Johnson & Johnson COVID -\n19 vaccines to administration sites all across the United  States and in support of the US government's \ninternational donation mission. "}, "hash": "a7374e5e8c29bce4d68a85c707bc23692439aff530c61c79285cc1a43acb4c98", "class_name": "RelatedNodeInfo"}}, "text": "We are also proud of our role in supporting the US government's pandemic response effort as the vaccine and \nbooster recom mendations for various age groups continues to expand and evolve. ", "start_char_idx": 1166, "end_char_idx": 1355, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a1b03d82-6430-41e5-bd7c-10d023ac5308": {"__data__": {"id_": "a1b03d82-6430-41e5-bd7c-10d023ac5308", "embedding": null, "metadata": {"window": "For generics, we continue to benefit from the success and strength of our sourcing operation with ClarusONE.  We \nhave not only the scale, but the procurement expertise to consistently source products at low cost, while \nprotecting the integrity and the safety of the supply chain.  \n \n We are also proud of our role in supporting the US government's pandemic response effort as the vaccine and \nbooster recom mendations for various age groups continues to expand and evolve.  Through January 31, our US \nPharmaceutical business has successfully distributed over 370 million Moderna and Johnson & Johnson COVID -\n19 vaccines to administration sites all across the United  States and in support of the US government's \ninternational donation mission.  In January, the US government extended the existing COVID -19 vaccine \ndistribution contract through July of 2022, which is roughly in line with the first quarter of our fiscal 202 3. \n \n In Prescription Technology Solutions, the segment had excellent momentum and delivered an 11% increase to \nsegment adjusted operating profit in the third quarter.  As I mentioned earlier, we offer a range of commercial \nservices primarily to biopharma com panies, and this quarter, the growth was led by third -party logistic services \nand our access, adherence and affordability solutions, including our access for more patients' product.  \n \n", "original_text": "Through January 31, our US \nPharmaceutical business has successfully distributed over 370 million Moderna and Johnson & Johnson COVID -\n19 vaccines to administration sites all across the United  States and in support of the US government's \ninternational donation mission. ", "page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ea37bd0c-fbe1-40ae-aa75-ffa08508dd21", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aa05efcb14edae5b17785cfe97740e25aa1bdbfb060bf5106d520e4e3113a759", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "51c98247-99f5-4e2a-91e2-8cc1fb435bb7", "node_type": "1", "metadata": {"window": "Through the third quarter and into January, branded pharmaceutical pricing has t racked in line with our \noriginal expectations and consistent with our experience over the past several years.  \n \n For generics, we continue to benefit from the success and strength of our sourcing operation with ClarusONE.  We \nhave not only the scale, but the procurement expertise to consistently source products at low cost, while \nprotecting the integrity and the safety of the supply chain.  \n \n We are also proud of our role in supporting the US government's pandemic response effort as the vaccine and \nbooster recom mendations for various age groups continues to expand and evolve.  Through January 31, our US \nPharmaceutical business has successfully distributed over 370 million Moderna and Johnson & Johnson COVID -\n19 vaccines to administration sites all across the United  States and in support of the US government's \ninternational donation mission.  In January, the US government extended the existing COVID -19 vaccine \ndistribution contract through July of 2022, which is roughly in line with the first quarter of our fiscal 202 3. \n \n In Prescription Technology Solutions, the segment had excellent momentum and delivered an 11% increase to \nsegment adjusted operating profit in the third quarter. ", "original_text": "We are also proud of our role in supporting the US government's pandemic response effort as the vaccine and \nbooster recom mendations for various age groups continues to expand and evolve. ", "page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3325bc9cd993252ba75b5c676f886795d936cb3125d61830b29975fcd4523064", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9c63a038-d36a-49a1-a5cb-2a42c7f25f38", "node_type": "1", "metadata": {"window": "We \nhave not only the scale, but the procurement expertise to consistently source products at low cost, while \nprotecting the integrity and the safety of the supply chain.  \n \n We are also proud of our role in supporting the US government's pandemic response effort as the vaccine and \nbooster recom mendations for various age groups continues to expand and evolve.  Through January 31, our US \nPharmaceutical business has successfully distributed over 370 million Moderna and Johnson & Johnson COVID -\n19 vaccines to administration sites all across the United  States and in support of the US government's \ninternational donation mission.  In January, the US government extended the existing COVID -19 vaccine \ndistribution contract through July of 2022, which is roughly in line with the first quarter of our fiscal 202 3. \n \n In Prescription Technology Solutions, the segment had excellent momentum and delivered an 11% increase to \nsegment adjusted operating profit in the third quarter.  As I mentioned earlier, we offer a range of commercial \nservices primarily to biopharma com panies, and this quarter, the growth was led by third -party logistic services \nand our access, adherence and affordability solutions, including our access for more patients' product.  \n \n This segment aligns with our focus on developing the biopharma services e cosystem. ", "original_text": "In January, the US government extended the existing COVID -19 vaccine \ndistribution contract through July of 2022, which is roughly in line with the first quarter of our fiscal 202 3. \n \n"}, "hash": "38b5d141d8879955f7a4e36e25ea85761267ddb4e8591059709397d9530a45e7", "class_name": "RelatedNodeInfo"}}, "text": "Through January 31, our US \nPharmaceutical business has successfully distributed over 370 million Moderna and Johnson & Johnson COVID -\n19 vaccines to administration sites all across the United  States and in support of the US government's \ninternational donation mission. ", "start_char_idx": 1355, "end_char_idx": 1628, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9c63a038-d36a-49a1-a5cb-2a42c7f25f38": {"__data__": {"id_": "9c63a038-d36a-49a1-a5cb-2a42c7f25f38", "embedding": null, "metadata": {"window": "We \nhave not only the scale, but the procurement expertise to consistently source products at low cost, while \nprotecting the integrity and the safety of the supply chain.  \n \n We are also proud of our role in supporting the US government's pandemic response effort as the vaccine and \nbooster recom mendations for various age groups continues to expand and evolve.  Through January 31, our US \nPharmaceutical business has successfully distributed over 370 million Moderna and Johnson & Johnson COVID -\n19 vaccines to administration sites all across the United  States and in support of the US government's \ninternational donation mission.  In January, the US government extended the existing COVID -19 vaccine \ndistribution contract through July of 2022, which is roughly in line with the first quarter of our fiscal 202 3. \n \n In Prescription Technology Solutions, the segment had excellent momentum and delivered an 11% increase to \nsegment adjusted operating profit in the third quarter.  As I mentioned earlier, we offer a range of commercial \nservices primarily to biopharma com panies, and this quarter, the growth was led by third -party logistic services \nand our access, adherence and affordability solutions, including our access for more patients' product.  \n \n This segment aligns with our focus on developing the biopharma services e cosystem. ", "original_text": "In January, the US government extended the existing COVID -19 vaccine \ndistribution contract through July of 2022, which is roughly in line with the first quarter of our fiscal 202 3. \n \n", "page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ea37bd0c-fbe1-40ae-aa75-ffa08508dd21", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aa05efcb14edae5b17785cfe97740e25aa1bdbfb060bf5106d520e4e3113a759", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a1b03d82-6430-41e5-bd7c-10d023ac5308", "node_type": "1", "metadata": {"window": "For generics, we continue to benefit from the success and strength of our sourcing operation with ClarusONE.  We \nhave not only the scale, but the procurement expertise to consistently source products at low cost, while \nprotecting the integrity and the safety of the supply chain.  \n \n We are also proud of our role in supporting the US government's pandemic response effort as the vaccine and \nbooster recom mendations for various age groups continues to expand and evolve.  Through January 31, our US \nPharmaceutical business has successfully distributed over 370 million Moderna and Johnson & Johnson COVID -\n19 vaccines to administration sites all across the United  States and in support of the US government's \ninternational donation mission.  In January, the US government extended the existing COVID -19 vaccine \ndistribution contract through July of 2022, which is roughly in line with the first quarter of our fiscal 202 3. \n \n In Prescription Technology Solutions, the segment had excellent momentum and delivered an 11% increase to \nsegment adjusted operating profit in the third quarter.  As I mentioned earlier, we offer a range of commercial \nservices primarily to biopharma com panies, and this quarter, the growth was led by third -party logistic services \nand our access, adherence and affordability solutions, including our access for more patients' product.  \n \n", "original_text": "Through January 31, our US \nPharmaceutical business has successfully distributed over 370 million Moderna and Johnson & Johnson COVID -\n19 vaccines to administration sites all across the United  States and in support of the US government's \ninternational donation mission. ", "page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e781a5b5f78df3d213f52687fc10945ace0eb00b05fbab627e5261a1bbde3cee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "90d54d54-a357-4046-87c8-2a6aa7e57d62", "node_type": "1", "metadata": {"window": "We are also proud of our role in supporting the US government's pandemic response effort as the vaccine and \nbooster recom mendations for various age groups continues to expand and evolve.  Through January 31, our US \nPharmaceutical business has successfully distributed over 370 million Moderna and Johnson & Johnson COVID -\n19 vaccines to administration sites all across the United  States and in support of the US government's \ninternational donation mission.  In January, the US government extended the existing COVID -19 vaccine \ndistribution contract through July of 2022, which is roughly in line with the first quarter of our fiscal 202 3. \n \n In Prescription Technology Solutions, the segment had excellent momentum and delivered an 11% increase to \nsegment adjusted operating profit in the third quarter.  As I mentioned earlier, we offer a range of commercial \nservices primarily to biopharma com panies, and this quarter, the growth was led by third -party logistic services \nand our access, adherence and affordability solutions, including our access for more patients' product.  \n \n This segment aligns with our focus on developing the biopharma services e cosystem.  The market that we're \nfocused on presents many exciting opportunities, and we estimate the total addressable market to be around $15 \nbillion with good growth potential and an attractive margin profile. ", "original_text": "In Prescription Technology Solutions, the segment had excellent momentum and delivered an 11% increase to \nsegment adjusted operating profit in the third quarter. "}, "hash": "bc25184c8dcbcdef364dc19f07eec0ac5daccc3252a83d85f2ce230c4d420f4d", "class_name": "RelatedNodeInfo"}}, "text": "In January, the US government extended the existing COVID -19 vaccine \ndistribution contract through July of 2022, which is roughly in line with the first quarter of our fiscal 202 3. \n \n", "start_char_idx": 1628, "end_char_idx": 1815, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "90d54d54-a357-4046-87c8-2a6aa7e57d62": {"__data__": {"id_": "90d54d54-a357-4046-87c8-2a6aa7e57d62", "embedding": null, "metadata": {"window": "We are also proud of our role in supporting the US government's pandemic response effort as the vaccine and \nbooster recom mendations for various age groups continues to expand and evolve.  Through January 31, our US \nPharmaceutical business has successfully distributed over 370 million Moderna and Johnson & Johnson COVID -\n19 vaccines to administration sites all across the United  States and in support of the US government's \ninternational donation mission.  In January, the US government extended the existing COVID -19 vaccine \ndistribution contract through July of 2022, which is roughly in line with the first quarter of our fiscal 202 3. \n \n In Prescription Technology Solutions, the segment had excellent momentum and delivered an 11% increase to \nsegment adjusted operating profit in the third quarter.  As I mentioned earlier, we offer a range of commercial \nservices primarily to biopharma com panies, and this quarter, the growth was led by third -party logistic services \nand our access, adherence and affordability solutions, including our access for more patients' product.  \n \n This segment aligns with our focus on developing the biopharma services e cosystem.  The market that we're \nfocused on presents many exciting opportunities, and we estimate the total addressable market to be around $15 \nbillion with good growth potential and an attractive margin profile. ", "original_text": "In Prescription Technology Solutions, the segment had excellent momentum and delivered an 11% increase to \nsegment adjusted operating profit in the third quarter. ", "page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ea37bd0c-fbe1-40ae-aa75-ffa08508dd21", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aa05efcb14edae5b17785cfe97740e25aa1bdbfb060bf5106d520e4e3113a759", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9c63a038-d36a-49a1-a5cb-2a42c7f25f38", "node_type": "1", "metadata": {"window": "We \nhave not only the scale, but the procurement expertise to consistently source products at low cost, while \nprotecting the integrity and the safety of the supply chain.  \n \n We are also proud of our role in supporting the US government's pandemic response effort as the vaccine and \nbooster recom mendations for various age groups continues to expand and evolve.  Through January 31, our US \nPharmaceutical business has successfully distributed over 370 million Moderna and Johnson & Johnson COVID -\n19 vaccines to administration sites all across the United  States and in support of the US government's \ninternational donation mission.  In January, the US government extended the existing COVID -19 vaccine \ndistribution contract through July of 2022, which is roughly in line with the first quarter of our fiscal 202 3. \n \n In Prescription Technology Solutions, the segment had excellent momentum and delivered an 11% increase to \nsegment adjusted operating profit in the third quarter.  As I mentioned earlier, we offer a range of commercial \nservices primarily to biopharma com panies, and this quarter, the growth was led by third -party logistic services \nand our access, adherence and affordability solutions, including our access for more patients' product.  \n \n This segment aligns with our focus on developing the biopharma services e cosystem. ", "original_text": "In January, the US government extended the existing COVID -19 vaccine \ndistribution contract through July of 2022, which is roughly in line with the first quarter of our fiscal 202 3. \n \n", "page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b224622b45c18ba4640a2fd9d53764c0674d58a0645f26dd77dbe7eabafc181c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb6b13cf-6d9d-4aa5-84e3-2b0de672c802", "node_type": "1", "metadata": {"window": "Through January 31, our US \nPharmaceutical business has successfully distributed over 370 million Moderna and Johnson & Johnson COVID -\n19 vaccines to administration sites all across the United  States and in support of the US government's \ninternational donation mission.  In January, the US government extended the existing COVID -19 vaccine \ndistribution contract through July of 2022, which is roughly in line with the first quarter of our fiscal 202 3. \n \n In Prescription Technology Solutions, the segment had excellent momentum and delivered an 11% increase to \nsegment adjusted operating profit in the third quarter.  As I mentioned earlier, we offer a range of commercial \nservices primarily to biopharma com panies, and this quarter, the growth was led by third -party logistic services \nand our access, adherence and affordability solutions, including our access for more patients' product.  \n \n This segment aligns with our focus on developing the biopharma services e cosystem.  The market that we're \nfocused on presents many exciting opportunities, and we estimate the total addressable market to be around $15 \nbillion with good growth potential and an attractive margin profile.  We are pleased with the financial performanc e \nand expect to continue to drive growth and innovation for McKesson.  \n \n", "original_text": "As I mentioned earlier, we offer a range of commercial \nservices primarily to biopharma com panies, and this quarter, the growth was led by third -party logistic services \nand our access, adherence and affordability solutions, including our access for more patients' product.  \n \n"}, "hash": "dd72388d21f13ab40d606aa767564ee3db4d9e99d5da3763d9faafb41b05b661", "class_name": "RelatedNodeInfo"}}, "text": "In Prescription Technology Solutions, the segment had excellent momentum and delivered an 11% increase to \nsegment adjusted operating profit in the third quarter. ", "start_char_idx": 1815, "end_char_idx": 1978, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb6b13cf-6d9d-4aa5-84e3-2b0de672c802": {"__data__": {"id_": "eb6b13cf-6d9d-4aa5-84e3-2b0de672c802", "embedding": null, "metadata": {"window": "Through January 31, our US \nPharmaceutical business has successfully distributed over 370 million Moderna and Johnson & Johnson COVID -\n19 vaccines to administration sites all across the United  States and in support of the US government's \ninternational donation mission.  In January, the US government extended the existing COVID -19 vaccine \ndistribution contract through July of 2022, which is roughly in line with the first quarter of our fiscal 202 3. \n \n In Prescription Technology Solutions, the segment had excellent momentum and delivered an 11% increase to \nsegment adjusted operating profit in the third quarter.  As I mentioned earlier, we offer a range of commercial \nservices primarily to biopharma com panies, and this quarter, the growth was led by third -party logistic services \nand our access, adherence and affordability solutions, including our access for more patients' product.  \n \n This segment aligns with our focus on developing the biopharma services e cosystem.  The market that we're \nfocused on presents many exciting opportunities, and we estimate the total addressable market to be around $15 \nbillion with good growth potential and an attractive margin profile.  We are pleased with the financial performanc e \nand expect to continue to drive growth and innovation for McKesson.  \n \n", "original_text": "As I mentioned earlier, we offer a range of commercial \nservices primarily to biopharma com panies, and this quarter, the growth was led by third -party logistic services \nand our access, adherence and affordability solutions, including our access for more patients' product.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ea37bd0c-fbe1-40ae-aa75-ffa08508dd21", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aa05efcb14edae5b17785cfe97740e25aa1bdbfb060bf5106d520e4e3113a759", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "90d54d54-a357-4046-87c8-2a6aa7e57d62", "node_type": "1", "metadata": {"window": "We are also proud of our role in supporting the US government's pandemic response effort as the vaccine and \nbooster recom mendations for various age groups continues to expand and evolve.  Through January 31, our US \nPharmaceutical business has successfully distributed over 370 million Moderna and Johnson & Johnson COVID -\n19 vaccines to administration sites all across the United  States and in support of the US government's \ninternational donation mission.  In January, the US government extended the existing COVID -19 vaccine \ndistribution contract through July of 2022, which is roughly in line with the first quarter of our fiscal 202 3. \n \n In Prescription Technology Solutions, the segment had excellent momentum and delivered an 11% increase to \nsegment adjusted operating profit in the third quarter.  As I mentioned earlier, we offer a range of commercial \nservices primarily to biopharma com panies, and this quarter, the growth was led by third -party logistic services \nand our access, adherence and affordability solutions, including our access for more patients' product.  \n \n This segment aligns with our focus on developing the biopharma services e cosystem.  The market that we're \nfocused on presents many exciting opportunities, and we estimate the total addressable market to be around $15 \nbillion with good growth potential and an attractive margin profile. ", "original_text": "In Prescription Technology Solutions, the segment had excellent momentum and delivered an 11% increase to \nsegment adjusted operating profit in the third quarter. ", "page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5861131d8984db6a4bcc45bf2e1e8d57a95dd5eb096e77edac8543f46b90a1e8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2a3ae4a4-3140-4e37-a105-628d71cf28d8", "node_type": "1", "metadata": {"window": "In January, the US government extended the existing COVID -19 vaccine \ndistribution contract through July of 2022, which is roughly in line with the first quarter of our fiscal 202 3. \n \n In Prescription Technology Solutions, the segment had excellent momentum and delivered an 11% increase to \nsegment adjusted operating profit in the third quarter.  As I mentioned earlier, we offer a range of commercial \nservices primarily to biopharma com panies, and this quarter, the growth was led by third -party logistic services \nand our access, adherence and affordability solutions, including our access for more patients' product.  \n \n This segment aligns with our focus on developing the biopharma services e cosystem.  The market that we're \nfocused on presents many exciting opportunities, and we estimate the total addressable market to be around $15 \nbillion with good growth potential and an attractive margin profile.  We are pleased with the financial performanc e \nand expect to continue to drive growth and innovation for McKesson.  \n \n In Medical -Surgical, we're navigating a dynamic market while growing the business. ", "original_text": "This segment aligns with our focus on developing the biopharma services e cosystem. "}, "hash": "c1c295302ec723bd425d9dcfde24d99a84fddaaba66b1ab5e18d986da535b5da", "class_name": "RelatedNodeInfo"}}, "text": "As I mentioned earlier, we offer a range of commercial \nservices primarily to biopharma com panies, and this quarter, the growth was led by third -party logistic services \nand our access, adherence and affordability solutions, including our access for more patients' product.  \n \n", "start_char_idx": 1978, "end_char_idx": 2258, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2a3ae4a4-3140-4e37-a105-628d71cf28d8": {"__data__": {"id_": "2a3ae4a4-3140-4e37-a105-628d71cf28d8", "embedding": null, "metadata": {"window": "In January, the US government extended the existing COVID -19 vaccine \ndistribution contract through July of 2022, which is roughly in line with the first quarter of our fiscal 202 3. \n \n In Prescription Technology Solutions, the segment had excellent momentum and delivered an 11% increase to \nsegment adjusted operating profit in the third quarter.  As I mentioned earlier, we offer a range of commercial \nservices primarily to biopharma com panies, and this quarter, the growth was led by third -party logistic services \nand our access, adherence and affordability solutions, including our access for more patients' product.  \n \n This segment aligns with our focus on developing the biopharma services e cosystem.  The market that we're \nfocused on presents many exciting opportunities, and we estimate the total addressable market to be around $15 \nbillion with good growth potential and an attractive margin profile.  We are pleased with the financial performanc e \nand expect to continue to drive growth and innovation for McKesson.  \n \n In Medical -Surgical, we're navigating a dynamic market while growing the business. ", "original_text": "This segment aligns with our focus on developing the biopharma services e cosystem. ", "page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ea37bd0c-fbe1-40ae-aa75-ffa08508dd21", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aa05efcb14edae5b17785cfe97740e25aa1bdbfb060bf5106d520e4e3113a759", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb6b13cf-6d9d-4aa5-84e3-2b0de672c802", "node_type": "1", "metadata": {"window": "Through January 31, our US \nPharmaceutical business has successfully distributed over 370 million Moderna and Johnson & Johnson COVID -\n19 vaccines to administration sites all across the United  States and in support of the US government's \ninternational donation mission.  In January, the US government extended the existing COVID -19 vaccine \ndistribution contract through July of 2022, which is roughly in line with the first quarter of our fiscal 202 3. \n \n In Prescription Technology Solutions, the segment had excellent momentum and delivered an 11% increase to \nsegment adjusted operating profit in the third quarter.  As I mentioned earlier, we offer a range of commercial \nservices primarily to biopharma com panies, and this quarter, the growth was led by third -party logistic services \nand our access, adherence and affordability solutions, including our access for more patients' product.  \n \n This segment aligns with our focus on developing the biopharma services e cosystem.  The market that we're \nfocused on presents many exciting opportunities, and we estimate the total addressable market to be around $15 \nbillion with good growth potential and an attractive margin profile.  We are pleased with the financial performanc e \nand expect to continue to drive growth and innovation for McKesson.  \n \n", "original_text": "As I mentioned earlier, we offer a range of commercial \nservices primarily to biopharma com panies, and this quarter, the growth was led by third -party logistic services \nand our access, adherence and affordability solutions, including our access for more patients' product.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "695c9eaffd616996b88108a497a1e62887bfc8785700ddb8b98e11f04dcd5dea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "13690820-35dd-40e1-a62c-bb85ab0f61fc", "node_type": "1", "metadata": {"window": "In Prescription Technology Solutions, the segment had excellent momentum and delivered an 11% increase to \nsegment adjusted operating profit in the third quarter.  As I mentioned earlier, we offer a range of commercial \nservices primarily to biopharma com panies, and this quarter, the growth was led by third -party logistic services \nand our access, adherence and affordability solutions, including our access for more patients' product.  \n \n This segment aligns with our focus on developing the biopharma services e cosystem.  The market that we're \nfocused on presents many exciting opportunities, and we estimate the total addressable market to be around $15 \nbillion with good growth potential and an attractive margin profile.  We are pleased with the financial performanc e \nand expect to continue to drive growth and innovation for McKesson.  \n \n In Medical -Surgical, we're navigating a dynamic market while growing the business.  With surging demand and a \ncomplex supply chain, our employees are working tirelessly to secure and del iver key products, playing an \nimportant role in the fight against the pandemic. ", "original_text": "The market that we're \nfocused on presents many exciting opportunities, and we estimate the total addressable market to be around $15 \nbillion with good growth potential and an attractive margin profile. "}, "hash": "fd765f49c534b7d29eece28690b1563063bc9f02988968226fc038f6d640c818", "class_name": "RelatedNodeInfo"}}, "text": "This segment aligns with our focus on developing the biopharma services e cosystem. ", "start_char_idx": 2258, "end_char_idx": 2342, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "13690820-35dd-40e1-a62c-bb85ab0f61fc": {"__data__": {"id_": "13690820-35dd-40e1-a62c-bb85ab0f61fc", "embedding": null, "metadata": {"window": "In Prescription Technology Solutions, the segment had excellent momentum and delivered an 11% increase to \nsegment adjusted operating profit in the third quarter.  As I mentioned earlier, we offer a range of commercial \nservices primarily to biopharma com panies, and this quarter, the growth was led by third -party logistic services \nand our access, adherence and affordability solutions, including our access for more patients' product.  \n \n This segment aligns with our focus on developing the biopharma services e cosystem.  The market that we're \nfocused on presents many exciting opportunities, and we estimate the total addressable market to be around $15 \nbillion with good growth potential and an attractive margin profile.  We are pleased with the financial performanc e \nand expect to continue to drive growth and innovation for McKesson.  \n \n In Medical -Surgical, we're navigating a dynamic market while growing the business.  With surging demand and a \ncomplex supply chain, our employees are working tirelessly to secure and del iver key products, playing an \nimportant role in the fight against the pandemic. ", "original_text": "The market that we're \nfocused on presents many exciting opportunities, and we estimate the total addressable market to be around $15 \nbillion with good growth potential and an attractive margin profile. ", "page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ea37bd0c-fbe1-40ae-aa75-ffa08508dd21", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aa05efcb14edae5b17785cfe97740e25aa1bdbfb060bf5106d520e4e3113a759", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2a3ae4a4-3140-4e37-a105-628d71cf28d8", "node_type": "1", "metadata": {"window": "In January, the US government extended the existing COVID -19 vaccine \ndistribution contract through July of 2022, which is roughly in line with the first quarter of our fiscal 202 3. \n \n In Prescription Technology Solutions, the segment had excellent momentum and delivered an 11% increase to \nsegment adjusted operating profit in the third quarter.  As I mentioned earlier, we offer a range of commercial \nservices primarily to biopharma com panies, and this quarter, the growth was led by third -party logistic services \nand our access, adherence and affordability solutions, including our access for more patients' product.  \n \n This segment aligns with our focus on developing the biopharma services e cosystem.  The market that we're \nfocused on presents many exciting opportunities, and we estimate the total addressable market to be around $15 \nbillion with good growth potential and an attractive margin profile.  We are pleased with the financial performanc e \nand expect to continue to drive growth and innovation for McKesson.  \n \n In Medical -Surgical, we're navigating a dynamic market while growing the business. ", "original_text": "This segment aligns with our focus on developing the biopharma services e cosystem. ", "page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2a28c14cc8786664ee0edef8562977518debad73446b4f4da66f5d7b3dc1755b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "41dbb4ee-fdef-4845-a395-03f32098e1b4", "node_type": "1", "metadata": {"window": "As I mentioned earlier, we offer a range of commercial \nservices primarily to biopharma com panies, and this quarter, the growth was led by third -party logistic services \nand our access, adherence and affordability solutions, including our access for more patients' product.  \n \n This segment aligns with our focus on developing the biopharma services e cosystem.  The market that we're \nfocused on presents many exciting opportunities, and we estimate the total addressable market to be around $15 \nbillion with good growth potential and an attractive margin profile.  We are pleased with the financial performanc e \nand expect to continue to drive growth and innovation for McKesson.  \n \n In Medical -Surgical, we're navigating a dynamic market while growing the business.  With surging demand and a \ncomplex supply chain, our employees are working tirelessly to secure and del iver key products, playing an \nimportant role in the fight against the pandemic.  The dedicated team in Med -Surg is the foundation to our \nbusiness growth, and we continue to invest to ensure operational continuity and excellence.  \n \n", "original_text": "We are pleased with the financial performanc e \nand expect to continue to drive growth and innovation for McKesson.  \n \n"}, "hash": "4c57ed0a53ca8c8b90ee92a06ad0ca521270606a1d2ef249a95d897cba74f72d", "class_name": "RelatedNodeInfo"}}, "text": "The market that we're \nfocused on presents many exciting opportunities, and we estimate the total addressable market to be around $15 \nbillion with good growth potential and an attractive margin profile. ", "start_char_idx": 2342, "end_char_idx": 2546, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "41dbb4ee-fdef-4845-a395-03f32098e1b4": {"__data__": {"id_": "41dbb4ee-fdef-4845-a395-03f32098e1b4", "embedding": null, "metadata": {"window": "As I mentioned earlier, we offer a range of commercial \nservices primarily to biopharma com panies, and this quarter, the growth was led by third -party logistic services \nand our access, adherence and affordability solutions, including our access for more patients' product.  \n \n This segment aligns with our focus on developing the biopharma services e cosystem.  The market that we're \nfocused on presents many exciting opportunities, and we estimate the total addressable market to be around $15 \nbillion with good growth potential and an attractive margin profile.  We are pleased with the financial performanc e \nand expect to continue to drive growth and innovation for McKesson.  \n \n In Medical -Surgical, we're navigating a dynamic market while growing the business.  With surging demand and a \ncomplex supply chain, our employees are working tirelessly to secure and del iver key products, playing an \nimportant role in the fight against the pandemic.  The dedicated team in Med -Surg is the foundation to our \nbusiness growth, and we continue to invest to ensure operational continuity and excellence.  \n \n", "original_text": "We are pleased with the financial performanc e \nand expect to continue to drive growth and innovation for McKesson.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ea37bd0c-fbe1-40ae-aa75-ffa08508dd21", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aa05efcb14edae5b17785cfe97740e25aa1bdbfb060bf5106d520e4e3113a759", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "13690820-35dd-40e1-a62c-bb85ab0f61fc", "node_type": "1", "metadata": {"window": "In Prescription Technology Solutions, the segment had excellent momentum and delivered an 11% increase to \nsegment adjusted operating profit in the third quarter.  As I mentioned earlier, we offer a range of commercial \nservices primarily to biopharma com panies, and this quarter, the growth was led by third -party logistic services \nand our access, adherence and affordability solutions, including our access for more patients' product.  \n \n This segment aligns with our focus on developing the biopharma services e cosystem.  The market that we're \nfocused on presents many exciting opportunities, and we estimate the total addressable market to be around $15 \nbillion with good growth potential and an attractive margin profile.  We are pleased with the financial performanc e \nand expect to continue to drive growth and innovation for McKesson.  \n \n In Medical -Surgical, we're navigating a dynamic market while growing the business.  With surging demand and a \ncomplex supply chain, our employees are working tirelessly to secure and del iver key products, playing an \nimportant role in the fight against the pandemic. ", "original_text": "The market that we're \nfocused on presents many exciting opportunities, and we estimate the total addressable market to be around $15 \nbillion with good growth potential and an attractive margin profile. ", "page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fcc963123187162d7527ca98f4515653fd9251e89c309ef2fc4565c41ca558df", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ef889cf-ffcb-4194-b6a5-e0af61053533", "node_type": "1", "metadata": {"window": "This segment aligns with our focus on developing the biopharma services e cosystem.  The market that we're \nfocused on presents many exciting opportunities, and we estimate the total addressable market to be around $15 \nbillion with good growth potential and an attractive margin profile.  We are pleased with the financial performanc e \nand expect to continue to drive growth and innovation for McKesson.  \n \n In Medical -Surgical, we're navigating a dynamic market while growing the business.  With surging demand and a \ncomplex supply chain, our employees are working tirelessly to secure and del iver key products, playing an \nimportant role in the fight against the pandemic.  The dedicated team in Med -Surg is the foundation to our \nbusiness growth, and we continue to invest to ensure operational continuity and excellence.  \n \n As it relates to our Intern ational segment, we continue to benefit from COVID -19-related programs in our \nEuropean operations and Canada. ", "original_text": "In Medical -Surgical, we're navigating a dynamic market while growing the business. "}, "hash": "bd6ff0abd0109474b2ad347b6eecf85b7ce76658a3174aed206f51640e551005", "class_name": "RelatedNodeInfo"}}, "text": "We are pleased with the financial performanc e \nand expect to continue to drive growth and innovation for McKesson.  \n \n", "start_char_idx": 2546, "end_char_idx": 2666, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5ef889cf-ffcb-4194-b6a5-e0af61053533": {"__data__": {"id_": "5ef889cf-ffcb-4194-b6a5-e0af61053533", "embedding": null, "metadata": {"window": "This segment aligns with our focus on developing the biopharma services e cosystem.  The market that we're \nfocused on presents many exciting opportunities, and we estimate the total addressable market to be around $15 \nbillion with good growth potential and an attractive margin profile.  We are pleased with the financial performanc e \nand expect to continue to drive growth and innovation for McKesson.  \n \n In Medical -Surgical, we're navigating a dynamic market while growing the business.  With surging demand and a \ncomplex supply chain, our employees are working tirelessly to secure and del iver key products, playing an \nimportant role in the fight against the pandemic.  The dedicated team in Med -Surg is the foundation to our \nbusiness growth, and we continue to invest to ensure operational continuity and excellence.  \n \n As it relates to our Intern ational segment, we continue to benefit from COVID -19-related programs in our \nEuropean operations and Canada. ", "original_text": "In Medical -Surgical, we're navigating a dynamic market while growing the business. ", "page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ea37bd0c-fbe1-40ae-aa75-ffa08508dd21", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aa05efcb14edae5b17785cfe97740e25aa1bdbfb060bf5106d520e4e3113a759", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "41dbb4ee-fdef-4845-a395-03f32098e1b4", "node_type": "1", "metadata": {"window": "As I mentioned earlier, we offer a range of commercial \nservices primarily to biopharma com panies, and this quarter, the growth was led by third -party logistic services \nand our access, adherence and affordability solutions, including our access for more patients' product.  \n \n This segment aligns with our focus on developing the biopharma services e cosystem.  The market that we're \nfocused on presents many exciting opportunities, and we estimate the total addressable market to be around $15 \nbillion with good growth potential and an attractive margin profile.  We are pleased with the financial performanc e \nand expect to continue to drive growth and innovation for McKesson.  \n \n In Medical -Surgical, we're navigating a dynamic market while growing the business.  With surging demand and a \ncomplex supply chain, our employees are working tirelessly to secure and del iver key products, playing an \nimportant role in the fight against the pandemic.  The dedicated team in Med -Surg is the foundation to our \nbusiness growth, and we continue to invest to ensure operational continuity and excellence.  \n \n", "original_text": "We are pleased with the financial performanc e \nand expect to continue to drive growth and innovation for McKesson.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6077bde69b95b6351d19b96258ca6a5900526cb42803bc95a93472aaf0e93b05", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6ae5a834-f0b6-427d-bc55-b8505962798b", "node_type": "1", "metadata": {"window": "The market that we're \nfocused on presents many exciting opportunities, and we estimate the total addressable market to be around $15 \nbillion with good growth potential and an attractive margin profile.  We are pleased with the financial performanc e \nand expect to continue to drive growth and innovation for McKesson.  \n \n In Medical -Surgical, we're navigating a dynamic market while growing the business.  With surging demand and a \ncomplex supply chain, our employees are working tirelessly to secure and del iver key products, playing an \nimportant role in the fight against the pandemic.  The dedicated team in Med -Surg is the foundation to our \nbusiness growth, and we continue to invest to ensure operational continuity and excellence.  \n \n As it relates to our Intern ational segment, we continue to benefit from COVID -19-related programs in our \nEuropean operations and Canada.  Through December, we've distributed over 81 million vaccines to \nadministration sites in select markets across our international geographies.  \n \n", "original_text": "With surging demand and a \ncomplex supply chain, our employees are working tirelessly to secure and del iver key products, playing an \nimportant role in the fight against the pandemic. "}, "hash": "ebfeb9c3816d80d721c22478c7e157bcf61fde391bd1e3125c578b152b11075c", "class_name": "RelatedNodeInfo"}}, "text": "In Medical -Surgical, we're navigating a dynamic market while growing the business. ", "start_char_idx": 2666, "end_char_idx": 2750, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6ae5a834-f0b6-427d-bc55-b8505962798b": {"__data__": {"id_": "6ae5a834-f0b6-427d-bc55-b8505962798b", "embedding": null, "metadata": {"window": "The market that we're \nfocused on presents many exciting opportunities, and we estimate the total addressable market to be around $15 \nbillion with good growth potential and an attractive margin profile.  We are pleased with the financial performanc e \nand expect to continue to drive growth and innovation for McKesson.  \n \n In Medical -Surgical, we're navigating a dynamic market while growing the business.  With surging demand and a \ncomplex supply chain, our employees are working tirelessly to secure and del iver key products, playing an \nimportant role in the fight against the pandemic.  The dedicated team in Med -Surg is the foundation to our \nbusiness growth, and we continue to invest to ensure operational continuity and excellence.  \n \n As it relates to our Intern ational segment, we continue to benefit from COVID -19-related programs in our \nEuropean operations and Canada.  Through December, we've distributed over 81 million vaccines to \nadministration sites in select markets across our international geographies.  \n \n", "original_text": "With surging demand and a \ncomplex supply chain, our employees are working tirelessly to secure and del iver key products, playing an \nimportant role in the fight against the pandemic. ", "page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ea37bd0c-fbe1-40ae-aa75-ffa08508dd21", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aa05efcb14edae5b17785cfe97740e25aa1bdbfb060bf5106d520e4e3113a759", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5ef889cf-ffcb-4194-b6a5-e0af61053533", "node_type": "1", "metadata": {"window": "This segment aligns with our focus on developing the biopharma services e cosystem.  The market that we're \nfocused on presents many exciting opportunities, and we estimate the total addressable market to be around $15 \nbillion with good growth potential and an attractive margin profile.  We are pleased with the financial performanc e \nand expect to continue to drive growth and innovation for McKesson.  \n \n In Medical -Surgical, we're navigating a dynamic market while growing the business.  With surging demand and a \ncomplex supply chain, our employees are working tirelessly to secure and del iver key products, playing an \nimportant role in the fight against the pandemic.  The dedicated team in Med -Surg is the foundation to our \nbusiness growth, and we continue to invest to ensure operational continuity and excellence.  \n \n As it relates to our Intern ational segment, we continue to benefit from COVID -19-related programs in our \nEuropean operations and Canada. ", "original_text": "In Medical -Surgical, we're navigating a dynamic market while growing the business. ", "page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88a9479cb3982acc69b2a0300c096355d875b45ba0f2e29953605cd9f4465687", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "808e2a5c-6181-4186-a5ba-10bb116fd617", "node_type": "1", "metadata": {"window": "We are pleased with the financial performanc e \nand expect to continue to drive growth and innovation for McKesson.  \n \n In Medical -Surgical, we're navigating a dynamic market while growing the business.  With surging demand and a \ncomplex supply chain, our employees are working tirelessly to secure and del iver key products, playing an \nimportant role in the fight against the pandemic.  The dedicated team in Med -Surg is the foundation to our \nbusiness growth, and we continue to invest to ensure operational continuity and excellence.  \n \n As it relates to our Intern ational segment, we continue to benefit from COVID -19-related programs in our \nEuropean operations and Canada.  Through December, we've distributed over 81 million vaccines to \nadministration sites in select markets across our international geographies.  \n \n As w e look forward to fiscal 2023, I'm most excited about the progress on the four company priorities. ", "original_text": "The dedicated team in Med -Surg is the foundation to our \nbusiness growth, and we continue to invest to ensure operational continuity and excellence.  \n \n"}, "hash": "6afe39dd237a92d7022d7ff9fbe89b0b3d42c0c2fe27d5db3ad919a153c746f8", "class_name": "RelatedNodeInfo"}}, "text": "With surging demand and a \ncomplex supply chain, our employees are working tirelessly to secure and del iver key products, playing an \nimportant role in the fight against the pandemic. ", "start_char_idx": 2750, "end_char_idx": 2935, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "808e2a5c-6181-4186-a5ba-10bb116fd617": {"__data__": {"id_": "808e2a5c-6181-4186-a5ba-10bb116fd617", "embedding": null, "metadata": {"window": "We are pleased with the financial performanc e \nand expect to continue to drive growth and innovation for McKesson.  \n \n In Medical -Surgical, we're navigating a dynamic market while growing the business.  With surging demand and a \ncomplex supply chain, our employees are working tirelessly to secure and del iver key products, playing an \nimportant role in the fight against the pandemic.  The dedicated team in Med -Surg is the foundation to our \nbusiness growth, and we continue to invest to ensure operational continuity and excellence.  \n \n As it relates to our Intern ational segment, we continue to benefit from COVID -19-related programs in our \nEuropean operations and Canada.  Through December, we've distributed over 81 million vaccines to \nadministration sites in select markets across our international geographies.  \n \n As w e look forward to fiscal 2023, I'm most excited about the progress on the four company priorities. ", "original_text": "The dedicated team in Med -Surg is the foundation to our \nbusiness growth, and we continue to invest to ensure operational continuity and excellence.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ea37bd0c-fbe1-40ae-aa75-ffa08508dd21", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aa05efcb14edae5b17785cfe97740e25aa1bdbfb060bf5106d520e4e3113a759", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6ae5a834-f0b6-427d-bc55-b8505962798b", "node_type": "1", "metadata": {"window": "The market that we're \nfocused on presents many exciting opportunities, and we estimate the total addressable market to be around $15 \nbillion with good growth potential and an attractive margin profile.  We are pleased with the financial performanc e \nand expect to continue to drive growth and innovation for McKesson.  \n \n In Medical -Surgical, we're navigating a dynamic market while growing the business.  With surging demand and a \ncomplex supply chain, our employees are working tirelessly to secure and del iver key products, playing an \nimportant role in the fight against the pandemic.  The dedicated team in Med -Surg is the foundation to our \nbusiness growth, and we continue to invest to ensure operational continuity and excellence.  \n \n As it relates to our Intern ational segment, we continue to benefit from COVID -19-related programs in our \nEuropean operations and Canada.  Through December, we've distributed over 81 million vaccines to \nadministration sites in select markets across our international geographies.  \n \n", "original_text": "With surging demand and a \ncomplex supply chain, our employees are working tirelessly to secure and del iver key products, playing an \nimportant role in the fight against the pandemic. ", "page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "07c7a54948c6e45021b71bd45e51abf17f11acae481e438d1aacae3054694cf7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "09eadf83-4dba-4fb9-876a-f43043330e63", "node_type": "1", "metadata": {"window": "In Medical -Surgical, we're navigating a dynamic market while growing the business.  With surging demand and a \ncomplex supply chain, our employees are working tirelessly to secure and del iver key products, playing an \nimportant role in the fight against the pandemic.  The dedicated team in Med -Surg is the foundation to our \nbusiness growth, and we continue to invest to ensure operational continuity and excellence.  \n \n As it relates to our Intern ational segment, we continue to benefit from COVID -19-related programs in our \nEuropean operations and Canada.  Through December, we've distributed over 81 million vaccines to \nadministration sites in select markets across our international geographies.  \n \n As w e look forward to fiscal 2023, I'm most excited about the progress on the four company priorities.  Since the \nrollout of these multi -year strategic initiatives in our fiscal 2019, we've been very focused on execution, making \nimpact and delivering results. ", "original_text": "As it relates to our Intern ational segment, we continue to benefit from COVID -19-related programs in our \nEuropean operations and Canada. "}, "hash": "a852e57db1ed602f3607ae8a0184af150f314deddfbb7c6f99e09a6c51150ec3", "class_name": "RelatedNodeInfo"}}, "text": "The dedicated team in Med -Surg is the foundation to our \nbusiness growth, and we continue to invest to ensure operational continuity and excellence.  \n \n", "start_char_idx": 2935, "end_char_idx": 3089, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "09eadf83-4dba-4fb9-876a-f43043330e63": {"__data__": {"id_": "09eadf83-4dba-4fb9-876a-f43043330e63", "embedding": null, "metadata": {"window": "In Medical -Surgical, we're navigating a dynamic market while growing the business.  With surging demand and a \ncomplex supply chain, our employees are working tirelessly to secure and del iver key products, playing an \nimportant role in the fight against the pandemic.  The dedicated team in Med -Surg is the foundation to our \nbusiness growth, and we continue to invest to ensure operational continuity and excellence.  \n \n As it relates to our Intern ational segment, we continue to benefit from COVID -19-related programs in our \nEuropean operations and Canada.  Through December, we've distributed over 81 million vaccines to \nadministration sites in select markets across our international geographies.  \n \n As w e look forward to fiscal 2023, I'm most excited about the progress on the four company priorities.  Since the \nrollout of these multi -year strategic initiatives in our fiscal 2019, we've been very focused on execution, making \nimpact and delivering results. ", "original_text": "As it relates to our Intern ational segment, we continue to benefit from COVID -19-related programs in our \nEuropean operations and Canada. ", "page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ea37bd0c-fbe1-40ae-aa75-ffa08508dd21", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aa05efcb14edae5b17785cfe97740e25aa1bdbfb060bf5106d520e4e3113a759", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "808e2a5c-6181-4186-a5ba-10bb116fd617", "node_type": "1", "metadata": {"window": "We are pleased with the financial performanc e \nand expect to continue to drive growth and innovation for McKesson.  \n \n In Medical -Surgical, we're navigating a dynamic market while growing the business.  With surging demand and a \ncomplex supply chain, our employees are working tirelessly to secure and del iver key products, playing an \nimportant role in the fight against the pandemic.  The dedicated team in Med -Surg is the foundation to our \nbusiness growth, and we continue to invest to ensure operational continuity and excellence.  \n \n As it relates to our Intern ational segment, we continue to benefit from COVID -19-related programs in our \nEuropean operations and Canada.  Through December, we've distributed over 81 million vaccines to \nadministration sites in select markets across our international geographies.  \n \n As w e look forward to fiscal 2023, I'm most excited about the progress on the four company priorities. ", "original_text": "The dedicated team in Med -Surg is the foundation to our \nbusiness growth, and we continue to invest to ensure operational continuity and excellence.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "82563169b29beadcf2119eb8d127382f690044bd7eca46d80ec5378c9ce68487", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4b2b8f30-3740-4408-b35f-26de6860852b", "node_type": "1", "metadata": {"window": "With surging demand and a \ncomplex supply chain, our employees are working tirelessly to secure and del iver key products, playing an \nimportant role in the fight against the pandemic.  The dedicated team in Med -Surg is the foundation to our \nbusiness growth, and we continue to invest to ensure operational continuity and excellence.  \n \n As it relates to our Intern ational segment, we continue to benefit from COVID -19-related programs in our \nEuropean operations and Canada.  Through December, we've distributed over 81 million vaccines to \nadministration sites in select markets across our international geographies.  \n \n As w e look forward to fiscal 2023, I'm most excited about the progress on the four company priorities.  Since the \nrollout of these multi -year strategic initiatives in our fiscal 2019, we've been very focused on execution, making \nimpact and delivering results.  W hile the pandemic continues to present unknowns, what is certain is that fiscal \n2023 will be another year in which we focus on strong execution and strategic advancement. ", "original_text": "Through December, we've distributed over 81 million vaccines to \nadministration sites in select markets across our international geographies.  \n \n"}, "hash": "97a1426ba3cc508da61f498559c69f345e928eb29115b38abd4f70ff989ebf59", "class_name": "RelatedNodeInfo"}}, "text": "As it relates to our Intern ational segment, we continue to benefit from COVID -19-related programs in our \nEuropean operations and Canada. ", "start_char_idx": 3089, "end_char_idx": 3229, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4b2b8f30-3740-4408-b35f-26de6860852b": {"__data__": {"id_": "4b2b8f30-3740-4408-b35f-26de6860852b", "embedding": null, "metadata": {"window": "With surging demand and a \ncomplex supply chain, our employees are working tirelessly to secure and del iver key products, playing an \nimportant role in the fight against the pandemic.  The dedicated team in Med -Surg is the foundation to our \nbusiness growth, and we continue to invest to ensure operational continuity and excellence.  \n \n As it relates to our Intern ational segment, we continue to benefit from COVID -19-related programs in our \nEuropean operations and Canada.  Through December, we've distributed over 81 million vaccines to \nadministration sites in select markets across our international geographies.  \n \n As w e look forward to fiscal 2023, I'm most excited about the progress on the four company priorities.  Since the \nrollout of these multi -year strategic initiatives in our fiscal 2019, we've been very focused on execution, making \nimpact and delivering results.  W hile the pandemic continues to present unknowns, what is certain is that fiscal \n2023 will be another year in which we focus on strong execution and strategic advancement. ", "original_text": "Through December, we've distributed over 81 million vaccines to \nadministration sites in select markets across our international geographies.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ea37bd0c-fbe1-40ae-aa75-ffa08508dd21", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aa05efcb14edae5b17785cfe97740e25aa1bdbfb060bf5106d520e4e3113a759", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "09eadf83-4dba-4fb9-876a-f43043330e63", "node_type": "1", "metadata": {"window": "In Medical -Surgical, we're navigating a dynamic market while growing the business.  With surging demand and a \ncomplex supply chain, our employees are working tirelessly to secure and del iver key products, playing an \nimportant role in the fight against the pandemic.  The dedicated team in Med -Surg is the foundation to our \nbusiness growth, and we continue to invest to ensure operational continuity and excellence.  \n \n As it relates to our Intern ational segment, we continue to benefit from COVID -19-related programs in our \nEuropean operations and Canada.  Through December, we've distributed over 81 million vaccines to \nadministration sites in select markets across our international geographies.  \n \n As w e look forward to fiscal 2023, I'm most excited about the progress on the four company priorities.  Since the \nrollout of these multi -year strategic initiatives in our fiscal 2019, we've been very focused on execution, making \nimpact and delivering results. ", "original_text": "As it relates to our Intern ational segment, we continue to benefit from COVID -19-related programs in our \nEuropean operations and Canada. ", "page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "07fbc931a32ea55eb192181f5e439155075d7bc30e9c92122557a9d3ae4802e8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9d0afe28-d901-4b8e-843a-8de394e43ed2", "node_type": "1", "metadata": {"window": "The dedicated team in Med -Surg is the foundation to our \nbusiness growth, and we continue to invest to ensure operational continuity and excellence.  \n \n As it relates to our Intern ational segment, we continue to benefit from COVID -19-related programs in our \nEuropean operations and Canada.  Through December, we've distributed over 81 million vaccines to \nadministration sites in select markets across our international geographies.  \n \n As w e look forward to fiscal 2023, I'm most excited about the progress on the four company priorities.  Since the \nrollout of these multi -year strategic initiatives in our fiscal 2019, we've been very focused on execution, making \nimpact and delivering results.  W hile the pandemic continues to present unknowns, what is certain is that fiscal \n2023 will be another year in which we focus on strong execution and strategic advancement.  Our continued \nprogress towards these four priorities will be a key driver to our sust ainable profit growth, strong cash flow, and \nshareholder value creation. ", "original_text": "As w e look forward to fiscal 2023, I'm most excited about the progress on the four company priorities. "}, "hash": "13e2ac8d35ed1d3ea45bd9898f932a57d5b72ce2da313357f86101287509337e", "class_name": "RelatedNodeInfo"}}, "text": "Through December, we've distributed over 81 million vaccines to \nadministration sites in select markets across our international geographies.  \n \n", "start_char_idx": 3229, "end_char_idx": 3375, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9d0afe28-d901-4b8e-843a-8de394e43ed2": {"__data__": {"id_": "9d0afe28-d901-4b8e-843a-8de394e43ed2", "embedding": null, "metadata": {"window": "The dedicated team in Med -Surg is the foundation to our \nbusiness growth, and we continue to invest to ensure operational continuity and excellence.  \n \n As it relates to our Intern ational segment, we continue to benefit from COVID -19-related programs in our \nEuropean operations and Canada.  Through December, we've distributed over 81 million vaccines to \nadministration sites in select markets across our international geographies.  \n \n As w e look forward to fiscal 2023, I'm most excited about the progress on the four company priorities.  Since the \nrollout of these multi -year strategic initiatives in our fiscal 2019, we've been very focused on execution, making \nimpact and delivering results.  W hile the pandemic continues to present unknowns, what is certain is that fiscal \n2023 will be another year in which we focus on strong execution and strategic advancement.  Our continued \nprogress towards these four priorities will be a key driver to our sust ainable profit growth, strong cash flow, and \nshareholder value creation. ", "original_text": "As w e look forward to fiscal 2023, I'm most excited about the progress on the four company priorities. ", "page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ea37bd0c-fbe1-40ae-aa75-ffa08508dd21", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aa05efcb14edae5b17785cfe97740e25aa1bdbfb060bf5106d520e4e3113a759", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4b2b8f30-3740-4408-b35f-26de6860852b", "node_type": "1", "metadata": {"window": "With surging demand and a \ncomplex supply chain, our employees are working tirelessly to secure and del iver key products, playing an \nimportant role in the fight against the pandemic.  The dedicated team in Med -Surg is the foundation to our \nbusiness growth, and we continue to invest to ensure operational continuity and excellence.  \n \n As it relates to our Intern ational segment, we continue to benefit from COVID -19-related programs in our \nEuropean operations and Canada.  Through December, we've distributed over 81 million vaccines to \nadministration sites in select markets across our international geographies.  \n \n As w e look forward to fiscal 2023, I'm most excited about the progress on the four company priorities.  Since the \nrollout of these multi -year strategic initiatives in our fiscal 2019, we've been very focused on execution, making \nimpact and delivering results.  W hile the pandemic continues to present unknowns, what is certain is that fiscal \n2023 will be another year in which we focus on strong execution and strategic advancement. ", "original_text": "Through December, we've distributed over 81 million vaccines to \nadministration sites in select markets across our international geographies.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9111d09f5ee6efbf21d5a7871cb0a30e9f5e254c53fe7fc58e0d9080b243d0a4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7648afff-36ba-4c0f-b332-7472d914ea31", "node_type": "1", "metadata": {"window": "As it relates to our Intern ational segment, we continue to benefit from COVID -19-related programs in our \nEuropean operations and Canada.  Through December, we've distributed over 81 million vaccines to \nadministration sites in select markets across our international geographies.  \n \n As w e look forward to fiscal 2023, I'm most excited about the progress on the four company priorities.  Since the \nrollout of these multi -year strategic initiatives in our fiscal 2019, we've been very focused on execution, making \nimpact and delivering results.  W hile the pandemic continues to present unknowns, what is certain is that fiscal \n2023 will be another year in which we focus on strong execution and strategic advancement.  Our continued \nprogress towards these four priorities will be a key driver to our sust ainable profit growth, strong cash flow, and \nshareholder value creation.  We continue to focus on the things that matter most to our customers, to our patients, \nto our employees, and to our shareholders.  \n ", "original_text": "Since the \nrollout of these multi -year strategic initiatives in our fiscal 2019, we've been very focused on execution, making \nimpact and delivering results. "}, "hash": "00191b9125fbe8796cb541a089fe6cdec3c3cb03a053d2bea269ab5a64e10ef4", "class_name": "RelatedNodeInfo"}}, "text": "As w e look forward to fiscal 2023, I'm most excited about the progress on the four company priorities. ", "start_char_idx": 3375, "end_char_idx": 3479, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7648afff-36ba-4c0f-b332-7472d914ea31": {"__data__": {"id_": "7648afff-36ba-4c0f-b332-7472d914ea31", "embedding": null, "metadata": {"window": "As it relates to our Intern ational segment, we continue to benefit from COVID -19-related programs in our \nEuropean operations and Canada.  Through December, we've distributed over 81 million vaccines to \nadministration sites in select markets across our international geographies.  \n \n As w e look forward to fiscal 2023, I'm most excited about the progress on the four company priorities.  Since the \nrollout of these multi -year strategic initiatives in our fiscal 2019, we've been very focused on execution, making \nimpact and delivering results.  W hile the pandemic continues to present unknowns, what is certain is that fiscal \n2023 will be another year in which we focus on strong execution and strategic advancement.  Our continued \nprogress towards these four priorities will be a key driver to our sust ainable profit growth, strong cash flow, and \nshareholder value creation.  We continue to focus on the things that matter most to our customers, to our patients, \nto our employees, and to our shareholders.  \n ", "original_text": "Since the \nrollout of these multi -year strategic initiatives in our fiscal 2019, we've been very focused on execution, making \nimpact and delivering results. ", "page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ea37bd0c-fbe1-40ae-aa75-ffa08508dd21", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aa05efcb14edae5b17785cfe97740e25aa1bdbfb060bf5106d520e4e3113a759", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9d0afe28-d901-4b8e-843a-8de394e43ed2", "node_type": "1", "metadata": {"window": "The dedicated team in Med -Surg is the foundation to our \nbusiness growth, and we continue to invest to ensure operational continuity and excellence.  \n \n As it relates to our Intern ational segment, we continue to benefit from COVID -19-related programs in our \nEuropean operations and Canada.  Through December, we've distributed over 81 million vaccines to \nadministration sites in select markets across our international geographies.  \n \n As w e look forward to fiscal 2023, I'm most excited about the progress on the four company priorities.  Since the \nrollout of these multi -year strategic initiatives in our fiscal 2019, we've been very focused on execution, making \nimpact and delivering results.  W hile the pandemic continues to present unknowns, what is certain is that fiscal \n2023 will be another year in which we focus on strong execution and strategic advancement.  Our continued \nprogress towards these four priorities will be a key driver to our sust ainable profit growth, strong cash flow, and \nshareholder value creation. ", "original_text": "As w e look forward to fiscal 2023, I'm most excited about the progress on the four company priorities. ", "page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "054a7da40d149972fa4bc4656864c75a4b25505451bb83656f2532b9610e6a89", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3c06ea3c-09a9-45b2-a95e-9cc524b2b5a3", "node_type": "1", "metadata": {"window": "Through December, we've distributed over 81 million vaccines to \nadministration sites in select markets across our international geographies.  \n \n As w e look forward to fiscal 2023, I'm most excited about the progress on the four company priorities.  Since the \nrollout of these multi -year strategic initiatives in our fiscal 2019, we've been very focused on execution, making \nimpact and delivering results.  W hile the pandemic continues to present unknowns, what is certain is that fiscal \n2023 will be another year in which we focus on strong execution and strategic advancement.  Our continued \nprogress towards these four priorities will be a key driver to our sust ainable profit growth, strong cash flow, and \nshareholder value creation.  We continue to focus on the things that matter most to our customers, to our patients, \nto our employees, and to our shareholders.  \n ", "original_text": "W hile the pandemic continues to present unknowns, what is certain is that fiscal \n2023 will be another year in which we focus on strong execution and strategic advancement. "}, "hash": "3d88482d1af9f0e50bedec0925bb6a09b27c4d47469382397c9250c769bb1576", "class_name": "RelatedNodeInfo"}}, "text": "Since the \nrollout of these multi -year strategic initiatives in our fiscal 2019, we've been very focused on execution, making \nimpact and delivering results. ", "start_char_idx": 3479, "end_char_idx": 3638, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3c06ea3c-09a9-45b2-a95e-9cc524b2b5a3": {"__data__": {"id_": "3c06ea3c-09a9-45b2-a95e-9cc524b2b5a3", "embedding": null, "metadata": {"window": "Through December, we've distributed over 81 million vaccines to \nadministration sites in select markets across our international geographies.  \n \n As w e look forward to fiscal 2023, I'm most excited about the progress on the four company priorities.  Since the \nrollout of these multi -year strategic initiatives in our fiscal 2019, we've been very focused on execution, making \nimpact and delivering results.  W hile the pandemic continues to present unknowns, what is certain is that fiscal \n2023 will be another year in which we focus on strong execution and strategic advancement.  Our continued \nprogress towards these four priorities will be a key driver to our sust ainable profit growth, strong cash flow, and \nshareholder value creation.  We continue to focus on the things that matter most to our customers, to our patients, \nto our employees, and to our shareholders.  \n ", "original_text": "W hile the pandemic continues to present unknowns, what is certain is that fiscal \n2023 will be another year in which we focus on strong execution and strategic advancement. ", "page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ea37bd0c-fbe1-40ae-aa75-ffa08508dd21", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aa05efcb14edae5b17785cfe97740e25aa1bdbfb060bf5106d520e4e3113a759", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7648afff-36ba-4c0f-b332-7472d914ea31", "node_type": "1", "metadata": {"window": "As it relates to our Intern ational segment, we continue to benefit from COVID -19-related programs in our \nEuropean operations and Canada.  Through December, we've distributed over 81 million vaccines to \nadministration sites in select markets across our international geographies.  \n \n As w e look forward to fiscal 2023, I'm most excited about the progress on the four company priorities.  Since the \nrollout of these multi -year strategic initiatives in our fiscal 2019, we've been very focused on execution, making \nimpact and delivering results.  W hile the pandemic continues to present unknowns, what is certain is that fiscal \n2023 will be another year in which we focus on strong execution and strategic advancement.  Our continued \nprogress towards these four priorities will be a key driver to our sust ainable profit growth, strong cash flow, and \nshareholder value creation.  We continue to focus on the things that matter most to our customers, to our patients, \nto our employees, and to our shareholders.  \n ", "original_text": "Since the \nrollout of these multi -year strategic initiatives in our fiscal 2019, we've been very focused on execution, making \nimpact and delivering results. ", "page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fb0fcf7e2b9e1b9c51ec15fd0e45e26904955123f960d7aad932536966a162e0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3c6f5f23-af90-4ec8-9e5d-d78f4ba7772c", "node_type": "1", "metadata": {"window": "As w e look forward to fiscal 2023, I'm most excited about the progress on the four company priorities.  Since the \nrollout of these multi -year strategic initiatives in our fiscal 2019, we've been very focused on execution, making \nimpact and delivering results.  W hile the pandemic continues to present unknowns, what is certain is that fiscal \n2023 will be another year in which we focus on strong execution and strategic advancement.  Our continued \nprogress towards these four priorities will be a key driver to our sust ainable profit growth, strong cash flow, and \nshareholder value creation.  We continue to focus on the things that matter most to our customers, to our patients, \nto our employees, and to our shareholders.  \n ", "original_text": "Our continued \nprogress towards these four priorities will be a key driver to our sust ainable profit growth, strong cash flow, and \nshareholder value creation. "}, "hash": "fe4bce6684cb19f77fdd9ea96f07f68e708fdaeeb56f92556ef4b217810af3a9", "class_name": "RelatedNodeInfo"}}, "text": "W hile the pandemic continues to present unknowns, what is certain is that fiscal \n2023 will be another year in which we focus on strong execution and strategic advancement. ", "start_char_idx": 3638, "end_char_idx": 3812, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3c6f5f23-af90-4ec8-9e5d-d78f4ba7772c": {"__data__": {"id_": "3c6f5f23-af90-4ec8-9e5d-d78f4ba7772c", "embedding": null, "metadata": {"window": "As w e look forward to fiscal 2023, I'm most excited about the progress on the four company priorities.  Since the \nrollout of these multi -year strategic initiatives in our fiscal 2019, we've been very focused on execution, making \nimpact and delivering results.  W hile the pandemic continues to present unknowns, what is certain is that fiscal \n2023 will be another year in which we focus on strong execution and strategic advancement.  Our continued \nprogress towards these four priorities will be a key driver to our sust ainable profit growth, strong cash flow, and \nshareholder value creation.  We continue to focus on the things that matter most to our customers, to our patients, \nto our employees, and to our shareholders.  \n ", "original_text": "Our continued \nprogress towards these four priorities will be a key driver to our sust ainable profit growth, strong cash flow, and \nshareholder value creation. ", "page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ea37bd0c-fbe1-40ae-aa75-ffa08508dd21", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aa05efcb14edae5b17785cfe97740e25aa1bdbfb060bf5106d520e4e3113a759", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3c06ea3c-09a9-45b2-a95e-9cc524b2b5a3", "node_type": "1", "metadata": {"window": "Through December, we've distributed over 81 million vaccines to \nadministration sites in select markets across our international geographies.  \n \n As w e look forward to fiscal 2023, I'm most excited about the progress on the four company priorities.  Since the \nrollout of these multi -year strategic initiatives in our fiscal 2019, we've been very focused on execution, making \nimpact and delivering results.  W hile the pandemic continues to present unknowns, what is certain is that fiscal \n2023 will be another year in which we focus on strong execution and strategic advancement.  Our continued \nprogress towards these four priorities will be a key driver to our sust ainable profit growth, strong cash flow, and \nshareholder value creation.  We continue to focus on the things that matter most to our customers, to our patients, \nto our employees, and to our shareholders.  \n ", "original_text": "W hile the pandemic continues to present unknowns, what is certain is that fiscal \n2023 will be another year in which we focus on strong execution and strategic advancement. ", "page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a51a979b099405584fd4db717d0399723655e651f4390d9087cf1c1652c9f3e2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a3cd0ff3-9ac8-470c-9f7a-482ecadb8236", "node_type": "1", "metadata": {"window": "Since the \nrollout of these multi -year strategic initiatives in our fiscal 2019, we've been very focused on execution, making \nimpact and delivering results.  W hile the pandemic continues to present unknowns, what is certain is that fiscal \n2023 will be another year in which we focus on strong execution and strategic advancement.  Our continued \nprogress towards these four priorities will be a key driver to our sust ainable profit growth, strong cash flow, and \nshareholder value creation.  We continue to focus on the things that matter most to our customers, to our patients, \nto our employees, and to our shareholders.  \n ", "original_text": "We continue to focus on the things that matter most to our customers, to our patients, \nto our employees, and to our shareholders.  \n "}, "hash": "3ac72faf5ae3f1fbced18377575e099f184226a7a0ab1e84c48cdd6436f92df7", "class_name": "RelatedNodeInfo"}}, "text": "Our continued \nprogress towards these four priorities will be a key driver to our sust ainable profit growth, strong cash flow, and \nshareholder value creation. ", "start_char_idx": 3812, "end_char_idx": 3973, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a3cd0ff3-9ac8-470c-9f7a-482ecadb8236": {"__data__": {"id_": "a3cd0ff3-9ac8-470c-9f7a-482ecadb8236", "embedding": null, "metadata": {"window": "Since the \nrollout of these multi -year strategic initiatives in our fiscal 2019, we've been very focused on execution, making \nimpact and delivering results.  W hile the pandemic continues to present unknowns, what is certain is that fiscal \n2023 will be another year in which we focus on strong execution and strategic advancement.  Our continued \nprogress towards these four priorities will be a key driver to our sust ainable profit growth, strong cash flow, and \nshareholder value creation.  We continue to focus on the things that matter most to our customers, to our patients, \nto our employees, and to our shareholders.  \n ", "original_text": "We continue to focus on the things that matter most to our customers, to our patients, \nto our employees, and to our shareholders.  \n ", "page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ea37bd0c-fbe1-40ae-aa75-ffa08508dd21", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aa05efcb14edae5b17785cfe97740e25aa1bdbfb060bf5106d520e4e3113a759", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3c6f5f23-af90-4ec8-9e5d-d78f4ba7772c", "node_type": "1", "metadata": {"window": "As w e look forward to fiscal 2023, I'm most excited about the progress on the four company priorities.  Since the \nrollout of these multi -year strategic initiatives in our fiscal 2019, we've been very focused on execution, making \nimpact and delivering results.  W hile the pandemic continues to present unknowns, what is certain is that fiscal \n2023 will be another year in which we focus on strong execution and strategic advancement.  Our continued \nprogress towards these four priorities will be a key driver to our sust ainable profit growth, strong cash flow, and \nshareholder value creation.  We continue to focus on the things that matter most to our customers, to our patients, \nto our employees, and to our shareholders.  \n ", "original_text": "Our continued \nprogress towards these four priorities will be a key driver to our sust ainable profit growth, strong cash flow, and \nshareholder value creation. ", "page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fe13f43da1a71a46797e72e99dc79e43fceeb899984f3c89074b16a8c5ff2980", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0094ecfc-7452-4f53-a816-eb9aeb53c0bd", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nIn closing, we continue to be excited about our futu re growth prospects as we meet the opportunity as a \ndiversified healthcare services company.  We have unique and differentiated assets in oncology and biopharma \nservices with unmatched scale and connectivity, and we're strategically positioned to win in the se growing \nmarkets.  \n \n And lastly, before I conclude, I want to take a moment to thank our dedicated team, including every one of the \n76,000 employees that make up Team McKesson. ", "original_text": "McKesson Corp.  "}, "hash": "030270528de924e403e1dd13ed7f5b7d4bd9ad5513a8ea0440151718599c8fda", "class_name": "RelatedNodeInfo"}}, "text": "We continue to focus on the things that matter most to our customers, to our patients, \nto our employees, and to our shareholders.  \n ", "start_char_idx": 3973, "end_char_idx": 4107, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0094ecfc-7452-4f53-a816-eb9aeb53c0bd": {"__data__": {"id_": "0094ecfc-7452-4f53-a816-eb9aeb53c0bd", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nIn closing, we continue to be excited about our futu re growth prospects as we meet the opportunity as a \ndiversified healthcare services company.  We have unique and differentiated assets in oncology and biopharma \nservices with unmatched scale and connectivity, and we're strategically positioned to win in the se growing \nmarkets.  \n \n And lastly, before I conclude, I want to take a moment to thank our dedicated team, including every one of the \n76,000 employees that make up Team McKesson. ", "original_text": "McKesson Corp.  ", "page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f4ddef2e-0215-4035-b117-0936dac4b268", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3bb1cfb278f9e546f5d92161d69de14581f1ead157216b7262f605b0c78521bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a3cd0ff3-9ac8-470c-9f7a-482ecadb8236", "node_type": "1", "metadata": {"window": "Since the \nrollout of these multi -year strategic initiatives in our fiscal 2019, we've been very focused on execution, making \nimpact and delivering results.  W hile the pandemic continues to present unknowns, what is certain is that fiscal \n2023 will be another year in which we focus on strong execution and strategic advancement.  Our continued \nprogress towards these four priorities will be a key driver to our sust ainable profit growth, strong cash flow, and \nshareholder value creation.  We continue to focus on the things that matter most to our customers, to our patients, \nto our employees, and to our shareholders.  \n ", "original_text": "We continue to focus on the things that matter most to our customers, to our patients, \nto our employees, and to our shareholders.  \n ", "page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a33736bbc02e0ec7cf1c16a7be62a1337cec100058dbff014dff8d97d7d4ef21", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "68716af3-7a5a-4200-bb4c-ad4325a4f3b7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nIn closing, we continue to be excited about our futu re growth prospects as we meet the opportunity as a \ndiversified healthcare services company.  We have unique and differentiated assets in oncology and biopharma \nservices with unmatched scale and connectivity, and we're strategically positioned to win in the se growing \nmarkets.  \n \n And lastly, before I conclude, I want to take a moment to thank our dedicated team, including every one of the \n76,000 employees that make up Team McKesson.  We share a mission to improve healthcare in every setting, \nand that will be achieved only with the dedication and the commitment from our people. ", "original_text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nIn closing, we continue to be excited about our futu re growth prospects as we meet the opportunity as a \ndiversified healthcare services company. "}, "hash": "7c7c5b59cd83182869f47012208f977e02a2551ce46b4c5b83952615368e13f2", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "68716af3-7a5a-4200-bb4c-ad4325a4f3b7": {"__data__": {"id_": "68716af3-7a5a-4200-bb4c-ad4325a4f3b7", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nIn closing, we continue to be excited about our futu re growth prospects as we meet the opportunity as a \ndiversified healthcare services company.  We have unique and differentiated assets in oncology and biopharma \nservices with unmatched scale and connectivity, and we're strategically positioned to win in the se growing \nmarkets.  \n \n And lastly, before I conclude, I want to take a moment to thank our dedicated team, including every one of the \n76,000 employees that make up Team McKesson.  We share a mission to improve healthcare in every setting, \nand that will be achieved only with the dedication and the commitment from our people. ", "original_text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nIn closing, we continue to be excited about our futu re growth prospects as we meet the opportunity as a \ndiversified healthcare services company. ", "page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f4ddef2e-0215-4035-b117-0936dac4b268", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3bb1cfb278f9e546f5d92161d69de14581f1ead157216b7262f605b0c78521bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0094ecfc-7452-4f53-a816-eb9aeb53c0bd", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nIn closing, we continue to be excited about our futu re growth prospects as we meet the opportunity as a \ndiversified healthcare services company.  We have unique and differentiated assets in oncology and biopharma \nservices with unmatched scale and connectivity, and we're strategically positioned to win in the se growing \nmarkets.  \n \n And lastly, before I conclude, I want to take a moment to thank our dedicated team, including every one of the \n76,000 employees that make up Team McKesson. ", "original_text": "McKesson Corp.  ", "page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7102ed5fbd3790c5f0e040d050bda7c03c5f2feb6807e5be9c08cb92effee1b8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cbb74205-c008-4f1d-94c6-00e553039e13", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nIn closing, we continue to be excited about our futu re growth prospects as we meet the opportunity as a \ndiversified healthcare services company.  We have unique and differentiated assets in oncology and biopharma \nservices with unmatched scale and connectivity, and we're strategically positioned to win in the se growing \nmarkets.  \n \n And lastly, before I conclude, I want to take a moment to thank our dedicated team, including every one of the \n76,000 employees that make up Team McKesson.  We share a mission to improve healthcare in every setting, \nand that will be achieved only with the dedication and the commitment from our people.  And for the opportunity to \nwork alongside this amazing team, I continue to be humbled and deeply grateful.  \n \n", "original_text": "We have unique and differentiated assets in oncology and biopharma \nservices with unmatched scale and connectivity, and we're strategically positioned to win in the se growing \nmarkets.  \n \n"}, "hash": "a444abc1d867baf564b46b01e1e7fc2f71ef145d2408b4830435a4252805f6e8", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nIn closing, we continue to be excited about our futu re growth prospects as we meet the opportunity as a \ndiversified healthcare services company. ", "start_char_idx": 16, "end_char_idx": 327, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cbb74205-c008-4f1d-94c6-00e553039e13": {"__data__": {"id_": "cbb74205-c008-4f1d-94c6-00e553039e13", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nIn closing, we continue to be excited about our futu re growth prospects as we meet the opportunity as a \ndiversified healthcare services company.  We have unique and differentiated assets in oncology and biopharma \nservices with unmatched scale and connectivity, and we're strategically positioned to win in the se growing \nmarkets.  \n \n And lastly, before I conclude, I want to take a moment to thank our dedicated team, including every one of the \n76,000 employees that make up Team McKesson.  We share a mission to improve healthcare in every setting, \nand that will be achieved only with the dedication and the commitment from our people.  And for the opportunity to \nwork alongside this amazing team, I continue to be humbled and deeply grateful.  \n \n", "original_text": "We have unique and differentiated assets in oncology and biopharma \nservices with unmatched scale and connectivity, and we're strategically positioned to win in the se growing \nmarkets.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f4ddef2e-0215-4035-b117-0936dac4b268", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3bb1cfb278f9e546f5d92161d69de14581f1ead157216b7262f605b0c78521bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "68716af3-7a5a-4200-bb4c-ad4325a4f3b7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nIn closing, we continue to be excited about our futu re growth prospects as we meet the opportunity as a \ndiversified healthcare services company.  We have unique and differentiated assets in oncology and biopharma \nservices with unmatched scale and connectivity, and we're strategically positioned to win in the se growing \nmarkets.  \n \n And lastly, before I conclude, I want to take a moment to thank our dedicated team, including every one of the \n76,000 employees that make up Team McKesson.  We share a mission to improve healthcare in every setting, \nand that will be achieved only with the dedication and the commitment from our people. ", "original_text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nIn closing, we continue to be excited about our futu re growth prospects as we meet the opportunity as a \ndiversified healthcare services company. ", "page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "03f992ff45fe130ee7c3549cccf956c6845ea4b08ac2364c1fb4828ff1bfbb88", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "74924b8a-1105-4962-8b31-bc3ca6e2859c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nIn closing, we continue to be excited about our futu re growth prospects as we meet the opportunity as a \ndiversified healthcare services company.  We have unique and differentiated assets in oncology and biopharma \nservices with unmatched scale and connectivity, and we're strategically positioned to win in the se growing \nmarkets.  \n \n And lastly, before I conclude, I want to take a moment to thank our dedicated team, including every one of the \n76,000 employees that make up Team McKesson.  We share a mission to improve healthcare in every setting, \nand that will be achieved only with the dedication and the commitment from our people.  And for the opportunity to \nwork alongside this amazing team, I continue to be humbled and deeply grateful.  \n \n Thank you for your time this afternoon. ", "original_text": "And lastly, before I conclude, I want to take a moment to thank our dedicated team, including every one of the \n76,000 employees that make up Team McKesson. "}, "hash": "61776ac0fea12f683d8a0d9e6f580a77380b19a6440abde04e342293d6c8645f", "class_name": "RelatedNodeInfo"}}, "text": "We have unique and differentiated assets in oncology and biopharma \nservices with unmatched scale and connectivity, and we're strategically positioned to win in the se growing \nmarkets.  \n \n", "start_char_idx": 327, "end_char_idx": 517, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "74924b8a-1105-4962-8b31-bc3ca6e2859c": {"__data__": {"id_": "74924b8a-1105-4962-8b31-bc3ca6e2859c", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nIn closing, we continue to be excited about our futu re growth prospects as we meet the opportunity as a \ndiversified healthcare services company.  We have unique and differentiated assets in oncology and biopharma \nservices with unmatched scale and connectivity, and we're strategically positioned to win in the se growing \nmarkets.  \n \n And lastly, before I conclude, I want to take a moment to thank our dedicated team, including every one of the \n76,000 employees that make up Team McKesson.  We share a mission to improve healthcare in every setting, \nand that will be achieved only with the dedication and the commitment from our people.  And for the opportunity to \nwork alongside this amazing team, I continue to be humbled and deeply grateful.  \n \n Thank you for your time this afternoon. ", "original_text": "And lastly, before I conclude, I want to take a moment to thank our dedicated team, including every one of the \n76,000 employees that make up Team McKesson. ", "page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f4ddef2e-0215-4035-b117-0936dac4b268", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3bb1cfb278f9e546f5d92161d69de14581f1ead157216b7262f605b0c78521bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cbb74205-c008-4f1d-94c6-00e553039e13", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nIn closing, we continue to be excited about our futu re growth prospects as we meet the opportunity as a \ndiversified healthcare services company.  We have unique and differentiated assets in oncology and biopharma \nservices with unmatched scale and connectivity, and we're strategically positioned to win in the se growing \nmarkets.  \n \n And lastly, before I conclude, I want to take a moment to thank our dedicated team, including every one of the \n76,000 employees that make up Team McKesson.  We share a mission to improve healthcare in every setting, \nand that will be achieved only with the dedication and the commitment from our people.  And for the opportunity to \nwork alongside this amazing team, I continue to be humbled and deeply grateful.  \n \n", "original_text": "We have unique and differentiated assets in oncology and biopharma \nservices with unmatched scale and connectivity, and we're strategically positioned to win in the se growing \nmarkets.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e09345639eadfdebd834f21a73440eb1e8ac9a1d319aa05e888719050c2e1970", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb3321fb-504a-43c3-9f4d-3c85a89772c5", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nIn closing, we continue to be excited about our futu re growth prospects as we meet the opportunity as a \ndiversified healthcare services company.  We have unique and differentiated assets in oncology and biopharma \nservices with unmatched scale and connectivity, and we're strategically positioned to win in the se growing \nmarkets.  \n \n And lastly, before I conclude, I want to take a moment to thank our dedicated team, including every one of the \n76,000 employees that make up Team McKesson.  We share a mission to improve healthcare in every setting, \nand that will be achieved only with the dedication and the commitment from our people.  And for the opportunity to \nwork alongside this amazing team, I continue to be humbled and deeply grateful.  \n \n Thank you for your time this afternoon.  Britt, I'll toss it to you.  \n ", "original_text": "We share a mission to improve healthcare in every setting, \nand that will be achieved only with the dedication and the commitment from our people. "}, "hash": "9ba9c7425c40007ab188a3cb966179469df8cae5f8c4fdec5a45c593c22d8ce1", "class_name": "RelatedNodeInfo"}}, "text": "And lastly, before I conclude, I want to take a moment to thank our dedicated team, including every one of the \n76,000 employees that make up Team McKesson. ", "start_char_idx": 517, "end_char_idx": 674, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb3321fb-504a-43c3-9f4d-3c85a89772c5": {"__data__": {"id_": "bb3321fb-504a-43c3-9f4d-3c85a89772c5", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nIn closing, we continue to be excited about our futu re growth prospects as we meet the opportunity as a \ndiversified healthcare services company.  We have unique and differentiated assets in oncology and biopharma \nservices with unmatched scale and connectivity, and we're strategically positioned to win in the se growing \nmarkets.  \n \n And lastly, before I conclude, I want to take a moment to thank our dedicated team, including every one of the \n76,000 employees that make up Team McKesson.  We share a mission to improve healthcare in every setting, \nand that will be achieved only with the dedication and the commitment from our people.  And for the opportunity to \nwork alongside this amazing team, I continue to be humbled and deeply grateful.  \n \n Thank you for your time this afternoon.  Britt, I'll toss it to you.  \n ", "original_text": "We share a mission to improve healthcare in every setting, \nand that will be achieved only with the dedication and the commitment from our people. ", "page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f4ddef2e-0215-4035-b117-0936dac4b268", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3bb1cfb278f9e546f5d92161d69de14581f1ead157216b7262f605b0c78521bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "74924b8a-1105-4962-8b31-bc3ca6e2859c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nIn closing, we continue to be excited about our futu re growth prospects as we meet the opportunity as a \ndiversified healthcare services company.  We have unique and differentiated assets in oncology and biopharma \nservices with unmatched scale and connectivity, and we're strategically positioned to win in the se growing \nmarkets.  \n \n And lastly, before I conclude, I want to take a moment to thank our dedicated team, including every one of the \n76,000 employees that make up Team McKesson.  We share a mission to improve healthcare in every setting, \nand that will be achieved only with the dedication and the commitment from our people.  And for the opportunity to \nwork alongside this amazing team, I continue to be humbled and deeply grateful.  \n \n Thank you for your time this afternoon. ", "original_text": "And lastly, before I conclude, I want to take a moment to thank our dedicated team, including every one of the \n76,000 employees that make up Team McKesson. ", "page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4c91fbe48191ce492ecb6222d8461a558ad79c3b768042a94710e08a23788178", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bec77d8c-1247-43d0-9116-44fccfea4da9", "node_type": "1", "metadata": {"window": "We have unique and differentiated assets in oncology and biopharma \nservices with unmatched scale and connectivity, and we're strategically positioned to win in the se growing \nmarkets.  \n \n And lastly, before I conclude, I want to take a moment to thank our dedicated team, including every one of the \n76,000 employees that make up Team McKesson.  We share a mission to improve healthcare in every setting, \nand that will be achieved only with the dedication and the commitment from our people.  And for the opportunity to \nwork alongside this amazing team, I continue to be humbled and deeply grateful.  \n \n Thank you for your time this afternoon.  Britt, I'll toss it to you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vi talone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n", "original_text": "And for the opportunity to \nwork alongside this amazing team, I continue to be humbled and deeply grateful.  \n \n"}, "hash": "8876e63435ad0d07cb833a37367ca0e5e8536f35fb8fa7fd00af236f8d3e0d61", "class_name": "RelatedNodeInfo"}}, "text": "We share a mission to improve healthcare in every setting, \nand that will be achieved only with the dedication and the commitment from our people. ", "start_char_idx": 674, "end_char_idx": 821, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bec77d8c-1247-43d0-9116-44fccfea4da9": {"__data__": {"id_": "bec77d8c-1247-43d0-9116-44fccfea4da9", "embedding": null, "metadata": {"window": "We have unique and differentiated assets in oncology and biopharma \nservices with unmatched scale and connectivity, and we're strategically positioned to win in the se growing \nmarkets.  \n \n And lastly, before I conclude, I want to take a moment to thank our dedicated team, including every one of the \n76,000 employees that make up Team McKesson.  We share a mission to improve healthcare in every setting, \nand that will be achieved only with the dedication and the commitment from our people.  And for the opportunity to \nwork alongside this amazing team, I continue to be humbled and deeply grateful.  \n \n Thank you for your time this afternoon.  Britt, I'll toss it to you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vi talone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n", "original_text": "And for the opportunity to \nwork alongside this amazing team, I continue to be humbled and deeply grateful.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f4ddef2e-0215-4035-b117-0936dac4b268", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3bb1cfb278f9e546f5d92161d69de14581f1ead157216b7262f605b0c78521bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb3321fb-504a-43c3-9f4d-3c85a89772c5", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nIn closing, we continue to be excited about our futu re growth prospects as we meet the opportunity as a \ndiversified healthcare services company.  We have unique and differentiated assets in oncology and biopharma \nservices with unmatched scale and connectivity, and we're strategically positioned to win in the se growing \nmarkets.  \n \n And lastly, before I conclude, I want to take a moment to thank our dedicated team, including every one of the \n76,000 employees that make up Team McKesson.  We share a mission to improve healthcare in every setting, \nand that will be achieved only with the dedication and the commitment from our people.  And for the opportunity to \nwork alongside this amazing team, I continue to be humbled and deeply grateful.  \n \n Thank you for your time this afternoon.  Britt, I'll toss it to you.  \n ", "original_text": "We share a mission to improve healthcare in every setting, \nand that will be achieved only with the dedication and the commitment from our people. ", "page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aef2e9b2b08f7637b94bcc1c2bffc95bf2f7132554b82647d85fc13e7c919614", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "758bfce2-77cd-4820-8c37-9941d781101c", "node_type": "1", "metadata": {"window": "And lastly, before I conclude, I want to take a moment to thank our dedicated team, including every one of the \n76,000 employees that make up Team McKesson.  We share a mission to improve healthcare in every setting, \nand that will be achieved only with the dedication and the commitment from our people.  And for the opportunity to \nwork alongside this amazing team, I continue to be humbled and deeply grateful.  \n \n Thank you for your time this afternoon.  Britt, I'll toss it to you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vi talone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon, everyone. ", "original_text": "Thank you for your time this afternoon. "}, "hash": "5638727e3b98c0af92e94968625329aff1f61b0c8f79a0a587e13d9cb9b7eea8", "class_name": "RelatedNodeInfo"}}, "text": "And for the opportunity to \nwork alongside this amazing team, I continue to be humbled and deeply grateful.  \n \n", "start_char_idx": 821, "end_char_idx": 933, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "758bfce2-77cd-4820-8c37-9941d781101c": {"__data__": {"id_": "758bfce2-77cd-4820-8c37-9941d781101c", "embedding": null, "metadata": {"window": "And lastly, before I conclude, I want to take a moment to thank our dedicated team, including every one of the \n76,000 employees that make up Team McKesson.  We share a mission to improve healthcare in every setting, \nand that will be achieved only with the dedication and the commitment from our people.  And for the opportunity to \nwork alongside this amazing team, I continue to be humbled and deeply grateful.  \n \n Thank you for your time this afternoon.  Britt, I'll toss it to you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vi talone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon, everyone. ", "original_text": "Thank you for your time this afternoon. ", "page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f4ddef2e-0215-4035-b117-0936dac4b268", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3bb1cfb278f9e546f5d92161d69de14581f1ead157216b7262f605b0c78521bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bec77d8c-1247-43d0-9116-44fccfea4da9", "node_type": "1", "metadata": {"window": "We have unique and differentiated assets in oncology and biopharma \nservices with unmatched scale and connectivity, and we're strategically positioned to win in the se growing \nmarkets.  \n \n And lastly, before I conclude, I want to take a moment to thank our dedicated team, including every one of the \n76,000 employees that make up Team McKesson.  We share a mission to improve healthcare in every setting, \nand that will be achieved only with the dedication and the commitment from our people.  And for the opportunity to \nwork alongside this amazing team, I continue to be humbled and deeply grateful.  \n \n Thank you for your time this afternoon.  Britt, I'll toss it to you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vi talone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n", "original_text": "And for the opportunity to \nwork alongside this amazing team, I continue to be humbled and deeply grateful.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5fc46b61c79ae5d63bcdfb29c5fedc59dd42f9056a25fae7f78557370795cc55", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5aee6360-e016-4333-b73d-a704fcbe12f3", "node_type": "1", "metadata": {"window": "We share a mission to improve healthcare in every setting, \nand that will be achieved only with the dedication and the commitment from our people.  And for the opportunity to \nwork alongside this amazing team, I continue to be humbled and deeply grateful.  \n \n Thank you for your time this afternoon.  Britt, I'll toss it to you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vi talone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon, everyone.  I'm pleased to be here today to discuss our fiscal third quarter \nresults, which reflect another quarter of strong performance across the business, driven by operational execution \nagainst our growth strategies. ", "original_text": "Britt, I'll toss it to you.  \n "}, "hash": "836ec536edacbc289d077a49f5413b5824669a6174d3083138e7d38d7ec8fd89", "class_name": "RelatedNodeInfo"}}, "text": "Thank you for your time this afternoon. ", "start_char_idx": 933, "end_char_idx": 973, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5aee6360-e016-4333-b73d-a704fcbe12f3": {"__data__": {"id_": "5aee6360-e016-4333-b73d-a704fcbe12f3", "embedding": null, "metadata": {"window": "We share a mission to improve healthcare in every setting, \nand that will be achieved only with the dedication and the commitment from our people.  And for the opportunity to \nwork alongside this amazing team, I continue to be humbled and deeply grateful.  \n \n Thank you for your time this afternoon.  Britt, I'll toss it to you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vi talone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon, everyone.  I'm pleased to be here today to discuss our fiscal third quarter \nresults, which reflect another quarter of strong performance across the business, driven by operational execution \nagainst our growth strategies. ", "original_text": "Britt, I'll toss it to you.  \n ", "page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f4ddef2e-0215-4035-b117-0936dac4b268", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3bb1cfb278f9e546f5d92161d69de14581f1ead157216b7262f605b0c78521bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "758bfce2-77cd-4820-8c37-9941d781101c", "node_type": "1", "metadata": {"window": "And lastly, before I conclude, I want to take a moment to thank our dedicated team, including every one of the \n76,000 employees that make up Team McKesson.  We share a mission to improve healthcare in every setting, \nand that will be achieved only with the dedication and the commitment from our people.  And for the opportunity to \nwork alongside this amazing team, I continue to be humbled and deeply grateful.  \n \n Thank you for your time this afternoon.  Britt, I'll toss it to you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vi talone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon, everyone. ", "original_text": "Thank you for your time this afternoon. ", "page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "955049586c8e9c99116f1c5c38c269a7d17e211b65960a0db06ffe083b5f97df", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6b567941-987c-4542-9f0c-b07b85dd6084", "node_type": "1", "metadata": {"window": "And for the opportunity to \nwork alongside this amazing team, I continue to be humbled and deeply grateful.  \n \n Thank you for your time this afternoon.  Britt, I'll toss it to you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vi talone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon, everyone.  I'm pleased to be here today to discuss our fiscal third quarter \nresults, which reflect another quarter of strong performance across the business, driven by operational execution \nagainst our growth strategies.  In the third quarter, we delivered overall growth compared to the prior -year results \nacross each of our segments, including growth over the prior year when excluding COVID -19-related programs.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vi talone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n"}, "hash": "22e6ee8d322420bafeb157c68d1401fb13ec957af3515079e8ef33c916ecab5d", "class_name": "RelatedNodeInfo"}}, "text": "Britt, I'll toss it to you.  \n ", "start_char_idx": 973, "end_char_idx": 1004, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6b567941-987c-4542-9f0c-b07b85dd6084": {"__data__": {"id_": "6b567941-987c-4542-9f0c-b07b85dd6084", "embedding": null, "metadata": {"window": "And for the opportunity to \nwork alongside this amazing team, I continue to be humbled and deeply grateful.  \n \n Thank you for your time this afternoon.  Britt, I'll toss it to you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vi talone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon, everyone.  I'm pleased to be here today to discuss our fiscal third quarter \nresults, which reflect another quarter of strong performance across the business, driven by operational execution \nagainst our growth strategies.  In the third quarter, we delivered overall growth compared to the prior -year results \nacross each of our segments, including growth over the prior year when excluding COVID -19-related programs.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vi talone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n", "page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f4ddef2e-0215-4035-b117-0936dac4b268", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3bb1cfb278f9e546f5d92161d69de14581f1ead157216b7262f605b0c78521bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5aee6360-e016-4333-b73d-a704fcbe12f3", "node_type": "1", "metadata": {"window": "We share a mission to improve healthcare in every setting, \nand that will be achieved only with the dedication and the commitment from our people.  And for the opportunity to \nwork alongside this amazing team, I continue to be humbled and deeply grateful.  \n \n Thank you for your time this afternoon.  Britt, I'll toss it to you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vi talone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon, everyone.  I'm pleased to be here today to discuss our fiscal third quarter \nresults, which reflect another quarter of strong performance across the business, driven by operational execution \nagainst our growth strategies. ", "original_text": "Britt, I'll toss it to you.  \n ", "page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64fd7a9e1ca85fa420628be683f390e1ca15297b98ae2a650f70ed63cc121b66", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fc810ece-4b89-4699-ad65-f3d63f855d78", "node_type": "1", "metadata": {"window": "Thank you for your time this afternoon.  Britt, I'll toss it to you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vi talone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon, everyone.  I'm pleased to be here today to discuss our fiscal third quarter \nresults, which reflect another quarter of strong performance across the business, driven by operational execution \nagainst our growth strategies.  In the third quarter, we delivered overall growth compared to the prior -year results \nacross each of our segments, including growth over the prior year when excluding COVID -19-related programs.  \n \n Let me start with an update on Europe. ", "original_text": "Thank you, Brian, and good afternoon, everyone. "}, "hash": "ae20a195336c8ee24ae1818a5cb77fba0b7f46d63b12f6dd6748b8a76f0d6f48", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vi talone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n", "start_char_idx": 1004, "end_char_idx": 1363, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fc810ece-4b89-4699-ad65-f3d63f855d78": {"__data__": {"id_": "fc810ece-4b89-4699-ad65-f3d63f855d78", "embedding": null, "metadata": {"window": "Thank you for your time this afternoon.  Britt, I'll toss it to you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vi talone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon, everyone.  I'm pleased to be here today to discuss our fiscal third quarter \nresults, which reflect another quarter of strong performance across the business, driven by operational execution \nagainst our growth strategies.  In the third quarter, we delivered overall growth compared to the prior -year results \nacross each of our segments, including growth over the prior year when excluding COVID -19-related programs.  \n \n Let me start with an update on Europe. ", "original_text": "Thank you, Brian, and good afternoon, everyone. ", "page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f4ddef2e-0215-4035-b117-0936dac4b268", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3bb1cfb278f9e546f5d92161d69de14581f1ead157216b7262f605b0c78521bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6b567941-987c-4542-9f0c-b07b85dd6084", "node_type": "1", "metadata": {"window": "And for the opportunity to \nwork alongside this amazing team, I continue to be humbled and deeply grateful.  \n \n Thank you for your time this afternoon.  Britt, I'll toss it to you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vi talone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon, everyone.  I'm pleased to be here today to discuss our fiscal third quarter \nresults, which reflect another quarter of strong performance across the business, driven by operational execution \nagainst our growth strategies.  In the third quarter, we delivered overall growth compared to the prior -year results \nacross each of our segments, including growth over the prior year when excluding COVID -19-related programs.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vi talone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n", "page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c53da945cbf7fa4ecd5e2f5b986a55cc1c105a451ce69df9bd35b298adc69e2b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8c7685e1-0181-4d25-a04b-d08470c2709b", "node_type": "1", "metadata": {"window": "Britt, I'll toss it to you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vi talone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon, everyone.  I'm pleased to be here today to discuss our fiscal third quarter \nresults, which reflect another quarter of strong performance across the business, driven by operational execution \nagainst our growth strategies.  In the third quarter, we delivered overall growth compared to the prior -year results \nacross each of our segments, including growth over the prior year when excluding COVID -19-related programs.  \n \n Let me start with an update on Europe.  We remain committed to fully exit the European region, and the progress \nof our exit activities are on track. ", "original_text": "I'm pleased to be here today to discuss our fiscal third quarter \nresults, which reflect another quarter of strong performance across the business, driven by operational execution \nagainst our growth strategies. "}, "hash": "4fa93ac59fd9ec779e1787740737809f2bdf2f3493560b71a2e6a3d02c318a62", "class_name": "RelatedNodeInfo"}}, "text": "Thank you, Brian, and good afternoon, everyone. ", "start_char_idx": 1363, "end_char_idx": 1411, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8c7685e1-0181-4d25-a04b-d08470c2709b": {"__data__": {"id_": "8c7685e1-0181-4d25-a04b-d08470c2709b", "embedding": null, "metadata": {"window": "Britt, I'll toss it to you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vi talone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon, everyone.  I'm pleased to be here today to discuss our fiscal third quarter \nresults, which reflect another quarter of strong performance across the business, driven by operational execution \nagainst our growth strategies.  In the third quarter, we delivered overall growth compared to the prior -year results \nacross each of our segments, including growth over the prior year when excluding COVID -19-related programs.  \n \n Let me start with an update on Europe.  We remain committed to fully exit the European region, and the progress \nof our exit activities are on track. ", "original_text": "I'm pleased to be here today to discuss our fiscal third quarter \nresults, which reflect another quarter of strong performance across the business, driven by operational execution \nagainst our growth strategies. ", "page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f4ddef2e-0215-4035-b117-0936dac4b268", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3bb1cfb278f9e546f5d92161d69de14581f1ead157216b7262f605b0c78521bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fc810ece-4b89-4699-ad65-f3d63f855d78", "node_type": "1", "metadata": {"window": "Thank you for your time this afternoon.  Britt, I'll toss it to you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vi talone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon, everyone.  I'm pleased to be here today to discuss our fiscal third quarter \nresults, which reflect another quarter of strong performance across the business, driven by operational execution \nagainst our growth strategies.  In the third quarter, we delivered overall growth compared to the prior -year results \nacross each of our segments, including growth over the prior year when excluding COVID -19-related programs.  \n \n Let me start with an update on Europe. ", "original_text": "Thank you, Brian, and good afternoon, everyone. ", "page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6d7e2166fd10d9031912c7596532d8fa4c6de38085b3f9a4b2d9d13e1c1ebf15", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "098e13f2-35a3-47c6-b86c-99aef54422bb", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vi talone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon, everyone.  I'm pleased to be here today to discuss our fiscal third quarter \nresults, which reflect another quarter of strong performance across the business, driven by operational execution \nagainst our growth strategies.  In the third quarter, we delivered overall growth compared to the prior -year results \nacross each of our segments, including growth over the prior year when excluding COVID -19-related programs.  \n \n Let me start with an update on Europe.  We remain committed to fully exit the European region, and the progress \nof our exit activities are on track.  Today, we announced that the transactions to sell our Austrian business to \nQuadrifolia Manage ment and the sale of McKesson's remaining share of our German joint ventures to Walgreens \nBoots Alliance closed on January 31, 2022. ", "original_text": "In the third quarter, we delivered overall growth compared to the prior -year results \nacross each of our segments, including growth over the prior year when excluding COVID -19-related programs.  \n \n"}, "hash": "6e04c4efdbdc4a4a4f84191f7a6546e8fe1be62ba547b29520df091484528fd5", "class_name": "RelatedNodeInfo"}}, "text": "I'm pleased to be here today to discuss our fiscal third quarter \nresults, which reflect another quarter of strong performance across the business, driven by operational execution \nagainst our growth strategies. ", "start_char_idx": 1411, "end_char_idx": 1623, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "098e13f2-35a3-47c6-b86c-99aef54422bb": {"__data__": {"id_": "098e13f2-35a3-47c6-b86c-99aef54422bb", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vi talone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon, everyone.  I'm pleased to be here today to discuss our fiscal third quarter \nresults, which reflect another quarter of strong performance across the business, driven by operational execution \nagainst our growth strategies.  In the third quarter, we delivered overall growth compared to the prior -year results \nacross each of our segments, including growth over the prior year when excluding COVID -19-related programs.  \n \n Let me start with an update on Europe.  We remain committed to fully exit the European region, and the progress \nof our exit activities are on track.  Today, we announced that the transactions to sell our Austrian business to \nQuadrifolia Manage ment and the sale of McKesson's remaining share of our German joint ventures to Walgreens \nBoots Alliance closed on January 31, 2022. ", "original_text": "In the third quarter, we delivered overall growth compared to the prior -year results \nacross each of our segments, including growth over the prior year when excluding COVID -19-related programs.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f4ddef2e-0215-4035-b117-0936dac4b268", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3bb1cfb278f9e546f5d92161d69de14581f1ead157216b7262f605b0c78521bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8c7685e1-0181-4d25-a04b-d08470c2709b", "node_type": "1", "metadata": {"window": "Britt, I'll toss it to you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vi talone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon, everyone.  I'm pleased to be here today to discuss our fiscal third quarter \nresults, which reflect another quarter of strong performance across the business, driven by operational execution \nagainst our growth strategies.  In the third quarter, we delivered overall growth compared to the prior -year results \nacross each of our segments, including growth over the prior year when excluding COVID -19-related programs.  \n \n Let me start with an update on Europe.  We remain committed to fully exit the European region, and the progress \nof our exit activities are on track. ", "original_text": "I'm pleased to be here today to discuss our fiscal third quarter \nresults, which reflect another quarter of strong performance across the business, driven by operational execution \nagainst our growth strategies. ", "page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7b1e2907948811b3fa0067c79ba304dbb565888cbf51cdad4cf5563d85f8d8e8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e1819288-732c-44c6-99e7-253496e4e9ee", "node_type": "1", "metadata": {"window": "Thank you, Brian, and good afternoon, everyone.  I'm pleased to be here today to discuss our fiscal third quarter \nresults, which reflect another quarter of strong performance across the business, driven by operational execution \nagainst our growth strategies.  In the third quarter, we delivered overall growth compared to the prior -year results \nacross each of our segments, including growth over the prior year when excluding COVID -19-related programs.  \n \n Let me start with an update on Europe.  We remain committed to fully exit the European region, and the progress \nof our exit activities are on track.  Today, we announced that the transactions to sell our Austrian business to \nQuadrifolia Manage ment and the sale of McKesson's remaining share of our German joint ventures to Walgreens \nBoots Alliance closed on January 31, 2022.  The assets involved in the Austrian transaction contributed \napproximately $1.5 billion in revenue and $50 million in adjust ed operating profit in fiscal 2021. ", "original_text": "Let me start with an update on Europe. "}, "hash": "92c4b392425287b1653744af33117976ffc02bba1e61154b923cdd9a3dcc1694", "class_name": "RelatedNodeInfo"}}, "text": "In the third quarter, we delivered overall growth compared to the prior -year results \nacross each of our segments, including growth over the prior year when excluding COVID -19-related programs.  \n \n", "start_char_idx": 1623, "end_char_idx": 1823, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e1819288-732c-44c6-99e7-253496e4e9ee": {"__data__": {"id_": "e1819288-732c-44c6-99e7-253496e4e9ee", "embedding": null, "metadata": {"window": "Thank you, Brian, and good afternoon, everyone.  I'm pleased to be here today to discuss our fiscal third quarter \nresults, which reflect another quarter of strong performance across the business, driven by operational execution \nagainst our growth strategies.  In the third quarter, we delivered overall growth compared to the prior -year results \nacross each of our segments, including growth over the prior year when excluding COVID -19-related programs.  \n \n Let me start with an update on Europe.  We remain committed to fully exit the European region, and the progress \nof our exit activities are on track.  Today, we announced that the transactions to sell our Austrian business to \nQuadrifolia Manage ment and the sale of McKesson's remaining share of our German joint ventures to Walgreens \nBoots Alliance closed on January 31, 2022.  The assets involved in the Austrian transaction contributed \napproximately $1.5 billion in revenue and $50 million in adjust ed operating profit in fiscal 2021. ", "original_text": "Let me start with an update on Europe. ", "page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f4ddef2e-0215-4035-b117-0936dac4b268", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3bb1cfb278f9e546f5d92161d69de14581f1ead157216b7262f605b0c78521bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "098e13f2-35a3-47c6-b86c-99aef54422bb", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vi talone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon, everyone.  I'm pleased to be here today to discuss our fiscal third quarter \nresults, which reflect another quarter of strong performance across the business, driven by operational execution \nagainst our growth strategies.  In the third quarter, we delivered overall growth compared to the prior -year results \nacross each of our segments, including growth over the prior year when excluding COVID -19-related programs.  \n \n Let me start with an update on Europe.  We remain committed to fully exit the European region, and the progress \nof our exit activities are on track.  Today, we announced that the transactions to sell our Austrian business to \nQuadrifolia Manage ment and the sale of McKesson's remaining share of our German joint ventures to Walgreens \nBoots Alliance closed on January 31, 2022. ", "original_text": "In the third quarter, we delivered overall growth compared to the prior -year results \nacross each of our segments, including growth over the prior year when excluding COVID -19-related programs.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ab9430992382f26ee3e8373568a1f32da0bd8297365658821b7890ff2004ad9d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ec7428ab-b246-486e-a79e-f8922f495028", "node_type": "1", "metadata": {"window": "I'm pleased to be here today to discuss our fiscal third quarter \nresults, which reflect another quarter of strong performance across the business, driven by operational execution \nagainst our growth strategies.  In the third quarter, we delivered overall growth compared to the prior -year results \nacross each of our segments, including growth over the prior year when excluding COVID -19-related programs.  \n \n Let me start with an update on Europe.  We remain committed to fully exit the European region, and the progress \nof our exit activities are on track.  Today, we announced that the transactions to sell our Austrian business to \nQuadrifolia Manage ment and the sale of McKesson's remaining share of our German joint ventures to Walgreens \nBoots Alliance closed on January 31, 2022.  The assets involved in the Austrian transaction contributed \napproximately $1.5 billion in revenue and $50 million in adjust ed operating profit in fiscal 2021.  The earnings \nrelated to our German joint venture were immaterial.  \n \n", "original_text": "We remain committed to fully exit the European region, and the progress \nof our exit activities are on track. "}, "hash": "ee57c8df429197077251069041e8aef32f66e18898a87f2f2a0dc775200963d2", "class_name": "RelatedNodeInfo"}}, "text": "Let me start with an update on Europe. ", "start_char_idx": 1823, "end_char_idx": 1862, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ec7428ab-b246-486e-a79e-f8922f495028": {"__data__": {"id_": "ec7428ab-b246-486e-a79e-f8922f495028", "embedding": null, "metadata": {"window": "I'm pleased to be here today to discuss our fiscal third quarter \nresults, which reflect another quarter of strong performance across the business, driven by operational execution \nagainst our growth strategies.  In the third quarter, we delivered overall growth compared to the prior -year results \nacross each of our segments, including growth over the prior year when excluding COVID -19-related programs.  \n \n Let me start with an update on Europe.  We remain committed to fully exit the European region, and the progress \nof our exit activities are on track.  Today, we announced that the transactions to sell our Austrian business to \nQuadrifolia Manage ment and the sale of McKesson's remaining share of our German joint ventures to Walgreens \nBoots Alliance closed on January 31, 2022.  The assets involved in the Austrian transaction contributed \napproximately $1.5 billion in revenue and $50 million in adjust ed operating profit in fiscal 2021.  The earnings \nrelated to our German joint venture were immaterial.  \n \n", "original_text": "We remain committed to fully exit the European region, and the progress \nof our exit activities are on track. ", "page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f4ddef2e-0215-4035-b117-0936dac4b268", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3bb1cfb278f9e546f5d92161d69de14581f1ead157216b7262f605b0c78521bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e1819288-732c-44c6-99e7-253496e4e9ee", "node_type": "1", "metadata": {"window": "Thank you, Brian, and good afternoon, everyone.  I'm pleased to be here today to discuss our fiscal third quarter \nresults, which reflect another quarter of strong performance across the business, driven by operational execution \nagainst our growth strategies.  In the third quarter, we delivered overall growth compared to the prior -year results \nacross each of our segments, including growth over the prior year when excluding COVID -19-related programs.  \n \n Let me start with an update on Europe.  We remain committed to fully exit the European region, and the progress \nof our exit activities are on track.  Today, we announced that the transactions to sell our Austrian business to \nQuadrifolia Manage ment and the sale of McKesson's remaining share of our German joint ventures to Walgreens \nBoots Alliance closed on January 31, 2022.  The assets involved in the Austrian transaction contributed \napproximately $1.5 billion in revenue and $50 million in adjust ed operating profit in fiscal 2021. ", "original_text": "Let me start with an update on Europe. ", "page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b9f74910770c7448c1967d6ad3df3c26f050068d7ecc76edcaf4413bd070eaa4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "816a18cd-e8ef-43e0-a00d-ad7add2b688c", "node_type": "1", "metadata": {"window": "In the third quarter, we delivered overall growth compared to the prior -year results \nacross each of our segments, including growth over the prior year when excluding COVID -19-related programs.  \n \n Let me start with an update on Europe.  We remain committed to fully exit the European region, and the progress \nof our exit activities are on track.  Today, we announced that the transactions to sell our Austrian business to \nQuadrifolia Manage ment and the sale of McKesson's remaining share of our German joint ventures to Walgreens \nBoots Alliance closed on January 31, 2022.  The assets involved in the Austrian transaction contributed \napproximately $1.5 billion in revenue and $50 million in adjust ed operating profit in fiscal 2021.  The earnings \nrelated to our German joint venture were immaterial.  \n \n Next, pursuant to the satisfaction of customary closing conditions, including receipt of regulatory approvals, we \nanticipate the pending divestiture to sell McKesson's UK retail and distribution businesses will close in the fourth \nquarter of fiscal 2022, and the transaction to sell certain European assets to the PHOENIX Group will close in the \nfirst half of fiscal 2023.  \n \n", "original_text": "Today, we announced that the transactions to sell our Austrian business to \nQuadrifolia Manage ment and the sale of McKesson's remaining share of our German joint ventures to Walgreens \nBoots Alliance closed on January 31, 2022. "}, "hash": "bbc58cdeb8a391b868efd28e44fd87ca8f25bc4e280537591f8a5a6c38e895d1", "class_name": "RelatedNodeInfo"}}, "text": "We remain committed to fully exit the European region, and the progress \nof our exit activities are on track. ", "start_char_idx": 1862, "end_char_idx": 1972, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "816a18cd-e8ef-43e0-a00d-ad7add2b688c": {"__data__": {"id_": "816a18cd-e8ef-43e0-a00d-ad7add2b688c", "embedding": null, "metadata": {"window": "In the third quarter, we delivered overall growth compared to the prior -year results \nacross each of our segments, including growth over the prior year when excluding COVID -19-related programs.  \n \n Let me start with an update on Europe.  We remain committed to fully exit the European region, and the progress \nof our exit activities are on track.  Today, we announced that the transactions to sell our Austrian business to \nQuadrifolia Manage ment and the sale of McKesson's remaining share of our German joint ventures to Walgreens \nBoots Alliance closed on January 31, 2022.  The assets involved in the Austrian transaction contributed \napproximately $1.5 billion in revenue and $50 million in adjust ed operating profit in fiscal 2021.  The earnings \nrelated to our German joint venture were immaterial.  \n \n Next, pursuant to the satisfaction of customary closing conditions, including receipt of regulatory approvals, we \nanticipate the pending divestiture to sell McKesson's UK retail and distribution businesses will close in the fourth \nquarter of fiscal 2022, and the transaction to sell certain European assets to the PHOENIX Group will close in the \nfirst half of fiscal 2023.  \n \n", "original_text": "Today, we announced that the transactions to sell our Austrian business to \nQuadrifolia Manage ment and the sale of McKesson's remaining share of our German joint ventures to Walgreens \nBoots Alliance closed on January 31, 2022. ", "page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f4ddef2e-0215-4035-b117-0936dac4b268", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3bb1cfb278f9e546f5d92161d69de14581f1ead157216b7262f605b0c78521bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ec7428ab-b246-486e-a79e-f8922f495028", "node_type": "1", "metadata": {"window": "I'm pleased to be here today to discuss our fiscal third quarter \nresults, which reflect another quarter of strong performance across the business, driven by operational execution \nagainst our growth strategies.  In the third quarter, we delivered overall growth compared to the prior -year results \nacross each of our segments, including growth over the prior year when excluding COVID -19-related programs.  \n \n Let me start with an update on Europe.  We remain committed to fully exit the European region, and the progress \nof our exit activities are on track.  Today, we announced that the transactions to sell our Austrian business to \nQuadrifolia Manage ment and the sale of McKesson's remaining share of our German joint ventures to Walgreens \nBoots Alliance closed on January 31, 2022.  The assets involved in the Austrian transaction contributed \napproximately $1.5 billion in revenue and $50 million in adjust ed operating profit in fiscal 2021.  The earnings \nrelated to our German joint venture were immaterial.  \n \n", "original_text": "We remain committed to fully exit the European region, and the progress \nof our exit activities are on track. ", "page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7b4381298dc0c9c008fb40a3af225e7d8850bb8203c4ab0c13869376a3dc3765", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6fe7546b-e677-48bb-8cb3-a482cb5d7500", "node_type": "1", "metadata": {"window": "Let me start with an update on Europe.  We remain committed to fully exit the European region, and the progress \nof our exit activities are on track.  Today, we announced that the transactions to sell our Austrian business to \nQuadrifolia Manage ment and the sale of McKesson's remaining share of our German joint ventures to Walgreens \nBoots Alliance closed on January 31, 2022.  The assets involved in the Austrian transaction contributed \napproximately $1.5 billion in revenue and $50 million in adjust ed operating profit in fiscal 2021.  The earnings \nrelated to our German joint venture were immaterial.  \n \n Next, pursuant to the satisfaction of customary closing conditions, including receipt of regulatory approvals, we \nanticipate the pending divestiture to sell McKesson's UK retail and distribution businesses will close in the fourth \nquarter of fiscal 2022, and the transaction to sell certain European assets to the PHOENIX Group will close in the \nfirst half of fiscal 2023.  \n \n The net assets included in these t ransactions are classified as held -for-sale. ", "original_text": "The assets involved in the Austrian transaction contributed \napproximately $1.5 billion in revenue and $50 million in adjust ed operating profit in fiscal 2021. "}, "hash": "d2b60911577bef1fcf876fcb9be925de3f4101f654949a3f99f7a6f4365a8a6e", "class_name": "RelatedNodeInfo"}}, "text": "Today, we announced that the transactions to sell our Austrian business to \nQuadrifolia Manage ment and the sale of McKesson's remaining share of our German joint ventures to Walgreens \nBoots Alliance closed on January 31, 2022. ", "start_char_idx": 1972, "end_char_idx": 2201, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6fe7546b-e677-48bb-8cb3-a482cb5d7500": {"__data__": {"id_": "6fe7546b-e677-48bb-8cb3-a482cb5d7500", "embedding": null, "metadata": {"window": "Let me start with an update on Europe.  We remain committed to fully exit the European region, and the progress \nof our exit activities are on track.  Today, we announced that the transactions to sell our Austrian business to \nQuadrifolia Manage ment and the sale of McKesson's remaining share of our German joint ventures to Walgreens \nBoots Alliance closed on January 31, 2022.  The assets involved in the Austrian transaction contributed \napproximately $1.5 billion in revenue and $50 million in adjust ed operating profit in fiscal 2021.  The earnings \nrelated to our German joint venture were immaterial.  \n \n Next, pursuant to the satisfaction of customary closing conditions, including receipt of regulatory approvals, we \nanticipate the pending divestiture to sell McKesson's UK retail and distribution businesses will close in the fourth \nquarter of fiscal 2022, and the transaction to sell certain European assets to the PHOENIX Group will close in the \nfirst half of fiscal 2023.  \n \n The net assets included in these t ransactions are classified as held -for-sale. ", "original_text": "The assets involved in the Austrian transaction contributed \napproximately $1.5 billion in revenue and $50 million in adjust ed operating profit in fiscal 2021. ", "page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f4ddef2e-0215-4035-b117-0936dac4b268", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3bb1cfb278f9e546f5d92161d69de14581f1ead157216b7262f605b0c78521bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "816a18cd-e8ef-43e0-a00d-ad7add2b688c", "node_type": "1", "metadata": {"window": "In the third quarter, we delivered overall growth compared to the prior -year results \nacross each of our segments, including growth over the prior year when excluding COVID -19-related programs.  \n \n Let me start with an update on Europe.  We remain committed to fully exit the European region, and the progress \nof our exit activities are on track.  Today, we announced that the transactions to sell our Austrian business to \nQuadrifolia Manage ment and the sale of McKesson's remaining share of our German joint ventures to Walgreens \nBoots Alliance closed on January 31, 2022.  The assets involved in the Austrian transaction contributed \napproximately $1.5 billion in revenue and $50 million in adjust ed operating profit in fiscal 2021.  The earnings \nrelated to our German joint venture were immaterial.  \n \n Next, pursuant to the satisfaction of customary closing conditions, including receipt of regulatory approvals, we \nanticipate the pending divestiture to sell McKesson's UK retail and distribution businesses will close in the fourth \nquarter of fiscal 2022, and the transaction to sell certain European assets to the PHOENIX Group will close in the \nfirst half of fiscal 2023.  \n \n", "original_text": "Today, we announced that the transactions to sell our Austrian business to \nQuadrifolia Manage ment and the sale of McKesson's remaining share of our German joint ventures to Walgreens \nBoots Alliance closed on January 31, 2022. ", "page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df838b0cdd80096a225774b9b799f4f48e58d17f6784728d869c85637135c028", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eee39b5a-5880-421d-a42d-9e39a91f490d", "node_type": "1", "metadata": {"window": "We remain committed to fully exit the European region, and the progress \nof our exit activities are on track.  Today, we announced that the transactions to sell our Austrian business to \nQuadrifolia Manage ment and the sale of McKesson's remaining share of our German joint ventures to Walgreens \nBoots Alliance closed on January 31, 2022.  The assets involved in the Austrian transaction contributed \napproximately $1.5 billion in revenue and $50 million in adjust ed operating profit in fiscal 2021.  The earnings \nrelated to our German joint venture were immaterial.  \n \n Next, pursuant to the satisfaction of customary closing conditions, including receipt of regulatory approvals, we \nanticipate the pending divestiture to sell McKesson's UK retail and distribution businesses will close in the fourth \nquarter of fiscal 2022, and the transaction to sell certain European assets to the PHOENIX Group will close in the \nfirst half of fiscal 2023.  \n \n The net assets included in these t ransactions are classified as held -for-sale.  Our fiscal 2022 guidance includes \napproximately $0.49 of adjusted earnings per diluted share accretion related to these pending transactions, which \nis recorded within our International segment. ", "original_text": "The earnings \nrelated to our German joint venture were immaterial.  \n \n"}, "hash": "c0c7da632a1652dbf34ccddd201f7dc345f0fb2dafd37bcd8c46f186ac5b6a67", "class_name": "RelatedNodeInfo"}}, "text": "The assets involved in the Austrian transaction contributed \napproximately $1.5 billion in revenue and $50 million in adjust ed operating profit in fiscal 2021. ", "start_char_idx": 2201, "end_char_idx": 2362, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eee39b5a-5880-421d-a42d-9e39a91f490d": {"__data__": {"id_": "eee39b5a-5880-421d-a42d-9e39a91f490d", "embedding": null, "metadata": {"window": "We remain committed to fully exit the European region, and the progress \nof our exit activities are on track.  Today, we announced that the transactions to sell our Austrian business to \nQuadrifolia Manage ment and the sale of McKesson's remaining share of our German joint ventures to Walgreens \nBoots Alliance closed on January 31, 2022.  The assets involved in the Austrian transaction contributed \napproximately $1.5 billion in revenue and $50 million in adjust ed operating profit in fiscal 2021.  The earnings \nrelated to our German joint venture were immaterial.  \n \n Next, pursuant to the satisfaction of customary closing conditions, including receipt of regulatory approvals, we \nanticipate the pending divestiture to sell McKesson's UK retail and distribution businesses will close in the fourth \nquarter of fiscal 2022, and the transaction to sell certain European assets to the PHOENIX Group will close in the \nfirst half of fiscal 2023.  \n \n The net assets included in these t ransactions are classified as held -for-sale.  Our fiscal 2022 guidance includes \napproximately $0.49 of adjusted earnings per diluted share accretion related to these pending transactions, which \nis recorded within our International segment. ", "original_text": "The earnings \nrelated to our German joint venture were immaterial.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f4ddef2e-0215-4035-b117-0936dac4b268", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3bb1cfb278f9e546f5d92161d69de14581f1ead157216b7262f605b0c78521bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6fe7546b-e677-48bb-8cb3-a482cb5d7500", "node_type": "1", "metadata": {"window": "Let me start with an update on Europe.  We remain committed to fully exit the European region, and the progress \nof our exit activities are on track.  Today, we announced that the transactions to sell our Austrian business to \nQuadrifolia Manage ment and the sale of McKesson's remaining share of our German joint ventures to Walgreens \nBoots Alliance closed on January 31, 2022.  The assets involved in the Austrian transaction contributed \napproximately $1.5 billion in revenue and $50 million in adjust ed operating profit in fiscal 2021.  The earnings \nrelated to our German joint venture were immaterial.  \n \n Next, pursuant to the satisfaction of customary closing conditions, including receipt of regulatory approvals, we \nanticipate the pending divestiture to sell McKesson's UK retail and distribution businesses will close in the fourth \nquarter of fiscal 2022, and the transaction to sell certain European assets to the PHOENIX Group will close in the \nfirst half of fiscal 2023.  \n \n The net assets included in these t ransactions are classified as held -for-sale. ", "original_text": "The assets involved in the Austrian transaction contributed \napproximately $1.5 billion in revenue and $50 million in adjust ed operating profit in fiscal 2021. ", "page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "29276867f1f3e835db6e50bfe0df37c2bb5f2efb3a9add92f3246b47facdfae3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1be0be6f-ad3c-4a65-a480-f4d19fc583cb", "node_type": "1", "metadata": {"window": "Today, we announced that the transactions to sell our Austrian business to \nQuadrifolia Manage ment and the sale of McKesson's remaining share of our German joint ventures to Walgreens \nBoots Alliance closed on January 31, 2022.  The assets involved in the Austrian transaction contributed \napproximately $1.5 billion in revenue and $50 million in adjust ed operating profit in fiscal 2021.  The earnings \nrelated to our German joint venture were immaterial.  \n \n Next, pursuant to the satisfaction of customary closing conditions, including receipt of regulatory approvals, we \nanticipate the pending divestiture to sell McKesson's UK retail and distribution businesses will close in the fourth \nquarter of fiscal 2022, and the transaction to sell certain European assets to the PHOENIX Group will close in the \nfirst half of fiscal 2023.  \n \n The net assets included in these t ransactions are classified as held -for-sale.  Our fiscal 2022 guidance includes \napproximately $0.49 of adjusted earnings per diluted share accretion related to these pending transactions, which \nis recorded within our International segment.  This $0.49 of acc retion resulting from the held -for-sale accounting \nwill conclude once each transaction has closed.  \n \n", "original_text": "Next, pursuant to the satisfaction of customary closing conditions, including receipt of regulatory approvals, we \nanticipate the pending divestiture to sell McKesson's UK retail and distribution businesses will close in the fourth \nquarter of fiscal 2022, and the transaction to sell certain European assets to the PHOENIX Group will close in the \nfirst half of fiscal 2023.  \n \n"}, "hash": "b41dc2ddc160a284f673c273ef97af7cf56d7b8958c1f57d4d1b9deb243d07d9", "class_name": "RelatedNodeInfo"}}, "text": "The earnings \nrelated to our German joint venture were immaterial.  \n \n", "start_char_idx": 2362, "end_char_idx": 2433, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1be0be6f-ad3c-4a65-a480-f4d19fc583cb": {"__data__": {"id_": "1be0be6f-ad3c-4a65-a480-f4d19fc583cb", "embedding": null, "metadata": {"window": "Today, we announced that the transactions to sell our Austrian business to \nQuadrifolia Manage ment and the sale of McKesson's remaining share of our German joint ventures to Walgreens \nBoots Alliance closed on January 31, 2022.  The assets involved in the Austrian transaction contributed \napproximately $1.5 billion in revenue and $50 million in adjust ed operating profit in fiscal 2021.  The earnings \nrelated to our German joint venture were immaterial.  \n \n Next, pursuant to the satisfaction of customary closing conditions, including receipt of regulatory approvals, we \nanticipate the pending divestiture to sell McKesson's UK retail and distribution businesses will close in the fourth \nquarter of fiscal 2022, and the transaction to sell certain European assets to the PHOENIX Group will close in the \nfirst half of fiscal 2023.  \n \n The net assets included in these t ransactions are classified as held -for-sale.  Our fiscal 2022 guidance includes \napproximately $0.49 of adjusted earnings per diluted share accretion related to these pending transactions, which \nis recorded within our International segment.  This $0.49 of acc retion resulting from the held -for-sale accounting \nwill conclude once each transaction has closed.  \n \n", "original_text": "Next, pursuant to the satisfaction of customary closing conditions, including receipt of regulatory approvals, we \nanticipate the pending divestiture to sell McKesson's UK retail and distribution businesses will close in the fourth \nquarter of fiscal 2022, and the transaction to sell certain European assets to the PHOENIX Group will close in the \nfirst half of fiscal 2023.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f4ddef2e-0215-4035-b117-0936dac4b268", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3bb1cfb278f9e546f5d92161d69de14581f1ead157216b7262f605b0c78521bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eee39b5a-5880-421d-a42d-9e39a91f490d", "node_type": "1", "metadata": {"window": "We remain committed to fully exit the European region, and the progress \nof our exit activities are on track.  Today, we announced that the transactions to sell our Austrian business to \nQuadrifolia Manage ment and the sale of McKesson's remaining share of our German joint ventures to Walgreens \nBoots Alliance closed on January 31, 2022.  The assets involved in the Austrian transaction contributed \napproximately $1.5 billion in revenue and $50 million in adjust ed operating profit in fiscal 2021.  The earnings \nrelated to our German joint venture were immaterial.  \n \n Next, pursuant to the satisfaction of customary closing conditions, including receipt of regulatory approvals, we \nanticipate the pending divestiture to sell McKesson's UK retail and distribution businesses will close in the fourth \nquarter of fiscal 2022, and the transaction to sell certain European assets to the PHOENIX Group will close in the \nfirst half of fiscal 2023.  \n \n The net assets included in these t ransactions are classified as held -for-sale.  Our fiscal 2022 guidance includes \napproximately $0.49 of adjusted earnings per diluted share accretion related to these pending transactions, which \nis recorded within our International segment. ", "original_text": "The earnings \nrelated to our German joint venture were immaterial.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cb89769d9a3c2dfff22d2ea1a6dfa8dbe2470d074e52228745e8c2c762bb346e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b80e5278-ea83-409f-a793-a9b26c156255", "node_type": "1", "metadata": {"window": "The assets involved in the Austrian transaction contributed \napproximately $1.5 billion in revenue and $50 million in adjust ed operating profit in fiscal 2021.  The earnings \nrelated to our German joint venture were immaterial.  \n \n Next, pursuant to the satisfaction of customary closing conditions, including receipt of regulatory approvals, we \nanticipate the pending divestiture to sell McKesson's UK retail and distribution businesses will close in the fourth \nquarter of fiscal 2022, and the transaction to sell certain European assets to the PHOENIX Group will close in the \nfirst half of fiscal 2023.  \n \n The net assets included in these t ransactions are classified as held -for-sale.  Our fiscal 2022 guidance includes \napproximately $0.49 of adjusted earnings per diluted share accretion related to these pending transactions, which \nis recorded within our International segment.  This $0.49 of acc retion resulting from the held -for-sale accounting \nwill conclude once each transaction has closed.  \n \n For fiscal 2023, we currently anticipate approximately $0.10 of adjusted earnings per diluted share accretion \nrelated to the held -for-sale accounting based on the current estimated close date for the PHOENIX Group \ntransaction. ", "original_text": "The net assets included in these t ransactions are classified as held -for-sale. "}, "hash": "43ef81f1b886f63bcaab6406b44e1f396812dae9bc29755ba3e48ff25d57dd86", "class_name": "RelatedNodeInfo"}}, "text": "Next, pursuant to the satisfaction of customary closing conditions, including receipt of regulatory approvals, we \nanticipate the pending divestiture to sell McKesson's UK retail and distribution businesses will close in the fourth \nquarter of fiscal 2022, and the transaction to sell certain European assets to the PHOENIX Group will close in the \nfirst half of fiscal 2023.  \n \n", "start_char_idx": 2433, "end_char_idx": 2813, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b80e5278-ea83-409f-a793-a9b26c156255": {"__data__": {"id_": "b80e5278-ea83-409f-a793-a9b26c156255", "embedding": null, "metadata": {"window": "The assets involved in the Austrian transaction contributed \napproximately $1.5 billion in revenue and $50 million in adjust ed operating profit in fiscal 2021.  The earnings \nrelated to our German joint venture were immaterial.  \n \n Next, pursuant to the satisfaction of customary closing conditions, including receipt of regulatory approvals, we \nanticipate the pending divestiture to sell McKesson's UK retail and distribution businesses will close in the fourth \nquarter of fiscal 2022, and the transaction to sell certain European assets to the PHOENIX Group will close in the \nfirst half of fiscal 2023.  \n \n The net assets included in these t ransactions are classified as held -for-sale.  Our fiscal 2022 guidance includes \napproximately $0.49 of adjusted earnings per diluted share accretion related to these pending transactions, which \nis recorded within our International segment.  This $0.49 of acc retion resulting from the held -for-sale accounting \nwill conclude once each transaction has closed.  \n \n For fiscal 2023, we currently anticipate approximately $0.10 of adjusted earnings per diluted share accretion \nrelated to the held -for-sale accounting based on the current estimated close date for the PHOENIX Group \ntransaction. ", "original_text": "The net assets included in these t ransactions are classified as held -for-sale. ", "page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f4ddef2e-0215-4035-b117-0936dac4b268", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3bb1cfb278f9e546f5d92161d69de14581f1ead157216b7262f605b0c78521bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1be0be6f-ad3c-4a65-a480-f4d19fc583cb", "node_type": "1", "metadata": {"window": "Today, we announced that the transactions to sell our Austrian business to \nQuadrifolia Manage ment and the sale of McKesson's remaining share of our German joint ventures to Walgreens \nBoots Alliance closed on January 31, 2022.  The assets involved in the Austrian transaction contributed \napproximately $1.5 billion in revenue and $50 million in adjust ed operating profit in fiscal 2021.  The earnings \nrelated to our German joint venture were immaterial.  \n \n Next, pursuant to the satisfaction of customary closing conditions, including receipt of regulatory approvals, we \nanticipate the pending divestiture to sell McKesson's UK retail and distribution businesses will close in the fourth \nquarter of fiscal 2022, and the transaction to sell certain European assets to the PHOENIX Group will close in the \nfirst half of fiscal 2023.  \n \n The net assets included in these t ransactions are classified as held -for-sale.  Our fiscal 2022 guidance includes \napproximately $0.49 of adjusted earnings per diluted share accretion related to these pending transactions, which \nis recorded within our International segment.  This $0.49 of acc retion resulting from the held -for-sale accounting \nwill conclude once each transaction has closed.  \n \n", "original_text": "Next, pursuant to the satisfaction of customary closing conditions, including receipt of regulatory approvals, we \nanticipate the pending divestiture to sell McKesson's UK retail and distribution businesses will close in the fourth \nquarter of fiscal 2022, and the transaction to sell certain European assets to the PHOENIX Group will close in the \nfirst half of fiscal 2023.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "60f76075c730fdc89cfc5834d0795f5e1981b2f2f460575c2d61e6f0285ab7f8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4821ef24-fa6b-46a8-bf23-a78f30e0b5f9", "node_type": "1", "metadata": {"window": "The earnings \nrelated to our German joint venture were immaterial.  \n \n Next, pursuant to the satisfaction of customary closing conditions, including receipt of regulatory approvals, we \nanticipate the pending divestiture to sell McKesson's UK retail and distribution businesses will close in the fourth \nquarter of fiscal 2022, and the transaction to sell certain European assets to the PHOENIX Group will close in the \nfirst half of fiscal 2023.  \n \n The net assets included in these t ransactions are classified as held -for-sale.  Our fiscal 2022 guidance includes \napproximately $0.49 of adjusted earnings per diluted share accretion related to these pending transactions, which \nis recorded within our International segment.  This $0.49 of acc retion resulting from the held -for-sale accounting \nwill conclude once each transaction has closed.  \n \n For fiscal 2023, we currently anticipate approximately $0.10 of adjusted earnings per diluted share accretion \nrelated to the held -for-sale accounting based on the current estimated close date for the PHOENIX Group \ntransaction.  Norway and Denmark remain the only countries that we have not entered into an agreement to sell. \n", "original_text": "Our fiscal 2022 guidance includes \napproximately $0.49 of adjusted earnings per diluted share accretion related to these pending transactions, which \nis recorded within our International segment. "}, "hash": "48c36f650ad05c22ebd0af870574f7431675271bad416db8b757d108bf2ac77a", "class_name": "RelatedNodeInfo"}}, "text": "The net assets included in these t ransactions are classified as held -for-sale. ", "start_char_idx": 2813, "end_char_idx": 2894, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4821ef24-fa6b-46a8-bf23-a78f30e0b5f9": {"__data__": {"id_": "4821ef24-fa6b-46a8-bf23-a78f30e0b5f9", "embedding": null, "metadata": {"window": "The earnings \nrelated to our German joint venture were immaterial.  \n \n Next, pursuant to the satisfaction of customary closing conditions, including receipt of regulatory approvals, we \nanticipate the pending divestiture to sell McKesson's UK retail and distribution businesses will close in the fourth \nquarter of fiscal 2022, and the transaction to sell certain European assets to the PHOENIX Group will close in the \nfirst half of fiscal 2023.  \n \n The net assets included in these t ransactions are classified as held -for-sale.  Our fiscal 2022 guidance includes \napproximately $0.49 of adjusted earnings per diluted share accretion related to these pending transactions, which \nis recorded within our International segment.  This $0.49 of acc retion resulting from the held -for-sale accounting \nwill conclude once each transaction has closed.  \n \n For fiscal 2023, we currently anticipate approximately $0.10 of adjusted earnings per diluted share accretion \nrelated to the held -for-sale accounting based on the current estimated close date for the PHOENIX Group \ntransaction.  Norway and Denmark remain the only countries that we have not entered into an agreement to sell. \n", "original_text": "Our fiscal 2022 guidance includes \napproximately $0.49 of adjusted earnings per diluted share accretion related to these pending transactions, which \nis recorded within our International segment. ", "page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f4ddef2e-0215-4035-b117-0936dac4b268", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3bb1cfb278f9e546f5d92161d69de14581f1ead157216b7262f605b0c78521bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b80e5278-ea83-409f-a793-a9b26c156255", "node_type": "1", "metadata": {"window": "The assets involved in the Austrian transaction contributed \napproximately $1.5 billion in revenue and $50 million in adjust ed operating profit in fiscal 2021.  The earnings \nrelated to our German joint venture were immaterial.  \n \n Next, pursuant to the satisfaction of customary closing conditions, including receipt of regulatory approvals, we \nanticipate the pending divestiture to sell McKesson's UK retail and distribution businesses will close in the fourth \nquarter of fiscal 2022, and the transaction to sell certain European assets to the PHOENIX Group will close in the \nfirst half of fiscal 2023.  \n \n The net assets included in these t ransactions are classified as held -for-sale.  Our fiscal 2022 guidance includes \napproximately $0.49 of adjusted earnings per diluted share accretion related to these pending transactions, which \nis recorded within our International segment.  This $0.49 of acc retion resulting from the held -for-sale accounting \nwill conclude once each transaction has closed.  \n \n For fiscal 2023, we currently anticipate approximately $0.10 of adjusted earnings per diluted share accretion \nrelated to the held -for-sale accounting based on the current estimated close date for the PHOENIX Group \ntransaction. ", "original_text": "The net assets included in these t ransactions are classified as held -for-sale. ", "page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1991e248fba49374c16a891b7377e936c0c1f92281745b6b6d30a5a6638de979", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0d031b4a-b76a-4fa4-be80-56a0b3ece706", "node_type": "1", "metadata": {"window": "Next, pursuant to the satisfaction of customary closing conditions, including receipt of regulatory approvals, we \nanticipate the pending divestiture to sell McKesson's UK retail and distribution businesses will close in the fourth \nquarter of fiscal 2022, and the transaction to sell certain European assets to the PHOENIX Group will close in the \nfirst half of fiscal 2023.  \n \n The net assets included in these t ransactions are classified as held -for-sale.  Our fiscal 2022 guidance includes \napproximately $0.49 of adjusted earnings per diluted share accretion related to these pending transactions, which \nis recorded within our International segment.  This $0.49 of acc retion resulting from the held -for-sale accounting \nwill conclude once each transaction has closed.  \n \n For fiscal 2023, we currently anticipate approximately $0.10 of adjusted earnings per diluted share accretion \nrelated to the held -for-sale accounting based on the current estimated close date for the PHOENIX Group \ntransaction.  Norway and Denmark remain the only countries that we have not entered into an agreement to sell. \n As previously discussed, we anticipate we will deploy capital to offset dilution resulti ng from all European \ndivestitures, principally through share repurchases.  \n \n", "original_text": "This $0.49 of acc retion resulting from the held -for-sale accounting \nwill conclude once each transaction has closed.  \n \n"}, "hash": "dbe2e5a810b70b7a04b94532128318eb1110aad9a93288bc1bcb2050927b32be", "class_name": "RelatedNodeInfo"}}, "text": "Our fiscal 2022 guidance includes \napproximately $0.49 of adjusted earnings per diluted share accretion related to these pending transactions, which \nis recorded within our International segment. ", "start_char_idx": 2894, "end_char_idx": 3090, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0d031b4a-b76a-4fa4-be80-56a0b3ece706": {"__data__": {"id_": "0d031b4a-b76a-4fa4-be80-56a0b3ece706", "embedding": null, "metadata": {"window": "Next, pursuant to the satisfaction of customary closing conditions, including receipt of regulatory approvals, we \nanticipate the pending divestiture to sell McKesson's UK retail and distribution businesses will close in the fourth \nquarter of fiscal 2022, and the transaction to sell certain European assets to the PHOENIX Group will close in the \nfirst half of fiscal 2023.  \n \n The net assets included in these t ransactions are classified as held -for-sale.  Our fiscal 2022 guidance includes \napproximately $0.49 of adjusted earnings per diluted share accretion related to these pending transactions, which \nis recorded within our International segment.  This $0.49 of acc retion resulting from the held -for-sale accounting \nwill conclude once each transaction has closed.  \n \n For fiscal 2023, we currently anticipate approximately $0.10 of adjusted earnings per diluted share accretion \nrelated to the held -for-sale accounting based on the current estimated close date for the PHOENIX Group \ntransaction.  Norway and Denmark remain the only countries that we have not entered into an agreement to sell. \n As previously discussed, we anticipate we will deploy capital to offset dilution resulti ng from all European \ndivestitures, principally through share repurchases.  \n \n", "original_text": "This $0.49 of acc retion resulting from the held -for-sale accounting \nwill conclude once each transaction has closed.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f4ddef2e-0215-4035-b117-0936dac4b268", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3bb1cfb278f9e546f5d92161d69de14581f1ead157216b7262f605b0c78521bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4821ef24-fa6b-46a8-bf23-a78f30e0b5f9", "node_type": "1", "metadata": {"window": "The earnings \nrelated to our German joint venture were immaterial.  \n \n Next, pursuant to the satisfaction of customary closing conditions, including receipt of regulatory approvals, we \nanticipate the pending divestiture to sell McKesson's UK retail and distribution businesses will close in the fourth \nquarter of fiscal 2022, and the transaction to sell certain European assets to the PHOENIX Group will close in the \nfirst half of fiscal 2023.  \n \n The net assets included in these t ransactions are classified as held -for-sale.  Our fiscal 2022 guidance includes \napproximately $0.49 of adjusted earnings per diluted share accretion related to these pending transactions, which \nis recorded within our International segment.  This $0.49 of acc retion resulting from the held -for-sale accounting \nwill conclude once each transaction has closed.  \n \n For fiscal 2023, we currently anticipate approximately $0.10 of adjusted earnings per diluted share accretion \nrelated to the held -for-sale accounting based on the current estimated close date for the PHOENIX Group \ntransaction.  Norway and Denmark remain the only countries that we have not entered into an agreement to sell. \n", "original_text": "Our fiscal 2022 guidance includes \napproximately $0.49 of adjusted earnings per diluted share accretion related to these pending transactions, which \nis recorded within our International segment. ", "page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9d35e8ad2f425b726f2dd9a20fcc37794ae153760abd3ece70378556ba1c43cc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "544b7fc1-4328-405f-be18-09f90d4e20f1", "node_type": "1", "metadata": {"window": "The net assets included in these t ransactions are classified as held -for-sale.  Our fiscal 2022 guidance includes \napproximately $0.49 of adjusted earnings per diluted share accretion related to these pending transactions, which \nis recorded within our International segment.  This $0.49 of acc retion resulting from the held -for-sale accounting \nwill conclude once each transaction has closed.  \n \n For fiscal 2023, we currently anticipate approximately $0.10 of adjusted earnings per diluted share accretion \nrelated to the held -for-sale accounting based on the current estimated close date for the PHOENIX Group \ntransaction.  Norway and Denmark remain the only countries that we have not entered into an agreement to sell. \n As previously discussed, we anticipate we will deploy capital to offset dilution resulti ng from all European \ndivestitures, principally through share repurchases.  \n \n Before I provide more details on our third quarter adjusted results, I want to point out one additional item that \nimpacted our GAAP -only results in the quarter. ", "original_text": "For fiscal 2023, we currently anticipate approximately $0.10 of adjusted earnings per diluted share accretion \nrelated to the held -for-sale accounting based on the current estimated close date for the PHOENIX Group \ntransaction. "}, "hash": "7704ca4e543c4847e1b9250adb184425aa96ccdc67993258327955f163e089d4", "class_name": "RelatedNodeInfo"}}, "text": "This $0.49 of acc retion resulting from the held -for-sale accounting \nwill conclude once each transaction has closed.  \n \n", "start_char_idx": 3090, "end_char_idx": 3213, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "544b7fc1-4328-405f-be18-09f90d4e20f1": {"__data__": {"id_": "544b7fc1-4328-405f-be18-09f90d4e20f1", "embedding": null, "metadata": {"window": "The net assets included in these t ransactions are classified as held -for-sale.  Our fiscal 2022 guidance includes \napproximately $0.49 of adjusted earnings per diluted share accretion related to these pending transactions, which \nis recorded within our International segment.  This $0.49 of acc retion resulting from the held -for-sale accounting \nwill conclude once each transaction has closed.  \n \n For fiscal 2023, we currently anticipate approximately $0.10 of adjusted earnings per diluted share accretion \nrelated to the held -for-sale accounting based on the current estimated close date for the PHOENIX Group \ntransaction.  Norway and Denmark remain the only countries that we have not entered into an agreement to sell. \n As previously discussed, we anticipate we will deploy capital to offset dilution resulti ng from all European \ndivestitures, principally through share repurchases.  \n \n Before I provide more details on our third quarter adjusted results, I want to point out one additional item that \nimpacted our GAAP -only results in the quarter. ", "original_text": "For fiscal 2023, we currently anticipate approximately $0.10 of adjusted earnings per diluted share accretion \nrelated to the held -for-sale accounting based on the current estimated close date for the PHOENIX Group \ntransaction. ", "page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f4ddef2e-0215-4035-b117-0936dac4b268", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3bb1cfb278f9e546f5d92161d69de14581f1ead157216b7262f605b0c78521bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0d031b4a-b76a-4fa4-be80-56a0b3ece706", "node_type": "1", "metadata": {"window": "Next, pursuant to the satisfaction of customary closing conditions, including receipt of regulatory approvals, we \nanticipate the pending divestiture to sell McKesson's UK retail and distribution businesses will close in the fourth \nquarter of fiscal 2022, and the transaction to sell certain European assets to the PHOENIX Group will close in the \nfirst half of fiscal 2023.  \n \n The net assets included in these t ransactions are classified as held -for-sale.  Our fiscal 2022 guidance includes \napproximately $0.49 of adjusted earnings per diluted share accretion related to these pending transactions, which \nis recorded within our International segment.  This $0.49 of acc retion resulting from the held -for-sale accounting \nwill conclude once each transaction has closed.  \n \n For fiscal 2023, we currently anticipate approximately $0.10 of adjusted earnings per diluted share accretion \nrelated to the held -for-sale accounting based on the current estimated close date for the PHOENIX Group \ntransaction.  Norway and Denmark remain the only countries that we have not entered into an agreement to sell. \n As previously discussed, we anticipate we will deploy capital to offset dilution resulti ng from all European \ndivestitures, principally through share repurchases.  \n \n", "original_text": "This $0.49 of acc retion resulting from the held -for-sale accounting \nwill conclude once each transaction has closed.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cf6efc744a53ca633f96406aa5b7ab983cb2b34e8897c8e335a7c51561aa0d60", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7597e6b5-d145-4bac-bd51-94d6630882ad", "node_type": "1", "metadata": {"window": "Our fiscal 2022 guidance includes \napproximately $0.49 of adjusted earnings per diluted share accretion related to these pending transactions, which \nis recorded within our International segment.  This $0.49 of acc retion resulting from the held -for-sale accounting \nwill conclude once each transaction has closed.  \n \n For fiscal 2023, we currently anticipate approximately $0.10 of adjusted earnings per diluted share accretion \nrelated to the held -for-sale accounting based on the current estimated close date for the PHOENIX Group \ntransaction.  Norway and Denmark remain the only countries that we have not entered into an agreement to sell. \n As previously discussed, we anticipate we will deploy capital to offset dilution resulti ng from all European \ndivestitures, principally through share repurchases.  \n \n Before I provide more details on our third quarter adjusted results, I want to point out one additional item that \nimpacted our GAAP -only results in the quarter.  We recorded a GAAP -only after -tax charge of $829 million related \nto the sale of retail and distribution businesses in the UK to account for the remeasurement of the net assets to \nthe lower carrying amount or fair value, less cost to sell. ", "original_text": "Norway and Denmark remain the only countries that we have not entered into an agreement to sell. \n"}, "hash": "b80736844003533860ab591c6a0764af4f9312a8de3b80f5b73aa64ad3992694", "class_name": "RelatedNodeInfo"}}, "text": "For fiscal 2023, we currently anticipate approximately $0.10 of adjusted earnings per diluted share accretion \nrelated to the held -for-sale accounting based on the current estimated close date for the PHOENIX Group \ntransaction. ", "start_char_idx": 3213, "end_char_idx": 3443, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7597e6b5-d145-4bac-bd51-94d6630882ad": {"__data__": {"id_": "7597e6b5-d145-4bac-bd51-94d6630882ad", "embedding": null, "metadata": {"window": "Our fiscal 2022 guidance includes \napproximately $0.49 of adjusted earnings per diluted share accretion related to these pending transactions, which \nis recorded within our International segment.  This $0.49 of acc retion resulting from the held -for-sale accounting \nwill conclude once each transaction has closed.  \n \n For fiscal 2023, we currently anticipate approximately $0.10 of adjusted earnings per diluted share accretion \nrelated to the held -for-sale accounting based on the current estimated close date for the PHOENIX Group \ntransaction.  Norway and Denmark remain the only countries that we have not entered into an agreement to sell. \n As previously discussed, we anticipate we will deploy capital to offset dilution resulti ng from all European \ndivestitures, principally through share repurchases.  \n \n Before I provide more details on our third quarter adjusted results, I want to point out one additional item that \nimpacted our GAAP -only results in the quarter.  We recorded a GAAP -only after -tax charge of $829 million related \nto the sale of retail and distribution businesses in the UK to account for the remeasurement of the net assets to \nthe lower carrying amount or fair value, less cost to sell. ", "original_text": "Norway and Denmark remain the only countries that we have not entered into an agreement to sell. \n", "page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f4ddef2e-0215-4035-b117-0936dac4b268", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3bb1cfb278f9e546f5d92161d69de14581f1ead157216b7262f605b0c78521bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "544b7fc1-4328-405f-be18-09f90d4e20f1", "node_type": "1", "metadata": {"window": "The net assets included in these t ransactions are classified as held -for-sale.  Our fiscal 2022 guidance includes \napproximately $0.49 of adjusted earnings per diluted share accretion related to these pending transactions, which \nis recorded within our International segment.  This $0.49 of acc retion resulting from the held -for-sale accounting \nwill conclude once each transaction has closed.  \n \n For fiscal 2023, we currently anticipate approximately $0.10 of adjusted earnings per diluted share accretion \nrelated to the held -for-sale accounting based on the current estimated close date for the PHOENIX Group \ntransaction.  Norway and Denmark remain the only countries that we have not entered into an agreement to sell. \n As previously discussed, we anticipate we will deploy capital to offset dilution resulti ng from all European \ndivestitures, principally through share repurchases.  \n \n Before I provide more details on our third quarter adjusted results, I want to point out one additional item that \nimpacted our GAAP -only results in the quarter. ", "original_text": "For fiscal 2023, we currently anticipate approximately $0.10 of adjusted earnings per diluted share accretion \nrelated to the held -for-sale accounting based on the current estimated close date for the PHOENIX Group \ntransaction. ", "page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0645740109f76510790fba98c11ad0e07ca66add6bd5bdd7e9bf145f5c2d0297", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "821f2aea-1c74-40e3-ae09-87c7b985496c", "node_type": "1", "metadata": {"window": "This $0.49 of acc retion resulting from the held -for-sale accounting \nwill conclude once each transaction has closed.  \n \n For fiscal 2023, we currently anticipate approximately $0.10 of adjusted earnings per diluted share accretion \nrelated to the held -for-sale accounting based on the current estimated close date for the PHOENIX Group \ntransaction.  Norway and Denmark remain the only countries that we have not entered into an agreement to sell. \n As previously discussed, we anticipate we will deploy capital to offset dilution resulti ng from all European \ndivestitures, principally through share repurchases.  \n \n Before I provide more details on our third quarter adjusted results, I want to point out one additional item that \nimpacted our GAAP -only results in the quarter.  We recorded a GAAP -only after -tax charge of $829 million related \nto the sale of retail and distribution businesses in the UK to account for the remeasurement of the net assets to \nthe lower carrying amount or fair value, less cost to sell.  These charges were largely driv en by declines in the \nBritish pound sterling.  \n ", "original_text": "As previously discussed, we anticipate we will deploy capital to offset dilution resulti ng from all European \ndivestitures, principally through share repurchases.  \n \n"}, "hash": "33932444eba392536d79849f9ed783c9a1ad52ec56d77a02843098705c540148", "class_name": "RelatedNodeInfo"}}, "text": "Norway and Denmark remain the only countries that we have not entered into an agreement to sell. \n", "start_char_idx": 3443, "end_char_idx": 3541, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "821f2aea-1c74-40e3-ae09-87c7b985496c": {"__data__": {"id_": "821f2aea-1c74-40e3-ae09-87c7b985496c", "embedding": null, "metadata": {"window": "This $0.49 of acc retion resulting from the held -for-sale accounting \nwill conclude once each transaction has closed.  \n \n For fiscal 2023, we currently anticipate approximately $0.10 of adjusted earnings per diluted share accretion \nrelated to the held -for-sale accounting based on the current estimated close date for the PHOENIX Group \ntransaction.  Norway and Denmark remain the only countries that we have not entered into an agreement to sell. \n As previously discussed, we anticipate we will deploy capital to offset dilution resulti ng from all European \ndivestitures, principally through share repurchases.  \n \n Before I provide more details on our third quarter adjusted results, I want to point out one additional item that \nimpacted our GAAP -only results in the quarter.  We recorded a GAAP -only after -tax charge of $829 million related \nto the sale of retail and distribution businesses in the UK to account for the remeasurement of the net assets to \nthe lower carrying amount or fair value, less cost to sell.  These charges were largely driv en by declines in the \nBritish pound sterling.  \n ", "original_text": "As previously discussed, we anticipate we will deploy capital to offset dilution resulti ng from all European \ndivestitures, principally through share repurchases.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f4ddef2e-0215-4035-b117-0936dac4b268", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3bb1cfb278f9e546f5d92161d69de14581f1ead157216b7262f605b0c78521bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7597e6b5-d145-4bac-bd51-94d6630882ad", "node_type": "1", "metadata": {"window": "Our fiscal 2022 guidance includes \napproximately $0.49 of adjusted earnings per diluted share accretion related to these pending transactions, which \nis recorded within our International segment.  This $0.49 of acc retion resulting from the held -for-sale accounting \nwill conclude once each transaction has closed.  \n \n For fiscal 2023, we currently anticipate approximately $0.10 of adjusted earnings per diluted share accretion \nrelated to the held -for-sale accounting based on the current estimated close date for the PHOENIX Group \ntransaction.  Norway and Denmark remain the only countries that we have not entered into an agreement to sell. \n As previously discussed, we anticipate we will deploy capital to offset dilution resulti ng from all European \ndivestitures, principally through share repurchases.  \n \n Before I provide more details on our third quarter adjusted results, I want to point out one additional item that \nimpacted our GAAP -only results in the quarter.  We recorded a GAAP -only after -tax charge of $829 million related \nto the sale of retail and distribution businesses in the UK to account for the remeasurement of the net assets to \nthe lower carrying amount or fair value, less cost to sell. ", "original_text": "Norway and Denmark remain the only countries that we have not entered into an agreement to sell. \n", "page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2e4d3380ebaef96ed5a96e59210c12120143d6f544c80b9ea55d4d2761ed09e7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "247ac1f4-5611-4287-8478-a0cbaca264fd", "node_type": "1", "metadata": {"window": "For fiscal 2023, we currently anticipate approximately $0.10 of adjusted earnings per diluted share accretion \nrelated to the held -for-sale accounting based on the current estimated close date for the PHOENIX Group \ntransaction.  Norway and Denmark remain the only countries that we have not entered into an agreement to sell. \n As previously discussed, we anticipate we will deploy capital to offset dilution resulti ng from all European \ndivestitures, principally through share repurchases.  \n \n Before I provide more details on our third quarter adjusted results, I want to point out one additional item that \nimpacted our GAAP -only results in the quarter.  We recorded a GAAP -only after -tax charge of $829 million related \nto the sale of retail and distribution businesses in the UK to account for the remeasurement of the net assets to \nthe lower carrying amount or fair value, less cost to sell.  These charges were largely driv en by declines in the \nBritish pound sterling.  \n ", "original_text": "Before I provide more details on our third quarter adjusted results, I want to point out one additional item that \nimpacted our GAAP -only results in the quarter. "}, "hash": "fdec834e2800efef87fea3ebab6bb72097064c85e7ec20d51ecc132d70d85a23", "class_name": "RelatedNodeInfo"}}, "text": "As previously discussed, we anticipate we will deploy capital to offset dilution resulti ng from all European \ndivestitures, principally through share repurchases.  \n \n", "start_char_idx": 3541, "end_char_idx": 3709, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "247ac1f4-5611-4287-8478-a0cbaca264fd": {"__data__": {"id_": "247ac1f4-5611-4287-8478-a0cbaca264fd", "embedding": null, "metadata": {"window": "For fiscal 2023, we currently anticipate approximately $0.10 of adjusted earnings per diluted share accretion \nrelated to the held -for-sale accounting based on the current estimated close date for the PHOENIX Group \ntransaction.  Norway and Denmark remain the only countries that we have not entered into an agreement to sell. \n As previously discussed, we anticipate we will deploy capital to offset dilution resulti ng from all European \ndivestitures, principally through share repurchases.  \n \n Before I provide more details on our third quarter adjusted results, I want to point out one additional item that \nimpacted our GAAP -only results in the quarter.  We recorded a GAAP -only after -tax charge of $829 million related \nto the sale of retail and distribution businesses in the UK to account for the remeasurement of the net assets to \nthe lower carrying amount or fair value, less cost to sell.  These charges were largely driv en by declines in the \nBritish pound sterling.  \n ", "original_text": "Before I provide more details on our third quarter adjusted results, I want to point out one additional item that \nimpacted our GAAP -only results in the quarter. ", "page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f4ddef2e-0215-4035-b117-0936dac4b268", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3bb1cfb278f9e546f5d92161d69de14581f1ead157216b7262f605b0c78521bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "821f2aea-1c74-40e3-ae09-87c7b985496c", "node_type": "1", "metadata": {"window": "This $0.49 of acc retion resulting from the held -for-sale accounting \nwill conclude once each transaction has closed.  \n \n For fiscal 2023, we currently anticipate approximately $0.10 of adjusted earnings per diluted share accretion \nrelated to the held -for-sale accounting based on the current estimated close date for the PHOENIX Group \ntransaction.  Norway and Denmark remain the only countries that we have not entered into an agreement to sell. \n As previously discussed, we anticipate we will deploy capital to offset dilution resulti ng from all European \ndivestitures, principally through share repurchases.  \n \n Before I provide more details on our third quarter adjusted results, I want to point out one additional item that \nimpacted our GAAP -only results in the quarter.  We recorded a GAAP -only after -tax charge of $829 million related \nto the sale of retail and distribution businesses in the UK to account for the remeasurement of the net assets to \nthe lower carrying amount or fair value, less cost to sell.  These charges were largely driv en by declines in the \nBritish pound sterling.  \n ", "original_text": "As previously discussed, we anticipate we will deploy capital to offset dilution resulti ng from all European \ndivestitures, principally through share repurchases.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a662c28189f437a7452a82337146115275ff993ae53a1ccc59c286cb48023e64", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f4161c25-1f35-4ce6-b202-915fc722ec4b", "node_type": "1", "metadata": {"window": "Norway and Denmark remain the only countries that we have not entered into an agreement to sell. \n As previously discussed, we anticipate we will deploy capital to offset dilution resulti ng from all European \ndivestitures, principally through share repurchases.  \n \n Before I provide more details on our third quarter adjusted results, I want to point out one additional item that \nimpacted our GAAP -only results in the quarter.  We recorded a GAAP -only after -tax charge of $829 million related \nto the sale of retail and distribution businesses in the UK to account for the remeasurement of the net assets to \nthe lower carrying amount or fair value, less cost to sell.  These charges were largely driv en by declines in the \nBritish pound sterling.  \n ", "original_text": "We recorded a GAAP -only after -tax charge of $829 million related \nto the sale of retail and distribution businesses in the UK to account for the remeasurement of the net assets to \nthe lower carrying amount or fair value, less cost to sell. "}, "hash": "7d92ab6711984a1e17446b4950773e85cc7b5eaa7da85edc958636471afd6430", "class_name": "RelatedNodeInfo"}}, "text": "Before I provide more details on our third quarter adjusted results, I want to point out one additional item that \nimpacted our GAAP -only results in the quarter. ", "start_char_idx": 3709, "end_char_idx": 3872, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f4161c25-1f35-4ce6-b202-915fc722ec4b": {"__data__": {"id_": "f4161c25-1f35-4ce6-b202-915fc722ec4b", "embedding": null, "metadata": {"window": "Norway and Denmark remain the only countries that we have not entered into an agreement to sell. \n As previously discussed, we anticipate we will deploy capital to offset dilution resulti ng from all European \ndivestitures, principally through share repurchases.  \n \n Before I provide more details on our third quarter adjusted results, I want to point out one additional item that \nimpacted our GAAP -only results in the quarter.  We recorded a GAAP -only after -tax charge of $829 million related \nto the sale of retail and distribution businesses in the UK to account for the remeasurement of the net assets to \nthe lower carrying amount or fair value, less cost to sell.  These charges were largely driv en by declines in the \nBritish pound sterling.  \n ", "original_text": "We recorded a GAAP -only after -tax charge of $829 million related \nto the sale of retail and distribution businesses in the UK to account for the remeasurement of the net assets to \nthe lower carrying amount or fair value, less cost to sell. ", "page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f4ddef2e-0215-4035-b117-0936dac4b268", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3bb1cfb278f9e546f5d92161d69de14581f1ead157216b7262f605b0c78521bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "247ac1f4-5611-4287-8478-a0cbaca264fd", "node_type": "1", "metadata": {"window": "For fiscal 2023, we currently anticipate approximately $0.10 of adjusted earnings per diluted share accretion \nrelated to the held -for-sale accounting based on the current estimated close date for the PHOENIX Group \ntransaction.  Norway and Denmark remain the only countries that we have not entered into an agreement to sell. \n As previously discussed, we anticipate we will deploy capital to offset dilution resulti ng from all European \ndivestitures, principally through share repurchases.  \n \n Before I provide more details on our third quarter adjusted results, I want to point out one additional item that \nimpacted our GAAP -only results in the quarter.  We recorded a GAAP -only after -tax charge of $829 million related \nto the sale of retail and distribution businesses in the UK to account for the remeasurement of the net assets to \nthe lower carrying amount or fair value, less cost to sell.  These charges were largely driv en by declines in the \nBritish pound sterling.  \n ", "original_text": "Before I provide more details on our third quarter adjusted results, I want to point out one additional item that \nimpacted our GAAP -only results in the quarter. ", "page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7b8fbad012087d59765570656d90d842156be6578cecbef7323c1ad0279269b9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8c0e7c05-ac46-4505-90ca-704abf3fd5d8", "node_type": "1", "metadata": {"window": "As previously discussed, we anticipate we will deploy capital to offset dilution resulti ng from all European \ndivestitures, principally through share repurchases.  \n \n Before I provide more details on our third quarter adjusted results, I want to point out one additional item that \nimpacted our GAAP -only results in the quarter.  We recorded a GAAP -only after -tax charge of $829 million related \nto the sale of retail and distribution businesses in the UK to account for the remeasurement of the net assets to \nthe lower carrying amount or fair value, less cost to sell.  These charges were largely driv en by declines in the \nBritish pound sterling.  \n ", "original_text": "These charges were largely driv en by declines in the \nBritish pound sterling.  \n "}, "hash": "58b78be742efb432c41e78463a66bc3ff379ac98672e4f6f296b88ef994665f0", "class_name": "RelatedNodeInfo"}}, "text": "We recorded a GAAP -only after -tax charge of $829 million related \nto the sale of retail and distribution businesses in the UK to account for the remeasurement of the net assets to \nthe lower carrying amount or fair value, less cost to sell. ", "start_char_idx": 3872, "end_char_idx": 4115, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8c0e7c05-ac46-4505-90ca-704abf3fd5d8": {"__data__": {"id_": "8c0e7c05-ac46-4505-90ca-704abf3fd5d8", "embedding": null, "metadata": {"window": "As previously discussed, we anticipate we will deploy capital to offset dilution resulti ng from all European \ndivestitures, principally through share repurchases.  \n \n Before I provide more details on our third quarter adjusted results, I want to point out one additional item that \nimpacted our GAAP -only results in the quarter.  We recorded a GAAP -only after -tax charge of $829 million related \nto the sale of retail and distribution businesses in the UK to account for the remeasurement of the net assets to \nthe lower carrying amount or fair value, less cost to sell.  These charges were largely driv en by declines in the \nBritish pound sterling.  \n ", "original_text": "These charges were largely driv en by declines in the \nBritish pound sterling.  \n ", "page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f4ddef2e-0215-4035-b117-0936dac4b268", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3bb1cfb278f9e546f5d92161d69de14581f1ead157216b7262f605b0c78521bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f4161c25-1f35-4ce6-b202-915fc722ec4b", "node_type": "1", "metadata": {"window": "Norway and Denmark remain the only countries that we have not entered into an agreement to sell. \n As previously discussed, we anticipate we will deploy capital to offset dilution resulti ng from all European \ndivestitures, principally through share repurchases.  \n \n Before I provide more details on our third quarter adjusted results, I want to point out one additional item that \nimpacted our GAAP -only results in the quarter.  We recorded a GAAP -only after -tax charge of $829 million related \nto the sale of retail and distribution businesses in the UK to account for the remeasurement of the net assets to \nthe lower carrying amount or fair value, less cost to sell.  These charges were largely driv en by declines in the \nBritish pound sterling.  \n ", "original_text": "We recorded a GAAP -only after -tax charge of $829 million related \nto the sale of retail and distribution businesses in the UK to account for the remeasurement of the net assets to \nthe lower carrying amount or fair value, less cost to sell. ", "page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5bfaec74ef5b318dd72e6cb077fa7f6a85d7c47c29a219d9b5161371f04aa489", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a416d8f-6973-47b3-a26b-ef6670c3d4e7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nMoving now to our adjusted results for the third quarter, beginning with our consolidated results which can be \nfound on slide 7.  As discussed at our Investor Day back in December, we managed the business for t he long \nterm, and our financial and strategic framework is focused on shareholder value creation.  Our financial framework \ncombines three key elements to generate sustainable adjusted EPS growth: organic growth, operating leverage, \nand capital allocation. ", "original_text": "McKesson Corp.  "}, "hash": "87a2df40eaac3829667f5db5d932b31c195cc66ffc3a0eca2b2d335efdfab0a2", "class_name": "RelatedNodeInfo"}}, "text": "These charges were largely driv en by declines in the \nBritish pound sterling.  \n ", "start_char_idx": 4115, "end_char_idx": 4197, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a416d8f-6973-47b3-a26b-ef6670c3d4e7": {"__data__": {"id_": "4a416d8f-6973-47b3-a26b-ef6670c3d4e7", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nMoving now to our adjusted results for the third quarter, beginning with our consolidated results which can be \nfound on slide 7.  As discussed at our Investor Day back in December, we managed the business for t he long \nterm, and our financial and strategic framework is focused on shareholder value creation.  Our financial framework \ncombines three key elements to generate sustainable adjusted EPS growth: organic growth, operating leverage, \nand capital allocation. ", "original_text": "McKesson Corp.  ", "page_label": "8", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "61ec5d58-e8e6-4fb6-84e9-6e9504c022e8", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffd5c71f741ef9c4b9932ba9b2502b8e2acdf6d96d4f117e98ddf8b8c885e775", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8c0e7c05-ac46-4505-90ca-704abf3fd5d8", "node_type": "1", "metadata": {"window": "As previously discussed, we anticipate we will deploy capital to offset dilution resulti ng from all European \ndivestitures, principally through share repurchases.  \n \n Before I provide more details on our third quarter adjusted results, I want to point out one additional item that \nimpacted our GAAP -only results in the quarter.  We recorded a GAAP -only after -tax charge of $829 million related \nto the sale of retail and distribution businesses in the UK to account for the remeasurement of the net assets to \nthe lower carrying amount or fair value, less cost to sell.  These charges were largely driv en by declines in the \nBritish pound sterling.  \n ", "original_text": "These charges were largely driv en by declines in the \nBritish pound sterling.  \n ", "page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fffd61eb4d71c62ce6e2230a97ab0219da6ea4a6a33bc3ddecea7ccac6b3905c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "60ba4309-17a1-4c2d-8bbf-9c9e18dba141", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nMoving now to our adjusted results for the third quarter, beginning with our consolidated results which can be \nfound on slide 7.  As discussed at our Investor Day back in December, we managed the business for t he long \nterm, and our financial and strategic framework is focused on shareholder value creation.  Our financial framework \ncombines three key elements to generate sustainable adjusted EPS growth: organic growth, operating leverage, \nand capital allocation.  T his framework is once again demonstrated by our strong third quarter fiscal 2022 results.  \n \n", "original_text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nMoving now to our adjusted results for the third quarter, beginning with our consolidated results which can be \nfound on slide 7. "}, "hash": "e761ff4e32e4f771c393b14e60b492bb81f3b2541d2c5f9ec6c226579bb5a3bd", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "60ba4309-17a1-4c2d-8bbf-9c9e18dba141": {"__data__": {"id_": "60ba4309-17a1-4c2d-8bbf-9c9e18dba141", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nMoving now to our adjusted results for the third quarter, beginning with our consolidated results which can be \nfound on slide 7.  As discussed at our Investor Day back in December, we managed the business for t he long \nterm, and our financial and strategic framework is focused on shareholder value creation.  Our financial framework \ncombines three key elements to generate sustainable adjusted EPS growth: organic growth, operating leverage, \nand capital allocation.  T his framework is once again demonstrated by our strong third quarter fiscal 2022 results.  \n \n", "original_text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nMoving now to our adjusted results for the third quarter, beginning with our consolidated results which can be \nfound on slide 7. ", "page_label": "8", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "61ec5d58-e8e6-4fb6-84e9-6e9504c022e8", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffd5c71f741ef9c4b9932ba9b2502b8e2acdf6d96d4f117e98ddf8b8c885e775", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a416d8f-6973-47b3-a26b-ef6670c3d4e7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nMoving now to our adjusted results for the third quarter, beginning with our consolidated results which can be \nfound on slide 7.  As discussed at our Investor Day back in December, we managed the business for t he long \nterm, and our financial and strategic framework is focused on shareholder value creation.  Our financial framework \ncombines three key elements to generate sustainable adjusted EPS growth: organic growth, operating leverage, \nand capital allocation. ", "original_text": "McKesson Corp.  ", "page_label": "8", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "755f508d318dc42e0d6612a09c7937a6ed1fb56e1775f512becbb99ad5d44713", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "79e71ee7-04d6-449b-aff7-a45d731645b6", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nMoving now to our adjusted results for the third quarter, beginning with our consolidated results which can be \nfound on slide 7.  As discussed at our Investor Day back in December, we managed the business for t he long \nterm, and our financial and strategic framework is focused on shareholder value creation.  Our financial framework \ncombines three key elements to generate sustainable adjusted EPS growth: organic growth, operating leverage, \nand capital allocation.  T his framework is once again demonstrated by our strong third quarter fiscal 2022 results.  \n \n Additionally, our leadership supporting the US government's COVID -19 domestic and International vaccine and \nkitting efforts continue to contribute to growth and the momentum we have built across the business.  \n \n", "original_text": "As discussed at our Investor Day back in December, we managed the business for t he long \nterm, and our financial and strategic framework is focused on shareholder value creation. "}, "hash": "65be3768be2d66a80de6870d686ea1625e2f8100949cedd6da4b5e68f7bf716e", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nMoving now to our adjusted results for the third quarter, beginning with our consolidated results which can be \nfound on slide 7. ", "start_char_idx": 16, "end_char_idx": 310, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "79e71ee7-04d6-449b-aff7-a45d731645b6": {"__data__": {"id_": "79e71ee7-04d6-449b-aff7-a45d731645b6", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nMoving now to our adjusted results for the third quarter, beginning with our consolidated results which can be \nfound on slide 7.  As discussed at our Investor Day back in December, we managed the business for t he long \nterm, and our financial and strategic framework is focused on shareholder value creation.  Our financial framework \ncombines three key elements to generate sustainable adjusted EPS growth: organic growth, operating leverage, \nand capital allocation.  T his framework is once again demonstrated by our strong third quarter fiscal 2022 results.  \n \n Additionally, our leadership supporting the US government's COVID -19 domestic and International vaccine and \nkitting efforts continue to contribute to growth and the momentum we have built across the business.  \n \n", "original_text": "As discussed at our Investor Day back in December, we managed the business for t he long \nterm, and our financial and strategic framework is focused on shareholder value creation. ", "page_label": "8", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "61ec5d58-e8e6-4fb6-84e9-6e9504c022e8", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffd5c71f741ef9c4b9932ba9b2502b8e2acdf6d96d4f117e98ddf8b8c885e775", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "60ba4309-17a1-4c2d-8bbf-9c9e18dba141", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nMoving now to our adjusted results for the third quarter, beginning with our consolidated results which can be \nfound on slide 7.  As discussed at our Investor Day back in December, we managed the business for t he long \nterm, and our financial and strategic framework is focused on shareholder value creation.  Our financial framework \ncombines three key elements to generate sustainable adjusted EPS growth: organic growth, operating leverage, \nand capital allocation.  T his framework is once again demonstrated by our strong third quarter fiscal 2022 results.  \n \n", "original_text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nMoving now to our adjusted results for the third quarter, beginning with our consolidated results which can be \nfound on slide 7. ", "page_label": "8", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbe88b5537897c9747f6cca9c18c6e36a5df30b9e9011d42eedcb750d317d87f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "42c97ddd-b746-4886-a6df-9b2edaf071eb", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nMoving now to our adjusted results for the third quarter, beginning with our consolidated results which can be \nfound on slide 7.  As discussed at our Investor Day back in December, we managed the business for t he long \nterm, and our financial and strategic framework is focused on shareholder value creation.  Our financial framework \ncombines three key elements to generate sustainable adjusted EPS growth: organic growth, operating leverage, \nand capital allocation.  T his framework is once again demonstrated by our strong third quarter fiscal 2022 results.  \n \n Additionally, our leadership supporting the US government's COVID -19 domestic and International vaccine and \nkitting efforts continue to contribute to growth and the momentum we have built across the business.  \n \n Third quarter adjusted earnings per diluted share was $6.15, an increase of 34% compared to the prior year. ", "original_text": "Our financial framework \ncombines three key elements to generate sustainable adjusted EPS growth: organic growth, operating leverage, \nand capital allocation. "}, "hash": "372da90608a266b6cf2acab3955a9c6166a3904cbc3ababec844d0c3ff4a08da", "class_name": "RelatedNodeInfo"}}, "text": "As discussed at our Investor Day back in December, we managed the business for t he long \nterm, and our financial and strategic framework is focused on shareholder value creation. ", "start_char_idx": 310, "end_char_idx": 490, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "42c97ddd-b746-4886-a6df-9b2edaf071eb": {"__data__": {"id_": "42c97ddd-b746-4886-a6df-9b2edaf071eb", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nMoving now to our adjusted results for the third quarter, beginning with our consolidated results which can be \nfound on slide 7.  As discussed at our Investor Day back in December, we managed the business for t he long \nterm, and our financial and strategic framework is focused on shareholder value creation.  Our financial framework \ncombines three key elements to generate sustainable adjusted EPS growth: organic growth, operating leverage, \nand capital allocation.  T his framework is once again demonstrated by our strong third quarter fiscal 2022 results.  \n \n Additionally, our leadership supporting the US government's COVID -19 domestic and International vaccine and \nkitting efforts continue to contribute to growth and the momentum we have built across the business.  \n \n Third quarter adjusted earnings per diluted share was $6.15, an increase of 34% compared to the prior year. ", "original_text": "Our financial framework \ncombines three key elements to generate sustainable adjusted EPS growth: organic growth, operating leverage, \nand capital allocation. ", "page_label": "8", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "61ec5d58-e8e6-4fb6-84e9-6e9504c022e8", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffd5c71f741ef9c4b9932ba9b2502b8e2acdf6d96d4f117e98ddf8b8c885e775", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "79e71ee7-04d6-449b-aff7-a45d731645b6", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nMoving now to our adjusted results for the third quarter, beginning with our consolidated results which can be \nfound on slide 7.  As discussed at our Investor Day back in December, we managed the business for t he long \nterm, and our financial and strategic framework is focused on shareholder value creation.  Our financial framework \ncombines three key elements to generate sustainable adjusted EPS growth: organic growth, operating leverage, \nand capital allocation.  T his framework is once again demonstrated by our strong third quarter fiscal 2022 results.  \n \n Additionally, our leadership supporting the US government's COVID -19 domestic and International vaccine and \nkitting efforts continue to contribute to growth and the momentum we have built across the business.  \n \n", "original_text": "As discussed at our Investor Day back in December, we managed the business for t he long \nterm, and our financial and strategic framework is focused on shareholder value creation. ", "page_label": "8", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0bcb6e17500cb9f5c8e3ad1d56a239f37399bbb646a18d4adee9bdf8bb860ee2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0271da0b-b971-4510-b680-2a5313c69fa4", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nMoving now to our adjusted results for the third quarter, beginning with our consolidated results which can be \nfound on slide 7.  As discussed at our Investor Day back in December, we managed the business for t he long \nterm, and our financial and strategic framework is focused on shareholder value creation.  Our financial framework \ncombines three key elements to generate sustainable adjusted EPS growth: organic growth, operating leverage, \nand capital allocation.  T his framework is once again demonstrated by our strong third quarter fiscal 2022 results.  \n \n Additionally, our leadership supporting the US government's COVID -19 domestic and International vaccine and \nkitting efforts continue to contribute to growth and the momentum we have built across the business.  \n \n Third quarter adjusted earnings per diluted share was $6.15, an increase of 34% compared to the prior year.  This \nresult was driven by strong operational performance across the segments, COVID -19-related items, w hich include \nthe contribution from COVID -19 vaccine distribution, kitting, and storage programs of the US government, COVID -\n19 tests and fiscal 2021 impairments for personal protective equipment and related products, and a lower share \ncount.  \n \n", "original_text": "T his framework is once again demonstrated by our strong third quarter fiscal 2022 results.  \n \n"}, "hash": "3950e6ecfe10f67b4e30441aced61f06947a11598732cc5ddd03348d7fefcc1d", "class_name": "RelatedNodeInfo"}}, "text": "Our financial framework \ncombines three key elements to generate sustainable adjusted EPS growth: organic growth, operating leverage, \nand capital allocation. ", "start_char_idx": 490, "end_char_idx": 649, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0271da0b-b971-4510-b680-2a5313c69fa4": {"__data__": {"id_": "0271da0b-b971-4510-b680-2a5313c69fa4", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nMoving now to our adjusted results for the third quarter, beginning with our consolidated results which can be \nfound on slide 7.  As discussed at our Investor Day back in December, we managed the business for t he long \nterm, and our financial and strategic framework is focused on shareholder value creation.  Our financial framework \ncombines three key elements to generate sustainable adjusted EPS growth: organic growth, operating leverage, \nand capital allocation.  T his framework is once again demonstrated by our strong third quarter fiscal 2022 results.  \n \n Additionally, our leadership supporting the US government's COVID -19 domestic and International vaccine and \nkitting efforts continue to contribute to growth and the momentum we have built across the business.  \n \n Third quarter adjusted earnings per diluted share was $6.15, an increase of 34% compared to the prior year.  This \nresult was driven by strong operational performance across the segments, COVID -19-related items, w hich include \nthe contribution from COVID -19 vaccine distribution, kitting, and storage programs of the US government, COVID -\n19 tests and fiscal 2021 impairments for personal protective equipment and related products, and a lower share \ncount.  \n \n", "original_text": "T his framework is once again demonstrated by our strong third quarter fiscal 2022 results.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "61ec5d58-e8e6-4fb6-84e9-6e9504c022e8", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffd5c71f741ef9c4b9932ba9b2502b8e2acdf6d96d4f117e98ddf8b8c885e775", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "42c97ddd-b746-4886-a6df-9b2edaf071eb", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nMoving now to our adjusted results for the third quarter, beginning with our consolidated results which can be \nfound on slide 7.  As discussed at our Investor Day back in December, we managed the business for t he long \nterm, and our financial and strategic framework is focused on shareholder value creation.  Our financial framework \ncombines three key elements to generate sustainable adjusted EPS growth: organic growth, operating leverage, \nand capital allocation.  T his framework is once again demonstrated by our strong third quarter fiscal 2022 results.  \n \n Additionally, our leadership supporting the US government's COVID -19 domestic and International vaccine and \nkitting efforts continue to contribute to growth and the momentum we have built across the business.  \n \n Third quarter adjusted earnings per diluted share was $6.15, an increase of 34% compared to the prior year. ", "original_text": "Our financial framework \ncombines three key elements to generate sustainable adjusted EPS growth: organic growth, operating leverage, \nand capital allocation. ", "page_label": "8", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "277fe29f7ba247797b9c70aa2c0ab28c717273f74f5394f3dd7c2eb3bf1f342f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ac1af8e0-b24d-4926-b892-d19d6f4446ea", "node_type": "1", "metadata": {"window": "As discussed at our Investor Day back in December, we managed the business for t he long \nterm, and our financial and strategic framework is focused on shareholder value creation.  Our financial framework \ncombines three key elements to generate sustainable adjusted EPS growth: organic growth, operating leverage, \nand capital allocation.  T his framework is once again demonstrated by our strong third quarter fiscal 2022 results.  \n \n Additionally, our leadership supporting the US government's COVID -19 domestic and International vaccine and \nkitting efforts continue to contribute to growth and the momentum we have built across the business.  \n \n Third quarter adjusted earnings per diluted share was $6.15, an increase of 34% compared to the prior year.  This \nresult was driven by strong operational performance across the segments, COVID -19-related items, w hich include \nthe contribution from COVID -19 vaccine distribution, kitting, and storage programs of the US government, COVID -\n19 tests and fiscal 2021 impairments for personal protective equipment and related products, and a lower share \ncount.  \n \n Consolidated revenues of $68.6 billion increased 10% above the prior year, primarily driven by growth in the US \nPharmaceutical segment largely due to higher volumes from our retail national account customers and branded \npharmaceutical price increases, which were in lin e with our initial guidance, partially offset by branded to generic \nconversions.  \n \n", "original_text": "Additionally, our leadership supporting the US government's COVID -19 domestic and International vaccine and \nkitting efforts continue to contribute to growth and the momentum we have built across the business.  \n \n"}, "hash": "f51b484a7e2c7962da9501429270661cd652be6703b80665b3b695d4c9a7e798", "class_name": "RelatedNodeInfo"}}, "text": "T his framework is once again demonstrated by our strong third quarter fiscal 2022 results.  \n \n", "start_char_idx": 649, "end_char_idx": 745, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ac1af8e0-b24d-4926-b892-d19d6f4446ea": {"__data__": {"id_": "ac1af8e0-b24d-4926-b892-d19d6f4446ea", "embedding": null, "metadata": {"window": "As discussed at our Investor Day back in December, we managed the business for t he long \nterm, and our financial and strategic framework is focused on shareholder value creation.  Our financial framework \ncombines three key elements to generate sustainable adjusted EPS growth: organic growth, operating leverage, \nand capital allocation.  T his framework is once again demonstrated by our strong third quarter fiscal 2022 results.  \n \n Additionally, our leadership supporting the US government's COVID -19 domestic and International vaccine and \nkitting efforts continue to contribute to growth and the momentum we have built across the business.  \n \n Third quarter adjusted earnings per diluted share was $6.15, an increase of 34% compared to the prior year.  This \nresult was driven by strong operational performance across the segments, COVID -19-related items, w hich include \nthe contribution from COVID -19 vaccine distribution, kitting, and storage programs of the US government, COVID -\n19 tests and fiscal 2021 impairments for personal protective equipment and related products, and a lower share \ncount.  \n \n Consolidated revenues of $68.6 billion increased 10% above the prior year, primarily driven by growth in the US \nPharmaceutical segment largely due to higher volumes from our retail national account customers and branded \npharmaceutical price increases, which were in lin e with our initial guidance, partially offset by branded to generic \nconversions.  \n \n", "original_text": "Additionally, our leadership supporting the US government's COVID -19 domestic and International vaccine and \nkitting efforts continue to contribute to growth and the momentum we have built across the business.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "61ec5d58-e8e6-4fb6-84e9-6e9504c022e8", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffd5c71f741ef9c4b9932ba9b2502b8e2acdf6d96d4f117e98ddf8b8c885e775", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0271da0b-b971-4510-b680-2a5313c69fa4", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nMoving now to our adjusted results for the third quarter, beginning with our consolidated results which can be \nfound on slide 7.  As discussed at our Investor Day back in December, we managed the business for t he long \nterm, and our financial and strategic framework is focused on shareholder value creation.  Our financial framework \ncombines three key elements to generate sustainable adjusted EPS growth: organic growth, operating leverage, \nand capital allocation.  T his framework is once again demonstrated by our strong third quarter fiscal 2022 results.  \n \n Additionally, our leadership supporting the US government's COVID -19 domestic and International vaccine and \nkitting efforts continue to contribute to growth and the momentum we have built across the business.  \n \n Third quarter adjusted earnings per diluted share was $6.15, an increase of 34% compared to the prior year.  This \nresult was driven by strong operational performance across the segments, COVID -19-related items, w hich include \nthe contribution from COVID -19 vaccine distribution, kitting, and storage programs of the US government, COVID -\n19 tests and fiscal 2021 impairments for personal protective equipment and related products, and a lower share \ncount.  \n \n", "original_text": "T his framework is once again demonstrated by our strong third quarter fiscal 2022 results.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8afe8d308737f7bfb37705a083ab3ac16c9401520177040ab452caba49b84aea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bd48f49b-267e-4657-a120-f9e1a6a3ac16", "node_type": "1", "metadata": {"window": "Our financial framework \ncombines three key elements to generate sustainable adjusted EPS growth: organic growth, operating leverage, \nand capital allocation.  T his framework is once again demonstrated by our strong third quarter fiscal 2022 results.  \n \n Additionally, our leadership supporting the US government's COVID -19 domestic and International vaccine and \nkitting efforts continue to contribute to growth and the momentum we have built across the business.  \n \n Third quarter adjusted earnings per diluted share was $6.15, an increase of 34% compared to the prior year.  This \nresult was driven by strong operational performance across the segments, COVID -19-related items, w hich include \nthe contribution from COVID -19 vaccine distribution, kitting, and storage programs of the US government, COVID -\n19 tests and fiscal 2021 impairments for personal protective equipment and related products, and a lower share \ncount.  \n \n Consolidated revenues of $68.6 billion increased 10% above the prior year, primarily driven by growth in the US \nPharmaceutical segment largely due to higher volumes from our retail national account customers and branded \npharmaceutical price increases, which were in lin e with our initial guidance, partially offset by branded to generic \nconversions.  \n \n Adjusted gross profit was $3.4 billion for the quarter, an increase of 8% compared to the prior year which \nbenefited from the increased contribution from our strong operation al performance and previously mentioned \nCOVID -19 programs and related items.  \n \n", "original_text": "Third quarter adjusted earnings per diluted share was $6.15, an increase of 34% compared to the prior year. "}, "hash": "5fc2aff2fcc2102d194c889666befcad7588d3459fd0129193604c77d0f7743f", "class_name": "RelatedNodeInfo"}}, "text": "Additionally, our leadership supporting the US government's COVID -19 domestic and International vaccine and \nkitting efforts continue to contribute to growth and the momentum we have built across the business.  \n \n", "start_char_idx": 745, "end_char_idx": 960, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bd48f49b-267e-4657-a120-f9e1a6a3ac16": {"__data__": {"id_": "bd48f49b-267e-4657-a120-f9e1a6a3ac16", "embedding": null, "metadata": {"window": "Our financial framework \ncombines three key elements to generate sustainable adjusted EPS growth: organic growth, operating leverage, \nand capital allocation.  T his framework is once again demonstrated by our strong third quarter fiscal 2022 results.  \n \n Additionally, our leadership supporting the US government's COVID -19 domestic and International vaccine and \nkitting efforts continue to contribute to growth and the momentum we have built across the business.  \n \n Third quarter adjusted earnings per diluted share was $6.15, an increase of 34% compared to the prior year.  This \nresult was driven by strong operational performance across the segments, COVID -19-related items, w hich include \nthe contribution from COVID -19 vaccine distribution, kitting, and storage programs of the US government, COVID -\n19 tests and fiscal 2021 impairments for personal protective equipment and related products, and a lower share \ncount.  \n \n Consolidated revenues of $68.6 billion increased 10% above the prior year, primarily driven by growth in the US \nPharmaceutical segment largely due to higher volumes from our retail national account customers and branded \npharmaceutical price increases, which were in lin e with our initial guidance, partially offset by branded to generic \nconversions.  \n \n Adjusted gross profit was $3.4 billion for the quarter, an increase of 8% compared to the prior year which \nbenefited from the increased contribution from our strong operation al performance and previously mentioned \nCOVID -19 programs and related items.  \n \n", "original_text": "Third quarter adjusted earnings per diluted share was $6.15, an increase of 34% compared to the prior year. ", "page_label": "8", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "61ec5d58-e8e6-4fb6-84e9-6e9504c022e8", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffd5c71f741ef9c4b9932ba9b2502b8e2acdf6d96d4f117e98ddf8b8c885e775", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ac1af8e0-b24d-4926-b892-d19d6f4446ea", "node_type": "1", "metadata": {"window": "As discussed at our Investor Day back in December, we managed the business for t he long \nterm, and our financial and strategic framework is focused on shareholder value creation.  Our financial framework \ncombines three key elements to generate sustainable adjusted EPS growth: organic growth, operating leverage, \nand capital allocation.  T his framework is once again demonstrated by our strong third quarter fiscal 2022 results.  \n \n Additionally, our leadership supporting the US government's COVID -19 domestic and International vaccine and \nkitting efforts continue to contribute to growth and the momentum we have built across the business.  \n \n Third quarter adjusted earnings per diluted share was $6.15, an increase of 34% compared to the prior year.  This \nresult was driven by strong operational performance across the segments, COVID -19-related items, w hich include \nthe contribution from COVID -19 vaccine distribution, kitting, and storage programs of the US government, COVID -\n19 tests and fiscal 2021 impairments for personal protective equipment and related products, and a lower share \ncount.  \n \n Consolidated revenues of $68.6 billion increased 10% above the prior year, primarily driven by growth in the US \nPharmaceutical segment largely due to higher volumes from our retail national account customers and branded \npharmaceutical price increases, which were in lin e with our initial guidance, partially offset by branded to generic \nconversions.  \n \n", "original_text": "Additionally, our leadership supporting the US government's COVID -19 domestic and International vaccine and \nkitting efforts continue to contribute to growth and the momentum we have built across the business.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a038ff56dfe5962c78efab880c8087f70b37c9ae9751a85945209adc6da9459a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2c45b983-605d-486a-9ac3-4b86f24ae205", "node_type": "1", "metadata": {"window": "T his framework is once again demonstrated by our strong third quarter fiscal 2022 results.  \n \n Additionally, our leadership supporting the US government's COVID -19 domestic and International vaccine and \nkitting efforts continue to contribute to growth and the momentum we have built across the business.  \n \n Third quarter adjusted earnings per diluted share was $6.15, an increase of 34% compared to the prior year.  This \nresult was driven by strong operational performance across the segments, COVID -19-related items, w hich include \nthe contribution from COVID -19 vaccine distribution, kitting, and storage programs of the US government, COVID -\n19 tests and fiscal 2021 impairments for personal protective equipment and related products, and a lower share \ncount.  \n \n Consolidated revenues of $68.6 billion increased 10% above the prior year, primarily driven by growth in the US \nPharmaceutical segment largely due to higher volumes from our retail national account customers and branded \npharmaceutical price increases, which were in lin e with our initial guidance, partially offset by branded to generic \nconversions.  \n \n Adjusted gross profit was $3.4 billion for the quarter, an increase of 8% compared to the prior year which \nbenefited from the increased contribution from our strong operation al performance and previously mentioned \nCOVID -19 programs and related items.  \n \n Adjusted operating expenses in the quarter increased 1% year -over-year. ", "original_text": "This \nresult was driven by strong operational performance across the segments, COVID -19-related items, w hich include \nthe contribution from COVID -19 vaccine distribution, kitting, and storage programs of the US government, COVID -\n19 tests and fiscal 2021 impairments for personal protective equipment and related products, and a lower share \ncount.  \n \n"}, "hash": "e636407bb0807e4fc5400423e7b8b5c2376474f755d25cb5d53b04fa8c71ef2d", "class_name": "RelatedNodeInfo"}}, "text": "Third quarter adjusted earnings per diluted share was $6.15, an increase of 34% compared to the prior year. ", "start_char_idx": 960, "end_char_idx": 1068, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2c45b983-605d-486a-9ac3-4b86f24ae205": {"__data__": {"id_": "2c45b983-605d-486a-9ac3-4b86f24ae205", "embedding": null, "metadata": {"window": "T his framework is once again demonstrated by our strong third quarter fiscal 2022 results.  \n \n Additionally, our leadership supporting the US government's COVID -19 domestic and International vaccine and \nkitting efforts continue to contribute to growth and the momentum we have built across the business.  \n \n Third quarter adjusted earnings per diluted share was $6.15, an increase of 34% compared to the prior year.  This \nresult was driven by strong operational performance across the segments, COVID -19-related items, w hich include \nthe contribution from COVID -19 vaccine distribution, kitting, and storage programs of the US government, COVID -\n19 tests and fiscal 2021 impairments for personal protective equipment and related products, and a lower share \ncount.  \n \n Consolidated revenues of $68.6 billion increased 10% above the prior year, primarily driven by growth in the US \nPharmaceutical segment largely due to higher volumes from our retail national account customers and branded \npharmaceutical price increases, which were in lin e with our initial guidance, partially offset by branded to generic \nconversions.  \n \n Adjusted gross profit was $3.4 billion for the quarter, an increase of 8% compared to the prior year which \nbenefited from the increased contribution from our strong operation al performance and previously mentioned \nCOVID -19 programs and related items.  \n \n Adjusted operating expenses in the quarter increased 1% year -over-year. ", "original_text": "This \nresult was driven by strong operational performance across the segments, COVID -19-related items, w hich include \nthe contribution from COVID -19 vaccine distribution, kitting, and storage programs of the US government, COVID -\n19 tests and fiscal 2021 impairments for personal protective equipment and related products, and a lower share \ncount.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "61ec5d58-e8e6-4fb6-84e9-6e9504c022e8", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffd5c71f741ef9c4b9932ba9b2502b8e2acdf6d96d4f117e98ddf8b8c885e775", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bd48f49b-267e-4657-a120-f9e1a6a3ac16", "node_type": "1", "metadata": {"window": "Our financial framework \ncombines three key elements to generate sustainable adjusted EPS growth: organic growth, operating leverage, \nand capital allocation.  T his framework is once again demonstrated by our strong third quarter fiscal 2022 results.  \n \n Additionally, our leadership supporting the US government's COVID -19 domestic and International vaccine and \nkitting efforts continue to contribute to growth and the momentum we have built across the business.  \n \n Third quarter adjusted earnings per diluted share was $6.15, an increase of 34% compared to the prior year.  This \nresult was driven by strong operational performance across the segments, COVID -19-related items, w hich include \nthe contribution from COVID -19 vaccine distribution, kitting, and storage programs of the US government, COVID -\n19 tests and fiscal 2021 impairments for personal protective equipment and related products, and a lower share \ncount.  \n \n Consolidated revenues of $68.6 billion increased 10% above the prior year, primarily driven by growth in the US \nPharmaceutical segment largely due to higher volumes from our retail national account customers and branded \npharmaceutical price increases, which were in lin e with our initial guidance, partially offset by branded to generic \nconversions.  \n \n Adjusted gross profit was $3.4 billion for the quarter, an increase of 8% compared to the prior year which \nbenefited from the increased contribution from our strong operation al performance and previously mentioned \nCOVID -19 programs and related items.  \n \n", "original_text": "Third quarter adjusted earnings per diluted share was $6.15, an increase of 34% compared to the prior year. ", "page_label": "8", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "06bb917a0caf018cc43b02679328da693bd79eb336d3cd84e04cd6d5af10f0d7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c960e201-7797-430f-b192-cfad665aa38e", "node_type": "1", "metadata": {"window": "Additionally, our leadership supporting the US government's COVID -19 domestic and International vaccine and \nkitting efforts continue to contribute to growth and the momentum we have built across the business.  \n \n Third quarter adjusted earnings per diluted share was $6.15, an increase of 34% compared to the prior year.  This \nresult was driven by strong operational performance across the segments, COVID -19-related items, w hich include \nthe contribution from COVID -19 vaccine distribution, kitting, and storage programs of the US government, COVID -\n19 tests and fiscal 2021 impairments for personal protective equipment and related products, and a lower share \ncount.  \n \n Consolidated revenues of $68.6 billion increased 10% above the prior year, primarily driven by growth in the US \nPharmaceutical segment largely due to higher volumes from our retail national account customers and branded \npharmaceutical price increases, which were in lin e with our initial guidance, partially offset by branded to generic \nconversions.  \n \n Adjusted gross profit was $3.4 billion for the quarter, an increase of 8% compared to the prior year which \nbenefited from the increased contribution from our strong operation al performance and previously mentioned \nCOVID -19 programs and related items.  \n \n Adjusted operating expenses in the quarter increased 1% year -over-year.  Excluding the impact of held for sale \naccounting on announced divestitures in the International segment, a djusted operating expenses increased 2% \nyear-over-year.  \n \n", "original_text": "Consolidated revenues of $68.6 billion increased 10% above the prior year, primarily driven by growth in the US \nPharmaceutical segment largely due to higher volumes from our retail national account customers and branded \npharmaceutical price increases, which were in lin e with our initial guidance, partially offset by branded to generic \nconversions.  \n \n"}, "hash": "9ed268f83d281f746089a74910739db491fc4b5222ed42ffb869fe7671c2ee98", "class_name": "RelatedNodeInfo"}}, "text": "This \nresult was driven by strong operational performance across the segments, COVID -19-related items, w hich include \nthe contribution from COVID -19 vaccine distribution, kitting, and storage programs of the US government, COVID -\n19 tests and fiscal 2021 impairments for personal protective equipment and related products, and a lower share \ncount.  \n \n", "start_char_idx": 1068, "end_char_idx": 1425, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c960e201-7797-430f-b192-cfad665aa38e": {"__data__": {"id_": "c960e201-7797-430f-b192-cfad665aa38e", "embedding": null, "metadata": {"window": "Additionally, our leadership supporting the US government's COVID -19 domestic and International vaccine and \nkitting efforts continue to contribute to growth and the momentum we have built across the business.  \n \n Third quarter adjusted earnings per diluted share was $6.15, an increase of 34% compared to the prior year.  This \nresult was driven by strong operational performance across the segments, COVID -19-related items, w hich include \nthe contribution from COVID -19 vaccine distribution, kitting, and storage programs of the US government, COVID -\n19 tests and fiscal 2021 impairments for personal protective equipment and related products, and a lower share \ncount.  \n \n Consolidated revenues of $68.6 billion increased 10% above the prior year, primarily driven by growth in the US \nPharmaceutical segment largely due to higher volumes from our retail national account customers and branded \npharmaceutical price increases, which were in lin e with our initial guidance, partially offset by branded to generic \nconversions.  \n \n Adjusted gross profit was $3.4 billion for the quarter, an increase of 8% compared to the prior year which \nbenefited from the increased contribution from our strong operation al performance and previously mentioned \nCOVID -19 programs and related items.  \n \n Adjusted operating expenses in the quarter increased 1% year -over-year.  Excluding the impact of held for sale \naccounting on announced divestitures in the International segment, a djusted operating expenses increased 2% \nyear-over-year.  \n \n", "original_text": "Consolidated revenues of $68.6 billion increased 10% above the prior year, primarily driven by growth in the US \nPharmaceutical segment largely due to higher volumes from our retail national account customers and branded \npharmaceutical price increases, which were in lin e with our initial guidance, partially offset by branded to generic \nconversions.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "61ec5d58-e8e6-4fb6-84e9-6e9504c022e8", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffd5c71f741ef9c4b9932ba9b2502b8e2acdf6d96d4f117e98ddf8b8c885e775", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2c45b983-605d-486a-9ac3-4b86f24ae205", "node_type": "1", "metadata": {"window": "T his framework is once again demonstrated by our strong third quarter fiscal 2022 results.  \n \n Additionally, our leadership supporting the US government's COVID -19 domestic and International vaccine and \nkitting efforts continue to contribute to growth and the momentum we have built across the business.  \n \n Third quarter adjusted earnings per diluted share was $6.15, an increase of 34% compared to the prior year.  This \nresult was driven by strong operational performance across the segments, COVID -19-related items, w hich include \nthe contribution from COVID -19 vaccine distribution, kitting, and storage programs of the US government, COVID -\n19 tests and fiscal 2021 impairments for personal protective equipment and related products, and a lower share \ncount.  \n \n Consolidated revenues of $68.6 billion increased 10% above the prior year, primarily driven by growth in the US \nPharmaceutical segment largely due to higher volumes from our retail national account customers and branded \npharmaceutical price increases, which were in lin e with our initial guidance, partially offset by branded to generic \nconversions.  \n \n Adjusted gross profit was $3.4 billion for the quarter, an increase of 8% compared to the prior year which \nbenefited from the increased contribution from our strong operation al performance and previously mentioned \nCOVID -19 programs and related items.  \n \n Adjusted operating expenses in the quarter increased 1% year -over-year. ", "original_text": "This \nresult was driven by strong operational performance across the segments, COVID -19-related items, w hich include \nthe contribution from COVID -19 vaccine distribution, kitting, and storage programs of the US government, COVID -\n19 tests and fiscal 2021 impairments for personal protective equipment and related products, and a lower share \ncount.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3ac596b1e3cd4178c723ccaf728983438215d2d4ff15c10f2e37d64d394a98f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1fcfdfd8-c7d3-4abf-9b7e-6479e46d6c4a", "node_type": "1", "metadata": {"window": "Third quarter adjusted earnings per diluted share was $6.15, an increase of 34% compared to the prior year.  This \nresult was driven by strong operational performance across the segments, COVID -19-related items, w hich include \nthe contribution from COVID -19 vaccine distribution, kitting, and storage programs of the US government, COVID -\n19 tests and fiscal 2021 impairments for personal protective equipment and related products, and a lower share \ncount.  \n \n Consolidated revenues of $68.6 billion increased 10% above the prior year, primarily driven by growth in the US \nPharmaceutical segment largely due to higher volumes from our retail national account customers and branded \npharmaceutical price increases, which were in lin e with our initial guidance, partially offset by branded to generic \nconversions.  \n \n Adjusted gross profit was $3.4 billion for the quarter, an increase of 8% compared to the prior year which \nbenefited from the increased contribution from our strong operation al performance and previously mentioned \nCOVID -19 programs and related items.  \n \n Adjusted operating expenses in the quarter increased 1% year -over-year.  Excluding the impact of held for sale \naccounting on announced divestitures in the International segment, a djusted operating expenses increased 2% \nyear-over-year.  \n \n Adjusted operating profit was $1.3 billion for the quarter, an increase of 19% compared to the prior year, led by \nstrong operational performance across the segments.  \n \n", "original_text": "Adjusted gross profit was $3.4 billion for the quarter, an increase of 8% compared to the prior year which \nbenefited from the increased contribution from our strong operation al performance and previously mentioned \nCOVID -19 programs and related items.  \n \n"}, "hash": "27c138c8503bcd6a79da529ec787bb39db76b67159e20b37a6195a5e2d8b2a5f", "class_name": "RelatedNodeInfo"}}, "text": "Consolidated revenues of $68.6 billion increased 10% above the prior year, primarily driven by growth in the US \nPharmaceutical segment largely due to higher volumes from our retail national account customers and branded \npharmaceutical price increases, which were in lin e with our initial guidance, partially offset by branded to generic \nconversions.  \n \n", "start_char_idx": 1425, "end_char_idx": 1783, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1fcfdfd8-c7d3-4abf-9b7e-6479e46d6c4a": {"__data__": {"id_": "1fcfdfd8-c7d3-4abf-9b7e-6479e46d6c4a", "embedding": null, "metadata": {"window": "Third quarter adjusted earnings per diluted share was $6.15, an increase of 34% compared to the prior year.  This \nresult was driven by strong operational performance across the segments, COVID -19-related items, w hich include \nthe contribution from COVID -19 vaccine distribution, kitting, and storage programs of the US government, COVID -\n19 tests and fiscal 2021 impairments for personal protective equipment and related products, and a lower share \ncount.  \n \n Consolidated revenues of $68.6 billion increased 10% above the prior year, primarily driven by growth in the US \nPharmaceutical segment largely due to higher volumes from our retail national account customers and branded \npharmaceutical price increases, which were in lin e with our initial guidance, partially offset by branded to generic \nconversions.  \n \n Adjusted gross profit was $3.4 billion for the quarter, an increase of 8% compared to the prior year which \nbenefited from the increased contribution from our strong operation al performance and previously mentioned \nCOVID -19 programs and related items.  \n \n Adjusted operating expenses in the quarter increased 1% year -over-year.  Excluding the impact of held for sale \naccounting on announced divestitures in the International segment, a djusted operating expenses increased 2% \nyear-over-year.  \n \n Adjusted operating profit was $1.3 billion for the quarter, an increase of 19% compared to the prior year, led by \nstrong operational performance across the segments.  \n \n", "original_text": "Adjusted gross profit was $3.4 billion for the quarter, an increase of 8% compared to the prior year which \nbenefited from the increased contribution from our strong operation al performance and previously mentioned \nCOVID -19 programs and related items.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "61ec5d58-e8e6-4fb6-84e9-6e9504c022e8", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffd5c71f741ef9c4b9932ba9b2502b8e2acdf6d96d4f117e98ddf8b8c885e775", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c960e201-7797-430f-b192-cfad665aa38e", "node_type": "1", "metadata": {"window": "Additionally, our leadership supporting the US government's COVID -19 domestic and International vaccine and \nkitting efforts continue to contribute to growth and the momentum we have built across the business.  \n \n Third quarter adjusted earnings per diluted share was $6.15, an increase of 34% compared to the prior year.  This \nresult was driven by strong operational performance across the segments, COVID -19-related items, w hich include \nthe contribution from COVID -19 vaccine distribution, kitting, and storage programs of the US government, COVID -\n19 tests and fiscal 2021 impairments for personal protective equipment and related products, and a lower share \ncount.  \n \n Consolidated revenues of $68.6 billion increased 10% above the prior year, primarily driven by growth in the US \nPharmaceutical segment largely due to higher volumes from our retail national account customers and branded \npharmaceutical price increases, which were in lin e with our initial guidance, partially offset by branded to generic \nconversions.  \n \n Adjusted gross profit was $3.4 billion for the quarter, an increase of 8% compared to the prior year which \nbenefited from the increased contribution from our strong operation al performance and previously mentioned \nCOVID -19 programs and related items.  \n \n Adjusted operating expenses in the quarter increased 1% year -over-year.  Excluding the impact of held for sale \naccounting on announced divestitures in the International segment, a djusted operating expenses increased 2% \nyear-over-year.  \n \n", "original_text": "Consolidated revenues of $68.6 billion increased 10% above the prior year, primarily driven by growth in the US \nPharmaceutical segment largely due to higher volumes from our retail national account customers and branded \npharmaceutical price increases, which were in lin e with our initial guidance, partially offset by branded to generic \nconversions.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "028baa393bb5d85a371aa065ae103f0907def08027a17757f32f8070e33a0bd8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "38570272-486a-4657-bba7-50b05d08e0bf", "node_type": "1", "metadata": {"window": "This \nresult was driven by strong operational performance across the segments, COVID -19-related items, w hich include \nthe contribution from COVID -19 vaccine distribution, kitting, and storage programs of the US government, COVID -\n19 tests and fiscal 2021 impairments for personal protective equipment and related products, and a lower share \ncount.  \n \n Consolidated revenues of $68.6 billion increased 10% above the prior year, primarily driven by growth in the US \nPharmaceutical segment largely due to higher volumes from our retail national account customers and branded \npharmaceutical price increases, which were in lin e with our initial guidance, partially offset by branded to generic \nconversions.  \n \n Adjusted gross profit was $3.4 billion for the quarter, an increase of 8% compared to the prior year which \nbenefited from the increased contribution from our strong operation al performance and previously mentioned \nCOVID -19 programs and related items.  \n \n Adjusted operating expenses in the quarter increased 1% year -over-year.  Excluding the impact of held for sale \naccounting on announced divestitures in the International segment, a djusted operating expenses increased 2% \nyear-over-year.  \n \n Adjusted operating profit was $1.3 billion for the quarter, an increase of 19% compared to the prior year, led by \nstrong operational performance across the segments.  \n \n Moving below the line, interest expense was $41 million in the quarter, an improvement of 25% compared to the \nprior year. ", "original_text": "Adjusted operating expenses in the quarter increased 1% year -over-year. "}, "hash": "5d819b8cbdbda510822654060cfb92bd937f9d568b72749d04f69534ae0a43bb", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted gross profit was $3.4 billion for the quarter, an increase of 8% compared to the prior year which \nbenefited from the increased contribution from our strong operation al performance and previously mentioned \nCOVID -19 programs and related items.  \n \n", "start_char_idx": 1783, "end_char_idx": 2042, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "38570272-486a-4657-bba7-50b05d08e0bf": {"__data__": {"id_": "38570272-486a-4657-bba7-50b05d08e0bf", "embedding": null, "metadata": {"window": "This \nresult was driven by strong operational performance across the segments, COVID -19-related items, w hich include \nthe contribution from COVID -19 vaccine distribution, kitting, and storage programs of the US government, COVID -\n19 tests and fiscal 2021 impairments for personal protective equipment and related products, and a lower share \ncount.  \n \n Consolidated revenues of $68.6 billion increased 10% above the prior year, primarily driven by growth in the US \nPharmaceutical segment largely due to higher volumes from our retail national account customers and branded \npharmaceutical price increases, which were in lin e with our initial guidance, partially offset by branded to generic \nconversions.  \n \n Adjusted gross profit was $3.4 billion for the quarter, an increase of 8% compared to the prior year which \nbenefited from the increased contribution from our strong operation al performance and previously mentioned \nCOVID -19 programs and related items.  \n \n Adjusted operating expenses in the quarter increased 1% year -over-year.  Excluding the impact of held for sale \naccounting on announced divestitures in the International segment, a djusted operating expenses increased 2% \nyear-over-year.  \n \n Adjusted operating profit was $1.3 billion for the quarter, an increase of 19% compared to the prior year, led by \nstrong operational performance across the segments.  \n \n Moving below the line, interest expense was $41 million in the quarter, an improvement of 25% compared to the \nprior year. ", "original_text": "Adjusted operating expenses in the quarter increased 1% year -over-year. ", "page_label": "8", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "61ec5d58-e8e6-4fb6-84e9-6e9504c022e8", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffd5c71f741ef9c4b9932ba9b2502b8e2acdf6d96d4f117e98ddf8b8c885e775", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1fcfdfd8-c7d3-4abf-9b7e-6479e46d6c4a", "node_type": "1", "metadata": {"window": "Third quarter adjusted earnings per diluted share was $6.15, an increase of 34% compared to the prior year.  This \nresult was driven by strong operational performance across the segments, COVID -19-related items, w hich include \nthe contribution from COVID -19 vaccine distribution, kitting, and storage programs of the US government, COVID -\n19 tests and fiscal 2021 impairments for personal protective equipment and related products, and a lower share \ncount.  \n \n Consolidated revenues of $68.6 billion increased 10% above the prior year, primarily driven by growth in the US \nPharmaceutical segment largely due to higher volumes from our retail national account customers and branded \npharmaceutical price increases, which were in lin e with our initial guidance, partially offset by branded to generic \nconversions.  \n \n Adjusted gross profit was $3.4 billion for the quarter, an increase of 8% compared to the prior year which \nbenefited from the increased contribution from our strong operation al performance and previously mentioned \nCOVID -19 programs and related items.  \n \n Adjusted operating expenses in the quarter increased 1% year -over-year.  Excluding the impact of held for sale \naccounting on announced divestitures in the International segment, a djusted operating expenses increased 2% \nyear-over-year.  \n \n Adjusted operating profit was $1.3 billion for the quarter, an increase of 19% compared to the prior year, led by \nstrong operational performance across the segments.  \n \n", "original_text": "Adjusted gross profit was $3.4 billion for the quarter, an increase of 8% compared to the prior year which \nbenefited from the increased contribution from our strong operation al performance and previously mentioned \nCOVID -19 programs and related items.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7d959cd36d5a11bf4aefe6846772535e68669b9297f2581fb16ce01c664b6d40", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8cc1f111-56a1-4622-9f32-0493facf2df1", "node_type": "1", "metadata": {"window": "Consolidated revenues of $68.6 billion increased 10% above the prior year, primarily driven by growth in the US \nPharmaceutical segment largely due to higher volumes from our retail national account customers and branded \npharmaceutical price increases, which were in lin e with our initial guidance, partially offset by branded to generic \nconversions.  \n \n Adjusted gross profit was $3.4 billion for the quarter, an increase of 8% compared to the prior year which \nbenefited from the increased contribution from our strong operation al performance and previously mentioned \nCOVID -19 programs and related items.  \n \n Adjusted operating expenses in the quarter increased 1% year -over-year.  Excluding the impact of held for sale \naccounting on announced divestitures in the International segment, a djusted operating expenses increased 2% \nyear-over-year.  \n \n Adjusted operating profit was $1.3 billion for the quarter, an increase of 19% compared to the prior year, led by \nstrong operational performance across the segments.  \n \n Moving below the line, interest expense was $41 million in the quarter, an improvement of 25% compared to the \nprior year.  Our adjusted tax rate was 19.6% for the quarter. ", "original_text": "Excluding the impact of held for sale \naccounting on announced divestitures in the International segment, a djusted operating expenses increased 2% \nyear-over-year.  \n \n"}, "hash": "e51479fe47f7e38b0edd70e937965507ca8ec5000f83212ebac5578863ec2332", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating expenses in the quarter increased 1% year -over-year. ", "start_char_idx": 2042, "end_char_idx": 2115, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8cc1f111-56a1-4622-9f32-0493facf2df1": {"__data__": {"id_": "8cc1f111-56a1-4622-9f32-0493facf2df1", "embedding": null, "metadata": {"window": "Consolidated revenues of $68.6 billion increased 10% above the prior year, primarily driven by growth in the US \nPharmaceutical segment largely due to higher volumes from our retail national account customers and branded \npharmaceutical price increases, which were in lin e with our initial guidance, partially offset by branded to generic \nconversions.  \n \n Adjusted gross profit was $3.4 billion for the quarter, an increase of 8% compared to the prior year which \nbenefited from the increased contribution from our strong operation al performance and previously mentioned \nCOVID -19 programs and related items.  \n \n Adjusted operating expenses in the quarter increased 1% year -over-year.  Excluding the impact of held for sale \naccounting on announced divestitures in the International segment, a djusted operating expenses increased 2% \nyear-over-year.  \n \n Adjusted operating profit was $1.3 billion for the quarter, an increase of 19% compared to the prior year, led by \nstrong operational performance across the segments.  \n \n Moving below the line, interest expense was $41 million in the quarter, an improvement of 25% compared to the \nprior year.  Our adjusted tax rate was 19.6% for the quarter. ", "original_text": "Excluding the impact of held for sale \naccounting on announced divestitures in the International segment, a djusted operating expenses increased 2% \nyear-over-year.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "61ec5d58-e8e6-4fb6-84e9-6e9504c022e8", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffd5c71f741ef9c4b9932ba9b2502b8e2acdf6d96d4f117e98ddf8b8c885e775", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "38570272-486a-4657-bba7-50b05d08e0bf", "node_type": "1", "metadata": {"window": "This \nresult was driven by strong operational performance across the segments, COVID -19-related items, w hich include \nthe contribution from COVID -19 vaccine distribution, kitting, and storage programs of the US government, COVID -\n19 tests and fiscal 2021 impairments for personal protective equipment and related products, and a lower share \ncount.  \n \n Consolidated revenues of $68.6 billion increased 10% above the prior year, primarily driven by growth in the US \nPharmaceutical segment largely due to higher volumes from our retail national account customers and branded \npharmaceutical price increases, which were in lin e with our initial guidance, partially offset by branded to generic \nconversions.  \n \n Adjusted gross profit was $3.4 billion for the quarter, an increase of 8% compared to the prior year which \nbenefited from the increased contribution from our strong operation al performance and previously mentioned \nCOVID -19 programs and related items.  \n \n Adjusted operating expenses in the quarter increased 1% year -over-year.  Excluding the impact of held for sale \naccounting on announced divestitures in the International segment, a djusted operating expenses increased 2% \nyear-over-year.  \n \n Adjusted operating profit was $1.3 billion for the quarter, an increase of 19% compared to the prior year, led by \nstrong operational performance across the segments.  \n \n Moving below the line, interest expense was $41 million in the quarter, an improvement of 25% compared to the \nprior year. ", "original_text": "Adjusted operating expenses in the quarter increased 1% year -over-year. ", "page_label": "8", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c1891955000468168a4b833cacb47691de95c5901b19317e436ef62dd34c146d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "29a86ea2-575c-4e2c-9d02-7acc2af37446", "node_type": "1", "metadata": {"window": "Adjusted gross profit was $3.4 billion for the quarter, an increase of 8% compared to the prior year which \nbenefited from the increased contribution from our strong operation al performance and previously mentioned \nCOVID -19 programs and related items.  \n \n Adjusted operating expenses in the quarter increased 1% year -over-year.  Excluding the impact of held for sale \naccounting on announced divestitures in the International segment, a djusted operating expenses increased 2% \nyear-over-year.  \n \n Adjusted operating profit was $1.3 billion for the quarter, an increase of 19% compared to the prior year, led by \nstrong operational performance across the segments.  \n \n Moving below the line, interest expense was $41 million in the quarter, an improvement of 25% compared to the \nprior year.  Our adjusted tax rate was 19.6% for the quarter.  And wrapping up our consolidated results, third \nquarter diluted weighted average shares were 153.5 million, a decreas e of 5% year -over-year.  \n \n", "original_text": "Adjusted operating profit was $1.3 billion for the quarter, an increase of 19% compared to the prior year, led by \nstrong operational performance across the segments.  \n \n"}, "hash": "b3e46fa90ffc23c3fbce24b66a8a873414353997a6e329d81f67fa76518306ad", "class_name": "RelatedNodeInfo"}}, "text": "Excluding the impact of held for sale \naccounting on announced divestitures in the International segment, a djusted operating expenses increased 2% \nyear-over-year.  \n \n", "start_char_idx": 2115, "end_char_idx": 2284, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "29a86ea2-575c-4e2c-9d02-7acc2af37446": {"__data__": {"id_": "29a86ea2-575c-4e2c-9d02-7acc2af37446", "embedding": null, "metadata": {"window": "Adjusted gross profit was $3.4 billion for the quarter, an increase of 8% compared to the prior year which \nbenefited from the increased contribution from our strong operation al performance and previously mentioned \nCOVID -19 programs and related items.  \n \n Adjusted operating expenses in the quarter increased 1% year -over-year.  Excluding the impact of held for sale \naccounting on announced divestitures in the International segment, a djusted operating expenses increased 2% \nyear-over-year.  \n \n Adjusted operating profit was $1.3 billion for the quarter, an increase of 19% compared to the prior year, led by \nstrong operational performance across the segments.  \n \n Moving below the line, interest expense was $41 million in the quarter, an improvement of 25% compared to the \nprior year.  Our adjusted tax rate was 19.6% for the quarter.  And wrapping up our consolidated results, third \nquarter diluted weighted average shares were 153.5 million, a decreas e of 5% year -over-year.  \n \n", "original_text": "Adjusted operating profit was $1.3 billion for the quarter, an increase of 19% compared to the prior year, led by \nstrong operational performance across the segments.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "61ec5d58-e8e6-4fb6-84e9-6e9504c022e8", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffd5c71f741ef9c4b9932ba9b2502b8e2acdf6d96d4f117e98ddf8b8c885e775", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8cc1f111-56a1-4622-9f32-0493facf2df1", "node_type": "1", "metadata": {"window": "Consolidated revenues of $68.6 billion increased 10% above the prior year, primarily driven by growth in the US \nPharmaceutical segment largely due to higher volumes from our retail national account customers and branded \npharmaceutical price increases, which were in lin e with our initial guidance, partially offset by branded to generic \nconversions.  \n \n Adjusted gross profit was $3.4 billion for the quarter, an increase of 8% compared to the prior year which \nbenefited from the increased contribution from our strong operation al performance and previously mentioned \nCOVID -19 programs and related items.  \n \n Adjusted operating expenses in the quarter increased 1% year -over-year.  Excluding the impact of held for sale \naccounting on announced divestitures in the International segment, a djusted operating expenses increased 2% \nyear-over-year.  \n \n Adjusted operating profit was $1.3 billion for the quarter, an increase of 19% compared to the prior year, led by \nstrong operational performance across the segments.  \n \n Moving below the line, interest expense was $41 million in the quarter, an improvement of 25% compared to the \nprior year.  Our adjusted tax rate was 19.6% for the quarter. ", "original_text": "Excluding the impact of held for sale \naccounting on announced divestitures in the International segment, a djusted operating expenses increased 2% \nyear-over-year.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "274f36f74572487f2ea7dd877b05569acee327835b3c89ddbe039ec3b0240dea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2dfd3e23-a11d-44ca-b22a-7cce44be461a", "node_type": "1", "metadata": {"window": "Adjusted operating expenses in the quarter increased 1% year -over-year.  Excluding the impact of held for sale \naccounting on announced divestitures in the International segment, a djusted operating expenses increased 2% \nyear-over-year.  \n \n Adjusted operating profit was $1.3 billion for the quarter, an increase of 19% compared to the prior year, led by \nstrong operational performance across the segments.  \n \n Moving below the line, interest expense was $41 million in the quarter, an improvement of 25% compared to the \nprior year.  Our adjusted tax rate was 19.6% for the quarter.  And wrapping up our consolidated results, third \nquarter diluted weighted average shares were 153.5 million, a decreas e of 5% year -over-year.  \n \n Moving now to our third quarter segment results, which can be found on slides 8 through 13, starting with US \nPharmaceutical. ", "original_text": "Moving below the line, interest expense was $41 million in the quarter, an improvement of 25% compared to the \nprior year. "}, "hash": "196d534fa1dbc3d24077deb7e5a2c60e6fd7e260d7a5b4d51a0cb3eed38d3370", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating profit was $1.3 billion for the quarter, an increase of 19% compared to the prior year, led by \nstrong operational performance across the segments.  \n \n", "start_char_idx": 2284, "end_char_idx": 2455, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2dfd3e23-a11d-44ca-b22a-7cce44be461a": {"__data__": {"id_": "2dfd3e23-a11d-44ca-b22a-7cce44be461a", "embedding": null, "metadata": {"window": "Adjusted operating expenses in the quarter increased 1% year -over-year.  Excluding the impact of held for sale \naccounting on announced divestitures in the International segment, a djusted operating expenses increased 2% \nyear-over-year.  \n \n Adjusted operating profit was $1.3 billion for the quarter, an increase of 19% compared to the prior year, led by \nstrong operational performance across the segments.  \n \n Moving below the line, interest expense was $41 million in the quarter, an improvement of 25% compared to the \nprior year.  Our adjusted tax rate was 19.6% for the quarter.  And wrapping up our consolidated results, third \nquarter diluted weighted average shares were 153.5 million, a decreas e of 5% year -over-year.  \n \n Moving now to our third quarter segment results, which can be found on slides 8 through 13, starting with US \nPharmaceutical. ", "original_text": "Moving below the line, interest expense was $41 million in the quarter, an improvement of 25% compared to the \nprior year. ", "page_label": "8", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "61ec5d58-e8e6-4fb6-84e9-6e9504c022e8", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffd5c71f741ef9c4b9932ba9b2502b8e2acdf6d96d4f117e98ddf8b8c885e775", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "29a86ea2-575c-4e2c-9d02-7acc2af37446", "node_type": "1", "metadata": {"window": "Adjusted gross profit was $3.4 billion for the quarter, an increase of 8% compared to the prior year which \nbenefited from the increased contribution from our strong operation al performance and previously mentioned \nCOVID -19 programs and related items.  \n \n Adjusted operating expenses in the quarter increased 1% year -over-year.  Excluding the impact of held for sale \naccounting on announced divestitures in the International segment, a djusted operating expenses increased 2% \nyear-over-year.  \n \n Adjusted operating profit was $1.3 billion for the quarter, an increase of 19% compared to the prior year, led by \nstrong operational performance across the segments.  \n \n Moving below the line, interest expense was $41 million in the quarter, an improvement of 25% compared to the \nprior year.  Our adjusted tax rate was 19.6% for the quarter.  And wrapping up our consolidated results, third \nquarter diluted weighted average shares were 153.5 million, a decreas e of 5% year -over-year.  \n \n", "original_text": "Adjusted operating profit was $1.3 billion for the quarter, an increase of 19% compared to the prior year, led by \nstrong operational performance across the segments.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4734303190a1a818a4a7f21667469b31f386bcd008a8c9d8e26d98a6112b1304", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d27b3aab-8c7d-4b9c-9944-df6005c2fae3", "node_type": "1", "metadata": {"window": "Excluding the impact of held for sale \naccounting on announced divestitures in the International segment, a djusted operating expenses increased 2% \nyear-over-year.  \n \n Adjusted operating profit was $1.3 billion for the quarter, an increase of 19% compared to the prior year, led by \nstrong operational performance across the segments.  \n \n Moving below the line, interest expense was $41 million in the quarter, an improvement of 25% compared to the \nprior year.  Our adjusted tax rate was 19.6% for the quarter.  And wrapping up our consolidated results, third \nquarter diluted weighted average shares were 153.5 million, a decreas e of 5% year -over-year.  \n \n Moving now to our third quarter segment results, which can be found on slides 8 through 13, starting with US \nPharmaceutical.  Revenues were $55 billion, an increase of 11% year -over-year, driven by higher volumes from \nour retail nat ional account customers and branded pharmaceutical price increases, partially offset by branded to \ngeneric conversions. ", "original_text": "Our adjusted tax rate was 19.6% for the quarter. "}, "hash": "40aa5642bfee08961731979c52c6474340fd3441d63f0a119491b338b3834bee", "class_name": "RelatedNodeInfo"}}, "text": "Moving below the line, interest expense was $41 million in the quarter, an improvement of 25% compared to the \nprior year. ", "start_char_idx": 2455, "end_char_idx": 2578, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d27b3aab-8c7d-4b9c-9944-df6005c2fae3": {"__data__": {"id_": "d27b3aab-8c7d-4b9c-9944-df6005c2fae3", "embedding": null, "metadata": {"window": "Excluding the impact of held for sale \naccounting on announced divestitures in the International segment, a djusted operating expenses increased 2% \nyear-over-year.  \n \n Adjusted operating profit was $1.3 billion for the quarter, an increase of 19% compared to the prior year, led by \nstrong operational performance across the segments.  \n \n Moving below the line, interest expense was $41 million in the quarter, an improvement of 25% compared to the \nprior year.  Our adjusted tax rate was 19.6% for the quarter.  And wrapping up our consolidated results, third \nquarter diluted weighted average shares were 153.5 million, a decreas e of 5% year -over-year.  \n \n Moving now to our third quarter segment results, which can be found on slides 8 through 13, starting with US \nPharmaceutical.  Revenues were $55 billion, an increase of 11% year -over-year, driven by higher volumes from \nour retail nat ional account customers and branded pharmaceutical price increases, partially offset by branded to \ngeneric conversions. ", "original_text": "Our adjusted tax rate was 19.6% for the quarter. ", "page_label": "8", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "61ec5d58-e8e6-4fb6-84e9-6e9504c022e8", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffd5c71f741ef9c4b9932ba9b2502b8e2acdf6d96d4f117e98ddf8b8c885e775", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2dfd3e23-a11d-44ca-b22a-7cce44be461a", "node_type": "1", "metadata": {"window": "Adjusted operating expenses in the quarter increased 1% year -over-year.  Excluding the impact of held for sale \naccounting on announced divestitures in the International segment, a djusted operating expenses increased 2% \nyear-over-year.  \n \n Adjusted operating profit was $1.3 billion for the quarter, an increase of 19% compared to the prior year, led by \nstrong operational performance across the segments.  \n \n Moving below the line, interest expense was $41 million in the quarter, an improvement of 25% compared to the \nprior year.  Our adjusted tax rate was 19.6% for the quarter.  And wrapping up our consolidated results, third \nquarter diluted weighted average shares were 153.5 million, a decreas e of 5% year -over-year.  \n \n Moving now to our third quarter segment results, which can be found on slides 8 through 13, starting with US \nPharmaceutical. ", "original_text": "Moving below the line, interest expense was $41 million in the quarter, an improvement of 25% compared to the \nprior year. ", "page_label": "8", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ec2fdec775f89983d9ccda8b167e808131203f04508d72c01291afe7592a9bac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cac554a4-a098-43e7-a068-f3ecacc60e50", "node_type": "1", "metadata": {"window": "Adjusted operating profit was $1.3 billion for the quarter, an increase of 19% compared to the prior year, led by \nstrong operational performance across the segments.  \n \n Moving below the line, interest expense was $41 million in the quarter, an improvement of 25% compared to the \nprior year.  Our adjusted tax rate was 19.6% for the quarter.  And wrapping up our consolidated results, third \nquarter diluted weighted average shares were 153.5 million, a decreas e of 5% year -over-year.  \n \n Moving now to our third quarter segment results, which can be found on slides 8 through 13, starting with US \nPharmaceutical.  Revenues were $55 billion, an increase of 11% year -over-year, driven by higher volumes from \nour retail nat ional account customers and branded pharmaceutical price increases, partially offset by branded to \ngeneric conversions.  Adjusted operating profit increased 12% to $735 million driven by the contribution from \nCOVID -19 vaccine distribution and growth in the distribution of specialty products to hospitals and community \nclinicians.  \n \n", "original_text": "And wrapping up our consolidated results, third \nquarter diluted weighted average shares were 153.5 million, a decreas e of 5% year -over-year.  \n \n"}, "hash": "365ef30ea4863e6098f2d0820d34a17efa350d11c64b146b1fa6805bef67f73f", "class_name": "RelatedNodeInfo"}}, "text": "Our adjusted tax rate was 19.6% for the quarter. ", "start_char_idx": 2578, "end_char_idx": 2627, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cac554a4-a098-43e7-a068-f3ecacc60e50": {"__data__": {"id_": "cac554a4-a098-43e7-a068-f3ecacc60e50", "embedding": null, "metadata": {"window": "Adjusted operating profit was $1.3 billion for the quarter, an increase of 19% compared to the prior year, led by \nstrong operational performance across the segments.  \n \n Moving below the line, interest expense was $41 million in the quarter, an improvement of 25% compared to the \nprior year.  Our adjusted tax rate was 19.6% for the quarter.  And wrapping up our consolidated results, third \nquarter diluted weighted average shares were 153.5 million, a decreas e of 5% year -over-year.  \n \n Moving now to our third quarter segment results, which can be found on slides 8 through 13, starting with US \nPharmaceutical.  Revenues were $55 billion, an increase of 11% year -over-year, driven by higher volumes from \nour retail nat ional account customers and branded pharmaceutical price increases, partially offset by branded to \ngeneric conversions.  Adjusted operating profit increased 12% to $735 million driven by the contribution from \nCOVID -19 vaccine distribution and growth in the distribution of specialty products to hospitals and community \nclinicians.  \n \n", "original_text": "And wrapping up our consolidated results, third \nquarter diluted weighted average shares were 153.5 million, a decreas e of 5% year -over-year.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "61ec5d58-e8e6-4fb6-84e9-6e9504c022e8", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffd5c71f741ef9c4b9932ba9b2502b8e2acdf6d96d4f117e98ddf8b8c885e775", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d27b3aab-8c7d-4b9c-9944-df6005c2fae3", "node_type": "1", "metadata": {"window": "Excluding the impact of held for sale \naccounting on announced divestitures in the International segment, a djusted operating expenses increased 2% \nyear-over-year.  \n \n Adjusted operating profit was $1.3 billion for the quarter, an increase of 19% compared to the prior year, led by \nstrong operational performance across the segments.  \n \n Moving below the line, interest expense was $41 million in the quarter, an improvement of 25% compared to the \nprior year.  Our adjusted tax rate was 19.6% for the quarter.  And wrapping up our consolidated results, third \nquarter diluted weighted average shares were 153.5 million, a decreas e of 5% year -over-year.  \n \n Moving now to our third quarter segment results, which can be found on slides 8 through 13, starting with US \nPharmaceutical.  Revenues were $55 billion, an increase of 11% year -over-year, driven by higher volumes from \nour retail nat ional account customers and branded pharmaceutical price increases, partially offset by branded to \ngeneric conversions. ", "original_text": "Our adjusted tax rate was 19.6% for the quarter. ", "page_label": "8", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97a9fc7e64d9e34976f9897153f1b2d73cc6389f5b649402eaee4f520a14e48e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "32b8af8f-53f8-49b2-9ca0-42466b90b24a", "node_type": "1", "metadata": {"window": "Moving below the line, interest expense was $41 million in the quarter, an improvement of 25% compared to the \nprior year.  Our adjusted tax rate was 19.6% for the quarter.  And wrapping up our consolidated results, third \nquarter diluted weighted average shares were 153.5 million, a decreas e of 5% year -over-year.  \n \n Moving now to our third quarter segment results, which can be found on slides 8 through 13, starting with US \nPharmaceutical.  Revenues were $55 billion, an increase of 11% year -over-year, driven by higher volumes from \nour retail nat ional account customers and branded pharmaceutical price increases, partially offset by branded to \ngeneric conversions.  Adjusted operating profit increased 12% to $735 million driven by the contribution from \nCOVID -19 vaccine distribution and growth in the distribution of specialty products to hospitals and community \nclinicians.  \n \n The contribution from our contract with the US government for the distribution of COVID -19 vaccines provided a \nbenefit of approximately $0.26 per share in the quarter, which was in line with our expectations.  \n \n", "original_text": "Moving now to our third quarter segment results, which can be found on slides 8 through 13, starting with US \nPharmaceutical. "}, "hash": "abdc7cb8a983edb42b506c3232f7363cf0ebef8d5ba8839733b007694765ad40", "class_name": "RelatedNodeInfo"}}, "text": "And wrapping up our consolidated results, third \nquarter diluted weighted average shares were 153.5 million, a decreas e of 5% year -over-year.  \n \n", "start_char_idx": 2627, "end_char_idx": 2775, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "32b8af8f-53f8-49b2-9ca0-42466b90b24a": {"__data__": {"id_": "32b8af8f-53f8-49b2-9ca0-42466b90b24a", "embedding": null, "metadata": {"window": "Moving below the line, interest expense was $41 million in the quarter, an improvement of 25% compared to the \nprior year.  Our adjusted tax rate was 19.6% for the quarter.  And wrapping up our consolidated results, third \nquarter diluted weighted average shares were 153.5 million, a decreas e of 5% year -over-year.  \n \n Moving now to our third quarter segment results, which can be found on slides 8 through 13, starting with US \nPharmaceutical.  Revenues were $55 billion, an increase of 11% year -over-year, driven by higher volumes from \nour retail nat ional account customers and branded pharmaceutical price increases, partially offset by branded to \ngeneric conversions.  Adjusted operating profit increased 12% to $735 million driven by the contribution from \nCOVID -19 vaccine distribution and growth in the distribution of specialty products to hospitals and community \nclinicians.  \n \n The contribution from our contract with the US government for the distribution of COVID -19 vaccines provided a \nbenefit of approximately $0.26 per share in the quarter, which was in line with our expectations.  \n \n", "original_text": "Moving now to our third quarter segment results, which can be found on slides 8 through 13, starting with US \nPharmaceutical. ", "page_label": "8", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "61ec5d58-e8e6-4fb6-84e9-6e9504c022e8", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffd5c71f741ef9c4b9932ba9b2502b8e2acdf6d96d4f117e98ddf8b8c885e775", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cac554a4-a098-43e7-a068-f3ecacc60e50", "node_type": "1", "metadata": {"window": "Adjusted operating profit was $1.3 billion for the quarter, an increase of 19% compared to the prior year, led by \nstrong operational performance across the segments.  \n \n Moving below the line, interest expense was $41 million in the quarter, an improvement of 25% compared to the \nprior year.  Our adjusted tax rate was 19.6% for the quarter.  And wrapping up our consolidated results, third \nquarter diluted weighted average shares were 153.5 million, a decreas e of 5% year -over-year.  \n \n Moving now to our third quarter segment results, which can be found on slides 8 through 13, starting with US \nPharmaceutical.  Revenues were $55 billion, an increase of 11% year -over-year, driven by higher volumes from \nour retail nat ional account customers and branded pharmaceutical price increases, partially offset by branded to \ngeneric conversions.  Adjusted operating profit increased 12% to $735 million driven by the contribution from \nCOVID -19 vaccine distribution and growth in the distribution of specialty products to hospitals and community \nclinicians.  \n \n", "original_text": "And wrapping up our consolidated results, third \nquarter diluted weighted average shares were 153.5 million, a decreas e of 5% year -over-year.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a0e0f7e8ebab05172199489c878e2c4f523a80e96e22d6d2c8c0d58ec77a7180", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b7a8c00e-88f4-41ee-8fec-6730b06ba00b", "node_type": "1", "metadata": {"window": "Our adjusted tax rate was 19.6% for the quarter.  And wrapping up our consolidated results, third \nquarter diluted weighted average shares were 153.5 million, a decreas e of 5% year -over-year.  \n \n Moving now to our third quarter segment results, which can be found on slides 8 through 13, starting with US \nPharmaceutical.  Revenues were $55 billion, an increase of 11% year -over-year, driven by higher volumes from \nour retail nat ional account customers and branded pharmaceutical price increases, partially offset by branded to \ngeneric conversions.  Adjusted operating profit increased 12% to $735 million driven by the contribution from \nCOVID -19 vaccine distribution and growth in the distribution of specialty products to hospitals and community \nclinicians.  \n \n The contribution from our contract with the US government for the distribution of COVID -19 vaccines provided a \nbenefit of approximately $0.26 per share in the quarter, which was in line with our expectations.  \n \n In the Prescription Technology Solutions segment, revenues were $1 billion, an increase of 33% driven by higher \nvolume growth related to biopharma services including third -party logistic services and increased technology \nservic e revenue, partially resulting from the growth of prescription volumes. ", "original_text": "Revenues were $55 billion, an increase of 11% year -over-year, driven by higher volumes from \nour retail nat ional account customers and branded pharmaceutical price increases, partially offset by branded to \ngeneric conversions. "}, "hash": "3f33072b640f545ded7c503da9d6263ad4f6e238ef5809de36307e87fbccdc3d", "class_name": "RelatedNodeInfo"}}, "text": "Moving now to our third quarter segment results, which can be found on slides 8 through 13, starting with US \nPharmaceutical. ", "start_char_idx": 2775, "end_char_idx": 2901, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b7a8c00e-88f4-41ee-8fec-6730b06ba00b": {"__data__": {"id_": "b7a8c00e-88f4-41ee-8fec-6730b06ba00b", "embedding": null, "metadata": {"window": "Our adjusted tax rate was 19.6% for the quarter.  And wrapping up our consolidated results, third \nquarter diluted weighted average shares were 153.5 million, a decreas e of 5% year -over-year.  \n \n Moving now to our third quarter segment results, which can be found on slides 8 through 13, starting with US \nPharmaceutical.  Revenues were $55 billion, an increase of 11% year -over-year, driven by higher volumes from \nour retail nat ional account customers and branded pharmaceutical price increases, partially offset by branded to \ngeneric conversions.  Adjusted operating profit increased 12% to $735 million driven by the contribution from \nCOVID -19 vaccine distribution and growth in the distribution of specialty products to hospitals and community \nclinicians.  \n \n The contribution from our contract with the US government for the distribution of COVID -19 vaccines provided a \nbenefit of approximately $0.26 per share in the quarter, which was in line with our expectations.  \n \n In the Prescription Technology Solutions segment, revenues were $1 billion, an increase of 33% driven by higher \nvolume growth related to biopharma services including third -party logistic services and increased technology \nservic e revenue, partially resulting from the growth of prescription volumes. ", "original_text": "Revenues were $55 billion, an increase of 11% year -over-year, driven by higher volumes from \nour retail nat ional account customers and branded pharmaceutical price increases, partially offset by branded to \ngeneric conversions. ", "page_label": "8", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "61ec5d58-e8e6-4fb6-84e9-6e9504c022e8", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffd5c71f741ef9c4b9932ba9b2502b8e2acdf6d96d4f117e98ddf8b8c885e775", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "32b8af8f-53f8-49b2-9ca0-42466b90b24a", "node_type": "1", "metadata": {"window": "Moving below the line, interest expense was $41 million in the quarter, an improvement of 25% compared to the \nprior year.  Our adjusted tax rate was 19.6% for the quarter.  And wrapping up our consolidated results, third \nquarter diluted weighted average shares were 153.5 million, a decreas e of 5% year -over-year.  \n \n Moving now to our third quarter segment results, which can be found on slides 8 through 13, starting with US \nPharmaceutical.  Revenues were $55 billion, an increase of 11% year -over-year, driven by higher volumes from \nour retail nat ional account customers and branded pharmaceutical price increases, partially offset by branded to \ngeneric conversions.  Adjusted operating profit increased 12% to $735 million driven by the contribution from \nCOVID -19 vaccine distribution and growth in the distribution of specialty products to hospitals and community \nclinicians.  \n \n The contribution from our contract with the US government for the distribution of COVID -19 vaccines provided a \nbenefit of approximately $0.26 per share in the quarter, which was in line with our expectations.  \n \n", "original_text": "Moving now to our third quarter segment results, which can be found on slides 8 through 13, starting with US \nPharmaceutical. ", "page_label": "8", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b7efd800f1781e1e2a3c130ce040b24b7f6ad0a3929e764abab6ef8aefc20322", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "49e08579-73aa-4b23-8a9d-9748e68d8de7", "node_type": "1", "metadata": {"window": "And wrapping up our consolidated results, third \nquarter diluted weighted average shares were 153.5 million, a decreas e of 5% year -over-year.  \n \n Moving now to our third quarter segment results, which can be found on slides 8 through 13, starting with US \nPharmaceutical.  Revenues were $55 billion, an increase of 11% year -over-year, driven by higher volumes from \nour retail nat ional account customers and branded pharmaceutical price increases, partially offset by branded to \ngeneric conversions.  Adjusted operating profit increased 12% to $735 million driven by the contribution from \nCOVID -19 vaccine distribution and growth in the distribution of specialty products to hospitals and community \nclinicians.  \n \n The contribution from our contract with the US government for the distribution of COVID -19 vaccines provided a \nbenefit of approximately $0.26 per share in the quarter, which was in line with our expectations.  \n \n In the Prescription Technology Solutions segment, revenues were $1 billion, an increase of 33% driven by higher \nvolume growth related to biopharma services including third -party logistic services and increased technology \nservic e revenue, partially resulting from the growth of prescription volumes.  Adjusted operating profit increased ", "original_text": "Adjusted operating profit increased 12% to $735 million driven by the contribution from \nCOVID -19 vaccine distribution and growth in the distribution of specialty products to hospitals and community \nclinicians.  \n \n"}, "hash": "220edc7bfb8be9f5479c0e7c103497aada32d9d5e7cd66ab90febd121d093620", "class_name": "RelatedNodeInfo"}}, "text": "Revenues were $55 billion, an increase of 11% year -over-year, driven by higher volumes from \nour retail nat ional account customers and branded pharmaceutical price increases, partially offset by branded to \ngeneric conversions. ", "start_char_idx": 2901, "end_char_idx": 3131, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "49e08579-73aa-4b23-8a9d-9748e68d8de7": {"__data__": {"id_": "49e08579-73aa-4b23-8a9d-9748e68d8de7", "embedding": null, "metadata": {"window": "And wrapping up our consolidated results, third \nquarter diluted weighted average shares were 153.5 million, a decreas e of 5% year -over-year.  \n \n Moving now to our third quarter segment results, which can be found on slides 8 through 13, starting with US \nPharmaceutical.  Revenues were $55 billion, an increase of 11% year -over-year, driven by higher volumes from \nour retail nat ional account customers and branded pharmaceutical price increases, partially offset by branded to \ngeneric conversions.  Adjusted operating profit increased 12% to $735 million driven by the contribution from \nCOVID -19 vaccine distribution and growth in the distribution of specialty products to hospitals and community \nclinicians.  \n \n The contribution from our contract with the US government for the distribution of COVID -19 vaccines provided a \nbenefit of approximately $0.26 per share in the quarter, which was in line with our expectations.  \n \n In the Prescription Technology Solutions segment, revenues were $1 billion, an increase of 33% driven by higher \nvolume growth related to biopharma services including third -party logistic services and increased technology \nservic e revenue, partially resulting from the growth of prescription volumes.  Adjusted operating profit increased ", "original_text": "Adjusted operating profit increased 12% to $735 million driven by the contribution from \nCOVID -19 vaccine distribution and growth in the distribution of specialty products to hospitals and community \nclinicians.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "61ec5d58-e8e6-4fb6-84e9-6e9504c022e8", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffd5c71f741ef9c4b9932ba9b2502b8e2acdf6d96d4f117e98ddf8b8c885e775", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b7a8c00e-88f4-41ee-8fec-6730b06ba00b", "node_type": "1", "metadata": {"window": "Our adjusted tax rate was 19.6% for the quarter.  And wrapping up our consolidated results, third \nquarter diluted weighted average shares were 153.5 million, a decreas e of 5% year -over-year.  \n \n Moving now to our third quarter segment results, which can be found on slides 8 through 13, starting with US \nPharmaceutical.  Revenues were $55 billion, an increase of 11% year -over-year, driven by higher volumes from \nour retail nat ional account customers and branded pharmaceutical price increases, partially offset by branded to \ngeneric conversions.  Adjusted operating profit increased 12% to $735 million driven by the contribution from \nCOVID -19 vaccine distribution and growth in the distribution of specialty products to hospitals and community \nclinicians.  \n \n The contribution from our contract with the US government for the distribution of COVID -19 vaccines provided a \nbenefit of approximately $0.26 per share in the quarter, which was in line with our expectations.  \n \n In the Prescription Technology Solutions segment, revenues were $1 billion, an increase of 33% driven by higher \nvolume growth related to biopharma services including third -party logistic services and increased technology \nservic e revenue, partially resulting from the growth of prescription volumes. ", "original_text": "Revenues were $55 billion, an increase of 11% year -over-year, driven by higher volumes from \nour retail nat ional account customers and branded pharmaceutical price increases, partially offset by branded to \ngeneric conversions. ", "page_label": "8", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f6d1f78c00cb9f2f20ed6860c06771e83fa535f933bb07dda8fdabe4659fec0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "05634269-8572-4ee3-8ba3-02c7a63196b4", "node_type": "1", "metadata": {"window": "Moving now to our third quarter segment results, which can be found on slides 8 through 13, starting with US \nPharmaceutical.  Revenues were $55 billion, an increase of 11% year -over-year, driven by higher volumes from \nour retail nat ional account customers and branded pharmaceutical price increases, partially offset by branded to \ngeneric conversions.  Adjusted operating profit increased 12% to $735 million driven by the contribution from \nCOVID -19 vaccine distribution and growth in the distribution of specialty products to hospitals and community \nclinicians.  \n \n The contribution from our contract with the US government for the distribution of COVID -19 vaccines provided a \nbenefit of approximately $0.26 per share in the quarter, which was in line with our expectations.  \n \n In the Prescription Technology Solutions segment, revenues were $1 billion, an increase of 33% driven by higher \nvolume growth related to biopharma services including third -party logistic services and increased technology \nservic e revenue, partially resulting from the growth of prescription volumes.  Adjusted operating profit increased ", "original_text": "The contribution from our contract with the US government for the distribution of COVID -19 vaccines provided a \nbenefit of approximately $0.26 per share in the quarter, which was in line with our expectations.  \n \n"}, "hash": "9afaa3d982e23a2d0e1cd4c6ac20a61466eb43168eed91a71ac442541968736f", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating profit increased 12% to $735 million driven by the contribution from \nCOVID -19 vaccine distribution and growth in the distribution of specialty products to hospitals and community \nclinicians.  \n \n", "start_char_idx": 3131, "end_char_idx": 3348, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "05634269-8572-4ee3-8ba3-02c7a63196b4": {"__data__": {"id_": "05634269-8572-4ee3-8ba3-02c7a63196b4", "embedding": null, "metadata": {"window": "Moving now to our third quarter segment results, which can be found on slides 8 through 13, starting with US \nPharmaceutical.  Revenues were $55 billion, an increase of 11% year -over-year, driven by higher volumes from \nour retail nat ional account customers and branded pharmaceutical price increases, partially offset by branded to \ngeneric conversions.  Adjusted operating profit increased 12% to $735 million driven by the contribution from \nCOVID -19 vaccine distribution and growth in the distribution of specialty products to hospitals and community \nclinicians.  \n \n The contribution from our contract with the US government for the distribution of COVID -19 vaccines provided a \nbenefit of approximately $0.26 per share in the quarter, which was in line with our expectations.  \n \n In the Prescription Technology Solutions segment, revenues were $1 billion, an increase of 33% driven by higher \nvolume growth related to biopharma services including third -party logistic services and increased technology \nservic e revenue, partially resulting from the growth of prescription volumes.  Adjusted operating profit increased ", "original_text": "The contribution from our contract with the US government for the distribution of COVID -19 vaccines provided a \nbenefit of approximately $0.26 per share in the quarter, which was in line with our expectations.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "61ec5d58-e8e6-4fb6-84e9-6e9504c022e8", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffd5c71f741ef9c4b9932ba9b2502b8e2acdf6d96d4f117e98ddf8b8c885e775", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "49e08579-73aa-4b23-8a9d-9748e68d8de7", "node_type": "1", "metadata": {"window": "And wrapping up our consolidated results, third \nquarter diluted weighted average shares were 153.5 million, a decreas e of 5% year -over-year.  \n \n Moving now to our third quarter segment results, which can be found on slides 8 through 13, starting with US \nPharmaceutical.  Revenues were $55 billion, an increase of 11% year -over-year, driven by higher volumes from \nour retail nat ional account customers and branded pharmaceutical price increases, partially offset by branded to \ngeneric conversions.  Adjusted operating profit increased 12% to $735 million driven by the contribution from \nCOVID -19 vaccine distribution and growth in the distribution of specialty products to hospitals and community \nclinicians.  \n \n The contribution from our contract with the US government for the distribution of COVID -19 vaccines provided a \nbenefit of approximately $0.26 per share in the quarter, which was in line with our expectations.  \n \n In the Prescription Technology Solutions segment, revenues were $1 billion, an increase of 33% driven by higher \nvolume growth related to biopharma services including third -party logistic services and increased technology \nservic e revenue, partially resulting from the growth of prescription volumes.  Adjusted operating profit increased ", "original_text": "Adjusted operating profit increased 12% to $735 million driven by the contribution from \nCOVID -19 vaccine distribution and growth in the distribution of specialty products to hospitals and community \nclinicians.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "07aca1e5125cdc3c87951f46eeba3d0a4958047d737a21c8dbe73be7daac687b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6a005061-bdef-41fb-b95b-3069f61ca453", "node_type": "1", "metadata": {"window": "Revenues were $55 billion, an increase of 11% year -over-year, driven by higher volumes from \nour retail nat ional account customers and branded pharmaceutical price increases, partially offset by branded to \ngeneric conversions.  Adjusted operating profit increased 12% to $735 million driven by the contribution from \nCOVID -19 vaccine distribution and growth in the distribution of specialty products to hospitals and community \nclinicians.  \n \n The contribution from our contract with the US government for the distribution of COVID -19 vaccines provided a \nbenefit of approximately $0.26 per share in the quarter, which was in line with our expectations.  \n \n In the Prescription Technology Solutions segment, revenues were $1 billion, an increase of 33% driven by higher \nvolume growth related to biopharma services including third -party logistic services and increased technology \nservic e revenue, partially resulting from the growth of prescription volumes.  Adjusted operating profit increased ", "original_text": "In the Prescription Technology Solutions segment, revenues were $1 billion, an increase of 33% driven by higher \nvolume growth related to biopharma services including third -party logistic services and increased technology \nservic e revenue, partially resulting from the growth of prescription volumes. "}, "hash": "3747e23c3169f82c6c4eed140e3b9dc2b3fdcddfaee6511faa723287fc2b145b", "class_name": "RelatedNodeInfo"}}, "text": "The contribution from our contract with the US government for the distribution of COVID -19 vaccines provided a \nbenefit of approximately $0.26 per share in the quarter, which was in line with our expectations.  \n \n", "start_char_idx": 3348, "end_char_idx": 3563, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6a005061-bdef-41fb-b95b-3069f61ca453": {"__data__": {"id_": "6a005061-bdef-41fb-b95b-3069f61ca453", "embedding": null, "metadata": {"window": "Revenues were $55 billion, an increase of 11% year -over-year, driven by higher volumes from \nour retail nat ional account customers and branded pharmaceutical price increases, partially offset by branded to \ngeneric conversions.  Adjusted operating profit increased 12% to $735 million driven by the contribution from \nCOVID -19 vaccine distribution and growth in the distribution of specialty products to hospitals and community \nclinicians.  \n \n The contribution from our contract with the US government for the distribution of COVID -19 vaccines provided a \nbenefit of approximately $0.26 per share in the quarter, which was in line with our expectations.  \n \n In the Prescription Technology Solutions segment, revenues were $1 billion, an increase of 33% driven by higher \nvolume growth related to biopharma services including third -party logistic services and increased technology \nservic e revenue, partially resulting from the growth of prescription volumes.  Adjusted operating profit increased ", "original_text": "In the Prescription Technology Solutions segment, revenues were $1 billion, an increase of 33% driven by higher \nvolume growth related to biopharma services including third -party logistic services and increased technology \nservic e revenue, partially resulting from the growth of prescription volumes. ", "page_label": "8", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "61ec5d58-e8e6-4fb6-84e9-6e9504c022e8", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffd5c71f741ef9c4b9932ba9b2502b8e2acdf6d96d4f117e98ddf8b8c885e775", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "05634269-8572-4ee3-8ba3-02c7a63196b4", "node_type": "1", "metadata": {"window": "Moving now to our third quarter segment results, which can be found on slides 8 through 13, starting with US \nPharmaceutical.  Revenues were $55 billion, an increase of 11% year -over-year, driven by higher volumes from \nour retail nat ional account customers and branded pharmaceutical price increases, partially offset by branded to \ngeneric conversions.  Adjusted operating profit increased 12% to $735 million driven by the contribution from \nCOVID -19 vaccine distribution and growth in the distribution of specialty products to hospitals and community \nclinicians.  \n \n The contribution from our contract with the US government for the distribution of COVID -19 vaccines provided a \nbenefit of approximately $0.26 per share in the quarter, which was in line with our expectations.  \n \n In the Prescription Technology Solutions segment, revenues were $1 billion, an increase of 33% driven by higher \nvolume growth related to biopharma services including third -party logistic services and increased technology \nservic e revenue, partially resulting from the growth of prescription volumes.  Adjusted operating profit increased ", "original_text": "The contribution from our contract with the US government for the distribution of COVID -19 vaccines provided a \nbenefit of approximately $0.26 per share in the quarter, which was in line with our expectations.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "06dbf826bd6cd90e0a10486286215fbffa5493d58a8926678b8451b7e120e609", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7205a9e2-8dc3-461b-abad-d0b879f8a0bc", "node_type": "1", "metadata": {"window": "Adjusted operating profit increased 12% to $735 million driven by the contribution from \nCOVID -19 vaccine distribution and growth in the distribution of specialty products to hospitals and community \nclinicians.  \n \n The contribution from our contract with the US government for the distribution of COVID -19 vaccines provided a \nbenefit of approximately $0.26 per share in the quarter, which was in line with our expectations.  \n \n In the Prescription Technology Solutions segment, revenues were $1 billion, an increase of 33% driven by higher \nvolume growth related to biopharma services including third -party logistic services and increased technology \nservic e revenue, partially resulting from the growth of prescription volumes.  Adjusted operating profit increased ", "original_text": "Adjusted operating profit increased "}, "hash": "435277528ae2fc9fa2ee96412a6ab9977a36870b157aeb1a6fe1de32dc02f370", "class_name": "RelatedNodeInfo"}}, "text": "In the Prescription Technology Solutions segment, revenues were $1 billion, an increase of 33% driven by higher \nvolume growth related to biopharma services including third -party logistic services and increased technology \nservic e revenue, partially resulting from the growth of prescription volumes. ", "start_char_idx": 3563, "end_char_idx": 3866, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7205a9e2-8dc3-461b-abad-d0b879f8a0bc": {"__data__": {"id_": "7205a9e2-8dc3-461b-abad-d0b879f8a0bc", "embedding": null, "metadata": {"window": "Adjusted operating profit increased 12% to $735 million driven by the contribution from \nCOVID -19 vaccine distribution and growth in the distribution of specialty products to hospitals and community \nclinicians.  \n \n The contribution from our contract with the US government for the distribution of COVID -19 vaccines provided a \nbenefit of approximately $0.26 per share in the quarter, which was in line with our expectations.  \n \n In the Prescription Technology Solutions segment, revenues were $1 billion, an increase of 33% driven by higher \nvolume growth related to biopharma services including third -party logistic services and increased technology \nservic e revenue, partially resulting from the growth of prescription volumes.  Adjusted operating profit increased ", "original_text": "Adjusted operating profit increased ", "page_label": "8", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "61ec5d58-e8e6-4fb6-84e9-6e9504c022e8", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffd5c71f741ef9c4b9932ba9b2502b8e2acdf6d96d4f117e98ddf8b8c885e775", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6a005061-bdef-41fb-b95b-3069f61ca453", "node_type": "1", "metadata": {"window": "Revenues were $55 billion, an increase of 11% year -over-year, driven by higher volumes from \nour retail nat ional account customers and branded pharmaceutical price increases, partially offset by branded to \ngeneric conversions.  Adjusted operating profit increased 12% to $735 million driven by the contribution from \nCOVID -19 vaccine distribution and growth in the distribution of specialty products to hospitals and community \nclinicians.  \n \n The contribution from our contract with the US government for the distribution of COVID -19 vaccines provided a \nbenefit of approximately $0.26 per share in the quarter, which was in line with our expectations.  \n \n In the Prescription Technology Solutions segment, revenues were $1 billion, an increase of 33% driven by higher \nvolume growth related to biopharma services including third -party logistic services and increased technology \nservic e revenue, partially resulting from the growth of prescription volumes.  Adjusted operating profit increased ", "original_text": "In the Prescription Technology Solutions segment, revenues were $1 billion, an increase of 33% driven by higher \nvolume growth related to biopharma services including third -party logistic services and increased technology \nservic e revenue, partially resulting from the growth of prescription volumes. ", "page_label": "8", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "123e3a37d82ab08f0e91c5d334c535cc0c8ad43f904a7b3c49e7c1fbb5eaf057", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8baff24b-4d81-4c4b-9842-65bcb9fe83e3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n11% to $145 million driven by growth from access and adherence solutions.  We continue to experience growth \nacross our broad spectrum, higher margin capabilities and offerings in this segment.  We're pleased with the \nincreased transaction volumes related to our access and adherence solutions and the increasing number of \nbrands that joined our platforms this year. ", "original_text": "McKesson Corp.  "}, "hash": "6cdcc4501fb5e0135c272f858a7ed542efa2271baa7fb7618567fe4f176b5a86", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating profit increased ", "start_char_idx": 3131, "end_char_idx": 3167, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8baff24b-4d81-4c4b-9842-65bcb9fe83e3": {"__data__": {"id_": "8baff24b-4d81-4c4b-9842-65bcb9fe83e3", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n11% to $145 million driven by growth from access and adherence solutions.  We continue to experience growth \nacross our broad spectrum, higher margin capabilities and offerings in this segment.  We're pleased with the \nincreased transaction volumes related to our access and adherence solutions and the increasing number of \nbrands that joined our platforms this year. ", "original_text": "McKesson Corp.  ", "page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "74570293-485c-474e-a351-234bb8205358", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "03166168eea2cc27d19b95f8aac5a64b1f866995b26470f97bc6e49469163ed0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7205a9e2-8dc3-461b-abad-d0b879f8a0bc", "node_type": "1", "metadata": {"window": "Adjusted operating profit increased 12% to $735 million driven by the contribution from \nCOVID -19 vaccine distribution and growth in the distribution of specialty products to hospitals and community \nclinicians.  \n \n The contribution from our contract with the US government for the distribution of COVID -19 vaccines provided a \nbenefit of approximately $0.26 per share in the quarter, which was in line with our expectations.  \n \n In the Prescription Technology Solutions segment, revenues were $1 billion, an increase of 33% driven by higher \nvolume growth related to biopharma services including third -party logistic services and increased technology \nservic e revenue, partially resulting from the growth of prescription volumes.  Adjusted operating profit increased ", "original_text": "Adjusted operating profit increased ", "page_label": "8", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28acdf5674846a75f7194d6eee5aaa2b7d8ac0e5f9a29ba35a6a711c43f2f397", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8eae83da-46ff-4fbb-9775-750b89167566", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n11% to $145 million driven by growth from access and adherence solutions.  We continue to experience growth \nacross our broad spectrum, higher margin capabilities and offerings in this segment.  We're pleased with the \nincreased transaction volumes related to our access and adherence solutions and the increasing number of \nbrands that joined our platforms this year.  We also experienced increased volumes in  our logistics and hub \nservices due to the continued recovery of prescription volumes.  \n \n", "original_text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n11% to $145 million driven by growth from access and adherence solutions. "}, "hash": "98b2b4a03482a7ec9f7b4f159be5a704bd2c76d3713e45178bc1bbdd682bae0b", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8eae83da-46ff-4fbb-9775-750b89167566": {"__data__": {"id_": "8eae83da-46ff-4fbb-9775-750b89167566", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n11% to $145 million driven by growth from access and adherence solutions.  We continue to experience growth \nacross our broad spectrum, higher margin capabilities and offerings in this segment.  We're pleased with the \nincreased transaction volumes related to our access and adherence solutions and the increasing number of \nbrands that joined our platforms this year.  We also experienced increased volumes in  our logistics and hub \nservices due to the continued recovery of prescription volumes.  \n \n", "original_text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n11% to $145 million driven by growth from access and adherence solutions. ", "page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "74570293-485c-474e-a351-234bb8205358", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "03166168eea2cc27d19b95f8aac5a64b1f866995b26470f97bc6e49469163ed0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8baff24b-4d81-4c4b-9842-65bcb9fe83e3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n11% to $145 million driven by growth from access and adherence solutions.  We continue to experience growth \nacross our broad spectrum, higher margin capabilities and offerings in this segment.  We're pleased with the \nincreased transaction volumes related to our access and adherence solutions and the increasing number of \nbrands that joined our platforms this year. ", "original_text": "McKesson Corp.  ", "page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "12a2dc2e8ca44a387be30527d4929a9a2a0f41fa1e8411404baeb89e39477f7a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6a9acc26-72f9-4383-b388-bacab12ae13b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n11% to $145 million driven by growth from access and adherence solutions.  We continue to experience growth \nacross our broad spectrum, higher margin capabilities and offerings in this segment.  We're pleased with the \nincreased transaction volumes related to our access and adherence solutions and the increasing number of \nbrands that joined our platforms this year.  We also experienced increased volumes in  our logistics and hub \nservices due to the continued recovery of prescription volumes.  \n \n Moving now to Medical -Surgical Solutions. ", "original_text": "We continue to experience growth \nacross our broad spectrum, higher margin capabilities and offerings in this segment. "}, "hash": "e31b28fc83f219a6d9a08c0b762392f7e5128214d06524920b2d65fc7d5d38bd", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n11% to $145 million driven by growth from access and adherence solutions. ", "start_char_idx": 16, "end_char_idx": 254, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6a9acc26-72f9-4383-b388-bacab12ae13b": {"__data__": {"id_": "6a9acc26-72f9-4383-b388-bacab12ae13b", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n11% to $145 million driven by growth from access and adherence solutions.  We continue to experience growth \nacross our broad spectrum, higher margin capabilities and offerings in this segment.  We're pleased with the \nincreased transaction volumes related to our access and adherence solutions and the increasing number of \nbrands that joined our platforms this year.  We also experienced increased volumes in  our logistics and hub \nservices due to the continued recovery of prescription volumes.  \n \n Moving now to Medical -Surgical Solutions. ", "original_text": "We continue to experience growth \nacross our broad spectrum, higher margin capabilities and offerings in this segment. ", "page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "74570293-485c-474e-a351-234bb8205358", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "03166168eea2cc27d19b95f8aac5a64b1f866995b26470f97bc6e49469163ed0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8eae83da-46ff-4fbb-9775-750b89167566", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n11% to $145 million driven by growth from access and adherence solutions.  We continue to experience growth \nacross our broad spectrum, higher margin capabilities and offerings in this segment.  We're pleased with the \nincreased transaction volumes related to our access and adherence solutions and the increasing number of \nbrands that joined our platforms this year.  We also experienced increased volumes in  our logistics and hub \nservices due to the continued recovery of prescription volumes.  \n \n", "original_text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n11% to $145 million driven by growth from access and adherence solutions. ", "page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d5176619471e637eba3578e587a008d00a3467a958a48428acc9b2e649a42f5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "727c1540-b098-4f33-9114-2abec99aed10", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n11% to $145 million driven by growth from access and adherence solutions.  We continue to experience growth \nacross our broad spectrum, higher margin capabilities and offerings in this segment.  We're pleased with the \nincreased transaction volumes related to our access and adherence solutions and the increasing number of \nbrands that joined our platforms this year.  We also experienced increased volumes in  our logistics and hub \nservices due to the continued recovery of prescription volumes.  \n \n Moving now to Medical -Surgical Solutions.  Revenues were $3.1 billion, an increase of 1% driven by growth in the \nprimary care business and the contribution from kitting,  storage, and distribution of ancillary supplies for COVID -\n19 vaccines, partially offset by lower revenue from COVID -19 tests in our primary care and extended care \nbusinesses as compared to the prior year.  \n \n", "original_text": "We're pleased with the \nincreased transaction volumes related to our access and adherence solutions and the increasing number of \nbrands that joined our platforms this year. "}, "hash": "261c11c3b8ce7ffdc81a64ab6d47d387ff35505a831e388314b990d22f3f8833", "class_name": "RelatedNodeInfo"}}, "text": "We continue to experience growth \nacross our broad spectrum, higher margin capabilities and offerings in this segment. ", "start_char_idx": 254, "end_char_idx": 373, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "727c1540-b098-4f33-9114-2abec99aed10": {"__data__": {"id_": "727c1540-b098-4f33-9114-2abec99aed10", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n11% to $145 million driven by growth from access and adherence solutions.  We continue to experience growth \nacross our broad spectrum, higher margin capabilities and offerings in this segment.  We're pleased with the \nincreased transaction volumes related to our access and adherence solutions and the increasing number of \nbrands that joined our platforms this year.  We also experienced increased volumes in  our logistics and hub \nservices due to the continued recovery of prescription volumes.  \n \n Moving now to Medical -Surgical Solutions.  Revenues were $3.1 billion, an increase of 1% driven by growth in the \nprimary care business and the contribution from kitting,  storage, and distribution of ancillary supplies for COVID -\n19 vaccines, partially offset by lower revenue from COVID -19 tests in our primary care and extended care \nbusinesses as compared to the prior year.  \n \n", "original_text": "We're pleased with the \nincreased transaction volumes related to our access and adherence solutions and the increasing number of \nbrands that joined our platforms this year. ", "page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "74570293-485c-474e-a351-234bb8205358", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "03166168eea2cc27d19b95f8aac5a64b1f866995b26470f97bc6e49469163ed0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6a9acc26-72f9-4383-b388-bacab12ae13b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n11% to $145 million driven by growth from access and adherence solutions.  We continue to experience growth \nacross our broad spectrum, higher margin capabilities and offerings in this segment.  We're pleased with the \nincreased transaction volumes related to our access and adherence solutions and the increasing number of \nbrands that joined our platforms this year.  We also experienced increased volumes in  our logistics and hub \nservices due to the continued recovery of prescription volumes.  \n \n Moving now to Medical -Surgical Solutions. ", "original_text": "We continue to experience growth \nacross our broad spectrum, higher margin capabilities and offerings in this segment. ", "page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cfbaba811852baa58e9d5fd5afe6a3a7449407e349defbaada568a3ecc832f02", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d23008ab-ebf7-489c-bcdf-2d83739c57b1", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n11% to $145 million driven by growth from access and adherence solutions.  We continue to experience growth \nacross our broad spectrum, higher margin capabilities and offerings in this segment.  We're pleased with the \nincreased transaction volumes related to our access and adherence solutions and the increasing number of \nbrands that joined our platforms this year.  We also experienced increased volumes in  our logistics and hub \nservices due to the continued recovery of prescription volumes.  \n \n Moving now to Medical -Surgical Solutions.  Revenues were $3.1 billion, an increase of 1% driven by growth in the \nprimary care business and the contribution from kitting,  storage, and distribution of ancillary supplies for COVID -\n19 vaccines, partially offset by lower revenue from COVID -19 tests in our primary care and extended care \nbusinesses as compared to the prior year.  \n \n Adjusted operating profit increased 18% to $330 m illion driven by the contribution from kitting, storage, and \ndistribution of ancillary supplies for the US government's COVID -19 vaccine program, the prior year impact of an \ninventory impairment charge related to PPE that incurred in the third quarter of f iscal 2021, and growth in the \nprimary care business.  \n \n", "original_text": "We also experienced increased volumes in  our logistics and hub \nservices due to the continued recovery of prescription volumes.  \n \n"}, "hash": "fcae3b12c90b5ba9dc035a9dc8ce6568b3759a699fadf1f1a4b1112290c3fb8c", "class_name": "RelatedNodeInfo"}}, "text": "We're pleased with the \nincreased transaction volumes related to our access and adherence solutions and the increasing number of \nbrands that joined our platforms this year. ", "start_char_idx": 373, "end_char_idx": 547, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d23008ab-ebf7-489c-bcdf-2d83739c57b1": {"__data__": {"id_": "d23008ab-ebf7-489c-bcdf-2d83739c57b1", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n11% to $145 million driven by growth from access and adherence solutions.  We continue to experience growth \nacross our broad spectrum, higher margin capabilities and offerings in this segment.  We're pleased with the \nincreased transaction volumes related to our access and adherence solutions and the increasing number of \nbrands that joined our platforms this year.  We also experienced increased volumes in  our logistics and hub \nservices due to the continued recovery of prescription volumes.  \n \n Moving now to Medical -Surgical Solutions.  Revenues were $3.1 billion, an increase of 1% driven by growth in the \nprimary care business and the contribution from kitting,  storage, and distribution of ancillary supplies for COVID -\n19 vaccines, partially offset by lower revenue from COVID -19 tests in our primary care and extended care \nbusinesses as compared to the prior year.  \n \n Adjusted operating profit increased 18% to $330 m illion driven by the contribution from kitting, storage, and \ndistribution of ancillary supplies for the US government's COVID -19 vaccine program, the prior year impact of an \ninventory impairment charge related to PPE that incurred in the third quarter of f iscal 2021, and growth in the \nprimary care business.  \n \n", "original_text": "We also experienced increased volumes in  our logistics and hub \nservices due to the continued recovery of prescription volumes.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "74570293-485c-474e-a351-234bb8205358", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "03166168eea2cc27d19b95f8aac5a64b1f866995b26470f97bc6e49469163ed0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "727c1540-b098-4f33-9114-2abec99aed10", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n11% to $145 million driven by growth from access and adherence solutions.  We continue to experience growth \nacross our broad spectrum, higher margin capabilities and offerings in this segment.  We're pleased with the \nincreased transaction volumes related to our access and adherence solutions and the increasing number of \nbrands that joined our platforms this year.  We also experienced increased volumes in  our logistics and hub \nservices due to the continued recovery of prescription volumes.  \n \n Moving now to Medical -Surgical Solutions.  Revenues were $3.1 billion, an increase of 1% driven by growth in the \nprimary care business and the contribution from kitting,  storage, and distribution of ancillary supplies for COVID -\n19 vaccines, partially offset by lower revenue from COVID -19 tests in our primary care and extended care \nbusinesses as compared to the prior year.  \n \n", "original_text": "We're pleased with the \nincreased transaction volumes related to our access and adherence solutions and the increasing number of \nbrands that joined our platforms this year. ", "page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e1b05c80302f2a40510276397114f47dc78653afb99e38b74a77e0eea611cbb7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4d4d51eb-9d33-42f8-bf91-4bcd6f2b6643", "node_type": "1", "metadata": {"window": "We continue to experience growth \nacross our broad spectrum, higher margin capabilities and offerings in this segment.  We're pleased with the \nincreased transaction volumes related to our access and adherence solutions and the increasing number of \nbrands that joined our platforms this year.  We also experienced increased volumes in  our logistics and hub \nservices due to the continued recovery of prescription volumes.  \n \n Moving now to Medical -Surgical Solutions.  Revenues were $3.1 billion, an increase of 1% driven by growth in the \nprimary care business and the contribution from kitting,  storage, and distribution of ancillary supplies for COVID -\n19 vaccines, partially offset by lower revenue from COVID -19 tests in our primary care and extended care \nbusinesses as compared to the prior year.  \n \n Adjusted operating profit increased 18% to $330 m illion driven by the contribution from kitting, storage, and \ndistribution of ancillary supplies for the US government's COVID -19 vaccine program, the prior year impact of an \ninventory impairment charge related to PPE that incurred in the third quarter of f iscal 2021, and growth in the \nprimary care business.  \n \n The contribution from our contract with the US government related to the kitting, distribution, and storage of \nancillary supplies for COVID -19 vaccines provided a benefit of approximately $0.31 per shar e in the quarter, \nwhich was above our original expectations.  \n \n", "original_text": "Moving now to Medical -Surgical Solutions. "}, "hash": "7ca2a0d7e940b9c286de0844bba72a1dda90e7949dedaf7e005769aaa88d0fe1", "class_name": "RelatedNodeInfo"}}, "text": "We also experienced increased volumes in  our logistics and hub \nservices due to the continued recovery of prescription volumes.  \n \n", "start_char_idx": 547, "end_char_idx": 680, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4d4d51eb-9d33-42f8-bf91-4bcd6f2b6643": {"__data__": {"id_": "4d4d51eb-9d33-42f8-bf91-4bcd6f2b6643", "embedding": null, "metadata": {"window": "We continue to experience growth \nacross our broad spectrum, higher margin capabilities and offerings in this segment.  We're pleased with the \nincreased transaction volumes related to our access and adherence solutions and the increasing number of \nbrands that joined our platforms this year.  We also experienced increased volumes in  our logistics and hub \nservices due to the continued recovery of prescription volumes.  \n \n Moving now to Medical -Surgical Solutions.  Revenues were $3.1 billion, an increase of 1% driven by growth in the \nprimary care business and the contribution from kitting,  storage, and distribution of ancillary supplies for COVID -\n19 vaccines, partially offset by lower revenue from COVID -19 tests in our primary care and extended care \nbusinesses as compared to the prior year.  \n \n Adjusted operating profit increased 18% to $330 m illion driven by the contribution from kitting, storage, and \ndistribution of ancillary supplies for the US government's COVID -19 vaccine program, the prior year impact of an \ninventory impairment charge related to PPE that incurred in the third quarter of f iscal 2021, and growth in the \nprimary care business.  \n \n The contribution from our contract with the US government related to the kitting, distribution, and storage of \nancillary supplies for COVID -19 vaccines provided a benefit of approximately $0.31 per shar e in the quarter, \nwhich was above our original expectations.  \n \n", "original_text": "Moving now to Medical -Surgical Solutions. ", "page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "74570293-485c-474e-a351-234bb8205358", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "03166168eea2cc27d19b95f8aac5a64b1f866995b26470f97bc6e49469163ed0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d23008ab-ebf7-489c-bcdf-2d83739c57b1", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n11% to $145 million driven by growth from access and adherence solutions.  We continue to experience growth \nacross our broad spectrum, higher margin capabilities and offerings in this segment.  We're pleased with the \nincreased transaction volumes related to our access and adherence solutions and the increasing number of \nbrands that joined our platforms this year.  We also experienced increased volumes in  our logistics and hub \nservices due to the continued recovery of prescription volumes.  \n \n Moving now to Medical -Surgical Solutions.  Revenues were $3.1 billion, an increase of 1% driven by growth in the \nprimary care business and the contribution from kitting,  storage, and distribution of ancillary supplies for COVID -\n19 vaccines, partially offset by lower revenue from COVID -19 tests in our primary care and extended care \nbusinesses as compared to the prior year.  \n \n Adjusted operating profit increased 18% to $330 m illion driven by the contribution from kitting, storage, and \ndistribution of ancillary supplies for the US government's COVID -19 vaccine program, the prior year impact of an \ninventory impairment charge related to PPE that incurred in the third quarter of f iscal 2021, and growth in the \nprimary care business.  \n \n", "original_text": "We also experienced increased volumes in  our logistics and hub \nservices due to the continued recovery of prescription volumes.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e460343ef4f1a76b681afd0d693aab0e7b12ecb14bf09f31eac87b2de545c153", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d26ac9b3-2fe5-4d61-bbf8-30f72c27d6c5", "node_type": "1", "metadata": {"window": "We're pleased with the \nincreased transaction volumes related to our access and adherence solutions and the increasing number of \nbrands that joined our platforms this year.  We also experienced increased volumes in  our logistics and hub \nservices due to the continued recovery of prescription volumes.  \n \n Moving now to Medical -Surgical Solutions.  Revenues were $3.1 billion, an increase of 1% driven by growth in the \nprimary care business and the contribution from kitting,  storage, and distribution of ancillary supplies for COVID -\n19 vaccines, partially offset by lower revenue from COVID -19 tests in our primary care and extended care \nbusinesses as compared to the prior year.  \n \n Adjusted operating profit increased 18% to $330 m illion driven by the contribution from kitting, storage, and \ndistribution of ancillary supplies for the US government's COVID -19 vaccine program, the prior year impact of an \ninventory impairment charge related to PPE that incurred in the third quarter of f iscal 2021, and growth in the \nprimary care business.  \n \n The contribution from our contract with the US government related to the kitting, distribution, and storage of \nancillary supplies for COVID -19 vaccines provided a benefit of approximately $0.31 per shar e in the quarter, \nwhich was above our original expectations.  \n \n Next, let me address our International results. ", "original_text": "Revenues were $3.1 billion, an increase of 1% driven by growth in the \nprimary care business and the contribution from kitting,  storage, and distribution of ancillary supplies for COVID -\n19 vaccines, partially offset by lower revenue from COVID -19 tests in our primary care and extended care \nbusinesses as compared to the prior year.  \n \n"}, "hash": "281ada72df9e24d91b9ecf9ac7e17a512953f683d060fe225539d76e20900dcd", "class_name": "RelatedNodeInfo"}}, "text": "Moving now to Medical -Surgical Solutions. ", "start_char_idx": 680, "end_char_idx": 723, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d26ac9b3-2fe5-4d61-bbf8-30f72c27d6c5": {"__data__": {"id_": "d26ac9b3-2fe5-4d61-bbf8-30f72c27d6c5", "embedding": null, "metadata": {"window": "We're pleased with the \nincreased transaction volumes related to our access and adherence solutions and the increasing number of \nbrands that joined our platforms this year.  We also experienced increased volumes in  our logistics and hub \nservices due to the continued recovery of prescription volumes.  \n \n Moving now to Medical -Surgical Solutions.  Revenues were $3.1 billion, an increase of 1% driven by growth in the \nprimary care business and the contribution from kitting,  storage, and distribution of ancillary supplies for COVID -\n19 vaccines, partially offset by lower revenue from COVID -19 tests in our primary care and extended care \nbusinesses as compared to the prior year.  \n \n Adjusted operating profit increased 18% to $330 m illion driven by the contribution from kitting, storage, and \ndistribution of ancillary supplies for the US government's COVID -19 vaccine program, the prior year impact of an \ninventory impairment charge related to PPE that incurred in the third quarter of f iscal 2021, and growth in the \nprimary care business.  \n \n The contribution from our contract with the US government related to the kitting, distribution, and storage of \nancillary supplies for COVID -19 vaccines provided a benefit of approximately $0.31 per shar e in the quarter, \nwhich was above our original expectations.  \n \n Next, let me address our International results. ", "original_text": "Revenues were $3.1 billion, an increase of 1% driven by growth in the \nprimary care business and the contribution from kitting,  storage, and distribution of ancillary supplies for COVID -\n19 vaccines, partially offset by lower revenue from COVID -19 tests in our primary care and extended care \nbusinesses as compared to the prior year.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "74570293-485c-474e-a351-234bb8205358", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "03166168eea2cc27d19b95f8aac5a64b1f866995b26470f97bc6e49469163ed0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4d4d51eb-9d33-42f8-bf91-4bcd6f2b6643", "node_type": "1", "metadata": {"window": "We continue to experience growth \nacross our broad spectrum, higher margin capabilities and offerings in this segment.  We're pleased with the \nincreased transaction volumes related to our access and adherence solutions and the increasing number of \nbrands that joined our platforms this year.  We also experienced increased volumes in  our logistics and hub \nservices due to the continued recovery of prescription volumes.  \n \n Moving now to Medical -Surgical Solutions.  Revenues were $3.1 billion, an increase of 1% driven by growth in the \nprimary care business and the contribution from kitting,  storage, and distribution of ancillary supplies for COVID -\n19 vaccines, partially offset by lower revenue from COVID -19 tests in our primary care and extended care \nbusinesses as compared to the prior year.  \n \n Adjusted operating profit increased 18% to $330 m illion driven by the contribution from kitting, storage, and \ndistribution of ancillary supplies for the US government's COVID -19 vaccine program, the prior year impact of an \ninventory impairment charge related to PPE that incurred in the third quarter of f iscal 2021, and growth in the \nprimary care business.  \n \n The contribution from our contract with the US government related to the kitting, distribution, and storage of \nancillary supplies for COVID -19 vaccines provided a benefit of approximately $0.31 per shar e in the quarter, \nwhich was above our original expectations.  \n \n", "original_text": "Moving now to Medical -Surgical Solutions. ", "page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7bf3963dee58b48c2a2c3b761c05084aefd2e684b14b4ed37799bd60f5ac6d1c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "41773650-053c-48ba-8540-ea04d1cba70b", "node_type": "1", "metadata": {"window": "We also experienced increased volumes in  our logistics and hub \nservices due to the continued recovery of prescription volumes.  \n \n Moving now to Medical -Surgical Solutions.  Revenues were $3.1 billion, an increase of 1% driven by growth in the \nprimary care business and the contribution from kitting,  storage, and distribution of ancillary supplies for COVID -\n19 vaccines, partially offset by lower revenue from COVID -19 tests in our primary care and extended care \nbusinesses as compared to the prior year.  \n \n Adjusted operating profit increased 18% to $330 m illion driven by the contribution from kitting, storage, and \ndistribution of ancillary supplies for the US government's COVID -19 vaccine program, the prior year impact of an \ninventory impairment charge related to PPE that incurred in the third quarter of f iscal 2021, and growth in the \nprimary care business.  \n \n The contribution from our contract with the US government related to the kitting, distribution, and storage of \nancillary supplies for COVID -19 vaccines provided a benefit of approximately $0.31 per shar e in the quarter, \nwhich was above our original expectations.  \n \n Next, let me address our International results.  Revenues in the quarter were $9.5 billion, an increase of 2% driven \nby new customer growth in our Canadian business and volume increases in the pharmaceutical distribution and \nretail businesses across the segment, which were partially offset by the contribution of McKesson's German \nwholesale business to a joint venture with Walgreens Boots Alliance.  \n \n", "original_text": "Adjusted operating profit increased 18% to $330 m illion driven by the contribution from kitting, storage, and \ndistribution of ancillary supplies for the US government's COVID -19 vaccine program, the prior year impact of an \ninventory impairment charge related to PPE that incurred in the third quarter of f iscal 2021, and growth in the \nprimary care business.  \n \n"}, "hash": "e626e2744f8cfdcad4d835d6cc042b3042a1573cffba130f6f1e4976134b30d3", "class_name": "RelatedNodeInfo"}}, "text": "Revenues were $3.1 billion, an increase of 1% driven by growth in the \nprimary care business and the contribution from kitting,  storage, and distribution of ancillary supplies for COVID -\n19 vaccines, partially offset by lower revenue from COVID -19 tests in our primary care and extended care \nbusinesses as compared to the prior year.  \n \n", "start_char_idx": 723, "end_char_idx": 1065, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "41773650-053c-48ba-8540-ea04d1cba70b": {"__data__": {"id_": "41773650-053c-48ba-8540-ea04d1cba70b", "embedding": null, "metadata": {"window": "We also experienced increased volumes in  our logistics and hub \nservices due to the continued recovery of prescription volumes.  \n \n Moving now to Medical -Surgical Solutions.  Revenues were $3.1 billion, an increase of 1% driven by growth in the \nprimary care business and the contribution from kitting,  storage, and distribution of ancillary supplies for COVID -\n19 vaccines, partially offset by lower revenue from COVID -19 tests in our primary care and extended care \nbusinesses as compared to the prior year.  \n \n Adjusted operating profit increased 18% to $330 m illion driven by the contribution from kitting, storage, and \ndistribution of ancillary supplies for the US government's COVID -19 vaccine program, the prior year impact of an \ninventory impairment charge related to PPE that incurred in the third quarter of f iscal 2021, and growth in the \nprimary care business.  \n \n The contribution from our contract with the US government related to the kitting, distribution, and storage of \nancillary supplies for COVID -19 vaccines provided a benefit of approximately $0.31 per shar e in the quarter, \nwhich was above our original expectations.  \n \n Next, let me address our International results.  Revenues in the quarter were $9.5 billion, an increase of 2% driven \nby new customer growth in our Canadian business and volume increases in the pharmaceutical distribution and \nretail businesses across the segment, which were partially offset by the contribution of McKesson's German \nwholesale business to a joint venture with Walgreens Boots Alliance.  \n \n", "original_text": "Adjusted operating profit increased 18% to $330 m illion driven by the contribution from kitting, storage, and \ndistribution of ancillary supplies for the US government's COVID -19 vaccine program, the prior year impact of an \ninventory impairment charge related to PPE that incurred in the third quarter of f iscal 2021, and growth in the \nprimary care business.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "74570293-485c-474e-a351-234bb8205358", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "03166168eea2cc27d19b95f8aac5a64b1f866995b26470f97bc6e49469163ed0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d26ac9b3-2fe5-4d61-bbf8-30f72c27d6c5", "node_type": "1", "metadata": {"window": "We're pleased with the \nincreased transaction volumes related to our access and adherence solutions and the increasing number of \nbrands that joined our platforms this year.  We also experienced increased volumes in  our logistics and hub \nservices due to the continued recovery of prescription volumes.  \n \n Moving now to Medical -Surgical Solutions.  Revenues were $3.1 billion, an increase of 1% driven by growth in the \nprimary care business and the contribution from kitting,  storage, and distribution of ancillary supplies for COVID -\n19 vaccines, partially offset by lower revenue from COVID -19 tests in our primary care and extended care \nbusinesses as compared to the prior year.  \n \n Adjusted operating profit increased 18% to $330 m illion driven by the contribution from kitting, storage, and \ndistribution of ancillary supplies for the US government's COVID -19 vaccine program, the prior year impact of an \ninventory impairment charge related to PPE that incurred in the third quarter of f iscal 2021, and growth in the \nprimary care business.  \n \n The contribution from our contract with the US government related to the kitting, distribution, and storage of \nancillary supplies for COVID -19 vaccines provided a benefit of approximately $0.31 per shar e in the quarter, \nwhich was above our original expectations.  \n \n Next, let me address our International results. ", "original_text": "Revenues were $3.1 billion, an increase of 1% driven by growth in the \nprimary care business and the contribution from kitting,  storage, and distribution of ancillary supplies for COVID -\n19 vaccines, partially offset by lower revenue from COVID -19 tests in our primary care and extended care \nbusinesses as compared to the prior year.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a6b66a8a1558e09b9378b29ec3bdc0705d7671a14d79c11952238ee9a5cebb26", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a89052df-ea23-483d-ba30-b3d4cdf6d871", "node_type": "1", "metadata": {"window": "Moving now to Medical -Surgical Solutions.  Revenues were $3.1 billion, an increase of 1% driven by growth in the \nprimary care business and the contribution from kitting,  storage, and distribution of ancillary supplies for COVID -\n19 vaccines, partially offset by lower revenue from COVID -19 tests in our primary care and extended care \nbusinesses as compared to the prior year.  \n \n Adjusted operating profit increased 18% to $330 m illion driven by the contribution from kitting, storage, and \ndistribution of ancillary supplies for the US government's COVID -19 vaccine program, the prior year impact of an \ninventory impairment charge related to PPE that incurred in the third quarter of f iscal 2021, and growth in the \nprimary care business.  \n \n The contribution from our contract with the US government related to the kitting, distribution, and storage of \nancillary supplies for COVID -19 vaccines provided a benefit of approximately $0.31 per shar e in the quarter, \nwhich was above our original expectations.  \n \n Next, let me address our International results.  Revenues in the quarter were $9.5 billion, an increase of 2% driven \nby new customer growth in our Canadian business and volume increases in the pharmaceutical distribution and \nretail businesses across the segment, which were partially offset by the contribution of McKesson's German \nwholesale business to a joint venture with Walgreens Boots Alliance.  \n \n On an FX -adjusted basis, adjusted operating pro fit increased 41% to $223 million driven by the reduction as \ncompared to the prior year of depreciation and amortization on certain European assets classified as held for \nsale, the distribution of COVID -19 vaccines and tests in Europe, and strong distribut ion results in our Canadian \nbusiness.  \n \n", "original_text": "The contribution from our contract with the US government related to the kitting, distribution, and storage of \nancillary supplies for COVID -19 vaccines provided a benefit of approximately $0.31 per shar e in the quarter, \nwhich was above our original expectations.  \n \n"}, "hash": "4d51e2a63a4f78a2d03bc9091d7dfe91f3c50c95ca7477dd8be2feb8513d6d4c", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating profit increased 18% to $330 m illion driven by the contribution from kitting, storage, and \ndistribution of ancillary supplies for the US government's COVID -19 vaccine program, the prior year impact of an \ninventory impairment charge related to PPE that incurred in the third quarter of f iscal 2021, and growth in the \nprimary care business.  \n \n", "start_char_idx": 1065, "end_char_idx": 1433, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a89052df-ea23-483d-ba30-b3d4cdf6d871": {"__data__": {"id_": "a89052df-ea23-483d-ba30-b3d4cdf6d871", "embedding": null, "metadata": {"window": "Moving now to Medical -Surgical Solutions.  Revenues were $3.1 billion, an increase of 1% driven by growth in the \nprimary care business and the contribution from kitting,  storage, and distribution of ancillary supplies for COVID -\n19 vaccines, partially offset by lower revenue from COVID -19 tests in our primary care and extended care \nbusinesses as compared to the prior year.  \n \n Adjusted operating profit increased 18% to $330 m illion driven by the contribution from kitting, storage, and \ndistribution of ancillary supplies for the US government's COVID -19 vaccine program, the prior year impact of an \ninventory impairment charge related to PPE that incurred in the third quarter of f iscal 2021, and growth in the \nprimary care business.  \n \n The contribution from our contract with the US government related to the kitting, distribution, and storage of \nancillary supplies for COVID -19 vaccines provided a benefit of approximately $0.31 per shar e in the quarter, \nwhich was above our original expectations.  \n \n Next, let me address our International results.  Revenues in the quarter were $9.5 billion, an increase of 2% driven \nby new customer growth in our Canadian business and volume increases in the pharmaceutical distribution and \nretail businesses across the segment, which were partially offset by the contribution of McKesson's German \nwholesale business to a joint venture with Walgreens Boots Alliance.  \n \n On an FX -adjusted basis, adjusted operating pro fit increased 41% to $223 million driven by the reduction as \ncompared to the prior year of depreciation and amortization on certain European assets classified as held for \nsale, the distribution of COVID -19 vaccines and tests in Europe, and strong distribut ion results in our Canadian \nbusiness.  \n \n", "original_text": "The contribution from our contract with the US government related to the kitting, distribution, and storage of \nancillary supplies for COVID -19 vaccines provided a benefit of approximately $0.31 per shar e in the quarter, \nwhich was above our original expectations.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "74570293-485c-474e-a351-234bb8205358", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "03166168eea2cc27d19b95f8aac5a64b1f866995b26470f97bc6e49469163ed0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "41773650-053c-48ba-8540-ea04d1cba70b", "node_type": "1", "metadata": {"window": "We also experienced increased volumes in  our logistics and hub \nservices due to the continued recovery of prescription volumes.  \n \n Moving now to Medical -Surgical Solutions.  Revenues were $3.1 billion, an increase of 1% driven by growth in the \nprimary care business and the contribution from kitting,  storage, and distribution of ancillary supplies for COVID -\n19 vaccines, partially offset by lower revenue from COVID -19 tests in our primary care and extended care \nbusinesses as compared to the prior year.  \n \n Adjusted operating profit increased 18% to $330 m illion driven by the contribution from kitting, storage, and \ndistribution of ancillary supplies for the US government's COVID -19 vaccine program, the prior year impact of an \ninventory impairment charge related to PPE that incurred in the third quarter of f iscal 2021, and growth in the \nprimary care business.  \n \n The contribution from our contract with the US government related to the kitting, distribution, and storage of \nancillary supplies for COVID -19 vaccines provided a benefit of approximately $0.31 per shar e in the quarter, \nwhich was above our original expectations.  \n \n Next, let me address our International results.  Revenues in the quarter were $9.5 billion, an increase of 2% driven \nby new customer growth in our Canadian business and volume increases in the pharmaceutical distribution and \nretail businesses across the segment, which were partially offset by the contribution of McKesson's German \nwholesale business to a joint venture with Walgreens Boots Alliance.  \n \n", "original_text": "Adjusted operating profit increased 18% to $330 m illion driven by the contribution from kitting, storage, and \ndistribution of ancillary supplies for the US government's COVID -19 vaccine program, the prior year impact of an \ninventory impairment charge related to PPE that incurred in the third quarter of f iscal 2021, and growth in the \nprimary care business.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "070d48524c4457de28a4e70ecc3dadfa6a2403f358c8ef88c4c6010cf2aeb8b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "78e1cf97-8c86-4675-a9b4-0c361fb58867", "node_type": "1", "metadata": {"window": "Revenues were $3.1 billion, an increase of 1% driven by growth in the \nprimary care business and the contribution from kitting,  storage, and distribution of ancillary supplies for COVID -\n19 vaccines, partially offset by lower revenue from COVID -19 tests in our primary care and extended care \nbusinesses as compared to the prior year.  \n \n Adjusted operating profit increased 18% to $330 m illion driven by the contribution from kitting, storage, and \ndistribution of ancillary supplies for the US government's COVID -19 vaccine program, the prior year impact of an \ninventory impairment charge related to PPE that incurred in the third quarter of f iscal 2021, and growth in the \nprimary care business.  \n \n The contribution from our contract with the US government related to the kitting, distribution, and storage of \nancillary supplies for COVID -19 vaccines provided a benefit of approximately $0.31 per shar e in the quarter, \nwhich was above our original expectations.  \n \n Next, let me address our International results.  Revenues in the quarter were $9.5 billion, an increase of 2% driven \nby new customer growth in our Canadian business and volume increases in the pharmaceutical distribution and \nretail businesses across the segment, which were partially offset by the contribution of McKesson's German \nwholesale business to a joint venture with Walgreens Boots Alliance.  \n \n On an FX -adjusted basis, adjusted operating pro fit increased 41% to $223 million driven by the reduction as \ncompared to the prior year of depreciation and amortization on certain European assets classified as held for \nsale, the distribution of COVID -19 vaccines and tests in Europe, and strong distribut ion results in our Canadian \nbusiness.  \n \n The held for sale accounting in the International segment contributed $0.18 to adjusted earnings in the quarter.  \n \n", "original_text": "Next, let me address our International results. "}, "hash": "165034616002b6227fd3a9adc4193f51ff2d108137fdd43a1fc281f3789897bd", "class_name": "RelatedNodeInfo"}}, "text": "The contribution from our contract with the US government related to the kitting, distribution, and storage of \nancillary supplies for COVID -19 vaccines provided a benefit of approximately $0.31 per shar e in the quarter, \nwhich was above our original expectations.  \n \n", "start_char_idx": 1433, "end_char_idx": 1704, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "78e1cf97-8c86-4675-a9b4-0c361fb58867": {"__data__": {"id_": "78e1cf97-8c86-4675-a9b4-0c361fb58867", "embedding": null, "metadata": {"window": "Revenues were $3.1 billion, an increase of 1% driven by growth in the \nprimary care business and the contribution from kitting,  storage, and distribution of ancillary supplies for COVID -\n19 vaccines, partially offset by lower revenue from COVID -19 tests in our primary care and extended care \nbusinesses as compared to the prior year.  \n \n Adjusted operating profit increased 18% to $330 m illion driven by the contribution from kitting, storage, and \ndistribution of ancillary supplies for the US government's COVID -19 vaccine program, the prior year impact of an \ninventory impairment charge related to PPE that incurred in the third quarter of f iscal 2021, and growth in the \nprimary care business.  \n \n The contribution from our contract with the US government related to the kitting, distribution, and storage of \nancillary supplies for COVID -19 vaccines provided a benefit of approximately $0.31 per shar e in the quarter, \nwhich was above our original expectations.  \n \n Next, let me address our International results.  Revenues in the quarter were $9.5 billion, an increase of 2% driven \nby new customer growth in our Canadian business and volume increases in the pharmaceutical distribution and \nretail businesses across the segment, which were partially offset by the contribution of McKesson's German \nwholesale business to a joint venture with Walgreens Boots Alliance.  \n \n On an FX -adjusted basis, adjusted operating pro fit increased 41% to $223 million driven by the reduction as \ncompared to the prior year of depreciation and amortization on certain European assets classified as held for \nsale, the distribution of COVID -19 vaccines and tests in Europe, and strong distribut ion results in our Canadian \nbusiness.  \n \n The held for sale accounting in the International segment contributed $0.18 to adjusted earnings in the quarter.  \n \n", "original_text": "Next, let me address our International results. ", "page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "74570293-485c-474e-a351-234bb8205358", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "03166168eea2cc27d19b95f8aac5a64b1f866995b26470f97bc6e49469163ed0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a89052df-ea23-483d-ba30-b3d4cdf6d871", "node_type": "1", "metadata": {"window": "Moving now to Medical -Surgical Solutions.  Revenues were $3.1 billion, an increase of 1% driven by growth in the \nprimary care business and the contribution from kitting,  storage, and distribution of ancillary supplies for COVID -\n19 vaccines, partially offset by lower revenue from COVID -19 tests in our primary care and extended care \nbusinesses as compared to the prior year.  \n \n Adjusted operating profit increased 18% to $330 m illion driven by the contribution from kitting, storage, and \ndistribution of ancillary supplies for the US government's COVID -19 vaccine program, the prior year impact of an \ninventory impairment charge related to PPE that incurred in the third quarter of f iscal 2021, and growth in the \nprimary care business.  \n \n The contribution from our contract with the US government related to the kitting, distribution, and storage of \nancillary supplies for COVID -19 vaccines provided a benefit of approximately $0.31 per shar e in the quarter, \nwhich was above our original expectations.  \n \n Next, let me address our International results.  Revenues in the quarter were $9.5 billion, an increase of 2% driven \nby new customer growth in our Canadian business and volume increases in the pharmaceutical distribution and \nretail businesses across the segment, which were partially offset by the contribution of McKesson's German \nwholesale business to a joint venture with Walgreens Boots Alliance.  \n \n On an FX -adjusted basis, adjusted operating pro fit increased 41% to $223 million driven by the reduction as \ncompared to the prior year of depreciation and amortization on certain European assets classified as held for \nsale, the distribution of COVID -19 vaccines and tests in Europe, and strong distribut ion results in our Canadian \nbusiness.  \n \n", "original_text": "The contribution from our contract with the US government related to the kitting, distribution, and storage of \nancillary supplies for COVID -19 vaccines provided a benefit of approximately $0.31 per shar e in the quarter, \nwhich was above our original expectations.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "681708fe1af79653fc725f2c6a15a3bc41d8995166ea48426b4912b937e2f934", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb61c10d-953f-41ae-8dcc-b94f9483125d", "node_type": "1", "metadata": {"window": "Adjusted operating profit increased 18% to $330 m illion driven by the contribution from kitting, storage, and \ndistribution of ancillary supplies for the US government's COVID -19 vaccine program, the prior year impact of an \ninventory impairment charge related to PPE that incurred in the third quarter of f iscal 2021, and growth in the \nprimary care business.  \n \n The contribution from our contract with the US government related to the kitting, distribution, and storage of \nancillary supplies for COVID -19 vaccines provided a benefit of approximately $0.31 per shar e in the quarter, \nwhich was above our original expectations.  \n \n Next, let me address our International results.  Revenues in the quarter were $9.5 billion, an increase of 2% driven \nby new customer growth in our Canadian business and volume increases in the pharmaceutical distribution and \nretail businesses across the segment, which were partially offset by the contribution of McKesson's German \nwholesale business to a joint venture with Walgreens Boots Alliance.  \n \n On an FX -adjusted basis, adjusted operating pro fit increased 41% to $223 million driven by the reduction as \ncompared to the prior year of depreciation and amortization on certain European assets classified as held for \nsale, the distribution of COVID -19 vaccines and tests in Europe, and strong distribut ion results in our Canadian \nbusiness.  \n \n The held for sale accounting in the International segment contributed $0.18 to adjusted earnings in the quarter.  \n \n Moving on to Corporate. ", "original_text": "Revenues in the quarter were $9.5 billion, an increase of 2% driven \nby new customer growth in our Canadian business and volume increases in the pharmaceutical distribution and \nretail businesses across the segment, which were partially offset by the contribution of McKesson's German \nwholesale business to a joint venture with Walgreens Boots Alliance.  \n \n"}, "hash": "8fd02819c15d550af453324935ab279b3ead51da5fe5a084625fbc7e1fab689b", "class_name": "RelatedNodeInfo"}}, "text": "Next, let me address our International results. ", "start_char_idx": 1704, "end_char_idx": 1752, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb61c10d-953f-41ae-8dcc-b94f9483125d": {"__data__": {"id_": "eb61c10d-953f-41ae-8dcc-b94f9483125d", "embedding": null, "metadata": {"window": "Adjusted operating profit increased 18% to $330 m illion driven by the contribution from kitting, storage, and \ndistribution of ancillary supplies for the US government's COVID -19 vaccine program, the prior year impact of an \ninventory impairment charge related to PPE that incurred in the third quarter of f iscal 2021, and growth in the \nprimary care business.  \n \n The contribution from our contract with the US government related to the kitting, distribution, and storage of \nancillary supplies for COVID -19 vaccines provided a benefit of approximately $0.31 per shar e in the quarter, \nwhich was above our original expectations.  \n \n Next, let me address our International results.  Revenues in the quarter were $9.5 billion, an increase of 2% driven \nby new customer growth in our Canadian business and volume increases in the pharmaceutical distribution and \nretail businesses across the segment, which were partially offset by the contribution of McKesson's German \nwholesale business to a joint venture with Walgreens Boots Alliance.  \n \n On an FX -adjusted basis, adjusted operating pro fit increased 41% to $223 million driven by the reduction as \ncompared to the prior year of depreciation and amortization on certain European assets classified as held for \nsale, the distribution of COVID -19 vaccines and tests in Europe, and strong distribut ion results in our Canadian \nbusiness.  \n \n The held for sale accounting in the International segment contributed $0.18 to adjusted earnings in the quarter.  \n \n Moving on to Corporate. ", "original_text": "Revenues in the quarter were $9.5 billion, an increase of 2% driven \nby new customer growth in our Canadian business and volume increases in the pharmaceutical distribution and \nretail businesses across the segment, which were partially offset by the contribution of McKesson's German \nwholesale business to a joint venture with Walgreens Boots Alliance.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "74570293-485c-474e-a351-234bb8205358", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "03166168eea2cc27d19b95f8aac5a64b1f866995b26470f97bc6e49469163ed0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "78e1cf97-8c86-4675-a9b4-0c361fb58867", "node_type": "1", "metadata": {"window": "Revenues were $3.1 billion, an increase of 1% driven by growth in the \nprimary care business and the contribution from kitting,  storage, and distribution of ancillary supplies for COVID -\n19 vaccines, partially offset by lower revenue from COVID -19 tests in our primary care and extended care \nbusinesses as compared to the prior year.  \n \n Adjusted operating profit increased 18% to $330 m illion driven by the contribution from kitting, storage, and \ndistribution of ancillary supplies for the US government's COVID -19 vaccine program, the prior year impact of an \ninventory impairment charge related to PPE that incurred in the third quarter of f iscal 2021, and growth in the \nprimary care business.  \n \n The contribution from our contract with the US government related to the kitting, distribution, and storage of \nancillary supplies for COVID -19 vaccines provided a benefit of approximately $0.31 per shar e in the quarter, \nwhich was above our original expectations.  \n \n Next, let me address our International results.  Revenues in the quarter were $9.5 billion, an increase of 2% driven \nby new customer growth in our Canadian business and volume increases in the pharmaceutical distribution and \nretail businesses across the segment, which were partially offset by the contribution of McKesson's German \nwholesale business to a joint venture with Walgreens Boots Alliance.  \n \n On an FX -adjusted basis, adjusted operating pro fit increased 41% to $223 million driven by the reduction as \ncompared to the prior year of depreciation and amortization on certain European assets classified as held for \nsale, the distribution of COVID -19 vaccines and tests in Europe, and strong distribut ion results in our Canadian \nbusiness.  \n \n The held for sale accounting in the International segment contributed $0.18 to adjusted earnings in the quarter.  \n \n", "original_text": "Next, let me address our International results. ", "page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "95686f09933fb87a012415e0ed5ede19f29a9f96eda58c6d292a433cd8ba4507", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b9a7d083-bd5d-483c-b711-696130e44abc", "node_type": "1", "metadata": {"window": "The contribution from our contract with the US government related to the kitting, distribution, and storage of \nancillary supplies for COVID -19 vaccines provided a benefit of approximately $0.31 per shar e in the quarter, \nwhich was above our original expectations.  \n \n Next, let me address our International results.  Revenues in the quarter were $9.5 billion, an increase of 2% driven \nby new customer growth in our Canadian business and volume increases in the pharmaceutical distribution and \nretail businesses across the segment, which were partially offset by the contribution of McKesson's German \nwholesale business to a joint venture with Walgreens Boots Alliance.  \n \n On an FX -adjusted basis, adjusted operating pro fit increased 41% to $223 million driven by the reduction as \ncompared to the prior year of depreciation and amortization on certain European assets classified as held for \nsale, the distribution of COVID -19 vaccines and tests in Europe, and strong distribut ion results in our Canadian \nbusiness.  \n \n The held for sale accounting in the International segment contributed $0.18 to adjusted earnings in the quarter.  \n \n Moving on to Corporate.  Adjusted Corporate expenses were $159 million, an increase of 1% year -over-year. ", "original_text": "On an FX -adjusted basis, adjusted operating pro fit increased 41% to $223 million driven by the reduction as \ncompared to the prior year of depreciation and amortization on certain European assets classified as held for \nsale, the distribution of COVID -19 vaccines and tests in Europe, and strong distribut ion results in our Canadian \nbusiness.  \n \n"}, "hash": "2b0284b58ee174fdda1357bbda361f53349652a1de55385952c647de7d9aa29b", "class_name": "RelatedNodeInfo"}}, "text": "Revenues in the quarter were $9.5 billion, an increase of 2% driven \nby new customer growth in our Canadian business and volume increases in the pharmaceutical distribution and \nretail businesses across the segment, which were partially offset by the contribution of McKesson's German \nwholesale business to a joint venture with Walgreens Boots Alliance.  \n \n", "start_char_idx": 1752, "end_char_idx": 2111, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b9a7d083-bd5d-483c-b711-696130e44abc": {"__data__": {"id_": "b9a7d083-bd5d-483c-b711-696130e44abc", "embedding": null, "metadata": {"window": "The contribution from our contract with the US government related to the kitting, distribution, and storage of \nancillary supplies for COVID -19 vaccines provided a benefit of approximately $0.31 per shar e in the quarter, \nwhich was above our original expectations.  \n \n Next, let me address our International results.  Revenues in the quarter were $9.5 billion, an increase of 2% driven \nby new customer growth in our Canadian business and volume increases in the pharmaceutical distribution and \nretail businesses across the segment, which were partially offset by the contribution of McKesson's German \nwholesale business to a joint venture with Walgreens Boots Alliance.  \n \n On an FX -adjusted basis, adjusted operating pro fit increased 41% to $223 million driven by the reduction as \ncompared to the prior year of depreciation and amortization on certain European assets classified as held for \nsale, the distribution of COVID -19 vaccines and tests in Europe, and strong distribut ion results in our Canadian \nbusiness.  \n \n The held for sale accounting in the International segment contributed $0.18 to adjusted earnings in the quarter.  \n \n Moving on to Corporate.  Adjusted Corporate expenses were $159 million, an increase of 1% year -over-year. ", "original_text": "On an FX -adjusted basis, adjusted operating pro fit increased 41% to $223 million driven by the reduction as \ncompared to the prior year of depreciation and amortization on certain European assets classified as held for \nsale, the distribution of COVID -19 vaccines and tests in Europe, and strong distribut ion results in our Canadian \nbusiness.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "74570293-485c-474e-a351-234bb8205358", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "03166168eea2cc27d19b95f8aac5a64b1f866995b26470f97bc6e49469163ed0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb61c10d-953f-41ae-8dcc-b94f9483125d", "node_type": "1", "metadata": {"window": "Adjusted operating profit increased 18% to $330 m illion driven by the contribution from kitting, storage, and \ndistribution of ancillary supplies for the US government's COVID -19 vaccine program, the prior year impact of an \ninventory impairment charge related to PPE that incurred in the third quarter of f iscal 2021, and growth in the \nprimary care business.  \n \n The contribution from our contract with the US government related to the kitting, distribution, and storage of \nancillary supplies for COVID -19 vaccines provided a benefit of approximately $0.31 per shar e in the quarter, \nwhich was above our original expectations.  \n \n Next, let me address our International results.  Revenues in the quarter were $9.5 billion, an increase of 2% driven \nby new customer growth in our Canadian business and volume increases in the pharmaceutical distribution and \nretail businesses across the segment, which were partially offset by the contribution of McKesson's German \nwholesale business to a joint venture with Walgreens Boots Alliance.  \n \n On an FX -adjusted basis, adjusted operating pro fit increased 41% to $223 million driven by the reduction as \ncompared to the prior year of depreciation and amortization on certain European assets classified as held for \nsale, the distribution of COVID -19 vaccines and tests in Europe, and strong distribut ion results in our Canadian \nbusiness.  \n \n The held for sale accounting in the International segment contributed $0.18 to adjusted earnings in the quarter.  \n \n Moving on to Corporate. ", "original_text": "Revenues in the quarter were $9.5 billion, an increase of 2% driven \nby new customer growth in our Canadian business and volume increases in the pharmaceutical distribution and \nretail businesses across the segment, which were partially offset by the contribution of McKesson's German \nwholesale business to a joint venture with Walgreens Boots Alliance.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d27266874a4a084c7c3ae106fce66488700beb9f2d22e844209c06ea63b23478", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0df0067e-dbb9-46fc-bb5d-0737d74ab8be", "node_type": "1", "metadata": {"window": "Next, let me address our International results.  Revenues in the quarter were $9.5 billion, an increase of 2% driven \nby new customer growth in our Canadian business and volume increases in the pharmaceutical distribution and \nretail businesses across the segment, which were partially offset by the contribution of McKesson's German \nwholesale business to a joint venture with Walgreens Boots Alliance.  \n \n On an FX -adjusted basis, adjusted operating pro fit increased 41% to $223 million driven by the reduction as \ncompared to the prior year of depreciation and amortization on certain European assets classified as held for \nsale, the distribution of COVID -19 vaccines and tests in Europe, and strong distribut ion results in our Canadian \nbusiness.  \n \n The held for sale accounting in the International segment contributed $0.18 to adjusted earnings in the quarter.  \n \n Moving on to Corporate.  Adjusted Corporate expenses were $159 million, an increase of 1% year -over-year.  We \nincurred opioid -related litigation expenses of $33 million for the third quarter, and we anticipate that fiscal 2022 \nopioid -related litigation expenses will be approximately $135 million.  \n \n", "original_text": "The held for sale accounting in the International segment contributed $0.18 to adjusted earnings in the quarter.  \n \n"}, "hash": "fd2e7d83e321cc8959a3981a5cc04d349a53fe9d95a5b1a8a880fd3e60286b25", "class_name": "RelatedNodeInfo"}}, "text": "On an FX -adjusted basis, adjusted operating pro fit increased 41% to $223 million driven by the reduction as \ncompared to the prior year of depreciation and amortization on certain European assets classified as held for \nsale, the distribution of COVID -19 vaccines and tests in Europe, and strong distribut ion results in our Canadian \nbusiness.  \n \n", "start_char_idx": 2111, "end_char_idx": 2463, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0df0067e-dbb9-46fc-bb5d-0737d74ab8be": {"__data__": {"id_": "0df0067e-dbb9-46fc-bb5d-0737d74ab8be", "embedding": null, "metadata": {"window": "Next, let me address our International results.  Revenues in the quarter were $9.5 billion, an increase of 2% driven \nby new customer growth in our Canadian business and volume increases in the pharmaceutical distribution and \nretail businesses across the segment, which were partially offset by the contribution of McKesson's German \nwholesale business to a joint venture with Walgreens Boots Alliance.  \n \n On an FX -adjusted basis, adjusted operating pro fit increased 41% to $223 million driven by the reduction as \ncompared to the prior year of depreciation and amortization on certain European assets classified as held for \nsale, the distribution of COVID -19 vaccines and tests in Europe, and strong distribut ion results in our Canadian \nbusiness.  \n \n The held for sale accounting in the International segment contributed $0.18 to adjusted earnings in the quarter.  \n \n Moving on to Corporate.  Adjusted Corporate expenses were $159 million, an increase of 1% year -over-year.  We \nincurred opioid -related litigation expenses of $33 million for the third quarter, and we anticipate that fiscal 2022 \nopioid -related litigation expenses will be approximately $135 million.  \n \n", "original_text": "The held for sale accounting in the International segment contributed $0.18 to adjusted earnings in the quarter.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "74570293-485c-474e-a351-234bb8205358", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "03166168eea2cc27d19b95f8aac5a64b1f866995b26470f97bc6e49469163ed0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b9a7d083-bd5d-483c-b711-696130e44abc", "node_type": "1", "metadata": {"window": "The contribution from our contract with the US government related to the kitting, distribution, and storage of \nancillary supplies for COVID -19 vaccines provided a benefit of approximately $0.31 per shar e in the quarter, \nwhich was above our original expectations.  \n \n Next, let me address our International results.  Revenues in the quarter were $9.5 billion, an increase of 2% driven \nby new customer growth in our Canadian business and volume increases in the pharmaceutical distribution and \nretail businesses across the segment, which were partially offset by the contribution of McKesson's German \nwholesale business to a joint venture with Walgreens Boots Alliance.  \n \n On an FX -adjusted basis, adjusted operating pro fit increased 41% to $223 million driven by the reduction as \ncompared to the prior year of depreciation and amortization on certain European assets classified as held for \nsale, the distribution of COVID -19 vaccines and tests in Europe, and strong distribut ion results in our Canadian \nbusiness.  \n \n The held for sale accounting in the International segment contributed $0.18 to adjusted earnings in the quarter.  \n \n Moving on to Corporate.  Adjusted Corporate expenses were $159 million, an increase of 1% year -over-year. ", "original_text": "On an FX -adjusted basis, adjusted operating pro fit increased 41% to $223 million driven by the reduction as \ncompared to the prior year of depreciation and amortization on certain European assets classified as held for \nsale, the distribution of COVID -19 vaccines and tests in Europe, and strong distribut ion results in our Canadian \nbusiness.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c8804d3c33cdd57a7b066d3767bbc2e841b2c26617e2bf675f706718e5bdf919", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aa49c725-0e17-4994-838a-d4d23e211a11", "node_type": "1", "metadata": {"window": "Revenues in the quarter were $9.5 billion, an increase of 2% driven \nby new customer growth in our Canadian business and volume increases in the pharmaceutical distribution and \nretail businesses across the segment, which were partially offset by the contribution of McKesson's German \nwholesale business to a joint venture with Walgreens Boots Alliance.  \n \n On an FX -adjusted basis, adjusted operating pro fit increased 41% to $223 million driven by the reduction as \ncompared to the prior year of depreciation and amortization on certain European assets classified as held for \nsale, the distribution of COVID -19 vaccines and tests in Europe, and strong distribut ion results in our Canadian \nbusiness.  \n \n The held for sale accounting in the International segment contributed $0.18 to adjusted earnings in the quarter.  \n \n Moving on to Corporate.  Adjusted Corporate expenses were $159 million, an increase of 1% year -over-year.  We \nincurred opioid -related litigation expenses of $33 million for the third quarter, and we anticipate that fiscal 2022 \nopioid -related litigation expenses will be approximately $135 million.  \n \n Let me now turn to our cash position, which can be found on sl ide 14. ", "original_text": "Moving on to Corporate. "}, "hash": "52d27f98aea07b872af1958e24abb5a1642dac2de4a74bbcb5fe9f9b9bc1a3cd", "class_name": "RelatedNodeInfo"}}, "text": "The held for sale accounting in the International segment contributed $0.18 to adjusted earnings in the quarter.  \n \n", "start_char_idx": 2463, "end_char_idx": 2580, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aa49c725-0e17-4994-838a-d4d23e211a11": {"__data__": {"id_": "aa49c725-0e17-4994-838a-d4d23e211a11", "embedding": null, "metadata": {"window": "Revenues in the quarter were $9.5 billion, an increase of 2% driven \nby new customer growth in our Canadian business and volume increases in the pharmaceutical distribution and \nretail businesses across the segment, which were partially offset by the contribution of McKesson's German \nwholesale business to a joint venture with Walgreens Boots Alliance.  \n \n On an FX -adjusted basis, adjusted operating pro fit increased 41% to $223 million driven by the reduction as \ncompared to the prior year of depreciation and amortization on certain European assets classified as held for \nsale, the distribution of COVID -19 vaccines and tests in Europe, and strong distribut ion results in our Canadian \nbusiness.  \n \n The held for sale accounting in the International segment contributed $0.18 to adjusted earnings in the quarter.  \n \n Moving on to Corporate.  Adjusted Corporate expenses were $159 million, an increase of 1% year -over-year.  We \nincurred opioid -related litigation expenses of $33 million for the third quarter, and we anticipate that fiscal 2022 \nopioid -related litigation expenses will be approximately $135 million.  \n \n Let me now turn to our cash position, which can be found on sl ide 14. ", "original_text": "Moving on to Corporate. ", "page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "74570293-485c-474e-a351-234bb8205358", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "03166168eea2cc27d19b95f8aac5a64b1f866995b26470f97bc6e49469163ed0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0df0067e-dbb9-46fc-bb5d-0737d74ab8be", "node_type": "1", "metadata": {"window": "Next, let me address our International results.  Revenues in the quarter were $9.5 billion, an increase of 2% driven \nby new customer growth in our Canadian business and volume increases in the pharmaceutical distribution and \nretail businesses across the segment, which were partially offset by the contribution of McKesson's German \nwholesale business to a joint venture with Walgreens Boots Alliance.  \n \n On an FX -adjusted basis, adjusted operating pro fit increased 41% to $223 million driven by the reduction as \ncompared to the prior year of depreciation and amortization on certain European assets classified as held for \nsale, the distribution of COVID -19 vaccines and tests in Europe, and strong distribut ion results in our Canadian \nbusiness.  \n \n The held for sale accounting in the International segment contributed $0.18 to adjusted earnings in the quarter.  \n \n Moving on to Corporate.  Adjusted Corporate expenses were $159 million, an increase of 1% year -over-year.  We \nincurred opioid -related litigation expenses of $33 million for the third quarter, and we anticipate that fiscal 2022 \nopioid -related litigation expenses will be approximately $135 million.  \n \n", "original_text": "The held for sale accounting in the International segment contributed $0.18 to adjusted earnings in the quarter.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "097b8ccd9a678a2cfce904076f2f11bed64c63b3eed5a4880ecf7f26439e9d1e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "af2ad513-6c36-4fd3-809c-2ffcfd2009bb", "node_type": "1", "metadata": {"window": "On an FX -adjusted basis, adjusted operating pro fit increased 41% to $223 million driven by the reduction as \ncompared to the prior year of depreciation and amortization on certain European assets classified as held for \nsale, the distribution of COVID -19 vaccines and tests in Europe, and strong distribut ion results in our Canadian \nbusiness.  \n \n The held for sale accounting in the International segment contributed $0.18 to adjusted earnings in the quarter.  \n \n Moving on to Corporate.  Adjusted Corporate expenses were $159 million, an increase of 1% year -over-year.  We \nincurred opioid -related litigation expenses of $33 million for the third quarter, and we anticipate that fiscal 2022 \nopioid -related litigation expenses will be approximately $135 million.  \n \n Let me now turn to our cash position, which can be found on sl ide 14.  We ended the quarter with a cash balance \nof $2.8 billion. ", "original_text": "Adjusted Corporate expenses were $159 million, an increase of 1% year -over-year. "}, "hash": "59c1b58a7e740ddd3b4e94fbed89dd09a837ed4248eb4329047940fde650011a", "class_name": "RelatedNodeInfo"}}, "text": "Moving on to Corporate. ", "start_char_idx": 2580, "end_char_idx": 2604, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "af2ad513-6c36-4fd3-809c-2ffcfd2009bb": {"__data__": {"id_": "af2ad513-6c36-4fd3-809c-2ffcfd2009bb", "embedding": null, "metadata": {"window": "On an FX -adjusted basis, adjusted operating pro fit increased 41% to $223 million driven by the reduction as \ncompared to the prior year of depreciation and amortization on certain European assets classified as held for \nsale, the distribution of COVID -19 vaccines and tests in Europe, and strong distribut ion results in our Canadian \nbusiness.  \n \n The held for sale accounting in the International segment contributed $0.18 to adjusted earnings in the quarter.  \n \n Moving on to Corporate.  Adjusted Corporate expenses were $159 million, an increase of 1% year -over-year.  We \nincurred opioid -related litigation expenses of $33 million for the third quarter, and we anticipate that fiscal 2022 \nopioid -related litigation expenses will be approximately $135 million.  \n \n Let me now turn to our cash position, which can be found on sl ide 14.  We ended the quarter with a cash balance \nof $2.8 billion. ", "original_text": "Adjusted Corporate expenses were $159 million, an increase of 1% year -over-year. ", "page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "74570293-485c-474e-a351-234bb8205358", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "03166168eea2cc27d19b95f8aac5a64b1f866995b26470f97bc6e49469163ed0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aa49c725-0e17-4994-838a-d4d23e211a11", "node_type": "1", "metadata": {"window": "Revenues in the quarter were $9.5 billion, an increase of 2% driven \nby new customer growth in our Canadian business and volume increases in the pharmaceutical distribution and \nretail businesses across the segment, which were partially offset by the contribution of McKesson's German \nwholesale business to a joint venture with Walgreens Boots Alliance.  \n \n On an FX -adjusted basis, adjusted operating pro fit increased 41% to $223 million driven by the reduction as \ncompared to the prior year of depreciation and amortization on certain European assets classified as held for \nsale, the distribution of COVID -19 vaccines and tests in Europe, and strong distribut ion results in our Canadian \nbusiness.  \n \n The held for sale accounting in the International segment contributed $0.18 to adjusted earnings in the quarter.  \n \n Moving on to Corporate.  Adjusted Corporate expenses were $159 million, an increase of 1% year -over-year.  We \nincurred opioid -related litigation expenses of $33 million for the third quarter, and we anticipate that fiscal 2022 \nopioid -related litigation expenses will be approximately $135 million.  \n \n Let me now turn to our cash position, which can be found on sl ide 14. ", "original_text": "Moving on to Corporate. ", "page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dc47541129e58b165b3480c1c43f238e90923672d66d07a9568694d2064b1634", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "becce4a1-a11b-42f9-b338-6c07fbbfbd7f", "node_type": "1", "metadata": {"window": "The held for sale accounting in the International segment contributed $0.18 to adjusted earnings in the quarter.  \n \n Moving on to Corporate.  Adjusted Corporate expenses were $159 million, an increase of 1% year -over-year.  We \nincurred opioid -related litigation expenses of $33 million for the third quarter, and we anticipate that fiscal 2022 \nopioid -related litigation expenses will be approximately $135 million.  \n \n Let me now turn to our cash position, which can be found on sl ide 14.  We ended the quarter with a cash balance \nof $2.8 billion.  For the first nine months of the fiscal year, we generated free cash flow of $1.2 billion. ", "original_text": "We \nincurred opioid -related litigation expenses of $33 million for the third quarter, and we anticipate that fiscal 2022 \nopioid -related litigation expenses will be approximately $135 million.  \n \n"}, "hash": "6c2958f1647b6e9a6c2367988620b9abd198d0a1aef6582be49d214acc3d114b", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Corporate expenses were $159 million, an increase of 1% year -over-year. ", "start_char_idx": 2604, "end_char_idx": 2686, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "becce4a1-a11b-42f9-b338-6c07fbbfbd7f": {"__data__": {"id_": "becce4a1-a11b-42f9-b338-6c07fbbfbd7f", "embedding": null, "metadata": {"window": "The held for sale accounting in the International segment contributed $0.18 to adjusted earnings in the quarter.  \n \n Moving on to Corporate.  Adjusted Corporate expenses were $159 million, an increase of 1% year -over-year.  We \nincurred opioid -related litigation expenses of $33 million for the third quarter, and we anticipate that fiscal 2022 \nopioid -related litigation expenses will be approximately $135 million.  \n \n Let me now turn to our cash position, which can be found on sl ide 14.  We ended the quarter with a cash balance \nof $2.8 billion.  For the first nine months of the fiscal year, we generated free cash flow of $1.2 billion. ", "original_text": "We \nincurred opioid -related litigation expenses of $33 million for the third quarter, and we anticipate that fiscal 2022 \nopioid -related litigation expenses will be approximately $135 million.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "74570293-485c-474e-a351-234bb8205358", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "03166168eea2cc27d19b95f8aac5a64b1f866995b26470f97bc6e49469163ed0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "af2ad513-6c36-4fd3-809c-2ffcfd2009bb", "node_type": "1", "metadata": {"window": "On an FX -adjusted basis, adjusted operating pro fit increased 41% to $223 million driven by the reduction as \ncompared to the prior year of depreciation and amortization on certain European assets classified as held for \nsale, the distribution of COVID -19 vaccines and tests in Europe, and strong distribut ion results in our Canadian \nbusiness.  \n \n The held for sale accounting in the International segment contributed $0.18 to adjusted earnings in the quarter.  \n \n Moving on to Corporate.  Adjusted Corporate expenses were $159 million, an increase of 1% year -over-year.  We \nincurred opioid -related litigation expenses of $33 million for the third quarter, and we anticipate that fiscal 2022 \nopioid -related litigation expenses will be approximately $135 million.  \n \n Let me now turn to our cash position, which can be found on sl ide 14.  We ended the quarter with a cash balance \nof $2.8 billion. ", "original_text": "Adjusted Corporate expenses were $159 million, an increase of 1% year -over-year. ", "page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd102ce01619e3fbf2c6ebe32696ea920a63ab850320aae2e6fc21b12ee308f4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "65d30bc8-0488-4a55-bbfc-dc326721829c", "node_type": "1", "metadata": {"window": "Moving on to Corporate.  Adjusted Corporate expenses were $159 million, an increase of 1% year -over-year.  We \nincurred opioid -related litigation expenses of $33 million for the third quarter, and we anticipate that fiscal 2022 \nopioid -related litigation expenses will be approximately $135 million.  \n \n Let me now turn to our cash position, which can be found on sl ide 14.  We ended the quarter with a cash balance \nof $2.8 billion.  For the first nine months of the fiscal year, we generated free cash flow of $1.2 billion.  Year -to-\ndate, we made $380 million of capital expenditures, which included investments to support o ur strategic pillars of \noncology and biopharma services.  \n \n", "original_text": "Let me now turn to our cash position, which can be found on sl ide 14. "}, "hash": "d2bdbe5478990ea9aea33bb72057e19e3b342aa6f1b72c14db9bf316dbd40be9", "class_name": "RelatedNodeInfo"}}, "text": "We \nincurred opioid -related litigation expenses of $33 million for the third quarter, and we anticipate that fiscal 2022 \nopioid -related litigation expenses will be approximately $135 million.  \n \n", "start_char_idx": 2686, "end_char_idx": 2885, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "65d30bc8-0488-4a55-bbfc-dc326721829c": {"__data__": {"id_": "65d30bc8-0488-4a55-bbfc-dc326721829c", "embedding": null, "metadata": {"window": "Moving on to Corporate.  Adjusted Corporate expenses were $159 million, an increase of 1% year -over-year.  We \nincurred opioid -related litigation expenses of $33 million for the third quarter, and we anticipate that fiscal 2022 \nopioid -related litigation expenses will be approximately $135 million.  \n \n Let me now turn to our cash position, which can be found on sl ide 14.  We ended the quarter with a cash balance \nof $2.8 billion.  For the first nine months of the fiscal year, we generated free cash flow of $1.2 billion.  Year -to-\ndate, we made $380 million of capital expenditures, which included investments to support o ur strategic pillars of \noncology and biopharma services.  \n \n", "original_text": "Let me now turn to our cash position, which can be found on sl ide 14. ", "page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "74570293-485c-474e-a351-234bb8205358", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "03166168eea2cc27d19b95f8aac5a64b1f866995b26470f97bc6e49469163ed0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "becce4a1-a11b-42f9-b338-6c07fbbfbd7f", "node_type": "1", "metadata": {"window": "The held for sale accounting in the International segment contributed $0.18 to adjusted earnings in the quarter.  \n \n Moving on to Corporate.  Adjusted Corporate expenses were $159 million, an increase of 1% year -over-year.  We \nincurred opioid -related litigation expenses of $33 million for the third quarter, and we anticipate that fiscal 2022 \nopioid -related litigation expenses will be approximately $135 million.  \n \n Let me now turn to our cash position, which can be found on sl ide 14.  We ended the quarter with a cash balance \nof $2.8 billion.  For the first nine months of the fiscal year, we generated free cash flow of $1.2 billion. ", "original_text": "We \nincurred opioid -related litigation expenses of $33 million for the third quarter, and we anticipate that fiscal 2022 \nopioid -related litigation expenses will be approximately $135 million.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8acb97fa31307c409c9921f60b4974beafa7b7adf256a5aa99688e68a6b8a4cc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b9a3d29-ebea-41d3-a7b2-e48a3c38d4e2", "node_type": "1", "metadata": {"window": "Adjusted Corporate expenses were $159 million, an increase of 1% year -over-year.  We \nincurred opioid -related litigation expenses of $33 million for the third quarter, and we anticipate that fiscal 2022 \nopioid -related litigation expenses will be approximately $135 million.  \n \n Let me now turn to our cash position, which can be found on sl ide 14.  We ended the quarter with a cash balance \nof $2.8 billion.  For the first nine months of the fiscal year, we generated free cash flow of $1.2 billion.  Year -to-\ndate, we made $380 million of capital expenditures, which included investments to support o ur strategic pillars of \noncology and biopharma services.  \n \n For the first nine months of the fiscal year, we returned $2.2 billion of cash to our shareholders, which included $2 \nbillion of share repurchases and the payment of $206 million in dividends. ", "original_text": "We ended the quarter with a cash balance \nof $2.8 billion. "}, "hash": "3775644b718936f6039dc8f2dda5a024847196c9dee2c6a55344a93f2502c356", "class_name": "RelatedNodeInfo"}}, "text": "Let me now turn to our cash position, which can be found on sl ide 14. ", "start_char_idx": 2885, "end_char_idx": 2956, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b9a3d29-ebea-41d3-a7b2-e48a3c38d4e2": {"__data__": {"id_": "3b9a3d29-ebea-41d3-a7b2-e48a3c38d4e2", "embedding": null, "metadata": {"window": "Adjusted Corporate expenses were $159 million, an increase of 1% year -over-year.  We \nincurred opioid -related litigation expenses of $33 million for the third quarter, and we anticipate that fiscal 2022 \nopioid -related litigation expenses will be approximately $135 million.  \n \n Let me now turn to our cash position, which can be found on sl ide 14.  We ended the quarter with a cash balance \nof $2.8 billion.  For the first nine months of the fiscal year, we generated free cash flow of $1.2 billion.  Year -to-\ndate, we made $380 million of capital expenditures, which included investments to support o ur strategic pillars of \noncology and biopharma services.  \n \n For the first nine months of the fiscal year, we returned $2.2 billion of cash to our shareholders, which included $2 \nbillion of share repurchases and the payment of $206 million in dividends. ", "original_text": "We ended the quarter with a cash balance \nof $2.8 billion. ", "page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "74570293-485c-474e-a351-234bb8205358", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "03166168eea2cc27d19b95f8aac5a64b1f866995b26470f97bc6e49469163ed0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "65d30bc8-0488-4a55-bbfc-dc326721829c", "node_type": "1", "metadata": {"window": "Moving on to Corporate.  Adjusted Corporate expenses were $159 million, an increase of 1% year -over-year.  We \nincurred opioid -related litigation expenses of $33 million for the third quarter, and we anticipate that fiscal 2022 \nopioid -related litigation expenses will be approximately $135 million.  \n \n Let me now turn to our cash position, which can be found on sl ide 14.  We ended the quarter with a cash balance \nof $2.8 billion.  For the first nine months of the fiscal year, we generated free cash flow of $1.2 billion.  Year -to-\ndate, we made $380 million of capital expenditures, which included investments to support o ur strategic pillars of \noncology and biopharma services.  \n \n", "original_text": "Let me now turn to our cash position, which can be found on sl ide 14. ", "page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2d92a78af1cbb09728d229deadd244be00c63f524eee6e83bea3ff8493fd74a8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4301fea8-52d6-4a8c-8e30-1555fe4035fb", "node_type": "1", "metadata": {"window": "We \nincurred opioid -related litigation expenses of $33 million for the third quarter, and we anticipate that fiscal 2022 \nopioid -related litigation expenses will be approximately $135 million.  \n \n Let me now turn to our cash position, which can be found on sl ide 14.  We ended the quarter with a cash balance \nof $2.8 billion.  For the first nine months of the fiscal year, we generated free cash flow of $1.2 billion.  Year -to-\ndate, we made $380 million of capital expenditures, which included investments to support o ur strategic pillars of \noncology and biopharma services.  \n \n For the first nine months of the fiscal year, we returned $2.2 billion of cash to our shareholders, which included $2 \nbillion of share repurchases and the payment of $206 million in dividends.  At ou r Investor Day event in December, \nwe announced that our board of directors approved an increase of $4 billion to our existing share repurchase \nprogram. ", "original_text": "For the first nine months of the fiscal year, we generated free cash flow of $1.2 billion. "}, "hash": "ab531782d43586b950cb19f1161a293d913a2b8bb84d9162aa500410f6c75f5a", "class_name": "RelatedNodeInfo"}}, "text": "We ended the quarter with a cash balance \nof $2.8 billion. ", "start_char_idx": 2956, "end_char_idx": 3015, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4301fea8-52d6-4a8c-8e30-1555fe4035fb": {"__data__": {"id_": "4301fea8-52d6-4a8c-8e30-1555fe4035fb", "embedding": null, "metadata": {"window": "We \nincurred opioid -related litigation expenses of $33 million for the third quarter, and we anticipate that fiscal 2022 \nopioid -related litigation expenses will be approximately $135 million.  \n \n Let me now turn to our cash position, which can be found on sl ide 14.  We ended the quarter with a cash balance \nof $2.8 billion.  For the first nine months of the fiscal year, we generated free cash flow of $1.2 billion.  Year -to-\ndate, we made $380 million of capital expenditures, which included investments to support o ur strategic pillars of \noncology and biopharma services.  \n \n For the first nine months of the fiscal year, we returned $2.2 billion of cash to our shareholders, which included $2 \nbillion of share repurchases and the payment of $206 million in dividends.  At ou r Investor Day event in December, \nwe announced that our board of directors approved an increase of $4 billion to our existing share repurchase \nprogram. ", "original_text": "For the first nine months of the fiscal year, we generated free cash flow of $1.2 billion. ", "page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "74570293-485c-474e-a351-234bb8205358", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "03166168eea2cc27d19b95f8aac5a64b1f866995b26470f97bc6e49469163ed0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b9a3d29-ebea-41d3-a7b2-e48a3c38d4e2", "node_type": "1", "metadata": {"window": "Adjusted Corporate expenses were $159 million, an increase of 1% year -over-year.  We \nincurred opioid -related litigation expenses of $33 million for the third quarter, and we anticipate that fiscal 2022 \nopioid -related litigation expenses will be approximately $135 million.  \n \n Let me now turn to our cash position, which can be found on sl ide 14.  We ended the quarter with a cash balance \nof $2.8 billion.  For the first nine months of the fiscal year, we generated free cash flow of $1.2 billion.  Year -to-\ndate, we made $380 million of capital expenditures, which included investments to support o ur strategic pillars of \noncology and biopharma services.  \n \n For the first nine months of the fiscal year, we returned $2.2 billion of cash to our shareholders, which included $2 \nbillion of share repurchases and the payment of $206 million in dividends. ", "original_text": "We ended the quarter with a cash balance \nof $2.8 billion. ", "page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d85fa2e145b2440b2a07ff3df2a71b842a789781b234727f50e5a27f921c59c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "20c51fc3-5a7e-4774-bd28-21e513a90442", "node_type": "1", "metadata": {"window": "Let me now turn to our cash position, which can be found on sl ide 14.  We ended the quarter with a cash balance \nof $2.8 billion.  For the first nine months of the fiscal year, we generated free cash flow of $1.2 billion.  Year -to-\ndate, we made $380 million of capital expenditures, which included investments to support o ur strategic pillars of \noncology and biopharma services.  \n \n For the first nine months of the fiscal year, we returned $2.2 billion of cash to our shareholders, which included $2 \nbillion of share repurchases and the payment of $206 million in dividends.  At ou r Investor Day event in December, \nwe announced that our board of directors approved an increase of $4 billion to our existing share repurchase \nprogram.  At the end of our third quarter, $4.8 billion remains on our share repurchase authorization.  \n \n", "original_text": "Year -to-\ndate, we made $380 million of capital expenditures, which included investments to support o ur strategic pillars of \noncology and biopharma services.  \n \n"}, "hash": "19df8b0bb4535531185d9f140149d2253a62dd494e93570c915bd33f9ff7ff54", "class_name": "RelatedNodeInfo"}}, "text": "For the first nine months of the fiscal year, we generated free cash flow of $1.2 billion. ", "start_char_idx": 3015, "end_char_idx": 3106, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "20c51fc3-5a7e-4774-bd28-21e513a90442": {"__data__": {"id_": "20c51fc3-5a7e-4774-bd28-21e513a90442", "embedding": null, "metadata": {"window": "Let me now turn to our cash position, which can be found on sl ide 14.  We ended the quarter with a cash balance \nof $2.8 billion.  For the first nine months of the fiscal year, we generated free cash flow of $1.2 billion.  Year -to-\ndate, we made $380 million of capital expenditures, which included investments to support o ur strategic pillars of \noncology and biopharma services.  \n \n For the first nine months of the fiscal year, we returned $2.2 billion of cash to our shareholders, which included $2 \nbillion of share repurchases and the payment of $206 million in dividends.  At ou r Investor Day event in December, \nwe announced that our board of directors approved an increase of $4 billion to our existing share repurchase \nprogram.  At the end of our third quarter, $4.8 billion remains on our share repurchase authorization.  \n \n", "original_text": "Year -to-\ndate, we made $380 million of capital expenditures, which included investments to support o ur strategic pillars of \noncology and biopharma services.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "74570293-485c-474e-a351-234bb8205358", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "03166168eea2cc27d19b95f8aac5a64b1f866995b26470f97bc6e49469163ed0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4301fea8-52d6-4a8c-8e30-1555fe4035fb", "node_type": "1", "metadata": {"window": "We \nincurred opioid -related litigation expenses of $33 million for the third quarter, and we anticipate that fiscal 2022 \nopioid -related litigation expenses will be approximately $135 million.  \n \n Let me now turn to our cash position, which can be found on sl ide 14.  We ended the quarter with a cash balance \nof $2.8 billion.  For the first nine months of the fiscal year, we generated free cash flow of $1.2 billion.  Year -to-\ndate, we made $380 million of capital expenditures, which included investments to support o ur strategic pillars of \noncology and biopharma services.  \n \n For the first nine months of the fiscal year, we returned $2.2 billion of cash to our shareholders, which included $2 \nbillion of share repurchases and the payment of $206 million in dividends.  At ou r Investor Day event in December, \nwe announced that our board of directors approved an increase of $4 billion to our existing share repurchase \nprogram. ", "original_text": "For the first nine months of the fiscal year, we generated free cash flow of $1.2 billion. ", "page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8a989ee34ca54e873857604fb305953d3e2278dd8223dbd75323d7cff85d78a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bf39bee7-daac-425c-aa5f-33e4b760c63a", "node_type": "1", "metadata": {"window": "We ended the quarter with a cash balance \nof $2.8 billion.  For the first nine months of the fiscal year, we generated free cash flow of $1.2 billion.  Year -to-\ndate, we made $380 million of capital expenditures, which included investments to support o ur strategic pillars of \noncology and biopharma services.  \n \n For the first nine months of the fiscal year, we returned $2.2 billion of cash to our shareholders, which included $2 \nbillion of share repurchases and the payment of $206 million in dividends.  At ou r Investor Day event in December, \nwe announced that our board of directors approved an increase of $4 billion to our existing share repurchase \nprogram.  At the end of our third quarter, $4.8 billion remains on our share repurchase authorization.  \n \n With this increased authorization, the completed sales of the Austrian business and remaining share in the \nGerman joint venture and the anticipated fiscal fourth quarter closure of the sale of the UK business, we anticipate ", "original_text": "For the first nine months of the fiscal year, we returned $2.2 billion of cash to our shareholders, which included $2 \nbillion of share repurchases and the payment of $206 million in dividends. "}, "hash": "aa384079b5327e9c95d9da4cd38c324cd61887efc89007293ce29ee79d6d3269", "class_name": "RelatedNodeInfo"}}, "text": "Year -to-\ndate, we made $380 million of capital expenditures, which included investments to support o ur strategic pillars of \noncology and biopharma services.  \n \n", "start_char_idx": 3106, "end_char_idx": 3270, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bf39bee7-daac-425c-aa5f-33e4b760c63a": {"__data__": {"id_": "bf39bee7-daac-425c-aa5f-33e4b760c63a", "embedding": null, "metadata": {"window": "We ended the quarter with a cash balance \nof $2.8 billion.  For the first nine months of the fiscal year, we generated free cash flow of $1.2 billion.  Year -to-\ndate, we made $380 million of capital expenditures, which included investments to support o ur strategic pillars of \noncology and biopharma services.  \n \n For the first nine months of the fiscal year, we returned $2.2 billion of cash to our shareholders, which included $2 \nbillion of share repurchases and the payment of $206 million in dividends.  At ou r Investor Day event in December, \nwe announced that our board of directors approved an increase of $4 billion to our existing share repurchase \nprogram.  At the end of our third quarter, $4.8 billion remains on our share repurchase authorization.  \n \n With this increased authorization, the completed sales of the Austrian business and remaining share in the \nGerman joint venture and the anticipated fiscal fourth quarter closure of the sale of the UK business, we anticipate ", "original_text": "For the first nine months of the fiscal year, we returned $2.2 billion of cash to our shareholders, which included $2 \nbillion of share repurchases and the payment of $206 million in dividends. ", "page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "74570293-485c-474e-a351-234bb8205358", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "03166168eea2cc27d19b95f8aac5a64b1f866995b26470f97bc6e49469163ed0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "20c51fc3-5a7e-4774-bd28-21e513a90442", "node_type": "1", "metadata": {"window": "Let me now turn to our cash position, which can be found on sl ide 14.  We ended the quarter with a cash balance \nof $2.8 billion.  For the first nine months of the fiscal year, we generated free cash flow of $1.2 billion.  Year -to-\ndate, we made $380 million of capital expenditures, which included investments to support o ur strategic pillars of \noncology and biopharma services.  \n \n For the first nine months of the fiscal year, we returned $2.2 billion of cash to our shareholders, which included $2 \nbillion of share repurchases and the payment of $206 million in dividends.  At ou r Investor Day event in December, \nwe announced that our board of directors approved an increase of $4 billion to our existing share repurchase \nprogram.  At the end of our third quarter, $4.8 billion remains on our share repurchase authorization.  \n \n", "original_text": "Year -to-\ndate, we made $380 million of capital expenditures, which included investments to support o ur strategic pillars of \noncology and biopharma services.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9050b4a59d0e29625046837a2965f7b7fc7c9424e7a6f24c5af547ff7554fedc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "df548ac4-047e-4d47-8dd6-0387f3ecbdff", "node_type": "1", "metadata": {"window": "For the first nine months of the fiscal year, we generated free cash flow of $1.2 billion.  Year -to-\ndate, we made $380 million of capital expenditures, which included investments to support o ur strategic pillars of \noncology and biopharma services.  \n \n For the first nine months of the fiscal year, we returned $2.2 billion of cash to our shareholders, which included $2 \nbillion of share repurchases and the payment of $206 million in dividends.  At ou r Investor Day event in December, \nwe announced that our board of directors approved an increase of $4 billion to our existing share repurchase \nprogram.  At the end of our third quarter, $4.8 billion remains on our share repurchase authorization.  \n \n With this increased authorization, the completed sales of the Austrian business and remaining share in the \nGerman joint venture and the anticipated fiscal fourth quarter closure of the sale of the UK business, we anticipate ", "original_text": "At ou r Investor Day event in December, \nwe announced that our board of directors approved an increase of $4 billion to our existing share repurchase \nprogram. "}, "hash": "328be1ea9dba868cf0726bc8ad1fed94e696ccfeaf2b897673d5079fec223153", "class_name": "RelatedNodeInfo"}}, "text": "For the first nine months of the fiscal year, we returned $2.2 billion of cash to our shareholders, which included $2 \nbillion of share repurchases and the payment of $206 million in dividends. ", "start_char_idx": 3270, "end_char_idx": 3464, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "df548ac4-047e-4d47-8dd6-0387f3ecbdff": {"__data__": {"id_": "df548ac4-047e-4d47-8dd6-0387f3ecbdff", "embedding": null, "metadata": {"window": "For the first nine months of the fiscal year, we generated free cash flow of $1.2 billion.  Year -to-\ndate, we made $380 million of capital expenditures, which included investments to support o ur strategic pillars of \noncology and biopharma services.  \n \n For the first nine months of the fiscal year, we returned $2.2 billion of cash to our shareholders, which included $2 \nbillion of share repurchases and the payment of $206 million in dividends.  At ou r Investor Day event in December, \nwe announced that our board of directors approved an increase of $4 billion to our existing share repurchase \nprogram.  At the end of our third quarter, $4.8 billion remains on our share repurchase authorization.  \n \n With this increased authorization, the completed sales of the Austrian business and remaining share in the \nGerman joint venture and the anticipated fiscal fourth quarter closure of the sale of the UK business, we anticipate ", "original_text": "At ou r Investor Day event in December, \nwe announced that our board of directors approved an increase of $4 billion to our existing share repurchase \nprogram. ", "page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "74570293-485c-474e-a351-234bb8205358", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "03166168eea2cc27d19b95f8aac5a64b1f866995b26470f97bc6e49469163ed0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bf39bee7-daac-425c-aa5f-33e4b760c63a", "node_type": "1", "metadata": {"window": "We ended the quarter with a cash balance \nof $2.8 billion.  For the first nine months of the fiscal year, we generated free cash flow of $1.2 billion.  Year -to-\ndate, we made $380 million of capital expenditures, which included investments to support o ur strategic pillars of \noncology and biopharma services.  \n \n For the first nine months of the fiscal year, we returned $2.2 billion of cash to our shareholders, which included $2 \nbillion of share repurchases and the payment of $206 million in dividends.  At ou r Investor Day event in December, \nwe announced that our board of directors approved an increase of $4 billion to our existing share repurchase \nprogram.  At the end of our third quarter, $4.8 billion remains on our share repurchase authorization.  \n \n With this increased authorization, the completed sales of the Austrian business and remaining share in the \nGerman joint venture and the anticipated fiscal fourth quarter closure of the sale of the UK business, we anticipate ", "original_text": "For the first nine months of the fiscal year, we returned $2.2 billion of cash to our shareholders, which included $2 \nbillion of share repurchases and the payment of $206 million in dividends. ", "page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f94793bdef1687f64a4dcc86761ab20516b1f9564ce9948b1468faa6207bef0f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4223aedf-4834-4877-9c06-dd26378fe0ff", "node_type": "1", "metadata": {"window": "Year -to-\ndate, we made $380 million of capital expenditures, which included investments to support o ur strategic pillars of \noncology and biopharma services.  \n \n For the first nine months of the fiscal year, we returned $2.2 billion of cash to our shareholders, which included $2 \nbillion of share repurchases and the payment of $206 million in dividends.  At ou r Investor Day event in December, \nwe announced that our board of directors approved an increase of $4 billion to our existing share repurchase \nprogram.  At the end of our third quarter, $4.8 billion remains on our share repurchase authorization.  \n \n With this increased authorization, the completed sales of the Austrian business and remaining share in the \nGerman joint venture and the anticipated fiscal fourth quarter closure of the sale of the UK business, we anticipate ", "original_text": "At the end of our third quarter, $4.8 billion remains on our share repurchase authorization.  \n \n"}, "hash": "4b848eeee0188d45ef2818a292392713a7a7bc2abd232235cdbbd46507023c64", "class_name": "RelatedNodeInfo"}}, "text": "At ou r Investor Day event in December, \nwe announced that our board of directors approved an increase of $4 billion to our existing share repurchase \nprogram. ", "start_char_idx": 3464, "end_char_idx": 3624, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4223aedf-4834-4877-9c06-dd26378fe0ff": {"__data__": {"id_": "4223aedf-4834-4877-9c06-dd26378fe0ff", "embedding": null, "metadata": {"window": "Year -to-\ndate, we made $380 million of capital expenditures, which included investments to support o ur strategic pillars of \noncology and biopharma services.  \n \n For the first nine months of the fiscal year, we returned $2.2 billion of cash to our shareholders, which included $2 \nbillion of share repurchases and the payment of $206 million in dividends.  At ou r Investor Day event in December, \nwe announced that our board of directors approved an increase of $4 billion to our existing share repurchase \nprogram.  At the end of our third quarter, $4.8 billion remains on our share repurchase authorization.  \n \n With this increased authorization, the completed sales of the Austrian business and remaining share in the \nGerman joint venture and the anticipated fiscal fourth quarter closure of the sale of the UK business, we anticipate ", "original_text": "At the end of our third quarter, $4.8 billion remains on our share repurchase authorization.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "74570293-485c-474e-a351-234bb8205358", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "03166168eea2cc27d19b95f8aac5a64b1f866995b26470f97bc6e49469163ed0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "df548ac4-047e-4d47-8dd6-0387f3ecbdff", "node_type": "1", "metadata": {"window": "For the first nine months of the fiscal year, we generated free cash flow of $1.2 billion.  Year -to-\ndate, we made $380 million of capital expenditures, which included investments to support o ur strategic pillars of \noncology and biopharma services.  \n \n For the first nine months of the fiscal year, we returned $2.2 billion of cash to our shareholders, which included $2 \nbillion of share repurchases and the payment of $206 million in dividends.  At ou r Investor Day event in December, \nwe announced that our board of directors approved an increase of $4 billion to our existing share repurchase \nprogram.  At the end of our third quarter, $4.8 billion remains on our share repurchase authorization.  \n \n With this increased authorization, the completed sales of the Austrian business and remaining share in the \nGerman joint venture and the anticipated fiscal fourth quarter closure of the sale of the UK business, we anticipate ", "original_text": "At ou r Investor Day event in December, \nwe announced that our board of directors approved an increase of $4 billion to our existing share repurchase \nprogram. ", "page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a0a058d671e1c2552059879330561f612f0a422829db8c4a8069aa46aabfdec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1c1e8ab1-e85a-4513-8074-b58d99d29589", "node_type": "1", "metadata": {"window": "For the first nine months of the fiscal year, we returned $2.2 billion of cash to our shareholders, which included $2 \nbillion of share repurchases and the payment of $206 million in dividends.  At ou r Investor Day event in December, \nwe announced that our board of directors approved an increase of $4 billion to our existing share repurchase \nprogram.  At the end of our third quarter, $4.8 billion remains on our share repurchase authorization.  \n \n With this increased authorization, the completed sales of the Austrian business and remaining share in the \nGerman joint venture and the anticipated fiscal fourth quarter closure of the sale of the UK business, we anticipate ", "original_text": "With this increased authorization, the completed sales of the Austrian business and remaining share in the \nGerman joint venture and the anticipated fiscal fourth quarter closure of the sale of the UK business, we anticipate "}, "hash": "f2088633ff4628b9537ef704c53c6ced227f57a55f31d8f2404a350797f5a0f3", "class_name": "RelatedNodeInfo"}}, "text": "At the end of our third quarter, $4.8 billion remains on our share repurchase authorization.  \n \n", "start_char_idx": 3624, "end_char_idx": 3721, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1c1e8ab1-e85a-4513-8074-b58d99d29589": {"__data__": {"id_": "1c1e8ab1-e85a-4513-8074-b58d99d29589", "embedding": null, "metadata": {"window": "For the first nine months of the fiscal year, we returned $2.2 billion of cash to our shareholders, which included $2 \nbillion of share repurchases and the payment of $206 million in dividends.  At ou r Investor Day event in December, \nwe announced that our board of directors approved an increase of $4 billion to our existing share repurchase \nprogram.  At the end of our third quarter, $4.8 billion remains on our share repurchase authorization.  \n \n With this increased authorization, the completed sales of the Austrian business and remaining share in the \nGerman joint venture and the anticipated fiscal fourth quarter closure of the sale of the UK business, we anticipate ", "original_text": "With this increased authorization, the completed sales of the Austrian business and remaining share in the \nGerman joint venture and the anticipated fiscal fourth quarter closure of the sale of the UK business, we anticipate ", "page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "74570293-485c-474e-a351-234bb8205358", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "03166168eea2cc27d19b95f8aac5a64b1f866995b26470f97bc6e49469163ed0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4223aedf-4834-4877-9c06-dd26378fe0ff", "node_type": "1", "metadata": {"window": "Year -to-\ndate, we made $380 million of capital expenditures, which included investments to support o ur strategic pillars of \noncology and biopharma services.  \n \n For the first nine months of the fiscal year, we returned $2.2 billion of cash to our shareholders, which included $2 \nbillion of share repurchases and the payment of $206 million in dividends.  At ou r Investor Day event in December, \nwe announced that our board of directors approved an increase of $4 billion to our existing share repurchase \nprogram.  At the end of our third quarter, $4.8 billion remains on our share repurchase authorization.  \n \n With this increased authorization, the completed sales of the Austrian business and remaining share in the \nGerman joint venture and the anticipated fiscal fourth quarter closure of the sale of the UK business, we anticipate ", "original_text": "At the end of our third quarter, $4.8 billion remains on our share repurchase authorization.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "294eb998398769ec83470ea9276d4e82f53d2f3643515c03ba5ceb9c7772483e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "02f98aa0-d06e-4e74-82a8-e1b44c3cca30", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nexecuting share repurchases of up to $1.5 billion in the fourth quarter.  As a result, we now anticipate returning \napproximately $3.5 billion to shareholders through share repurchases in fiscal 2022.  \n \n Our strong operating performance, combined with our return of capital to shareholders, reinforces our \ncommitment to driving shareholder value.  \n \n", "original_text": "McKesson Corp.  "}, "hash": "df81e0f136ee44ff90a76c42fc8b70dbe02b3cd3ba66072a47fe4679aaff1df2", "class_name": "RelatedNodeInfo"}}, "text": "With this increased authorization, the completed sales of the Austrian business and remaining share in the \nGerman joint venture and the anticipated fiscal fourth quarter closure of the sale of the UK business, we anticipate ", "start_char_idx": 3721, "end_char_idx": 3946, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "02f98aa0-d06e-4e74-82a8-e1b44c3cca30": {"__data__": {"id_": "02f98aa0-d06e-4e74-82a8-e1b44c3cca30", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nexecuting share repurchases of up to $1.5 billion in the fourth quarter.  As a result, we now anticipate returning \napproximately $3.5 billion to shareholders through share repurchases in fiscal 2022.  \n \n Our strong operating performance, combined with our return of capital to shareholders, reinforces our \ncommitment to driving shareholder value.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c4835e48-c324-4b54-8fdb-9d717b314aef", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e95db66cd790d7dca47ceed93595581bc934889447139199fec3f0fe96ad0ece", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c1e8ab1-e85a-4513-8074-b58d99d29589", "node_type": "1", "metadata": {"window": "For the first nine months of the fiscal year, we returned $2.2 billion of cash to our shareholders, which included $2 \nbillion of share repurchases and the payment of $206 million in dividends.  At ou r Investor Day event in December, \nwe announced that our board of directors approved an increase of $4 billion to our existing share repurchase \nprogram.  At the end of our third quarter, $4.8 billion remains on our share repurchase authorization.  \n \n With this increased authorization, the completed sales of the Austrian business and remaining share in the \nGerman joint venture and the anticipated fiscal fourth quarter closure of the sale of the UK business, we anticipate ", "original_text": "With this increased authorization, the completed sales of the Austrian business and remaining share in the \nGerman joint venture and the anticipated fiscal fourth quarter closure of the sale of the UK business, we anticipate ", "page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "501de49dd77ca7b1907286078ec3d58b82a43ee17c26a29d9913e99770c96835", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "06eea0de-0289-43f4-823a-8eb324689b7e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nexecuting share repurchases of up to $1.5 billion in the fourth quarter.  As a result, we now anticipate returning \napproximately $3.5 billion to shareholders through share repurchases in fiscal 2022.  \n \n Our strong operating performance, combined with our return of capital to shareholders, reinforces our \ncommitment to driving shareholder value.  \n \n Let me transition and speak to our outlook for the remainder of fiscal 2022. ", "original_text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nexecuting share repurchases of up to $1.5 billion in the fourth quarter. "}, "hash": "f27853fc3802f7593359a7df772eb16eae04ae46d3579ed05434fdb0419aec5c", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "06eea0de-0289-43f4-823a-8eb324689b7e": {"__data__": {"id_": "06eea0de-0289-43f4-823a-8eb324689b7e", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nexecuting share repurchases of up to $1.5 billion in the fourth quarter.  As a result, we now anticipate returning \napproximately $3.5 billion to shareholders through share repurchases in fiscal 2022.  \n \n Our strong operating performance, combined with our return of capital to shareholders, reinforces our \ncommitment to driving shareholder value.  \n \n Let me transition and speak to our outlook for the remainder of fiscal 2022. ", "original_text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nexecuting share repurchases of up to $1.5 billion in the fourth quarter. ", "page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c4835e48-c324-4b54-8fdb-9d717b314aef", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e95db66cd790d7dca47ceed93595581bc934889447139199fec3f0fe96ad0ece", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "02f98aa0-d06e-4e74-82a8-e1b44c3cca30", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nexecuting share repurchases of up to $1.5 billion in the fourth quarter.  As a result, we now anticipate returning \napproximately $3.5 billion to shareholders through share repurchases in fiscal 2022.  \n \n Our strong operating performance, combined with our return of capital to shareholders, reinforces our \ncommitment to driving shareholder value.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3fe386134bc2cf8e8f93c87165b7519171d6dafe6a18542009f6a47748f61a2b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f6d3f8ef-ced1-420c-abb6-9162c5ee9bc0", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nexecuting share repurchases of up to $1.5 billion in the fourth quarter.  As a result, we now anticipate returning \napproximately $3.5 billion to shareholders through share repurchases in fiscal 2022.  \n \n Our strong operating performance, combined with our return of capital to shareholders, reinforces our \ncommitment to driving shareholder value.  \n \n Let me transition and speak to our outlook for the remainder of fiscal 2022.  A full list of our fiscal 2022 \nassumptions can be found in slides 16 through 18. ", "original_text": "As a result, we now anticipate returning \napproximately $3.5 billion to shareholders through share repurchases in fiscal 2022.  \n \n"}, "hash": "8c158522f3be08671ecb49c853f47333c363ec81845ae249abc46e267e4faef6", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nexecuting share repurchases of up to $1.5 billion in the fourth quarter. ", "start_char_idx": 16, "end_char_idx": 254, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f6d3f8ef-ced1-420c-abb6-9162c5ee9bc0": {"__data__": {"id_": "f6d3f8ef-ced1-420c-abb6-9162c5ee9bc0", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nexecuting share repurchases of up to $1.5 billion in the fourth quarter.  As a result, we now anticipate returning \napproximately $3.5 billion to shareholders through share repurchases in fiscal 2022.  \n \n Our strong operating performance, combined with our return of capital to shareholders, reinforces our \ncommitment to driving shareholder value.  \n \n Let me transition and speak to our outlook for the remainder of fiscal 2022.  A full list of our fiscal 2022 \nassumptions can be found in slides 16 through 18. ", "original_text": "As a result, we now anticipate returning \napproximately $3.5 billion to shareholders through share repurchases in fiscal 2022.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c4835e48-c324-4b54-8fdb-9d717b314aef", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e95db66cd790d7dca47ceed93595581bc934889447139199fec3f0fe96ad0ece", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "06eea0de-0289-43f4-823a-8eb324689b7e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nexecuting share repurchases of up to $1.5 billion in the fourth quarter.  As a result, we now anticipate returning \napproximately $3.5 billion to shareholders through share repurchases in fiscal 2022.  \n \n Our strong operating performance, combined with our return of capital to shareholders, reinforces our \ncommitment to driving shareholder value.  \n \n Let me transition and speak to our outlook for the remainder of fiscal 2022. ", "original_text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nexecuting share repurchases of up to $1.5 billion in the fourth quarter. ", "page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e0c6f2a7c3fc54e4fee6931c2fc33880e3cb686206863c148432658fd6317628", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9dc09fbc-8614-4f9b-aa8a-980443b3226a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nexecuting share repurchases of up to $1.5 billion in the fourth quarter.  As a result, we now anticipate returning \napproximately $3.5 billion to shareholders through share repurchases in fiscal 2022.  \n \n Our strong operating performance, combined with our return of capital to shareholders, reinforces our \ncommitment to driving shareholder value.  \n \n Let me transition and speak to our outlook for the remainder of fiscal 2022.  A full list of our fiscal 2022 \nassumptions can be found in slides 16 through 18.  We continue to anticipate a full recovery of prescri ption \nvolumes. ", "original_text": "Our strong operating performance, combined with our return of capital to shareholders, reinforces our \ncommitment to driving shareholder value.  \n \n"}, "hash": "498e48fcace3ae76706f625ffed95fb72b24b4f4b3c53457c40f7ed77286253a", "class_name": "RelatedNodeInfo"}}, "text": "As a result, we now anticipate returning \napproximately $3.5 billion to shareholders through share repurchases in fiscal 2022.  \n \n", "start_char_idx": 254, "end_char_idx": 385, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9dc09fbc-8614-4f9b-aa8a-980443b3226a": {"__data__": {"id_": "9dc09fbc-8614-4f9b-aa8a-980443b3226a", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nexecuting share repurchases of up to $1.5 billion in the fourth quarter.  As a result, we now anticipate returning \napproximately $3.5 billion to shareholders through share repurchases in fiscal 2022.  \n \n Our strong operating performance, combined with our return of capital to shareholders, reinforces our \ncommitment to driving shareholder value.  \n \n Let me transition and speak to our outlook for the remainder of fiscal 2022.  A full list of our fiscal 2022 \nassumptions can be found in slides 16 through 18.  We continue to anticipate a full recovery of prescri ption \nvolumes. ", "original_text": "Our strong operating performance, combined with our return of capital to shareholders, reinforces our \ncommitment to driving shareholder value.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c4835e48-c324-4b54-8fdb-9d717b314aef", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e95db66cd790d7dca47ceed93595581bc934889447139199fec3f0fe96ad0ece", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f6d3f8ef-ced1-420c-abb6-9162c5ee9bc0", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nexecuting share repurchases of up to $1.5 billion in the fourth quarter.  As a result, we now anticipate returning \napproximately $3.5 billion to shareholders through share repurchases in fiscal 2022.  \n \n Our strong operating performance, combined with our return of capital to shareholders, reinforces our \ncommitment to driving shareholder value.  \n \n Let me transition and speak to our outlook for the remainder of fiscal 2022.  A full list of our fiscal 2022 \nassumptions can be found in slides 16 through 18. ", "original_text": "As a result, we now anticipate returning \napproximately $3.5 billion to shareholders through share repurchases in fiscal 2022.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "366fec60c6073800fe2ff427588cdbd1f6d0eba8d27d69cfddc04eab8eb1591f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "66bf18aa-9177-4ddc-8ef1-ede94365999a", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nexecuting share repurchases of up to $1.5 billion in the fourth quarter.  As a result, we now anticipate returning \napproximately $3.5 billion to shareholders through share repurchases in fiscal 2022.  \n \n Our strong operating performance, combined with our return of capital to shareholders, reinforces our \ncommitment to driving shareholder value.  \n \n Let me transition and speak to our outlook for the remainder of fiscal 2022.  A full list of our fiscal 2022 \nassumptions can be found in slides 16 through 18.  We continue to anticipate a full recovery of prescri ption \nvolumes.  However, the persistence of COVID -19 and its variants, such as Omicron, is leading to a non -linear \ntrajectory.  \n \n", "original_text": "Let me transition and speak to our outlook for the remainder of fiscal 2022. "}, "hash": "b61147ca7fa54dc45c960094217e0cf9363c1825939b38476d3410ab118c2d3d", "class_name": "RelatedNodeInfo"}}, "text": "Our strong operating performance, combined with our return of capital to shareholders, reinforces our \ncommitment to driving shareholder value.  \n \n", "start_char_idx": 385, "end_char_idx": 533, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "66bf18aa-9177-4ddc-8ef1-ede94365999a": {"__data__": {"id_": "66bf18aa-9177-4ddc-8ef1-ede94365999a", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nexecuting share repurchases of up to $1.5 billion in the fourth quarter.  As a result, we now anticipate returning \napproximately $3.5 billion to shareholders through share repurchases in fiscal 2022.  \n \n Our strong operating performance, combined with our return of capital to shareholders, reinforces our \ncommitment to driving shareholder value.  \n \n Let me transition and speak to our outlook for the remainder of fiscal 2022.  A full list of our fiscal 2022 \nassumptions can be found in slides 16 through 18.  We continue to anticipate a full recovery of prescri ption \nvolumes.  However, the persistence of COVID -19 and its variants, such as Omicron, is leading to a non -linear \ntrajectory.  \n \n", "original_text": "Let me transition and speak to our outlook for the remainder of fiscal 2022. ", "page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c4835e48-c324-4b54-8fdb-9d717b314aef", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e95db66cd790d7dca47ceed93595581bc934889447139199fec3f0fe96ad0ece", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9dc09fbc-8614-4f9b-aa8a-980443b3226a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nexecuting share repurchases of up to $1.5 billion in the fourth quarter.  As a result, we now anticipate returning \napproximately $3.5 billion to shareholders through share repurchases in fiscal 2022.  \n \n Our strong operating performance, combined with our return of capital to shareholders, reinforces our \ncommitment to driving shareholder value.  \n \n Let me transition and speak to our outlook for the remainder of fiscal 2022.  A full list of our fiscal 2022 \nassumptions can be found in slides 16 through 18.  We continue to anticipate a full recovery of prescri ption \nvolumes. ", "original_text": "Our strong operating performance, combined with our return of capital to shareholders, reinforces our \ncommitment to driving shareholder value.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2ff36e695411c02dea005e33481f63a3f671db88da8033b71ebd040de699becd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e7aa8ae-6ce1-4a30-83fb-1896ea98c553", "node_type": "1", "metadata": {"window": "As a result, we now anticipate returning \napproximately $3.5 billion to shareholders through share repurchases in fiscal 2022.  \n \n Our strong operating performance, combined with our return of capital to shareholders, reinforces our \ncommitment to driving shareholder value.  \n \n Let me transition and speak to our outlook for the remainder of fiscal 2022.  A full list of our fiscal 2022 \nassumptions can be found in slides 16 through 18.  We continue to anticipate a full recovery of prescri ption \nvolumes.  However, the persistence of COVID -19 and its variants, such as Omicron, is leading to a non -linear \ntrajectory.  \n \n In the US Pharmaceutical segment, we anticipate revenue to increase 8% to 11% and adjusted operating profit to \ndeliver 8% to 10% growth over the prior year. ", "original_text": "A full list of our fiscal 2022 \nassumptions can be found in slides 16 through 18. "}, "hash": "e6f5de45206912ad26d845e71a3efc1bc7ddc3ce2e45a163f4d42b68d848cc62", "class_name": "RelatedNodeInfo"}}, "text": "Let me transition and speak to our outlook for the remainder of fiscal 2022. ", "start_char_idx": 533, "end_char_idx": 610, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e7aa8ae-6ce1-4a30-83fb-1896ea98c553": {"__data__": {"id_": "7e7aa8ae-6ce1-4a30-83fb-1896ea98c553", "embedding": null, "metadata": {"window": "As a result, we now anticipate returning \napproximately $3.5 billion to shareholders through share repurchases in fiscal 2022.  \n \n Our strong operating performance, combined with our return of capital to shareholders, reinforces our \ncommitment to driving shareholder value.  \n \n Let me transition and speak to our outlook for the remainder of fiscal 2022.  A full list of our fiscal 2022 \nassumptions can be found in slides 16 through 18.  We continue to anticipate a full recovery of prescri ption \nvolumes.  However, the persistence of COVID -19 and its variants, such as Omicron, is leading to a non -linear \ntrajectory.  \n \n In the US Pharmaceutical segment, we anticipate revenue to increase 8% to 11% and adjusted operating profit to \ndeliver 8% to 10% growth over the prior year. ", "original_text": "A full list of our fiscal 2022 \nassumptions can be found in slides 16 through 18. ", "page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c4835e48-c324-4b54-8fdb-9d717b314aef", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e95db66cd790d7dca47ceed93595581bc934889447139199fec3f0fe96ad0ece", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "66bf18aa-9177-4ddc-8ef1-ede94365999a", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nexecuting share repurchases of up to $1.5 billion in the fourth quarter.  As a result, we now anticipate returning \napproximately $3.5 billion to shareholders through share repurchases in fiscal 2022.  \n \n Our strong operating performance, combined with our return of capital to shareholders, reinforces our \ncommitment to driving shareholder value.  \n \n Let me transition and speak to our outlook for the remainder of fiscal 2022.  A full list of our fiscal 2022 \nassumptions can be found in slides 16 through 18.  We continue to anticipate a full recovery of prescri ption \nvolumes.  However, the persistence of COVID -19 and its variants, such as Omicron, is leading to a non -linear \ntrajectory.  \n \n", "original_text": "Let me transition and speak to our outlook for the remainder of fiscal 2022. ", "page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54bff54f28843602e0170d32baa8d12391c7e15edb7dfacc28a068efd4ec7c0c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f6780622-dfec-45de-aabd-30c51640a944", "node_type": "1", "metadata": {"window": "Our strong operating performance, combined with our return of capital to shareholders, reinforces our \ncommitment to driving shareholder value.  \n \n Let me transition and speak to our outlook for the remainder of fiscal 2022.  A full list of our fiscal 2022 \nassumptions can be found in slides 16 through 18.  We continue to anticipate a full recovery of prescri ption \nvolumes.  However, the persistence of COVID -19 and its variants, such as Omicron, is leading to a non -linear \ntrajectory.  \n \n In the US Pharmaceutical segment, we anticipate revenue to increase 8% to 11% and adjusted operating profit to \ndeliver 8% to 10% growth over the prior year.  We continue to see stable fundamentals in our US Pharmaceutical \nbusiness. ", "original_text": "We continue to anticipate a full recovery of prescri ption \nvolumes. "}, "hash": "58a35661a72d9427d63690a9acd476fd731f4ca720d7a8b57eae54e2be84797f", "class_name": "RelatedNodeInfo"}}, "text": "A full list of our fiscal 2022 \nassumptions can be found in slides 16 through 18. ", "start_char_idx": 610, "end_char_idx": 692, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f6780622-dfec-45de-aabd-30c51640a944": {"__data__": {"id_": "f6780622-dfec-45de-aabd-30c51640a944", "embedding": null, "metadata": {"window": "Our strong operating performance, combined with our return of capital to shareholders, reinforces our \ncommitment to driving shareholder value.  \n \n Let me transition and speak to our outlook for the remainder of fiscal 2022.  A full list of our fiscal 2022 \nassumptions can be found in slides 16 through 18.  We continue to anticipate a full recovery of prescri ption \nvolumes.  However, the persistence of COVID -19 and its variants, such as Omicron, is leading to a non -linear \ntrajectory.  \n \n In the US Pharmaceutical segment, we anticipate revenue to increase 8% to 11% and adjusted operating profit to \ndeliver 8% to 10% growth over the prior year.  We continue to see stable fundamentals in our US Pharmaceutical \nbusiness. ", "original_text": "We continue to anticipate a full recovery of prescri ption \nvolumes. ", "page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c4835e48-c324-4b54-8fdb-9d717b314aef", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e95db66cd790d7dca47ceed93595581bc934889447139199fec3f0fe96ad0ece", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e7aa8ae-6ce1-4a30-83fb-1896ea98c553", "node_type": "1", "metadata": {"window": "As a result, we now anticipate returning \napproximately $3.5 billion to shareholders through share repurchases in fiscal 2022.  \n \n Our strong operating performance, combined with our return of capital to shareholders, reinforces our \ncommitment to driving shareholder value.  \n \n Let me transition and speak to our outlook for the remainder of fiscal 2022.  A full list of our fiscal 2022 \nassumptions can be found in slides 16 through 18.  We continue to anticipate a full recovery of prescri ption \nvolumes.  However, the persistence of COVID -19 and its variants, such as Omicron, is leading to a non -linear \ntrajectory.  \n \n In the US Pharmaceutical segment, we anticipate revenue to increase 8% to 11% and adjusted operating profit to \ndeliver 8% to 10% growth over the prior year. ", "original_text": "A full list of our fiscal 2022 \nassumptions can be found in slides 16 through 18. ", "page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edf7b3634dd333560a17a301b9a1ee58ffb9c0abf1fd0f555ad0b75243d1c89c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ce6d279d-a90c-4444-9afc-e8fb7b81baed", "node_type": "1", "metadata": {"window": "Let me transition and speak to our outlook for the remainder of fiscal 2022.  A full list of our fiscal 2022 \nassumptions can be found in slides 16 through 18.  We continue to anticipate a full recovery of prescri ption \nvolumes.  However, the persistence of COVID -19 and its variants, such as Omicron, is leading to a non -linear \ntrajectory.  \n \n In the US Pharmaceutical segment, we anticipate revenue to increase 8% to 11% and adjusted operating profit to \ndeliver 8% to 10% growth over the prior year.  We continue to see stable fundamentals in our US Pharmaceutical \nbusiness.  Specifically, our outlook for branded pharmaceutical pricing of mid -single digit increases in fiscal 2022 \nremains consistent with both our original guidan ce and prior year and our view of the generics environment \nremains competitive, yet stable.  \n \n", "original_text": "However, the persistence of COVID -19 and its variants, such as Omicron, is leading to a non -linear \ntrajectory.  \n \n"}, "hash": "b0b4c4e1b473388146d821514e4312f3d5f383d2d29c1a7313905b8d7729341f", "class_name": "RelatedNodeInfo"}}, "text": "We continue to anticipate a full recovery of prescri ption \nvolumes. ", "start_char_idx": 692, "end_char_idx": 761, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ce6d279d-a90c-4444-9afc-e8fb7b81baed": {"__data__": {"id_": "ce6d279d-a90c-4444-9afc-e8fb7b81baed", "embedding": null, "metadata": {"window": "Let me transition and speak to our outlook for the remainder of fiscal 2022.  A full list of our fiscal 2022 \nassumptions can be found in slides 16 through 18.  We continue to anticipate a full recovery of prescri ption \nvolumes.  However, the persistence of COVID -19 and its variants, such as Omicron, is leading to a non -linear \ntrajectory.  \n \n In the US Pharmaceutical segment, we anticipate revenue to increase 8% to 11% and adjusted operating profit to \ndeliver 8% to 10% growth over the prior year.  We continue to see stable fundamentals in our US Pharmaceutical \nbusiness.  Specifically, our outlook for branded pharmaceutical pricing of mid -single digit increases in fiscal 2022 \nremains consistent with both our original guidan ce and prior year and our view of the generics environment \nremains competitive, yet stable.  \n \n", "original_text": "However, the persistence of COVID -19 and its variants, such as Omicron, is leading to a non -linear \ntrajectory.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c4835e48-c324-4b54-8fdb-9d717b314aef", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e95db66cd790d7dca47ceed93595581bc934889447139199fec3f0fe96ad0ece", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f6780622-dfec-45de-aabd-30c51640a944", "node_type": "1", "metadata": {"window": "Our strong operating performance, combined with our return of capital to shareholders, reinforces our \ncommitment to driving shareholder value.  \n \n Let me transition and speak to our outlook for the remainder of fiscal 2022.  A full list of our fiscal 2022 \nassumptions can be found in slides 16 through 18.  We continue to anticipate a full recovery of prescri ption \nvolumes.  However, the persistence of COVID -19 and its variants, such as Omicron, is leading to a non -linear \ntrajectory.  \n \n In the US Pharmaceutical segment, we anticipate revenue to increase 8% to 11% and adjusted operating profit to \ndeliver 8% to 10% growth over the prior year.  We continue to see stable fundamentals in our US Pharmaceutical \nbusiness. ", "original_text": "We continue to anticipate a full recovery of prescri ption \nvolumes. ", "page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "045b1265f830389e9496d2e3c5ed42a2058e8f0b6ddc245a9819dabd141f423e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6d7000d7-98d3-4070-b8c3-74fa3c56fbed", "node_type": "1", "metadata": {"window": "A full list of our fiscal 2022 \nassumptions can be found in slides 16 through 18.  We continue to anticipate a full recovery of prescri ption \nvolumes.  However, the persistence of COVID -19 and its variants, such as Omicron, is leading to a non -linear \ntrajectory.  \n \n In the US Pharmaceutical segment, we anticipate revenue to increase 8% to 11% and adjusted operating profit to \ndeliver 8% to 10% growth over the prior year.  We continue to see stable fundamentals in our US Pharmaceutical \nbusiness.  Specifically, our outlook for branded pharmaceutical pricing of mid -single digit increases in fiscal 2022 \nremains consistent with both our original guidan ce and prior year and our view of the generics environment \nremains competitive, yet stable.  \n \n Our guidance remains aligned to the volume distribution schedule provided by the CDC and US government and \nincludes the contribution related to our role as a centr alized distributor for the US government's COVID -19 \nvaccine distribution program. ", "original_text": "In the US Pharmaceutical segment, we anticipate revenue to increase 8% to 11% and adjusted operating profit to \ndeliver 8% to 10% growth over the prior year. "}, "hash": "604fd1c5985db8e7256ec60296bc5fb5d55fc0dc9e02a7a94fba1c2eb1905909", "class_name": "RelatedNodeInfo"}}, "text": "However, the persistence of COVID -19 and its variants, such as Omicron, is leading to a non -linear \ntrajectory.  \n \n", "start_char_idx": 761, "end_char_idx": 879, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6d7000d7-98d3-4070-b8c3-74fa3c56fbed": {"__data__": {"id_": "6d7000d7-98d3-4070-b8c3-74fa3c56fbed", "embedding": null, "metadata": {"window": "A full list of our fiscal 2022 \nassumptions can be found in slides 16 through 18.  We continue to anticipate a full recovery of prescri ption \nvolumes.  However, the persistence of COVID -19 and its variants, such as Omicron, is leading to a non -linear \ntrajectory.  \n \n In the US Pharmaceutical segment, we anticipate revenue to increase 8% to 11% and adjusted operating profit to \ndeliver 8% to 10% growth over the prior year.  We continue to see stable fundamentals in our US Pharmaceutical \nbusiness.  Specifically, our outlook for branded pharmaceutical pricing of mid -single digit increases in fiscal 2022 \nremains consistent with both our original guidan ce and prior year and our view of the generics environment \nremains competitive, yet stable.  \n \n Our guidance remains aligned to the volume distribution schedule provided by the CDC and US government and \nincludes the contribution related to our role as a centr alized distributor for the US government's COVID -19 \nvaccine distribution program. ", "original_text": "In the US Pharmaceutical segment, we anticipate revenue to increase 8% to 11% and adjusted operating profit to \ndeliver 8% to 10% growth over the prior year. ", "page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c4835e48-c324-4b54-8fdb-9d717b314aef", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e95db66cd790d7dca47ceed93595581bc934889447139199fec3f0fe96ad0ece", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ce6d279d-a90c-4444-9afc-e8fb7b81baed", "node_type": "1", "metadata": {"window": "Let me transition and speak to our outlook for the remainder of fiscal 2022.  A full list of our fiscal 2022 \nassumptions can be found in slides 16 through 18.  We continue to anticipate a full recovery of prescri ption \nvolumes.  However, the persistence of COVID -19 and its variants, such as Omicron, is leading to a non -linear \ntrajectory.  \n \n In the US Pharmaceutical segment, we anticipate revenue to increase 8% to 11% and adjusted operating profit to \ndeliver 8% to 10% growth over the prior year.  We continue to see stable fundamentals in our US Pharmaceutical \nbusiness.  Specifically, our outlook for branded pharmaceutical pricing of mid -single digit increases in fiscal 2022 \nremains consistent with both our original guidan ce and prior year and our view of the generics environment \nremains competitive, yet stable.  \n \n", "original_text": "However, the persistence of COVID -19 and its variants, such as Omicron, is leading to a non -linear \ntrajectory.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "09931c80815ce9379ac8da70d32e0a11741c0257c6ab32c40274223876adf04d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8be15bbc-b207-4bee-a650-4ec6c8c9e821", "node_type": "1", "metadata": {"window": "We continue to anticipate a full recovery of prescri ption \nvolumes.  However, the persistence of COVID -19 and its variants, such as Omicron, is leading to a non -linear \ntrajectory.  \n \n In the US Pharmaceutical segment, we anticipate revenue to increase 8% to 11% and adjusted operating profit to \ndeliver 8% to 10% growth over the prior year.  We continue to see stable fundamentals in our US Pharmaceutical \nbusiness.  Specifically, our outlook for branded pharmaceutical pricing of mid -single digit increases in fiscal 2022 \nremains consistent with both our original guidan ce and prior year and our view of the generics environment \nremains competitive, yet stable.  \n \n Our guidance remains aligned to the volume distribution schedule provided by the CDC and US government and \nincludes the contribution related to our role as a centr alized distributor for the US government's COVID -19 \nvaccine distribution program.  We'll continue to update you on the progress and contribution from this program.  \n \n", "original_text": "We continue to see stable fundamentals in our US Pharmaceutical \nbusiness. "}, "hash": "b6dbe5d153e2a2e1f102f5ab47bd616b277e76288a3fc16270a23f5af053dfed", "class_name": "RelatedNodeInfo"}}, "text": "In the US Pharmaceutical segment, we anticipate revenue to increase 8% to 11% and adjusted operating profit to \ndeliver 8% to 10% growth over the prior year. ", "start_char_idx": 879, "end_char_idx": 1037, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8be15bbc-b207-4bee-a650-4ec6c8c9e821": {"__data__": {"id_": "8be15bbc-b207-4bee-a650-4ec6c8c9e821", "embedding": null, "metadata": {"window": "We continue to anticipate a full recovery of prescri ption \nvolumes.  However, the persistence of COVID -19 and its variants, such as Omicron, is leading to a non -linear \ntrajectory.  \n \n In the US Pharmaceutical segment, we anticipate revenue to increase 8% to 11% and adjusted operating profit to \ndeliver 8% to 10% growth over the prior year.  We continue to see stable fundamentals in our US Pharmaceutical \nbusiness.  Specifically, our outlook for branded pharmaceutical pricing of mid -single digit increases in fiscal 2022 \nremains consistent with both our original guidan ce and prior year and our view of the generics environment \nremains competitive, yet stable.  \n \n Our guidance remains aligned to the volume distribution schedule provided by the CDC and US government and \nincludes the contribution related to our role as a centr alized distributor for the US government's COVID -19 \nvaccine distribution program.  We'll continue to update you on the progress and contribution from this program.  \n \n", "original_text": "We continue to see stable fundamentals in our US Pharmaceutical \nbusiness. ", "page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c4835e48-c324-4b54-8fdb-9d717b314aef", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e95db66cd790d7dca47ceed93595581bc934889447139199fec3f0fe96ad0ece", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6d7000d7-98d3-4070-b8c3-74fa3c56fbed", "node_type": "1", "metadata": {"window": "A full list of our fiscal 2022 \nassumptions can be found in slides 16 through 18.  We continue to anticipate a full recovery of prescri ption \nvolumes.  However, the persistence of COVID -19 and its variants, such as Omicron, is leading to a non -linear \ntrajectory.  \n \n In the US Pharmaceutical segment, we anticipate revenue to increase 8% to 11% and adjusted operating profit to \ndeliver 8% to 10% growth over the prior year.  We continue to see stable fundamentals in our US Pharmaceutical \nbusiness.  Specifically, our outlook for branded pharmaceutical pricing of mid -single digit increases in fiscal 2022 \nremains consistent with both our original guidan ce and prior year and our view of the generics environment \nremains competitive, yet stable.  \n \n Our guidance remains aligned to the volume distribution schedule provided by the CDC and US government and \nincludes the contribution related to our role as a centr alized distributor for the US government's COVID -19 \nvaccine distribution program. ", "original_text": "In the US Pharmaceutical segment, we anticipate revenue to increase 8% to 11% and adjusted operating profit to \ndeliver 8% to 10% growth over the prior year. ", "page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "eb7864cad6ba4e1bf401a9c43c5044385999888cd2be0441b9b725e0e6c8ca2a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "029eed23-ba9d-4484-9092-4718d189dfdf", "node_type": "1", "metadata": {"window": "However, the persistence of COVID -19 and its variants, such as Omicron, is leading to a non -linear \ntrajectory.  \n \n In the US Pharmaceutical segment, we anticipate revenue to increase 8% to 11% and adjusted operating profit to \ndeliver 8% to 10% growth over the prior year.  We continue to see stable fundamentals in our US Pharmaceutical \nbusiness.  Specifically, our outlook for branded pharmaceutical pricing of mid -single digit increases in fiscal 2022 \nremains consistent with both our original guidan ce and prior year and our view of the generics environment \nremains competitive, yet stable.  \n \n Our guidance remains aligned to the volume distribution schedule provided by the CDC and US government and \nincludes the contribution related to our role as a centr alized distributor for the US government's COVID -19 \nvaccine distribution program.  We'll continue to update you on the progress and contribution from this program.  \n \n When excluding COVID -19 vaccine distribution in this segment, we anticipate approximately 3%  to 6% adjusted \noperating profit growth. ", "original_text": "Specifically, our outlook for branded pharmaceutical pricing of mid -single digit increases in fiscal 2022 \nremains consistent with both our original guidan ce and prior year and our view of the generics environment \nremains competitive, yet stable.  \n \n"}, "hash": "c47df9821f4042add1b8f7c9993c4e8f03c13978324d93772c24bbf5c4b64564", "class_name": "RelatedNodeInfo"}}, "text": "We continue to see stable fundamentals in our US Pharmaceutical \nbusiness. ", "start_char_idx": 1037, "end_char_idx": 1112, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "029eed23-ba9d-4484-9092-4718d189dfdf": {"__data__": {"id_": "029eed23-ba9d-4484-9092-4718d189dfdf", "embedding": null, "metadata": {"window": "However, the persistence of COVID -19 and its variants, such as Omicron, is leading to a non -linear \ntrajectory.  \n \n In the US Pharmaceutical segment, we anticipate revenue to increase 8% to 11% and adjusted operating profit to \ndeliver 8% to 10% growth over the prior year.  We continue to see stable fundamentals in our US Pharmaceutical \nbusiness.  Specifically, our outlook for branded pharmaceutical pricing of mid -single digit increases in fiscal 2022 \nremains consistent with both our original guidan ce and prior year and our view of the generics environment \nremains competitive, yet stable.  \n \n Our guidance remains aligned to the volume distribution schedule provided by the CDC and US government and \nincludes the contribution related to our role as a centr alized distributor for the US government's COVID -19 \nvaccine distribution program.  We'll continue to update you on the progress and contribution from this program.  \n \n When excluding COVID -19 vaccine distribution in this segment, we anticipate approximately 3%  to 6% adjusted \noperating profit growth. ", "original_text": "Specifically, our outlook for branded pharmaceutical pricing of mid -single digit increases in fiscal 2022 \nremains consistent with both our original guidan ce and prior year and our view of the generics environment \nremains competitive, yet stable.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c4835e48-c324-4b54-8fdb-9d717b314aef", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e95db66cd790d7dca47ceed93595581bc934889447139199fec3f0fe96ad0ece", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8be15bbc-b207-4bee-a650-4ec6c8c9e821", "node_type": "1", "metadata": {"window": "We continue to anticipate a full recovery of prescri ption \nvolumes.  However, the persistence of COVID -19 and its variants, such as Omicron, is leading to a non -linear \ntrajectory.  \n \n In the US Pharmaceutical segment, we anticipate revenue to increase 8% to 11% and adjusted operating profit to \ndeliver 8% to 10% growth over the prior year.  We continue to see stable fundamentals in our US Pharmaceutical \nbusiness.  Specifically, our outlook for branded pharmaceutical pricing of mid -single digit increases in fiscal 2022 \nremains consistent with both our original guidan ce and prior year and our view of the generics environment \nremains competitive, yet stable.  \n \n Our guidance remains aligned to the volume distribution schedule provided by the CDC and US government and \nincludes the contribution related to our role as a centr alized distributor for the US government's COVID -19 \nvaccine distribution program.  We'll continue to update you on the progress and contribution from this program.  \n \n", "original_text": "We continue to see stable fundamentals in our US Pharmaceutical \nbusiness. ", "page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9f50e883be7e9d48c32dae3ec4d9ec9596ecaba0559d9ae477929f248da4744e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c4eb5308-8c4d-448a-8150-9b38265af213", "node_type": "1", "metadata": {"window": "In the US Pharmaceutical segment, we anticipate revenue to increase 8% to 11% and adjusted operating profit to \ndeliver 8% to 10% growth over the prior year.  We continue to see stable fundamentals in our US Pharmaceutical \nbusiness.  Specifically, our outlook for branded pharmaceutical pricing of mid -single digit increases in fiscal 2022 \nremains consistent with both our original guidan ce and prior year and our view of the generics environment \nremains competitive, yet stable.  \n \n Our guidance remains aligned to the volume distribution schedule provided by the CDC and US government and \nincludes the contribution related to our role as a centr alized distributor for the US government's COVID -19 \nvaccine distribution program.  We'll continue to update you on the progress and contribution from this program.  \n \n When excluding COVID -19 vaccine distribution in this segment, we anticipate approximately 3%  to 6% adjusted \noperating profit growth.  And as a reminder, our investments in our leading and differentiated position in oncology \nwill continue to represent an approximate $0.20 headwind in fiscal 2022.  \n \n", "original_text": "Our guidance remains aligned to the volume distribution schedule provided by the CDC and US government and \nincludes the contribution related to our role as a centr alized distributor for the US government's COVID -19 \nvaccine distribution program. "}, "hash": "eea1d788b7c0611a410cb0a628b9153457e1b2598c71cfc019b83ebe4ed7e9fc", "class_name": "RelatedNodeInfo"}}, "text": "Specifically, our outlook for branded pharmaceutical pricing of mid -single digit increases in fiscal 2022 \nremains consistent with both our original guidan ce and prior year and our view of the generics environment \nremains competitive, yet stable.  \n \n", "start_char_idx": 1112, "end_char_idx": 1366, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c4eb5308-8c4d-448a-8150-9b38265af213": {"__data__": {"id_": "c4eb5308-8c4d-448a-8150-9b38265af213", "embedding": null, "metadata": {"window": "In the US Pharmaceutical segment, we anticipate revenue to increase 8% to 11% and adjusted operating profit to \ndeliver 8% to 10% growth over the prior year.  We continue to see stable fundamentals in our US Pharmaceutical \nbusiness.  Specifically, our outlook for branded pharmaceutical pricing of mid -single digit increases in fiscal 2022 \nremains consistent with both our original guidan ce and prior year and our view of the generics environment \nremains competitive, yet stable.  \n \n Our guidance remains aligned to the volume distribution schedule provided by the CDC and US government and \nincludes the contribution related to our role as a centr alized distributor for the US government's COVID -19 \nvaccine distribution program.  We'll continue to update you on the progress and contribution from this program.  \n \n When excluding COVID -19 vaccine distribution in this segment, we anticipate approximately 3%  to 6% adjusted \noperating profit growth.  And as a reminder, our investments in our leading and differentiated position in oncology \nwill continue to represent an approximate $0.20 headwind in fiscal 2022.  \n \n", "original_text": "Our guidance remains aligned to the volume distribution schedule provided by the CDC and US government and \nincludes the contribution related to our role as a centr alized distributor for the US government's COVID -19 \nvaccine distribution program. ", "page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c4835e48-c324-4b54-8fdb-9d717b314aef", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e95db66cd790d7dca47ceed93595581bc934889447139199fec3f0fe96ad0ece", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "029eed23-ba9d-4484-9092-4718d189dfdf", "node_type": "1", "metadata": {"window": "However, the persistence of COVID -19 and its variants, such as Omicron, is leading to a non -linear \ntrajectory.  \n \n In the US Pharmaceutical segment, we anticipate revenue to increase 8% to 11% and adjusted operating profit to \ndeliver 8% to 10% growth over the prior year.  We continue to see stable fundamentals in our US Pharmaceutical \nbusiness.  Specifically, our outlook for branded pharmaceutical pricing of mid -single digit increases in fiscal 2022 \nremains consistent with both our original guidan ce and prior year and our view of the generics environment \nremains competitive, yet stable.  \n \n Our guidance remains aligned to the volume distribution schedule provided by the CDC and US government and \nincludes the contribution related to our role as a centr alized distributor for the US government's COVID -19 \nvaccine distribution program.  We'll continue to update you on the progress and contribution from this program.  \n \n When excluding COVID -19 vaccine distribution in this segment, we anticipate approximately 3%  to 6% adjusted \noperating profit growth. ", "original_text": "Specifically, our outlook for branded pharmaceutical pricing of mid -single digit increases in fiscal 2022 \nremains consistent with both our original guidan ce and prior year and our view of the generics environment \nremains competitive, yet stable.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e95ad98bf1b2d12b7fac759b2fcd6d1d07736079e199598c0a15255b1a868123", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7c863a50-9b4e-44bc-89e9-748ba9f01886", "node_type": "1", "metadata": {"window": "We continue to see stable fundamentals in our US Pharmaceutical \nbusiness.  Specifically, our outlook for branded pharmaceutical pricing of mid -single digit increases in fiscal 2022 \nremains consistent with both our original guidan ce and prior year and our view of the generics environment \nremains competitive, yet stable.  \n \n Our guidance remains aligned to the volume distribution schedule provided by the CDC and US government and \nincludes the contribution related to our role as a centr alized distributor for the US government's COVID -19 \nvaccine distribution program.  We'll continue to update you on the progress and contribution from this program.  \n \n When excluding COVID -19 vaccine distribution in this segment, we anticipate approximately 3%  to 6% adjusted \noperating profit growth.  And as a reminder, our investments in our leading and differentiated position in oncology \nwill continue to represent an approximate $0.20 headwind in fiscal 2022.  \n \n In our Prescription Technology Solutions segment, w e anticipate revenue growth of 32% to 36% and adjusted \noperating profit growth of 24% to 28%. ", "original_text": "We'll continue to update you on the progress and contribution from this program.  \n \n"}, "hash": "3d3417d1546bef3452a5a4a30e32ba93fe709d2c2bff701b05e5c8f3121ce9ff", "class_name": "RelatedNodeInfo"}}, "text": "Our guidance remains aligned to the volume distribution schedule provided by the CDC and US government and \nincludes the contribution related to our role as a centr alized distributor for the US government's COVID -19 \nvaccine distribution program. ", "start_char_idx": 1366, "end_char_idx": 1615, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7c863a50-9b4e-44bc-89e9-748ba9f01886": {"__data__": {"id_": "7c863a50-9b4e-44bc-89e9-748ba9f01886", "embedding": null, "metadata": {"window": "We continue to see stable fundamentals in our US Pharmaceutical \nbusiness.  Specifically, our outlook for branded pharmaceutical pricing of mid -single digit increases in fiscal 2022 \nremains consistent with both our original guidan ce and prior year and our view of the generics environment \nremains competitive, yet stable.  \n \n Our guidance remains aligned to the volume distribution schedule provided by the CDC and US government and \nincludes the contribution related to our role as a centr alized distributor for the US government's COVID -19 \nvaccine distribution program.  We'll continue to update you on the progress and contribution from this program.  \n \n When excluding COVID -19 vaccine distribution in this segment, we anticipate approximately 3%  to 6% adjusted \noperating profit growth.  And as a reminder, our investments in our leading and differentiated position in oncology \nwill continue to represent an approximate $0.20 headwind in fiscal 2022.  \n \n In our Prescription Technology Solutions segment, w e anticipate revenue growth of 32% to 36% and adjusted \noperating profit growth of 24% to 28%. ", "original_text": "We'll continue to update you on the progress and contribution from this program.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c4835e48-c324-4b54-8fdb-9d717b314aef", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e95db66cd790d7dca47ceed93595581bc934889447139199fec3f0fe96ad0ece", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c4eb5308-8c4d-448a-8150-9b38265af213", "node_type": "1", "metadata": {"window": "In the US Pharmaceutical segment, we anticipate revenue to increase 8% to 11% and adjusted operating profit to \ndeliver 8% to 10% growth over the prior year.  We continue to see stable fundamentals in our US Pharmaceutical \nbusiness.  Specifically, our outlook for branded pharmaceutical pricing of mid -single digit increases in fiscal 2022 \nremains consistent with both our original guidan ce and prior year and our view of the generics environment \nremains competitive, yet stable.  \n \n Our guidance remains aligned to the volume distribution schedule provided by the CDC and US government and \nincludes the contribution related to our role as a centr alized distributor for the US government's COVID -19 \nvaccine distribution program.  We'll continue to update you on the progress and contribution from this program.  \n \n When excluding COVID -19 vaccine distribution in this segment, we anticipate approximately 3%  to 6% adjusted \noperating profit growth.  And as a reminder, our investments in our leading and differentiated position in oncology \nwill continue to represent an approximate $0.20 headwind in fiscal 2022.  \n \n", "original_text": "Our guidance remains aligned to the volume distribution schedule provided by the CDC and US government and \nincludes the contribution related to our role as a centr alized distributor for the US government's COVID -19 \nvaccine distribution program. ", "page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d7edd448eae64023b9d8d08ea22c84736167b032f346ac3651ab942096ebf89f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1413d02a-5d15-4ec6-b9cf-15d2be1b3b5d", "node_type": "1", "metadata": {"window": "Specifically, our outlook for branded pharmaceutical pricing of mid -single digit increases in fiscal 2022 \nremains consistent with both our original guidan ce and prior year and our view of the generics environment \nremains competitive, yet stable.  \n \n Our guidance remains aligned to the volume distribution schedule provided by the CDC and US government and \nincludes the contribution related to our role as a centr alized distributor for the US government's COVID -19 \nvaccine distribution program.  We'll continue to update you on the progress and contribution from this program.  \n \n When excluding COVID -19 vaccine distribution in this segment, we anticipate approximately 3%  to 6% adjusted \noperating profit growth.  And as a reminder, our investments in our leading and differentiated position in oncology \nwill continue to represent an approximate $0.20 headwind in fiscal 2022.  \n \n In our Prescription Technology Solutions segment, w e anticipate revenue growth of 32% to 36% and adjusted \noperating profit growth of 24% to 28%.  This growth reflects the strong momentum in the business as we project \nincreased volumes across new and existing biopharma solutions and customers.  \n \n", "original_text": "When excluding COVID -19 vaccine distribution in this segment, we anticipate approximately 3%  to 6% adjusted \noperating profit growth. "}, "hash": "854fdddfc121d621a69fc601ac20c41a81895624d0181a228628c1f2d583b86a", "class_name": "RelatedNodeInfo"}}, "text": "We'll continue to update you on the progress and contribution from this program.  \n \n", "start_char_idx": 1615, "end_char_idx": 1700, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1413d02a-5d15-4ec6-b9cf-15d2be1b3b5d": {"__data__": {"id_": "1413d02a-5d15-4ec6-b9cf-15d2be1b3b5d", "embedding": null, "metadata": {"window": "Specifically, our outlook for branded pharmaceutical pricing of mid -single digit increases in fiscal 2022 \nremains consistent with both our original guidan ce and prior year and our view of the generics environment \nremains competitive, yet stable.  \n \n Our guidance remains aligned to the volume distribution schedule provided by the CDC and US government and \nincludes the contribution related to our role as a centr alized distributor for the US government's COVID -19 \nvaccine distribution program.  We'll continue to update you on the progress and contribution from this program.  \n \n When excluding COVID -19 vaccine distribution in this segment, we anticipate approximately 3%  to 6% adjusted \noperating profit growth.  And as a reminder, our investments in our leading and differentiated position in oncology \nwill continue to represent an approximate $0.20 headwind in fiscal 2022.  \n \n In our Prescription Technology Solutions segment, w e anticipate revenue growth of 32% to 36% and adjusted \noperating profit growth of 24% to 28%.  This growth reflects the strong momentum in the business as we project \nincreased volumes across new and existing biopharma solutions and customers.  \n \n", "original_text": "When excluding COVID -19 vaccine distribution in this segment, we anticipate approximately 3%  to 6% adjusted \noperating profit growth. ", "page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c4835e48-c324-4b54-8fdb-9d717b314aef", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e95db66cd790d7dca47ceed93595581bc934889447139199fec3f0fe96ad0ece", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7c863a50-9b4e-44bc-89e9-748ba9f01886", "node_type": "1", "metadata": {"window": "We continue to see stable fundamentals in our US Pharmaceutical \nbusiness.  Specifically, our outlook for branded pharmaceutical pricing of mid -single digit increases in fiscal 2022 \nremains consistent with both our original guidan ce and prior year and our view of the generics environment \nremains competitive, yet stable.  \n \n Our guidance remains aligned to the volume distribution schedule provided by the CDC and US government and \nincludes the contribution related to our role as a centr alized distributor for the US government's COVID -19 \nvaccine distribution program.  We'll continue to update you on the progress and contribution from this program.  \n \n When excluding COVID -19 vaccine distribution in this segment, we anticipate approximately 3%  to 6% adjusted \noperating profit growth.  And as a reminder, our investments in our leading and differentiated position in oncology \nwill continue to represent an approximate $0.20 headwind in fiscal 2022.  \n \n In our Prescription Technology Solutions segment, w e anticipate revenue growth of 32% to 36% and adjusted \noperating profit growth of 24% to 28%. ", "original_text": "We'll continue to update you on the progress and contribution from this program.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dfb308f9928b5aae6f51932e030f03783c93dcfe79df60a1c51d1e1b0116d4b4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d822f27e-ddb6-48b4-943d-f047d6519b19", "node_type": "1", "metadata": {"window": "Our guidance remains aligned to the volume distribution schedule provided by the CDC and US government and \nincludes the contribution related to our role as a centr alized distributor for the US government's COVID -19 \nvaccine distribution program.  We'll continue to update you on the progress and contribution from this program.  \n \n When excluding COVID -19 vaccine distribution in this segment, we anticipate approximately 3%  to 6% adjusted \noperating profit growth.  And as a reminder, our investments in our leading and differentiated position in oncology \nwill continue to represent an approximate $0.20 headwind in fiscal 2022.  \n \n In our Prescription Technology Solutions segment, w e anticipate revenue growth of 32% to 36% and adjusted \noperating profit growth of 24% to 28%.  This growth reflects the strong momentum in the business as we project \nincreased volumes across new and existing biopharma solutions and customers.  \n \n Transitioning  to Medical -Surgical, our outlook assumes 15% to 19% revenue growth and adjusted operating profit \ngrowth of 51% to 55% over the prior year. ", "original_text": "And as a reminder, our investments in our leading and differentiated position in oncology \nwill continue to represent an approximate $0.20 headwind in fiscal 2022.  \n \n"}, "hash": "0ecbfe9a8b6585b04125e976c3ac7eaf1b22233e5967241e3d1b443bedfb64ad", "class_name": "RelatedNodeInfo"}}, "text": "When excluding COVID -19 vaccine distribution in this segment, we anticipate approximately 3%  to 6% adjusted \noperating profit growth. ", "start_char_idx": 1700, "end_char_idx": 1836, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d822f27e-ddb6-48b4-943d-f047d6519b19": {"__data__": {"id_": "d822f27e-ddb6-48b4-943d-f047d6519b19", "embedding": null, "metadata": {"window": "Our guidance remains aligned to the volume distribution schedule provided by the CDC and US government and \nincludes the contribution related to our role as a centr alized distributor for the US government's COVID -19 \nvaccine distribution program.  We'll continue to update you on the progress and contribution from this program.  \n \n When excluding COVID -19 vaccine distribution in this segment, we anticipate approximately 3%  to 6% adjusted \noperating profit growth.  And as a reminder, our investments in our leading and differentiated position in oncology \nwill continue to represent an approximate $0.20 headwind in fiscal 2022.  \n \n In our Prescription Technology Solutions segment, w e anticipate revenue growth of 32% to 36% and adjusted \noperating profit growth of 24% to 28%.  This growth reflects the strong momentum in the business as we project \nincreased volumes across new and existing biopharma solutions and customers.  \n \n Transitioning  to Medical -Surgical, our outlook assumes 15% to 19% revenue growth and adjusted operating profit \ngrowth of 51% to 55% over the prior year. ", "original_text": "And as a reminder, our investments in our leading and differentiated position in oncology \nwill continue to represent an approximate $0.20 headwind in fiscal 2022.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c4835e48-c324-4b54-8fdb-9d717b314aef", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e95db66cd790d7dca47ceed93595581bc934889447139199fec3f0fe96ad0ece", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1413d02a-5d15-4ec6-b9cf-15d2be1b3b5d", "node_type": "1", "metadata": {"window": "Specifically, our outlook for branded pharmaceutical pricing of mid -single digit increases in fiscal 2022 \nremains consistent with both our original guidan ce and prior year and our view of the generics environment \nremains competitive, yet stable.  \n \n Our guidance remains aligned to the volume distribution schedule provided by the CDC and US government and \nincludes the contribution related to our role as a centr alized distributor for the US government's COVID -19 \nvaccine distribution program.  We'll continue to update you on the progress and contribution from this program.  \n \n When excluding COVID -19 vaccine distribution in this segment, we anticipate approximately 3%  to 6% adjusted \noperating profit growth.  And as a reminder, our investments in our leading and differentiated position in oncology \nwill continue to represent an approximate $0.20 headwind in fiscal 2022.  \n \n In our Prescription Technology Solutions segment, w e anticipate revenue growth of 32% to 36% and adjusted \noperating profit growth of 24% to 28%.  This growth reflects the strong momentum in the business as we project \nincreased volumes across new and existing biopharma solutions and customers.  \n \n", "original_text": "When excluding COVID -19 vaccine distribution in this segment, we anticipate approximately 3%  to 6% adjusted \noperating profit growth. ", "page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "76f6439953478b7ad88362e77c7c456f1a6aed23f7da8b18698645e24a9a956d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5c0051ac-b040-4fba-af49-86205690aff6", "node_type": "1", "metadata": {"window": "We'll continue to update you on the progress and contribution from this program.  \n \n When excluding COVID -19 vaccine distribution in this segment, we anticipate approximately 3%  to 6% adjusted \noperating profit growth.  And as a reminder, our investments in our leading and differentiated position in oncology \nwill continue to represent an approximate $0.20 headwind in fiscal 2022.  \n \n In our Prescription Technology Solutions segment, w e anticipate revenue growth of 32% to 36% and adjusted \noperating profit growth of 24% to 28%.  This growth reflects the strong momentum in the business as we project \nincreased volumes across new and existing biopharma solutions and customers.  \n \n Transitioning  to Medical -Surgical, our outlook assumes 15% to 19% revenue growth and adjusted operating profit \ngrowth of 51% to 55% over the prior year.  Our outlook includes $0.85 to $1.05 related to the contribution from the \nUS government's distribution of ancillary s upply kits and storage programs and $0.75 to $0.95 related to the net \nimpact of COVID -19 tests and PPE impairments and related products. ", "original_text": "In our Prescription Technology Solutions segment, w e anticipate revenue growth of 32% to 36% and adjusted \noperating profit growth of 24% to 28%. "}, "hash": "31f641d32bab45e0f13e38d695b18334c54de1e03024d3f7835f55987a9ef614", "class_name": "RelatedNodeInfo"}}, "text": "And as a reminder, our investments in our leading and differentiated position in oncology \nwill continue to represent an approximate $0.20 headwind in fiscal 2022.  \n \n", "start_char_idx": 1836, "end_char_idx": 2004, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5c0051ac-b040-4fba-af49-86205690aff6": {"__data__": {"id_": "5c0051ac-b040-4fba-af49-86205690aff6", "embedding": null, "metadata": {"window": "We'll continue to update you on the progress and contribution from this program.  \n \n When excluding COVID -19 vaccine distribution in this segment, we anticipate approximately 3%  to 6% adjusted \noperating profit growth.  And as a reminder, our investments in our leading and differentiated position in oncology \nwill continue to represent an approximate $0.20 headwind in fiscal 2022.  \n \n In our Prescription Technology Solutions segment, w e anticipate revenue growth of 32% to 36% and adjusted \noperating profit growth of 24% to 28%.  This growth reflects the strong momentum in the business as we project \nincreased volumes across new and existing biopharma solutions and customers.  \n \n Transitioning  to Medical -Surgical, our outlook assumes 15% to 19% revenue growth and adjusted operating profit \ngrowth of 51% to 55% over the prior year.  Our outlook includes $0.85 to $1.05 related to the contribution from the \nUS government's distribution of ancillary s upply kits and storage programs and $0.75 to $0.95 related to the net \nimpact of COVID -19 tests and PPE impairments and related products. ", "original_text": "In our Prescription Technology Solutions segment, w e anticipate revenue growth of 32% to 36% and adjusted \noperating profit growth of 24% to 28%. ", "page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c4835e48-c324-4b54-8fdb-9d717b314aef", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e95db66cd790d7dca47ceed93595581bc934889447139199fec3f0fe96ad0ece", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d822f27e-ddb6-48b4-943d-f047d6519b19", "node_type": "1", "metadata": {"window": "Our guidance remains aligned to the volume distribution schedule provided by the CDC and US government and \nincludes the contribution related to our role as a centr alized distributor for the US government's COVID -19 \nvaccine distribution program.  We'll continue to update you on the progress and contribution from this program.  \n \n When excluding COVID -19 vaccine distribution in this segment, we anticipate approximately 3%  to 6% adjusted \noperating profit growth.  And as a reminder, our investments in our leading and differentiated position in oncology \nwill continue to represent an approximate $0.20 headwind in fiscal 2022.  \n \n In our Prescription Technology Solutions segment, w e anticipate revenue growth of 32% to 36% and adjusted \noperating profit growth of 24% to 28%.  This growth reflects the strong momentum in the business as we project \nincreased volumes across new and existing biopharma solutions and customers.  \n \n Transitioning  to Medical -Surgical, our outlook assumes 15% to 19% revenue growth and adjusted operating profit \ngrowth of 51% to 55% over the prior year. ", "original_text": "And as a reminder, our investments in our leading and differentiated position in oncology \nwill continue to represent an approximate $0.20 headwind in fiscal 2022.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6edb99763f2aefd37ba88f9ec3235dc8b2adf86cda6cb7d5f0f3c5785ed0a10a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "25ae07d1-0b28-4364-ad78-0255bd560cef", "node_type": "1", "metadata": {"window": "When excluding COVID -19 vaccine distribution in this segment, we anticipate approximately 3%  to 6% adjusted \noperating profit growth.  And as a reminder, our investments in our leading and differentiated position in oncology \nwill continue to represent an approximate $0.20 headwind in fiscal 2022.  \n \n In our Prescription Technology Solutions segment, w e anticipate revenue growth of 32% to 36% and adjusted \noperating profit growth of 24% to 28%.  This growth reflects the strong momentum in the business as we project \nincreased volumes across new and existing biopharma solutions and customers.  \n \n Transitioning  to Medical -Surgical, our outlook assumes 15% to 19% revenue growth and adjusted operating profit \ngrowth of 51% to 55% over the prior year.  Our outlook includes $0.85 to $1.05 related to the contribution from the \nUS government's distribution of ancillary s upply kits and storage programs and $0.75 to $0.95 related to the net \nimpact of COVID -19 tests and PPE impairments and related products.  When excluding the impacts of these items \nin this segment, we anticipate 22% to 26% growth over the prior year.  \n \n", "original_text": "This growth reflects the strong momentum in the business as we project \nincreased volumes across new and existing biopharma solutions and customers.  \n \n"}, "hash": "e87e6700c1279d0c548af137017cdbaa481ddd6c01341aef7b4c290540bb0ccf", "class_name": "RelatedNodeInfo"}}, "text": "In our Prescription Technology Solutions segment, w e anticipate revenue growth of 32% to 36% and adjusted \noperating profit growth of 24% to 28%. ", "start_char_idx": 2004, "end_char_idx": 2151, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "25ae07d1-0b28-4364-ad78-0255bd560cef": {"__data__": {"id_": "25ae07d1-0b28-4364-ad78-0255bd560cef", "embedding": null, "metadata": {"window": "When excluding COVID -19 vaccine distribution in this segment, we anticipate approximately 3%  to 6% adjusted \noperating profit growth.  And as a reminder, our investments in our leading and differentiated position in oncology \nwill continue to represent an approximate $0.20 headwind in fiscal 2022.  \n \n In our Prescription Technology Solutions segment, w e anticipate revenue growth of 32% to 36% and adjusted \noperating profit growth of 24% to 28%.  This growth reflects the strong momentum in the business as we project \nincreased volumes across new and existing biopharma solutions and customers.  \n \n Transitioning  to Medical -Surgical, our outlook assumes 15% to 19% revenue growth and adjusted operating profit \ngrowth of 51% to 55% over the prior year.  Our outlook includes $0.85 to $1.05 related to the contribution from the \nUS government's distribution of ancillary s upply kits and storage programs and $0.75 to $0.95 related to the net \nimpact of COVID -19 tests and PPE impairments and related products.  When excluding the impacts of these items \nin this segment, we anticipate 22% to 26% growth over the prior year.  \n \n", "original_text": "This growth reflects the strong momentum in the business as we project \nincreased volumes across new and existing biopharma solutions and customers.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c4835e48-c324-4b54-8fdb-9d717b314aef", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e95db66cd790d7dca47ceed93595581bc934889447139199fec3f0fe96ad0ece", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5c0051ac-b040-4fba-af49-86205690aff6", "node_type": "1", "metadata": {"window": "We'll continue to update you on the progress and contribution from this program.  \n \n When excluding COVID -19 vaccine distribution in this segment, we anticipate approximately 3%  to 6% adjusted \noperating profit growth.  And as a reminder, our investments in our leading and differentiated position in oncology \nwill continue to represent an approximate $0.20 headwind in fiscal 2022.  \n \n In our Prescription Technology Solutions segment, w e anticipate revenue growth of 32% to 36% and adjusted \noperating profit growth of 24% to 28%.  This growth reflects the strong momentum in the business as we project \nincreased volumes across new and existing biopharma solutions and customers.  \n \n Transitioning  to Medical -Surgical, our outlook assumes 15% to 19% revenue growth and adjusted operating profit \ngrowth of 51% to 55% over the prior year.  Our outlook includes $0.85 to $1.05 related to the contribution from the \nUS government's distribution of ancillary s upply kits and storage programs and $0.75 to $0.95 related to the net \nimpact of COVID -19 tests and PPE impairments and related products. ", "original_text": "In our Prescription Technology Solutions segment, w e anticipate revenue growth of 32% to 36% and adjusted \noperating profit growth of 24% to 28%. ", "page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8678cd0d793e8c932d23a2b568c74d726dbaab3c0c89c1b50c1bff4f1088af44", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ecfc150-38bf-4c9a-bdb1-9f7e5c85534e", "node_type": "1", "metadata": {"window": "And as a reminder, our investments in our leading and differentiated position in oncology \nwill continue to represent an approximate $0.20 headwind in fiscal 2022.  \n \n In our Prescription Technology Solutions segment, w e anticipate revenue growth of 32% to 36% and adjusted \noperating profit growth of 24% to 28%.  This growth reflects the strong momentum in the business as we project \nincreased volumes across new and existing biopharma solutions and customers.  \n \n Transitioning  to Medical -Surgical, our outlook assumes 15% to 19% revenue growth and adjusted operating profit \ngrowth of 51% to 55% over the prior year.  Our outlook includes $0.85 to $1.05 related to the contribution from the \nUS government's distribution of ancillary s upply kits and storage programs and $0.75 to $0.95 related to the net \nimpact of COVID -19 tests and PPE impairments and related products.  When excluding the impacts of these items \nin this segment, we anticipate 22% to 26% growth over the prior year.  \n \n One additional reminder related to our US distribution businesses. ", "original_text": "Transitioning  to Medical -Surgical, our outlook assumes 15% to 19% revenue growth and adjusted operating profit \ngrowth of 51% to 55% over the prior year. "}, "hash": "728e4107aad684cf59e74b37c68648963bee02700d09c9c76558d59d1727dc29", "class_name": "RelatedNodeInfo"}}, "text": "This growth reflects the strong momentum in the business as we project \nincreased volumes across new and existing biopharma solutions and customers.  \n \n", "start_char_idx": 2151, "end_char_idx": 2304, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0ecfc150-38bf-4c9a-bdb1-9f7e5c85534e": {"__data__": {"id_": "0ecfc150-38bf-4c9a-bdb1-9f7e5c85534e", "embedding": null, "metadata": {"window": "And as a reminder, our investments in our leading and differentiated position in oncology \nwill continue to represent an approximate $0.20 headwind in fiscal 2022.  \n \n In our Prescription Technology Solutions segment, w e anticipate revenue growth of 32% to 36% and adjusted \noperating profit growth of 24% to 28%.  This growth reflects the strong momentum in the business as we project \nincreased volumes across new and existing biopharma solutions and customers.  \n \n Transitioning  to Medical -Surgical, our outlook assumes 15% to 19% revenue growth and adjusted operating profit \ngrowth of 51% to 55% over the prior year.  Our outlook includes $0.85 to $1.05 related to the contribution from the \nUS government's distribution of ancillary s upply kits and storage programs and $0.75 to $0.95 related to the net \nimpact of COVID -19 tests and PPE impairments and related products.  When excluding the impacts of these items \nin this segment, we anticipate 22% to 26% growth over the prior year.  \n \n One additional reminder related to our US distribution businesses. ", "original_text": "Transitioning  to Medical -Surgical, our outlook assumes 15% to 19% revenue growth and adjusted operating profit \ngrowth of 51% to 55% over the prior year. ", "page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c4835e48-c324-4b54-8fdb-9d717b314aef", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e95db66cd790d7dca47ceed93595581bc934889447139199fec3f0fe96ad0ece", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "25ae07d1-0b28-4364-ad78-0255bd560cef", "node_type": "1", "metadata": {"window": "When excluding COVID -19 vaccine distribution in this segment, we anticipate approximately 3%  to 6% adjusted \noperating profit growth.  And as a reminder, our investments in our leading and differentiated position in oncology \nwill continue to represent an approximate $0.20 headwind in fiscal 2022.  \n \n In our Prescription Technology Solutions segment, w e anticipate revenue growth of 32% to 36% and adjusted \noperating profit growth of 24% to 28%.  This growth reflects the strong momentum in the business as we project \nincreased volumes across new and existing biopharma solutions and customers.  \n \n Transitioning  to Medical -Surgical, our outlook assumes 15% to 19% revenue growth and adjusted operating profit \ngrowth of 51% to 55% over the prior year.  Our outlook includes $0.85 to $1.05 related to the contribution from the \nUS government's distribution of ancillary s upply kits and storage programs and $0.75 to $0.95 related to the net \nimpact of COVID -19 tests and PPE impairments and related products.  When excluding the impacts of these items \nin this segment, we anticipate 22% to 26% growth over the prior year.  \n \n", "original_text": "This growth reflects the strong momentum in the business as we project \nincreased volumes across new and existing biopharma solutions and customers.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f63cb66b0cce69e76d4cc2e46207601af98164bba79cabcffd90da7baebd48d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "db96eb6b-7a4b-4f79-904e-7c9b559d6396", "node_type": "1", "metadata": {"window": "In our Prescription Technology Solutions segment, w e anticipate revenue growth of 32% to 36% and adjusted \noperating profit growth of 24% to 28%.  This growth reflects the strong momentum in the business as we project \nincreased volumes across new and existing biopharma solutions and customers.  \n \n Transitioning  to Medical -Surgical, our outlook assumes 15% to 19% revenue growth and adjusted operating profit \ngrowth of 51% to 55% over the prior year.  Our outlook includes $0.85 to $1.05 related to the contribution from the \nUS government's distribution of ancillary s upply kits and storage programs and $0.75 to $0.95 related to the net \nimpact of COVID -19 tests and PPE impairments and related products.  When excluding the impacts of these items \nin this segment, we anticipate 22% to 26% growth over the prior year.  \n \n One additional reminder related to our US distribution businesses.  On our earnings call in November, we \ndiscussed the highly competitive labor market, which continues to persist. ", "original_text": "Our outlook includes $0.85 to $1.05 related to the contribution from the \nUS government's distribution of ancillary s upply kits and storage programs and $0.75 to $0.95 related to the net \nimpact of COVID -19 tests and PPE impairments and related products. "}, "hash": "4dc6ffd8b5bae31b5b37bd582110c1a9c9750b53d0b30ba02392b5f65b8a1e91", "class_name": "RelatedNodeInfo"}}, "text": "Transitioning  to Medical -Surgical, our outlook assumes 15% to 19% revenue growth and adjusted operating profit \ngrowth of 51% to 55% over the prior year. ", "start_char_idx": 2304, "end_char_idx": 2460, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "db96eb6b-7a4b-4f79-904e-7c9b559d6396": {"__data__": {"id_": "db96eb6b-7a4b-4f79-904e-7c9b559d6396", "embedding": null, "metadata": {"window": "In our Prescription Technology Solutions segment, w e anticipate revenue growth of 32% to 36% and adjusted \noperating profit growth of 24% to 28%.  This growth reflects the strong momentum in the business as we project \nincreased volumes across new and existing biopharma solutions and customers.  \n \n Transitioning  to Medical -Surgical, our outlook assumes 15% to 19% revenue growth and adjusted operating profit \ngrowth of 51% to 55% over the prior year.  Our outlook includes $0.85 to $1.05 related to the contribution from the \nUS government's distribution of ancillary s upply kits and storage programs and $0.75 to $0.95 related to the net \nimpact of COVID -19 tests and PPE impairments and related products.  When excluding the impacts of these items \nin this segment, we anticipate 22% to 26% growth over the prior year.  \n \n One additional reminder related to our US distribution businesses.  On our earnings call in November, we \ndiscussed the highly competitive labor market, which continues to persist. ", "original_text": "Our outlook includes $0.85 to $1.05 related to the contribution from the \nUS government's distribution of ancillary s upply kits and storage programs and $0.75 to $0.95 related to the net \nimpact of COVID -19 tests and PPE impairments and related products. ", "page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c4835e48-c324-4b54-8fdb-9d717b314aef", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e95db66cd790d7dca47ceed93595581bc934889447139199fec3f0fe96ad0ece", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0ecfc150-38bf-4c9a-bdb1-9f7e5c85534e", "node_type": "1", "metadata": {"window": "And as a reminder, our investments in our leading and differentiated position in oncology \nwill continue to represent an approximate $0.20 headwind in fiscal 2022.  \n \n In our Prescription Technology Solutions segment, w e anticipate revenue growth of 32% to 36% and adjusted \noperating profit growth of 24% to 28%.  This growth reflects the strong momentum in the business as we project \nincreased volumes across new and existing biopharma solutions and customers.  \n \n Transitioning  to Medical -Surgical, our outlook assumes 15% to 19% revenue growth and adjusted operating profit \ngrowth of 51% to 55% over the prior year.  Our outlook includes $0.85 to $1.05 related to the contribution from the \nUS government's distribution of ancillary s upply kits and storage programs and $0.75 to $0.95 related to the net \nimpact of COVID -19 tests and PPE impairments and related products.  When excluding the impacts of these items \nin this segment, we anticipate 22% to 26% growth over the prior year.  \n \n One additional reminder related to our US distribution businesses. ", "original_text": "Transitioning  to Medical -Surgical, our outlook assumes 15% to 19% revenue growth and adjusted operating profit \ngrowth of 51% to 55% over the prior year. ", "page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d4acb2879c75b83317988918c5a1a3033f6e3aa2b6766c51df3bd864ebaa19d0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cda4ded9-b9d3-4d99-8e9e-61ef62d9de04", "node_type": "1", "metadata": {"window": "This growth reflects the strong momentum in the business as we project \nincreased volumes across new and existing biopharma solutions and customers.  \n \n Transitioning  to Medical -Surgical, our outlook assumes 15% to 19% revenue growth and adjusted operating profit \ngrowth of 51% to 55% over the prior year.  Our outlook includes $0.85 to $1.05 related to the contribution from the \nUS government's distribution of ancillary s upply kits and storage programs and $0.75 to $0.95 related to the net \nimpact of COVID -19 tests and PPE impairments and related products.  When excluding the impacts of these items \nin this segment, we anticipate 22% to 26% growth over the prior year.  \n \n One additional reminder related to our US distribution businesses.  On our earnings call in November, we \ndiscussed the highly competitive labor market, which continues to persist.  We also outlined an assumption for \nmodest labor -related expense impact to ensure support of our talent strategy and continued service continuity \nthrough the second half of our fiscal year.  \n \n", "original_text": "When excluding the impacts of these items \nin this segment, we anticipate 22% to 26% growth over the prior year.  \n \n"}, "hash": "2016a65b05f5f88d7175d4bfd851fa74fd523ce4f4014dbaf5ee2270e44ab0e5", "class_name": "RelatedNodeInfo"}}, "text": "Our outlook includes $0.85 to $1.05 related to the contribution from the \nUS government's distribution of ancillary s upply kits and storage programs and $0.75 to $0.95 related to the net \nimpact of COVID -19 tests and PPE impairments and related products. ", "start_char_idx": 2460, "end_char_idx": 2717, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cda4ded9-b9d3-4d99-8e9e-61ef62d9de04": {"__data__": {"id_": "cda4ded9-b9d3-4d99-8e9e-61ef62d9de04", "embedding": null, "metadata": {"window": "This growth reflects the strong momentum in the business as we project \nincreased volumes across new and existing biopharma solutions and customers.  \n \n Transitioning  to Medical -Surgical, our outlook assumes 15% to 19% revenue growth and adjusted operating profit \ngrowth of 51% to 55% over the prior year.  Our outlook includes $0.85 to $1.05 related to the contribution from the \nUS government's distribution of ancillary s upply kits and storage programs and $0.75 to $0.95 related to the net \nimpact of COVID -19 tests and PPE impairments and related products.  When excluding the impacts of these items \nin this segment, we anticipate 22% to 26% growth over the prior year.  \n \n One additional reminder related to our US distribution businesses.  On our earnings call in November, we \ndiscussed the highly competitive labor market, which continues to persist.  We also outlined an assumption for \nmodest labor -related expense impact to ensure support of our talent strategy and continued service continuity \nthrough the second half of our fiscal year.  \n \n", "original_text": "When excluding the impacts of these items \nin this segment, we anticipate 22% to 26% growth over the prior year.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c4835e48-c324-4b54-8fdb-9d717b314aef", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e95db66cd790d7dca47ceed93595581bc934889447139199fec3f0fe96ad0ece", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "db96eb6b-7a4b-4f79-904e-7c9b559d6396", "node_type": "1", "metadata": {"window": "In our Prescription Technology Solutions segment, w e anticipate revenue growth of 32% to 36% and adjusted \noperating profit growth of 24% to 28%.  This growth reflects the strong momentum in the business as we project \nincreased volumes across new and existing biopharma solutions and customers.  \n \n Transitioning  to Medical -Surgical, our outlook assumes 15% to 19% revenue growth and adjusted operating profit \ngrowth of 51% to 55% over the prior year.  Our outlook includes $0.85 to $1.05 related to the contribution from the \nUS government's distribution of ancillary s upply kits and storage programs and $0.75 to $0.95 related to the net \nimpact of COVID -19 tests and PPE impairments and related products.  When excluding the impacts of these items \nin this segment, we anticipate 22% to 26% growth over the prior year.  \n \n One additional reminder related to our US distribution businesses.  On our earnings call in November, we \ndiscussed the highly competitive labor market, which continues to persist. ", "original_text": "Our outlook includes $0.85 to $1.05 related to the contribution from the \nUS government's distribution of ancillary s upply kits and storage programs and $0.75 to $0.95 related to the net \nimpact of COVID -19 tests and PPE impairments and related products. ", "page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b7bf3dbaea0115d6367119e069d3eacd4ab06ce262ef9c772ad89deccb49c589", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d4c2826d-b8b8-49d2-866a-46af637d7b92", "node_type": "1", "metadata": {"window": "Transitioning  to Medical -Surgical, our outlook assumes 15% to 19% revenue growth and adjusted operating profit \ngrowth of 51% to 55% over the prior year.  Our outlook includes $0.85 to $1.05 related to the contribution from the \nUS government's distribution of ancillary s upply kits and storage programs and $0.75 to $0.95 related to the net \nimpact of COVID -19 tests and PPE impairments and related products.  When excluding the impacts of these items \nin this segment, we anticipate 22% to 26% growth over the prior year.  \n \n One additional reminder related to our US distribution businesses.  On our earnings call in November, we \ndiscussed the highly competitive labor market, which continues to persist.  We also outlined an assumption for \nmodest labor -related expense impact to ensure support of our talent strategy and continued service continuity \nthrough the second half of our fiscal year.  \n \n Based on labor market trends experienced in the third quarter and our expectations for remainder of the fiscal \nyear, we continue to anticipate appr oximately $0.10 to $0.20 of adjusted operating expense impact in our US \ndistribution businesses in the second half of the year, weighted slightly higher in our Medical segment.  \n \n", "original_text": "One additional reminder related to our US distribution businesses. "}, "hash": "daad6ca1f15fd625f8f86360f55747e8240a66f4f740c7863a1c1442b0c383e5", "class_name": "RelatedNodeInfo"}}, "text": "When excluding the impacts of these items \nin this segment, we anticipate 22% to 26% growth over the prior year.  \n \n", "start_char_idx": 2717, "end_char_idx": 2834, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d4c2826d-b8b8-49d2-866a-46af637d7b92": {"__data__": {"id_": "d4c2826d-b8b8-49d2-866a-46af637d7b92", "embedding": null, "metadata": {"window": "Transitioning  to Medical -Surgical, our outlook assumes 15% to 19% revenue growth and adjusted operating profit \ngrowth of 51% to 55% over the prior year.  Our outlook includes $0.85 to $1.05 related to the contribution from the \nUS government's distribution of ancillary s upply kits and storage programs and $0.75 to $0.95 related to the net \nimpact of COVID -19 tests and PPE impairments and related products.  When excluding the impacts of these items \nin this segment, we anticipate 22% to 26% growth over the prior year.  \n \n One additional reminder related to our US distribution businesses.  On our earnings call in November, we \ndiscussed the highly competitive labor market, which continues to persist.  We also outlined an assumption for \nmodest labor -related expense impact to ensure support of our talent strategy and continued service continuity \nthrough the second half of our fiscal year.  \n \n Based on labor market trends experienced in the third quarter and our expectations for remainder of the fiscal \nyear, we continue to anticipate appr oximately $0.10 to $0.20 of adjusted operating expense impact in our US \ndistribution businesses in the second half of the year, weighted slightly higher in our Medical segment.  \n \n", "original_text": "One additional reminder related to our US distribution businesses. ", "page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c4835e48-c324-4b54-8fdb-9d717b314aef", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e95db66cd790d7dca47ceed93595581bc934889447139199fec3f0fe96ad0ece", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cda4ded9-b9d3-4d99-8e9e-61ef62d9de04", "node_type": "1", "metadata": {"window": "This growth reflects the strong momentum in the business as we project \nincreased volumes across new and existing biopharma solutions and customers.  \n \n Transitioning  to Medical -Surgical, our outlook assumes 15% to 19% revenue growth and adjusted operating profit \ngrowth of 51% to 55% over the prior year.  Our outlook includes $0.85 to $1.05 related to the contribution from the \nUS government's distribution of ancillary s upply kits and storage programs and $0.75 to $0.95 related to the net \nimpact of COVID -19 tests and PPE impairments and related products.  When excluding the impacts of these items \nin this segment, we anticipate 22% to 26% growth over the prior year.  \n \n One additional reminder related to our US distribution businesses.  On our earnings call in November, we \ndiscussed the highly competitive labor market, which continues to persist.  We also outlined an assumption for \nmodest labor -related expense impact to ensure support of our talent strategy and continued service continuity \nthrough the second half of our fiscal year.  \n \n", "original_text": "When excluding the impacts of these items \nin this segment, we anticipate 22% to 26% growth over the prior year.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "78e114116b9a28def765656cc6790530ba92dbdcc284324ba2ff1e461d6ea772", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "86ee9854-1aee-4b69-97fc-406b1f7904ee", "node_type": "1", "metadata": {"window": "Our outlook includes $0.85 to $1.05 related to the contribution from the \nUS government's distribution of ancillary s upply kits and storage programs and $0.75 to $0.95 related to the net \nimpact of COVID -19 tests and PPE impairments and related products.  When excluding the impacts of these items \nin this segment, we anticipate 22% to 26% growth over the prior year.  \n \n One additional reminder related to our US distribution businesses.  On our earnings call in November, we \ndiscussed the highly competitive labor market, which continues to persist.  We also outlined an assumption for \nmodest labor -related expense impact to ensure support of our talent strategy and continued service continuity \nthrough the second half of our fiscal year.  \n \n Based on labor market trends experienced in the third quarter and our expectations for remainder of the fiscal \nyear, we continue to anticipate appr oximately $0.10 to $0.20 of adjusted operating expense impact in our US \ndistribution businesses in the second half of the year, weighted slightly higher in our Medical segment.  \n \n Finally, in the International segment, our revenue guidance is 2% decline to 1 % growth as compared to the prior \nyear. ", "original_text": "On our earnings call in November, we \ndiscussed the highly competitive labor market, which continues to persist. "}, "hash": "2dd9f2fdbc82c22d063eb0e9f3bc7b1fbc46f5482cb59ea8cbd4f5f3f732b9ff", "class_name": "RelatedNodeInfo"}}, "text": "One additional reminder related to our US distribution businesses. ", "start_char_idx": 2834, "end_char_idx": 2901, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "86ee9854-1aee-4b69-97fc-406b1f7904ee": {"__data__": {"id_": "86ee9854-1aee-4b69-97fc-406b1f7904ee", "embedding": null, "metadata": {"window": "Our outlook includes $0.85 to $1.05 related to the contribution from the \nUS government's distribution of ancillary s upply kits and storage programs and $0.75 to $0.95 related to the net \nimpact of COVID -19 tests and PPE impairments and related products.  When excluding the impacts of these items \nin this segment, we anticipate 22% to 26% growth over the prior year.  \n \n One additional reminder related to our US distribution businesses.  On our earnings call in November, we \ndiscussed the highly competitive labor market, which continues to persist.  We also outlined an assumption for \nmodest labor -related expense impact to ensure support of our talent strategy and continued service continuity \nthrough the second half of our fiscal year.  \n \n Based on labor market trends experienced in the third quarter and our expectations for remainder of the fiscal \nyear, we continue to anticipate appr oximately $0.10 to $0.20 of adjusted operating expense impact in our US \ndistribution businesses in the second half of the year, weighted slightly higher in our Medical segment.  \n \n Finally, in the International segment, our revenue guidance is 2% decline to 1 % growth as compared to the prior \nyear. ", "original_text": "On our earnings call in November, we \ndiscussed the highly competitive labor market, which continues to persist. ", "page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c4835e48-c324-4b54-8fdb-9d717b314aef", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e95db66cd790d7dca47ceed93595581bc934889447139199fec3f0fe96ad0ece", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d4c2826d-b8b8-49d2-866a-46af637d7b92", "node_type": "1", "metadata": {"window": "Transitioning  to Medical -Surgical, our outlook assumes 15% to 19% revenue growth and adjusted operating profit \ngrowth of 51% to 55% over the prior year.  Our outlook includes $0.85 to $1.05 related to the contribution from the \nUS government's distribution of ancillary s upply kits and storage programs and $0.75 to $0.95 related to the net \nimpact of COVID -19 tests and PPE impairments and related products.  When excluding the impacts of these items \nin this segment, we anticipate 22% to 26% growth over the prior year.  \n \n One additional reminder related to our US distribution businesses.  On our earnings call in November, we \ndiscussed the highly competitive labor market, which continues to persist.  We also outlined an assumption for \nmodest labor -related expense impact to ensure support of our talent strategy and continued service continuity \nthrough the second half of our fiscal year.  \n \n Based on labor market trends experienced in the third quarter and our expectations for remainder of the fiscal \nyear, we continue to anticipate appr oximately $0.10 to $0.20 of adjusted operating expense impact in our US \ndistribution businesses in the second half of the year, weighted slightly higher in our Medical segment.  \n \n", "original_text": "One additional reminder related to our US distribution businesses. ", "page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbc0562dd7efcff4773673a3e51361f0bc27cf6877b22bc79a127bf6dfa561c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5991b8ef-718f-4fc9-993c-b6e48df4641c", "node_type": "1", "metadata": {"window": "When excluding the impacts of these items \nin this segment, we anticipate 22% to 26% growth over the prior year.  \n \n One additional reminder related to our US distribution businesses.  On our earnings call in November, we \ndiscussed the highly competitive labor market, which continues to persist.  We also outlined an assumption for \nmodest labor -related expense impact to ensure support of our talent strategy and continued service continuity \nthrough the second half of our fiscal year.  \n \n Based on labor market trends experienced in the third quarter and our expectations for remainder of the fiscal \nyear, we continue to anticipate appr oximately $0.10 to $0.20 of adjusted operating expense impact in our US \ndistribution businesses in the second half of the year, weighted slightly higher in our Medical segment.  \n \n Finally, in the International segment, our revenue guidance is 2% decline to 1 % growth as compared to the prior \nyear.  And as a reminder, this reflects the impact from the contribution of our German wholesale business to a joint \nventure with Walgreens Boots Alliance in the third quarter of fiscal 2021.  \n ", "original_text": "We also outlined an assumption for \nmodest labor -related expense impact to ensure support of our talent strategy and continued service continuity \nthrough the second half of our fiscal year.  \n \n"}, "hash": "fcec11016131e493b2127e4507c944749f898a5a234cff1cd05ac2e9d428b388", "class_name": "RelatedNodeInfo"}}, "text": "On our earnings call in November, we \ndiscussed the highly competitive labor market, which continues to persist. ", "start_char_idx": 2901, "end_char_idx": 3014, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5991b8ef-718f-4fc9-993c-b6e48df4641c": {"__data__": {"id_": "5991b8ef-718f-4fc9-993c-b6e48df4641c", "embedding": null, "metadata": {"window": "When excluding the impacts of these items \nin this segment, we anticipate 22% to 26% growth over the prior year.  \n \n One additional reminder related to our US distribution businesses.  On our earnings call in November, we \ndiscussed the highly competitive labor market, which continues to persist.  We also outlined an assumption for \nmodest labor -related expense impact to ensure support of our talent strategy and continued service continuity \nthrough the second half of our fiscal year.  \n \n Based on labor market trends experienced in the third quarter and our expectations for remainder of the fiscal \nyear, we continue to anticipate appr oximately $0.10 to $0.20 of adjusted operating expense impact in our US \ndistribution businesses in the second half of the year, weighted slightly higher in our Medical segment.  \n \n Finally, in the International segment, our revenue guidance is 2% decline to 1 % growth as compared to the prior \nyear.  And as a reminder, this reflects the impact from the contribution of our German wholesale business to a joint \nventure with Walgreens Boots Alliance in the third quarter of fiscal 2021.  \n ", "original_text": "We also outlined an assumption for \nmodest labor -related expense impact to ensure support of our talent strategy and continued service continuity \nthrough the second half of our fiscal year.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c4835e48-c324-4b54-8fdb-9d717b314aef", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e95db66cd790d7dca47ceed93595581bc934889447139199fec3f0fe96ad0ece", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "86ee9854-1aee-4b69-97fc-406b1f7904ee", "node_type": "1", "metadata": {"window": "Our outlook includes $0.85 to $1.05 related to the contribution from the \nUS government's distribution of ancillary s upply kits and storage programs and $0.75 to $0.95 related to the net \nimpact of COVID -19 tests and PPE impairments and related products.  When excluding the impacts of these items \nin this segment, we anticipate 22% to 26% growth over the prior year.  \n \n One additional reminder related to our US distribution businesses.  On our earnings call in November, we \ndiscussed the highly competitive labor market, which continues to persist.  We also outlined an assumption for \nmodest labor -related expense impact to ensure support of our talent strategy and continued service continuity \nthrough the second half of our fiscal year.  \n \n Based on labor market trends experienced in the third quarter and our expectations for remainder of the fiscal \nyear, we continue to anticipate appr oximately $0.10 to $0.20 of adjusted operating expense impact in our US \ndistribution businesses in the second half of the year, weighted slightly higher in our Medical segment.  \n \n Finally, in the International segment, our revenue guidance is 2% decline to 1 % growth as compared to the prior \nyear. ", "original_text": "On our earnings call in November, we \ndiscussed the highly competitive labor market, which continues to persist. ", "page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "509a866a76e5f9acd7a4fb1d543ca772bf4186b44caf2a75aef9dea3950e61d6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "045416b8-dabe-45c1-a0ff-738e3b4b9419", "node_type": "1", "metadata": {"window": "One additional reminder related to our US distribution businesses.  On our earnings call in November, we \ndiscussed the highly competitive labor market, which continues to persist.  We also outlined an assumption for \nmodest labor -related expense impact to ensure support of our talent strategy and continued service continuity \nthrough the second half of our fiscal year.  \n \n Based on labor market trends experienced in the third quarter and our expectations for remainder of the fiscal \nyear, we continue to anticipate appr oximately $0.10 to $0.20 of adjusted operating expense impact in our US \ndistribution businesses in the second half of the year, weighted slightly higher in our Medical segment.  \n \n Finally, in the International segment, our revenue guidance is 2% decline to 1 % growth as compared to the prior \nyear.  And as a reminder, this reflects the impact from the contribution of our German wholesale business to a joint \nventure with Walgreens Boots Alliance in the third quarter of fiscal 2021.  \n ", "original_text": "Based on labor market trends experienced in the third quarter and our expectations for remainder of the fiscal \nyear, we continue to anticipate appr oximately $0.10 to $0.20 of adjusted operating expense impact in our US \ndistribution businesses in the second half of the year, weighted slightly higher in our Medical segment.  \n \n"}, "hash": "6f112f93315116ff653e633ef1b82501e2d2488c999903eb9e439ae15cb3cfff", "class_name": "RelatedNodeInfo"}}, "text": "We also outlined an assumption for \nmodest labor -related expense impact to ensure support of our talent strategy and continued service continuity \nthrough the second half of our fiscal year.  \n \n", "start_char_idx": 3014, "end_char_idx": 3210, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "045416b8-dabe-45c1-a0ff-738e3b4b9419": {"__data__": {"id_": "045416b8-dabe-45c1-a0ff-738e3b4b9419", "embedding": null, "metadata": {"window": "One additional reminder related to our US distribution businesses.  On our earnings call in November, we \ndiscussed the highly competitive labor market, which continues to persist.  We also outlined an assumption for \nmodest labor -related expense impact to ensure support of our talent strategy and continued service continuity \nthrough the second half of our fiscal year.  \n \n Based on labor market trends experienced in the third quarter and our expectations for remainder of the fiscal \nyear, we continue to anticipate appr oximately $0.10 to $0.20 of adjusted operating expense impact in our US \ndistribution businesses in the second half of the year, weighted slightly higher in our Medical segment.  \n \n Finally, in the International segment, our revenue guidance is 2% decline to 1 % growth as compared to the prior \nyear.  And as a reminder, this reflects the impact from the contribution of our German wholesale business to a joint \nventure with Walgreens Boots Alliance in the third quarter of fiscal 2021.  \n ", "original_text": "Based on labor market trends experienced in the third quarter and our expectations for remainder of the fiscal \nyear, we continue to anticipate appr oximately $0.10 to $0.20 of adjusted operating expense impact in our US \ndistribution businesses in the second half of the year, weighted slightly higher in our Medical segment.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c4835e48-c324-4b54-8fdb-9d717b314aef", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e95db66cd790d7dca47ceed93595581bc934889447139199fec3f0fe96ad0ece", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5991b8ef-718f-4fc9-993c-b6e48df4641c", "node_type": "1", "metadata": {"window": "When excluding the impacts of these items \nin this segment, we anticipate 22% to 26% growth over the prior year.  \n \n One additional reminder related to our US distribution businesses.  On our earnings call in November, we \ndiscussed the highly competitive labor market, which continues to persist.  We also outlined an assumption for \nmodest labor -related expense impact to ensure support of our talent strategy and continued service continuity \nthrough the second half of our fiscal year.  \n \n Based on labor market trends experienced in the third quarter and our expectations for remainder of the fiscal \nyear, we continue to anticipate appr oximately $0.10 to $0.20 of adjusted operating expense impact in our US \ndistribution businesses in the second half of the year, weighted slightly higher in our Medical segment.  \n \n Finally, in the International segment, our revenue guidance is 2% decline to 1 % growth as compared to the prior \nyear.  And as a reminder, this reflects the impact from the contribution of our German wholesale business to a joint \nventure with Walgreens Boots Alliance in the third quarter of fiscal 2021.  \n ", "original_text": "We also outlined an assumption for \nmodest labor -related expense impact to ensure support of our talent strategy and continued service continuity \nthrough the second half of our fiscal year.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9607a414718fc9720f668ccf167f5fc7f7ea0c5c33204ab97233ec57d8ca6f0d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dbde3349-9f40-4423-a60d-9df84ac1dddd", "node_type": "1", "metadata": {"window": "On our earnings call in November, we \ndiscussed the highly competitive labor market, which continues to persist.  We also outlined an assumption for \nmodest labor -related expense impact to ensure support of our talent strategy and continued service continuity \nthrough the second half of our fiscal year.  \n \n Based on labor market trends experienced in the third quarter and our expectations for remainder of the fiscal \nyear, we continue to anticipate appr oximately $0.10 to $0.20 of adjusted operating expense impact in our US \ndistribution businesses in the second half of the year, weighted slightly higher in our Medical segment.  \n \n Finally, in the International segment, our revenue guidance is 2% decline to 1 % growth as compared to the prior \nyear.  And as a reminder, this reflects the impact from the contribution of our German wholesale business to a joint \nventure with Walgreens Boots Alliance in the third quarter of fiscal 2021.  \n ", "original_text": "Finally, in the International segment, our revenue guidance is 2% decline to 1 % growth as compared to the prior \nyear. "}, "hash": "92f11f6973fb4a0ccd2184f33f69def324ba908b18fa7b1a636ed20e0f31375f", "class_name": "RelatedNodeInfo"}}, "text": "Based on labor market trends experienced in the third quarter and our expectations for remainder of the fiscal \nyear, we continue to anticipate appr oximately $0.10 to $0.20 of adjusted operating expense impact in our US \ndistribution businesses in the second half of the year, weighted slightly higher in our Medical segment.  \n \n", "start_char_idx": 3210, "end_char_idx": 3541, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dbde3349-9f40-4423-a60d-9df84ac1dddd": {"__data__": {"id_": "dbde3349-9f40-4423-a60d-9df84ac1dddd", "embedding": null, "metadata": {"window": "On our earnings call in November, we \ndiscussed the highly competitive labor market, which continues to persist.  We also outlined an assumption for \nmodest labor -related expense impact to ensure support of our talent strategy and continued service continuity \nthrough the second half of our fiscal year.  \n \n Based on labor market trends experienced in the third quarter and our expectations for remainder of the fiscal \nyear, we continue to anticipate appr oximately $0.10 to $0.20 of adjusted operating expense impact in our US \ndistribution businesses in the second half of the year, weighted slightly higher in our Medical segment.  \n \n Finally, in the International segment, our revenue guidance is 2% decline to 1 % growth as compared to the prior \nyear.  And as a reminder, this reflects the impact from the contribution of our German wholesale business to a joint \nventure with Walgreens Boots Alliance in the third quarter of fiscal 2021.  \n ", "original_text": "Finally, in the International segment, our revenue guidance is 2% decline to 1 % growth as compared to the prior \nyear. ", "page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c4835e48-c324-4b54-8fdb-9d717b314aef", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e95db66cd790d7dca47ceed93595581bc934889447139199fec3f0fe96ad0ece", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "045416b8-dabe-45c1-a0ff-738e3b4b9419", "node_type": "1", "metadata": {"window": "One additional reminder related to our US distribution businesses.  On our earnings call in November, we \ndiscussed the highly competitive labor market, which continues to persist.  We also outlined an assumption for \nmodest labor -related expense impact to ensure support of our talent strategy and continued service continuity \nthrough the second half of our fiscal year.  \n \n Based on labor market trends experienced in the third quarter and our expectations for remainder of the fiscal \nyear, we continue to anticipate appr oximately $0.10 to $0.20 of adjusted operating expense impact in our US \ndistribution businesses in the second half of the year, weighted slightly higher in our Medical segment.  \n \n Finally, in the International segment, our revenue guidance is 2% decline to 1 % growth as compared to the prior \nyear.  And as a reminder, this reflects the impact from the contribution of our German wholesale business to a joint \nventure with Walgreens Boots Alliance in the third quarter of fiscal 2021.  \n ", "original_text": "Based on labor market trends experienced in the third quarter and our expectations for remainder of the fiscal \nyear, we continue to anticipate appr oximately $0.10 to $0.20 of adjusted operating expense impact in our US \ndistribution businesses in the second half of the year, weighted slightly higher in our Medical segment.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4cb3c6e1a75bc1dc35d2c30035483859deb0165f5daa8fc1432d27efc59673f1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "96bf0892-867d-4b12-b7e5-8c406deec22b", "node_type": "1", "metadata": {"window": "We also outlined an assumption for \nmodest labor -related expense impact to ensure support of our talent strategy and continued service continuity \nthrough the second half of our fiscal year.  \n \n Based on labor market trends experienced in the third quarter and our expectations for remainder of the fiscal \nyear, we continue to anticipate appr oximately $0.10 to $0.20 of adjusted operating expense impact in our US \ndistribution businesses in the second half of the year, weighted slightly higher in our Medical segment.  \n \n Finally, in the International segment, our revenue guidance is 2% decline to 1 % growth as compared to the prior \nyear.  And as a reminder, this reflects the impact from the contribution of our German wholesale business to a joint \nventure with Walgreens Boots Alliance in the third quarter of fiscal 2021.  \n ", "original_text": "And as a reminder, this reflects the impact from the contribution of our German wholesale business to a joint \nventure with Walgreens Boots Alliance in the third quarter of fiscal 2021.  \n "}, "hash": "674a7a88cb0032ce27b3e7fdce3ac3d676b40ffe7397ef9692ae1f39de8f9646", "class_name": "RelatedNodeInfo"}}, "text": "Finally, in the International segment, our revenue guidance is 2% decline to 1 % growth as compared to the prior \nyear. ", "start_char_idx": 3541, "end_char_idx": 3661, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "96bf0892-867d-4b12-b7e5-8c406deec22b": {"__data__": {"id_": "96bf0892-867d-4b12-b7e5-8c406deec22b", "embedding": null, "metadata": {"window": "We also outlined an assumption for \nmodest labor -related expense impact to ensure support of our talent strategy and continued service continuity \nthrough the second half of our fiscal year.  \n \n Based on labor market trends experienced in the third quarter and our expectations for remainder of the fiscal \nyear, we continue to anticipate appr oximately $0.10 to $0.20 of adjusted operating expense impact in our US \ndistribution businesses in the second half of the year, weighted slightly higher in our Medical segment.  \n \n Finally, in the International segment, our revenue guidance is 2% decline to 1 % growth as compared to the prior \nyear.  And as a reminder, this reflects the impact from the contribution of our German wholesale business to a joint \nventure with Walgreens Boots Alliance in the third quarter of fiscal 2021.  \n ", "original_text": "And as a reminder, this reflects the impact from the contribution of our German wholesale business to a joint \nventure with Walgreens Boots Alliance in the third quarter of fiscal 2021.  \n ", "page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c4835e48-c324-4b54-8fdb-9d717b314aef", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e95db66cd790d7dca47ceed93595581bc934889447139199fec3f0fe96ad0ece", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dbde3349-9f40-4423-a60d-9df84ac1dddd", "node_type": "1", "metadata": {"window": "On our earnings call in November, we \ndiscussed the highly competitive labor market, which continues to persist.  We also outlined an assumption for \nmodest labor -related expense impact to ensure support of our talent strategy and continued service continuity \nthrough the second half of our fiscal year.  \n \n Based on labor market trends experienced in the third quarter and our expectations for remainder of the fiscal \nyear, we continue to anticipate appr oximately $0.10 to $0.20 of adjusted operating expense impact in our US \ndistribution businesses in the second half of the year, weighted slightly higher in our Medical segment.  \n \n Finally, in the International segment, our revenue guidance is 2% decline to 1 % growth as compared to the prior \nyear.  And as a reminder, this reflects the impact from the contribution of our German wholesale business to a joint \nventure with Walgreens Boots Alliance in the third quarter of fiscal 2021.  \n ", "original_text": "Finally, in the International segment, our revenue guidance is 2% decline to 1 % growth as compared to the prior \nyear. ", "page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5370a68e4c71c2116a0997701dfaf1fc09a9030a63adf705dc0e8894b30af3ce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "66180e6a-9cf6-468a-b9d9-e75b8d555121", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nFor adjusted operating profit,  our guidance reflects growth in the segment of 43% to 47%.  This includes \napproximately $0.49 of adjusted earnings accretion in fiscal 2022 resulting from held -for-sale accounting related \nto our agreement to sell certain European assets.  \n \n Turning now to th e consolidated view. ", "original_text": "McKesson Corp.  "}, "hash": "4a7696d70e0848079aab0e48a8f4b52d883bb4aa1e4141bfb490afe1b53463c6", "class_name": "RelatedNodeInfo"}}, "text": "And as a reminder, this reflects the impact from the contribution of our German wholesale business to a joint \nventure with Walgreens Boots Alliance in the third quarter of fiscal 2021.  \n ", "start_char_idx": 3661, "end_char_idx": 3850, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "66180e6a-9cf6-468a-b9d9-e75b8d555121": {"__data__": {"id_": "66180e6a-9cf6-468a-b9d9-e75b8d555121", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nFor adjusted operating profit,  our guidance reflects growth in the segment of 43% to 47%.  This includes \napproximately $0.49 of adjusted earnings accretion in fiscal 2022 resulting from held -for-sale accounting related \nto our agreement to sell certain European assets.  \n \n Turning now to th e consolidated view. ", "original_text": "McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f7e2d2dd-66c9-4d9a-9d5a-780ab89c5595", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "064981fa9dba8cb6d85dd4c1bebc81e647f1d60ad3a75dbc51c19a730b907148", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "96bf0892-867d-4b12-b7e5-8c406deec22b", "node_type": "1", "metadata": {"window": "We also outlined an assumption for \nmodest labor -related expense impact to ensure support of our talent strategy and continued service continuity \nthrough the second half of our fiscal year.  \n \n Based on labor market trends experienced in the third quarter and our expectations for remainder of the fiscal \nyear, we continue to anticipate appr oximately $0.10 to $0.20 of adjusted operating expense impact in our US \ndistribution businesses in the second half of the year, weighted slightly higher in our Medical segment.  \n \n Finally, in the International segment, our revenue guidance is 2% decline to 1 % growth as compared to the prior \nyear.  And as a reminder, this reflects the impact from the contribution of our German wholesale business to a joint \nventure with Walgreens Boots Alliance in the third quarter of fiscal 2021.  \n ", "original_text": "And as a reminder, this reflects the impact from the contribution of our German wholesale business to a joint \nventure with Walgreens Boots Alliance in the third quarter of fiscal 2021.  \n ", "page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5f0c6a0c8ba634e024305ad91b0eb88eb2971966e1e161ab946474c2fdb66abd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9af6c85c-aa25-49ef-aa56-e0e0a17616a2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nFor adjusted operating profit,  our guidance reflects growth in the segment of 43% to 47%.  This includes \napproximately $0.49 of adjusted earnings accretion in fiscal 2022 resulting from held -for-sale accounting related \nto our agreement to sell certain European assets.  \n \n Turning now to th e consolidated view.  Our increased guidance assumes 8% to 11% revenue growth and 24% to \n27% adjusted operating profit growth compared to fiscal 2021. ", "original_text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nFor adjusted operating profit,  our guidance reflects growth in the segment of 43% to 47%. "}, "hash": "3ae1fd8174665b8f45da9070af5598c0ef02894afbaebf3212355eaf3beb6143", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9af6c85c-aa25-49ef-aa56-e0e0a17616a2": {"__data__": {"id_": "9af6c85c-aa25-49ef-aa56-e0e0a17616a2", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nFor adjusted operating profit,  our guidance reflects growth in the segment of 43% to 47%.  This includes \napproximately $0.49 of adjusted earnings accretion in fiscal 2022 resulting from held -for-sale accounting related \nto our agreement to sell certain European assets.  \n \n Turning now to th e consolidated view.  Our increased guidance assumes 8% to 11% revenue growth and 24% to \n27% adjusted operating profit growth compared to fiscal 2021. ", "original_text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nFor adjusted operating profit,  our guidance reflects growth in the segment of 43% to 47%. ", "page_label": "11", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f7e2d2dd-66c9-4d9a-9d5a-780ab89c5595", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "064981fa9dba8cb6d85dd4c1bebc81e647f1d60ad3a75dbc51c19a730b907148", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "66180e6a-9cf6-468a-b9d9-e75b8d555121", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nFor adjusted operating profit,  our guidance reflects growth in the segment of 43% to 47%.  This includes \napproximately $0.49 of adjusted earnings accretion in fiscal 2022 resulting from held -for-sale accounting related \nto our agreement to sell certain European assets.  \n \n Turning now to th e consolidated view. ", "original_text": "McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3a5183193268dcd23ab4b4428c37b1cea674d7ca0799c0a238e91dd1278b34de", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f025706e-2bcf-4632-beb6-b7cca7ec2707", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nFor adjusted operating profit,  our guidance reflects growth in the segment of 43% to 47%.  This includes \napproximately $0.49 of adjusted earnings accretion in fiscal 2022 resulting from held -for-sale accounting related \nto our agreement to sell certain European assets.  \n \n Turning now to th e consolidated view.  Our increased guidance assumes 8% to 11% revenue growth and 24% to \n27% adjusted operating profit growth compared to fiscal 2021.  Our full year adjusted effective tax rate guidance of \n18% to 19% remains unchanged. ", "original_text": "This includes \napproximately $0.49 of adjusted earnings accretion in fiscal 2022 resulting from held -for-sale accounting related \nto our agreement to sell certain European assets.  \n \n"}, "hash": "1d9a1226ed466fd8c8963d54e71d870f54fc20a7b395a2c544e42fa0903566fc", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nFor adjusted operating profit,  our guidance reflects growth in the segment of 43% to 47%. ", "start_char_idx": 16, "end_char_idx": 272, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f025706e-2bcf-4632-beb6-b7cca7ec2707": {"__data__": {"id_": "f025706e-2bcf-4632-beb6-b7cca7ec2707", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nFor adjusted operating profit,  our guidance reflects growth in the segment of 43% to 47%.  This includes \napproximately $0.49 of adjusted earnings accretion in fiscal 2022 resulting from held -for-sale accounting related \nto our agreement to sell certain European assets.  \n \n Turning now to th e consolidated view.  Our increased guidance assumes 8% to 11% revenue growth and 24% to \n27% adjusted operating profit growth compared to fiscal 2021.  Our full year adjusted effective tax rate guidance of \n18% to 19% remains unchanged. ", "original_text": "This includes \napproximately $0.49 of adjusted earnings accretion in fiscal 2022 resulting from held -for-sale accounting related \nto our agreement to sell certain European assets.  \n \n", "page_label": "11", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f7e2d2dd-66c9-4d9a-9d5a-780ab89c5595", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "064981fa9dba8cb6d85dd4c1bebc81e647f1d60ad3a75dbc51c19a730b907148", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9af6c85c-aa25-49ef-aa56-e0e0a17616a2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nFor adjusted operating profit,  our guidance reflects growth in the segment of 43% to 47%.  This includes \napproximately $0.49 of adjusted earnings accretion in fiscal 2022 resulting from held -for-sale accounting related \nto our agreement to sell certain European assets.  \n \n Turning now to th e consolidated view.  Our increased guidance assumes 8% to 11% revenue growth and 24% to \n27% adjusted operating profit growth compared to fiscal 2021. ", "original_text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nFor adjusted operating profit,  our guidance reflects growth in the segment of 43% to 47%. ", "page_label": "11", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8cdc2c60433f5318cae80c8d54e50d795d672e895849c0c9fe0b559a42793fb2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "322a2c5f-8f4a-413f-bdf3-77795aec9e19", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nFor adjusted operating profit,  our guidance reflects growth in the segment of 43% to 47%.  This includes \napproximately $0.49 of adjusted earnings accretion in fiscal 2022 resulting from held -for-sale accounting related \nto our agreement to sell certain European assets.  \n \n Turning now to th e consolidated view.  Our increased guidance assumes 8% to 11% revenue growth and 24% to \n27% adjusted operating profit growth compared to fiscal 2021.  Our full year adjusted effective tax rate guidance of \n18% to 19% remains unchanged.  And we anticipate corp orate expenses in the range of $570 million to $620 \nmillion, an improvement from the previous range of $610 million to $660 million related to our focus on operating \nleverage, which we highlighted at our recent Investor Day event.  \n \n", "original_text": "Turning now to th e consolidated view. "}, "hash": "ab6102249047b4af85791e495d812c755acbc9716d480ed926648bf14e79b654", "class_name": "RelatedNodeInfo"}}, "text": "This includes \napproximately $0.49 of adjusted earnings accretion in fiscal 2022 resulting from held -for-sale accounting related \nto our agreement to sell certain European assets.  \n \n", "start_char_idx": 272, "end_char_idx": 457, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "322a2c5f-8f4a-413f-bdf3-77795aec9e19": {"__data__": {"id_": "322a2c5f-8f4a-413f-bdf3-77795aec9e19", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nFor adjusted operating profit,  our guidance reflects growth in the segment of 43% to 47%.  This includes \napproximately $0.49 of adjusted earnings accretion in fiscal 2022 resulting from held -for-sale accounting related \nto our agreement to sell certain European assets.  \n \n Turning now to th e consolidated view.  Our increased guidance assumes 8% to 11% revenue growth and 24% to \n27% adjusted operating profit growth compared to fiscal 2021.  Our full year adjusted effective tax rate guidance of \n18% to 19% remains unchanged.  And we anticipate corp orate expenses in the range of $570 million to $620 \nmillion, an improvement from the previous range of $610 million to $660 million related to our focus on operating \nleverage, which we highlighted at our recent Investor Day event.  \n \n", "original_text": "Turning now to th e consolidated view. ", "page_label": "11", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f7e2d2dd-66c9-4d9a-9d5a-780ab89c5595", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "064981fa9dba8cb6d85dd4c1bebc81e647f1d60ad3a75dbc51c19a730b907148", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f025706e-2bcf-4632-beb6-b7cca7ec2707", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nFor adjusted operating profit,  our guidance reflects growth in the segment of 43% to 47%.  This includes \napproximately $0.49 of adjusted earnings accretion in fiscal 2022 resulting from held -for-sale accounting related \nto our agreement to sell certain European assets.  \n \n Turning now to th e consolidated view.  Our increased guidance assumes 8% to 11% revenue growth and 24% to \n27% adjusted operating profit growth compared to fiscal 2021.  Our full year adjusted effective tax rate guidance of \n18% to 19% remains unchanged. ", "original_text": "This includes \napproximately $0.49 of adjusted earnings accretion in fiscal 2022 resulting from held -for-sale accounting related \nto our agreement to sell certain European assets.  \n \n", "page_label": "11", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "723411cd23f139c0bc16332cc0bc3b50c164cf39f00d7f73a7b468941c1b7953", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ad162914-f7ba-4c31-a7c8-c9a3a724fcb0", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nFor adjusted operating profit,  our guidance reflects growth in the segment of 43% to 47%.  This includes \napproximately $0.49 of adjusted earnings accretion in fiscal 2022 resulting from held -for-sale accounting related \nto our agreement to sell certain European assets.  \n \n Turning now to th e consolidated view.  Our increased guidance assumes 8% to 11% revenue growth and 24% to \n27% adjusted operating profit growth compared to fiscal 2021.  Our full year adjusted effective tax rate guidance of \n18% to 19% remains unchanged.  And we anticipate corp orate expenses in the range of $570 million to $620 \nmillion, an improvement from the previous range of $610 million to $660 million related to our focus on operating \nleverage, which we highlighted at our recent Investor Day event.  \n \n Let me now turn to cash flow and capital deployment. ", "original_text": "Our increased guidance assumes 8% to 11% revenue growth and 24% to \n27% adjusted operating profit growth compared to fiscal 2021. "}, "hash": "4c234c1fd269224e0217b9d1e72407aa01e68026785f193c55b6def4df70b972", "class_name": "RelatedNodeInfo"}}, "text": "Turning now to th e consolidated view. ", "start_char_idx": 457, "end_char_idx": 496, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ad162914-f7ba-4c31-a7c8-c9a3a724fcb0": {"__data__": {"id_": "ad162914-f7ba-4c31-a7c8-c9a3a724fcb0", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nFor adjusted operating profit,  our guidance reflects growth in the segment of 43% to 47%.  This includes \napproximately $0.49 of adjusted earnings accretion in fiscal 2022 resulting from held -for-sale accounting related \nto our agreement to sell certain European assets.  \n \n Turning now to th e consolidated view.  Our increased guidance assumes 8% to 11% revenue growth and 24% to \n27% adjusted operating profit growth compared to fiscal 2021.  Our full year adjusted effective tax rate guidance of \n18% to 19% remains unchanged.  And we anticipate corp orate expenses in the range of $570 million to $620 \nmillion, an improvement from the previous range of $610 million to $660 million related to our focus on operating \nleverage, which we highlighted at our recent Investor Day event.  \n \n Let me now turn to cash flow and capital deployment. ", "original_text": "Our increased guidance assumes 8% to 11% revenue growth and 24% to \n27% adjusted operating profit growth compared to fiscal 2021. ", "page_label": "11", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f7e2d2dd-66c9-4d9a-9d5a-780ab89c5595", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "064981fa9dba8cb6d85dd4c1bebc81e647f1d60ad3a75dbc51c19a730b907148", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "322a2c5f-8f4a-413f-bdf3-77795aec9e19", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nFor adjusted operating profit,  our guidance reflects growth in the segment of 43% to 47%.  This includes \napproximately $0.49 of adjusted earnings accretion in fiscal 2022 resulting from held -for-sale accounting related \nto our agreement to sell certain European assets.  \n \n Turning now to th e consolidated view.  Our increased guidance assumes 8% to 11% revenue growth and 24% to \n27% adjusted operating profit growth compared to fiscal 2021.  Our full year adjusted effective tax rate guidance of \n18% to 19% remains unchanged.  And we anticipate corp orate expenses in the range of $570 million to $620 \nmillion, an improvement from the previous range of $610 million to $660 million related to our focus on operating \nleverage, which we highlighted at our recent Investor Day event.  \n \n", "original_text": "Turning now to th e consolidated view. ", "page_label": "11", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a2b8dcb99bec487d20e110d8f6e977dce5a2006c218e10b23607d21f841db3f7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dccbf095-87c8-4e28-a46b-45b0ff9ee73d", "node_type": "1", "metadata": {"window": "This includes \napproximately $0.49 of adjusted earnings accretion in fiscal 2022 resulting from held -for-sale accounting related \nto our agreement to sell certain European assets.  \n \n Turning now to th e consolidated view.  Our increased guidance assumes 8% to 11% revenue growth and 24% to \n27% adjusted operating profit growth compared to fiscal 2021.  Our full year adjusted effective tax rate guidance of \n18% to 19% remains unchanged.  And we anticipate corp orate expenses in the range of $570 million to $620 \nmillion, an improvement from the previous range of $610 million to $660 million related to our focus on operating \nleverage, which we highlighted at our recent Investor Day event.  \n \n Let me now turn to cash flow and capital deployment.  We expect our businesses to continue to drive strong free \ncash flows and returns on capital, even as we continue reinvesting to support sustainable, long -term growth. ", "original_text": "Our full year adjusted effective tax rate guidance of \n18% to 19% remains unchanged. "}, "hash": "27853134f3c4681949b4dbbe891fe24fcbb981c13083a5dc67d699f1562cb9ff", "class_name": "RelatedNodeInfo"}}, "text": "Our increased guidance assumes 8% to 11% revenue growth and 24% to \n27% adjusted operating profit growth compared to fiscal 2021. ", "start_char_idx": 496, "end_char_idx": 626, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dccbf095-87c8-4e28-a46b-45b0ff9ee73d": {"__data__": {"id_": "dccbf095-87c8-4e28-a46b-45b0ff9ee73d", "embedding": null, "metadata": {"window": "This includes \napproximately $0.49 of adjusted earnings accretion in fiscal 2022 resulting from held -for-sale accounting related \nto our agreement to sell certain European assets.  \n \n Turning now to th e consolidated view.  Our increased guidance assumes 8% to 11% revenue growth and 24% to \n27% adjusted operating profit growth compared to fiscal 2021.  Our full year adjusted effective tax rate guidance of \n18% to 19% remains unchanged.  And we anticipate corp orate expenses in the range of $570 million to $620 \nmillion, an improvement from the previous range of $610 million to $660 million related to our focus on operating \nleverage, which we highlighted at our recent Investor Day event.  \n \n Let me now turn to cash flow and capital deployment.  We expect our businesses to continue to drive strong free \ncash flows and returns on capital, even as we continue reinvesting to support sustainable, long -term growth. ", "original_text": "Our full year adjusted effective tax rate guidance of \n18% to 19% remains unchanged. ", "page_label": "11", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f7e2d2dd-66c9-4d9a-9d5a-780ab89c5595", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "064981fa9dba8cb6d85dd4c1bebc81e647f1d60ad3a75dbc51c19a730b907148", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ad162914-f7ba-4c31-a7c8-c9a3a724fcb0", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nFor adjusted operating profit,  our guidance reflects growth in the segment of 43% to 47%.  This includes \napproximately $0.49 of adjusted earnings accretion in fiscal 2022 resulting from held -for-sale accounting related \nto our agreement to sell certain European assets.  \n \n Turning now to th e consolidated view.  Our increased guidance assumes 8% to 11% revenue growth and 24% to \n27% adjusted operating profit growth compared to fiscal 2021.  Our full year adjusted effective tax rate guidance of \n18% to 19% remains unchanged.  And we anticipate corp orate expenses in the range of $570 million to $620 \nmillion, an improvement from the previous range of $610 million to $660 million related to our focus on operating \nleverage, which we highlighted at our recent Investor Day event.  \n \n Let me now turn to cash flow and capital deployment. ", "original_text": "Our increased guidance assumes 8% to 11% revenue growth and 24% to \n27% adjusted operating profit growth compared to fiscal 2021. ", "page_label": "11", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "00c0d1cf6261d7401c54c0958a6b859acf55ab33c5947560e5bf45182241939e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "de19cbb8-a38e-49be-9ecb-62d40d7998e2", "node_type": "1", "metadata": {"window": "Turning now to th e consolidated view.  Our increased guidance assumes 8% to 11% revenue growth and 24% to \n27% adjusted operating profit growth compared to fiscal 2021.  Our full year adjusted effective tax rate guidance of \n18% to 19% remains unchanged.  And we anticipate corp orate expenses in the range of $570 million to $620 \nmillion, an improvement from the previous range of $610 million to $660 million related to our focus on operating \nleverage, which we highlighted at our recent Investor Day event.  \n \n Let me now turn to cash flow and capital deployment.  We expect our businesses to continue to drive strong free \ncash flows and returns on capital, even as we continue reinvesting to support sustainable, long -term growth.  This \nstrong free cash flow generation provides financial fle xibility to execute a balanced capital allocation approach, \nincluding investing in our strategic growth pillars of oncology and biopharma services, while remaining committed \nto returning capital to shareholders through our growing dividend and share repurc hases. ", "original_text": "And we anticipate corp orate expenses in the range of $570 million to $620 \nmillion, an improvement from the previous range of $610 million to $660 million related to our focus on operating \nleverage, which we highlighted at our recent Investor Day event.  \n \n"}, "hash": "0b5dd64979d8722c59f47a0bb188886fb8c6422862f4df02767ab8beac3ff782", "class_name": "RelatedNodeInfo"}}, "text": "Our full year adjusted effective tax rate guidance of \n18% to 19% remains unchanged. ", "start_char_idx": 626, "end_char_idx": 711, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "de19cbb8-a38e-49be-9ecb-62d40d7998e2": {"__data__": {"id_": "de19cbb8-a38e-49be-9ecb-62d40d7998e2", "embedding": null, "metadata": {"window": "Turning now to th e consolidated view.  Our increased guidance assumes 8% to 11% revenue growth and 24% to \n27% adjusted operating profit growth compared to fiscal 2021.  Our full year adjusted effective tax rate guidance of \n18% to 19% remains unchanged.  And we anticipate corp orate expenses in the range of $570 million to $620 \nmillion, an improvement from the previous range of $610 million to $660 million related to our focus on operating \nleverage, which we highlighted at our recent Investor Day event.  \n \n Let me now turn to cash flow and capital deployment.  We expect our businesses to continue to drive strong free \ncash flows and returns on capital, even as we continue reinvesting to support sustainable, long -term growth.  This \nstrong free cash flow generation provides financial fle xibility to execute a balanced capital allocation approach, \nincluding investing in our strategic growth pillars of oncology and biopharma services, while remaining committed \nto returning capital to shareholders through our growing dividend and share repurc hases. ", "original_text": "And we anticipate corp orate expenses in the range of $570 million to $620 \nmillion, an improvement from the previous range of $610 million to $660 million related to our focus on operating \nleverage, which we highlighted at our recent Investor Day event.  \n \n", "page_label": "11", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f7e2d2dd-66c9-4d9a-9d5a-780ab89c5595", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "064981fa9dba8cb6d85dd4c1bebc81e647f1d60ad3a75dbc51c19a730b907148", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dccbf095-87c8-4e28-a46b-45b0ff9ee73d", "node_type": "1", "metadata": {"window": "This includes \napproximately $0.49 of adjusted earnings accretion in fiscal 2022 resulting from held -for-sale accounting related \nto our agreement to sell certain European assets.  \n \n Turning now to th e consolidated view.  Our increased guidance assumes 8% to 11% revenue growth and 24% to \n27% adjusted operating profit growth compared to fiscal 2021.  Our full year adjusted effective tax rate guidance of \n18% to 19% remains unchanged.  And we anticipate corp orate expenses in the range of $570 million to $620 \nmillion, an improvement from the previous range of $610 million to $660 million related to our focus on operating \nleverage, which we highlighted at our recent Investor Day event.  \n \n Let me now turn to cash flow and capital deployment.  We expect our businesses to continue to drive strong free \ncash flows and returns on capital, even as we continue reinvesting to support sustainable, long -term growth. ", "original_text": "Our full year adjusted effective tax rate guidance of \n18% to 19% remains unchanged. ", "page_label": "11", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7dc1b24a9d6e3231885f99e533fcecdbcbc94eb3fd0bfd1777265630345ab4c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0680e701-d168-48aa-a6c5-0da8988dd2f3", "node_type": "1", "metadata": {"window": "Our increased guidance assumes 8% to 11% revenue growth and 24% to \n27% adjusted operating profit growth compared to fiscal 2021.  Our full year adjusted effective tax rate guidance of \n18% to 19% remains unchanged.  And we anticipate corp orate expenses in the range of $570 million to $620 \nmillion, an improvement from the previous range of $610 million to $660 million related to our focus on operating \nleverage, which we highlighted at our recent Investor Day event.  \n \n Let me now turn to cash flow and capital deployment.  We expect our businesses to continue to drive strong free \ncash flows and returns on capital, even as we continue reinvesting to support sustainable, long -term growth.  This \nstrong free cash flow generation provides financial fle xibility to execute a balanced capital allocation approach, \nincluding investing in our strategic growth pillars of oncology and biopharma services, while remaining committed \nto returning capital to shareholders through our growing dividend and share repurc hases.  Our investment -grade \ncredit rating remains a priority, and it underpins our financial flexibility.  \n \n", "original_text": "Let me now turn to cash flow and capital deployment. "}, "hash": "29abfa56292aa5300a758bc93e1c08c792548f19c7cf8d08bb6607215a4beaf0", "class_name": "RelatedNodeInfo"}}, "text": "And we anticipate corp orate expenses in the range of $570 million to $620 \nmillion, an improvement from the previous range of $610 million to $660 million related to our focus on operating \nleverage, which we highlighted at our recent Investor Day event.  \n \n", "start_char_idx": 711, "end_char_idx": 971, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0680e701-d168-48aa-a6c5-0da8988dd2f3": {"__data__": {"id_": "0680e701-d168-48aa-a6c5-0da8988dd2f3", "embedding": null, "metadata": {"window": "Our increased guidance assumes 8% to 11% revenue growth and 24% to \n27% adjusted operating profit growth compared to fiscal 2021.  Our full year adjusted effective tax rate guidance of \n18% to 19% remains unchanged.  And we anticipate corp orate expenses in the range of $570 million to $620 \nmillion, an improvement from the previous range of $610 million to $660 million related to our focus on operating \nleverage, which we highlighted at our recent Investor Day event.  \n \n Let me now turn to cash flow and capital deployment.  We expect our businesses to continue to drive strong free \ncash flows and returns on capital, even as we continue reinvesting to support sustainable, long -term growth.  This \nstrong free cash flow generation provides financial fle xibility to execute a balanced capital allocation approach, \nincluding investing in our strategic growth pillars of oncology and biopharma services, while remaining committed \nto returning capital to shareholders through our growing dividend and share repurc hases.  Our investment -grade \ncredit rating remains a priority, and it underpins our financial flexibility.  \n \n", "original_text": "Let me now turn to cash flow and capital deployment. ", "page_label": "11", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f7e2d2dd-66c9-4d9a-9d5a-780ab89c5595", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "064981fa9dba8cb6d85dd4c1bebc81e647f1d60ad3a75dbc51c19a730b907148", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "de19cbb8-a38e-49be-9ecb-62d40d7998e2", "node_type": "1", "metadata": {"window": "Turning now to th e consolidated view.  Our increased guidance assumes 8% to 11% revenue growth and 24% to \n27% adjusted operating profit growth compared to fiscal 2021.  Our full year adjusted effective tax rate guidance of \n18% to 19% remains unchanged.  And we anticipate corp orate expenses in the range of $570 million to $620 \nmillion, an improvement from the previous range of $610 million to $660 million related to our focus on operating \nleverage, which we highlighted at our recent Investor Day event.  \n \n Let me now turn to cash flow and capital deployment.  We expect our businesses to continue to drive strong free \ncash flows and returns on capital, even as we continue reinvesting to support sustainable, long -term growth.  This \nstrong free cash flow generation provides financial fle xibility to execute a balanced capital allocation approach, \nincluding investing in our strategic growth pillars of oncology and biopharma services, while remaining committed \nto returning capital to shareholders through our growing dividend and share repurc hases. ", "original_text": "And we anticipate corp orate expenses in the range of $570 million to $620 \nmillion, an improvement from the previous range of $610 million to $660 million related to our focus on operating \nleverage, which we highlighted at our recent Investor Day event.  \n \n", "page_label": "11", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "522a46fdd2ef8c94ffa772ddf35816d7d79800a109c15e4cac95457714e8dc98", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8e55637e-061c-4ac9-a5bf-e0e34f70fedc", "node_type": "1", "metadata": {"window": "Our full year adjusted effective tax rate guidance of \n18% to 19% remains unchanged.  And we anticipate corp orate expenses in the range of $570 million to $620 \nmillion, an improvement from the previous range of $610 million to $660 million related to our focus on operating \nleverage, which we highlighted at our recent Investor Day event.  \n \n Let me now turn to cash flow and capital deployment.  We expect our businesses to continue to drive strong free \ncash flows and returns on capital, even as we continue reinvesting to support sustainable, long -term growth.  This \nstrong free cash flow generation provides financial fle xibility to execute a balanced capital allocation approach, \nincluding investing in our strategic growth pillars of oncology and biopharma services, while remaining committed \nto returning capital to shareholders through our growing dividend and share repurc hases.  Our investment -grade \ncredit rating remains a priority, and it underpins our financial flexibility.  \n \n For fiscal 2022, we continue to anticipate free cash flow of approximately $3.5 billion to $3.9 billion, which is net of \nproperty acquisitions and ca pitalized software expenses. ", "original_text": "We expect our businesses to continue to drive strong free \ncash flows and returns on capital, even as we continue reinvesting to support sustainable, long -term growth. "}, "hash": "d8eef2d029c9b29948cf496400ae526e91473328c5f5aec86f43a1194f8eeb36", "class_name": "RelatedNodeInfo"}}, "text": "Let me now turn to cash flow and capital deployment. ", "start_char_idx": 971, "end_char_idx": 1024, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8e55637e-061c-4ac9-a5bf-e0e34f70fedc": {"__data__": {"id_": "8e55637e-061c-4ac9-a5bf-e0e34f70fedc", "embedding": null, "metadata": {"window": "Our full year adjusted effective tax rate guidance of \n18% to 19% remains unchanged.  And we anticipate corp orate expenses in the range of $570 million to $620 \nmillion, an improvement from the previous range of $610 million to $660 million related to our focus on operating \nleverage, which we highlighted at our recent Investor Day event.  \n \n Let me now turn to cash flow and capital deployment.  We expect our businesses to continue to drive strong free \ncash flows and returns on capital, even as we continue reinvesting to support sustainable, long -term growth.  This \nstrong free cash flow generation provides financial fle xibility to execute a balanced capital allocation approach, \nincluding investing in our strategic growth pillars of oncology and biopharma services, while remaining committed \nto returning capital to shareholders through our growing dividend and share repurc hases.  Our investment -grade \ncredit rating remains a priority, and it underpins our financial flexibility.  \n \n For fiscal 2022, we continue to anticipate free cash flow of approximately $3.5 billion to $3.9 billion, which is net of \nproperty acquisitions and ca pitalized software expenses. ", "original_text": "We expect our businesses to continue to drive strong free \ncash flows and returns on capital, even as we continue reinvesting to support sustainable, long -term growth. ", "page_label": "11", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f7e2d2dd-66c9-4d9a-9d5a-780ab89c5595", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "064981fa9dba8cb6d85dd4c1bebc81e647f1d60ad3a75dbc51c19a730b907148", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0680e701-d168-48aa-a6c5-0da8988dd2f3", "node_type": "1", "metadata": {"window": "Our increased guidance assumes 8% to 11% revenue growth and 24% to \n27% adjusted operating profit growth compared to fiscal 2021.  Our full year adjusted effective tax rate guidance of \n18% to 19% remains unchanged.  And we anticipate corp orate expenses in the range of $570 million to $620 \nmillion, an improvement from the previous range of $610 million to $660 million related to our focus on operating \nleverage, which we highlighted at our recent Investor Day event.  \n \n Let me now turn to cash flow and capital deployment.  We expect our businesses to continue to drive strong free \ncash flows and returns on capital, even as we continue reinvesting to support sustainable, long -term growth.  This \nstrong free cash flow generation provides financial fle xibility to execute a balanced capital allocation approach, \nincluding investing in our strategic growth pillars of oncology and biopharma services, while remaining committed \nto returning capital to shareholders through our growing dividend and share repurc hases.  Our investment -grade \ncredit rating remains a priority, and it underpins our financial flexibility.  \n \n", "original_text": "Let me now turn to cash flow and capital deployment. ", "page_label": "11", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "949dbbca49d14f0b0c063f3225be7ed3457d4061ac704b689869b9b39384f5f1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "31e99e59-c6e0-4a85-be9e-da0c14e86164", "node_type": "1", "metadata": {"window": "And we anticipate corp orate expenses in the range of $570 million to $620 \nmillion, an improvement from the previous range of $610 million to $660 million related to our focus on operating \nleverage, which we highlighted at our recent Investor Day event.  \n \n Let me now turn to cash flow and capital deployment.  We expect our businesses to continue to drive strong free \ncash flows and returns on capital, even as we continue reinvesting to support sustainable, long -term growth.  This \nstrong free cash flow generation provides financial fle xibility to execute a balanced capital allocation approach, \nincluding investing in our strategic growth pillars of oncology and biopharma services, while remaining committed \nto returning capital to shareholders through our growing dividend and share repurc hases.  Our investment -grade \ncredit rating remains a priority, and it underpins our financial flexibility.  \n \n For fiscal 2022, we continue to anticipate free cash flow of approximately $3.5 billion to $3.9 billion, which is net of \nproperty acquisitions and ca pitalized software expenses.  As a reminder, historically we generate a larger portion \nof our cash flows in the fourth quarter of our fiscal year. ", "original_text": "This \nstrong free cash flow generation provides financial fle xibility to execute a balanced capital allocation approach, \nincluding investing in our strategic growth pillars of oncology and biopharma services, while remaining committed \nto returning capital to shareholders through our growing dividend and share repurc hases. "}, "hash": "10e98a8edeefa4bf39586f7ada3021d54cca3be06da3f3f4ae61cf3a1e05fced", "class_name": "RelatedNodeInfo"}}, "text": "We expect our businesses to continue to drive strong free \ncash flows and returns on capital, even as we continue reinvesting to support sustainable, long -term growth. ", "start_char_idx": 1024, "end_char_idx": 1193, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "31e99e59-c6e0-4a85-be9e-da0c14e86164": {"__data__": {"id_": "31e99e59-c6e0-4a85-be9e-da0c14e86164", "embedding": null, "metadata": {"window": "And we anticipate corp orate expenses in the range of $570 million to $620 \nmillion, an improvement from the previous range of $610 million to $660 million related to our focus on operating \nleverage, which we highlighted at our recent Investor Day event.  \n \n Let me now turn to cash flow and capital deployment.  We expect our businesses to continue to drive strong free \ncash flows and returns on capital, even as we continue reinvesting to support sustainable, long -term growth.  This \nstrong free cash flow generation provides financial fle xibility to execute a balanced capital allocation approach, \nincluding investing in our strategic growth pillars of oncology and biopharma services, while remaining committed \nto returning capital to shareholders through our growing dividend and share repurc hases.  Our investment -grade \ncredit rating remains a priority, and it underpins our financial flexibility.  \n \n For fiscal 2022, we continue to anticipate free cash flow of approximately $3.5 billion to $3.9 billion, which is net of \nproperty acquisitions and ca pitalized software expenses.  As a reminder, historically we generate a larger portion \nof our cash flows in the fourth quarter of our fiscal year. ", "original_text": "This \nstrong free cash flow generation provides financial fle xibility to execute a balanced capital allocation approach, \nincluding investing in our strategic growth pillars of oncology and biopharma services, while remaining committed \nto returning capital to shareholders through our growing dividend and share repurc hases. ", "page_label": "11", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f7e2d2dd-66c9-4d9a-9d5a-780ab89c5595", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "064981fa9dba8cb6d85dd4c1bebc81e647f1d60ad3a75dbc51c19a730b907148", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8e55637e-061c-4ac9-a5bf-e0e34f70fedc", "node_type": "1", "metadata": {"window": "Our full year adjusted effective tax rate guidance of \n18% to 19% remains unchanged.  And we anticipate corp orate expenses in the range of $570 million to $620 \nmillion, an improvement from the previous range of $610 million to $660 million related to our focus on operating \nleverage, which we highlighted at our recent Investor Day event.  \n \n Let me now turn to cash flow and capital deployment.  We expect our businesses to continue to drive strong free \ncash flows and returns on capital, even as we continue reinvesting to support sustainable, long -term growth.  This \nstrong free cash flow generation provides financial fle xibility to execute a balanced capital allocation approach, \nincluding investing in our strategic growth pillars of oncology and biopharma services, while remaining committed \nto returning capital to shareholders through our growing dividend and share repurc hases.  Our investment -grade \ncredit rating remains a priority, and it underpins our financial flexibility.  \n \n For fiscal 2022, we continue to anticipate free cash flow of approximately $3.5 billion to $3.9 billion, which is net of \nproperty acquisitions and ca pitalized software expenses. ", "original_text": "We expect our businesses to continue to drive strong free \ncash flows and returns on capital, even as we continue reinvesting to support sustainable, long -term growth. ", "page_label": "11", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c6161070b6d689fff63e1efdd378485d412e9c957c4afb3fdd634e8bbb2bb3be", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1bff5aac-0336-4399-a27b-36e6840f002c", "node_type": "1", "metadata": {"window": "Let me now turn to cash flow and capital deployment.  We expect our businesses to continue to drive strong free \ncash flows and returns on capital, even as we continue reinvesting to support sustainable, long -term growth.  This \nstrong free cash flow generation provides financial fle xibility to execute a balanced capital allocation approach, \nincluding investing in our strategic growth pillars of oncology and biopharma services, while remaining committed \nto returning capital to shareholders through our growing dividend and share repurc hases.  Our investment -grade \ncredit rating remains a priority, and it underpins our financial flexibility.  \n \n For fiscal 2022, we continue to anticipate free cash flow of approximately $3.5 billion to $3.9 billion, which is net of \nproperty acquisitions and ca pitalized software expenses.  As a reminder, historically we generate a larger portion \nof our cash flows in the fourth quarter of our fiscal year.  Our working capital metrics and resulting cash flows vary \nfrom quarter to quarter, impacted by timing, which c ould include the timing of planned European divestiture \nactivity.  \n \n", "original_text": "Our investment -grade \ncredit rating remains a priority, and it underpins our financial flexibility.  \n \n"}, "hash": "be73b383f702691d4ade269f95377deb8c77510fd62f7025297dd31dca5433d0", "class_name": "RelatedNodeInfo"}}, "text": "This \nstrong free cash flow generation provides financial fle xibility to execute a balanced capital allocation approach, \nincluding investing in our strategic growth pillars of oncology and biopharma services, while remaining committed \nto returning capital to shareholders through our growing dividend and share repurc hases. ", "start_char_idx": 1193, "end_char_idx": 1521, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1bff5aac-0336-4399-a27b-36e6840f002c": {"__data__": {"id_": "1bff5aac-0336-4399-a27b-36e6840f002c", "embedding": null, "metadata": {"window": "Let me now turn to cash flow and capital deployment.  We expect our businesses to continue to drive strong free \ncash flows and returns on capital, even as we continue reinvesting to support sustainable, long -term growth.  This \nstrong free cash flow generation provides financial fle xibility to execute a balanced capital allocation approach, \nincluding investing in our strategic growth pillars of oncology and biopharma services, while remaining committed \nto returning capital to shareholders through our growing dividend and share repurc hases.  Our investment -grade \ncredit rating remains a priority, and it underpins our financial flexibility.  \n \n For fiscal 2022, we continue to anticipate free cash flow of approximately $3.5 billion to $3.9 billion, which is net of \nproperty acquisitions and ca pitalized software expenses.  As a reminder, historically we generate a larger portion \nof our cash flows in the fourth quarter of our fiscal year.  Our working capital metrics and resulting cash flows vary \nfrom quarter to quarter, impacted by timing, which c ould include the timing of planned European divestiture \nactivity.  \n \n", "original_text": "Our investment -grade \ncredit rating remains a priority, and it underpins our financial flexibility.  \n \n", "page_label": "11", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f7e2d2dd-66c9-4d9a-9d5a-780ab89c5595", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "064981fa9dba8cb6d85dd4c1bebc81e647f1d60ad3a75dbc51c19a730b907148", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "31e99e59-c6e0-4a85-be9e-da0c14e86164", "node_type": "1", "metadata": {"window": "And we anticipate corp orate expenses in the range of $570 million to $620 \nmillion, an improvement from the previous range of $610 million to $660 million related to our focus on operating \nleverage, which we highlighted at our recent Investor Day event.  \n \n Let me now turn to cash flow and capital deployment.  We expect our businesses to continue to drive strong free \ncash flows and returns on capital, even as we continue reinvesting to support sustainable, long -term growth.  This \nstrong free cash flow generation provides financial fle xibility to execute a balanced capital allocation approach, \nincluding investing in our strategic growth pillars of oncology and biopharma services, while remaining committed \nto returning capital to shareholders through our growing dividend and share repurc hases.  Our investment -grade \ncredit rating remains a priority, and it underpins our financial flexibility.  \n \n For fiscal 2022, we continue to anticipate free cash flow of approximately $3.5 billion to $3.9 billion, which is net of \nproperty acquisitions and ca pitalized software expenses.  As a reminder, historically we generate a larger portion \nof our cash flows in the fourth quarter of our fiscal year. ", "original_text": "This \nstrong free cash flow generation provides financial fle xibility to execute a balanced capital allocation approach, \nincluding investing in our strategic growth pillars of oncology and biopharma services, while remaining committed \nto returning capital to shareholders through our growing dividend and share repurc hases. ", "page_label": "11", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c141f33a43ec541fce6a972fa77ba85801c0a8528357aa0830906162443adc4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "551bd446-fb15-4021-80ac-36ca6fe34b96", "node_type": "1", "metadata": {"window": "We expect our businesses to continue to drive strong free \ncash flows and returns on capital, even as we continue reinvesting to support sustainable, long -term growth.  This \nstrong free cash flow generation provides financial fle xibility to execute a balanced capital allocation approach, \nincluding investing in our strategic growth pillars of oncology and biopharma services, while remaining committed \nto returning capital to shareholders through our growing dividend and share repurc hases.  Our investment -grade \ncredit rating remains a priority, and it underpins our financial flexibility.  \n \n For fiscal 2022, we continue to anticipate free cash flow of approximately $3.5 billion to $3.9 billion, which is net of \nproperty acquisitions and ca pitalized software expenses.  As a reminder, historically we generate a larger portion \nof our cash flows in the fourth quarter of our fiscal year.  Our working capital metrics and resulting cash flows vary \nfrom quarter to quarter, impacted by timing, which c ould include the timing of planned European divestiture \nactivity.  \n \n We also now anticipate diluted weighted shares outstanding to range from 154 million to 155 million for fiscal \n2022. ", "original_text": "For fiscal 2022, we continue to anticipate free cash flow of approximately $3.5 billion to $3.9 billion, which is net of \nproperty acquisitions and ca pitalized software expenses. "}, "hash": "5098134af91cb1ba5634ba1c705b30b9e9881dd14ace77684ca596f9d22d056d", "class_name": "RelatedNodeInfo"}}, "text": "Our investment -grade \ncredit rating remains a priority, and it underpins our financial flexibility.  \n \n", "start_char_idx": 1521, "end_char_idx": 1626, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "551bd446-fb15-4021-80ac-36ca6fe34b96": {"__data__": {"id_": "551bd446-fb15-4021-80ac-36ca6fe34b96", "embedding": null, "metadata": {"window": "We expect our businesses to continue to drive strong free \ncash flows and returns on capital, even as we continue reinvesting to support sustainable, long -term growth.  This \nstrong free cash flow generation provides financial fle xibility to execute a balanced capital allocation approach, \nincluding investing in our strategic growth pillars of oncology and biopharma services, while remaining committed \nto returning capital to shareholders through our growing dividend and share repurc hases.  Our investment -grade \ncredit rating remains a priority, and it underpins our financial flexibility.  \n \n For fiscal 2022, we continue to anticipate free cash flow of approximately $3.5 billion to $3.9 billion, which is net of \nproperty acquisitions and ca pitalized software expenses.  As a reminder, historically we generate a larger portion \nof our cash flows in the fourth quarter of our fiscal year.  Our working capital metrics and resulting cash flows vary \nfrom quarter to quarter, impacted by timing, which c ould include the timing of planned European divestiture \nactivity.  \n \n We also now anticipate diluted weighted shares outstanding to range from 154 million to 155 million for fiscal \n2022. ", "original_text": "For fiscal 2022, we continue to anticipate free cash flow of approximately $3.5 billion to $3.9 billion, which is net of \nproperty acquisitions and ca pitalized software expenses. ", "page_label": "11", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f7e2d2dd-66c9-4d9a-9d5a-780ab89c5595", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "064981fa9dba8cb6d85dd4c1bebc81e647f1d60ad3a75dbc51c19a730b907148", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1bff5aac-0336-4399-a27b-36e6840f002c", "node_type": "1", "metadata": {"window": "Let me now turn to cash flow and capital deployment.  We expect our businesses to continue to drive strong free \ncash flows and returns on capital, even as we continue reinvesting to support sustainable, long -term growth.  This \nstrong free cash flow generation provides financial fle xibility to execute a balanced capital allocation approach, \nincluding investing in our strategic growth pillars of oncology and biopharma services, while remaining committed \nto returning capital to shareholders through our growing dividend and share repurc hases.  Our investment -grade \ncredit rating remains a priority, and it underpins our financial flexibility.  \n \n For fiscal 2022, we continue to anticipate free cash flow of approximately $3.5 billion to $3.9 billion, which is net of \nproperty acquisitions and ca pitalized software expenses.  As a reminder, historically we generate a larger portion \nof our cash flows in the fourth quarter of our fiscal year.  Our working capital metrics and resulting cash flows vary \nfrom quarter to quarter, impacted by timing, which c ould include the timing of planned European divestiture \nactivity.  \n \n", "original_text": "Our investment -grade \ncredit rating remains a priority, and it underpins our financial flexibility.  \n \n", "page_label": "11", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "45a7d00f724a2c51feb6e23a3c1bd7353d25b4181c12b42dff0ed39b6e6bed32", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4bd2039b-9f94-41b3-9f65-b19bc647d3a9", "node_type": "1", "metadata": {"window": "This \nstrong free cash flow generation provides financial fle xibility to execute a balanced capital allocation approach, \nincluding investing in our strategic growth pillars of oncology and biopharma services, while remaining committed \nto returning capital to shareholders through our growing dividend and share repurc hases.  Our investment -grade \ncredit rating remains a priority, and it underpins our financial flexibility.  \n \n For fiscal 2022, we continue to anticipate free cash flow of approximately $3.5 billion to $3.9 billion, which is net of \nproperty acquisitions and ca pitalized software expenses.  As a reminder, historically we generate a larger portion \nof our cash flows in the fourth quarter of our fiscal year.  Our working capital metrics and resulting cash flows vary \nfrom quarter to quarter, impacted by timing, which c ould include the timing of planned European divestiture \nactivity.  \n \n We also now anticipate diluted weighted shares outstanding to range from 154 million to 155 million for fiscal \n2022.  This includes the impact of the anticipated $1.5 billion of fourth quart er share repurchases mentioned \nearlier.  \n \n", "original_text": "As a reminder, historically we generate a larger portion \nof our cash flows in the fourth quarter of our fiscal year. "}, "hash": "83a01e6f6ef9589ca39f239385ccd20b7d9f416902a673a87c74e27d54b95011", "class_name": "RelatedNodeInfo"}}, "text": "For fiscal 2022, we continue to anticipate free cash flow of approximately $3.5 billion to $3.9 billion, which is net of \nproperty acquisitions and ca pitalized software expenses. ", "start_char_idx": 1626, "end_char_idx": 1806, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4bd2039b-9f94-41b3-9f65-b19bc647d3a9": {"__data__": {"id_": "4bd2039b-9f94-41b3-9f65-b19bc647d3a9", "embedding": null, "metadata": {"window": "This \nstrong free cash flow generation provides financial fle xibility to execute a balanced capital allocation approach, \nincluding investing in our strategic growth pillars of oncology and biopharma services, while remaining committed \nto returning capital to shareholders through our growing dividend and share repurc hases.  Our investment -grade \ncredit rating remains a priority, and it underpins our financial flexibility.  \n \n For fiscal 2022, we continue to anticipate free cash flow of approximately $3.5 billion to $3.9 billion, which is net of \nproperty acquisitions and ca pitalized software expenses.  As a reminder, historically we generate a larger portion \nof our cash flows in the fourth quarter of our fiscal year.  Our working capital metrics and resulting cash flows vary \nfrom quarter to quarter, impacted by timing, which c ould include the timing of planned European divestiture \nactivity.  \n \n We also now anticipate diluted weighted shares outstanding to range from 154 million to 155 million for fiscal \n2022.  This includes the impact of the anticipated $1.5 billion of fourth quart er share repurchases mentioned \nearlier.  \n \n", "original_text": "As a reminder, historically we generate a larger portion \nof our cash flows in the fourth quarter of our fiscal year. ", "page_label": "11", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f7e2d2dd-66c9-4d9a-9d5a-780ab89c5595", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "064981fa9dba8cb6d85dd4c1bebc81e647f1d60ad3a75dbc51c19a730b907148", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "551bd446-fb15-4021-80ac-36ca6fe34b96", "node_type": "1", "metadata": {"window": "We expect our businesses to continue to drive strong free \ncash flows and returns on capital, even as we continue reinvesting to support sustainable, long -term growth.  This \nstrong free cash flow generation provides financial fle xibility to execute a balanced capital allocation approach, \nincluding investing in our strategic growth pillars of oncology and biopharma services, while remaining committed \nto returning capital to shareholders through our growing dividend and share repurc hases.  Our investment -grade \ncredit rating remains a priority, and it underpins our financial flexibility.  \n \n For fiscal 2022, we continue to anticipate free cash flow of approximately $3.5 billion to $3.9 billion, which is net of \nproperty acquisitions and ca pitalized software expenses.  As a reminder, historically we generate a larger portion \nof our cash flows in the fourth quarter of our fiscal year.  Our working capital metrics and resulting cash flows vary \nfrom quarter to quarter, impacted by timing, which c ould include the timing of planned European divestiture \nactivity.  \n \n We also now anticipate diluted weighted shares outstanding to range from 154 million to 155 million for fiscal \n2022. ", "original_text": "For fiscal 2022, we continue to anticipate free cash flow of approximately $3.5 billion to $3.9 billion, which is net of \nproperty acquisitions and ca pitalized software expenses. ", "page_label": "11", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4480dd76a78a47dd4d898f9470816128afd769d70e30c84b78067b317cccf49e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a6cb4269-ddb1-4e0c-8d1c-ee7b3356e31e", "node_type": "1", "metadata": {"window": "Our investment -grade \ncredit rating remains a priority, and it underpins our financial flexibility.  \n \n For fiscal 2022, we continue to anticipate free cash flow of approximately $3.5 billion to $3.9 billion, which is net of \nproperty acquisitions and ca pitalized software expenses.  As a reminder, historically we generate a larger portion \nof our cash flows in the fourth quarter of our fiscal year.  Our working capital metrics and resulting cash flows vary \nfrom quarter to quarter, impacted by timing, which c ould include the timing of planned European divestiture \nactivity.  \n \n We also now anticipate diluted weighted shares outstanding to range from 154 million to 155 million for fiscal \n2022.  This includes the impact of the anticipated $1.5 billion of fourth quart er share repurchases mentioned \nearlier.  \n \n As a result of our strong year -to-date performance and our outlook for the remainder of the fiscal year, we are \nraising and narrowing our previous adjusted earnings per share guidance range to $23.55 to $23.95, whic h is \nabove our previous range of $22.35 to $22.95. ", "original_text": "Our working capital metrics and resulting cash flows vary \nfrom quarter to quarter, impacted by timing, which c ould include the timing of planned European divestiture \nactivity.  \n \n"}, "hash": "f2eca19a05c026285c4b83cd8342d418cfad5d5900e0c6b995bd15498fa63cb2", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, historically we generate a larger portion \nof our cash flows in the fourth quarter of our fiscal year. ", "start_char_idx": 1806, "end_char_idx": 1924, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a6cb4269-ddb1-4e0c-8d1c-ee7b3356e31e": {"__data__": {"id_": "a6cb4269-ddb1-4e0c-8d1c-ee7b3356e31e", "embedding": null, "metadata": {"window": "Our investment -grade \ncredit rating remains a priority, and it underpins our financial flexibility.  \n \n For fiscal 2022, we continue to anticipate free cash flow of approximately $3.5 billion to $3.9 billion, which is net of \nproperty acquisitions and ca pitalized software expenses.  As a reminder, historically we generate a larger portion \nof our cash flows in the fourth quarter of our fiscal year.  Our working capital metrics and resulting cash flows vary \nfrom quarter to quarter, impacted by timing, which c ould include the timing of planned European divestiture \nactivity.  \n \n We also now anticipate diluted weighted shares outstanding to range from 154 million to 155 million for fiscal \n2022.  This includes the impact of the anticipated $1.5 billion of fourth quart er share repurchases mentioned \nearlier.  \n \n As a result of our strong year -to-date performance and our outlook for the remainder of the fiscal year, we are \nraising and narrowing our previous adjusted earnings per share guidance range to $23.55 to $23.95, whic h is \nabove our previous range of $22.35 to $22.95. ", "original_text": "Our working capital metrics and resulting cash flows vary \nfrom quarter to quarter, impacted by timing, which c ould include the timing of planned European divestiture \nactivity.  \n \n", "page_label": "11", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f7e2d2dd-66c9-4d9a-9d5a-780ab89c5595", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "064981fa9dba8cb6d85dd4c1bebc81e647f1d60ad3a75dbc51c19a730b907148", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4bd2039b-9f94-41b3-9f65-b19bc647d3a9", "node_type": "1", "metadata": {"window": "This \nstrong free cash flow generation provides financial fle xibility to execute a balanced capital allocation approach, \nincluding investing in our strategic growth pillars of oncology and biopharma services, while remaining committed \nto returning capital to shareholders through our growing dividend and share repurc hases.  Our investment -grade \ncredit rating remains a priority, and it underpins our financial flexibility.  \n \n For fiscal 2022, we continue to anticipate free cash flow of approximately $3.5 billion to $3.9 billion, which is net of \nproperty acquisitions and ca pitalized software expenses.  As a reminder, historically we generate a larger portion \nof our cash flows in the fourth quarter of our fiscal year.  Our working capital metrics and resulting cash flows vary \nfrom quarter to quarter, impacted by timing, which c ould include the timing of planned European divestiture \nactivity.  \n \n We also now anticipate diluted weighted shares outstanding to range from 154 million to 155 million for fiscal \n2022.  This includes the impact of the anticipated $1.5 billion of fourth quart er share repurchases mentioned \nearlier.  \n \n", "original_text": "As a reminder, historically we generate a larger portion \nof our cash flows in the fourth quarter of our fiscal year. ", "page_label": "11", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b02ae60915add5b29db341e78ae84aa427be9d0195aec379970322039d191623", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "915ba775-ced9-42be-97ea-745b3aaded44", "node_type": "1", "metadata": {"window": "For fiscal 2022, we continue to anticipate free cash flow of approximately $3.5 billion to $3.9 billion, which is net of \nproperty acquisitions and ca pitalized software expenses.  As a reminder, historically we generate a larger portion \nof our cash flows in the fourth quarter of our fiscal year.  Our working capital metrics and resulting cash flows vary \nfrom quarter to quarter, impacted by timing, which c ould include the timing of planned European divestiture \nactivity.  \n \n We also now anticipate diluted weighted shares outstanding to range from 154 million to 155 million for fiscal \n2022.  This includes the impact of the anticipated $1.5 billion of fourth quart er share repurchases mentioned \nearlier.  \n \n As a result of our strong year -to-date performance and our outlook for the remainder of the fiscal year, we are \nraising and narrowing our previous adjusted earnings per share guidance range to $23.55 to $23.95, whic h is \nabove our previous range of $22.35 to $22.95.  Our updated outlook for adjusted earnings per diluted share \nreflects 37% to 39% growth compared to the prior year.  \n \n", "original_text": "We also now anticipate diluted weighted shares outstanding to range from 154 million to 155 million for fiscal \n2022. "}, "hash": "a90fcd4e313869465a8bb63fa86eac84190d3384f52799b1e3ea26c3e56841d0", "class_name": "RelatedNodeInfo"}}, "text": "Our working capital metrics and resulting cash flows vary \nfrom quarter to quarter, impacted by timing, which c ould include the timing of planned European divestiture \nactivity.  \n \n", "start_char_idx": 1924, "end_char_idx": 2107, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "915ba775-ced9-42be-97ea-745b3aaded44": {"__data__": {"id_": "915ba775-ced9-42be-97ea-745b3aaded44", "embedding": null, "metadata": {"window": "For fiscal 2022, we continue to anticipate free cash flow of approximately $3.5 billion to $3.9 billion, which is net of \nproperty acquisitions and ca pitalized software expenses.  As a reminder, historically we generate a larger portion \nof our cash flows in the fourth quarter of our fiscal year.  Our working capital metrics and resulting cash flows vary \nfrom quarter to quarter, impacted by timing, which c ould include the timing of planned European divestiture \nactivity.  \n \n We also now anticipate diluted weighted shares outstanding to range from 154 million to 155 million for fiscal \n2022.  This includes the impact of the anticipated $1.5 billion of fourth quart er share repurchases mentioned \nearlier.  \n \n As a result of our strong year -to-date performance and our outlook for the remainder of the fiscal year, we are \nraising and narrowing our previous adjusted earnings per share guidance range to $23.55 to $23.95, whic h is \nabove our previous range of $22.35 to $22.95.  Our updated outlook for adjusted earnings per diluted share \nreflects 37% to 39% growth compared to the prior year.  \n \n", "original_text": "We also now anticipate diluted weighted shares outstanding to range from 154 million to 155 million for fiscal \n2022. ", "page_label": "11", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f7e2d2dd-66c9-4d9a-9d5a-780ab89c5595", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "064981fa9dba8cb6d85dd4c1bebc81e647f1d60ad3a75dbc51c19a730b907148", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a6cb4269-ddb1-4e0c-8d1c-ee7b3356e31e", "node_type": "1", "metadata": {"window": "Our investment -grade \ncredit rating remains a priority, and it underpins our financial flexibility.  \n \n For fiscal 2022, we continue to anticipate free cash flow of approximately $3.5 billion to $3.9 billion, which is net of \nproperty acquisitions and ca pitalized software expenses.  As a reminder, historically we generate a larger portion \nof our cash flows in the fourth quarter of our fiscal year.  Our working capital metrics and resulting cash flows vary \nfrom quarter to quarter, impacted by timing, which c ould include the timing of planned European divestiture \nactivity.  \n \n We also now anticipate diluted weighted shares outstanding to range from 154 million to 155 million for fiscal \n2022.  This includes the impact of the anticipated $1.5 billion of fourth quart er share repurchases mentioned \nearlier.  \n \n As a result of our strong year -to-date performance and our outlook for the remainder of the fiscal year, we are \nraising and narrowing our previous adjusted earnings per share guidance range to $23.55 to $23.95, whic h is \nabove our previous range of $22.35 to $22.95. ", "original_text": "Our working capital metrics and resulting cash flows vary \nfrom quarter to quarter, impacted by timing, which c ould include the timing of planned European divestiture \nactivity.  \n \n", "page_label": "11", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3c414d3c1051e2ded67bc72e94dbe302ca38cfdb2a644e86227aa0b2b59aafcc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0487e2ca-a05f-44fe-9f2d-e357486172f2", "node_type": "1", "metadata": {"window": "As a reminder, historically we generate a larger portion \nof our cash flows in the fourth quarter of our fiscal year.  Our working capital metrics and resulting cash flows vary \nfrom quarter to quarter, impacted by timing, which c ould include the timing of planned European divestiture \nactivity.  \n \n We also now anticipate diluted weighted shares outstanding to range from 154 million to 155 million for fiscal \n2022.  This includes the impact of the anticipated $1.5 billion of fourth quart er share repurchases mentioned \nearlier.  \n \n As a result of our strong year -to-date performance and our outlook for the remainder of the fiscal year, we are \nraising and narrowing our previous adjusted earnings per share guidance range to $23.55 to $23.95, whic h is \nabove our previous range of $22.35 to $22.95.  Our updated outlook for adjusted earnings per diluted share \nreflects 37% to 39% growth compared to the prior year.  \n \n Fiscal 2022 adjusted earnings per diluted share guidance also includes $2.99 to $3.59 of contribution attributable \nto the following items: $0.90 to $1.10 related to the US government's COVID -19 vaccine distribution, $0.85 to \n$1.05 related to the kitting, storage, and distribution of ancillary supplies, $0.75 to $0.95 related to COVID -19 \ntests and the fiscal 2021 impairments for PPE and related products, which is an increase from the previous range \nof $0.50 to $0.75, and approximately $0.49 from gains and losses associated with McKesson Ventures' equity \ninvestments, which are within our Corporat e segment.  \n \n", "original_text": "This includes the impact of the anticipated $1.5 billion of fourth quart er share repurchases mentioned \nearlier.  \n \n"}, "hash": "b16b191eba905a30e8fa0aa71fd823b0ccb374107691cbba6806b62d2d8cfea9", "class_name": "RelatedNodeInfo"}}, "text": "We also now anticipate diluted weighted shares outstanding to range from 154 million to 155 million for fiscal \n2022. ", "start_char_idx": 2107, "end_char_idx": 2225, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0487e2ca-a05f-44fe-9f2d-e357486172f2": {"__data__": {"id_": "0487e2ca-a05f-44fe-9f2d-e357486172f2", "embedding": null, "metadata": {"window": "As a reminder, historically we generate a larger portion \nof our cash flows in the fourth quarter of our fiscal year.  Our working capital metrics and resulting cash flows vary \nfrom quarter to quarter, impacted by timing, which c ould include the timing of planned European divestiture \nactivity.  \n \n We also now anticipate diluted weighted shares outstanding to range from 154 million to 155 million for fiscal \n2022.  This includes the impact of the anticipated $1.5 billion of fourth quart er share repurchases mentioned \nearlier.  \n \n As a result of our strong year -to-date performance and our outlook for the remainder of the fiscal year, we are \nraising and narrowing our previous adjusted earnings per share guidance range to $23.55 to $23.95, whic h is \nabove our previous range of $22.35 to $22.95.  Our updated outlook for adjusted earnings per diluted share \nreflects 37% to 39% growth compared to the prior year.  \n \n Fiscal 2022 adjusted earnings per diluted share guidance also includes $2.99 to $3.59 of contribution attributable \nto the following items: $0.90 to $1.10 related to the US government's COVID -19 vaccine distribution, $0.85 to \n$1.05 related to the kitting, storage, and distribution of ancillary supplies, $0.75 to $0.95 related to COVID -19 \ntests and the fiscal 2021 impairments for PPE and related products, which is an increase from the previous range \nof $0.50 to $0.75, and approximately $0.49 from gains and losses associated with McKesson Ventures' equity \ninvestments, which are within our Corporat e segment.  \n \n", "original_text": "This includes the impact of the anticipated $1.5 billion of fourth quart er share repurchases mentioned \nearlier.  \n \n", "page_label": "11", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f7e2d2dd-66c9-4d9a-9d5a-780ab89c5595", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "064981fa9dba8cb6d85dd4c1bebc81e647f1d60ad3a75dbc51c19a730b907148", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "915ba775-ced9-42be-97ea-745b3aaded44", "node_type": "1", "metadata": {"window": "For fiscal 2022, we continue to anticipate free cash flow of approximately $3.5 billion to $3.9 billion, which is net of \nproperty acquisitions and ca pitalized software expenses.  As a reminder, historically we generate a larger portion \nof our cash flows in the fourth quarter of our fiscal year.  Our working capital metrics and resulting cash flows vary \nfrom quarter to quarter, impacted by timing, which c ould include the timing of planned European divestiture \nactivity.  \n \n We also now anticipate diluted weighted shares outstanding to range from 154 million to 155 million for fiscal \n2022.  This includes the impact of the anticipated $1.5 billion of fourth quart er share repurchases mentioned \nearlier.  \n \n As a result of our strong year -to-date performance and our outlook for the remainder of the fiscal year, we are \nraising and narrowing our previous adjusted earnings per share guidance range to $23.55 to $23.95, whic h is \nabove our previous range of $22.35 to $22.95.  Our updated outlook for adjusted earnings per diluted share \nreflects 37% to 39% growth compared to the prior year.  \n \n", "original_text": "We also now anticipate diluted weighted shares outstanding to range from 154 million to 155 million for fiscal \n2022. ", "page_label": "11", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9b4060845c9763e88be435949abe45a33ed5d30a01632d952811cd7d50d955bc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f5bbc06e-f848-4043-aed5-a6c196f18861", "node_type": "1", "metadata": {"window": "Our working capital metrics and resulting cash flows vary \nfrom quarter to quarter, impacted by timing, which c ould include the timing of planned European divestiture \nactivity.  \n \n We also now anticipate diluted weighted shares outstanding to range from 154 million to 155 million for fiscal \n2022.  This includes the impact of the anticipated $1.5 billion of fourth quart er share repurchases mentioned \nearlier.  \n \n As a result of our strong year -to-date performance and our outlook for the remainder of the fiscal year, we are \nraising and narrowing our previous adjusted earnings per share guidance range to $23.55 to $23.95, whic h is \nabove our previous range of $22.35 to $22.95.  Our updated outlook for adjusted earnings per diluted share \nreflects 37% to 39% growth compared to the prior year.  \n \n Fiscal 2022 adjusted earnings per diluted share guidance also includes $2.99 to $3.59 of contribution attributable \nto the following items: $0.90 to $1.10 related to the US government's COVID -19 vaccine distribution, $0.85 to \n$1.05 related to the kitting, storage, and distribution of ancillary supplies, $0.75 to $0.95 related to COVID -19 \ntests and the fiscal 2021 impairments for PPE and related products, which is an increase from the previous range \nof $0.50 to $0.75, and approximately $0.49 from gains and losses associated with McKesson Ventures' equity \ninvestments, which are within our Corporat e segment.  \n \n Excluding the impacts of these items from both fiscal 2022 guidance and fiscal 2021 results, this indicates 27% to \n33% forecast growth over the prior year.  \n \n", "original_text": "As a result of our strong year -to-date performance and our outlook for the remainder of the fiscal year, we are \nraising and narrowing our previous adjusted earnings per share guidance range to $23.55 to $23.95, whic h is \nabove our previous range of $22.35 to $22.95. "}, "hash": "c2189c5d7bf535ec03c60b6d0371960386fa95b11392f21929627ac0416bfc02", "class_name": "RelatedNodeInfo"}}, "text": "This includes the impact of the anticipated $1.5 billion of fourth quart er share repurchases mentioned \nearlier.  \n \n", "start_char_idx": 2225, "end_char_idx": 2343, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f5bbc06e-f848-4043-aed5-a6c196f18861": {"__data__": {"id_": "f5bbc06e-f848-4043-aed5-a6c196f18861", "embedding": null, "metadata": {"window": "Our working capital metrics and resulting cash flows vary \nfrom quarter to quarter, impacted by timing, which c ould include the timing of planned European divestiture \nactivity.  \n \n We also now anticipate diluted weighted shares outstanding to range from 154 million to 155 million for fiscal \n2022.  This includes the impact of the anticipated $1.5 billion of fourth quart er share repurchases mentioned \nearlier.  \n \n As a result of our strong year -to-date performance and our outlook for the remainder of the fiscal year, we are \nraising and narrowing our previous adjusted earnings per share guidance range to $23.55 to $23.95, whic h is \nabove our previous range of $22.35 to $22.95.  Our updated outlook for adjusted earnings per diluted share \nreflects 37% to 39% growth compared to the prior year.  \n \n Fiscal 2022 adjusted earnings per diluted share guidance also includes $2.99 to $3.59 of contribution attributable \nto the following items: $0.90 to $1.10 related to the US government's COVID -19 vaccine distribution, $0.85 to \n$1.05 related to the kitting, storage, and distribution of ancillary supplies, $0.75 to $0.95 related to COVID -19 \ntests and the fiscal 2021 impairments for PPE and related products, which is an increase from the previous range \nof $0.50 to $0.75, and approximately $0.49 from gains and losses associated with McKesson Ventures' equity \ninvestments, which are within our Corporat e segment.  \n \n Excluding the impacts of these items from both fiscal 2022 guidance and fiscal 2021 results, this indicates 27% to \n33% forecast growth over the prior year.  \n \n", "original_text": "As a result of our strong year -to-date performance and our outlook for the remainder of the fiscal year, we are \nraising and narrowing our previous adjusted earnings per share guidance range to $23.55 to $23.95, whic h is \nabove our previous range of $22.35 to $22.95. ", "page_label": "11", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f7e2d2dd-66c9-4d9a-9d5a-780ab89c5595", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "064981fa9dba8cb6d85dd4c1bebc81e647f1d60ad3a75dbc51c19a730b907148", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0487e2ca-a05f-44fe-9f2d-e357486172f2", "node_type": "1", "metadata": {"window": "As a reminder, historically we generate a larger portion \nof our cash flows in the fourth quarter of our fiscal year.  Our working capital metrics and resulting cash flows vary \nfrom quarter to quarter, impacted by timing, which c ould include the timing of planned European divestiture \nactivity.  \n \n We also now anticipate diluted weighted shares outstanding to range from 154 million to 155 million for fiscal \n2022.  This includes the impact of the anticipated $1.5 billion of fourth quart er share repurchases mentioned \nearlier.  \n \n As a result of our strong year -to-date performance and our outlook for the remainder of the fiscal year, we are \nraising and narrowing our previous adjusted earnings per share guidance range to $23.55 to $23.95, whic h is \nabove our previous range of $22.35 to $22.95.  Our updated outlook for adjusted earnings per diluted share \nreflects 37% to 39% growth compared to the prior year.  \n \n Fiscal 2022 adjusted earnings per diluted share guidance also includes $2.99 to $3.59 of contribution attributable \nto the following items: $0.90 to $1.10 related to the US government's COVID -19 vaccine distribution, $0.85 to \n$1.05 related to the kitting, storage, and distribution of ancillary supplies, $0.75 to $0.95 related to COVID -19 \ntests and the fiscal 2021 impairments for PPE and related products, which is an increase from the previous range \nof $0.50 to $0.75, and approximately $0.49 from gains and losses associated with McKesson Ventures' equity \ninvestments, which are within our Corporat e segment.  \n \n", "original_text": "This includes the impact of the anticipated $1.5 billion of fourth quart er share repurchases mentioned \nearlier.  \n \n", "page_label": "11", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e502c0998ed7f1986ad268c6a02f0c968016c2972858e09fd4ff8347a9dbb5e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7268c014-beef-465c-bf7e-90b3125a1786", "node_type": "1", "metadata": {"window": "We also now anticipate diluted weighted shares outstanding to range from 154 million to 155 million for fiscal \n2022.  This includes the impact of the anticipated $1.5 billion of fourth quart er share repurchases mentioned \nearlier.  \n \n As a result of our strong year -to-date performance and our outlook for the remainder of the fiscal year, we are \nraising and narrowing our previous adjusted earnings per share guidance range to $23.55 to $23.95, whic h is \nabove our previous range of $22.35 to $22.95.  Our updated outlook for adjusted earnings per diluted share \nreflects 37% to 39% growth compared to the prior year.  \n \n Fiscal 2022 adjusted earnings per diluted share guidance also includes $2.99 to $3.59 of contribution attributable \nto the following items: $0.90 to $1.10 related to the US government's COVID -19 vaccine distribution, $0.85 to \n$1.05 related to the kitting, storage, and distribution of ancillary supplies, $0.75 to $0.95 related to COVID -19 \ntests and the fiscal 2021 impairments for PPE and related products, which is an increase from the previous range \nof $0.50 to $0.75, and approximately $0.49 from gains and losses associated with McKesson Ventures' equity \ninvestments, which are within our Corporat e segment.  \n \n Excluding the impacts of these items from both fiscal 2022 guidance and fiscal 2021 results, this indicates 27% to \n33% forecast growth over the prior year.  \n \n When you pull it all together, our strong performance in our outlook equates to an adju sted earnings per diluted \nshare guidance increase of $1.10 compared to our previous fiscal 2022 outlook provided at Investor Day. ", "original_text": "Our updated outlook for adjusted earnings per diluted share \nreflects 37% to 39% growth compared to the prior year.  \n \n"}, "hash": "342f8563950d5388e598f8841b451f75b7f9b04ba7e6dec8373a9fa8ca4c01dd", "class_name": "RelatedNodeInfo"}}, "text": "As a result of our strong year -to-date performance and our outlook for the remainder of the fiscal year, we are \nraising and narrowing our previous adjusted earnings per share guidance range to $23.55 to $23.95, whic h is \nabove our previous range of $22.35 to $22.95. ", "start_char_idx": 2343, "end_char_idx": 2613, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7268c014-beef-465c-bf7e-90b3125a1786": {"__data__": {"id_": "7268c014-beef-465c-bf7e-90b3125a1786", "embedding": null, "metadata": {"window": "We also now anticipate diluted weighted shares outstanding to range from 154 million to 155 million for fiscal \n2022.  This includes the impact of the anticipated $1.5 billion of fourth quart er share repurchases mentioned \nearlier.  \n \n As a result of our strong year -to-date performance and our outlook for the remainder of the fiscal year, we are \nraising and narrowing our previous adjusted earnings per share guidance range to $23.55 to $23.95, whic h is \nabove our previous range of $22.35 to $22.95.  Our updated outlook for adjusted earnings per diluted share \nreflects 37% to 39% growth compared to the prior year.  \n \n Fiscal 2022 adjusted earnings per diluted share guidance also includes $2.99 to $3.59 of contribution attributable \nto the following items: $0.90 to $1.10 related to the US government's COVID -19 vaccine distribution, $0.85 to \n$1.05 related to the kitting, storage, and distribution of ancillary supplies, $0.75 to $0.95 related to COVID -19 \ntests and the fiscal 2021 impairments for PPE and related products, which is an increase from the previous range \nof $0.50 to $0.75, and approximately $0.49 from gains and losses associated with McKesson Ventures' equity \ninvestments, which are within our Corporat e segment.  \n \n Excluding the impacts of these items from both fiscal 2022 guidance and fiscal 2021 results, this indicates 27% to \n33% forecast growth over the prior year.  \n \n When you pull it all together, our strong performance in our outlook equates to an adju sted earnings per diluted \nshare guidance increase of $1.10 compared to our previous fiscal 2022 outlook provided at Investor Day. ", "original_text": "Our updated outlook for adjusted earnings per diluted share \nreflects 37% to 39% growth compared to the prior year.  \n \n", "page_label": "11", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f7e2d2dd-66c9-4d9a-9d5a-780ab89c5595", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "064981fa9dba8cb6d85dd4c1bebc81e647f1d60ad3a75dbc51c19a730b907148", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f5bbc06e-f848-4043-aed5-a6c196f18861", "node_type": "1", "metadata": {"window": "Our working capital metrics and resulting cash flows vary \nfrom quarter to quarter, impacted by timing, which c ould include the timing of planned European divestiture \nactivity.  \n \n We also now anticipate diluted weighted shares outstanding to range from 154 million to 155 million for fiscal \n2022.  This includes the impact of the anticipated $1.5 billion of fourth quart er share repurchases mentioned \nearlier.  \n \n As a result of our strong year -to-date performance and our outlook for the remainder of the fiscal year, we are \nraising and narrowing our previous adjusted earnings per share guidance range to $23.55 to $23.95, whic h is \nabove our previous range of $22.35 to $22.95.  Our updated outlook for adjusted earnings per diluted share \nreflects 37% to 39% growth compared to the prior year.  \n \n Fiscal 2022 adjusted earnings per diluted share guidance also includes $2.99 to $3.59 of contribution attributable \nto the following items: $0.90 to $1.10 related to the US government's COVID -19 vaccine distribution, $0.85 to \n$1.05 related to the kitting, storage, and distribution of ancillary supplies, $0.75 to $0.95 related to COVID -19 \ntests and the fiscal 2021 impairments for PPE and related products, which is an increase from the previous range \nof $0.50 to $0.75, and approximately $0.49 from gains and losses associated with McKesson Ventures' equity \ninvestments, which are within our Corporat e segment.  \n \n Excluding the impacts of these items from both fiscal 2022 guidance and fiscal 2021 results, this indicates 27% to \n33% forecast growth over the prior year.  \n \n", "original_text": "As a result of our strong year -to-date performance and our outlook for the remainder of the fiscal year, we are \nraising and narrowing our previous adjusted earnings per share guidance range to $23.55 to $23.95, whic h is \nabove our previous range of $22.35 to $22.95. ", "page_label": "11", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e47d78562785102cedd880d5b496937abd0194c7d93642b195ccb96157b7c3e3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "51c2a2d6-0639-4e01-8f78-33456232bd01", "node_type": "1", "metadata": {"window": "This includes the impact of the anticipated $1.5 billion of fourth quart er share repurchases mentioned \nearlier.  \n \n As a result of our strong year -to-date performance and our outlook for the remainder of the fiscal year, we are \nraising and narrowing our previous adjusted earnings per share guidance range to $23.55 to $23.95, whic h is \nabove our previous range of $22.35 to $22.95.  Our updated outlook for adjusted earnings per diluted share \nreflects 37% to 39% growth compared to the prior year.  \n \n Fiscal 2022 adjusted earnings per diluted share guidance also includes $2.99 to $3.59 of contribution attributable \nto the following items: $0.90 to $1.10 related to the US government's COVID -19 vaccine distribution, $0.85 to \n$1.05 related to the kitting, storage, and distribution of ancillary supplies, $0.75 to $0.95 related to COVID -19 \ntests and the fiscal 2021 impairments for PPE and related products, which is an increase from the previous range \nof $0.50 to $0.75, and approximately $0.49 from gains and losses associated with McKesson Ventures' equity \ninvestments, which are within our Corporat e segment.  \n \n Excluding the impacts of these items from both fiscal 2022 guidance and fiscal 2021 results, this indicates 27% to \n33% forecast growth over the prior year.  \n \n When you pull it all together, our strong performance in our outlook equates to an adju sted earnings per diluted \nshare guidance increase of $1.10 compared to our previous fiscal 2022 outlook provided at Investor Day.  The \n$1.10 adjusted earnings per diluted share increase includes the following: approximately $0.45 driven by strong \nunderlying  business performance and operating leverage, approximately $0.22 related to COVID -19 tests, \napproximately $0.22 related to held for sale accounting and reduced opioid litigation expenses, and approximately \n$0.20 related to NCI, interest expense and lower weighted average shares outstanding.  ", "original_text": "Fiscal 2022 adjusted earnings per diluted share guidance also includes $2.99 to $3.59 of contribution attributable \nto the following items: $0.90 to $1.10 related to the US government's COVID -19 vaccine distribution, $0.85 to \n$1.05 related to the kitting, storage, and distribution of ancillary supplies, $0.75 to $0.95 related to COVID -19 \ntests and the fiscal 2021 impairments for PPE and related products, which is an increase from the previous range \nof $0.50 to $0.75, and approximately $0.49 from gains and losses associated with McKesson Ventures' equity \ninvestments, which are within our Corporat e segment.  \n \n"}, "hash": "24a3702ed9a95d37b815c7027fd6dc7d9898f9d90957b6e7d6a9a10284c95006", "class_name": "RelatedNodeInfo"}}, "text": "Our updated outlook for adjusted earnings per diluted share \nreflects 37% to 39% growth compared to the prior year.  \n \n", "start_char_idx": 2613, "end_char_idx": 2733, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "51c2a2d6-0639-4e01-8f78-33456232bd01": {"__data__": {"id_": "51c2a2d6-0639-4e01-8f78-33456232bd01", "embedding": null, "metadata": {"window": "This includes the impact of the anticipated $1.5 billion of fourth quart er share repurchases mentioned \nearlier.  \n \n As a result of our strong year -to-date performance and our outlook for the remainder of the fiscal year, we are \nraising and narrowing our previous adjusted earnings per share guidance range to $23.55 to $23.95, whic h is \nabove our previous range of $22.35 to $22.95.  Our updated outlook for adjusted earnings per diluted share \nreflects 37% to 39% growth compared to the prior year.  \n \n Fiscal 2022 adjusted earnings per diluted share guidance also includes $2.99 to $3.59 of contribution attributable \nto the following items: $0.90 to $1.10 related to the US government's COVID -19 vaccine distribution, $0.85 to \n$1.05 related to the kitting, storage, and distribution of ancillary supplies, $0.75 to $0.95 related to COVID -19 \ntests and the fiscal 2021 impairments for PPE and related products, which is an increase from the previous range \nof $0.50 to $0.75, and approximately $0.49 from gains and losses associated with McKesson Ventures' equity \ninvestments, which are within our Corporat e segment.  \n \n Excluding the impacts of these items from both fiscal 2022 guidance and fiscal 2021 results, this indicates 27% to \n33% forecast growth over the prior year.  \n \n When you pull it all together, our strong performance in our outlook equates to an adju sted earnings per diluted \nshare guidance increase of $1.10 compared to our previous fiscal 2022 outlook provided at Investor Day.  The \n$1.10 adjusted earnings per diluted share increase includes the following: approximately $0.45 driven by strong \nunderlying  business performance and operating leverage, approximately $0.22 related to COVID -19 tests, \napproximately $0.22 related to held for sale accounting and reduced opioid litigation expenses, and approximately \n$0.20 related to NCI, interest expense and lower weighted average shares outstanding.  ", "original_text": "Fiscal 2022 adjusted earnings per diluted share guidance also includes $2.99 to $3.59 of contribution attributable \nto the following items: $0.90 to $1.10 related to the US government's COVID -19 vaccine distribution, $0.85 to \n$1.05 related to the kitting, storage, and distribution of ancillary supplies, $0.75 to $0.95 related to COVID -19 \ntests and the fiscal 2021 impairments for PPE and related products, which is an increase from the previous range \nof $0.50 to $0.75, and approximately $0.49 from gains and losses associated with McKesson Ventures' equity \ninvestments, which are within our Corporat e segment.  \n \n", "page_label": "11", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f7e2d2dd-66c9-4d9a-9d5a-780ab89c5595", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "064981fa9dba8cb6d85dd4c1bebc81e647f1d60ad3a75dbc51c19a730b907148", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7268c014-beef-465c-bf7e-90b3125a1786", "node_type": "1", "metadata": {"window": "We also now anticipate diluted weighted shares outstanding to range from 154 million to 155 million for fiscal \n2022.  This includes the impact of the anticipated $1.5 billion of fourth quart er share repurchases mentioned \nearlier.  \n \n As a result of our strong year -to-date performance and our outlook for the remainder of the fiscal year, we are \nraising and narrowing our previous adjusted earnings per share guidance range to $23.55 to $23.95, whic h is \nabove our previous range of $22.35 to $22.95.  Our updated outlook for adjusted earnings per diluted share \nreflects 37% to 39% growth compared to the prior year.  \n \n Fiscal 2022 adjusted earnings per diluted share guidance also includes $2.99 to $3.59 of contribution attributable \nto the following items: $0.90 to $1.10 related to the US government's COVID -19 vaccine distribution, $0.85 to \n$1.05 related to the kitting, storage, and distribution of ancillary supplies, $0.75 to $0.95 related to COVID -19 \ntests and the fiscal 2021 impairments for PPE and related products, which is an increase from the previous range \nof $0.50 to $0.75, and approximately $0.49 from gains and losses associated with McKesson Ventures' equity \ninvestments, which are within our Corporat e segment.  \n \n Excluding the impacts of these items from both fiscal 2022 guidance and fiscal 2021 results, this indicates 27% to \n33% forecast growth over the prior year.  \n \n When you pull it all together, our strong performance in our outlook equates to an adju sted earnings per diluted \nshare guidance increase of $1.10 compared to our previous fiscal 2022 outlook provided at Investor Day. ", "original_text": "Our updated outlook for adjusted earnings per diluted share \nreflects 37% to 39% growth compared to the prior year.  \n \n", "page_label": "11", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0424c08b08d17f8a36b33548b41df13df5e71ddfc9526a1dc38772b609e66f1f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d06dd9e8-aa9b-4d70-a49e-d76a76847115", "node_type": "1", "metadata": {"window": "As a result of our strong year -to-date performance and our outlook for the remainder of the fiscal year, we are \nraising and narrowing our previous adjusted earnings per share guidance range to $23.55 to $23.95, whic h is \nabove our previous range of $22.35 to $22.95.  Our updated outlook for adjusted earnings per diluted share \nreflects 37% to 39% growth compared to the prior year.  \n \n Fiscal 2022 adjusted earnings per diluted share guidance also includes $2.99 to $3.59 of contribution attributable \nto the following items: $0.90 to $1.10 related to the US government's COVID -19 vaccine distribution, $0.85 to \n$1.05 related to the kitting, storage, and distribution of ancillary supplies, $0.75 to $0.95 related to COVID -19 \ntests and the fiscal 2021 impairments for PPE and related products, which is an increase from the previous range \nof $0.50 to $0.75, and approximately $0.49 from gains and losses associated with McKesson Ventures' equity \ninvestments, which are within our Corporat e segment.  \n \n Excluding the impacts of these items from both fiscal 2022 guidance and fiscal 2021 results, this indicates 27% to \n33% forecast growth over the prior year.  \n \n When you pull it all together, our strong performance in our outlook equates to an adju sted earnings per diluted \nshare guidance increase of $1.10 compared to our previous fiscal 2022 outlook provided at Investor Day.  The \n$1.10 adjusted earnings per diluted share increase includes the following: approximately $0.45 driven by strong \nunderlying  business performance and operating leverage, approximately $0.22 related to COVID -19 tests, \napproximately $0.22 related to held for sale accounting and reduced opioid litigation expenses, and approximately \n$0.20 related to NCI, interest expense and lower weighted average shares outstanding.  ", "original_text": "Excluding the impacts of these items from both fiscal 2022 guidance and fiscal 2021 results, this indicates 27% to \n33% forecast growth over the prior year.  \n \n"}, "hash": "1e906dadec7b509270613090dc9057aa90be123956a0ebe9434b17dbffc34519", "class_name": "RelatedNodeInfo"}}, "text": "Fiscal 2022 adjusted earnings per diluted share guidance also includes $2.99 to $3.59 of contribution attributable \nto the following items: $0.90 to $1.10 related to the US government's COVID -19 vaccine distribution, $0.85 to \n$1.05 related to the kitting, storage, and distribution of ancillary supplies, $0.75 to $0.95 related to COVID -19 \ntests and the fiscal 2021 impairments for PPE and related products, which is an increase from the previous range \nof $0.50 to $0.75, and approximately $0.49 from gains and losses associated with McKesson Ventures' equity \ninvestments, which are within our Corporat e segment.  \n \n", "start_char_idx": 2733, "end_char_idx": 3357, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d06dd9e8-aa9b-4d70-a49e-d76a76847115": {"__data__": {"id_": "d06dd9e8-aa9b-4d70-a49e-d76a76847115", "embedding": null, "metadata": {"window": "As a result of our strong year -to-date performance and our outlook for the remainder of the fiscal year, we are \nraising and narrowing our previous adjusted earnings per share guidance range to $23.55 to $23.95, whic h is \nabove our previous range of $22.35 to $22.95.  Our updated outlook for adjusted earnings per diluted share \nreflects 37% to 39% growth compared to the prior year.  \n \n Fiscal 2022 adjusted earnings per diluted share guidance also includes $2.99 to $3.59 of contribution attributable \nto the following items: $0.90 to $1.10 related to the US government's COVID -19 vaccine distribution, $0.85 to \n$1.05 related to the kitting, storage, and distribution of ancillary supplies, $0.75 to $0.95 related to COVID -19 \ntests and the fiscal 2021 impairments for PPE and related products, which is an increase from the previous range \nof $0.50 to $0.75, and approximately $0.49 from gains and losses associated with McKesson Ventures' equity \ninvestments, which are within our Corporat e segment.  \n \n Excluding the impacts of these items from both fiscal 2022 guidance and fiscal 2021 results, this indicates 27% to \n33% forecast growth over the prior year.  \n \n When you pull it all together, our strong performance in our outlook equates to an adju sted earnings per diluted \nshare guidance increase of $1.10 compared to our previous fiscal 2022 outlook provided at Investor Day.  The \n$1.10 adjusted earnings per diluted share increase includes the following: approximately $0.45 driven by strong \nunderlying  business performance and operating leverage, approximately $0.22 related to COVID -19 tests, \napproximately $0.22 related to held for sale accounting and reduced opioid litigation expenses, and approximately \n$0.20 related to NCI, interest expense and lower weighted average shares outstanding.  ", "original_text": "Excluding the impacts of these items from both fiscal 2022 guidance and fiscal 2021 results, this indicates 27% to \n33% forecast growth over the prior year.  \n \n", "page_label": "11", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f7e2d2dd-66c9-4d9a-9d5a-780ab89c5595", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "064981fa9dba8cb6d85dd4c1bebc81e647f1d60ad3a75dbc51c19a730b907148", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "51c2a2d6-0639-4e01-8f78-33456232bd01", "node_type": "1", "metadata": {"window": "This includes the impact of the anticipated $1.5 billion of fourth quart er share repurchases mentioned \nearlier.  \n \n As a result of our strong year -to-date performance and our outlook for the remainder of the fiscal year, we are \nraising and narrowing our previous adjusted earnings per share guidance range to $23.55 to $23.95, whic h is \nabove our previous range of $22.35 to $22.95.  Our updated outlook for adjusted earnings per diluted share \nreflects 37% to 39% growth compared to the prior year.  \n \n Fiscal 2022 adjusted earnings per diluted share guidance also includes $2.99 to $3.59 of contribution attributable \nto the following items: $0.90 to $1.10 related to the US government's COVID -19 vaccine distribution, $0.85 to \n$1.05 related to the kitting, storage, and distribution of ancillary supplies, $0.75 to $0.95 related to COVID -19 \ntests and the fiscal 2021 impairments for PPE and related products, which is an increase from the previous range \nof $0.50 to $0.75, and approximately $0.49 from gains and losses associated with McKesson Ventures' equity \ninvestments, which are within our Corporat e segment.  \n \n Excluding the impacts of these items from both fiscal 2022 guidance and fiscal 2021 results, this indicates 27% to \n33% forecast growth over the prior year.  \n \n When you pull it all together, our strong performance in our outlook equates to an adju sted earnings per diluted \nshare guidance increase of $1.10 compared to our previous fiscal 2022 outlook provided at Investor Day.  The \n$1.10 adjusted earnings per diluted share increase includes the following: approximately $0.45 driven by strong \nunderlying  business performance and operating leverage, approximately $0.22 related to COVID -19 tests, \napproximately $0.22 related to held for sale accounting and reduced opioid litigation expenses, and approximately \n$0.20 related to NCI, interest expense and lower weighted average shares outstanding.  ", "original_text": "Fiscal 2022 adjusted earnings per diluted share guidance also includes $2.99 to $3.59 of contribution attributable \nto the following items: $0.90 to $1.10 related to the US government's COVID -19 vaccine distribution, $0.85 to \n$1.05 related to the kitting, storage, and distribution of ancillary supplies, $0.75 to $0.95 related to COVID -19 \ntests and the fiscal 2021 impairments for PPE and related products, which is an increase from the previous range \nof $0.50 to $0.75, and approximately $0.49 from gains and losses associated with McKesson Ventures' equity \ninvestments, which are within our Corporat e segment.  \n \n", "page_label": "11", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dc6b998f9c6b521a12ca3b02f1d16443c2547dd8ebbc5d2fbeacd01d3798f1ea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b271b38b-a9fe-453e-b928-851e76b029ca", "node_type": "1", "metadata": {"window": "Our updated outlook for adjusted earnings per diluted share \nreflects 37% to 39% growth compared to the prior year.  \n \n Fiscal 2022 adjusted earnings per diluted share guidance also includes $2.99 to $3.59 of contribution attributable \nto the following items: $0.90 to $1.10 related to the US government's COVID -19 vaccine distribution, $0.85 to \n$1.05 related to the kitting, storage, and distribution of ancillary supplies, $0.75 to $0.95 related to COVID -19 \ntests and the fiscal 2021 impairments for PPE and related products, which is an increase from the previous range \nof $0.50 to $0.75, and approximately $0.49 from gains and losses associated with McKesson Ventures' equity \ninvestments, which are within our Corporat e segment.  \n \n Excluding the impacts of these items from both fiscal 2022 guidance and fiscal 2021 results, this indicates 27% to \n33% forecast growth over the prior year.  \n \n When you pull it all together, our strong performance in our outlook equates to an adju sted earnings per diluted \nshare guidance increase of $1.10 compared to our previous fiscal 2022 outlook provided at Investor Day.  The \n$1.10 adjusted earnings per diluted share increase includes the following: approximately $0.45 driven by strong \nunderlying  business performance and operating leverage, approximately $0.22 related to COVID -19 tests, \napproximately $0.22 related to held for sale accounting and reduced opioid litigation expenses, and approximately \n$0.20 related to NCI, interest expense and lower weighted average shares outstanding.  ", "original_text": "When you pull it all together, our strong performance in our outlook equates to an adju sted earnings per diluted \nshare guidance increase of $1.10 compared to our previous fiscal 2022 outlook provided at Investor Day. "}, "hash": "70aa387aded4f8ceec07ce40b4435b4110ad485100506932aabd0a23b8700437", "class_name": "RelatedNodeInfo"}}, "text": "Excluding the impacts of these items from both fiscal 2022 guidance and fiscal 2021 results, this indicates 27% to \n33% forecast growth over the prior year.  \n \n", "start_char_idx": 3357, "end_char_idx": 3518, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b271b38b-a9fe-453e-b928-851e76b029ca": {"__data__": {"id_": "b271b38b-a9fe-453e-b928-851e76b029ca", "embedding": null, "metadata": {"window": "Our updated outlook for adjusted earnings per diluted share \nreflects 37% to 39% growth compared to the prior year.  \n \n Fiscal 2022 adjusted earnings per diluted share guidance also includes $2.99 to $3.59 of contribution attributable \nto the following items: $0.90 to $1.10 related to the US government's COVID -19 vaccine distribution, $0.85 to \n$1.05 related to the kitting, storage, and distribution of ancillary supplies, $0.75 to $0.95 related to COVID -19 \ntests and the fiscal 2021 impairments for PPE and related products, which is an increase from the previous range \nof $0.50 to $0.75, and approximately $0.49 from gains and losses associated with McKesson Ventures' equity \ninvestments, which are within our Corporat e segment.  \n \n Excluding the impacts of these items from both fiscal 2022 guidance and fiscal 2021 results, this indicates 27% to \n33% forecast growth over the prior year.  \n \n When you pull it all together, our strong performance in our outlook equates to an adju sted earnings per diluted \nshare guidance increase of $1.10 compared to our previous fiscal 2022 outlook provided at Investor Day.  The \n$1.10 adjusted earnings per diluted share increase includes the following: approximately $0.45 driven by strong \nunderlying  business performance and operating leverage, approximately $0.22 related to COVID -19 tests, \napproximately $0.22 related to held for sale accounting and reduced opioid litigation expenses, and approximately \n$0.20 related to NCI, interest expense and lower weighted average shares outstanding.  ", "original_text": "When you pull it all together, our strong performance in our outlook equates to an adju sted earnings per diluted \nshare guidance increase of $1.10 compared to our previous fiscal 2022 outlook provided at Investor Day. ", "page_label": "11", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f7e2d2dd-66c9-4d9a-9d5a-780ab89c5595", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "064981fa9dba8cb6d85dd4c1bebc81e647f1d60ad3a75dbc51c19a730b907148", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d06dd9e8-aa9b-4d70-a49e-d76a76847115", "node_type": "1", "metadata": {"window": "As a result of our strong year -to-date performance and our outlook for the remainder of the fiscal year, we are \nraising and narrowing our previous adjusted earnings per share guidance range to $23.55 to $23.95, whic h is \nabove our previous range of $22.35 to $22.95.  Our updated outlook for adjusted earnings per diluted share \nreflects 37% to 39% growth compared to the prior year.  \n \n Fiscal 2022 adjusted earnings per diluted share guidance also includes $2.99 to $3.59 of contribution attributable \nto the following items: $0.90 to $1.10 related to the US government's COVID -19 vaccine distribution, $0.85 to \n$1.05 related to the kitting, storage, and distribution of ancillary supplies, $0.75 to $0.95 related to COVID -19 \ntests and the fiscal 2021 impairments for PPE and related products, which is an increase from the previous range \nof $0.50 to $0.75, and approximately $0.49 from gains and losses associated with McKesson Ventures' equity \ninvestments, which are within our Corporat e segment.  \n \n Excluding the impacts of these items from both fiscal 2022 guidance and fiscal 2021 results, this indicates 27% to \n33% forecast growth over the prior year.  \n \n When you pull it all together, our strong performance in our outlook equates to an adju sted earnings per diluted \nshare guidance increase of $1.10 compared to our previous fiscal 2022 outlook provided at Investor Day.  The \n$1.10 adjusted earnings per diluted share increase includes the following: approximately $0.45 driven by strong \nunderlying  business performance and operating leverage, approximately $0.22 related to COVID -19 tests, \napproximately $0.22 related to held for sale accounting and reduced opioid litigation expenses, and approximately \n$0.20 related to NCI, interest expense and lower weighted average shares outstanding.  ", "original_text": "Excluding the impacts of these items from both fiscal 2022 guidance and fiscal 2021 results, this indicates 27% to \n33% forecast growth over the prior year.  \n \n", "page_label": "11", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b7dbf29fa2f577d254b8e7baf1c9c94f9023d2a761a1759e94e088f132451039", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bba65e5e-d41c-4b2d-bb83-f178a4ed65b1", "node_type": "1", "metadata": {"window": "Fiscal 2022 adjusted earnings per diluted share guidance also includes $2.99 to $3.59 of contribution attributable \nto the following items: $0.90 to $1.10 related to the US government's COVID -19 vaccine distribution, $0.85 to \n$1.05 related to the kitting, storage, and distribution of ancillary supplies, $0.75 to $0.95 related to COVID -19 \ntests and the fiscal 2021 impairments for PPE and related products, which is an increase from the previous range \nof $0.50 to $0.75, and approximately $0.49 from gains and losses associated with McKesson Ventures' equity \ninvestments, which are within our Corporat e segment.  \n \n Excluding the impacts of these items from both fiscal 2022 guidance and fiscal 2021 results, this indicates 27% to \n33% forecast growth over the prior year.  \n \n When you pull it all together, our strong performance in our outlook equates to an adju sted earnings per diluted \nshare guidance increase of $1.10 compared to our previous fiscal 2022 outlook provided at Investor Day.  The \n$1.10 adjusted earnings per diluted share increase includes the following: approximately $0.45 driven by strong \nunderlying  business performance and operating leverage, approximately $0.22 related to COVID -19 tests, \napproximately $0.22 related to held for sale accounting and reduced opioid litigation expenses, and approximately \n$0.20 related to NCI, interest expense and lower weighted average shares outstanding.  ", "original_text": "The \n$1.10 adjusted earnings per diluted share increase includes the following: approximately $0.45 driven by strong \nunderlying  business performance and operating leverage, approximately $0.22 related to COVID -19 tests, \napproximately $0.22 related to held for sale accounting and reduced opioid litigation expenses, and approximately \n$0.20 related to NCI, interest expense and lower weighted average shares outstanding.  "}, "hash": "0480c60c4ed932634d9c75d4617590a7501e977a5a8b6ed640b50cbf2a0fde08", "class_name": "RelatedNodeInfo"}}, "text": "When you pull it all together, our strong performance in our outlook equates to an adju sted earnings per diluted \nshare guidance increase of $1.10 compared to our previous fiscal 2022 outlook provided at Investor Day. ", "start_char_idx": 3518, "end_char_idx": 3737, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bba65e5e-d41c-4b2d-bb83-f178a4ed65b1": {"__data__": {"id_": "bba65e5e-d41c-4b2d-bb83-f178a4ed65b1", "embedding": null, "metadata": {"window": "Fiscal 2022 adjusted earnings per diluted share guidance also includes $2.99 to $3.59 of contribution attributable \nto the following items: $0.90 to $1.10 related to the US government's COVID -19 vaccine distribution, $0.85 to \n$1.05 related to the kitting, storage, and distribution of ancillary supplies, $0.75 to $0.95 related to COVID -19 \ntests and the fiscal 2021 impairments for PPE and related products, which is an increase from the previous range \nof $0.50 to $0.75, and approximately $0.49 from gains and losses associated with McKesson Ventures' equity \ninvestments, which are within our Corporat e segment.  \n \n Excluding the impacts of these items from both fiscal 2022 guidance and fiscal 2021 results, this indicates 27% to \n33% forecast growth over the prior year.  \n \n When you pull it all together, our strong performance in our outlook equates to an adju sted earnings per diluted \nshare guidance increase of $1.10 compared to our previous fiscal 2022 outlook provided at Investor Day.  The \n$1.10 adjusted earnings per diluted share increase includes the following: approximately $0.45 driven by strong \nunderlying  business performance and operating leverage, approximately $0.22 related to COVID -19 tests, \napproximately $0.22 related to held for sale accounting and reduced opioid litigation expenses, and approximately \n$0.20 related to NCI, interest expense and lower weighted average shares outstanding.  ", "original_text": "The \n$1.10 adjusted earnings per diluted share increase includes the following: approximately $0.45 driven by strong \nunderlying  business performance and operating leverage, approximately $0.22 related to COVID -19 tests, \napproximately $0.22 related to held for sale accounting and reduced opioid litigation expenses, and approximately \n$0.20 related to NCI, interest expense and lower weighted average shares outstanding.  ", "page_label": "11", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f7e2d2dd-66c9-4d9a-9d5a-780ab89c5595", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "064981fa9dba8cb6d85dd4c1bebc81e647f1d60ad3a75dbc51c19a730b907148", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b271b38b-a9fe-453e-b928-851e76b029ca", "node_type": "1", "metadata": {"window": "Our updated outlook for adjusted earnings per diluted share \nreflects 37% to 39% growth compared to the prior year.  \n \n Fiscal 2022 adjusted earnings per diluted share guidance also includes $2.99 to $3.59 of contribution attributable \nto the following items: $0.90 to $1.10 related to the US government's COVID -19 vaccine distribution, $0.85 to \n$1.05 related to the kitting, storage, and distribution of ancillary supplies, $0.75 to $0.95 related to COVID -19 \ntests and the fiscal 2021 impairments for PPE and related products, which is an increase from the previous range \nof $0.50 to $0.75, and approximately $0.49 from gains and losses associated with McKesson Ventures' equity \ninvestments, which are within our Corporat e segment.  \n \n Excluding the impacts of these items from both fiscal 2022 guidance and fiscal 2021 results, this indicates 27% to \n33% forecast growth over the prior year.  \n \n When you pull it all together, our strong performance in our outlook equates to an adju sted earnings per diluted \nshare guidance increase of $1.10 compared to our previous fiscal 2022 outlook provided at Investor Day.  The \n$1.10 adjusted earnings per diluted share increase includes the following: approximately $0.45 driven by strong \nunderlying  business performance and operating leverage, approximately $0.22 related to COVID -19 tests, \napproximately $0.22 related to held for sale accounting and reduced opioid litigation expenses, and approximately \n$0.20 related to NCI, interest expense and lower weighted average shares outstanding.  ", "original_text": "When you pull it all together, our strong performance in our outlook equates to an adju sted earnings per diluted \nshare guidance increase of $1.10 compared to our previous fiscal 2022 outlook provided at Investor Day. ", "page_label": "11", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ad232d404032c045a9dacb928c8df958da3bdbfd2598f7837f7acbc81afb063b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8c576334-9de0-4f18-aa0f-9f8ed59631b7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nLet me spend just a minute providing some initial thoughts on fiscal 2023.  I want to point out that we are not \nproviding fiscal 2023 guidance at this time.  However, I thought it would be instructive to walk you through  some of \nthe items that could impact fiscal 2023 as we sit here today.  \n \n", "original_text": "McKesson Corp.  "}, "hash": "053e8590e5cf7b82d607dce6b78659248c43718bf5ebe3dad4cd82b978b8d99d", "class_name": "RelatedNodeInfo"}}, "text": "The \n$1.10 adjusted earnings per diluted share increase includes the following: approximately $0.45 driven by strong \nunderlying  business performance and operating leverage, approximately $0.22 related to COVID -19 tests, \napproximately $0.22 related to held for sale accounting and reduced opioid litigation expenses, and approximately \n$0.20 related to NCI, interest expense and lower weighted average shares outstanding.  ", "start_char_idx": 3737, "end_char_idx": 4163, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8c576334-9de0-4f18-aa0f-9f8ed59631b7": {"__data__": {"id_": "8c576334-9de0-4f18-aa0f-9f8ed59631b7", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nLet me spend just a minute providing some initial thoughts on fiscal 2023.  I want to point out that we are not \nproviding fiscal 2023 guidance at this time.  However, I thought it would be instructive to walk you through  some of \nthe items that could impact fiscal 2023 as we sit here today.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01bc6e5f-cc79-4b05-99f5-5a1b943788f8", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "129f4d1de267bceb48e7ffbc5930fc91067bab0d0748d19326e56e94433fc7f1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bba65e5e-d41c-4b2d-bb83-f178a4ed65b1", "node_type": "1", "metadata": {"window": "Fiscal 2022 adjusted earnings per diluted share guidance also includes $2.99 to $3.59 of contribution attributable \nto the following items: $0.90 to $1.10 related to the US government's COVID -19 vaccine distribution, $0.85 to \n$1.05 related to the kitting, storage, and distribution of ancillary supplies, $0.75 to $0.95 related to COVID -19 \ntests and the fiscal 2021 impairments for PPE and related products, which is an increase from the previous range \nof $0.50 to $0.75, and approximately $0.49 from gains and losses associated with McKesson Ventures' equity \ninvestments, which are within our Corporat e segment.  \n \n Excluding the impacts of these items from both fiscal 2022 guidance and fiscal 2021 results, this indicates 27% to \n33% forecast growth over the prior year.  \n \n When you pull it all together, our strong performance in our outlook equates to an adju sted earnings per diluted \nshare guidance increase of $1.10 compared to our previous fiscal 2022 outlook provided at Investor Day.  The \n$1.10 adjusted earnings per diluted share increase includes the following: approximately $0.45 driven by strong \nunderlying  business performance and operating leverage, approximately $0.22 related to COVID -19 tests, \napproximately $0.22 related to held for sale accounting and reduced opioid litigation expenses, and approximately \n$0.20 related to NCI, interest expense and lower weighted average shares outstanding.  ", "original_text": "The \n$1.10 adjusted earnings per diluted share increase includes the following: approximately $0.45 driven by strong \nunderlying  business performance and operating leverage, approximately $0.22 related to COVID -19 tests, \napproximately $0.22 related to held for sale accounting and reduced opioid litigation expenses, and approximately \n$0.20 related to NCI, interest expense and lower weighted average shares outstanding.  ", "page_label": "11", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "15ce2aa064463ad2bce236538524b4b429dc3065671f58a853a8c8ac23c9b7a5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f60f19d6-e0f6-405b-9073-116af28870fb", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nLet me spend just a minute providing some initial thoughts on fiscal 2023.  I want to point out that we are not \nproviding fiscal 2023 guidance at this time.  However, I thought it would be instructive to walk you through  some of \nthe items that could impact fiscal 2023 as we sit here today.  \n \n First, the COVID -19 pandemic continues to present many unknowns. ", "original_text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nLet me spend just a minute providing some initial thoughts on fiscal 2023. "}, "hash": "d676c242fa4c6e97f24847abb3ef5eeee1f25c740cffacd0e637bb263f5e9f46", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f60f19d6-e0f6-405b-9073-116af28870fb": {"__data__": {"id_": "f60f19d6-e0f6-405b-9073-116af28870fb", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nLet me spend just a minute providing some initial thoughts on fiscal 2023.  I want to point out that we are not \nproviding fiscal 2023 guidance at this time.  However, I thought it would be instructive to walk you through  some of \nthe items that could impact fiscal 2023 as we sit here today.  \n \n First, the COVID -19 pandemic continues to present many unknowns. ", "original_text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nLet me spend just a minute providing some initial thoughts on fiscal 2023. ", "page_label": "12", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01bc6e5f-cc79-4b05-99f5-5a1b943788f8", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "129f4d1de267bceb48e7ffbc5930fc91067bab0d0748d19326e56e94433fc7f1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8c576334-9de0-4f18-aa0f-9f8ed59631b7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nLet me spend just a minute providing some initial thoughts on fiscal 2023.  I want to point out that we are not \nproviding fiscal 2023 guidance at this time.  However, I thought it would be instructive to walk you through  some of \nthe items that could impact fiscal 2023 as we sit here today.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "026b1059b77cf7745ed4b83040e8f327136db47806da822c41faf2102fcfe3d4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "000de7d5-dd08-430c-b762-b4c68fcaf984", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nLet me spend just a minute providing some initial thoughts on fiscal 2023.  I want to point out that we are not \nproviding fiscal 2023 guidance at this time.  However, I thought it would be instructive to walk you through  some of \nthe items that could impact fiscal 2023 as we sit here today.  \n \n First, the COVID -19 pandemic continues to present many unknowns.  We continue to expect a full recovery. \n", "original_text": "I want to point out that we are not \nproviding fiscal 2023 guidance at this time. "}, "hash": "e4a387f60f4726e50ea7816e8ead3c782ff602989ec59943c717aa727c2932db", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nLet me spend just a minute providing some initial thoughts on fiscal 2023. ", "start_char_idx": 16, "end_char_idx": 258, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "000de7d5-dd08-430c-b762-b4c68fcaf984": {"__data__": {"id_": "000de7d5-dd08-430c-b762-b4c68fcaf984", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nLet me spend just a minute providing some initial thoughts on fiscal 2023.  I want to point out that we are not \nproviding fiscal 2023 guidance at this time.  However, I thought it would be instructive to walk you through  some of \nthe items that could impact fiscal 2023 as we sit here today.  \n \n First, the COVID -19 pandemic continues to present many unknowns.  We continue to expect a full recovery. \n", "original_text": "I want to point out that we are not \nproviding fiscal 2023 guidance at this time. ", "page_label": "12", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01bc6e5f-cc79-4b05-99f5-5a1b943788f8", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "129f4d1de267bceb48e7ffbc5930fc91067bab0d0748d19326e56e94433fc7f1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f60f19d6-e0f6-405b-9073-116af28870fb", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nLet me spend just a minute providing some initial thoughts on fiscal 2023.  I want to point out that we are not \nproviding fiscal 2023 guidance at this time.  However, I thought it would be instructive to walk you through  some of \nthe items that could impact fiscal 2023 as we sit here today.  \n \n First, the COVID -19 pandemic continues to present many unknowns. ", "original_text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nLet me spend just a minute providing some initial thoughts on fiscal 2023. ", "page_label": "12", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d0922be7dd03043019868c2a9f86d2e3eb79fa14309417d5db88ad78573788e0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b61365a3-7cc7-43d0-8353-a044b3a8ac85", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nLet me spend just a minute providing some initial thoughts on fiscal 2023.  I want to point out that we are not \nproviding fiscal 2023 guidance at this time.  However, I thought it would be instructive to walk you through  some of \nthe items that could impact fiscal 2023 as we sit here today.  \n \n First, the COVID -19 pandemic continues to present many unknowns.  We continue to expect a full recovery. \n However, it is likely to continue to be nonlinear into fiscal 2023, and it could  impact the quarterly cadence.  \n \n", "original_text": "However, I thought it would be instructive to walk you through  some of \nthe items that could impact fiscal 2023 as we sit here today.  \n \n"}, "hash": "2ac23daca524e8bdda5590d439c6d681b47ade2004723e60dccbc402a3746466", "class_name": "RelatedNodeInfo"}}, "text": "I want to point out that we are not \nproviding fiscal 2023 guidance at this time. ", "start_char_idx": 258, "end_char_idx": 340, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b61365a3-7cc7-43d0-8353-a044b3a8ac85": {"__data__": {"id_": "b61365a3-7cc7-43d0-8353-a044b3a8ac85", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nLet me spend just a minute providing some initial thoughts on fiscal 2023.  I want to point out that we are not \nproviding fiscal 2023 guidance at this time.  However, I thought it would be instructive to walk you through  some of \nthe items that could impact fiscal 2023 as we sit here today.  \n \n First, the COVID -19 pandemic continues to present many unknowns.  We continue to expect a full recovery. \n However, it is likely to continue to be nonlinear into fiscal 2023, and it could  impact the quarterly cadence.  \n \n", "original_text": "However, I thought it would be instructive to walk you through  some of \nthe items that could impact fiscal 2023 as we sit here today.  \n \n", "page_label": "12", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01bc6e5f-cc79-4b05-99f5-5a1b943788f8", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "129f4d1de267bceb48e7ffbc5930fc91067bab0d0748d19326e56e94433fc7f1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "000de7d5-dd08-430c-b762-b4c68fcaf984", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nLet me spend just a minute providing some initial thoughts on fiscal 2023.  I want to point out that we are not \nproviding fiscal 2023 guidance at this time.  However, I thought it would be instructive to walk you through  some of \nthe items that could impact fiscal 2023 as we sit here today.  \n \n First, the COVID -19 pandemic continues to present many unknowns.  We continue to expect a full recovery. \n", "original_text": "I want to point out that we are not \nproviding fiscal 2023 guidance at this time. ", "page_label": "12", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bb6749bc7491720d7f8e0ff704e19daed1d96bd432888f8f0ba5190d89afbec9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "64f9b6fb-99bb-44f6-8e99-3f31ebc1064e", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nLet me spend just a minute providing some initial thoughts on fiscal 2023.  I want to point out that we are not \nproviding fiscal 2023 guidance at this time.  However, I thought it would be instructive to walk you through  some of \nthe items that could impact fiscal 2023 as we sit here today.  \n \n First, the COVID -19 pandemic continues to present many unknowns.  We continue to expect a full recovery. \n However, it is likely to continue to be nonlinear into fiscal 2023, and it could  impact the quarterly cadence.  \n \n In the US Pharmaceutical and Medical -Surgical Solutions segments, our contract with the US government to \nserve as a centralized distributor of COVID -19 vaccines and to assist with the kitting, storage, and distribution of \nancillary supplies are scheduled to expire in July of 2022. ", "original_text": "First, the COVID -19 pandemic continues to present many unknowns. "}, "hash": "343e9cee3e7434ab283bbd163850c029f8ec2bd31baf3edf0b7d0b073104cb5e", "class_name": "RelatedNodeInfo"}}, "text": "However, I thought it would be instructive to walk you through  some of \nthe items that could impact fiscal 2023 as we sit here today.  \n \n", "start_char_idx": 340, "end_char_idx": 479, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "64f9b6fb-99bb-44f6-8e99-3f31ebc1064e": {"__data__": {"id_": "64f9b6fb-99bb-44f6-8e99-3f31ebc1064e", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nLet me spend just a minute providing some initial thoughts on fiscal 2023.  I want to point out that we are not \nproviding fiscal 2023 guidance at this time.  However, I thought it would be instructive to walk you through  some of \nthe items that could impact fiscal 2023 as we sit here today.  \n \n First, the COVID -19 pandemic continues to present many unknowns.  We continue to expect a full recovery. \n However, it is likely to continue to be nonlinear into fiscal 2023, and it could  impact the quarterly cadence.  \n \n In the US Pharmaceutical and Medical -Surgical Solutions segments, our contract with the US government to \nserve as a centralized distributor of COVID -19 vaccines and to assist with the kitting, storage, and distribution of \nancillary supplies are scheduled to expire in July of 2022. ", "original_text": "First, the COVID -19 pandemic continues to present many unknowns. ", "page_label": "12", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01bc6e5f-cc79-4b05-99f5-5a1b943788f8", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "129f4d1de267bceb48e7ffbc5930fc91067bab0d0748d19326e56e94433fc7f1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b61365a3-7cc7-43d0-8353-a044b3a8ac85", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nLet me spend just a minute providing some initial thoughts on fiscal 2023.  I want to point out that we are not \nproviding fiscal 2023 guidance at this time.  However, I thought it would be instructive to walk you through  some of \nthe items that could impact fiscal 2023 as we sit here today.  \n \n First, the COVID -19 pandemic continues to present many unknowns.  We continue to expect a full recovery. \n However, it is likely to continue to be nonlinear into fiscal 2023, and it could  impact the quarterly cadence.  \n \n", "original_text": "However, I thought it would be instructive to walk you through  some of \nthe items that could impact fiscal 2023 as we sit here today.  \n \n", "page_label": "12", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3dfa5c1fa8e29c05216adb2a2ba7fa6254ec16c96151e3891b801e5e7670b11d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "68abde1a-70b1-4c57-abe3-dfaa19975c98", "node_type": "1", "metadata": {"window": "I want to point out that we are not \nproviding fiscal 2023 guidance at this time.  However, I thought it would be instructive to walk you through  some of \nthe items that could impact fiscal 2023 as we sit here today.  \n \n First, the COVID -19 pandemic continues to present many unknowns.  We continue to expect a full recovery. \n However, it is likely to continue to be nonlinear into fiscal 2023, and it could  impact the quarterly cadence.  \n \n In the US Pharmaceutical and Medical -Surgical Solutions segments, our contract with the US government to \nserve as a centralized distributor of COVID -19 vaccines and to assist with the kitting, storage, and distribution of \nancillary supplies are scheduled to expire in July of 2022.  Outside the contract with the US government for \nCOVID -19 vaccine distribution, we anticipate normal customer renewal activity in the US Pharmaceutical \nsegment.  \n \n", "original_text": "We continue to expect a full recovery. \n"}, "hash": "7e9759ace5621db88407bd0cede5d294c389f84428a68a1aa56e45f85b6da383", "class_name": "RelatedNodeInfo"}}, "text": "First, the COVID -19 pandemic continues to present many unknowns. ", "start_char_idx": 479, "end_char_idx": 545, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "68abde1a-70b1-4c57-abe3-dfaa19975c98": {"__data__": {"id_": "68abde1a-70b1-4c57-abe3-dfaa19975c98", "embedding": null, "metadata": {"window": "I want to point out that we are not \nproviding fiscal 2023 guidance at this time.  However, I thought it would be instructive to walk you through  some of \nthe items that could impact fiscal 2023 as we sit here today.  \n \n First, the COVID -19 pandemic continues to present many unknowns.  We continue to expect a full recovery. \n However, it is likely to continue to be nonlinear into fiscal 2023, and it could  impact the quarterly cadence.  \n \n In the US Pharmaceutical and Medical -Surgical Solutions segments, our contract with the US government to \nserve as a centralized distributor of COVID -19 vaccines and to assist with the kitting, storage, and distribution of \nancillary supplies are scheduled to expire in July of 2022.  Outside the contract with the US government for \nCOVID -19 vaccine distribution, we anticipate normal customer renewal activity in the US Pharmaceutical \nsegment.  \n \n", "original_text": "We continue to expect a full recovery. \n", "page_label": "12", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01bc6e5f-cc79-4b05-99f5-5a1b943788f8", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "129f4d1de267bceb48e7ffbc5930fc91067bab0d0748d19326e56e94433fc7f1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "64f9b6fb-99bb-44f6-8e99-3f31ebc1064e", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nLet me spend just a minute providing some initial thoughts on fiscal 2023.  I want to point out that we are not \nproviding fiscal 2023 guidance at this time.  However, I thought it would be instructive to walk you through  some of \nthe items that could impact fiscal 2023 as we sit here today.  \n \n First, the COVID -19 pandemic continues to present many unknowns.  We continue to expect a full recovery. \n However, it is likely to continue to be nonlinear into fiscal 2023, and it could  impact the quarterly cadence.  \n \n In the US Pharmaceutical and Medical -Surgical Solutions segments, our contract with the US government to \nserve as a centralized distributor of COVID -19 vaccines and to assist with the kitting, storage, and distribution of \nancillary supplies are scheduled to expire in July of 2022. ", "original_text": "First, the COVID -19 pandemic continues to present many unknowns. ", "page_label": "12", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "66499c196be6687c2319633fe3cc18f7ad1ba56cb5655320f4f4923e9a52a0db", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9bf5d397-98aa-4c6a-b655-adf938ba25d3", "node_type": "1", "metadata": {"window": "However, I thought it would be instructive to walk you through  some of \nthe items that could impact fiscal 2023 as we sit here today.  \n \n First, the COVID -19 pandemic continues to present many unknowns.  We continue to expect a full recovery. \n However, it is likely to continue to be nonlinear into fiscal 2023, and it could  impact the quarterly cadence.  \n \n In the US Pharmaceutical and Medical -Surgical Solutions segments, our contract with the US government to \nserve as a centralized distributor of COVID -19 vaccines and to assist with the kitting, storage, and distribution of \nancillary supplies are scheduled to expire in July of 2022.  Outside the contract with the US government for \nCOVID -19 vaccine distribution, we anticipate normal customer renewal activity in the US Pharmaceutical \nsegment.  \n \n As it relates to COVID -19 tests, we  continue to anticipate that demand will be closely associated with the rate of \nCOVID case levels and impact from variants will moderate from prior -year levels.  \n \n", "original_text": "However, it is likely to continue to be nonlinear into fiscal 2023, and it could  impact the quarterly cadence.  \n \n"}, "hash": "deef66ef262df010b1224e22075d1d0a01ddba23e6e84ea137d5b7bdf6896dc5", "class_name": "RelatedNodeInfo"}}, "text": "We continue to expect a full recovery. \n", "start_char_idx": 545, "end_char_idx": 585, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9bf5d397-98aa-4c6a-b655-adf938ba25d3": {"__data__": {"id_": "9bf5d397-98aa-4c6a-b655-adf938ba25d3", "embedding": null, "metadata": {"window": "However, I thought it would be instructive to walk you through  some of \nthe items that could impact fiscal 2023 as we sit here today.  \n \n First, the COVID -19 pandemic continues to present many unknowns.  We continue to expect a full recovery. \n However, it is likely to continue to be nonlinear into fiscal 2023, and it could  impact the quarterly cadence.  \n \n In the US Pharmaceutical and Medical -Surgical Solutions segments, our contract with the US government to \nserve as a centralized distributor of COVID -19 vaccines and to assist with the kitting, storage, and distribution of \nancillary supplies are scheduled to expire in July of 2022.  Outside the contract with the US government for \nCOVID -19 vaccine distribution, we anticipate normal customer renewal activity in the US Pharmaceutical \nsegment.  \n \n As it relates to COVID -19 tests, we  continue to anticipate that demand will be closely associated with the rate of \nCOVID case levels and impact from variants will moderate from prior -year levels.  \n \n", "original_text": "However, it is likely to continue to be nonlinear into fiscal 2023, and it could  impact the quarterly cadence.  \n \n", "page_label": "12", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01bc6e5f-cc79-4b05-99f5-5a1b943788f8", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "129f4d1de267bceb48e7ffbc5930fc91067bab0d0748d19326e56e94433fc7f1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "68abde1a-70b1-4c57-abe3-dfaa19975c98", "node_type": "1", "metadata": {"window": "I want to point out that we are not \nproviding fiscal 2023 guidance at this time.  However, I thought it would be instructive to walk you through  some of \nthe items that could impact fiscal 2023 as we sit here today.  \n \n First, the COVID -19 pandemic continues to present many unknowns.  We continue to expect a full recovery. \n However, it is likely to continue to be nonlinear into fiscal 2023, and it could  impact the quarterly cadence.  \n \n In the US Pharmaceutical and Medical -Surgical Solutions segments, our contract with the US government to \nserve as a centralized distributor of COVID -19 vaccines and to assist with the kitting, storage, and distribution of \nancillary supplies are scheduled to expire in July of 2022.  Outside the contract with the US government for \nCOVID -19 vaccine distribution, we anticipate normal customer renewal activity in the US Pharmaceutical \nsegment.  \n \n", "original_text": "We continue to expect a full recovery. \n", "page_label": "12", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e4e359580ac0844b282de2cca9dbeaefab84c7657bc0740a0eb0ad221e539465", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "86e8b7fc-6187-4975-9d44-6b82a4399ee9", "node_type": "1", "metadata": {"window": "First, the COVID -19 pandemic continues to present many unknowns.  We continue to expect a full recovery. \n However, it is likely to continue to be nonlinear into fiscal 2023, and it could  impact the quarterly cadence.  \n \n In the US Pharmaceutical and Medical -Surgical Solutions segments, our contract with the US government to \nserve as a centralized distributor of COVID -19 vaccines and to assist with the kitting, storage, and distribution of \nancillary supplies are scheduled to expire in July of 2022.  Outside the contract with the US government for \nCOVID -19 vaccine distribution, we anticipate normal customer renewal activity in the US Pharmaceutical \nsegment.  \n \n As it relates to COVID -19 tests, we  continue to anticipate that demand will be closely associated with the rate of \nCOVID case levels and impact from variants will moderate from prior -year levels.  \n \n For the International segment, we anticipate $0.10 of adjusted earnings per diluted share accr etion in the first half \nof fiscal 2023 related to the held for sale accounting based on the current estimated close date for the PHOENIX \nGroup transaction. ", "original_text": "In the US Pharmaceutical and Medical -Surgical Solutions segments, our contract with the US government to \nserve as a centralized distributor of COVID -19 vaccines and to assist with the kitting, storage, and distribution of \nancillary supplies are scheduled to expire in July of 2022. "}, "hash": "bb3be538ae270c05c17b9bab67f64880131fd8b2f220747c55ef4c89728b4ab4", "class_name": "RelatedNodeInfo"}}, "text": "However, it is likely to continue to be nonlinear into fiscal 2023, and it could  impact the quarterly cadence.  \n \n", "start_char_idx": 585, "end_char_idx": 701, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "86e8b7fc-6187-4975-9d44-6b82a4399ee9": {"__data__": {"id_": "86e8b7fc-6187-4975-9d44-6b82a4399ee9", "embedding": null, "metadata": {"window": "First, the COVID -19 pandemic continues to present many unknowns.  We continue to expect a full recovery. \n However, it is likely to continue to be nonlinear into fiscal 2023, and it could  impact the quarterly cadence.  \n \n In the US Pharmaceutical and Medical -Surgical Solutions segments, our contract with the US government to \nserve as a centralized distributor of COVID -19 vaccines and to assist with the kitting, storage, and distribution of \nancillary supplies are scheduled to expire in July of 2022.  Outside the contract with the US government for \nCOVID -19 vaccine distribution, we anticipate normal customer renewal activity in the US Pharmaceutical \nsegment.  \n \n As it relates to COVID -19 tests, we  continue to anticipate that demand will be closely associated with the rate of \nCOVID case levels and impact from variants will moderate from prior -year levels.  \n \n For the International segment, we anticipate $0.10 of adjusted earnings per diluted share accr etion in the first half \nof fiscal 2023 related to the held for sale accounting based on the current estimated close date for the PHOENIX \nGroup transaction. ", "original_text": "In the US Pharmaceutical and Medical -Surgical Solutions segments, our contract with the US government to \nserve as a centralized distributor of COVID -19 vaccines and to assist with the kitting, storage, and distribution of \nancillary supplies are scheduled to expire in July of 2022. ", "page_label": "12", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01bc6e5f-cc79-4b05-99f5-5a1b943788f8", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "129f4d1de267bceb48e7ffbc5930fc91067bab0d0748d19326e56e94433fc7f1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9bf5d397-98aa-4c6a-b655-adf938ba25d3", "node_type": "1", "metadata": {"window": "However, I thought it would be instructive to walk you through  some of \nthe items that could impact fiscal 2023 as we sit here today.  \n \n First, the COVID -19 pandemic continues to present many unknowns.  We continue to expect a full recovery. \n However, it is likely to continue to be nonlinear into fiscal 2023, and it could  impact the quarterly cadence.  \n \n In the US Pharmaceutical and Medical -Surgical Solutions segments, our contract with the US government to \nserve as a centralized distributor of COVID -19 vaccines and to assist with the kitting, storage, and distribution of \nancillary supplies are scheduled to expire in July of 2022.  Outside the contract with the US government for \nCOVID -19 vaccine distribution, we anticipate normal customer renewal activity in the US Pharmaceutical \nsegment.  \n \n As it relates to COVID -19 tests, we  continue to anticipate that demand will be closely associated with the rate of \nCOVID case levels and impact from variants will moderate from prior -year levels.  \n \n", "original_text": "However, it is likely to continue to be nonlinear into fiscal 2023, and it could  impact the quarterly cadence.  \n \n", "page_label": "12", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b3ee5fa83b87453fd4190f774bf065dc20e4a8c50a6a174d1737cfb57b7ff795", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b9c4d557-979d-4740-b305-cd02c528430f", "node_type": "1", "metadata": {"window": "We continue to expect a full recovery. \n However, it is likely to continue to be nonlinear into fiscal 2023, and it could  impact the quarterly cadence.  \n \n In the US Pharmaceutical and Medical -Surgical Solutions segments, our contract with the US government to \nserve as a centralized distributor of COVID -19 vaccines and to assist with the kitting, storage, and distribution of \nancillary supplies are scheduled to expire in July of 2022.  Outside the contract with the US government for \nCOVID -19 vaccine distribution, we anticipate normal customer renewal activity in the US Pharmaceutical \nsegment.  \n \n As it relates to COVID -19 tests, we  continue to anticipate that demand will be closely associated with the rate of \nCOVID case levels and impact from variants will moderate from prior -year levels.  \n \n For the International segment, we anticipate $0.10 of adjusted earnings per diluted share accr etion in the first half \nof fiscal 2023 related to the held for sale accounting based on the current estimated close date for the PHOENIX \nGroup transaction.  We will no longer report revenue, adjusted operating profit, or held for sale accounting benefits \nrelated to these transactions once the transactions close.  \n \n", "original_text": "Outside the contract with the US government for \nCOVID -19 vaccine distribution, we anticipate normal customer renewal activity in the US Pharmaceutical \nsegment.  \n \n"}, "hash": "7490d5da81018aa5667861f54677dccb9aebd923dff28cc9828780a3a8674e4d", "class_name": "RelatedNodeInfo"}}, "text": "In the US Pharmaceutical and Medical -Surgical Solutions segments, our contract with the US government to \nserve as a centralized distributor of COVID -19 vaccines and to assist with the kitting, storage, and distribution of \nancillary supplies are scheduled to expire in July of 2022. ", "start_char_idx": 701, "end_char_idx": 987, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b9c4d557-979d-4740-b305-cd02c528430f": {"__data__": {"id_": "b9c4d557-979d-4740-b305-cd02c528430f", "embedding": null, "metadata": {"window": "We continue to expect a full recovery. \n However, it is likely to continue to be nonlinear into fiscal 2023, and it could  impact the quarterly cadence.  \n \n In the US Pharmaceutical and Medical -Surgical Solutions segments, our contract with the US government to \nserve as a centralized distributor of COVID -19 vaccines and to assist with the kitting, storage, and distribution of \nancillary supplies are scheduled to expire in July of 2022.  Outside the contract with the US government for \nCOVID -19 vaccine distribution, we anticipate normal customer renewal activity in the US Pharmaceutical \nsegment.  \n \n As it relates to COVID -19 tests, we  continue to anticipate that demand will be closely associated with the rate of \nCOVID case levels and impact from variants will moderate from prior -year levels.  \n \n For the International segment, we anticipate $0.10 of adjusted earnings per diluted share accr etion in the first half \nof fiscal 2023 related to the held for sale accounting based on the current estimated close date for the PHOENIX \nGroup transaction.  We will no longer report revenue, adjusted operating profit, or held for sale accounting benefits \nrelated to these transactions once the transactions close.  \n \n", "original_text": "Outside the contract with the US government for \nCOVID -19 vaccine distribution, we anticipate normal customer renewal activity in the US Pharmaceutical \nsegment.  \n \n", "page_label": "12", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01bc6e5f-cc79-4b05-99f5-5a1b943788f8", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "129f4d1de267bceb48e7ffbc5930fc91067bab0d0748d19326e56e94433fc7f1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "86e8b7fc-6187-4975-9d44-6b82a4399ee9", "node_type": "1", "metadata": {"window": "First, the COVID -19 pandemic continues to present many unknowns.  We continue to expect a full recovery. \n However, it is likely to continue to be nonlinear into fiscal 2023, and it could  impact the quarterly cadence.  \n \n In the US Pharmaceutical and Medical -Surgical Solutions segments, our contract with the US government to \nserve as a centralized distributor of COVID -19 vaccines and to assist with the kitting, storage, and distribution of \nancillary supplies are scheduled to expire in July of 2022.  Outside the contract with the US government for \nCOVID -19 vaccine distribution, we anticipate normal customer renewal activity in the US Pharmaceutical \nsegment.  \n \n As it relates to COVID -19 tests, we  continue to anticipate that demand will be closely associated with the rate of \nCOVID case levels and impact from variants will moderate from prior -year levels.  \n \n For the International segment, we anticipate $0.10 of adjusted earnings per diluted share accr etion in the first half \nof fiscal 2023 related to the held for sale accounting based on the current estimated close date for the PHOENIX \nGroup transaction. ", "original_text": "In the US Pharmaceutical and Medical -Surgical Solutions segments, our contract with the US government to \nserve as a centralized distributor of COVID -19 vaccines and to assist with the kitting, storage, and distribution of \nancillary supplies are scheduled to expire in July of 2022. ", "page_label": "12", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d4f2d1e521f36f444fbc0fae14c0e4750674ab3d2b148acedaf1b16e589577db", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "86b2c0d0-b59a-419f-8ee4-69cb1bd75b06", "node_type": "1", "metadata": {"window": "However, it is likely to continue to be nonlinear into fiscal 2023, and it could  impact the quarterly cadence.  \n \n In the US Pharmaceutical and Medical -Surgical Solutions segments, our contract with the US government to \nserve as a centralized distributor of COVID -19 vaccines and to assist with the kitting, storage, and distribution of \nancillary supplies are scheduled to expire in July of 2022.  Outside the contract with the US government for \nCOVID -19 vaccine distribution, we anticipate normal customer renewal activity in the US Pharmaceutical \nsegment.  \n \n As it relates to COVID -19 tests, we  continue to anticipate that demand will be closely associated with the rate of \nCOVID case levels and impact from variants will moderate from prior -year levels.  \n \n For the International segment, we anticipate $0.10 of adjusted earnings per diluted share accr etion in the first half \nof fiscal 2023 related to the held for sale accounting based on the current estimated close date for the PHOENIX \nGroup transaction.  We will no longer report revenue, adjusted operating profit, or held for sale accounting benefits \nrelated to these transactions once the transactions close.  \n \n We anticipate that opioid litigation expenses will remain relatively in line with our fiscal 2022 guidance until we \nhave a completed assessment of government entity participation in the proposed set tlement and a final \ndetermination regarding that settlement. ", "original_text": "As it relates to COVID -19 tests, we  continue to anticipate that demand will be closely associated with the rate of \nCOVID case levels and impact from variants will moderate from prior -year levels.  \n \n"}, "hash": "6f5a6bc4ae12cf8a27ac3375759faad1ac1210ee9c17dad5b54c53d489c56964", "class_name": "RelatedNodeInfo"}}, "text": "Outside the contract with the US government for \nCOVID -19 vaccine distribution, we anticipate normal customer renewal activity in the US Pharmaceutical \nsegment.  \n \n", "start_char_idx": 987, "end_char_idx": 1154, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "86b2c0d0-b59a-419f-8ee4-69cb1bd75b06": {"__data__": {"id_": "86b2c0d0-b59a-419f-8ee4-69cb1bd75b06", "embedding": null, "metadata": {"window": "However, it is likely to continue to be nonlinear into fiscal 2023, and it could  impact the quarterly cadence.  \n \n In the US Pharmaceutical and Medical -Surgical Solutions segments, our contract with the US government to \nserve as a centralized distributor of COVID -19 vaccines and to assist with the kitting, storage, and distribution of \nancillary supplies are scheduled to expire in July of 2022.  Outside the contract with the US government for \nCOVID -19 vaccine distribution, we anticipate normal customer renewal activity in the US Pharmaceutical \nsegment.  \n \n As it relates to COVID -19 tests, we  continue to anticipate that demand will be closely associated with the rate of \nCOVID case levels and impact from variants will moderate from prior -year levels.  \n \n For the International segment, we anticipate $0.10 of adjusted earnings per diluted share accr etion in the first half \nof fiscal 2023 related to the held for sale accounting based on the current estimated close date for the PHOENIX \nGroup transaction.  We will no longer report revenue, adjusted operating profit, or held for sale accounting benefits \nrelated to these transactions once the transactions close.  \n \n We anticipate that opioid litigation expenses will remain relatively in line with our fiscal 2022 guidance until we \nhave a completed assessment of government entity participation in the proposed set tlement and a final \ndetermination regarding that settlement. ", "original_text": "As it relates to COVID -19 tests, we  continue to anticipate that demand will be closely associated with the rate of \nCOVID case levels and impact from variants will moderate from prior -year levels.  \n \n", "page_label": "12", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01bc6e5f-cc79-4b05-99f5-5a1b943788f8", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "129f4d1de267bceb48e7ffbc5930fc91067bab0d0748d19326e56e94433fc7f1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b9c4d557-979d-4740-b305-cd02c528430f", "node_type": "1", "metadata": {"window": "We continue to expect a full recovery. \n However, it is likely to continue to be nonlinear into fiscal 2023, and it could  impact the quarterly cadence.  \n \n In the US Pharmaceutical and Medical -Surgical Solutions segments, our contract with the US government to \nserve as a centralized distributor of COVID -19 vaccines and to assist with the kitting, storage, and distribution of \nancillary supplies are scheduled to expire in July of 2022.  Outside the contract with the US government for \nCOVID -19 vaccine distribution, we anticipate normal customer renewal activity in the US Pharmaceutical \nsegment.  \n \n As it relates to COVID -19 tests, we  continue to anticipate that demand will be closely associated with the rate of \nCOVID case levels and impact from variants will moderate from prior -year levels.  \n \n For the International segment, we anticipate $0.10 of adjusted earnings per diluted share accr etion in the first half \nof fiscal 2023 related to the held for sale accounting based on the current estimated close date for the PHOENIX \nGroup transaction.  We will no longer report revenue, adjusted operating profit, or held for sale accounting benefits \nrelated to these transactions once the transactions close.  \n \n", "original_text": "Outside the contract with the US government for \nCOVID -19 vaccine distribution, we anticipate normal customer renewal activity in the US Pharmaceutical \nsegment.  \n \n", "page_label": "12", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8935171e18591f530233a4403bbd97f44f843675dd963864e2a5450974be07c1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d3e00e96-dbba-49b5-b398-8b35a747d518", "node_type": "1", "metadata": {"window": "In the US Pharmaceutical and Medical -Surgical Solutions segments, our contract with the US government to \nserve as a centralized distributor of COVID -19 vaccines and to assist with the kitting, storage, and distribution of \nancillary supplies are scheduled to expire in July of 2022.  Outside the contract with the US government for \nCOVID -19 vaccine distribution, we anticipate normal customer renewal activity in the US Pharmaceutical \nsegment.  \n \n As it relates to COVID -19 tests, we  continue to anticipate that demand will be closely associated with the rate of \nCOVID case levels and impact from variants will moderate from prior -year levels.  \n \n For the International segment, we anticipate $0.10 of adjusted earnings per diluted share accr etion in the first half \nof fiscal 2023 related to the held for sale accounting based on the current estimated close date for the PHOENIX \nGroup transaction.  We will no longer report revenue, adjusted operating profit, or held for sale accounting benefits \nrelated to these transactions once the transactions close.  \n \n We anticipate that opioid litigation expenses will remain relatively in line with our fiscal 2022 guidance until we \nhave a completed assessment of government entity participation in the proposed set tlement and a final \ndetermination regarding that settlement.  We'll continue to update you on the outcome of that determination and \nremaining opioid litigation expenses. ", "original_text": "For the International segment, we anticipate $0.10 of adjusted earnings per diluted share accr etion in the first half \nof fiscal 2023 related to the held for sale accounting based on the current estimated close date for the PHOENIX \nGroup transaction. "}, "hash": "f2bc2dce3249767c9ef2b5f21e1408ac180a4ef9b5fb770d6c16fbaf51e0d99b", "class_name": "RelatedNodeInfo"}}, "text": "As it relates to COVID -19 tests, we  continue to anticipate that demand will be closely associated with the rate of \nCOVID case levels and impact from variants will moderate from prior -year levels.  \n \n", "start_char_idx": 1154, "end_char_idx": 1358, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d3e00e96-dbba-49b5-b398-8b35a747d518": {"__data__": {"id_": "d3e00e96-dbba-49b5-b398-8b35a747d518", "embedding": null, "metadata": {"window": "In the US Pharmaceutical and Medical -Surgical Solutions segments, our contract with the US government to \nserve as a centralized distributor of COVID -19 vaccines and to assist with the kitting, storage, and distribution of \nancillary supplies are scheduled to expire in July of 2022.  Outside the contract with the US government for \nCOVID -19 vaccine distribution, we anticipate normal customer renewal activity in the US Pharmaceutical \nsegment.  \n \n As it relates to COVID -19 tests, we  continue to anticipate that demand will be closely associated with the rate of \nCOVID case levels and impact from variants will moderate from prior -year levels.  \n \n For the International segment, we anticipate $0.10 of adjusted earnings per diluted share accr etion in the first half \nof fiscal 2023 related to the held for sale accounting based on the current estimated close date for the PHOENIX \nGroup transaction.  We will no longer report revenue, adjusted operating profit, or held for sale accounting benefits \nrelated to these transactions once the transactions close.  \n \n We anticipate that opioid litigation expenses will remain relatively in line with our fiscal 2022 guidance until we \nhave a completed assessment of government entity participation in the proposed set tlement and a final \ndetermination regarding that settlement.  We'll continue to update you on the outcome of that determination and \nremaining opioid litigation expenses. ", "original_text": "For the International segment, we anticipate $0.10 of adjusted earnings per diluted share accr etion in the first half \nof fiscal 2023 related to the held for sale accounting based on the current estimated close date for the PHOENIX \nGroup transaction. ", "page_label": "12", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01bc6e5f-cc79-4b05-99f5-5a1b943788f8", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "129f4d1de267bceb48e7ffbc5930fc91067bab0d0748d19326e56e94433fc7f1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "86b2c0d0-b59a-419f-8ee4-69cb1bd75b06", "node_type": "1", "metadata": {"window": "However, it is likely to continue to be nonlinear into fiscal 2023, and it could  impact the quarterly cadence.  \n \n In the US Pharmaceutical and Medical -Surgical Solutions segments, our contract with the US government to \nserve as a centralized distributor of COVID -19 vaccines and to assist with the kitting, storage, and distribution of \nancillary supplies are scheduled to expire in July of 2022.  Outside the contract with the US government for \nCOVID -19 vaccine distribution, we anticipate normal customer renewal activity in the US Pharmaceutical \nsegment.  \n \n As it relates to COVID -19 tests, we  continue to anticipate that demand will be closely associated with the rate of \nCOVID case levels and impact from variants will moderate from prior -year levels.  \n \n For the International segment, we anticipate $0.10 of adjusted earnings per diluted share accr etion in the first half \nof fiscal 2023 related to the held for sale accounting based on the current estimated close date for the PHOENIX \nGroup transaction.  We will no longer report revenue, adjusted operating profit, or held for sale accounting benefits \nrelated to these transactions once the transactions close.  \n \n We anticipate that opioid litigation expenses will remain relatively in line with our fiscal 2022 guidance until we \nhave a completed assessment of government entity participation in the proposed set tlement and a final \ndetermination regarding that settlement. ", "original_text": "As it relates to COVID -19 tests, we  continue to anticipate that demand will be closely associated with the rate of \nCOVID case levels and impact from variants will moderate from prior -year levels.  \n \n", "page_label": "12", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6dc586304d04ead30e01923ede9fbb19886880bc02f7a406c58d063df89aaf8d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8e5b619b-dac8-446c-ba6c-1e4ad163d224", "node_type": "1", "metadata": {"window": "Outside the contract with the US government for \nCOVID -19 vaccine distribution, we anticipate normal customer renewal activity in the US Pharmaceutical \nsegment.  \n \n As it relates to COVID -19 tests, we  continue to anticipate that demand will be closely associated with the rate of \nCOVID case levels and impact from variants will moderate from prior -year levels.  \n \n For the International segment, we anticipate $0.10 of adjusted earnings per diluted share accr etion in the first half \nof fiscal 2023 related to the held for sale accounting based on the current estimated close date for the PHOENIX \nGroup transaction.  We will no longer report revenue, adjusted operating profit, or held for sale accounting benefits \nrelated to these transactions once the transactions close.  \n \n We anticipate that opioid litigation expenses will remain relatively in line with our fiscal 2022 guidance until we \nhave a completed assessment of government entity participation in the proposed set tlement and a final \ndetermination regarding that settlement.  We'll continue to update you on the outcome of that determination and \nremaining opioid litigation expenses.  We anticipate further investment to support the growth of our two key \nstrategies of onc ology and biopharma services.  \n \n", "original_text": "We will no longer report revenue, adjusted operating profit, or held for sale accounting benefits \nrelated to these transactions once the transactions close.  \n \n"}, "hash": "e8c5fae275a7db9cb7ca264a8645e3a557ddce73a23a1d829616e406ec3e8449", "class_name": "RelatedNodeInfo"}}, "text": "For the International segment, we anticipate $0.10 of adjusted earnings per diluted share accr etion in the first half \nof fiscal 2023 related to the held for sale accounting based on the current estimated close date for the PHOENIX \nGroup transaction. ", "start_char_idx": 1358, "end_char_idx": 1611, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8e5b619b-dac8-446c-ba6c-1e4ad163d224": {"__data__": {"id_": "8e5b619b-dac8-446c-ba6c-1e4ad163d224", "embedding": null, "metadata": {"window": "Outside the contract with the US government for \nCOVID -19 vaccine distribution, we anticipate normal customer renewal activity in the US Pharmaceutical \nsegment.  \n \n As it relates to COVID -19 tests, we  continue to anticipate that demand will be closely associated with the rate of \nCOVID case levels and impact from variants will moderate from prior -year levels.  \n \n For the International segment, we anticipate $0.10 of adjusted earnings per diluted share accr etion in the first half \nof fiscal 2023 related to the held for sale accounting based on the current estimated close date for the PHOENIX \nGroup transaction.  We will no longer report revenue, adjusted operating profit, or held for sale accounting benefits \nrelated to these transactions once the transactions close.  \n \n We anticipate that opioid litigation expenses will remain relatively in line with our fiscal 2022 guidance until we \nhave a completed assessment of government entity participation in the proposed set tlement and a final \ndetermination regarding that settlement.  We'll continue to update you on the outcome of that determination and \nremaining opioid litigation expenses.  We anticipate further investment to support the growth of our two key \nstrategies of onc ology and biopharma services.  \n \n", "original_text": "We will no longer report revenue, adjusted operating profit, or held for sale accounting benefits \nrelated to these transactions once the transactions close.  \n \n", "page_label": "12", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01bc6e5f-cc79-4b05-99f5-5a1b943788f8", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "129f4d1de267bceb48e7ffbc5930fc91067bab0d0748d19326e56e94433fc7f1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d3e00e96-dbba-49b5-b398-8b35a747d518", "node_type": "1", "metadata": {"window": "In the US Pharmaceutical and Medical -Surgical Solutions segments, our contract with the US government to \nserve as a centralized distributor of COVID -19 vaccines and to assist with the kitting, storage, and distribution of \nancillary supplies are scheduled to expire in July of 2022.  Outside the contract with the US government for \nCOVID -19 vaccine distribution, we anticipate normal customer renewal activity in the US Pharmaceutical \nsegment.  \n \n As it relates to COVID -19 tests, we  continue to anticipate that demand will be closely associated with the rate of \nCOVID case levels and impact from variants will moderate from prior -year levels.  \n \n For the International segment, we anticipate $0.10 of adjusted earnings per diluted share accr etion in the first half \nof fiscal 2023 related to the held for sale accounting based on the current estimated close date for the PHOENIX \nGroup transaction.  We will no longer report revenue, adjusted operating profit, or held for sale accounting benefits \nrelated to these transactions once the transactions close.  \n \n We anticipate that opioid litigation expenses will remain relatively in line with our fiscal 2022 guidance until we \nhave a completed assessment of government entity participation in the proposed set tlement and a final \ndetermination regarding that settlement.  We'll continue to update you on the outcome of that determination and \nremaining opioid litigation expenses. ", "original_text": "For the International segment, we anticipate $0.10 of adjusted earnings per diluted share accr etion in the first half \nof fiscal 2023 related to the held for sale accounting based on the current estimated close date for the PHOENIX \nGroup transaction. ", "page_label": "12", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "654edd29424a668548c83b091735824e4b3b4ee3e54a5e74ad663ebdad964e97", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b1506125-6f9e-46a3-a739-dd82ddd3e2b7", "node_type": "1", "metadata": {"window": "As it relates to COVID -19 tests, we  continue to anticipate that demand will be closely associated with the rate of \nCOVID case levels and impact from variants will moderate from prior -year levels.  \n \n For the International segment, we anticipate $0.10 of adjusted earnings per diluted share accr etion in the first half \nof fiscal 2023 related to the held for sale accounting based on the current estimated close date for the PHOENIX \nGroup transaction.  We will no longer report revenue, adjusted operating profit, or held for sale accounting benefits \nrelated to these transactions once the transactions close.  \n \n We anticipate that opioid litigation expenses will remain relatively in line with our fiscal 2022 guidance until we \nhave a completed assessment of government entity participation in the proposed set tlement and a final \ndetermination regarding that settlement.  We'll continue to update you on the outcome of that determination and \nremaining opioid litigation expenses.  We anticipate further investment to support the growth of our two key \nstrategies of onc ology and biopharma services.  \n \n Overall, we continue to see strength and stability in the underlying fundamentals of the business heading into \nfiscal 2023, and we remain optimistic about future growth opportunities. ", "original_text": "We anticipate that opioid litigation expenses will remain relatively in line with our fiscal 2022 guidance until we \nhave a completed assessment of government entity participation in the proposed set tlement and a final \ndetermination regarding that settlement. "}, "hash": "91c1a90d2b5c235a44d6bf181733d10a38a77ebdf6c4a1ccdbde69e9356d18f3", "class_name": "RelatedNodeInfo"}}, "text": "We will no longer report revenue, adjusted operating profit, or held for sale accounting benefits \nrelated to these transactions once the transactions close.  \n \n", "start_char_idx": 1611, "end_char_idx": 1773, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b1506125-6f9e-46a3-a739-dd82ddd3e2b7": {"__data__": {"id_": "b1506125-6f9e-46a3-a739-dd82ddd3e2b7", "embedding": null, "metadata": {"window": "As it relates to COVID -19 tests, we  continue to anticipate that demand will be closely associated with the rate of \nCOVID case levels and impact from variants will moderate from prior -year levels.  \n \n For the International segment, we anticipate $0.10 of adjusted earnings per diluted share accr etion in the first half \nof fiscal 2023 related to the held for sale accounting based on the current estimated close date for the PHOENIX \nGroup transaction.  We will no longer report revenue, adjusted operating profit, or held for sale accounting benefits \nrelated to these transactions once the transactions close.  \n \n We anticipate that opioid litigation expenses will remain relatively in line with our fiscal 2022 guidance until we \nhave a completed assessment of government entity participation in the proposed set tlement and a final \ndetermination regarding that settlement.  We'll continue to update you on the outcome of that determination and \nremaining opioid litigation expenses.  We anticipate further investment to support the growth of our two key \nstrategies of onc ology and biopharma services.  \n \n Overall, we continue to see strength and stability in the underlying fundamentals of the business heading into \nfiscal 2023, and we remain optimistic about future growth opportunities. ", "original_text": "We anticipate that opioid litigation expenses will remain relatively in line with our fiscal 2022 guidance until we \nhave a completed assessment of government entity participation in the proposed set tlement and a final \ndetermination regarding that settlement. ", "page_label": "12", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01bc6e5f-cc79-4b05-99f5-5a1b943788f8", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "129f4d1de267bceb48e7ffbc5930fc91067bab0d0748d19326e56e94433fc7f1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8e5b619b-dac8-446c-ba6c-1e4ad163d224", "node_type": "1", "metadata": {"window": "Outside the contract with the US government for \nCOVID -19 vaccine distribution, we anticipate normal customer renewal activity in the US Pharmaceutical \nsegment.  \n \n As it relates to COVID -19 tests, we  continue to anticipate that demand will be closely associated with the rate of \nCOVID case levels and impact from variants will moderate from prior -year levels.  \n \n For the International segment, we anticipate $0.10 of adjusted earnings per diluted share accr etion in the first half \nof fiscal 2023 related to the held for sale accounting based on the current estimated close date for the PHOENIX \nGroup transaction.  We will no longer report revenue, adjusted operating profit, or held for sale accounting benefits \nrelated to these transactions once the transactions close.  \n \n We anticipate that opioid litigation expenses will remain relatively in line with our fiscal 2022 guidance until we \nhave a completed assessment of government entity participation in the proposed set tlement and a final \ndetermination regarding that settlement.  We'll continue to update you on the outcome of that determination and \nremaining opioid litigation expenses.  We anticipate further investment to support the growth of our two key \nstrategies of onc ology and biopharma services.  \n \n", "original_text": "We will no longer report revenue, adjusted operating profit, or held for sale accounting benefits \nrelated to these transactions once the transactions close.  \n \n", "page_label": "12", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "eeba9eae037ff0f565c7617cfc04e070f844a40ed5dfa17956482dec84d2a9d9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d850eb94-3de3-4e3b-ad5c-d1098193b9fa", "node_type": "1", "metadata": {"window": "For the International segment, we anticipate $0.10 of adjusted earnings per diluted share accr etion in the first half \nof fiscal 2023 related to the held for sale accounting based on the current estimated close date for the PHOENIX \nGroup transaction.  We will no longer report revenue, adjusted operating profit, or held for sale accounting benefits \nrelated to these transactions once the transactions close.  \n \n We anticipate that opioid litigation expenses will remain relatively in line with our fiscal 2022 guidance until we \nhave a completed assessment of government entity participation in the proposed set tlement and a final \ndetermination regarding that settlement.  We'll continue to update you on the outcome of that determination and \nremaining opioid litigation expenses.  We anticipate further investment to support the growth of our two key \nstrategies of onc ology and biopharma services.  \n \n Overall, we continue to see strength and stability in the underlying fundamentals of the business heading into \nfiscal 2023, and we remain optimistic about future growth opportunities.  We'll share more details with you about \nour fiscal 2023 outlook in our fourth quarter earnings call in May.  \n \n", "original_text": "We'll continue to update you on the outcome of that determination and \nremaining opioid litigation expenses. "}, "hash": "3107f49cf3b79d58b44f0fb24bf1c110c35b2b04eb6e19dffb227724cb70c489", "class_name": "RelatedNodeInfo"}}, "text": "We anticipate that opioid litigation expenses will remain relatively in line with our fiscal 2022 guidance until we \nhave a completed assessment of government entity participation in the proposed set tlement and a final \ndetermination regarding that settlement. ", "start_char_idx": 1773, "end_char_idx": 2035, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d850eb94-3de3-4e3b-ad5c-d1098193b9fa": {"__data__": {"id_": "d850eb94-3de3-4e3b-ad5c-d1098193b9fa", "embedding": null, "metadata": {"window": "For the International segment, we anticipate $0.10 of adjusted earnings per diluted share accr etion in the first half \nof fiscal 2023 related to the held for sale accounting based on the current estimated close date for the PHOENIX \nGroup transaction.  We will no longer report revenue, adjusted operating profit, or held for sale accounting benefits \nrelated to these transactions once the transactions close.  \n \n We anticipate that opioid litigation expenses will remain relatively in line with our fiscal 2022 guidance until we \nhave a completed assessment of government entity participation in the proposed set tlement and a final \ndetermination regarding that settlement.  We'll continue to update you on the outcome of that determination and \nremaining opioid litigation expenses.  We anticipate further investment to support the growth of our two key \nstrategies of onc ology and biopharma services.  \n \n Overall, we continue to see strength and stability in the underlying fundamentals of the business heading into \nfiscal 2023, and we remain optimistic about future growth opportunities.  We'll share more details with you about \nour fiscal 2023 outlook in our fourth quarter earnings call in May.  \n \n", "original_text": "We'll continue to update you on the outcome of that determination and \nremaining opioid litigation expenses. ", "page_label": "12", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01bc6e5f-cc79-4b05-99f5-5a1b943788f8", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "129f4d1de267bceb48e7ffbc5930fc91067bab0d0748d19326e56e94433fc7f1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b1506125-6f9e-46a3-a739-dd82ddd3e2b7", "node_type": "1", "metadata": {"window": "As it relates to COVID -19 tests, we  continue to anticipate that demand will be closely associated with the rate of \nCOVID case levels and impact from variants will moderate from prior -year levels.  \n \n For the International segment, we anticipate $0.10 of adjusted earnings per diluted share accr etion in the first half \nof fiscal 2023 related to the held for sale accounting based on the current estimated close date for the PHOENIX \nGroup transaction.  We will no longer report revenue, adjusted operating profit, or held for sale accounting benefits \nrelated to these transactions once the transactions close.  \n \n We anticipate that opioid litigation expenses will remain relatively in line with our fiscal 2022 guidance until we \nhave a completed assessment of government entity participation in the proposed set tlement and a final \ndetermination regarding that settlement.  We'll continue to update you on the outcome of that determination and \nremaining opioid litigation expenses.  We anticipate further investment to support the growth of our two key \nstrategies of onc ology and biopharma services.  \n \n Overall, we continue to see strength and stability in the underlying fundamentals of the business heading into \nfiscal 2023, and we remain optimistic about future growth opportunities. ", "original_text": "We anticipate that opioid litigation expenses will remain relatively in line with our fiscal 2022 guidance until we \nhave a completed assessment of government entity participation in the proposed set tlement and a final \ndetermination regarding that settlement. ", "page_label": "12", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f2db1d6dc9a874080f18628a08569241697da152ea663c4f1dcbc07769172c7c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "24b51985-037c-48c4-82fa-38e9d99006e4", "node_type": "1", "metadata": {"window": "We will no longer report revenue, adjusted operating profit, or held for sale accounting benefits \nrelated to these transactions once the transactions close.  \n \n We anticipate that opioid litigation expenses will remain relatively in line with our fiscal 2022 guidance until we \nhave a completed assessment of government entity participation in the proposed set tlement and a final \ndetermination regarding that settlement.  We'll continue to update you on the outcome of that determination and \nremaining opioid litigation expenses.  We anticipate further investment to support the growth of our two key \nstrategies of onc ology and biopharma services.  \n \n Overall, we continue to see strength and stability in the underlying fundamentals of the business heading into \nfiscal 2023, and we remain optimistic about future growth opportunities.  We'll share more details with you about \nour fiscal 2023 outlook in our fourth quarter earnings call in May.  \n \n In closing, we are pleased with the results of our fiscal third quarter, and we have a strong financial outlook. \n", "original_text": "We anticipate further investment to support the growth of our two key \nstrategies of onc ology and biopharma services.  \n \n"}, "hash": "24c8631259ebbcaba30e988c0134cbe274681ed9fd2afeb73f765635ddd930ba", "class_name": "RelatedNodeInfo"}}, "text": "We'll continue to update you on the outcome of that determination and \nremaining opioid litigation expenses. ", "start_char_idx": 2035, "end_char_idx": 2144, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "24b51985-037c-48c4-82fa-38e9d99006e4": {"__data__": {"id_": "24b51985-037c-48c4-82fa-38e9d99006e4", "embedding": null, "metadata": {"window": "We will no longer report revenue, adjusted operating profit, or held for sale accounting benefits \nrelated to these transactions once the transactions close.  \n \n We anticipate that opioid litigation expenses will remain relatively in line with our fiscal 2022 guidance until we \nhave a completed assessment of government entity participation in the proposed set tlement and a final \ndetermination regarding that settlement.  We'll continue to update you on the outcome of that determination and \nremaining opioid litigation expenses.  We anticipate further investment to support the growth of our two key \nstrategies of onc ology and biopharma services.  \n \n Overall, we continue to see strength and stability in the underlying fundamentals of the business heading into \nfiscal 2023, and we remain optimistic about future growth opportunities.  We'll share more details with you about \nour fiscal 2023 outlook in our fourth quarter earnings call in May.  \n \n In closing, we are pleased with the results of our fiscal third quarter, and we have a strong financial outlook. \n", "original_text": "We anticipate further investment to support the growth of our two key \nstrategies of onc ology and biopharma services.  \n \n", "page_label": "12", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01bc6e5f-cc79-4b05-99f5-5a1b943788f8", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "129f4d1de267bceb48e7ffbc5930fc91067bab0d0748d19326e56e94433fc7f1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d850eb94-3de3-4e3b-ad5c-d1098193b9fa", "node_type": "1", "metadata": {"window": "For the International segment, we anticipate $0.10 of adjusted earnings per diluted share accr etion in the first half \nof fiscal 2023 related to the held for sale accounting based on the current estimated close date for the PHOENIX \nGroup transaction.  We will no longer report revenue, adjusted operating profit, or held for sale accounting benefits \nrelated to these transactions once the transactions close.  \n \n We anticipate that opioid litigation expenses will remain relatively in line with our fiscal 2022 guidance until we \nhave a completed assessment of government entity participation in the proposed set tlement and a final \ndetermination regarding that settlement.  We'll continue to update you on the outcome of that determination and \nremaining opioid litigation expenses.  We anticipate further investment to support the growth of our two key \nstrategies of onc ology and biopharma services.  \n \n Overall, we continue to see strength and stability in the underlying fundamentals of the business heading into \nfiscal 2023, and we remain optimistic about future growth opportunities.  We'll share more details with you about \nour fiscal 2023 outlook in our fourth quarter earnings call in May.  \n \n", "original_text": "We'll continue to update you on the outcome of that determination and \nremaining opioid litigation expenses. ", "page_label": "12", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1870c562cf67df6484518d84c40c9e40cfbddcae3f9bd0dcfce6e8bb018c3fe0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "010525f2-4776-4940-bf30-b43f9ad5efb1", "node_type": "1", "metadata": {"window": "We anticipate that opioid litigation expenses will remain relatively in line with our fiscal 2022 guidance until we \nhave a completed assessment of government entity participation in the proposed set tlement and a final \ndetermination regarding that settlement.  We'll continue to update you on the outcome of that determination and \nremaining opioid litigation expenses.  We anticipate further investment to support the growth of our two key \nstrategies of onc ology and biopharma services.  \n \n Overall, we continue to see strength and stability in the underlying fundamentals of the business heading into \nfiscal 2023, and we remain optimistic about future growth opportunities.  We'll share more details with you about \nour fiscal 2023 outlook in our fourth quarter earnings call in May.  \n \n In closing, we are pleased with the results of our fiscal third quarter, and we have a strong financial outlook. \n McKesson continues to deliver strong results as we successfully execute aga inst our strategic and financial \nframework. ", "original_text": "Overall, we continue to see strength and stability in the underlying fundamentals of the business heading into \nfiscal 2023, and we remain optimistic about future growth opportunities. "}, "hash": "1059491d7b70b31b02aba3c0b8069566deb14e26af928d80b4b3bc2c0c592666", "class_name": "RelatedNodeInfo"}}, "text": "We anticipate further investment to support the growth of our two key \nstrategies of onc ology and biopharma services.  \n \n", "start_char_idx": 2144, "end_char_idx": 2267, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "010525f2-4776-4940-bf30-b43f9ad5efb1": {"__data__": {"id_": "010525f2-4776-4940-bf30-b43f9ad5efb1", "embedding": null, "metadata": {"window": "We anticipate that opioid litigation expenses will remain relatively in line with our fiscal 2022 guidance until we \nhave a completed assessment of government entity participation in the proposed set tlement and a final \ndetermination regarding that settlement.  We'll continue to update you on the outcome of that determination and \nremaining opioid litigation expenses.  We anticipate further investment to support the growth of our two key \nstrategies of onc ology and biopharma services.  \n \n Overall, we continue to see strength and stability in the underlying fundamentals of the business heading into \nfiscal 2023, and we remain optimistic about future growth opportunities.  We'll share more details with you about \nour fiscal 2023 outlook in our fourth quarter earnings call in May.  \n \n In closing, we are pleased with the results of our fiscal third quarter, and we have a strong financial outlook. \n McKesson continues to deliver strong results as we successfully execute aga inst our strategic and financial \nframework. ", "original_text": "Overall, we continue to see strength and stability in the underlying fundamentals of the business heading into \nfiscal 2023, and we remain optimistic about future growth opportunities. ", "page_label": "12", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01bc6e5f-cc79-4b05-99f5-5a1b943788f8", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "129f4d1de267bceb48e7ffbc5930fc91067bab0d0748d19326e56e94433fc7f1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "24b51985-037c-48c4-82fa-38e9d99006e4", "node_type": "1", "metadata": {"window": "We will no longer report revenue, adjusted operating profit, or held for sale accounting benefits \nrelated to these transactions once the transactions close.  \n \n We anticipate that opioid litigation expenses will remain relatively in line with our fiscal 2022 guidance until we \nhave a completed assessment of government entity participation in the proposed set tlement and a final \ndetermination regarding that settlement.  We'll continue to update you on the outcome of that determination and \nremaining opioid litigation expenses.  We anticipate further investment to support the growth of our two key \nstrategies of onc ology and biopharma services.  \n \n Overall, we continue to see strength and stability in the underlying fundamentals of the business heading into \nfiscal 2023, and we remain optimistic about future growth opportunities.  We'll share more details with you about \nour fiscal 2023 outlook in our fourth quarter earnings call in May.  \n \n In closing, we are pleased with the results of our fiscal third quarter, and we have a strong financial outlook. \n", "original_text": "We anticipate further investment to support the growth of our two key \nstrategies of onc ology and biopharma services.  \n \n", "page_label": "12", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5d42896c3a9f7d1c77988762736c76b86bdc53a530319f7c9f0b377d9aef45e8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9837a007-9c17-4a0b-a4bd-b2fd8e2692f2", "node_type": "1", "metadata": {"window": "We'll continue to update you on the outcome of that determination and \nremaining opioid litigation expenses.  We anticipate further investment to support the growth of our two key \nstrategies of onc ology and biopharma services.  \n \n Overall, we continue to see strength and stability in the underlying fundamentals of the business heading into \nfiscal 2023, and we remain optimistic about future growth opportunities.  We'll share more details with you about \nour fiscal 2023 outlook in our fourth quarter earnings call in May.  \n \n In closing, we are pleased with the results of our fiscal third quarter, and we have a strong financial outlook. \n McKesson continues to deliver strong results as we successfully execute aga inst our strategic and financial \nframework.  We continue to focus on the things that matter most to our customers, patients and shareholders as a \ndiversified healthcare services company.  \n \n", "original_text": "We'll share more details with you about \nour fiscal 2023 outlook in our fourth quarter earnings call in May.  \n \n"}, "hash": "f7b005bb66cb626603d1552e397e10c9ca54eee575c30c5625312588be322d8c", "class_name": "RelatedNodeInfo"}}, "text": "Overall, we continue to see strength and stability in the underlying fundamentals of the business heading into \nfiscal 2023, and we remain optimistic about future growth opportunities. ", "start_char_idx": 2267, "end_char_idx": 2452, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9837a007-9c17-4a0b-a4bd-b2fd8e2692f2": {"__data__": {"id_": "9837a007-9c17-4a0b-a4bd-b2fd8e2692f2", "embedding": null, "metadata": {"window": "We'll continue to update you on the outcome of that determination and \nremaining opioid litigation expenses.  We anticipate further investment to support the growth of our two key \nstrategies of onc ology and biopharma services.  \n \n Overall, we continue to see strength and stability in the underlying fundamentals of the business heading into \nfiscal 2023, and we remain optimistic about future growth opportunities.  We'll share more details with you about \nour fiscal 2023 outlook in our fourth quarter earnings call in May.  \n \n In closing, we are pleased with the results of our fiscal third quarter, and we have a strong financial outlook. \n McKesson continues to deliver strong results as we successfully execute aga inst our strategic and financial \nframework.  We continue to focus on the things that matter most to our customers, patients and shareholders as a \ndiversified healthcare services company.  \n \n", "original_text": "We'll share more details with you about \nour fiscal 2023 outlook in our fourth quarter earnings call in May.  \n \n", "page_label": "12", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01bc6e5f-cc79-4b05-99f5-5a1b943788f8", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "129f4d1de267bceb48e7ffbc5930fc91067bab0d0748d19326e56e94433fc7f1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "010525f2-4776-4940-bf30-b43f9ad5efb1", "node_type": "1", "metadata": {"window": "We anticipate that opioid litigation expenses will remain relatively in line with our fiscal 2022 guidance until we \nhave a completed assessment of government entity participation in the proposed set tlement and a final \ndetermination regarding that settlement.  We'll continue to update you on the outcome of that determination and \nremaining opioid litigation expenses.  We anticipate further investment to support the growth of our two key \nstrategies of onc ology and biopharma services.  \n \n Overall, we continue to see strength and stability in the underlying fundamentals of the business heading into \nfiscal 2023, and we remain optimistic about future growth opportunities.  We'll share more details with you about \nour fiscal 2023 outlook in our fourth quarter earnings call in May.  \n \n In closing, we are pleased with the results of our fiscal third quarter, and we have a strong financial outlook. \n McKesson continues to deliver strong results as we successfully execute aga inst our strategic and financial \nframework. ", "original_text": "Overall, we continue to see strength and stability in the underlying fundamentals of the business heading into \nfiscal 2023, and we remain optimistic about future growth opportunities. ", "page_label": "12", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "22d09f8f70ab2bcdfb203fe3f8adc3a4413db9a330ab169f1d6fb5fddbd0d991", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2e219d54-22b0-44ad-b994-bfa14abf8dca", "node_type": "1", "metadata": {"window": "We anticipate further investment to support the growth of our two key \nstrategies of onc ology and biopharma services.  \n \n Overall, we continue to see strength and stability in the underlying fundamentals of the business heading into \nfiscal 2023, and we remain optimistic about future growth opportunities.  We'll share more details with you about \nour fiscal 2023 outlook in our fourth quarter earnings call in May.  \n \n In closing, we are pleased with the results of our fiscal third quarter, and we have a strong financial outlook. \n McKesson continues to deliver strong results as we successfully execute aga inst our strategic and financial \nframework.  We continue to focus on the things that matter most to our customers, patients and shareholders as a \ndiversified healthcare services company.  \n \n We want to thank you and thank all of our employees for all their har d work and dedication. ", "original_text": "In closing, we are pleased with the results of our fiscal third quarter, and we have a strong financial outlook. \n"}, "hash": "9018e6ea620f47cddbf1eadd7ed861328b0eb50504b1a3bbbee65306deddf635", "class_name": "RelatedNodeInfo"}}, "text": "We'll share more details with you about \nour fiscal 2023 outlook in our fourth quarter earnings call in May.  \n \n", "start_char_idx": 2452, "end_char_idx": 2565, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2e219d54-22b0-44ad-b994-bfa14abf8dca": {"__data__": {"id_": "2e219d54-22b0-44ad-b994-bfa14abf8dca", "embedding": null, "metadata": {"window": "We anticipate further investment to support the growth of our two key \nstrategies of onc ology and biopharma services.  \n \n Overall, we continue to see strength and stability in the underlying fundamentals of the business heading into \nfiscal 2023, and we remain optimistic about future growth opportunities.  We'll share more details with you about \nour fiscal 2023 outlook in our fourth quarter earnings call in May.  \n \n In closing, we are pleased with the results of our fiscal third quarter, and we have a strong financial outlook. \n McKesson continues to deliver strong results as we successfully execute aga inst our strategic and financial \nframework.  We continue to focus on the things that matter most to our customers, patients and shareholders as a \ndiversified healthcare services company.  \n \n We want to thank you and thank all of our employees for all their har d work and dedication. ", "original_text": "In closing, we are pleased with the results of our fiscal third quarter, and we have a strong financial outlook. \n", "page_label": "12", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01bc6e5f-cc79-4b05-99f5-5a1b943788f8", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "129f4d1de267bceb48e7ffbc5930fc91067bab0d0748d19326e56e94433fc7f1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9837a007-9c17-4a0b-a4bd-b2fd8e2692f2", "node_type": "1", "metadata": {"window": "We'll continue to update you on the outcome of that determination and \nremaining opioid litigation expenses.  We anticipate further investment to support the growth of our two key \nstrategies of onc ology and biopharma services.  \n \n Overall, we continue to see strength and stability in the underlying fundamentals of the business heading into \nfiscal 2023, and we remain optimistic about future growth opportunities.  We'll share more details with you about \nour fiscal 2023 outlook in our fourth quarter earnings call in May.  \n \n In closing, we are pleased with the results of our fiscal third quarter, and we have a strong financial outlook. \n McKesson continues to deliver strong results as we successfully execute aga inst our strategic and financial \nframework.  We continue to focus on the things that matter most to our customers, patients and shareholders as a \ndiversified healthcare services company.  \n \n", "original_text": "We'll share more details with you about \nour fiscal 2023 outlook in our fourth quarter earnings call in May.  \n \n", "page_label": "12", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "75e14ec4cd24a34879163f28d1f3aa3c1a5273ff821221fdd6e7a0857dc1dce8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f115d3c3-3000-4364-8689-3920a08aa3bb", "node_type": "1", "metadata": {"window": "Overall, we continue to see strength and stability in the underlying fundamentals of the business heading into \nfiscal 2023, and we remain optimistic about future growth opportunities.  We'll share more details with you about \nour fiscal 2023 outlook in our fourth quarter earnings call in May.  \n \n In closing, we are pleased with the results of our fiscal third quarter, and we have a strong financial outlook. \n McKesson continues to deliver strong results as we successfully execute aga inst our strategic and financial \nframework.  We continue to focus on the things that matter most to our customers, patients and shareholders as a \ndiversified healthcare services company.  \n \n We want to thank you and thank all of our employees for all their har d work and dedication.  And now I'll turn the \ncall over to the operator for your questions.  \n  ", "original_text": "McKesson continues to deliver strong results as we successfully execute aga inst our strategic and financial \nframework. "}, "hash": "65f3cdd6a9bb610b1b4b1934d94e15a38fb93c1104a0f088c08e1eababc8284d", "class_name": "RelatedNodeInfo"}}, "text": "In closing, we are pleased with the results of our fiscal third quarter, and we have a strong financial outlook. \n", "start_char_idx": 2565, "end_char_idx": 2679, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f115d3c3-3000-4364-8689-3920a08aa3bb": {"__data__": {"id_": "f115d3c3-3000-4364-8689-3920a08aa3bb", "embedding": null, "metadata": {"window": "Overall, we continue to see strength and stability in the underlying fundamentals of the business heading into \nfiscal 2023, and we remain optimistic about future growth opportunities.  We'll share more details with you about \nour fiscal 2023 outlook in our fourth quarter earnings call in May.  \n \n In closing, we are pleased with the results of our fiscal third quarter, and we have a strong financial outlook. \n McKesson continues to deliver strong results as we successfully execute aga inst our strategic and financial \nframework.  We continue to focus on the things that matter most to our customers, patients and shareholders as a \ndiversified healthcare services company.  \n \n We want to thank you and thank all of our employees for all their har d work and dedication.  And now I'll turn the \ncall over to the operator for your questions.  \n  ", "original_text": "McKesson continues to deliver strong results as we successfully execute aga inst our strategic and financial \nframework. ", "page_label": "12", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01bc6e5f-cc79-4b05-99f5-5a1b943788f8", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "129f4d1de267bceb48e7ffbc5930fc91067bab0d0748d19326e56e94433fc7f1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2e219d54-22b0-44ad-b994-bfa14abf8dca", "node_type": "1", "metadata": {"window": "We anticipate further investment to support the growth of our two key \nstrategies of onc ology and biopharma services.  \n \n Overall, we continue to see strength and stability in the underlying fundamentals of the business heading into \nfiscal 2023, and we remain optimistic about future growth opportunities.  We'll share more details with you about \nour fiscal 2023 outlook in our fourth quarter earnings call in May.  \n \n In closing, we are pleased with the results of our fiscal third quarter, and we have a strong financial outlook. \n McKesson continues to deliver strong results as we successfully execute aga inst our strategic and financial \nframework.  We continue to focus on the things that matter most to our customers, patients and shareholders as a \ndiversified healthcare services company.  \n \n We want to thank you and thank all of our employees for all their har d work and dedication. ", "original_text": "In closing, we are pleased with the results of our fiscal third quarter, and we have a strong financial outlook. \n", "page_label": "12", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df71b5bab51688c4b8fce60090497fd25829d9c03bd168ec76bb90a90c3256a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5fcde533-85b1-4d83-86c4-727a0ad3ad48", "node_type": "1", "metadata": {"window": "We'll share more details with you about \nour fiscal 2023 outlook in our fourth quarter earnings call in May.  \n \n In closing, we are pleased with the results of our fiscal third quarter, and we have a strong financial outlook. \n McKesson continues to deliver strong results as we successfully execute aga inst our strategic and financial \nframework.  We continue to focus on the things that matter most to our customers, patients and shareholders as a \ndiversified healthcare services company.  \n \n We want to thank you and thank all of our employees for all their har d work and dedication.  And now I'll turn the \ncall over to the operator for your questions.  \n  ", "original_text": "We continue to focus on the things that matter most to our customers, patients and shareholders as a \ndiversified healthcare services company.  \n \n"}, "hash": "93802ac2de7a035c002fbbf6b8df72b7cc231afa57983603617b633193fbfa1d", "class_name": "RelatedNodeInfo"}}, "text": "McKesson continues to deliver strong results as we successfully execute aga inst our strategic and financial \nframework. ", "start_char_idx": 2679, "end_char_idx": 2800, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5fcde533-85b1-4d83-86c4-727a0ad3ad48": {"__data__": {"id_": "5fcde533-85b1-4d83-86c4-727a0ad3ad48", "embedding": null, "metadata": {"window": "We'll share more details with you about \nour fiscal 2023 outlook in our fourth quarter earnings call in May.  \n \n In closing, we are pleased with the results of our fiscal third quarter, and we have a strong financial outlook. \n McKesson continues to deliver strong results as we successfully execute aga inst our strategic and financial \nframework.  We continue to focus on the things that matter most to our customers, patients and shareholders as a \ndiversified healthcare services company.  \n \n We want to thank you and thank all of our employees for all their har d work and dedication.  And now I'll turn the \ncall over to the operator for your questions.  \n  ", "original_text": "We continue to focus on the things that matter most to our customers, patients and shareholders as a \ndiversified healthcare services company.  \n \n", "page_label": "12", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01bc6e5f-cc79-4b05-99f5-5a1b943788f8", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "129f4d1de267bceb48e7ffbc5930fc91067bab0d0748d19326e56e94433fc7f1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f115d3c3-3000-4364-8689-3920a08aa3bb", "node_type": "1", "metadata": {"window": "Overall, we continue to see strength and stability in the underlying fundamentals of the business heading into \nfiscal 2023, and we remain optimistic about future growth opportunities.  We'll share more details with you about \nour fiscal 2023 outlook in our fourth quarter earnings call in May.  \n \n In closing, we are pleased with the results of our fiscal third quarter, and we have a strong financial outlook. \n McKesson continues to deliver strong results as we successfully execute aga inst our strategic and financial \nframework.  We continue to focus on the things that matter most to our customers, patients and shareholders as a \ndiversified healthcare services company.  \n \n We want to thank you and thank all of our employees for all their har d work and dedication.  And now I'll turn the \ncall over to the operator for your questions.  \n  ", "original_text": "McKesson continues to deliver strong results as we successfully execute aga inst our strategic and financial \nframework. ", "page_label": "12", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "66efaf77729d079be516bb528ab867d3757e26e5c046a3e82ba0c055d379a3d0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e1fbfbb0-9bdf-4610-8a94-9045aef6e82d", "node_type": "1", "metadata": {"window": "In closing, we are pleased with the results of our fiscal third quarter, and we have a strong financial outlook. \n McKesson continues to deliver strong results as we successfully execute aga inst our strategic and financial \nframework.  We continue to focus on the things that matter most to our customers, patients and shareholders as a \ndiversified healthcare services company.  \n \n We want to thank you and thank all of our employees for all their har d work and dedication.  And now I'll turn the \ncall over to the operator for your questions.  \n  ", "original_text": "We want to thank you and thank all of our employees for all their har d work and dedication. "}, "hash": "2db737a3bc5178206e4760945196e08e51968e1fb14eacfd4dc80300e94bca57", "class_name": "RelatedNodeInfo"}}, "text": "We continue to focus on the things that matter most to our customers, patients and shareholders as a \ndiversified healthcare services company.  \n \n", "start_char_idx": 2800, "end_char_idx": 2947, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e1fbfbb0-9bdf-4610-8a94-9045aef6e82d": {"__data__": {"id_": "e1fbfbb0-9bdf-4610-8a94-9045aef6e82d", "embedding": null, "metadata": {"window": "In closing, we are pleased with the results of our fiscal third quarter, and we have a strong financial outlook. \n McKesson continues to deliver strong results as we successfully execute aga inst our strategic and financial \nframework.  We continue to focus on the things that matter most to our customers, patients and shareholders as a \ndiversified healthcare services company.  \n \n We want to thank you and thank all of our employees for all their har d work and dedication.  And now I'll turn the \ncall over to the operator for your questions.  \n  ", "original_text": "We want to thank you and thank all of our employees for all their har d work and dedication. ", "page_label": "12", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01bc6e5f-cc79-4b05-99f5-5a1b943788f8", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "129f4d1de267bceb48e7ffbc5930fc91067bab0d0748d19326e56e94433fc7f1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5fcde533-85b1-4d83-86c4-727a0ad3ad48", "node_type": "1", "metadata": {"window": "We'll share more details with you about \nour fiscal 2023 outlook in our fourth quarter earnings call in May.  \n \n In closing, we are pleased with the results of our fiscal third quarter, and we have a strong financial outlook. \n McKesson continues to deliver strong results as we successfully execute aga inst our strategic and financial \nframework.  We continue to focus on the things that matter most to our customers, patients and shareholders as a \ndiversified healthcare services company.  \n \n We want to thank you and thank all of our employees for all their har d work and dedication.  And now I'll turn the \ncall over to the operator for your questions.  \n  ", "original_text": "We continue to focus on the things that matter most to our customers, patients and shareholders as a \ndiversified healthcare services company.  \n \n", "page_label": "12", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "19fe30e8daaee5c5f260fcb0693754c927f76ed90da15a13fb0a06e8f8ae3de9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "935ca256-96da-4175-be0d-b98dfea082c1", "node_type": "1", "metadata": {"window": "McKesson continues to deliver strong results as we successfully execute aga inst our strategic and financial \nframework.  We continue to focus on the things that matter most to our customers, patients and shareholders as a \ndiversified healthcare services company.  \n \n We want to thank you and thank all of our employees for all their har d work and dedication.  And now I'll turn the \ncall over to the operator for your questions.  \n  ", "original_text": "And now I'll turn the \ncall over to the operator for your questions.  \n  "}, "hash": "3c9f64b6e715398a924118216d922872003dd96a095c69e987732a340cdbbbb6", "class_name": "RelatedNodeInfo"}}, "text": "We want to thank you and thank all of our employees for all their har d work and dedication. ", "start_char_idx": 2947, "end_char_idx": 3040, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "935ca256-96da-4175-be0d-b98dfea082c1": {"__data__": {"id_": "935ca256-96da-4175-be0d-b98dfea082c1", "embedding": null, "metadata": {"window": "McKesson continues to deliver strong results as we successfully execute aga inst our strategic and financial \nframework.  We continue to focus on the things that matter most to our customers, patients and shareholders as a \ndiversified healthcare services company.  \n \n We want to thank you and thank all of our employees for all their har d work and dedication.  And now I'll turn the \ncall over to the operator for your questions.  \n  ", "original_text": "And now I'll turn the \ncall over to the operator for your questions.  \n  ", "page_label": "12", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01bc6e5f-cc79-4b05-99f5-5a1b943788f8", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "129f4d1de267bceb48e7ffbc5930fc91067bab0d0748d19326e56e94433fc7f1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e1fbfbb0-9bdf-4610-8a94-9045aef6e82d", "node_type": "1", "metadata": {"window": "In closing, we are pleased with the results of our fiscal third quarter, and we have a strong financial outlook. \n McKesson continues to deliver strong results as we successfully execute aga inst our strategic and financial \nframework.  We continue to focus on the things that matter most to our customers, patients and shareholders as a \ndiversified healthcare services company.  \n \n We want to thank you and thank all of our employees for all their har d work and dedication.  And now I'll turn the \ncall over to the operator for your questions.  \n  ", "original_text": "We want to thank you and thank all of our employees for all their har d work and dedication. ", "page_label": "12", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d578960f9c93fed9d5176a9cd3eba5615d225bd5569e5e6679f3e08905b08807", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "27c17fa8-e243-492f-896d-dfa899fba284", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] Our first question will come from Eric Percher with Nephron \nResearch.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you, and appreciate the commentary on fiscal year 2023 at this point. ", "original_text": "McKesson Corp.  "}, "hash": "35b256e7f437709251d7879b5e30403589cf2ac3c9e38dd7189cd0e2a7ae3670", "class_name": "RelatedNodeInfo"}}, "text": "And now I'll turn the \ncall over to the operator for your questions.  \n  ", "start_char_idx": 3040, "end_char_idx": 3113, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "27c17fa8-e243-492f-896d-dfa899fba284": {"__data__": {"id_": "27c17fa8-e243-492f-896d-dfa899fba284", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] Our first question will come from Eric Percher with Nephron \nResearch.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you, and appreciate the commentary on fiscal year 2023 at this point. ", "original_text": "McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f068cc0d-3c7f-417d-91f3-136afa17b579", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f0fb2efafc021a37706fc20da54d10f4c2572335f2953923cc818e170f79c18", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "935ca256-96da-4175-be0d-b98dfea082c1", "node_type": "1", "metadata": {"window": "McKesson continues to deliver strong results as we successfully execute aga inst our strategic and financial \nframework.  We continue to focus on the things that matter most to our customers, patients and shareholders as a \ndiversified healthcare services company.  \n \n We want to thank you and thank all of our employees for all their har d work and dedication.  And now I'll turn the \ncall over to the operator for your questions.  \n  ", "original_text": "And now I'll turn the \ncall over to the operator for your questions.  \n  ", "page_label": "12", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d7862351033da982c43dc7f24b98f3790b6823d66b1feee105131bf3560b00e5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "545b9e6d-2d02-4214-8ce6-f3cec831360d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] Our first question will come from Eric Percher with Nephron \nResearch.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you, and appreciate the commentary on fiscal year 2023 at this point.  One thing I want to zero in on \nrelative to the EU, so you'll remove most of the factors, $0.10 of benefit continuing to flow through. ", "original_text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. "}, "hash": "c0f95e32bb41cd8677a5bbdc9d5591e3badffa23e5b821374c0db6facf416483", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "545b9e6d-2d02-4214-8ce6-f3cec831360d": {"__data__": {"id_": "545b9e6d-2d02-4214-8ce6-f3cec831360d", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] Our first question will come from Eric Percher with Nephron \nResearch.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you, and appreciate the commentary on fiscal year 2023 at this point.  One thing I want to zero in on \nrelative to the EU, so you'll remove most of the factors, $0.10 of benefit continuing to flow through. ", "original_text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. ", "page_label": "13", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f068cc0d-3c7f-417d-91f3-136afa17b579", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f0fb2efafc021a37706fc20da54d10f4c2572335f2953923cc818e170f79c18", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "27c17fa8-e243-492f-896d-dfa899fba284", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] Our first question will come from Eric Percher with Nephron \nResearch.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you, and appreciate the commentary on fiscal year 2023 at this point. ", "original_text": "McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df8fb3fde658e99f7acc77cc55419fe1868b5d22f3261d03c6d1c0f1077fe3eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d5c29af9-a84e-434b-83f1-c3e92d127506", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] Our first question will come from Eric Percher with Nephron \nResearch.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you, and appreciate the commentary on fiscal year 2023 at this point.  One thing I want to zero in on \nrelative to the EU, so you'll remove most of the factors, $0.10 of benefit continuing to flow through.  As you speak \nto offsetting with repurchase, is that part of what the repo that you suggested for Q4 is getting in front of? ", "original_text": "[Operator Instructions] Our first question will come from Eric Percher with Nephron \nResearch.  \n "}, "hash": "9c0062fe3780a932bcffb8882d497cbe1607b4265ff5acce707e8dcaa41f638c", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. ", "start_char_idx": 16, "end_char_idx": 238, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d5c29af9-a84e-434b-83f1-c3e92d127506": {"__data__": {"id_": "d5c29af9-a84e-434b-83f1-c3e92d127506", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] Our first question will come from Eric Percher with Nephron \nResearch.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you, and appreciate the commentary on fiscal year 2023 at this point.  One thing I want to zero in on \nrelative to the EU, so you'll remove most of the factors, $0.10 of benefit continuing to flow through.  As you speak \nto offsetting with repurchase, is that part of what the repo that you suggested for Q4 is getting in front of? ", "original_text": "[Operator Instructions] Our first question will come from Eric Percher with Nephron \nResearch.  \n ", "page_label": "13", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f068cc0d-3c7f-417d-91f3-136afa17b579", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f0fb2efafc021a37706fc20da54d10f4c2572335f2953923cc818e170f79c18", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "545b9e6d-2d02-4214-8ce6-f3cec831360d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] Our first question will come from Eric Percher with Nephron \nResearch.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you, and appreciate the commentary on fiscal year 2023 at this point.  One thing I want to zero in on \nrelative to the EU, so you'll remove most of the factors, $0.10 of benefit continuing to flow through. ", "original_text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. ", "page_label": "13", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b100f11a97d214cbc523b87a36a903d734896955524359b07d290796d301d5cb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "489049fe-3776-4b23-95f6-753979b1c77b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] Our first question will come from Eric Percher with Nephron \nResearch.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you, and appreciate the commentary on fiscal year 2023 at this point.  One thing I want to zero in on \nrelative to the EU, so you'll remove most of the factors, $0.10 of benefit continuing to flow through.  As you speak \nto offsetting with repurchase, is that part of what the repo that you suggested for Q4 is getting in front of?  And do \nyou expect you'll \u2013 how will you judge that? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you, and appreciate the commentary on fiscal year 2023 at this point. "}, "hash": "51098cdde47bad36f5e4328a2b96c50613230e920d15f7c7dff9d7250098e124", "class_name": "RelatedNodeInfo"}}, "text": "[Operator Instructions] Our first question will come from Eric Percher with Nephron \nResearch.  \n ", "start_char_idx": 238, "end_char_idx": 336, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "489049fe-3776-4b23-95f6-753979b1c77b": {"__data__": {"id_": "489049fe-3776-4b23-95f6-753979b1c77b", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] Our first question will come from Eric Percher with Nephron \nResearch.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you, and appreciate the commentary on fiscal year 2023 at this point.  One thing I want to zero in on \nrelative to the EU, so you'll remove most of the factors, $0.10 of benefit continuing to flow through.  As you speak \nto offsetting with repurchase, is that part of what the repo that you suggested for Q4 is getting in front of?  And do \nyou expect you'll \u2013 how will you judge that? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you, and appreciate the commentary on fiscal year 2023 at this point. ", "page_label": "13", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f068cc0d-3c7f-417d-91f3-136afa17b579", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f0fb2efafc021a37706fc20da54d10f4c2572335f2953923cc818e170f79c18", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d5c29af9-a84e-434b-83f1-c3e92d127506", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] Our first question will come from Eric Percher with Nephron \nResearch.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you, and appreciate the commentary on fiscal year 2023 at this point.  One thing I want to zero in on \nrelative to the EU, so you'll remove most of the factors, $0.10 of benefit continuing to flow through.  As you speak \nto offsetting with repurchase, is that part of what the repo that you suggested for Q4 is getting in front of? ", "original_text": "[Operator Instructions] Our first question will come from Eric Percher with Nephron \nResearch.  \n ", "page_label": "13", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "118a75a18df6301f493157bbc35908e93f592b4999c66c67fffa73f74ddee703", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0e4b76eb-fa6c-4f45-85e7-eae89756e411", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] Our first question will come from Eric Percher with Nephron \nResearch.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you, and appreciate the commentary on fiscal year 2023 at this point.  One thing I want to zero in on \nrelative to the EU, so you'll remove most of the factors, $0.10 of benefit continuing to flow through.  As you speak \nto offsetting with repurchase, is that part of what the repo that you suggested for Q4 is getting in front of?  And do \nyou expect you'll \u2013 how will you judge that?  Will you judge it over the full fiscal year given that the timing is still \nvariable?  \n ", "original_text": "One thing I want to zero in on \nrelative to the EU, so you'll remove most of the factors, $0.10 of benefit continuing to flow through. "}, "hash": "8fa10a4fd8a75310cce2e01d139c7471ade25880fac7cfecb7ecd6a52701da98", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you, and appreciate the commentary on fiscal year 2023 at this point. ", "start_char_idx": 336, "end_char_idx": 733, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0e4b76eb-fa6c-4f45-85e7-eae89756e411": {"__data__": {"id_": "0e4b76eb-fa6c-4f45-85e7-eae89756e411", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] Our first question will come from Eric Percher with Nephron \nResearch.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you, and appreciate the commentary on fiscal year 2023 at this point.  One thing I want to zero in on \nrelative to the EU, so you'll remove most of the factors, $0.10 of benefit continuing to flow through.  As you speak \nto offsetting with repurchase, is that part of what the repo that you suggested for Q4 is getting in front of?  And do \nyou expect you'll \u2013 how will you judge that?  Will you judge it over the full fiscal year given that the timing is still \nvariable?  \n ", "original_text": "One thing I want to zero in on \nrelative to the EU, so you'll remove most of the factors, $0.10 of benefit continuing to flow through. ", "page_label": "13", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f068cc0d-3c7f-417d-91f3-136afa17b579", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f0fb2efafc021a37706fc20da54d10f4c2572335f2953923cc818e170f79c18", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "489049fe-3776-4b23-95f6-753979b1c77b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] Our first question will come from Eric Percher with Nephron \nResearch.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you, and appreciate the commentary on fiscal year 2023 at this point.  One thing I want to zero in on \nrelative to the EU, so you'll remove most of the factors, $0.10 of benefit continuing to flow through.  As you speak \nto offsetting with repurchase, is that part of what the repo that you suggested for Q4 is getting in front of?  And do \nyou expect you'll \u2013 how will you judge that? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you, and appreciate the commentary on fiscal year 2023 at this point. ", "page_label": "13", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dcb4a6126fc8b9ac3c455460e6c5b11e4794f218b38bbb0a6f19ff35d853916c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "013244b2-4e46-4ff2-a500-822a58606b72", "node_type": "1", "metadata": {"window": "[Operator Instructions] Our first question will come from Eric Percher with Nephron \nResearch.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you, and appreciate the commentary on fiscal year 2023 at this point.  One thing I want to zero in on \nrelative to the EU, so you'll remove most of the factors, $0.10 of benefit continuing to flow through.  As you speak \nto offsetting with repurchase, is that part of what the repo that you suggested for Q4 is getting in front of?  And do \nyou expect you'll \u2013 how will you judge that?  Will you judge it over the full fiscal year given that the timing is still \nvariable?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vi talone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "As you speak \nto offsetting with repurchase, is that part of what the repo that you suggested for Q4 is getting in front of? "}, "hash": "0c0814c9803759f8814b92c2838d55d141ef89ce55213c5728681300495ad324", "class_name": "RelatedNodeInfo"}}, "text": "One thing I want to zero in on \nrelative to the EU, so you'll remove most of the factors, $0.10 of benefit continuing to flow through. ", "start_char_idx": 733, "end_char_idx": 868, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "013244b2-4e46-4ff2-a500-822a58606b72": {"__data__": {"id_": "013244b2-4e46-4ff2-a500-822a58606b72", "embedding": null, "metadata": {"window": "[Operator Instructions] Our first question will come from Eric Percher with Nephron \nResearch.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you, and appreciate the commentary on fiscal year 2023 at this point.  One thing I want to zero in on \nrelative to the EU, so you'll remove most of the factors, $0.10 of benefit continuing to flow through.  As you speak \nto offsetting with repurchase, is that part of what the repo that you suggested for Q4 is getting in front of?  And do \nyou expect you'll \u2013 how will you judge that?  Will you judge it over the full fiscal year given that the timing is still \nvariable?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vi talone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "As you speak \nto offsetting with repurchase, is that part of what the repo that you suggested for Q4 is getting in front of? ", "page_label": "13", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f068cc0d-3c7f-417d-91f3-136afa17b579", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f0fb2efafc021a37706fc20da54d10f4c2572335f2953923cc818e170f79c18", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0e4b76eb-fa6c-4f45-85e7-eae89756e411", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] Our first question will come from Eric Percher with Nephron \nResearch.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you, and appreciate the commentary on fiscal year 2023 at this point.  One thing I want to zero in on \nrelative to the EU, so you'll remove most of the factors, $0.10 of benefit continuing to flow through.  As you speak \nto offsetting with repurchase, is that part of what the repo that you suggested for Q4 is getting in front of?  And do \nyou expect you'll \u2013 how will you judge that?  Will you judge it over the full fiscal year given that the timing is still \nvariable?  \n ", "original_text": "One thing I want to zero in on \nrelative to the EU, so you'll remove most of the factors, $0.10 of benefit continuing to flow through. ", "page_label": "13", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8306f43a65b6e5f0a119d9c7a62c47286f77ffc6b5df063e4ed67d03dd064ab9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f73bc254-7e3e-433d-b2fd-b0e62822cee8", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you, and appreciate the commentary on fiscal year 2023 at this point.  One thing I want to zero in on \nrelative to the EU, so you'll remove most of the factors, $0.10 of benefit continuing to flow through.  As you speak \nto offsetting with repurchase, is that part of what the repo that you suggested for Q4 is getting in front of?  And do \nyou expect you'll \u2013 how will you judge that?  Will you judge it over the full fiscal year given that the timing is still \nvariable?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vi talone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks, Eric, for that question. ", "original_text": "And do \nyou expect you'll \u2013 how will you judge that? "}, "hash": "81fa3c9904a855155af717f58beb6920e7c770672d841293149a384547b90f73", "class_name": "RelatedNodeInfo"}}, "text": "As you speak \nto offsetting with repurchase, is that part of what the repo that you suggested for Q4 is getting in front of? ", "start_char_idx": 868, "end_char_idx": 993, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f73bc254-7e3e-433d-b2fd-b0e62822cee8": {"__data__": {"id_": "f73bc254-7e3e-433d-b2fd-b0e62822cee8", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you, and appreciate the commentary on fiscal year 2023 at this point.  One thing I want to zero in on \nrelative to the EU, so you'll remove most of the factors, $0.10 of benefit continuing to flow through.  As you speak \nto offsetting with repurchase, is that part of what the repo that you suggested for Q4 is getting in front of?  And do \nyou expect you'll \u2013 how will you judge that?  Will you judge it over the full fiscal year given that the timing is still \nvariable?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vi talone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks, Eric, for that question. ", "original_text": "And do \nyou expect you'll \u2013 how will you judge that? ", "page_label": "13", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f068cc0d-3c7f-417d-91f3-136afa17b579", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f0fb2efafc021a37706fc20da54d10f4c2572335f2953923cc818e170f79c18", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "013244b2-4e46-4ff2-a500-822a58606b72", "node_type": "1", "metadata": {"window": "[Operator Instructions] Our first question will come from Eric Percher with Nephron \nResearch.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you, and appreciate the commentary on fiscal year 2023 at this point.  One thing I want to zero in on \nrelative to the EU, so you'll remove most of the factors, $0.10 of benefit continuing to flow through.  As you speak \nto offsetting with repurchase, is that part of what the repo that you suggested for Q4 is getting in front of?  And do \nyou expect you'll \u2013 how will you judge that?  Will you judge it over the full fiscal year given that the timing is still \nvariable?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vi talone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "As you speak \nto offsetting with repurchase, is that part of what the repo that you suggested for Q4 is getting in front of? ", "page_label": "13", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c292f70ae15c28f23c4f6e927e73acba714a914885b4020bf002d746b2d0931", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "02e50800-2664-43d8-9b65-f478368d4ba5", "node_type": "1", "metadata": {"window": "One thing I want to zero in on \nrelative to the EU, so you'll remove most of the factors, $0.10 of benefit continuing to flow through.  As you speak \nto offsetting with repurchase, is that part of what the repo that you suggested for Q4 is getting in front of?  And do \nyou expect you'll \u2013 how will you judge that?  Will you judge it over the full fiscal year given that the timing is still \nvariable?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vi talone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks, Eric, for that question.  As I talked about in my remarks, we do anticipate that the Austrian transaction, the \nGerman transaction, which have already closed, we anticipate that the UK transaction will also close in the fourth \nquarter. ", "original_text": "Will you judge it over the full fiscal year given that the timing is still \nvariable?  \n "}, "hash": "211a781ea7e3268e169992d50cb9bee383300fadf72e3e3afd1a2fc3081b38d1", "class_name": "RelatedNodeInfo"}}, "text": "And do \nyou expect you'll \u2013 how will you judge that? ", "start_char_idx": 993, "end_char_idx": 1046, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "02e50800-2664-43d8-9b65-f478368d4ba5": {"__data__": {"id_": "02e50800-2664-43d8-9b65-f478368d4ba5", "embedding": null, "metadata": {"window": "One thing I want to zero in on \nrelative to the EU, so you'll remove most of the factors, $0.10 of benefit continuing to flow through.  As you speak \nto offsetting with repurchase, is that part of what the repo that you suggested for Q4 is getting in front of?  And do \nyou expect you'll \u2013 how will you judge that?  Will you judge it over the full fiscal year given that the timing is still \nvariable?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vi talone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks, Eric, for that question.  As I talked about in my remarks, we do anticipate that the Austrian transaction, the \nGerman transaction, which have already closed, we anticipate that the UK transaction will also close in the fourth \nquarter. ", "original_text": "Will you judge it over the full fiscal year given that the timing is still \nvariable?  \n ", "page_label": "13", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f068cc0d-3c7f-417d-91f3-136afa17b579", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f0fb2efafc021a37706fc20da54d10f4c2572335f2953923cc818e170f79c18", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f73bc254-7e3e-433d-b2fd-b0e62822cee8", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you, and appreciate the commentary on fiscal year 2023 at this point.  One thing I want to zero in on \nrelative to the EU, so you'll remove most of the factors, $0.10 of benefit continuing to flow through.  As you speak \nto offsetting with repurchase, is that part of what the repo that you suggested for Q4 is getting in front of?  And do \nyou expect you'll \u2013 how will you judge that?  Will you judge it over the full fiscal year given that the timing is still \nvariable?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vi talone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks, Eric, for that question. ", "original_text": "And do \nyou expect you'll \u2013 how will you judge that? ", "page_label": "13", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c2055e8250aadca1296b9652d3aeddd28c3617ad60a10fc1b2ff5ea91d399a1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6487439b-2f6e-4023-9912-bbbad63eb202", "node_type": "1", "metadata": {"window": "As you speak \nto offsetting with repurchase, is that part of what the repo that you suggested for Q4 is getting in front of?  And do \nyou expect you'll \u2013 how will you judge that?  Will you judge it over the full fiscal year given that the timing is still \nvariable?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vi talone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks, Eric, for that question.  As I talked about in my remarks, we do anticipate that the Austrian transaction, the \nGerman transaction, which have already closed, we anticipate that the UK transaction will also close in the fourth \nquarter.  So consistent with our comments, we do intend to offset the dilution, and that is one of the reasons why \nwe intended to do some fourth quarter share repurchases.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vi talone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "6d00c39523a53cf822cdc20ed7ae8f938d59e9b0dd121224a19c48db7cf18105", "class_name": "RelatedNodeInfo"}}, "text": "Will you judge it over the full fiscal year given that the timing is still \nvariable?  \n ", "start_char_idx": 1046, "end_char_idx": 1135, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6487439b-2f6e-4023-9912-bbbad63eb202": {"__data__": {"id_": "6487439b-2f6e-4023-9912-bbbad63eb202", "embedding": null, "metadata": {"window": "As you speak \nto offsetting with repurchase, is that part of what the repo that you suggested for Q4 is getting in front of?  And do \nyou expect you'll \u2013 how will you judge that?  Will you judge it over the full fiscal year given that the timing is still \nvariable?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vi talone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks, Eric, for that question.  As I talked about in my remarks, we do anticipate that the Austrian transaction, the \nGerman transaction, which have already closed, we anticipate that the UK transaction will also close in the fourth \nquarter.  So consistent with our comments, we do intend to offset the dilution, and that is one of the reasons why \nwe intended to do some fourth quarter share repurchases.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vi talone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f068cc0d-3c7f-417d-91f3-136afa17b579", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f0fb2efafc021a37706fc20da54d10f4c2572335f2953923cc818e170f79c18", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "02e50800-2664-43d8-9b65-f478368d4ba5", "node_type": "1", "metadata": {"window": "One thing I want to zero in on \nrelative to the EU, so you'll remove most of the factors, $0.10 of benefit continuing to flow through.  As you speak \nto offsetting with repurchase, is that part of what the repo that you suggested for Q4 is getting in front of?  And do \nyou expect you'll \u2013 how will you judge that?  Will you judge it over the full fiscal year given that the timing is still \nvariable?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vi talone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks, Eric, for that question.  As I talked about in my remarks, we do anticipate that the Austrian transaction, the \nGerman transaction, which have already closed, we anticipate that the UK transaction will also close in the fourth \nquarter. ", "original_text": "Will you judge it over the full fiscal year given that the timing is still \nvariable?  \n ", "page_label": "13", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5e23460e25fcbc5a37ef9216848e264d83bd7499c1039d4019ad8bd3e549d859", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b35e1fa9-e22a-4cfd-93af-10226064a87a", "node_type": "1", "metadata": {"window": "And do \nyou expect you'll \u2013 how will you judge that?  Will you judge it over the full fiscal year given that the timing is still \nvariable?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vi talone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks, Eric, for that question.  As I talked about in my remarks, we do anticipate that the Austrian transaction, the \nGerman transaction, which have already closed, we anticipate that the UK transaction will also close in the fourth \nquarter.  So consistent with our comments, we do intend to offset the dilution, and that is one of the reasons why \nwe intended to do some fourth quarter share repurchases.  \n \n We will continue to apply the principles of our share repurchase activity, and certainly we'll look at cash that is in \nexcess of what we need to operate the business as well as other opportunities that we have to deploy that capital, \nwhether that be additional share repurchases for our  shareholders or if we have M&A transactions  \n \nSo certainly we told you we would offset the dilution, and we're closing transactions now and anticipate more in \nthe fourth quarter. ", "original_text": "A \nThanks, Eric, for that question. "}, "hash": "1e9570446191b916da8d99f3f916a44817f67bbfff787073c36a14dfe1f21439", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vi talone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 1135, "end_char_idx": 1493, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b35e1fa9-e22a-4cfd-93af-10226064a87a": {"__data__": {"id_": "b35e1fa9-e22a-4cfd-93af-10226064a87a", "embedding": null, "metadata": {"window": "And do \nyou expect you'll \u2013 how will you judge that?  Will you judge it over the full fiscal year given that the timing is still \nvariable?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vi talone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks, Eric, for that question.  As I talked about in my remarks, we do anticipate that the Austrian transaction, the \nGerman transaction, which have already closed, we anticipate that the UK transaction will also close in the fourth \nquarter.  So consistent with our comments, we do intend to offset the dilution, and that is one of the reasons why \nwe intended to do some fourth quarter share repurchases.  \n \n We will continue to apply the principles of our share repurchase activity, and certainly we'll look at cash that is in \nexcess of what we need to operate the business as well as other opportunities that we have to deploy that capital, \nwhether that be additional share repurchases for our  shareholders or if we have M&A transactions  \n \nSo certainly we told you we would offset the dilution, and we're closing transactions now and anticipate more in \nthe fourth quarter. ", "original_text": "A \nThanks, Eric, for that question. ", "page_label": "13", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f068cc0d-3c7f-417d-91f3-136afa17b579", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f0fb2efafc021a37706fc20da54d10f4c2572335f2953923cc818e170f79c18", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6487439b-2f6e-4023-9912-bbbad63eb202", "node_type": "1", "metadata": {"window": "As you speak \nto offsetting with repurchase, is that part of what the repo that you suggested for Q4 is getting in front of?  And do \nyou expect you'll \u2013 how will you judge that?  Will you judge it over the full fiscal year given that the timing is still \nvariable?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vi talone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks, Eric, for that question.  As I talked about in my remarks, we do anticipate that the Austrian transaction, the \nGerman transaction, which have already closed, we anticipate that the UK transaction will also close in the fourth \nquarter.  So consistent with our comments, we do intend to offset the dilution, and that is one of the reasons why \nwe intended to do some fourth quarter share repurchases.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vi talone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "938ac22830db18ec1416738ca9affa2aa0cc79d1ceef33c2513ffa34705adb5a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "446f5174-f372-415a-8d24-a427df982421", "node_type": "1", "metadata": {"window": "Will you judge it over the full fiscal year given that the timing is still \nvariable?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vi talone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks, Eric, for that question.  As I talked about in my remarks, we do anticipate that the Austrian transaction, the \nGerman transaction, which have already closed, we anticipate that the UK transaction will also close in the fourth \nquarter.  So consistent with our comments, we do intend to offset the dilution, and that is one of the reasons why \nwe intended to do some fourth quarter share repurchases.  \n \n We will continue to apply the principles of our share repurchase activity, and certainly we'll look at cash that is in \nexcess of what we need to operate the business as well as other opportunities that we have to deploy that capital, \nwhether that be additional share repurchases for our  shareholders or if we have M&A transactions  \n \nSo certainly we told you we would offset the dilution, and we're closing transactions now and anticipate more in \nthe fourth quarter.  And so that was one of the reasons why we wanted to begin the share repurchas e activity in \naddition to being very consistent with our share repurchase principles.  \n ", "original_text": "As I talked about in my remarks, we do anticipate that the Austrian transaction, the \nGerman transaction, which have already closed, we anticipate that the UK transaction will also close in the fourth \nquarter. "}, "hash": "e6102ec02a3a9cce26c24c7c586620ba94d7c2322b26e61ae7a05158d45301ec", "class_name": "RelatedNodeInfo"}}, "text": "A \nThanks, Eric, for that question. ", "start_char_idx": 1493, "end_char_idx": 1529, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "446f5174-f372-415a-8d24-a427df982421": {"__data__": {"id_": "446f5174-f372-415a-8d24-a427df982421", "embedding": null, "metadata": {"window": "Will you judge it over the full fiscal year given that the timing is still \nvariable?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vi talone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks, Eric, for that question.  As I talked about in my remarks, we do anticipate that the Austrian transaction, the \nGerman transaction, which have already closed, we anticipate that the UK transaction will also close in the fourth \nquarter.  So consistent with our comments, we do intend to offset the dilution, and that is one of the reasons why \nwe intended to do some fourth quarter share repurchases.  \n \n We will continue to apply the principles of our share repurchase activity, and certainly we'll look at cash that is in \nexcess of what we need to operate the business as well as other opportunities that we have to deploy that capital, \nwhether that be additional share repurchases for our  shareholders or if we have M&A transactions  \n \nSo certainly we told you we would offset the dilution, and we're closing transactions now and anticipate more in \nthe fourth quarter.  And so that was one of the reasons why we wanted to begin the share repurchas e activity in \naddition to being very consistent with our share repurchase principles.  \n ", "original_text": "As I talked about in my remarks, we do anticipate that the Austrian transaction, the \nGerman transaction, which have already closed, we anticipate that the UK transaction will also close in the fourth \nquarter. ", "page_label": "13", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f068cc0d-3c7f-417d-91f3-136afa17b579", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f0fb2efafc021a37706fc20da54d10f4c2572335f2953923cc818e170f79c18", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b35e1fa9-e22a-4cfd-93af-10226064a87a", "node_type": "1", "metadata": {"window": "And do \nyou expect you'll \u2013 how will you judge that?  Will you judge it over the full fiscal year given that the timing is still \nvariable?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vi talone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks, Eric, for that question.  As I talked about in my remarks, we do anticipate that the Austrian transaction, the \nGerman transaction, which have already closed, we anticipate that the UK transaction will also close in the fourth \nquarter.  So consistent with our comments, we do intend to offset the dilution, and that is one of the reasons why \nwe intended to do some fourth quarter share repurchases.  \n \n We will continue to apply the principles of our share repurchase activity, and certainly we'll look at cash that is in \nexcess of what we need to operate the business as well as other opportunities that we have to deploy that capital, \nwhether that be additional share repurchases for our  shareholders or if we have M&A transactions  \n \nSo certainly we told you we would offset the dilution, and we're closing transactions now and anticipate more in \nthe fourth quarter. ", "original_text": "A \nThanks, Eric, for that question. ", "page_label": "13", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c3d93b52dd3f2bc43e896432531fbd3095ade5007716aa167c7defa65d963c41", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1e488c39-3fcd-45c7-90c2-98537aaf85e1", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vi talone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks, Eric, for that question.  As I talked about in my remarks, we do anticipate that the Austrian transaction, the \nGerman transaction, which have already closed, we anticipate that the UK transaction will also close in the fourth \nquarter.  So consistent with our comments, we do intend to offset the dilution, and that is one of the reasons why \nwe intended to do some fourth quarter share repurchases.  \n \n We will continue to apply the principles of our share repurchase activity, and certainly we'll look at cash that is in \nexcess of what we need to operate the business as well as other opportunities that we have to deploy that capital, \nwhether that be additional share repurchases for our  shareholders or if we have M&A transactions  \n \nSo certainly we told you we would offset the dilution, and we're closing transactions now and anticipate more in \nthe fourth quarter.  And so that was one of the reasons why we wanted to begin the share repurchas e activity in \naddition to being very consistent with our share repurchase principles.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n ", "original_text": "So consistent with our comments, we do intend to offset the dilution, and that is one of the reasons why \nwe intended to do some fourth quarter share repurchases.  \n \n"}, "hash": "667687d1346702b85f831376cd514dc150294897820a7a6c413d5f0a1080e15d", "class_name": "RelatedNodeInfo"}}, "text": "As I talked about in my remarks, we do anticipate that the Austrian transaction, the \nGerman transaction, which have already closed, we anticipate that the UK transaction will also close in the fourth \nquarter. ", "start_char_idx": 1529, "end_char_idx": 1740, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1e488c39-3fcd-45c7-90c2-98537aaf85e1": {"__data__": {"id_": "1e488c39-3fcd-45c7-90c2-98537aaf85e1", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vi talone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks, Eric, for that question.  As I talked about in my remarks, we do anticipate that the Austrian transaction, the \nGerman transaction, which have already closed, we anticipate that the UK transaction will also close in the fourth \nquarter.  So consistent with our comments, we do intend to offset the dilution, and that is one of the reasons why \nwe intended to do some fourth quarter share repurchases.  \n \n We will continue to apply the principles of our share repurchase activity, and certainly we'll look at cash that is in \nexcess of what we need to operate the business as well as other opportunities that we have to deploy that capital, \nwhether that be additional share repurchases for our  shareholders or if we have M&A transactions  \n \nSo certainly we told you we would offset the dilution, and we're closing transactions now and anticipate more in \nthe fourth quarter.  And so that was one of the reasons why we wanted to begin the share repurchas e activity in \naddition to being very consistent with our share repurchase principles.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n ", "original_text": "So consistent with our comments, we do intend to offset the dilution, and that is one of the reasons why \nwe intended to do some fourth quarter share repurchases.  \n \n", "page_label": "13", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f068cc0d-3c7f-417d-91f3-136afa17b579", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f0fb2efafc021a37706fc20da54d10f4c2572335f2953923cc818e170f79c18", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "446f5174-f372-415a-8d24-a427df982421", "node_type": "1", "metadata": {"window": "Will you judge it over the full fiscal year given that the timing is still \nvariable?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vi talone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks, Eric, for that question.  As I talked about in my remarks, we do anticipate that the Austrian transaction, the \nGerman transaction, which have already closed, we anticipate that the UK transaction will also close in the fourth \nquarter.  So consistent with our comments, we do intend to offset the dilution, and that is one of the reasons why \nwe intended to do some fourth quarter share repurchases.  \n \n We will continue to apply the principles of our share repurchase activity, and certainly we'll look at cash that is in \nexcess of what we need to operate the business as well as other opportunities that we have to deploy that capital, \nwhether that be additional share repurchases for our  shareholders or if we have M&A transactions  \n \nSo certainly we told you we would offset the dilution, and we're closing transactions now and anticipate more in \nthe fourth quarter.  And so that was one of the reasons why we wanted to begin the share repurchas e activity in \naddition to being very consistent with our share repurchase principles.  \n ", "original_text": "As I talked about in my remarks, we do anticipate that the Austrian transaction, the \nGerman transaction, which have already closed, we anticipate that the UK transaction will also close in the fourth \nquarter. ", "page_label": "13", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9ca383c3c316f8fde77fcf7b2960f7e69040eb101472915525b68f80dc553b7d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "90adf858-5b12-4f4b-a2e5-0c5157e1e84c", "node_type": "1", "metadata": {"window": "A \nThanks, Eric, for that question.  As I talked about in my remarks, we do anticipate that the Austrian transaction, the \nGerman transaction, which have already closed, we anticipate that the UK transaction will also close in the fourth \nquarter.  So consistent with our comments, we do intend to offset the dilution, and that is one of the reasons why \nwe intended to do some fourth quarter share repurchases.  \n \n We will continue to apply the principles of our share repurchase activity, and certainly we'll look at cash that is in \nexcess of what we need to operate the business as well as other opportunities that we have to deploy that capital, \nwhether that be additional share repurchases for our  shareholders or if we have M&A transactions  \n \nSo certainly we told you we would offset the dilution, and we're closing transactions now and anticipate more in \nthe fourth quarter.  And so that was one of the reasons why we wanted to begin the share repurchas e activity in \naddition to being very consistent with our share repurchase principles.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And our next will be from Lisa Gill with JPMorgan.  \n ", "original_text": "We will continue to apply the principles of our share repurchase activity, and certainly we'll look at cash that is in \nexcess of what we need to operate the business as well as other opportunities that we have to deploy that capital, \nwhether that be additional share repurchases for our  shareholders or if we have M&A transactions  \n \nSo certainly we told you we would offset the dilution, and we're closing transactions now and anticipate more in \nthe fourth quarter. "}, "hash": "83fcc16fcbc66f0102d4bfd7e60dfe10d508b34aab77ed94fc00ee00a59c9cc0", "class_name": "RelatedNodeInfo"}}, "text": "So consistent with our comments, we do intend to offset the dilution, and that is one of the reasons why \nwe intended to do some fourth quarter share repurchases.  \n \n", "start_char_idx": 1740, "end_char_idx": 1907, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "90adf858-5b12-4f4b-a2e5-0c5157e1e84c": {"__data__": {"id_": "90adf858-5b12-4f4b-a2e5-0c5157e1e84c", "embedding": null, "metadata": {"window": "A \nThanks, Eric, for that question.  As I talked about in my remarks, we do anticipate that the Austrian transaction, the \nGerman transaction, which have already closed, we anticipate that the UK transaction will also close in the fourth \nquarter.  So consistent with our comments, we do intend to offset the dilution, and that is one of the reasons why \nwe intended to do some fourth quarter share repurchases.  \n \n We will continue to apply the principles of our share repurchase activity, and certainly we'll look at cash that is in \nexcess of what we need to operate the business as well as other opportunities that we have to deploy that capital, \nwhether that be additional share repurchases for our  shareholders or if we have M&A transactions  \n \nSo certainly we told you we would offset the dilution, and we're closing transactions now and anticipate more in \nthe fourth quarter.  And so that was one of the reasons why we wanted to begin the share repurchas e activity in \naddition to being very consistent with our share repurchase principles.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And our next will be from Lisa Gill with JPMorgan.  \n ", "original_text": "We will continue to apply the principles of our share repurchase activity, and certainly we'll look at cash that is in \nexcess of what we need to operate the business as well as other opportunities that we have to deploy that capital, \nwhether that be additional share repurchases for our  shareholders or if we have M&A transactions  \n \nSo certainly we told you we would offset the dilution, and we're closing transactions now and anticipate more in \nthe fourth quarter. ", "page_label": "13", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f068cc0d-3c7f-417d-91f3-136afa17b579", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f0fb2efafc021a37706fc20da54d10f4c2572335f2953923cc818e170f79c18", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1e488c39-3fcd-45c7-90c2-98537aaf85e1", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vi talone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks, Eric, for that question.  As I talked about in my remarks, we do anticipate that the Austrian transaction, the \nGerman transaction, which have already closed, we anticipate that the UK transaction will also close in the fourth \nquarter.  So consistent with our comments, we do intend to offset the dilution, and that is one of the reasons why \nwe intended to do some fourth quarter share repurchases.  \n \n We will continue to apply the principles of our share repurchase activity, and certainly we'll look at cash that is in \nexcess of what we need to operate the business as well as other opportunities that we have to deploy that capital, \nwhether that be additional share repurchases for our  shareholders or if we have M&A transactions  \n \nSo certainly we told you we would offset the dilution, and we're closing transactions now and anticipate more in \nthe fourth quarter.  And so that was one of the reasons why we wanted to begin the share repurchas e activity in \naddition to being very consistent with our share repurchase principles.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n ", "original_text": "So consistent with our comments, we do intend to offset the dilution, and that is one of the reasons why \nwe intended to do some fourth quarter share repurchases.  \n \n", "page_label": "13", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f3e83e444cd9acd81038b8f1f034b2330191752ff5fa84f635feb69347164aa2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2adac713-3523-439e-add6-3e3cd319277a", "node_type": "1", "metadata": {"window": "As I talked about in my remarks, we do anticipate that the Austrian transaction, the \nGerman transaction, which have already closed, we anticipate that the UK transaction will also close in the fourth \nquarter.  So consistent with our comments, we do intend to offset the dilution, and that is one of the reasons why \nwe intended to do some fourth quarter share repurchases.  \n \n We will continue to apply the principles of our share repurchase activity, and certainly we'll look at cash that is in \nexcess of what we need to operate the business as well as other opportunities that we have to deploy that capital, \nwhether that be additional share repurchases for our  shareholders or if we have M&A transactions  \n \nSo certainly we told you we would offset the dilution, and we're closing transactions now and anticipate more in \nthe fourth quarter.  And so that was one of the reasons why we wanted to begin the share repurchas e activity in \naddition to being very consistent with our share repurchase principles.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And our next will be from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much. ", "original_text": "And so that was one of the reasons why we wanted to begin the share repurchas e activity in \naddition to being very consistent with our share repurchase principles.  \n "}, "hash": "d447a17a63d69c1f46f91bdb70aeecb37eaa1c7501d2d0ca78153dfd325042e9", "class_name": "RelatedNodeInfo"}}, "text": "We will continue to apply the principles of our share repurchase activity, and certainly we'll look at cash that is in \nexcess of what we need to operate the business as well as other opportunities that we have to deploy that capital, \nwhether that be additional share repurchases for our  shareholders or if we have M&A transactions  \n \nSo certainly we told you we would offset the dilution, and we're closing transactions now and anticipate more in \nthe fourth quarter. ", "start_char_idx": 1907, "end_char_idx": 2379, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2adac713-3523-439e-add6-3e3cd319277a": {"__data__": {"id_": "2adac713-3523-439e-add6-3e3cd319277a", "embedding": null, "metadata": {"window": "As I talked about in my remarks, we do anticipate that the Austrian transaction, the \nGerman transaction, which have already closed, we anticipate that the UK transaction will also close in the fourth \nquarter.  So consistent with our comments, we do intend to offset the dilution, and that is one of the reasons why \nwe intended to do some fourth quarter share repurchases.  \n \n We will continue to apply the principles of our share repurchase activity, and certainly we'll look at cash that is in \nexcess of what we need to operate the business as well as other opportunities that we have to deploy that capital, \nwhether that be additional share repurchases for our  shareholders or if we have M&A transactions  \n \nSo certainly we told you we would offset the dilution, and we're closing transactions now and anticipate more in \nthe fourth quarter.  And so that was one of the reasons why we wanted to begin the share repurchas e activity in \naddition to being very consistent with our share repurchase principles.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And our next will be from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much. ", "original_text": "And so that was one of the reasons why we wanted to begin the share repurchas e activity in \naddition to being very consistent with our share repurchase principles.  \n ", "page_label": "13", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f068cc0d-3c7f-417d-91f3-136afa17b579", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f0fb2efafc021a37706fc20da54d10f4c2572335f2953923cc818e170f79c18", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "90adf858-5b12-4f4b-a2e5-0c5157e1e84c", "node_type": "1", "metadata": {"window": "A \nThanks, Eric, for that question.  As I talked about in my remarks, we do anticipate that the Austrian transaction, the \nGerman transaction, which have already closed, we anticipate that the UK transaction will also close in the fourth \nquarter.  So consistent with our comments, we do intend to offset the dilution, and that is one of the reasons why \nwe intended to do some fourth quarter share repurchases.  \n \n We will continue to apply the principles of our share repurchase activity, and certainly we'll look at cash that is in \nexcess of what we need to operate the business as well as other opportunities that we have to deploy that capital, \nwhether that be additional share repurchases for our  shareholders or if we have M&A transactions  \n \nSo certainly we told you we would offset the dilution, and we're closing transactions now and anticipate more in \nthe fourth quarter.  And so that was one of the reasons why we wanted to begin the share repurchas e activity in \naddition to being very consistent with our share repurchase principles.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And our next will be from Lisa Gill with JPMorgan.  \n ", "original_text": "We will continue to apply the principles of our share repurchase activity, and certainly we'll look at cash that is in \nexcess of what we need to operate the business as well as other opportunities that we have to deploy that capital, \nwhether that be additional share repurchases for our  shareholders or if we have M&A transactions  \n \nSo certainly we told you we would offset the dilution, and we're closing transactions now and anticipate more in \nthe fourth quarter. ", "page_label": "13", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "be2be934b7d959f476871bbf93a69bbc8c6ca8102b6411a9cec842b807183c4d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "601d6918-c01b-4111-bac4-72d01cfeed01", "node_type": "1", "metadata": {"window": "So consistent with our comments, we do intend to offset the dilution, and that is one of the reasons why \nwe intended to do some fourth quarter share repurchases.  \n \n We will continue to apply the principles of our share repurchase activity, and certainly we'll look at cash that is in \nexcess of what we need to operate the business as well as other opportunities that we have to deploy that capital, \nwhether that be additional share repurchases for our  shareholders or if we have M&A transactions  \n \nSo certainly we told you we would offset the dilution, and we're closing transactions now and anticipate more in \nthe fourth quarter.  And so that was one of the reasons why we wanted to begin the share repurchas e activity in \naddition to being very consistent with our share repurchase principles.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And our next will be from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Good afternoon, and thanks for all the detail. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n "}, "hash": "ca064b22c343d767eb76279b61a127d09cfde0647de64387c7d540bc6ebb260d", "class_name": "RelatedNodeInfo"}}, "text": "And so that was one of the reasons why we wanted to begin the share repurchas e activity in \naddition to being very consistent with our share repurchase principles.  \n ", "start_char_idx": 2379, "end_char_idx": 2547, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "601d6918-c01b-4111-bac4-72d01cfeed01": {"__data__": {"id_": "601d6918-c01b-4111-bac4-72d01cfeed01", "embedding": null, "metadata": {"window": "So consistent with our comments, we do intend to offset the dilution, and that is one of the reasons why \nwe intended to do some fourth quarter share repurchases.  \n \n We will continue to apply the principles of our share repurchase activity, and certainly we'll look at cash that is in \nexcess of what we need to operate the business as well as other opportunities that we have to deploy that capital, \nwhether that be additional share repurchases for our  shareholders or if we have M&A transactions  \n \nSo certainly we told you we would offset the dilution, and we're closing transactions now and anticipate more in \nthe fourth quarter.  And so that was one of the reasons why we wanted to begin the share repurchas e activity in \naddition to being very consistent with our share repurchase principles.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And our next will be from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Good afternoon, and thanks for all the detail. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n ", "page_label": "13", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f068cc0d-3c7f-417d-91f3-136afa17b579", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f0fb2efafc021a37706fc20da54d10f4c2572335f2953923cc818e170f79c18", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2adac713-3523-439e-add6-3e3cd319277a", "node_type": "1", "metadata": {"window": "As I talked about in my remarks, we do anticipate that the Austrian transaction, the \nGerman transaction, which have already closed, we anticipate that the UK transaction will also close in the fourth \nquarter.  So consistent with our comments, we do intend to offset the dilution, and that is one of the reasons why \nwe intended to do some fourth quarter share repurchases.  \n \n We will continue to apply the principles of our share repurchase activity, and certainly we'll look at cash that is in \nexcess of what we need to operate the business as well as other opportunities that we have to deploy that capital, \nwhether that be additional share repurchases for our  shareholders or if we have M&A transactions  \n \nSo certainly we told you we would offset the dilution, and we're closing transactions now and anticipate more in \nthe fourth quarter.  And so that was one of the reasons why we wanted to begin the share repurchas e activity in \naddition to being very consistent with our share repurchase principles.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And our next will be from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much. ", "original_text": "And so that was one of the reasons why we wanted to begin the share repurchas e activity in \naddition to being very consistent with our share repurchase principles.  \n ", "page_label": "13", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "36bee2cc090af0a8c6500e89a3befdb90e76f06f89ce0125342f9d64a3bb15ca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d94f69f7-cfba-41bb-9b5c-eba30f678243", "node_type": "1", "metadata": {"window": "We will continue to apply the principles of our share repurchase activity, and certainly we'll look at cash that is in \nexcess of what we need to operate the business as well as other opportunities that we have to deploy that capital, \nwhether that be additional share repurchases for our  shareholders or if we have M&A transactions  \n \nSo certainly we told you we would offset the dilution, and we're closing transactions now and anticipate more in \nthe fourth quarter.  And so that was one of the reasons why we wanted to begin the share repurchas e activity in \naddition to being very consistent with our share repurchase principles.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And our next will be from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Good afternoon, and thanks for all the detail.  Britt, I just want to go back and talk about \ninflation. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And our next will be from Lisa Gill with JPMorgan.  \n "}, "hash": "b16e6724798cecf7f96379651ac302e6c019b4b2024b890ee8f526690ecdc319", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n ", "start_char_idx": 2547, "end_char_idx": 2910, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d94f69f7-cfba-41bb-9b5c-eba30f678243": {"__data__": {"id_": "d94f69f7-cfba-41bb-9b5c-eba30f678243", "embedding": null, "metadata": {"window": "We will continue to apply the principles of our share repurchase activity, and certainly we'll look at cash that is in \nexcess of what we need to operate the business as well as other opportunities that we have to deploy that capital, \nwhether that be additional share repurchases for our  shareholders or if we have M&A transactions  \n \nSo certainly we told you we would offset the dilution, and we're closing transactions now and anticipate more in \nthe fourth quarter.  And so that was one of the reasons why we wanted to begin the share repurchas e activity in \naddition to being very consistent with our share repurchase principles.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And our next will be from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Good afternoon, and thanks for all the detail.  Britt, I just want to go back and talk about \ninflation. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And our next will be from Lisa Gill with JPMorgan.  \n ", "page_label": "13", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f068cc0d-3c7f-417d-91f3-136afa17b579", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f0fb2efafc021a37706fc20da54d10f4c2572335f2953923cc818e170f79c18", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "601d6918-c01b-4111-bac4-72d01cfeed01", "node_type": "1", "metadata": {"window": "So consistent with our comments, we do intend to offset the dilution, and that is one of the reasons why \nwe intended to do some fourth quarter share repurchases.  \n \n We will continue to apply the principles of our share repurchase activity, and certainly we'll look at cash that is in \nexcess of what we need to operate the business as well as other opportunities that we have to deploy that capital, \nwhether that be additional share repurchases for our  shareholders or if we have M&A transactions  \n \nSo certainly we told you we would offset the dilution, and we're closing transactions now and anticipate more in \nthe fourth quarter.  And so that was one of the reasons why we wanted to begin the share repurchas e activity in \naddition to being very consistent with our share repurchase principles.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And our next will be from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Good afternoon, and thanks for all the detail. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n ", "page_label": "13", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8614d570e36efc5d7441728ab0ff53377fdbf3be97d8417a4f29a7bbab9e9564", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7029f77a-e2c9-45f0-a584-5924cd62b65a", "node_type": "1", "metadata": {"window": "And so that was one of the reasons why we wanted to begin the share repurchas e activity in \naddition to being very consistent with our share repurchase principles.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And our next will be from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Good afternoon, and thanks for all the detail.  Britt, I just want to go back and talk about \ninflation.  You talked a little bit about labor, and I know you and Brian talked last quarter about some specia l \nbonuses and increasing wages, but how do we think about wages going forward as we continue to have wage \ninflation would be my first part of the inflation question.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much. "}, "hash": "e6212b2017e23ee7cc78830443bb8c769eacc06d0b4b7e9064c9d85cd36ad75e", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And our next will be from Lisa Gill with JPMorgan.  \n ", "start_char_idx": 2910, "end_char_idx": 3249, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7029f77a-e2c9-45f0-a584-5924cd62b65a": {"__data__": {"id_": "7029f77a-e2c9-45f0-a584-5924cd62b65a", "embedding": null, "metadata": {"window": "And so that was one of the reasons why we wanted to begin the share repurchas e activity in \naddition to being very consistent with our share repurchase principles.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And our next will be from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Good afternoon, and thanks for all the detail.  Britt, I just want to go back and talk about \ninflation.  You talked a little bit about labor, and I know you and Brian talked last quarter about some specia l \nbonuses and increasing wages, but how do we think about wages going forward as we continue to have wage \ninflation would be my first part of the inflation question.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much. ", "page_label": "13", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f068cc0d-3c7f-417d-91f3-136afa17b579", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f0fb2efafc021a37706fc20da54d10f4c2572335f2953923cc818e170f79c18", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d94f69f7-cfba-41bb-9b5c-eba30f678243", "node_type": "1", "metadata": {"window": "We will continue to apply the principles of our share repurchase activity, and certainly we'll look at cash that is in \nexcess of what we need to operate the business as well as other opportunities that we have to deploy that capital, \nwhether that be additional share repurchases for our  shareholders or if we have M&A transactions  \n \nSo certainly we told you we would offset the dilution, and we're closing transactions now and anticipate more in \nthe fourth quarter.  And so that was one of the reasons why we wanted to begin the share repurchas e activity in \naddition to being very consistent with our share repurchase principles.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And our next will be from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Good afternoon, and thanks for all the detail.  Britt, I just want to go back and talk about \ninflation. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And our next will be from Lisa Gill with JPMorgan.  \n ", "page_label": "13", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f47cb792355157dcffd90c085882fe81f5f4892d926f71cc5ab7a0d4605563a7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cc2a4546-d91b-42de-8c09-5b09951d86ca", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And our next will be from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Good afternoon, and thanks for all the detail.  Britt, I just want to go back and talk about \ninflation.  You talked a little bit about labor, and I know you and Brian talked last quarter about some specia l \nbonuses and increasing wages, but how do we think about wages going forward as we continue to have wage \ninflation would be my first part of the inflation question.  \n \n And then secondly, as we think about product inflation or transportation, I know generall y speaking, it's a pass -\nthrough on the pharmaceutical side of things, but how do we think about any PPE on your Medical side of your \nbusiness?  \n ", "original_text": "Good afternoon, and thanks for all the detail. "}, "hash": "24031d1d4b68bb180afef4c80bea589ef87315a4ea3bd23e9dae53b782cb761c", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much. ", "start_char_idx": 3249, "end_char_idx": 3591, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc2a4546-d91b-42de-8c09-5b09951d86ca": {"__data__": {"id_": "cc2a4546-d91b-42de-8c09-5b09951d86ca", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And our next will be from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Good afternoon, and thanks for all the detail.  Britt, I just want to go back and talk about \ninflation.  You talked a little bit about labor, and I know you and Brian talked last quarter about some specia l \nbonuses and increasing wages, but how do we think about wages going forward as we continue to have wage \ninflation would be my first part of the inflation question.  \n \n And then secondly, as we think about product inflation or transportation, I know generall y speaking, it's a pass -\nthrough on the pharmaceutical side of things, but how do we think about any PPE on your Medical side of your \nbusiness?  \n ", "original_text": "Good afternoon, and thanks for all the detail. ", "page_label": "13", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f068cc0d-3c7f-417d-91f3-136afa17b579", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f0fb2efafc021a37706fc20da54d10f4c2572335f2953923cc818e170f79c18", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7029f77a-e2c9-45f0-a584-5924cd62b65a", "node_type": "1", "metadata": {"window": "And so that was one of the reasons why we wanted to begin the share repurchas e activity in \naddition to being very consistent with our share repurchase principles.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And our next will be from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Good afternoon, and thanks for all the detail.  Britt, I just want to go back and talk about \ninflation.  You talked a little bit about labor, and I know you and Brian talked last quarter about some specia l \nbonuses and increasing wages, but how do we think about wages going forward as we continue to have wage \ninflation would be my first part of the inflation question.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much. ", "page_label": "13", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c423fefba24e9ff70080ebb4e5db7ce3bee068a41a653a62bd91a6bacba00c7d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ac577c6a-399c-4f17-a656-63e4a9210340", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And our next will be from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Good afternoon, and thanks for all the detail.  Britt, I just want to go back and talk about \ninflation.  You talked a little bit about labor, and I know you and Brian talked last quarter about some specia l \nbonuses and increasing wages, but how do we think about wages going forward as we continue to have wage \ninflation would be my first part of the inflation question.  \n \n And then secondly, as we think about product inflation or transportation, I know generall y speaking, it's a pass -\nthrough on the pharmaceutical side of things, but how do we think about any PPE on your Medical side of your \nbusiness?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "Britt, I just want to go back and talk about \ninflation. "}, "hash": "d0282faf44cec7794986d2a716909532a9443459fded511cbd1021e89e11cc67", "class_name": "RelatedNodeInfo"}}, "text": "Good afternoon, and thanks for all the detail. ", "start_char_idx": 3591, "end_char_idx": 3638, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ac577c6a-399c-4f17-a656-63e4a9210340": {"__data__": {"id_": "ac577c6a-399c-4f17-a656-63e4a9210340", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And our next will be from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Good afternoon, and thanks for all the detail.  Britt, I just want to go back and talk about \ninflation.  You talked a little bit about labor, and I know you and Brian talked last quarter about some specia l \nbonuses and increasing wages, but how do we think about wages going forward as we continue to have wage \ninflation would be my first part of the inflation question.  \n \n And then secondly, as we think about product inflation or transportation, I know generall y speaking, it's a pass -\nthrough on the pharmaceutical side of things, but how do we think about any PPE on your Medical side of your \nbusiness?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "Britt, I just want to go back and talk about \ninflation. ", "page_label": "13", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f068cc0d-3c7f-417d-91f3-136afa17b579", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f0fb2efafc021a37706fc20da54d10f4c2572335f2953923cc818e170f79c18", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc2a4546-d91b-42de-8c09-5b09951d86ca", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And our next will be from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Good afternoon, and thanks for all the detail.  Britt, I just want to go back and talk about \ninflation.  You talked a little bit about labor, and I know you and Brian talked last quarter about some specia l \nbonuses and increasing wages, but how do we think about wages going forward as we continue to have wage \ninflation would be my first part of the inflation question.  \n \n And then secondly, as we think about product inflation or transportation, I know generall y speaking, it's a pass -\nthrough on the pharmaceutical side of things, but how do we think about any PPE on your Medical side of your \nbusiness?  \n ", "original_text": "Good afternoon, and thanks for all the detail. ", "page_label": "13", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b5295efa0d1f37be067f2f3d1a01f3e96cc5ddd9c0a55fcee77029ade8bac959", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "87c0a656-58f0-497e-a651-84fa0d6aa06b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Good afternoon, and thanks for all the detail.  Britt, I just want to go back and talk about \ninflation.  You talked a little bit about labor, and I know you and Brian talked last quarter about some specia l \nbonuses and increasing wages, but how do we think about wages going forward as we continue to have wage \ninflation would be my first part of the inflation question.  \n \n And then secondly, as we think about product inflation or transportation, I know generall y speaking, it's a pass -\nthrough on the pharmaceutical side of things, but how do we think about any PPE on your Medical side of your \nbusiness?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "You talked a little bit about labor, and I know you and Brian talked last quarter about some specia l \nbonuses and increasing wages, but how do we think about wages going forward as we continue to have wage \ninflation would be my first part of the inflation question.  \n \n"}, "hash": "9ed38356452474ae5f03850e104095e71193112dfdd6af55c790e8effa3c0a15", "class_name": "RelatedNodeInfo"}}, "text": "Britt, I just want to go back and talk about \ninflation. ", "start_char_idx": 3638, "end_char_idx": 3695, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "87c0a656-58f0-497e-a651-84fa0d6aa06b": {"__data__": {"id_": "87c0a656-58f0-497e-a651-84fa0d6aa06b", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Good afternoon, and thanks for all the detail.  Britt, I just want to go back and talk about \ninflation.  You talked a little bit about labor, and I know you and Brian talked last quarter about some specia l \nbonuses and increasing wages, but how do we think about wages going forward as we continue to have wage \ninflation would be my first part of the inflation question.  \n \n And then secondly, as we think about product inflation or transportation, I know generall y speaking, it's a pass -\nthrough on the pharmaceutical side of things, but how do we think about any PPE on your Medical side of your \nbusiness?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "You talked a little bit about labor, and I know you and Brian talked last quarter about some specia l \nbonuses and increasing wages, but how do we think about wages going forward as we continue to have wage \ninflation would be my first part of the inflation question.  \n \n", "page_label": "13", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f068cc0d-3c7f-417d-91f3-136afa17b579", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f0fb2efafc021a37706fc20da54d10f4c2572335f2953923cc818e170f79c18", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ac577c6a-399c-4f17-a656-63e4a9210340", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And our next will be from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Good afternoon, and thanks for all the detail.  Britt, I just want to go back and talk about \ninflation.  You talked a little bit about labor, and I know you and Brian talked last quarter about some specia l \nbonuses and increasing wages, but how do we think about wages going forward as we continue to have wage \ninflation would be my first part of the inflation question.  \n \n And then secondly, as we think about product inflation or transportation, I know generall y speaking, it's a pass -\nthrough on the pharmaceutical side of things, but how do we think about any PPE on your Medical side of your \nbusiness?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "Britt, I just want to go back and talk about \ninflation. ", "page_label": "13", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6158a605d4afd02eb6f0be9f05e21aef4fb92a03c4a010a0e7470fdde1cb48cf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ef08bdb2-708f-43bf-b2b2-fc374a6d02f2", "node_type": "1", "metadata": {"window": "Good afternoon, and thanks for all the detail.  Britt, I just want to go back and talk about \ninflation.  You talked a little bit about labor, and I know you and Brian talked last quarter about some specia l \nbonuses and increasing wages, but how do we think about wages going forward as we continue to have wage \ninflation would be my first part of the inflation question.  \n \n And then secondly, as we think about product inflation or transportation, I know generall y speaking, it's a pass -\nthrough on the pharmaceutical side of things, but how do we think about any PPE on your Medical side of your \nbusiness?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "And then secondly, as we think about product inflation or transportation, I know generall y speaking, it's a pass -\nthrough on the pharmaceutical side of things, but how do we think about any PPE on your Medical side of your \nbusiness?  \n "}, "hash": "156e0bfb476abf7a3ce744132748af5be6fedd8feb486edb9ab6203e84ff00b0", "class_name": "RelatedNodeInfo"}}, "text": "You talked a little bit about labor, and I know you and Brian talked last quarter about some specia l \nbonuses and increasing wages, but how do we think about wages going forward as we continue to have wage \ninflation would be my first part of the inflation question.  \n \n", "start_char_idx": 3695, "end_char_idx": 3967, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ef08bdb2-708f-43bf-b2b2-fc374a6d02f2": {"__data__": {"id_": "ef08bdb2-708f-43bf-b2b2-fc374a6d02f2", "embedding": null, "metadata": {"window": "Good afternoon, and thanks for all the detail.  Britt, I just want to go back and talk about \ninflation.  You talked a little bit about labor, and I know you and Brian talked last quarter about some specia l \nbonuses and increasing wages, but how do we think about wages going forward as we continue to have wage \ninflation would be my first part of the inflation question.  \n \n And then secondly, as we think about product inflation or transportation, I know generall y speaking, it's a pass -\nthrough on the pharmaceutical side of things, but how do we think about any PPE on your Medical side of your \nbusiness?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "And then secondly, as we think about product inflation or transportation, I know generall y speaking, it's a pass -\nthrough on the pharmaceutical side of things, but how do we think about any PPE on your Medical side of your \nbusiness?  \n ", "page_label": "13", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f068cc0d-3c7f-417d-91f3-136afa17b579", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f0fb2efafc021a37706fc20da54d10f4c2572335f2953923cc818e170f79c18", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "87c0a656-58f0-497e-a651-84fa0d6aa06b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much.  Good afternoon, and thanks for all the detail.  Britt, I just want to go back and talk about \ninflation.  You talked a little bit about labor, and I know you and Brian talked last quarter about some specia l \nbonuses and increasing wages, but how do we think about wages going forward as we continue to have wage \ninflation would be my first part of the inflation question.  \n \n And then secondly, as we think about product inflation or transportation, I know generall y speaking, it's a pass -\nthrough on the pharmaceutical side of things, but how do we think about any PPE on your Medical side of your \nbusiness?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "You talked a little bit about labor, and I know you and Brian talked last quarter about some specia l \nbonuses and increasing wages, but how do we think about wages going forward as we continue to have wage \ninflation would be my first part of the inflation question.  \n \n", "page_label": "13", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0f2cc35f58f963e92276692ec6796d4809b04cea4b7a79ea82e788a2c6632bbc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5fd93bde-5ddc-453c-bd08-333e6414994b", "node_type": "1", "metadata": {"window": "Britt, I just want to go back and talk about \ninflation.  You talked a little bit about labor, and I know you and Brian talked last quarter about some specia l \nbonuses and increasing wages, but how do we think about wages going forward as we continue to have wage \ninflation would be my first part of the inflation question.  \n \n And then secondly, as we think about product inflation or transportation, I know generall y speaking, it's a pass -\nthrough on the pharmaceutical side of things, but how do we think about any PPE on your Medical side of your \nbusiness?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  "}, "hash": "141d20d1b942e1fdcd7786a45141eca7e54ab4a61979595e59b73b43189c4d07", "class_name": "RelatedNodeInfo"}}, "text": "And then secondly, as we think about product inflation or transportation, I know generall y speaking, it's a pass -\nthrough on the pharmaceutical side of things, but how do we think about any PPE on your Medical side of your \nbusiness?  \n ", "start_char_idx": 3967, "end_char_idx": 4206, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5fd93bde-5ddc-453c-bd08-333e6414994b": {"__data__": {"id_": "5fd93bde-5ddc-453c-bd08-333e6414994b", "embedding": null, "metadata": {"window": "Britt, I just want to go back and talk about \ninflation.  You talked a little bit about labor, and I know you and Brian talked last quarter about some specia l \nbonuses and increasing wages, but how do we think about wages going forward as we continue to have wage \ninflation would be my first part of the inflation question.  \n \n And then secondly, as we think about product inflation or transportation, I know generall y speaking, it's a pass -\nthrough on the pharmaceutical side of things, but how do we think about any PPE on your Medical side of your \nbusiness?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "page_label": "13", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f068cc0d-3c7f-417d-91f3-136afa17b579", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f0fb2efafc021a37706fc20da54d10f4c2572335f2953923cc818e170f79c18", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ef08bdb2-708f-43bf-b2b2-fc374a6d02f2", "node_type": "1", "metadata": {"window": "Good afternoon, and thanks for all the detail.  Britt, I just want to go back and talk about \ninflation.  You talked a little bit about labor, and I know you and Brian talked last quarter about some specia l \nbonuses and increasing wages, but how do we think about wages going forward as we continue to have wage \ninflation would be my first part of the inflation question.  \n \n And then secondly, as we think about product inflation or transportation, I know generall y speaking, it's a pass -\nthrough on the pharmaceutical side of things, but how do we think about any PPE on your Medical side of your \nbusiness?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "And then secondly, as we think about product inflation or transportation, I know generall y speaking, it's a pass -\nthrough on the pharmaceutical side of things, but how do we think about any PPE on your Medical side of your \nbusiness?  \n ", "page_label": "13", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0de50f5c39601a26b28f5af8bd82a9a0868515ad50fd0ee6879cda8011a7e4a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d7c6282e-1e38-42ac-a7ad-31609c6dcb82", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nLisa, thanks for that question.  Maybe I'll just step back for a minute and just address labor and inflation \nseparately, and maybe I'll just start with inflation. ", "original_text": "McKesson Corp.  "}, "hash": "4ecc7ced6411005b88f8f1317be43571a8e65568302b9af219fd120fe27b5652", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "start_char_idx": 336, "end_char_idx": 607, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d7c6282e-1e38-42ac-a7ad-31609c6dcb82": {"__data__": {"id_": "d7c6282e-1e38-42ac-a7ad-31609c6dcb82", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nLisa, thanks for that question.  Maybe I'll just step back for a minute and just address labor and inflation \nseparately, and maybe I'll just start with inflation. ", "original_text": "McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0bc2914-1a28-4a02-aa06-32ec80578111", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f8450850550bfb80c662544f537a2ae330be8d221c2a8da7320264cba785aa4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5fd93bde-5ddc-453c-bd08-333e6414994b", "node_type": "1", "metadata": {"window": "Britt, I just want to go back and talk about \ninflation.  You talked a little bit about labor, and I know you and Brian talked last quarter about some specia l \nbonuses and increasing wages, but how do we think about wages going forward as we continue to have wage \ninflation would be my first part of the inflation question.  \n \n And then secondly, as we think about product inflation or transportation, I know generall y speaking, it's a pass -\nthrough on the pharmaceutical side of things, but how do we think about any PPE on your Medical side of your \nbusiness?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "page_label": "13", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1efebc83fb46e741617bd8abafbeab6184df289e165265670901bbc0c26a502a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b054093e-d96c-43a0-ac79-ff0cdfd49a69", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nLisa, thanks for that question.  Maybe I'll just step back for a minute and just address labor and inflation \nseparately, and maybe I'll just start with inflation.  Our business model has a normal component that's built into it \nthat relates to pricing. ", "original_text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "1532d885a2fe8cb705ae93edbbafa39e48333e1a473c209a2b400e5ad1efbf31", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b054093e-d96c-43a0-ac79-ff0cdfd49a69": {"__data__": {"id_": "b054093e-d96c-43a0-ac79-ff0cdfd49a69", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nLisa, thanks for that question.  Maybe I'll just step back for a minute and just address labor and inflation \nseparately, and maybe I'll just start with inflation.  Our business model has a normal component that's built into it \nthat relates to pricing. ", "original_text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0bc2914-1a28-4a02-aa06-32ec80578111", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f8450850550bfb80c662544f537a2ae330be8d221c2a8da7320264cba785aa4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d7c6282e-1e38-42ac-a7ad-31609c6dcb82", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nLisa, thanks for that question.  Maybe I'll just step back for a minute and just address labor and inflation \nseparately, and maybe I'll just start with inflation. ", "original_text": "McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "850f08a570cc6e5cf3277829c20bcaa7571d3e262e9cacc3ae4e5f1e133b6cc2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "54e6e201-fcfd-4120-b897-f7022404399e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nLisa, thanks for that question.  Maybe I'll just step back for a minute and just address labor and inflation \nseparately, and maybe I'll just start with inflation.  Our business model has a normal component that's built into it \nthat relates to pricing.  When you have a model like w e do that's founded on both supply and service stability and \nconsistency that solves problems in a better way for customers and patients, you're able to incorporate some of \nthese higher input costs through pricing.  \n \n", "original_text": "A \nLisa, thanks for that question. "}, "hash": "f49bc02b17f20897efe54fe0796d3b28500fd37234f841196e34436337356e34", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 16, "end_char_idx": 266, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "54e6e201-fcfd-4120-b897-f7022404399e": {"__data__": {"id_": "54e6e201-fcfd-4120-b897-f7022404399e", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nLisa, thanks for that question.  Maybe I'll just step back for a minute and just address labor and inflation \nseparately, and maybe I'll just start with inflation.  Our business model has a normal component that's built into it \nthat relates to pricing.  When you have a model like w e do that's founded on both supply and service stability and \nconsistency that solves problems in a better way for customers and patients, you're able to incorporate some of \nthese higher input costs through pricing.  \n \n", "original_text": "A \nLisa, thanks for that question. ", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0bc2914-1a28-4a02-aa06-32ec80578111", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f8450850550bfb80c662544f537a2ae330be8d221c2a8da7320264cba785aa4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b054093e-d96c-43a0-ac79-ff0cdfd49a69", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nLisa, thanks for that question.  Maybe I'll just step back for a minute and just address labor and inflation \nseparately, and maybe I'll just start with inflation.  Our business model has a normal component that's built into it \nthat relates to pricing. ", "original_text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dc148e49accc344a0e5b001707779fa370a5e56557a366d6fc5a7c0e038f4cb7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "75b843f1-1c42-47fb-b796-bb99a7c8aace", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nLisa, thanks for that question.  Maybe I'll just step back for a minute and just address labor and inflation \nseparately, and maybe I'll just start with inflation.  Our business model has a normal component that's built into it \nthat relates to pricing.  When you have a model like w e do that's founded on both supply and service stability and \nconsistency that solves problems in a better way for customers and patients, you're able to incorporate some of \nthese higher input costs through pricing.  \n \n Our organization, Brian has talked about , continues to do really a tremendous job on productivity efforts, and \nthose productivity efforts enable us to offset some of this cost. ", "original_text": "Maybe I'll just step back for a minute and just address labor and inflation \nseparately, and maybe I'll just start with inflation. "}, "hash": "591a8a073fab8e15a801051ee5d2a9de65d08b8ddd38e8fafd316367321bc643", "class_name": "RelatedNodeInfo"}}, "text": "A \nLisa, thanks for that question. ", "start_char_idx": 266, "end_char_idx": 301, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "75b843f1-1c42-47fb-b796-bb99a7c8aace": {"__data__": {"id_": "75b843f1-1c42-47fb-b796-bb99a7c8aace", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nLisa, thanks for that question.  Maybe I'll just step back for a minute and just address labor and inflation \nseparately, and maybe I'll just start with inflation.  Our business model has a normal component that's built into it \nthat relates to pricing.  When you have a model like w e do that's founded on both supply and service stability and \nconsistency that solves problems in a better way for customers and patients, you're able to incorporate some of \nthese higher input costs through pricing.  \n \n Our organization, Brian has talked about , continues to do really a tremendous job on productivity efforts, and \nthose productivity efforts enable us to offset some of this cost. ", "original_text": "Maybe I'll just step back for a minute and just address labor and inflation \nseparately, and maybe I'll just start with inflation. ", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0bc2914-1a28-4a02-aa06-32ec80578111", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f8450850550bfb80c662544f537a2ae330be8d221c2a8da7320264cba785aa4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "54e6e201-fcfd-4120-b897-f7022404399e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nLisa, thanks for that question.  Maybe I'll just step back for a minute and just address labor and inflation \nseparately, and maybe I'll just start with inflation.  Our business model has a normal component that's built into it \nthat relates to pricing.  When you have a model like w e do that's founded on both supply and service stability and \nconsistency that solves problems in a better way for customers and patients, you're able to incorporate some of \nthese higher input costs through pricing.  \n \n", "original_text": "A \nLisa, thanks for that question. ", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ca239af8deb99eea6c3ac2ec9526322beb66d37b28d602285431868a89e5cf63", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "40db3751-e058-40c2-a6c9-6d42e0809c88", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nLisa, thanks for that question.  Maybe I'll just step back for a minute and just address labor and inflation \nseparately, and maybe I'll just start with inflation.  Our business model has a normal component that's built into it \nthat relates to pricing.  When you have a model like w e do that's founded on both supply and service stability and \nconsistency that solves problems in a better way for customers and patients, you're able to incorporate some of \nthese higher input costs through pricing.  \n \n Our organization, Brian has talked about , continues to do really a tremendous job on productivity efforts, and \nthose productivity efforts enable us to offset some of this cost.  And then of course, there is a pricing component.  \n \n", "original_text": "Our business model has a normal component that's built into it \nthat relates to pricing. "}, "hash": "6408f2e4ab36155fc8822303d0d96ed899836ef7da6c38d032d65c56b5b9ec0c", "class_name": "RelatedNodeInfo"}}, "text": "Maybe I'll just step back for a minute and just address labor and inflation \nseparately, and maybe I'll just start with inflation. ", "start_char_idx": 301, "end_char_idx": 432, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "40db3751-e058-40c2-a6c9-6d42e0809c88": {"__data__": {"id_": "40db3751-e058-40c2-a6c9-6d42e0809c88", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nLisa, thanks for that question.  Maybe I'll just step back for a minute and just address labor and inflation \nseparately, and maybe I'll just start with inflation.  Our business model has a normal component that's built into it \nthat relates to pricing.  When you have a model like w e do that's founded on both supply and service stability and \nconsistency that solves problems in a better way for customers and patients, you're able to incorporate some of \nthese higher input costs through pricing.  \n \n Our organization, Brian has talked about , continues to do really a tremendous job on productivity efforts, and \nthose productivity efforts enable us to offset some of this cost.  And then of course, there is a pricing component.  \n \n", "original_text": "Our business model has a normal component that's built into it \nthat relates to pricing. ", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0bc2914-1a28-4a02-aa06-32ec80578111", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f8450850550bfb80c662544f537a2ae330be8d221c2a8da7320264cba785aa4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "75b843f1-1c42-47fb-b796-bb99a7c8aace", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nLisa, thanks for that question.  Maybe I'll just step back for a minute and just address labor and inflation \nseparately, and maybe I'll just start with inflation.  Our business model has a normal component that's built into it \nthat relates to pricing.  When you have a model like w e do that's founded on both supply and service stability and \nconsistency that solves problems in a better way for customers and patients, you're able to incorporate some of \nthese higher input costs through pricing.  \n \n Our organization, Brian has talked about , continues to do really a tremendous job on productivity efforts, and \nthose productivity efforts enable us to offset some of this cost. ", "original_text": "Maybe I'll just step back for a minute and just address labor and inflation \nseparately, and maybe I'll just start with inflation. ", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "adcf59d0d71c4564577e101a90dd4741bc096d610696ce21452c7f7b19a88573", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "574d386a-0679-4462-9762-d37ef504526a", "node_type": "1", "metadata": {"window": "A \nLisa, thanks for that question.  Maybe I'll just step back for a minute and just address labor and inflation \nseparately, and maybe I'll just start with inflation.  Our business model has a normal component that's built into it \nthat relates to pricing.  When you have a model like w e do that's founded on both supply and service stability and \nconsistency that solves problems in a better way for customers and patients, you're able to incorporate some of \nthese higher input costs through pricing.  \n \n Our organization, Brian has talked about , continues to do really a tremendous job on productivity efforts, and \nthose productivity efforts enable us to offset some of this cost.  And then of course, there is a pricing component.  \n \n And just finally, we have an organization of really smart people tha t are continuously working to find better \nsolutions, greater efficiencies, and leveraging the scale and the broad expertise that we have to provide quality \nand reliability that our customers have come to expect from McKesson.  \n \n", "original_text": "When you have a model like w e do that's founded on both supply and service stability and \nconsistency that solves problems in a better way for customers and patients, you're able to incorporate some of \nthese higher input costs through pricing.  \n \n"}, "hash": "a825a27497d0234fdc62994a5833d83702700202ebabc0a2890cc7d6288cb1bc", "class_name": "RelatedNodeInfo"}}, "text": "Our business model has a normal component that's built into it \nthat relates to pricing. ", "start_char_idx": 432, "end_char_idx": 521, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "574d386a-0679-4462-9762-d37ef504526a": {"__data__": {"id_": "574d386a-0679-4462-9762-d37ef504526a", "embedding": null, "metadata": {"window": "A \nLisa, thanks for that question.  Maybe I'll just step back for a minute and just address labor and inflation \nseparately, and maybe I'll just start with inflation.  Our business model has a normal component that's built into it \nthat relates to pricing.  When you have a model like w e do that's founded on both supply and service stability and \nconsistency that solves problems in a better way for customers and patients, you're able to incorporate some of \nthese higher input costs through pricing.  \n \n Our organization, Brian has talked about , continues to do really a tremendous job on productivity efforts, and \nthose productivity efforts enable us to offset some of this cost.  And then of course, there is a pricing component.  \n \n And just finally, we have an organization of really smart people tha t are continuously working to find better \nsolutions, greater efficiencies, and leveraging the scale and the broad expertise that we have to provide quality \nand reliability that our customers have come to expect from McKesson.  \n \n", "original_text": "When you have a model like w e do that's founded on both supply and service stability and \nconsistency that solves problems in a better way for customers and patients, you're able to incorporate some of \nthese higher input costs through pricing.  \n \n", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0bc2914-1a28-4a02-aa06-32ec80578111", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f8450850550bfb80c662544f537a2ae330be8d221c2a8da7320264cba785aa4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "40db3751-e058-40c2-a6c9-6d42e0809c88", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nLisa, thanks for that question.  Maybe I'll just step back for a minute and just address labor and inflation \nseparately, and maybe I'll just start with inflation.  Our business model has a normal component that's built into it \nthat relates to pricing.  When you have a model like w e do that's founded on both supply and service stability and \nconsistency that solves problems in a better way for customers and patients, you're able to incorporate some of \nthese higher input costs through pricing.  \n \n Our organization, Brian has talked about , continues to do really a tremendous job on productivity efforts, and \nthose productivity efforts enable us to offset some of this cost.  And then of course, there is a pricing component.  \n \n", "original_text": "Our business model has a normal component that's built into it \nthat relates to pricing. ", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c82f3f2c4b0061c14553697c3ba6b73f9d4280066e4a346557ba233fb9707b7e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "efdaf7a2-02ec-436b-bd80-85f7e0f8b409", "node_type": "1", "metadata": {"window": "Maybe I'll just step back for a minute and just address labor and inflation \nseparately, and maybe I'll just start with inflation.  Our business model has a normal component that's built into it \nthat relates to pricing.  When you have a model like w e do that's founded on both supply and service stability and \nconsistency that solves problems in a better way for customers and patients, you're able to incorporate some of \nthese higher input costs through pricing.  \n \n Our organization, Brian has talked about , continues to do really a tremendous job on productivity efforts, and \nthose productivity efforts enable us to offset some of this cost.  And then of course, there is a pricing component.  \n \n And just finally, we have an organization of really smart people tha t are continuously working to find better \nsolutions, greater efficiencies, and leveraging the scale and the broad expertise that we have to provide quality \nand reliability that our customers have come to expect from McKesson.  \n \n So that's maybe just answerin g some of the questions on the inflation front.  \n \n", "original_text": "Our organization, Brian has talked about , continues to do really a tremendous job on productivity efforts, and \nthose productivity efforts enable us to offset some of this cost. "}, "hash": "8a4892f74a99a81b9d002912dfca10ce1d21082f7c269e62aa9438c8b65a79a6", "class_name": "RelatedNodeInfo"}}, "text": "When you have a model like w e do that's founded on both supply and service stability and \nconsistency that solves problems in a better way for customers and patients, you're able to incorporate some of \nthese higher input costs through pricing.  \n \n", "start_char_idx": 521, "end_char_idx": 771, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "efdaf7a2-02ec-436b-bd80-85f7e0f8b409": {"__data__": {"id_": "efdaf7a2-02ec-436b-bd80-85f7e0f8b409", "embedding": null, "metadata": {"window": "Maybe I'll just step back for a minute and just address labor and inflation \nseparately, and maybe I'll just start with inflation.  Our business model has a normal component that's built into it \nthat relates to pricing.  When you have a model like w e do that's founded on both supply and service stability and \nconsistency that solves problems in a better way for customers and patients, you're able to incorporate some of \nthese higher input costs through pricing.  \n \n Our organization, Brian has talked about , continues to do really a tremendous job on productivity efforts, and \nthose productivity efforts enable us to offset some of this cost.  And then of course, there is a pricing component.  \n \n And just finally, we have an organization of really smart people tha t are continuously working to find better \nsolutions, greater efficiencies, and leveraging the scale and the broad expertise that we have to provide quality \nand reliability that our customers have come to expect from McKesson.  \n \n So that's maybe just answerin g some of the questions on the inflation front.  \n \n", "original_text": "Our organization, Brian has talked about , continues to do really a tremendous job on productivity efforts, and \nthose productivity efforts enable us to offset some of this cost. ", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0bc2914-1a28-4a02-aa06-32ec80578111", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f8450850550bfb80c662544f537a2ae330be8d221c2a8da7320264cba785aa4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "574d386a-0679-4462-9762-d37ef504526a", "node_type": "1", "metadata": {"window": "A \nLisa, thanks for that question.  Maybe I'll just step back for a minute and just address labor and inflation \nseparately, and maybe I'll just start with inflation.  Our business model has a normal component that's built into it \nthat relates to pricing.  When you have a model like w e do that's founded on both supply and service stability and \nconsistency that solves problems in a better way for customers and patients, you're able to incorporate some of \nthese higher input costs through pricing.  \n \n Our organization, Brian has talked about , continues to do really a tremendous job on productivity efforts, and \nthose productivity efforts enable us to offset some of this cost.  And then of course, there is a pricing component.  \n \n And just finally, we have an organization of really smart people tha t are continuously working to find better \nsolutions, greater efficiencies, and leveraging the scale and the broad expertise that we have to provide quality \nand reliability that our customers have come to expect from McKesson.  \n \n", "original_text": "When you have a model like w e do that's founded on both supply and service stability and \nconsistency that solves problems in a better way for customers and patients, you're able to incorporate some of \nthese higher input costs through pricing.  \n \n", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64f393c3e058e29bc43e758e820c5d848ee7e3c238b3bb686a79ad290bf319f2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3e202d3e-589e-495c-8508-c8e44d750f79", "node_type": "1", "metadata": {"window": "Our business model has a normal component that's built into it \nthat relates to pricing.  When you have a model like w e do that's founded on both supply and service stability and \nconsistency that solves problems in a better way for customers and patients, you're able to incorporate some of \nthese higher input costs through pricing.  \n \n Our organization, Brian has talked about , continues to do really a tremendous job on productivity efforts, and \nthose productivity efforts enable us to offset some of this cost.  And then of course, there is a pricing component.  \n \n And just finally, we have an organization of really smart people tha t are continuously working to find better \nsolutions, greater efficiencies, and leveraging the scale and the broad expertise that we have to provide quality \nand reliability that our customers have come to expect from McKesson.  \n \n So that's maybe just answerin g some of the questions on the inflation front.  \n \n On the labor front, Brian's talked about talent being one of our key components of our strategy. ", "original_text": "And then of course, there is a pricing component.  \n \n"}, "hash": "d6f06824e0dfce8a2ac603c1e8ee3beee06b149dbbff26edd8af8e665d8fcb7d", "class_name": "RelatedNodeInfo"}}, "text": "Our organization, Brian has talked about , continues to do really a tremendous job on productivity efforts, and \nthose productivity efforts enable us to offset some of this cost. ", "start_char_idx": 771, "end_char_idx": 950, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3e202d3e-589e-495c-8508-c8e44d750f79": {"__data__": {"id_": "3e202d3e-589e-495c-8508-c8e44d750f79", "embedding": null, "metadata": {"window": "Our business model has a normal component that's built into it \nthat relates to pricing.  When you have a model like w e do that's founded on both supply and service stability and \nconsistency that solves problems in a better way for customers and patients, you're able to incorporate some of \nthese higher input costs through pricing.  \n \n Our organization, Brian has talked about , continues to do really a tremendous job on productivity efforts, and \nthose productivity efforts enable us to offset some of this cost.  And then of course, there is a pricing component.  \n \n And just finally, we have an organization of really smart people tha t are continuously working to find better \nsolutions, greater efficiencies, and leveraging the scale and the broad expertise that we have to provide quality \nand reliability that our customers have come to expect from McKesson.  \n \n So that's maybe just answerin g some of the questions on the inflation front.  \n \n On the labor front, Brian's talked about talent being one of our key components of our strategy. ", "original_text": "And then of course, there is a pricing component.  \n \n", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0bc2914-1a28-4a02-aa06-32ec80578111", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f8450850550bfb80c662544f537a2ae330be8d221c2a8da7320264cba785aa4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "efdaf7a2-02ec-436b-bd80-85f7e0f8b409", "node_type": "1", "metadata": {"window": "Maybe I'll just step back for a minute and just address labor and inflation \nseparately, and maybe I'll just start with inflation.  Our business model has a normal component that's built into it \nthat relates to pricing.  When you have a model like w e do that's founded on both supply and service stability and \nconsistency that solves problems in a better way for customers and patients, you're able to incorporate some of \nthese higher input costs through pricing.  \n \n Our organization, Brian has talked about , continues to do really a tremendous job on productivity efforts, and \nthose productivity efforts enable us to offset some of this cost.  And then of course, there is a pricing component.  \n \n And just finally, we have an organization of really smart people tha t are continuously working to find better \nsolutions, greater efficiencies, and leveraging the scale and the broad expertise that we have to provide quality \nand reliability that our customers have come to expect from McKesson.  \n \n So that's maybe just answerin g some of the questions on the inflation front.  \n \n", "original_text": "Our organization, Brian has talked about , continues to do really a tremendous job on productivity efforts, and \nthose productivity efforts enable us to offset some of this cost. ", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1f5740d71f6f10fbbc6dfbe472c899613071e86dc449e70d977089fd3d6ff0ab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3814e4b0-a747-4055-98c4-321c22bd8ae3", "node_type": "1", "metadata": {"window": "When you have a model like w e do that's founded on both supply and service stability and \nconsistency that solves problems in a better way for customers and patients, you're able to incorporate some of \nthese higher input costs through pricing.  \n \n Our organization, Brian has talked about , continues to do really a tremendous job on productivity efforts, and \nthose productivity efforts enable us to offset some of this cost.  And then of course, there is a pricing component.  \n \n And just finally, we have an organization of really smart people tha t are continuously working to find better \nsolutions, greater efficiencies, and leveraging the scale and the broad expertise that we have to provide quality \nand reliability that our customers have come to expect from McKesson.  \n \n So that's maybe just answerin g some of the questions on the inflation front.  \n \n On the labor front, Brian's talked about talent being one of our key components of our strategy.  It will remain that. \n", "original_text": "And just finally, we have an organization of really smart people tha t are continuously working to find better \nsolutions, greater efficiencies, and leveraging the scale and the broad expertise that we have to provide quality \nand reliability that our customers have come to expect from McKesson.  \n \n"}, "hash": "a778819ae136c55a3fb4b1c377e9a556294dea5e3e08a4cf8267eea1c4b11a9c", "class_name": "RelatedNodeInfo"}}, "text": "And then of course, there is a pricing component.  \n \n", "start_char_idx": 950, "end_char_idx": 1004, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3814e4b0-a747-4055-98c4-321c22bd8ae3": {"__data__": {"id_": "3814e4b0-a747-4055-98c4-321c22bd8ae3", "embedding": null, "metadata": {"window": "When you have a model like w e do that's founded on both supply and service stability and \nconsistency that solves problems in a better way for customers and patients, you're able to incorporate some of \nthese higher input costs through pricing.  \n \n Our organization, Brian has talked about , continues to do really a tremendous job on productivity efforts, and \nthose productivity efforts enable us to offset some of this cost.  And then of course, there is a pricing component.  \n \n And just finally, we have an organization of really smart people tha t are continuously working to find better \nsolutions, greater efficiencies, and leveraging the scale and the broad expertise that we have to provide quality \nand reliability that our customers have come to expect from McKesson.  \n \n So that's maybe just answerin g some of the questions on the inflation front.  \n \n On the labor front, Brian's talked about talent being one of our key components of our strategy.  It will remain that. \n", "original_text": "And just finally, we have an organization of really smart people tha t are continuously working to find better \nsolutions, greater efficiencies, and leveraging the scale and the broad expertise that we have to provide quality \nand reliability that our customers have come to expect from McKesson.  \n \n", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0bc2914-1a28-4a02-aa06-32ec80578111", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f8450850550bfb80c662544f537a2ae330be8d221c2a8da7320264cba785aa4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3e202d3e-589e-495c-8508-c8e44d750f79", "node_type": "1", "metadata": {"window": "Our business model has a normal component that's built into it \nthat relates to pricing.  When you have a model like w e do that's founded on both supply and service stability and \nconsistency that solves problems in a better way for customers and patients, you're able to incorporate some of \nthese higher input costs through pricing.  \n \n Our organization, Brian has talked about , continues to do really a tremendous job on productivity efforts, and \nthose productivity efforts enable us to offset some of this cost.  And then of course, there is a pricing component.  \n \n And just finally, we have an organization of really smart people tha t are continuously working to find better \nsolutions, greater efficiencies, and leveraging the scale and the broad expertise that we have to provide quality \nand reliability that our customers have come to expect from McKesson.  \n \n So that's maybe just answerin g some of the questions on the inflation front.  \n \n On the labor front, Brian's talked about talent being one of our key components of our strategy. ", "original_text": "And then of course, there is a pricing component.  \n \n", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df149aaa23e80b77d6f2b3120319d6e606f3a4aa393ea8edc69fa688321ab9c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "814fc27f-18ef-4f24-bf43-0448bbab213b", "node_type": "1", "metadata": {"window": "Our organization, Brian has talked about , continues to do really a tremendous job on productivity efforts, and \nthose productivity efforts enable us to offset some of this cost.  And then of course, there is a pricing component.  \n \n And just finally, we have an organization of really smart people tha t are continuously working to find better \nsolutions, greater efficiencies, and leveraging the scale and the broad expertise that we have to provide quality \nand reliability that our customers have come to expect from McKesson.  \n \n So that's maybe just answerin g some of the questions on the inflation front.  \n \n On the labor front, Brian's talked about talent being one of our key components of our strategy.  It will remain that. \n And of course, this is a very challenging market. ", "original_text": "So that's maybe just answerin g some of the questions on the inflation front.  \n \n"}, "hash": "b0f6abe9a7e8c57227dd96fd639f747912a6684a08694577c1f81a4ca0884f4d", "class_name": "RelatedNodeInfo"}}, "text": "And just finally, we have an organization of really smart people tha t are continuously working to find better \nsolutions, greater efficiencies, and leveraging the scale and the broad expertise that we have to provide quality \nand reliability that our customers have come to expect from McKesson.  \n \n", "start_char_idx": 1004, "end_char_idx": 1305, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "814fc27f-18ef-4f24-bf43-0448bbab213b": {"__data__": {"id_": "814fc27f-18ef-4f24-bf43-0448bbab213b", "embedding": null, "metadata": {"window": "Our organization, Brian has talked about , continues to do really a tremendous job on productivity efforts, and \nthose productivity efforts enable us to offset some of this cost.  And then of course, there is a pricing component.  \n \n And just finally, we have an organization of really smart people tha t are continuously working to find better \nsolutions, greater efficiencies, and leveraging the scale and the broad expertise that we have to provide quality \nand reliability that our customers have come to expect from McKesson.  \n \n So that's maybe just answerin g some of the questions on the inflation front.  \n \n On the labor front, Brian's talked about talent being one of our key components of our strategy.  It will remain that. \n And of course, this is a very challenging market. ", "original_text": "So that's maybe just answerin g some of the questions on the inflation front.  \n \n", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0bc2914-1a28-4a02-aa06-32ec80578111", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f8450850550bfb80c662544f537a2ae330be8d221c2a8da7320264cba785aa4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3814e4b0-a747-4055-98c4-321c22bd8ae3", "node_type": "1", "metadata": {"window": "When you have a model like w e do that's founded on both supply and service stability and \nconsistency that solves problems in a better way for customers and patients, you're able to incorporate some of \nthese higher input costs through pricing.  \n \n Our organization, Brian has talked about , continues to do really a tremendous job on productivity efforts, and \nthose productivity efforts enable us to offset some of this cost.  And then of course, there is a pricing component.  \n \n And just finally, we have an organization of really smart people tha t are continuously working to find better \nsolutions, greater efficiencies, and leveraging the scale and the broad expertise that we have to provide quality \nand reliability that our customers have come to expect from McKesson.  \n \n So that's maybe just answerin g some of the questions on the inflation front.  \n \n On the labor front, Brian's talked about talent being one of our key components of our strategy.  It will remain that. \n", "original_text": "And just finally, we have an organization of really smart people tha t are continuously working to find better \nsolutions, greater efficiencies, and leveraging the scale and the broad expertise that we have to provide quality \nand reliability that our customers have come to expect from McKesson.  \n \n", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cf4a5d0abff3566b38df98f6cf65ed68dfc244500f0d6d6bfe93529286e945dd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b87335db-458d-41fa-a624-83d4742dc34a", "node_type": "1", "metadata": {"window": "And then of course, there is a pricing component.  \n \n And just finally, we have an organization of really smart people tha t are continuously working to find better \nsolutions, greater efficiencies, and leveraging the scale and the broad expertise that we have to provide quality \nand reliability that our customers have come to expect from McKesson.  \n \n So that's maybe just answerin g some of the questions on the inflation front.  \n \n On the labor front, Brian's talked about talent being one of our key components of our strategy.  It will remain that. \n And of course, this is a very challenging market.  We're seeing pressures in the labor mar ket. ", "original_text": "On the labor front, Brian's talked about talent being one of our key components of our strategy. "}, "hash": "39495da3ec9f9aa8b9a3fe3e4a636f790a02bbca2c9a873356a13bd91247fa2d", "class_name": "RelatedNodeInfo"}}, "text": "So that's maybe just answerin g some of the questions on the inflation front.  \n \n", "start_char_idx": 1305, "end_char_idx": 1387, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b87335db-458d-41fa-a624-83d4742dc34a": {"__data__": {"id_": "b87335db-458d-41fa-a624-83d4742dc34a", "embedding": null, "metadata": {"window": "And then of course, there is a pricing component.  \n \n And just finally, we have an organization of really smart people tha t are continuously working to find better \nsolutions, greater efficiencies, and leveraging the scale and the broad expertise that we have to provide quality \nand reliability that our customers have come to expect from McKesson.  \n \n So that's maybe just answerin g some of the questions on the inflation front.  \n \n On the labor front, Brian's talked about talent being one of our key components of our strategy.  It will remain that. \n And of course, this is a very challenging market.  We're seeing pressures in the labor mar ket. ", "original_text": "On the labor front, Brian's talked about talent being one of our key components of our strategy. ", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0bc2914-1a28-4a02-aa06-32ec80578111", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f8450850550bfb80c662544f537a2ae330be8d221c2a8da7320264cba785aa4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "814fc27f-18ef-4f24-bf43-0448bbab213b", "node_type": "1", "metadata": {"window": "Our organization, Brian has talked about , continues to do really a tremendous job on productivity efforts, and \nthose productivity efforts enable us to offset some of this cost.  And then of course, there is a pricing component.  \n \n And just finally, we have an organization of really smart people tha t are continuously working to find better \nsolutions, greater efficiencies, and leveraging the scale and the broad expertise that we have to provide quality \nand reliability that our customers have come to expect from McKesson.  \n \n So that's maybe just answerin g some of the questions on the inflation front.  \n \n On the labor front, Brian's talked about talent being one of our key components of our strategy.  It will remain that. \n And of course, this is a very challenging market. ", "original_text": "So that's maybe just answerin g some of the questions on the inflation front.  \n \n", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5be1acc120d296edc48b6c3e38b436acda89b45daaba161cfd237be670254e90", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b39305bf-95a5-4055-83b1-5d48d52e8632", "node_type": "1", "metadata": {"window": "And just finally, we have an organization of really smart people tha t are continuously working to find better \nsolutions, greater efficiencies, and leveraging the scale and the broad expertise that we have to provide quality \nand reliability that our customers have come to expect from McKesson.  \n \n So that's maybe just answerin g some of the questions on the inflation front.  \n \n On the labor front, Brian's talked about talent being one of our key components of our strategy.  It will remain that. \n And of course, this is a very challenging market.  We're seeing pressures in the labor mar ket.  And so we've talked \nabout the fact that we expect some of these labor pressures to find their way into operating expenses in the \nsecond half of the year, $0.10 to $0.20. ", "original_text": "It will remain that. \n"}, "hash": "9c11fa9252898e284c5c14b376c75ab5aa5aa4d143cf589415b190d9f5a21fa9", "class_name": "RelatedNodeInfo"}}, "text": "On the labor front, Brian's talked about talent being one of our key components of our strategy. ", "start_char_idx": 1387, "end_char_idx": 1484, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b39305bf-95a5-4055-83b1-5d48d52e8632": {"__data__": {"id_": "b39305bf-95a5-4055-83b1-5d48d52e8632", "embedding": null, "metadata": {"window": "And just finally, we have an organization of really smart people tha t are continuously working to find better \nsolutions, greater efficiencies, and leveraging the scale and the broad expertise that we have to provide quality \nand reliability that our customers have come to expect from McKesson.  \n \n So that's maybe just answerin g some of the questions on the inflation front.  \n \n On the labor front, Brian's talked about talent being one of our key components of our strategy.  It will remain that. \n And of course, this is a very challenging market.  We're seeing pressures in the labor mar ket.  And so we've talked \nabout the fact that we expect some of these labor pressures to find their way into operating expenses in the \nsecond half of the year, $0.10 to $0.20. ", "original_text": "It will remain that. \n", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0bc2914-1a28-4a02-aa06-32ec80578111", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f8450850550bfb80c662544f537a2ae330be8d221c2a8da7320264cba785aa4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b87335db-458d-41fa-a624-83d4742dc34a", "node_type": "1", "metadata": {"window": "And then of course, there is a pricing component.  \n \n And just finally, we have an organization of really smart people tha t are continuously working to find better \nsolutions, greater efficiencies, and leveraging the scale and the broad expertise that we have to provide quality \nand reliability that our customers have come to expect from McKesson.  \n \n So that's maybe just answerin g some of the questions on the inflation front.  \n \n On the labor front, Brian's talked about talent being one of our key components of our strategy.  It will remain that. \n And of course, this is a very challenging market.  We're seeing pressures in the labor mar ket. ", "original_text": "On the labor front, Brian's talked about talent being one of our key components of our strategy. ", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3d12060f17fb22feb3c8d1e2fbdc640b3d7af675531651fc384e618769c69286", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6529b730-871b-4dc3-8c62-1ba24ff12cbb", "node_type": "1", "metadata": {"window": "So that's maybe just answerin g some of the questions on the inflation front.  \n \n On the labor front, Brian's talked about talent being one of our key components of our strategy.  It will remain that. \n And of course, this is a very challenging market.  We're seeing pressures in the labor mar ket.  And so we've talked \nabout the fact that we expect some of these labor pressures to find their way into operating expenses in the \nsecond half of the year, $0.10 to $0.20.  We've not guided beyond FY 2022. ", "original_text": "And of course, this is a very challenging market. "}, "hash": "43a36e6ce61c7f3591f2797465ec4941f71c952cd31d1f972bfa499b89a4dc5a", "class_name": "RelatedNodeInfo"}}, "text": "It will remain that. \n", "start_char_idx": 1484, "end_char_idx": 1506, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6529b730-871b-4dc3-8c62-1ba24ff12cbb": {"__data__": {"id_": "6529b730-871b-4dc3-8c62-1ba24ff12cbb", "embedding": null, "metadata": {"window": "So that's maybe just answerin g some of the questions on the inflation front.  \n \n On the labor front, Brian's talked about talent being one of our key components of our strategy.  It will remain that. \n And of course, this is a very challenging market.  We're seeing pressures in the labor mar ket.  And so we've talked \nabout the fact that we expect some of these labor pressures to find their way into operating expenses in the \nsecond half of the year, $0.10 to $0.20.  We've not guided beyond FY 2022. ", "original_text": "And of course, this is a very challenging market. ", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0bc2914-1a28-4a02-aa06-32ec80578111", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f8450850550bfb80c662544f537a2ae330be8d221c2a8da7320264cba785aa4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b39305bf-95a5-4055-83b1-5d48d52e8632", "node_type": "1", "metadata": {"window": "And just finally, we have an organization of really smart people tha t are continuously working to find better \nsolutions, greater efficiencies, and leveraging the scale and the broad expertise that we have to provide quality \nand reliability that our customers have come to expect from McKesson.  \n \n So that's maybe just answerin g some of the questions on the inflation front.  \n \n On the labor front, Brian's talked about talent being one of our key components of our strategy.  It will remain that. \n And of course, this is a very challenging market.  We're seeing pressures in the labor mar ket.  And so we've talked \nabout the fact that we expect some of these labor pressures to find their way into operating expenses in the \nsecond half of the year, $0.10 to $0.20. ", "original_text": "It will remain that. \n", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "caa0f76bd6e0695dcdb0ca6ee77f3f4bba2df15dda75a3a9e4f0a0aa54f046e1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "64777fc7-8394-499c-b7e8-7227c4732c67", "node_type": "1", "metadata": {"window": "On the labor front, Brian's talked about talent being one of our key components of our strategy.  It will remain that. \n And of course, this is a very challenging market.  We're seeing pressures in the labor mar ket.  And so we've talked \nabout the fact that we expect some of these labor pressures to find their way into operating expenses in the \nsecond half of the year, $0.10 to $0.20.  We've not guided beyond FY 2022.  We'll obviously assess if we think that \nthose co sts are going to be sustained at any way. ", "original_text": "We're seeing pressures in the labor mar ket. "}, "hash": "59722da3bf493975840d58c06164f8b10107155256fa0e18ffd6d080319b395d", "class_name": "RelatedNodeInfo"}}, "text": "And of course, this is a very challenging market. ", "start_char_idx": 1506, "end_char_idx": 1556, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "64777fc7-8394-499c-b7e8-7227c4732c67": {"__data__": {"id_": "64777fc7-8394-499c-b7e8-7227c4732c67", "embedding": null, "metadata": {"window": "On the labor front, Brian's talked about talent being one of our key components of our strategy.  It will remain that. \n And of course, this is a very challenging market.  We're seeing pressures in the labor mar ket.  And so we've talked \nabout the fact that we expect some of these labor pressures to find their way into operating expenses in the \nsecond half of the year, $0.10 to $0.20.  We've not guided beyond FY 2022.  We'll obviously assess if we think that \nthose co sts are going to be sustained at any way. ", "original_text": "We're seeing pressures in the labor mar ket. ", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0bc2914-1a28-4a02-aa06-32ec80578111", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f8450850550bfb80c662544f537a2ae330be8d221c2a8da7320264cba785aa4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6529b730-871b-4dc3-8c62-1ba24ff12cbb", "node_type": "1", "metadata": {"window": "So that's maybe just answerin g some of the questions on the inflation front.  \n \n On the labor front, Brian's talked about talent being one of our key components of our strategy.  It will remain that. \n And of course, this is a very challenging market.  We're seeing pressures in the labor mar ket.  And so we've talked \nabout the fact that we expect some of these labor pressures to find their way into operating expenses in the \nsecond half of the year, $0.10 to $0.20.  We've not guided beyond FY 2022. ", "original_text": "And of course, this is a very challenging market. ", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b1b26ac6b924e7bd47dcbe54749f3bb188375322d5488f7bce2ad4ae9126a5f7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "db04f0ea-cbb0-4b8a-9dd0-d99771fd7d30", "node_type": "1", "metadata": {"window": "It will remain that. \n And of course, this is a very challenging market.  We're seeing pressures in the labor mar ket.  And so we've talked \nabout the fact that we expect some of these labor pressures to find their way into operating expenses in the \nsecond half of the year, $0.10 to $0.20.  We've not guided beyond FY 2022.  We'll obviously assess if we think that \nthose co sts are going to be sustained at any way.  At this point we just see a $0.10 to $0.20 impact in our US \ndistribution businesses in the second half. ", "original_text": "And so we've talked \nabout the fact that we expect some of these labor pressures to find their way into operating expenses in the \nsecond half of the year, $0.10 to $0.20. "}, "hash": "37fd89b9bb5042fba37d25965f1522a01e85fd906216091d1cc50b69618ca49d", "class_name": "RelatedNodeInfo"}}, "text": "We're seeing pressures in the labor mar ket. ", "start_char_idx": 1556, "end_char_idx": 1601, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "db04f0ea-cbb0-4b8a-9dd0-d99771fd7d30": {"__data__": {"id_": "db04f0ea-cbb0-4b8a-9dd0-d99771fd7d30", "embedding": null, "metadata": {"window": "It will remain that. \n And of course, this is a very challenging market.  We're seeing pressures in the labor mar ket.  And so we've talked \nabout the fact that we expect some of these labor pressures to find their way into operating expenses in the \nsecond half of the year, $0.10 to $0.20.  We've not guided beyond FY 2022.  We'll obviously assess if we think that \nthose co sts are going to be sustained at any way.  At this point we just see a $0.10 to $0.20 impact in our US \ndistribution businesses in the second half. ", "original_text": "And so we've talked \nabout the fact that we expect some of these labor pressures to find their way into operating expenses in the \nsecond half of the year, $0.10 to $0.20. ", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0bc2914-1a28-4a02-aa06-32ec80578111", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f8450850550bfb80c662544f537a2ae330be8d221c2a8da7320264cba785aa4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "64777fc7-8394-499c-b7e8-7227c4732c67", "node_type": "1", "metadata": {"window": "On the labor front, Brian's talked about talent being one of our key components of our strategy.  It will remain that. \n And of course, this is a very challenging market.  We're seeing pressures in the labor mar ket.  And so we've talked \nabout the fact that we expect some of these labor pressures to find their way into operating expenses in the \nsecond half of the year, $0.10 to $0.20.  We've not guided beyond FY 2022.  We'll obviously assess if we think that \nthose co sts are going to be sustained at any way. ", "original_text": "We're seeing pressures in the labor mar ket. ", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b2e99e134ba351a5b416e453faca78fef56e45bd15b6c6d1d571189cebc2a52f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "821b7432-6582-4f0b-a083-faec7bc4dadd", "node_type": "1", "metadata": {"window": "And of course, this is a very challenging market.  We're seeing pressures in the labor mar ket.  And so we've talked \nabout the fact that we expect some of these labor pressures to find their way into operating expenses in the \nsecond half of the year, $0.10 to $0.20.  We've not guided beyond FY 2022.  We'll obviously assess if we think that \nthose co sts are going to be sustained at any way.  At this point we just see a $0.10 to $0.20 impact in our US \ndistribution businesses in the second half.  And what we've seen so far in the third quarter it's tracking right in line \nwith that.  \n ", "original_text": "We've not guided beyond FY 2022. "}, "hash": "af2eaac5903785f671305c8389f55c40749827c840a0d1c637c8470d8faa458d", "class_name": "RelatedNodeInfo"}}, "text": "And so we've talked \nabout the fact that we expect some of these labor pressures to find their way into operating expenses in the \nsecond half of the year, $0.10 to $0.20. ", "start_char_idx": 1601, "end_char_idx": 1773, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "821b7432-6582-4f0b-a083-faec7bc4dadd": {"__data__": {"id_": "821b7432-6582-4f0b-a083-faec7bc4dadd", "embedding": null, "metadata": {"window": "And of course, this is a very challenging market.  We're seeing pressures in the labor mar ket.  And so we've talked \nabout the fact that we expect some of these labor pressures to find their way into operating expenses in the \nsecond half of the year, $0.10 to $0.20.  We've not guided beyond FY 2022.  We'll obviously assess if we think that \nthose co sts are going to be sustained at any way.  At this point we just see a $0.10 to $0.20 impact in our US \ndistribution businesses in the second half.  And what we've seen so far in the third quarter it's tracking right in line \nwith that.  \n ", "original_text": "We've not guided beyond FY 2022. ", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0bc2914-1a28-4a02-aa06-32ec80578111", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f8450850550bfb80c662544f537a2ae330be8d221c2a8da7320264cba785aa4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "db04f0ea-cbb0-4b8a-9dd0-d99771fd7d30", "node_type": "1", "metadata": {"window": "It will remain that. \n And of course, this is a very challenging market.  We're seeing pressures in the labor mar ket.  And so we've talked \nabout the fact that we expect some of these labor pressures to find their way into operating expenses in the \nsecond half of the year, $0.10 to $0.20.  We've not guided beyond FY 2022.  We'll obviously assess if we think that \nthose co sts are going to be sustained at any way.  At this point we just see a $0.10 to $0.20 impact in our US \ndistribution businesses in the second half. ", "original_text": "And so we've talked \nabout the fact that we expect some of these labor pressures to find their way into operating expenses in the \nsecond half of the year, $0.10 to $0.20. ", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dde2f5ab758d9ff428cb2d7686f17cf0ce5a8a3d268a2183fb458676acf8caf8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3cdab136-1c39-43ff-b29e-cb26843e06e2", "node_type": "1", "metadata": {"window": "We're seeing pressures in the labor mar ket.  And so we've talked \nabout the fact that we expect some of these labor pressures to find their way into operating expenses in the \nsecond half of the year, $0.10 to $0.20.  We've not guided beyond FY 2022.  We'll obviously assess if we think that \nthose co sts are going to be sustained at any way.  At this point we just see a $0.10 to $0.20 impact in our US \ndistribution businesses in the second half.  And what we've seen so far in the third quarter it's tracking right in line \nwith that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "We'll obviously assess if we think that \nthose co sts are going to be sustained at any way. "}, "hash": "310a4bfef18eac536ffb5eb19fa8f5463965bd79e0482b88aa606fbaea458e38", "class_name": "RelatedNodeInfo"}}, "text": "We've not guided beyond FY 2022. ", "start_char_idx": 1773, "end_char_idx": 1806, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3cdab136-1c39-43ff-b29e-cb26843e06e2": {"__data__": {"id_": "3cdab136-1c39-43ff-b29e-cb26843e06e2", "embedding": null, "metadata": {"window": "We're seeing pressures in the labor mar ket.  And so we've talked \nabout the fact that we expect some of these labor pressures to find their way into operating expenses in the \nsecond half of the year, $0.10 to $0.20.  We've not guided beyond FY 2022.  We'll obviously assess if we think that \nthose co sts are going to be sustained at any way.  At this point we just see a $0.10 to $0.20 impact in our US \ndistribution businesses in the second half.  And what we've seen so far in the third quarter it's tracking right in line \nwith that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "We'll obviously assess if we think that \nthose co sts are going to be sustained at any way. ", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0bc2914-1a28-4a02-aa06-32ec80578111", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f8450850550bfb80c662544f537a2ae330be8d221c2a8da7320264cba785aa4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "821b7432-6582-4f0b-a083-faec7bc4dadd", "node_type": "1", "metadata": {"window": "And of course, this is a very challenging market.  We're seeing pressures in the labor mar ket.  And so we've talked \nabout the fact that we expect some of these labor pressures to find their way into operating expenses in the \nsecond half of the year, $0.10 to $0.20.  We've not guided beyond FY 2022.  We'll obviously assess if we think that \nthose co sts are going to be sustained at any way.  At this point we just see a $0.10 to $0.20 impact in our US \ndistribution businesses in the second half.  And what we've seen so far in the third quarter it's tracking right in line \nwith that.  \n ", "original_text": "We've not guided beyond FY 2022. ", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3cf43ff845c6615ad603a0e60aec4a1389934e41a5e1dbca0d427dbbfca5ee9f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8bd7737d-b8d9-4cc0-b2f3-3270820f2c2e", "node_type": "1", "metadata": {"window": "And so we've talked \nabout the fact that we expect some of these labor pressures to find their way into operating expenses in the \nsecond half of the year, $0.10 to $0.20.  We've not guided beyond FY 2022.  We'll obviously assess if we think that \nthose co sts are going to be sustained at any way.  At this point we just see a $0.10 to $0.20 impact in our US \ndistribution businesses in the second half.  And what we've seen so far in the third quarter it's tracking right in line \nwith that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "At this point we just see a $0.10 to $0.20 impact in our US \ndistribution businesses in the second half. "}, "hash": "282ae6574a32c9af8399dfb56cda13f8357d9a1e1892fed46f402edf0d93caf5", "class_name": "RelatedNodeInfo"}}, "text": "We'll obviously assess if we think that \nthose co sts are going to be sustained at any way. ", "start_char_idx": 1806, "end_char_idx": 1898, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8bd7737d-b8d9-4cc0-b2f3-3270820f2c2e": {"__data__": {"id_": "8bd7737d-b8d9-4cc0-b2f3-3270820f2c2e", "embedding": null, "metadata": {"window": "And so we've talked \nabout the fact that we expect some of these labor pressures to find their way into operating expenses in the \nsecond half of the year, $0.10 to $0.20.  We've not guided beyond FY 2022.  We'll obviously assess if we think that \nthose co sts are going to be sustained at any way.  At this point we just see a $0.10 to $0.20 impact in our US \ndistribution businesses in the second half.  And what we've seen so far in the third quarter it's tracking right in line \nwith that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "At this point we just see a $0.10 to $0.20 impact in our US \ndistribution businesses in the second half. ", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0bc2914-1a28-4a02-aa06-32ec80578111", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f8450850550bfb80c662544f537a2ae330be8d221c2a8da7320264cba785aa4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3cdab136-1c39-43ff-b29e-cb26843e06e2", "node_type": "1", "metadata": {"window": "We're seeing pressures in the labor mar ket.  And so we've talked \nabout the fact that we expect some of these labor pressures to find their way into operating expenses in the \nsecond half of the year, $0.10 to $0.20.  We've not guided beyond FY 2022.  We'll obviously assess if we think that \nthose co sts are going to be sustained at any way.  At this point we just see a $0.10 to $0.20 impact in our US \ndistribution businesses in the second half.  And what we've seen so far in the third quarter it's tracking right in line \nwith that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "We'll obviously assess if we think that \nthose co sts are going to be sustained at any way. ", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3fcb1b01262cbd00e7b4e67819c10be4e37ac3cd25cdf75960ce3794127d5726", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "74eb880f-fc23-499b-91a0-afc8786a5df9", "node_type": "1", "metadata": {"window": "We've not guided beyond FY 2022.  We'll obviously assess if we think that \nthose co sts are going to be sustained at any way.  At this point we just see a $0.10 to $0.20 impact in our US \ndistribution businesses in the second half.  And what we've seen so far in the third quarter it's tracking right in line \nwith that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  We'll stay on top of the market. ", "original_text": "And what we've seen so far in the third quarter it's tracking right in line \nwith that.  \n "}, "hash": "d7e5fe003e5c0370851bfd198b47abc08bca3557d6497ed9e0a21eef2fe587e7", "class_name": "RelatedNodeInfo"}}, "text": "At this point we just see a $0.10 to $0.20 impact in our US \ndistribution businesses in the second half. ", "start_char_idx": 1898, "end_char_idx": 2003, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "74eb880f-fc23-499b-91a0-afc8786a5df9": {"__data__": {"id_": "74eb880f-fc23-499b-91a0-afc8786a5df9", "embedding": null, "metadata": {"window": "We've not guided beyond FY 2022.  We'll obviously assess if we think that \nthose co sts are going to be sustained at any way.  At this point we just see a $0.10 to $0.20 impact in our US \ndistribution businesses in the second half.  And what we've seen so far in the third quarter it's tracking right in line \nwith that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  We'll stay on top of the market. ", "original_text": "And what we've seen so far in the third quarter it's tracking right in line \nwith that.  \n ", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0bc2914-1a28-4a02-aa06-32ec80578111", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f8450850550bfb80c662544f537a2ae330be8d221c2a8da7320264cba785aa4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8bd7737d-b8d9-4cc0-b2f3-3270820f2c2e", "node_type": "1", "metadata": {"window": "And so we've talked \nabout the fact that we expect some of these labor pressures to find their way into operating expenses in the \nsecond half of the year, $0.10 to $0.20.  We've not guided beyond FY 2022.  We'll obviously assess if we think that \nthose co sts are going to be sustained at any way.  At this point we just see a $0.10 to $0.20 impact in our US \ndistribution businesses in the second half.  And what we've seen so far in the third quarter it's tracking right in line \nwith that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "At this point we just see a $0.10 to $0.20 impact in our US \ndistribution businesses in the second half. ", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b9e6312f0a6f263aeb2660eddfef843cbfac7b356629d7f90267d292f4e0c467", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b3b33047-e393-4a7a-91ea-ecac7ab9bf5d", "node_type": "1", "metadata": {"window": "We'll obviously assess if we think that \nthose co sts are going to be sustained at any way.  At this point we just see a $0.10 to $0.20 impact in our US \ndistribution businesses in the second half.  And what we've seen so far in the third quarter it's tracking right in line \nwith that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  We'll stay on top of the market.  We'll be responsive to it. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "a7797268445b4bf6ca57b75c3fde695017fa0625f269f0a489ad0357125f405b", "class_name": "RelatedNodeInfo"}}, "text": "And what we've seen so far in the third quarter it's tracking right in line \nwith that.  \n ", "start_char_idx": 2003, "end_char_idx": 2094, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b3b33047-e393-4a7a-91ea-ecac7ab9bf5d": {"__data__": {"id_": "b3b33047-e393-4a7a-91ea-ecac7ab9bf5d", "embedding": null, "metadata": {"window": "We'll obviously assess if we think that \nthose co sts are going to be sustained at any way.  At this point we just see a $0.10 to $0.20 impact in our US \ndistribution businesses in the second half.  And what we've seen so far in the third quarter it's tracking right in line \nwith that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  We'll stay on top of the market.  We'll be responsive to it. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0bc2914-1a28-4a02-aa06-32ec80578111", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f8450850550bfb80c662544f537a2ae330be8d221c2a8da7320264cba785aa4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "74eb880f-fc23-499b-91a0-afc8786a5df9", "node_type": "1", "metadata": {"window": "We've not guided beyond FY 2022.  We'll obviously assess if we think that \nthose co sts are going to be sustained at any way.  At this point we just see a $0.10 to $0.20 impact in our US \ndistribution businesses in the second half.  And what we've seen so far in the third quarter it's tracking right in line \nwith that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  We'll stay on top of the market. ", "original_text": "And what we've seen so far in the third quarter it's tracking right in line \nwith that.  \n ", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "30ec13f829dc26858885b940d5ef2131f52d20e6e4b81a6539e9000bf6de29a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d8022c74-fdd0-4073-af5a-61c2a40edd39", "node_type": "1", "metadata": {"window": "At this point we just see a $0.10 to $0.20 impact in our US \ndistribution businesses in the second half.  And what we've seen so far in the third quarter it's tracking right in line \nwith that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  We'll stay on top of the market.  We'll be responsive to it.  We've got a lot of confidence in our team's ability \nto adjust, and we actually think we've got an asset in terms of the company culture, our p urpose, our mission, the \ninvestments we make in our teams. ", "original_text": "A \nYeah. "}, "hash": "f37a83b869261738b10de052d7f394472bdfb58ec1cc1de02116eafe454eed14", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 2094, "end_char_idx": 2435, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d8022c74-fdd0-4073-af5a-61c2a40edd39": {"__data__": {"id_": "d8022c74-fdd0-4073-af5a-61c2a40edd39", "embedding": null, "metadata": {"window": "At this point we just see a $0.10 to $0.20 impact in our US \ndistribution businesses in the second half.  And what we've seen so far in the third quarter it's tracking right in line \nwith that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  We'll stay on top of the market.  We'll be responsive to it.  We've got a lot of confidence in our team's ability \nto adjust, and we actually think we've got an asset in terms of the company culture, our p urpose, our mission, the \ninvestments we make in our teams. ", "original_text": "A \nYeah. ", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0bc2914-1a28-4a02-aa06-32ec80578111", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f8450850550bfb80c662544f537a2ae330be8d221c2a8da7320264cba785aa4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b3b33047-e393-4a7a-91ea-ecac7ab9bf5d", "node_type": "1", "metadata": {"window": "We'll obviously assess if we think that \nthose co sts are going to be sustained at any way.  At this point we just see a $0.10 to $0.20 impact in our US \ndistribution businesses in the second half.  And what we've seen so far in the third quarter it's tracking right in line \nwith that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  We'll stay on top of the market.  We'll be responsive to it. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b1923c3b30d90863aad447e92c0be0e61f1f14f13c7a3b7d04b3e2396f2cf323", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6b1179b2-8b93-488e-be31-b93527e3307c", "node_type": "1", "metadata": {"window": "And what we've seen so far in the third quarter it's tracking right in line \nwith that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  We'll stay on top of the market.  We'll be responsive to it.  We've got a lot of confidence in our team's ability \nto adjust, and we actually think we've got an asset in terms of the company culture, our p urpose, our mission, the \ninvestments we make in our teams.  We think this is a great place to work, and we'll continue to find ways to \nattract the best talent.  \n ", "original_text": "We'll stay on top of the market. "}, "hash": "aa960ca6aa39fbf6b2a544ec87b480ce901dcfdc86d502f45731fc38a57c6c8d", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah. ", "start_char_idx": 2435, "end_char_idx": 2444, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6b1179b2-8b93-488e-be31-b93527e3307c": {"__data__": {"id_": "6b1179b2-8b93-488e-be31-b93527e3307c", "embedding": null, "metadata": {"window": "And what we've seen so far in the third quarter it's tracking right in line \nwith that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  We'll stay on top of the market.  We'll be responsive to it.  We've got a lot of confidence in our team's ability \nto adjust, and we actually think we've got an asset in terms of the company culture, our p urpose, our mission, the \ninvestments we make in our teams.  We think this is a great place to work, and we'll continue to find ways to \nattract the best talent.  \n ", "original_text": "We'll stay on top of the market. ", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0bc2914-1a28-4a02-aa06-32ec80578111", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f8450850550bfb80c662544f537a2ae330be8d221c2a8da7320264cba785aa4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d8022c74-fdd0-4073-af5a-61c2a40edd39", "node_type": "1", "metadata": {"window": "At this point we just see a $0.10 to $0.20 impact in our US \ndistribution businesses in the second half.  And what we've seen so far in the third quarter it's tracking right in line \nwith that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  We'll stay on top of the market.  We'll be responsive to it.  We've got a lot of confidence in our team's ability \nto adjust, and we actually think we've got an asset in terms of the company culture, our p urpose, our mission, the \ninvestments we make in our teams. ", "original_text": "A \nYeah. ", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f4aff732572e6c37d153f26c12bdbfd3374051a5e25a63a06b23a127e42b6f9a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ed00f4d9-ad17-4127-bec1-7c35a3cad936", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  We'll stay on top of the market.  We'll be responsive to it.  We've got a lot of confidence in our team's ability \nto adjust, and we actually think we've got an asset in terms of the company culture, our p urpose, our mission, the \ninvestments we make in our teams.  We think this is a great place to work, and we'll continue to find ways to \nattract the best talent.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n ", "original_text": "We'll be responsive to it. "}, "hash": "1684a81ab05b13a61e88b6b4e7dec21c43b6de655ee585efe35958b44d1401ea", "class_name": "RelatedNodeInfo"}}, "text": "We'll stay on top of the market. ", "start_char_idx": 2444, "end_char_idx": 2477, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ed00f4d9-ad17-4127-bec1-7c35a3cad936": {"__data__": {"id_": "ed00f4d9-ad17-4127-bec1-7c35a3cad936", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  We'll stay on top of the market.  We'll be responsive to it.  We've got a lot of confidence in our team's ability \nto adjust, and we actually think we've got an asset in terms of the company culture, our p urpose, our mission, the \ninvestments we make in our teams.  We think this is a great place to work, and we'll continue to find ways to \nattract the best talent.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n ", "original_text": "We'll be responsive to it. ", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0bc2914-1a28-4a02-aa06-32ec80578111", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f8450850550bfb80c662544f537a2ae330be8d221c2a8da7320264cba785aa4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6b1179b2-8b93-488e-be31-b93527e3307c", "node_type": "1", "metadata": {"window": "And what we've seen so far in the third quarter it's tracking right in line \nwith that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  We'll stay on top of the market.  We'll be responsive to it.  We've got a lot of confidence in our team's ability \nto adjust, and we actually think we've got an asset in terms of the company culture, our p urpose, our mission, the \ninvestments we make in our teams.  We think this is a great place to work, and we'll continue to find ways to \nattract the best talent.  \n ", "original_text": "We'll stay on top of the market. ", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "98bc1b4fb9e2aa4995799c44aaa62d8cebc87deef6ea536f38e7e93f3e48ba77", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1da0802a-ed0d-4f3b-be7c-0b36e225af39", "node_type": "1", "metadata": {"window": "A \nYeah.  We'll stay on top of the market.  We'll be responsive to it.  We've got a lot of confidence in our team's ability \nto adjust, and we actually think we've got an asset in terms of the company culture, our p urpose, our mission, the \ninvestments we make in our teams.  We think this is a great place to work, and we'll continue to find ways to \nattract the best talent.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with Cowen. ", "original_text": "We've got a lot of confidence in our team's ability \nto adjust, and we actually think we've got an asset in terms of the company culture, our p urpose, our mission, the \ninvestments we make in our teams. "}, "hash": "359d818ece4be69b0beb6e5ee54df1cf9358301bd55d4671de7a6279e90971cd", "class_name": "RelatedNodeInfo"}}, "text": "We'll be responsive to it. ", "start_char_idx": 2477, "end_char_idx": 2504, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1da0802a-ed0d-4f3b-be7c-0b36e225af39": {"__data__": {"id_": "1da0802a-ed0d-4f3b-be7c-0b36e225af39", "embedding": null, "metadata": {"window": "A \nYeah.  We'll stay on top of the market.  We'll be responsive to it.  We've got a lot of confidence in our team's ability \nto adjust, and we actually think we've got an asset in terms of the company culture, our p urpose, our mission, the \ninvestments we make in our teams.  We think this is a great place to work, and we'll continue to find ways to \nattract the best talent.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with Cowen. ", "original_text": "We've got a lot of confidence in our team's ability \nto adjust, and we actually think we've got an asset in terms of the company culture, our p urpose, our mission, the \ninvestments we make in our teams. ", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0bc2914-1a28-4a02-aa06-32ec80578111", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f8450850550bfb80c662544f537a2ae330be8d221c2a8da7320264cba785aa4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ed00f4d9-ad17-4127-bec1-7c35a3cad936", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  We'll stay on top of the market.  We'll be responsive to it.  We've got a lot of confidence in our team's ability \nto adjust, and we actually think we've got an asset in terms of the company culture, our p urpose, our mission, the \ninvestments we make in our teams.  We think this is a great place to work, and we'll continue to find ways to \nattract the best talent.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n ", "original_text": "We'll be responsive to it. ", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dd309041700c3e141d009a73f7fe68fffeca2d4a1ce55b85ed7d60baccb14d96", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "720ca742-f4ff-482e-ae41-871b7f624b4a", "node_type": "1", "metadata": {"window": "We'll stay on top of the market.  We'll be responsive to it.  We've got a lot of confidence in our team's ability \nto adjust, and we actually think we've got an asset in terms of the company culture, our p urpose, our mission, the \ninvestments we make in our teams.  We think this is a great place to work, and we'll continue to find ways to \nattract the best talent.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with Cowen.  Please go ahead.  \n ", "original_text": "We think this is a great place to work, and we'll continue to find ways to \nattract the best talent.  \n "}, "hash": "ca79407228e88dda05434b0e0964d96158753688f1372674f28e396e83ee44c9", "class_name": "RelatedNodeInfo"}}, "text": "We've got a lot of confidence in our team's ability \nto adjust, and we actually think we've got an asset in terms of the company culture, our p urpose, our mission, the \ninvestments we make in our teams. ", "start_char_idx": 2504, "end_char_idx": 2708, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "720ca742-f4ff-482e-ae41-871b7f624b4a": {"__data__": {"id_": "720ca742-f4ff-482e-ae41-871b7f624b4a", "embedding": null, "metadata": {"window": "We'll stay on top of the market.  We'll be responsive to it.  We've got a lot of confidence in our team's ability \nto adjust, and we actually think we've got an asset in terms of the company culture, our p urpose, our mission, the \ninvestments we make in our teams.  We think this is a great place to work, and we'll continue to find ways to \nattract the best talent.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with Cowen.  Please go ahead.  \n ", "original_text": "We think this is a great place to work, and we'll continue to find ways to \nattract the best talent.  \n ", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0bc2914-1a28-4a02-aa06-32ec80578111", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f8450850550bfb80c662544f537a2ae330be8d221c2a8da7320264cba785aa4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1da0802a-ed0d-4f3b-be7c-0b36e225af39", "node_type": "1", "metadata": {"window": "A \nYeah.  We'll stay on top of the market.  We'll be responsive to it.  We've got a lot of confidence in our team's ability \nto adjust, and we actually think we've got an asset in terms of the company culture, our p urpose, our mission, the \ninvestments we make in our teams.  We think this is a great place to work, and we'll continue to find ways to \nattract the best talent.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with Cowen. ", "original_text": "We've got a lot of confidence in our team's ability \nto adjust, and we actually think we've got an asset in terms of the company culture, our p urpose, our mission, the \ninvestments we make in our teams. ", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b829a62c069ab3394d5c632bbcc5a3fb4cfe39722628706dfafeeef495140f28", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c8a18dbf-0c14-4682-a00a-3e21c992bbc7", "node_type": "1", "metadata": {"window": "We'll be responsive to it.  We've got a lot of confidence in our team's ability \nto adjust, and we actually think we've got an asset in terms of the company culture, our p urpose, our mission, the \ninvestments we make in our teams.  We think this is a great place to work, and we'll continue to find ways to \nattract the best talent.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with Cowen.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n "}, "hash": "f949e1dead1451be3d8616d67db315efbb387e7576c2beb8d1d4755748c3f3bd", "class_name": "RelatedNodeInfo"}}, "text": "We think this is a great place to work, and we'll continue to find ways to \nattract the best talent.  \n ", "start_char_idx": 2708, "end_char_idx": 2812, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c8a18dbf-0c14-4682-a00a-3e21c992bbc7": {"__data__": {"id_": "c8a18dbf-0c14-4682-a00a-3e21c992bbc7", "embedding": null, "metadata": {"window": "We'll be responsive to it.  We've got a lot of confidence in our team's ability \nto adjust, and we actually think we've got an asset in terms of the company culture, our p urpose, our mission, the \ninvestments we make in our teams.  We think this is a great place to work, and we'll continue to find ways to \nattract the best talent.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with Cowen.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n ", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0bc2914-1a28-4a02-aa06-32ec80578111", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f8450850550bfb80c662544f537a2ae330be8d221c2a8da7320264cba785aa4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "720ca742-f4ff-482e-ae41-871b7f624b4a", "node_type": "1", "metadata": {"window": "We'll stay on top of the market.  We'll be responsive to it.  We've got a lot of confidence in our team's ability \nto adjust, and we actually think we've got an asset in terms of the company culture, our p urpose, our mission, the \ninvestments we make in our teams.  We think this is a great place to work, and we'll continue to find ways to \nattract the best talent.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with Cowen.  Please go ahead.  \n ", "original_text": "We think this is a great place to work, and we'll continue to find ways to \nattract the best talent.  \n ", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d6183e5d5401010f7e9b278f0d152b7d3b19216814713f14fcbf0832013c6a64", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b2e2b0f5-8400-46a0-a606-16db4c4299a4", "node_type": "1", "metadata": {"window": "We've got a lot of confidence in our team's ability \nto adjust, and we actually think we've got an asset in terms of the company culture, our p urpose, our mission, the \ninvestments we make in our teams.  We think this is a great place to work, and we'll continue to find ways to \nattract the best talent.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with Cowen.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with Cowen. "}, "hash": "4ef120e3b390a46dca9323e71a284718a7f7b5c9759a260750458c01ab0a6e42", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n ", "start_char_idx": 2812, "end_char_idx": 3175, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b2e2b0f5-8400-46a0-a606-16db4c4299a4": {"__data__": {"id_": "b2e2b0f5-8400-46a0-a606-16db4c4299a4", "embedding": null, "metadata": {"window": "We've got a lot of confidence in our team's ability \nto adjust, and we actually think we've got an asset in terms of the company culture, our p urpose, our mission, the \ninvestments we make in our teams.  We think this is a great place to work, and we'll continue to find ways to \nattract the best talent.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with Cowen.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with Cowen. ", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0bc2914-1a28-4a02-aa06-32ec80578111", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f8450850550bfb80c662544f537a2ae330be8d221c2a8da7320264cba785aa4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c8a18dbf-0c14-4682-a00a-3e21c992bbc7", "node_type": "1", "metadata": {"window": "We'll be responsive to it.  We've got a lot of confidence in our team's ability \nto adjust, and we actually think we've got an asset in terms of the company culture, our p urpose, our mission, the \ninvestments we make in our teams.  We think this is a great place to work, and we'll continue to find ways to \nattract the best talent.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with Cowen.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n ", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e9d8e2ba85399801e9a2ce3d83e4ac3de2f50bb067575729f168267188d1b7b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6665f588-869c-4c6d-9f7f-916790e9f899", "node_type": "1", "metadata": {"window": "We think this is a great place to work, and we'll continue to find ways to \nattract the best talent.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with Cowen.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Hey. ", "original_text": "Please go ahead.  \n "}, "hash": "fff4839b84f63f440cc506a000082a5aeebedaecb956b4447b1742bb8d8e01d9", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with Cowen. ", "start_char_idx": 3175, "end_char_idx": 3503, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6665f588-869c-4c6d-9f7f-916790e9f899": {"__data__": {"id_": "6665f588-869c-4c6d-9f7f-916790e9f899", "embedding": null, "metadata": {"window": "We think this is a great place to work, and we'll continue to find ways to \nattract the best talent.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with Cowen.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Hey. ", "original_text": "Please go ahead.  \n ", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0bc2914-1a28-4a02-aa06-32ec80578111", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f8450850550bfb80c662544f537a2ae330be8d221c2a8da7320264cba785aa4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b2e2b0f5-8400-46a0-a606-16db4c4299a4", "node_type": "1", "metadata": {"window": "We've got a lot of confidence in our team's ability \nto adjust, and we actually think we've got an asset in terms of the company culture, our p urpose, our mission, the \ninvestments we make in our teams.  We think this is a great place to work, and we'll continue to find ways to \nattract the best talent.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with Cowen.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with Cowen. ", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0fce4001ee485e0fe6c327352aaf695ad16636b0792e0a17d0bdef2378f8bf40", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2f2d7cd0-92f9-420d-a80e-9715c6bb8554", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with Cowen.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Hey.  Thanks for taking the question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co. "}, "hash": "0a381e53dc7a0770d55a20d7db323dbb421a1cb1f424d102730d771834ec9b37", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n ", "start_char_idx": 3503, "end_char_idx": 3523, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2f2d7cd0-92f9-420d-a80e-9715c6bb8554": {"__data__": {"id_": "2f2d7cd0-92f9-420d-a80e-9715c6bb8554", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with Cowen.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Hey.  Thanks for taking the question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0bc2914-1a28-4a02-aa06-32ec80578111", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f8450850550bfb80c662544f537a2ae330be8d221c2a8da7320264cba785aa4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6665f588-869c-4c6d-9f7f-916790e9f899", "node_type": "1", "metadata": {"window": "We think this is a great place to work, and we'll continue to find ways to \nattract the best talent.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with Cowen.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Hey. ", "original_text": "Please go ahead.  \n ", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0cec633fe2a61269f0b86b9f7593798fd5e30dda4e24679c9f686a3f6d92cf3b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e62f5765-bb7a-4ea2-afd4-db151608002d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with Cowen.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Hey.  Thanks for taking the question.  Britt, you talked earlier in your prepared comments about \u2013 in the \nPharma (sic) [Prescription] Tech nology Solutions segment about access to medications, and you highlighted a \ncouple businesses. ", "original_text": "LLC  Q \nYeah. "}, "hash": "31556bbc7e263c97ba047e5eff6b5d47f01ad8099832e8421d90a5e8feea66e5", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "start_char_idx": 3523, "end_char_idx": 3832, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e62f5765-bb7a-4ea2-afd4-db151608002d": {"__data__": {"id_": "e62f5765-bb7a-4ea2-afd4-db151608002d", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with Cowen.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Hey.  Thanks for taking the question.  Britt, you talked earlier in your prepared comments about \u2013 in the \nPharma (sic) [Prescription] Tech nology Solutions segment about access to medications, and you highlighted a \ncouple businesses. ", "original_text": "LLC  Q \nYeah. ", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0bc2914-1a28-4a02-aa06-32ec80578111", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f8450850550bfb80c662544f537a2ae330be8d221c2a8da7320264cba785aa4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2f2d7cd0-92f9-420d-a80e-9715c6bb8554", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with Cowen.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Hey.  Thanks for taking the question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1b5ad3ca3c39ab73d0876ef7dd0f3ae288c5e80faf27e16c2e40b7a3896da047", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f88a158d-ad86-4e15-b962-62e4148eff42", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Hey.  Thanks for taking the question.  Britt, you talked earlier in your prepared comments about \u2013 in the \nPharma (sic) [Prescription] Tech nology Solutions segment about access to medications, and you highlighted a \ncouple businesses.  You mentioned a $15 billion market opportunity here. ", "original_text": "Hey. "}, "hash": "5b603e0c7b44b87b3a4b0b32214e603de2c806944f5d23de0ba945c1b5a5ac0a", "class_name": "RelatedNodeInfo"}}, "text": "LLC  Q \nYeah. ", "start_char_idx": 3832, "end_char_idx": 3846, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f88a158d-ad86-4e15-b962-62e4148eff42": {"__data__": {"id_": "f88a158d-ad86-4e15-b962-62e4148eff42", "embedding": null, "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Hey.  Thanks for taking the question.  Britt, you talked earlier in your prepared comments about \u2013 in the \nPharma (sic) [Prescription] Tech nology Solutions segment about access to medications, and you highlighted a \ncouple businesses.  You mentioned a $15 billion market opportunity here. ", "original_text": "Hey. ", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0bc2914-1a28-4a02-aa06-32ec80578111", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f8450850550bfb80c662544f537a2ae330be8d221c2a8da7320264cba785aa4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e62f5765-bb7a-4ea2-afd4-db151608002d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Charles Rhyee with Cowen.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Hey.  Thanks for taking the question.  Britt, you talked earlier in your prepared comments about \u2013 in the \nPharma (sic) [Prescription] Tech nology Solutions segment about access to medications, and you highlighted a \ncouple businesses. ", "original_text": "LLC  Q \nYeah. ", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1154fccf22bcd91ee72816b30a7225c561f1d76bdb4832782c0f47304078339c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b60c3b6-add8-4648-b5ce-736b564d747b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Hey.  Thanks for taking the question.  Britt, you talked earlier in your prepared comments about \u2013 in the \nPharma (sic) [Prescription] Tech nology Solutions segment about access to medications, and you highlighted a \ncouple businesses.  You mentioned a $15 billion market opportunity here.  Maybe if you can just give us a little \nmore details around sort of your position in the market, in this part  of the market particularly? ", "original_text": "Thanks for taking the question. "}, "hash": "6442e61151f54b11eda9401ac653702741ee8e24440e2d91b962a25adf0dc1e4", "class_name": "RelatedNodeInfo"}}, "text": "Hey. ", "start_char_idx": 3846, "end_char_idx": 3851, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b60c3b6-add8-4648-b5ce-736b564d747b": {"__data__": {"id_": "0b60c3b6-add8-4648-b5ce-736b564d747b", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Hey.  Thanks for taking the question.  Britt, you talked earlier in your prepared comments about \u2013 in the \nPharma (sic) [Prescription] Tech nology Solutions segment about access to medications, and you highlighted a \ncouple businesses.  You mentioned a $15 billion market opportunity here.  Maybe if you can just give us a little \nmore details around sort of your position in the market, in this part  of the market particularly? ", "original_text": "Thanks for taking the question. ", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0bc2914-1a28-4a02-aa06-32ec80578111", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f8450850550bfb80c662544f537a2ae330be8d221c2a8da7320264cba785aa4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f88a158d-ad86-4e15-b962-62e4148eff42", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Hey.  Thanks for taking the question.  Britt, you talked earlier in your prepared comments about \u2013 in the \nPharma (sic) [Prescription] Tech nology Solutions segment about access to medications, and you highlighted a \ncouple businesses.  You mentioned a $15 billion market opportunity here. ", "original_text": "Hey. ", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a77a6ca04d4a3bed4cb7a5a8b69b7a8eae799e2642f363be6f9aa2f1c599ca63", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e073c53d-d7a8-4fc0-80a4-81281798561d", "node_type": "1", "metadata": {"window": "LLC  Q \nYeah.  Hey.  Thanks for taking the question.  Britt, you talked earlier in your prepared comments about \u2013 in the \nPharma (sic) [Prescription] Tech nology Solutions segment about access to medications, and you highlighted a \ncouple businesses.  You mentioned a $15 billion market opportunity here.  Maybe if you can just give us a little \nmore details around sort of your position in the market, in this part  of the market particularly?  And what is the \ncompetitive landscape? ", "original_text": "Britt, you talked earlier in your prepared comments about \u2013 in the \nPharma (sic) [Prescription] Tech nology Solutions segment about access to medications, and you highlighted a \ncouple businesses. "}, "hash": "3823f7bae48ac66e998d84c257c4ae3d0c72940b0419a7e5c24c49392b8b2897", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for taking the question. ", "start_char_idx": 3851, "end_char_idx": 3883, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e073c53d-d7a8-4fc0-80a4-81281798561d": {"__data__": {"id_": "e073c53d-d7a8-4fc0-80a4-81281798561d", "embedding": null, "metadata": {"window": "LLC  Q \nYeah.  Hey.  Thanks for taking the question.  Britt, you talked earlier in your prepared comments about \u2013 in the \nPharma (sic) [Prescription] Tech nology Solutions segment about access to medications, and you highlighted a \ncouple businesses.  You mentioned a $15 billion market opportunity here.  Maybe if you can just give us a little \nmore details around sort of your position in the market, in this part  of the market particularly?  And what is the \ncompetitive landscape? ", "original_text": "Britt, you talked earlier in your prepared comments about \u2013 in the \nPharma (sic) [Prescription] Tech nology Solutions segment about access to medications, and you highlighted a \ncouple businesses. ", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0bc2914-1a28-4a02-aa06-32ec80578111", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f8450850550bfb80c662544f537a2ae330be8d221c2a8da7320264cba785aa4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b60c3b6-add8-4648-b5ce-736b564d747b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Hey.  Thanks for taking the question.  Britt, you talked earlier in your prepared comments about \u2013 in the \nPharma (sic) [Prescription] Tech nology Solutions segment about access to medications, and you highlighted a \ncouple businesses.  You mentioned a $15 billion market opportunity here.  Maybe if you can just give us a little \nmore details around sort of your position in the market, in this part  of the market particularly? ", "original_text": "Thanks for taking the question. ", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7f2cf102db0b08d8680fa798fff92a2e06c4316f8d1908c7bdf7147098e2d3d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "576dada0-f453-4d3e-9de0-4f7537d7e321", "node_type": "1", "metadata": {"window": "Hey.  Thanks for taking the question.  Britt, you talked earlier in your prepared comments about \u2013 in the \nPharma (sic) [Prescription] Tech nology Solutions segment about access to medications, and you highlighted a \ncouple businesses.  You mentioned a $15 billion market opportunity here.  Maybe if you can just give us a little \nmore details around sort of your position in the market, in this part  of the market particularly?  And what is the \ncompetitive landscape?  And do you see an opportunity here for McKesson to consolidate this industry?  \n ", "original_text": "You mentioned a $15 billion market opportunity here. "}, "hash": "4e10e8ad37bb081df75345c7d73b46877da7ea91748d2ec089c5dd00a365cba4", "class_name": "RelatedNodeInfo"}}, "text": "Britt, you talked earlier in your prepared comments about \u2013 in the \nPharma (sic) [Prescription] Tech nology Solutions segment about access to medications, and you highlighted a \ncouple businesses. ", "start_char_idx": 3883, "end_char_idx": 4080, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "576dada0-f453-4d3e-9de0-4f7537d7e321": {"__data__": {"id_": "576dada0-f453-4d3e-9de0-4f7537d7e321", "embedding": null, "metadata": {"window": "Hey.  Thanks for taking the question.  Britt, you talked earlier in your prepared comments about \u2013 in the \nPharma (sic) [Prescription] Tech nology Solutions segment about access to medications, and you highlighted a \ncouple businesses.  You mentioned a $15 billion market opportunity here.  Maybe if you can just give us a little \nmore details around sort of your position in the market, in this part  of the market particularly?  And what is the \ncompetitive landscape?  And do you see an opportunity here for McKesson to consolidate this industry?  \n ", "original_text": "You mentioned a $15 billion market opportunity here. ", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0bc2914-1a28-4a02-aa06-32ec80578111", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f8450850550bfb80c662544f537a2ae330be8d221c2a8da7320264cba785aa4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e073c53d-d7a8-4fc0-80a4-81281798561d", "node_type": "1", "metadata": {"window": "LLC  Q \nYeah.  Hey.  Thanks for taking the question.  Britt, you talked earlier in your prepared comments about \u2013 in the \nPharma (sic) [Prescription] Tech nology Solutions segment about access to medications, and you highlighted a \ncouple businesses.  You mentioned a $15 billion market opportunity here.  Maybe if you can just give us a little \nmore details around sort of your position in the market, in this part  of the market particularly?  And what is the \ncompetitive landscape? ", "original_text": "Britt, you talked earlier in your prepared comments about \u2013 in the \nPharma (sic) [Prescription] Tech nology Solutions segment about access to medications, and you highlighted a \ncouple businesses. ", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "84c726797cb0655eac6380fd0f135009272801547588a142cd9ed6271263b6c3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9048b87a-4137-415a-bcff-3d2c29e5c6d1", "node_type": "1", "metadata": {"window": "Thanks for taking the question.  Britt, you talked earlier in your prepared comments about \u2013 in the \nPharma (sic) [Prescription] Tech nology Solutions segment about access to medications, and you highlighted a \ncouple businesses.  You mentioned a $15 billion market opportunity here.  Maybe if you can just give us a little \nmore details around sort of your position in the market, in this part  of the market particularly?  And what is the \ncompetitive landscape?  And do you see an opportunity here for McKesson to consolidate this industry?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "Maybe if you can just give us a little \nmore details around sort of your position in the market, in this part  of the market particularly? "}, "hash": "1fdf9eb7d0ce648b091217ffa796da8e9e0948cfcc0ab0a6d035a12620f248c2", "class_name": "RelatedNodeInfo"}}, "text": "You mentioned a $15 billion market opportunity here. ", "start_char_idx": 4080, "end_char_idx": 4133, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9048b87a-4137-415a-bcff-3d2c29e5c6d1": {"__data__": {"id_": "9048b87a-4137-415a-bcff-3d2c29e5c6d1", "embedding": null, "metadata": {"window": "Thanks for taking the question.  Britt, you talked earlier in your prepared comments about \u2013 in the \nPharma (sic) [Prescription] Tech nology Solutions segment about access to medications, and you highlighted a \ncouple businesses.  You mentioned a $15 billion market opportunity here.  Maybe if you can just give us a little \nmore details around sort of your position in the market, in this part  of the market particularly?  And what is the \ncompetitive landscape?  And do you see an opportunity here for McKesson to consolidate this industry?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "Maybe if you can just give us a little \nmore details around sort of your position in the market, in this part  of the market particularly? ", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0bc2914-1a28-4a02-aa06-32ec80578111", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f8450850550bfb80c662544f537a2ae330be8d221c2a8da7320264cba785aa4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "576dada0-f453-4d3e-9de0-4f7537d7e321", "node_type": "1", "metadata": {"window": "Hey.  Thanks for taking the question.  Britt, you talked earlier in your prepared comments about \u2013 in the \nPharma (sic) [Prescription] Tech nology Solutions segment about access to medications, and you highlighted a \ncouple businesses.  You mentioned a $15 billion market opportunity here.  Maybe if you can just give us a little \nmore details around sort of your position in the market, in this part  of the market particularly?  And what is the \ncompetitive landscape?  And do you see an opportunity here for McKesson to consolidate this industry?  \n ", "original_text": "You mentioned a $15 billion market opportunity here. ", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b729c8cc28924ef8632dd8828d84adfdefb14c528c489160c02f2975de5c2007", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d1cb13f3-0392-4e9d-9ca1-77ef214da619", "node_type": "1", "metadata": {"window": "Britt, you talked earlier in your prepared comments about \u2013 in the \nPharma (sic) [Prescription] Tech nology Solutions segment about access to medications, and you highlighted a \ncouple businesses.  You mentioned a $15 billion market opportunity here.  Maybe if you can just give us a little \nmore details around sort of your position in the market, in this part  of the market particularly?  And what is the \ncompetitive landscape?  And do you see an opportunity here for McKesson to consolidate this industry?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "And what is the \ncompetitive landscape? "}, "hash": "4d73d9d4475ccd347002113951f2018a29008f5de9a123dc03edc1f7e6646ae0", "class_name": "RelatedNodeInfo"}}, "text": "Maybe if you can just give us a little \nmore details around sort of your position in the market, in this part  of the market particularly? ", "start_char_idx": 4133, "end_char_idx": 4272, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d1cb13f3-0392-4e9d-9ca1-77ef214da619": {"__data__": {"id_": "d1cb13f3-0392-4e9d-9ca1-77ef214da619", "embedding": null, "metadata": {"window": "Britt, you talked earlier in your prepared comments about \u2013 in the \nPharma (sic) [Prescription] Tech nology Solutions segment about access to medications, and you highlighted a \ncouple businesses.  You mentioned a $15 billion market opportunity here.  Maybe if you can just give us a little \nmore details around sort of your position in the market, in this part  of the market particularly?  And what is the \ncompetitive landscape?  And do you see an opportunity here for McKesson to consolidate this industry?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "And what is the \ncompetitive landscape? ", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0bc2914-1a28-4a02-aa06-32ec80578111", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f8450850550bfb80c662544f537a2ae330be8d221c2a8da7320264cba785aa4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9048b87a-4137-415a-bcff-3d2c29e5c6d1", "node_type": "1", "metadata": {"window": "Thanks for taking the question.  Britt, you talked earlier in your prepared comments about \u2013 in the \nPharma (sic) [Prescription] Tech nology Solutions segment about access to medications, and you highlighted a \ncouple businesses.  You mentioned a $15 billion market opportunity here.  Maybe if you can just give us a little \nmore details around sort of your position in the market, in this part  of the market particularly?  And what is the \ncompetitive landscape?  And do you see an opportunity here for McKesson to consolidate this industry?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "Maybe if you can just give us a little \nmore details around sort of your position in the market, in this part  of the market particularly? ", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c7224a282a5303242fd601e4d3b2bd8d1929f96addadae97f6200cb0ba98ee13", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "755f080c-77ff-41fc-8ea9-de406873ea2f", "node_type": "1", "metadata": {"window": "You mentioned a $15 billion market opportunity here.  Maybe if you can just give us a little \nmore details around sort of your position in the market, in this part  of the market particularly?  And what is the \ncompetitive landscape?  And do you see an opportunity here for McKesson to consolidate this industry?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "And do you see an opportunity here for McKesson to consolidate this industry?  \n "}, "hash": "63b9656d805bfad1d933779fc224cb68879e303b5f47dd77dd98f3999dec704a", "class_name": "RelatedNodeInfo"}}, "text": "And what is the \ncompetitive landscape? ", "start_char_idx": 4272, "end_char_idx": 4312, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "755f080c-77ff-41fc-8ea9-de406873ea2f": {"__data__": {"id_": "755f080c-77ff-41fc-8ea9-de406873ea2f", "embedding": null, "metadata": {"window": "You mentioned a $15 billion market opportunity here.  Maybe if you can just give us a little \nmore details around sort of your position in the market, in this part  of the market particularly?  And what is the \ncompetitive landscape?  And do you see an opportunity here for McKesson to consolidate this industry?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "And do you see an opportunity here for McKesson to consolidate this industry?  \n ", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0bc2914-1a28-4a02-aa06-32ec80578111", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f8450850550bfb80c662544f537a2ae330be8d221c2a8da7320264cba785aa4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d1cb13f3-0392-4e9d-9ca1-77ef214da619", "node_type": "1", "metadata": {"window": "Britt, you talked earlier in your prepared comments about \u2013 in the \nPharma (sic) [Prescription] Tech nology Solutions segment about access to medications, and you highlighted a \ncouple businesses.  You mentioned a $15 billion market opportunity here.  Maybe if you can just give us a little \nmore details around sort of your position in the market, in this part  of the market particularly?  And what is the \ncompetitive landscape?  And do you see an opportunity here for McKesson to consolidate this industry?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "And what is the \ncompetitive landscape? ", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dcd40fe8d9c63b7a5eb6e4e7a51eb5dbd7b240f5af05ca60a88e6e325d65b6ea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ae5567d-1672-4136-b2d4-9857b3cbc113", "node_type": "1", "metadata": {"window": "Maybe if you can just give us a little \nmore details around sort of your position in the market, in this part  of the market particularly?  And what is the \ncompetitive landscape?  And do you see an opportunity here for McKesson to consolidate this industry?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  "}, "hash": "6da7a1fd8c3d573c816c5c4a5a66a38e032611e29cceba326545c8d3edd683d7", "class_name": "RelatedNodeInfo"}}, "text": "And do you see an opportunity here for McKesson to consolidate this industry?  \n ", "start_char_idx": 4312, "end_char_idx": 4393, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0ae5567d-1672-4136-b2d4-9857b3cbc113": {"__data__": {"id_": "0ae5567d-1672-4136-b2d4-9857b3cbc113", "embedding": null, "metadata": {"window": "Maybe if you can just give us a little \nmore details around sort of your position in the market, in this part  of the market particularly?  And what is the \ncompetitive landscape?  And do you see an opportunity here for McKesson to consolidate this industry?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c0bc2914-1a28-4a02-aa06-32ec80578111", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f8450850550bfb80c662544f537a2ae330be8d221c2a8da7320264cba785aa4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "755f080c-77ff-41fc-8ea9-de406873ea2f", "node_type": "1", "metadata": {"window": "You mentioned a $15 billion market opportunity here.  Maybe if you can just give us a little \nmore details around sort of your position in the market, in this part  of the market particularly?  And what is the \ncompetitive landscape?  And do you see an opportunity here for McKesson to consolidate this industry?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "And do you see an opportunity here for McKesson to consolidate this industry?  \n ", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "82f37bcb12eeee0008da49d2565fb55624edaa948c62b80f94d22b8571c50aba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "17a98fc6-9805-44c7-ae14-0d4d3ae71367", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you for the question.  I think you  addressed it to Britt, but I'll jump in and start with my thoughts. ", "original_text": "McKesson Corp.  "}, "hash": "8163cfc87c03f8963c73682f7455f7f3931a406103d95a25054ab4d934a102a0", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "start_char_idx": 2094, "end_char_idx": 2365, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "17a98fc6-9805-44c7-ae14-0d4d3ae71367": {"__data__": {"id_": "17a98fc6-9805-44c7-ae14-0d4d3ae71367", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you for the question.  I think you  addressed it to Britt, but I'll jump in and start with my thoughts. ", "original_text": "McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc629de4-825c-4a81-8fe5-d4c62e367c38", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ae7f25de25af20cb283d7ffa58afdb15c062ec247254da5a21a74d863dc9d50", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0ae5567d-1672-4136-b2d4-9857b3cbc113", "node_type": "1", "metadata": {"window": "Maybe if you can just give us a little \nmore details around sort of your position in the market, in this part  of the market particularly?  And what is the \ncompetitive landscape?  And do you see an opportunity here for McKesson to consolidate this industry?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bf15bb7d1d51088151b2978b91be46e7589f104a0343d3b51a3d00e4b4aa05ed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7b292413-525f-4cf7-aef8-711bac157454", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you for the question.  I think you  addressed it to Britt, but I'll jump in and start with my thoughts.  I mean, so \nthis \u2013 we think we're extremely well -positioned in this marketplace, and one of the things when we're anchoring \nour growth strategies we try to anchor around is making sure we have differentiation, that we have things that are \ndifficult to replicate. ", "original_text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "ea7836ff1428b8b77d2afb413f8c22dc4435895c51b54952956ddcf0ddcfa962", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7b292413-525f-4cf7-aef8-711bac157454": {"__data__": {"id_": "7b292413-525f-4cf7-aef8-711bac157454", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you for the question.  I think you  addressed it to Britt, but I'll jump in and start with my thoughts.  I mean, so \nthis \u2013 we think we're extremely well -positioned in this marketplace, and one of the things when we're anchoring \nour growth strategies we try to anchor around is making sure we have differentiation, that we have things that are \ndifficult to replicate. ", "original_text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc629de4-825c-4a81-8fe5-d4c62e367c38", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ae7f25de25af20cb283d7ffa58afdb15c062ec247254da5a21a74d863dc9d50", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "17a98fc6-9805-44c7-ae14-0d4d3ae71367", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you for the question.  I think you  addressed it to Britt, but I'll jump in and start with my thoughts. ", "original_text": "McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fcbe3762b715daf99aa372b374e5898ef830599ef07437772792d7bef06c5ed7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "48aec9a1-8eeb-4a4e-8d9b-7bfe3daa4951", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you for the question.  I think you  addressed it to Britt, but I'll jump in and start with my thoughts.  I mean, so \nthis \u2013 we think we're extremely well -positioned in this marketplace, and one of the things when we're anchoring \nour growth strategies we try to anchor around is making sure we have differentiation, that we have things that are \ndifficult to replicate.  And the reason we brought these businesses together as a segment is because we think \nindividually they all had their strengths and were winning in their market, but collectively tog ether, accessing the \nreach of our networks, utilizing the advanced technologies we have in CoverMyMeds and then the clinical \nexpertise and the biopharma relationships we had in RxCrossroads, that they kind of reinforce and compound \neach other.  \n \n", "original_text": "A \nThank you for the question. "}, "hash": "2345c7abe713d2248539e3b62de382cd1b61b81b745724667e37c7c28c7e9d17", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 16, "end_char_idx": 250, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "48aec9a1-8eeb-4a4e-8d9b-7bfe3daa4951": {"__data__": {"id_": "48aec9a1-8eeb-4a4e-8d9b-7bfe3daa4951", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you for the question.  I think you  addressed it to Britt, but I'll jump in and start with my thoughts.  I mean, so \nthis \u2013 we think we're extremely well -positioned in this marketplace, and one of the things when we're anchoring \nour growth strategies we try to anchor around is making sure we have differentiation, that we have things that are \ndifficult to replicate.  And the reason we brought these businesses together as a segment is because we think \nindividually they all had their strengths and were winning in their market, but collectively tog ether, accessing the \nreach of our networks, utilizing the advanced technologies we have in CoverMyMeds and then the clinical \nexpertise and the biopharma relationships we had in RxCrossroads, that they kind of reinforce and compound \neach other.  \n \n", "original_text": "A \nThank you for the question. ", "page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc629de4-825c-4a81-8fe5-d4c62e367c38", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ae7f25de25af20cb283d7ffa58afdb15c062ec247254da5a21a74d863dc9d50", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7b292413-525f-4cf7-aef8-711bac157454", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you for the question.  I think you  addressed it to Britt, but I'll jump in and start with my thoughts.  I mean, so \nthis \u2013 we think we're extremely well -positioned in this marketplace, and one of the things when we're anchoring \nour growth strategies we try to anchor around is making sure we have differentiation, that we have things that are \ndifficult to replicate. ", "original_text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2b1f8e8063305567ab1bd9849bf59fc35c709738b1f3acf9036e6097cb92d5e9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "528ba616-910a-4bbf-8b37-24a0570f01e8", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you for the question.  I think you  addressed it to Britt, but I'll jump in and start with my thoughts.  I mean, so \nthis \u2013 we think we're extremely well -positioned in this marketplace, and one of the things when we're anchoring \nour growth strategies we try to anchor around is making sure we have differentiation, that we have things that are \ndifficult to replicate.  And the reason we brought these businesses together as a segment is because we think \nindividually they all had their strengths and were winning in their market, but collectively tog ether, accessing the \nreach of our networks, utilizing the advanced technologies we have in CoverMyMeds and then the clinical \nexpertise and the biopharma relationships we had in RxCrossroads, that they kind of reinforce and compound \neach other.  \n \n And so, whe n we think about the access is a distinct market, adherence is a distinct market, outcomes is a distinct \nmarket; but putting these together, it allows us to really more effectively compete across all of those. ", "original_text": "I think you  addressed it to Britt, but I'll jump in and start with my thoughts. "}, "hash": "b515fab5680c5f482579621f2d77453ffd8b3169dcaf19299b51b5b8c7e626d6", "class_name": "RelatedNodeInfo"}}, "text": "A \nThank you for the question. ", "start_char_idx": 250, "end_char_idx": 281, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "528ba616-910a-4bbf-8b37-24a0570f01e8": {"__data__": {"id_": "528ba616-910a-4bbf-8b37-24a0570f01e8", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you for the question.  I think you  addressed it to Britt, but I'll jump in and start with my thoughts.  I mean, so \nthis \u2013 we think we're extremely well -positioned in this marketplace, and one of the things when we're anchoring \nour growth strategies we try to anchor around is making sure we have differentiation, that we have things that are \ndifficult to replicate.  And the reason we brought these businesses together as a segment is because we think \nindividually they all had their strengths and were winning in their market, but collectively tog ether, accessing the \nreach of our networks, utilizing the advanced technologies we have in CoverMyMeds and then the clinical \nexpertise and the biopharma relationships we had in RxCrossroads, that they kind of reinforce and compound \neach other.  \n \n And so, whe n we think about the access is a distinct market, adherence is a distinct market, outcomes is a distinct \nmarket; but putting these together, it allows us to really more effectively compete across all of those. ", "original_text": "I think you  addressed it to Britt, but I'll jump in and start with my thoughts. ", "page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc629de4-825c-4a81-8fe5-d4c62e367c38", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ae7f25de25af20cb283d7ffa58afdb15c062ec247254da5a21a74d863dc9d50", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "48aec9a1-8eeb-4a4e-8d9b-7bfe3daa4951", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you for the question.  I think you  addressed it to Britt, but I'll jump in and start with my thoughts.  I mean, so \nthis \u2013 we think we're extremely well -positioned in this marketplace, and one of the things when we're anchoring \nour growth strategies we try to anchor around is making sure we have differentiation, that we have things that are \ndifficult to replicate.  And the reason we brought these businesses together as a segment is because we think \nindividually they all had their strengths and were winning in their market, but collectively tog ether, accessing the \nreach of our networks, utilizing the advanced technologies we have in CoverMyMeds and then the clinical \nexpertise and the biopharma relationships we had in RxCrossroads, that they kind of reinforce and compound \neach other.  \n \n", "original_text": "A \nThank you for the question. ", "page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7880562fdf2fe5f4b1f90d0b505446821967c32e01abee9c81d64ead6ae0d2f4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "145ef048-18e6-4143-8242-c50c96326bf0", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you for the question.  I think you  addressed it to Britt, but I'll jump in and start with my thoughts.  I mean, so \nthis \u2013 we think we're extremely well -positioned in this marketplace, and one of the things when we're anchoring \nour growth strategies we try to anchor around is making sure we have differentiation, that we have things that are \ndifficult to replicate.  And the reason we brought these businesses together as a segment is because we think \nindividually they all had their strengths and were winning in their market, but collectively tog ether, accessing the \nreach of our networks, utilizing the advanced technologies we have in CoverMyMeds and then the clinical \nexpertise and the biopharma relationships we had in RxCrossroads, that they kind of reinforce and compound \neach other.  \n \n And so, whe n we think about the access is a distinct market, adherence is a distinct market, outcomes is a distinct \nmarket; but putting these together, it allows us to really more effectively compete across all of those.  Some of that \nis reinventing a better solution for a market that exists. ", "original_text": "I mean, so \nthis \u2013 we think we're extremely well -positioned in this marketplace, and one of the things when we're anchoring \nour growth strategies we try to anchor around is making sure we have differentiation, that we have things that are \ndifficult to replicate. "}, "hash": "67105a88526af9b22b2bdc3abfd7bec2f884b56408385114ba998a9248f9e082", "class_name": "RelatedNodeInfo"}}, "text": "I think you  addressed it to Britt, but I'll jump in and start with my thoughts. ", "start_char_idx": 281, "end_char_idx": 362, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "145ef048-18e6-4143-8242-c50c96326bf0": {"__data__": {"id_": "145ef048-18e6-4143-8242-c50c96326bf0", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you for the question.  I think you  addressed it to Britt, but I'll jump in and start with my thoughts.  I mean, so \nthis \u2013 we think we're extremely well -positioned in this marketplace, and one of the things when we're anchoring \nour growth strategies we try to anchor around is making sure we have differentiation, that we have things that are \ndifficult to replicate.  And the reason we brought these businesses together as a segment is because we think \nindividually they all had their strengths and were winning in their market, but collectively tog ether, accessing the \nreach of our networks, utilizing the advanced technologies we have in CoverMyMeds and then the clinical \nexpertise and the biopharma relationships we had in RxCrossroads, that they kind of reinforce and compound \neach other.  \n \n And so, whe n we think about the access is a distinct market, adherence is a distinct market, outcomes is a distinct \nmarket; but putting these together, it allows us to really more effectively compete across all of those.  Some of that \nis reinventing a better solution for a market that exists. ", "original_text": "I mean, so \nthis \u2013 we think we're extremely well -positioned in this marketplace, and one of the things when we're anchoring \nour growth strategies we try to anchor around is making sure we have differentiation, that we have things that are \ndifficult to replicate. ", "page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc629de4-825c-4a81-8fe5-d4c62e367c38", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ae7f25de25af20cb283d7ffa58afdb15c062ec247254da5a21a74d863dc9d50", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "528ba616-910a-4bbf-8b37-24a0570f01e8", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you for the question.  I think you  addressed it to Britt, but I'll jump in and start with my thoughts.  I mean, so \nthis \u2013 we think we're extremely well -positioned in this marketplace, and one of the things when we're anchoring \nour growth strategies we try to anchor around is making sure we have differentiation, that we have things that are \ndifficult to replicate.  And the reason we brought these businesses together as a segment is because we think \nindividually they all had their strengths and were winning in their market, but collectively tog ether, accessing the \nreach of our networks, utilizing the advanced technologies we have in CoverMyMeds and then the clinical \nexpertise and the biopharma relationships we had in RxCrossroads, that they kind of reinforce and compound \neach other.  \n \n And so, whe n we think about the access is a distinct market, adherence is a distinct market, outcomes is a distinct \nmarket; but putting these together, it allows us to really more effectively compete across all of those. ", "original_text": "I think you  addressed it to Britt, but I'll jump in and start with my thoughts. ", "page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ae327f8ddd00f2065d21983b40d91e3e594c88808c261602c891e69972926c75", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5d269d40-9acc-43f5-91e2-ef83d82ad221", "node_type": "1", "metadata": {"window": "A \nThank you for the question.  I think you  addressed it to Britt, but I'll jump in and start with my thoughts.  I mean, so \nthis \u2013 we think we're extremely well -positioned in this marketplace, and one of the things when we're anchoring \nour growth strategies we try to anchor around is making sure we have differentiation, that we have things that are \ndifficult to replicate.  And the reason we brought these businesses together as a segment is because we think \nindividually they all had their strengths and were winning in their market, but collectively tog ether, accessing the \nreach of our networks, utilizing the advanced technologies we have in CoverMyMeds and then the clinical \nexpertise and the biopharma relationships we had in RxCrossroads, that they kind of reinforce and compound \neach other.  \n \n And so, whe n we think about the access is a distinct market, adherence is a distinct market, outcomes is a distinct \nmarket; but putting these together, it allows us to really more effectively compete across all of those.  Some of that \nis reinventing a better solution for a market that exists.  That's sort of what we did with AMP. ", "original_text": "And the reason we brought these businesses together as a segment is because we think \nindividually they all had their strengths and were winning in their market, but collectively tog ether, accessing the \nreach of our networks, utilizing the advanced technologies we have in CoverMyMeds and then the clinical \nexpertise and the biopharma relationships we had in RxCrossroads, that they kind of reinforce and compound \neach other.  \n \n"}, "hash": "3e879d1f92f16d6f5d4a337664f811306273853a3358dd3ca1908f30dd548b1d", "class_name": "RelatedNodeInfo"}}, "text": "I mean, so \nthis \u2013 we think we're extremely well -positioned in this marketplace, and one of the things when we're anchoring \nour growth strategies we try to anchor around is making sure we have differentiation, that we have things that are \ndifficult to replicate. ", "start_char_idx": 362, "end_char_idx": 628, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5d269d40-9acc-43f5-91e2-ef83d82ad221": {"__data__": {"id_": "5d269d40-9acc-43f5-91e2-ef83d82ad221", "embedding": null, "metadata": {"window": "A \nThank you for the question.  I think you  addressed it to Britt, but I'll jump in and start with my thoughts.  I mean, so \nthis \u2013 we think we're extremely well -positioned in this marketplace, and one of the things when we're anchoring \nour growth strategies we try to anchor around is making sure we have differentiation, that we have things that are \ndifficult to replicate.  And the reason we brought these businesses together as a segment is because we think \nindividually they all had their strengths and were winning in their market, but collectively tog ether, accessing the \nreach of our networks, utilizing the advanced technologies we have in CoverMyMeds and then the clinical \nexpertise and the biopharma relationships we had in RxCrossroads, that they kind of reinforce and compound \neach other.  \n \n And so, whe n we think about the access is a distinct market, adherence is a distinct market, outcomes is a distinct \nmarket; but putting these together, it allows us to really more effectively compete across all of those.  Some of that \nis reinventing a better solution for a market that exists.  That's sort of what we did with AMP. ", "original_text": "And the reason we brought these businesses together as a segment is because we think \nindividually they all had their strengths and were winning in their market, but collectively tog ether, accessing the \nreach of our networks, utilizing the advanced technologies we have in CoverMyMeds and then the clinical \nexpertise and the biopharma relationships we had in RxCrossroads, that they kind of reinforce and compound \neach other.  \n \n", "page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc629de4-825c-4a81-8fe5-d4c62e367c38", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ae7f25de25af20cb283d7ffa58afdb15c062ec247254da5a21a74d863dc9d50", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "145ef048-18e6-4143-8242-c50c96326bf0", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you for the question.  I think you  addressed it to Britt, but I'll jump in and start with my thoughts.  I mean, so \nthis \u2013 we think we're extremely well -positioned in this marketplace, and one of the things when we're anchoring \nour growth strategies we try to anchor around is making sure we have differentiation, that we have things that are \ndifficult to replicate.  And the reason we brought these businesses together as a segment is because we think \nindividually they all had their strengths and were winning in their market, but collectively tog ether, accessing the \nreach of our networks, utilizing the advanced technologies we have in CoverMyMeds and then the clinical \nexpertise and the biopharma relationships we had in RxCrossroads, that they kind of reinforce and compound \neach other.  \n \n And so, whe n we think about the access is a distinct market, adherence is a distinct market, outcomes is a distinct \nmarket; but putting these together, it allows us to really more effectively compete across all of those.  Some of that \nis reinventing a better solution for a market that exists. ", "original_text": "I mean, so \nthis \u2013 we think we're extremely well -positioned in this marketplace, and one of the things when we're anchoring \nour growth strategies we try to anchor around is making sure we have differentiation, that we have things that are \ndifficult to replicate. ", "page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6deaa8569133d163e5b96a1e39b0ba46f189bc700a7149dc0968be14658730fa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e3582738-efda-46bb-bcca-d3d590544aeb", "node_type": "1", "metadata": {"window": "I think you  addressed it to Britt, but I'll jump in and start with my thoughts.  I mean, so \nthis \u2013 we think we're extremely well -positioned in this marketplace, and one of the things when we're anchoring \nour growth strategies we try to anchor around is making sure we have differentiation, that we have things that are \ndifficult to replicate.  And the reason we brought these businesses together as a segment is because we think \nindividually they all had their strengths and were winning in their market, but collectively tog ether, accessing the \nreach of our networks, utilizing the advanced technologies we have in CoverMyMeds and then the clinical \nexpertise and the biopharma relationships we had in RxCrossroads, that they kind of reinforce and compound \neach other.  \n \n And so, whe n we think about the access is a distinct market, adherence is a distinct market, outcomes is a distinct \nmarket; but putting these together, it allows us to really more effectively compete across all of those.  Some of that \nis reinventing a better solution for a market that exists.  That's sort of what we did with AMP.  We brought an \ninfusion of technology to really redesign and greatly enhance the value we deliver to manufacturers, giving us \nwhat we think is significant competitive advantage. ", "original_text": "And so, whe n we think about the access is a distinct market, adherence is a distinct market, outcomes is a distinct \nmarket; but putting these together, it allows us to really more effectively compete across all of those. "}, "hash": "161a44706eb3c45bc5ca3ec0e1458742bd14f4454a725f119f89c6a7c05941c4", "class_name": "RelatedNodeInfo"}}, "text": "And the reason we brought these businesses together as a segment is because we think \nindividually they all had their strengths and were winning in their market, but collectively tog ether, accessing the \nreach of our networks, utilizing the advanced technologies we have in CoverMyMeds and then the clinical \nexpertise and the biopharma relationships we had in RxCrossroads, that they kind of reinforce and compound \neach other.  \n \n", "start_char_idx": 628, "end_char_idx": 1062, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e3582738-efda-46bb-bcca-d3d590544aeb": {"__data__": {"id_": "e3582738-efda-46bb-bcca-d3d590544aeb", "embedding": null, "metadata": {"window": "I think you  addressed it to Britt, but I'll jump in and start with my thoughts.  I mean, so \nthis \u2013 we think we're extremely well -positioned in this marketplace, and one of the things when we're anchoring \nour growth strategies we try to anchor around is making sure we have differentiation, that we have things that are \ndifficult to replicate.  And the reason we brought these businesses together as a segment is because we think \nindividually they all had their strengths and were winning in their market, but collectively tog ether, accessing the \nreach of our networks, utilizing the advanced technologies we have in CoverMyMeds and then the clinical \nexpertise and the biopharma relationships we had in RxCrossroads, that they kind of reinforce and compound \neach other.  \n \n And so, whe n we think about the access is a distinct market, adherence is a distinct market, outcomes is a distinct \nmarket; but putting these together, it allows us to really more effectively compete across all of those.  Some of that \nis reinventing a better solution for a market that exists.  That's sort of what we did with AMP.  We brought an \ninfusion of technology to really redesign and greatly enhance the value we deliver to manufacturers, giving us \nwhat we think is significant competitive advantage. ", "original_text": "And so, whe n we think about the access is a distinct market, adherence is a distinct market, outcomes is a distinct \nmarket; but putting these together, it allows us to really more effectively compete across all of those. ", "page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc629de4-825c-4a81-8fe5-d4c62e367c38", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ae7f25de25af20cb283d7ffa58afdb15c062ec247254da5a21a74d863dc9d50", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5d269d40-9acc-43f5-91e2-ef83d82ad221", "node_type": "1", "metadata": {"window": "A \nThank you for the question.  I think you  addressed it to Britt, but I'll jump in and start with my thoughts.  I mean, so \nthis \u2013 we think we're extremely well -positioned in this marketplace, and one of the things when we're anchoring \nour growth strategies we try to anchor around is making sure we have differentiation, that we have things that are \ndifficult to replicate.  And the reason we brought these businesses together as a segment is because we think \nindividually they all had their strengths and were winning in their market, but collectively tog ether, accessing the \nreach of our networks, utilizing the advanced technologies we have in CoverMyMeds and then the clinical \nexpertise and the biopharma relationships we had in RxCrossroads, that they kind of reinforce and compound \neach other.  \n \n And so, whe n we think about the access is a distinct market, adherence is a distinct market, outcomes is a distinct \nmarket; but putting these together, it allows us to really more effectively compete across all of those.  Some of that \nis reinventing a better solution for a market that exists.  That's sort of what we did with AMP. ", "original_text": "And the reason we brought these businesses together as a segment is because we think \nindividually they all had their strengths and were winning in their market, but collectively tog ether, accessing the \nreach of our networks, utilizing the advanced technologies we have in CoverMyMeds and then the clinical \nexpertise and the biopharma relationships we had in RxCrossroads, that they kind of reinforce and compound \neach other.  \n \n", "page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0e34fb78d9667f08713382dbd7307001510f25795eaca839d69f3c61ce929322", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aeea6de9-ff4e-466b-a39f-ef30847e02bd", "node_type": "1", "metadata": {"window": "I mean, so \nthis \u2013 we think we're extremely well -positioned in this marketplace, and one of the things when we're anchoring \nour growth strategies we try to anchor around is making sure we have differentiation, that we have things that are \ndifficult to replicate.  And the reason we brought these businesses together as a segment is because we think \nindividually they all had their strengths and were winning in their market, but collectively tog ether, accessing the \nreach of our networks, utilizing the advanced technologies we have in CoverMyMeds and then the clinical \nexpertise and the biopharma relationships we had in RxCrossroads, that they kind of reinforce and compound \neach other.  \n \n And so, whe n we think about the access is a distinct market, adherence is a distinct market, outcomes is a distinct \nmarket; but putting these together, it allows us to really more effectively compete across all of those.  Some of that \nis reinventing a better solution for a market that exists.  That's sort of what we did with AMP.  We brought an \ninfusion of technology to really redesign and greatly enhance the value we deliver to manufacturers, giving us \nwhat we think is significant competitive advantage.  We'll continue t o do those kinds of innovations as we grow into \nit. \n \n", "original_text": "Some of that \nis reinventing a better solution for a market that exists. "}, "hash": "c61e67bca58d2950e57623502d2b36f6c8ce43756ac4a5c7450059e3b02d1afe", "class_name": "RelatedNodeInfo"}}, "text": "And so, whe n we think about the access is a distinct market, adherence is a distinct market, outcomes is a distinct \nmarket; but putting these together, it allows us to really more effectively compete across all of those. ", "start_char_idx": 1062, "end_char_idx": 1285, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aeea6de9-ff4e-466b-a39f-ef30847e02bd": {"__data__": {"id_": "aeea6de9-ff4e-466b-a39f-ef30847e02bd", "embedding": null, "metadata": {"window": "I mean, so \nthis \u2013 we think we're extremely well -positioned in this marketplace, and one of the things when we're anchoring \nour growth strategies we try to anchor around is making sure we have differentiation, that we have things that are \ndifficult to replicate.  And the reason we brought these businesses together as a segment is because we think \nindividually they all had their strengths and were winning in their market, but collectively tog ether, accessing the \nreach of our networks, utilizing the advanced technologies we have in CoverMyMeds and then the clinical \nexpertise and the biopharma relationships we had in RxCrossroads, that they kind of reinforce and compound \neach other.  \n \n And so, whe n we think about the access is a distinct market, adherence is a distinct market, outcomes is a distinct \nmarket; but putting these together, it allows us to really more effectively compete across all of those.  Some of that \nis reinventing a better solution for a market that exists.  That's sort of what we did with AMP.  We brought an \ninfusion of technology to really redesign and greatly enhance the value we deliver to manufacturers, giving us \nwhat we think is significant competitive advantage.  We'll continue t o do those kinds of innovations as we grow into \nit. \n \n", "original_text": "Some of that \nis reinventing a better solution for a market that exists. ", "page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc629de4-825c-4a81-8fe5-d4c62e367c38", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ae7f25de25af20cb283d7ffa58afdb15c062ec247254da5a21a74d863dc9d50", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e3582738-efda-46bb-bcca-d3d590544aeb", "node_type": "1", "metadata": {"window": "I think you  addressed it to Britt, but I'll jump in and start with my thoughts.  I mean, so \nthis \u2013 we think we're extremely well -positioned in this marketplace, and one of the things when we're anchoring \nour growth strategies we try to anchor around is making sure we have differentiation, that we have things that are \ndifficult to replicate.  And the reason we brought these businesses together as a segment is because we think \nindividually they all had their strengths and were winning in their market, but collectively tog ether, accessing the \nreach of our networks, utilizing the advanced technologies we have in CoverMyMeds and then the clinical \nexpertise and the biopharma relationships we had in RxCrossroads, that they kind of reinforce and compound \neach other.  \n \n And so, whe n we think about the access is a distinct market, adherence is a distinct market, outcomes is a distinct \nmarket; but putting these together, it allows us to really more effectively compete across all of those.  Some of that \nis reinventing a better solution for a market that exists.  That's sort of what we did with AMP.  We brought an \ninfusion of technology to really redesign and greatly enhance the value we deliver to manufacturers, giving us \nwhat we think is significant competitive advantage. ", "original_text": "And so, whe n we think about the access is a distinct market, adherence is a distinct market, outcomes is a distinct \nmarket; but putting these together, it allows us to really more effectively compete across all of those. ", "page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "68da27616b03add47c40c5de229bab2eb9c3839c7438b8763cd3dddef2639c91", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "673f94a4-1bff-4356-940e-bdf9437e078b", "node_type": "1", "metadata": {"window": "And the reason we brought these businesses together as a segment is because we think \nindividually they all had their strengths and were winning in their market, but collectively tog ether, accessing the \nreach of our networks, utilizing the advanced technologies we have in CoverMyMeds and then the clinical \nexpertise and the biopharma relationships we had in RxCrossroads, that they kind of reinforce and compound \neach other.  \n \n And so, whe n we think about the access is a distinct market, adherence is a distinct market, outcomes is a distinct \nmarket; but putting these together, it allows us to really more effectively compete across all of those.  Some of that \nis reinventing a better solution for a market that exists.  That's sort of what we did with AMP.  We brought an \ninfusion of technology to really redesign and greatly enhance the value we deliver to manufacturers, giving us \nwhat we think is significant competitive advantage.  We'll continue t o do those kinds of innovations as we grow into \nit. \n \n I mean, it is a pretty fragmented landscape. ", "original_text": "That's sort of what we did with AMP. "}, "hash": "7d73c535171ebe5703e88eea6ecec275f4fee38eccd9afd9b3ad0859576511af", "class_name": "RelatedNodeInfo"}}, "text": "Some of that \nis reinventing a better solution for a market that exists. ", "start_char_idx": 1285, "end_char_idx": 1358, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "673f94a4-1bff-4356-940e-bdf9437e078b": {"__data__": {"id_": "673f94a4-1bff-4356-940e-bdf9437e078b", "embedding": null, "metadata": {"window": "And the reason we brought these businesses together as a segment is because we think \nindividually they all had their strengths and were winning in their market, but collectively tog ether, accessing the \nreach of our networks, utilizing the advanced technologies we have in CoverMyMeds and then the clinical \nexpertise and the biopharma relationships we had in RxCrossroads, that they kind of reinforce and compound \neach other.  \n \n And so, whe n we think about the access is a distinct market, adherence is a distinct market, outcomes is a distinct \nmarket; but putting these together, it allows us to really more effectively compete across all of those.  Some of that \nis reinventing a better solution for a market that exists.  That's sort of what we did with AMP.  We brought an \ninfusion of technology to really redesign and greatly enhance the value we deliver to manufacturers, giving us \nwhat we think is significant competitive advantage.  We'll continue t o do those kinds of innovations as we grow into \nit. \n \n I mean, it is a pretty fragmented landscape. ", "original_text": "That's sort of what we did with AMP. ", "page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc629de4-825c-4a81-8fe5-d4c62e367c38", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ae7f25de25af20cb283d7ffa58afdb15c062ec247254da5a21a74d863dc9d50", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aeea6de9-ff4e-466b-a39f-ef30847e02bd", "node_type": "1", "metadata": {"window": "I mean, so \nthis \u2013 we think we're extremely well -positioned in this marketplace, and one of the things when we're anchoring \nour growth strategies we try to anchor around is making sure we have differentiation, that we have things that are \ndifficult to replicate.  And the reason we brought these businesses together as a segment is because we think \nindividually they all had their strengths and were winning in their market, but collectively tog ether, accessing the \nreach of our networks, utilizing the advanced technologies we have in CoverMyMeds and then the clinical \nexpertise and the biopharma relationships we had in RxCrossroads, that they kind of reinforce and compound \neach other.  \n \n And so, whe n we think about the access is a distinct market, adherence is a distinct market, outcomes is a distinct \nmarket; but putting these together, it allows us to really more effectively compete across all of those.  Some of that \nis reinventing a better solution for a market that exists.  That's sort of what we did with AMP.  We brought an \ninfusion of technology to really redesign and greatly enhance the value we deliver to manufacturers, giving us \nwhat we think is significant competitive advantage.  We'll continue t o do those kinds of innovations as we grow into \nit. \n \n", "original_text": "Some of that \nis reinventing a better solution for a market that exists. ", "page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "60f2a6f46e30d69e56d0cae46745a9c8ae2391fbf89191176a778fe2a0518623", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4cdc6e6c-7f51-4713-a05e-f3ba97f8ee27", "node_type": "1", "metadata": {"window": "And so, whe n we think about the access is a distinct market, adherence is a distinct market, outcomes is a distinct \nmarket; but putting these together, it allows us to really more effectively compete across all of those.  Some of that \nis reinventing a better solution for a market that exists.  That's sort of what we did with AMP.  We brought an \ninfusion of technology to really redesign and greatly enhance the value we deliver to manufacturers, giving us \nwhat we think is significant competitive advantage.  We'll continue t o do those kinds of innovations as we grow into \nit. \n \n I mean, it is a pretty fragmented landscape.  There are some competitors' names you know. ", "original_text": "We brought an \ninfusion of technology to really redesign and greatly enhance the value we deliver to manufacturers, giving us \nwhat we think is significant competitive advantage. "}, "hash": "3e459700811275013a53431d4b27a61250053c915f2e6e32385beceb031751fa", "class_name": "RelatedNodeInfo"}}, "text": "That's sort of what we did with AMP. ", "start_char_idx": 1358, "end_char_idx": 1395, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4cdc6e6c-7f51-4713-a05e-f3ba97f8ee27": {"__data__": {"id_": "4cdc6e6c-7f51-4713-a05e-f3ba97f8ee27", "embedding": null, "metadata": {"window": "And so, whe n we think about the access is a distinct market, adherence is a distinct market, outcomes is a distinct \nmarket; but putting these together, it allows us to really more effectively compete across all of those.  Some of that \nis reinventing a better solution for a market that exists.  That's sort of what we did with AMP.  We brought an \ninfusion of technology to really redesign and greatly enhance the value we deliver to manufacturers, giving us \nwhat we think is significant competitive advantage.  We'll continue t o do those kinds of innovations as we grow into \nit. \n \n I mean, it is a pretty fragmented landscape.  There are some competitors' names you know. ", "original_text": "We brought an \ninfusion of technology to really redesign and greatly enhance the value we deliver to manufacturers, giving us \nwhat we think is significant competitive advantage. ", "page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc629de4-825c-4a81-8fe5-d4c62e367c38", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ae7f25de25af20cb283d7ffa58afdb15c062ec247254da5a21a74d863dc9d50", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "673f94a4-1bff-4356-940e-bdf9437e078b", "node_type": "1", "metadata": {"window": "And the reason we brought these businesses together as a segment is because we think \nindividually they all had their strengths and were winning in their market, but collectively tog ether, accessing the \nreach of our networks, utilizing the advanced technologies we have in CoverMyMeds and then the clinical \nexpertise and the biopharma relationships we had in RxCrossroads, that they kind of reinforce and compound \neach other.  \n \n And so, whe n we think about the access is a distinct market, adherence is a distinct market, outcomes is a distinct \nmarket; but putting these together, it allows us to really more effectively compete across all of those.  Some of that \nis reinventing a better solution for a market that exists.  That's sort of what we did with AMP.  We brought an \ninfusion of technology to really redesign and greatly enhance the value we deliver to manufacturers, giving us \nwhat we think is significant competitive advantage.  We'll continue t o do those kinds of innovations as we grow into \nit. \n \n I mean, it is a pretty fragmented landscape. ", "original_text": "That's sort of what we did with AMP. ", "page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6e0ccb26cf22b43062a7c12156006cf077209f9fabbad24b90ea72ce01d624e0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c4846d6b-8090-4bc2-91a0-93b121962976", "node_type": "1", "metadata": {"window": "Some of that \nis reinventing a better solution for a market that exists.  That's sort of what we did with AMP.  We brought an \ninfusion of technology to really redesign and greatly enhance the value we deliver to manufacturers, giving us \nwhat we think is significant competitive advantage.  We'll continue t o do those kinds of innovations as we grow into \nit. \n \n I mean, it is a pretty fragmented landscape.  There are some competitors' names you know.  There's frankly lots of \nlittle ones. ", "original_text": "We'll continue t o do those kinds of innovations as we grow into \nit. \n \n"}, "hash": "d68116b186845d1c09ac836704b4df10b89509d38c5138282c87219578156e7c", "class_name": "RelatedNodeInfo"}}, "text": "We brought an \ninfusion of technology to really redesign and greatly enhance the value we deliver to manufacturers, giving us \nwhat we think is significant competitive advantage. ", "start_char_idx": 1395, "end_char_idx": 1574, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c4846d6b-8090-4bc2-91a0-93b121962976": {"__data__": {"id_": "c4846d6b-8090-4bc2-91a0-93b121962976", "embedding": null, "metadata": {"window": "Some of that \nis reinventing a better solution for a market that exists.  That's sort of what we did with AMP.  We brought an \ninfusion of technology to really redesign and greatly enhance the value we deliver to manufacturers, giving us \nwhat we think is significant competitive advantage.  We'll continue t o do those kinds of innovations as we grow into \nit. \n \n I mean, it is a pretty fragmented landscape.  There are some competitors' names you know.  There's frankly lots of \nlittle ones. ", "original_text": "We'll continue t o do those kinds of innovations as we grow into \nit. \n \n", "page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc629de4-825c-4a81-8fe5-d4c62e367c38", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ae7f25de25af20cb283d7ffa58afdb15c062ec247254da5a21a74d863dc9d50", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4cdc6e6c-7f51-4713-a05e-f3ba97f8ee27", "node_type": "1", "metadata": {"window": "And so, whe n we think about the access is a distinct market, adherence is a distinct market, outcomes is a distinct \nmarket; but putting these together, it allows us to really more effectively compete across all of those.  Some of that \nis reinventing a better solution for a market that exists.  That's sort of what we did with AMP.  We brought an \ninfusion of technology to really redesign and greatly enhance the value we deliver to manufacturers, giving us \nwhat we think is significant competitive advantage.  We'll continue t o do those kinds of innovations as we grow into \nit. \n \n I mean, it is a pretty fragmented landscape.  There are some competitors' names you know. ", "original_text": "We brought an \ninfusion of technology to really redesign and greatly enhance the value we deliver to manufacturers, giving us \nwhat we think is significant competitive advantage. ", "page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dcf36e16732f7af58ace2be041c421f8faab767672cea824a40dd425f161ea6d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e17f7320-280a-4767-a4af-59a817d6041a", "node_type": "1", "metadata": {"window": "That's sort of what we did with AMP.  We brought an \ninfusion of technology to really redesign and greatly enhance the value we deliver to manufacturers, giving us \nwhat we think is significant competitive advantage.  We'll continue t o do those kinds of innovations as we grow into \nit. \n \n I mean, it is a pretty fragmented landscape.  There are some competitors' names you know.  There's frankly lots of \nlittle ones.  This is an area that we would like to use the strength of our balance sheet t o be acquisitive, to be \nadditive to that ecosystem through additional capability or additional scale. ", "original_text": "I mean, it is a pretty fragmented landscape. "}, "hash": "f3960803c5605235c898402049a0c4877e25bdc0855c2b19f47f0099c78a5fd2", "class_name": "RelatedNodeInfo"}}, "text": "We'll continue t o do those kinds of innovations as we grow into \nit. \n \n", "start_char_idx": 1574, "end_char_idx": 1647, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e17f7320-280a-4767-a4af-59a817d6041a": {"__data__": {"id_": "e17f7320-280a-4767-a4af-59a817d6041a", "embedding": null, "metadata": {"window": "That's sort of what we did with AMP.  We brought an \ninfusion of technology to really redesign and greatly enhance the value we deliver to manufacturers, giving us \nwhat we think is significant competitive advantage.  We'll continue t o do those kinds of innovations as we grow into \nit. \n \n I mean, it is a pretty fragmented landscape.  There are some competitors' names you know.  There's frankly lots of \nlittle ones.  This is an area that we would like to use the strength of our balance sheet t o be acquisitive, to be \nadditive to that ecosystem through additional capability or additional scale. ", "original_text": "I mean, it is a pretty fragmented landscape. ", "page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc629de4-825c-4a81-8fe5-d4c62e367c38", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ae7f25de25af20cb283d7ffa58afdb15c062ec247254da5a21a74d863dc9d50", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c4846d6b-8090-4bc2-91a0-93b121962976", "node_type": "1", "metadata": {"window": "Some of that \nis reinventing a better solution for a market that exists.  That's sort of what we did with AMP.  We brought an \ninfusion of technology to really redesign and greatly enhance the value we deliver to manufacturers, giving us \nwhat we think is significant competitive advantage.  We'll continue t o do those kinds of innovations as we grow into \nit. \n \n I mean, it is a pretty fragmented landscape.  There are some competitors' names you know.  There's frankly lots of \nlittle ones. ", "original_text": "We'll continue t o do those kinds of innovations as we grow into \nit. \n \n", "page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9f9031b52e13091d2b57f5ce8778e6d6a79684240558e818f80c66c20b340e13", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a86fbb91-ec9a-4bd5-a7e7-7bacd14c0145", "node_type": "1", "metadata": {"window": "We brought an \ninfusion of technology to really redesign and greatly enhance the value we deliver to manufacturers, giving us \nwhat we think is significant competitive advantage.  We'll continue t o do those kinds of innovations as we grow into \nit. \n \n I mean, it is a pretty fragmented landscape.  There are some competitors' names you know.  There's frankly lots of \nlittle ones.  This is an area that we would like to use the strength of our balance sheet t o be acquisitive, to be \nadditive to that ecosystem through additional capability or additional scale.  As long as we find that strategically \naligned asset and it can meet our financial hurdles and stand up well to other means we have to deploy capital, \nwe'll certainly look to execute on that.  \n ", "original_text": "There are some competitors' names you know. "}, "hash": "b7a09785497f4ba364930c54f0a9c8733f6e4d5d66e90a4de6b7c77f6339fd3c", "class_name": "RelatedNodeInfo"}}, "text": "I mean, it is a pretty fragmented landscape. ", "start_char_idx": 1647, "end_char_idx": 1692, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a86fbb91-ec9a-4bd5-a7e7-7bacd14c0145": {"__data__": {"id_": "a86fbb91-ec9a-4bd5-a7e7-7bacd14c0145", "embedding": null, "metadata": {"window": "We brought an \ninfusion of technology to really redesign and greatly enhance the value we deliver to manufacturers, giving us \nwhat we think is significant competitive advantage.  We'll continue t o do those kinds of innovations as we grow into \nit. \n \n I mean, it is a pretty fragmented landscape.  There are some competitors' names you know.  There's frankly lots of \nlittle ones.  This is an area that we would like to use the strength of our balance sheet t o be acquisitive, to be \nadditive to that ecosystem through additional capability or additional scale.  As long as we find that strategically \naligned asset and it can meet our financial hurdles and stand up well to other means we have to deploy capital, \nwe'll certainly look to execute on that.  \n ", "original_text": "There are some competitors' names you know. ", "page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc629de4-825c-4a81-8fe5-d4c62e367c38", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ae7f25de25af20cb283d7ffa58afdb15c062ec247254da5a21a74d863dc9d50", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e17f7320-280a-4767-a4af-59a817d6041a", "node_type": "1", "metadata": {"window": "That's sort of what we did with AMP.  We brought an \ninfusion of technology to really redesign and greatly enhance the value we deliver to manufacturers, giving us \nwhat we think is significant competitive advantage.  We'll continue t o do those kinds of innovations as we grow into \nit. \n \n I mean, it is a pretty fragmented landscape.  There are some competitors' names you know.  There's frankly lots of \nlittle ones.  This is an area that we would like to use the strength of our balance sheet t o be acquisitive, to be \nadditive to that ecosystem through additional capability or additional scale. ", "original_text": "I mean, it is a pretty fragmented landscape. ", "page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7eb78fa6ca59b840284b8b15c041af154d79c643888984d03a24358a3455f5d6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4ac46ae2-0ba8-440f-ada6-cf7086c283f6", "node_type": "1", "metadata": {"window": "We'll continue t o do those kinds of innovations as we grow into \nit. \n \n I mean, it is a pretty fragmented landscape.  There are some competitors' names you know.  There's frankly lots of \nlittle ones.  This is an area that we would like to use the strength of our balance sheet t o be acquisitive, to be \nadditive to that ecosystem through additional capability or additional scale.  As long as we find that strategically \naligned asset and it can meet our financial hurdles and stand up well to other means we have to deploy capital, \nwe'll certainly look to execute on that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n ", "original_text": "There's frankly lots of \nlittle ones. "}, "hash": "f500872ef37733705913fb55359a6bb32d0293f66eb13f75671e49129437b6a9", "class_name": "RelatedNodeInfo"}}, "text": "There are some competitors' names you know. ", "start_char_idx": 1692, "end_char_idx": 1736, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4ac46ae2-0ba8-440f-ada6-cf7086c283f6": {"__data__": {"id_": "4ac46ae2-0ba8-440f-ada6-cf7086c283f6", "embedding": null, "metadata": {"window": "We'll continue t o do those kinds of innovations as we grow into \nit. \n \n I mean, it is a pretty fragmented landscape.  There are some competitors' names you know.  There's frankly lots of \nlittle ones.  This is an area that we would like to use the strength of our balance sheet t o be acquisitive, to be \nadditive to that ecosystem through additional capability or additional scale.  As long as we find that strategically \naligned asset and it can meet our financial hurdles and stand up well to other means we have to deploy capital, \nwe'll certainly look to execute on that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n ", "original_text": "There's frankly lots of \nlittle ones. ", "page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc629de4-825c-4a81-8fe5-d4c62e367c38", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ae7f25de25af20cb283d7ffa58afdb15c062ec247254da5a21a74d863dc9d50", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a86fbb91-ec9a-4bd5-a7e7-7bacd14c0145", "node_type": "1", "metadata": {"window": "We brought an \ninfusion of technology to really redesign and greatly enhance the value we deliver to manufacturers, giving us \nwhat we think is significant competitive advantage.  We'll continue t o do those kinds of innovations as we grow into \nit. \n \n I mean, it is a pretty fragmented landscape.  There are some competitors' names you know.  There's frankly lots of \nlittle ones.  This is an area that we would like to use the strength of our balance sheet t o be acquisitive, to be \nadditive to that ecosystem through additional capability or additional scale.  As long as we find that strategically \naligned asset and it can meet our financial hurdles and stand up well to other means we have to deploy capital, \nwe'll certainly look to execute on that.  \n ", "original_text": "There are some competitors' names you know. ", "page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1397f70171e8453504002a026475c2d172d3bc66ce06313a95f2c73a1b350205", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "98352a9a-9c44-4757-9074-d9d55cc88d8a", "node_type": "1", "metadata": {"window": "I mean, it is a pretty fragmented landscape.  There are some competitors' names you know.  There's frankly lots of \nlittle ones.  This is an area that we would like to use the strength of our balance sheet t o be acquisitive, to be \nadditive to that ecosystem through additional capability or additional scale.  As long as we find that strategically \naligned asset and it can meet our financial hurdles and stand up well to other means we have to deploy capital, \nwe'll certainly look to execute on that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And the next one will be from Jailendra Singh with Credit Suisse. ", "original_text": "This is an area that we would like to use the strength of our balance sheet t o be acquisitive, to be \nadditive to that ecosystem through additional capability or additional scale. "}, "hash": "4f83e67bb80d2ccf0cf8f4cbaa7ddd913654a18bcc86b73e18c48712d3006383", "class_name": "RelatedNodeInfo"}}, "text": "There's frankly lots of \nlittle ones. ", "start_char_idx": 1736, "end_char_idx": 1774, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "98352a9a-9c44-4757-9074-d9d55cc88d8a": {"__data__": {"id_": "98352a9a-9c44-4757-9074-d9d55cc88d8a", "embedding": null, "metadata": {"window": "I mean, it is a pretty fragmented landscape.  There are some competitors' names you know.  There's frankly lots of \nlittle ones.  This is an area that we would like to use the strength of our balance sheet t o be acquisitive, to be \nadditive to that ecosystem through additional capability or additional scale.  As long as we find that strategically \naligned asset and it can meet our financial hurdles and stand up well to other means we have to deploy capital, \nwe'll certainly look to execute on that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And the next one will be from Jailendra Singh with Credit Suisse. ", "original_text": "This is an area that we would like to use the strength of our balance sheet t o be acquisitive, to be \nadditive to that ecosystem through additional capability or additional scale. ", "page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc629de4-825c-4a81-8fe5-d4c62e367c38", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ae7f25de25af20cb283d7ffa58afdb15c062ec247254da5a21a74d863dc9d50", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4ac46ae2-0ba8-440f-ada6-cf7086c283f6", "node_type": "1", "metadata": {"window": "We'll continue t o do those kinds of innovations as we grow into \nit. \n \n I mean, it is a pretty fragmented landscape.  There are some competitors' names you know.  There's frankly lots of \nlittle ones.  This is an area that we would like to use the strength of our balance sheet t o be acquisitive, to be \nadditive to that ecosystem through additional capability or additional scale.  As long as we find that strategically \naligned asset and it can meet our financial hurdles and stand up well to other means we have to deploy capital, \nwe'll certainly look to execute on that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n ", "original_text": "There's frankly lots of \nlittle ones. ", "page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0acc1de737b787c1cd932d9e7e2b5a037a51e6683d1144302841550cc74cb7a1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1abea367-6dab-413b-ab92-52f2a5b5c098", "node_type": "1", "metadata": {"window": "There are some competitors' names you know.  There's frankly lots of \nlittle ones.  This is an area that we would like to use the strength of our balance sheet t o be acquisitive, to be \nadditive to that ecosystem through additional capability or additional scale.  As long as we find that strategically \naligned asset and it can meet our financial hurdles and stand up well to other means we have to deploy capital, \nwe'll certainly look to execute on that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And the next one will be from Jailendra Singh with Credit Suisse.  Please go ahead.  \n ", "original_text": "As long as we find that strategically \naligned asset and it can meet our financial hurdles and stand up well to other means we have to deploy capital, \nwe'll certainly look to execute on that.  \n "}, "hash": "8e59b27f4c5690c41758b96fbf692b765489d6bd237ac3f033906bca53ede2b1", "class_name": "RelatedNodeInfo"}}, "text": "This is an area that we would like to use the strength of our balance sheet t o be acquisitive, to be \nadditive to that ecosystem through additional capability or additional scale. ", "start_char_idx": 1774, "end_char_idx": 1955, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1abea367-6dab-413b-ab92-52f2a5b5c098": {"__data__": {"id_": "1abea367-6dab-413b-ab92-52f2a5b5c098", "embedding": null, "metadata": {"window": "There are some competitors' names you know.  There's frankly lots of \nlittle ones.  This is an area that we would like to use the strength of our balance sheet t o be acquisitive, to be \nadditive to that ecosystem through additional capability or additional scale.  As long as we find that strategically \naligned asset and it can meet our financial hurdles and stand up well to other means we have to deploy capital, \nwe'll certainly look to execute on that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And the next one will be from Jailendra Singh with Credit Suisse.  Please go ahead.  \n ", "original_text": "As long as we find that strategically \naligned asset and it can meet our financial hurdles and stand up well to other means we have to deploy capital, \nwe'll certainly look to execute on that.  \n ", "page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc629de4-825c-4a81-8fe5-d4c62e367c38", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ae7f25de25af20cb283d7ffa58afdb15c062ec247254da5a21a74d863dc9d50", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "98352a9a-9c44-4757-9074-d9d55cc88d8a", "node_type": "1", "metadata": {"window": "I mean, it is a pretty fragmented landscape.  There are some competitors' names you know.  There's frankly lots of \nlittle ones.  This is an area that we would like to use the strength of our balance sheet t o be acquisitive, to be \nadditive to that ecosystem through additional capability or additional scale.  As long as we find that strategically \naligned asset and it can meet our financial hurdles and stand up well to other means we have to deploy capital, \nwe'll certainly look to execute on that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And the next one will be from Jailendra Singh with Credit Suisse. ", "original_text": "This is an area that we would like to use the strength of our balance sheet t o be acquisitive, to be \nadditive to that ecosystem through additional capability or additional scale. ", "page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "70ef22d22071a2a0e484d8d195b4dfbc0661e3e468aa1497dfc2ed3b24639381", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "717404f0-efb7-4ae0-b756-33c1d2e1f29e", "node_type": "1", "metadata": {"window": "There's frankly lots of \nlittle ones.  This is an area that we would like to use the strength of our balance sheet t o be acquisitive, to be \nadditive to that ecosystem through additional capability or additional scale.  As long as we find that strategically \naligned asset and it can meet our financial hurdles and stand up well to other means we have to deploy capital, \nwe'll certainly look to execute on that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And the next one will be from Jailendra Singh with Credit Suisse.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThank you, and hello, everyone. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n "}, "hash": "6ffd9089ef77441b74f2d49b7682181a7490a790e7e284a378e7896cb5f5f512", "class_name": "RelatedNodeInfo"}}, "text": "As long as we find that strategically \naligned asset and it can meet our financial hurdles and stand up well to other means we have to deploy capital, \nwe'll certainly look to execute on that.  \n ", "start_char_idx": 1955, "end_char_idx": 2151, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "717404f0-efb7-4ae0-b756-33c1d2e1f29e": {"__data__": {"id_": "717404f0-efb7-4ae0-b756-33c1d2e1f29e", "embedding": null, "metadata": {"window": "There's frankly lots of \nlittle ones.  This is an area that we would like to use the strength of our balance sheet t o be acquisitive, to be \nadditive to that ecosystem through additional capability or additional scale.  As long as we find that strategically \naligned asset and it can meet our financial hurdles and stand up well to other means we have to deploy capital, \nwe'll certainly look to execute on that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And the next one will be from Jailendra Singh with Credit Suisse.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThank you, and hello, everyone. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n ", "page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc629de4-825c-4a81-8fe5-d4c62e367c38", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ae7f25de25af20cb283d7ffa58afdb15c062ec247254da5a21a74d863dc9d50", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1abea367-6dab-413b-ab92-52f2a5b5c098", "node_type": "1", "metadata": {"window": "There are some competitors' names you know.  There's frankly lots of \nlittle ones.  This is an area that we would like to use the strength of our balance sheet t o be acquisitive, to be \nadditive to that ecosystem through additional capability or additional scale.  As long as we find that strategically \naligned asset and it can meet our financial hurdles and stand up well to other means we have to deploy capital, \nwe'll certainly look to execute on that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And the next one will be from Jailendra Singh with Credit Suisse.  Please go ahead.  \n ", "original_text": "As long as we find that strategically \naligned asset and it can meet our financial hurdles and stand up well to other means we have to deploy capital, \nwe'll certainly look to execute on that.  \n ", "page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73c7aa25a224ad40acc9fe008d4cf7066e2b01650d9140dbc72fa53a170edd18", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6c917ddf-8972-4006-acd4-88e243f8d83f", "node_type": "1", "metadata": {"window": "This is an area that we would like to use the strength of our balance sheet t o be acquisitive, to be \nadditive to that ecosystem through additional capability or additional scale.  As long as we find that strategically \naligned asset and it can meet our financial hurdles and stand up well to other means we have to deploy capital, \nwe'll certainly look to execute on that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And the next one will be from Jailendra Singh with Credit Suisse.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThank you, and hello, everyone.  So with respect to $0.45 core business outperformance you called out, which is \nnow captured in your fiscal 2022 outlook, how do you think about the sustainability of some of those drivers \nbehin d that outperformance? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And the next one will be from Jailendra Singh with Credit Suisse. "}, "hash": "75b395a0d57d2cbab2d0e57016a9c7756d796f027809a740ecfa703831e337c7", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n ", "start_char_idx": 2151, "end_char_idx": 2514, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6c917ddf-8972-4006-acd4-88e243f8d83f": {"__data__": {"id_": "6c917ddf-8972-4006-acd4-88e243f8d83f", "embedding": null, "metadata": {"window": "This is an area that we would like to use the strength of our balance sheet t o be acquisitive, to be \nadditive to that ecosystem through additional capability or additional scale.  As long as we find that strategically \naligned asset and it can meet our financial hurdles and stand up well to other means we have to deploy capital, \nwe'll certainly look to execute on that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And the next one will be from Jailendra Singh with Credit Suisse.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThank you, and hello, everyone.  So with respect to $0.45 core business outperformance you called out, which is \nnow captured in your fiscal 2022 outlook, how do you think about the sustainability of some of those drivers \nbehin d that outperformance? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And the next one will be from Jailendra Singh with Credit Suisse. ", "page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc629de4-825c-4a81-8fe5-d4c62e367c38", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ae7f25de25af20cb283d7ffa58afdb15c062ec247254da5a21a74d863dc9d50", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "717404f0-efb7-4ae0-b756-33c1d2e1f29e", "node_type": "1", "metadata": {"window": "There's frankly lots of \nlittle ones.  This is an area that we would like to use the strength of our balance sheet t o be acquisitive, to be \nadditive to that ecosystem through additional capability or additional scale.  As long as we find that strategically \naligned asset and it can meet our financial hurdles and stand up well to other means we have to deploy capital, \nwe'll certainly look to execute on that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And the next one will be from Jailendra Singh with Credit Suisse.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThank you, and hello, everyone. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n ", "page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9f3a4fc314f73cf328f63bce952949377a5325f3a137773ac87eaf95ff803a0a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bc227165-ddf2-4a33-9d68-ad3119d4d199", "node_type": "1", "metadata": {"window": "As long as we find that strategically \naligned asset and it can meet our financial hurdles and stand up well to other means we have to deploy capital, \nwe'll certainly look to execute on that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And the next one will be from Jailendra Singh with Credit Suisse.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThank you, and hello, everyone.  So with respect to $0.45 core business outperformance you called out, which is \nnow captured in your fiscal 2022 outlook, how do you think about the sustainability of some of those drivers \nbehin d that outperformance?  And related to that, how should we think about the fiscal 2022 baseline EPS of \n$17.50 to $18 you shared at your Investor Day?  \n ", "original_text": "Please go ahead.  \n "}, "hash": "88011c22367e159631de9396e20de9ecf91c5c0777a9476740fe47529d77ffbd", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And the next one will be from Jailendra Singh with Credit Suisse. ", "start_char_idx": 2514, "end_char_idx": 2865, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bc227165-ddf2-4a33-9d68-ad3119d4d199": {"__data__": {"id_": "bc227165-ddf2-4a33-9d68-ad3119d4d199", "embedding": null, "metadata": {"window": "As long as we find that strategically \naligned asset and it can meet our financial hurdles and stand up well to other means we have to deploy capital, \nwe'll certainly look to execute on that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And the next one will be from Jailendra Singh with Credit Suisse.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThank you, and hello, everyone.  So with respect to $0.45 core business outperformance you called out, which is \nnow captured in your fiscal 2022 outlook, how do you think about the sustainability of some of those drivers \nbehin d that outperformance?  And related to that, how should we think about the fiscal 2022 baseline EPS of \n$17.50 to $18 you shared at your Investor Day?  \n ", "original_text": "Please go ahead.  \n ", "page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc629de4-825c-4a81-8fe5-d4c62e367c38", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ae7f25de25af20cb283d7ffa58afdb15c062ec247254da5a21a74d863dc9d50", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6c917ddf-8972-4006-acd4-88e243f8d83f", "node_type": "1", "metadata": {"window": "This is an area that we would like to use the strength of our balance sheet t o be acquisitive, to be \nadditive to that ecosystem through additional capability or additional scale.  As long as we find that strategically \naligned asset and it can meet our financial hurdles and stand up well to other means we have to deploy capital, \nwe'll certainly look to execute on that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And the next one will be from Jailendra Singh with Credit Suisse.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThank you, and hello, everyone.  So with respect to $0.45 core business outperformance you called out, which is \nnow captured in your fiscal 2022 outlook, how do you think about the sustainability of some of those drivers \nbehin d that outperformance? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And the next one will be from Jailendra Singh with Credit Suisse. ", "page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ea5ec8a02d13567ff592ac99fe2d9ae81e79bb799ad451f72f2bce0305362504", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8aa92e93-a308-4505-a63d-e31620bc109c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And the next one will be from Jailendra Singh with Credit Suisse.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThank you, and hello, everyone.  So with respect to $0.45 core business outperformance you called out, which is \nnow captured in your fiscal 2022 outlook, how do you think about the sustainability of some of those drivers \nbehin d that outperformance?  And related to that, how should we think about the fiscal 2022 baseline EPS of \n$17.50 to $18 you shared at your Investor Day?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThank you, and hello, everyone. "}, "hash": "7e8e6adf3d3efadf25dd97e5da67be878e5a4cd8132ddf725e1ae603ba42b1b0", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n ", "start_char_idx": 2865, "end_char_idx": 2885, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8aa92e93-a308-4505-a63d-e31620bc109c": {"__data__": {"id_": "8aa92e93-a308-4505-a63d-e31620bc109c", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And the next one will be from Jailendra Singh with Credit Suisse.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThank you, and hello, everyone.  So with respect to $0.45 core business outperformance you called out, which is \nnow captured in your fiscal 2022 outlook, how do you think about the sustainability of some of those drivers \nbehin d that outperformance?  And related to that, how should we think about the fiscal 2022 baseline EPS of \n$17.50 to $18 you shared at your Investor Day?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThank you, and hello, everyone. ", "page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc629de4-825c-4a81-8fe5-d4c62e367c38", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ae7f25de25af20cb283d7ffa58afdb15c062ec247254da5a21a74d863dc9d50", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bc227165-ddf2-4a33-9d68-ad3119d4d199", "node_type": "1", "metadata": {"window": "As long as we find that strategically \naligned asset and it can meet our financial hurdles and stand up well to other means we have to deploy capital, \nwe'll certainly look to execute on that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And the next one will be from Jailendra Singh with Credit Suisse.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThank you, and hello, everyone.  So with respect to $0.45 core business outperformance you called out, which is \nnow captured in your fiscal 2022 outlook, how do you think about the sustainability of some of those drivers \nbehin d that outperformance?  And related to that, how should we think about the fiscal 2022 baseline EPS of \n$17.50 to $18 you shared at your Investor Day?  \n ", "original_text": "Please go ahead.  \n ", "page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "499c7a480acceb3ef02286473ef52da757d7d21c33af7e8f7b61e23a760aba1c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "953e15bf-e429-4a15-ad0f-bae0f3bd694c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And the next one will be from Jailendra Singh with Credit Suisse.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThank you, and hello, everyone.  So with respect to $0.45 core business outperformance you called out, which is \nnow captured in your fiscal 2022 outlook, how do you think about the sustainability of some of those drivers \nbehin d that outperformance?  And related to that, how should we think about the fiscal 2022 baseline EPS of \n$17.50 to $18 you shared at your Investor Day?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nLet me take those in  two pieces. ", "original_text": "So with respect to $0.45 core business outperformance you called out, which is \nnow captured in your fiscal 2022 outlook, how do you think about the sustainability of some of those drivers \nbehin d that outperformance? "}, "hash": "1d05c4e1fd30f7d2f0d3a062c9fa1b642ef7f6c5d5f69a3790f1d401ee66ed42", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThank you, and hello, everyone. ", "start_char_idx": 2885, "end_char_idx": 3255, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "953e15bf-e429-4a15-ad0f-bae0f3bd694c": {"__data__": {"id_": "953e15bf-e429-4a15-ad0f-bae0f3bd694c", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And the next one will be from Jailendra Singh with Credit Suisse.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThank you, and hello, everyone.  So with respect to $0.45 core business outperformance you called out, which is \nnow captured in your fiscal 2022 outlook, how do you think about the sustainability of some of those drivers \nbehin d that outperformance?  And related to that, how should we think about the fiscal 2022 baseline EPS of \n$17.50 to $18 you shared at your Investor Day?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nLet me take those in  two pieces. ", "original_text": "So with respect to $0.45 core business outperformance you called out, which is \nnow captured in your fiscal 2022 outlook, how do you think about the sustainability of some of those drivers \nbehin d that outperformance? ", "page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc629de4-825c-4a81-8fe5-d4c62e367c38", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ae7f25de25af20cb283d7ffa58afdb15c062ec247254da5a21a74d863dc9d50", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8aa92e93-a308-4505-a63d-e31620bc109c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And the next one will be from Jailendra Singh with Credit Suisse.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThank you, and hello, everyone.  So with respect to $0.45 core business outperformance you called out, which is \nnow captured in your fiscal 2022 outlook, how do you think about the sustainability of some of those drivers \nbehin d that outperformance?  And related to that, how should we think about the fiscal 2022 baseline EPS of \n$17.50 to $18 you shared at your Investor Day?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThank you, and hello, everyone. ", "page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "65f7dadcaca4a6be6d281eff74f37beca48864ab481a0413f40a35fa3e529c35", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "25ad743d-07df-4748-a6b3-cf92797c8054", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThank you, and hello, everyone.  So with respect to $0.45 core business outperformance you called out, which is \nnow captured in your fiscal 2022 outlook, how do you think about the sustainability of some of those drivers \nbehin d that outperformance?  And related to that, how should we think about the fiscal 2022 baseline EPS of \n$17.50 to $18 you shared at your Investor Day?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nLet me take those in  two pieces.  We're pleased with another quarter of strong operating performance, and \nobviously, you saw growth across each of our segments. ", "original_text": "And related to that, how should we think about the fiscal 2022 baseline EPS of \n$17.50 to $18 you shared at your Investor Day?  \n "}, "hash": "930abd937baa62fb95600d310393306a0a01e51212b15851de4b7884fc6b13f9", "class_name": "RelatedNodeInfo"}}, "text": "So with respect to $0.45 core business outperformance you called out, which is \nnow captured in your fiscal 2022 outlook, how do you think about the sustainability of some of those drivers \nbehin d that outperformance? ", "start_char_idx": 3255, "end_char_idx": 3474, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "25ad743d-07df-4748-a6b3-cf92797c8054": {"__data__": {"id_": "25ad743d-07df-4748-a6b3-cf92797c8054", "embedding": null, "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThank you, and hello, everyone.  So with respect to $0.45 core business outperformance you called out, which is \nnow captured in your fiscal 2022 outlook, how do you think about the sustainability of some of those drivers \nbehin d that outperformance?  And related to that, how should we think about the fiscal 2022 baseline EPS of \n$17.50 to $18 you shared at your Investor Day?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nLet me take those in  two pieces.  We're pleased with another quarter of strong operating performance, and \nobviously, you saw growth across each of our segments. ", "original_text": "And related to that, how should we think about the fiscal 2022 baseline EPS of \n$17.50 to $18 you shared at your Investor Day?  \n ", "page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc629de4-825c-4a81-8fe5-d4c62e367c38", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ae7f25de25af20cb283d7ffa58afdb15c062ec247254da5a21a74d863dc9d50", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "953e15bf-e429-4a15-ad0f-bae0f3bd694c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And the next one will be from Jailendra Singh with Credit Suisse.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThank you, and hello, everyone.  So with respect to $0.45 core business outperformance you called out, which is \nnow captured in your fiscal 2022 outlook, how do you think about the sustainability of some of those drivers \nbehin d that outperformance?  And related to that, how should we think about the fiscal 2022 baseline EPS of \n$17.50 to $18 you shared at your Investor Day?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nLet me take those in  two pieces. ", "original_text": "So with respect to $0.45 core business outperformance you called out, which is \nnow captured in your fiscal 2022 outlook, how do you think about the sustainability of some of those drivers \nbehin d that outperformance? ", "page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "460d60542303a6d20c262085f50c2f5c48e262d4981f252d64d3ded8c7f3eca9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a3dc1602-fcc4-4181-8c2e-b406433d5cb4", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThank you, and hello, everyone.  So with respect to $0.45 core business outperformance you called out, which is \nnow captured in your fiscal 2022 outlook, how do you think about the sustainability of some of those drivers \nbehin d that outperformance?  And related to that, how should we think about the fiscal 2022 baseline EPS of \n$17.50 to $18 you shared at your Investor Day?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nLet me take those in  two pieces.  We're pleased with another quarter of strong operating performance, and \nobviously, you saw growth across each of our segments.  So as we look at the outlook for the remainder of the \nyear, we expect that the momentum in our business is going to continue.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "b6683ac00a403c61e6c2d89497c860c12117f0f83bf7f479979fdda548c530ff", "class_name": "RelatedNodeInfo"}}, "text": "And related to that, how should we think about the fiscal 2022 baseline EPS of \n$17.50 to $18 you shared at your Investor Day?  \n ", "start_char_idx": 3474, "end_char_idx": 3604, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a3dc1602-fcc4-4181-8c2e-b406433d5cb4": {"__data__": {"id_": "a3dc1602-fcc4-4181-8c2e-b406433d5cb4", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThank you, and hello, everyone.  So with respect to $0.45 core business outperformance you called out, which is \nnow captured in your fiscal 2022 outlook, how do you think about the sustainability of some of those drivers \nbehin d that outperformance?  And related to that, how should we think about the fiscal 2022 baseline EPS of \n$17.50 to $18 you shared at your Investor Day?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nLet me take those in  two pieces.  We're pleased with another quarter of strong operating performance, and \nobviously, you saw growth across each of our segments.  So as we look at the outlook for the remainder of the \nyear, we expect that the momentum in our business is going to continue.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc629de4-825c-4a81-8fe5-d4c62e367c38", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ae7f25de25af20cb283d7ffa58afdb15c062ec247254da5a21a74d863dc9d50", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "25ad743d-07df-4748-a6b3-cf92797c8054", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThank you, and hello, everyone.  So with respect to $0.45 core business outperformance you called out, which is \nnow captured in your fiscal 2022 outlook, how do you think about the sustainability of some of those drivers \nbehin d that outperformance?  And related to that, how should we think about the fiscal 2022 baseline EPS of \n$17.50 to $18 you shared at your Investor Day?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nLet me take those in  two pieces.  We're pleased with another quarter of strong operating performance, and \nobviously, you saw growth across each of our segments. ", "original_text": "And related to that, how should we think about the fiscal 2022 baseline EPS of \n$17.50 to $18 you shared at your Investor Day?  \n ", "page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1923dcb675961e17bb8bf563dc8c2d12cc1e6e95f5be4ad3ad0d104ee530e302", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6d3000b1-6feb-42a8-85d8-65ec6a7f6d9e", "node_type": "1", "metadata": {"window": "So with respect to $0.45 core business outperformance you called out, which is \nnow captured in your fiscal 2022 outlook, how do you think about the sustainability of some of those drivers \nbehin d that outperformance?  And related to that, how should we think about the fiscal 2022 baseline EPS of \n$17.50 to $18 you shared at your Investor Day?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nLet me take those in  two pieces.  We're pleased with another quarter of strong operating performance, and \nobviously, you saw growth across each of our segments.  So as we look at the outlook for the remainder of the \nyear, we expect that the momentum in our business is going to continue.  \n \n And we haven't provided any guidance as it relates to FY 2023, but at our Investor Day, we did provide long -term \ntargets, where we suggested and felt very confident that we'll continue to see growth in each of those segments ", "original_text": "A \nLet me take those in  two pieces. "}, "hash": "e0edbfb25f9e8702a00bfc4b702da0a683061bd8727d49ab3cc056a00d635cd1", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 3604, "end_char_idx": 3961, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6d3000b1-6feb-42a8-85d8-65ec6a7f6d9e": {"__data__": {"id_": "6d3000b1-6feb-42a8-85d8-65ec6a7f6d9e", "embedding": null, "metadata": {"window": "So with respect to $0.45 core business outperformance you called out, which is \nnow captured in your fiscal 2022 outlook, how do you think about the sustainability of some of those drivers \nbehin d that outperformance?  And related to that, how should we think about the fiscal 2022 baseline EPS of \n$17.50 to $18 you shared at your Investor Day?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nLet me take those in  two pieces.  We're pleased with another quarter of strong operating performance, and \nobviously, you saw growth across each of our segments.  So as we look at the outlook for the remainder of the \nyear, we expect that the momentum in our business is going to continue.  \n \n And we haven't provided any guidance as it relates to FY 2023, but at our Investor Day, we did provide long -term \ntargets, where we suggested and felt very confident that we'll continue to see growth in each of those segments ", "original_text": "A \nLet me take those in  two pieces. ", "page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc629de4-825c-4a81-8fe5-d4c62e367c38", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ae7f25de25af20cb283d7ffa58afdb15c062ec247254da5a21a74d863dc9d50", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a3dc1602-fcc4-4181-8c2e-b406433d5cb4", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nJailendra Singh  \nAnalyst, Credit Suisse Securities (USA) LLC  Q \nThank you, and hello, everyone.  So with respect to $0.45 core business outperformance you called out, which is \nnow captured in your fiscal 2022 outlook, how do you think about the sustainability of some of those drivers \nbehin d that outperformance?  And related to that, how should we think about the fiscal 2022 baseline EPS of \n$17.50 to $18 you shared at your Investor Day?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nLet me take those in  two pieces.  We're pleased with another quarter of strong operating performance, and \nobviously, you saw growth across each of our segments.  So as we look at the outlook for the remainder of the \nyear, we expect that the momentum in our business is going to continue.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d476935be1918a4be2812763e305cfc792521ec790b182045c2736e7f3b1dfc3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "90db45c9-8c56-4b19-b000-96ca573dcb83", "node_type": "1", "metadata": {"window": "And related to that, how should we think about the fiscal 2022 baseline EPS of \n$17.50 to $18 you shared at your Investor Day?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nLet me take those in  two pieces.  We're pleased with another quarter of strong operating performance, and \nobviously, you saw growth across each of our segments.  So as we look at the outlook for the remainder of the \nyear, we expect that the momentum in our business is going to continue.  \n \n And we haven't provided any guidance as it relates to FY 2023, but at our Investor Day, we did provide long -term \ntargets, where we suggested and felt very confident that we'll continue to see growth in each of those segments ", "original_text": "We're pleased with another quarter of strong operating performance, and \nobviously, you saw growth across each of our segments. "}, "hash": "c4226174da067bb8e2973d3c729ff605922c5e4b5fb7738bfcb202c0cdf01fe6", "class_name": "RelatedNodeInfo"}}, "text": "A \nLet me take those in  two pieces. ", "start_char_idx": 3961, "end_char_idx": 3998, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "90db45c9-8c56-4b19-b000-96ca573dcb83": {"__data__": {"id_": "90db45c9-8c56-4b19-b000-96ca573dcb83", "embedding": null, "metadata": {"window": "And related to that, how should we think about the fiscal 2022 baseline EPS of \n$17.50 to $18 you shared at your Investor Day?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nLet me take those in  two pieces.  We're pleased with another quarter of strong operating performance, and \nobviously, you saw growth across each of our segments.  So as we look at the outlook for the remainder of the \nyear, we expect that the momentum in our business is going to continue.  \n \n And we haven't provided any guidance as it relates to FY 2023, but at our Investor Day, we did provide long -term \ntargets, where we suggested and felt very confident that we'll continue to see growth in each of those segments ", "original_text": "We're pleased with another quarter of strong operating performance, and \nobviously, you saw growth across each of our segments. ", "page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc629de4-825c-4a81-8fe5-d4c62e367c38", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ae7f25de25af20cb283d7ffa58afdb15c062ec247254da5a21a74d863dc9d50", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6d3000b1-6feb-42a8-85d8-65ec6a7f6d9e", "node_type": "1", "metadata": {"window": "So with respect to $0.45 core business outperformance you called out, which is \nnow captured in your fiscal 2022 outlook, how do you think about the sustainability of some of those drivers \nbehin d that outperformance?  And related to that, how should we think about the fiscal 2022 baseline EPS of \n$17.50 to $18 you shared at your Investor Day?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nLet me take those in  two pieces.  We're pleased with another quarter of strong operating performance, and \nobviously, you saw growth across each of our segments.  So as we look at the outlook for the remainder of the \nyear, we expect that the momentum in our business is going to continue.  \n \n And we haven't provided any guidance as it relates to FY 2023, but at our Investor Day, we did provide long -term \ntargets, where we suggested and felt very confident that we'll continue to see growth in each of those segments ", "original_text": "A \nLet me take those in  two pieces. ", "page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6104be0ea37791b0881921dc6c9de1ee971766fa22c5d6824c4db6bbabb995f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8f318303-8e61-4aec-92d0-8aba6cc477c6", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nLet me take those in  two pieces.  We're pleased with another quarter of strong operating performance, and \nobviously, you saw growth across each of our segments.  So as we look at the outlook for the remainder of the \nyear, we expect that the momentum in our business is going to continue.  \n \n And we haven't provided any guidance as it relates to FY 2023, but at our Investor Day, we did provide long -term \ntargets, where we suggested and felt very confident that we'll continue to see growth in each of those segments ", "original_text": "So as we look at the outlook for the remainder of the \nyear, we expect that the momentum in our business is going to continue.  \n \n"}, "hash": "32353d002cd0dc0b7ad432b01bc44516959558ca9873dc395be6e66a5699204b", "class_name": "RelatedNodeInfo"}}, "text": "We're pleased with another quarter of strong operating performance, and \nobviously, you saw growth across each of our segments. ", "start_char_idx": 3998, "end_char_idx": 4126, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8f318303-8e61-4aec-92d0-8aba6cc477c6": {"__data__": {"id_": "8f318303-8e61-4aec-92d0-8aba6cc477c6", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nLet me take those in  two pieces.  We're pleased with another quarter of strong operating performance, and \nobviously, you saw growth across each of our segments.  So as we look at the outlook for the remainder of the \nyear, we expect that the momentum in our business is going to continue.  \n \n And we haven't provided any guidance as it relates to FY 2023, but at our Investor Day, we did provide long -term \ntargets, where we suggested and felt very confident that we'll continue to see growth in each of those segments ", "original_text": "So as we look at the outlook for the remainder of the \nyear, we expect that the momentum in our business is going to continue.  \n \n", "page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc629de4-825c-4a81-8fe5-d4c62e367c38", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ae7f25de25af20cb283d7ffa58afdb15c062ec247254da5a21a74d863dc9d50", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "90db45c9-8c56-4b19-b000-96ca573dcb83", "node_type": "1", "metadata": {"window": "And related to that, how should we think about the fiscal 2022 baseline EPS of \n$17.50 to $18 you shared at your Investor Day?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nLet me take those in  two pieces.  We're pleased with another quarter of strong operating performance, and \nobviously, you saw growth across each of our segments.  So as we look at the outlook for the remainder of the \nyear, we expect that the momentum in our business is going to continue.  \n \n And we haven't provided any guidance as it relates to FY 2023, but at our Investor Day, we did provide long -term \ntargets, where we suggested and felt very confident that we'll continue to see growth in each of those segments ", "original_text": "We're pleased with another quarter of strong operating performance, and \nobviously, you saw growth across each of our segments. ", "page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd366afbf838187816bdd5353a5bbf8357f6aec1ba4add24bd02b4e263176fba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e3fab23d-b2b2-409b-8733-1894cdeff436", "node_type": "1", "metadata": {"window": "A \nLet me take those in  two pieces.  We're pleased with another quarter of strong operating performance, and \nobviously, you saw growth across each of our segments.  So as we look at the outlook for the remainder of the \nyear, we expect that the momentum in our business is going to continue.  \n \n And we haven't provided any guidance as it relates to FY 2023, but at our Investor Day, we did provide long -term \ntargets, where we suggested and felt very confident that we'll continue to see growth in each of those segments ", "original_text": "And we haven't provided any guidance as it relates to FY 2023, but at our Investor Day, we did provide long -term \ntargets, where we suggested and felt very confident that we'll continue to see growth in each of those segments "}, "hash": "6f769bcb32a726a2d59da71078cc99437d20b7632f32cd95a398df9cb680c0c3", "class_name": "RelatedNodeInfo"}}, "text": "So as we look at the outlook for the remainder of the \nyear, we expect that the momentum in our business is going to continue.  \n \n", "start_char_idx": 4126, "end_char_idx": 4257, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e3fab23d-b2b2-409b-8733-1894cdeff436": {"__data__": {"id_": "e3fab23d-b2b2-409b-8733-1894cdeff436", "embedding": null, "metadata": {"window": "A \nLet me take those in  two pieces.  We're pleased with another quarter of strong operating performance, and \nobviously, you saw growth across each of our segments.  So as we look at the outlook for the remainder of the \nyear, we expect that the momentum in our business is going to continue.  \n \n And we haven't provided any guidance as it relates to FY 2023, but at our Investor Day, we did provide long -term \ntargets, where we suggested and felt very confident that we'll continue to see growth in each of those segments ", "original_text": "And we haven't provided any guidance as it relates to FY 2023, but at our Investor Day, we did provide long -term \ntargets, where we suggested and felt very confident that we'll continue to see growth in each of those segments ", "page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc629de4-825c-4a81-8fe5-d4c62e367c38", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ae7f25de25af20cb283d7ffa58afdb15c062ec247254da5a21a74d863dc9d50", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8f318303-8e61-4aec-92d0-8aba6cc477c6", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nLet me take those in  two pieces.  We're pleased with another quarter of strong operating performance, and \nobviously, you saw growth across each of our segments.  So as we look at the outlook for the remainder of the \nyear, we expect that the momentum in our business is going to continue.  \n \n And we haven't provided any guidance as it relates to FY 2023, but at our Investor Day, we did provide long -term \ntargets, where we suggested and felt very confident that we'll continue to see growth in each of those segments ", "original_text": "So as we look at the outlook for the remainder of the \nyear, we expect that the momentum in our business is going to continue.  \n \n", "page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db2a65cc696c7aa4c9648b2456fff898a7e3d27d0f083a422d9b7e7e8beda900", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "89f1971c-d0a5-4174-8ff2-54f6b209b560", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nfor the long term.  So, we feel very good about the performance that we're seeing in our business.  And consistent \nwith our Investor Day, we expect that to continue.  \n \n", "original_text": "McKesson Corp.  "}, "hash": "c1155c6db2e8920edebb2c8a4aa6cabe663aa5752b16ec7fe14e022487a1dd0f", "class_name": "RelatedNodeInfo"}}, "text": "And we haven't provided any guidance as it relates to FY 2023, but at our Investor Day, we did provide long -term \ntargets, where we suggested and felt very confident that we'll continue to see growth in each of those segments ", "start_char_idx": 4257, "end_char_idx": 4484, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "89f1971c-d0a5-4174-8ff2-54f6b209b560": {"__data__": {"id_": "89f1971c-d0a5-4174-8ff2-54f6b209b560", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nfor the long term.  So, we feel very good about the performance that we're seeing in our business.  And consistent \nwith our Investor Day, we expect that to continue.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "692933c6-e017-4d68-907a-60e809f96ddd", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "22b93ece2d146eb9ac30968837125e52c9026dc861b7c3d96c31621bdd0992f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e3fab23d-b2b2-409b-8733-1894cdeff436", "node_type": "1", "metadata": {"window": "A \nLet me take those in  two pieces.  We're pleased with another quarter of strong operating performance, and \nobviously, you saw growth across each of our segments.  So as we look at the outlook for the remainder of the \nyear, we expect that the momentum in our business is going to continue.  \n \n And we haven't provided any guidance as it relates to FY 2023, but at our Investor Day, we did provide long -term \ntargets, where we suggested and felt very confident that we'll continue to see growth in each of those segments ", "original_text": "And we haven't provided any guidance as it relates to FY 2023, but at our Investor Day, we did provide long -term \ntargets, where we suggested and felt very confident that we'll continue to see growth in each of those segments ", "page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c4f754306f6a557bc74ae90f2be18d1f24dd888334d7a814153471e4871f62eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "67dcf5c0-00cb-43ec-8cb8-0329065def1c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nfor the long term.  So, we feel very good about the performance that we're seeing in our business.  And consistent \nwith our Investor Day, we expect that to continue.  \n \n So, I think that is really the point that you should see here is just continued strong performance for several  years \nnow across all of our segments. ", "original_text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nfor the long term. "}, "hash": "ba108d4355a34b4f69b646ea67678ba8c8df4043e7ce75018276715fa4136b2f", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "67dcf5c0-00cb-43ec-8cb8-0329065def1c": {"__data__": {"id_": "67dcf5c0-00cb-43ec-8cb8-0329065def1c", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nfor the long term.  So, we feel very good about the performance that we're seeing in our business.  And consistent \nwith our Investor Day, we expect that to continue.  \n \n So, I think that is really the point that you should see here is just continued strong performance for several  years \nnow across all of our segments. ", "original_text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nfor the long term. ", "page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "692933c6-e017-4d68-907a-60e809f96ddd", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "22b93ece2d146eb9ac30968837125e52c9026dc861b7c3d96c31621bdd0992f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "89f1971c-d0a5-4174-8ff2-54f6b209b560", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nfor the long term.  So, we feel very good about the performance that we're seeing in our business.  And consistent \nwith our Investor Day, we expect that to continue.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "083fccb2b62b992d0183a2130c52c5dc021d0e1056b40bfa8acb149b20b391b8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "108a56c8-e2dd-4997-bef5-50ff15a06325", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nfor the long term.  So, we feel very good about the performance that we're seeing in our business.  And consistent \nwith our Investor Day, we expect that to continue.  \n \n So, I think that is really the point that you should see here is just continued strong performance for several  years \nnow across all of our segments.  The fundamentals of our businesses are strong. ", "original_text": "So, we feel very good about the performance that we're seeing in our business. "}, "hash": "5751e0db95a8f2139b8cee7ffe7916d62a62094c30d1a95fd88489516995d496", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nfor the long term. ", "start_char_idx": 16, "end_char_idx": 200, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "108a56c8-e2dd-4997-bef5-50ff15a06325": {"__data__": {"id_": "108a56c8-e2dd-4997-bef5-50ff15a06325", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nfor the long term.  So, we feel very good about the performance that we're seeing in our business.  And consistent \nwith our Investor Day, we expect that to continue.  \n \n So, I think that is really the point that you should see here is just continued strong performance for several  years \nnow across all of our segments.  The fundamentals of our businesses are strong. ", "original_text": "So, we feel very good about the performance that we're seeing in our business. ", "page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "692933c6-e017-4d68-907a-60e809f96ddd", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "22b93ece2d146eb9ac30968837125e52c9026dc861b7c3d96c31621bdd0992f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "67dcf5c0-00cb-43ec-8cb8-0329065def1c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nfor the long term.  So, we feel very good about the performance that we're seeing in our business.  And consistent \nwith our Investor Day, we expect that to continue.  \n \n So, I think that is really the point that you should see here is just continued strong performance for several  years \nnow across all of our segments. ", "original_text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nfor the long term. ", "page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46e0c0d0ed09229cae4b2adac6010bd4413f26de9071da0d6b78d6ab69d0e068", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7ea86e05-e244-4e40-83fd-e2a952caf437", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nfor the long term.  So, we feel very good about the performance that we're seeing in our business.  And consistent \nwith our Investor Day, we expect that to continue.  \n \n So, I think that is really the point that you should see here is just continued strong performance for several  years \nnow across all of our segments.  The fundamentals of our businesses are strong.  We're investing in these \nbusinesses for future growth. ", "original_text": "And consistent \nwith our Investor Day, we expect that to continue.  \n \n"}, "hash": "4a5cedb601939d8ceca5140d512ee93384d3ec01d385a2bb126bc1296f73d744", "class_name": "RelatedNodeInfo"}}, "text": "So, we feel very good about the performance that we're seeing in our business. ", "start_char_idx": 200, "end_char_idx": 279, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7ea86e05-e244-4e40-83fd-e2a952caf437": {"__data__": {"id_": "7ea86e05-e244-4e40-83fd-e2a952caf437", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nfor the long term.  So, we feel very good about the performance that we're seeing in our business.  And consistent \nwith our Investor Day, we expect that to continue.  \n \n So, I think that is really the point that you should see here is just continued strong performance for several  years \nnow across all of our segments.  The fundamentals of our businesses are strong.  We're investing in these \nbusinesses for future growth. ", "original_text": "And consistent \nwith our Investor Day, we expect that to continue.  \n \n", "page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "692933c6-e017-4d68-907a-60e809f96ddd", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "22b93ece2d146eb9ac30968837125e52c9026dc861b7c3d96c31621bdd0992f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "108a56c8-e2dd-4997-bef5-50ff15a06325", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nfor the long term.  So, we feel very good about the performance that we're seeing in our business.  And consistent \nwith our Investor Day, we expect that to continue.  \n \n So, I think that is really the point that you should see here is just continued strong performance for several  years \nnow across all of our segments.  The fundamentals of our businesses are strong. ", "original_text": "So, we feel very good about the performance that we're seeing in our business. ", "page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f566fb63f05676bb770951121d814ffd1c1ebd150dfe2c15d3d1fc08305cd0a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cf594c66-6bbc-40e9-a7bc-4348336a79b8", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nfor the long term.  So, we feel very good about the performance that we're seeing in our business.  And consistent \nwith our Investor Day, we expect that to continue.  \n \n So, I think that is really the point that you should see here is just continued strong performance for several  years \nnow across all of our segments.  The fundamentals of our businesses are strong.  We're investing in these \nbusinesses for future growth.  And we're in markets that we think are going to continue to grow, and we're in very \ngood positions to take advantag e of that with some differentiated capabilities.  \n ", "original_text": "So, I think that is really the point that you should see here is just continued strong performance for several  years \nnow across all of our segments. "}, "hash": "6ee09306e90d887df1ab1924fccd770ff84027b56fb577dfc782cb9888d9c558", "class_name": "RelatedNodeInfo"}}, "text": "And consistent \nwith our Investor Day, we expect that to continue.  \n \n", "start_char_idx": 279, "end_char_idx": 350, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cf594c66-6bbc-40e9-a7bc-4348336a79b8": {"__data__": {"id_": "cf594c66-6bbc-40e9-a7bc-4348336a79b8", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nfor the long term.  So, we feel very good about the performance that we're seeing in our business.  And consistent \nwith our Investor Day, we expect that to continue.  \n \n So, I think that is really the point that you should see here is just continued strong performance for several  years \nnow across all of our segments.  The fundamentals of our businesses are strong.  We're investing in these \nbusinesses for future growth.  And we're in markets that we think are going to continue to grow, and we're in very \ngood positions to take advantag e of that with some differentiated capabilities.  \n ", "original_text": "So, I think that is really the point that you should see here is just continued strong performance for several  years \nnow across all of our segments. ", "page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "692933c6-e017-4d68-907a-60e809f96ddd", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "22b93ece2d146eb9ac30968837125e52c9026dc861b7c3d96c31621bdd0992f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7ea86e05-e244-4e40-83fd-e2a952caf437", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nfor the long term.  So, we feel very good about the performance that we're seeing in our business.  And consistent \nwith our Investor Day, we expect that to continue.  \n \n So, I think that is really the point that you should see here is just continued strong performance for several  years \nnow across all of our segments.  The fundamentals of our businesses are strong.  We're investing in these \nbusinesses for future growth. ", "original_text": "And consistent \nwith our Investor Day, we expect that to continue.  \n \n", "page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63d954a08a73127a304f32d9c6720d2d650c59c5f3b0204ad058e43bbe9a659e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "82d7100d-ac7e-445d-8439-1a1221bd59b9", "node_type": "1", "metadata": {"window": "So, we feel very good about the performance that we're seeing in our business.  And consistent \nwith our Investor Day, we expect that to continue.  \n \n So, I think that is really the point that you should see here is just continued strong performance for several  years \nnow across all of our segments.  The fundamentals of our businesses are strong.  We're investing in these \nbusinesses for future growth.  And we're in markets that we think are going to continue to grow, and we're in very \ngood positions to take advantag e of that with some differentiated capabilities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n ", "original_text": "The fundamentals of our businesses are strong. "}, "hash": "9dd1b453a33d1d66791826748e8e9063b0eb4b6ab981347bf33741d8fb47cfcb", "class_name": "RelatedNodeInfo"}}, "text": "So, I think that is really the point that you should see here is just continued strong performance for several  years \nnow across all of our segments. ", "start_char_idx": 350, "end_char_idx": 501, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "82d7100d-ac7e-445d-8439-1a1221bd59b9": {"__data__": {"id_": "82d7100d-ac7e-445d-8439-1a1221bd59b9", "embedding": null, "metadata": {"window": "So, we feel very good about the performance that we're seeing in our business.  And consistent \nwith our Investor Day, we expect that to continue.  \n \n So, I think that is really the point that you should see here is just continued strong performance for several  years \nnow across all of our segments.  The fundamentals of our businesses are strong.  We're investing in these \nbusinesses for future growth.  And we're in markets that we think are going to continue to grow, and we're in very \ngood positions to take advantag e of that with some differentiated capabilities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n ", "original_text": "The fundamentals of our businesses are strong. ", "page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "692933c6-e017-4d68-907a-60e809f96ddd", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "22b93ece2d146eb9ac30968837125e52c9026dc861b7c3d96c31621bdd0992f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cf594c66-6bbc-40e9-a7bc-4348336a79b8", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nfor the long term.  So, we feel very good about the performance that we're seeing in our business.  And consistent \nwith our Investor Day, we expect that to continue.  \n \n So, I think that is really the point that you should see here is just continued strong performance for several  years \nnow across all of our segments.  The fundamentals of our businesses are strong.  We're investing in these \nbusinesses for future growth.  And we're in markets that we think are going to continue to grow, and we're in very \ngood positions to take advantag e of that with some differentiated capabilities.  \n ", "original_text": "So, I think that is really the point that you should see here is just continued strong performance for several  years \nnow across all of our segments. ", "page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a2fcc6549c48a75ab7bfbd61139127fe9a5c7b878673bfb3fd1ea79a855a69c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6113ee01-d6e4-4307-a23f-488edcdb653b", "node_type": "1", "metadata": {"window": "And consistent \nwith our Investor Day, we expect that to continue.  \n \n So, I think that is really the point that you should see here is just continued strong performance for several  years \nnow across all of our segments.  The fundamentals of our businesses are strong.  We're investing in these \nbusinesses for future growth.  And we're in markets that we think are going to continue to grow, and we're in very \ngood positions to take advantag e of that with some differentiated capabilities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Bank of America.  \n ", "original_text": "We're investing in these \nbusinesses for future growth. "}, "hash": "d9249e89528b5620ba9f630bc55b9bfbbe2b951603ae3de541790bb3078ad6ed", "class_name": "RelatedNodeInfo"}}, "text": "The fundamentals of our businesses are strong. ", "start_char_idx": 501, "end_char_idx": 548, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6113ee01-d6e4-4307-a23f-488edcdb653b": {"__data__": {"id_": "6113ee01-d6e4-4307-a23f-488edcdb653b", "embedding": null, "metadata": {"window": "And consistent \nwith our Investor Day, we expect that to continue.  \n \n So, I think that is really the point that you should see here is just continued strong performance for several  years \nnow across all of our segments.  The fundamentals of our businesses are strong.  We're investing in these \nbusinesses for future growth.  And we're in markets that we think are going to continue to grow, and we're in very \ngood positions to take advantag e of that with some differentiated capabilities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Bank of America.  \n ", "original_text": "We're investing in these \nbusinesses for future growth. ", "page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "692933c6-e017-4d68-907a-60e809f96ddd", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "22b93ece2d146eb9ac30968837125e52c9026dc861b7c3d96c31621bdd0992f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "82d7100d-ac7e-445d-8439-1a1221bd59b9", "node_type": "1", "metadata": {"window": "So, we feel very good about the performance that we're seeing in our business.  And consistent \nwith our Investor Day, we expect that to continue.  \n \n So, I think that is really the point that you should see here is just continued strong performance for several  years \nnow across all of our segments.  The fundamentals of our businesses are strong.  We're investing in these \nbusinesses for future growth.  And we're in markets that we think are going to continue to grow, and we're in very \ngood positions to take advantag e of that with some differentiated capabilities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n ", "original_text": "The fundamentals of our businesses are strong. ", "page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c58228ca72336dd1883e708f890a34836534187f44992c7048b1faaf93f23ba0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a7792f8e-fbe6-4b47-9726-8dc11e40b994", "node_type": "1", "metadata": {"window": "So, I think that is really the point that you should see here is just continued strong performance for several  years \nnow across all of our segments.  The fundamentals of our businesses are strong.  We're investing in these \nbusinesses for future growth.  And we're in markets that we think are going to continue to grow, and we're in very \ngood positions to take advantag e of that with some differentiated capabilities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "original_text": "And we're in markets that we think are going to continue to grow, and we're in very \ngood positions to take advantag e of that with some differentiated capabilities.  \n "}, "hash": "c5c9a91558f181fd049239737539c36016be87f511bec58a50242f3f552832ea", "class_name": "RelatedNodeInfo"}}, "text": "We're investing in these \nbusinesses for future growth. ", "start_char_idx": 548, "end_char_idx": 604, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a7792f8e-fbe6-4b47-9726-8dc11e40b994": {"__data__": {"id_": "a7792f8e-fbe6-4b47-9726-8dc11e40b994", "embedding": null, "metadata": {"window": "So, I think that is really the point that you should see here is just continued strong performance for several  years \nnow across all of our segments.  The fundamentals of our businesses are strong.  We're investing in these \nbusinesses for future growth.  And we're in markets that we think are going to continue to grow, and we're in very \ngood positions to take advantag e of that with some differentiated capabilities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "original_text": "And we're in markets that we think are going to continue to grow, and we're in very \ngood positions to take advantag e of that with some differentiated capabilities.  \n ", "page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "692933c6-e017-4d68-907a-60e809f96ddd", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "22b93ece2d146eb9ac30968837125e52c9026dc861b7c3d96c31621bdd0992f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6113ee01-d6e4-4307-a23f-488edcdb653b", "node_type": "1", "metadata": {"window": "And consistent \nwith our Investor Day, we expect that to continue.  \n \n So, I think that is really the point that you should see here is just continued strong performance for several  years \nnow across all of our segments.  The fundamentals of our businesses are strong.  We're investing in these \nbusinesses for future growth.  And we're in markets that we think are going to continue to grow, and we're in very \ngood positions to take advantag e of that with some differentiated capabilities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Bank of America.  \n ", "original_text": "We're investing in these \nbusinesses for future growth. ", "page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b54f5ff08b150d422501c504132418edf2d1739f2f188d12b7aecc547e5e1c82", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f63c3445-702c-4c68-b0bc-a2989c8c713a", "node_type": "1", "metadata": {"window": "The fundamentals of our businesses are strong.  We're investing in these \nbusinesses for future growth.  And we're in markets that we think are going to continue to grow, and we're in very \ngood positions to take advantag e of that with some differentiated capabilities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nAfternoon, and thanks for all the color so far. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n "}, "hash": "d5f2b2e023dad6d529ae4216d5cbaad5747f3dfe2c612fb5c93333354105a80a", "class_name": "RelatedNodeInfo"}}, "text": "And we're in markets that we think are going to continue to grow, and we're in very \ngood positions to take advantag e of that with some differentiated capabilities.  \n ", "start_char_idx": 604, "end_char_idx": 773, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f63c3445-702c-4c68-b0bc-a2989c8c713a": {"__data__": {"id_": "f63c3445-702c-4c68-b0bc-a2989c8c713a", "embedding": null, "metadata": {"window": "The fundamentals of our businesses are strong.  We're investing in these \nbusinesses for future growth.  And we're in markets that we think are going to continue to grow, and we're in very \ngood positions to take advantag e of that with some differentiated capabilities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nAfternoon, and thanks for all the color so far. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n ", "page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "692933c6-e017-4d68-907a-60e809f96ddd", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "22b93ece2d146eb9ac30968837125e52c9026dc861b7c3d96c31621bdd0992f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a7792f8e-fbe6-4b47-9726-8dc11e40b994", "node_type": "1", "metadata": {"window": "So, I think that is really the point that you should see here is just continued strong performance for several  years \nnow across all of our segments.  The fundamentals of our businesses are strong.  We're investing in these \nbusinesses for future growth.  And we're in markets that we think are going to continue to grow, and we're in very \ngood positions to take advantag e of that with some differentiated capabilities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "original_text": "And we're in markets that we think are going to continue to grow, and we're in very \ngood positions to take advantag e of that with some differentiated capabilities.  \n ", "page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6730117547c7f76f06f4b49dda485663bccd2403e75bfc820c5acad091e412c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f3797f0-f7a1-4c43-86e9-b4288e2a2619", "node_type": "1", "metadata": {"window": "We're investing in these \nbusinesses for future growth.  And we're in markets that we think are going to continue to grow, and we're in very \ngood positions to take advantag e of that with some differentiated capabilities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nAfternoon, and thanks for all the color so far.  I want to talk a little bit about the US Pharma segment. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Bank of America.  \n "}, "hash": "9ad0e5745ff06711aed0d681c243126436c464ed6bdc31a14b7a6728a7044bb6", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n ", "start_char_idx": 773, "end_char_idx": 1136, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f3797f0-f7a1-4c43-86e9-b4288e2a2619": {"__data__": {"id_": "0f3797f0-f7a1-4c43-86e9-b4288e2a2619", "embedding": null, "metadata": {"window": "We're investing in these \nbusinesses for future growth.  And we're in markets that we think are going to continue to grow, and we're in very \ngood positions to take advantag e of that with some differentiated capabilities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nAfternoon, and thanks for all the color so far.  I want to talk a little bit about the US Pharma segment. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Bank of America.  \n ", "page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "692933c6-e017-4d68-907a-60e809f96ddd", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "22b93ece2d146eb9ac30968837125e52c9026dc861b7c3d96c31621bdd0992f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f63c3445-702c-4c68-b0bc-a2989c8c713a", "node_type": "1", "metadata": {"window": "The fundamentals of our businesses are strong.  We're investing in these \nbusinesses for future growth.  And we're in markets that we think are going to continue to grow, and we're in very \ngood positions to take advantag e of that with some differentiated capabilities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nAfternoon, and thanks for all the color so far. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n ", "page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1d035e4e8b1040061849cb0b6a2aa70e1bcc2425599957fee0cbfd0a43ecb4de", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a0a72b3c-28ab-4344-8f5e-0a46ce62647b", "node_type": "1", "metadata": {"window": "And we're in markets that we think are going to continue to grow, and we're in very \ngood positions to take advantag e of that with some differentiated capabilities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nAfternoon, and thanks for all the color so far.  I want to talk a little bit about the US Pharma segment.  As you think \nabout into next year and thinking more qualitatively as much as anything else, but how do you think about outside \nof the COVID -related scr ipt and volume recovery, the other moving pieces? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  "}, "hash": "c5d5c5f8b62e46c2f2bab5cc99537d0bdc453529b501e1754cfd8435a1f30ad5", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Bank of America.  \n ", "start_char_idx": 1136, "end_char_idx": 1478, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a0a72b3c-28ab-4344-8f5e-0a46ce62647b": {"__data__": {"id_": "a0a72b3c-28ab-4344-8f5e-0a46ce62647b", "embedding": null, "metadata": {"window": "And we're in markets that we think are going to continue to grow, and we're in very \ngood positions to take advantag e of that with some differentiated capabilities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nAfternoon, and thanks for all the color so far.  I want to talk a little bit about the US Pharma segment.  As you think \nabout into next year and thinking more qualitatively as much as anything else, but how do you think about outside \nof the COVID -related scr ipt and volume recovery, the other moving pieces? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "692933c6-e017-4d68-907a-60e809f96ddd", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "22b93ece2d146eb9ac30968837125e52c9026dc861b7c3d96c31621bdd0992f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f3797f0-f7a1-4c43-86e9-b4288e2a2619", "node_type": "1", "metadata": {"window": "We're investing in these \nbusinesses for future growth.  And we're in markets that we think are going to continue to grow, and we're in very \ngood positions to take advantag e of that with some differentiated capabilities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nAfternoon, and thanks for all the color so far.  I want to talk a little bit about the US Pharma segment. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Bank of America.  \n ", "page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d82f17dcd240ec8f4067148dcf5c88e034a2490241c9f195e5145affbc34751a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "beae7579-cf96-4cb3-851b-e6c048a076ba", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nAfternoon, and thanks for all the color so far.  I want to talk a little bit about the US Pharma segment.  As you think \nabout into next year and thinking more qualitatively as much as anything else, but how do you think about outside \nof the COVID -related scr ipt and volume recovery, the other moving pieces?  You did comment on a normalized \nrenewal year. ", "original_text": "Q \nAfternoon, and thanks for all the color so far. "}, "hash": "eac075dcca989826e0b2ac0db4cbaecb4b1c14555722af8965e6b9b530f711a7", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "start_char_idx": 1478, "end_char_idx": 1799, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "beae7579-cf96-4cb3-851b-e6c048a076ba": {"__data__": {"id_": "beae7579-cf96-4cb3-851b-e6c048a076ba", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nAfternoon, and thanks for all the color so far.  I want to talk a little bit about the US Pharma segment.  As you think \nabout into next year and thinking more qualitatively as much as anything else, but how do you think about outside \nof the COVID -related scr ipt and volume recovery, the other moving pieces?  You did comment on a normalized \nrenewal year. ", "original_text": "Q \nAfternoon, and thanks for all the color so far. ", "page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "692933c6-e017-4d68-907a-60e809f96ddd", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "22b93ece2d146eb9ac30968837125e52c9026dc861b7c3d96c31621bdd0992f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a0a72b3c-28ab-4344-8f5e-0a46ce62647b", "node_type": "1", "metadata": {"window": "And we're in markets that we think are going to continue to grow, and we're in very \ngood positions to take advantag e of that with some differentiated capabilities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nAfternoon, and thanks for all the color so far.  I want to talk a little bit about the US Pharma segment.  As you think \nabout into next year and thinking more qualitatively as much as anything else, but how do you think about outside \nof the COVID -related scr ipt and volume recovery, the other moving pieces? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "834b86bdf39403e62f38d650ac9ae1de438cf0cf8786e2bbacd996ad30be1d1c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "81b8f3f0-91a7-470a-9689-6e3cdc4b1501", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nAfternoon, and thanks for all the color so far.  I want to talk a little bit about the US Pharma segment.  As you think \nabout into next year and thinking more qualitatively as much as anything else, but how do you think about outside \nof the COVID -related scr ipt and volume recovery, the other moving pieces?  You did comment on a normalized \nrenewal year.  So, are there anything you're seeing there, big renewals? ", "original_text": "I want to talk a little bit about the US Pharma segment. "}, "hash": "bb8237b9afae7f553af1fa7da2c2b30b5ae3fc9531be95eb9261c1a345498958", "class_name": "RelatedNodeInfo"}}, "text": "Q \nAfternoon, and thanks for all the color so far. ", "start_char_idx": 1799, "end_char_idx": 1850, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "81b8f3f0-91a7-470a-9689-6e3cdc4b1501": {"__data__": {"id_": "81b8f3f0-91a7-470a-9689-6e3cdc4b1501", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nAfternoon, and thanks for all the color so far.  I want to talk a little bit about the US Pharma segment.  As you think \nabout into next year and thinking more qualitatively as much as anything else, but how do you think about outside \nof the COVID -related scr ipt and volume recovery, the other moving pieces?  You did comment on a normalized \nrenewal year.  So, are there anything you're seeing there, big renewals? ", "original_text": "I want to talk a little bit about the US Pharma segment. ", "page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "692933c6-e017-4d68-907a-60e809f96ddd", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "22b93ece2d146eb9ac30968837125e52c9026dc861b7c3d96c31621bdd0992f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "beae7579-cf96-4cb3-851b-e6c048a076ba", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nAfternoon, and thanks for all the color so far.  I want to talk a little bit about the US Pharma segment.  As you think \nabout into next year and thinking more qualitatively as much as anything else, but how do you think about outside \nof the COVID -related scr ipt and volume recovery, the other moving pieces?  You did comment on a normalized \nrenewal year. ", "original_text": "Q \nAfternoon, and thanks for all the color so far. ", "page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "10ac6be5731ec4b553e7a8818c5714b2bf3c1817a3facbd270c5c467acad506c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "65a6280c-4795-45c3-96e9-1899029325e3", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nAfternoon, and thanks for all the color so far.  I want to talk a little bit about the US Pharma segment.  As you think \nabout into next year and thinking more qualitatively as much as anything else, but how do you think about outside \nof the COVID -related scr ipt and volume recovery, the other moving pieces?  You did comment on a normalized \nrenewal year.  So, are there anything you're seeing there, big renewals?  And how do you think about the areas of \ngrowth that have remained steady maybe within specialty and th e potential for biosimilars, and how that should \nfactor into that long -term growth trajectory and where that falls relative to 2023 broadly?  \n ", "original_text": "As you think \nabout into next year and thinking more qualitatively as much as anything else, but how do you think about outside \nof the COVID -related scr ipt and volume recovery, the other moving pieces? "}, "hash": "9e0a4f3b4df0f948173ac9f07a07a6566ff4e1661fc3fa0d1a05578534dc710f", "class_name": "RelatedNodeInfo"}}, "text": "I want to talk a little bit about the US Pharma segment. ", "start_char_idx": 1850, "end_char_idx": 1907, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "65a6280c-4795-45c3-96e9-1899029325e3": {"__data__": {"id_": "65a6280c-4795-45c3-96e9-1899029325e3", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nAfternoon, and thanks for all the color so far.  I want to talk a little bit about the US Pharma segment.  As you think \nabout into next year and thinking more qualitatively as much as anything else, but how do you think about outside \nof the COVID -related scr ipt and volume recovery, the other moving pieces?  You did comment on a normalized \nrenewal year.  So, are there anything you're seeing there, big renewals?  And how do you think about the areas of \ngrowth that have remained steady maybe within specialty and th e potential for biosimilars, and how that should \nfactor into that long -term growth trajectory and where that falls relative to 2023 broadly?  \n ", "original_text": "As you think \nabout into next year and thinking more qualitatively as much as anything else, but how do you think about outside \nof the COVID -related scr ipt and volume recovery, the other moving pieces? ", "page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "692933c6-e017-4d68-907a-60e809f96ddd", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "22b93ece2d146eb9ac30968837125e52c9026dc861b7c3d96c31621bdd0992f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "81b8f3f0-91a7-470a-9689-6e3cdc4b1501", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nAfternoon, and thanks for all the color so far.  I want to talk a little bit about the US Pharma segment.  As you think \nabout into next year and thinking more qualitatively as much as anything else, but how do you think about outside \nof the COVID -related scr ipt and volume recovery, the other moving pieces?  You did comment on a normalized \nrenewal year.  So, are there anything you're seeing there, big renewals? ", "original_text": "I want to talk a little bit about the US Pharma segment. ", "page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4b5af340b21e566192ddc72419cd9a2f8830a81d5345aa0eb4eb5306168bd233", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8901681f-dd2e-4e2e-b312-e2161e398c7e", "node_type": "1", "metadata": {"window": "Q \nAfternoon, and thanks for all the color so far.  I want to talk a little bit about the US Pharma segment.  As you think \nabout into next year and thinking more qualitatively as much as anything else, but how do you think about outside \nof the COVID -related scr ipt and volume recovery, the other moving pieces?  You did comment on a normalized \nrenewal year.  So, are there anything you're seeing there, big renewals?  And how do you think about the areas of \ngrowth that have remained steady maybe within specialty and th e potential for biosimilars, and how that should \nfactor into that long -term growth trajectory and where that falls relative to 2023 broadly?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "You did comment on a normalized \nrenewal year. "}, "hash": "5da605baaac71ffe2122f87bc4d55f2ff9de12bfaf883ad9497e64fc066f1135", "class_name": "RelatedNodeInfo"}}, "text": "As you think \nabout into next year and thinking more qualitatively as much as anything else, but how do you think about outside \nof the COVID -related scr ipt and volume recovery, the other moving pieces? ", "start_char_idx": 1907, "end_char_idx": 2112, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8901681f-dd2e-4e2e-b312-e2161e398c7e": {"__data__": {"id_": "8901681f-dd2e-4e2e-b312-e2161e398c7e", "embedding": null, "metadata": {"window": "Q \nAfternoon, and thanks for all the color so far.  I want to talk a little bit about the US Pharma segment.  As you think \nabout into next year and thinking more qualitatively as much as anything else, but how do you think about outside \nof the COVID -related scr ipt and volume recovery, the other moving pieces?  You did comment on a normalized \nrenewal year.  So, are there anything you're seeing there, big renewals?  And how do you think about the areas of \ngrowth that have remained steady maybe within specialty and th e potential for biosimilars, and how that should \nfactor into that long -term growth trajectory and where that falls relative to 2023 broadly?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "You did comment on a normalized \nrenewal year. ", "page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "692933c6-e017-4d68-907a-60e809f96ddd", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "22b93ece2d146eb9ac30968837125e52c9026dc861b7c3d96c31621bdd0992f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "65a6280c-4795-45c3-96e9-1899029325e3", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nAfternoon, and thanks for all the color so far.  I want to talk a little bit about the US Pharma segment.  As you think \nabout into next year and thinking more qualitatively as much as anything else, but how do you think about outside \nof the COVID -related scr ipt and volume recovery, the other moving pieces?  You did comment on a normalized \nrenewal year.  So, are there anything you're seeing there, big renewals?  And how do you think about the areas of \ngrowth that have remained steady maybe within specialty and th e potential for biosimilars, and how that should \nfactor into that long -term growth trajectory and where that falls relative to 2023 broadly?  \n ", "original_text": "As you think \nabout into next year and thinking more qualitatively as much as anything else, but how do you think about outside \nof the COVID -related scr ipt and volume recovery, the other moving pieces? ", "page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5e9d3bd98d72967741c59662b996b5634650481ac335299746a0920197503b03", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2e38d70b-b1ef-4d49-97a6-249ee8c8dc52", "node_type": "1", "metadata": {"window": "I want to talk a little bit about the US Pharma segment.  As you think \nabout into next year and thinking more qualitatively as much as anything else, but how do you think about outside \nof the COVID -related scr ipt and volume recovery, the other moving pieces?  You did comment on a normalized \nrenewal year.  So, are there anything you're seeing there, big renewals?  And how do you think about the areas of \ngrowth that have remained steady maybe within specialty and th e potential for biosimilars, and how that should \nfactor into that long -term growth trajectory and where that falls relative to 2023 broadly?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nMike, thanks for the question. ", "original_text": "So, are there anything you're seeing there, big renewals? "}, "hash": "fcadaf354e924d27fd057a5d33ef9eb94922e47dd19049c45782d5ee2e0aa331", "class_name": "RelatedNodeInfo"}}, "text": "You did comment on a normalized \nrenewal year. ", "start_char_idx": 2112, "end_char_idx": 2159, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2e38d70b-b1ef-4d49-97a6-249ee8c8dc52": {"__data__": {"id_": "2e38d70b-b1ef-4d49-97a6-249ee8c8dc52", "embedding": null, "metadata": {"window": "I want to talk a little bit about the US Pharma segment.  As you think \nabout into next year and thinking more qualitatively as much as anything else, but how do you think about outside \nof the COVID -related scr ipt and volume recovery, the other moving pieces?  You did comment on a normalized \nrenewal year.  So, are there anything you're seeing there, big renewals?  And how do you think about the areas of \ngrowth that have remained steady maybe within specialty and th e potential for biosimilars, and how that should \nfactor into that long -term growth trajectory and where that falls relative to 2023 broadly?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nMike, thanks for the question. ", "original_text": "So, are there anything you're seeing there, big renewals? ", "page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "692933c6-e017-4d68-907a-60e809f96ddd", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "22b93ece2d146eb9ac30968837125e52c9026dc861b7c3d96c31621bdd0992f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8901681f-dd2e-4e2e-b312-e2161e398c7e", "node_type": "1", "metadata": {"window": "Q \nAfternoon, and thanks for all the color so far.  I want to talk a little bit about the US Pharma segment.  As you think \nabout into next year and thinking more qualitatively as much as anything else, but how do you think about outside \nof the COVID -related scr ipt and volume recovery, the other moving pieces?  You did comment on a normalized \nrenewal year.  So, are there anything you're seeing there, big renewals?  And how do you think about the areas of \ngrowth that have remained steady maybe within specialty and th e potential for biosimilars, and how that should \nfactor into that long -term growth trajectory and where that falls relative to 2023 broadly?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "You did comment on a normalized \nrenewal year. ", "page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "21d3a916eff55f0b84f27928cabf588ffcb86f3961c6e9618538acce6754421e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "889a5dcc-d472-47b9-a570-9205e5be8c9f", "node_type": "1", "metadata": {"window": "As you think \nabout into next year and thinking more qualitatively as much as anything else, but how do you think about outside \nof the COVID -related scr ipt and volume recovery, the other moving pieces?  You did comment on a normalized \nrenewal year.  So, are there anything you're seeing there, big renewals?  And how do you think about the areas of \ngrowth that have remained steady maybe within specialty and th e potential for biosimilars, and how that should \nfactor into that long -term growth trajectory and where that falls relative to 2023 broadly?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nMike, thanks for the question.  Maybe I'll start and then I'll let Brian jump in here. ", "original_text": "And how do you think about the areas of \ngrowth that have remained steady maybe within specialty and th e potential for biosimilars, and how that should \nfactor into that long -term growth trajectory and where that falls relative to 2023 broadly?  \n "}, "hash": "4bab0b10511447dd5dde2510354e41148080b01ce76770dadfd994bdf4aa5725", "class_name": "RelatedNodeInfo"}}, "text": "So, are there anything you're seeing there, big renewals? ", "start_char_idx": 2159, "end_char_idx": 2217, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "889a5dcc-d472-47b9-a570-9205e5be8c9f": {"__data__": {"id_": "889a5dcc-d472-47b9-a570-9205e5be8c9f", "embedding": null, "metadata": {"window": "As you think \nabout into next year and thinking more qualitatively as much as anything else, but how do you think about outside \nof the COVID -related scr ipt and volume recovery, the other moving pieces?  You did comment on a normalized \nrenewal year.  So, are there anything you're seeing there, big renewals?  And how do you think about the areas of \ngrowth that have remained steady maybe within specialty and th e potential for biosimilars, and how that should \nfactor into that long -term growth trajectory and where that falls relative to 2023 broadly?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nMike, thanks for the question.  Maybe I'll start and then I'll let Brian jump in here. ", "original_text": "And how do you think about the areas of \ngrowth that have remained steady maybe within specialty and th e potential for biosimilars, and how that should \nfactor into that long -term growth trajectory and where that falls relative to 2023 broadly?  \n ", "page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "692933c6-e017-4d68-907a-60e809f96ddd", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "22b93ece2d146eb9ac30968837125e52c9026dc861b7c3d96c31621bdd0992f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2e38d70b-b1ef-4d49-97a6-249ee8c8dc52", "node_type": "1", "metadata": {"window": "I want to talk a little bit about the US Pharma segment.  As you think \nabout into next year and thinking more qualitatively as much as anything else, but how do you think about outside \nof the COVID -related scr ipt and volume recovery, the other moving pieces?  You did comment on a normalized \nrenewal year.  So, are there anything you're seeing there, big renewals?  And how do you think about the areas of \ngrowth that have remained steady maybe within specialty and th e potential for biosimilars, and how that should \nfactor into that long -term growth trajectory and where that falls relative to 2023 broadly?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nMike, thanks for the question. ", "original_text": "So, are there anything you're seeing there, big renewals? ", "page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3cf02897b7940e10bd0700a8d0861d08f6d3c6872f28d7ab6b98f29deac0704", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1802e46a-834f-4a5d-843c-7f8df7fb89fa", "node_type": "1", "metadata": {"window": "You did comment on a normalized \nrenewal year.  So, are there anything you're seeing there, big renewals?  And how do you think about the areas of \ngrowth that have remained steady maybe within specialty and th e potential for biosimilars, and how that should \nfactor into that long -term growth trajectory and where that falls relative to 2023 broadly?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nMike, thanks for the question.  Maybe I'll start and then I'll let Brian jump in here.  Again, as we think about it and \nsome of the things that I mentioned here, we do expect a full recovery of prescription transaction volumes. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "4f4fb40c58a741472b18265d3a130d7fb821c5bcc3f6cd9a6d58fb8a96eef711", "class_name": "RelatedNodeInfo"}}, "text": "And how do you think about the areas of \ngrowth that have remained steady maybe within specialty and th e potential for biosimilars, and how that should \nfactor into that long -term growth trajectory and where that falls relative to 2023 broadly?  \n ", "start_char_idx": 2217, "end_char_idx": 2467, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1802e46a-834f-4a5d-843c-7f8df7fb89fa": {"__data__": {"id_": "1802e46a-834f-4a5d-843c-7f8df7fb89fa", "embedding": null, "metadata": {"window": "You did comment on a normalized \nrenewal year.  So, are there anything you're seeing there, big renewals?  And how do you think about the areas of \ngrowth that have remained steady maybe within specialty and th e potential for biosimilars, and how that should \nfactor into that long -term growth trajectory and where that falls relative to 2023 broadly?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nMike, thanks for the question.  Maybe I'll start and then I'll let Brian jump in here.  Again, as we think about it and \nsome of the things that I mentioned here, we do expect a full recovery of prescription transaction volumes. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "692933c6-e017-4d68-907a-60e809f96ddd", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "22b93ece2d146eb9ac30968837125e52c9026dc861b7c3d96c31621bdd0992f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "889a5dcc-d472-47b9-a570-9205e5be8c9f", "node_type": "1", "metadata": {"window": "As you think \nabout into next year and thinking more qualitatively as much as anything else, but how do you think about outside \nof the COVID -related scr ipt and volume recovery, the other moving pieces?  You did comment on a normalized \nrenewal year.  So, are there anything you're seeing there, big renewals?  And how do you think about the areas of \ngrowth that have remained steady maybe within specialty and th e potential for biosimilars, and how that should \nfactor into that long -term growth trajectory and where that falls relative to 2023 broadly?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nMike, thanks for the question.  Maybe I'll start and then I'll let Brian jump in here. ", "original_text": "And how do you think about the areas of \ngrowth that have remained steady maybe within specialty and th e potential for biosimilars, and how that should \nfactor into that long -term growth trajectory and where that falls relative to 2023 broadly?  \n ", "page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "997820fb29e6d5ef245272624ec3e2f16e75f1dee695e264c7bb75cc2815dbe0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "60faaac2-a517-4f69-9197-b671ac2eed3c", "node_type": "1", "metadata": {"window": "So, are there anything you're seeing there, big renewals?  And how do you think about the areas of \ngrowth that have remained steady maybe within specialty and th e potential for biosimilars, and how that should \nfactor into that long -term growth trajectory and where that falls relative to 2023 broadly?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nMike, thanks for the question.  Maybe I'll start and then I'll let Brian jump in here.  Again, as we think about it and \nsome of the things that I mentioned here, we do expect a full recovery of prescription transaction volumes.  And \nwe're certainly pleased that transaction volume s have continued to increase throughout the year. ", "original_text": "A \nMike, thanks for the question. "}, "hash": "0c0de4c5ef628e315007c5be03f6ff87ef5de999983f3813fcb26cf8b634f9fb", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 2467, "end_char_idx": 2824, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "60faaac2-a517-4f69-9197-b671ac2eed3c": {"__data__": {"id_": "60faaac2-a517-4f69-9197-b671ac2eed3c", "embedding": null, "metadata": {"window": "So, are there anything you're seeing there, big renewals?  And how do you think about the areas of \ngrowth that have remained steady maybe within specialty and th e potential for biosimilars, and how that should \nfactor into that long -term growth trajectory and where that falls relative to 2023 broadly?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nMike, thanks for the question.  Maybe I'll start and then I'll let Brian jump in here.  Again, as we think about it and \nsome of the things that I mentioned here, we do expect a full recovery of prescription transaction volumes.  And \nwe're certainly pleased that transaction volume s have continued to increase throughout the year. ", "original_text": "A \nMike, thanks for the question. ", "page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "692933c6-e017-4d68-907a-60e809f96ddd", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "22b93ece2d146eb9ac30968837125e52c9026dc861b7c3d96c31621bdd0992f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1802e46a-834f-4a5d-843c-7f8df7fb89fa", "node_type": "1", "metadata": {"window": "You did comment on a normalized \nrenewal year.  So, are there anything you're seeing there, big renewals?  And how do you think about the areas of \ngrowth that have remained steady maybe within specialty and th e potential for biosimilars, and how that should \nfactor into that long -term growth trajectory and where that falls relative to 2023 broadly?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nMike, thanks for the question.  Maybe I'll start and then I'll let Brian jump in here.  Again, as we think about it and \nsome of the things that I mentioned here, we do expect a full recovery of prescription transaction volumes. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2e83bb7995cf1dde66b979436f79b544d44b275d22885ca2a9800d2b1ca259e1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9d651bed-a472-4285-9acd-349db4acf267", "node_type": "1", "metadata": {"window": "And how do you think about the areas of \ngrowth that have remained steady maybe within specialty and th e potential for biosimilars, and how that should \nfactor into that long -term growth trajectory and where that falls relative to 2023 broadly?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nMike, thanks for the question.  Maybe I'll start and then I'll let Brian jump in here.  Again, as we think about it and \nsome of the things that I mentioned here, we do expect a full recovery of prescription transaction volumes.  And \nwe're certainly pleased that transaction volume s have continued to increase throughout the year.  It has not been \nin a straight line, but we do expect that full recovery to continue.  \n \n", "original_text": "Maybe I'll start and then I'll let Brian jump in here. "}, "hash": "8ece3479009600c6870087cfc0d99bfb3953e6d4d76f370e4d8918a54b75f201", "class_name": "RelatedNodeInfo"}}, "text": "A \nMike, thanks for the question. ", "start_char_idx": 2824, "end_char_idx": 2858, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9d651bed-a472-4285-9acd-349db4acf267": {"__data__": {"id_": "9d651bed-a472-4285-9acd-349db4acf267", "embedding": null, "metadata": {"window": "And how do you think about the areas of \ngrowth that have remained steady maybe within specialty and th e potential for biosimilars, and how that should \nfactor into that long -term growth trajectory and where that falls relative to 2023 broadly?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nMike, thanks for the question.  Maybe I'll start and then I'll let Brian jump in here.  Again, as we think about it and \nsome of the things that I mentioned here, we do expect a full recovery of prescription transaction volumes.  And \nwe're certainly pleased that transaction volume s have continued to increase throughout the year.  It has not been \nin a straight line, but we do expect that full recovery to continue.  \n \n", "original_text": "Maybe I'll start and then I'll let Brian jump in here. ", "page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "692933c6-e017-4d68-907a-60e809f96ddd", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "22b93ece2d146eb9ac30968837125e52c9026dc861b7c3d96c31621bdd0992f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "60faaac2-a517-4f69-9197-b671ac2eed3c", "node_type": "1", "metadata": {"window": "So, are there anything you're seeing there, big renewals?  And how do you think about the areas of \ngrowth that have remained steady maybe within specialty and th e potential for biosimilars, and how that should \nfactor into that long -term growth trajectory and where that falls relative to 2023 broadly?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nMike, thanks for the question.  Maybe I'll start and then I'll let Brian jump in here.  Again, as we think about it and \nsome of the things that I mentioned here, we do expect a full recovery of prescription transaction volumes.  And \nwe're certainly pleased that transaction volume s have continued to increase throughout the year. ", "original_text": "A \nMike, thanks for the question. ", "page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d23548e3daf4828362fbcd61a197e8d8392804d680b2af9ff2fa3b72964356d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "01ed948c-6584-40e8-a6a0-88dd7c6ae4bb", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nMike, thanks for the question.  Maybe I'll start and then I'll let Brian jump in here.  Again, as we think about it and \nsome of the things that I mentioned here, we do expect a full recovery of prescription transaction volumes.  And \nwe're certainly pleased that transaction volume s have continued to increase throughout the year.  It has not been \nin a straight line, but we do expect that full recovery to continue.  \n \n We're very well -positioned in the specialty clinic space as well as oncology. ", "original_text": "Again, as we think about it and \nsome of the things that I mentioned here, we do expect a full recovery of prescription transaction volumes. "}, "hash": "717eb7c59f7d9f58cf589b61e6011ce596b4b6cafd46946d4c7f1928df43a566", "class_name": "RelatedNodeInfo"}}, "text": "Maybe I'll start and then I'll let Brian jump in here. ", "start_char_idx": 2858, "end_char_idx": 2913, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "01ed948c-6584-40e8-a6a0-88dd7c6ae4bb": {"__data__": {"id_": "01ed948c-6584-40e8-a6a0-88dd7c6ae4bb", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nMike, thanks for the question.  Maybe I'll start and then I'll let Brian jump in here.  Again, as we think about it and \nsome of the things that I mentioned here, we do expect a full recovery of prescription transaction volumes.  And \nwe're certainly pleased that transaction volume s have continued to increase throughout the year.  It has not been \nin a straight line, but we do expect that full recovery to continue.  \n \n We're very well -positioned in the specialty clinic space as well as oncology. ", "original_text": "Again, as we think about it and \nsome of the things that I mentioned here, we do expect a full recovery of prescription transaction volumes. ", "page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "692933c6-e017-4d68-907a-60e809f96ddd", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "22b93ece2d146eb9ac30968837125e52c9026dc861b7c3d96c31621bdd0992f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9d651bed-a472-4285-9acd-349db4acf267", "node_type": "1", "metadata": {"window": "And how do you think about the areas of \ngrowth that have remained steady maybe within specialty and th e potential for biosimilars, and how that should \nfactor into that long -term growth trajectory and where that falls relative to 2023 broadly?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nMike, thanks for the question.  Maybe I'll start and then I'll let Brian jump in here.  Again, as we think about it and \nsome of the things that I mentioned here, we do expect a full recovery of prescription transaction volumes.  And \nwe're certainly pleased that transaction volume s have continued to increase throughout the year.  It has not been \nin a straight line, but we do expect that full recovery to continue.  \n \n", "original_text": "Maybe I'll start and then I'll let Brian jump in here. ", "page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8965d14aa87908dbd27046c24664fdeee874cf70d4cd3a729bc66475d0cef8b7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "47a00123-9947-4c7f-b5a5-bc31e8a59d9d", "node_type": "1", "metadata": {"window": "A \nMike, thanks for the question.  Maybe I'll start and then I'll let Brian jump in here.  Again, as we think about it and \nsome of the things that I mentioned here, we do expect a full recovery of prescription transaction volumes.  And \nwe're certainly pleased that transaction volume s have continued to increase throughout the year.  It has not been \nin a straight line, but we do expect that full recovery to continue.  \n \n We're very well -positioned in the specialty clinic space as well as oncology.  We're making investments in those \nareas th at we think are going to continue to pay off over the long term. ", "original_text": "And \nwe're certainly pleased that transaction volume s have continued to increase throughout the year. "}, "hash": "567439c1a6887e3e45aa1522526dd67218d161a8e3db75e6feb1d803e62ab45f", "class_name": "RelatedNodeInfo"}}, "text": "Again, as we think about it and \nsome of the things that I mentioned here, we do expect a full recovery of prescription transaction volumes. ", "start_char_idx": 2913, "end_char_idx": 3054, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "47a00123-9947-4c7f-b5a5-bc31e8a59d9d": {"__data__": {"id_": "47a00123-9947-4c7f-b5a5-bc31e8a59d9d", "embedding": null, "metadata": {"window": "A \nMike, thanks for the question.  Maybe I'll start and then I'll let Brian jump in here.  Again, as we think about it and \nsome of the things that I mentioned here, we do expect a full recovery of prescription transaction volumes.  And \nwe're certainly pleased that transaction volume s have continued to increase throughout the year.  It has not been \nin a straight line, but we do expect that full recovery to continue.  \n \n We're very well -positioned in the specialty clinic space as well as oncology.  We're making investments in those \nareas th at we think are going to continue to pay off over the long term. ", "original_text": "And \nwe're certainly pleased that transaction volume s have continued to increase throughout the year. ", "page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "692933c6-e017-4d68-907a-60e809f96ddd", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "22b93ece2d146eb9ac30968837125e52c9026dc861b7c3d96c31621bdd0992f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "01ed948c-6584-40e8-a6a0-88dd7c6ae4bb", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nMike, thanks for the question.  Maybe I'll start and then I'll let Brian jump in here.  Again, as we think about it and \nsome of the things that I mentioned here, we do expect a full recovery of prescription transaction volumes.  And \nwe're certainly pleased that transaction volume s have continued to increase throughout the year.  It has not been \nin a straight line, but we do expect that full recovery to continue.  \n \n We're very well -positioned in the specialty clinic space as well as oncology. ", "original_text": "Again, as we think about it and \nsome of the things that I mentioned here, we do expect a full recovery of prescription transaction volumes. ", "page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fd401b1636406304b5a2dc4b4b67bd8eb10d5f7817a1d7afe98517f68e018d19", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a06ea56e-bc5a-4e1d-960a-17bef9aa0e92", "node_type": "1", "metadata": {"window": "Maybe I'll start and then I'll let Brian jump in here.  Again, as we think about it and \nsome of the things that I mentioned here, we do expect a full recovery of prescription transaction volumes.  And \nwe're certainly pleased that transaction volume s have continued to increase throughout the year.  It has not been \nin a straight line, but we do expect that full recovery to continue.  \n \n We're very well -positioned in the specialty clinic space as well as oncology.  We're making investments in those \nareas th at we think are going to continue to pay off over the long term.  And biosimilars is one of those areas that \ngiven our position, particularly in oncology, we believe that it's going to be a growth driver for us over the long \nterm. ", "original_text": "It has not been \nin a straight line, but we do expect that full recovery to continue.  \n \n"}, "hash": "0c607c71c17365feee3387702fb7892825bd730a4e2594ec600af6ec2db02077", "class_name": "RelatedNodeInfo"}}, "text": "And \nwe're certainly pleased that transaction volume s have continued to increase throughout the year. ", "start_char_idx": 3054, "end_char_idx": 3157, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a06ea56e-bc5a-4e1d-960a-17bef9aa0e92": {"__data__": {"id_": "a06ea56e-bc5a-4e1d-960a-17bef9aa0e92", "embedding": null, "metadata": {"window": "Maybe I'll start and then I'll let Brian jump in here.  Again, as we think about it and \nsome of the things that I mentioned here, we do expect a full recovery of prescription transaction volumes.  And \nwe're certainly pleased that transaction volume s have continued to increase throughout the year.  It has not been \nin a straight line, but we do expect that full recovery to continue.  \n \n We're very well -positioned in the specialty clinic space as well as oncology.  We're making investments in those \nareas th at we think are going to continue to pay off over the long term.  And biosimilars is one of those areas that \ngiven our position, particularly in oncology, we believe that it's going to be a growth driver for us over the long \nterm. ", "original_text": "It has not been \nin a straight line, but we do expect that full recovery to continue.  \n \n", "page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "692933c6-e017-4d68-907a-60e809f96ddd", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "22b93ece2d146eb9ac30968837125e52c9026dc861b7c3d96c31621bdd0992f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "47a00123-9947-4c7f-b5a5-bc31e8a59d9d", "node_type": "1", "metadata": {"window": "A \nMike, thanks for the question.  Maybe I'll start and then I'll let Brian jump in here.  Again, as we think about it and \nsome of the things that I mentioned here, we do expect a full recovery of prescription transaction volumes.  And \nwe're certainly pleased that transaction volume s have continued to increase throughout the year.  It has not been \nin a straight line, but we do expect that full recovery to continue.  \n \n We're very well -positioned in the specialty clinic space as well as oncology.  We're making investments in those \nareas th at we think are going to continue to pay off over the long term. ", "original_text": "And \nwe're certainly pleased that transaction volume s have continued to increase throughout the year. ", "page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f35d170c2c99c3cde6c26e20301807b80d751a3feeb042f908b66a6bb7cb1112", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "306e411f-e5a4-42a8-b0f1-b444c1857e7a", "node_type": "1", "metadata": {"window": "Again, as we think about it and \nsome of the things that I mentioned here, we do expect a full recovery of prescription transaction volumes.  And \nwe're certainly pleased that transaction volume s have continued to increase throughout the year.  It has not been \nin a straight line, but we do expect that full recovery to continue.  \n \n We're very well -positioned in the specialty clinic space as well as oncology.  We're making investments in those \nareas th at we think are going to continue to pay off over the long term.  And biosimilars is one of those areas that \ngiven our position, particularly in oncology, we believe that it's going to be a growth driver for us over the long \nterm.  And we're pleased with the  development of biosimilars to this point. ", "original_text": "We're very well -positioned in the specialty clinic space as well as oncology. "}, "hash": "59bbb0ec454553bb6a1b72df41da2b061da09b5f94c51fc29e9dfee44d5baa1a", "class_name": "RelatedNodeInfo"}}, "text": "It has not been \nin a straight line, but we do expect that full recovery to continue.  \n \n", "start_char_idx": 3157, "end_char_idx": 3247, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "306e411f-e5a4-42a8-b0f1-b444c1857e7a": {"__data__": {"id_": "306e411f-e5a4-42a8-b0f1-b444c1857e7a", "embedding": null, "metadata": {"window": "Again, as we think about it and \nsome of the things that I mentioned here, we do expect a full recovery of prescription transaction volumes.  And \nwe're certainly pleased that transaction volume s have continued to increase throughout the year.  It has not been \nin a straight line, but we do expect that full recovery to continue.  \n \n We're very well -positioned in the specialty clinic space as well as oncology.  We're making investments in those \nareas th at we think are going to continue to pay off over the long term.  And biosimilars is one of those areas that \ngiven our position, particularly in oncology, we believe that it's going to be a growth driver for us over the long \nterm.  And we're pleased with the  development of biosimilars to this point. ", "original_text": "We're very well -positioned in the specialty clinic space as well as oncology. ", "page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "692933c6-e017-4d68-907a-60e809f96ddd", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "22b93ece2d146eb9ac30968837125e52c9026dc861b7c3d96c31621bdd0992f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a06ea56e-bc5a-4e1d-960a-17bef9aa0e92", "node_type": "1", "metadata": {"window": "Maybe I'll start and then I'll let Brian jump in here.  Again, as we think about it and \nsome of the things that I mentioned here, we do expect a full recovery of prescription transaction volumes.  And \nwe're certainly pleased that transaction volume s have continued to increase throughout the year.  It has not been \nin a straight line, but we do expect that full recovery to continue.  \n \n We're very well -positioned in the specialty clinic space as well as oncology.  We're making investments in those \nareas th at we think are going to continue to pay off over the long term.  And biosimilars is one of those areas that \ngiven our position, particularly in oncology, we believe that it's going to be a growth driver for us over the long \nterm. ", "original_text": "It has not been \nin a straight line, but we do expect that full recovery to continue.  \n \n", "page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "043af87ae646d6289ed2342df8dc1c4be043cff09bca14edfbab14c8771c60ba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5bf5ebb0-b3b9-4ea5-b680-b2c77a573cd4", "node_type": "1", "metadata": {"window": "And \nwe're certainly pleased that transaction volume s have continued to increase throughout the year.  It has not been \nin a straight line, but we do expect that full recovery to continue.  \n \n We're very well -positioned in the specialty clinic space as well as oncology.  We're making investments in those \nareas th at we think are going to continue to pay off over the long term.  And biosimilars is one of those areas that \ngiven our position, particularly in oncology, we believe that it's going to be a growth driver for us over the long \nterm.  And we're pleased with the  development of biosimilars to this point.  We think that they offer better returns \nthan branded and specialty products, maybe not at the same level as generics from a margin perspective, but still, \nwe believe and we're optimistic that they're going to cont inue to add value to the segment over time.  \n \n", "original_text": "We're making investments in those \nareas th at we think are going to continue to pay off over the long term. "}, "hash": "4584ffefc789e84fe75f38a3c8b815c8d3a6ea6a75bbff921d25ef63b9d13b09", "class_name": "RelatedNodeInfo"}}, "text": "We're very well -positioned in the specialty clinic space as well as oncology. ", "start_char_idx": 3247, "end_char_idx": 3326, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5bf5ebb0-b3b9-4ea5-b680-b2c77a573cd4": {"__data__": {"id_": "5bf5ebb0-b3b9-4ea5-b680-b2c77a573cd4", "embedding": null, "metadata": {"window": "And \nwe're certainly pleased that transaction volume s have continued to increase throughout the year.  It has not been \nin a straight line, but we do expect that full recovery to continue.  \n \n We're very well -positioned in the specialty clinic space as well as oncology.  We're making investments in those \nareas th at we think are going to continue to pay off over the long term.  And biosimilars is one of those areas that \ngiven our position, particularly in oncology, we believe that it's going to be a growth driver for us over the long \nterm.  And we're pleased with the  development of biosimilars to this point.  We think that they offer better returns \nthan branded and specialty products, maybe not at the same level as generics from a margin perspective, but still, \nwe believe and we're optimistic that they're going to cont inue to add value to the segment over time.  \n \n", "original_text": "We're making investments in those \nareas th at we think are going to continue to pay off over the long term. ", "page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "692933c6-e017-4d68-907a-60e809f96ddd", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "22b93ece2d146eb9ac30968837125e52c9026dc861b7c3d96c31621bdd0992f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "306e411f-e5a4-42a8-b0f1-b444c1857e7a", "node_type": "1", "metadata": {"window": "Again, as we think about it and \nsome of the things that I mentioned here, we do expect a full recovery of prescription transaction volumes.  And \nwe're certainly pleased that transaction volume s have continued to increase throughout the year.  It has not been \nin a straight line, but we do expect that full recovery to continue.  \n \n We're very well -positioned in the specialty clinic space as well as oncology.  We're making investments in those \nareas th at we think are going to continue to pay off over the long term.  And biosimilars is one of those areas that \ngiven our position, particularly in oncology, we believe that it's going to be a growth driver for us over the long \nterm.  And we're pleased with the  development of biosimilars to this point. ", "original_text": "We're very well -positioned in the specialty clinic space as well as oncology. ", "page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5a3741beb6ec5ed298f9484f8c7a4599571c870f04a8eb0a7d9645c1e9ff136c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4ea73195-86d1-47dc-af18-df30391d451e", "node_type": "1", "metadata": {"window": "It has not been \nin a straight line, but we do expect that full recovery to continue.  \n \n We're very well -positioned in the specialty clinic space as well as oncology.  We're making investments in those \nareas th at we think are going to continue to pay off over the long term.  And biosimilars is one of those areas that \ngiven our position, particularly in oncology, we believe that it's going to be a growth driver for us over the long \nterm.  And we're pleased with the  development of biosimilars to this point.  We think that they offer better returns \nthan branded and specialty products, maybe not at the same level as generics from a margin perspective, but still, \nwe believe and we're optimistic that they're going to cont inue to add value to the segment over time.  \n \n So, the position that we have, the strength that we have across segments, particularly our differentiated \ncapabilities in oncology, positions us very well for further growth.  \n ", "original_text": "And biosimilars is one of those areas that \ngiven our position, particularly in oncology, we believe that it's going to be a growth driver for us over the long \nterm. "}, "hash": "28664884c9b5f2cd741a3a552b80b0594c918fdb62331583cea5a00e32e94c92", "class_name": "RelatedNodeInfo"}}, "text": "We're making investments in those \nareas th at we think are going to continue to pay off over the long term. ", "start_char_idx": 3326, "end_char_idx": 3435, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4ea73195-86d1-47dc-af18-df30391d451e": {"__data__": {"id_": "4ea73195-86d1-47dc-af18-df30391d451e", "embedding": null, "metadata": {"window": "It has not been \nin a straight line, but we do expect that full recovery to continue.  \n \n We're very well -positioned in the specialty clinic space as well as oncology.  We're making investments in those \nareas th at we think are going to continue to pay off over the long term.  And biosimilars is one of those areas that \ngiven our position, particularly in oncology, we believe that it's going to be a growth driver for us over the long \nterm.  And we're pleased with the  development of biosimilars to this point.  We think that they offer better returns \nthan branded and specialty products, maybe not at the same level as generics from a margin perspective, but still, \nwe believe and we're optimistic that they're going to cont inue to add value to the segment over time.  \n \n So, the position that we have, the strength that we have across segments, particularly our differentiated \ncapabilities in oncology, positions us very well for further growth.  \n ", "original_text": "And biosimilars is one of those areas that \ngiven our position, particularly in oncology, we believe that it's going to be a growth driver for us over the long \nterm. ", "page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "692933c6-e017-4d68-907a-60e809f96ddd", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "22b93ece2d146eb9ac30968837125e52c9026dc861b7c3d96c31621bdd0992f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5bf5ebb0-b3b9-4ea5-b680-b2c77a573cd4", "node_type": "1", "metadata": {"window": "And \nwe're certainly pleased that transaction volume s have continued to increase throughout the year.  It has not been \nin a straight line, but we do expect that full recovery to continue.  \n \n We're very well -positioned in the specialty clinic space as well as oncology.  We're making investments in those \nareas th at we think are going to continue to pay off over the long term.  And biosimilars is one of those areas that \ngiven our position, particularly in oncology, we believe that it's going to be a growth driver for us over the long \nterm.  And we're pleased with the  development of biosimilars to this point.  We think that they offer better returns \nthan branded and specialty products, maybe not at the same level as generics from a margin perspective, but still, \nwe believe and we're optimistic that they're going to cont inue to add value to the segment over time.  \n \n", "original_text": "We're making investments in those \nareas th at we think are going to continue to pay off over the long term. ", "page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "118d2b2945b051915a5020b9d722b72463100a8e374acc87951b20c886b2b410", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d337d002-6f04-4ed1-af0b-322526b5a2f6", "node_type": "1", "metadata": {"window": "We're very well -positioned in the specialty clinic space as well as oncology.  We're making investments in those \nareas th at we think are going to continue to pay off over the long term.  And biosimilars is one of those areas that \ngiven our position, particularly in oncology, we believe that it's going to be a growth driver for us over the long \nterm.  And we're pleased with the  development of biosimilars to this point.  We think that they offer better returns \nthan branded and specialty products, maybe not at the same level as generics from a margin perspective, but still, \nwe believe and we're optimistic that they're going to cont inue to add value to the segment over time.  \n \n So, the position that we have, the strength that we have across segments, particularly our differentiated \ncapabilities in oncology, positions us very well for further growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relation s Contact, McKesson Corp  A \nNext question, please?  \n ", "original_text": "And we're pleased with the  development of biosimilars to this point. "}, "hash": "8c165099a0239e0708c6d1e79848edb9c12758ea0085ca1e7894d83cda6bc55d", "class_name": "RelatedNodeInfo"}}, "text": "And biosimilars is one of those areas that \ngiven our position, particularly in oncology, we believe that it's going to be a growth driver for us over the long \nterm. ", "start_char_idx": 3435, "end_char_idx": 3602, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d337d002-6f04-4ed1-af0b-322526b5a2f6": {"__data__": {"id_": "d337d002-6f04-4ed1-af0b-322526b5a2f6", "embedding": null, "metadata": {"window": "We're very well -positioned in the specialty clinic space as well as oncology.  We're making investments in those \nareas th at we think are going to continue to pay off over the long term.  And biosimilars is one of those areas that \ngiven our position, particularly in oncology, we believe that it's going to be a growth driver for us over the long \nterm.  And we're pleased with the  development of biosimilars to this point.  We think that they offer better returns \nthan branded and specialty products, maybe not at the same level as generics from a margin perspective, but still, \nwe believe and we're optimistic that they're going to cont inue to add value to the segment over time.  \n \n So, the position that we have, the strength that we have across segments, particularly our differentiated \ncapabilities in oncology, positions us very well for further growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relation s Contact, McKesson Corp  A \nNext question, please?  \n ", "original_text": "And we're pleased with the  development of biosimilars to this point. ", "page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "692933c6-e017-4d68-907a-60e809f96ddd", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "22b93ece2d146eb9ac30968837125e52c9026dc861b7c3d96c31621bdd0992f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4ea73195-86d1-47dc-af18-df30391d451e", "node_type": "1", "metadata": {"window": "It has not been \nin a straight line, but we do expect that full recovery to continue.  \n \n We're very well -positioned in the specialty clinic space as well as oncology.  We're making investments in those \nareas th at we think are going to continue to pay off over the long term.  And biosimilars is one of those areas that \ngiven our position, particularly in oncology, we believe that it's going to be a growth driver for us over the long \nterm.  And we're pleased with the  development of biosimilars to this point.  We think that they offer better returns \nthan branded and specialty products, maybe not at the same level as generics from a margin perspective, but still, \nwe believe and we're optimistic that they're going to cont inue to add value to the segment over time.  \n \n So, the position that we have, the strength that we have across segments, particularly our differentiated \ncapabilities in oncology, positions us very well for further growth.  \n ", "original_text": "And biosimilars is one of those areas that \ngiven our position, particularly in oncology, we believe that it's going to be a growth driver for us over the long \nterm. ", "page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "593b86c3b26e96ec92023fd2f37f1a2769f24e3471adf19fe34ee7e9a16aeb28", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4ce2e81f-6471-475f-924d-d8105b41e972", "node_type": "1", "metadata": {"window": "We're making investments in those \nareas th at we think are going to continue to pay off over the long term.  And biosimilars is one of those areas that \ngiven our position, particularly in oncology, we believe that it's going to be a growth driver for us over the long \nterm.  And we're pleased with the  development of biosimilars to this point.  We think that they offer better returns \nthan branded and specialty products, maybe not at the same level as generics from a margin perspective, but still, \nwe believe and we're optimistic that they're going to cont inue to add value to the segment over time.  \n \n So, the position that we have, the strength that we have across segments, particularly our differentiated \ncapabilities in oncology, positions us very well for further growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relation s Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  \n ", "original_text": "We think that they offer better returns \nthan branded and specialty products, maybe not at the same level as generics from a margin perspective, but still, \nwe believe and we're optimistic that they're going to cont inue to add value to the segment over time.  \n \n"}, "hash": "9a836037b90bf8335641dbdeee56d683e0bf982f704a1be6f366dcc428c34014", "class_name": "RelatedNodeInfo"}}, "text": "And we're pleased with the  development of biosimilars to this point. ", "start_char_idx": 3602, "end_char_idx": 3672, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4ce2e81f-6471-475f-924d-d8105b41e972": {"__data__": {"id_": "4ce2e81f-6471-475f-924d-d8105b41e972", "embedding": null, "metadata": {"window": "We're making investments in those \nareas th at we think are going to continue to pay off over the long term.  And biosimilars is one of those areas that \ngiven our position, particularly in oncology, we believe that it's going to be a growth driver for us over the long \nterm.  And we're pleased with the  development of biosimilars to this point.  We think that they offer better returns \nthan branded and specialty products, maybe not at the same level as generics from a margin perspective, but still, \nwe believe and we're optimistic that they're going to cont inue to add value to the segment over time.  \n \n So, the position that we have, the strength that we have across segments, particularly our differentiated \ncapabilities in oncology, positions us very well for further growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relation s Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  \n ", "original_text": "We think that they offer better returns \nthan branded and specialty products, maybe not at the same level as generics from a margin perspective, but still, \nwe believe and we're optimistic that they're going to cont inue to add value to the segment over time.  \n \n", "page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "692933c6-e017-4d68-907a-60e809f96ddd", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "22b93ece2d146eb9ac30968837125e52c9026dc861b7c3d96c31621bdd0992f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d337d002-6f04-4ed1-af0b-322526b5a2f6", "node_type": "1", "metadata": {"window": "We're very well -positioned in the specialty clinic space as well as oncology.  We're making investments in those \nareas th at we think are going to continue to pay off over the long term.  And biosimilars is one of those areas that \ngiven our position, particularly in oncology, we believe that it's going to be a growth driver for us over the long \nterm.  And we're pleased with the  development of biosimilars to this point.  We think that they offer better returns \nthan branded and specialty products, maybe not at the same level as generics from a margin perspective, but still, \nwe believe and we're optimistic that they're going to cont inue to add value to the segment over time.  \n \n So, the position that we have, the strength that we have across segments, particularly our differentiated \ncapabilities in oncology, positions us very well for further growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relation s Contact, McKesson Corp  A \nNext question, please?  \n ", "original_text": "And we're pleased with the  development of biosimilars to this point. ", "page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "051d09bce8e6bc9f4b9bad9f7acb0d04cb04a37f01ea392b0d7bd998ab4a286d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4ae07687-c6ad-433a-a321-b05b005f65fb", "node_type": "1", "metadata": {"window": "And biosimilars is one of those areas that \ngiven our position, particularly in oncology, we believe that it's going to be a growth driver for us over the long \nterm.  And we're pleased with the  development of biosimilars to this point.  We think that they offer better returns \nthan branded and specialty products, maybe not at the same level as generics from a margin perspective, but still, \nwe believe and we're optimistic that they're going to cont inue to add value to the segment over time.  \n \n So, the position that we have, the strength that we have across segments, particularly our differentiated \ncapabilities in oncology, positions us very well for further growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relation s Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "So, the position that we have, the strength that we have across segments, particularly our differentiated \ncapabilities in oncology, positions us very well for further growth.  \n "}, "hash": "c54248bc7f94337676f9bc13ce8debcbb85add1f0daae456186c5e5209da3a5d", "class_name": "RelatedNodeInfo"}}, "text": "We think that they offer better returns \nthan branded and specialty products, maybe not at the same level as generics from a margin perspective, but still, \nwe believe and we're optimistic that they're going to cont inue to add value to the segment over time.  \n \n", "start_char_idx": 3672, "end_char_idx": 3936, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4ae07687-c6ad-433a-a321-b05b005f65fb": {"__data__": {"id_": "4ae07687-c6ad-433a-a321-b05b005f65fb", "embedding": null, "metadata": {"window": "And biosimilars is one of those areas that \ngiven our position, particularly in oncology, we believe that it's going to be a growth driver for us over the long \nterm.  And we're pleased with the  development of biosimilars to this point.  We think that they offer better returns \nthan branded and specialty products, maybe not at the same level as generics from a margin perspective, but still, \nwe believe and we're optimistic that they're going to cont inue to add value to the segment over time.  \n \n So, the position that we have, the strength that we have across segments, particularly our differentiated \ncapabilities in oncology, positions us very well for further growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relation s Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "So, the position that we have, the strength that we have across segments, particularly our differentiated \ncapabilities in oncology, positions us very well for further growth.  \n ", "page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "692933c6-e017-4d68-907a-60e809f96ddd", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "22b93ece2d146eb9ac30968837125e52c9026dc861b7c3d96c31621bdd0992f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4ce2e81f-6471-475f-924d-d8105b41e972", "node_type": "1", "metadata": {"window": "We're making investments in those \nareas th at we think are going to continue to pay off over the long term.  And biosimilars is one of those areas that \ngiven our position, particularly in oncology, we believe that it's going to be a growth driver for us over the long \nterm.  And we're pleased with the  development of biosimilars to this point.  We think that they offer better returns \nthan branded and specialty products, maybe not at the same level as generics from a margin perspective, but still, \nwe believe and we're optimistic that they're going to cont inue to add value to the segment over time.  \n \n So, the position that we have, the strength that we have across segments, particularly our differentiated \ncapabilities in oncology, positions us very well for further growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relation s Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  \n ", "original_text": "We think that they offer better returns \nthan branded and specialty products, maybe not at the same level as generics from a margin perspective, but still, \nwe believe and we're optimistic that they're going to cont inue to add value to the segment over time.  \n \n", "page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5d556dddf12226598f4f22cf25a6d6fdcd0fcc895ba88c5412d20a8afc0128c1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bdf3f953-3051-4586-858d-7277d7fe7c9f", "node_type": "1", "metadata": {"window": "And we're pleased with the  development of biosimilars to this point.  We think that they offer better returns \nthan branded and specialty products, maybe not at the same level as generics from a margin perspective, but still, \nwe believe and we're optimistic that they're going to cont inue to add value to the segment over time.  \n \n So, the position that we have, the strength that we have across segments, particularly our differentiated \ncapabilities in oncology, positions us very well for further growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relation s Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relation s Contact, McKesson Corp  A \nNext question, please?  \n "}, "hash": "96a7c00859a170802913fa2efd11cba2d02624643c9ba59f8bdcff0dffdcd1be", "class_name": "RelatedNodeInfo"}}, "text": "So, the position that we have, the strength that we have across segments, particularly our differentiated \ncapabilities in oncology, positions us very well for further growth.  \n ", "start_char_idx": 3936, "end_char_idx": 4115, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bdf3f953-3051-4586-858d-7277d7fe7c9f": {"__data__": {"id_": "bdf3f953-3051-4586-858d-7277d7fe7c9f", "embedding": null, "metadata": {"window": "And we're pleased with the  development of biosimilars to this point.  We think that they offer better returns \nthan branded and specialty products, maybe not at the same level as generics from a margin perspective, but still, \nwe believe and we're optimistic that they're going to cont inue to add value to the segment over time.  \n \n So, the position that we have, the strength that we have across segments, particularly our differentiated \ncapabilities in oncology, positions us very well for further growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relation s Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relation s Contact, McKesson Corp  A \nNext question, please?  \n ", "page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "692933c6-e017-4d68-907a-60e809f96ddd", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "22b93ece2d146eb9ac30968837125e52c9026dc861b7c3d96c31621bdd0992f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4ae07687-c6ad-433a-a321-b05b005f65fb", "node_type": "1", "metadata": {"window": "And biosimilars is one of those areas that \ngiven our position, particularly in oncology, we believe that it's going to be a growth driver for us over the long \nterm.  And we're pleased with the  development of biosimilars to this point.  We think that they offer better returns \nthan branded and specialty products, maybe not at the same level as generics from a margin perspective, but still, \nwe believe and we're optimistic that they're going to cont inue to add value to the segment over time.  \n \n So, the position that we have, the strength that we have across segments, particularly our differentiated \ncapabilities in oncology, positions us very well for further growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relation s Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "So, the position that we have, the strength that we have across segments, particularly our differentiated \ncapabilities in oncology, positions us very well for further growth.  \n ", "page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "14c32b8cdb3573712488e3c01ea4f646b8d5833e9668d04e4694e1efb0205f41", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3cd3c5b2-22e1-41cb-9755-582a704272a7", "node_type": "1", "metadata": {"window": "We think that they offer better returns \nthan branded and specialty products, maybe not at the same level as generics from a margin perspective, but still, \nwe believe and we're optimistic that they're going to cont inue to add value to the segment over time.  \n \n So, the position that we have, the strength that we have across segments, particularly our differentiated \ncapabilities in oncology, positions us very well for further growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relation s Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  \n "}, "hash": "aa530178cbf266a3e803481bef68a767e07694da3531a8ae1f5225de5b347b55", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relation s Contact, McKesson Corp  A \nNext question, please?  \n ", "start_char_idx": 4115, "end_char_idx": 4479, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3cd3c5b2-22e1-41cb-9755-582a704272a7": {"__data__": {"id_": "3cd3c5b2-22e1-41cb-9755-582a704272a7", "embedding": null, "metadata": {"window": "We think that they offer better returns \nthan branded and specialty products, maybe not at the same level as generics from a margin perspective, but still, \nwe believe and we're optimistic that they're going to cont inue to add value to the segment over time.  \n \n So, the position that we have, the strength that we have across segments, particularly our differentiated \ncapabilities in oncology, positions us very well for further growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relation s Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  \n ", "page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "692933c6-e017-4d68-907a-60e809f96ddd", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "22b93ece2d146eb9ac30968837125e52c9026dc861b7c3d96c31621bdd0992f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bdf3f953-3051-4586-858d-7277d7fe7c9f", "node_type": "1", "metadata": {"window": "And we're pleased with the  development of biosimilars to this point.  We think that they offer better returns \nthan branded and specialty products, maybe not at the same level as generics from a margin perspective, but still, \nwe believe and we're optimistic that they're going to cont inue to add value to the segment over time.  \n \n So, the position that we have, the strength that we have across segments, particularly our differentiated \ncapabilities in oncology, positions us very well for further growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relation s Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relation s Contact, McKesson Corp  A \nNext question, please?  \n ", "page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "33bd051280380bb2dab105f248f07a3d6086a469971eb5279c7bfb459291c77c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4318b08e-d385-4200-9a42-2f0ba6302aac", "node_type": "1", "metadata": {"window": "So, the position that we have, the strength that we have across segments, particularly our differentiated \ncapabilities in oncology, positions us very well for further growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relation s Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  "}, "hash": "59cd1ad512c326a62403ecf124d73307682fc81bf863338cc60b728f1af375e7", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  \n ", "start_char_idx": 4479, "end_char_idx": 4816, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4318b08e-d385-4200-9a42-2f0ba6302aac": {"__data__": {"id_": "4318b08e-d385-4200-9a42-2f0ba6302aac", "embedding": null, "metadata": {"window": "So, the position that we have, the strength that we have across segments, particularly our differentiated \ncapabilities in oncology, positions us very well for further growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relation s Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "692933c6-e017-4d68-907a-60e809f96ddd", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "22b93ece2d146eb9ac30968837125e52c9026dc861b7c3d96c31621bdd0992f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3cd3c5b2-22e1-41cb-9755-582a704272a7", "node_type": "1", "metadata": {"window": "We think that they offer better returns \nthan branded and specialty products, maybe not at the same level as generics from a margin perspective, but still, \nwe believe and we're optimistic that they're going to cont inue to add value to the segment over time.  \n \n So, the position that we have, the strength that we have across segments, particularly our differentiated \ncapabilities in oncology, positions us very well for further growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relation s Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  \n ", "page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "338afaa7eca67ce6dda934eec5c215081f1745191af4d8e857fe2fb2855125ea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "76a43378-df7c-4cc9-9b4f-9c46250442fe", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  Congrats on the quarter. ", "original_text": "McKesson Corp.  "}, "hash": "4f4f282d161d20b370d358c812aee2d2eedef203d4bdee0c501b8e52a33c38ba", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "start_char_idx": 773, "end_char_idx": 1044, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "76a43378-df7c-4cc9-9b4f-9c46250442fe": {"__data__": {"id_": "76a43378-df7c-4cc9-9b4f-9c46250442fe", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  Congrats on the quarter. ", "original_text": "McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97ceba1beb430b7da50d320fa57f501bfe36295f6a376a473f524103bf8858f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4318b08e-d385-4200-9a42-2f0ba6302aac", "node_type": "1", "metadata": {"window": "So, the position that we have, the strength that we have across segments, particularly our differentiated \ncapabilities in oncology, positions us very well for further growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relation s Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85b0f9751dc155c8759523b6d471b5d1820cf7ce83cc3310be0f62179b7ff751", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a964c50e-b4ca-432e-9b3f-15e73b4517b3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  Congrats on the quarter.  I guess, Britt, my question is the Medical segment operating \nincome raise was pretty significant even if you backed out COVID. ", "original_text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey. "}, "hash": "920eb396caa7410060b9850365d289d85043638f41d203189415d8d82b255477", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a964c50e-b4ca-432e-9b3f-15e73b4517b3": {"__data__": {"id_": "a964c50e-b4ca-432e-9b3f-15e73b4517b3", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  Congrats on the quarter.  I guess, Britt, my question is the Medical segment operating \nincome raise was pretty significant even if you backed out COVID. ", "original_text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey. ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97ceba1beb430b7da50d320fa57f501bfe36295f6a376a473f524103bf8858f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "76a43378-df7c-4cc9-9b4f-9c46250442fe", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  Congrats on the quarter. ", "original_text": "McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "656169fdbaa93935442c44adb1504fe2ad3b1100b22dcca885236a7054acda4d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c693198e-925e-42f3-82a6-8b17c3d6804b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  Congrats on the quarter.  I guess, Britt, my question is the Medical segment operating \nincome raise was pretty significant even if you backed out COVID.  Can you just dissect for us that \noutperformance and how should we be thinking about the sustainability of earnings in that segment past 2022?  \n ", "original_text": "Good afternoon, guys. "}, "hash": "ce154897ae952872b01eb4d50e0e4ef1720f6affd8334eb21a88fc0806836af0", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey. ", "start_char_idx": 16, "end_char_idx": 231, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c693198e-925e-42f3-82a6-8b17c3d6804b": {"__data__": {"id_": "c693198e-925e-42f3-82a6-8b17c3d6804b", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  Congrats on the quarter.  I guess, Britt, my question is the Medical segment operating \nincome raise was pretty significant even if you backed out COVID.  Can you just dissect for us that \noutperformance and how should we be thinking about the sustainability of earnings in that segment past 2022?  \n ", "original_text": "Good afternoon, guys. ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97ceba1beb430b7da50d320fa57f501bfe36295f6a376a473f524103bf8858f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a964c50e-b4ca-432e-9b3f-15e73b4517b3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  Congrats on the quarter.  I guess, Britt, my question is the Medical segment operating \nincome raise was pretty significant even if you backed out COVID. ", "original_text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey. ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cba62d5afe919885e7c367411444cfaedcc80afb6a7f85e660359004af35c0c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7f047ca8-f77b-4027-a73b-53c6d7c220d5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  Congrats on the quarter.  I guess, Britt, my question is the Medical segment operating \nincome raise was pretty significant even if you backed out COVID.  Can you just dissect for us that \noutperformance and how should we be thinking about the sustainability of earnings in that segment past 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financi al Officer & Executive Vice President, McKesson Corp.  ", "original_text": "Congrats on the quarter. "}, "hash": "c4df6fa486f3d22e09e6e3a149722d2e203f17e8a278048c119bf5a290d173ca", "class_name": "RelatedNodeInfo"}}, "text": "Good afternoon, guys. ", "start_char_idx": 231, "end_char_idx": 253, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7f047ca8-f77b-4027-a73b-53c6d7c220d5": {"__data__": {"id_": "7f047ca8-f77b-4027-a73b-53c6d7c220d5", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  Congrats on the quarter.  I guess, Britt, my question is the Medical segment operating \nincome raise was pretty significant even if you backed out COVID.  Can you just dissect for us that \noutperformance and how should we be thinking about the sustainability of earnings in that segment past 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financi al Officer & Executive Vice President, McKesson Corp.  ", "original_text": "Congrats on the quarter. ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97ceba1beb430b7da50d320fa57f501bfe36295f6a376a473f524103bf8858f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c693198e-925e-42f3-82a6-8b17c3d6804b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  Congrats on the quarter.  I guess, Britt, my question is the Medical segment operating \nincome raise was pretty significant even if you backed out COVID.  Can you just dissect for us that \noutperformance and how should we be thinking about the sustainability of earnings in that segment past 2022?  \n ", "original_text": "Good afternoon, guys. ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "84e0934980af68c0cd379199110e6ec4ade872abbfce9764c6eb316c5a503253", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5e218156-5493-4804-a293-0c588c79e4fc", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  Congrats on the quarter.  I guess, Britt, my question is the Medical segment operating \nincome raise was pretty significant even if you backed out COVID.  Can you just dissect for us that \noutperformance and how should we be thinking about the sustainability of earnings in that segment past 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financi al Officer & Executive Vice President, McKesson Corp.   A \nYeah. ", "original_text": "I guess, Britt, my question is the Medical segment operating \nincome raise was pretty significant even if you backed out COVID. "}, "hash": "79579762a768bdde0bee22e3c9d4760f7560dbc632bb70be0e7d85c409cb05e3", "class_name": "RelatedNodeInfo"}}, "text": "Congrats on the quarter. ", "start_char_idx": 253, "end_char_idx": 278, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5e218156-5493-4804-a293-0c588c79e4fc": {"__data__": {"id_": "5e218156-5493-4804-a293-0c588c79e4fc", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  Congrats on the quarter.  I guess, Britt, my question is the Medical segment operating \nincome raise was pretty significant even if you backed out COVID.  Can you just dissect for us that \noutperformance and how should we be thinking about the sustainability of earnings in that segment past 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financi al Officer & Executive Vice President, McKesson Corp.   A \nYeah. ", "original_text": "I guess, Britt, my question is the Medical segment operating \nincome raise was pretty significant even if you backed out COVID. ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97ceba1beb430b7da50d320fa57f501bfe36295f6a376a473f524103bf8858f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7f047ca8-f77b-4027-a73b-53c6d7c220d5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  Congrats on the quarter.  I guess, Britt, my question is the Medical segment operating \nincome raise was pretty significant even if you backed out COVID.  Can you just dissect for us that \noutperformance and how should we be thinking about the sustainability of earnings in that segment past 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financi al Officer & Executive Vice President, McKesson Corp.  ", "original_text": "Congrats on the quarter. ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6b22e177a10c56d91ccad0c94bdb348e123375e2be006f95cac7887ff7a932a7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2bf1228c-287b-4f69-905e-06a2d2c32854", "node_type": "1", "metadata": {"window": "Good afternoon, guys.  Congrats on the quarter.  I guess, Britt, my question is the Medical segment operating \nincome raise was pretty significant even if you backed out COVID.  Can you just dissect for us that \noutperformance and how should we be thinking about the sustainability of earnings in that segment past 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financi al Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for the question, Brian. ", "original_text": "Can you just dissect for us that \noutperformance and how should we be thinking about the sustainability of earnings in that segment past 2022?  \n "}, "hash": "3a2e34877a1acf6a74b98f805e304b7cf3ed56160c65b6c5dab3aa47f3926e0c", "class_name": "RelatedNodeInfo"}}, "text": "I guess, Britt, my question is the Medical segment operating \nincome raise was pretty significant even if you backed out COVID. ", "start_char_idx": 278, "end_char_idx": 406, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2bf1228c-287b-4f69-905e-06a2d2c32854": {"__data__": {"id_": "2bf1228c-287b-4f69-905e-06a2d2c32854", "embedding": null, "metadata": {"window": "Good afternoon, guys.  Congrats on the quarter.  I guess, Britt, my question is the Medical segment operating \nincome raise was pretty significant even if you backed out COVID.  Can you just dissect for us that \noutperformance and how should we be thinking about the sustainability of earnings in that segment past 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financi al Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for the question, Brian. ", "original_text": "Can you just dissect for us that \noutperformance and how should we be thinking about the sustainability of earnings in that segment past 2022?  \n ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97ceba1beb430b7da50d320fa57f501bfe36295f6a376a473f524103bf8858f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5e218156-5493-4804-a293-0c588c79e4fc", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  Congrats on the quarter.  I guess, Britt, my question is the Medical segment operating \nincome raise was pretty significant even if you backed out COVID.  Can you just dissect for us that \noutperformance and how should we be thinking about the sustainability of earnings in that segment past 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financi al Officer & Executive Vice President, McKesson Corp.   A \nYeah. ", "original_text": "I guess, Britt, my question is the Medical segment operating \nincome raise was pretty significant even if you backed out COVID. ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "69e17395273b5c5779043c9b9d99ee974b9124ca346f643428a48fc28e93aaae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cb8ff01c-661a-4397-8a38-d05e8492d338", "node_type": "1", "metadata": {"window": "Congrats on the quarter.  I guess, Britt, my question is the Medical segment operating \nincome raise was pretty significant even if you backed out COVID.  Can you just dissect for us that \noutperformance and how should we be thinking about the sustainability of earnings in that segment past 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financi al Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for the question, Brian.  Maybe I'll just start. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financi al Officer & Executive Vice President, McKesson Corp.  "}, "hash": "3fdf673425bef81214a4b9bce6110abbfae63521a682b510bb1e5c7a4db7d653", "class_name": "RelatedNodeInfo"}}, "text": "Can you just dissect for us that \noutperformance and how should we be thinking about the sustainability of earnings in that segment past 2022?  \n ", "start_char_idx": 406, "end_char_idx": 552, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cb8ff01c-661a-4397-8a38-d05e8492d338": {"__data__": {"id_": "cb8ff01c-661a-4397-8a38-d05e8492d338", "embedding": null, "metadata": {"window": "Congrats on the quarter.  I guess, Britt, my question is the Medical segment operating \nincome raise was pretty significant even if you backed out COVID.  Can you just dissect for us that \noutperformance and how should we be thinking about the sustainability of earnings in that segment past 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financi al Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for the question, Brian.  Maybe I'll just start. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financi al Officer & Executive Vice President, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97ceba1beb430b7da50d320fa57f501bfe36295f6a376a473f524103bf8858f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2bf1228c-287b-4f69-905e-06a2d2c32854", "node_type": "1", "metadata": {"window": "Good afternoon, guys.  Congrats on the quarter.  I guess, Britt, my question is the Medical segment operating \nincome raise was pretty significant even if you backed out COVID.  Can you just dissect for us that \noutperformance and how should we be thinking about the sustainability of earnings in that segment past 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financi al Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for the question, Brian. ", "original_text": "Can you just dissect for us that \noutperformance and how should we be thinking about the sustainability of earnings in that segment past 2022?  \n ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "569b03c1fefb7f7e684d562cb1b092f11a873ac46101b41d3f6d2d3b551b16b0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1b7c3c1f-1e6a-47d5-9f6a-0ed681b409a3", "node_type": "1", "metadata": {"window": "I guess, Britt, my question is the Medical segment operating \nincome raise was pretty significant even if you backed out COVID.  Can you just dissect for us that \noutperformance and how should we be thinking about the sustainability of earnings in that segment past 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financi al Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for the question, Brian.  Maybe I'll just start.  Just to remind you, since fiscal 2019, this business has \ngrown at 10% from an adjusted operating profit perspective on the core basis, out side of COVID programs. ", "original_text": "A \nYeah. "}, "hash": "0d73cc876273c48a63c9b08de0275a2537a66ec6440cda181006d6c0fde45cc5", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financi al Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 552, "end_char_idx": 910, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1b7c3c1f-1e6a-47d5-9f6a-0ed681b409a3": {"__data__": {"id_": "1b7c3c1f-1e6a-47d5-9f6a-0ed681b409a3", "embedding": null, "metadata": {"window": "I guess, Britt, my question is the Medical segment operating \nincome raise was pretty significant even if you backed out COVID.  Can you just dissect for us that \noutperformance and how should we be thinking about the sustainability of earnings in that segment past 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financi al Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for the question, Brian.  Maybe I'll just start.  Just to remind you, since fiscal 2019, this business has \ngrown at 10% from an adjusted operating profit perspective on the core basis, out side of COVID programs. ", "original_text": "A \nYeah. ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97ceba1beb430b7da50d320fa57f501bfe36295f6a376a473f524103bf8858f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cb8ff01c-661a-4397-8a38-d05e8492d338", "node_type": "1", "metadata": {"window": "Congrats on the quarter.  I guess, Britt, my question is the Medical segment operating \nincome raise was pretty significant even if you backed out COVID.  Can you just dissect for us that \noutperformance and how should we be thinking about the sustainability of earnings in that segment past 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financi al Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for the question, Brian.  Maybe I'll just start. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financi al Officer & Executive Vice President, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbb3ec54f553deba3dff4e9c24218eea2e31c0a825a83d2f6591f038994e191f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e96345b7-3f75-42f3-9ccf-5862986a49ef", "node_type": "1", "metadata": {"window": "Can you just dissect for us that \noutperformance and how should we be thinking about the sustainability of earnings in that segment past 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financi al Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for the question, Brian.  Maybe I'll just start.  Just to remind you, since fiscal 2019, this business has \ngrown at 10% from an adjusted operating profit perspective on the core basis, out side of COVID programs.  So, \nwe've seen strong growth in this business now for a number of years. ", "original_text": "Thanks for the question, Brian. "}, "hash": "ff1aa029018705143efe13be4d232b85202628c49ebc4abfd3e4462b6822233f", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah. ", "start_char_idx": 910, "end_char_idx": 919, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e96345b7-3f75-42f3-9ccf-5862986a49ef": {"__data__": {"id_": "e96345b7-3f75-42f3-9ccf-5862986a49ef", "embedding": null, "metadata": {"window": "Can you just dissect for us that \noutperformance and how should we be thinking about the sustainability of earnings in that segment past 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financi al Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for the question, Brian.  Maybe I'll just start.  Just to remind you, since fiscal 2019, this business has \ngrown at 10% from an adjusted operating profit perspective on the core basis, out side of COVID programs.  So, \nwe've seen strong growth in this business now for a number of years. ", "original_text": "Thanks for the question, Brian. ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97ceba1beb430b7da50d320fa57f501bfe36295f6a376a473f524103bf8858f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1b7c3c1f-1e6a-47d5-9f6a-0ed681b409a3", "node_type": "1", "metadata": {"window": "I guess, Britt, my question is the Medical segment operating \nincome raise was pretty significant even if you backed out COVID.  Can you just dissect for us that \noutperformance and how should we be thinking about the sustainability of earnings in that segment past 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financi al Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for the question, Brian.  Maybe I'll just start.  Just to remind you, since fiscal 2019, this business has \ngrown at 10% from an adjusted operating profit perspective on the core basis, out side of COVID programs. ", "original_text": "A \nYeah. ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4a4a672e138ef9bfe2a9a4b9d596fe8fd267c2e098b51b0686ea9e971d11b079", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cc326a5f-7a3a-4bfc-9276-d4f094ae434d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financi al Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for the question, Brian.  Maybe I'll just start.  Just to remind you, since fiscal 2019, this business has \ngrown at 10% from an adjusted operating profit perspective on the core basis, out side of COVID programs.  So, \nwe've seen strong growth in this business now for a number of years.  It's one of our higher -margin segments. ", "original_text": "Maybe I'll just start. "}, "hash": "1ebdc5d7ef3dd391b8a5adea5a322e4806f8695336b81877026f0f9979ab40bf", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for the question, Brian. ", "start_char_idx": 919, "end_char_idx": 951, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc326a5f-7a3a-4bfc-9276-d4f094ae434d": {"__data__": {"id_": "cc326a5f-7a3a-4bfc-9276-d4f094ae434d", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financi al Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for the question, Brian.  Maybe I'll just start.  Just to remind you, since fiscal 2019, this business has \ngrown at 10% from an adjusted operating profit perspective on the core basis, out side of COVID programs.  So, \nwe've seen strong growth in this business now for a number of years.  It's one of our higher -margin segments. ", "original_text": "Maybe I'll just start. ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97ceba1beb430b7da50d320fa57f501bfe36295f6a376a473f524103bf8858f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e96345b7-3f75-42f3-9ccf-5862986a49ef", "node_type": "1", "metadata": {"window": "Can you just dissect for us that \noutperformance and how should we be thinking about the sustainability of earnings in that segment past 2022?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financi al Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for the question, Brian.  Maybe I'll just start.  Just to remind you, since fiscal 2019, this business has \ngrown at 10% from an adjusted operating profit perspective on the core basis, out side of COVID programs.  So, \nwe've seen strong growth in this business now for a number of years. ", "original_text": "Thanks for the question, Brian. ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "45e95dc183a08fa8c8afa59019ee91f255577677f31d0f1569ee68a94d571764", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f8b93dcb-70c9-4558-97df-d4aba0e895f0", "node_type": "1", "metadata": {"window": "A \nYeah.  Thanks for the question, Brian.  Maybe I'll just start.  Just to remind you, since fiscal 2019, this business has \ngrown at 10% from an adjusted operating profit perspective on the core basis, out side of COVID programs.  So, \nwe've seen strong growth in this business now for a number of years.  It's one of our higher -margin segments.  We \nhave very strong positions across the primary care segment of the business and across all alternate sites. ", "original_text": "Just to remind you, since fiscal 2019, this business has \ngrown at 10% from an adjusted operating profit perspective on the core basis, out side of COVID programs. "}, "hash": "099487faa96554dce58fded5666eec3b42aaa6154716c17459c042a753be982e", "class_name": "RelatedNodeInfo"}}, "text": "Maybe I'll just start. ", "start_char_idx": 951, "end_char_idx": 974, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f8b93dcb-70c9-4558-97df-d4aba0e895f0": {"__data__": {"id_": "f8b93dcb-70c9-4558-97df-d4aba0e895f0", "embedding": null, "metadata": {"window": "A \nYeah.  Thanks for the question, Brian.  Maybe I'll just start.  Just to remind you, since fiscal 2019, this business has \ngrown at 10% from an adjusted operating profit perspective on the core basis, out side of COVID programs.  So, \nwe've seen strong growth in this business now for a number of years.  It's one of our higher -margin segments.  We \nhave very strong positions across the primary care segment of the business and across all alternate sites. ", "original_text": "Just to remind you, since fiscal 2019, this business has \ngrown at 10% from an adjusted operating profit perspective on the core basis, out side of COVID programs. ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97ceba1beb430b7da50d320fa57f501bfe36295f6a376a473f524103bf8858f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc326a5f-7a3a-4bfc-9276-d4f094ae434d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financi al Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Thanks for the question, Brian.  Maybe I'll just start.  Just to remind you, since fiscal 2019, this business has \ngrown at 10% from an adjusted operating profit perspective on the core basis, out side of COVID programs.  So, \nwe've seen strong growth in this business now for a number of years.  It's one of our higher -margin segments. ", "original_text": "Maybe I'll just start. ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fe29a7746b8bb7b8d09d65a992f13ab8bbf7150fbdffe5cec984620521595881", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "322cfc7c-4cd8-4c92-a1b4-6604fca47c66", "node_type": "1", "metadata": {"window": "Thanks for the question, Brian.  Maybe I'll just start.  Just to remind you, since fiscal 2019, this business has \ngrown at 10% from an adjusted operating profit perspective on the core basis, out side of COVID programs.  So, \nwe've seen strong growth in this business now for a number of years.  It's one of our higher -margin segments.  We \nhave very strong positions across the primary care segment of the business and across all alternate sites.  Our \nexten ded care business has grown nicely over time as well.  \n \n", "original_text": "So, \nwe've seen strong growth in this business now for a number of years. "}, "hash": "f5d41e564d23fbad855da3d19d2b965ca76e7089d44521d8730d4f412a8723d0", "class_name": "RelatedNodeInfo"}}, "text": "Just to remind you, since fiscal 2019, this business has \ngrown at 10% from an adjusted operating profit perspective on the core basis, out side of COVID programs. ", "start_char_idx": 974, "end_char_idx": 1138, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "322cfc7c-4cd8-4c92-a1b4-6604fca47c66": {"__data__": {"id_": "322cfc7c-4cd8-4c92-a1b4-6604fca47c66", "embedding": null, "metadata": {"window": "Thanks for the question, Brian.  Maybe I'll just start.  Just to remind you, since fiscal 2019, this business has \ngrown at 10% from an adjusted operating profit perspective on the core basis, out side of COVID programs.  So, \nwe've seen strong growth in this business now for a number of years.  It's one of our higher -margin segments.  We \nhave very strong positions across the primary care segment of the business and across all alternate sites.  Our \nexten ded care business has grown nicely over time as well.  \n \n", "original_text": "So, \nwe've seen strong growth in this business now for a number of years. ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97ceba1beb430b7da50d320fa57f501bfe36295f6a376a473f524103bf8858f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f8b93dcb-70c9-4558-97df-d4aba0e895f0", "node_type": "1", "metadata": {"window": "A \nYeah.  Thanks for the question, Brian.  Maybe I'll just start.  Just to remind you, since fiscal 2019, this business has \ngrown at 10% from an adjusted operating profit perspective on the core basis, out side of COVID programs.  So, \nwe've seen strong growth in this business now for a number of years.  It's one of our higher -margin segments.  We \nhave very strong positions across the primary care segment of the business and across all alternate sites. ", "original_text": "Just to remind you, since fiscal 2019, this business has \ngrown at 10% from an adjusted operating profit perspective on the core basis, out side of COVID programs. ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2daf695cc69c444ed6f43cb4fa3bc1a2072208ff88c0ed38b4fa885f7f3efde4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c0d229d9-947e-4dc1-9e05-e0f237662457", "node_type": "1", "metadata": {"window": "Maybe I'll just start.  Just to remind you, since fiscal 2019, this business has \ngrown at 10% from an adjusted operating profit perspective on the core basis, out side of COVID programs.  So, \nwe've seen strong growth in this business now for a number of years.  It's one of our higher -margin segments.  We \nhave very strong positions across the primary care segment of the business and across all alternate sites.  Our \nexten ded care business has grown nicely over time as well.  \n \n We've added a lot of capabilities and investment over time, whether that be acquisitions to position us well in the \nlab. ", "original_text": "It's one of our higher -margin segments. "}, "hash": "140d9a93ec56e5d0d8f65a3d782595e71d6d5df33708240f9dd33261b667265c", "class_name": "RelatedNodeInfo"}}, "text": "So, \nwe've seen strong growth in this business now for a number of years. ", "start_char_idx": 1138, "end_char_idx": 1212, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c0d229d9-947e-4dc1-9e05-e0f237662457": {"__data__": {"id_": "c0d229d9-947e-4dc1-9e05-e0f237662457", "embedding": null, "metadata": {"window": "Maybe I'll just start.  Just to remind you, since fiscal 2019, this business has \ngrown at 10% from an adjusted operating profit perspective on the core basis, out side of COVID programs.  So, \nwe've seen strong growth in this business now for a number of years.  It's one of our higher -margin segments.  We \nhave very strong positions across the primary care segment of the business and across all alternate sites.  Our \nexten ded care business has grown nicely over time as well.  \n \n We've added a lot of capabilities and investment over time, whether that be acquisitions to position us well in the \nlab. ", "original_text": "It's one of our higher -margin segments. ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97ceba1beb430b7da50d320fa57f501bfe36295f6a376a473f524103bf8858f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "322cfc7c-4cd8-4c92-a1b4-6604fca47c66", "node_type": "1", "metadata": {"window": "Thanks for the question, Brian.  Maybe I'll just start.  Just to remind you, since fiscal 2019, this business has \ngrown at 10% from an adjusted operating profit perspective on the core basis, out side of COVID programs.  So, \nwe've seen strong growth in this business now for a number of years.  It's one of our higher -margin segments.  We \nhave very strong positions across the primary care segment of the business and across all alternate sites.  Our \nexten ded care business has grown nicely over time as well.  \n \n", "original_text": "So, \nwe've seen strong growth in this business now for a number of years. ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b0fbbfafbfa725107ee9ce541149bb2b169c40ab25fa58b9f7b80cd4aa4020db", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cbede393-3c0b-4ef7-b708-e31727b0a928", "node_type": "1", "metadata": {"window": "Just to remind you, since fiscal 2019, this business has \ngrown at 10% from an adjusted operating profit perspective on the core basis, out side of COVID programs.  So, \nwe've seen strong growth in this business now for a number of years.  It's one of our higher -margin segments.  We \nhave very strong positions across the primary care segment of the business and across all alternate sites.  Our \nexten ded care business has grown nicely over time as well.  \n \n We've added a lot of capabilities and investment over time, whether that be acquisitions to position us well in the \nlab.  We've seen private brand be an important component and we've seen growth in Rx a s well. ", "original_text": "We \nhave very strong positions across the primary care segment of the business and across all alternate sites. "}, "hash": "9dd6ed3f5c05417142522533b444a50d3337aa1c7f7397bf747226002de77ace", "class_name": "RelatedNodeInfo"}}, "text": "It's one of our higher -margin segments. ", "start_char_idx": 1212, "end_char_idx": 1253, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cbede393-3c0b-4ef7-b708-e31727b0a928": {"__data__": {"id_": "cbede393-3c0b-4ef7-b708-e31727b0a928", "embedding": null, "metadata": {"window": "Just to remind you, since fiscal 2019, this business has \ngrown at 10% from an adjusted operating profit perspective on the core basis, out side of COVID programs.  So, \nwe've seen strong growth in this business now for a number of years.  It's one of our higher -margin segments.  We \nhave very strong positions across the primary care segment of the business and across all alternate sites.  Our \nexten ded care business has grown nicely over time as well.  \n \n We've added a lot of capabilities and investment over time, whether that be acquisitions to position us well in the \nlab.  We've seen private brand be an important component and we've seen growth in Rx a s well. ", "original_text": "We \nhave very strong positions across the primary care segment of the business and across all alternate sites. ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97ceba1beb430b7da50d320fa57f501bfe36295f6a376a473f524103bf8858f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c0d229d9-947e-4dc1-9e05-e0f237662457", "node_type": "1", "metadata": {"window": "Maybe I'll just start.  Just to remind you, since fiscal 2019, this business has \ngrown at 10% from an adjusted operating profit perspective on the core basis, out side of COVID programs.  So, \nwe've seen strong growth in this business now for a number of years.  It's one of our higher -margin segments.  We \nhave very strong positions across the primary care segment of the business and across all alternate sites.  Our \nexten ded care business has grown nicely over time as well.  \n \n We've added a lot of capabilities and investment over time, whether that be acquisitions to position us well in the \nlab. ", "original_text": "It's one of our higher -margin segments. ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c2f63ebce5d27d99abc1979dacfeaede5ad3246569ae9b75ab8fec8b509d543c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "de4b9656-85ce-4656-ac45-9a0cb6910f13", "node_type": "1", "metadata": {"window": "So, \nwe've seen strong growth in this business now for a number of years.  It's one of our higher -margin segments.  We \nhave very strong positions across the primary care segment of the business and across all alternate sites.  Our \nexten ded care business has grown nicely over time as well.  \n \n We've added a lot of capabilities and investment over time, whether that be acquisitions to position us well in the \nlab.  We've seen private brand be an important component and we've seen growth in Rx a s well.  So, we've got a \nlot of capabilities across the entire alternate site. ", "original_text": "Our \nexten ded care business has grown nicely over time as well.  \n \n"}, "hash": "6293a793151b7c10ed738d3a1e31a5710f81546857c8174ddcbaffe59c9ae8e9", "class_name": "RelatedNodeInfo"}}, "text": "We \nhave very strong positions across the primary care segment of the business and across all alternate sites. ", "start_char_idx": 1253, "end_char_idx": 1364, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "de4b9656-85ce-4656-ac45-9a0cb6910f13": {"__data__": {"id_": "de4b9656-85ce-4656-ac45-9a0cb6910f13", "embedding": null, "metadata": {"window": "So, \nwe've seen strong growth in this business now for a number of years.  It's one of our higher -margin segments.  We \nhave very strong positions across the primary care segment of the business and across all alternate sites.  Our \nexten ded care business has grown nicely over time as well.  \n \n We've added a lot of capabilities and investment over time, whether that be acquisitions to position us well in the \nlab.  We've seen private brand be an important component and we've seen growth in Rx a s well.  So, we've got a \nlot of capabilities across the entire alternate site. ", "original_text": "Our \nexten ded care business has grown nicely over time as well.  \n \n", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97ceba1beb430b7da50d320fa57f501bfe36295f6a376a473f524103bf8858f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cbede393-3c0b-4ef7-b708-e31727b0a928", "node_type": "1", "metadata": {"window": "Just to remind you, since fiscal 2019, this business has \ngrown at 10% from an adjusted operating profit perspective on the core basis, out side of COVID programs.  So, \nwe've seen strong growth in this business now for a number of years.  It's one of our higher -margin segments.  We \nhave very strong positions across the primary care segment of the business and across all alternate sites.  Our \nexten ded care business has grown nicely over time as well.  \n \n We've added a lot of capabilities and investment over time, whether that be acquisitions to position us well in the \nlab.  We've seen private brand be an important component and we've seen growth in Rx a s well. ", "original_text": "We \nhave very strong positions across the primary care segment of the business and across all alternate sites. ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "55f6dcfc8970e1d9c35419c831a96d5190b7b49862d95b1dfb4a87e1a9321fd5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0e805e66-8af9-4b3b-bf3a-52232d1c5bb5", "node_type": "1", "metadata": {"window": "It's one of our higher -margin segments.  We \nhave very strong positions across the primary care segment of the business and across all alternate sites.  Our \nexten ded care business has grown nicely over time as well.  \n \n We've added a lot of capabilities and investment over time, whether that be acquisitions to position us well in the \nlab.  We've seen private brand be an important component and we've seen growth in Rx a s well.  So, we've got a \nlot of capabilities across the entire alternate site.  We've invested in these capabilities over time. ", "original_text": "We've added a lot of capabilities and investment over time, whether that be acquisitions to position us well in the \nlab. "}, "hash": "a8c4265ff23074e2f3e4235af854d8c9d2fd70db4a57b7785eda9c51a361dec0", "class_name": "RelatedNodeInfo"}}, "text": "Our \nexten ded care business has grown nicely over time as well.  \n \n", "start_char_idx": 1364, "end_char_idx": 1433, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0e805e66-8af9-4b3b-bf3a-52232d1c5bb5": {"__data__": {"id_": "0e805e66-8af9-4b3b-bf3a-52232d1c5bb5", "embedding": null, "metadata": {"window": "It's one of our higher -margin segments.  We \nhave very strong positions across the primary care segment of the business and across all alternate sites.  Our \nexten ded care business has grown nicely over time as well.  \n \n We've added a lot of capabilities and investment over time, whether that be acquisitions to position us well in the \nlab.  We've seen private brand be an important component and we've seen growth in Rx a s well.  So, we've got a \nlot of capabilities across the entire alternate site.  We've invested in these capabilities over time. ", "original_text": "We've added a lot of capabilities and investment over time, whether that be acquisitions to position us well in the \nlab. ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97ceba1beb430b7da50d320fa57f501bfe36295f6a376a473f524103bf8858f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "de4b9656-85ce-4656-ac45-9a0cb6910f13", "node_type": "1", "metadata": {"window": "So, \nwe've seen strong growth in this business now for a number of years.  It's one of our higher -margin segments.  We \nhave very strong positions across the primary care segment of the business and across all alternate sites.  Our \nexten ded care business has grown nicely over time as well.  \n \n We've added a lot of capabilities and investment over time, whether that be acquisitions to position us well in the \nlab.  We've seen private brand be an important component and we've seen growth in Rx a s well.  So, we've got a \nlot of capabilities across the entire alternate site. ", "original_text": "Our \nexten ded care business has grown nicely over time as well.  \n \n", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "32806ccf8c4cb00dcd957faf189c48a6ae5ac3a6c392c0a446502656ec1027e0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f3a14a36-86c8-4c08-80f7-210d3f4fbf67", "node_type": "1", "metadata": {"window": "We \nhave very strong positions across the primary care segment of the business and across all alternate sites.  Our \nexten ded care business has grown nicely over time as well.  \n \n We've added a lot of capabilities and investment over time, whether that be acquisitions to position us well in the \nlab.  We've seen private brand be an important component and we've seen growth in Rx a s well.  So, we've got a \nlot of capabilities across the entire alternate site.  We've invested in these capabilities over time.  It's positioned us \nwell not only from a core perspective, but certainly now, as COVID has taken on, we've been in a really good \nposition to handle the kitting and the storage programs as well.  \n ", "original_text": "We've seen private brand be an important component and we've seen growth in Rx a s well. "}, "hash": "5650419e67cf77701a466bdca55c79eeedd5c1351f40f9d8b7bc56b60c6d8138", "class_name": "RelatedNodeInfo"}}, "text": "We've added a lot of capabilities and investment over time, whether that be acquisitions to position us well in the \nlab. ", "start_char_idx": 1433, "end_char_idx": 1555, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f3a14a36-86c8-4c08-80f7-210d3f4fbf67": {"__data__": {"id_": "f3a14a36-86c8-4c08-80f7-210d3f4fbf67", "embedding": null, "metadata": {"window": "We \nhave very strong positions across the primary care segment of the business and across all alternate sites.  Our \nexten ded care business has grown nicely over time as well.  \n \n We've added a lot of capabilities and investment over time, whether that be acquisitions to position us well in the \nlab.  We've seen private brand be an important component and we've seen growth in Rx a s well.  So, we've got a \nlot of capabilities across the entire alternate site.  We've invested in these capabilities over time.  It's positioned us \nwell not only from a core perspective, but certainly now, as COVID has taken on, we've been in a really good \nposition to handle the kitting and the storage programs as well.  \n ", "original_text": "We've seen private brand be an important component and we've seen growth in Rx a s well. ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97ceba1beb430b7da50d320fa57f501bfe36295f6a376a473f524103bf8858f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0e805e66-8af9-4b3b-bf3a-52232d1c5bb5", "node_type": "1", "metadata": {"window": "It's one of our higher -margin segments.  We \nhave very strong positions across the primary care segment of the business and across all alternate sites.  Our \nexten ded care business has grown nicely over time as well.  \n \n We've added a lot of capabilities and investment over time, whether that be acquisitions to position us well in the \nlab.  We've seen private brand be an important component and we've seen growth in Rx a s well.  So, we've got a \nlot of capabilities across the entire alternate site.  We've invested in these capabilities over time. ", "original_text": "We've added a lot of capabilities and investment over time, whether that be acquisitions to position us well in the \nlab. ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4c32d72cdc8f0dac2c893ad9b164c78860d00317ba0da46bc1e232b93d0ef9b0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0fcb5a52-c6f1-4b68-a3da-01e4f4c2935e", "node_type": "1", "metadata": {"window": "Our \nexten ded care business has grown nicely over time as well.  \n \n We've added a lot of capabilities and investment over time, whether that be acquisitions to position us well in the \nlab.  We've seen private brand be an important component and we've seen growth in Rx a s well.  So, we've got a \nlot of capabilities across the entire alternate site.  We've invested in these capabilities over time.  It's positioned us \nwell not only from a core perspective, but certainly now, as COVID has taken on, we've been in a really good \nposition to handle the kitting and the storage programs as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n ", "original_text": "So, we've got a \nlot of capabilities across the entire alternate site. "}, "hash": "53f48ebd25a4dd1b78203364dabf0327a49e99d0998ab0259241805d493d1024", "class_name": "RelatedNodeInfo"}}, "text": "We've seen private brand be an important component and we've seen growth in Rx a s well. ", "start_char_idx": 1555, "end_char_idx": 1644, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0fcb5a52-c6f1-4b68-a3da-01e4f4c2935e": {"__data__": {"id_": "0fcb5a52-c6f1-4b68-a3da-01e4f4c2935e", "embedding": null, "metadata": {"window": "Our \nexten ded care business has grown nicely over time as well.  \n \n We've added a lot of capabilities and investment over time, whether that be acquisitions to position us well in the \nlab.  We've seen private brand be an important component and we've seen growth in Rx a s well.  So, we've got a \nlot of capabilities across the entire alternate site.  We've invested in these capabilities over time.  It's positioned us \nwell not only from a core perspective, but certainly now, as COVID has taken on, we've been in a really good \nposition to handle the kitting and the storage programs as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n ", "original_text": "So, we've got a \nlot of capabilities across the entire alternate site. ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97ceba1beb430b7da50d320fa57f501bfe36295f6a376a473f524103bf8858f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f3a14a36-86c8-4c08-80f7-210d3f4fbf67", "node_type": "1", "metadata": {"window": "We \nhave very strong positions across the primary care segment of the business and across all alternate sites.  Our \nexten ded care business has grown nicely over time as well.  \n \n We've added a lot of capabilities and investment over time, whether that be acquisitions to position us well in the \nlab.  We've seen private brand be an important component and we've seen growth in Rx a s well.  So, we've got a \nlot of capabilities across the entire alternate site.  We've invested in these capabilities over time.  It's positioned us \nwell not only from a core perspective, but certainly now, as COVID has taken on, we've been in a really good \nposition to handle the kitting and the storage programs as well.  \n ", "original_text": "We've seen private brand be an important component and we've seen growth in Rx a s well. ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e67c90d8a6f9f992ee1bf034161a7464e1b52f0c84fb5b256f2ad37a64ba2180", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4837095d-9d4e-44f5-b508-2b181c13ac24", "node_type": "1", "metadata": {"window": "We've added a lot of capabilities and investment over time, whether that be acquisitions to position us well in the \nlab.  We've seen private brand be an important component and we've seen growth in Rx a s well.  So, we've got a \nlot of capabilities across the entire alternate site.  We've invested in these capabilities over time.  It's positioned us \nwell not only from a core perspective, but certainly now, as COVID has taken on, we've been in a really good \nposition to handle the kitting and the storage programs as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldwasser with Morgan Stanley.  \n ", "original_text": "We've invested in these capabilities over time. "}, "hash": "f73acfb9d909c57e0fb2d97c1c5ce3188a597a1cf5936473e63591f907e914a9", "class_name": "RelatedNodeInfo"}}, "text": "So, we've got a \nlot of capabilities across the entire alternate site. ", "start_char_idx": 1644, "end_char_idx": 1715, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4837095d-9d4e-44f5-b508-2b181c13ac24": {"__data__": {"id_": "4837095d-9d4e-44f5-b508-2b181c13ac24", "embedding": null, "metadata": {"window": "We've added a lot of capabilities and investment over time, whether that be acquisitions to position us well in the \nlab.  We've seen private brand be an important component and we've seen growth in Rx a s well.  So, we've got a \nlot of capabilities across the entire alternate site.  We've invested in these capabilities over time.  It's positioned us \nwell not only from a core perspective, but certainly now, as COVID has taken on, we've been in a really good \nposition to handle the kitting and the storage programs as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldwasser with Morgan Stanley.  \n ", "original_text": "We've invested in these capabilities over time. ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97ceba1beb430b7da50d320fa57f501bfe36295f6a376a473f524103bf8858f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0fcb5a52-c6f1-4b68-a3da-01e4f4c2935e", "node_type": "1", "metadata": {"window": "Our \nexten ded care business has grown nicely over time as well.  \n \n We've added a lot of capabilities and investment over time, whether that be acquisitions to position us well in the \nlab.  We've seen private brand be an important component and we've seen growth in Rx a s well.  So, we've got a \nlot of capabilities across the entire alternate site.  We've invested in these capabilities over time.  It's positioned us \nwell not only from a core perspective, but certainly now, as COVID has taken on, we've been in a really good \nposition to handle the kitting and the storage programs as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n ", "original_text": "So, we've got a \nlot of capabilities across the entire alternate site. ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "994f997770f7aa74843418c643ad8185ba1fcf6335c6a0156cd1e1999a216db8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e0fc47b1-95a5-4a2a-b974-a931d64054b4", "node_type": "1", "metadata": {"window": "We've seen private brand be an important component and we've seen growth in Rx a s well.  So, we've got a \nlot of capabilities across the entire alternate site.  We've invested in these capabilities over time.  It's positioned us \nwell not only from a core perspective, but certainly now, as COVID has taken on, we've been in a really good \nposition to handle the kitting and the storage programs as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "It's positioned us \nwell not only from a core perspective, but certainly now, as COVID has taken on, we've been in a really good \nposition to handle the kitting and the storage programs as well.  \n "}, "hash": "7252d86a75745cc9eaa573463def3cb7018272a48aad8abe3f1e2d76170593b9", "class_name": "RelatedNodeInfo"}}, "text": "We've invested in these capabilities over time. ", "start_char_idx": 1715, "end_char_idx": 1763, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e0fc47b1-95a5-4a2a-b974-a931d64054b4": {"__data__": {"id_": "e0fc47b1-95a5-4a2a-b974-a931d64054b4", "embedding": null, "metadata": {"window": "We've seen private brand be an important component and we've seen growth in Rx a s well.  So, we've got a \nlot of capabilities across the entire alternate site.  We've invested in these capabilities over time.  It's positioned us \nwell not only from a core perspective, but certainly now, as COVID has taken on, we've been in a really good \nposition to handle the kitting and the storage programs as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "It's positioned us \nwell not only from a core perspective, but certainly now, as COVID has taken on, we've been in a really good \nposition to handle the kitting and the storage programs as well.  \n ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97ceba1beb430b7da50d320fa57f501bfe36295f6a376a473f524103bf8858f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4837095d-9d4e-44f5-b508-2b181c13ac24", "node_type": "1", "metadata": {"window": "We've added a lot of capabilities and investment over time, whether that be acquisitions to position us well in the \nlab.  We've seen private brand be an important component and we've seen growth in Rx a s well.  So, we've got a \nlot of capabilities across the entire alternate site.  We've invested in these capabilities over time.  It's positioned us \nwell not only from a core perspective, but certainly now, as COVID has taken on, we've been in a really good \nposition to handle the kitting and the storage programs as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldwasser with Morgan Stanley.  \n ", "original_text": "We've invested in these capabilities over time. ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6ff12cc100e00bb5f580eeb9e2c6ab006074d8e4dd17d0e6c52b395f9005adc3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "911a5434-ed5a-4af6-8042-6be5052b32d6", "node_type": "1", "metadata": {"window": "So, we've got a \nlot of capabilities across the entire alternate site.  We've invested in these capabilities over time.  It's positioned us \nwell not only from a core perspective, but certainly now, as COVID has taken on, we've been in a really good \nposition to handle the kitting and the storage programs as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n "}, "hash": "daacca80c9e8b2c15343bf6f6cbbbfae38e95d55538a5c4de7d5f051310e743c", "class_name": "RelatedNodeInfo"}}, "text": "It's positioned us \nwell not only from a core perspective, but certainly now, as COVID has taken on, we've been in a really good \nposition to handle the kitting and the storage programs as well.  \n ", "start_char_idx": 1763, "end_char_idx": 1961, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "911a5434-ed5a-4af6-8042-6be5052b32d6": {"__data__": {"id_": "911a5434-ed5a-4af6-8042-6be5052b32d6", "embedding": null, "metadata": {"window": "So, we've got a \nlot of capabilities across the entire alternate site.  We've invested in these capabilities over time.  It's positioned us \nwell not only from a core perspective, but certainly now, as COVID has taken on, we've been in a really good \nposition to handle the kitting and the storage programs as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97ceba1beb430b7da50d320fa57f501bfe36295f6a376a473f524103bf8858f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e0fc47b1-95a5-4a2a-b974-a931d64054b4", "node_type": "1", "metadata": {"window": "We've seen private brand be an important component and we've seen growth in Rx a s well.  So, we've got a \nlot of capabilities across the entire alternate site.  We've invested in these capabilities over time.  It's positioned us \nwell not only from a core perspective, but certainly now, as COVID has taken on, we've been in a really good \nposition to handle the kitting and the storage programs as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "It's positioned us \nwell not only from a core perspective, but certainly now, as COVID has taken on, we've been in a really good \nposition to handle the kitting and the storage programs as well.  \n ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "57d47b8a3c1512331e8adb175087c9047f9c099d5c3551a231014a501eefc741", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "351a20a7-f019-48d3-aa4f-cf159fc27f64", "node_type": "1", "metadata": {"window": "We've invested in these capabilities over time.  It's positioned us \nwell not only from a core perspective, but certainly now, as COVID has taken on, we've been in a really good \nposition to handle the kitting and the storage programs as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldwasser with Morgan Stanley.  \n "}, "hash": "d797f9b172dc03c583cdedf2c6fed7962c93bf828c61d3b3a37a53122b86fc2e", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n ", "start_char_idx": 1961, "end_char_idx": 2324, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "351a20a7-f019-48d3-aa4f-cf159fc27f64": {"__data__": {"id_": "351a20a7-f019-48d3-aa4f-cf159fc27f64", "embedding": null, "metadata": {"window": "We've invested in these capabilities over time.  It's positioned us \nwell not only from a core perspective, but certainly now, as COVID has taken on, we've been in a really good \nposition to handle the kitting and the storage programs as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldwasser with Morgan Stanley.  \n ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97ceba1beb430b7da50d320fa57f501bfe36295f6a376a473f524103bf8858f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "911a5434-ed5a-4af6-8042-6be5052b32d6", "node_type": "1", "metadata": {"window": "So, we've got a \nlot of capabilities across the entire alternate site.  We've invested in these capabilities over time.  It's positioned us \nwell not only from a core perspective, but certainly now, as COVID has taken on, we've been in a really good \nposition to handle the kitting and the storage programs as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5c1af91914dbfbc7b33c01092c4cbe4cf4e64b455c32f86ae05e702e3685588f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "16b3a2c2-0338-49f1-8658-791dea6d1218", "node_type": "1", "metadata": {"window": "It's positioned us \nwell not only from a core perspective, but certainly now, as COVID has taken on, we've been in a really good \nposition to handle the kitting and the storage programs as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good evening and thanks for the very comprehensive details. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. "}, "hash": "0178287706ca7b1ecfcd300f8e4bbc1ea9f290a0be96bc789df706627c441dd5", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldwasser with Morgan Stanley.  \n ", "start_char_idx": 2324, "end_char_idx": 2667, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "16b3a2c2-0338-49f1-8658-791dea6d1218": {"__data__": {"id_": "16b3a2c2-0338-49f1-8658-791dea6d1218", "embedding": null, "metadata": {"window": "It's positioned us \nwell not only from a core perspective, but certainly now, as COVID has taken on, we've been in a really good \nposition to handle the kitting and the storage programs as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good evening and thanks for the very comprehensive details. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97ceba1beb430b7da50d320fa57f501bfe36295f6a376a473f524103bf8858f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "351a20a7-f019-48d3-aa4f-cf159fc27f64", "node_type": "1", "metadata": {"window": "We've invested in these capabilities over time.  It's positioned us \nwell not only from a core perspective, but certainly now, as COVID has taken on, we've been in a really good \nposition to handle the kitting and the storage programs as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldwasser with Morgan Stanley.  \n ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dc86cee5828c3a17fa5d5d29c3b57bfd6077e07d3be0bbb449437559ca00b695", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "705369fd-b974-48f0-836a-188ce18c6eb6", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good evening and thanks for the very comprehensive details.  So, two follow -ups here. ", "original_text": "LLC  Q \nYeah. "}, "hash": "e8b8da0e2c0457a6fb2e938d142790a4040319c167aad958a5db30d1da0d7e15", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "start_char_idx": 2667, "end_char_idx": 2991, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "705369fd-b974-48f0-836a-188ce18c6eb6": {"__data__": {"id_": "705369fd-b974-48f0-836a-188ce18c6eb6", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good evening and thanks for the very comprehensive details.  So, two follow -ups here. ", "original_text": "LLC  Q \nYeah. ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97ceba1beb430b7da50d320fa57f501bfe36295f6a376a473f524103bf8858f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "16b3a2c2-0338-49f1-8658-791dea6d1218", "node_type": "1", "metadata": {"window": "It's positioned us \nwell not only from a core perspective, but certainly now, as COVID has taken on, we've been in a really good \nposition to handle the kitting and the storage programs as well.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good evening and thanks for the very comprehensive details. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "853e0f7afd5b295d93e97f0d1b2076db8e49cb6d7954e93628cb692fed40c129", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e451c9dd-4d69-4484-bc85-e01d5b647d81", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good evening and thanks for the very comprehensive details.  So, two follow -ups here.  One, just to \nclarify, as you think about 2023, should we assume that all the buyback activity is going to be offsetting the \ndilution from th e European divestitures? ", "original_text": "Hi. "}, "hash": "899776df9b887e12c43c5fc60e51bf8ec0e6358c1c26d1310283da50a29ed554", "class_name": "RelatedNodeInfo"}}, "text": "LLC  Q \nYeah. ", "start_char_idx": 2991, "end_char_idx": 3005, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e451c9dd-4d69-4484-bc85-e01d5b647d81": {"__data__": {"id_": "e451c9dd-4d69-4484-bc85-e01d5b647d81", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good evening and thanks for the very comprehensive details.  So, two follow -ups here.  One, just to \nclarify, as you think about 2023, should we assume that all the buyback activity is going to be offsetting the \ndilution from th e European divestitures? ", "original_text": "Hi. ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97ceba1beb430b7da50d320fa57f501bfe36295f6a376a473f524103bf8858f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "705369fd-b974-48f0-836a-188ce18c6eb6", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good evening and thanks for the very comprehensive details.  So, two follow -ups here. ", "original_text": "LLC  Q \nYeah. ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "baee0950eed3a0fbaee8aefcdd1d79cd2c4eedfeceb05fb462ff64cb2fc5bba7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bf896820-f893-4a6f-9653-bf037b8a6bd2", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good evening and thanks for the very comprehensive details.  So, two follow -ups here.  One, just to \nclarify, as you think about 2023, should we assume that all the buyback activity is going to be offsetting the \ndilution from th e European divestitures?  That's first.  \n \n", "original_text": "Good evening and thanks for the very comprehensive details. "}, "hash": "5dd0cfb23872b6b3f81127c7687ec7309dfa76a91b5092c71c0e4c454266b52f", "class_name": "RelatedNodeInfo"}}, "text": "Hi. ", "start_char_idx": 3005, "end_char_idx": 3009, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bf896820-f893-4a6f-9653-bf037b8a6bd2": {"__data__": {"id_": "bf896820-f893-4a6f-9653-bf037b8a6bd2", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good evening and thanks for the very comprehensive details.  So, two follow -ups here.  One, just to \nclarify, as you think about 2023, should we assume that all the buyback activity is going to be offsetting the \ndilution from th e European divestitures?  That's first.  \n \n", "original_text": "Good evening and thanks for the very comprehensive details. ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97ceba1beb430b7da50d320fa57f501bfe36295f6a376a473f524103bf8858f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e451c9dd-4d69-4484-bc85-e01d5b647d81", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good evening and thanks for the very comprehensive details.  So, two follow -ups here.  One, just to \nclarify, as you think about 2023, should we assume that all the buyback activity is going to be offsetting the \ndilution from th e European divestitures? ", "original_text": "Hi. ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9f4d4334fd2fbcd7783a315532bba933fdf5f55cebd0f3ecb67465165bdebd7a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1112f724-a91e-49d4-86ec-554e9d973753", "node_type": "1", "metadata": {"window": "LLC  Q \nYeah.  Hi.  Good evening and thanks for the very comprehensive details.  So, two follow -ups here.  One, just to \nclarify, as you think about 2023, should we assume that all the buyback activity is going to be offsetting the \ndilution from th e European divestitures?  That's first.  \n \n And then, secondly, as we think about the COVID impact, I mean, clearly, nice contribution in the last couple of \nyears. ", "original_text": "So, two follow -ups here. "}, "hash": "5ac89b2e48fdba41f53a00151dac0adebc13ff8b2e6f019aaa9174813772a5f2", "class_name": "RelatedNodeInfo"}}, "text": "Good evening and thanks for the very comprehensive details. ", "start_char_idx": 3009, "end_char_idx": 3069, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1112f724-a91e-49d4-86ec-554e9d973753": {"__data__": {"id_": "1112f724-a91e-49d4-86ec-554e9d973753", "embedding": null, "metadata": {"window": "LLC  Q \nYeah.  Hi.  Good evening and thanks for the very comprehensive details.  So, two follow -ups here.  One, just to \nclarify, as you think about 2023, should we assume that all the buyback activity is going to be offsetting the \ndilution from th e European divestitures?  That's first.  \n \n And then, secondly, as we think about the COVID impact, I mean, clearly, nice contribution in the last couple of \nyears. ", "original_text": "So, two follow -ups here. ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97ceba1beb430b7da50d320fa57f501bfe36295f6a376a473f524103bf8858f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bf896820-f893-4a6f-9653-bf037b8a6bd2", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good evening and thanks for the very comprehensive details.  So, two follow -ups here.  One, just to \nclarify, as you think about 2023, should we assume that all the buyback activity is going to be offsetting the \ndilution from th e European divestitures?  That's first.  \n \n", "original_text": "Good evening and thanks for the very comprehensive details. ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73b4546b55e8d0cbe89735b0d37c040e63aa00dc6ca9c4eff8126bdff3a6c994", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aa58ab6f-19ef-4d37-b1a2-380a01c68137", "node_type": "1", "metadata": {"window": "Hi.  Good evening and thanks for the very comprehensive details.  So, two follow -ups here.  One, just to \nclarify, as you think about 2023, should we assume that all the buyback activity is going to be offsetting the \ndilution from th e European divestitures?  That's first.  \n \n And then, secondly, as we think about the COVID impact, I mean, clearly, nice contribution in the last couple of \nyears.  How do you think the economics of vaccine and testing will evolve as sort of COVID becomes more of an \nannuity? ", "original_text": "One, just to \nclarify, as you think about 2023, should we assume that all the buyback activity is going to be offsetting the \ndilution from th e European divestitures? "}, "hash": "f77916012198737c7e1ca87449dec5f29e96a07ef9d9a8f0c5cd652486bbb52a", "class_name": "RelatedNodeInfo"}}, "text": "So, two follow -ups here. ", "start_char_idx": 3069, "end_char_idx": 3095, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aa58ab6f-19ef-4d37-b1a2-380a01c68137": {"__data__": {"id_": "aa58ab6f-19ef-4d37-b1a2-380a01c68137", "embedding": null, "metadata": {"window": "Hi.  Good evening and thanks for the very comprehensive details.  So, two follow -ups here.  One, just to \nclarify, as you think about 2023, should we assume that all the buyback activity is going to be offsetting the \ndilution from th e European divestitures?  That's first.  \n \n And then, secondly, as we think about the COVID impact, I mean, clearly, nice contribution in the last couple of \nyears.  How do you think the economics of vaccine and testing will evolve as sort of COVID becomes more of an \nannuity? ", "original_text": "One, just to \nclarify, as you think about 2023, should we assume that all the buyback activity is going to be offsetting the \ndilution from th e European divestitures? ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97ceba1beb430b7da50d320fa57f501bfe36295f6a376a473f524103bf8858f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1112f724-a91e-49d4-86ec-554e9d973753", "node_type": "1", "metadata": {"window": "LLC  Q \nYeah.  Hi.  Good evening and thanks for the very comprehensive details.  So, two follow -ups here.  One, just to \nclarify, as you think about 2023, should we assume that all the buyback activity is going to be offsetting the \ndilution from th e European divestitures?  That's first.  \n \n And then, secondly, as we think about the COVID impact, I mean, clearly, nice contribution in the last couple of \nyears. ", "original_text": "So, two follow -ups here. ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b09bd33dab8e537a6286c351f8b61f6e657914ec6601ad00572a04705bc9d88e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "31cd2655-4091-4293-8450-001e7efb990c", "node_type": "1", "metadata": {"window": "Good evening and thanks for the very comprehensive details.  So, two follow -ups here.  One, just to \nclarify, as you think about 2023, should we assume that all the buyback activity is going to be offsetting the \ndilution from th e European divestitures?  That's first.  \n \n And then, secondly, as we think about the COVID impact, I mean, clearly, nice contribution in the last couple of \nyears.  How do you think the economics of vaccine and testing will evolve as sort of COVID becomes more of an \nannuity?  Should we think about it as flu -type economics?  \n ", "original_text": "That's first.  \n \n"}, "hash": "3f0f719f728b68afff8c79161cbd51f355411153c47e61f9bb5d16c607a6d8f0", "class_name": "RelatedNodeInfo"}}, "text": "One, just to \nclarify, as you think about 2023, should we assume that all the buyback activity is going to be offsetting the \ndilution from th e European divestitures? ", "start_char_idx": 3095, "end_char_idx": 3263, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "31cd2655-4091-4293-8450-001e7efb990c": {"__data__": {"id_": "31cd2655-4091-4293-8450-001e7efb990c", "embedding": null, "metadata": {"window": "Good evening and thanks for the very comprehensive details.  So, two follow -ups here.  One, just to \nclarify, as you think about 2023, should we assume that all the buyback activity is going to be offsetting the \ndilution from th e European divestitures?  That's first.  \n \n And then, secondly, as we think about the COVID impact, I mean, clearly, nice contribution in the last couple of \nyears.  How do you think the economics of vaccine and testing will evolve as sort of COVID becomes more of an \nannuity?  Should we think about it as flu -type economics?  \n ", "original_text": "That's first.  \n \n", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97ceba1beb430b7da50d320fa57f501bfe36295f6a376a473f524103bf8858f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aa58ab6f-19ef-4d37-b1a2-380a01c68137", "node_type": "1", "metadata": {"window": "Hi.  Good evening and thanks for the very comprehensive details.  So, two follow -ups here.  One, just to \nclarify, as you think about 2023, should we assume that all the buyback activity is going to be offsetting the \ndilution from th e European divestitures?  That's first.  \n \n And then, secondly, as we think about the COVID impact, I mean, clearly, nice contribution in the last couple of \nyears.  How do you think the economics of vaccine and testing will evolve as sort of COVID becomes more of an \nannuity? ", "original_text": "One, just to \nclarify, as you think about 2023, should we assume that all the buyback activity is going to be offsetting the \ndilution from th e European divestitures? ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e1e08cc2277b5eccb0c6ee17623bcf74a19fd36cd3a7f61ff4bf6bf5b29670db", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aba8540d-75d1-4e27-966b-b3836985933f", "node_type": "1", "metadata": {"window": "So, two follow -ups here.  One, just to \nclarify, as you think about 2023, should we assume that all the buyback activity is going to be offsetting the \ndilution from th e European divestitures?  That's first.  \n \n And then, secondly, as we think about the COVID impact, I mean, clearly, nice contribution in the last couple of \nyears.  How do you think the economics of vaccine and testing will evolve as sort of COVID becomes more of an \nannuity?  Should we think about it as flu -type economics?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "And then, secondly, as we think about the COVID impact, I mean, clearly, nice contribution in the last couple of \nyears. "}, "hash": "67d732e636401302cc74b42df2101530511fff49335dc838001fadd66fb53802", "class_name": "RelatedNodeInfo"}}, "text": "That's first.  \n \n", "start_char_idx": 3263, "end_char_idx": 3281, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aba8540d-75d1-4e27-966b-b3836985933f": {"__data__": {"id_": "aba8540d-75d1-4e27-966b-b3836985933f", "embedding": null, "metadata": {"window": "So, two follow -ups here.  One, just to \nclarify, as you think about 2023, should we assume that all the buyback activity is going to be offsetting the \ndilution from th e European divestitures?  That's first.  \n \n And then, secondly, as we think about the COVID impact, I mean, clearly, nice contribution in the last couple of \nyears.  How do you think the economics of vaccine and testing will evolve as sort of COVID becomes more of an \nannuity?  Should we think about it as flu -type economics?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "And then, secondly, as we think about the COVID impact, I mean, clearly, nice contribution in the last couple of \nyears. ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97ceba1beb430b7da50d320fa57f501bfe36295f6a376a473f524103bf8858f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "31cd2655-4091-4293-8450-001e7efb990c", "node_type": "1", "metadata": {"window": "Good evening and thanks for the very comprehensive details.  So, two follow -ups here.  One, just to \nclarify, as you think about 2023, should we assume that all the buyback activity is going to be offsetting the \ndilution from th e European divestitures?  That's first.  \n \n And then, secondly, as we think about the COVID impact, I mean, clearly, nice contribution in the last couple of \nyears.  How do you think the economics of vaccine and testing will evolve as sort of COVID becomes more of an \nannuity?  Should we think about it as flu -type economics?  \n ", "original_text": "That's first.  \n \n", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "66323adec023be7d343973a7502d2a04b16f4f3e900950e8c9c223f7b0cf62a5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cdee0445-584e-4607-8918-7db4bc57da3e", "node_type": "1", "metadata": {"window": "One, just to \nclarify, as you think about 2023, should we assume that all the buyback activity is going to be offsetting the \ndilution from th e European divestitures?  That's first.  \n \n And then, secondly, as we think about the COVID impact, I mean, clearly, nice contribution in the last couple of \nyears.  How do you think the economics of vaccine and testing will evolve as sort of COVID becomes more of an \nannuity?  Should we think about it as flu -type economics?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nRicky, let me take the first one and then I'll let Brian comment on the second just because it's a more me chanical \nquestion. ", "original_text": "How do you think the economics of vaccine and testing will evolve as sort of COVID becomes more of an \nannuity? "}, "hash": "927f375d6b620a5c491781c6a8ccde0749ff98346e2f738eb95b2ef5efb6d1fa", "class_name": "RelatedNodeInfo"}}, "text": "And then, secondly, as we think about the COVID impact, I mean, clearly, nice contribution in the last couple of \nyears. ", "start_char_idx": 3281, "end_char_idx": 3402, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cdee0445-584e-4607-8918-7db4bc57da3e": {"__data__": {"id_": "cdee0445-584e-4607-8918-7db4bc57da3e", "embedding": null, "metadata": {"window": "One, just to \nclarify, as you think about 2023, should we assume that all the buyback activity is going to be offsetting the \ndilution from th e European divestitures?  That's first.  \n \n And then, secondly, as we think about the COVID impact, I mean, clearly, nice contribution in the last couple of \nyears.  How do you think the economics of vaccine and testing will evolve as sort of COVID becomes more of an \nannuity?  Should we think about it as flu -type economics?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nRicky, let me take the first one and then I'll let Brian comment on the second just because it's a more me chanical \nquestion. ", "original_text": "How do you think the economics of vaccine and testing will evolve as sort of COVID becomes more of an \nannuity? ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97ceba1beb430b7da50d320fa57f501bfe36295f6a376a473f524103bf8858f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aba8540d-75d1-4e27-966b-b3836985933f", "node_type": "1", "metadata": {"window": "So, two follow -ups here.  One, just to \nclarify, as you think about 2023, should we assume that all the buyback activity is going to be offsetting the \ndilution from th e European divestitures?  That's first.  \n \n And then, secondly, as we think about the COVID impact, I mean, clearly, nice contribution in the last couple of \nyears.  How do you think the economics of vaccine and testing will evolve as sort of COVID becomes more of an \nannuity?  Should we think about it as flu -type economics?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "And then, secondly, as we think about the COVID impact, I mean, clearly, nice contribution in the last couple of \nyears. ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53ca60bf829d21afc6ec262686fcdcad7023c36084ccac7f62cee6379f4d973a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "35fc96f8-0e2c-4515-970a-1a1d4fce9b45", "node_type": "1", "metadata": {"window": "That's first.  \n \n And then, secondly, as we think about the COVID impact, I mean, clearly, nice contribution in the last couple of \nyears.  How do you think the economics of vaccine and testing will evolve as sort of COVID becomes more of an \nannuity?  Should we think about it as flu -type economics?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nRicky, let me take the first one and then I'll let Brian comment on the second just because it's a more me chanical \nquestion.  As I mentioned in my comments, we do expect to offset any dilution from the European divestitures \nthrough capital deployment, and that could be share repurchase activity like we're doing in the fourth quarter. ", "original_text": "Should we think about it as flu -type economics?  \n "}, "hash": "62738ccf2725e953fa53bfad89813ecbbe3544278e5ca8625c430cc42ddde17b", "class_name": "RelatedNodeInfo"}}, "text": "How do you think the economics of vaccine and testing will evolve as sort of COVID becomes more of an \nannuity? ", "start_char_idx": 3402, "end_char_idx": 3514, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "35fc96f8-0e2c-4515-970a-1a1d4fce9b45": {"__data__": {"id_": "35fc96f8-0e2c-4515-970a-1a1d4fce9b45", "embedding": null, "metadata": {"window": "That's first.  \n \n And then, secondly, as we think about the COVID impact, I mean, clearly, nice contribution in the last couple of \nyears.  How do you think the economics of vaccine and testing will evolve as sort of COVID becomes more of an \nannuity?  Should we think about it as flu -type economics?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nRicky, let me take the first one and then I'll let Brian comment on the second just because it's a more me chanical \nquestion.  As I mentioned in my comments, we do expect to offset any dilution from the European divestitures \nthrough capital deployment, and that could be share repurchase activity like we're doing in the fourth quarter. ", "original_text": "Should we think about it as flu -type economics?  \n ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97ceba1beb430b7da50d320fa57f501bfe36295f6a376a473f524103bf8858f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cdee0445-584e-4607-8918-7db4bc57da3e", "node_type": "1", "metadata": {"window": "One, just to \nclarify, as you think about 2023, should we assume that all the buyback activity is going to be offsetting the \ndilution from th e European divestitures?  That's first.  \n \n And then, secondly, as we think about the COVID impact, I mean, clearly, nice contribution in the last couple of \nyears.  How do you think the economics of vaccine and testing will evolve as sort of COVID becomes more of an \nannuity?  Should we think about it as flu -type economics?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nRicky, let me take the first one and then I'll let Brian comment on the second just because it's a more me chanical \nquestion. ", "original_text": "How do you think the economics of vaccine and testing will evolve as sort of COVID becomes more of an \nannuity? ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ba35d98e179d6432b1ee9b97b93f76da9cae80cc8beec2c6e8f2369dd2375313", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ece2adb-60c9-49ba-ac5c-8b07e610b8c2", "node_type": "1", "metadata": {"window": "And then, secondly, as we think about the COVID impact, I mean, clearly, nice contribution in the last couple of \nyears.  How do you think the economics of vaccine and testing will evolve as sort of COVID becomes more of an \nannuity?  Should we think about it as flu -type economics?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nRicky, let me take the first one and then I'll let Brian comment on the second just because it's a more me chanical \nquestion.  As I mentioned in my comments, we do expect to offset any dilution from the European divestitures \nthrough capital deployment, and that could be share repurchase activity like we're doing in the fourth quarter.  So \njust to reaffirm that, w e will be \u2013 we do plan on offsetting that dilution.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "8f57b0d611c19a6eeb49dd07a014b4852a11d63f24dd80fe1c7d08af4853e9ec", "class_name": "RelatedNodeInfo"}}, "text": "Should we think about it as flu -type economics?  \n ", "start_char_idx": 3514, "end_char_idx": 3566, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0ece2adb-60c9-49ba-ac5c-8b07e610b8c2": {"__data__": {"id_": "0ece2adb-60c9-49ba-ac5c-8b07e610b8c2", "embedding": null, "metadata": {"window": "And then, secondly, as we think about the COVID impact, I mean, clearly, nice contribution in the last couple of \nyears.  How do you think the economics of vaccine and testing will evolve as sort of COVID becomes more of an \nannuity?  Should we think about it as flu -type economics?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nRicky, let me take the first one and then I'll let Brian comment on the second just because it's a more me chanical \nquestion.  As I mentioned in my comments, we do expect to offset any dilution from the European divestitures \nthrough capital deployment, and that could be share repurchase activity like we're doing in the fourth quarter.  So \njust to reaffirm that, w e will be \u2013 we do plan on offsetting that dilution.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97ceba1beb430b7da50d320fa57f501bfe36295f6a376a473f524103bf8858f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "35fc96f8-0e2c-4515-970a-1a1d4fce9b45", "node_type": "1", "metadata": {"window": "That's first.  \n \n And then, secondly, as we think about the COVID impact, I mean, clearly, nice contribution in the last couple of \nyears.  How do you think the economics of vaccine and testing will evolve as sort of COVID becomes more of an \nannuity?  Should we think about it as flu -type economics?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nRicky, let me take the first one and then I'll let Brian comment on the second just because it's a more me chanical \nquestion.  As I mentioned in my comments, we do expect to offset any dilution from the European divestitures \nthrough capital deployment, and that could be share repurchase activity like we're doing in the fourth quarter. ", "original_text": "Should we think about it as flu -type economics?  \n ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3a3d10389723333f7c844204f7e307b9d458cfccb5a1e3d28d47d9b7f4aae642", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "20eb3eeb-6410-4147-8a66-7a3a24bb3b61", "node_type": "1", "metadata": {"window": "How do you think the economics of vaccine and testing will evolve as sort of COVID becomes more of an \nannuity?  Should we think about it as flu -type economics?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nRicky, let me take the first one and then I'll let Brian comment on the second just because it's a more me chanical \nquestion.  As I mentioned in my comments, we do expect to offset any dilution from the European divestitures \nthrough capital deployment, and that could be share repurchase activity like we're doing in the fourth quarter.  So \njust to reaffirm that, w e will be \u2013 we do plan on offsetting that dilution.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "A \nRicky, let me take the first one and then I'll let Brian comment on the second just because it's a more me chanical \nquestion. "}, "hash": "ec59d7705b24219e347f7c104a29f7e7e0f3431703710b98789c9441a6400ea8", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 3566, "end_char_idx": 3923, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "20eb3eeb-6410-4147-8a66-7a3a24bb3b61": {"__data__": {"id_": "20eb3eeb-6410-4147-8a66-7a3a24bb3b61", "embedding": null, "metadata": {"window": "How do you think the economics of vaccine and testing will evolve as sort of COVID becomes more of an \nannuity?  Should we think about it as flu -type economics?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nRicky, let me take the first one and then I'll let Brian comment on the second just because it's a more me chanical \nquestion.  As I mentioned in my comments, we do expect to offset any dilution from the European divestitures \nthrough capital deployment, and that could be share repurchase activity like we're doing in the fourth quarter.  So \njust to reaffirm that, w e will be \u2013 we do plan on offsetting that dilution.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "A \nRicky, let me take the first one and then I'll let Brian comment on the second just because it's a more me chanical \nquestion. ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97ceba1beb430b7da50d320fa57f501bfe36295f6a376a473f524103bf8858f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0ece2adb-60c9-49ba-ac5c-8b07e610b8c2", "node_type": "1", "metadata": {"window": "And then, secondly, as we think about the COVID impact, I mean, clearly, nice contribution in the last couple of \nyears.  How do you think the economics of vaccine and testing will evolve as sort of COVID becomes more of an \nannuity?  Should we think about it as flu -type economics?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nRicky, let me take the first one and then I'll let Brian comment on the second just because it's a more me chanical \nquestion.  As I mentioned in my comments, we do expect to offset any dilution from the European divestitures \nthrough capital deployment, and that could be share repurchase activity like we're doing in the fourth quarter.  So \njust to reaffirm that, w e will be \u2013 we do plan on offsetting that dilution.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "681dc29d34d14bc568ecdadbe351855562987e740a9cc45649828152d6d0f452", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8cc8e2ba-2b8d-4821-a3f3-92ae7504934f", "node_type": "1", "metadata": {"window": "Should we think about it as flu -type economics?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nRicky, let me take the first one and then I'll let Brian comment on the second just because it's a more me chanical \nquestion.  As I mentioned in my comments, we do expect to offset any dilution from the European divestitures \nthrough capital deployment, and that could be share repurchase activity like we're doing in the fourth quarter.  So \njust to reaffirm that, w e will be \u2013 we do plan on offsetting that dilution.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A ", "original_text": "As I mentioned in my comments, we do expect to offset any dilution from the European divestitures \nthrough capital deployment, and that could be share repurchase activity like we're doing in the fourth quarter. "}, "hash": "c2fd7f2d65b1a593c72d9ec49f1e0cfe23dd677dd8c30fb4c2c87cbb89bdb44d", "class_name": "RelatedNodeInfo"}}, "text": "A \nRicky, let me take the first one and then I'll let Brian comment on the second just because it's a more me chanical \nquestion. ", "start_char_idx": 3923, "end_char_idx": 4053, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8cc8e2ba-2b8d-4821-a3f3-92ae7504934f": {"__data__": {"id_": "8cc8e2ba-2b8d-4821-a3f3-92ae7504934f", "embedding": null, "metadata": {"window": "Should we think about it as flu -type economics?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nRicky, let me take the first one and then I'll let Brian comment on the second just because it's a more me chanical \nquestion.  As I mentioned in my comments, we do expect to offset any dilution from the European divestitures \nthrough capital deployment, and that could be share repurchase activity like we're doing in the fourth quarter.  So \njust to reaffirm that, w e will be \u2013 we do plan on offsetting that dilution.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A ", "original_text": "As I mentioned in my comments, we do expect to offset any dilution from the European divestitures \nthrough capital deployment, and that could be share repurchase activity like we're doing in the fourth quarter. ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97ceba1beb430b7da50d320fa57f501bfe36295f6a376a473f524103bf8858f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "20eb3eeb-6410-4147-8a66-7a3a24bb3b61", "node_type": "1", "metadata": {"window": "How do you think the economics of vaccine and testing will evolve as sort of COVID becomes more of an \nannuity?  Should we think about it as flu -type economics?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nRicky, let me take the first one and then I'll let Brian comment on the second just because it's a more me chanical \nquestion.  As I mentioned in my comments, we do expect to offset any dilution from the European divestitures \nthrough capital deployment, and that could be share repurchase activity like we're doing in the fourth quarter.  So \njust to reaffirm that, w e will be \u2013 we do plan on offsetting that dilution.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "A \nRicky, let me take the first one and then I'll let Brian comment on the second just because it's a more me chanical \nquestion. ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "30ef631c5755eb9342071b5863f8b635069523e665a643230a16679600e71696", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "94f5116c-8168-4e30-b113-55305a47f085", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nRicky, let me take the first one and then I'll let Brian comment on the second just because it's a more me chanical \nquestion.  As I mentioned in my comments, we do expect to offset any dilution from the European divestitures \nthrough capital deployment, and that could be share repurchase activity like we're doing in the fourth quarter.  So \njust to reaffirm that, w e will be \u2013 we do plan on offsetting that dilution.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A ", "original_text": "So \njust to reaffirm that, w e will be \u2013 we do plan on offsetting that dilution.  \n "}, "hash": "d7e68ff8b414f6e09c02c8b2e60821a099584677578b7ab9005f7a2264f0cfb0", "class_name": "RelatedNodeInfo"}}, "text": "As I mentioned in my comments, we do expect to offset any dilution from the European divestitures \nthrough capital deployment, and that could be share repurchase activity like we're doing in the fourth quarter. ", "start_char_idx": 4053, "end_char_idx": 4264, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "94f5116c-8168-4e30-b113-55305a47f085": {"__data__": {"id_": "94f5116c-8168-4e30-b113-55305a47f085", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nRicky, let me take the first one and then I'll let Brian comment on the second just because it's a more me chanical \nquestion.  As I mentioned in my comments, we do expect to offset any dilution from the European divestitures \nthrough capital deployment, and that could be share repurchase activity like we're doing in the fourth quarter.  So \njust to reaffirm that, w e will be \u2013 we do plan on offsetting that dilution.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A ", "original_text": "So \njust to reaffirm that, w e will be \u2013 we do plan on offsetting that dilution.  \n ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97ceba1beb430b7da50d320fa57f501bfe36295f6a376a473f524103bf8858f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8cc8e2ba-2b8d-4821-a3f3-92ae7504934f", "node_type": "1", "metadata": {"window": "Should we think about it as flu -type economics?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nRicky, let me take the first one and then I'll let Brian comment on the second just because it's a more me chanical \nquestion.  As I mentioned in my comments, we do expect to offset any dilution from the European divestitures \nthrough capital deployment, and that could be share repurchase activity like we're doing in the fourth quarter.  So \njust to reaffirm that, w e will be \u2013 we do plan on offsetting that dilution.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A ", "original_text": "As I mentioned in my comments, we do expect to offset any dilution from the European divestitures \nthrough capital deployment, and that could be share repurchase activity like we're doing in the fourth quarter. ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "033dc9886676c648c103dcd93afecd2385169c57969e48821a8f180e47eb7cc8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1eb69da6-caf0-4bb5-95e5-a2c0cd365189", "node_type": "1", "metadata": {"window": "A \nRicky, let me take the first one and then I'll let Brian comment on the second just because it's a more me chanical \nquestion.  As I mentioned in my comments, we do expect to offset any dilution from the European divestitures \nthrough capital deployment, and that could be share repurchase activity like we're doing in the fourth quarter.  So \njust to reaffirm that, w e will be \u2013 we do plan on offsetting that dilution.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "c7046c60f6079d1b56a2f8befcd29e433c376f9491ebeb57bcb2ca6f033d0d00", "class_name": "RelatedNodeInfo"}}, "text": "So \njust to reaffirm that, w e will be \u2013 we do plan on offsetting that dilution.  \n ", "start_char_idx": 4264, "end_char_idx": 4348, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1eb69da6-caf0-4bb5-95e5-a2c0cd365189": {"__data__": {"id_": "1eb69da6-caf0-4bb5-95e5-a2c0cd365189", "embedding": null, "metadata": {"window": "A \nRicky, let me take the first one and then I'll let Brian comment on the second just because it's a more me chanical \nquestion.  As I mentioned in my comments, we do expect to offset any dilution from the European divestitures \nthrough capital deployment, and that could be share repurchase activity like we're doing in the fourth quarter.  So \njust to reaffirm that, w e will be \u2013 we do plan on offsetting that dilution.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97ceba1beb430b7da50d320fa57f501bfe36295f6a376a473f524103bf8858f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "94f5116c-8168-4e30-b113-55305a47f085", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nRicky, let me take the first one and then I'll let Brian comment on the second just because it's a more me chanical \nquestion.  As I mentioned in my comments, we do expect to offset any dilution from the European divestitures \nthrough capital deployment, and that could be share repurchase activity like we're doing in the fourth quarter.  So \njust to reaffirm that, w e will be \u2013 we do plan on offsetting that dilution.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A ", "original_text": "So \njust to reaffirm that, w e will be \u2013 we do plan on offsetting that dilution.  \n ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5e51f3fde420449f1ccbc23b4c5ee9cf56ad56ba93d4ed26f8fca1390296d78b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b4dbe733-9642-4954-b89d-ffd5f3878e6e", "node_type": "1", "metadata": {"window": "As I mentioned in my comments, we do expect to offset any dilution from the European divestitures \nthrough capital deployment, and that could be share repurchase activity like we're doing in the fourth quarter.  So \njust to reaffirm that, w e will be \u2013 we do plan on offsetting that dilution.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A ", "original_text": "A "}, "hash": "a8a1dd935d4b9f93604e7120016e8cacfedd30b3fd15f90b5f37db29753da631", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 4348, "end_char_idx": 4689, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b4dbe733-9642-4954-b89d-ffd5f3878e6e": {"__data__": {"id_": "b4dbe733-9642-4954-b89d-ffd5f3878e6e", "embedding": null, "metadata": {"window": "As I mentioned in my comments, we do expect to offset any dilution from the European divestitures \nthrough capital deployment, and that could be share repurchase activity like we're doing in the fourth quarter.  So \njust to reaffirm that, w e will be \u2013 we do plan on offsetting that dilution.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A ", "original_text": "A ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97ceba1beb430b7da50d320fa57f501bfe36295f6a376a473f524103bf8858f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1eb69da6-caf0-4bb5-95e5-a2c0cd365189", "node_type": "1", "metadata": {"window": "A \nRicky, let me take the first one and then I'll let Brian comment on the second just because it's a more me chanical \nquestion.  As I mentioned in my comments, we do expect to offset any dilution from the European divestitures \nthrough capital deployment, and that could be share repurchase activity like we're doing in the fourth quarter.  So \njust to reaffirm that, w e will be \u2013 we do plan on offsetting that dilution.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0889cce2149ce2aa1d1d497896f61ab351fbba517cc249589fa17a49af66a3ad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "37e8c761-f4ed-40dc-b5ec-d87e05227bba", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRicky, relative to, I guess let's call it the future of testing, that's a little bit, I think, difficult to forecast.  A lot o f it will \ndepend on the science, the development.  A lot of it will depend on the current testing hold -up to current and future \npotential variants, what will be the mix between in a medical setting versus over -the-counter, do those become \nmore reliable. ", "original_text": "McKesson Corp.  "}, "hash": "c7dd68b5145c8b676bb448945f0494f5ca9e60366fdf7116d36bb6dda9a5b467", "class_name": "RelatedNodeInfo"}}, "text": "A ", "start_char_idx": 910, "end_char_idx": 912, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "37e8c761-f4ed-40dc-b5ec-d87e05227bba": {"__data__": {"id_": "37e8c761-f4ed-40dc-b5ec-d87e05227bba", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRicky, relative to, I guess let's call it the future of testing, that's a little bit, I think, difficult to forecast.  A lot o f it will \ndepend on the science, the development.  A lot of it will depend on the current testing hold -up to current and future \npotential variants, what will be the mix between in a medical setting versus over -the-counter, do those become \nmore reliable. ", "original_text": "McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ceb4a5e5728ef9a64b29f8e8f1afb599589c8043147110c669a5ca8eb3c335f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b4dbe733-9642-4954-b89d-ffd5f3878e6e", "node_type": "1", "metadata": {"window": "As I mentioned in my comments, we do expect to offset any dilution from the European divestitures \nthrough capital deployment, and that could be share repurchase activity like we're doing in the fourth quarter.  So \njust to reaffirm that, w e will be \u2013 we do plan on offsetting that dilution.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A ", "original_text": "A ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20f2c19a653efe09cee9f2b0f5e3158d56ab2dff354568982bdc62f0d7f67e61", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9effcd4c-d238-4067-bee1-33d5485aaf76", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRicky, relative to, I guess let's call it the future of testing, that's a little bit, I think, difficult to forecast.  A lot o f it will \ndepend on the science, the development.  A lot of it will depend on the current testing hold -up to current and future \npotential variants, what will be the mix between in a medical setting versus over -the-counter, do those become \nmore reliable.  I think there's a lot of questions that still have to resolve themselves there.  \n \n", "original_text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRicky, relative to, I guess let's call it the future of testing, that's a little bit, I think, difficult to forecast. "}, "hash": "ecfd64a8da03706e34c8da6e0332fe387f0e3ff60c408d3924e400baf20b5eb3", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9effcd4c-d238-4067-bee1-33d5485aaf76": {"__data__": {"id_": "9effcd4c-d238-4067-bee1-33d5485aaf76", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRicky, relative to, I guess let's call it the future of testing, that's a little bit, I think, difficult to forecast.  A lot o f it will \ndepend on the science, the development.  A lot of it will depend on the current testing hold -up to current and future \npotential variants, what will be the mix between in a medical setting versus over -the-counter, do those become \nmore reliable.  I think there's a lot of questions that still have to resolve themselves there.  \n \n", "original_text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRicky, relative to, I guess let's call it the future of testing, that's a little bit, I think, difficult to forecast. ", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ceb4a5e5728ef9a64b29f8e8f1afb599589c8043147110c669a5ca8eb3c335f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "37e8c761-f4ed-40dc-b5ec-d87e05227bba", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRicky, relative to, I guess let's call it the future of testing, that's a little bit, I think, difficult to forecast.  A lot o f it will \ndepend on the science, the development.  A lot of it will depend on the current testing hold -up to current and future \npotential variants, what will be the mix between in a medical setting versus over -the-counter, do those become \nmore reliable. ", "original_text": "McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1b4963f303b735d27ae0754f5cb016dfff5eea943698cb957194f43e7817f5f4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f5215618-5b8e-4676-9f97-a07ea2234c33", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRicky, relative to, I guess let's call it the future of testing, that's a little bit, I think, difficult to forecast.  A lot o f it will \ndepend on the science, the development.  A lot of it will depend on the current testing hold -up to current and future \npotential variants, what will be the mix between in a medical setting versus over -the-counter, do those become \nmore reliable.  I think there's a lot of questions that still have to resolve themselves there.  \n \n What I would say, though, is that regardless of how that evolves, we think McKesson is in an excellent position to \ncapitalize on that. ", "original_text": "A lot o f it will \ndepend on the science, the development. "}, "hash": "9eb2b3b91f7bd42323f344b6d89a39157fefb5131ea468d2f1ca44fe6409b16e", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRicky, relative to, I guess let's call it the future of testing, that's a little bit, I think, difficult to forecast. ", "start_char_idx": 16, "end_char_idx": 299, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f5215618-5b8e-4676-9f97-a07ea2234c33": {"__data__": {"id_": "f5215618-5b8e-4676-9f97-a07ea2234c33", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRicky, relative to, I guess let's call it the future of testing, that's a little bit, I think, difficult to forecast.  A lot o f it will \ndepend on the science, the development.  A lot of it will depend on the current testing hold -up to current and future \npotential variants, what will be the mix between in a medical setting versus over -the-counter, do those become \nmore reliable.  I think there's a lot of questions that still have to resolve themselves there.  \n \n What I would say, though, is that regardless of how that evolves, we think McKesson is in an excellent position to \ncapitalize on that. ", "original_text": "A lot o f it will \ndepend on the science, the development. ", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ceb4a5e5728ef9a64b29f8e8f1afb599589c8043147110c669a5ca8eb3c335f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9effcd4c-d238-4067-bee1-33d5485aaf76", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRicky, relative to, I guess let's call it the future of testing, that's a little bit, I think, difficult to forecast.  A lot o f it will \ndepend on the science, the development.  A lot of it will depend on the current testing hold -up to current and future \npotential variants, what will be the mix between in a medical setting versus over -the-counter, do those become \nmore reliable.  I think there's a lot of questions that still have to resolve themselves there.  \n \n", "original_text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRicky, relative to, I guess let's call it the future of testing, that's a little bit, I think, difficult to forecast. ", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f9183fe9361fa9df14b9177d56ed2dc386d016452fa9475c907ba61d2fb781c7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "421a70b9-35c8-4e7d-bfbb-48ba1a7d8e2a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRicky, relative to, I guess let's call it the future of testing, that's a little bit, I think, difficult to forecast.  A lot o f it will \ndepend on the science, the development.  A lot of it will depend on the current testing hold -up to current and future \npotential variants, what will be the mix between in a medical setting versus over -the-counter, do those become \nmore reliable.  I think there's a lot of questions that still have to resolve themselves there.  \n \n What I would say, though, is that regardless of how that evolves, we think McKesson is in an excellent position to \ncapitalize on that.  We are currently the largest distributor. ", "original_text": "A lot of it will depend on the current testing hold -up to current and future \npotential variants, what will be the mix between in a medical setting versus over -the-counter, do those become \nmore reliable. "}, "hash": "741dc41a89ac4cdce8e4b508a207a5582c4caf155e50279d6168064b83e379e7", "class_name": "RelatedNodeInfo"}}, "text": "A lot o f it will \ndepend on the science, the development. ", "start_char_idx": 299, "end_char_idx": 358, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "421a70b9-35c8-4e7d-bfbb-48ba1a7d8e2a": {"__data__": {"id_": "421a70b9-35c8-4e7d-bfbb-48ba1a7d8e2a", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRicky, relative to, I guess let's call it the future of testing, that's a little bit, I think, difficult to forecast.  A lot o f it will \ndepend on the science, the development.  A lot of it will depend on the current testing hold -up to current and future \npotential variants, what will be the mix between in a medical setting versus over -the-counter, do those become \nmore reliable.  I think there's a lot of questions that still have to resolve themselves there.  \n \n What I would say, though, is that regardless of how that evolves, we think McKesson is in an excellent position to \ncapitalize on that.  We are currently the largest distributor. ", "original_text": "A lot of it will depend on the current testing hold -up to current and future \npotential variants, what will be the mix between in a medical setting versus over -the-counter, do those become \nmore reliable. ", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ceb4a5e5728ef9a64b29f8e8f1afb599589c8043147110c669a5ca8eb3c335f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f5215618-5b8e-4676-9f97-a07ea2234c33", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRicky, relative to, I guess let's call it the future of testing, that's a little bit, I think, difficult to forecast.  A lot o f it will \ndepend on the science, the development.  A lot of it will depend on the current testing hold -up to current and future \npotential variants, what will be the mix between in a medical setting versus over -the-counter, do those become \nmore reliable.  I think there's a lot of questions that still have to resolve themselves there.  \n \n What I would say, though, is that regardless of how that evolves, we think McKesson is in an excellent position to \ncapitalize on that. ", "original_text": "A lot o f it will \ndepend on the science, the development. ", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fb3e4fd81b98b2880c91f0bd847e4a0e152c153f49c0119d12410ab21c2d62e9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d1c81eb7-54b7-4051-966d-08344256c3ab", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRicky, relative to, I guess let's call it the future of testing, that's a little bit, I think, difficult to forecast.  A lot o f it will \ndepend on the science, the development.  A lot of it will depend on the current testing hold -up to current and future \npotential variants, what will be the mix between in a medical setting versus over -the-counter, do those become \nmore reliable.  I think there's a lot of questions that still have to resolve themselves there.  \n \n What I would say, though, is that regardless of how that evolves, we think McKesson is in an excellent position to \ncapitalize on that.  We are currently the largest distributor.  We dis tribute more flu vaccines than anyone. ", "original_text": "I think there's a lot of questions that still have to resolve themselves there.  \n \n"}, "hash": "39904c0aad5c3bf7f4c578d39c66e60642839326d769cb28988cbc81b08b3a2f", "class_name": "RelatedNodeInfo"}}, "text": "A lot of it will depend on the current testing hold -up to current and future \npotential variants, what will be the mix between in a medical setting versus over -the-counter, do those become \nmore reliable. ", "start_char_idx": 358, "end_char_idx": 565, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d1c81eb7-54b7-4051-966d-08344256c3ab": {"__data__": {"id_": "d1c81eb7-54b7-4051-966d-08344256c3ab", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRicky, relative to, I guess let's call it the future of testing, that's a little bit, I think, difficult to forecast.  A lot o f it will \ndepend on the science, the development.  A lot of it will depend on the current testing hold -up to current and future \npotential variants, what will be the mix between in a medical setting versus over -the-counter, do those become \nmore reliable.  I think there's a lot of questions that still have to resolve themselves there.  \n \n What I would say, though, is that regardless of how that evolves, we think McKesson is in an excellent position to \ncapitalize on that.  We are currently the largest distributor.  We dis tribute more flu vaccines than anyone. ", "original_text": "I think there's a lot of questions that still have to resolve themselves there.  \n \n", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ceb4a5e5728ef9a64b29f8e8f1afb599589c8043147110c669a5ca8eb3c335f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "421a70b9-35c8-4e7d-bfbb-48ba1a7d8e2a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRicky, relative to, I guess let's call it the future of testing, that's a little bit, I think, difficult to forecast.  A lot o f it will \ndepend on the science, the development.  A lot of it will depend on the current testing hold -up to current and future \npotential variants, what will be the mix between in a medical setting versus over -the-counter, do those become \nmore reliable.  I think there's a lot of questions that still have to resolve themselves there.  \n \n What I would say, though, is that regardless of how that evolves, we think McKesson is in an excellent position to \ncapitalize on that.  We are currently the largest distributor. ", "original_text": "A lot of it will depend on the current testing hold -up to current and future \npotential variants, what will be the mix between in a medical setting versus over -the-counter, do those become \nmore reliable. ", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0190713974ca2ca976d1bab8976776d57739fccd3c273700dc5dcd1dff0045d7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "160cbdee-0379-4031-a62b-eb9b44b930f6", "node_type": "1", "metadata": {"window": "A lot o f it will \ndepend on the science, the development.  A lot of it will depend on the current testing hold -up to current and future \npotential variants, what will be the mix between in a medical setting versus over -the-counter, do those become \nmore reliable.  I think there's a lot of questions that still have to resolve themselves there.  \n \n What I would say, though, is that regardless of how that evolves, we think McKesson is in an excellent position to \ncapitalize on that.  We are currently the largest distributor.  We dis tribute more flu vaccines than anyone.  We have \na great franchise in the physician alternate site setting. ", "original_text": "What I would say, though, is that regardless of how that evolves, we think McKesson is in an excellent position to \ncapitalize on that. "}, "hash": "94437bf22c80736aad6ceb264c24639414bb98a43dd78af02e083109bd175582", "class_name": "RelatedNodeInfo"}}, "text": "I think there's a lot of questions that still have to resolve themselves there.  \n \n", "start_char_idx": 565, "end_char_idx": 649, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "160cbdee-0379-4031-a62b-eb9b44b930f6": {"__data__": {"id_": "160cbdee-0379-4031-a62b-eb9b44b930f6", "embedding": null, "metadata": {"window": "A lot o f it will \ndepend on the science, the development.  A lot of it will depend on the current testing hold -up to current and future \npotential variants, what will be the mix between in a medical setting versus over -the-counter, do those become \nmore reliable.  I think there's a lot of questions that still have to resolve themselves there.  \n \n What I would say, though, is that regardless of how that evolves, we think McKesson is in an excellent position to \ncapitalize on that.  We are currently the largest distributor.  We dis tribute more flu vaccines than anyone.  We have \na great franchise in the physician alternate site setting. ", "original_text": "What I would say, though, is that regardless of how that evolves, we think McKesson is in an excellent position to \ncapitalize on that. ", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ceb4a5e5728ef9a64b29f8e8f1afb599589c8043147110c669a5ca8eb3c335f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d1c81eb7-54b7-4051-966d-08344256c3ab", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRicky, relative to, I guess let's call it the future of testing, that's a little bit, I think, difficult to forecast.  A lot o f it will \ndepend on the science, the development.  A lot of it will depend on the current testing hold -up to current and future \npotential variants, what will be the mix between in a medical setting versus over -the-counter, do those become \nmore reliable.  I think there's a lot of questions that still have to resolve themselves there.  \n \n What I would say, though, is that regardless of how that evolves, we think McKesson is in an excellent position to \ncapitalize on that.  We are currently the largest distributor.  We dis tribute more flu vaccines than anyone. ", "original_text": "I think there's a lot of questions that still have to resolve themselves there.  \n \n", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ce1ece5eed8147427c966af9169fc46b7f7734d73e65af333c8f908fe79601d8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a4947939-c4c5-40e8-bab8-7a1047ada5aa", "node_type": "1", "metadata": {"window": "A lot of it will depend on the current testing hold -up to current and future \npotential variants, what will be the mix between in a medical setting versus over -the-counter, do those become \nmore reliable.  I think there's a lot of questions that still have to resolve themselves there.  \n \n What I would say, though, is that regardless of how that evolves, we think McKesson is in an excellent position to \ncapitalize on that.  We are currently the largest distributor.  We dis tribute more flu vaccines than anyone.  We have \na great franchise in the physician alternate site setting.  We distribute to pharmacies because of our presence in \nthe communities in both our Medical and Pharmaceutical business, our relationships with the lab s and I think the \nreal credibility we've built up over the last couple of years, I think we're extremely well -positioned to capture that \nopportunity, however it unfolds.  \n ", "original_text": "We are currently the largest distributor. "}, "hash": "c2ee1da6e36931bbe41b990a7b30e021fb91d5f7ee18b88349719d8572a20e0e", "class_name": "RelatedNodeInfo"}}, "text": "What I would say, though, is that regardless of how that evolves, we think McKesson is in an excellent position to \ncapitalize on that. ", "start_char_idx": 649, "end_char_idx": 785, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a4947939-c4c5-40e8-bab8-7a1047ada5aa": {"__data__": {"id_": "a4947939-c4c5-40e8-bab8-7a1047ada5aa", "embedding": null, "metadata": {"window": "A lot of it will depend on the current testing hold -up to current and future \npotential variants, what will be the mix between in a medical setting versus over -the-counter, do those become \nmore reliable.  I think there's a lot of questions that still have to resolve themselves there.  \n \n What I would say, though, is that regardless of how that evolves, we think McKesson is in an excellent position to \ncapitalize on that.  We are currently the largest distributor.  We dis tribute more flu vaccines than anyone.  We have \na great franchise in the physician alternate site setting.  We distribute to pharmacies because of our presence in \nthe communities in both our Medical and Pharmaceutical business, our relationships with the lab s and I think the \nreal credibility we've built up over the last couple of years, I think we're extremely well -positioned to capture that \nopportunity, however it unfolds.  \n ", "original_text": "We are currently the largest distributor. ", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ceb4a5e5728ef9a64b29f8e8f1afb599589c8043147110c669a5ca8eb3c335f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "160cbdee-0379-4031-a62b-eb9b44b930f6", "node_type": "1", "metadata": {"window": "A lot o f it will \ndepend on the science, the development.  A lot of it will depend on the current testing hold -up to current and future \npotential variants, what will be the mix between in a medical setting versus over -the-counter, do those become \nmore reliable.  I think there's a lot of questions that still have to resolve themselves there.  \n \n What I would say, though, is that regardless of how that evolves, we think McKesson is in an excellent position to \ncapitalize on that.  We are currently the largest distributor.  We dis tribute more flu vaccines than anyone.  We have \na great franchise in the physician alternate site setting. ", "original_text": "What I would say, though, is that regardless of how that evolves, we think McKesson is in an excellent position to \ncapitalize on that. ", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3fa4e6c4dde8889fbb23100370168d286d4732ec73db43bf13348ec3bbd79f48", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a88fe4a5-6b54-456b-a89a-d88652c67001", "node_type": "1", "metadata": {"window": "I think there's a lot of questions that still have to resolve themselves there.  \n \n What I would say, though, is that regardless of how that evolves, we think McKesson is in an excellent position to \ncapitalize on that.  We are currently the largest distributor.  We dis tribute more flu vaccines than anyone.  We have \na great franchise in the physician alternate site setting.  We distribute to pharmacies because of our presence in \nthe communities in both our Medical and Pharmaceutical business, our relationships with the lab s and I think the \nreal credibility we've built up over the last couple of years, I think we're extremely well -positioned to capture that \nopportunity, however it unfolds.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nAnd we have time for o ne more question.  \n ", "original_text": "We dis tribute more flu vaccines than anyone. "}, "hash": "9e3479f8c077b7d5ba1cd54106e20c533757eb556a2721582da1f49f8b176477", "class_name": "RelatedNodeInfo"}}, "text": "We are currently the largest distributor. ", "start_char_idx": 785, "end_char_idx": 827, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a88fe4a5-6b54-456b-a89a-d88652c67001": {"__data__": {"id_": "a88fe4a5-6b54-456b-a89a-d88652c67001", "embedding": null, "metadata": {"window": "I think there's a lot of questions that still have to resolve themselves there.  \n \n What I would say, though, is that regardless of how that evolves, we think McKesson is in an excellent position to \ncapitalize on that.  We are currently the largest distributor.  We dis tribute more flu vaccines than anyone.  We have \na great franchise in the physician alternate site setting.  We distribute to pharmacies because of our presence in \nthe communities in both our Medical and Pharmaceutical business, our relationships with the lab s and I think the \nreal credibility we've built up over the last couple of years, I think we're extremely well -positioned to capture that \nopportunity, however it unfolds.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nAnd we have time for o ne more question.  \n ", "original_text": "We dis tribute more flu vaccines than anyone. ", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ceb4a5e5728ef9a64b29f8e8f1afb599589c8043147110c669a5ca8eb3c335f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a4947939-c4c5-40e8-bab8-7a1047ada5aa", "node_type": "1", "metadata": {"window": "A lot of it will depend on the current testing hold -up to current and future \npotential variants, what will be the mix between in a medical setting versus over -the-counter, do those become \nmore reliable.  I think there's a lot of questions that still have to resolve themselves there.  \n \n What I would say, though, is that regardless of how that evolves, we think McKesson is in an excellent position to \ncapitalize on that.  We are currently the largest distributor.  We dis tribute more flu vaccines than anyone.  We have \na great franchise in the physician alternate site setting.  We distribute to pharmacies because of our presence in \nthe communities in both our Medical and Pharmaceutical business, our relationships with the lab s and I think the \nreal credibility we've built up over the last couple of years, I think we're extremely well -positioned to capture that \nopportunity, however it unfolds.  \n ", "original_text": "We are currently the largest distributor. ", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "78a49dc807e81dcf80990086011e01da7f2e5e96bd62a080cf0e60c59c287c5c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2d00700e-0041-4dce-ba30-91e192d2ac0f", "node_type": "1", "metadata": {"window": "What I would say, though, is that regardless of how that evolves, we think McKesson is in an excellent position to \ncapitalize on that.  We are currently the largest distributor.  We dis tribute more flu vaccines than anyone.  We have \na great franchise in the physician alternate site setting.  We distribute to pharmacies because of our presence in \nthe communities in both our Medical and Pharmaceutical business, our relationships with the lab s and I think the \nreal credibility we've built up over the last couple of years, I think we're extremely well -positioned to capture that \nopportunity, however it unfolds.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nAnd we have time for o ne more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Most certainly. ", "original_text": "We have \na great franchise in the physician alternate site setting. "}, "hash": "d103eb8deb5fa1ddbc0c8ff7371db85d3ec975cf76a8b74eb721ee60afb9716b", "class_name": "RelatedNodeInfo"}}, "text": "We dis tribute more flu vaccines than anyone. ", "start_char_idx": 827, "end_char_idx": 873, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2d00700e-0041-4dce-ba30-91e192d2ac0f": {"__data__": {"id_": "2d00700e-0041-4dce-ba30-91e192d2ac0f", "embedding": null, "metadata": {"window": "What I would say, though, is that regardless of how that evolves, we think McKesson is in an excellent position to \ncapitalize on that.  We are currently the largest distributor.  We dis tribute more flu vaccines than anyone.  We have \na great franchise in the physician alternate site setting.  We distribute to pharmacies because of our presence in \nthe communities in both our Medical and Pharmaceutical business, our relationships with the lab s and I think the \nreal credibility we've built up over the last couple of years, I think we're extremely well -positioned to capture that \nopportunity, however it unfolds.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nAnd we have time for o ne more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Most certainly. ", "original_text": "We have \na great franchise in the physician alternate site setting. ", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ceb4a5e5728ef9a64b29f8e8f1afb599589c8043147110c669a5ca8eb3c335f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a88fe4a5-6b54-456b-a89a-d88652c67001", "node_type": "1", "metadata": {"window": "I think there's a lot of questions that still have to resolve themselves there.  \n \n What I would say, though, is that regardless of how that evolves, we think McKesson is in an excellent position to \ncapitalize on that.  We are currently the largest distributor.  We dis tribute more flu vaccines than anyone.  We have \na great franchise in the physician alternate site setting.  We distribute to pharmacies because of our presence in \nthe communities in both our Medical and Pharmaceutical business, our relationships with the lab s and I think the \nreal credibility we've built up over the last couple of years, I think we're extremely well -positioned to capture that \nopportunity, however it unfolds.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nAnd we have time for o ne more question.  \n ", "original_text": "We dis tribute more flu vaccines than anyone. ", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7b35308efea8f090dfc4447941f4793d13b096836d5afe112186abd18bcc3c3f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "138591e4-5934-4766-8bcb-aefb513db15a", "node_type": "1", "metadata": {"window": "We are currently the largest distributor.  We dis tribute more flu vaccines than anyone.  We have \na great franchise in the physician alternate site setting.  We distribute to pharmacies because of our presence in \nthe communities in both our Medical and Pharmaceutical business, our relationships with the lab s and I think the \nreal credibility we've built up over the last couple of years, I think we're extremely well -positioned to capture that \nopportunity, however it unfolds.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nAnd we have time for o ne more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Most certainly.  This question will come from Steve Valiquette with Barclays.  \n ", "original_text": "We distribute to pharmacies because of our presence in \nthe communities in both our Medical and Pharmaceutical business, our relationships with the lab s and I think the \nreal credibility we've built up over the last couple of years, I think we're extremely well -positioned to capture that \nopportunity, however it unfolds.  \n "}, "hash": "8f38a8a6ec7bdd2716523d3e0cca77debacf5c5d741937c5318c1f0850d49435", "class_name": "RelatedNodeInfo"}}, "text": "We have \na great franchise in the physician alternate site setting. ", "start_char_idx": 873, "end_char_idx": 941, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "138591e4-5934-4766-8bcb-aefb513db15a": {"__data__": {"id_": "138591e4-5934-4766-8bcb-aefb513db15a", "embedding": null, "metadata": {"window": "We are currently the largest distributor.  We dis tribute more flu vaccines than anyone.  We have \na great franchise in the physician alternate site setting.  We distribute to pharmacies because of our presence in \nthe communities in both our Medical and Pharmaceutical business, our relationships with the lab s and I think the \nreal credibility we've built up over the last couple of years, I think we're extremely well -positioned to capture that \nopportunity, however it unfolds.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nAnd we have time for o ne more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Most certainly.  This question will come from Steve Valiquette with Barclays.  \n ", "original_text": "We distribute to pharmacies because of our presence in \nthe communities in both our Medical and Pharmaceutical business, our relationships with the lab s and I think the \nreal credibility we've built up over the last couple of years, I think we're extremely well -positioned to capture that \nopportunity, however it unfolds.  \n ", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ceb4a5e5728ef9a64b29f8e8f1afb599589c8043147110c669a5ca8eb3c335f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2d00700e-0041-4dce-ba30-91e192d2ac0f", "node_type": "1", "metadata": {"window": "What I would say, though, is that regardless of how that evolves, we think McKesson is in an excellent position to \ncapitalize on that.  We are currently the largest distributor.  We dis tribute more flu vaccines than anyone.  We have \na great franchise in the physician alternate site setting.  We distribute to pharmacies because of our presence in \nthe communities in both our Medical and Pharmaceutical business, our relationships with the lab s and I think the \nreal credibility we've built up over the last couple of years, I think we're extremely well -positioned to capture that \nopportunity, however it unfolds.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nAnd we have time for o ne more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Most certainly. ", "original_text": "We have \na great franchise in the physician alternate site setting. ", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0bc6403b7eff7d59354b28b2c7998c9a28464bf1f61b95c89cd094c3ab7f2597", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b237b776-12e9-40b3-a4c8-e178c2b2b0d8", "node_type": "1", "metadata": {"window": "We dis tribute more flu vaccines than anyone.  We have \na great franchise in the physician alternate site setting.  We distribute to pharmacies because of our presence in \nthe communities in both our Medical and Pharmaceutical business, our relationships with the lab s and I think the \nreal credibility we've built up over the last couple of years, I think we're extremely well -positioned to capture that \nopportunity, however it unfolds.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nAnd we have time for o ne more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Most certainly.  This question will come from Steve Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nAnd we have time for o ne more question.  \n "}, "hash": "c11a980aa2ff02b54e021fe4e6c710329ef40c8b0240261b4bba69a9966b98fe", "class_name": "RelatedNodeInfo"}}, "text": "We distribute to pharmacies because of our presence in \nthe communities in both our Medical and Pharmaceutical business, our relationships with the lab s and I think the \nreal credibility we've built up over the last couple of years, I think we're extremely well -positioned to capture that \nopportunity, however it unfolds.  \n ", "start_char_idx": 941, "end_char_idx": 1269, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b237b776-12e9-40b3-a4c8-e178c2b2b0d8": {"__data__": {"id_": "b237b776-12e9-40b3-a4c8-e178c2b2b0d8", "embedding": null, "metadata": {"window": "We dis tribute more flu vaccines than anyone.  We have \na great franchise in the physician alternate site setting.  We distribute to pharmacies because of our presence in \nthe communities in both our Medical and Pharmaceutical business, our relationships with the lab s and I think the \nreal credibility we've built up over the last couple of years, I think we're extremely well -positioned to capture that \nopportunity, however it unfolds.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nAnd we have time for o ne more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Most certainly.  This question will come from Steve Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nAnd we have time for o ne more question.  \n ", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ceb4a5e5728ef9a64b29f8e8f1afb599589c8043147110c669a5ca8eb3c335f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "138591e4-5934-4766-8bcb-aefb513db15a", "node_type": "1", "metadata": {"window": "We are currently the largest distributor.  We dis tribute more flu vaccines than anyone.  We have \na great franchise in the physician alternate site setting.  We distribute to pharmacies because of our presence in \nthe communities in both our Medical and Pharmaceutical business, our relationships with the lab s and I think the \nreal credibility we've built up over the last couple of years, I think we're extremely well -positioned to capture that \nopportunity, however it unfolds.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nAnd we have time for o ne more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Most certainly.  This question will come from Steve Valiquette with Barclays.  \n ", "original_text": "We distribute to pharmacies because of our presence in \nthe communities in both our Medical and Pharmaceutical business, our relationships with the lab s and I think the \nreal credibility we've built up over the last couple of years, I think we're extremely well -positioned to capture that \nopportunity, however it unfolds.  \n ", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cc104011ecd28af8e6e2bf681a81b649de031eadb100b98b36f3d3cace3319a5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2d159cbb-d7b6-4f24-84f5-191736c88c63", "node_type": "1", "metadata": {"window": "We have \na great franchise in the physician alternate site setting.  We distribute to pharmacies because of our presence in \nthe communities in both our Medical and Pharmaceutical business, our relationships with the lab s and I think the \nreal credibility we've built up over the last couple of years, I think we're extremely well -positioned to capture that \nopportunity, however it unfolds.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nAnd we have time for o ne more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Most certainly.  This question will come from Steve Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Most certainly. "}, "hash": "35705985bf48d5bb7fc264e56d6bdd1d8258cee0788c652bddbfee3baed08383", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nAnd we have time for o ne more question.  \n ", "start_char_idx": 1269, "end_char_idx": 1650, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2d159cbb-d7b6-4f24-84f5-191736c88c63": {"__data__": {"id_": "2d159cbb-d7b6-4f24-84f5-191736c88c63", "embedding": null, "metadata": {"window": "We have \na great franchise in the physician alternate site setting.  We distribute to pharmacies because of our presence in \nthe communities in both our Medical and Pharmaceutical business, our relationships with the lab s and I think the \nreal credibility we've built up over the last couple of years, I think we're extremely well -positioned to capture that \nopportunity, however it unfolds.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nAnd we have time for o ne more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Most certainly.  This question will come from Steve Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Most certainly. ", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ceb4a5e5728ef9a64b29f8e8f1afb599589c8043147110c669a5ca8eb3c335f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b237b776-12e9-40b3-a4c8-e178c2b2b0d8", "node_type": "1", "metadata": {"window": "We dis tribute more flu vaccines than anyone.  We have \na great franchise in the physician alternate site setting.  We distribute to pharmacies because of our presence in \nthe communities in both our Medical and Pharmaceutical business, our relationships with the lab s and I think the \nreal credibility we've built up over the last couple of years, I think we're extremely well -positioned to capture that \nopportunity, however it unfolds.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nAnd we have time for o ne more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Most certainly.  This question will come from Steve Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nAnd we have time for o ne more question.  \n ", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "796792a9e1d4a1953bc176fe37b5b9eb95015410e749d556d33888891d7c9926", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b61d9fef-41fa-4c41-aca4-155a99aa8364", "node_type": "1", "metadata": {"window": "We distribute to pharmacies because of our presence in \nthe communities in both our Medical and Pharmaceutical business, our relationships with the lab s and I think the \nreal credibility we've built up over the last couple of years, I think we're extremely well -positioned to capture that \nopportunity, however it unfolds.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nAnd we have time for o ne more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Most certainly.  This question will come from Steve Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks.  Good afternoon. ", "original_text": "This question will come from Steve Valiquette with Barclays.  \n "}, "hash": "31b6a727358ec049262fec4ab93037d1582d4ccc1643ed6254954dc8dc6f2bea", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Most certainly. ", "start_char_idx": 1650, "end_char_idx": 1951, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b61d9fef-41fa-4c41-aca4-155a99aa8364": {"__data__": {"id_": "b61d9fef-41fa-4c41-aca4-155a99aa8364", "embedding": null, "metadata": {"window": "We distribute to pharmacies because of our presence in \nthe communities in both our Medical and Pharmaceutical business, our relationships with the lab s and I think the \nreal credibility we've built up over the last couple of years, I think we're extremely well -positioned to capture that \nopportunity, however it unfolds.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nAnd we have time for o ne more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Most certainly.  This question will come from Steve Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks.  Good afternoon. ", "original_text": "This question will come from Steve Valiquette with Barclays.  \n ", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ceb4a5e5728ef9a64b29f8e8f1afb599589c8043147110c669a5ca8eb3c335f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2d159cbb-d7b6-4f24-84f5-191736c88c63", "node_type": "1", "metadata": {"window": "We have \na great franchise in the physician alternate site setting.  We distribute to pharmacies because of our presence in \nthe communities in both our Medical and Pharmaceutical business, our relationships with the lab s and I think the \nreal credibility we've built up over the last couple of years, I think we're extremely well -positioned to capture that \nopportunity, however it unfolds.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nAnd we have time for o ne more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Most certainly.  This question will come from Steve Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Most certainly. ", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee793363d0b36e9337dfd8cbc79633cb32914b88d7110777ac59fdfebdd6a645", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c1bb8b9e-0d94-4d8a-b54f-8f454ab7eb40", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nAnd we have time for o ne more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Most certainly.  This question will come from Steve Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks.  Good afternoon.  I also had a question just around the \u2013 your comment around the normal customer \nrenewal activity in fiscal 2023. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.  "}, "hash": "1ecc9ea7cc1c42945bd000d578da37d6267cc9e1e8106d89ed674bd94a738a22", "class_name": "RelatedNodeInfo"}}, "text": "This question will come from Steve Valiquette with Barclays.  \n ", "start_char_idx": 1951, "end_char_idx": 2015, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c1bb8b9e-0d94-4d8a-b54f-8f454ab7eb40": {"__data__": {"id_": "c1bb8b9e-0d94-4d8a-b54f-8f454ab7eb40", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nAnd we have time for o ne more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Most certainly.  This question will come from Steve Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks.  Good afternoon.  I also had a question just around the \u2013 your comment around the normal customer \nrenewal activity in fiscal 2023. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ceb4a5e5728ef9a64b29f8e8f1afb599589c8043147110c669a5ca8eb3c335f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b61d9fef-41fa-4c41-aca4-155a99aa8364", "node_type": "1", "metadata": {"window": "We distribute to pharmacies because of our presence in \nthe communities in both our Medical and Pharmaceutical business, our relationships with the lab s and I think the \nreal credibility we've built up over the last couple of years, I think we're extremely well -positioned to capture that \nopportunity, however it unfolds.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nAnd we have time for o ne more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Most certainly.  This question will come from Steve Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks.  Good afternoon. ", "original_text": "This question will come from Steve Valiquette with Barclays.  \n ", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "073fe8947d61a2a407d628988ef567d2114f90ef4c81fe4d9057646497bea1cf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "abdf4e4a-21f9-40df-9cfd-b1ac7c3dda36", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Most certainly.  This question will come from Steve Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks.  Good afternoon.  I also had a question just around the \u2013 your comment around the normal customer \nrenewal activity in fiscal 2023.  I guess I just wanted to make sure and confirm the messaging around that. ", "original_text": "Q \nThanks. "}, "hash": "27f1acdc60d1634f6e568819612b1891f704db01ee509de47cc5f3ebf4b63f3e", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "start_char_idx": 2015, "end_char_idx": 2342, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "abdf4e4a-21f9-40df-9cfd-b1ac7c3dda36": {"__data__": {"id_": "abdf4e4a-21f9-40df-9cfd-b1ac7c3dda36", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Most certainly.  This question will come from Steve Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks.  Good afternoon.  I also had a question just around the \u2013 your comment around the normal customer \nrenewal activity in fiscal 2023.  I guess I just wanted to make sure and confirm the messaging around that. ", "original_text": "Q \nThanks. ", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ceb4a5e5728ef9a64b29f8e8f1afb599589c8043147110c669a5ca8eb3c335f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c1bb8b9e-0d94-4d8a-b54f-8f454ab7eb40", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  A \nAnd we have time for o ne more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Most certainly.  This question will come from Steve Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks.  Good afternoon.  I also had a question just around the \u2013 your comment around the normal customer \nrenewal activity in fiscal 2023. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.  ", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "049e709800af69a7f998249c731c8b52f5a930b039583d0b2138fc57824a5a4c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ca1a5566-c699-4947-9596-eac261e1276a", "node_type": "1", "metadata": {"window": "This question will come from Steve Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks.  Good afternoon.  I also had a question just around the \u2013 your comment around the normal customer \nrenewal activity in fiscal 2023.  I guess I just wanted to make sure and confirm the messaging around that.  So I \nguess first, can you remind us how customer renewal activity and any related pricing step -downs trended for fiscal \n2022? ", "original_text": "Good afternoon. "}, "hash": "fdb6749899772eed5f983571ff8d647826d494d69b7baac9b8fd9dd566c03460", "class_name": "RelatedNodeInfo"}}, "text": "Q \nThanks. ", "start_char_idx": 2342, "end_char_idx": 2353, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ca1a5566-c699-4947-9596-eac261e1276a": {"__data__": {"id_": "ca1a5566-c699-4947-9596-eac261e1276a", "embedding": null, "metadata": {"window": "This question will come from Steve Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks.  Good afternoon.  I also had a question just around the \u2013 your comment around the normal customer \nrenewal activity in fiscal 2023.  I guess I just wanted to make sure and confirm the messaging around that.  So I \nguess first, can you remind us how customer renewal activity and any related pricing step -downs trended for fiscal \n2022? ", "original_text": "Good afternoon. ", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ceb4a5e5728ef9a64b29f8e8f1afb599589c8043147110c669a5ca8eb3c335f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "abdf4e4a-21f9-40df-9cfd-b1ac7c3dda36", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Most certainly.  This question will come from Steve Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks.  Good afternoon.  I also had a question just around the \u2013 your comment around the normal customer \nrenewal activity in fiscal 2023.  I guess I just wanted to make sure and confirm the messaging around that. ", "original_text": "Q \nThanks. ", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a4d8b1feae7bb7f2c82eb429f6993c023e50fb9c8276bd39f010fe69b30a8277", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7fbb5d70-1ae4-47e4-9289-21826503cd3f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks.  Good afternoon.  I also had a question just around the \u2013 your comment around the normal customer \nrenewal activity in fiscal 2023.  I guess I just wanted to make sure and confirm the messaging around that.  So I \nguess first, can you remind us how customer renewal activity and any related pricing step -downs trended for fiscal \n2022?  And thu s, if that activity is going to be normal in 2023, is that net positive, net negative or net neutral as \nyou think about the \u2013 how all that flows year -over-year? ", "original_text": "I also had a question just around the \u2013 your comment around the normal customer \nrenewal activity in fiscal 2023. "}, "hash": "e4215c05de5e2ef7f04401919aa501931e9d39c225efe3e530c7e2adab8114db", "class_name": "RelatedNodeInfo"}}, "text": "Good afternoon. ", "start_char_idx": 2353, "end_char_idx": 2369, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7fbb5d70-1ae4-47e4-9289-21826503cd3f": {"__data__": {"id_": "7fbb5d70-1ae4-47e4-9289-21826503cd3f", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks.  Good afternoon.  I also had a question just around the \u2013 your comment around the normal customer \nrenewal activity in fiscal 2023.  I guess I just wanted to make sure and confirm the messaging around that.  So I \nguess first, can you remind us how customer renewal activity and any related pricing step -downs trended for fiscal \n2022?  And thu s, if that activity is going to be normal in 2023, is that net positive, net negative or net neutral as \nyou think about the \u2013 how all that flows year -over-year? ", "original_text": "I also had a question just around the \u2013 your comment around the normal customer \nrenewal activity in fiscal 2023. ", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ceb4a5e5728ef9a64b29f8e8f1afb599589c8043147110c669a5ca8eb3c335f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ca1a5566-c699-4947-9596-eac261e1276a", "node_type": "1", "metadata": {"window": "This question will come from Steve Valiquette with Barclays.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks.  Good afternoon.  I also had a question just around the \u2013 your comment around the normal customer \nrenewal activity in fiscal 2023.  I guess I just wanted to make sure and confirm the messaging around that.  So I \nguess first, can you remind us how customer renewal activity and any related pricing step -downs trended for fiscal \n2022? ", "original_text": "Good afternoon. ", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f89710dd41b86acb6682c063a3c5b304bd3edf5a37ff0c9c9339df3db84dc13a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bf294838-d494-4568-ba5a-cac06883a78c", "node_type": "1", "metadata": {"window": "Q \nThanks.  Good afternoon.  I also had a question just around the \u2013 your comment around the normal customer \nrenewal activity in fiscal 2023.  I guess I just wanted to make sure and confirm the messaging around that.  So I \nguess first, can you remind us how customer renewal activity and any related pricing step -downs trended for fiscal \n2022?  And thu s, if that activity is going to be normal in 2023, is that net positive, net negative or net neutral as \nyou think about the \u2013 how all that flows year -over-year?  Hopefully, that question makes sense. ", "original_text": "I guess I just wanted to make sure and confirm the messaging around that. "}, "hash": "04a791912ef82182614bd1a7dc37fb7f887cf0614c362312bb2e588b0ef5a677", "class_name": "RelatedNodeInfo"}}, "text": "I also had a question just around the \u2013 your comment around the normal customer \nrenewal activity in fiscal 2023. ", "start_char_idx": 2369, "end_char_idx": 2483, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bf294838-d494-4568-ba5a-cac06883a78c": {"__data__": {"id_": "bf294838-d494-4568-ba5a-cac06883a78c", "embedding": null, "metadata": {"window": "Q \nThanks.  Good afternoon.  I also had a question just around the \u2013 your comment around the normal customer \nrenewal activity in fiscal 2023.  I guess I just wanted to make sure and confirm the messaging around that.  So I \nguess first, can you remind us how customer renewal activity and any related pricing step -downs trended for fiscal \n2022?  And thu s, if that activity is going to be normal in 2023, is that net positive, net negative or net neutral as \nyou think about the \u2013 how all that flows year -over-year?  Hopefully, that question makes sense. ", "original_text": "I guess I just wanted to make sure and confirm the messaging around that. ", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ceb4a5e5728ef9a64b29f8e8f1afb599589c8043147110c669a5ca8eb3c335f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7fbb5d70-1ae4-47e4-9289-21826503cd3f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nSteve J. Valiquette  \nAnalyst, Barclays Capital, Inc.   Q \nThanks.  Good afternoon.  I also had a question just around the \u2013 your comment around the normal customer \nrenewal activity in fiscal 2023.  I guess I just wanted to make sure and confirm the messaging around that.  So I \nguess first, can you remind us how customer renewal activity and any related pricing step -downs trended for fiscal \n2022?  And thu s, if that activity is going to be normal in 2023, is that net positive, net negative or net neutral as \nyou think about the \u2013 how all that flows year -over-year? ", "original_text": "I also had a question just around the \u2013 your comment around the normal customer \nrenewal activity in fiscal 2023. ", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "252eabbaa5ec85df274fb4cf7d19b67a2327d41ddeee70a36f9c1303adeaf3a6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4bd048e0-2873-4a02-b267-6261b1fb89b9", "node_type": "1", "metadata": {"window": "Good afternoon.  I also had a question just around the \u2013 your comment around the normal customer \nrenewal activity in fiscal 2023.  I guess I just wanted to make sure and confirm the messaging around that.  So I \nguess first, can you remind us how customer renewal activity and any related pricing step -downs trended for fiscal \n2022?  And thu s, if that activity is going to be normal in 2023, is that net positive, net negative or net neutral as \nyou think about the \u2013 how all that flows year -over-year?  Hopefully, that question makes sense.  Thanks.  \n ", "original_text": "So I \nguess first, can you remind us how customer renewal activity and any related pricing step -downs trended for fiscal \n2022? "}, "hash": "6f2263e05fb807582acf6bdfbb4c0a00caf8dfd581834d22596f5ec44586b8c6", "class_name": "RelatedNodeInfo"}}, "text": "I guess I just wanted to make sure and confirm the messaging around that. ", "start_char_idx": 2483, "end_char_idx": 2557, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4bd048e0-2873-4a02-b267-6261b1fb89b9": {"__data__": {"id_": "4bd048e0-2873-4a02-b267-6261b1fb89b9", "embedding": null, "metadata": {"window": "Good afternoon.  I also had a question just around the \u2013 your comment around the normal customer \nrenewal activity in fiscal 2023.  I guess I just wanted to make sure and confirm the messaging around that.  So I \nguess first, can you remind us how customer renewal activity and any related pricing step -downs trended for fiscal \n2022?  And thu s, if that activity is going to be normal in 2023, is that net positive, net negative or net neutral as \nyou think about the \u2013 how all that flows year -over-year?  Hopefully, that question makes sense.  Thanks.  \n ", "original_text": "So I \nguess first, can you remind us how customer renewal activity and any related pricing step -downs trended for fiscal \n2022? ", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ceb4a5e5728ef9a64b29f8e8f1afb599589c8043147110c669a5ca8eb3c335f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bf294838-d494-4568-ba5a-cac06883a78c", "node_type": "1", "metadata": {"window": "Q \nThanks.  Good afternoon.  I also had a question just around the \u2013 your comment around the normal customer \nrenewal activity in fiscal 2023.  I guess I just wanted to make sure and confirm the messaging around that.  So I \nguess first, can you remind us how customer renewal activity and any related pricing step -downs trended for fiscal \n2022?  And thu s, if that activity is going to be normal in 2023, is that net positive, net negative or net neutral as \nyou think about the \u2013 how all that flows year -over-year?  Hopefully, that question makes sense. ", "original_text": "I guess I just wanted to make sure and confirm the messaging around that. ", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "387bd072a613094d76ca016f5115cf87ce34e38fcef5fb847fe358230b6e9cb7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "33335a5e-6f39-4394-89d4-957aeaa6477e", "node_type": "1", "metadata": {"window": "I also had a question just around the \u2013 your comment around the normal customer \nrenewal activity in fiscal 2023.  I guess I just wanted to make sure and confirm the messaging around that.  So I \nguess first, can you remind us how customer renewal activity and any related pricing step -downs trended for fiscal \n2022?  And thu s, if that activity is going to be normal in 2023, is that net positive, net negative or net neutral as \nyou think about the \u2013 how all that flows year -over-year?  Hopefully, that question makes sense.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.  ", "original_text": "And thu s, if that activity is going to be normal in 2023, is that net positive, net negative or net neutral as \nyou think about the \u2013 how all that flows year -over-year? "}, "hash": "6a7b12cc6c3166435ae08f2eac953eafb1acaeb7f5c76cde61138910348e22e0", "class_name": "RelatedNodeInfo"}}, "text": "So I \nguess first, can you remind us how customer renewal activity and any related pricing step -downs trended for fiscal \n2022? ", "start_char_idx": 2557, "end_char_idx": 2686, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "33335a5e-6f39-4394-89d4-957aeaa6477e": {"__data__": {"id_": "33335a5e-6f39-4394-89d4-957aeaa6477e", "embedding": null, "metadata": {"window": "I also had a question just around the \u2013 your comment around the normal customer \nrenewal activity in fiscal 2023.  I guess I just wanted to make sure and confirm the messaging around that.  So I \nguess first, can you remind us how customer renewal activity and any related pricing step -downs trended for fiscal \n2022?  And thu s, if that activity is going to be normal in 2023, is that net positive, net negative or net neutral as \nyou think about the \u2013 how all that flows year -over-year?  Hopefully, that question makes sense.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.  ", "original_text": "And thu s, if that activity is going to be normal in 2023, is that net positive, net negative or net neutral as \nyou think about the \u2013 how all that flows year -over-year? ", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ceb4a5e5728ef9a64b29f8e8f1afb599589c8043147110c669a5ca8eb3c335f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4bd048e0-2873-4a02-b267-6261b1fb89b9", "node_type": "1", "metadata": {"window": "Good afternoon.  I also had a question just around the \u2013 your comment around the normal customer \nrenewal activity in fiscal 2023.  I guess I just wanted to make sure and confirm the messaging around that.  So I \nguess first, can you remind us how customer renewal activity and any related pricing step -downs trended for fiscal \n2022?  And thu s, if that activity is going to be normal in 2023, is that net positive, net negative or net neutral as \nyou think about the \u2013 how all that flows year -over-year?  Hopefully, that question makes sense.  Thanks.  \n ", "original_text": "So I \nguess first, can you remind us how customer renewal activity and any related pricing step -downs trended for fiscal \n2022? ", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cef5f0472e03f45408302f667476a01c4bda928ba52e298ae3d7a9ef2ebe33c7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b38135fa-cb5e-4255-abb6-88c03b991048", "node_type": "1", "metadata": {"window": "I guess I just wanted to make sure and confirm the messaging around that.  So I \nguess first, can you remind us how customer renewal activity and any related pricing step -downs trended for fiscal \n2022?  And thu s, if that activity is going to be normal in 2023, is that net positive, net negative or net neutral as \nyou think about the \u2013 how all that flows year -over-year?  Hopefully, that question makes sense.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.   A \nYeah. ", "original_text": "Hopefully, that question makes sense. "}, "hash": "46aa9745cbdaf99ba5fd4e04a18323ebdb77512ad7ecd586d76820c014898c84", "class_name": "RelatedNodeInfo"}}, "text": "And thu s, if that activity is going to be normal in 2023, is that net positive, net negative or net neutral as \nyou think about the \u2013 how all that flows year -over-year? ", "start_char_idx": 2686, "end_char_idx": 2857, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b38135fa-cb5e-4255-abb6-88c03b991048": {"__data__": {"id_": "b38135fa-cb5e-4255-abb6-88c03b991048", "embedding": null, "metadata": {"window": "I guess I just wanted to make sure and confirm the messaging around that.  So I \nguess first, can you remind us how customer renewal activity and any related pricing step -downs trended for fiscal \n2022?  And thu s, if that activity is going to be normal in 2023, is that net positive, net negative or net neutral as \nyou think about the \u2013 how all that flows year -over-year?  Hopefully, that question makes sense.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.   A \nYeah. ", "original_text": "Hopefully, that question makes sense. ", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ceb4a5e5728ef9a64b29f8e8f1afb599589c8043147110c669a5ca8eb3c335f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "33335a5e-6f39-4394-89d4-957aeaa6477e", "node_type": "1", "metadata": {"window": "I also had a question just around the \u2013 your comment around the normal customer \nrenewal activity in fiscal 2023.  I guess I just wanted to make sure and confirm the messaging around that.  So I \nguess first, can you remind us how customer renewal activity and any related pricing step -downs trended for fiscal \n2022?  And thu s, if that activity is going to be normal in 2023, is that net positive, net negative or net neutral as \nyou think about the \u2013 how all that flows year -over-year?  Hopefully, that question makes sense.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.  ", "original_text": "And thu s, if that activity is going to be normal in 2023, is that net positive, net negative or net neutral as \nyou think about the \u2013 how all that flows year -over-year? ", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f9f3b780815944d4714dcf30b2aae43ffbcbf1bee34e14c5c2522ac280ea1c5a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7fd63844-6c4a-46e5-87f9-41ab0cd5e3a2", "node_type": "1", "metadata": {"window": "So I \nguess first, can you remind us how customer renewal activity and any related pricing step -downs trended for fiscal \n2022?  And thu s, if that activity is going to be normal in 2023, is that net positive, net negative or net neutral as \nyou think about the \u2013 how all that flows year -over-year?  Hopefully, that question makes sense.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.   A \nYeah.  Thanks, Steve. ", "original_text": "Thanks.  \n "}, "hash": "6ba11c415ffef01ed1c304b96758e51fd85c135645da6124db3f34fd5aa0b93c", "class_name": "RelatedNodeInfo"}}, "text": "Hopefully, that question makes sense. ", "start_char_idx": 2857, "end_char_idx": 2895, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7fd63844-6c4a-46e5-87f9-41ab0cd5e3a2": {"__data__": {"id_": "7fd63844-6c4a-46e5-87f9-41ab0cd5e3a2", "embedding": null, "metadata": {"window": "So I \nguess first, can you remind us how customer renewal activity and any related pricing step -downs trended for fiscal \n2022?  And thu s, if that activity is going to be normal in 2023, is that net positive, net negative or net neutral as \nyou think about the \u2013 how all that flows year -over-year?  Hopefully, that question makes sense.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.   A \nYeah.  Thanks, Steve. ", "original_text": "Thanks.  \n ", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ceb4a5e5728ef9a64b29f8e8f1afb599589c8043147110c669a5ca8eb3c335f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b38135fa-cb5e-4255-abb6-88c03b991048", "node_type": "1", "metadata": {"window": "I guess I just wanted to make sure and confirm the messaging around that.  So I \nguess first, can you remind us how customer renewal activity and any related pricing step -downs trended for fiscal \n2022?  And thu s, if that activity is going to be normal in 2023, is that net positive, net negative or net neutral as \nyou think about the \u2013 how all that flows year -over-year?  Hopefully, that question makes sense.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.   A \nYeah. ", "original_text": "Hopefully, that question makes sense. ", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5e4d6cbedcc2e37ee692887b49681049c08dc6e8bd4fc82cf25c96f62ec0724b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "676d731d-8de5-4385-bb2e-8f2ea1b69c47", "node_type": "1", "metadata": {"window": "And thu s, if that activity is going to be normal in 2023, is that net positive, net negative or net neutral as \nyou think about the \u2013 how all that flows year -over-year?  Hopefully, that question makes sense.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.   A \nYeah.  Thanks, Steve.  That's a good question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.  "}, "hash": "2715eec492d660291bab638387938ea3b90d000959860b042c820cc792231fe3", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n ", "start_char_idx": 2895, "end_char_idx": 2906, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "676d731d-8de5-4385-bb2e-8f2ea1b69c47": {"__data__": {"id_": "676d731d-8de5-4385-bb2e-8f2ea1b69c47", "embedding": null, "metadata": {"window": "And thu s, if that activity is going to be normal in 2023, is that net positive, net negative or net neutral as \nyou think about the \u2013 how all that flows year -over-year?  Hopefully, that question makes sense.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.   A \nYeah.  Thanks, Steve.  That's a good question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ceb4a5e5728ef9a64b29f8e8f1afb599589c8043147110c669a5ca8eb3c335f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7fd63844-6c4a-46e5-87f9-41ab0cd5e3a2", "node_type": "1", "metadata": {"window": "So I \nguess first, can you remind us how customer renewal activity and any related pricing step -downs trended for fiscal \n2022?  And thu s, if that activity is going to be normal in 2023, is that net positive, net negative or net neutral as \nyou think about the \u2013 how all that flows year -over-year?  Hopefully, that question makes sense.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.   A \nYeah.  Thanks, Steve. ", "original_text": "Thanks.  \n ", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f749b78b676dcdfb4242f624d3ac09888997a4311c16a5db74e63c4c7e7c0fc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7c5341d8-7cc2-40fd-8530-e5927580477a", "node_type": "1", "metadata": {"window": "Hopefully, that question makes sense.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.   A \nYeah.  Thanks, Steve.  That's a good question.  I'm happy to answer that and I'm happy to clarify. ", "original_text": "A \nYeah. "}, "hash": "a18e32b9a5fb4cf261195f657df1442a23b270b17e39ba80beb712188b899869", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.  ", "start_char_idx": 2906, "end_char_idx": 3264, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7c5341d8-7cc2-40fd-8530-e5927580477a": {"__data__": {"id_": "7c5341d8-7cc2-40fd-8530-e5927580477a", "embedding": null, "metadata": {"window": "Hopefully, that question makes sense.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.   A \nYeah.  Thanks, Steve.  That's a good question.  I'm happy to answer that and I'm happy to clarify. ", "original_text": "A \nYeah. ", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ceb4a5e5728ef9a64b29f8e8f1afb599589c8043147110c669a5ca8eb3c335f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "676d731d-8de5-4385-bb2e-8f2ea1b69c47", "node_type": "1", "metadata": {"window": "And thu s, if that activity is going to be normal in 2023, is that net positive, net negative or net neutral as \nyou think about the \u2013 how all that flows year -over-year?  Hopefully, that question makes sense.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.   A \nYeah.  Thanks, Steve.  That's a good question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "080bbe6da838a456581ceae22ebc72024548c9f5a6b7fb12b1a7611b9c512149", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f6c5f39e-7bf3-4863-9bcd-75ee1a68d42a", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.   A \nYeah.  Thanks, Steve.  That's a good question.  I'm happy to answer that and I'm happy to clarify.  When I speak of \nnormal, what I mean by that is in any year, we typically see about a third of our US Pharmaceutical book r enew. \n", "original_text": "Thanks, Steve. "}, "hash": "0d9c220d42faac9f7b74d778cc3ec33b9adb65c6252566d35f03132f18cef81e", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah. ", "start_char_idx": 3264, "end_char_idx": 3273, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f6c5f39e-7bf3-4863-9bcd-75ee1a68d42a": {"__data__": {"id_": "f6c5f39e-7bf3-4863-9bcd-75ee1a68d42a", "embedding": null, "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.   A \nYeah.  Thanks, Steve.  That's a good question.  I'm happy to answer that and I'm happy to clarify.  When I speak of \nnormal, what I mean by that is in any year, we typically see about a third of our US Pharmaceutical book r enew. \n", "original_text": "Thanks, Steve. ", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ceb4a5e5728ef9a64b29f8e8f1afb599589c8043147110c669a5ca8eb3c335f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7c5341d8-7cc2-40fd-8530-e5927580477a", "node_type": "1", "metadata": {"window": "Hopefully, that question makes sense.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.   A \nYeah.  Thanks, Steve.  That's a good question.  I'm happy to answer that and I'm happy to clarify. ", "original_text": "A \nYeah. ", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffe733242dc17bd34356b47723b6ca856275ae19a84e76601dbbe5ef85f6cfa6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "97366399-7aea-4fc4-9552-2e2b19e8658f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.   A \nYeah.  Thanks, Steve.  That's a good question.  I'm happy to answer that and I'm happy to clarify.  When I speak of \nnormal, what I mean by that is in any year, we typically see about a third of our US Pharmaceutical book r enew. \n As we have seen over the last few years, there have been no material impacts to that and certainly have been \nable to renew all of our customers successfully within our guidance and I would not anticipate that we would see \nanything material from our r enewal next year.  \n \n", "original_text": "That's a good question. "}, "hash": "7c343baa55bf5826e36eb2e34b3044f145412202556da76b94640c7f7e8ffd29", "class_name": "RelatedNodeInfo"}}, "text": "Thanks, Steve. ", "start_char_idx": 3273, "end_char_idx": 3288, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "97366399-7aea-4fc4-9552-2e2b19e8658f": {"__data__": {"id_": "97366399-7aea-4fc4-9552-2e2b19e8658f", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.   A \nYeah.  Thanks, Steve.  That's a good question.  I'm happy to answer that and I'm happy to clarify.  When I speak of \nnormal, what I mean by that is in any year, we typically see about a third of our US Pharmaceutical book r enew. \n As we have seen over the last few years, there have been no material impacts to that and certainly have been \nable to renew all of our customers successfully within our guidance and I would not anticipate that we would see \nanything material from our r enewal next year.  \n \n", "original_text": "That's a good question. ", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ceb4a5e5728ef9a64b29f8e8f1afb599589c8043147110c669a5ca8eb3c335f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f6c5f39e-7bf3-4863-9bcd-75ee1a68d42a", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.   A \nYeah.  Thanks, Steve.  That's a good question.  I'm happy to answer that and I'm happy to clarify.  When I speak of \nnormal, what I mean by that is in any year, we typically see about a third of our US Pharmaceutical book r enew. \n", "original_text": "Thanks, Steve. ", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b9fafbe5e1cf331d085dc0f4bbee0342c2e5b61075ecb936a441437e18d7140a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "db630e17-964f-4c59-9ce4-6211bd28765b", "node_type": "1", "metadata": {"window": "A \nYeah.  Thanks, Steve.  That's a good question.  I'm happy to answer that and I'm happy to clarify.  When I speak of \nnormal, what I mean by that is in any year, we typically see about a third of our US Pharmaceutical book r enew. \n As we have seen over the last few years, there have been no material impacts to that and certainly have been \nable to renew all of our customers successfully within our guidance and I would not anticipate that we would see \nanything material from our r enewal next year.  \n \n It's early, obviously. ", "original_text": "I'm happy to answer that and I'm happy to clarify. "}, "hash": "3ca91e5b7f46634905b81b512f539ff90c8b3d1cdf0f65548202cb40baff8fca", "class_name": "RelatedNodeInfo"}}, "text": "That's a good question. ", "start_char_idx": 3288, "end_char_idx": 3312, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "db630e17-964f-4c59-9ce4-6211bd28765b": {"__data__": {"id_": "db630e17-964f-4c59-9ce4-6211bd28765b", "embedding": null, "metadata": {"window": "A \nYeah.  Thanks, Steve.  That's a good question.  I'm happy to answer that and I'm happy to clarify.  When I speak of \nnormal, what I mean by that is in any year, we typically see about a third of our US Pharmaceutical book r enew. \n As we have seen over the last few years, there have been no material impacts to that and certainly have been \nable to renew all of our customers successfully within our guidance and I would not anticipate that we would see \nanything material from our r enewal next year.  \n \n It's early, obviously. ", "original_text": "I'm happy to answer that and I'm happy to clarify. ", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ceb4a5e5728ef9a64b29f8e8f1afb599589c8043147110c669a5ca8eb3c335f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "97366399-7aea-4fc4-9552-2e2b19e8658f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt Vitalone  \nChief Financial Officer & Execut ive Vice President, McKesson Corp.   A \nYeah.  Thanks, Steve.  That's a good question.  I'm happy to answer that and I'm happy to clarify.  When I speak of \nnormal, what I mean by that is in any year, we typically see about a third of our US Pharmaceutical book r enew. \n As we have seen over the last few years, there have been no material impacts to that and certainly have been \nable to renew all of our customers successfully within our guidance and I would not anticipate that we would see \nanything material from our r enewal next year.  \n \n", "original_text": "That's a good question. ", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ba805a9483d718b2c69146ec8dc58e50cb5ceeea5c3650d1a2cd2895e59beea1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "51c32790-0bde-4c62-b1c5-80a7ccf617bc", "node_type": "1", "metadata": {"window": "Thanks, Steve.  That's a good question.  I'm happy to answer that and I'm happy to clarify.  When I speak of \nnormal, what I mean by that is in any year, we typically see about a third of our US Pharmaceutical book r enew. \n As we have seen over the last few years, there have been no material impacts to that and certainly have been \nable to renew all of our customers successfully within our guidance and I would not anticipate that we would see \nanything material from our r enewal next year.  \n \n It's early, obviously.  If there's an update to that information, we'll provide it on our May earnings call. ", "original_text": "When I speak of \nnormal, what I mean by that is in any year, we typically see about a third of our US Pharmaceutical book r enew. \n"}, "hash": "efc54c57b947ffb936dea67b49ab93014ae05d78a3dc7df93142a5698c7574d7", "class_name": "RelatedNodeInfo"}}, "text": "I'm happy to answer that and I'm happy to clarify. ", "start_char_idx": 3312, "end_char_idx": 3363, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "51c32790-0bde-4c62-b1c5-80a7ccf617bc": {"__data__": {"id_": "51c32790-0bde-4c62-b1c5-80a7ccf617bc", "embedding": null, "metadata": {"window": "Thanks, Steve.  That's a good question.  I'm happy to answer that and I'm happy to clarify.  When I speak of \nnormal, what I mean by that is in any year, we typically see about a third of our US Pharmaceutical book r enew. \n As we have seen over the last few years, there have been no material impacts to that and certainly have been \nable to renew all of our customers successfully within our guidance and I would not anticipate that we would see \nanything material from our r enewal next year.  \n \n It's early, obviously.  If there's an update to that information, we'll provide it on our May earnings call. ", "original_text": "When I speak of \nnormal, what I mean by that is in any year, we typically see about a third of our US Pharmaceutical book r enew. \n", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ceb4a5e5728ef9a64b29f8e8f1afb599589c8043147110c669a5ca8eb3c335f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "db630e17-964f-4c59-9ce4-6211bd28765b", "node_type": "1", "metadata": {"window": "A \nYeah.  Thanks, Steve.  That's a good question.  I'm happy to answer that and I'm happy to clarify.  When I speak of \nnormal, what I mean by that is in any year, we typically see about a third of our US Pharmaceutical book r enew. \n As we have seen over the last few years, there have been no material impacts to that and certainly have been \nable to renew all of our customers successfully within our guidance and I would not anticipate that we would see \nanything material from our r enewal next year.  \n \n It's early, obviously. ", "original_text": "I'm happy to answer that and I'm happy to clarify. ", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "86b7bc9f52868c37f5265624b71f3e3bad0b5a12cd6e6d3a267dc4dcb862df29", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "591e4c76-d657-4c57-b617-12ff2618ac1b", "node_type": "1", "metadata": {"window": "That's a good question.  I'm happy to answer that and I'm happy to clarify.  When I speak of \nnormal, what I mean by that is in any year, we typically see about a third of our US Pharmaceutical book r enew. \n As we have seen over the last few years, there have been no material impacts to that and certainly have been \nable to renew all of our customers successfully within our guidance and I would not anticipate that we would see \nanything material from our r enewal next year.  \n \n It's early, obviously.  If there's an update to that information, we'll provide it on our May earnings call.  But normal, \nwhat I was referring to is that about a third of our book renews every year would not anticipate anything that would \nbe a material driver from that activity.  \n ", "original_text": "As we have seen over the last few years, there have been no material impacts to that and certainly have been \nable to renew all of our customers successfully within our guidance and I would not anticipate that we would see \nanything material from our r enewal next year.  \n \n"}, "hash": "6d1203c73137b6341627030cf7dbaa5909cb6098a81f0f189ffd1d08bd0c781b", "class_name": "RelatedNodeInfo"}}, "text": "When I speak of \nnormal, what I mean by that is in any year, we typically see about a third of our US Pharmaceutical book r enew. \n", "start_char_idx": 3363, "end_char_idx": 3494, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "591e4c76-d657-4c57-b617-12ff2618ac1b": {"__data__": {"id_": "591e4c76-d657-4c57-b617-12ff2618ac1b", "embedding": null, "metadata": {"window": "That's a good question.  I'm happy to answer that and I'm happy to clarify.  When I speak of \nnormal, what I mean by that is in any year, we typically see about a third of our US Pharmaceutical book r enew. \n As we have seen over the last few years, there have been no material impacts to that and certainly have been \nable to renew all of our customers successfully within our guidance and I would not anticipate that we would see \nanything material from our r enewal next year.  \n \n It's early, obviously.  If there's an update to that information, we'll provide it on our May earnings call.  But normal, \nwhat I was referring to is that about a third of our book renews every year would not anticipate anything that would \nbe a material driver from that activity.  \n ", "original_text": "As we have seen over the last few years, there have been no material impacts to that and certainly have been \nable to renew all of our customers successfully within our guidance and I would not anticipate that we would see \nanything material from our r enewal next year.  \n \n", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ceb4a5e5728ef9a64b29f8e8f1afb599589c8043147110c669a5ca8eb3c335f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "51c32790-0bde-4c62-b1c5-80a7ccf617bc", "node_type": "1", "metadata": {"window": "Thanks, Steve.  That's a good question.  I'm happy to answer that and I'm happy to clarify.  When I speak of \nnormal, what I mean by that is in any year, we typically see about a third of our US Pharmaceutical book r enew. \n As we have seen over the last few years, there have been no material impacts to that and certainly have been \nable to renew all of our customers successfully within our guidance and I would not anticipate that we would see \nanything material from our r enewal next year.  \n \n It's early, obviously.  If there's an update to that information, we'll provide it on our May earnings call. ", "original_text": "When I speak of \nnormal, what I mean by that is in any year, we typically see about a third of our US Pharmaceutical book r enew. \n", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "376ab855a6549fa3c015d32df5420e9104f6b684bfd6fd5dd77756225160fb63", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b577c23d-ecea-47c3-882e-923818852b28", "node_type": "1", "metadata": {"window": "I'm happy to answer that and I'm happy to clarify.  When I speak of \nnormal, what I mean by that is in any year, we typically see about a third of our US Pharmaceutical book r enew. \n As we have seen over the last few years, there have been no material impacts to that and certainly have been \nable to renew all of our customers successfully within our guidance and I would not anticipate that we would see \nanything material from our r enewal next year.  \n \n It's early, obviously.  If there's an update to that information, we'll provide it on our May earnings call.  But normal, \nwhat I was referring to is that about a third of our book renews every year would not anticipate anything that would \nbe a material driver from that activity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "It's early, obviously. "}, "hash": "74cd945c69e40c8261ccf3d968be6df827d6a95c72099e196441e19449329ea3", "class_name": "RelatedNodeInfo"}}, "text": "As we have seen over the last few years, there have been no material impacts to that and certainly have been \nable to renew all of our customers successfully within our guidance and I would not anticipate that we would see \nanything material from our r enewal next year.  \n \n", "start_char_idx": 3494, "end_char_idx": 3769, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b577c23d-ecea-47c3-882e-923818852b28": {"__data__": {"id_": "b577c23d-ecea-47c3-882e-923818852b28", "embedding": null, "metadata": {"window": "I'm happy to answer that and I'm happy to clarify.  When I speak of \nnormal, what I mean by that is in any year, we typically see about a third of our US Pharmaceutical book r enew. \n As we have seen over the last few years, there have been no material impacts to that and certainly have been \nable to renew all of our customers successfully within our guidance and I would not anticipate that we would see \nanything material from our r enewal next year.  \n \n It's early, obviously.  If there's an update to that information, we'll provide it on our May earnings call.  But normal, \nwhat I was referring to is that about a third of our book renews every year would not anticipate anything that would \nbe a material driver from that activity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "It's early, obviously. ", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ceb4a5e5728ef9a64b29f8e8f1afb599589c8043147110c669a5ca8eb3c335f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "591e4c76-d657-4c57-b617-12ff2618ac1b", "node_type": "1", "metadata": {"window": "That's a good question.  I'm happy to answer that and I'm happy to clarify.  When I speak of \nnormal, what I mean by that is in any year, we typically see about a third of our US Pharmaceutical book r enew. \n As we have seen over the last few years, there have been no material impacts to that and certainly have been \nable to renew all of our customers successfully within our guidance and I would not anticipate that we would see \nanything material from our r enewal next year.  \n \n It's early, obviously.  If there's an update to that information, we'll provide it on our May earnings call.  But normal, \nwhat I was referring to is that about a third of our book renews every year would not anticipate anything that would \nbe a material driver from that activity.  \n ", "original_text": "As we have seen over the last few years, there have been no material impacts to that and certainly have been \nable to renew all of our customers successfully within our guidance and I would not anticipate that we would see \nanything material from our r enewal next year.  \n \n", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "81c1fdebde2bb2dde41f01f3c6a53cab825f7850f565532e498d083fe85c99fc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e47dd07a-ed80-4198-b567-3bc998f2eec0", "node_type": "1", "metadata": {"window": "When I speak of \nnormal, what I mean by that is in any year, we typically see about a third of our US Pharmaceutical book r enew. \n As we have seen over the last few years, there have been no material impacts to that and certainly have been \nable to renew all of our customers successfully within our guidance and I would not anticipate that we would see \nanything material from our r enewal next year.  \n \n It's early, obviously.  If there's an update to that information, we'll provide it on our May earnings call.  But normal, \nwhat I was referring to is that about a third of our book renews every year would not anticipate anything that would \nbe a material driver from that activity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Great. ", "original_text": "If there's an update to that information, we'll provide it on our May earnings call. "}, "hash": "89a5a083b7923e379ce201c41ca1d93693640dab7467f695e4e9e5745d5513e3", "class_name": "RelatedNodeInfo"}}, "text": "It's early, obviously. ", "start_char_idx": 3769, "end_char_idx": 3792, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e47dd07a-ed80-4198-b567-3bc998f2eec0": {"__data__": {"id_": "e47dd07a-ed80-4198-b567-3bc998f2eec0", "embedding": null, "metadata": {"window": "When I speak of \nnormal, what I mean by that is in any year, we typically see about a third of our US Pharmaceutical book r enew. \n As we have seen over the last few years, there have been no material impacts to that and certainly have been \nable to renew all of our customers successfully within our guidance and I would not anticipate that we would see \nanything material from our r enewal next year.  \n \n It's early, obviously.  If there's an update to that information, we'll provide it on our May earnings call.  But normal, \nwhat I was referring to is that about a third of our book renews every year would not anticipate anything that would \nbe a material driver from that activity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Great. ", "original_text": "If there's an update to that information, we'll provide it on our May earnings call. ", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ceb4a5e5728ef9a64b29f8e8f1afb599589c8043147110c669a5ca8eb3c335f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b577c23d-ecea-47c3-882e-923818852b28", "node_type": "1", "metadata": {"window": "I'm happy to answer that and I'm happy to clarify.  When I speak of \nnormal, what I mean by that is in any year, we typically see about a third of our US Pharmaceutical book r enew. \n As we have seen over the last few years, there have been no material impacts to that and certainly have been \nable to renew all of our customers successfully within our guidance and I would not anticipate that we would see \nanything material from our r enewal next year.  \n \n It's early, obviously.  If there's an update to that information, we'll provide it on our May earnings call.  But normal, \nwhat I was referring to is that about a third of our book renews every year would not anticipate anything that would \nbe a material driver from that activity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "It's early, obviously. ", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1a54cb3e114bd022377fefc6374bd182bd4853d21ede800356ca350a2d6e8ac2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b08d32f5-b8bf-4279-bd5c-40f4ff2b1275", "node_type": "1", "metadata": {"window": "As we have seen over the last few years, there have been no material impacts to that and certainly have been \nable to renew all of our customers successfully within our guidance and I would not anticipate that we would see \nanything material from our r enewal next year.  \n \n It's early, obviously.  If there's an update to that information, we'll provide it on our May earnings call.  But normal, \nwhat I was referring to is that about a third of our book renews every year would not anticipate anything that would \nbe a material driver from that activity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Great.  Well, thanks again, everyone, for joining us on this call, and thank you for the insightful and very thoughtful \nquestions. ", "original_text": "But normal, \nwhat I was referring to is that about a third of our book renews every year would not anticipate anything that would \nbe a material driver from that activity.  \n "}, "hash": "7ec637225362f351f7d54b4a74e643b3cc6d9b4a4a5ed8630dd496d575db8f58", "class_name": "RelatedNodeInfo"}}, "text": "If there's an update to that information, we'll provide it on our May earnings call. ", "start_char_idx": 3792, "end_char_idx": 3877, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b08d32f5-b8bf-4279-bd5c-40f4ff2b1275": {"__data__": {"id_": "b08d32f5-b8bf-4279-bd5c-40f4ff2b1275", "embedding": null, "metadata": {"window": "As we have seen over the last few years, there have been no material impacts to that and certainly have been \nable to renew all of our customers successfully within our guidance and I would not anticipate that we would see \nanything material from our r enewal next year.  \n \n It's early, obviously.  If there's an update to that information, we'll provide it on our May earnings call.  But normal, \nwhat I was referring to is that about a third of our book renews every year would not anticipate anything that would \nbe a material driver from that activity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Great.  Well, thanks again, everyone, for joining us on this call, and thank you for the insightful and very thoughtful \nquestions. ", "original_text": "But normal, \nwhat I was referring to is that about a third of our book renews every year would not anticipate anything that would \nbe a material driver from that activity.  \n ", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ceb4a5e5728ef9a64b29f8e8f1afb599589c8043147110c669a5ca8eb3c335f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e47dd07a-ed80-4198-b567-3bc998f2eec0", "node_type": "1", "metadata": {"window": "When I speak of \nnormal, what I mean by that is in any year, we typically see about a third of our US Pharmaceutical book r enew. \n As we have seen over the last few years, there have been no material impacts to that and certainly have been \nable to renew all of our customers successfully within our guidance and I would not anticipate that we would see \nanything material from our r enewal next year.  \n \n It's early, obviously.  If there's an update to that information, we'll provide it on our May earnings call.  But normal, \nwhat I was referring to is that about a third of our book renews every year would not anticipate anything that would \nbe a material driver from that activity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Great. ", "original_text": "If there's an update to that information, we'll provide it on our May earnings call. ", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e0e4e1f7f954395fdb502eb129084d7f4015de21c44aba15be0379b7f50452f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cc382ac9-14e0-415c-a743-576be6449dcc", "node_type": "1", "metadata": {"window": "It's early, obviously.  If there's an update to that information, we'll provide it on our May earnings call.  But normal, \nwhat I was referring to is that about a third of our book renews every year would not anticipate anything that would \nbe a material driver from that activity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Great.  Well, thanks again, everyone, for joining us on this call, and thank you for the insightful and very thoughtful \nquestions.  Keith, thank you  for help facilitating the call.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n"}, "hash": "17b6b97675f73b122bea5461d95b34879c73eaee6d38c1419f2c9c3fd778bc5a", "class_name": "RelatedNodeInfo"}}, "text": "But normal, \nwhat I was referring to is that about a third of our book renews every year would not anticipate anything that would \nbe a material driver from that activity.  \n ", "start_char_idx": 3877, "end_char_idx": 4052, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc382ac9-14e0-415c-a743-576be6449dcc": {"__data__": {"id_": "cc382ac9-14e0-415c-a743-576be6449dcc", "embedding": null, "metadata": {"window": "It's early, obviously.  If there's an update to that information, we'll provide it on our May earnings call.  But normal, \nwhat I was referring to is that about a third of our book renews every year would not anticipate anything that would \nbe a material driver from that activity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Great.  Well, thanks again, everyone, for joining us on this call, and thank you for the insightful and very thoughtful \nquestions.  Keith, thank you  for help facilitating the call.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ceb4a5e5728ef9a64b29f8e8f1afb599589c8043147110c669a5ca8eb3c335f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b08d32f5-b8bf-4279-bd5c-40f4ff2b1275", "node_type": "1", "metadata": {"window": "As we have seen over the last few years, there have been no material impacts to that and certainly have been \nable to renew all of our customers successfully within our guidance and I would not anticipate that we would see \nanything material from our r enewal next year.  \n \n It's early, obviously.  If there's an update to that information, we'll provide it on our May earnings call.  But normal, \nwhat I was referring to is that about a third of our book renews every year would not anticipate anything that would \nbe a material driver from that activity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Great.  Well, thanks again, everyone, for joining us on this call, and thank you for the insightful and very thoughtful \nquestions. ", "original_text": "But normal, \nwhat I was referring to is that about a third of our book renews every year would not anticipate anything that would \nbe a material driver from that activity.  \n ", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b3f7aa4b9e040cf6ab035745a42316687d176314285470375ab372379dc830fe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1684688b-2f28-44fa-8dfd-64c01478b49f", "node_type": "1", "metadata": {"window": "If there's an update to that information, we'll provide it on our May earnings call.  But normal, \nwhat I was referring to is that about a third of our book renews every year would not anticipate anything that would \nbe a material driver from that activity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Great.  Well, thanks again, everyone, for joining us on this call, and thank you for the insightful and very thoughtful \nquestions.  Keith, thank you  for help facilitating the call.  \n \n I want to just conclude by reiterating McKesson executed really well in the third quarter with double -digit adjusted \noperating profit growth in all segments. ", "original_text": "Great. "}, "hash": "04c5606f9c94b73ca08ae26f0bd4077248daaada9c80fc6b5d1401aacaf44da9", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "start_char_idx": 4052, "end_char_idx": 4394, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1684688b-2f28-44fa-8dfd-64c01478b49f": {"__data__": {"id_": "1684688b-2f28-44fa-8dfd-64c01478b49f", "embedding": null, "metadata": {"window": "If there's an update to that information, we'll provide it on our May earnings call.  But normal, \nwhat I was referring to is that about a third of our book renews every year would not anticipate anything that would \nbe a material driver from that activity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Great.  Well, thanks again, everyone, for joining us on this call, and thank you for the insightful and very thoughtful \nquestions.  Keith, thank you  for help facilitating the call.  \n \n I want to just conclude by reiterating McKesson executed really well in the third quarter with double -digit adjusted \noperating profit growth in all segments. ", "original_text": "Great. ", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ceb4a5e5728ef9a64b29f8e8f1afb599589c8043147110c669a5ca8eb3c335f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc382ac9-14e0-415c-a743-576be6449dcc", "node_type": "1", "metadata": {"window": "It's early, obviously.  If there's an update to that information, we'll provide it on our May earnings call.  But normal, \nwhat I was referring to is that about a third of our book renews every year would not anticipate anything that would \nbe a material driver from that activity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Great.  Well, thanks again, everyone, for joining us on this call, and thank you for the insightful and very thoughtful \nquestions.  Keith, thank you  for help facilitating the call.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "82e27404d907aa8921e03c6437253d06a47d99a8ef6a9e7e45020f68bacd8258", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c9f01e8d-6cc4-45ac-9ed1-ffbeed42bae9", "node_type": "1", "metadata": {"window": "But normal, \nwhat I was referring to is that about a third of our book renews every year would not anticipate anything that would \nbe a material driver from that activity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Great.  Well, thanks again, everyone, for joining us on this call, and thank you for the insightful and very thoughtful \nquestions.  Keith, thank you  for help facilitating the call.  \n \n I want to just conclude by reiterating McKesson executed really well in the third quarter with double -digit adjusted \noperating profit growth in all segments.  I continue to be excited about the focus on our company prioriti es and the ", "original_text": "Well, thanks again, everyone, for joining us on this call, and thank you for the insightful and very thoughtful \nquestions. "}, "hash": "26a6934bed0d1bd3a24b0a62b908cdefedebafa7da46e72d7aba678636a74247", "class_name": "RelatedNodeInfo"}}, "text": "Great. ", "start_char_idx": 4394, "end_char_idx": 4401, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c9f01e8d-6cc4-45ac-9ed1-ffbeed42bae9": {"__data__": {"id_": "c9f01e8d-6cc4-45ac-9ed1-ffbeed42bae9", "embedding": null, "metadata": {"window": "But normal, \nwhat I was referring to is that about a third of our book renews every year would not anticipate anything that would \nbe a material driver from that activity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Great.  Well, thanks again, everyone, for joining us on this call, and thank you for the insightful and very thoughtful \nquestions.  Keith, thank you  for help facilitating the call.  \n \n I want to just conclude by reiterating McKesson executed really well in the third quarter with double -digit adjusted \noperating profit growth in all segments.  I continue to be excited about the focus on our company prioriti es and the ", "original_text": "Well, thanks again, everyone, for joining us on this call, and thank you for the insightful and very thoughtful \nquestions. ", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ceb4a5e5728ef9a64b29f8e8f1afb599589c8043147110c669a5ca8eb3c335f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1684688b-2f28-44fa-8dfd-64c01478b49f", "node_type": "1", "metadata": {"window": "If there's an update to that information, we'll provide it on our May earnings call.  But normal, \nwhat I was referring to is that about a third of our book renews every year would not anticipate anything that would \nbe a material driver from that activity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Great.  Well, thanks again, everyone, for joining us on this call, and thank you for the insightful and very thoughtful \nquestions.  Keith, thank you  for help facilitating the call.  \n \n I want to just conclude by reiterating McKesson executed really well in the third quarter with double -digit adjusted \noperating profit growth in all segments. ", "original_text": "Great. ", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "98d37dc7ddf80a102163bb4851f632f7911f7e429bda5ce9a11adaf4acbc23b4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a48c7dff-f249-47d4-8cb7-6bd6a680347b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Great.  Well, thanks again, everyone, for joining us on this call, and thank you for the insightful and very thoughtful \nquestions.  Keith, thank you  for help facilitating the call.  \n \n I want to just conclude by reiterating McKesson executed really well in the third quarter with double -digit adjusted \noperating profit growth in all segments.  I continue to be excited about the focus on our company prioriti es and the ", "original_text": "Keith, thank you  for help facilitating the call.  \n \n"}, "hash": "7c8b6b3d54db87041a202495e9e31ffa2a37d5d25b2c786693cca01121598527", "class_name": "RelatedNodeInfo"}}, "text": "Well, thanks again, everyone, for joining us on this call, and thank you for the insightful and very thoughtful \nquestions. ", "start_char_idx": 4401, "end_char_idx": 4525, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a48c7dff-f249-47d4-8cb7-6bd6a680347b": {"__data__": {"id_": "a48c7dff-f249-47d4-8cb7-6bd6a680347b", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Great.  Well, thanks again, everyone, for joining us on this call, and thank you for the insightful and very thoughtful \nquestions.  Keith, thank you  for help facilitating the call.  \n \n I want to just conclude by reiterating McKesson executed really well in the third quarter with double -digit adjusted \noperating profit growth in all segments.  I continue to be excited about the focus on our company prioriti es and the ", "original_text": "Keith, thank you  for help facilitating the call.  \n \n", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ceb4a5e5728ef9a64b29f8e8f1afb599589c8043147110c669a5ca8eb3c335f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c9f01e8d-6cc4-45ac-9ed1-ffbeed42bae9", "node_type": "1", "metadata": {"window": "But normal, \nwhat I was referring to is that about a third of our book renews every year would not anticipate anything that would \nbe a material driver from that activity.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Great.  Well, thanks again, everyone, for joining us on this call, and thank you for the insightful and very thoughtful \nquestions.  Keith, thank you  for help facilitating the call.  \n \n I want to just conclude by reiterating McKesson executed really well in the third quarter with double -digit adjusted \noperating profit growth in all segments.  I continue to be excited about the focus on our company prioriti es and the ", "original_text": "Well, thanks again, everyone, for joining us on this call, and thank you for the insightful and very thoughtful \nquestions. ", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6adcc761bfa9d1f910899fd02e7eba2251ef93b09c8c2b593f8b6afb9898a458", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3595e7cf-d999-47f5-b7c3-2437cfe3d36d", "node_type": "1", "metadata": {"window": "Great.  Well, thanks again, everyone, for joining us on this call, and thank you for the insightful and very thoughtful \nquestions.  Keith, thank you  for help facilitating the call.  \n \n I want to just conclude by reiterating McKesson executed really well in the third quarter with double -digit adjusted \noperating profit growth in all segments.  I continue to be excited about the focus on our company prioriti es and the ", "original_text": "I want to just conclude by reiterating McKesson executed really well in the third quarter with double -digit adjusted \noperating profit growth in all segments. "}, "hash": "e844433cb32f5994292895f55c60df07b97357a6c63e2f40c0cf23125b1e28e4", "class_name": "RelatedNodeInfo"}}, "text": "Keith, thank you  for help facilitating the call.  \n \n", "start_char_idx": 4525, "end_char_idx": 4579, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3595e7cf-d999-47f5-b7c3-2437cfe3d36d": {"__data__": {"id_": "3595e7cf-d999-47f5-b7c3-2437cfe3d36d", "embedding": null, "metadata": {"window": "Great.  Well, thanks again, everyone, for joining us on this call, and thank you for the insightful and very thoughtful \nquestions.  Keith, thank you  for help facilitating the call.  \n \n I want to just conclude by reiterating McKesson executed really well in the third quarter with double -digit adjusted \noperating profit growth in all segments.  I continue to be excited about the focus on our company prioriti es and the ", "original_text": "I want to just conclude by reiterating McKesson executed really well in the third quarter with double -digit adjusted \noperating profit growth in all segments. ", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ceb4a5e5728ef9a64b29f8e8f1afb599589c8043147110c669a5ca8eb3c335f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a48c7dff-f249-47d4-8cb7-6bd6a680347b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Great.  Well, thanks again, everyone, for joining us on this call, and thank you for the insightful and very thoughtful \nquestions.  Keith, thank you  for help facilitating the call.  \n \n I want to just conclude by reiterating McKesson executed really well in the third quarter with double -digit adjusted \noperating profit growth in all segments.  I continue to be excited about the focus on our company prioriti es and the ", "original_text": "Keith, thank you  for help facilitating the call.  \n \n", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3ff1e1d41e8b8c16ad4ac64c2b1d784a2a70efe32224906cb51ac1ba12297362", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "089e3374-ff99-4caa-9ce6-5f9d6dc360e2", "node_type": "1", "metadata": {"window": "Well, thanks again, everyone, for joining us on this call, and thank you for the insightful and very thoughtful \nquestions.  Keith, thank you  for help facilitating the call.  \n \n I want to just conclude by reiterating McKesson executed really well in the third quarter with double -digit adjusted \noperating profit growth in all segments.  I continue to be excited about the focus on our company prioriti es and the ", "original_text": "I continue to be excited about the focus on our company prioriti es and the "}, "hash": "1bc8bcd714f685ea0285e4dc3f996abf54ae4c4dff50c03b42f1ba01ca5c11da", "class_name": "RelatedNodeInfo"}}, "text": "I want to just conclude by reiterating McKesson executed really well in the third quarter with double -digit adjusted \noperating profit growth in all segments. ", "start_char_idx": 4579, "end_char_idx": 4739, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "089e3374-ff99-4caa-9ce6-5f9d6dc360e2": {"__data__": {"id_": "089e3374-ff99-4caa-9ce6-5f9d6dc360e2", "embedding": null, "metadata": {"window": "Well, thanks again, everyone, for joining us on this call, and thank you for the insightful and very thoughtful \nquestions.  Keith, thank you  for help facilitating the call.  \n \n I want to just conclude by reiterating McKesson executed really well in the third quarter with double -digit adjusted \noperating profit growth in all segments.  I continue to be excited about the focus on our company prioriti es and the ", "original_text": "I continue to be excited about the focus on our company prioriti es and the ", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ceb4a5e5728ef9a64b29f8e8f1afb599589c8043147110c669a5ca8eb3c335f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3595e7cf-d999-47f5-b7c3-2437cfe3d36d", "node_type": "1", "metadata": {"window": "Great.  Well, thanks again, everyone, for joining us on this call, and thank you for the insightful and very thoughtful \nquestions.  Keith, thank you  for help facilitating the call.  \n \n I want to just conclude by reiterating McKesson executed really well in the third quarter with double -digit adjusted \noperating profit growth in all segments.  I continue to be excited about the focus on our company prioriti es and the ", "original_text": "I want to just conclude by reiterating McKesson executed really well in the third quarter with double -digit adjusted \noperating profit growth in all segments. ", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7c76b22fe5f34012b7d6c29a05ec9cc049c81a9404bb10915d58314d52b082e6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3e1d76b2-cacd-4b52-9fd9-1e6656a2eac0", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ncontributions we can see that making the strong financial results.  It's really the driver between \u2013 the driver of our \nshareholder value creation.  \n \n So, none of that happens without the team that makes up McKesson. ", "original_text": "McKesson Corp.  "}, "hash": "89e9a9ec77cd8bb0e41d89836c2ef0db5adae7d940c7d3c4c65eaf782e0d258f", "class_name": "RelatedNodeInfo"}}, "text": "I continue to be excited about the focus on our company prioriti es and the ", "start_char_idx": 4739, "end_char_idx": 4815, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3e1d76b2-cacd-4b52-9fd9-1e6656a2eac0": {"__data__": {"id_": "3e1d76b2-cacd-4b52-9fd9-1e6656a2eac0", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ncontributions we can see that making the strong financial results.  It's really the driver between \u2013 the driver of our \nshareholder value creation.  \n \n So, none of that happens without the team that makes up McKesson. ", "original_text": "McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b649837-3c05-4710-82a2-37e772b6efc5", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c5f7987dceb5d2699c41989a020c4189394c6ba073525458708e7025a782b8c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "089e3374-ff99-4caa-9ce6-5f9d6dc360e2", "node_type": "1", "metadata": {"window": "Well, thanks again, everyone, for joining us on this call, and thank you for the insightful and very thoughtful \nquestions.  Keith, thank you  for help facilitating the call.  \n \n I want to just conclude by reiterating McKesson executed really well in the third quarter with double -digit adjusted \noperating profit growth in all segments.  I continue to be excited about the focus on our company prioriti es and the ", "original_text": "I continue to be excited about the focus on our company prioriti es and the ", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "410b5d90579f12b9c1f6513be5debce4531bb951c783bd5f29e54b40f7f2f907", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1cf60df4-19eb-45a8-8ed1-c2a84a21871b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ncontributions we can see that making the strong financial results.  It's really the driver between \u2013 the driver of our \nshareholder value creation.  \n \n So, none of that happens without the team that makes up McKesson.  And so, to everyone in McKesson,  no \nmatter what your role, no matter what geography you work in, whether you're on the frontline or elsewhere in the \nbusiness, I'm so appreciative of their hard work, their dedication to our purpose and our mission, their \ncommitment to our customers. ", "original_text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ncontributions we can see that making the strong financial results. "}, "hash": "ef6ba8779cb0f652021221a5525a3f919759c3a5722b804642b9e32a11b0e2bd", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1cf60df4-19eb-45a8-8ed1-c2a84a21871b": {"__data__": {"id_": "1cf60df4-19eb-45a8-8ed1-c2a84a21871b", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ncontributions we can see that making the strong financial results.  It's really the driver between \u2013 the driver of our \nshareholder value creation.  \n \n So, none of that happens without the team that makes up McKesson.  And so, to everyone in McKesson,  no \nmatter what your role, no matter what geography you work in, whether you're on the frontline or elsewhere in the \nbusiness, I'm so appreciative of their hard work, their dedication to our purpose and our mission, their \ncommitment to our customers. ", "original_text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ncontributions we can see that making the strong financial results. ", "page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b649837-3c05-4710-82a2-37e772b6efc5", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c5f7987dceb5d2699c41989a020c4189394c6ba073525458708e7025a782b8c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3e1d76b2-cacd-4b52-9fd9-1e6656a2eac0", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ncontributions we can see that making the strong financial results.  It's really the driver between \u2013 the driver of our \nshareholder value creation.  \n \n So, none of that happens without the team that makes up McKesson. ", "original_text": "McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "40e3a64f2b9ba7bfa1484405317690080aad78da14b01205e341d0de4a250a1f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f4ffe36e-0443-4072-a88b-8884caa1939e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ncontributions we can see that making the strong financial results.  It's really the driver between \u2013 the driver of our \nshareholder value creation.  \n \n So, none of that happens without the team that makes up McKesson.  And so, to everyone in McKesson,  no \nmatter what your role, no matter what geography you work in, whether you're on the frontline or elsewhere in the \nbusiness, I'm so appreciative of their hard work, their dedication to our purpose and our mission, their \ncommitment to our customers.  They really are what makes this a special place. ", "original_text": "It's really the driver between \u2013 the driver of our \nshareholder value creation.  \n \n"}, "hash": "2d2ca15d361f39ae42b99d3a27896af895a45157812673fb5372449b66f535dd", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ncontributions we can see that making the strong financial results. ", "start_char_idx": 16, "end_char_idx": 248, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f4ffe36e-0443-4072-a88b-8884caa1939e": {"__data__": {"id_": "f4ffe36e-0443-4072-a88b-8884caa1939e", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ncontributions we can see that making the strong financial results.  It's really the driver between \u2013 the driver of our \nshareholder value creation.  \n \n So, none of that happens without the team that makes up McKesson.  And so, to everyone in McKesson,  no \nmatter what your role, no matter what geography you work in, whether you're on the frontline or elsewhere in the \nbusiness, I'm so appreciative of their hard work, their dedication to our purpose and our mission, their \ncommitment to our customers.  They really are what makes this a special place. ", "original_text": "It's really the driver between \u2013 the driver of our \nshareholder value creation.  \n \n", "page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b649837-3c05-4710-82a2-37e772b6efc5", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c5f7987dceb5d2699c41989a020c4189394c6ba073525458708e7025a782b8c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1cf60df4-19eb-45a8-8ed1-c2a84a21871b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ncontributions we can see that making the strong financial results.  It's really the driver between \u2013 the driver of our \nshareholder value creation.  \n \n So, none of that happens without the team that makes up McKesson.  And so, to everyone in McKesson,  no \nmatter what your role, no matter what geography you work in, whether you're on the frontline or elsewhere in the \nbusiness, I'm so appreciative of their hard work, their dedication to our purpose and our mission, their \ncommitment to our customers. ", "original_text": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ncontributions we can see that making the strong financial results. ", "page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5e557e66c9922e8f7512f9cdd08efb95ce88726f36e6b04cc4b6c1b21205caea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "587e5860-5d33-4952-9128-ebf2a5cb6d03", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ncontributions we can see that making the strong financial results.  It's really the driver between \u2013 the driver of our \nshareholder value creation.  \n \n So, none of that happens without the team that makes up McKesson.  And so, to everyone in McKesson,  no \nmatter what your role, no matter what geography you work in, whether you're on the frontline or elsewhere in the \nbusiness, I'm so appreciative of their hard work, their dedication to our purpose and our mission, their \ncommitment to our customers.  They really are what makes this a special place.  So, thanks for them.  \n \n", "original_text": "So, none of that happens without the team that makes up McKesson. "}, "hash": "30d9fbb06d0596262ac7574c85903996b837c1e2976daed526ad2a22c173e937", "class_name": "RelatedNodeInfo"}}, "text": "It's really the driver between \u2013 the driver of our \nshareholder value creation.  \n \n", "start_char_idx": 248, "end_char_idx": 332, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "587e5860-5d33-4952-9128-ebf2a5cb6d03": {"__data__": {"id_": "587e5860-5d33-4952-9128-ebf2a5cb6d03", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ncontributions we can see that making the strong financial results.  It's really the driver between \u2013 the driver of our \nshareholder value creation.  \n \n So, none of that happens without the team that makes up McKesson.  And so, to everyone in McKesson,  no \nmatter what your role, no matter what geography you work in, whether you're on the frontline or elsewhere in the \nbusiness, I'm so appreciative of their hard work, their dedication to our purpose and our mission, their \ncommitment to our customers.  They really are what makes this a special place.  So, thanks for them.  \n \n", "original_text": "So, none of that happens without the team that makes up McKesson. ", "page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b649837-3c05-4710-82a2-37e772b6efc5", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c5f7987dceb5d2699c41989a020c4189394c6ba073525458708e7025a782b8c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f4ffe36e-0443-4072-a88b-8884caa1939e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ncontributions we can see that making the strong financial results.  It's really the driver between \u2013 the driver of our \nshareholder value creation.  \n \n So, none of that happens without the team that makes up McKesson.  And so, to everyone in McKesson,  no \nmatter what your role, no matter what geography you work in, whether you're on the frontline or elsewhere in the \nbusiness, I'm so appreciative of their hard work, their dedication to our purpose and our mission, their \ncommitment to our customers.  They really are what makes this a special place. ", "original_text": "It's really the driver between \u2013 the driver of our \nshareholder value creation.  \n \n", "page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e5cd1ccd0bef05b1d40a0d89190ffa86daafef57eb701a9e818c1d3c0f66edad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "acca44ba-0c49-4628-9cfa-2f56c3e3fe50", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ncontributions we can see that making the strong financial results.  It's really the driver between \u2013 the driver of our \nshareholder value creation.  \n \n So, none of that happens without the team that makes up McKesson.  And so, to everyone in McKesson,  no \nmatter what your role, no matter what geography you work in, whether you're on the frontline or elsewhere in the \nbusiness, I'm so appreciative of their hard work, their dedication to our purpose and our mission, their \ncommitment to our customers.  They really are what makes this a special place.  So, thanks for them.  \n \n Again, thank you, everyone. ", "original_text": "And so, to everyone in McKesson,  no \nmatter what your role, no matter what geography you work in, whether you're on the frontline or elsewhere in the \nbusiness, I'm so appreciative of their hard work, their dedication to our purpose and our mission, their \ncommitment to our customers. "}, "hash": "7a38e790e8c6214527762025f529b17f1f546c3b67323673369b54f97f297216", "class_name": "RelatedNodeInfo"}}, "text": "So, none of that happens without the team that makes up McKesson. ", "start_char_idx": 332, "end_char_idx": 398, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "acca44ba-0c49-4628-9cfa-2f56c3e3fe50": {"__data__": {"id_": "acca44ba-0c49-4628-9cfa-2f56c3e3fe50", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ncontributions we can see that making the strong financial results.  It's really the driver between \u2013 the driver of our \nshareholder value creation.  \n \n So, none of that happens without the team that makes up McKesson.  And so, to everyone in McKesson,  no \nmatter what your role, no matter what geography you work in, whether you're on the frontline or elsewhere in the \nbusiness, I'm so appreciative of their hard work, their dedication to our purpose and our mission, their \ncommitment to our customers.  They really are what makes this a special place.  So, thanks for them.  \n \n Again, thank you, everyone. ", "original_text": "And so, to everyone in McKesson,  no \nmatter what your role, no matter what geography you work in, whether you're on the frontline or elsewhere in the \nbusiness, I'm so appreciative of their hard work, their dedication to our purpose and our mission, their \ncommitment to our customers. ", "page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b649837-3c05-4710-82a2-37e772b6efc5", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c5f7987dceb5d2699c41989a020c4189394c6ba073525458708e7025a782b8c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "587e5860-5d33-4952-9128-ebf2a5cb6d03", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ncontributions we can see that making the strong financial results.  It's really the driver between \u2013 the driver of our \nshareholder value creation.  \n \n So, none of that happens without the team that makes up McKesson.  And so, to everyone in McKesson,  no \nmatter what your role, no matter what geography you work in, whether you're on the frontline or elsewhere in the \nbusiness, I'm so appreciative of their hard work, their dedication to our purpose and our mission, their \ncommitment to our customers.  They really are what makes this a special place.  So, thanks for them.  \n \n", "original_text": "So, none of that happens without the team that makes up McKesson. ", "page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "438178de1a8b8db64a843c83550942ef1603ae300efa5921a795da9f1d4d83c0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1d0dd021-31ed-44fc-a2a9-a2df5c977a49", "node_type": "1", "metadata": {"window": "It's really the driver between \u2013 the driver of our \nshareholder value creation.  \n \n So, none of that happens without the team that makes up McKesson.  And so, to everyone in McKesson,  no \nmatter what your role, no matter what geography you work in, whether you're on the frontline or elsewhere in the \nbusiness, I'm so appreciative of their hard work, their dedication to our purpose and our mission, their \ncommitment to our customers.  They really are what makes this a special place.  So, thanks for them.  \n \n Again, thank you, everyone.  I hope you have a terrific evening. ", "original_text": "They really are what makes this a special place. "}, "hash": "906bb598fab49335f74be117181e1435bb83aaf2a2cda698f6eb1874b8912961", "class_name": "RelatedNodeInfo"}}, "text": "And so, to everyone in McKesson,  no \nmatter what your role, no matter what geography you work in, whether you're on the frontline or elsewhere in the \nbusiness, I'm so appreciative of their hard work, their dedication to our purpose and our mission, their \ncommitment to our customers. ", "start_char_idx": 398, "end_char_idx": 685, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1d0dd021-31ed-44fc-a2a9-a2df5c977a49": {"__data__": {"id_": "1d0dd021-31ed-44fc-a2a9-a2df5c977a49", "embedding": null, "metadata": {"window": "It's really the driver between \u2013 the driver of our \nshareholder value creation.  \n \n So, none of that happens without the team that makes up McKesson.  And so, to everyone in McKesson,  no \nmatter what your role, no matter what geography you work in, whether you're on the frontline or elsewhere in the \nbusiness, I'm so appreciative of their hard work, their dedication to our purpose and our mission, their \ncommitment to our customers.  They really are what makes this a special place.  So, thanks for them.  \n \n Again, thank you, everyone.  I hope you have a terrific evening. ", "original_text": "They really are what makes this a special place. ", "page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b649837-3c05-4710-82a2-37e772b6efc5", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c5f7987dceb5d2699c41989a020c4189394c6ba073525458708e7025a782b8c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "acca44ba-0c49-4628-9cfa-2f56c3e3fe50", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ncontributions we can see that making the strong financial results.  It's really the driver between \u2013 the driver of our \nshareholder value creation.  \n \n So, none of that happens without the team that makes up McKesson.  And so, to everyone in McKesson,  no \nmatter what your role, no matter what geography you work in, whether you're on the frontline or elsewhere in the \nbusiness, I'm so appreciative of their hard work, their dedication to our purpose and our mission, their \ncommitment to our customers.  They really are what makes this a special place.  So, thanks for them.  \n \n Again, thank you, everyone. ", "original_text": "And so, to everyone in McKesson,  no \nmatter what your role, no matter what geography you work in, whether you're on the frontline or elsewhere in the \nbusiness, I'm so appreciative of their hard work, their dedication to our purpose and our mission, their \ncommitment to our customers. ", "page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "627aa80bd6b2a4604a31554bb29a3f9f94debc91a5f7182c171eb2430106f866", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "99c55606-ace2-48a7-82bd-9e57d689197c", "node_type": "1", "metadata": {"window": "So, none of that happens without the team that makes up McKesson.  And so, to everyone in McKesson,  no \nmatter what your role, no matter what geography you work in, whether you're on the frontline or elsewhere in the \nbusiness, I'm so appreciative of their hard work, their dedication to our purpose and our mission, their \ncommitment to our customers.  They really are what makes this a special place.  So, thanks for them.  \n \n Again, thank you, everyone.  I hope you have a terrific evening.  Be safe and stay healthy.  \n ", "original_text": "So, thanks for them.  \n \n"}, "hash": "c54c756a43690af667ddf0438e98ff08581328ef952112c8f63c8a9abbfb49be", "class_name": "RelatedNodeInfo"}}, "text": "They really are what makes this a special place. ", "start_char_idx": 685, "end_char_idx": 734, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "99c55606-ace2-48a7-82bd-9e57d689197c": {"__data__": {"id_": "99c55606-ace2-48a7-82bd-9e57d689197c", "embedding": null, "metadata": {"window": "So, none of that happens without the team that makes up McKesson.  And so, to everyone in McKesson,  no \nmatter what your role, no matter what geography you work in, whether you're on the frontline or elsewhere in the \nbusiness, I'm so appreciative of their hard work, their dedication to our purpose and our mission, their \ncommitment to our customers.  They really are what makes this a special place.  So, thanks for them.  \n \n Again, thank you, everyone.  I hope you have a terrific evening.  Be safe and stay healthy.  \n ", "original_text": "So, thanks for them.  \n \n", "page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b649837-3c05-4710-82a2-37e772b6efc5", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c5f7987dceb5d2699c41989a020c4189394c6ba073525458708e7025a782b8c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1d0dd021-31ed-44fc-a2a9-a2df5c977a49", "node_type": "1", "metadata": {"window": "It's really the driver between \u2013 the driver of our \nshareholder value creation.  \n \n So, none of that happens without the team that makes up McKesson.  And so, to everyone in McKesson,  no \nmatter what your role, no matter what geography you work in, whether you're on the frontline or elsewhere in the \nbusiness, I'm so appreciative of their hard work, their dedication to our purpose and our mission, their \ncommitment to our customers.  They really are what makes this a special place.  So, thanks for them.  \n \n Again, thank you, everyone.  I hope you have a terrific evening. ", "original_text": "They really are what makes this a special place. ", "page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e12c3c6fde8f789117e890254f347d85a09e5f1fc516354af001e9abc76afb79", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7a3ff8d8-9ef3-44a7-bfa3-b3eee7073614", "node_type": "1", "metadata": {"window": "And so, to everyone in McKesson,  no \nmatter what your role, no matter what geography you work in, whether you're on the frontline or elsewhere in the \nbusiness, I'm so appreciative of their hard work, their dedication to our purpose and our mission, their \ncommitment to our customers.  They really are what makes this a special place.  So, thanks for them.  \n \n Again, thank you, everyone.  I hope you have a terrific evening.  Be safe and stay healthy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call. ", "original_text": "Again, thank you, everyone. "}, "hash": "0aa5f8b40ce00a26617b8289b0ab22774aa861b5c2015e7bcfb14b6ae0154878", "class_name": "RelatedNodeInfo"}}, "text": "So, thanks for them.  \n \n", "start_char_idx": 734, "end_char_idx": 759, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7a3ff8d8-9ef3-44a7-bfa3-b3eee7073614": {"__data__": {"id_": "7a3ff8d8-9ef3-44a7-bfa3-b3eee7073614", "embedding": null, "metadata": {"window": "And so, to everyone in McKesson,  no \nmatter what your role, no matter what geography you work in, whether you're on the frontline or elsewhere in the \nbusiness, I'm so appreciative of their hard work, their dedication to our purpose and our mission, their \ncommitment to our customers.  They really are what makes this a special place.  So, thanks for them.  \n \n Again, thank you, everyone.  I hope you have a terrific evening.  Be safe and stay healthy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call. ", "original_text": "Again, thank you, everyone. ", "page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b649837-3c05-4710-82a2-37e772b6efc5", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c5f7987dceb5d2699c41989a020c4189394c6ba073525458708e7025a782b8c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "99c55606-ace2-48a7-82bd-9e57d689197c", "node_type": "1", "metadata": {"window": "So, none of that happens without the team that makes up McKesson.  And so, to everyone in McKesson,  no \nmatter what your role, no matter what geography you work in, whether you're on the frontline or elsewhere in the \nbusiness, I'm so appreciative of their hard work, their dedication to our purpose and our mission, their \ncommitment to our customers.  They really are what makes this a special place.  So, thanks for them.  \n \n Again, thank you, everyone.  I hope you have a terrific evening.  Be safe and stay healthy.  \n ", "original_text": "So, thanks for them.  \n \n", "page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6006ea0ef0e4fc6c30bdbbd531d41bfe05002bcfce3479b0f4a216d789e9af6c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "38e90ac2-35dc-4557-bed2-82afbe22974d", "node_type": "1", "metadata": {"window": "They really are what makes this a special place.  So, thanks for them.  \n \n Again, thank you, everyone.  I hope you have a terrific evening.  Be safe and stay healthy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day. \n \n \n \n \n \n \n \n \n \n \n \n", "original_text": "I hope you have a terrific evening. "}, "hash": "0a61b01abab5e273f344350b48f594d7ebd809ef282e69e2c65585feeee99c39", "class_name": "RelatedNodeInfo"}}, "text": "Again, thank you, everyone. ", "start_char_idx": 759, "end_char_idx": 787, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "38e90ac2-35dc-4557-bed2-82afbe22974d": {"__data__": {"id_": "38e90ac2-35dc-4557-bed2-82afbe22974d", "embedding": null, "metadata": {"window": "They really are what makes this a special place.  So, thanks for them.  \n \n Again, thank you, everyone.  I hope you have a terrific evening.  Be safe and stay healthy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day. \n \n \n \n \n \n \n \n \n \n \n \n", "original_text": "I hope you have a terrific evening. ", "page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b649837-3c05-4710-82a2-37e772b6efc5", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c5f7987dceb5d2699c41989a020c4189394c6ba073525458708e7025a782b8c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7a3ff8d8-9ef3-44a7-bfa3-b3eee7073614", "node_type": "1", "metadata": {"window": "And so, to everyone in McKesson,  no \nmatter what your role, no matter what geography you work in, whether you're on the frontline or elsewhere in the \nbusiness, I'm so appreciative of their hard work, their dedication to our purpose and our mission, their \ncommitment to our customers.  They really are what makes this a special place.  So, thanks for them.  \n \n Again, thank you, everyone.  I hope you have a terrific evening.  Be safe and stay healthy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call. ", "original_text": "Again, thank you, everyone. ", "page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c9f6df8d00cf016c5ab46b2a05779e61185041ea3b27217bcbd1e3af0c56c48", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "42c96c9a-fb44-4edf-87c3-392dac0ad0dd", "node_type": "1", "metadata": {"window": "So, thanks for them.  \n \n Again, thank you, everyone.  I hope you have a terrific evening.  Be safe and stay healthy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day. \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n", "original_text": "Be safe and stay healthy.  \n "}, "hash": "c093fc299f32cb9b2e89df835a918b30ed0ac24efdc361bbf1eb8ddb1e005e5c", "class_name": "RelatedNodeInfo"}}, "text": "I hope you have a terrific evening. ", "start_char_idx": 787, "end_char_idx": 823, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "42c96c9a-fb44-4edf-87c3-392dac0ad0dd": {"__data__": {"id_": "42c96c9a-fb44-4edf-87c3-392dac0ad0dd", "embedding": null, "metadata": {"window": "So, thanks for them.  \n \n Again, thank you, everyone.  I hope you have a terrific evening.  Be safe and stay healthy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day. \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n", "original_text": "Be safe and stay healthy.  \n ", "page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b649837-3c05-4710-82a2-37e772b6efc5", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c5f7987dceb5d2699c41989a020c4189394c6ba073525458708e7025a782b8c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "38e90ac2-35dc-4557-bed2-82afbe22974d", "node_type": "1", "metadata": {"window": "They really are what makes this a special place.  So, thanks for them.  \n \n Again, thank you, everyone.  I hope you have a terrific evening.  Be safe and stay healthy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day. \n \n \n \n \n \n \n \n \n \n \n \n", "original_text": "I hope you have a terrific evening. ", "page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "11d06b7736a767a97015bea1a62cd80e0e3671c40ee1405b63c6fbfd37ae3be1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7945a51f-a255-42a5-ac31-9094d48061d9", "node_type": "1", "metadata": {"window": "Again, thank you, everyone.  I hope you have a terrific evening.  Be safe and stay healthy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day. \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call. "}, "hash": "4c1ed656d093353d82bf560523a27258299095265df308d9d1829a2d9e39ea35", "class_name": "RelatedNodeInfo"}}, "text": "Be safe and stay healthy.  \n ", "start_char_idx": 823, "end_char_idx": 852, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7945a51f-a255-42a5-ac31-9094d48061d9": {"__data__": {"id_": "7945a51f-a255-42a5-ac31-9094d48061d9", "embedding": null, "metadata": {"window": "Again, thank you, everyone.  I hope you have a terrific evening.  Be safe and stay healthy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day. \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call. ", "page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b649837-3c05-4710-82a2-37e772b6efc5", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c5f7987dceb5d2699c41989a020c4189394c6ba073525458708e7025a782b8c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "42c96c9a-fb44-4edf-87c3-392dac0ad0dd", "node_type": "1", "metadata": {"window": "So, thanks for them.  \n \n Again, thank you, everyone.  I hope you have a terrific evening.  Be safe and stay healthy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day. \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n", "original_text": "Be safe and stay healthy.  \n ", "page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2e4e410a6df8a75258362735528899046fa5a0e8cf1ad24d41e24df0f04f9582", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f08e07a4-9efd-4dcf-b30e-91e2f29f67da", "node_type": "1", "metadata": {"window": "I hope you have a terrific evening.  Be safe and stay healthy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day. \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all  risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety  or usefulness of such information. ", "original_text": "You may now disconnect and have a great day. \n \n \n \n \n \n \n \n \n \n \n \n"}, "hash": "d7acc36971a1c173d952af3783ee8854681174b04ea30097896f69b3f619a509", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call. ", "start_char_idx": 852, "end_char_idx": 1184, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f08e07a4-9efd-4dcf-b30e-91e2f29f67da": {"__data__": {"id_": "f08e07a4-9efd-4dcf-b30e-91e2f29f67da", "embedding": null, "metadata": {"window": "I hope you have a terrific evening.  Be safe and stay healthy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day. \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all  risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety  or usefulness of such information. ", "original_text": "You may now disconnect and have a great day. \n \n \n \n \n \n \n \n \n \n \n \n", "page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b649837-3c05-4710-82a2-37e772b6efc5", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c5f7987dceb5d2699c41989a020c4189394c6ba073525458708e7025a782b8c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7945a51f-a255-42a5-ac31-9094d48061d9", "node_type": "1", "metadata": {"window": "Again, thank you, everyone.  I hope you have a terrific evening.  Be safe and stay healthy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day. \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call. ", "page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8dcba91d2d3a3d22e5a5a6f784f5093c0fd43e1b92323d4482f626c1cd765611", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f5f0a081-a3f9-4382-ac99-67fc9dac4cb2", "node_type": "1", "metadata": {"window": "Be safe and stay healthy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day. \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all  risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety  or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions. ", "original_text": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n"}, "hash": "2ec9151254f960af85409ea89a28d67782815bb7ce064b0a3f4878a1ae6732e3", "class_name": "RelatedNodeInfo"}}, "text": "You may now disconnect and have a great day. \n \n \n \n \n \n \n \n \n \n \n \n", "start_char_idx": 1184, "end_char_idx": 1252, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f5f0a081-a3f9-4382-ac99-67fc9dac4cb2": {"__data__": {"id_": "f5f0a081-a3f9-4382-ac99-67fc9dac4cb2", "embedding": null, "metadata": {"window": "Be safe and stay healthy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day. \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all  risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety  or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions. ", "original_text": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n", "page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b649837-3c05-4710-82a2-37e772b6efc5", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c5f7987dceb5d2699c41989a020c4189394c6ba073525458708e7025a782b8c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f08e07a4-9efd-4dcf-b30e-91e2f29f67da", "node_type": "1", "metadata": {"window": "I hope you have a terrific evening.  Be safe and stay healthy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day. \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all  risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety  or usefulness of such information. ", "original_text": "You may now disconnect and have a great day. \n \n \n \n \n \n \n \n \n \n \n \n", "page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e6f14e437976b8c7f9843812a11575e557a8fc6523132141eb9259b2b1b64e79", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b709052-4162-471c-b743-91ba3e4890ab", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day. \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all  risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety  or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published so lely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal. ", "original_text": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. "}, "hash": "9853cec4517879f9ca4afa19fc0666d4c5f2c83972784aa0120f548ed0c4eeb1", "class_name": "RelatedNodeInfo"}}, "text": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n", "start_char_idx": 1252, "end_char_idx": 1461, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b709052-4162-471c-b743-91ba3e4890ab": {"__data__": {"id_": "3b709052-4162-471c-b743-91ba3e4890ab", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day. \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all  risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety  or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published so lely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal. ", "original_text": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. ", "page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b649837-3c05-4710-82a2-37e772b6efc5", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c5f7987dceb5d2699c41989a020c4189394c6ba073525458708e7025a782b8c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f5f0a081-a3f9-4382-ac99-67fc9dac4cb2", "node_type": "1", "metadata": {"window": "Be safe and stay healthy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day. \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all  risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety  or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions. ", "original_text": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n", "page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88374c828a89a2a281472dd7b70fe6eb0b3d14d0d76f6185d5f7af7595b37275", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5d6d4461-d192-457d-ab01-f755ce3925b8", "node_type": "1", "metadata": {"window": "You may now disconnect and have a great day. \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all  risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety  or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published so lely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed h erein on this date is subject to change without notice. ", "original_text": "You must evaluate, and bear all  risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety  or usefulness of such information. "}, "hash": "e18aaf7886d8bd2c0c588ca2eaec0daf8355bf56ecd7ef2a4618d440ea0e7df2", "class_name": "RelatedNodeInfo"}}, "text": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. ", "start_char_idx": 1461, "end_char_idx": 1583, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5d6d4461-d192-457d-ab01-f755ce3925b8": {"__data__": {"id_": "5d6d4461-d192-457d-ab01-f755ce3925b8", "embedding": null, "metadata": {"window": "You may now disconnect and have a great day. \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all  risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety  or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published so lely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed h erein on this date is subject to change without notice. ", "original_text": "You must evaluate, and bear all  risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety  or usefulness of such information. ", "page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b649837-3c05-4710-82a2-37e772b6efc5", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c5f7987dceb5d2699c41989a020c4189394c6ba073525458708e7025a782b8c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b709052-4162-471c-b743-91ba3e4890ab", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day. \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all  risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety  or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published so lely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal. ", "original_text": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. ", "page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "18b40ca9db9dfec16b5d67c14010b946d577bc398bbe700500d1cf8c73fb70b1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e32804cc-93f0-4f97-b313-f9e496451b1f", "node_type": "1", "metadata": {"window": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all  risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety  or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published so lely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed h erein on this date is subject to change without notice.  Any opinions or assertions contained in this information do not repre sent the opinions or beliefs of FactSet \nCallStreet, LLC. ", "original_text": "This information is not intended to be used as the primary basis \nof investment decisions. "}, "hash": "cc0e225ed3af95bc2ae159a86054a8b6dc20342c5cc3ed0ca369490c41c572ce", "class_name": "RelatedNodeInfo"}}, "text": "You must evaluate, and bear all  risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety  or usefulness of such information. ", "start_char_idx": 1583, "end_char_idx": 1784, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e32804cc-93f0-4f97-b313-f9e496451b1f": {"__data__": {"id_": "e32804cc-93f0-4f97-b313-f9e496451b1f", "embedding": null, "metadata": {"window": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all  risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety  or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published so lely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed h erein on this date is subject to change without notice.  Any opinions or assertions contained in this information do not repre sent the opinions or beliefs of FactSet \nCallStreet, LLC. ", "original_text": "This information is not intended to be used as the primary basis \nof investment decisions. ", "page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b649837-3c05-4710-82a2-37e772b6efc5", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c5f7987dceb5d2699c41989a020c4189394c6ba073525458708e7025a782b8c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5d6d4461-d192-457d-ab01-f755ce3925b8", "node_type": "1", "metadata": {"window": "You may now disconnect and have a great day. \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all  risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety  or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published so lely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed h erein on this date is subject to change without notice. ", "original_text": "You must evaluate, and bear all  risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety  or usefulness of such information. ", "page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0f1ee046a392bd3ed0b1536f38b5af9cdd8d452f516245729403f1ec2acb4951", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c2a02ef2-2345-4d45-a0e7-b316cd09526f", "node_type": "1", "metadata": {"window": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all  risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety  or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published so lely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed h erein on this date is subject to change without notice.  Any opinions or assertions contained in this information do not repre sent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the wr iter of this report, may have a position in any of the securities discussed herein.  \n \n", "original_text": "It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published so lely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal. "}, "hash": "d6a13ca7fbbe8e99d6359c8734b288a0f1b1f4448f3841f4c0dc29f35cf676b9", "class_name": "RelatedNodeInfo"}}, "text": "This information is not intended to be used as the primary basis \nof investment decisions. ", "start_char_idx": 1784, "end_char_idx": 1875, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c2a02ef2-2345-4d45-a0e7-b316cd09526f": {"__data__": {"id_": "c2a02ef2-2345-4d45-a0e7-b316cd09526f", "embedding": null, "metadata": {"window": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all  risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety  or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published so lely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed h erein on this date is subject to change without notice.  Any opinions or assertions contained in this information do not repre sent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the wr iter of this report, may have a position in any of the securities discussed herein.  \n \n", "original_text": "It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published so lely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal. ", "page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b649837-3c05-4710-82a2-37e772b6efc5", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c5f7987dceb5d2699c41989a020c4189394c6ba073525458708e7025a782b8c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e32804cc-93f0-4f97-b313-f9e496451b1f", "node_type": "1", "metadata": {"window": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all  risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety  or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published so lely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed h erein on this date is subject to change without notice.  Any opinions or assertions contained in this information do not repre sent the opinions or beliefs of FactSet \nCallStreet, LLC. ", "original_text": "This information is not intended to be used as the primary basis \nof investment decisions. ", "page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f9a75a5590047fd26834f04a6ac4f96ea476a60b5d69f3278c5b56e37ba02dd6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ad528226-7d88-482b-8db2-64ee9b6496c3", "node_type": "1", "metadata": {"window": "You must evaluate, and bear all  risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety  or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published so lely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed h erein on this date is subject to change without notice.  Any opinions or assertions contained in this information do not repre sent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the wr iter of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS A SSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT L IMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT . ", "original_text": "Any \ninformation expressed h erein on this date is subject to change without notice. "}, "hash": "288bb34afeeaa8aaf078f46181699e110dd98cd4a0595a6eeda1a2888fcb2fb3", "class_name": "RelatedNodeInfo"}}, "text": "It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published so lely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal. ", "start_char_idx": 1875, "end_char_idx": 2238, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ad528226-7d88-482b-8db2-64ee9b6496c3": {"__data__": {"id_": "ad528226-7d88-482b-8db2-64ee9b6496c3", "embedding": null, "metadata": {"window": "You must evaluate, and bear all  risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety  or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published so lely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed h erein on this date is subject to change without notice.  Any opinions or assertions contained in this information do not repre sent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the wr iter of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS A SSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT L IMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT . ", "original_text": "Any \ninformation expressed h erein on this date is subject to change without notice. ", "page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b649837-3c05-4710-82a2-37e772b6efc5", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c5f7987dceb5d2699c41989a020c4189394c6ba073525458708e7025a782b8c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c2a02ef2-2345-4d45-a0e7-b316cd09526f", "node_type": "1", "metadata": {"window": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all  risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety  or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published so lely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed h erein on this date is subject to change without notice.  Any opinions or assertions contained in this information do not repre sent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the wr iter of this report, may have a position in any of the securities discussed herein.  \n \n", "original_text": "It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published so lely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal. ", "page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "712a83945e402b4c353c416d7ec5ea27c59b1150866685d3ae7f8961e3bbf999", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c0ee073b-d3ce-4482-9c1c-6d4a98821ff2", "node_type": "1", "metadata": {"window": "This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published so lely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed h erein on this date is subject to change without notice.  Any opinions or assertions contained in this information do not repre sent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the wr iter of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS A SSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT L IMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT .  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL  OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH P ARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n", "original_text": "Any opinions or assertions contained in this information do not repre sent the opinions or beliefs of FactSet \nCallStreet, LLC. "}, "hash": "f8e64db90c9a6e57b2c8eb9aac5d7516ebdecf459e30bc3d8e1b7ea904b69265", "class_name": "RelatedNodeInfo"}}, "text": "Any \ninformation expressed h erein on this date is subject to change without notice. ", "start_char_idx": 2238, "end_char_idx": 2323, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c0ee073b-d3ce-4482-9c1c-6d4a98821ff2": {"__data__": {"id_": "c0ee073b-d3ce-4482-9c1c-6d4a98821ff2", "embedding": null, "metadata": {"window": "This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published so lely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed h erein on this date is subject to change without notice.  Any opinions or assertions contained in this information do not repre sent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the wr iter of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS A SSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT L IMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT .  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL  OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH P ARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n", "original_text": "Any opinions or assertions contained in this information do not repre sent the opinions or beliefs of FactSet \nCallStreet, LLC. ", "page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b649837-3c05-4710-82a2-37e772b6efc5", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c5f7987dceb5d2699c41989a020c4189394c6ba073525458708e7025a782b8c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ad528226-7d88-482b-8db2-64ee9b6496c3", "node_type": "1", "metadata": {"window": "You must evaluate, and bear all  risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety  or usefulness of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published so lely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed h erein on this date is subject to change without notice.  Any opinions or assertions contained in this information do not repre sent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the wr iter of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS A SSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT L IMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT . ", "original_text": "Any \ninformation expressed h erein on this date is subject to change without notice. ", "page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3b4c0f37c012718300d7c69cf11b0774dccb6af87cdeef99783246ad3ab96b4e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "09ebd885-4635-4c2f-8015-7924bffa4432", "node_type": "1", "metadata": {"window": "It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published so lely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed h erein on this date is subject to change without notice.  Any opinions or assertions contained in this information do not repre sent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the wr iter of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS A SSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT L IMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT .  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL  OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH P ARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2022  CallStreet  and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "original_text": "FactSet CallStreet, LLC, or one or more of its employees, including the wr iter of this report, may have a position in any of the securities discussed herein.  \n \n"}, "hash": "f5d316737cbf5fcb35b1f5acaf21a67e1d67fd723b32ab9f5ec2788fa33f6312", "class_name": "RelatedNodeInfo"}}, "text": "Any opinions or assertions contained in this information do not repre sent the opinions or beliefs of FactSet \nCallStreet, LLC. ", "start_char_idx": 2323, "end_char_idx": 2451, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "09ebd885-4635-4c2f-8015-7924bffa4432": {"__data__": {"id_": "09ebd885-4635-4c2f-8015-7924bffa4432", "embedding": null, "metadata": {"window": "It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published so lely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed h erein on this date is subject to change without notice.  Any opinions or assertions contained in this information do not repre sent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the wr iter of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS A SSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT L IMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT .  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL  OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH P ARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2022  CallStreet  and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "original_text": "FactSet CallStreet, LLC, or one or more of its employees, including the wr iter of this report, may have a position in any of the securities discussed herein.  \n \n", "page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b649837-3c05-4710-82a2-37e772b6efc5", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c5f7987dceb5d2699c41989a020c4189394c6ba073525458708e7025a782b8c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c0ee073b-d3ce-4482-9c1c-6d4a98821ff2", "node_type": "1", "metadata": {"window": "This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published so lely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed h erein on this date is subject to change without notice.  Any opinions or assertions contained in this information do not repre sent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the wr iter of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS A SSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT L IMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT .  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL  OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH P ARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n", "original_text": "Any opinions or assertions contained in this information do not repre sent the opinions or beliefs of FactSet \nCallStreet, LLC. ", "page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a72faad124f447e7512997c7e83a9daf246e3fca97d2d5316a45b5d4d7595894", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bf66b6da-0424-460f-871a-c299981d4077", "node_type": "1", "metadata": {"window": "Any \ninformation expressed h erein on this date is subject to change without notice.  Any opinions or assertions contained in this information do not repre sent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the wr iter of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS A SSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT L IMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT .  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL  OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH P ARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2022  CallStreet  and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies. ", "original_text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS A SSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT L IMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT . "}, "hash": "5f546fcf2041175c257ef01d65460014de53ed01938618544aaeca37b3624206", "class_name": "RelatedNodeInfo"}}, "text": "FactSet CallStreet, LLC, or one or more of its employees, including the wr iter of this report, may have a position in any of the securities discussed herein.  \n \n", "start_char_idx": 2451, "end_char_idx": 2614, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bf66b6da-0424-460f-871a-c299981d4077": {"__data__": {"id_": "bf66b6da-0424-460f-871a-c299981d4077", "embedding": null, "metadata": {"window": "Any \ninformation expressed h erein on this date is subject to change without notice.  Any opinions or assertions contained in this information do not repre sent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the wr iter of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS A SSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT L IMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT .  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL  OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH P ARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2022  CallStreet  and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies. ", "original_text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS A SSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT L IMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT . ", "page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b649837-3c05-4710-82a2-37e772b6efc5", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c5f7987dceb5d2699c41989a020c4189394c6ba073525458708e7025a782b8c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "09ebd885-4635-4c2f-8015-7924bffa4432", "node_type": "1", "metadata": {"window": "It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published so lely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed h erein on this date is subject to change without notice.  Any opinions or assertions contained in this information do not repre sent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the wr iter of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS A SSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT L IMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT .  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL  OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH P ARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2022  CallStreet  and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "original_text": "FactSet CallStreet, LLC, or one or more of its employees, including the wr iter of this report, may have a position in any of the securities discussed herein.  \n \n", "page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "977e3812921cc93b515bbcebb64e5c9c390e9c285f4bdaa15b8a79c19793f635", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "738ba953-4525-41ec-8f21-73160e76b096", "node_type": "1", "metadata": {"window": "Any opinions or assertions contained in this information do not repre sent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the wr iter of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS A SSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT L IMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT .  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL  OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH P ARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2022  CallStreet  and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL  OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH P ARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n"}, "hash": "608ee5d568e46391a73e799f19803ddc32fc68cf47fc7a575fbe3aa28923486c", "class_name": "RelatedNodeInfo"}}, "text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS A SSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT L IMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT . ", "start_char_idx": 2614, "end_char_idx": 3050, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "738ba953-4525-41ec-8f21-73160e76b096": {"__data__": {"id_": "738ba953-4525-41ec-8f21-73160e76b096", "embedding": null, "metadata": {"window": "Any opinions or assertions contained in this information do not repre sent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the wr iter of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS A SSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT L IMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT .  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL  OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH P ARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2022  CallStreet  and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL  OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH P ARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n", "page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b649837-3c05-4710-82a2-37e772b6efc5", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c5f7987dceb5d2699c41989a020c4189394c6ba073525458708e7025a782b8c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bf66b6da-0424-460f-871a-c299981d4077", "node_type": "1", "metadata": {"window": "Any \ninformation expressed h erein on this date is subject to change without notice.  Any opinions or assertions contained in this information do not repre sent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the wr iter of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS A SSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT L IMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT .  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL  OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH P ARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2022  CallStreet  and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies. ", "original_text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS A SSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT L IMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT . ", "page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3ea6eeb8915f3d7ab538d6ac50b57493b8d742f3b20e6d8472a0b36ccb2f25b9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fab8d38b-8e25-4c8a-8516-4cc84ef0860a", "node_type": "1", "metadata": {"window": "FactSet CallStreet, LLC, or one or more of its employees, including the wr iter of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS A SSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT L IMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT .  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL  OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH P ARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2022  CallStreet  and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2022  CallStreet  and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. "}, "hash": "311d6b8f321e36c263cc311458ddd06d957fba29c8e1f731779a6305f3fbcc8d", "class_name": "RelatedNodeInfo"}}, "text": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL  OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH P ARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n", "start_char_idx": 3050, "end_char_idx": 3730, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fab8d38b-8e25-4c8a-8516-4cc84ef0860a": {"__data__": {"id_": "fab8d38b-8e25-4c8a-8516-4cc84ef0860a", "embedding": null, "metadata": {"window": "FactSet CallStreet, LLC, or one or more of its employees, including the wr iter of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS A SSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT L IMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT .  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL  OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH P ARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2022  CallStreet  and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2022  CallStreet  and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b649837-3c05-4710-82a2-37e772b6efc5", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c5f7987dceb5d2699c41989a020c4189394c6ba073525458708e7025a782b8c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "738ba953-4525-41ec-8f21-73160e76b096", "node_type": "1", "metadata": {"window": "Any opinions or assertions contained in this information do not repre sent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the wr iter of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS A SSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT L IMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT .  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL  OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH P ARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2022  CallStreet  and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL  OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH P ARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n", "page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "be7a5dcae33bd93335487b31936b5ca7c1ff22231fa07f7716fc86427b38c5a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e22ff1f9-8a06-4368-bff8-ede13215cd9d", "node_type": "1", "metadata": {"window": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS A SSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT L IMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT .  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL  OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH P ARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2022  CallStreet  and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All \nother trademarks mentioned are trademarks of their respective companies. "}, "hash": "9f7350bce5db84060f6fe0882ca6fa1dadb638083cc7f7b1665ee7ad101adbfc", "class_name": "RelatedNodeInfo"}}, "text": "The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2022  CallStreet  and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "start_char_idx": 3730, "end_char_idx": 3920, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e22ff1f9-8a06-4368-bff8-ede13215cd9d": {"__data__": {"id_": "e22ff1f9-8a06-4368-bff8-ede13215cd9d", "embedding": null, "metadata": {"window": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS A SSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT L IMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT .  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL  OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH P ARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2022  CallStreet  and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All \nother trademarks mentioned are trademarks of their respective companies. ", "page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b649837-3c05-4710-82a2-37e772b6efc5", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c5f7987dceb5d2699c41989a020c4189394c6ba073525458708e7025a782b8c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fab8d38b-8e25-4c8a-8516-4cc84ef0860a", "node_type": "1", "metadata": {"window": "FactSet CallStreet, LLC, or one or more of its employees, including the wr iter of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS A SSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT L IMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT .  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL  OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH P ARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2022  CallStreet  and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2022  CallStreet  and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f571cc7f384c5607338b4ae75a60dbac097b004cb3ba6b0bb94403d44d297510", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "45b4f3b4-d32c-4949-b9ac-00678de4d463", "node_type": "1", "metadata": {"window": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL  OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH P ARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2022  CallStreet  and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All rights reserved.  "}, "hash": "aa3ca5be0dc366660e1d4d08cea8cb21ebb2d643d4d66550ca4eb866b136cddc", "class_name": "RelatedNodeInfo"}}, "text": "All \nother trademarks mentioned are trademarks of their respective companies. ", "start_char_idx": 3920, "end_char_idx": 3998, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "45b4f3b4-d32c-4949-b9ac-00678de4d463": {"__data__": {"id_": "45b4f3b4-d32c-4949-b9ac-00678de4d463", "embedding": null, "metadata": {"window": "TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL  OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH P ARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2022  CallStreet  and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All rights reserved.  ", "page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b649837-3c05-4710-82a2-37e772b6efc5", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c5f7987dceb5d2699c41989a020c4189394c6ba073525458708e7025a782b8c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e22ff1f9-8a06-4368-bff8-ede13215cd9d", "node_type": "1", "metadata": {"window": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS A SSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT L IMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT .  TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL  OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH P ARTIES IS ADVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2022  CallStreet  and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All \nother trademarks mentioned are trademarks of their respective companies. ", "page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ea37c10ad9e0ae25f8220c436b71d75a0110ca45d8f1b2f2091fc08215d70f03", "class_name": "RelatedNodeInfo"}}, "text": "All rights reserved.  ", "start_char_idx": 3998, "end_char_idx": 4020, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/metadata": {"e646e0fd-f57f-41c9-9d7e-50ce6fbc15e3": {"doc_hash": "0182a3bd37a5d352748d848551889d17471104eaf196d774e4c7ea17df1ac427", "ref_doc_id": "f1de019c-ee93-431e-83f5-688557649411"}, "6bd3b4dc-856c-46e0-b943-fe828ddb5ede": {"doc_hash": "882acb76f0adba6eedd17da7776cf167762dc25e9f3829e64c701778a3e5d3c5", "ref_doc_id": "f1de019c-ee93-431e-83f5-688557649411"}, "d575b349-ba00-4d24-98a5-00ba5fe86008": {"doc_hash": "bc975452186e8b9f4fc78fc8e5c6c5dd23da7f066cffb26dd27b042fe34061b3", "ref_doc_id": "edddd1cd-f6f6-41c2-b7ea-bb7d91760227"}, "59579895-53da-4bd4-9a79-539b1492c451": {"doc_hash": "db141cd516f7c38df61972b5afb449673f929f1e9df27b2c26c47f18119b6106", "ref_doc_id": "edddd1cd-f6f6-41c2-b7ea-bb7d91760227"}, "a3c5b0fa-b6a9-4bbf-994f-6f0ba66c4093": {"doc_hash": "896ee1e3145de5dfdf4bb968a4a7f2c1d246619e3ae60edbf82eb8fe7e871941", "ref_doc_id": "edddd1cd-f6f6-41c2-b7ea-bb7d91760227"}, "a2f08546-6c81-4801-a2bd-6d76e2511802": {"doc_hash": "ce2bb349a8f37d81cf2b380aab15d4609034dcb560c1a47e47573cbd0f2c5675", "ref_doc_id": "edddd1cd-f6f6-41c2-b7ea-bb7d91760227"}, "18779052-4a57-4cd7-826b-aa88736ccb44": {"doc_hash": "159cd741fb657066ea782f53cf17372581ca0b2801c8b16fb32d4e4591606f98", "ref_doc_id": "edddd1cd-f6f6-41c2-b7ea-bb7d91760227"}, "84888ded-99fe-43a8-bd52-b48d77c36be1": {"doc_hash": "1ed43ae2d3951ae06013b6e1d0cf935df50fee7ba87f7b945e1da936026930bf", "ref_doc_id": "edddd1cd-f6f6-41c2-b7ea-bb7d91760227"}, "0d8bc9e7-8f3e-4503-b604-ff5b455cb2aa": {"doc_hash": "c051aa1c776245d8d8add588be15759a297e0a6d12441514c3422f4323de20bf", "ref_doc_id": "edddd1cd-f6f6-41c2-b7ea-bb7d91760227"}, "a3a029d4-2c20-44d2-9ba8-2040631223a2": {"doc_hash": "240ba9adfbb5daf7990a65c827537a3ccd325ab7957692843ac78ec5e5e631cd", "ref_doc_id": "edddd1cd-f6f6-41c2-b7ea-bb7d91760227"}, "a806af34-c310-4a78-9d3c-09f2237e9538": {"doc_hash": "0f43cec37de12da67f067dc35b1a301961e3edfebd70e0f9875be4a829a71fa9", "ref_doc_id": "edddd1cd-f6f6-41c2-b7ea-bb7d91760227"}, "64de42c9-2a0d-443e-b172-8fa15f4a56f2": {"doc_hash": "b15c5306bb1260f2eb7e6a1483e76f3daecead67f226782fbb8f194d23e67e81", "ref_doc_id": "edddd1cd-f6f6-41c2-b7ea-bb7d91760227"}, "75622da2-8a77-450f-8120-ce716bb89c21": {"doc_hash": "a8b6e242345c89d6727638ef3d92cfa60b76a1e0a9f77816f918a6cbabf9b942", "ref_doc_id": "edddd1cd-f6f6-41c2-b7ea-bb7d91760227"}, "4a01cca2-c589-4a83-b9c8-a35332967b83": {"doc_hash": "b03ad93e008e3484cf1ca772c73e227ea9bf54dcc2346c6bbc1dc84f08edab8f", "ref_doc_id": "edddd1cd-f6f6-41c2-b7ea-bb7d91760227"}, "a0286b72-ede3-4a91-8d03-906d0faffcc4": {"doc_hash": "cbfd9ba753b4568c2eab4332884c19e9b32412b2c532dca654d81a116c26f7c7", "ref_doc_id": "edddd1cd-f6f6-41c2-b7ea-bb7d91760227"}, "7ff2612b-e637-4733-a4ed-3769022e2965": {"doc_hash": "d23a01e18c267b0b462396fa0ded8ab0898bf0e7615f16563c582589bdb449ff", "ref_doc_id": "edddd1cd-f6f6-41c2-b7ea-bb7d91760227"}, "b509d8f0-b69c-40df-90e7-1da97cacc4ad": {"doc_hash": "a9ccb7959223c0e9f8371e4a6b45b89650bacbcad0541d87633acaf8523be8d1", "ref_doc_id": "edddd1cd-f6f6-41c2-b7ea-bb7d91760227"}, "6a447823-afff-4ef1-a1e6-5f8f84dcf5b6": {"doc_hash": "57073a9966dd956167805a4dffb17602d8b41f9b0b0fc751f362a02d8918a215", "ref_doc_id": "edddd1cd-f6f6-41c2-b7ea-bb7d91760227"}, "cd8e8e70-8379-47be-a193-6d61700969bb": {"doc_hash": "aa4f48376c51f4b75baeaaf43fd03d488b502f57e96571002829c05363301b44", "ref_doc_id": "edddd1cd-f6f6-41c2-b7ea-bb7d91760227"}, "213c25be-6c18-46b9-bc61-98411824b897": {"doc_hash": "5997a52bd97788989c0a17284565715dbc67bbaeddbce25d4974d937c2af5d65", "ref_doc_id": "edddd1cd-f6f6-41c2-b7ea-bb7d91760227"}, "04275573-d7b3-4544-8201-1e9543c15528": {"doc_hash": "f5a39da4a1f7d3dc3464bfc85a6582edb19c6f6c7f2f9b365161eb589329f82e", "ref_doc_id": "edddd1cd-f6f6-41c2-b7ea-bb7d91760227"}, "5ed98d39-26cb-455a-bc74-83cfe5265996": {"doc_hash": "72bd405ac2af7312dcbd82ab9acff03c349d7f900f381af3056abdcbab2c3d03", "ref_doc_id": "a6099167-af59-46fd-99a8-7c7f028b5ea4"}, "f1524133-35b3-42ab-a861-041a1cc185f7": {"doc_hash": "96cb01ba4652d9cb1ab5910cc97369fa891e9b6ea53cdbf879cb789aa2b65917", "ref_doc_id": "a6099167-af59-46fd-99a8-7c7f028b5ea4"}, "42a4a8d1-8e25-44a9-b8aa-f54a4d9c0e22": {"doc_hash": "ed5b7eb35ac34e562f4f05c0ad5d9e06bf8fecb8d83710ce26a3f793c626822d", "ref_doc_id": "a6099167-af59-46fd-99a8-7c7f028b5ea4"}, "bb76a09c-9c23-4065-9a9e-d3542dd9a8fb": {"doc_hash": "5763974a006d2136125225c3322de3c6b5eec877eef4591960a9e768c0aa8cfe", "ref_doc_id": "a6099167-af59-46fd-99a8-7c7f028b5ea4"}, "d2fb990b-8f56-4c8d-95e2-f4451495fa7f": {"doc_hash": "8c8a07f4b2002a0a2ebeda0d37343e6f6ced38ed0277ba031adc6cf0b57ac90d", "ref_doc_id": "a6099167-af59-46fd-99a8-7c7f028b5ea4"}, "1bfa31cd-76de-470f-a02f-2547094afda2": {"doc_hash": "b2d10bba2378f962ebc051fdee4efd13c2b97dff39ec597b848628a2abb0a301", "ref_doc_id": "a6099167-af59-46fd-99a8-7c7f028b5ea4"}, "38b029e0-f8a8-49f9-9daa-a5b41daec436": {"doc_hash": "218d7d9a80d63948e02b240e611ab0d6a7c5ca9756ac4a3497285168acc8ee3e", "ref_doc_id": "a6099167-af59-46fd-99a8-7c7f028b5ea4"}, "3c942233-1832-4f63-9260-2b94d3225fa2": {"doc_hash": "c0bba6f5e41397c59c053cdcd96164810ca81a62d7c434c5e5075d9a56a67926", "ref_doc_id": "a6099167-af59-46fd-99a8-7c7f028b5ea4"}, "a4b1f1d8-3012-435a-abfd-fa64cc5c9b67": {"doc_hash": "b19c211ee93b527dd20094ce5d1d33e893cac2e6c67e4a475ba41bf972ae90ae", "ref_doc_id": "a6099167-af59-46fd-99a8-7c7f028b5ea4"}, "83cb1f47-7bdb-4f60-973e-60664b9c1545": {"doc_hash": "41a614b73c67ab96f79aa8f13aa0f51a90728d930a6e478cac5edc9f028ca1a6", "ref_doc_id": "a6099167-af59-46fd-99a8-7c7f028b5ea4"}, "33030885-3af4-4088-aee9-4925fefdcd7f": {"doc_hash": "cdae59b2e048b339c63781206453911794a72f55725455bcdcc729f8e74478c5", "ref_doc_id": "a6099167-af59-46fd-99a8-7c7f028b5ea4"}, "64d5b098-dc25-4eca-8eb7-ce552eb8de8a": {"doc_hash": "75328c1e9ceee7bc6c3fda8520ad0508439429344fe0686f4fabcd9ebc8e7ee4", "ref_doc_id": "a6099167-af59-46fd-99a8-7c7f028b5ea4"}, "2ffd2410-d9f9-4e10-9ec0-2629fd764876": {"doc_hash": "282d54ddd401ae9b0fa51f70c691900630d58879b7cd6458517437d20e0c1d1a", "ref_doc_id": "a6099167-af59-46fd-99a8-7c7f028b5ea4"}, "456a4aeb-58f2-4fde-8d06-f4d6eda5599a": {"doc_hash": "35d07bec1dedd559a38cdb2cb26f2341f7ffc7234c11910647e5667314ab2d4f", "ref_doc_id": "a6099167-af59-46fd-99a8-7c7f028b5ea4"}, "96026bf6-6411-47a3-aaee-a1f9d6ae4af8": {"doc_hash": "ffe1475a869fc4a7ed565f2a355ad31159daf50fcaa8e9bc9a241f103f79d923", "ref_doc_id": "a6099167-af59-46fd-99a8-7c7f028b5ea4"}, "263e5bc3-24ff-4da2-887c-6ecbe33e4cdc": {"doc_hash": "d410b6e776bfda8d74c940ea66b56cec342992c84884f98f3e1e876daa24e230", "ref_doc_id": "a6099167-af59-46fd-99a8-7c7f028b5ea4"}, "0aa3fec1-2b8f-42ef-a895-5f76bbd303a5": {"doc_hash": "3730abb1c296e7e387f4ad0a3effb51c6da7d0706569daade404a2bc4e60c89d", "ref_doc_id": "a6099167-af59-46fd-99a8-7c7f028b5ea4"}, "925e272f-b81e-4828-b250-2a18d7178728": {"doc_hash": "1645078064b8ebb14eb612602e9b2e31ce09a4e43d10d0b2e8ff8cdd78679214", "ref_doc_id": "a6099167-af59-46fd-99a8-7c7f028b5ea4"}, "a507df3b-c3ee-44ae-8656-f067ee679fc1": {"doc_hash": "826bb8f843d74d96e4c93700353621a1b023295790c98b0b4472e20afdfc9602", "ref_doc_id": "a6099167-af59-46fd-99a8-7c7f028b5ea4"}, "50f92404-c7cd-4b9d-a7e0-dda012994e24": {"doc_hash": "59885770706dd765a7840e41ae9b4f96246ab1b3c1ee31a192506d5b33f6ff3c", "ref_doc_id": "a6099167-af59-46fd-99a8-7c7f028b5ea4"}, "fe016eb8-117e-4790-a5c8-0675ead5bb5b": {"doc_hash": "96ccfa5d27b63ab716fb23bddcf4c74b5cdb98b29c4ecad2a90fcf3bad08503c", "ref_doc_id": "a6099167-af59-46fd-99a8-7c7f028b5ea4"}, "e4af05a4-2ebe-40c9-9347-be0b111e4d05": {"doc_hash": "bd9c2943583a6c7d899bd61b0c07b757c73424f25ec9da94c137dc89a15ab8eb", "ref_doc_id": "a6099167-af59-46fd-99a8-7c7f028b5ea4"}, "2f8d3820-b140-4dd1-80ce-887782cf523d": {"doc_hash": "4bb9e49c3e4140d9dd67f9633ff1dc2e671bdb8b7966cfcc26a33f6db1d7beb4", "ref_doc_id": "a6099167-af59-46fd-99a8-7c7f028b5ea4"}, "ff268f41-851f-446e-a78b-9a089011dbd6": {"doc_hash": "0a41b5516756c31eda01c837377320f19f769eadfd62e850bfc61d6453ab13c5", "ref_doc_id": "a6099167-af59-46fd-99a8-7c7f028b5ea4"}, "6d3708eb-fd30-439b-aadc-aad7ffebcc27": {"doc_hash": "69e377ebe649f4af5db0b94a8815299332868a1873c1246119a09a909644d4bb", "ref_doc_id": "a6099167-af59-46fd-99a8-7c7f028b5ea4"}, "b3d7bb83-db8a-4f02-b12d-cadb20610ec5": {"doc_hash": "0390671af07ba18f51d31b95abc5034cce7ac851d2e39dee9a4a16376fda67d2", "ref_doc_id": "a6099167-af59-46fd-99a8-7c7f028b5ea4"}, "3db867be-77b5-40e2-acc5-bc752bc7b778": {"doc_hash": "8dcd9da12ec1ec49f9ae41ec4241e7769c19559d4e413a31acaf9a1a66fb8819", "ref_doc_id": "a6099167-af59-46fd-99a8-7c7f028b5ea4"}, "81452c94-929d-4c31-b60a-339efd74d994": {"doc_hash": "8d1434459a4a403f9c042fa31357b918823e7a88644d03a0a685874f08b4b826", "ref_doc_id": "a6099167-af59-46fd-99a8-7c7f028b5ea4"}, "0f37ea09-571e-466b-99ad-a20692bf7bd5": {"doc_hash": "046acde4b75185575f87c6a9dc53623a653dd97fbed102051dcf9c44747925b2", "ref_doc_id": "a6099167-af59-46fd-99a8-7c7f028b5ea4"}, "d4de066d-8ee4-46c7-bea0-6b7640867e61": {"doc_hash": "2533934650478c348ff08c46c373fdf0b0bc8f6ae362153bb1ffc617e8480205", "ref_doc_id": "a6099167-af59-46fd-99a8-7c7f028b5ea4"}, "c067af5d-352c-4e48-8fff-bbb9598dfd19": {"doc_hash": "0c9e0b925c88415dde038892f97c51ea180989e6b11e74b1ce2b34bb3effaada", "ref_doc_id": "2657d877-6c2d-4cd2-9c56-265576a1cdee"}, "55be5aff-45a9-4209-bb0b-fe7e56a5cf31": {"doc_hash": "5c3d27e5a3829b2815b83f12a05c173e5766a5896ae8e8d9bfd1d2e56aba5f25", "ref_doc_id": "2657d877-6c2d-4cd2-9c56-265576a1cdee"}, "4f88069d-f7f4-4e5b-a610-fe288c857dd6": {"doc_hash": "b95c6c77c933542d9b0351bcc1aebde81ac934ac4d08bf97c32121219641c219", "ref_doc_id": "2657d877-6c2d-4cd2-9c56-265576a1cdee"}, "1bbe9603-efd6-43c8-9d10-af4e8a038e69": {"doc_hash": "502766cb037991b7fa3e58f378697336d84bdf187d4fdab61c64450a030fd320", "ref_doc_id": "2657d877-6c2d-4cd2-9c56-265576a1cdee"}, "9d4d37a9-a0cc-4e6c-a1d9-0c13d7bf4980": {"doc_hash": "c4f930881b50311c0f3cafb9009ba50f2171a20cca9c907ec15ebfe19a45dbe7", "ref_doc_id": "2657d877-6c2d-4cd2-9c56-265576a1cdee"}, "9753bbb7-b117-4d4d-9a8a-925b2064ec63": {"doc_hash": "05e6e0ded7580b79e3c6f9e835ca31d23ed6900c15add984d09e1bf30d43f05b", "ref_doc_id": "2657d877-6c2d-4cd2-9c56-265576a1cdee"}, "1cdf88f6-7a6d-4247-8087-bcaa8577025c": {"doc_hash": "aac3fcef150e641fb2733d4b38cf3c4f1f893eb9e91e67167b776f0511b28077", "ref_doc_id": "2657d877-6c2d-4cd2-9c56-265576a1cdee"}, "a421e3f3-650e-4ce9-9257-0e8b6b9aed00": {"doc_hash": "c2e446dc8c501dab2167c1ca1d0c3dcbd98a603569883c94b5ad71d8f691d898", "ref_doc_id": "2657d877-6c2d-4cd2-9c56-265576a1cdee"}, "5e80ff09-5ba4-48fb-bc96-02e574563eff": {"doc_hash": "6e0de682b56d2a14fa3144890fb6427f65ea6773ef259e5be271c36006f3043e", "ref_doc_id": "2657d877-6c2d-4cd2-9c56-265576a1cdee"}, "5dc58ca1-5d1a-4f76-aa35-e1f751201544": {"doc_hash": "dd97100b357e0709a09047a242bb46d2f6e9c007fd285380edde2f3873d34249", "ref_doc_id": "2657d877-6c2d-4cd2-9c56-265576a1cdee"}, "6a5b58fb-dd17-4721-b56a-3406a2c428a5": {"doc_hash": "b021d5a4f21d6bf32696038278cda0d178680ff5b404adc43ddc58890ddfa878", "ref_doc_id": "2657d877-6c2d-4cd2-9c56-265576a1cdee"}, "70f232af-594f-47cb-8016-490ffcd7f9c5": {"doc_hash": "4783fab77ad85f522e7c1b088ed212a247f9e069780dbc60b0ebd3d9b6c701ca", "ref_doc_id": "2657d877-6c2d-4cd2-9c56-265576a1cdee"}, "a4db77b4-a29b-4551-a651-f3cd1c8d8e45": {"doc_hash": "353d8c209c246bde600e09c1f92cfb48af0138230fcfc4b6c7a6188e8ec19833", "ref_doc_id": "2657d877-6c2d-4cd2-9c56-265576a1cdee"}, "fada4ae4-119d-40b2-88e3-7ee898b0b6d7": {"doc_hash": "4fcc04a9acc7571e31b64aa94e181c8ab59a29e9df4f3aba98b83aed3b083678", "ref_doc_id": "2657d877-6c2d-4cd2-9c56-265576a1cdee"}, "57c21ed2-7d03-465d-82dc-1c3448658b59": {"doc_hash": "815caedde0b0e65f953a2b22115705e1a7df2676fc711accd916cbae8874068a", "ref_doc_id": "2657d877-6c2d-4cd2-9c56-265576a1cdee"}, "d1a6f385-a027-4d73-8132-22161d630704": {"doc_hash": "677b325e0b8d38147925d89cf07b684e62fb06efa6393c0df3519c2e0591db99", "ref_doc_id": "2657d877-6c2d-4cd2-9c56-265576a1cdee"}, "98be5750-3483-46fb-8611-609aefc19ae6": {"doc_hash": "0ebbea32019480c67a3a64371eca0ae5c77efd27e8e6a1277e749f4653aa2c23", "ref_doc_id": "2657d877-6c2d-4cd2-9c56-265576a1cdee"}, "1fee1a09-b409-4c54-8724-8710d0797765": {"doc_hash": "04e3a9d98837d6bf17bfe1fa162a87622d970c10fe949536ee299941ce21618b", "ref_doc_id": "2657d877-6c2d-4cd2-9c56-265576a1cdee"}, "8e5f57b6-0f02-4a18-9bde-b27e23f99ac3": {"doc_hash": "1ffb65bc70ce5c0574cb95638efad098a7ba426076ce25598764e9be57ad2b2f", "ref_doc_id": "2657d877-6c2d-4cd2-9c56-265576a1cdee"}, "0f15ac60-66e1-4deb-a1f4-8bbf404238d9": {"doc_hash": "c52b121cfc67a28d02601cbf706bc443dc6493b1714e7c78cf0dfc25ea3a619f", "ref_doc_id": "2657d877-6c2d-4cd2-9c56-265576a1cdee"}, "e41ca812-34ae-44d9-962d-029742b9d2d8": {"doc_hash": "729aea7039e79a853dbeb63582a3ee31aeac69bd22738120882c4a8c826e28ae", "ref_doc_id": "2657d877-6c2d-4cd2-9c56-265576a1cdee"}, "50aea7ab-528e-4ff9-984a-f1b1a8a7b4ad": {"doc_hash": "9651cb562f616a2b56baaf8fd8638ed18c9cff95ccb6a538c181ff9f4ae9276c", "ref_doc_id": "2657d877-6c2d-4cd2-9c56-265576a1cdee"}, "a5171deb-d415-4af1-ac40-7182db334d30": {"doc_hash": "e52ab004068d8c48aeec7def4866500310f7900a008e0efb78bce69d226bfbce", "ref_doc_id": "2657d877-6c2d-4cd2-9c56-265576a1cdee"}, "d09cce28-58ed-4e87-8b91-7fef607e7c5c": {"doc_hash": "a91eb0b8711432cdf788e63640455c9cb63a28177cbd960a4784402f08b09fad", "ref_doc_id": "2657d877-6c2d-4cd2-9c56-265576a1cdee"}, "6e7edafe-4a85-4771-b2e4-9bcc4e8495bc": {"doc_hash": "d94c6591113d29b4ecdb63a30a341fb4efb2d626cd85ff39f1a30dfc3dacb24d", "ref_doc_id": "2657d877-6c2d-4cd2-9c56-265576a1cdee"}, "b4b015c5-f548-4f6b-838d-6b538e084fd6": {"doc_hash": "2d73b794024418dfaddc915c5e636a9ba182a062fbf552f09b050063c575be98", "ref_doc_id": "70da607e-7d19-47fd-81bf-839e155c79d6"}, "aa1d20a5-df67-4a93-a139-1abc98830009": {"doc_hash": "a3b15e01e75a1159b6f68a6060452f9709a881fdab3c829789307ba51e3a80e0", "ref_doc_id": "70da607e-7d19-47fd-81bf-839e155c79d6"}, "634ca735-845b-4105-99a8-84c0dd462500": {"doc_hash": "50a6b817d5b72439ffb6301de4016ff2d80efc1c9a4e8ad93b2b2429e0d29904", "ref_doc_id": "70da607e-7d19-47fd-81bf-839e155c79d6"}, "725dc139-4e44-4a57-9f90-aa333aa90209": {"doc_hash": "e23e93ebd564095435702979920bae0b5c9af894e844f8bf071a83409905f5b3", "ref_doc_id": "70da607e-7d19-47fd-81bf-839e155c79d6"}, "8d8fa293-34d2-4b17-b034-976f7ce36055": {"doc_hash": "0c2d8da868a1b2a4df2efe83191e8877039f61828b1acac8ee694db925d023c1", "ref_doc_id": "70da607e-7d19-47fd-81bf-839e155c79d6"}, "c6c12c04-6302-498a-a509-b0e845e6aeb1": {"doc_hash": "c0c7a24f1b8e3c6ca8212b2a3cf3edb78e66f215ede54f43d295276064e5dd8e", "ref_doc_id": "70da607e-7d19-47fd-81bf-839e155c79d6"}, "8478f3f3-2b33-46e4-b9f3-43d5fb8109af": {"doc_hash": "771a315c6dc7e94345cf90797417aa827e3603a8f69e1698ce11ca24155e9492", "ref_doc_id": "70da607e-7d19-47fd-81bf-839e155c79d6"}, "33705a49-f63f-4c73-bd47-06ce4eb1dab0": {"doc_hash": "67ba37d878214936930b7bd8e421d85ed4ed9b7f5a3e491992c705a466d0f110", "ref_doc_id": "70da607e-7d19-47fd-81bf-839e155c79d6"}, "c411ec14-e3fe-45ec-b889-aa785134a5d7": {"doc_hash": "0d4742c55eeda2f252a81ab06ed00efea161890cc673beb73d5fb88681cad625", "ref_doc_id": "70da607e-7d19-47fd-81bf-839e155c79d6"}, "ffa573ef-dea8-4e84-899b-5898d6e2cc3f": {"doc_hash": "f6c7b32d74338c849d1f11f479087ac4a3988b5cb104bd66470ab6a46a092d76", "ref_doc_id": "70da607e-7d19-47fd-81bf-839e155c79d6"}, "ddeb0920-b1b8-4b80-88d7-4bba3bea28a7": {"doc_hash": "5999ddc8ccbe474b9b470d88b3a33a98401fabc58b566bcdd097f16620ff7349", "ref_doc_id": "70da607e-7d19-47fd-81bf-839e155c79d6"}, "c57e2082-9ec5-4b25-bf15-9f816b83e910": {"doc_hash": "7143bf7c66cecfead1abfbf32972515c3f3d65294ffffef76e844913bb2878ae", "ref_doc_id": "70da607e-7d19-47fd-81bf-839e155c79d6"}, "f270d553-674d-4e9a-af17-2d046271f47a": {"doc_hash": "85eca7811ded35aa9b2fa3ad8d503bf0caf344842ca1b20dedb963acfe95ad38", "ref_doc_id": "70da607e-7d19-47fd-81bf-839e155c79d6"}, "73b8efa0-617d-4472-8084-fb0a245826d0": {"doc_hash": "da6625f3218f8993ead43790fd5105d0ecfe166aba29691ba62df871c551f9b0", "ref_doc_id": "70da607e-7d19-47fd-81bf-839e155c79d6"}, "56768881-e6a2-4f6f-85ba-51067d398aec": {"doc_hash": "40d13f6b98c9bf6d5b65aa27897d828d0fcfb2867ae52195628e0462f8222a62", "ref_doc_id": "70da607e-7d19-47fd-81bf-839e155c79d6"}, "5ccf9017-219a-4422-a744-6116a14463bf": {"doc_hash": "2369c5e189b3be8efe1e9be48e87fa785775837d44fa44d0b9d6dbef52bb993f", "ref_doc_id": "70da607e-7d19-47fd-81bf-839e155c79d6"}, "d410f7fb-5b8f-4b11-9722-04e957e5a9d2": {"doc_hash": "7fbc333d621017a20b3f968dfbdcebfd578b371a540b969e86c3113c597b7770", "ref_doc_id": "70da607e-7d19-47fd-81bf-839e155c79d6"}, "9f64acaa-167c-4083-bb4a-5404cc673a7b": {"doc_hash": "e585c09e63b0e5368e0a41edd2c0deffe32608d2e676bb6ad3ecef1e54718bf4", "ref_doc_id": "70da607e-7d19-47fd-81bf-839e155c79d6"}, "0a9cbe31-545e-4ee7-acf7-8b6f3f33abad": {"doc_hash": "2ffdddf20045d0e9623dbf7770ecfc8c5806d4b2fea11c4bb34d5663d77f3876", "ref_doc_id": "70da607e-7d19-47fd-81bf-839e155c79d6"}, "06c8d1d1-9781-4d51-9c8d-de67a48f2152": {"doc_hash": "9e234b1794235c7df489a87ffcb6eedc3bb474582777cff47903cd1a4b881a75", "ref_doc_id": "70da607e-7d19-47fd-81bf-839e155c79d6"}, "bbd193fb-35e4-4ff3-a3ab-f36b5701bb62": {"doc_hash": "c651e2f580f010dbcec00c5dcaeae2c82a2c099e8f93dca7903e3802fbf9f593", "ref_doc_id": "70da607e-7d19-47fd-81bf-839e155c79d6"}, "ac67a572-79dc-4953-bb2b-401da20871ec": {"doc_hash": "487f78a1fcedceaa3d5aa33ca7447a09261136a7716391eb8a7ce88728cb93c5", "ref_doc_id": "70da607e-7d19-47fd-81bf-839e155c79d6"}, "61853ba4-7eab-41ad-adb2-1f46a9d041e6": {"doc_hash": "e8f08404c4fdcf2961edef75a0797f08c2567b7e299cf7680e18626fd757ca5c", "ref_doc_id": "70da607e-7d19-47fd-81bf-839e155c79d6"}, "8457722b-d6af-4bc8-adcd-a0bb79281f8b": {"doc_hash": "4ba869c48b15e396928df78ed3341dd1f05ac05cb89055f7c2fd1d4ad3bf3750", "ref_doc_id": "70da607e-7d19-47fd-81bf-839e155c79d6"}, "d89069f0-cf12-42ff-8d14-f07af910cab2": {"doc_hash": "1ce2c658c6379356ed43a3a61469d02d8f729866396733cad8514b1c699ea996", "ref_doc_id": "70da607e-7d19-47fd-81bf-839e155c79d6"}, "b051128d-89e6-485e-9c12-fd7bc32d4b56": {"doc_hash": "a45c380fdc89f9676cfe9899238050d72b643dc0b10f689f423d9f26bcad2faf", "ref_doc_id": "70da607e-7d19-47fd-81bf-839e155c79d6"}, "c0d07f0f-c7b9-4fa3-ae1e-7da456577a31": {"doc_hash": "8e803bbcebb8d8541469f35a1d66c8b64df8133a72f64bf79a9bb9a1a1040fcc", "ref_doc_id": "70da607e-7d19-47fd-81bf-839e155c79d6"}, "58f52f9a-d989-45e1-bf79-e1c4abcab881": {"doc_hash": "600b8e12492477a39453c5db4dc604956c12356d7eeb2aaa94b589c7dd444aca", "ref_doc_id": "70da607e-7d19-47fd-81bf-839e155c79d6"}, "883ce365-fbfb-403d-8b0a-8bee1ae1303b": {"doc_hash": "6782798f8cee69cd128e16b5fcb1e6abd403d3e51ed6f7ebd9b9588f90a515a5", "ref_doc_id": "70da607e-7d19-47fd-81bf-839e155c79d6"}, "bfa9c64d-023f-4dad-9f67-660b907b1e51": {"doc_hash": "e7ed144f88851ebe49cf931a48a9a855a6a06ec60dedc5e098311958b3a58850", "ref_doc_id": "70da607e-7d19-47fd-81bf-839e155c79d6"}, "8e4368a9-f037-46be-b4ce-b87fb7f600c1": {"doc_hash": "77c009545a6e7fdbbeb13d69c32e7754f0ae90a6449a9d67023d2904b79174f7", "ref_doc_id": "ea37bd0c-fbe1-40ae-aa75-ffa08508dd21"}, "2f187df5-cbf9-4722-8477-3128a20244b6": {"doc_hash": "eb7099632bb39918263c052001ee1a759b4e23d8dd37dad41d973f54e5ee786c", "ref_doc_id": "ea37bd0c-fbe1-40ae-aa75-ffa08508dd21"}, "5b2bdd58-f465-49a4-9b90-414522bb4107": {"doc_hash": "a1f2b0f0ec042ef1f25fcad56deddd5cdeb8a003031c6c38b8b0feb8cb9076e8", "ref_doc_id": "ea37bd0c-fbe1-40ae-aa75-ffa08508dd21"}, "38fe2b25-3fa9-4855-9579-c060e0076c50": {"doc_hash": "8201bacdfac370ed025e67d6813ccb7a9463bfd6374727b2f3fd056983d9accd", "ref_doc_id": "ea37bd0c-fbe1-40ae-aa75-ffa08508dd21"}, "086981e8-b73c-4cb8-a3f7-4da221613f18": {"doc_hash": "071ad30e8e5f6b71fc3b1927c4cdb26f927bd02057f2e00185eb4f017aed2043", "ref_doc_id": "ea37bd0c-fbe1-40ae-aa75-ffa08508dd21"}, "bda270ba-819a-4481-8c6d-5bedb2af63dd": {"doc_hash": "76b62358a4b2beb2480aaeb46d231dbe34d8fe09674b7f726c760e925d6be831", "ref_doc_id": "ea37bd0c-fbe1-40ae-aa75-ffa08508dd21"}, "8388bdbf-921b-42d0-ac78-03b28c46fe09": {"doc_hash": "194d4696f5abaf1131078d4cecea8ca814727813eb19976258a59cc1560446f5", "ref_doc_id": "ea37bd0c-fbe1-40ae-aa75-ffa08508dd21"}, "7940deef-3c3a-4cd1-b396-60b409fe4d76": {"doc_hash": "46422ab1fdb106cf047b5dbc0ca997ace5ee20dca4070ba9f90809f7af27b64f", "ref_doc_id": "ea37bd0c-fbe1-40ae-aa75-ffa08508dd21"}, "51c98247-99f5-4e2a-91e2-8cc1fb435bb7": {"doc_hash": "3325bc9cd993252ba75b5c676f886795d936cb3125d61830b29975fcd4523064", "ref_doc_id": "ea37bd0c-fbe1-40ae-aa75-ffa08508dd21"}, "a1b03d82-6430-41e5-bd7c-10d023ac5308": {"doc_hash": "e781a5b5f78df3d213f52687fc10945ace0eb00b05fbab627e5261a1bbde3cee", "ref_doc_id": "ea37bd0c-fbe1-40ae-aa75-ffa08508dd21"}, "9c63a038-d36a-49a1-a5cb-2a42c7f25f38": {"doc_hash": "b224622b45c18ba4640a2fd9d53764c0674d58a0645f26dd77dbe7eabafc181c", "ref_doc_id": "ea37bd0c-fbe1-40ae-aa75-ffa08508dd21"}, "90d54d54-a357-4046-87c8-2a6aa7e57d62": {"doc_hash": "5861131d8984db6a4bcc45bf2e1e8d57a95dd5eb096e77edac8543f46b90a1e8", "ref_doc_id": "ea37bd0c-fbe1-40ae-aa75-ffa08508dd21"}, "eb6b13cf-6d9d-4aa5-84e3-2b0de672c802": {"doc_hash": "695c9eaffd616996b88108a497a1e62887bfc8785700ddb8b98e11f04dcd5dea", "ref_doc_id": "ea37bd0c-fbe1-40ae-aa75-ffa08508dd21"}, "2a3ae4a4-3140-4e37-a105-628d71cf28d8": {"doc_hash": "2a28c14cc8786664ee0edef8562977518debad73446b4f4da66f5d7b3dc1755b", "ref_doc_id": "ea37bd0c-fbe1-40ae-aa75-ffa08508dd21"}, "13690820-35dd-40e1-a62c-bb85ab0f61fc": {"doc_hash": "fcc963123187162d7527ca98f4515653fd9251e89c309ef2fc4565c41ca558df", "ref_doc_id": "ea37bd0c-fbe1-40ae-aa75-ffa08508dd21"}, "41dbb4ee-fdef-4845-a395-03f32098e1b4": {"doc_hash": "6077bde69b95b6351d19b96258ca6a5900526cb42803bc95a93472aaf0e93b05", "ref_doc_id": "ea37bd0c-fbe1-40ae-aa75-ffa08508dd21"}, "5ef889cf-ffcb-4194-b6a5-e0af61053533": {"doc_hash": "88a9479cb3982acc69b2a0300c096355d875b45ba0f2e29953605cd9f4465687", "ref_doc_id": "ea37bd0c-fbe1-40ae-aa75-ffa08508dd21"}, "6ae5a834-f0b6-427d-bc55-b8505962798b": {"doc_hash": "07c7a54948c6e45021b71bd45e51abf17f11acae481e438d1aacae3054694cf7", "ref_doc_id": "ea37bd0c-fbe1-40ae-aa75-ffa08508dd21"}, "808e2a5c-6181-4186-a5ba-10bb116fd617": {"doc_hash": "82563169b29beadcf2119eb8d127382f690044bd7eca46d80ec5378c9ce68487", "ref_doc_id": "ea37bd0c-fbe1-40ae-aa75-ffa08508dd21"}, "09eadf83-4dba-4fb9-876a-f43043330e63": {"doc_hash": "07fbc931a32ea55eb192181f5e439155075d7bc30e9c92122557a9d3ae4802e8", "ref_doc_id": "ea37bd0c-fbe1-40ae-aa75-ffa08508dd21"}, "4b2b8f30-3740-4408-b35f-26de6860852b": {"doc_hash": "9111d09f5ee6efbf21d5a7871cb0a30e9f5e254c53fe7fc58e0d9080b243d0a4", "ref_doc_id": "ea37bd0c-fbe1-40ae-aa75-ffa08508dd21"}, "9d0afe28-d901-4b8e-843a-8de394e43ed2": {"doc_hash": "054a7da40d149972fa4bc4656864c75a4b25505451bb83656f2532b9610e6a89", "ref_doc_id": "ea37bd0c-fbe1-40ae-aa75-ffa08508dd21"}, "7648afff-36ba-4c0f-b332-7472d914ea31": {"doc_hash": "fb0fcf7e2b9e1b9c51ec15fd0e45e26904955123f960d7aad932536966a162e0", "ref_doc_id": "ea37bd0c-fbe1-40ae-aa75-ffa08508dd21"}, "3c06ea3c-09a9-45b2-a95e-9cc524b2b5a3": {"doc_hash": "a51a979b099405584fd4db717d0399723655e651f4390d9087cf1c1652c9f3e2", "ref_doc_id": "ea37bd0c-fbe1-40ae-aa75-ffa08508dd21"}, "3c6f5f23-af90-4ec8-9e5d-d78f4ba7772c": {"doc_hash": "fe13f43da1a71a46797e72e99dc79e43fceeb899984f3c89074b16a8c5ff2980", "ref_doc_id": "ea37bd0c-fbe1-40ae-aa75-ffa08508dd21"}, "a3cd0ff3-9ac8-470c-9f7a-482ecadb8236": {"doc_hash": "a33736bbc02e0ec7cf1c16a7be62a1337cec100058dbff014dff8d97d7d4ef21", "ref_doc_id": "ea37bd0c-fbe1-40ae-aa75-ffa08508dd21"}, "0094ecfc-7452-4f53-a816-eb9aeb53c0bd": {"doc_hash": "7102ed5fbd3790c5f0e040d050bda7c03c5f2feb6807e5be9c08cb92effee1b8", "ref_doc_id": "f4ddef2e-0215-4035-b117-0936dac4b268"}, "68716af3-7a5a-4200-bb4c-ad4325a4f3b7": {"doc_hash": "03f992ff45fe130ee7c3549cccf956c6845ea4b08ac2364c1fb4828ff1bfbb88", "ref_doc_id": "f4ddef2e-0215-4035-b117-0936dac4b268"}, "cbb74205-c008-4f1d-94c6-00e553039e13": {"doc_hash": "e09345639eadfdebd834f21a73440eb1e8ac9a1d319aa05e888719050c2e1970", "ref_doc_id": "f4ddef2e-0215-4035-b117-0936dac4b268"}, "74924b8a-1105-4962-8b31-bc3ca6e2859c": {"doc_hash": "4c91fbe48191ce492ecb6222d8461a558ad79c3b768042a94710e08a23788178", "ref_doc_id": "f4ddef2e-0215-4035-b117-0936dac4b268"}, "bb3321fb-504a-43c3-9f4d-3c85a89772c5": {"doc_hash": "aef2e9b2b08f7637b94bcc1c2bffc95bf2f7132554b82647d85fc13e7c919614", "ref_doc_id": "f4ddef2e-0215-4035-b117-0936dac4b268"}, "bec77d8c-1247-43d0-9116-44fccfea4da9": {"doc_hash": "5fc46b61c79ae5d63bcdfb29c5fedc59dd42f9056a25fae7f78557370795cc55", "ref_doc_id": "f4ddef2e-0215-4035-b117-0936dac4b268"}, "758bfce2-77cd-4820-8c37-9941d781101c": {"doc_hash": "955049586c8e9c99116f1c5c38c269a7d17e211b65960a0db06ffe083b5f97df", "ref_doc_id": "f4ddef2e-0215-4035-b117-0936dac4b268"}, "5aee6360-e016-4333-b73d-a704fcbe12f3": {"doc_hash": "64fd7a9e1ca85fa420628be683f390e1ca15297b98ae2a650f70ed63cc121b66", "ref_doc_id": "f4ddef2e-0215-4035-b117-0936dac4b268"}, "6b567941-987c-4542-9f0c-b07b85dd6084": {"doc_hash": "c53da945cbf7fa4ecd5e2f5b986a55cc1c105a451ce69df9bd35b298adc69e2b", "ref_doc_id": "f4ddef2e-0215-4035-b117-0936dac4b268"}, "fc810ece-4b89-4699-ad65-f3d63f855d78": {"doc_hash": "6d7e2166fd10d9031912c7596532d8fa4c6de38085b3f9a4b2d9d13e1c1ebf15", "ref_doc_id": "f4ddef2e-0215-4035-b117-0936dac4b268"}, "8c7685e1-0181-4d25-a04b-d08470c2709b": {"doc_hash": "7b1e2907948811b3fa0067c79ba304dbb565888cbf51cdad4cf5563d85f8d8e8", "ref_doc_id": "f4ddef2e-0215-4035-b117-0936dac4b268"}, "098e13f2-35a3-47c6-b86c-99aef54422bb": {"doc_hash": "ab9430992382f26ee3e8373568a1f32da0bd8297365658821b7890ff2004ad9d", "ref_doc_id": "f4ddef2e-0215-4035-b117-0936dac4b268"}, "e1819288-732c-44c6-99e7-253496e4e9ee": {"doc_hash": "b9f74910770c7448c1967d6ad3df3c26f050068d7ecc76edcaf4413bd070eaa4", "ref_doc_id": "f4ddef2e-0215-4035-b117-0936dac4b268"}, "ec7428ab-b246-486e-a79e-f8922f495028": {"doc_hash": "7b4381298dc0c9c008fb40a3af225e7d8850bb8203c4ab0c13869376a3dc3765", "ref_doc_id": "f4ddef2e-0215-4035-b117-0936dac4b268"}, "816a18cd-e8ef-43e0-a00d-ad7add2b688c": {"doc_hash": "df838b0cdd80096a225774b9b799f4f48e58d17f6784728d869c85637135c028", "ref_doc_id": "f4ddef2e-0215-4035-b117-0936dac4b268"}, "6fe7546b-e677-48bb-8cb3-a482cb5d7500": {"doc_hash": "29276867f1f3e835db6e50bfe0df37c2bb5f2efb3a9add92f3246b47facdfae3", "ref_doc_id": "f4ddef2e-0215-4035-b117-0936dac4b268"}, "eee39b5a-5880-421d-a42d-9e39a91f490d": {"doc_hash": "cb89769d9a3c2dfff22d2ea1a6dfa8dbe2470d074e52228745e8c2c762bb346e", "ref_doc_id": "f4ddef2e-0215-4035-b117-0936dac4b268"}, "1be0be6f-ad3c-4a65-a480-f4d19fc583cb": {"doc_hash": "60f76075c730fdc89cfc5834d0795f5e1981b2f2f460575c2d61e6f0285ab7f8", "ref_doc_id": "f4ddef2e-0215-4035-b117-0936dac4b268"}, "b80e5278-ea83-409f-a793-a9b26c156255": {"doc_hash": "1991e248fba49374c16a891b7377e936c0c1f92281745b6b6d30a5a6638de979", "ref_doc_id": "f4ddef2e-0215-4035-b117-0936dac4b268"}, "4821ef24-fa6b-46a8-bf23-a78f30e0b5f9": {"doc_hash": "9d35e8ad2f425b726f2dd9a20fcc37794ae153760abd3ece70378556ba1c43cc", "ref_doc_id": "f4ddef2e-0215-4035-b117-0936dac4b268"}, "0d031b4a-b76a-4fa4-be80-56a0b3ece706": {"doc_hash": "cf6efc744a53ca633f96406aa5b7ab983cb2b34e8897c8e335a7c51561aa0d60", "ref_doc_id": "f4ddef2e-0215-4035-b117-0936dac4b268"}, "544b7fc1-4328-405f-be18-09f90d4e20f1": {"doc_hash": "0645740109f76510790fba98c11ad0e07ca66add6bd5bdd7e9bf145f5c2d0297", "ref_doc_id": "f4ddef2e-0215-4035-b117-0936dac4b268"}, "7597e6b5-d145-4bac-bd51-94d6630882ad": {"doc_hash": "2e4d3380ebaef96ed5a96e59210c12120143d6f544c80b9ea55d4d2761ed09e7", "ref_doc_id": "f4ddef2e-0215-4035-b117-0936dac4b268"}, "821f2aea-1c74-40e3-ae09-87c7b985496c": {"doc_hash": "a662c28189f437a7452a82337146115275ff993ae53a1ccc59c286cb48023e64", "ref_doc_id": "f4ddef2e-0215-4035-b117-0936dac4b268"}, "247ac1f4-5611-4287-8478-a0cbaca264fd": {"doc_hash": "7b8fbad012087d59765570656d90d842156be6578cecbef7323c1ad0279269b9", "ref_doc_id": "f4ddef2e-0215-4035-b117-0936dac4b268"}, "f4161c25-1f35-4ce6-b202-915fc722ec4b": {"doc_hash": "5bfaec74ef5b318dd72e6cb077fa7f6a85d7c47c29a219d9b5161371f04aa489", "ref_doc_id": "f4ddef2e-0215-4035-b117-0936dac4b268"}, "8c0e7c05-ac46-4505-90ca-704abf3fd5d8": {"doc_hash": "fffd61eb4d71c62ce6e2230a97ab0219da6ea4a6a33bc3ddecea7ccac6b3905c", "ref_doc_id": "f4ddef2e-0215-4035-b117-0936dac4b268"}, "4a416d8f-6973-47b3-a26b-ef6670c3d4e7": {"doc_hash": "755f508d318dc42e0d6612a09c7937a6ed1fb56e1775f512becbb99ad5d44713", "ref_doc_id": "61ec5d58-e8e6-4fb6-84e9-6e9504c022e8"}, "60ba4309-17a1-4c2d-8bbf-9c9e18dba141": {"doc_hash": "fbe88b5537897c9747f6cca9c18c6e36a5df30b9e9011d42eedcb750d317d87f", "ref_doc_id": "61ec5d58-e8e6-4fb6-84e9-6e9504c022e8"}, "79e71ee7-04d6-449b-aff7-a45d731645b6": {"doc_hash": "0bcb6e17500cb9f5c8e3ad1d56a239f37399bbb646a18d4adee9bdf8bb860ee2", "ref_doc_id": "61ec5d58-e8e6-4fb6-84e9-6e9504c022e8"}, "42c97ddd-b746-4886-a6df-9b2edaf071eb": {"doc_hash": "277fe29f7ba247797b9c70aa2c0ab28c717273f74f5394f3dd7c2eb3bf1f342f", "ref_doc_id": "61ec5d58-e8e6-4fb6-84e9-6e9504c022e8"}, "0271da0b-b971-4510-b680-2a5313c69fa4": {"doc_hash": "8afe8d308737f7bfb37705a083ab3ac16c9401520177040ab452caba49b84aea", "ref_doc_id": "61ec5d58-e8e6-4fb6-84e9-6e9504c022e8"}, "ac1af8e0-b24d-4926-b892-d19d6f4446ea": {"doc_hash": "a038ff56dfe5962c78efab880c8087f70b37c9ae9751a85945209adc6da9459a", "ref_doc_id": "61ec5d58-e8e6-4fb6-84e9-6e9504c022e8"}, "bd48f49b-267e-4657-a120-f9e1a6a3ac16": {"doc_hash": "06bb917a0caf018cc43b02679328da693bd79eb336d3cd84e04cd6d5af10f0d7", "ref_doc_id": "61ec5d58-e8e6-4fb6-84e9-6e9504c022e8"}, "2c45b983-605d-486a-9ac3-4b86f24ae205": {"doc_hash": "d3ac596b1e3cd4178c723ccaf728983438215d2d4ff15c10f2e37d64d394a98f", "ref_doc_id": "61ec5d58-e8e6-4fb6-84e9-6e9504c022e8"}, "c960e201-7797-430f-b192-cfad665aa38e": {"doc_hash": "028baa393bb5d85a371aa065ae103f0907def08027a17757f32f8070e33a0bd8", "ref_doc_id": "61ec5d58-e8e6-4fb6-84e9-6e9504c022e8"}, "1fcfdfd8-c7d3-4abf-9b7e-6479e46d6c4a": {"doc_hash": "7d959cd36d5a11bf4aefe6846772535e68669b9297f2581fb16ce01c664b6d40", "ref_doc_id": "61ec5d58-e8e6-4fb6-84e9-6e9504c022e8"}, "38570272-486a-4657-bba7-50b05d08e0bf": {"doc_hash": "c1891955000468168a4b833cacb47691de95c5901b19317e436ef62dd34c146d", "ref_doc_id": "61ec5d58-e8e6-4fb6-84e9-6e9504c022e8"}, "8cc1f111-56a1-4622-9f32-0493facf2df1": {"doc_hash": "274f36f74572487f2ea7dd877b05569acee327835b3c89ddbe039ec3b0240dea", "ref_doc_id": "61ec5d58-e8e6-4fb6-84e9-6e9504c022e8"}, "29a86ea2-575c-4e2c-9d02-7acc2af37446": {"doc_hash": "4734303190a1a818a4a7f21667469b31f386bcd008a8c9d8e26d98a6112b1304", "ref_doc_id": "61ec5d58-e8e6-4fb6-84e9-6e9504c022e8"}, "2dfd3e23-a11d-44ca-b22a-7cce44be461a": {"doc_hash": "ec2fdec775f89983d9ccda8b167e808131203f04508d72c01291afe7592a9bac", "ref_doc_id": "61ec5d58-e8e6-4fb6-84e9-6e9504c022e8"}, "d27b3aab-8c7d-4b9c-9944-df6005c2fae3": {"doc_hash": "97a9fc7e64d9e34976f9897153f1b2d73cc6389f5b649402eaee4f520a14e48e", "ref_doc_id": "61ec5d58-e8e6-4fb6-84e9-6e9504c022e8"}, "cac554a4-a098-43e7-a068-f3ecacc60e50": {"doc_hash": "a0e0f7e8ebab05172199489c878e2c4f523a80e96e22d6d2c8c0d58ec77a7180", "ref_doc_id": "61ec5d58-e8e6-4fb6-84e9-6e9504c022e8"}, "32b8af8f-53f8-49b2-9ca0-42466b90b24a": {"doc_hash": "b7efd800f1781e1e2a3c130ce040b24b7f6ad0a3929e764abab6ef8aefc20322", "ref_doc_id": "61ec5d58-e8e6-4fb6-84e9-6e9504c022e8"}, "b7a8c00e-88f4-41ee-8fec-6730b06ba00b": {"doc_hash": "8f6d1f78c00cb9f2f20ed6860c06771e83fa535f933bb07dda8fdabe4659fec0", "ref_doc_id": "61ec5d58-e8e6-4fb6-84e9-6e9504c022e8"}, "49e08579-73aa-4b23-8a9d-9748e68d8de7": {"doc_hash": "07aca1e5125cdc3c87951f46eeba3d0a4958047d737a21c8dbe73be7daac687b", "ref_doc_id": "61ec5d58-e8e6-4fb6-84e9-6e9504c022e8"}, "05634269-8572-4ee3-8ba3-02c7a63196b4": {"doc_hash": "06dbf826bd6cd90e0a10486286215fbffa5493d58a8926678b8451b7e120e609", "ref_doc_id": "61ec5d58-e8e6-4fb6-84e9-6e9504c022e8"}, "6a005061-bdef-41fb-b95b-3069f61ca453": {"doc_hash": "123e3a37d82ab08f0e91c5d334c535cc0c8ad43f904a7b3c49e7c1fbb5eaf057", "ref_doc_id": "61ec5d58-e8e6-4fb6-84e9-6e9504c022e8"}, "7205a9e2-8dc3-461b-abad-d0b879f8a0bc": {"doc_hash": "28acdf5674846a75f7194d6eee5aaa2b7d8ac0e5f9a29ba35a6a711c43f2f397", "ref_doc_id": "61ec5d58-e8e6-4fb6-84e9-6e9504c022e8"}, "8baff24b-4d81-4c4b-9842-65bcb9fe83e3": {"doc_hash": "12a2dc2e8ca44a387be30527d4929a9a2a0f41fa1e8411404baeb89e39477f7a", "ref_doc_id": "74570293-485c-474e-a351-234bb8205358"}, "8eae83da-46ff-4fbb-9775-750b89167566": {"doc_hash": "4d5176619471e637eba3578e587a008d00a3467a958a48428acc9b2e649a42f5", "ref_doc_id": "74570293-485c-474e-a351-234bb8205358"}, "6a9acc26-72f9-4383-b388-bacab12ae13b": {"doc_hash": "cfbaba811852baa58e9d5fd5afe6a3a7449407e349defbaada568a3ecc832f02", "ref_doc_id": "74570293-485c-474e-a351-234bb8205358"}, "727c1540-b098-4f33-9114-2abec99aed10": {"doc_hash": "e1b05c80302f2a40510276397114f47dc78653afb99e38b74a77e0eea611cbb7", "ref_doc_id": "74570293-485c-474e-a351-234bb8205358"}, "d23008ab-ebf7-489c-bcdf-2d83739c57b1": {"doc_hash": "e460343ef4f1a76b681afd0d693aab0e7b12ecb14bf09f31eac87b2de545c153", "ref_doc_id": "74570293-485c-474e-a351-234bb8205358"}, "4d4d51eb-9d33-42f8-bf91-4bcd6f2b6643": {"doc_hash": "7bf3963dee58b48c2a2c3b761c05084aefd2e684b14b4ed37799bd60f5ac6d1c", "ref_doc_id": "74570293-485c-474e-a351-234bb8205358"}, "d26ac9b3-2fe5-4d61-bbf8-30f72c27d6c5": {"doc_hash": "a6b66a8a1558e09b9378b29ec3bdc0705d7671a14d79c11952238ee9a5cebb26", "ref_doc_id": "74570293-485c-474e-a351-234bb8205358"}, "41773650-053c-48ba-8540-ea04d1cba70b": {"doc_hash": "070d48524c4457de28a4e70ecc3dadfa6a2403f358c8ef88c4c6010cf2aeb8b2", "ref_doc_id": "74570293-485c-474e-a351-234bb8205358"}, "a89052df-ea23-483d-ba30-b3d4cdf6d871": {"doc_hash": "681708fe1af79653fc725f2c6a15a3bc41d8995166ea48426b4912b937e2f934", "ref_doc_id": "74570293-485c-474e-a351-234bb8205358"}, "78e1cf97-8c86-4675-a9b4-0c361fb58867": {"doc_hash": "95686f09933fb87a012415e0ed5ede19f29a9f96eda58c6d292a433cd8ba4507", "ref_doc_id": "74570293-485c-474e-a351-234bb8205358"}, "eb61c10d-953f-41ae-8dcc-b94f9483125d": {"doc_hash": "d27266874a4a084c7c3ae106fce66488700beb9f2d22e844209c06ea63b23478", "ref_doc_id": "74570293-485c-474e-a351-234bb8205358"}, "b9a7d083-bd5d-483c-b711-696130e44abc": {"doc_hash": "c8804d3c33cdd57a7b066d3767bbc2e841b2c26617e2bf675f706718e5bdf919", "ref_doc_id": "74570293-485c-474e-a351-234bb8205358"}, "0df0067e-dbb9-46fc-bb5d-0737d74ab8be": {"doc_hash": "097b8ccd9a678a2cfce904076f2f11bed64c63b3eed5a4880ecf7f26439e9d1e", "ref_doc_id": "74570293-485c-474e-a351-234bb8205358"}, "aa49c725-0e17-4994-838a-d4d23e211a11": {"doc_hash": "dc47541129e58b165b3480c1c43f238e90923672d66d07a9568694d2064b1634", "ref_doc_id": "74570293-485c-474e-a351-234bb8205358"}, "af2ad513-6c36-4fd3-809c-2ffcfd2009bb": {"doc_hash": "cd102ce01619e3fbf2c6ebe32696ea920a63ab850320aae2e6fc21b12ee308f4", "ref_doc_id": "74570293-485c-474e-a351-234bb8205358"}, "becce4a1-a11b-42f9-b338-6c07fbbfbd7f": {"doc_hash": "8acb97fa31307c409c9921f60b4974beafa7b7adf256a5aa99688e68a6b8a4cc", "ref_doc_id": "74570293-485c-474e-a351-234bb8205358"}, "65d30bc8-0488-4a55-bbfc-dc326721829c": {"doc_hash": "2d92a78af1cbb09728d229deadd244be00c63f524eee6e83bea3ff8493fd74a8", "ref_doc_id": "74570293-485c-474e-a351-234bb8205358"}, "3b9a3d29-ebea-41d3-a7b2-e48a3c38d4e2": {"doc_hash": "0d85fa2e145b2440b2a07ff3df2a71b842a789781b234727f50e5a27f921c59c", "ref_doc_id": "74570293-485c-474e-a351-234bb8205358"}, "4301fea8-52d6-4a8c-8e30-1555fe4035fb": {"doc_hash": "8a989ee34ca54e873857604fb305953d3e2278dd8223dbd75323d7cff85d78a9", "ref_doc_id": "74570293-485c-474e-a351-234bb8205358"}, "20c51fc3-5a7e-4774-bd28-21e513a90442": {"doc_hash": "9050b4a59d0e29625046837a2965f7b7fc7c9424e7a6f24c5af547ff7554fedc", "ref_doc_id": "74570293-485c-474e-a351-234bb8205358"}, "bf39bee7-daac-425c-aa5f-33e4b760c63a": {"doc_hash": "f94793bdef1687f64a4dcc86761ab20516b1f9564ce9948b1468faa6207bef0f", "ref_doc_id": "74570293-485c-474e-a351-234bb8205358"}, "df548ac4-047e-4d47-8dd6-0387f3ecbdff": {"doc_hash": "7a0a058d671e1c2552059879330561f612f0a422829db8c4a8069aa46aabfdec", "ref_doc_id": "74570293-485c-474e-a351-234bb8205358"}, "4223aedf-4834-4877-9c06-dd26378fe0ff": {"doc_hash": "294eb998398769ec83470ea9276d4e82f53d2f3643515c03ba5ceb9c7772483e", "ref_doc_id": "74570293-485c-474e-a351-234bb8205358"}, "1c1e8ab1-e85a-4513-8074-b58d99d29589": {"doc_hash": "501de49dd77ca7b1907286078ec3d58b82a43ee17c26a29d9913e99770c96835", "ref_doc_id": "74570293-485c-474e-a351-234bb8205358"}, "02f98aa0-d06e-4e74-82a8-e1b44c3cca30": {"doc_hash": "3fe386134bc2cf8e8f93c87165b7519171d6dafe6a18542009f6a47748f61a2b", "ref_doc_id": "c4835e48-c324-4b54-8fdb-9d717b314aef"}, "06eea0de-0289-43f4-823a-8eb324689b7e": {"doc_hash": "e0c6f2a7c3fc54e4fee6931c2fc33880e3cb686206863c148432658fd6317628", "ref_doc_id": "c4835e48-c324-4b54-8fdb-9d717b314aef"}, "f6d3f8ef-ced1-420c-abb6-9162c5ee9bc0": {"doc_hash": "366fec60c6073800fe2ff427588cdbd1f6d0eba8d27d69cfddc04eab8eb1591f", "ref_doc_id": "c4835e48-c324-4b54-8fdb-9d717b314aef"}, "9dc09fbc-8614-4f9b-aa8a-980443b3226a": {"doc_hash": "2ff36e695411c02dea005e33481f63a3f671db88da8033b71ebd040de699becd", "ref_doc_id": "c4835e48-c324-4b54-8fdb-9d717b314aef"}, "66bf18aa-9177-4ddc-8ef1-ede94365999a": {"doc_hash": "54bff54f28843602e0170d32baa8d12391c7e15edb7dfacc28a068efd4ec7c0c", "ref_doc_id": "c4835e48-c324-4b54-8fdb-9d717b314aef"}, "7e7aa8ae-6ce1-4a30-83fb-1896ea98c553": {"doc_hash": "edf7b3634dd333560a17a301b9a1ee58ffb9c0abf1fd0f555ad0b75243d1c89c", "ref_doc_id": "c4835e48-c324-4b54-8fdb-9d717b314aef"}, "f6780622-dfec-45de-aabd-30c51640a944": {"doc_hash": "045b1265f830389e9496d2e3c5ed42a2058e8f0b6ddc245a9819dabd141f423e", "ref_doc_id": "c4835e48-c324-4b54-8fdb-9d717b314aef"}, "ce6d279d-a90c-4444-9afc-e8fb7b81baed": {"doc_hash": "09931c80815ce9379ac8da70d32e0a11741c0257c6ab32c40274223876adf04d", "ref_doc_id": "c4835e48-c324-4b54-8fdb-9d717b314aef"}, "6d7000d7-98d3-4070-b8c3-74fa3c56fbed": {"doc_hash": "eb7864cad6ba4e1bf401a9c43c5044385999888cd2be0441b9b725e0e6c8ca2a", "ref_doc_id": "c4835e48-c324-4b54-8fdb-9d717b314aef"}, "8be15bbc-b207-4bee-a650-4ec6c8c9e821": {"doc_hash": "9f50e883be7e9d48c32dae3ec4d9ec9596ecaba0559d9ae477929f248da4744e", "ref_doc_id": "c4835e48-c324-4b54-8fdb-9d717b314aef"}, "029eed23-ba9d-4484-9092-4718d189dfdf": {"doc_hash": "e95ad98bf1b2d12b7fac759b2fcd6d1d07736079e199598c0a15255b1a868123", "ref_doc_id": "c4835e48-c324-4b54-8fdb-9d717b314aef"}, "c4eb5308-8c4d-448a-8150-9b38265af213": {"doc_hash": "d7edd448eae64023b9d8d08ea22c84736167b032f346ac3651ab942096ebf89f", "ref_doc_id": "c4835e48-c324-4b54-8fdb-9d717b314aef"}, "7c863a50-9b4e-44bc-89e9-748ba9f01886": {"doc_hash": "dfb308f9928b5aae6f51932e030f03783c93dcfe79df60a1c51d1e1b0116d4b4", "ref_doc_id": "c4835e48-c324-4b54-8fdb-9d717b314aef"}, "1413d02a-5d15-4ec6-b9cf-15d2be1b3b5d": {"doc_hash": "76f6439953478b7ad88362e77c7c456f1a6aed23f7da8b18698645e24a9a956d", "ref_doc_id": "c4835e48-c324-4b54-8fdb-9d717b314aef"}, "d822f27e-ddb6-48b4-943d-f047d6519b19": {"doc_hash": "6edb99763f2aefd37ba88f9ec3235dc8b2adf86cda6cb7d5f0f3c5785ed0a10a", "ref_doc_id": "c4835e48-c324-4b54-8fdb-9d717b314aef"}, "5c0051ac-b040-4fba-af49-86205690aff6": {"doc_hash": "8678cd0d793e8c932d23a2b568c74d726dbaab3c0c89c1b50c1bff4f1088af44", "ref_doc_id": "c4835e48-c324-4b54-8fdb-9d717b314aef"}, "25ae07d1-0b28-4364-ad78-0255bd560cef": {"doc_hash": "6f63cb66b0cce69e76d4cc2e46207601af98164bba79cabcffd90da7baebd48d", "ref_doc_id": "c4835e48-c324-4b54-8fdb-9d717b314aef"}, "0ecfc150-38bf-4c9a-bdb1-9f7e5c85534e": {"doc_hash": "d4acb2879c75b83317988918c5a1a3033f6e3aa2b6766c51df3bd864ebaa19d0", "ref_doc_id": "c4835e48-c324-4b54-8fdb-9d717b314aef"}, "db96eb6b-7a4b-4f79-904e-7c9b559d6396": {"doc_hash": "b7bf3dbaea0115d6367119e069d3eacd4ab06ce262ef9c772ad89deccb49c589", "ref_doc_id": "c4835e48-c324-4b54-8fdb-9d717b314aef"}, "cda4ded9-b9d3-4d99-8e9e-61ef62d9de04": {"doc_hash": "78e114116b9a28def765656cc6790530ba92dbdcc284324ba2ff1e461d6ea772", "ref_doc_id": "c4835e48-c324-4b54-8fdb-9d717b314aef"}, "d4c2826d-b8b8-49d2-866a-46af637d7b92": {"doc_hash": "fbc0562dd7efcff4773673a3e51361f0bc27cf6877b22bc79a127bf6dfa561c8", "ref_doc_id": "c4835e48-c324-4b54-8fdb-9d717b314aef"}, "86ee9854-1aee-4b69-97fc-406b1f7904ee": {"doc_hash": "509a866a76e5f9acd7a4fb1d543ca772bf4186b44caf2a75aef9dea3950e61d6", "ref_doc_id": "c4835e48-c324-4b54-8fdb-9d717b314aef"}, "5991b8ef-718f-4fc9-993c-b6e48df4641c": {"doc_hash": "9607a414718fc9720f668ccf167f5fc7f7ea0c5c33204ab97233ec57d8ca6f0d", "ref_doc_id": "c4835e48-c324-4b54-8fdb-9d717b314aef"}, "045416b8-dabe-45c1-a0ff-738e3b4b9419": {"doc_hash": "4cb3c6e1a75bc1dc35d2c30035483859deb0165f5daa8fc1432d27efc59673f1", "ref_doc_id": "c4835e48-c324-4b54-8fdb-9d717b314aef"}, "dbde3349-9f40-4423-a60d-9df84ac1dddd": {"doc_hash": "5370a68e4c71c2116a0997701dfaf1fc09a9030a63adf705dc0e8894b30af3ce", "ref_doc_id": "c4835e48-c324-4b54-8fdb-9d717b314aef"}, "96bf0892-867d-4b12-b7e5-8c406deec22b": {"doc_hash": "5f0c6a0c8ba634e024305ad91b0eb88eb2971966e1e161ab946474c2fdb66abd", "ref_doc_id": "c4835e48-c324-4b54-8fdb-9d717b314aef"}, "66180e6a-9cf6-468a-b9d9-e75b8d555121": {"doc_hash": "3a5183193268dcd23ab4b4428c37b1cea674d7ca0799c0a238e91dd1278b34de", "ref_doc_id": "f7e2d2dd-66c9-4d9a-9d5a-780ab89c5595"}, "9af6c85c-aa25-49ef-aa56-e0e0a17616a2": {"doc_hash": "8cdc2c60433f5318cae80c8d54e50d795d672e895849c0c9fe0b559a42793fb2", "ref_doc_id": "f7e2d2dd-66c9-4d9a-9d5a-780ab89c5595"}, "f025706e-2bcf-4632-beb6-b7cca7ec2707": {"doc_hash": "723411cd23f139c0bc16332cc0bc3b50c164cf39f00d7f73a7b468941c1b7953", "ref_doc_id": "f7e2d2dd-66c9-4d9a-9d5a-780ab89c5595"}, "322a2c5f-8f4a-413f-bdf3-77795aec9e19": {"doc_hash": "a2b8dcb99bec487d20e110d8f6e977dce5a2006c218e10b23607d21f841db3f7", "ref_doc_id": "f7e2d2dd-66c9-4d9a-9d5a-780ab89c5595"}, "ad162914-f7ba-4c31-a7c8-c9a3a724fcb0": {"doc_hash": "00c0d1cf6261d7401c54c0958a6b859acf55ab33c5947560e5bf45182241939e", "ref_doc_id": "f7e2d2dd-66c9-4d9a-9d5a-780ab89c5595"}, "dccbf095-87c8-4e28-a46b-45b0ff9ee73d": {"doc_hash": "7dc1b24a9d6e3231885f99e533fcecdbcbc94eb3fd0bfd1777265630345ab4c8", "ref_doc_id": "f7e2d2dd-66c9-4d9a-9d5a-780ab89c5595"}, "de19cbb8-a38e-49be-9ecb-62d40d7998e2": {"doc_hash": "522a46fdd2ef8c94ffa772ddf35816d7d79800a109c15e4cac95457714e8dc98", "ref_doc_id": "f7e2d2dd-66c9-4d9a-9d5a-780ab89c5595"}, "0680e701-d168-48aa-a6c5-0da8988dd2f3": {"doc_hash": "949dbbca49d14f0b0c063f3225be7ed3457d4061ac704b689869b9b39384f5f1", "ref_doc_id": "f7e2d2dd-66c9-4d9a-9d5a-780ab89c5595"}, "8e55637e-061c-4ac9-a5bf-e0e34f70fedc": {"doc_hash": "c6161070b6d689fff63e1efdd378485d412e9c957c4afb3fdd634e8bbb2bb3be", "ref_doc_id": "f7e2d2dd-66c9-4d9a-9d5a-780ab89c5595"}, "31e99e59-c6e0-4a85-be9e-da0c14e86164": {"doc_hash": "6c141f33a43ec541fce6a972fa77ba85801c0a8528357aa0830906162443adc4", "ref_doc_id": "f7e2d2dd-66c9-4d9a-9d5a-780ab89c5595"}, "1bff5aac-0336-4399-a27b-36e6840f002c": {"doc_hash": "45a7d00f724a2c51feb6e23a3c1bd7353d25b4181c12b42dff0ed39b6e6bed32", "ref_doc_id": "f7e2d2dd-66c9-4d9a-9d5a-780ab89c5595"}, "551bd446-fb15-4021-80ac-36ca6fe34b96": {"doc_hash": "4480dd76a78a47dd4d898f9470816128afd769d70e30c84b78067b317cccf49e", "ref_doc_id": "f7e2d2dd-66c9-4d9a-9d5a-780ab89c5595"}, "4bd2039b-9f94-41b3-9f65-b19bc647d3a9": {"doc_hash": "b02ae60915add5b29db341e78ae84aa427be9d0195aec379970322039d191623", "ref_doc_id": "f7e2d2dd-66c9-4d9a-9d5a-780ab89c5595"}, "a6cb4269-ddb1-4e0c-8d1c-ee7b3356e31e": {"doc_hash": "3c414d3c1051e2ded67bc72e94dbe302ca38cfdb2a644e86227aa0b2b59aafcc", "ref_doc_id": "f7e2d2dd-66c9-4d9a-9d5a-780ab89c5595"}, "915ba775-ced9-42be-97ea-745b3aaded44": {"doc_hash": "9b4060845c9763e88be435949abe45a33ed5d30a01632d952811cd7d50d955bc", "ref_doc_id": "f7e2d2dd-66c9-4d9a-9d5a-780ab89c5595"}, "0487e2ca-a05f-44fe-9f2d-e357486172f2": {"doc_hash": "1e502c0998ed7f1986ad268c6a02f0c968016c2972858e09fd4ff8347a9dbb5e", "ref_doc_id": "f7e2d2dd-66c9-4d9a-9d5a-780ab89c5595"}, "f5bbc06e-f848-4043-aed5-a6c196f18861": {"doc_hash": "e47d78562785102cedd880d5b496937abd0194c7d93642b195ccb96157b7c3e3", "ref_doc_id": "f7e2d2dd-66c9-4d9a-9d5a-780ab89c5595"}, "7268c014-beef-465c-bf7e-90b3125a1786": {"doc_hash": "0424c08b08d17f8a36b33548b41df13df5e71ddfc9526a1dc38772b609e66f1f", "ref_doc_id": "f7e2d2dd-66c9-4d9a-9d5a-780ab89c5595"}, "51c2a2d6-0639-4e01-8f78-33456232bd01": {"doc_hash": "dc6b998f9c6b521a12ca3b02f1d16443c2547dd8ebbc5d2fbeacd01d3798f1ea", "ref_doc_id": "f7e2d2dd-66c9-4d9a-9d5a-780ab89c5595"}, "d06dd9e8-aa9b-4d70-a49e-d76a76847115": {"doc_hash": "b7dbf29fa2f577d254b8e7baf1c9c94f9023d2a761a1759e94e088f132451039", "ref_doc_id": "f7e2d2dd-66c9-4d9a-9d5a-780ab89c5595"}, "b271b38b-a9fe-453e-b928-851e76b029ca": {"doc_hash": "ad232d404032c045a9dacb928c8df958da3bdbfd2598f7837f7acbc81afb063b", "ref_doc_id": "f7e2d2dd-66c9-4d9a-9d5a-780ab89c5595"}, "bba65e5e-d41c-4b2d-bb83-f178a4ed65b1": {"doc_hash": "15ce2aa064463ad2bce236538524b4b429dc3065671f58a853a8c8ac23c9b7a5", "ref_doc_id": "f7e2d2dd-66c9-4d9a-9d5a-780ab89c5595"}, "8c576334-9de0-4f18-aa0f-9f8ed59631b7": {"doc_hash": "026b1059b77cf7745ed4b83040e8f327136db47806da822c41faf2102fcfe3d4", "ref_doc_id": "01bc6e5f-cc79-4b05-99f5-5a1b943788f8"}, "f60f19d6-e0f6-405b-9073-116af28870fb": {"doc_hash": "d0922be7dd03043019868c2a9f86d2e3eb79fa14309417d5db88ad78573788e0", "ref_doc_id": "01bc6e5f-cc79-4b05-99f5-5a1b943788f8"}, "000de7d5-dd08-430c-b762-b4c68fcaf984": {"doc_hash": "bb6749bc7491720d7f8e0ff704e19daed1d96bd432888f8f0ba5190d89afbec9", "ref_doc_id": "01bc6e5f-cc79-4b05-99f5-5a1b943788f8"}, "b61365a3-7cc7-43d0-8353-a044b3a8ac85": {"doc_hash": "3dfa5c1fa8e29c05216adb2a2ba7fa6254ec16c96151e3891b801e5e7670b11d", "ref_doc_id": "01bc6e5f-cc79-4b05-99f5-5a1b943788f8"}, "64f9b6fb-99bb-44f6-8e99-3f31ebc1064e": {"doc_hash": "66499c196be6687c2319633fe3cc18f7ad1ba56cb5655320f4f4923e9a52a0db", "ref_doc_id": "01bc6e5f-cc79-4b05-99f5-5a1b943788f8"}, "68abde1a-70b1-4c57-abe3-dfaa19975c98": {"doc_hash": "e4e359580ac0844b282de2cca9dbeaefab84c7657bc0740a0eb0ad221e539465", "ref_doc_id": "01bc6e5f-cc79-4b05-99f5-5a1b943788f8"}, "9bf5d397-98aa-4c6a-b655-adf938ba25d3": {"doc_hash": "b3ee5fa83b87453fd4190f774bf065dc20e4a8c50a6a174d1737cfb57b7ff795", "ref_doc_id": "01bc6e5f-cc79-4b05-99f5-5a1b943788f8"}, "86e8b7fc-6187-4975-9d44-6b82a4399ee9": {"doc_hash": "d4f2d1e521f36f444fbc0fae14c0e4750674ab3d2b148acedaf1b16e589577db", "ref_doc_id": "01bc6e5f-cc79-4b05-99f5-5a1b943788f8"}, "b9c4d557-979d-4740-b305-cd02c528430f": {"doc_hash": "8935171e18591f530233a4403bbd97f44f843675dd963864e2a5450974be07c1", "ref_doc_id": "01bc6e5f-cc79-4b05-99f5-5a1b943788f8"}, "86b2c0d0-b59a-419f-8ee4-69cb1bd75b06": {"doc_hash": "6dc586304d04ead30e01923ede9fbb19886880bc02f7a406c58d063df89aaf8d", "ref_doc_id": "01bc6e5f-cc79-4b05-99f5-5a1b943788f8"}, "d3e00e96-dbba-49b5-b398-8b35a747d518": {"doc_hash": "654edd29424a668548c83b091735824e4b3b4ee3e54a5e74ad663ebdad964e97", "ref_doc_id": "01bc6e5f-cc79-4b05-99f5-5a1b943788f8"}, "8e5b619b-dac8-446c-ba6c-1e4ad163d224": {"doc_hash": "eeba9eae037ff0f565c7617cfc04e070f844a40ed5dfa17956482dec84d2a9d9", "ref_doc_id": "01bc6e5f-cc79-4b05-99f5-5a1b943788f8"}, "b1506125-6f9e-46a3-a739-dd82ddd3e2b7": {"doc_hash": "f2db1d6dc9a874080f18628a08569241697da152ea663c4f1dcbc07769172c7c", "ref_doc_id": "01bc6e5f-cc79-4b05-99f5-5a1b943788f8"}, "d850eb94-3de3-4e3b-ad5c-d1098193b9fa": {"doc_hash": "1870c562cf67df6484518d84c40c9e40cfbddcae3f9bd0dcfce6e8bb018c3fe0", "ref_doc_id": "01bc6e5f-cc79-4b05-99f5-5a1b943788f8"}, "24b51985-037c-48c4-82fa-38e9d99006e4": {"doc_hash": "5d42896c3a9f7d1c77988762736c76b86bdc53a530319f7c9f0b377d9aef45e8", "ref_doc_id": "01bc6e5f-cc79-4b05-99f5-5a1b943788f8"}, "010525f2-4776-4940-bf30-b43f9ad5efb1": {"doc_hash": "22d09f8f70ab2bcdfb203fe3f8adc3a4413db9a330ab169f1d6fb5fddbd0d991", "ref_doc_id": "01bc6e5f-cc79-4b05-99f5-5a1b943788f8"}, "9837a007-9c17-4a0b-a4bd-b2fd8e2692f2": {"doc_hash": "75e14ec4cd24a34879163f28d1f3aa3c1a5273ff821221fdd6e7a0857dc1dce8", "ref_doc_id": "01bc6e5f-cc79-4b05-99f5-5a1b943788f8"}, "2e219d54-22b0-44ad-b994-bfa14abf8dca": {"doc_hash": "df71b5bab51688c4b8fce60090497fd25829d9c03bd168ec76bb90a90c3256a9", "ref_doc_id": "01bc6e5f-cc79-4b05-99f5-5a1b943788f8"}, "f115d3c3-3000-4364-8689-3920a08aa3bb": {"doc_hash": "66efaf77729d079be516bb528ab867d3757e26e5c046a3e82ba0c055d379a3d0", "ref_doc_id": "01bc6e5f-cc79-4b05-99f5-5a1b943788f8"}, "5fcde533-85b1-4d83-86c4-727a0ad3ad48": {"doc_hash": "19fe30e8daaee5c5f260fcb0693754c927f76ed90da15a13fb0a06e8f8ae3de9", "ref_doc_id": "01bc6e5f-cc79-4b05-99f5-5a1b943788f8"}, "e1fbfbb0-9bdf-4610-8a94-9045aef6e82d": {"doc_hash": "d578960f9c93fed9d5176a9cd3eba5615d225bd5569e5e6679f3e08905b08807", "ref_doc_id": "01bc6e5f-cc79-4b05-99f5-5a1b943788f8"}, "935ca256-96da-4175-be0d-b98dfea082c1": {"doc_hash": "d7862351033da982c43dc7f24b98f3790b6823d66b1feee105131bf3560b00e5", "ref_doc_id": "01bc6e5f-cc79-4b05-99f5-5a1b943788f8"}, "27c17fa8-e243-492f-896d-dfa899fba284": {"doc_hash": "df8fb3fde658e99f7acc77cc55419fe1868b5d22f3261d03c6d1c0f1077fe3eb", "ref_doc_id": "f068cc0d-3c7f-417d-91f3-136afa17b579"}, "545b9e6d-2d02-4214-8ce6-f3cec831360d": {"doc_hash": "b100f11a97d214cbc523b87a36a903d734896955524359b07d290796d301d5cb", "ref_doc_id": "f068cc0d-3c7f-417d-91f3-136afa17b579"}, "d5c29af9-a84e-434b-83f1-c3e92d127506": {"doc_hash": "118a75a18df6301f493157bbc35908e93f592b4999c66c67fffa73f74ddee703", "ref_doc_id": "f068cc0d-3c7f-417d-91f3-136afa17b579"}, "489049fe-3776-4b23-95f6-753979b1c77b": {"doc_hash": "dcb4a6126fc8b9ac3c455460e6c5b11e4794f218b38bbb0a6f19ff35d853916c", "ref_doc_id": "f068cc0d-3c7f-417d-91f3-136afa17b579"}, "0e4b76eb-fa6c-4f45-85e7-eae89756e411": {"doc_hash": "8306f43a65b6e5f0a119d9c7a62c47286f77ffc6b5df063e4ed67d03dd064ab9", "ref_doc_id": "f068cc0d-3c7f-417d-91f3-136afa17b579"}, "013244b2-4e46-4ff2-a500-822a58606b72": {"doc_hash": "8c292f70ae15c28f23c4f6e927e73acba714a914885b4020bf002d746b2d0931", "ref_doc_id": "f068cc0d-3c7f-417d-91f3-136afa17b579"}, "f73bc254-7e3e-433d-b2fd-b0e62822cee8": {"doc_hash": "8c2055e8250aadca1296b9652d3aeddd28c3617ad60a10fc1b2ff5ea91d399a1", "ref_doc_id": "f068cc0d-3c7f-417d-91f3-136afa17b579"}, "02e50800-2664-43d8-9b65-f478368d4ba5": {"doc_hash": "5e23460e25fcbc5a37ef9216848e264d83bd7499c1039d4019ad8bd3e549d859", "ref_doc_id": "f068cc0d-3c7f-417d-91f3-136afa17b579"}, "6487439b-2f6e-4023-9912-bbbad63eb202": {"doc_hash": "938ac22830db18ec1416738ca9affa2aa0cc79d1ceef33c2513ffa34705adb5a", "ref_doc_id": "f068cc0d-3c7f-417d-91f3-136afa17b579"}, "b35e1fa9-e22a-4cfd-93af-10226064a87a": {"doc_hash": "c3d93b52dd3f2bc43e896432531fbd3095ade5007716aa167c7defa65d963c41", "ref_doc_id": "f068cc0d-3c7f-417d-91f3-136afa17b579"}, "446f5174-f372-415a-8d24-a427df982421": {"doc_hash": "9ca383c3c316f8fde77fcf7b2960f7e69040eb101472915525b68f80dc553b7d", "ref_doc_id": "f068cc0d-3c7f-417d-91f3-136afa17b579"}, "1e488c39-3fcd-45c7-90c2-98537aaf85e1": {"doc_hash": "f3e83e444cd9acd81038b8f1f034b2330191752ff5fa84f635feb69347164aa2", "ref_doc_id": "f068cc0d-3c7f-417d-91f3-136afa17b579"}, "90adf858-5b12-4f4b-a2e5-0c5157e1e84c": {"doc_hash": "be2be934b7d959f476871bbf93a69bbc8c6ca8102b6411a9cec842b807183c4d", "ref_doc_id": "f068cc0d-3c7f-417d-91f3-136afa17b579"}, "2adac713-3523-439e-add6-3e3cd319277a": {"doc_hash": "36bee2cc090af0a8c6500e89a3befdb90e76f06f89ce0125342f9d64a3bb15ca", "ref_doc_id": "f068cc0d-3c7f-417d-91f3-136afa17b579"}, "601d6918-c01b-4111-bac4-72d01cfeed01": {"doc_hash": "8614d570e36efc5d7441728ab0ff53377fdbf3be97d8417a4f29a7bbab9e9564", "ref_doc_id": "f068cc0d-3c7f-417d-91f3-136afa17b579"}, "d94f69f7-cfba-41bb-9b5c-eba30f678243": {"doc_hash": "f47cb792355157dcffd90c085882fe81f5f4892d926f71cc5ab7a0d4605563a7", "ref_doc_id": "f068cc0d-3c7f-417d-91f3-136afa17b579"}, "7029f77a-e2c9-45f0-a584-5924cd62b65a": {"doc_hash": "c423fefba24e9ff70080ebb4e5db7ce3bee068a41a653a62bd91a6bacba00c7d", "ref_doc_id": "f068cc0d-3c7f-417d-91f3-136afa17b579"}, "cc2a4546-d91b-42de-8c09-5b09951d86ca": {"doc_hash": "b5295efa0d1f37be067f2f3d1a01f3e96cc5ddd9c0a55fcee77029ade8bac959", "ref_doc_id": "f068cc0d-3c7f-417d-91f3-136afa17b579"}, "ac577c6a-399c-4f17-a656-63e4a9210340": {"doc_hash": "6158a605d4afd02eb6f0be9f05e21aef4fb92a03c4a010a0e7470fdde1cb48cf", "ref_doc_id": "f068cc0d-3c7f-417d-91f3-136afa17b579"}, "87c0a656-58f0-497e-a651-84fa0d6aa06b": {"doc_hash": "0f2cc35f58f963e92276692ec6796d4809b04cea4b7a79ea82e788a2c6632bbc", "ref_doc_id": "f068cc0d-3c7f-417d-91f3-136afa17b579"}, "ef08bdb2-708f-43bf-b2b2-fc374a6d02f2": {"doc_hash": "0de50f5c39601a26b28f5af8bd82a9a0868515ad50fd0ee6879cda8011a7e4a3", "ref_doc_id": "f068cc0d-3c7f-417d-91f3-136afa17b579"}, "5fd93bde-5ddc-453c-bd08-333e6414994b": {"doc_hash": "1efebc83fb46e741617bd8abafbeab6184df289e165265670901bbc0c26a502a", "ref_doc_id": "f068cc0d-3c7f-417d-91f3-136afa17b579"}, "d7c6282e-1e38-42ac-a7ad-31609c6dcb82": {"doc_hash": "850f08a570cc6e5cf3277829c20bcaa7571d3e262e9cacc3ae4e5f1e133b6cc2", "ref_doc_id": "c0bc2914-1a28-4a02-aa06-32ec80578111"}, "b054093e-d96c-43a0-ac79-ff0cdfd49a69": {"doc_hash": "dc148e49accc344a0e5b001707779fa370a5e56557a366d6fc5a7c0e038f4cb7", "ref_doc_id": "c0bc2914-1a28-4a02-aa06-32ec80578111"}, "54e6e201-fcfd-4120-b897-f7022404399e": {"doc_hash": "ca239af8deb99eea6c3ac2ec9526322beb66d37b28d602285431868a89e5cf63", "ref_doc_id": "c0bc2914-1a28-4a02-aa06-32ec80578111"}, "75b843f1-1c42-47fb-b796-bb99a7c8aace": {"doc_hash": "adcf59d0d71c4564577e101a90dd4741bc096d610696ce21452c7f7b19a88573", "ref_doc_id": "c0bc2914-1a28-4a02-aa06-32ec80578111"}, "40db3751-e058-40c2-a6c9-6d42e0809c88": {"doc_hash": "c82f3f2c4b0061c14553697c3ba6b73f9d4280066e4a346557ba233fb9707b7e", "ref_doc_id": "c0bc2914-1a28-4a02-aa06-32ec80578111"}, "574d386a-0679-4462-9762-d37ef504526a": {"doc_hash": "64f393c3e058e29bc43e758e820c5d848ee7e3c238b3bb686a79ad290bf319f2", "ref_doc_id": "c0bc2914-1a28-4a02-aa06-32ec80578111"}, "efdaf7a2-02ec-436b-bd80-85f7e0f8b409": {"doc_hash": "1f5740d71f6f10fbbc6dfbe472c899613071e86dc449e70d977089fd3d6ff0ab", "ref_doc_id": "c0bc2914-1a28-4a02-aa06-32ec80578111"}, "3e202d3e-589e-495c-8508-c8e44d750f79": {"doc_hash": "df149aaa23e80b77d6f2b3120319d6e606f3a4aa393ea8edc69fa688321ab9c8", "ref_doc_id": "c0bc2914-1a28-4a02-aa06-32ec80578111"}, "3814e4b0-a747-4055-98c4-321c22bd8ae3": {"doc_hash": "cf4a5d0abff3566b38df98f6cf65ed68dfc244500f0d6d6bfe93529286e945dd", "ref_doc_id": "c0bc2914-1a28-4a02-aa06-32ec80578111"}, "814fc27f-18ef-4f24-bf43-0448bbab213b": {"doc_hash": "5be1acc120d296edc48b6c3e38b436acda89b45daaba161cfd237be670254e90", "ref_doc_id": "c0bc2914-1a28-4a02-aa06-32ec80578111"}, "b87335db-458d-41fa-a624-83d4742dc34a": {"doc_hash": "3d12060f17fb22feb3c8d1e2fbdc640b3d7af675531651fc384e618769c69286", "ref_doc_id": "c0bc2914-1a28-4a02-aa06-32ec80578111"}, "b39305bf-95a5-4055-83b1-5d48d52e8632": {"doc_hash": "caa0f76bd6e0695dcdb0ca6ee77f3f4bba2df15dda75a3a9e4f0a0aa54f046e1", "ref_doc_id": "c0bc2914-1a28-4a02-aa06-32ec80578111"}, "6529b730-871b-4dc3-8c62-1ba24ff12cbb": {"doc_hash": "b1b26ac6b924e7bd47dcbe54749f3bb188375322d5488f7bce2ad4ae9126a5f7", "ref_doc_id": "c0bc2914-1a28-4a02-aa06-32ec80578111"}, "64777fc7-8394-499c-b7e8-7227c4732c67": {"doc_hash": "b2e99e134ba351a5b416e453faca78fef56e45bd15b6c6d1d571189cebc2a52f", "ref_doc_id": "c0bc2914-1a28-4a02-aa06-32ec80578111"}, "db04f0ea-cbb0-4b8a-9dd0-d99771fd7d30": {"doc_hash": "dde2f5ab758d9ff428cb2d7686f17cf0ce5a8a3d268a2183fb458676acf8caf8", "ref_doc_id": "c0bc2914-1a28-4a02-aa06-32ec80578111"}, "821b7432-6582-4f0b-a083-faec7bc4dadd": {"doc_hash": "3cf43ff845c6615ad603a0e60aec4a1389934e41a5e1dbca0d427dbbfca5ee9f", "ref_doc_id": "c0bc2914-1a28-4a02-aa06-32ec80578111"}, "3cdab136-1c39-43ff-b29e-cb26843e06e2": {"doc_hash": "3fcb1b01262cbd00e7b4e67819c10be4e37ac3cd25cdf75960ce3794127d5726", "ref_doc_id": "c0bc2914-1a28-4a02-aa06-32ec80578111"}, "8bd7737d-b8d9-4cc0-b2f3-3270820f2c2e": {"doc_hash": "b9e6312f0a6f263aeb2660eddfef843cbfac7b356629d7f90267d292f4e0c467", "ref_doc_id": "c0bc2914-1a28-4a02-aa06-32ec80578111"}, "74eb880f-fc23-499b-91a0-afc8786a5df9": {"doc_hash": "30ec13f829dc26858885b940d5ef2131f52d20e6e4b81a6539e9000bf6de29a3", "ref_doc_id": "c0bc2914-1a28-4a02-aa06-32ec80578111"}, "b3b33047-e393-4a7a-91ea-ecac7ab9bf5d": {"doc_hash": "b1923c3b30d90863aad447e92c0be0e61f1f14f13c7a3b7d04b3e2396f2cf323", "ref_doc_id": "c0bc2914-1a28-4a02-aa06-32ec80578111"}, "d8022c74-fdd0-4073-af5a-61c2a40edd39": {"doc_hash": "f4aff732572e6c37d153f26c12bdbfd3374051a5e25a63a06b23a127e42b6f9a", "ref_doc_id": "c0bc2914-1a28-4a02-aa06-32ec80578111"}, "6b1179b2-8b93-488e-be31-b93527e3307c": {"doc_hash": "98bc1b4fb9e2aa4995799c44aaa62d8cebc87deef6ea536f38e7e93f3e48ba77", "ref_doc_id": "c0bc2914-1a28-4a02-aa06-32ec80578111"}, "ed00f4d9-ad17-4127-bec1-7c35a3cad936": {"doc_hash": "dd309041700c3e141d009a73f7fe68fffeca2d4a1ce55b85ed7d60baccb14d96", "ref_doc_id": "c0bc2914-1a28-4a02-aa06-32ec80578111"}, "1da0802a-ed0d-4f3b-be7c-0b36e225af39": {"doc_hash": "b829a62c069ab3394d5c632bbcc5a3fb4cfe39722628706dfafeeef495140f28", "ref_doc_id": "c0bc2914-1a28-4a02-aa06-32ec80578111"}, "720ca742-f4ff-482e-ae41-871b7f624b4a": {"doc_hash": "d6183e5d5401010f7e9b278f0d152b7d3b19216814713f14fcbf0832013c6a64", "ref_doc_id": "c0bc2914-1a28-4a02-aa06-32ec80578111"}, "c8a18dbf-0c14-4682-a00a-3e21c992bbc7": {"doc_hash": "e9d8e2ba85399801e9a2ce3d83e4ac3de2f50bb067575729f168267188d1b7b2", "ref_doc_id": "c0bc2914-1a28-4a02-aa06-32ec80578111"}, "b2e2b0f5-8400-46a0-a606-16db4c4299a4": {"doc_hash": "0fce4001ee485e0fe6c327352aaf695ad16636b0792e0a17d0bdef2378f8bf40", "ref_doc_id": "c0bc2914-1a28-4a02-aa06-32ec80578111"}, "6665f588-869c-4c6d-9f7f-916790e9f899": {"doc_hash": "0cec633fe2a61269f0b86b9f7593798fd5e30dda4e24679c9f686a3f6d92cf3b", "ref_doc_id": "c0bc2914-1a28-4a02-aa06-32ec80578111"}, "2f2d7cd0-92f9-420d-a80e-9715c6bb8554": {"doc_hash": "1b5ad3ca3c39ab73d0876ef7dd0f3ae288c5e80faf27e16c2e40b7a3896da047", "ref_doc_id": "c0bc2914-1a28-4a02-aa06-32ec80578111"}, "e62f5765-bb7a-4ea2-afd4-db151608002d": {"doc_hash": "1154fccf22bcd91ee72816b30a7225c561f1d76bdb4832782c0f47304078339c", "ref_doc_id": "c0bc2914-1a28-4a02-aa06-32ec80578111"}, "f88a158d-ad86-4e15-b962-62e4148eff42": {"doc_hash": "a77a6ca04d4a3bed4cb7a5a8b69b7a8eae799e2642f363be6f9aa2f1c599ca63", "ref_doc_id": "c0bc2914-1a28-4a02-aa06-32ec80578111"}, "0b60c3b6-add8-4648-b5ce-736b564d747b": {"doc_hash": "a7f2cf102db0b08d8680fa798fff92a2e06c4316f8d1908c7bdf7147098e2d3d", "ref_doc_id": "c0bc2914-1a28-4a02-aa06-32ec80578111"}, "e073c53d-d7a8-4fc0-80a4-81281798561d": {"doc_hash": "84c726797cb0655eac6380fd0f135009272801547588a142cd9ed6271263b6c3", "ref_doc_id": "c0bc2914-1a28-4a02-aa06-32ec80578111"}, "576dada0-f453-4d3e-9de0-4f7537d7e321": {"doc_hash": "b729c8cc28924ef8632dd8828d84adfdefb14c528c489160c02f2975de5c2007", "ref_doc_id": "c0bc2914-1a28-4a02-aa06-32ec80578111"}, "9048b87a-4137-415a-bcff-3d2c29e5c6d1": {"doc_hash": "c7224a282a5303242fd601e4d3b2bd8d1929f96addadae97f6200cb0ba98ee13", "ref_doc_id": "c0bc2914-1a28-4a02-aa06-32ec80578111"}, "d1cb13f3-0392-4e9d-9ca1-77ef214da619": {"doc_hash": "dcd40fe8d9c63b7a5eb6e4e7a51eb5dbd7b240f5af05ca60a88e6e325d65b6ea", "ref_doc_id": "c0bc2914-1a28-4a02-aa06-32ec80578111"}, "755f080c-77ff-41fc-8ea9-de406873ea2f": {"doc_hash": "82f37bcb12eeee0008da49d2565fb55624edaa948c62b80f94d22b8571c50aba", "ref_doc_id": "c0bc2914-1a28-4a02-aa06-32ec80578111"}, "0ae5567d-1672-4136-b2d4-9857b3cbc113": {"doc_hash": "bf15bb7d1d51088151b2978b91be46e7589f104a0343d3b51a3d00e4b4aa05ed", "ref_doc_id": "c0bc2914-1a28-4a02-aa06-32ec80578111"}, "17a98fc6-9805-44c7-ae14-0d4d3ae71367": {"doc_hash": "fcbe3762b715daf99aa372b374e5898ef830599ef07437772792d7bef06c5ed7", "ref_doc_id": "bc629de4-825c-4a81-8fe5-d4c62e367c38"}, "7b292413-525f-4cf7-aef8-711bac157454": {"doc_hash": "2b1f8e8063305567ab1bd9849bf59fc35c709738b1f3acf9036e6097cb92d5e9", "ref_doc_id": "bc629de4-825c-4a81-8fe5-d4c62e367c38"}, "48aec9a1-8eeb-4a4e-8d9b-7bfe3daa4951": {"doc_hash": "7880562fdf2fe5f4b1f90d0b505446821967c32e01abee9c81d64ead6ae0d2f4", "ref_doc_id": "bc629de4-825c-4a81-8fe5-d4c62e367c38"}, "528ba616-910a-4bbf-8b37-24a0570f01e8": {"doc_hash": "ae327f8ddd00f2065d21983b40d91e3e594c88808c261602c891e69972926c75", "ref_doc_id": "bc629de4-825c-4a81-8fe5-d4c62e367c38"}, "145ef048-18e6-4143-8242-c50c96326bf0": {"doc_hash": "6deaa8569133d163e5b96a1e39b0ba46f189bc700a7149dc0968be14658730fa", "ref_doc_id": "bc629de4-825c-4a81-8fe5-d4c62e367c38"}, "5d269d40-9acc-43f5-91e2-ef83d82ad221": {"doc_hash": "0e34fb78d9667f08713382dbd7307001510f25795eaca839d69f3c61ce929322", "ref_doc_id": "bc629de4-825c-4a81-8fe5-d4c62e367c38"}, "e3582738-efda-46bb-bcca-d3d590544aeb": {"doc_hash": "68da27616b03add47c40c5de229bab2eb9c3839c7438b8763cd3dddef2639c91", "ref_doc_id": "bc629de4-825c-4a81-8fe5-d4c62e367c38"}, "aeea6de9-ff4e-466b-a39f-ef30847e02bd": {"doc_hash": "60f2a6f46e30d69e56d0cae46745a9c8ae2391fbf89191176a778fe2a0518623", "ref_doc_id": "bc629de4-825c-4a81-8fe5-d4c62e367c38"}, "673f94a4-1bff-4356-940e-bdf9437e078b": {"doc_hash": "6e0ccb26cf22b43062a7c12156006cf077209f9fabbad24b90ea72ce01d624e0", "ref_doc_id": "bc629de4-825c-4a81-8fe5-d4c62e367c38"}, "4cdc6e6c-7f51-4713-a05e-f3ba97f8ee27": {"doc_hash": "dcf36e16732f7af58ace2be041c421f8faab767672cea824a40dd425f161ea6d", "ref_doc_id": "bc629de4-825c-4a81-8fe5-d4c62e367c38"}, "c4846d6b-8090-4bc2-91a0-93b121962976": {"doc_hash": "9f9031b52e13091d2b57f5ce8778e6d6a79684240558e818f80c66c20b340e13", "ref_doc_id": "bc629de4-825c-4a81-8fe5-d4c62e367c38"}, "e17f7320-280a-4767-a4af-59a817d6041a": {"doc_hash": "7eb78fa6ca59b840284b8b15c041af154d79c643888984d03a24358a3455f5d6", "ref_doc_id": "bc629de4-825c-4a81-8fe5-d4c62e367c38"}, "a86fbb91-ec9a-4bd5-a7e7-7bacd14c0145": {"doc_hash": "1397f70171e8453504002a026475c2d172d3bc66ce06313a95f2c73a1b350205", "ref_doc_id": "bc629de4-825c-4a81-8fe5-d4c62e367c38"}, "4ac46ae2-0ba8-440f-ada6-cf7086c283f6": {"doc_hash": "0acc1de737b787c1cd932d9e7e2b5a037a51e6683d1144302841550cc74cb7a1", "ref_doc_id": "bc629de4-825c-4a81-8fe5-d4c62e367c38"}, "98352a9a-9c44-4757-9074-d9d55cc88d8a": {"doc_hash": "70ef22d22071a2a0e484d8d195b4dfbc0661e3e468aa1497dfc2ed3b24639381", "ref_doc_id": "bc629de4-825c-4a81-8fe5-d4c62e367c38"}, "1abea367-6dab-413b-ab92-52f2a5b5c098": {"doc_hash": "73c7aa25a224ad40acc9fe008d4cf7066e2b01650d9140dbc72fa53a170edd18", "ref_doc_id": "bc629de4-825c-4a81-8fe5-d4c62e367c38"}, "717404f0-efb7-4ae0-b756-33c1d2e1f29e": {"doc_hash": "9f3a4fc314f73cf328f63bce952949377a5325f3a137773ac87eaf95ff803a0a", "ref_doc_id": "bc629de4-825c-4a81-8fe5-d4c62e367c38"}, "6c917ddf-8972-4006-acd4-88e243f8d83f": {"doc_hash": "ea5ec8a02d13567ff592ac99fe2d9ae81e79bb799ad451f72f2bce0305362504", "ref_doc_id": "bc629de4-825c-4a81-8fe5-d4c62e367c38"}, "bc227165-ddf2-4a33-9d68-ad3119d4d199": {"doc_hash": "499c7a480acceb3ef02286473ef52da757d7d21c33af7e8f7b61e23a760aba1c", "ref_doc_id": "bc629de4-825c-4a81-8fe5-d4c62e367c38"}, "8aa92e93-a308-4505-a63d-e31620bc109c": {"doc_hash": "65f7dadcaca4a6be6d281eff74f37beca48864ab481a0413f40a35fa3e529c35", "ref_doc_id": "bc629de4-825c-4a81-8fe5-d4c62e367c38"}, "953e15bf-e429-4a15-ad0f-bae0f3bd694c": {"doc_hash": "460d60542303a6d20c262085f50c2f5c48e262d4981f252d64d3ded8c7f3eca9", "ref_doc_id": "bc629de4-825c-4a81-8fe5-d4c62e367c38"}, "25ad743d-07df-4748-a6b3-cf92797c8054": {"doc_hash": "1923dcb675961e17bb8bf563dc8c2d12cc1e6e95f5be4ad3ad0d104ee530e302", "ref_doc_id": "bc629de4-825c-4a81-8fe5-d4c62e367c38"}, "a3dc1602-fcc4-4181-8c2e-b406433d5cb4": {"doc_hash": "d476935be1918a4be2812763e305cfc792521ec790b182045c2736e7f3b1dfc3", "ref_doc_id": "bc629de4-825c-4a81-8fe5-d4c62e367c38"}, "6d3000b1-6feb-42a8-85d8-65ec6a7f6d9e": {"doc_hash": "6104be0ea37791b0881921dc6c9de1ee971766fa22c5d6824c4db6bbabb995f3", "ref_doc_id": "bc629de4-825c-4a81-8fe5-d4c62e367c38"}, "90db45c9-8c56-4b19-b000-96ca573dcb83": {"doc_hash": "cd366afbf838187816bdd5353a5bbf8357f6aec1ba4add24bd02b4e263176fba", "ref_doc_id": "bc629de4-825c-4a81-8fe5-d4c62e367c38"}, "8f318303-8e61-4aec-92d0-8aba6cc477c6": {"doc_hash": "db2a65cc696c7aa4c9648b2456fff898a7e3d27d0f083a422d9b7e7e8beda900", "ref_doc_id": "bc629de4-825c-4a81-8fe5-d4c62e367c38"}, "e3fab23d-b2b2-409b-8733-1894cdeff436": {"doc_hash": "c4f754306f6a557bc74ae90f2be18d1f24dd888334d7a814153471e4871f62eb", "ref_doc_id": "bc629de4-825c-4a81-8fe5-d4c62e367c38"}, "89f1971c-d0a5-4174-8ff2-54f6b209b560": {"doc_hash": "083fccb2b62b992d0183a2130c52c5dc021d0e1056b40bfa8acb149b20b391b8", "ref_doc_id": "692933c6-e017-4d68-907a-60e809f96ddd"}, "67dcf5c0-00cb-43ec-8cb8-0329065def1c": {"doc_hash": "46e0c0d0ed09229cae4b2adac6010bd4413f26de9071da0d6b78d6ab69d0e068", "ref_doc_id": "692933c6-e017-4d68-907a-60e809f96ddd"}, "108a56c8-e2dd-4997-bef5-50ff15a06325": {"doc_hash": "f566fb63f05676bb770951121d814ffd1c1ebd150dfe2c15d3d1fc08305cd0a0", "ref_doc_id": "692933c6-e017-4d68-907a-60e809f96ddd"}, "7ea86e05-e244-4e40-83fd-e2a952caf437": {"doc_hash": "63d954a08a73127a304f32d9c6720d2d650c59c5f3b0204ad058e43bbe9a659e", "ref_doc_id": "692933c6-e017-4d68-907a-60e809f96ddd"}, "cf594c66-6bbc-40e9-a7bc-4348336a79b8": {"doc_hash": "9a2fcc6549c48a75ab7bfbd61139127fe9a5c7b878673bfb3fd1ea79a855a69c", "ref_doc_id": "692933c6-e017-4d68-907a-60e809f96ddd"}, "82d7100d-ac7e-445d-8439-1a1221bd59b9": {"doc_hash": "c58228ca72336dd1883e708f890a34836534187f44992c7048b1faaf93f23ba0", "ref_doc_id": "692933c6-e017-4d68-907a-60e809f96ddd"}, "6113ee01-d6e4-4307-a23f-488edcdb653b": {"doc_hash": "b54f5ff08b150d422501c504132418edf2d1739f2f188d12b7aecc547e5e1c82", "ref_doc_id": "692933c6-e017-4d68-907a-60e809f96ddd"}, "a7792f8e-fbe6-4b47-9726-8dc11e40b994": {"doc_hash": "6730117547c7f76f06f4b49dda485663bccd2403e75bfc820c5acad091e412c8", "ref_doc_id": "692933c6-e017-4d68-907a-60e809f96ddd"}, "f63c3445-702c-4c68-b0bc-a2989c8c713a": {"doc_hash": "1d035e4e8b1040061849cb0b6a2aa70e1bcc2425599957fee0cbfd0a43ecb4de", "ref_doc_id": "692933c6-e017-4d68-907a-60e809f96ddd"}, "0f3797f0-f7a1-4c43-86e9-b4288e2a2619": {"doc_hash": "d82f17dcd240ec8f4067148dcf5c88e034a2490241c9f195e5145affbc34751a", "ref_doc_id": "692933c6-e017-4d68-907a-60e809f96ddd"}, "a0a72b3c-28ab-4344-8f5e-0a46ce62647b": {"doc_hash": "834b86bdf39403e62f38d650ac9ae1de438cf0cf8786e2bbacd996ad30be1d1c", "ref_doc_id": "692933c6-e017-4d68-907a-60e809f96ddd"}, "beae7579-cf96-4cb3-851b-e6c048a076ba": {"doc_hash": "10ac6be5731ec4b553e7a8818c5714b2bf3c1817a3facbd270c5c467acad506c", "ref_doc_id": "692933c6-e017-4d68-907a-60e809f96ddd"}, "81b8f3f0-91a7-470a-9689-6e3cdc4b1501": {"doc_hash": "4b5af340b21e566192ddc72419cd9a2f8830a81d5345aa0eb4eb5306168bd233", "ref_doc_id": "692933c6-e017-4d68-907a-60e809f96ddd"}, "65a6280c-4795-45c3-96e9-1899029325e3": {"doc_hash": "5e9d3bd98d72967741c59662b996b5634650481ac335299746a0920197503b03", "ref_doc_id": "692933c6-e017-4d68-907a-60e809f96ddd"}, "8901681f-dd2e-4e2e-b312-e2161e398c7e": {"doc_hash": "21d3a916eff55f0b84f27928cabf588ffcb86f3961c6e9618538acce6754421e", "ref_doc_id": "692933c6-e017-4d68-907a-60e809f96ddd"}, "2e38d70b-b1ef-4d49-97a6-249ee8c8dc52": {"doc_hash": "d3cf02897b7940e10bd0700a8d0861d08f6d3c6872f28d7ab6b98f29deac0704", "ref_doc_id": "692933c6-e017-4d68-907a-60e809f96ddd"}, "889a5dcc-d472-47b9-a570-9205e5be8c9f": {"doc_hash": "997820fb29e6d5ef245272624ec3e2f16e75f1dee695e264c7bb75cc2815dbe0", "ref_doc_id": "692933c6-e017-4d68-907a-60e809f96ddd"}, "1802e46a-834f-4a5d-843c-7f8df7fb89fa": {"doc_hash": "2e83bb7995cf1dde66b979436f79b544d44b275d22885ca2a9800d2b1ca259e1", "ref_doc_id": "692933c6-e017-4d68-907a-60e809f96ddd"}, "60faaac2-a517-4f69-9197-b671ac2eed3c": {"doc_hash": "4d23548e3daf4828362fbcd61a197e8d8392804d680b2af9ff2fa3b72964356d", "ref_doc_id": "692933c6-e017-4d68-907a-60e809f96ddd"}, "9d651bed-a472-4285-9acd-349db4acf267": {"doc_hash": "8965d14aa87908dbd27046c24664fdeee874cf70d4cd3a729bc66475d0cef8b7", "ref_doc_id": "692933c6-e017-4d68-907a-60e809f96ddd"}, "01ed948c-6584-40e8-a6a0-88dd7c6ae4bb": {"doc_hash": "fd401b1636406304b5a2dc4b4b67bd8eb10d5f7817a1d7afe98517f68e018d19", "ref_doc_id": "692933c6-e017-4d68-907a-60e809f96ddd"}, "47a00123-9947-4c7f-b5a5-bc31e8a59d9d": {"doc_hash": "f35d170c2c99c3cde6c26e20301807b80d751a3feeb042f908b66a6bb7cb1112", "ref_doc_id": "692933c6-e017-4d68-907a-60e809f96ddd"}, "a06ea56e-bc5a-4e1d-960a-17bef9aa0e92": {"doc_hash": "043af87ae646d6289ed2342df8dc1c4be043cff09bca14edfbab14c8771c60ba", "ref_doc_id": "692933c6-e017-4d68-907a-60e809f96ddd"}, "306e411f-e5a4-42a8-b0f1-b444c1857e7a": {"doc_hash": "5a3741beb6ec5ed298f9484f8c7a4599571c870f04a8eb0a7d9645c1e9ff136c", "ref_doc_id": "692933c6-e017-4d68-907a-60e809f96ddd"}, "5bf5ebb0-b3b9-4ea5-b680-b2c77a573cd4": {"doc_hash": "118d2b2945b051915a5020b9d722b72463100a8e374acc87951b20c886b2b410", "ref_doc_id": "692933c6-e017-4d68-907a-60e809f96ddd"}, "4ea73195-86d1-47dc-af18-df30391d451e": {"doc_hash": "593b86c3b26e96ec92023fd2f37f1a2769f24e3471adf19fe34ee7e9a16aeb28", "ref_doc_id": "692933c6-e017-4d68-907a-60e809f96ddd"}, "d337d002-6f04-4ed1-af0b-322526b5a2f6": {"doc_hash": "051d09bce8e6bc9f4b9bad9f7acb0d04cb04a37f01ea392b0d7bd998ab4a286d", "ref_doc_id": "692933c6-e017-4d68-907a-60e809f96ddd"}, "4ce2e81f-6471-475f-924d-d8105b41e972": {"doc_hash": "5d556dddf12226598f4f22cf25a6d6fdcd0fcc895ba88c5412d20a8afc0128c1", "ref_doc_id": "692933c6-e017-4d68-907a-60e809f96ddd"}, "4ae07687-c6ad-433a-a321-b05b005f65fb": {"doc_hash": "14c32b8cdb3573712488e3c01ea4f646b8d5833e9668d04e4694e1efb0205f41", "ref_doc_id": "692933c6-e017-4d68-907a-60e809f96ddd"}, "bdf3f953-3051-4586-858d-7277d7fe7c9f": {"doc_hash": "33bd051280380bb2dab105f248f07a3d6086a469971eb5279c7bfb459291c77c", "ref_doc_id": "692933c6-e017-4d68-907a-60e809f96ddd"}, "3cd3c5b2-22e1-41cb-9755-582a704272a7": {"doc_hash": "338afaa7eca67ce6dda934eec5c215081f1745191af4d8e857fe2fb2855125ea", "ref_doc_id": "692933c6-e017-4d68-907a-60e809f96ddd"}, "4318b08e-d385-4200-9a42-2f0ba6302aac": {"doc_hash": "85b0f9751dc155c8759523b6d471b5d1820cf7ce83cc3310be0f62179b7ff751", "ref_doc_id": "692933c6-e017-4d68-907a-60e809f96ddd"}, "76a43378-df7c-4cc9-9b4f-9c46250442fe": {"doc_hash": "656169fdbaa93935442c44adb1504fe2ad3b1100b22dcca885236a7054acda4d", "ref_doc_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6"}, "a964c50e-b4ca-432e-9b3f-15e73b4517b3": {"doc_hash": "cba62d5afe919885e7c367411444cfaedcc80afb6a7f85e660359004af35c0c8", "ref_doc_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6"}, "c693198e-925e-42f3-82a6-8b17c3d6804b": {"doc_hash": "84e0934980af68c0cd379199110e6ec4ade872abbfce9764c6eb316c5a503253", "ref_doc_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6"}, "7f047ca8-f77b-4027-a73b-53c6d7c220d5": {"doc_hash": "6b22e177a10c56d91ccad0c94bdb348e123375e2be006f95cac7887ff7a932a7", "ref_doc_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6"}, "5e218156-5493-4804-a293-0c588c79e4fc": {"doc_hash": "69e17395273b5c5779043c9b9d99ee974b9124ca346f643428a48fc28e93aaae", "ref_doc_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6"}, "2bf1228c-287b-4f69-905e-06a2d2c32854": {"doc_hash": "569b03c1fefb7f7e684d562cb1b092f11a873ac46101b41d3f6d2d3b551b16b0", "ref_doc_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6"}, "cb8ff01c-661a-4397-8a38-d05e8492d338": {"doc_hash": "fbb3ec54f553deba3dff4e9c24218eea2e31c0a825a83d2f6591f038994e191f", "ref_doc_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6"}, "1b7c3c1f-1e6a-47d5-9f6a-0ed681b409a3": {"doc_hash": "4a4a672e138ef9bfe2a9a4b9d596fe8fd267c2e098b51b0686ea9e971d11b079", "ref_doc_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6"}, "e96345b7-3f75-42f3-9ccf-5862986a49ef": {"doc_hash": "45e95dc183a08fa8c8afa59019ee91f255577677f31d0f1569ee68a94d571764", "ref_doc_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6"}, "cc326a5f-7a3a-4bfc-9276-d4f094ae434d": {"doc_hash": "fe29a7746b8bb7b8d09d65a992f13ab8bbf7150fbdffe5cec984620521595881", "ref_doc_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6"}, "f8b93dcb-70c9-4558-97df-d4aba0e895f0": {"doc_hash": "2daf695cc69c444ed6f43cb4fa3bc1a2072208ff88c0ed38b4fa885f7f3efde4", "ref_doc_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6"}, "322cfc7c-4cd8-4c92-a1b4-6604fca47c66": {"doc_hash": "b0fbbfafbfa725107ee9ce541149bb2b169c40ab25fa58b9f7b80cd4aa4020db", "ref_doc_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6"}, "c0d229d9-947e-4dc1-9e05-e0f237662457": {"doc_hash": "c2f63ebce5d27d99abc1979dacfeaede5ad3246569ae9b75ab8fec8b509d543c", "ref_doc_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6"}, "cbede393-3c0b-4ef7-b708-e31727b0a928": {"doc_hash": "55f6dcfc8970e1d9c35419c831a96d5190b7b49862d95b1dfb4a87e1a9321fd5", "ref_doc_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6"}, "de4b9656-85ce-4656-ac45-9a0cb6910f13": {"doc_hash": "32806ccf8c4cb00dcd957faf189c48a6ae5ac3a6c392c0a446502656ec1027e0", "ref_doc_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6"}, "0e805e66-8af9-4b3b-bf3a-52232d1c5bb5": {"doc_hash": "4c32d72cdc8f0dac2c893ad9b164c78860d00317ba0da46bc1e232b93d0ef9b0", "ref_doc_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6"}, "f3a14a36-86c8-4c08-80f7-210d3f4fbf67": {"doc_hash": "e67c90d8a6f9f992ee1bf034161a7464e1b52f0c84fb5b256f2ad37a64ba2180", "ref_doc_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6"}, "0fcb5a52-c6f1-4b68-a3da-01e4f4c2935e": {"doc_hash": "994f997770f7aa74843418c643ad8185ba1fcf6335c6a0156cd1e1999a216db8", "ref_doc_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6"}, "4837095d-9d4e-44f5-b508-2b181c13ac24": {"doc_hash": "6ff12cc100e00bb5f580eeb9e2c6ab006074d8e4dd17d0e6c52b395f9005adc3", "ref_doc_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6"}, "e0fc47b1-95a5-4a2a-b974-a931d64054b4": {"doc_hash": "57d47b8a3c1512331e8adb175087c9047f9c099d5c3551a231014a501eefc741", "ref_doc_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6"}, "911a5434-ed5a-4af6-8042-6be5052b32d6": {"doc_hash": "5c1af91914dbfbc7b33c01092c4cbe4cf4e64b455c32f86ae05e702e3685588f", "ref_doc_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6"}, "351a20a7-f019-48d3-aa4f-cf159fc27f64": {"doc_hash": "dc86cee5828c3a17fa5d5d29c3b57bfd6077e07d3be0bbb449437559ca00b695", "ref_doc_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6"}, "16b3a2c2-0338-49f1-8658-791dea6d1218": {"doc_hash": "853e0f7afd5b295d93e97f0d1b2076db8e49cb6d7954e93628cb692fed40c129", "ref_doc_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6"}, "705369fd-b974-48f0-836a-188ce18c6eb6": {"doc_hash": "baee0950eed3a0fbaee8aefcdd1d79cd2c4eedfeceb05fb462ff64cb2fc5bba7", "ref_doc_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6"}, "e451c9dd-4d69-4484-bc85-e01d5b647d81": {"doc_hash": "9f4d4334fd2fbcd7783a315532bba933fdf5f55cebd0f3ecb67465165bdebd7a", "ref_doc_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6"}, "bf896820-f893-4a6f-9653-bf037b8a6bd2": {"doc_hash": "73b4546b55e8d0cbe89735b0d37c040e63aa00dc6ca9c4eff8126bdff3a6c994", "ref_doc_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6"}, "1112f724-a91e-49d4-86ec-554e9d973753": {"doc_hash": "b09bd33dab8e537a6286c351f8b61f6e657914ec6601ad00572a04705bc9d88e", "ref_doc_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6"}, "aa58ab6f-19ef-4d37-b1a2-380a01c68137": {"doc_hash": "e1e08cc2277b5eccb0c6ee17623bcf74a19fd36cd3a7f61ff4bf6bf5b29670db", "ref_doc_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6"}, "31cd2655-4091-4293-8450-001e7efb990c": {"doc_hash": "66323adec023be7d343973a7502d2a04b16f4f3e900950e8c9c223f7b0cf62a5", "ref_doc_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6"}, "aba8540d-75d1-4e27-966b-b3836985933f": {"doc_hash": "53ca60bf829d21afc6ec262686fcdcad7023c36084ccac7f62cee6379f4d973a", "ref_doc_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6"}, "cdee0445-584e-4607-8918-7db4bc57da3e": {"doc_hash": "ba35d98e179d6432b1ee9b97b93f76da9cae80cc8beec2c6e8f2369dd2375313", "ref_doc_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6"}, "35fc96f8-0e2c-4515-970a-1a1d4fce9b45": {"doc_hash": "3a3d10389723333f7c844204f7e307b9d458cfccb5a1e3d28d47d9b7f4aae642", "ref_doc_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6"}, "0ece2adb-60c9-49ba-ac5c-8b07e610b8c2": {"doc_hash": "681dc29d34d14bc568ecdadbe351855562987e740a9cc45649828152d6d0f452", "ref_doc_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6"}, "20eb3eeb-6410-4147-8a66-7a3a24bb3b61": {"doc_hash": "30ef631c5755eb9342071b5863f8b635069523e665a643230a16679600e71696", "ref_doc_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6"}, "8cc8e2ba-2b8d-4821-a3f3-92ae7504934f": {"doc_hash": "033dc9886676c648c103dcd93afecd2385169c57969e48821a8f180e47eb7cc8", "ref_doc_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6"}, "94f5116c-8168-4e30-b113-55305a47f085": {"doc_hash": "5e51f3fde420449f1ccbc23b4c5ee9cf56ad56ba93d4ed26f8fca1390296d78b", "ref_doc_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6"}, "1eb69da6-caf0-4bb5-95e5-a2c0cd365189": {"doc_hash": "0889cce2149ce2aa1d1d497896f61ab351fbba517cc249589fa17a49af66a3ad", "ref_doc_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6"}, "b4dbe733-9642-4954-b89d-ffd5f3878e6e": {"doc_hash": "20f2c19a653efe09cee9f2b0f5e3158d56ab2dff354568982bdc62f0d7f67e61", "ref_doc_id": "e172725d-2ee1-4815-ab91-b8f70a3e9bd6"}, "37e8c761-f4ed-40dc-b5ec-d87e05227bba": {"doc_hash": "1b4963f303b735d27ae0754f5cb016dfff5eea943698cb957194f43e7817f5f4", "ref_doc_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a"}, "9effcd4c-d238-4067-bee1-33d5485aaf76": {"doc_hash": "f9183fe9361fa9df14b9177d56ed2dc386d016452fa9475c907ba61d2fb781c7", "ref_doc_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a"}, "f5215618-5b8e-4676-9f97-a07ea2234c33": {"doc_hash": "fb3e4fd81b98b2880c91f0bd847e4a0e152c153f49c0119d12410ab21c2d62e9", "ref_doc_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a"}, "421a70b9-35c8-4e7d-bfbb-48ba1a7d8e2a": {"doc_hash": "0190713974ca2ca976d1bab8976776d57739fccd3c273700dc5dcd1dff0045d7", "ref_doc_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a"}, "d1c81eb7-54b7-4051-966d-08344256c3ab": {"doc_hash": "ce1ece5eed8147427c966af9169fc46b7f7734d73e65af333c8f908fe79601d8", "ref_doc_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a"}, "160cbdee-0379-4031-a62b-eb9b44b930f6": {"doc_hash": "3fa4e6c4dde8889fbb23100370168d286d4732ec73db43bf13348ec3bbd79f48", "ref_doc_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a"}, "a4947939-c4c5-40e8-bab8-7a1047ada5aa": {"doc_hash": "78a49dc807e81dcf80990086011e01da7f2e5e96bd62a080cf0e60c59c287c5c", "ref_doc_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a"}, "a88fe4a5-6b54-456b-a89a-d88652c67001": {"doc_hash": "7b35308efea8f090dfc4447941f4793d13b096836d5afe112186abd18bcc3c3f", "ref_doc_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a"}, "2d00700e-0041-4dce-ba30-91e192d2ac0f": {"doc_hash": "0bc6403b7eff7d59354b28b2c7998c9a28464bf1f61b95c89cd094c3ab7f2597", "ref_doc_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a"}, "138591e4-5934-4766-8bcb-aefb513db15a": {"doc_hash": "cc104011ecd28af8e6e2bf681a81b649de031eadb100b98b36f3d3cace3319a5", "ref_doc_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a"}, "b237b776-12e9-40b3-a4c8-e178c2b2b0d8": {"doc_hash": "796792a9e1d4a1953bc176fe37b5b9eb95015410e749d556d33888891d7c9926", "ref_doc_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a"}, "2d159cbb-d7b6-4f24-84f5-191736c88c63": {"doc_hash": "ee793363d0b36e9337dfd8cbc79633cb32914b88d7110777ac59fdfebdd6a645", "ref_doc_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a"}, "b61d9fef-41fa-4c41-aca4-155a99aa8364": {"doc_hash": "073fe8947d61a2a407d628988ef567d2114f90ef4c81fe4d9057646497bea1cf", "ref_doc_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a"}, "c1bb8b9e-0d94-4d8a-b54f-8f454ab7eb40": {"doc_hash": "049e709800af69a7f998249c731c8b52f5a930b039583d0b2138fc57824a5a4c", "ref_doc_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a"}, "abdf4e4a-21f9-40df-9cfd-b1ac7c3dda36": {"doc_hash": "a4d8b1feae7bb7f2c82eb429f6993c023e50fb9c8276bd39f010fe69b30a8277", "ref_doc_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a"}, "ca1a5566-c699-4947-9596-eac261e1276a": {"doc_hash": "f89710dd41b86acb6682c063a3c5b304bd3edf5a37ff0c9c9339df3db84dc13a", "ref_doc_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a"}, "7fbb5d70-1ae4-47e4-9289-21826503cd3f": {"doc_hash": "252eabbaa5ec85df274fb4cf7d19b67a2327d41ddeee70a36f9c1303adeaf3a6", "ref_doc_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a"}, "bf294838-d494-4568-ba5a-cac06883a78c": {"doc_hash": "387bd072a613094d76ca016f5115cf87ce34e38fcef5fb847fe358230b6e9cb7", "ref_doc_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a"}, "4bd048e0-2873-4a02-b267-6261b1fb89b9": {"doc_hash": "cef5f0472e03f45408302f667476a01c4bda928ba52e298ae3d7a9ef2ebe33c7", "ref_doc_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a"}, "33335a5e-6f39-4394-89d4-957aeaa6477e": {"doc_hash": "f9f3b780815944d4714dcf30b2aae43ffbcbf1bee34e14c5c2522ac280ea1c5a", "ref_doc_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a"}, "b38135fa-cb5e-4255-abb6-88c03b991048": {"doc_hash": "5e4d6cbedcc2e37ee692887b49681049c08dc6e8bd4fc82cf25c96f62ec0724b", "ref_doc_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a"}, "7fd63844-6c4a-46e5-87f9-41ab0cd5e3a2": {"doc_hash": "2f749b78b676dcdfb4242f624d3ac09888997a4311c16a5db74e63c4c7e7c0fc", "ref_doc_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a"}, "676d731d-8de5-4385-bb2e-8f2ea1b69c47": {"doc_hash": "080bbe6da838a456581ceae22ebc72024548c9f5a6b7fb12b1a7611b9c512149", "ref_doc_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a"}, "7c5341d8-7cc2-40fd-8530-e5927580477a": {"doc_hash": "ffe733242dc17bd34356b47723b6ca856275ae19a84e76601dbbe5ef85f6cfa6", "ref_doc_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a"}, "f6c5f39e-7bf3-4863-9bcd-75ee1a68d42a": {"doc_hash": "b9fafbe5e1cf331d085dc0f4bbee0342c2e5b61075ecb936a441437e18d7140a", "ref_doc_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a"}, "97366399-7aea-4fc4-9552-2e2b19e8658f": {"doc_hash": "ba805a9483d718b2c69146ec8dc58e50cb5ceeea5c3650d1a2cd2895e59beea1", "ref_doc_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a"}, "db630e17-964f-4c59-9ce4-6211bd28765b": {"doc_hash": "86b7bc9f52868c37f5265624b71f3e3bad0b5a12cd6e6d3a267dc4dcb862df29", "ref_doc_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a"}, "51c32790-0bde-4c62-b1c5-80a7ccf617bc": {"doc_hash": "376ab855a6549fa3c015d32df5420e9104f6b684bfd6fd5dd77756225160fb63", "ref_doc_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a"}, "591e4c76-d657-4c57-b617-12ff2618ac1b": {"doc_hash": "81c1fdebde2bb2dde41f01f3c6a53cab825f7850f565532e498d083fe85c99fc", "ref_doc_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a"}, "b577c23d-ecea-47c3-882e-923818852b28": {"doc_hash": "1a54cb3e114bd022377fefc6374bd182bd4853d21ede800356ca350a2d6e8ac2", "ref_doc_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a"}, "e47dd07a-ed80-4198-b567-3bc998f2eec0": {"doc_hash": "1e0e4e1f7f954395fdb502eb129084d7f4015de21c44aba15be0379b7f50452f", "ref_doc_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a"}, "b08d32f5-b8bf-4279-bd5c-40f4ff2b1275": {"doc_hash": "b3f7aa4b9e040cf6ab035745a42316687d176314285470375ab372379dc830fe", "ref_doc_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a"}, "cc382ac9-14e0-415c-a743-576be6449dcc": {"doc_hash": "82e27404d907aa8921e03c6437253d06a47d99a8ef6a9e7e45020f68bacd8258", "ref_doc_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a"}, "1684688b-2f28-44fa-8dfd-64c01478b49f": {"doc_hash": "98d37dc7ddf80a102163bb4851f632f7911f7e429bda5ce9a11adaf4acbc23b4", "ref_doc_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a"}, "c9f01e8d-6cc4-45ac-9ed1-ffbeed42bae9": {"doc_hash": "6adcc761bfa9d1f910899fd02e7eba2251ef93b09c8c2b593f8b6afb9898a458", "ref_doc_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a"}, "a48c7dff-f249-47d4-8cb7-6bd6a680347b": {"doc_hash": "3ff1e1d41e8b8c16ad4ac64c2b1d784a2a70efe32224906cb51ac1ba12297362", "ref_doc_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a"}, "3595e7cf-d999-47f5-b7c3-2437cfe3d36d": {"doc_hash": "7c76b22fe5f34012b7d6c29a05ec9cc049c81a9404bb10915d58314d52b082e6", "ref_doc_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a"}, "089e3374-ff99-4caa-9ce6-5f9d6dc360e2": {"doc_hash": "410b5d90579f12b9c1f6513be5debce4531bb951c783bd5f29e54b40f7f2f907", "ref_doc_id": "b0a4684d-5c22-4f6a-80a8-908c1dd1176a"}, "3e1d76b2-cacd-4b52-9fd9-1e6656a2eac0": {"doc_hash": "40e3a64f2b9ba7bfa1484405317690080aad78da14b01205e341d0de4a250a1f", "ref_doc_id": "0b649837-3c05-4710-82a2-37e772b6efc5"}, "1cf60df4-19eb-45a8-8ed1-c2a84a21871b": {"doc_hash": "5e557e66c9922e8f7512f9cdd08efb95ce88726f36e6b04cc4b6c1b21205caea", "ref_doc_id": "0b649837-3c05-4710-82a2-37e772b6efc5"}, "f4ffe36e-0443-4072-a88b-8884caa1939e": {"doc_hash": "e5cd1ccd0bef05b1d40a0d89190ffa86daafef57eb701a9e818c1d3c0f66edad", "ref_doc_id": "0b649837-3c05-4710-82a2-37e772b6efc5"}, "587e5860-5d33-4952-9128-ebf2a5cb6d03": {"doc_hash": "438178de1a8b8db64a843c83550942ef1603ae300efa5921a795da9f1d4d83c0", "ref_doc_id": "0b649837-3c05-4710-82a2-37e772b6efc5"}, "acca44ba-0c49-4628-9cfa-2f56c3e3fe50": {"doc_hash": "627aa80bd6b2a4604a31554bb29a3f9f94debc91a5f7182c171eb2430106f866", "ref_doc_id": "0b649837-3c05-4710-82a2-37e772b6efc5"}, "1d0dd021-31ed-44fc-a2a9-a2df5c977a49": {"doc_hash": "e12c3c6fde8f789117e890254f347d85a09e5f1fc516354af001e9abc76afb79", "ref_doc_id": "0b649837-3c05-4710-82a2-37e772b6efc5"}, "99c55606-ace2-48a7-82bd-9e57d689197c": {"doc_hash": "6006ea0ef0e4fc6c30bdbbd531d41bfe05002bcfce3479b0f4a216d789e9af6c", "ref_doc_id": "0b649837-3c05-4710-82a2-37e772b6efc5"}, "7a3ff8d8-9ef3-44a7-bfa3-b3eee7073614": {"doc_hash": "8c9f6df8d00cf016c5ab46b2a05779e61185041ea3b27217bcbd1e3af0c56c48", "ref_doc_id": "0b649837-3c05-4710-82a2-37e772b6efc5"}, "38e90ac2-35dc-4557-bed2-82afbe22974d": {"doc_hash": "11d06b7736a767a97015bea1a62cd80e0e3671c40ee1405b63c6fbfd37ae3be1", "ref_doc_id": "0b649837-3c05-4710-82a2-37e772b6efc5"}, "42c96c9a-fb44-4edf-87c3-392dac0ad0dd": {"doc_hash": "2e4e410a6df8a75258362735528899046fa5a0e8cf1ad24d41e24df0f04f9582", "ref_doc_id": "0b649837-3c05-4710-82a2-37e772b6efc5"}, "7945a51f-a255-42a5-ac31-9094d48061d9": {"doc_hash": "8dcba91d2d3a3d22e5a5a6f784f5093c0fd43e1b92323d4482f626c1cd765611", "ref_doc_id": "0b649837-3c05-4710-82a2-37e772b6efc5"}, "f08e07a4-9efd-4dcf-b30e-91e2f29f67da": {"doc_hash": "e6f14e437976b8c7f9843812a11575e557a8fc6523132141eb9259b2b1b64e79", "ref_doc_id": "0b649837-3c05-4710-82a2-37e772b6efc5"}, "f5f0a081-a3f9-4382-ac99-67fc9dac4cb2": {"doc_hash": "88374c828a89a2a281472dd7b70fe6eb0b3d14d0d76f6185d5f7af7595b37275", "ref_doc_id": "0b649837-3c05-4710-82a2-37e772b6efc5"}, "3b709052-4162-471c-b743-91ba3e4890ab": {"doc_hash": "18b40ca9db9dfec16b5d67c14010b946d577bc398bbe700500d1cf8c73fb70b1", "ref_doc_id": "0b649837-3c05-4710-82a2-37e772b6efc5"}, "5d6d4461-d192-457d-ab01-f755ce3925b8": {"doc_hash": "0f1ee046a392bd3ed0b1536f38b5af9cdd8d452f516245729403f1ec2acb4951", "ref_doc_id": "0b649837-3c05-4710-82a2-37e772b6efc5"}, "e32804cc-93f0-4f97-b313-f9e496451b1f": {"doc_hash": "f9a75a5590047fd26834f04a6ac4f96ea476a60b5d69f3278c5b56e37ba02dd6", "ref_doc_id": "0b649837-3c05-4710-82a2-37e772b6efc5"}, "c2a02ef2-2345-4d45-a0e7-b316cd09526f": {"doc_hash": "712a83945e402b4c353c416d7ec5ea27c59b1150866685d3ae7f8961e3bbf999", "ref_doc_id": "0b649837-3c05-4710-82a2-37e772b6efc5"}, "ad528226-7d88-482b-8db2-64ee9b6496c3": {"doc_hash": "3b4c0f37c012718300d7c69cf11b0774dccb6af87cdeef99783246ad3ab96b4e", "ref_doc_id": "0b649837-3c05-4710-82a2-37e772b6efc5"}, "c0ee073b-d3ce-4482-9c1c-6d4a98821ff2": {"doc_hash": "a72faad124f447e7512997c7e83a9daf246e3fca97d2d5316a45b5d4d7595894", "ref_doc_id": "0b649837-3c05-4710-82a2-37e772b6efc5"}, "09ebd885-4635-4c2f-8015-7924bffa4432": {"doc_hash": "977e3812921cc93b515bbcebb64e5c9c390e9c285f4bdaa15b8a79c19793f635", "ref_doc_id": "0b649837-3c05-4710-82a2-37e772b6efc5"}, "bf66b6da-0424-460f-871a-c299981d4077": {"doc_hash": "3ea6eeb8915f3d7ab538d6ac50b57493b8d742f3b20e6d8472a0b36ccb2f25b9", "ref_doc_id": "0b649837-3c05-4710-82a2-37e772b6efc5"}, "738ba953-4525-41ec-8f21-73160e76b096": {"doc_hash": "be7a5dcae33bd93335487b31936b5ca7c1ff22231fa07f7716fc86427b38c5a9", "ref_doc_id": "0b649837-3c05-4710-82a2-37e772b6efc5"}, "fab8d38b-8e25-4c8a-8516-4cc84ef0860a": {"doc_hash": "f571cc7f384c5607338b4ae75a60dbac097b004cb3ba6b0bb94403d44d297510", "ref_doc_id": "0b649837-3c05-4710-82a2-37e772b6efc5"}, "e22ff1f9-8a06-4368-bff8-ede13215cd9d": {"doc_hash": "ea37c10ad9e0ae25f8220c436b71d75a0110ca45d8f1b2f2091fc08215d70f03", "ref_doc_id": "0b649837-3c05-4710-82a2-37e772b6efc5"}, "45b4f3b4-d32c-4949-b9ac-00678de4d463": {"doc_hash": "7d4cdc5ccafcbe2f14e8c899a38c13a1bddb58e73feb49930b525d53da65f221", "ref_doc_id": "0b649837-3c05-4710-82a2-37e772b6efc5"}}, "docstore/ref_doc_info": {"f1de019c-ee93-431e-83f5-688557649411": {"node_ids": ["e646e0fd-f57f-41c9-9d7e-50ce6fbc15e3", "6bd3b4dc-856c-46e0-b943-fe828ddb5ede"], "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 19 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n02-Feb-2022  \nMcKesson Corp.   (MCK ) \nQ3 2022 Earnings Call    ", "original_text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 19 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n02-Feb-2022  \nMcKesson Corp.  ", "page_label": "1", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "edddd1cd-f6f6-41c2-b7ea-bb7d91760227": {"node_ids": ["d575b349-ba00-4d24-98a5-00ba5fe86008", "59579895-53da-4bd4-9a79-539b1492c451", "a3c5b0fa-b6a9-4bbf-994f-6f0ba66c4093", "a2f08546-6c81-4801-a2bd-6d76e2511802", "18779052-4a57-4cd7-826b-aa88736ccb44", "84888ded-99fe-43a8-bd52-b48d77c36be1", "0d8bc9e7-8f3e-4503-b604-ff5b455cb2aa", "a3a029d4-2c20-44d2-9ba8-2040631223a2", "a806af34-c310-4a78-9d3c-09f2237e9538", "64de42c9-2a0d-443e-b172-8fa15f4a56f2", "75622da2-8a77-450f-8120-ce716bb89c21", "4a01cca2-c589-4a83-b9c8-a35332967b83", "a0286b72-ede3-4a91-8d03-906d0faffcc4", "7ff2612b-e637-4733-a4ed-3769022e2965", "b509d8f0-b69c-40df-90e7-1da97cacc4ad", "6a447823-afff-4ef1-a1e6-5f8f84dcf5b6", "cd8e8e70-8379-47be-a193-6d61700969bb", "213c25be-6c18-46b9-bc61-98411824b897", "04275573-d7b3-4544-8201-1e9543c15528"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nInvestor Relations Contact, McKesson Corp  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "a6099167-af59-46fd-99a8-7c7f028b5ea4": {"node_ids": ["5ed98d39-26cb-455a-bc74-83cfe5265996", "f1524133-35b3-42ab-a861-041a1cc185f7", "42a4a8d1-8e25-44a9-b8aa-f54a4d9c0e22", "bb76a09c-9c23-4065-9a9e-d3542dd9a8fb", "d2fb990b-8f56-4c8d-95e2-f4451495fa7f", "1bfa31cd-76de-470f-a02f-2547094afda2", "38b029e0-f8a8-49f9-9daa-a5b41daec436", "3c942233-1832-4f63-9260-2b94d3225fa2", "a4b1f1d8-3012-435a-abfd-fa64cc5c9b67", "83cb1f47-7bdb-4f60-973e-60664b9c1545", "33030885-3af4-4088-aee9-4925fefdcd7f", "64d5b098-dc25-4eca-8eb7-ce552eb8de8a", "2ffd2410-d9f9-4e10-9ec0-2629fd764876", "456a4aeb-58f2-4fde-8d06-f4d6eda5599a", "96026bf6-6411-47a3-aaee-a1f9d6ae4af8", "263e5bc3-24ff-4da2-887c-6ecbe33e4cdc", "0aa3fec1-2b8f-42ef-a895-5f76bbd303a5", "925e272f-b81e-4828-b250-2a18d7178728", "a507df3b-c3ee-44ae-8656-f067ee679fc1", "50f92404-c7cd-4b9d-a7e0-dda012994e24", "fe016eb8-117e-4790-a5c8-0675ead5bb5b", "e4af05a4-2ebe-40c9-9347-be0b111e4d05", "2f8d3820-b140-4dd1-80ce-887782cf523d", "ff268f41-851f-446e-a78b-9a089011dbd6", "6d3708eb-fd30-439b-aadc-aad7ffebcc27", "b3d7bb83-db8a-4f02-b12d-cadb20610ec5", "3db867be-77b5-40e2-acc5-bc752bc7b778", "81452c94-929d-4c31-b60a-339efd74d994", "0f37ea09-571e-466b-99ad-a20692bf7bd5", "d4de066d-8ee4-46c7-bea0-6b7640867e61"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nWith that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Exec utive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and thank everyone for joining us on our call today. ", "original_text": "McKesson Corp.  ", "page_label": "3", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "2657d877-6c2d-4cd2-9c56-265576a1cdee": {"node_ids": ["c067af5d-352c-4e48-8fff-bbb9598dfd19", "55be5aff-45a9-4209-bb0b-fe7e56a5cf31", "4f88069d-f7f4-4e5b-a610-fe288c857dd6", "1bbe9603-efd6-43c8-9d10-af4e8a038e69", "9d4d37a9-a0cc-4e6c-a1d9-0c13d7bf4980", "9753bbb7-b117-4d4d-9a8a-925b2064ec63", "1cdf88f6-7a6d-4247-8087-bcaa8577025c", "a421e3f3-650e-4ce9-9257-0e8b6b9aed00", "5e80ff09-5ba4-48fb-bc96-02e574563eff", "5dc58ca1-5d1a-4f76-aa35-e1f751201544", "6a5b58fb-dd17-4721-b56a-3406a2c428a5", "70f232af-594f-47cb-8016-490ffcd7f9c5", "a4db77b4-a29b-4551-a651-f3cd1c8d8e45", "fada4ae4-119d-40b2-88e3-7ee898b0b6d7", "57c21ed2-7d03-465d-82dc-1c3448658b59", "d1a6f385-a027-4d73-8132-22161d630704", "98be5750-3483-46fb-8611-609aefc19ae6", "1fee1a09-b409-4c54-8724-8710d0797765", "8e5f57b6-0f02-4a18-9bde-b27e23f99ac3", "0f15ac60-66e1-4deb-a1f4-8bbf404238d9", "e41ca812-34ae-44d9-962d-029742b9d2d8", "50aea7ab-528e-4ff9-984a-f1b1a8a7b4ad", "a5171deb-d415-4af1-ac40-7182db334d30", "d09cce28-58ed-4e87-8b91-7fef607e7c5c", "6e7edafe-4a85-4771-b2e4-9bcc4e8495bc"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nOur next priority is to drive sustainable growth in our core pharmaceutical and medical distribution businesses. \n We have a vast skilled distribution network and deep expertise in global supply chain management, which have \nbeen a critical and foundational part of our long history.  We're  proud of our operational excellence and our ability \nto capture efficiency and deliver consistent and high quality service to our customers while optimizing operating \nmargin.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "4", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "70da607e-7d19-47fd-81bf-839e155c79d6": {"node_ids": ["b4b015c5-f548-4f6b-838d-6b538e084fd6", "aa1d20a5-df67-4a93-a139-1abc98830009", "634ca735-845b-4105-99a8-84c0dd462500", "725dc139-4e44-4a57-9f90-aa333aa90209", "8d8fa293-34d2-4b17-b034-976f7ce36055", "c6c12c04-6302-498a-a509-b0e845e6aeb1", "8478f3f3-2b33-46e4-b9f3-43d5fb8109af", "33705a49-f63f-4c73-bd47-06ce4eb1dab0", "c411ec14-e3fe-45ec-b889-aa785134a5d7", "ffa573ef-dea8-4e84-899b-5898d6e2cc3f", "ddeb0920-b1b8-4b80-88d7-4bba3bea28a7", "c57e2082-9ec5-4b25-bf15-9f816b83e910", "f270d553-674d-4e9a-af17-2d046271f47a", "73b8efa0-617d-4472-8084-fb0a245826d0", "56768881-e6a2-4f6f-85ba-51067d398aec", "5ccf9017-219a-4422-a744-6116a14463bf", "d410f7fb-5b8f-4b11-9722-04e957e5a9d2", "9f64acaa-167c-4083-bb4a-5404cc673a7b", "0a9cbe31-545e-4ee7-acf7-8b6f3f33abad", "06c8d1d1-9781-4d51-9c8d-de67a48f2152", "bbd193fb-35e4-4ff3-a3ab-f36b5701bb62", "ac67a572-79dc-4953-bb2b-401da20871ec", "61853ba4-7eab-41ad-adb2-1f46a9d041e6", "8457722b-d6af-4bc8-adcd-a0bb79281f8b", "d89069f0-cf12-42ff-8d14-f07af910cab2", "b051128d-89e6-485e-9c12-fd7bc32d4b56", "c0d07f0f-c7b9-4fa3-ae1e-7da456577a31", "58f52f9a-d989-45e1-bf79-e1c4abcab881", "883ce365-fbfb-403d-8b0a-8bee1ae1303b", "bfa9c64d-023f-4dad-9f67-660b907b1e51"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ntechnology and insights business dedicated to help advance cancer research and advance patient care.  We \nrecently highlighted this business a t our Investor Day.  \n \n Since its launch in December of 2020, the team has made great progress transforming ideas into reality. ", "original_text": "McKesson Corp.  ", "page_label": "5", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "ea37bd0c-fbe1-40ae-aa75-ffa08508dd21": {"node_ids": ["8e4368a9-f037-46be-b4ce-b87fb7f600c1", "2f187df5-cbf9-4722-8477-3128a20244b6", "5b2bdd58-f465-49a4-9b90-414522bb4107", "38fe2b25-3fa9-4855-9579-c060e0076c50", "086981e8-b73c-4cb8-a3f7-4da221613f18", "bda270ba-819a-4481-8c6d-5bedb2af63dd", "8388bdbf-921b-42d0-ac78-03b28c46fe09", "7940deef-3c3a-4cd1-b396-60b409fe4d76", "51c98247-99f5-4e2a-91e2-8cc1fb435bb7", "a1b03d82-6430-41e5-bd7c-10d023ac5308", "9c63a038-d36a-49a1-a5cb-2a42c7f25f38", "90d54d54-a357-4046-87c8-2a6aa7e57d62", "eb6b13cf-6d9d-4aa5-84e3-2b0de672c802", "2a3ae4a4-3140-4e37-a105-628d71cf28d8", "13690820-35dd-40e1-a62c-bb85ab0f61fc", "41dbb4ee-fdef-4845-a395-03f32098e1b4", "5ef889cf-ffcb-4194-b6a5-e0af61053533", "6ae5a834-f0b6-427d-bc55-b8505962798b", "808e2a5c-6181-4186-a5ba-10bb116fd617", "09eadf83-4dba-4fb9-876a-f43043330e63", "4b2b8f30-3740-4408-b35f-26de6860852b", "9d0afe28-d901-4b8e-843a-8de394e43ed2", "7648afff-36ba-4c0f-b332-7472d914ea31", "3c06ea3c-09a9-45b2-a95e-9cc524b2b5a3", "3c6f5f23-af90-4ec8-9e5d-d78f4ba7772c", "a3cd0ff3-9ac8-470c-9f7a-482ecadb8236"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nOne thing we've learned in the past two years is the resilience of our business and our communities.  Regardless \nof the trajectory of the pandemic, we're confident about our ability to adjust and adapt to support our customers \nand their patients in these challenging times.  \n \n Let's turn to the US Pharmaceutical segment. ", "original_text": "McKesson Corp.  ", "page_label": "6", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "f4ddef2e-0215-4035-b117-0936dac4b268": {"node_ids": ["0094ecfc-7452-4f53-a816-eb9aeb53c0bd", "68716af3-7a5a-4200-bb4c-ad4325a4f3b7", "cbb74205-c008-4f1d-94c6-00e553039e13", "74924b8a-1105-4962-8b31-bc3ca6e2859c", "bb3321fb-504a-43c3-9f4d-3c85a89772c5", "bec77d8c-1247-43d0-9116-44fccfea4da9", "758bfce2-77cd-4820-8c37-9941d781101c", "5aee6360-e016-4333-b73d-a704fcbe12f3", "6b567941-987c-4542-9f0c-b07b85dd6084", "fc810ece-4b89-4699-ad65-f3d63f855d78", "8c7685e1-0181-4d25-a04b-d08470c2709b", "098e13f2-35a3-47c6-b86c-99aef54422bb", "e1819288-732c-44c6-99e7-253496e4e9ee", "ec7428ab-b246-486e-a79e-f8922f495028", "816a18cd-e8ef-43e0-a00d-ad7add2b688c", "6fe7546b-e677-48bb-8cb3-a482cb5d7500", "eee39b5a-5880-421d-a42d-9e39a91f490d", "1be0be6f-ad3c-4a65-a480-f4d19fc583cb", "b80e5278-ea83-409f-a793-a9b26c156255", "4821ef24-fa6b-46a8-bf23-a78f30e0b5f9", "0d031b4a-b76a-4fa4-be80-56a0b3ece706", "544b7fc1-4328-405f-be18-09f90d4e20f1", "7597e6b5-d145-4bac-bd51-94d6630882ad", "821f2aea-1c74-40e3-ae09-87c7b985496c", "247ac1f4-5611-4287-8478-a0cbaca264fd", "f4161c25-1f35-4ce6-b202-915fc722ec4b", "8c0e7c05-ac46-4505-90ca-704abf3fd5d8"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nIn closing, we continue to be excited about our futu re growth prospects as we meet the opportunity as a \ndiversified healthcare services company.  We have unique and differentiated assets in oncology and biopharma \nservices with unmatched scale and connectivity, and we're strategically positioned to win in the se growing \nmarkets.  \n \n And lastly, before I conclude, I want to take a moment to thank our dedicated team, including every one of the \n76,000 employees that make up Team McKesson. ", "original_text": "McKesson Corp.  ", "page_label": "7", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "61ec5d58-e8e6-4fb6-84e9-6e9504c022e8": {"node_ids": ["4a416d8f-6973-47b3-a26b-ef6670c3d4e7", "60ba4309-17a1-4c2d-8bbf-9c9e18dba141", "79e71ee7-04d6-449b-aff7-a45d731645b6", "42c97ddd-b746-4886-a6df-9b2edaf071eb", "0271da0b-b971-4510-b680-2a5313c69fa4", "ac1af8e0-b24d-4926-b892-d19d6f4446ea", "bd48f49b-267e-4657-a120-f9e1a6a3ac16", "2c45b983-605d-486a-9ac3-4b86f24ae205", "c960e201-7797-430f-b192-cfad665aa38e", "1fcfdfd8-c7d3-4abf-9b7e-6479e46d6c4a", "38570272-486a-4657-bba7-50b05d08e0bf", "8cc1f111-56a1-4622-9f32-0493facf2df1", "29a86ea2-575c-4e2c-9d02-7acc2af37446", "2dfd3e23-a11d-44ca-b22a-7cce44be461a", "d27b3aab-8c7d-4b9c-9944-df6005c2fae3", "cac554a4-a098-43e7-a068-f3ecacc60e50", "32b8af8f-53f8-49b2-9ca0-42466b90b24a", "b7a8c00e-88f4-41ee-8fec-6730b06ba00b", "49e08579-73aa-4b23-8a9d-9748e68d8de7", "05634269-8572-4ee3-8ba3-02c7a63196b4", "6a005061-bdef-41fb-b95b-3069f61ca453", "7205a9e2-8dc3-461b-abad-d0b879f8a0bc"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nMoving now to our adjusted results for the third quarter, beginning with our consolidated results which can be \nfound on slide 7.  As discussed at our Investor Day back in December, we managed the business for t he long \nterm, and our financial and strategic framework is focused on shareholder value creation.  Our financial framework \ncombines three key elements to generate sustainable adjusted EPS growth: organic growth, operating leverage, \nand capital allocation. ", "original_text": "McKesson Corp.  ", "page_label": "8", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "74570293-485c-474e-a351-234bb8205358": {"node_ids": ["8baff24b-4d81-4c4b-9842-65bcb9fe83e3", "8eae83da-46ff-4fbb-9775-750b89167566", "6a9acc26-72f9-4383-b388-bacab12ae13b", "727c1540-b098-4f33-9114-2abec99aed10", "d23008ab-ebf7-489c-bcdf-2d83739c57b1", "4d4d51eb-9d33-42f8-bf91-4bcd6f2b6643", "d26ac9b3-2fe5-4d61-bbf8-30f72c27d6c5", "41773650-053c-48ba-8540-ea04d1cba70b", "a89052df-ea23-483d-ba30-b3d4cdf6d871", "78e1cf97-8c86-4675-a9b4-0c361fb58867", "eb61c10d-953f-41ae-8dcc-b94f9483125d", "b9a7d083-bd5d-483c-b711-696130e44abc", "0df0067e-dbb9-46fc-bb5d-0737d74ab8be", "aa49c725-0e17-4994-838a-d4d23e211a11", "af2ad513-6c36-4fd3-809c-2ffcfd2009bb", "becce4a1-a11b-42f9-b338-6c07fbbfbd7f", "65d30bc8-0488-4a55-bbfc-dc326721829c", "3b9a3d29-ebea-41d3-a7b2-e48a3c38d4e2", "4301fea8-52d6-4a8c-8e30-1555fe4035fb", "20c51fc3-5a7e-4774-bd28-21e513a90442", "bf39bee7-daac-425c-aa5f-33e4b760c63a", "df548ac4-047e-4d47-8dd6-0387f3ecbdff", "4223aedf-4834-4877-9c06-dd26378fe0ff", "1c1e8ab1-e85a-4513-8074-b58d99d29589"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n11% to $145 million driven by growth from access and adherence solutions.  We continue to experience growth \nacross our broad spectrum, higher margin capabilities and offerings in this segment.  We're pleased with the \nincreased transaction volumes related to our access and adherence solutions and the increasing number of \nbrands that joined our platforms this year. ", "original_text": "McKesson Corp.  ", "page_label": "9", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "c4835e48-c324-4b54-8fdb-9d717b314aef": {"node_ids": ["02f98aa0-d06e-4e74-82a8-e1b44c3cca30", "06eea0de-0289-43f4-823a-8eb324689b7e", "f6d3f8ef-ced1-420c-abb6-9162c5ee9bc0", "9dc09fbc-8614-4f9b-aa8a-980443b3226a", "66bf18aa-9177-4ddc-8ef1-ede94365999a", "7e7aa8ae-6ce1-4a30-83fb-1896ea98c553", "f6780622-dfec-45de-aabd-30c51640a944", "ce6d279d-a90c-4444-9afc-e8fb7b81baed", "6d7000d7-98d3-4070-b8c3-74fa3c56fbed", "8be15bbc-b207-4bee-a650-4ec6c8c9e821", "029eed23-ba9d-4484-9092-4718d189dfdf", "c4eb5308-8c4d-448a-8150-9b38265af213", "7c863a50-9b4e-44bc-89e9-748ba9f01886", "1413d02a-5d15-4ec6-b9cf-15d2be1b3b5d", "d822f27e-ddb6-48b4-943d-f047d6519b19", "5c0051ac-b040-4fba-af49-86205690aff6", "25ae07d1-0b28-4364-ad78-0255bd560cef", "0ecfc150-38bf-4c9a-bdb1-9f7e5c85534e", "db96eb6b-7a4b-4f79-904e-7c9b559d6396", "cda4ded9-b9d3-4d99-8e9e-61ef62d9de04", "d4c2826d-b8b8-49d2-866a-46af637d7b92", "86ee9854-1aee-4b69-97fc-406b1f7904ee", "5991b8ef-718f-4fc9-993c-b6e48df4641c", "045416b8-dabe-45c1-a0ff-738e3b4b9419", "dbde3349-9f40-4423-a60d-9df84ac1dddd", "96bf0892-867d-4b12-b7e5-8c406deec22b"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nexecuting share repurchases of up to $1.5 billion in the fourth quarter.  As a result, we now anticipate returning \napproximately $3.5 billion to shareholders through share repurchases in fiscal 2022.  \n \n Our strong operating performance, combined with our return of capital to shareholders, reinforces our \ncommitment to driving shareholder value.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "10", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "f7e2d2dd-66c9-4d9a-9d5a-780ab89c5595": {"node_ids": ["66180e6a-9cf6-468a-b9d9-e75b8d555121", "9af6c85c-aa25-49ef-aa56-e0e0a17616a2", "f025706e-2bcf-4632-beb6-b7cca7ec2707", "322a2c5f-8f4a-413f-bdf3-77795aec9e19", "ad162914-f7ba-4c31-a7c8-c9a3a724fcb0", "dccbf095-87c8-4e28-a46b-45b0ff9ee73d", "de19cbb8-a38e-49be-9ecb-62d40d7998e2", "0680e701-d168-48aa-a6c5-0da8988dd2f3", "8e55637e-061c-4ac9-a5bf-e0e34f70fedc", "31e99e59-c6e0-4a85-be9e-da0c14e86164", "1bff5aac-0336-4399-a27b-36e6840f002c", "551bd446-fb15-4021-80ac-36ca6fe34b96", "4bd2039b-9f94-41b3-9f65-b19bc647d3a9", "a6cb4269-ddb1-4e0c-8d1c-ee7b3356e31e", "915ba775-ced9-42be-97ea-745b3aaded44", "0487e2ca-a05f-44fe-9f2d-e357486172f2", "f5bbc06e-f848-4043-aed5-a6c196f18861", "7268c014-beef-465c-bf7e-90b3125a1786", "51c2a2d6-0639-4e01-8f78-33456232bd01", "d06dd9e8-aa9b-4d70-a49e-d76a76847115", "b271b38b-a9fe-453e-b928-851e76b029ca", "bba65e5e-d41c-4b2d-bb83-f178a4ed65b1"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nFor adjusted operating profit,  our guidance reflects growth in the segment of 43% to 47%.  This includes \napproximately $0.49 of adjusted earnings accretion in fiscal 2022 resulting from held -for-sale accounting related \nto our agreement to sell certain European assets.  \n \n Turning now to th e consolidated view. ", "original_text": "McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "01bc6e5f-cc79-4b05-99f5-5a1b943788f8": {"node_ids": ["8c576334-9de0-4f18-aa0f-9f8ed59631b7", "f60f19d6-e0f6-405b-9073-116af28870fb", "000de7d5-dd08-430c-b762-b4c68fcaf984", "b61365a3-7cc7-43d0-8353-a044b3a8ac85", "64f9b6fb-99bb-44f6-8e99-3f31ebc1064e", "68abde1a-70b1-4c57-abe3-dfaa19975c98", "9bf5d397-98aa-4c6a-b655-adf938ba25d3", "86e8b7fc-6187-4975-9d44-6b82a4399ee9", "b9c4d557-979d-4740-b305-cd02c528430f", "86b2c0d0-b59a-419f-8ee4-69cb1bd75b06", "d3e00e96-dbba-49b5-b398-8b35a747d518", "8e5b619b-dac8-446c-ba6c-1e4ad163d224", "b1506125-6f9e-46a3-a739-dd82ddd3e2b7", "d850eb94-3de3-4e3b-ad5c-d1098193b9fa", "24b51985-037c-48c4-82fa-38e9d99006e4", "010525f2-4776-4940-bf30-b43f9ad5efb1", "9837a007-9c17-4a0b-a4bd-b2fd8e2692f2", "2e219d54-22b0-44ad-b994-bfa14abf8dca", "f115d3c3-3000-4364-8689-3920a08aa3bb", "5fcde533-85b1-4d83-86c4-727a0ad3ad48", "e1fbfbb0-9bdf-4610-8a94-9045aef6e82d", "935ca256-96da-4175-be0d-b98dfea082c1"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nLet me spend just a minute providing some initial thoughts on fiscal 2023.  I want to point out that we are not \nproviding fiscal 2023 guidance at this time.  However, I thought it would be instructive to walk you through  some of \nthe items that could impact fiscal 2023 as we sit here today.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "f068cc0d-3c7f-417d-91f3-136afa17b579": {"node_ids": ["27c17fa8-e243-492f-896d-dfa899fba284", "545b9e6d-2d02-4214-8ce6-f3cec831360d", "d5c29af9-a84e-434b-83f1-c3e92d127506", "489049fe-3776-4b23-95f6-753979b1c77b", "0e4b76eb-fa6c-4f45-85e7-eae89756e411", "013244b2-4e46-4ff2-a500-822a58606b72", "f73bc254-7e3e-433d-b2fd-b0e62822cee8", "02e50800-2664-43d8-9b65-f478368d4ba5", "6487439b-2f6e-4023-9912-bbbad63eb202", "b35e1fa9-e22a-4cfd-93af-10226064a87a", "446f5174-f372-415a-8d24-a427df982421", "1e488c39-3fcd-45c7-90c2-98537aaf85e1", "90adf858-5b12-4f4b-a2e5-0c5157e1e84c", "2adac713-3523-439e-add6-3e3cd319277a", "601d6918-c01b-4111-bac4-72d01cfeed01", "d94f69f7-cfba-41bb-9b5c-eba30f678243", "7029f77a-e2c9-45f0-a584-5924cd62b65a", "cc2a4546-d91b-42de-8c09-5b09951d86ca", "ac577c6a-399c-4f17-a656-63e4a9210340", "87c0a656-58f0-497e-a651-84fa0d6aa06b", "ef08bdb2-708f-43bf-b2b2-fc374a6d02f2", "5fd93bde-5ddc-453c-bd08-333e6414994b"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] Our first question will come from Eric Percher with Nephron \nResearch.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you, and appreciate the commentary on fiscal year 2023 at this point. ", "original_text": "McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "c0bc2914-1a28-4a02-aa06-32ec80578111": {"node_ids": ["d7c6282e-1e38-42ac-a7ad-31609c6dcb82", "b054093e-d96c-43a0-ac79-ff0cdfd49a69", "54e6e201-fcfd-4120-b897-f7022404399e", "75b843f1-1c42-47fb-b796-bb99a7c8aace", "40db3751-e058-40c2-a6c9-6d42e0809c88", "574d386a-0679-4462-9762-d37ef504526a", "efdaf7a2-02ec-436b-bd80-85f7e0f8b409", "3e202d3e-589e-495c-8508-c8e44d750f79", "3814e4b0-a747-4055-98c4-321c22bd8ae3", "814fc27f-18ef-4f24-bf43-0448bbab213b", "b87335db-458d-41fa-a624-83d4742dc34a", "b39305bf-95a5-4055-83b1-5d48d52e8632", "6529b730-871b-4dc3-8c62-1ba24ff12cbb", "64777fc7-8394-499c-b7e8-7227c4732c67", "db04f0ea-cbb0-4b8a-9dd0-d99771fd7d30", "821b7432-6582-4f0b-a083-faec7bc4dadd", "3cdab136-1c39-43ff-b29e-cb26843e06e2", "8bd7737d-b8d9-4cc0-b2f3-3270820f2c2e", "74eb880f-fc23-499b-91a0-afc8786a5df9", "b3b33047-e393-4a7a-91ea-ecac7ab9bf5d", "d8022c74-fdd0-4073-af5a-61c2a40edd39", "6b1179b2-8b93-488e-be31-b93527e3307c", "ed00f4d9-ad17-4127-bec1-7c35a3cad936", "1da0802a-ed0d-4f3b-be7c-0b36e225af39", "720ca742-f4ff-482e-ae41-871b7f624b4a", "c8a18dbf-0c14-4682-a00a-3e21c992bbc7", "b2e2b0f5-8400-46a0-a606-16db4c4299a4", "6665f588-869c-4c6d-9f7f-916790e9f899", "2f2d7cd0-92f9-420d-a80e-9715c6bb8554", "e62f5765-bb7a-4ea2-afd4-db151608002d", "f88a158d-ad86-4e15-b962-62e4148eff42", "0b60c3b6-add8-4648-b5ce-736b564d747b", "e073c53d-d7a8-4fc0-80a4-81281798561d", "576dada0-f453-4d3e-9de0-4f7537d7e321", "9048b87a-4137-415a-bcff-3d2c29e5c6d1", "d1cb13f3-0392-4e9d-9ca1-77ef214da619", "755f080c-77ff-41fc-8ea9-de406873ea2f", "0ae5567d-1672-4136-b2d4-9857b3cbc113"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBritt Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nLisa, thanks for that question.  Maybe I'll just step back for a minute and just address labor and inflation \nseparately, and maybe I'll just start with inflation. ", "original_text": "McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "bc629de4-825c-4a81-8fe5-d4c62e367c38": {"node_ids": ["17a98fc6-9805-44c7-ae14-0d4d3ae71367", "7b292413-525f-4cf7-aef8-711bac157454", "48aec9a1-8eeb-4a4e-8d9b-7bfe3daa4951", "528ba616-910a-4bbf-8b37-24a0570f01e8", "145ef048-18e6-4143-8242-c50c96326bf0", "5d269d40-9acc-43f5-91e2-ef83d82ad221", "e3582738-efda-46bb-bcca-d3d590544aeb", "aeea6de9-ff4e-466b-a39f-ef30847e02bd", "673f94a4-1bff-4356-940e-bdf9437e078b", "4cdc6e6c-7f51-4713-a05e-f3ba97f8ee27", "c4846d6b-8090-4bc2-91a0-93b121962976", "e17f7320-280a-4767-a4af-59a817d6041a", "a86fbb91-ec9a-4bd5-a7e7-7bacd14c0145", "4ac46ae2-0ba8-440f-ada6-cf7086c283f6", "98352a9a-9c44-4757-9074-d9d55cc88d8a", "1abea367-6dab-413b-ab92-52f2a5b5c098", "717404f0-efb7-4ae0-b756-33c1d2e1f29e", "6c917ddf-8972-4006-acd4-88e243f8d83f", "bc227165-ddf2-4a33-9d68-ad3119d4d199", "8aa92e93-a308-4505-a63d-e31620bc109c", "953e15bf-e429-4a15-ad0f-bae0f3bd694c", "25ad743d-07df-4748-a6b3-cf92797c8054", "a3dc1602-fcc4-4181-8c2e-b406433d5cb4", "6d3000b1-6feb-42a8-85d8-65ec6a7f6d9e", "90db45c9-8c56-4b19-b000-96ca573dcb83", "8f318303-8e61-4aec-92d0-8aba6cc477c6", "e3fab23d-b2b2-409b-8733-1894cdeff436"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you for the question.  I think you  addressed it to Britt, but I'll jump in and start with my thoughts. ", "original_text": "McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "692933c6-e017-4d68-907a-60e809f96ddd": {"node_ids": ["89f1971c-d0a5-4174-8ff2-54f6b209b560", "67dcf5c0-00cb-43ec-8cb8-0329065def1c", "108a56c8-e2dd-4997-bef5-50ff15a06325", "7ea86e05-e244-4e40-83fd-e2a952caf437", "cf594c66-6bbc-40e9-a7bc-4348336a79b8", "82d7100d-ac7e-445d-8439-1a1221bd59b9", "6113ee01-d6e4-4307-a23f-488edcdb653b", "a7792f8e-fbe6-4b47-9726-8dc11e40b994", "f63c3445-702c-4c68-b0bc-a2989c8c713a", "0f3797f0-f7a1-4c43-86e9-b4288e2a2619", "a0a72b3c-28ab-4344-8f5e-0a46ce62647b", "beae7579-cf96-4cb3-851b-e6c048a076ba", "81b8f3f0-91a7-470a-9689-6e3cdc4b1501", "65a6280c-4795-45c3-96e9-1899029325e3", "8901681f-dd2e-4e2e-b312-e2161e398c7e", "2e38d70b-b1ef-4d49-97a6-249ee8c8dc52", "889a5dcc-d472-47b9-a570-9205e5be8c9f", "1802e46a-834f-4a5d-843c-7f8df7fb89fa", "60faaac2-a517-4f69-9197-b671ac2eed3c", "9d651bed-a472-4285-9acd-349db4acf267", "01ed948c-6584-40e8-a6a0-88dd7c6ae4bb", "47a00123-9947-4c7f-b5a5-bc31e8a59d9d", "a06ea56e-bc5a-4e1d-960a-17bef9aa0e92", "306e411f-e5a4-42a8-b0f1-b444c1857e7a", "5bf5ebb0-b3b9-4ea5-b680-b2c77a573cd4", "4ea73195-86d1-47dc-af18-df30391d451e", "d337d002-6f04-4ed1-af0b-322526b5a2f6", "4ce2e81f-6471-475f-924d-d8105b41e972", "4ae07687-c6ad-433a-a321-b05b005f65fb", "bdf3f953-3051-4586-858d-7277d7fe7c9f", "3cd3c5b2-22e1-41cb-9755-582a704272a7", "4318b08e-d385-4200-9a42-2f0ba6302aac"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nfor the long term.  So, we feel very good about the performance that we're seeing in our business.  And consistent \nwith our Investor Day, we expect that to continue.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "e172725d-2ee1-4815-ab91-b8f70a3e9bd6": {"node_ids": ["76a43378-df7c-4cc9-9b4f-9c46250442fe", "a964c50e-b4ca-432e-9b3f-15e73b4517b3", "c693198e-925e-42f3-82a6-8b17c3d6804b", "7f047ca8-f77b-4027-a73b-53c6d7c220d5", "5e218156-5493-4804-a293-0c588c79e4fc", "2bf1228c-287b-4f69-905e-06a2d2c32854", "cb8ff01c-661a-4397-8a38-d05e8492d338", "1b7c3c1f-1e6a-47d5-9f6a-0ed681b409a3", "e96345b7-3f75-42f3-9ccf-5862986a49ef", "cc326a5f-7a3a-4bfc-9276-d4f094ae434d", "f8b93dcb-70c9-4558-97df-d4aba0e895f0", "322cfc7c-4cd8-4c92-a1b4-6604fca47c66", "c0d229d9-947e-4dc1-9e05-e0f237662457", "cbede393-3c0b-4ef7-b708-e31727b0a928", "de4b9656-85ce-4656-ac45-9a0cb6910f13", "0e805e66-8af9-4b3b-bf3a-52232d1c5bb5", "f3a14a36-86c8-4c08-80f7-210d3f4fbf67", "0fcb5a52-c6f1-4b68-a3da-01e4f4c2935e", "4837095d-9d4e-44f5-b508-2b181c13ac24", "e0fc47b1-95a5-4a2a-b974-a931d64054b4", "911a5434-ed5a-4af6-8042-6be5052b32d6", "351a20a7-f019-48d3-aa4f-cf159fc27f64", "16b3a2c2-0338-49f1-8658-791dea6d1218", "705369fd-b974-48f0-836a-188ce18c6eb6", "e451c9dd-4d69-4484-bc85-e01d5b647d81", "bf896820-f893-4a6f-9653-bf037b8a6bd2", "1112f724-a91e-49d4-86ec-554e9d973753", "aa58ab6f-19ef-4d37-b1a2-380a01c68137", "31cd2655-4091-4293-8450-001e7efb990c", "aba8540d-75d1-4e27-966b-b3836985933f", "cdee0445-584e-4607-8918-7db4bc57da3e", "35fc96f8-0e2c-4515-970a-1a1d4fce9b45", "0ece2adb-60c9-49ba-ac5c-8b07e610b8c2", "20eb3eeb-6410-4147-8a66-7a3a24bb3b61", "8cc8e2ba-2b8d-4821-a3f3-92ae7504934f", "94f5116c-8168-4e30-b113-55305a47f085", "1eb69da6-caf0-4bb5-95e5-a2c0cd365189", "b4dbe733-9642-4954-b89d-ffd5f3878e6e"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  Congrats on the quarter. ", "original_text": "McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "b0a4684d-5c22-4f6a-80a8-908c1dd1176a": {"node_ids": ["37e8c761-f4ed-40dc-b5ec-d87e05227bba", "9effcd4c-d238-4067-bee1-33d5485aaf76", "f5215618-5b8e-4676-9f97-a07ea2234c33", "421a70b9-35c8-4e7d-bfbb-48ba1a7d8e2a", "d1c81eb7-54b7-4051-966d-08344256c3ab", "160cbdee-0379-4031-a62b-eb9b44b930f6", "a4947939-c4c5-40e8-bab8-7a1047ada5aa", "a88fe4a5-6b54-456b-a89a-d88652c67001", "2d00700e-0041-4dce-ba30-91e192d2ac0f", "138591e4-5934-4766-8bcb-aefb513db15a", "b237b776-12e9-40b3-a4c8-e178c2b2b0d8", "2d159cbb-d7b6-4f24-84f5-191736c88c63", "b61d9fef-41fa-4c41-aca4-155a99aa8364", "c1bb8b9e-0d94-4d8a-b54f-8f454ab7eb40", "abdf4e4a-21f9-40df-9cfd-b1ac7c3dda36", "ca1a5566-c699-4947-9596-eac261e1276a", "7fbb5d70-1ae4-47e4-9289-21826503cd3f", "bf294838-d494-4568-ba5a-cac06883a78c", "4bd048e0-2873-4a02-b267-6261b1fb89b9", "33335a5e-6f39-4394-89d4-957aeaa6477e", "b38135fa-cb5e-4255-abb6-88c03b991048", "7fd63844-6c4a-46e5-87f9-41ab0cd5e3a2", "676d731d-8de5-4385-bb2e-8f2ea1b69c47", "7c5341d8-7cc2-40fd-8530-e5927580477a", "f6c5f39e-7bf3-4863-9bcd-75ee1a68d42a", "97366399-7aea-4fc4-9552-2e2b19e8658f", "db630e17-964f-4c59-9ce4-6211bd28765b", "51c32790-0bde-4c62-b1c5-80a7ccf617bc", "591e4c76-d657-4c57-b617-12ff2618ac1b", "b577c23d-ecea-47c3-882e-923818852b28", "e47dd07a-ed80-4198-b567-3bc998f2eec0", "b08d32f5-b8bf-4279-bd5c-40f4ff2b1275", "cc382ac9-14e0-415c-a743-576be6449dcc", "1684688b-2f28-44fa-8dfd-64c01478b49f", "c9f01e8d-6cc4-45ac-9ed1-ffbeed42bae9", "a48c7dff-f249-47d4-8cb7-6bd6a680347b", "3595e7cf-d999-47f5-b7c3-2437cfe3d36d", "089e3374-ff99-4caa-9ce6-5f9d6dc360e2"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \nRicky, relative to, I guess let's call it the future of testing, that's a little bit, I think, difficult to forecast.  A lot o f it will \ndepend on the science, the development.  A lot of it will depend on the current testing hold -up to current and future \npotential variants, what will be the mix between in a medical setting versus over -the-counter, do those become \nmore reliable. ", "original_text": "McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "0b649837-3c05-4710-82a2-37e772b6efc5": {"node_ids": ["3e1d76b2-cacd-4b52-9fd9-1e6656a2eac0", "1cf60df4-19eb-45a8-8ed1-c2a84a21871b", "f4ffe36e-0443-4072-a88b-8884caa1939e", "587e5860-5d33-4952-9128-ebf2a5cb6d03", "acca44ba-0c49-4628-9cfa-2f56c3e3fe50", "1d0dd021-31ed-44fc-a2a9-a2df5c977a49", "99c55606-ace2-48a7-82bd-9e57d689197c", "7a3ff8d8-9ef3-44a7-bfa3-b3eee7073614", "38e90ac2-35dc-4557-bed2-82afbe22974d", "42c96c9a-fb44-4edf-87c3-392dac0ad0dd", "7945a51f-a255-42a5-ac31-9094d48061d9", "f08e07a4-9efd-4dcf-b30e-91e2f29f67da", "f5f0a081-a3f9-4382-ac99-67fc9dac4cb2", "3b709052-4162-471c-b743-91ba3e4890ab", "5d6d4461-d192-457d-ab01-f755ce3925b8", "e32804cc-93f0-4f97-b313-f9e496451b1f", "c2a02ef2-2345-4d45-a0e7-b316cd09526f", "ad528226-7d88-482b-8db2-64ee9b6496c3", "c0ee073b-d3ce-4482-9c1c-6d4a98821ff2", "09ebd885-4635-4c2f-8015-7924bffa4432", "bf66b6da-0424-460f-871a-c299981d4077", "738ba953-4525-41ec-8f21-73160e76b096", "fab8d38b-8e25-4c8a-8516-4cc84ef0860a", "e22ff1f9-8a06-4368-bff8-ede13215cd9d", "45b4f3b4-d32c-4949-b9ac-00678de4d463"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2022 Earnings Call  Corrected Transcript  \n02-Feb-2022   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2022  FactSet  CallStreet, LLC  \n \ncontributions we can see that making the strong financial results.  It's really the driver between \u2013 the driver of our \nshareholder value creation.  \n \n So, none of that happens without the team that makes up McKesson. ", "original_text": "McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q3-FY22-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 357221, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}}}